PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	PG	WC	SC	GA	UT	PM
J	Ideguchi, M; Kajiwara, K; Goto, H; Sugimoto, K; Nomura, S; Ikeda, E; Suzuki, M				Ideguchi, Makoto; Kajiwara, Koji; Goto, Hisaharu; Sugimoto, Kazutaka; Nomura, Sadahiro; Ikeda, Eiji; Suzuki, Michiyasu			MRI findings and pathological features in early-stage glioblastoma	JOURNAL OF NEURO-ONCOLOGY			English	Article						MRI; Early-stage; Glioblastoma; IDH1; de novo type; Secondary type	POSITRON-EMISSION-TOMOGRAPHY; SECONDARY GLIOBLASTOMAS; DEMYELINATING LESIONS; MALIGNANT GLIOMA; GENETIC PATHWAYS; GRADE GLIOMAS; BRAIN-TUMORS; DE-NOVO; POPULATION; SURVIVAL	Magnetic resonance imaging (MRI) is an important diagnostic tool for glioblastoma, with almost all cases showing characteristic imaging findings such as a heterogeneous-ring enhanced pattern associated with significant edema. However, MRI findings for early-stage glioblastoma are less clear. In this study, a retrospective review of MRI findings in five patients showed slight T2WI signal changes on initial scans that developed into typical imaging findings of a ring-like or heterogeneously enhanced bulky tumor within 6 months. The diagnoses based on initial MRI were low grade glioma in three cases, venous thrombosis in one case, and uncertain in one case. Four cases were treated with gross total resection, while one case underwent biopsy. Immunohistochemical examinations showed that two cases were p53-positive, and that all cases were IDH1 R132H-negative and had overexpression of EGFR. FISH analysis showed that all cases were 1p19q LOH-negative. De novo glioblastoma was the final diagnosis in all cases. Our results show that initial MRI findings in early-stage glioblastoma of small ill-defined T2WI hyperintense lesions with poor contrast develop to bulky mass lesions with typical findings for glioblastoma in as short a period as 2.5 months. The early MRI findings are difficult to distinguish from those for non-neoplastic conditions, including ischemic, degenerative or demyelinating processes. Thus, there is a need for proactive diagnosis of glioblastoma using short-interval MRI scans over several weeks, other imaging modalities, and biopsy or resection, particularly given the extremely poor prognosis of this disease.	[Ideguchi, Makoto; Goto, Hisaharu; Sugimoto, Kazutaka; Nomura, Sadahiro; Suzuki, Michiyasu] Yamaguchi Univ, Grad Sch Med, Dept Neurosurg, Ube, Yamaguchi 7558505, Japan; [Kajiwara, Koji] Ube Nishi Rehabil Hosp, Dept Neurosurg, Ube, Yamaguchi, Japan; [Ikeda, Eiji] Yamaguchi Univ, Grad Sch Med, Dept Pathol, Ube, Yamaguchi 7558505, Japan	Ideguchi, M (reprint author), Yamaguchi Univ, Grad Sch Med, Dept Neurosurg, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	ideguchi@yamaguchi-u.ac.jp					Scott JN, 2002, NEUROLOGY, V59, P947; Pirotte BJM, 2009, NEUROSURGERY, V64, P471, DOI 10.1227/01.NEU.0000338949.94496.85; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479; Friedman HS, 1998, J CLIN ONCOL, V16, P3851; Fujisawa H, 2000, LAB INVEST, V80, P65, DOI 10.1038/labinvest.3780009; Dagher AP, 1996, NEURORADIOLOGY, V38, P560; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998; Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Ginsberg LE, 1998, SURG NEUROL, V49, P436, DOI 10.1016/S0090-3019(97)00360-1; Landy HJ, 2000, J NEURO-ONCOL, V47, P65, DOI 10.1023/A:1006494604527; Barker FG, 1997, CANCER, V80, P936; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Bader JB, 1999, EUR J NUCL MED, V26, P144, DOI 10.1007/s002590050370; Baehring JM, 2007, J NEURO-ONCOL, V82, P221, DOI 10.1007/s11060-006-9273-3; Balss J, 2008, ACTA NEUROPATHOL, V116, P597, DOI 10.1007/s00401-008-0455-2; Bradley WG, 2000, RADIOLOGY, V214, P651; Chang KW, 2000, CARCINOGENESIS, V21, P1441, DOI 10.1093/carcin/21.7.1441; Cohen-Gadol AA, 2004, NEUROSURG REV, V27, P281, DOI 10.1007/s10143-004-0346-5; Gumprecht H, 2007, ZBL NEUROCHIR, V68, P19, DOI 10.1055/s-2007-970601; Hammoud MA, 1996, J NEURO-ONCOL, V27, P65, DOI 10.1007/BF00146086; Kramar F, 2007, J NEURO-ONCOL, V84, P201, DOI 10.1007/s11060-007-9358-7; Louis DN, 2007, WHO CLASSIFICATION T; Nakamura M, 2000, J NEUROPATH EXP NEUR, V59, P539; Newcomb EW, 1998, BRAIN PATHOL, V8, P655; Okamoto K, 2002, NEURORADIOLOGY, V44, P395, DOI 10.1007/s00234-001-0725-3; Ono K, 2000, No To Shinkei, V52, P325; Osborn AG, 1994, DIAGNOSTIC NEURORADI, P529; Oyama H, 2010, NEUROL MED-CHIR, V50, P414; Torii K, 2005, ANN NUCL MED, V19, P677, DOI 10.1007/BF02985116; Utsuki S, 2012, ICJM, V3, P439, DOI [10.4236/ijcm.2012.36082, DOI 10.4236/IJCM.2012.36082]; Wharton SB, 2007, ACTA NEUROPATHOL, V113, P119, DOI 10.1007/s00401-006-0177-2; YETKIN Z, 1995, NEURORADIOLOGY, V37, P284	36	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0167-594X	1573-7373		J NEURO-ONCOL	J. Neuro-Oncol.	JUN	2015	123	2					289	297		10.1007/s11060-015-1797-y		9	Oncology; Clinical Neurology	Oncology; Neurosciences & Neurology	CJ6VJ	WOS:000355632800012		
J	Kurokawa, A; Narukawa, M; Ohmoto, M; Yoshimoto, J; Abe, K; Misaka, T				Kurokawa, Azusa; Narukawa, Masataka; Ohmoto, Makoto; Yoshimoto, Joto; Abe, Keiko; Misaka, Takumi			Expression of the synaptic exocytosis-regulating molecule complexin 2 in taste buds and its participation in peripheral taste transduction	JOURNAL OF NEUROCHEMISTRY			English	Article						CPLX2; sour; taste	NEUROTRANSMITTER RELEASE; DOCKING/FUSION COMPLEX; CELL LINEAGE; ION-CHANNEL; SYNAPSES; RECEPTOR; PROTEINS; MOUSE; MICE; IMMUNOREACTIVITY	Taste information from type III taste cells to gustatory neurons is thought to be transmitted via synapses. However, the molecular mechanisms underlying taste transduction through this pathway have not been fully elucidated. In this study, to identify molecules that participate in synaptic taste transduction, we investigated whether complexins (Cplxs), which play roles in regulating membrane fusion in synaptic vesicle exocytosis, were expressed in taste bud cells. Among four Cplx isoforms, strong expression of Cplx2 mRNA was detected in type III taste cells. To investigate the function of CPLX2 in taste transduction, we observed taste responses in CPLX2-knockout mice. When assessed with electrophysiological and behavioral assays, taste responses to some sour stimuli in CPLX2-knockout mice were significantly lower than those in wild-type mice. These results suggested that CPLX2 participated in synaptic taste transduction from type III taste cells to gustatory neurons.	[Kurokawa, Azusa; Narukawa, Masataka; Ohmoto, Makoto; Yoshimoto, Joto; Abe, Keiko; Misaka, Takumi] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; [Abe, Keiko] Kanagawa Acad Sci & Technol, Kawasaki, Kanagawa, Japan	Misaka, T (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, I-1-1 Yayoi, Tokyo 1138657, Japan.	amisaka@mail.ecc.u-tokyo.ac.jp			Funding Program for Next Generation World-Leading Researchers from the Japan Society for the Promotion of Science [LS037]; Japan Society for the Promotion of Science [26712014]; Council for Science, Technology and Innovation (CSTI)	We thank Dr Hideto Kaba (Kochi Medical School, Japan) for providing CPLX2-KO mice and Ms Taeko Fukuda (the University of Tokyo, Japan) for supporting animal care. This work was supported, in part, by the Funding Program for Next Generation World-Leading Researchers from the Japan Society for the Promotion of Science (LS037 to TM), by a Grant-in-Aid for Young Scientists (A) (26712014 to MN) in the Priority Area Food Science from the Japan Society for the Promotion of Science, and by Council for Science, Technology and Innovation (CSTI), Cross-ministerial Strategic Innovation Promotion Program (SIP), 'Technologies for creating next-generation agriculture, forestry and fisheries'.	Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Miura H, 2006, ARCH HISTOL CYTOL, V69, P209, DOI 10.1679/aohc.69.209; Carleton A, 2010, TRENDS NEUROSCI, V33, P326, DOI 10.1016/j.tins.2010.04.002; Oka Y, 2013, NATURE, V494, P472, DOI 10.1038/nature11905; Yang XF, 2013, P NATL ACAD SCI USA, V110, P20777, DOI 10.1073/pnas.1321367110; Chandrashekar J, 2006, NATURE, V444, P288, DOI 10.1038/nature05401; Yarmolinsky DA, 2009, CELL, V139, P234, DOI 10.1016/j.cell.2009.10.001; Huang YJ, 2005, J NEUROSCI, V25, P843, DOI 10.1523/JNEUROSCI.4446-04.2005; Yang RB, 2000, J COMP NEUROL, V424, P205, DOI 10.1002/1096-9861(20000821)424:2<205::AID-CNE2>3.0.CO;2-F; Yang XF, 2010, NEURON, V68, P907, DOI 10.1016/j.neuron.2010.11.001; Ohmoto M, 2008, MOL CELL NEUROSCI, V38, P505, DOI 10.1016/j.mcn.2008.04.011; Chandrashekar J, 2009, SCIENCE, V326, P443, DOI 10.1126/science.1174601; Matsumoto I, 2011, NAT NEUROSCI, V14, P685, DOI 10.1038/nn.2820; Reim K, 2005, J CELL BIOL, V169, P669, DOI 10.1083/jcb.200502115; ISHIZUKA T, 1995, BIOCHEM BIOPH RES CO, V213, P1107, DOI 10.1006/bbrc.1995.2241; Takahashi S, 1999, EUR J NEUROSCI, V11, P2359, DOI 10.1046/j.1460-9568.1999.00652.x; Xue MS, 2008, P NATL ACAD SCI USA, V105, P7875, DOI [10.1073/pnas.0803012105, 10.1072/pnas.0803012105]; Ishimaru Y, 2006, P NATL ACAD SCI USA, V103, P12569, DOI 10.1073/pnas.0602702103; Caterina MJ, 1997, NATURE, V389, P816; Kasai H, 2012, PHYSIOL REV, V92, P1915, DOI 10.1152/physrev.00007.2012; Huang AL, 2006, NATURE, V442, P934, DOI [10.1038/nature05084, 10.1038/nature050084]; Kaeser-Woo YJ, 2012, J NEUROSCI, V32, P2877, DOI 10.1523/JNEUROSCI.3360-11.2012; Maximov A, 2009, SCIENCE, V323, P516, DOI 10.1126/science.1166505; Yang RB, 2004, J COMP NEUROL, V471, P59, DOI 10.1002/cne.20021; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Chandrashekar J, 2010, NATURE, V464, P297, DOI 10.1038/nature08783; Taruno A, 2013, NATURE, V495, P223, DOI 10.1038/nature11906; Freeman W, 2004, BRAIN RES BULL, V63, P33, DOI 10.1016/j.brainresbull.2003.12.003; Gibson HE, 2005, EUR J NEUROSCI, V22, P1701, DOI 10.1111/j.1460-9568.2005.04349.x; Horio N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020007; Huang GZ, 2000, JPN J PHARMACOL, V84, P179, DOI 10.1254/jjp.84.179; Ishizuka T, 1999, NEUROSCIENCE, V88, P295, DOI 10.1016/S0306-4522(98)00223-1; Murray RG, 1973, ULTRASTRUCTURE SENSO, P1; Radyushkin K, 2010, GENES BRAIN BEHAV, V9, P592, DOI 10.1111/j.1601-183X.2010.00590.x; TAKAHASHI S, 1995, FEBS LETT, V368, P455, DOI 10.1016/0014-5793(95)00713-J; Ueda K, 2006, ARCH HISTOL CYTOL, V69, P289, DOI 10.1679/aohc.69.289; Yang RB, 2007, J COMP NEUROL, V502, P883, DOI 10.1002/cne.21317	37	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2015	133	6					806	814		10.1111/jnc.13073		9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CK2AI	WOS:000356011300004		
J	Nakajima, K; Nakata, T				Nakajima, Kenichi; Nakata, Tomoaki			Cardiac I-123-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan	JOURNAL OF NUCLEAR MEDICINE			English	Article						I-123-MIBG; scintigraphic technique; heart failure; risk stratification; prognosis	CHRONIC HEART-FAILURE; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; SYMPATHETIC-NERVE ACTIVITY; LEFT-VENTRICULAR FUNCTION; IDIOPATHIC DILATED CARDIOMYOPATHY; PROGNOSTIC VALUE; RESYNCHRONIZATION THERAPY; RATE-VARIABILITY; METAIODOBENZYLGUANIDINE UPTAKE; MYOCARDIAL SCINTIGRAPHY	Cardiac neuroimaging with I-123-metaiodobenzylguanidine (I-123-MIBG) has been officially used in clinical practice in Japan since 1992. The nuclear cardiology guidelines of the Japanese Circulation Society, revised in 2010, recommended cardiac I-123-MIBG imaging for the management of heart failure (HF) patients, particularly for the assessment of HF severity and prognosis of HF patients. Consensus in North American and European countries regarding incorporation into clinical practice, however, has not been established yet. This article summarizes 22 y of clinical applications in Japan of I-123-MIBG imaging in the field of cardiology; these applications are reflected in cardiology guidelines, including recent methodologic advances. A standardized cardiac I-123-MIBG parameter, the heart-to-mediastinum ratio (HMR), is the basis for clinical decision making and enables common use of parameters beyond differences in institutions and studies. Several clinical studies unanimously demonstrated its potent independent roles in prognosis evaluation and risk stratification irrespective of HF etiologies. An HMR of less than 1.6-1.8 and an accelerated washout rate are recognized as high-risk indicators of pump failure death, sudden cardiac death, and fatal arrhythmias and have independent and incremental prognostic values together with known clinical variables, such as left ventricular ejection fraction and brain natriuretic peptide. Another possible use of this imaging technique is the selection of therapeutic strategy, such as pharmacologic treatment and nonpharmacologic treatment with an implantable cardioverter-defibrillator or cardiac resynchronization device; however, this possibility remains to be investigated. Recent multiple-cohort database analyses definitively demonstrated that patients who were at low risk for lethal events and who were defined by an HMR of greater than 2.0 on I-123-MIBG studies had a good long-term prognosis. Future investigations of cardiac I-123-MIBG imaging will contribute to better risk stratification of low-risk and high-risk populations, to the establishment of cost-effective use of this imaging technique for the management of HF patients, and to worldwide acceptance of this imaging technique in clinical cardiology practice.	[Nakajima, Kenichi] Kanazawa Univ Hosp, Dept Nucl Med, Kanazawa, Ishikawa 9208641, Japan; [Nakata, Tomoaki] Hakodate Goryoukaku Hosp, Dept Cardiol, Hakodate, Hokkaido, Japan	Nakajima, K (reprint author), Kanazawa Univ Hosp, Dept Nucl Med, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.	nakajima@med.kanazawa-u.ac.jp	刘, 李陆/H-8469-2015		Japanese Society of Nuclear Medicine	This work was partly supported by the working group activity of the Japanese Society of Nuclear Medicine and by Grants-in-Aid for Scientific Research in Japan (to Kenichi Nakajima). Kenichi Nakajima has done collaborative research with Fujifilm RI Pharma Co., Ltd., which supplies <SUP>123</SUP>I-MIBG in Japan. No other potential conflict of interest relevant to this article was reported.	Agostini D, 2000, J NUCL MED, V41, P845; Abraham WT, 2013, NAT REV CARDIOL, V10, P98, DOI 10.1038/nrcardio.2012.178; Ogita H, 2001, HEART, V86, P656, DOI 10.1136/heart.86.6.656; Toyama T, 1999, J NUCL MED, V40, P217; Tamaki S, 2009, J AM COLL CARDIOL, V53, P426, DOI 10.1016/j.jacc.2008.10.025; Jacobson AF, 2010, J AM COLL CARDIOL, V55, P2212, DOI 10.1016/j.jacc.2010.01.014; Nagahara D, 2008, J NUCL MED, V49, P225, DOI 10.2967/jnumed.107.042564; Toyama T, 2008, J NUCL CARDIOL, V15, P57, DOI 10.1016/j.nuclcard.2007.08.006; Veltman CE, 2012, EUR J NUCL MED MOL I, V39, P1599, DOI 10.1007/s00259-012-2180-2; Gerson MC, 2003, J CARD FAIL, V9, P384, DOI 10.1054/S1071-9164(03)00134-9; NAKAJIMA K, 1990, AM HEART J, V119, P1329, DOI 10.1016/S0002-8703(05)80183-8; Kasama S, 2003, J AM COLL CARDIOL, V41, P574, DOI 10.1016/S0735-1097(02)02855-3; Matsunari I, 2000, CIRCULATION, V101, P2579; Sipahi I, 2011, ARCH INTERN MED, V171, P1454, DOI 10.1001/archinternmed.2011.247; Takeishi Y, 1997, J NUCL MED, V38, P1085; Wakabayashi T, 2001, J NUCL MED, V42, P1757; Kuck KH, 2000, CIRCULATION, V102, P748; Hattori N, 1996, J NUCL MED, V37, P1985; Marshall A, 2012, HEART, V98, P1359, DOI 10.1136/heartjnl-2012-302321; Katoh S, 2010, ANN NUCL MED, V24, P679, DOI 10.1007/s12149-010-0409-3; Kasama S, 2003, J NUCL MED, V44, P884; Arimoto T, 2007, J CARD FAIL, V13, P34, DOI 10.1016/j.cardfail.2006.09.002; Nakata T, 1998, J NUCL CARDIOL, V5, P579, DOI 10.1016/S1071-3581(98)90112-X; Arora R, 2003, J NUCL CARDIOL, V10, P121, DOI 10.1067/mnc.2003.2; Boogers MJ, 2010, J AM COLL CARDIOL, V55, P2769, DOI 10.1016/j.jacc.2009.12.066; O'Brien BJ, 2001, CIRCULATION, V103, P1416; Nakata T, 2013, JACC-CARDIOVASC IMAG, V6, P772, DOI 10.1016/j.jcmg.2013.02.007; Ketchum ES, 2012, J NUCL CARDIOL, V19, P1007, DOI 10.1007/s12350-012-9603-0; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Nishioka SAD, 2007, J NUCL CARDIOL, V14, P852, DOI 10.1016/j.nuclcard.2007.08.004; Suwa M, 1997, AM HEART J, V133, P353, DOI 10.1016/S0002-8703(97)70232-1; Flotats A, 2010, EUR J NUCL MED MOL I, V37, P1802, DOI 10.1007/s00259-010-1491-4; MERLET P, 1992, J NUCL MED, V33, P471; Tanaka H, 2012, CIRC J, V76, P382, DOI 10.1253/circj.CJ-11-0752; Nishisato K, 2010, J NUCL MED, V51, P1241, DOI 10.2967/jnumed.110.074971; Matsui T, 2002, CIRC J, V66, P537, DOI 10.1253/circj.66.537; Bengel FM, 2001, NEW ENGL J MED, V345, P731, DOI 10.1056/NEJMoa010519; Burri Haran, 2008, Europace, V10, P374, DOI 10.1093/europace/eun017; CALKINS H, 1993, CIRCULATION, V88, P172; Cha YM, 2008, J CARDIOVASC ELECTR, V19, P1045, DOI 10.1111/j.1540-8167.2008.01190.x; Choi JY, 2001, J NUCL CARDIOL, V8, P4, DOI 10.1067/mnc.2001.109452; DEMARCO T, 1995, J AM COLL CARDIOL, V25, P927, DOI 10.1016/0735-1097(94)00463-Z; Doi T, 2012, J NUCL MED, V53, P731, DOI 10.2967/jnumed.111.095786; Fallavollita JA, 2014, J AM COLL CARDIOL, V63, P141, DOI 10.1016/j.jacc.2013.07.096; Flotats A, 2011, EUR J NUCL MED MOL I, V38, P190, DOI 10.1007/s00259-010-1671-2; GUERTNER C, 1995, EUR J NUCL MED, V22, P443, DOI 10.1007/BF00839059; HENDERSON EB, 1988, CIRCULATION, V78, P1192; Imamura Y, 1996, J AM COLL CARDIOL, V28, P371, DOI 10.1016/0735-1097(96)00165-9; Imamura Y, 2001, JPN CIRC J, V65, P155, DOI 10.1253/jcj.65.155; Kakuchi H, 1999, HEART, V81, P148; Kasama S, 2012, EUR J NUCL MED MOL I, V39, P1056, DOI 10.1007/s00259-012-2092-1; Kyuma M, 2004, J NUCL MED, V45, P155; Llorca CR, 2008, TRANSPL P, V40, P3020, DOI 10.1016/j.transproceed.2008.08.107; Lovric SS, 2004, EUR J CARDIO-THORAC, V26, P736, DOI 10.1016/j.ejcts.2004.07.025; Momose M, 2011, ANN NUCL MED, V25, P419, DOI 10.1007/s12149-011-0479-x; Nakajima K, 2008, Q J NUCL MED MOL IM, V52, P378; Nakajima K, 2007, J NUCL CARDIOL, V14, P843, DOI 10.1016/j.nucicard.2007.08.002; Nakajima K, 2010, ANN NUCL MED, V24, P125, DOI 10.1007/s12149-009-0337-2; Nakajima K, 2014, EUR J NUCL MED MOL I, V41, P1673, DOI 10.1007/s00259-014-2759-x; Nakajima K, 2014, J NUCL CARDIOL, V21, P970, DOI 10.1007/s12350-014-9916-2; Nakata T, 2005, EUR J NUCL MED MOL I, V32, P186, DOI 10.1007/s00259-004-1624-8; Nakata T, 2003, J CARD FAIL, V9, P113, DOI 10.1054/jcaf.2003.14; Okuda K, 2011, J NUCL CARDIOL, V18, P82, DOI 10.1007/s12350-010-9313-4; Petretta M, 2014, EUR J NUCL MED MOL I, V41, P1663, DOI 10.1007/s00259-014-2827-2; Sakata K, 1997, J AM COLL CARDIOL, V30, P370, DOI 10.1016/S0735-1097(97)00159-9; Sanchez-Lazaro IJ, 2011, INT J CARDIOL, V152, P83, DOI 10.1016/j.ijcard.2010.07.010; Schwartz PJ, 1992, CIRCULATION S1, V85, P177; Shinohara H, 2002, HEART VESSELS, V17, P47, DOI 10.1007/s003800200042; Shinohara T, 2011, PACE, V34, P1225, DOI 10.1111/j.1540-8159.2011.03156.x; STANTON MS, 1989, J AM COLL CARDIOL, V14, P1519, DOI 10.1016/0735-1097(89)90391-4; Tamaki N, 2012, CIRC J, V76, P761, DOI 10.1253/circj.CJ-88-0019; Verschure DO, 2014, EUR HEART J-CARD IMG, V15, P996, DOI 10.1093/ehjci/jeu044; Watanabe K, 2002, J NUCL MED, V43, P1476; Yamada T, 2003, J AM COLL CARDIOL, V41, P231, DOI 10.1016/S0735-1097(02)02700-6	74	1	1	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	JUN	2015	56			4			11S	19S		10.2967/jnumed.114.142794		9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CJ6ZH	WOS:000355643200004		
J	Lin, C; Kume, K; Mori, T; Martinez, ME; Okazawa, H; Kiyono, Y				Lin, Chao; Kume, Kyo; Mori, Tetsuya; Martinez, Miguel E.; Okazawa, Hidehiko; Kiyono, Yasushi			Predictive Value of Early-Stage Uptake of 3 '-Deoxy-3 '-F-18-Fluorothymidine in Cancer Cells Treated with Charged Particle Irradiation	JOURNAL OF NUCLEAR MEDICINE			English	Article						3 '-deoxy-3 '-F-18-fluorothymidine (F-18-FLT); positron emission tomography (PET); charged particle irradiation; tumor volume; cell proliferation ability	POSITRON-EMISSION-TOMOGRAPHY; FDG-PET; IMAGING PROLIFERATION; RADIATION-THERAPY; TUMOR VOLUME; LUNG-CANCER; IN-VIVO; RADIOTHERAPY; F-18-FLT; LYMPHOMA	The aim of this study was to investigate whether 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) can monitor the early response of tumor cell proliferation to charged particle irradiation in vitro and in vivo. Methods: In vitro, after 0.1, 0.5, 1, 5, and 10 Gy of proton or carbon ion irradiation, F-18-FLT cell uptake was examined at 24 h and cell proliferation ability was measured from days 1 to 4. In vivo, after 0.5, 1, and 5 Gy of proton or carbon ion irradiation, F-18-FLT PET imaging was performed on tumor-bearing BALB/c nu/nu mice at 24 h and tumor growth was measured from days 1 to 7. Tumor-to-background ratios of standardized uptake values were calculated to assess the F-18-FLT accumulation in tumors. Both cells and mice also received x-irradiation as a control. Results: In vitro, F-18-FLT cell uptake was significantly lower after 1 Gy of proton irradiation (P < 0.05) and carbon ion irradiation (P < 0.05) and after 5 Gy of x-irradiation (P < 0.01), but cell proliferation ability at these doses did not show significant differences until day 3. In vivo, F-18-FLT tumor uptake was significantly lower after 1 Gy of proton (P < 0.001) and carbon ion irradiation (P < 0.01) and after 5 Gy of x-irradiation (P < 0.001), but tumor growth did not significantly differ at these doses until day 4 after proton irradiation, day 3 after carbon ion irradiation, and day 5 after x-irradiation. Conclusion: The reduction in F-18-FLT uptake after charged particle irradiation was more rapid than the change in tumor growth in vivo or the change in cell proliferation ability in vitro. Therefore, F-18-FLT is a promising tracer for monitoring the early response of cancer to charged particle irradiation.	[Lin, Chao; Mori, Tetsuya; Martinez, Miguel E.; Okazawa, Hidehiko; Kiyono, Yasushi] Univ Fukui, Biomed Imaging Res Ctr, Eiheiji, Fukui 9101193, Japan; [Kume, Kyo] Wakasa Wan Energy Res Ctr, Div Res & Dev, Fukui, Japan; [Kiyono, Yasushi] Univ Fukui, Res & Educ Program Life Sci, Eiheiji, Fukui 9101193, Japan	Kiyono, Y (reprint author), Univ Fukui, Biomed Imaging Res Ctr, 23-3 Matsuoka Shimoaizuki, Eiheiji, Fukui 9101193, Japan.	ykiyono@u-fukui.ac.jp			Wakasa Wan Energy Research Center; JSPS KAKENHI [24249065]	The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This study was partially supported by research funds from the Wakasa Wan Energy Research Center and by grant 24249065 from JSPS KAKENHI. No other potential conflict of interest relevant to this article was reported.	Everitt SJ, 2014, J NUCL MED, V55, P1069, DOI 10.2967/jnumed.113.131631; Buck AK, 2003, J NUCL MED, V44, P1426; Lomax AJ, 2003, RADIOTHER ONCOL, V66, P11, DOI 10.1016/S0167-8140(02)00308-0; Zhu AZ, 2011, SEMIN ONCOL, V38, P55, DOI 10.1053/j.seminoncol.2010.11.012; Francis DL, 2003, GUT, V52, P1602, DOI 10.1136/gut.52.11.1602; Zhu AZ, 2012, RADIAT RES, V177, P436, DOI 10.1667/RR2702.1; Picchio M, 2009, Q J NUCL MED MOL IM, V53, P245; Yang YJ, 2006, EUR J NUCL MED MOL I, V33, P412, DOI 10.1007/s00259-005-0011-4; Murphy JD, 2011, INT J RADIAT ONCOL, V80, P514, DOI 10.1016/j.ijrobp.2010.01.057; Strauss LG, 1996, EUR J NUCL MED, V23, P1409, DOI 10.1007/BF01367602; Sugiyama M, 2004, J NUCL MED, V45, P1754; Wang H, 2013, EUR J RADIOL, V82, pE484, DOI 10.1016/j.ejrad.2013.03.017; Wagner M, 2003, CANCER RES, V63, P2681; Wilkens JJ, 2008, INT J RADIAT ONCOL, V70, P262, DOI 10.1016/j.ijrobp.2007.08.029; Schulz-Ertner D, 2006, SEMIN RADIAT ONCOL, V16, P249, DOI 10.1016/j.semradonc.2006.04.008; Shields AF, 1998, NAT MED, V4, P1334, DOI 10.1038/3337; Geets X, 2004, RADIOTHER ONCOL, V71, P267, DOI 10.1016/j.radonc.2004.02.013; Baumert BG, 2004, INT J RADIAT ONCOL, V60, P1314, DOI 10.1016/j.ijrobp.2004.06.212; Loeffler JS, 2013, NAT REV CLIN ONCOL, V10, P411, DOI 10.1038/nrclinonc.2013.79; Durante M, 2010, NAT REV CLIN ONCOL, V7, P37, DOI 10.1038/nrclinonc.2009.183; Inubushi M, 2013, ANN NUCL MED, V27, P1, DOI 10.1007/s12149-012-0652-x; Shreve PD, 1999, RADIOGRAPHICS, V19, P61; Li ZL, 2012, CANCER RES, V72, P5014, DOI 10.1158/0008-5472.CAN-12-0635; Trigonis I, 2014, EUR J NUCL MED MOL I, V41, P682, DOI 10.1007/s00259-013-2632-3; Avallone A, 2012, EUR J NUCL MED MOL I, V39, P1848, DOI 10.1007/s00259-012-2229-2; Buck AK, 2006, CANCER RES, V66, P11055, DOI 10.1158/0008-5472.CAN-06-1955; Ford EC, 2009, J NUCL MED, V50, P1655, DOI 10.2967/jnumed.108.055780; Koizumi M, 2011, MOL IMAGING BIOL, V13, P577, DOI 10.1007/s11307-010-0363-4; Lopci Egesta, 2014, Am J Nucl Med Mol Imaging, V4, P365; Lundkvist J, 2005, ACTA ONCOL, V44, P850, DOI 10.1080/02841860500341157; Murayama C, 2009, J NUCL MED, V50, P290, DOI 10.2967/jnumed.108.057091; Okada O, 2000, P 13 INT C HIGH POW, P1067; Saga T, 2011, NUCL MED COMMUN, V32, P348, DOI 10.1097/MNM.0b013e328344a427; Seitz U, 2002, EUR J NUCL MED MOL I, V29, P1174, DOI 10.1007/s00259-002-0851-0; van Waarde A, 2004, J NUCL MED, V45, P695; Yamada R, 2008, IEEE T NUCL SCI, V55, P906, DOI 10.1109/TNS.2008.922813	36	1	1	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	JUN 1	2015	56	6					945	950		10.2967/jnumed.114.152983		6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CJ5YO	WOS:000355570300027		
J	Kasai, M; Aoki, S; Ogawa, M; Kurasawa, K; Takahashi, T; Hirahara, F				Kasai, Michi; Aoki, Shigeru; Ogawa, Miyuki; Kurasawa, Kentaro; Takahashi, Tsuneo; Hirahara, Fumiki			Prediction of perinatal outcomes based on primary symptoms in women with placental abruption	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						abdominal pain; concealed abruption; external bleeding; placental abruption; revealed abruption	CEREBRAL-PALSY; RISK-FACTORS; MORTALITY; PREVIA	AimsPlacental abruption is an important cause of perinatal mortality and morbidity. Although there are many reports on the risk factors for placental abruption, there are few on its classification. Our aim is to evaluate the associations between primary symptoms and the outcomes of placental abruption. Material and MethodsWe carried out a retrospective cohort study of 12474 births at the Perinatal Center for Maternity and Neonates of the Yokohama City University Medical Center between January 2000 and December 2012. There were 151 women with placental abruption, 136 of whom were included in this study. The subjects were classified into two groups according to their primary symptoms: those with bleeding (external bleeding group) and those with abdominal pain (abdominal pain group). Maternal and neonatal outcomes were compared between the two groups. ResultsBoth fetal and maternal outcomes were significantly poorer in the abdominal pain group than in the external bleeding group in terms of intrauterine fetal death (6.5% vs 33.3%, P<0.001), perinatal mortality (8.1% vs 33.3%, P=0.001), umbilical arterial pH<7.1 (15.7% vs 57.1%, P<0.001), bleeding volume, rate of blood transfusion, and disseminated intravascular coagulation incidence. ConclusionsThis classification based on primary symptoms was found to be useful for predicting both maternal and neonatal outcomes of placental abruption.	[Kasai, Michi; Aoki, Shigeru; Kurasawa, Kentaro; Takahashi, Tsuneo] Yokohama City Univ, Med Ctr, Perinatal Ctr Matern & Neonates, Yokohama, Kanagawa 2320024, Japan; [Ogawa, Miyuki; Hirahara, Fumiki] Yokohama City Univ Med, Dept Obstet & Gynecol, Yokohama, Kanagawa, Japan	Aoki, S (reprint author), Yokohama City Univ, Med Ctr, Perinatal Ctr Matern & Neonates, Minami Ku, 4-57 Urafunecho, Yokohama, Kanagawa 2320024, Japan.	smyyaoki@yahoo.co.jp		Aoki, Shigeru/0000-0001-5307-575X			American College of Obstetricians and Gy-necologists, 2010, OBSTET GYNECOL, V116, P1232; Ananth CV, 2006, EUR J OBSTET GYN R B, V128, P15, DOI 10.1016/j.ejogrb.2006.01.016; Yamada T, 2012, EARLY HUM DEV, V88, P861, DOI 10.1016/j.earlhumdev.2012.06.008; Lindqvist PG, 2006, EUR J OBSTET GYN R B, V126, P160, DOI 10.1016/j.ejogrb.2005.08.003; Tikkanen M, 2006, ACTA OBSTET GYN SCAN, V85, P700, DOI 10.1080/00016340500449915; Ananth CV, 2011, AM J EPIDEMIOL, V174, P99, DOI 10.1093/aje/kwr045; Ananth CV, 2001, AM J EPIDEMIOL, V153, P332, DOI 10.1093/aje/153.4.332; Oyelese Y, 2006, OBSTET GYNECOL, V108, P1005, DOI 10.1097/01.AOG.0000239439.04364.9a; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327; Ananth CV, 2006, OBSTET GYNECOL, V107, P785, DOI 10.1097/01.AOG.0000207560.41604.19; Elsasser DA, 2010, EUR J OBSTET GYN R B, V148, P125, DOI 10.1016/j.ejogrb.2009.10.005; Aoki S, 2014, ARCH GYNECOL OBSTET, V289, P307, DOI 10.1007/s00404-013-2972-z; Baron F, 1998, CLIN OBSTET GYNECOL, V41, P527, DOI 10.1097/00003081-199809000-00008; Chang YL, 2001, INT J GYNECOL OBSTET, V75, P193, DOI 10.1016/S0020-7292(01)00439-8; Elliott JP, 1998, J REPROD MED, V43, P418; Matsuda Y, 2003, EUR J OBSTET GYN R B, V106, P125, DOI 10.1016/S0301-2115(02)00219-1; Nath CA, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.06.012; Pariente G, 2011, J MATERN-FETAL NEO M, V24, P698, DOI 10.3109/14767058.2010.511346; Tikkanen M, 2013, ACTA OBSTET GYN SCAN, V92, P298, DOI 10.1111/aogs.12030	19	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	JUN	2015	41	6					850	856		10.1111/jog.12637		7	Obstetrics & Gynecology	Obstetrics & Gynecology	CJ8II	WOS:000355743000003		
J	Yokouchi, T; Murakoshi, T; Mishima, T; Yano, H; Ohashi, M; Suzuki, T; Shinno, T; Matsushita, M; Nakayama, S; Torii, Y				Yokouchi, Tae; Murakoshi, Takeshi; Mishima, Takashi; Yano, Hiroko; Ohashi, Madoka; Suzuki, Takashi; Shinno, Takashi; Matsushita, Mitsuru; Nakayama, Satoru; Torii, Yuichi			Incidence of spontaneous twin anemia-polycythemia sequence in monochorionic-diamniotic twin pregnancies: Single-center prospective study	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						acute feto-fetal hemorrhage; hemoglobin difference; monochorionic-diamniotic twin pregnancy; reticulocyte count; twin anemia-polycythemia sequence	PLACENTAL CHARACTERISTICS; TRANSFUSION SYNDROME; ANASTOMOSES; MANAGEMENT	AimThe purpose of this study was to prospectively estimate the incidence of spontaneous twin anemia-polycythemia sequence (TAPS) in monochorionic-diamniotic twin pregnancies. MethodsWe prospectively examined umbilical cord hemoglobin (Hb) and reticulocyte count of consecutive monochorionic-diamniotic twin pregnancies delivered at Seirei Hamamatsu General Hospital from December 2006 to September 2013. We excluded cases of twin-twin transfusion syndrome, intrauterine fetal demise, and missing data (Hb and reticulocyte count missing from the medical record). TAPS was diagnosed using the postnatal criteria of intertwin Hb difference >8.0g/dL and reticulocyte count ratio >1.7. Acute feto-fetal hemorrhage was defined as Hb difference >7g/dL and reticulocyte count ratio <1.7. ResultsA total of 185 monochorionic-diamniotic twin pregnancies were included in this study. Three fulfilled the diagnostic criteria for postnatal TAPS, and one fulfilled the diagnostic criteria for acute feto-fetal hemorrhage. ConclusionThe incidence of spontaneous TAPS in monochorionic-diamniotic twin pregnancies was 1.6% (3/185) at Seirei Hamamatsu General Hospital.	[Yokouchi, Tae; Murakoshi, Takeshi; Mishima, Takashi; Yano, Hiroko; Ohashi, Madoka; Suzuki, Takashi; Shinno, Takashi; Matsushita, Mitsuru; Nakayama, Satoru; Torii, Yuichi] Seirei Hamamatsu Gen Hosp, Div Obstet & Perinatol, Maternal & Perinatal Care Ctr, Shizuoka, Japan	Yokouchi, T (reprint author), 2-12-12 Sumiyoshi,Naka ku, Hamamatsu, Shizuoka 4308558, Japan.	yokouchitae@sis.seirei.or.jp					de Villiers S, 2012, PLACENTA, V33, P227, DOI 10.1016/j.placenta.2012.01.009; Slaghekke F, 2010, FETAL DIAGN THER, V27, P181, DOI 10.1159/000304512; Lopriore E, 2014, J OBSTET GYNAECOL RE, V40, P18, DOI 10.1111/jog.12114; Robyr R, 2006, AM J OBSTET GYNECOL, V194, P796, DOI 10.1016/j.ajog.2005.08.069; Lopriore E, 2008, OBSTET GYNECOL, V112, P753, DOI 10.1097/AOG.0b013e318187e1ff; Lopriore E, 2007, PLACENTA, V28, P47, DOI 10.1016/j.placenta.2006.01.010; Lewi L, 2008, AM J OBSTET GYNECOL, V199, P511	7	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	JUN	2015	41	6					857	860		10.1111/jog.12641		4	Obstetrics & Gynecology	Obstetrics & Gynecology	CJ8II	WOS:000355743000004		
J	Nakagami, H; Kajihara, T; Kamei, Y; Ishihara, O; Kayano, H; Sasaki, A; Itakura, A				Nakagami, Hiroko; Kajihara, Takeshi; Kamei, Yoshimasa; Ishihara, Osamu; Kayano, Hidekazu; Sasaki, Atsushi; Itakura, Atsuo			Amniotic components in the uterine vasculature and their role in amniotic fluid embolism	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						alcian blue; amniotic fluid embolism; disseminated intravascular coagulation; post-partum hysterectomy	MATERNAL PULMONARY CIRCULATION; MONOCLONAL-ANTIBODY TKH-2; ATYPICAL PRESENTATION; ISOLATED COAGULOPATHY; DIAGNOSIS; CELLS; REGISTRY; DEATH	AimTo evaluate whether the presence of amniotic components in the maternal uterine vasculature could be a specific pathological indicator for amniotic fluid embolism (AFE). MethodsMedical records of patients treated between January 2006 and March 2013 were retrospectively examined to identify patients who underwent post-partum hysterectomy or autopsy due to maternal death. Three subjects with AFE with disseminated intravascular coagulation (DIC)-type post-partum hemorrhage (PPH), and 13 non-AFE subjects were included in analysis. Histochemical staining using hematoxylin-eosin (HE) and alcian blue, and immunohistochemical staining for sialyl-Tn were conducted to detect amniotic components in the maternal uterine vasculature. ResultsAlcian blue was positive for amniotic components in the uterine vasculature of all subjects with AFE and of several subjects without AFE. Similarly, HE and sialyl-Tn were negative in some AFE subjects and positive in some non-AFE subjects. ConclusionsThe presence of maternal intravascular fetal material is not a specific indicator for AFE with DIC-type PPH. Therefore, the presence of fetal components in the uterine vasculature is unlikely to be a definitive indicator for AFE.	[Nakagami, Hiroko; Kajihara, Takeshi; Kamei, Yoshimasa; Ishihara, Osamu] Saitama Med Univ, Dept Obstet & Gynecol, Saitama, Japan; [Kayano, Hidekazu; Sasaki, Atsushi] Saitama Med Univ, Dept Pathol, Saitama, Japan; [Itakura, Atsuo] Juntendo Univ, Dept Obstet & Gynecol, Tokyo, Japan	Kajihara, T (reprint author), Saitama Med Univ, Dept Obstet & Gynecol, Fac Med, 38 Morohongo, Iruma, Saitama 3500495, Japan.	kajihara@saitama-med.ac.jp					Kobayashi T, 2014, J OBSTET GYNAECOL RE, V40, P1500, DOI 10.1111/jog.12426; Benson MD, 2007, MED HYPOTHESES, V68, P1019, DOI 10.1016/j.mehy.2006.09.052; Kanayama N, 2014, J OBSTET GYNAECOL RE, V40, P1507, DOI 10.1111/jog.12428; Kobayashi H, 1997, HUM PATHOL, V28, P428, DOI 10.1016/S0046-8177(97)90031-9; Thomson  AJ, 2000, BEST PRACT RES CL OB, V14, P19, DOI 10.1053/beog.1999.0061; Benson MD, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/946576; Awad IT, 2001, EUR J ANAESTH, V18, P410, DOI 10.1046/j.0265-0215.2001.00859.x; Bastien JL, 1998, ANESTH ANALG, V87, P124, DOI 10.1097/00000539-199807000-00027; CHEUNG ANY, 1994, ARCH GYNECOL OBSTET, V255, P101, DOI 10.1007/s004040050036; CLARK SL, 1995, AM J OBSTET GYNECOL, V172, P1158, DOI 10.1016/0002-9378(95)91474-9; CLARK SL, 1986, AM J OBSTET GYNECOL, V154, P104; COURTNEY LD, 1970, BRIT MED J, V1, P691; Furuta N, 2012, PLACENTA, V33, P24, DOI 10.1016/j.placenta.2011.10.007; Kajihara T, 2009, MED MOL MORPHOL, V42, P216, DOI 10.1007/s00795-009-0466-7; Kajihara T, 2006, MED MOL MORPHOL, V39, P203, DOI 10.1007/s00795-006-0334-7; Kanayama N, 2011, J OBSTET GYNAECOL RE, V37, P58, DOI 10.1111/j.1447-0756.2010.01319.x; KOBAYASHI H, 1993, AM J OBSTET GYNECOL, V168, P848; LAU GKK, 1994, MED SCI LAW, V34, P213; LEE W, 1986, AM J OBSTET GYNECOL, V155, P999; Levy R, 2004, ACTA ANAESTH SCAND, V48, P1214, DOI 10.1111/j.1399-6576.2004.00511.x; Oi H, 1998, SEMIN THROMB HEMOST, V24, P479, DOI 10.1055/s-2007-996043; PLAUCHE WC, 1983, AM J OBSTET GYNECOL, V147, P982; Romero Roberto, 2009, AM J OBSTET GYNECOL, V201; Yang JI, 2006, J REPROD MED, V51, P64	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	JUN	2015	41	6					870	875		10.1111/jog.12650		6	Obstetrics & Gynecology	Obstetrics & Gynecology	CJ8II	WOS:000355743000006		
J	Suzuki, K; Itoh, H; Mukai, M; Yamazaki, K; Uchida, T; Maeda, H; Oda, M; Yamaki, E; Suzuki, H; Kanayama, N				Suzuki, Kazunao; Itoh, Hiroaki; Mukai, Mari; Yamazaki, Kaori; Uchida, Toshiyuki; Maeda, Hideki; Oda, Motoki; Yamaki, Etsuko; Suzuki, Hiroaki; Kanayama, Naohiro			Measurement of maternal cerebral tissue hemoglobin on near-infrared time-resolved spectroscopy in the peripartum period	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						delivery; eclampsia; hypertension; near-infrared spectroscopy; pregnancy	REVERSIBLE ENCEPHALOPATHY SYNDROME; PLACENTAL OXYGENATION; OPTICAL-PROPERTIES; PREGNANCY; NIRS; SATURATION; ANESTHESIA; MORTALITY; DEATHS	AimTo measure cerebral tissue hemoglobin in uncomplicated and complicated pregnant women during the peripartum period. MethodsTime-resolved spectroscopy (TRS-20) can measure absolute concentration of oxygenated, deoxygenated, and total tissue hemoglobin based on the transit time of individual photons. Therefore, we used TRS-20 to measured tissue hemoglobin in the hemi-prefrontal lobes of normotensive pregnant women with (n=51) or without (n=19) epidural anesthesia, hypertensive pregnant women with pre-eclampsia (n=10), a pregnant woman with acute onset of hypertension soon after delivery, and a hypertensive woman after hemorrhagic stroke in delivery. ResultsCyclic labor concomitant with intra-abdominal pressure caused synergistic elevation in cerebral tissue hemoglobin. In contrast, epidural anesthesia reduced the amplitude of the cyclic increase of cerebral tissue hemoglobin in normotensive pregnant women. Hypertension in labor due to pre-eclampsia increased the amplitude of synergistic elevation of cerebral tissue hemoglobin caused by cyclic labor and intra-abdominal pressure. A prolonged high basal level of cerebral tissue hemoglobin was observed in a case of acute onset of hypertension soon after delivery. A decrease in cerebral tissue hemoglobin in the hemi-prefrontal lobe was observed in a woman 2h after the onset of hemorrhagic stroke in labor. ConclusionsTRS-20 can detect specific changes in maternal cerebral tissue hemoglobin level in response to physiological and pathophysiological changes in delivery. Thus, it represents a promising new conventional tool for maternal cerebral monitoring in the peripartum period.	[Suzuki, Kazunao; Itoh, Hiroaki; Mukai, Mari; Yamazaki, Kaori; Uchida, Toshiyuki; Kanayama, Naohiro] Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Hamamatsu, Shizuoka 4313192, Japan; [Maeda, Hideki; Oda, Motoki; Yamaki, Etsuko; Suzuki, Hiroaki] Hamamatsu Photon KK, Hamamatsu, Shizuoka, Japan	Itoh, H (reprint author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	hitou-endo@umin.ac.jp			Ministry of Education, Science, Culture and Sports, Japan [25462554, 25670490, 24390273]	The authors thank Mrs Nahoko Hakamada, Mrs Yumiko Yamamoto, and Mrs Naoko Kondo for their assistance with the manuscript. This study was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Culture and Sports, Japan (no. 25462554, no. 25670490 and no. 24390273).	[Anonymous], 2002, OBSTET GYNECOL, V99, P159; Hamaoka T, 2000, J BIOMED OPT, V5, P102, DOI 10.1117/1.429975; Berg CJ, 2003, OBSTET GYNECOL, V101, P289, DOI 10.1016/S0029-7844(02)02587-5; Ijichi S, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1899184; NISHIMURA RA, 1986, MAYO CLIN PROC, V61, P211; PATTERSON MS, 1989, APPL OPTICS, V28, P2331, DOI 10.1364/AO.28.002331; Ijichi S, 2005, PEDIATR RES, V58, P568, DOI 10.1203/01.PDR.0000175638.98041.0E; Bartynski WS, 2008, AM J NEURORADIOL, V29, P1036, DOI 10.3174/ajnr.A0928; Kakogawa J, 2010, AM J PERINAT, V27, P463, DOI 10.1055/s-0030-1247600; Kawamura T, 2007, AM J PERINAT, V24, P161, DOI 10.1055/s-2006-958155; Kakogawa J, 2010, AM J PERINAT, V27, P25, DOI 10.1055/s-0029-1234038; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Madsen PL, 1999, PROG NEUROBIOL, V58, P541, DOI 10.1016/S0301-0082(98)00093-8; Ghulmiyyah L, 2012, SEMIN PERINATOL, V36, P56, DOI 10.1053/j.semperi.2011.09.011; Berg CJ, 2005, OBSTET GYNECOL, V106, P1228, DOI 10.1097/01.AOG.0000187894.71913.e8; Stevens CJ, 2012, BRIT J RADIOL, V85, P1566, DOI 10.1259/bjr/25273221; Bushnell C, 2011, STROKE RES TREAT, V2011, DOI [10.4061/2011/858134, DOI 10.4061/2011/858134]; Cunningham FG, 2010, WILLIAMS OBSTET, V23rd, P1164; Cunningham FG, 2010, WILLIAMS OBSTET, P706; Cunningham FG, 2010, WILLIAMS OBSTET, P136; Hoshino T, 2010, ADV EXP MED BIOL, V662, P491, DOI 10.1007/978-1-4419-1241-1_71; Khan M, 2013, INT J STROKE, V8, P265, DOI 10.1111/j.1747-4949.2012.00853.x; Kinoshita T, 2003, CLIN IMAG, V27, P307, DOI 10.1016/S0899-7071(02)00592-2; Lovell AT, 1997, ADV EXP MED BIOL, V428, P213; Lovell AT, 1997, ADV EXP MED BIOL, V428, P629; Mathieu Daniel, 2007, Int J Low Extrem Wounds, V6, P273, DOI 10.1177/1534734607310299; MELROSE EB, 1984, S AFR MED J, V65, P161; Oda M, 2000, SPIE, V4160, P204; Oda M, 1999, SPIE, V3597, P611; Ohmae E, 2007, J BIOMED OPT, V12; RICHARDS A, 1988, J NEUROL NEUROSUR PS, V51, P416, DOI 10.1136/jnnp.51.3.416; Silva Marcos, 2010, Local Reg Anesth, V3, P143, DOI 10.2147/LRA.S10237; Soucek Miroslav, 2009, Clin Cardiol, V32, pE32, DOI 10.1002/clc.20390; Suzuki Kazunao, 2009, Congenital Anomalies, V49, P71, DOI 10.1111/j.1741-4520.2009.00226.x; Suzukin K, 2012, CLIN EXP OBSTET GYN, V39, P293; van Kraaij DJ, 1999, J AM GERIATR SOC, V47, P1384; Vardi M, 2008, EUR J VASC ENDOVASC, V35, P68, DOI 10.1016/j.ejvs.2007.07.015; Veltkamp R, 2000, J NEUROL NEUROSUR PS, V69, P824, DOI 10.1136/jnnp.69.6.824; Yamada E, 2008, CLIN PHYSIOL FUNCT I, V28, P216, DOI 10.1111/j.1475-097X.2008.00798.x; Yamazaki K, 2013, CLIN PHYSIOL FUNCT I, V33, P109, DOI 10.1111/cpf.12001; Yokose N, 2010, ADV EXP MED BIOL, V662, P505, DOI 10.1007/978-1-4419-1241-1_73	41	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	JUN	2015	41	6					876	883		10.1111/jog.12639		8	Obstetrics & Gynecology	Obstetrics & Gynecology	CJ8II	WOS:000355743000007		
J	Nakajima, A; Ueda, Y; Sameshima, H; Ikenoue, T				Nakajima, Akira; Ueda, Yuto; Sameshima, Hiroshi; Ikenoue, Tsuyomu			Intracerebral antioxidant ability of mature rats after neonatal hypoxic-ischemic brain injury estimated using the microdialysis-electron spin resonance method	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						antioxidant ability; ascorbic acid; glutathione; hypoxia-ischemia; microdialysis-electron spin resonance method; neonatal rat	IN-VIVO; LIPID-PEROXIDATION; EXTRACELLULAR LEVELS; FREE-RADICALS; NEWBORN RATS; NITRIC-OXIDE; HIPPOCAMPUS; GLUTATHIONE; DAMAGE; ACID	AimThe intracerebral antioxidant ability of mature rats after neonatal hypoxic-ischemic (HI) brain injury was estimated using the microdialysis-electron spin resonance method. Material and MethodsSeven-day-old Wistar rats were subjected to a modified Levine's procedure for producing HI brain injury. After HI insult, pups were returned and reared with their dams. Seven weeks after HI insult, their intracerebral antioxidant abilities were measured using the microdialysis-electron spin resonance method after the intraperitoneal injection of 3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine-1-oxyl. Ascorbic acid, L-cysteine, and glutathione (GSH) were also determined. The rats without HI insult were used as a control. ResultsThe decay rate of 3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine-1-oxyl in the non-ligated side of the cerebral hemisphere of the HI group was significantly larger than that of the control group. The amounts of ascorbic acid in the perfusate from the non-ligated side of the HI group were about four times larger than those of the control group. The amounts of L-cysteine and GSH of the HI group were about 10 times larger than those of the control group. ConclusionsThe antioxidant ability in the non-ligated sides of the cerebral hemispheres of the mature rats 7 weeks after neonatal HI insult was higher than that of the control group. Higher amounts of ascorbic acid and GSH supported the higher antioxidant ability. The increase of the intracerebral antioxidant ability of the non-ligated side indicates the compensation of motor function for the lost side. The present results should offer important insights into the prognosis for hypoxic-ischemic encephalopathy.	[Nakajima, Akira; Sameshima, Hiroshi; Ikenoue, Tsuyomu] Miyazaki Univ, Sect Obstet & Gynecol, Dept Reprod & Dev Med, Fac Med, Miyazaki, Japan; [Ueda, Yuto] Miyazaki Univ, Sect Psychiat, Dept Clin Neurosci, Miyazaki, Japan	Sameshima, H (reprint author), Miyazaki Univ, Sect Obstet & Gynecol, Dept Reprod & Dev Med, Fac Med, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.	hsameshima@med.miyazaki-u.ac.jp					Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Liu K, 2009, BRAIN RES, V1253, P161, DOI 10.1016/j.brainres.2008.11.096; Bobko AA, 2007, FREE RADICAL BIO MED, V42, P404, DOI 10.1016/j.freeradbiomed.2006.11.007; Ikeda T, 2001, BEHAV BRAIN RES, V118, P17, DOI 10.1016/S0166-4328(00)00287-4; LEVINE S, 1960, AM J PATHOL, V36, P1; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Wallin C, 2000, DEV BRAIN RES, V125, P51, DOI 10.1016/S0165-3806(00)00112-7; MORTOLA JP, 1992, AM J PHYSIOL, V263, pR267; Aotani H, 1998, No To Shinkei, V50, P339; ASSALI NS, 1974, AM J OBSTET GYNECOL, V120, P411; Crespi F, 1996, NEUROSCI LETT, V215, P189; Hayashi Y, 2002, BRAIN RES, V941, P107, DOI 10.1016/S0006-8993(02)02614-8; HILLERED L, 1990, NEUROSCI LETT, V113, P328, DOI 10.1016/0304-3940(90)90606-A; Ikeno S, 2000, J Obstet Gynaecol Res, V26, P227; Moor E, 2001, NEUROSCI LETT, V316, P169, DOI 10.1016/S0304-3940(01)02394-1; Nakajima A, 2011, APPL MAGN RESON, V40, P535, DOI 10.1007/s00723-011-0230-8; Noor JI, 2005, AM J OBSTET GYNECOL, V193, P1703, DOI 10.1016/j.ajog.2005.03.069; Ota A, 1997, AM J OBSTET GYNECOL, V177, P519, DOI 10.1016/S0002-9378(97)70139-X; PukaSundvall M, 1997, BRAIN RES, V750, P325, DOI 10.1016/S0006-8993(97)00024-3; Ueda Y, 2003, NEUROCHEM RES, V28, P1895, DOI 10.1023/A:1026136211759; Ueda Y, 2007, BRAIN RES, V1178, P20, DOI 10.1016/j.brainres.2007.08.022; Ueda Y, 2004, NEUROCHEM RES, V29, P1695, DOI 10.1023/B:NERE.0000035804.80383.a1; Ueda Y, 2005, NEUROCHEM RES, V30, P1117, DOI 10.1007/s11064-005-7586-9; Ueda Y, 2006, EXP BRAIN RES, V169, P117, DOI 10.1007/s00221-005-0122-y; Ueda Y, 2007, NEUROSCI LETT, V417, P46, DOI 10.1016/j.neulet.2007.02.031; Yokoyama H, 2004, MAGN RESON IMAGING, V22, P1305, DOI 10.1016/j.jmri.2004.09.003	27	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	JUN	2015	41	6					884	889		10.1111/jog.12660		6	Obstetrics & Gynecology	Obstetrics & Gynecology	CJ8II	WOS:000355743000008		
J	Kataoka, K; Tomiya, Y; Sakamoto, A; Kamada, Y; Hiramatsu, Y; Nakatsuka, M				Kataoka, Kumie; Tomiya, Yumi; Sakamoto, Ai; Kamada, Yasuhiko; Hiramatsu, Yuji; Nakatsuka, Mikiya			Altered autonomic nervous system activity in women with unexplained recurrent pregnancy loss	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						anxiety; autonomic nervous system; depression; heart rate variability; recurrent pregnancy loss	HEART-RATE-VARIABILITY; PSYCHOSOCIAL STRESS; DEPRESSION; ANXIETY; HEALTH	AimAutonomic nervous system activity was studied to evaluate the physical and mental state of women with unexplained recurrent pregnancy loss (RPL). MethodsHeart rate variability (HRV) is a measure of beat-to-beat temporal changes in heart rate and provides indirect insight into autonomic nervous system tone and can be used to assess sympathetic and parasympathetic tone. We studied autonomic nervous system activity by measuring HRV in 100 women with unexplained RPL and 61 healthy female volunteers as controls. The degree of mental distress was assessed using the Kessler 6 (K6) scale. ResultsThe K6 score in women with unexplained RPL was significantly higher than in control women. HRV evaluated on standard deviation of the normal-to-normal interval (SDNN) and total power was significantly lower in women with unexplained RPL compared with control women. These indices were further lower in women with unexplained RPL 4. On spectral analysis, high-frequency (HF) power, an index of parasympathetic nervous system activity, was significantly lower in women with unexplained RPL compared with control women, but there was no significant difference in the ratio of low-frequency (LF) power to HF power (LF/HF), an index of sympathetic nervous system activity, between the groups. ConclusionsThe physical and mental state of women with unexplained RPL should be evaluated using HRV to offer mental support. Furthermore, study of HRV may elucidate the risk of cardiovascular diseases and the mechanisms underlying unexplained RPL.	[Kataoka, Kumie; Tomiya, Yumi; Nakatsuka, Mikiya] Okayama Univ, Grad Sch Hlth Sci, Okayama, Japan; [Sakamoto, Ai; Hiramatsu, Yuji] Okayama Univ, Grad Sch Med, Dent & Pharmaceut Sci, Okayama, Japan; [Kataoka, Kumie; Nakatsuka, Mikiya] Okayama Univ Hosp, Infertil Specialist Consultat Ctr, Okayama, Japan; [Sakamoto, Ai; Kamada, Yasuhiko; Hiramatsu, Yuji; Nakatsuka, Mikiya] Okayama Univ Hosp, Dept Obstet & Gynecol, Okayama, Japan	Nakatsuka, M (reprint author), Okayama Univ, Grad Sch Hlth Sci, Kita Ku, 2-5-1 Shikata, Okayama, Okayama 7008558, Japan.	mikiya@cc.okayama-u.ac.jp					American Society of Reproductive Medicine, 2013, FERTIL STERIL, V99, P22; Cohen H, 2006, AUTON NEUROSCI-BASIC, V128, P1, DOI 10.1016/j.autneu.2005.06.007; Blackmore ER, 2011, BRIT J PSYCHIAT, V198, P373, DOI 10.1192/bjp.bp.110.083105; Christiansen OB, 2005, FERTIL STERIL, V83, P821, DOI 10.1016/j.fertnstert.2004.12.018; Jarczok MN, 2013, NEUROSCI BIOBEHAV R, V37, P1810, DOI 10.1016/j.neubiorev.2013.07.004; Habara T, 2002, HUM REPROD, V17, P190, DOI 10.1093/humrep/17.1.190; Yang CCH, 2000, AM J PHYSIOL-HEART C, V278, pH1269; Kemp AH, 2013, INT J PSYCHOPHYSIOL, V89, P288, DOI 10.1016/j.ijpsycho.2013.06.018; Togo F, 2009, IND HEALTH, V47, P589; Wahbeh H, 2013, APPL PSYCHOPHYS BIOF, V38, P57, DOI 10.1007/s10484-012-9208-z; Chandola T, 2010, NEUROSCI BIOBEHAV R, V35, P51, DOI 10.1016/j.neubiorev.2009.11.005; Haensel A, 2008, PSYCHONEUROENDOCRINO, V33, P1305, DOI 10.1016/j.psyneuen.2008.08.007; Bajko Z, 2012, J NEUROL SCI, V317, P112, DOI 10.1016/j.jns.2012.02.014; Braeken MAKA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083186; Chang HA, 2013, PSYCHIAT INVEST, V10, P326, DOI 10.4306/pi.2013.10.4.326; Chen PL, 2012, NEUROL SCI, V314, P57; Klaperski S, 2014, J BEHAV MED, V37, P1118, DOI 10.1007/s10865-014-9562-9; Janssen I, 2011, AM HEART J, V161, P1186, DOI 10.1016/j.ahj.2011.03.017; Kagami M, 2012, HUM REPROD, V27, P787, DOI 10.1093/humrep/der441; Kutteh WH, 1999, CURR OPIN OBSTET GYN, V11, P435, DOI 10.1097/00001703-199910000-00004; Lin X, 1996, AM J ORTHPHYCHIATY, V66, P262; Lok IH, 2010, FERTIL STERIL, V93, P1966; Lok IH, 2007, BEST PRACT RES CLIN, V21, P229; Nakatsuka M, 2012, RECENT ADV CARDIOVAS, P123; Olafiranye O., 2011, MIND BRAIN, V2, P32; Simula S, 2014, CLIN AUTON RES, V24, P31, DOI 10.1007/s10286-013-0220-z; Sugiura-Ogasawara M, 2013, J OBSTET GYNAECOL, V33, P171, DOI 10.3109/01443615.2012.745490; Camm AJ, 1996, CIRCULATION, V93, P1043; Wang YM, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-187	29	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	JUN	2015	41	6					912	918		10.1111/jog.12653		7	Obstetrics & Gynecology	Obstetrics & Gynecology	CJ8II	WOS:000355743000012		
J	Matsumoto, M; Koike, S; Matsubara, S; Kashima, S; Ide, H; Yasunaga, H				Matsumoto, Masatoshi; Koike, Soichi; Matsubara, Shigeki; Kashima, Saori; Ide, Hiroo; Yasunaga, Hideo			Selection and concentration of obstetric facilities in Japan: Longitudinal study based on national census data	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						health policy; health resource; Japan; obstetric delivery; workload	SIZE	AimA shortage of obstetricians with increased workload is a social problem in Japan. In response, the government and professional bodies have accelerated the selection and concentration' of obstetric facilities. The aim of this study was to evaluate the recent trend of selection and concentration. MethodsWe used data on the number of deliveries and of obstetricians in each hospital and clinic in Japan, according to the Static Survey of Medical Institutions in 2005, 2008 and 2011. To evaluate the inter-facility equality of distribution of the number of deliveries, number of obstetricians and number of deliveries per obstetrician, Gini coefficients were calculated. ResultsThe number of obstetric hospitals decreased by 20% and the number of deliveries per hospital increased by 26% between 2005 and 2011. Hospital obstetricians increased by 16% and the average number of obstetricians per hospital increased by 19% between 2008 and 2011. Gini coefficient of deliveries has significantly decreased. In contrast, Gini coefficient of deliveries per obstetrician has significantly increased. The degree of increase in obstetricians and of decrease in deliveries per obstetrician was largest at the hospitals with the highest proportion of cesarean sections. The proportion of obstetric hospitals with the optimal volume of deliveries and obstetricians, as defined by Japan Society of Obstetrics and Gynecology, was 4% in 2008, and it had doubled to 8.1% 3 years later. ConclusionThe selection and concentration of obstetric facilities is progressing rapidly and effectively in Japan.	[Matsumoto, Masatoshi] Hiroshima Univ, Dept Community Based Med Syst, Fac Med, Hiroshima 7348551, Japan; [Kashima, Saori] Hiroshima Univ, Dept Publ Hlth & Hlth Policy, Inst Biomed & Hlth Sci, Hiroshima 7348551, Japan; [Koike, Soichi] Jichi Med Univ, Div Hlth Policy & Management, Ctr Community Med, Shimotsuke, Tochigi, Japan; [Matsubara, Shigeki] Jichi Med Univ, Dept Obstet & Gynecol, Shimotsuke, Tochigi, Japan; [Ide, Hiroo] Chiba Univ Hosp, Dept Med Community Network & Discharge, Chiba, Japan; [Yasunaga, Hideo] Univ Tokyo, Sch Publ Hlth, Dept Clin Epidemiol & Hlth Econ, Tokyo, Japan	Matsumoto, M (reprint author), Hiroshima Univ, Dept Community Based Med Syst, Fac Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	matmo10@jb3.so-net.ne.jp		Yasunaga, Hideo/0000-0002-6017-469X	Health Labour Sciences Research Grant of the Ministry of Health, Labour and Welfare, Tokyo, Japan [H25 - Research on Region Medical - 006]	This study was supported by Health Labour Sciences Research Grant of the Ministry of Health, Labour and Welfare, Tokyo, Japan (H25 - Research on Region Medical - 006).	Biewen M, 2002, J ECONOMETRICS, V108, P317, DOI 10.1016/S0304-4076(01)00138-5; [Anonymous], 2007, NY TIMES; Lasswell SM, 2010, JAMA-J AM MED ASSOC, V304, P992, DOI 10.1001/jama.2010.1226; Heller G, 2002, INT J EPIDEMIOL, V31, P1061, DOI 10.1093/ije/31.5.1061; Ide H, 2009, J OBSTET GYNAECOL RE, V35, P761, DOI 10.1111/j.1447-0756.2009.01039.x; Ishikawa K, 2013, J JAPAN SOC PERINAT, V493, P83; Japan Association of Obstetricians and Gynecologists, SURV REP IMPR WORK C; Japan Society of Obstetrics and Gynecology, 2013, PROP BETT WORK ENV O; Japan Society of Obstetrics and Gynecology (Unno N as representative), GRAND DES IMPR OBST; Matsubara S, 2014, ACTA OBSTET GYN SCAN, V93, P218, DOI 10.1111/aogs.12272; Ministry of Health Labour and Welfare, SUMM PAYM SYST MED S; Ministry of Health Labour and Welfare, FISC BUDG SEC NUMB D; Ministry of Health Labour and Welfare, WORK PART REP NAT SU; Ministry of Health Labour and Welfare, PLAN SEC OBST CAR; Ministry of Health Labour and Welfare, 2009 FISC BUDG EM CA; Ministry of Health Labour and Welfare, VIT STAT 2012; Ministry of Health Labour and Welfare, FISC BUDG MAT CHILD; Ministry of Health Labour and Welfare, ABSTRACT PHYS DENT P; Ministry of Health Labour and Welfare, SUMM STRAT SEC DOCT; Ministry of Health Labour and Welfare Ministry of Education Culture Sports Science and Technology Ministry of Internal Affairs, FAC CONC PED OBST RE; Ministry of Health Labour andWelfare, ATT DOC 142 SOC INS; Moster D, 1999, ARCH DIS CHILD, V80, pF221; Nakai A, TRENDS OBGYN CAR WOR; Snowden JM, 2012, AM J OBSTET GYNECOL, V207; Sudo A, 2013, ISRN OBSTET GYNECOL, V2013; The Editorial of The Japan Times, 2007, JAPAN TIMES; Unno N (Japan Society of Obstetrics and Gynecology), DECR OBST FAC THEIR	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	JUN	2015	41	6					919	925		10.1111/jog.12663		7	Obstetrics & Gynecology	Obstetrics & Gynecology	CJ8II	WOS:000355743000013		
J	Nakae, R; Matsuzaki, S; Egawa-Takata, T; Mimura, K; Kanagawa, T; Kimura, T				Nakae, Ruriko; Matsuzaki, Shinya; Egawa-Takata, Tomomi; Mimura, Kazuya; Kanagawa, Takeshi; Kimura, Tadashi			Pregnancy management for a patient with graft occlusion after right iliac artery bypass surgery	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						bypass surgery; graft occlusion; pregnancy	INFRAINGUINAL BYPASS; DISEASE; PATENCY; GUIDELINES	We describe an extremely rare case of a pregnant woman who had a successful delivery despite developing bypass graft occlusion after right external iliac bypass surgery. External and common iliac artery bypass surgery is often performed when arteriosclerosis obliterans or thromboangiitis obliterans result in iliac artery occlusion or when revascularization is required because of iliac artery injury. Because arteriosclerosis obliterans and thromboangiitis obliterans rarely develop in young women or girls, most physicians have little experience with graft occlusion after iliac artery bypass surgery. Here we describe and discuss the published work pertaining to this extremely rare case.	[Nakae, Ruriko; Matsuzaki, Shinya; Egawa-Takata, Tomomi; Mimura, Kazuya; Kanagawa, Takeshi; Kimura, Tadashi] Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, Osaka, Japan	Matsuzaki, S (reprint author), Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	zacky@gyne.med.osaka-u.ac.jp					Henke PK, 2004, J VASC SURG, V39, P357, DOI 10.1016/j.jvs.2003.08.030; Mohler ER, 2003, ARCH INTERN MED, V163, P2306, DOI 10.1001/archinte.163.19.2306; Hirsch AT, 2006, J AM COLL CARDIOL, V47, P1239, DOI 10.1016/j.jacc.2005.10.009; Sarac TP, 1998, J VASC SURG, V28, P446, DOI 10.1016/S0741-5214(98)70130-2; Warkentin TE, 2012, NEW ENGL J MED, V367, P2039, DOI 10.1056/NEJMe1211480; Norgren L, 2007, J VASC SURG, V45, pS5, DOI 10.1016/j.jvs.2006.12.037; Rooke TW, 2011, J AM COLL CARDIOL, V58, P2020, DOI 10.1016/j.jacc.2011.08.023; Abbruzzese TA, 2004, J VASC SURG, V39, P1178, DOI 10.1016/j.jvs.2003.12.027; Bleich AT, 2007, AM J OBSTET GYNECOL, V197; Grenon S Marlene, 2009, N Engl J Med, V361, pe40, DOI 10.1056/NEJMvcm0807012; HUNINK MGM, 1994, MED DECIS MAKING, V14, P71, DOI 10.1177/0272989X9401400109; Muntner P, 2005, DIABETES CARE, V28, P1981, DOI 10.2337/diacare.28.8.1981; Pursell R, 2005, BRIT J SURG, V92, P565, DOI 10.1002/bjs.4880; Visser K, 2001, J VASC SURG, V33, P123, DOI 10.1067/mva.2001.109745	14	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	JUN	2015	41	6					979	984		10.1111/jog.12636		6	Obstetrics & Gynecology	Obstetrics & Gynecology	CJ8II	WOS:000355743000024		
J	Mabuchi, Y; Yahata, T; Kobayashi, A; Tanizaki, Y; Minami, S; Ino, K				Mabuchi, Yasushi; Yahata, Tamaki; Kobayashi, Aya; Tanizaki, Yuko; Minami, Sawako; Ino, Kazuhiko			Vaginal carcinoma in a young woman who underwent fertility-sparing treatment involving chemotherapy and conservative surgery	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						chemotherapy; fertility-sparing treatment; squamous cell carcinoma; vaginal carcinoma	SQUAMOUS-CELL CARCINOMA; CANCER; IRINOTECAN	Vaginal carcinoma is a rare gynecological malignancy that is usually treated by radiation therapy and/or surgery combined with chemotherapy. Here, we report a case of invasive vaginal carcinoma in a young woman who underwent fertility-sparing treatment involving neoadjuvant chemotherapy and conservative surgery. A 36-year-old non-parous woman had a solid tumor in the vagina. Positron emission tomography/computed tomography showed a tumor in the vagina with high FDG uptake (SUV=17.33) but no metastatic lesions. The patient was diagnosed with vaginal squamous cell carcinoma, FIGO stage I, T1N0M0. Because she wished to retain her fertility, neoadjuvant chemotherapy consisting of irinotecan hydrochloride and nedaplatin was initiated. After four courses of chemotherapy, partial vaginectomy was carried out and the pathological diagnosis of the residual lesion was VAIN 3. Following two further courses of the same chemotherapy, she obtained complete response, and has shown no evidence of disease for 14 months.	[Mabuchi, Yasushi; Yahata, Tamaki; Kobayashi, Aya; Tanizaki, Yuko; Minami, Sawako; Ino, Kazuhiko] Wakayama Med Univ, Dept Obstet & Gynecol, Sch Med, Wakayama 6410012, Japan	Mabuchi, Y (reprint author), Wakayama Med Univ, Dept Obstet & Gynecol, Sch Med, 811-1 Kimiidera, Wakayama 6410012, Japan.	booyan@wakayama-med.ac.jp					Creasman WT, 1998, CANCER, V83, P1033, DOI 10.1002/(SICI)1097-0142(19980901)83:5<1033::AID-CNCR30>3.0.CO;2-6; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Hiniker SM, 2013, GYNECOL ONCOL, V131, P380, DOI 10.1016/j.ygyno.2013.08.012; Yamaguchi S, 2012, ONCOL REP, V28, P487, DOI 10.3892/or.2012.1814; Benedetti Panici Pierluigi, 2008, Gynecol Oncol, V111, P307, DOI 10.1016/j.ygyno.2008.07.005; Cutillo G, 2006, GYNECOL ONCOL, V103, P234, DOI 10.1016/j.ygyno.2006.02.032; Fujita K, 2005, GYNECOL ONCOL, V98, P513, DOI 10.1016/j.ygyno.2005.05.007; Larsson GL, 2013, GYNECOL ONCOL, V129, P406, DOI 10.1016/j.ygyno.2013.02.004; Umesaki N, 1999, ONCOL REP, V6, P123	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	JUN	2015	41	6					989	992		10.1111/jog.12638		4	Obstetrics & Gynecology	Obstetrics & Gynecology	CJ8II	WOS:000355743000026		
J	Nakaya, S; Usami, A; Yorimoto, T; Miyazawa, M				Nakaya, Satoshi; Usami, Atsushi; Yorimoto, Tomohito; Miyazawa, Mitsuo			Characteristic Chemical Components and Aromaactive Compounds of the Essential Oils from Ranunculus nipponicus var. submersus Used in Japanese Traditional Food	JOURNAL OF OLEO SCIENCE			English	Article						Ranunculus nipponicus var. submersus; essential oil; GC-O; aroma extract dilution analysis (AEDA); odor activity value (OAV)	AROMA EVALUATION; CONSTITUENTS; PLANTS	Ranunculus nipponicus var. submersus is an aquatic macrophyte; it is known as a wild edible plant in Japan for a long time. In this study, the essential oils from the fresh and dried aerial parts of R. nipponicus var. submersus were extracted by hydrodistillation and analyzed by gas chromatography (GC) and GC-mass spectrometry (GC-MS). Moreover, important aroma-active compounds were also detected in the oil using GC-olfactometry (GC-O) and aroma extract dilution analysis (AEDA). Thus, 98 compounds (accounting for 93.86%) of the oil were identified. The major compounds in fresh plant oil were phytol (41.94%), heptadecane (5.92%), and geranyl propionate (5.76%), while those of. Dried plant oil were beta-ionone (23.54%), 2-hexenal (8.75%), and dihydrobovolide (4.81%). The fresh and dried oils had the green-floral and citrus-floral odor, respectively. The GC-0 and AEDA results show that phenylacetaldehyde (green, floral odor, FD-factor = 8) and beta-ionone (violet-floral odor, FD-factor = 8) were the most characteristic odor compounds of the fresh oils. beta-Cyclocitral (citrus odor, FD-factor = 64) and beta-ionone (violet-floral odor, FD-factor = 64) were the most characteristic odor compounds of the dried oil. These compounds are thought to contribute to the flavor of R. nipponicus var. submersus.	[Nakaya, Satoshi; Usami, Atsushi; Yorimoto, Tomohito; Miyazawa, Mitsuo] Kindai Univ, Kinki Univ, Fac Sci & Engn, Dept Appl Chem, Higashiosaka, Osaka 5778502, Japan	Miyazawa, M (reprint author), Kindai Univ, Kinki Univ, Fac Sci & Engn, Dept Appl Chem, 3-4-1 Kowakae, Higashiosaka, Osaka 5778502, Japan.	miyazawa@apch.kindai.ac.jp					Adams RP, 2001, IDENTIFICATION ESSEN; Miyazawa M, 2012, PHYTOCHEM ANALYSIS, V23, P208, DOI 10.1002/pca.1344; Bruneton J, 1999, PHARMACOGNOSY PHYTOC; Cavalli JF, 2006, FLAVOUR FRAG J, V21, P111, DOI 10.1002/ffj.1531; Chalannavar R. K., 2013, Journal of Medicinal Plants Research, V7, P783; Guth H., 2001, FLAVOR CHEM 30 YEARS, P377; Heywood V, 2007, FLOWERING PLANT FAMI; Kashima Y, 2014, CHEM BIODIVERS, V11, P396, DOI 10.1002/cbdv.201300234; Keiichi K., 2007, J PL RES, V120, P167; Ladislav K., 2012, CHEM BIODIVERS, V9, P151; Metin T., 2003, ACTA AGR SCAND B-S P, V53, P129; MIYAZAWA M, 1988, AGR BIOL CHEM TOKYO, V52, P1053; Miyazawa M., 1988, AGR BIOL CHEM TOKYO, V52, P2961; Miyazawa M., 1978, PHYTOCHEMISTRY, V16, P1054; MIYAZAWA M, 1978, J AGR CHEM SOC JPN, V52, P449; Miyazawa M, 2008, J ESSENT OIL BEAR PL, V11, P413; MIYAZAWA M, 1979, AGR BIOL CHEM TOKYO, V43, P2199; Miyazawa M, 2009, J OLEO SCI, V58, P163, DOI 10.5650/jos.58.163; Miyazawa M., 1979, NIPPON NOGEI KAGAKU, V53, P349; Miyazawa M, 2006, NAT PROD RES, V20, P542, DOI 10.1080/14786410500182037; Miyazawa M., 2007, J ESSENT OIL RES, V20, P125; MIYAZAWA M, 1977, YAKUGAKU ZASSHI, V97, P120; Miyazawa Mitsuo, 2007, J Oleo Sci, V56, P457; Nakamura A, 2013, J OLEO SCI, V62, P645, DOI 10.5650/jos.62.645; Utsumi Y, 2011, INT J FOOD PROP, V14, P1090, DOI 10.1080/10942910903580942; Wang H., 2009, HUNAN ZHONGYIYAO DAX, V29, P44; Xu Fang, 2011, Zhong Yao Cai, V34, P1887; Xu R., 2013, NANCHANG DAXUE XUEBA, V35, P22	28	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUN	2015	64	6					595	601		10.5650/jos.ess14265		7	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CJ3BX	WOS:000355359500001		
J	Saito, H; Kurogi, H; Chow, S; Mochioka, N				Saito, Hiroaki; Kurogi, Hiroaki; Chow, Seinen; Mochioka, Noritaka			Variation of Lipids and Fatty Acids of the Japanese Freshwater Eel, Anguilla japonica, during Spawning Migration	JOURNAL OF OLEO SCIENCE			English	Article						arachidonic acid; chemoecology; spawning migration; fatty acid; marine lipid; monounsaturated fatty acid; polyunsaturated fatty acid	RAINBOW-TROUT; FISH; WILD; MARINE; LARVAE; SURVIVAL; TISSUES; MUSCLE; GROWTH; PREY	The lipid and fatty acid composition of the muscle of the wild Japanese freshwater eel, Anguilla japonica, was analyzed between the initial and terminal stages of spawning migration to clarify the relationship between lipid physiology and maturation. Triacylglycerols were the only major component in the initial-phase eels, which contained high levels of lipids, while comparatively low triacylglycerol levels were observed in terminal-phase eels (Mariana silvers) at spawning area. Significant levels of plasmalogens were found in its phosphatidylethanolamine, different from other common fish species, which have their little levels. The major fatty acids in A. japonica depot triacylglycerols were 14:0, 16:0, 18:0, 16:1n-7, 18:1n-18:1n-9, and 18:2n-6. Noticeable levels of 20:4n-6, EPA, 22:5n-3, and DHA were also found in initial-phase sample TAG at the yellow and initial silver stages. High 18:2n-6 levels in all A. japonica lipids were similar to those in other common freshwater fishes. In all A. japonica tissue phospholipids, high levels of n-6 and n-3 PUFA, such as 20:4n-6, EPA, 22:5n-3, and DHA, were observed except for the matured terminal female sample. High n-6 PUFA levels in terminal-phase samples caught at the spawning area suggest that A. japonica maintains and uses initial fatty acids from inland waters without feeding during long spawning migrations. The post-spawning sample, containing low levels of 20:4n-6 and DHA with unusually high levels of its degradation products (18:3n-6, 20:2n-6, and 18:4n-3), indicates that A. japonica may finally use its most important PUFA as energy for spawning before ending its life.	[Saito, Hiroaki] Ishikawa Prefectural Univ, Nonoichi, Ishikawa 9218836, Japan; [Kurogi, Hiroaki] Natl Res Inst Aquaculture, Yokosuka Chosha, Yokosuka, Kanagawa 2380316, Japan; [Chow, Seinen] Natl Res Inst Fisheries Sci, Kanazawa Ku, Yokohama, Kanagawa 2368648, Japan; [Mochioka, Noritaka] Kyushu Univ, Fukuoka 8128581, Japan	Saito, H (reprint author), Ishikawa Prefectural Univ, 1-308 Suematsu, Nonoichi, Ishikawa 9218836, Japan.	hiroakis@ishikawa-pu.ac.jp			Fisheries Research Agency of Japan	We are especially indebted to the captains and crew of the Research Vessels "Kaiyo-maru" and "Hokko-maru" of the Fisheries Agency for their cooperation and enthusiasm throughout the work. The authors also thank Ms. Sumiko Terada, Ms. Noriko Tsutsui, and Mr. Akihito Takashima for their skilled technical assistance. This work was supported in part by the research projects from the Fisheries Research Agency of Japan. H. S. performed all aspects of the study including the design of the experiments, analyzing the data, and writing the manuscript. H. K., S. C., and N. M. caught the animals and determined biological data.	Aarestrup K, 2009, SCIENCE, V325, P1660, DOI 10.1126/science.1178120; OWEN JM, 1975, LIPIDS, V10, P528, DOI 10.1007/BF02532354; Deibel D, 2012, LIPIDS, V47, P623, DOI 10.1007/s11745-012-3670-5; van Ginneken VJT, 2005, REV FISH BIOL FISHER, V15, P367, DOI 10.1007/s11160-006-0005-8; Dunstan GA, 1996, AQUACULTURE, V140, P115, DOI 10.1016/0044-8486(95)01191-9; van Ginneken VJT, 2000, NATURE, V403, P156, DOI 10.1038/35003110; Saito H, 2014, FOOD CHEM, V145, P135, DOI 10.1016/j.foodchem.2013.08.011; YAMADA K, 1980, B JPN SOC SCI FISH, V46, P1231; Tocher DR, 2010, AQUAC RES, V41, P717, DOI 10.1111/j.1365-2109.2008.02150.x; Saito H, 2005, LIPIDS, V40, P941, DOI 10.1007/s11745-005-1455-4; Durif C, 2005, J FISH BIOL, V66, P1025, DOI 10.1111/j.1095-8649.2005.00662.x; Bessonart M, 1999, AQUACULTURE, V179, P265, DOI 10.1016/S0044-8486(99)00164-7; Saito H, 1999, LIPIDS, V34, P1073, DOI 10.1007/s11745-999-0459-4; Chow S, 2010, MAR ECOL PROG SER, V402, P233, DOI 10.3354/meps08448; PANKHURST NW, 1984, CAN J ZOOL, V62, P1143; Villalta M, 2005, AQUACULTURE, V245, P193, DOI 10.1016/j.aquaculture.2004.11.035; FOLCH J, 1957, J BIOL CHEM, V226, P497; Kaneniwa M, 2000, J AM OIL CHEM SOC, V77, P825, DOI 10.1007/s11746-000-0132-3; Koizumi K, 2014, J OLEO SCI, V63, P461, DOI 10.5650/jos.ess13224; Koven W, 2001, AQUACULTURE, V193, P107, DOI 10.1016/S0044-8486(00)00479-8; Medina I., 2006, LIPIDS, V41, P473; Mukhopadhyay T., 2004, J OLEO SCI, V53, P323; NEVENZEL JC, 1985, COMP BIOCHEM PHYS B, V82, P293, DOI 10.1016/0305-0491(85)90244-5; Oku T, 2009, FOOD CHEM, V115, P436, DOI 10.1016/j.foodchem.2008.12.032; Osako K, 2006, LIPIDS, V41, P473, DOI 10.1007/s11745-006-5121-7; Osako K, 2006, LIPIDS, V41, P713, DOI 10.1007/s11745-006-5022-9; Ozaki Y, 2008, FISHERIES SCI, V74, P362, DOI 10.1111/j.1444-2906.2008.01525.x; Saito H, 2012, FOOD CHEM, V131, P1104, DOI 10.1016/j.foodchem.2011.09.069; Saito H, 2012, FOOD CHEM, V135, P1718, DOI 10.1016/j.foodchem.2012.05.122; Saito H, 2014, DEEP-SEA RES PT I, V94, P150, DOI 10.1016/j.dsr.2014.09.008; Saito H., 2011, LIPIDS, V45, P537; Saito H, 2014, EUR J LIPID SCI TECH, V116, P360, DOI 10.1002/ejlt.201300230; Sargent JR, 1989, MARINE BIOGENIC LIPI, VI, P175; Shen KN, 2007, ZOOL STUD, V46, P441; SUMNER JL, 1976, J SCI FOOD AGR, V27, P933, DOI 10.1002/jsfa.2740271007; SUZUKI H, 1986, J AGR FOOD CHEM, V34, P58, DOI 10.1021/jf00067a016; van Ginneken V. J. T., 2008, J EXP BIOL, V208, P1329; YU QT, 1989, LIPIDS, V24, P79, DOI 10.1007/BF02535269	38	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUN	2015	64	6					603	616		10.5650/jos.ess14293		14	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CJ3BX	WOS:000355359500002		
J	Yoshinaga, K; Kawamura, Y; Kitayama, T; Nagai, T; Mizobe, H; Kojima, K; Watanabe, Y; Sato, S; Beppu, F; Gotoh, N				Yoshinaga, Kazuaki; Kawamura, Yoshinori; Kitayama, Takashi; Nagai, Toshiharu; Mizobe, Hoyo; Kojima, Koichi; Watanabe, Yomi; Sato, Shinichi; Beppu, Fumiaki; Gotoh, Naohiro			Regiospecific Distribution of trans-Octadecenoic Acid Positional Isomers in Triacylglycerols of Partially Hydrogenated Vegetable Oil and Ruminant Fat	JOURNAL OF OLEO SCIENCE			English	Article						trans fatty acid; triacylglycerol; hydrogenated fat; milk fat	CORONARY-HEART-DISEASE; MILK-FAT; GAS-CHROMATOGRAPHY; TRIGLYCERIDES; COLUMN; RISK; MEAT; RATS; CIS	It is revealed that binding position of fatty acid in triacylglycerol (TAG) deeply relates to the expression of its function. Therefore, we investigated the binding positions of individual trans-octadecenoic acid (trans-C18:1) positional isomers, known as unhealthy fatty acids, on TAG in partially hydrogenated canola oil (PHCO), milk fat (MF), and beef tallow (BT). The analysis was carried out by the sn-1(3)-selective transesterification of Candida antarctica Lipase B and by using a highly polar ionic liquid capillary column for gas chromatography flame ionization detection. Trans-9-C18:1, the major trans-C18:1 positional isomer, was selectively located at the sn-2 position of TAG in PHCO, although considerable amounts of trans9-C18:1 were also esterified at the sn-1(3) position. Meanwhile, trans-11-C18:1, the major isomer in MF and BT, was preferentially located at the sn-1(3) position. These results revealed that the binding position of trans-C18:1 positional isomer varies between various fats and oils.	[Yoshinaga, Kazuaki; Kitayama, Takashi; Nagai, Toshiharu; Mizobe, Hoyo; Kojima, Koichi] Tsukishima Foods Ind Co Ltd, Edogawa Ku, Tokyo 1348520, Japan; [Kawamura, Yoshinori; Beppu, Fumiaki; Gotoh, Naohiro] Tokyo Univ Marine Sci & Technol, Dept Food Sci & Technol, Minato Ku, Tokyo 1088477, Japan; [Watanabe, Yomi] Osaka Municipal Tech Res Inst, Joto Ku, Osaka 5368553, Japan; [Sato, Shinichi] Japan Food Res Labs, Nagoya Branch, Naka Ku, Nagoya, Aichi 4600011, Japan	Gotoh, N (reprint author), Tokyo Univ Marine Sci & Technol, Dept Food Sci & Technol, Minato Ku, 4-5-7 Konan, Tokyo 1088477, Japan.	ngotoh@kaiyodai.ac.jp	BEPPU, Fumiaki/O-1986-2014; GOTOH, Naohiro/O-1975-2014				American Oil Chemists' Society, 2005, 1H05 AOCS; American Oil Chemists' Society. AOCS, 1997, 1B89 AOCS; Mozaffarian D, 2006, NEW ENGL J MED, V354, P1601, DOI 10.1056/NEJMra054035; Teegala SM, 2009, J AOAC INT, V92, P1250; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; Allison DB, 1999, J AM DIET ASSOC, V99, P166, DOI 10.1016/S0002-8223(99)00041-3; Watanabe Y, 2014, J AM OIL CHEM SOC, V91, P1323, DOI 10.1007/s11746-014-2481-7; Goto H, 2012, J OLEO SCI, V61, P49, DOI 10.5650/jos.61.49; LAWSON LD, 1981, BIOCHIM BIOPHYS ACTA, V665, P60, DOI 10.1016/0005-2760(81)90232-0; Yoshinaga K, 2014, FOOD CHEM, V160, P39, DOI 10.1016/j.foodchem.2014.03.069; LUDDY FE, 1964, J AM OIL CHEM SOC, V41, P693, DOI 10.1007/BF02661412; Mozaffarian D, 2006, ATHEROSCLEROSIS SUPP, V7, P29, DOI 10.1016/j.atherosclerosissup.2006.04.007; Jakobsen MU, 2008, INT J EPIDEMIOL, V37, P173, DOI 10.1093/ije/dym243; Emken E, 2013, J OLEO SCI, V62, P245, DOI 10.5650/jos.62.245; PARODI PW, 1982, J DAIRY RES, V49, P73; AOAC International, 2001, 99606 AOAC INT; Barbano D. M., 1974, J DAIRY SCI, V58, P1; Botham K. M., 2006, HARPERS ILLUSTRATED, V27th, P210; BRECKENR.WC, 1969, CAN J BIOCHEM CELL B, V47, P761; BROCKERH.H, 1968, LIPIDS, V3, P24, DOI 10.1007/BF02530964; BROCKERH.H, 1966, BIOCHIM BIOPHYS ACTA, V116, P67, DOI 10.1016/0005-2760(66)90092-0; Chardigny JM, 2003, J NUTR, V133, P4212; Dhiman TR, 2005, CRIT REV FOOD SCI, V45, P463, DOI 10.1080/10408390591034463; EMERY RS, 1973, J DAIRY SCI, V56, P1187; FILER LJ, 1969, J NUTR, V99, P293; Gunstone F. D, 1973, J AM OIL CHEM SOC, V50, P486; Ikeda I, 1998, LIPIDS, V33, P897, DOI 10.1007/s11745-998-0286-7; Kallio H, 2006, J AM OIL CHEM SOC, V83, P407, DOI 10.1007/s11746-006-1219-6; Kosugi Y., 2002, Journal of Oleo Science, V51, P599; Kresge N., 2005, J BIOL CHEM, V280, P22; Martin JC, 1998, J AM OIL CHEM SOC, V75, P1065, DOI 10.1007/s11746-998-0114-8; Mir PS, 2003, CAN J ANIM SCI, V83, P53; Precht D, 2001, LIPIDS, V36, P827, DOI 10.1007/s11745-001-0791-8; Precht D, 1996, INT DAIRY J, V6, P791, DOI 10.1016/0958-6946(96)00004-0; The Japan Oil Chemists' Society, 2013, STAND METH AN FATS O; Wolff RL, 2000, LIPIDS, V35, P815, DOI 10.1007/S11745-000-0590-2; WOODROW IL, 1968, BIOCHIM BIOPHYS ACTA, V152, P472, DOI 10.1016/0005-2760(68)90088-X; Yoshinaga K., 2014, J NUTR BIOCH, V26, P57	38	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUN	2015	64	6					617	624		10.5650/jos.ess15008		8	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CJ3BX	WOS:000355359500003		
J	Tokuda, H; Sueyasu, T; Kontani, M; Kawashima, H; Shibata, H; Koga, Y				Tokuda, Hisanori; Sueyasu, Toshiaki; Kontani, Masanori; Kawashima, Hiroshi; Shibata, Hiroshi; Koga, Yoshihiko			Low Doses of Long-chain Polyunsaturated Fatty Acids Affect Cognitive Function in Elderly Japanese Men: A Randomized Controlled Trial	JOURNAL OF OLEO SCIENCE			English	Article						event-related potentials; P300; cognitive function; arachidonic acid; docosahexaenoic acid; eicosapentaenoic acid; long-chain polyunsaturated fatty acid	EVENT-RELATED POTENTIALS; ARACHIDONIC-ACID; DOCOSAHEXAENOIC ACID; AGED RATS; MEMBRANE-FLUIDITY; P300 LATENCY; N-3; SUPPLEMENTATION; PHOSPHOLIPIDS; INCREASES	Several studies have reported that the supplementation of long-chain polyunsaturated fatty acids (LCPUFA), such as docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and arachidonic acid (ARA) improve cognitive function in the elderly. However, the doses used in these studies were higher than general dietary LCPUFA intake levels. This randomized, double-blind, placebo-controlled trial evaluated the effects of low doses of LCPUFA supplementation corresponding to general dietary intake on cognitive function in non-demented elderly Japanese participants. Japanese men aged 55-64 years were enrolled and randomly allocated to the placebo or LCPUFA group. Participants received 4 weeks of supplementation with LCPUFA-containing oil (DHA, 300 mg/day; EPA, 100 mg/day; and ARA, 120 mg/day) or purified olive oil as placebo. Event-related potential P300, reflecting cognitive processes, was measured before and after supplementation. A total of 113 participants completed the supplementation period, and the per-protocol analysis included 69 participants. Changes in P300 latency were significantly different between the placebo group (+13.6 msec) and the LCPUFA group (-1.8 msec) after supplementation. Significant increases in DHA (+0.9%) and ARA (+0.6%) contents in plasma phospholipids were observed in the LCPUFA group; no changes were observed in the placebo group. Dietary DHA, EPA, and ARA intake were in the normal range for Japan participants and remained unchanged during the study. These results suggest that low doses of LCPUFA supplementation have the potential to improve cognitive function in elderly Japanese men.	[Tokuda, Hisanori; Sueyasu, Toshiaki; Kontani, Masanori; Kawashima, Hiroshi; Shibata, Hiroshi] Suntory Wellness Ltd, Inst Hlth Care Sci, Shimamoto, Osaka 6188503, Japan; [Koga, Yoshihiko] Kyorin Univ, Sch Med, Dept Neuropsychiat, Mitaka, Tokyo 1818611, Japan	Tokuda, H (reprint author), Suntory Wellness Ltd, Inst Hlth Care Sci, 1-1-1 Wakayamadai, Shimamoto, Osaka 6188503, Japan.	Hisanori_Tokuda@suntory.co.jp			Suntory Wellness Ltd.	This work was supported by Suntory Wellness Ltd. We thank laboratory members of institute for Health Care Science for stimulating discussions and comments of this work. We are also grateful to Noriko Osumi, the professor of Department of Developmental Neuroscience, Tohoku University Graduate School of Medicine, for helpful discussions.	Dangour AD, 2010, AM J CLIN NUTR, V91, P1725, DOI 10.3945/ajcn.2009.29121; Tokuda H, 2014, J OLEO SCI, V63, P219, DOI 10.5650/jos.ess13195; van Gelder BM, 2007, AM J CLIN NUTR, V85, P1142; Yurko-Mauro K, 2010, ALZHEIMERS DEMENT, V6, P456, DOI 10.1016/j.jalz.2010.01.013; Kawakita E, 2006, NEUROSCIENCE, V139, P991, DOI 10.1016/j.neuroscience.2006.01.021; SODERBERG M, 1991, LIPIDS, V26, P421, DOI 10.1007/BF02536067; Fukaya T, 2007, NEUROBIOL AGING, V28, P1179, DOI 10.1016/j.neurobiolaging.2006.05.023; Ninomiya T, 2013, ATHEROSCLEROSIS, V231, P261, DOI 10.1016/j.atherosclerosis.2013.09.023; Suzuki H, 1998, MECH AGEING DEV, V101, P119, DOI 10.1016/S0047-6374(97)00169-3; Zhang XN, 2014, CELL BIOCHEM BIOPHYS, V70, P1591, DOI 10.1007/s12013-014-0100-8; Murakami K, 2008, NUTRITION, V24, P140, DOI 10.1016/j.nut.2007.10.013; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; Konagai C, 2013, CLIN INTERV AGING, V8, P1247, DOI 10.2147/CIA.S50349; Titova OE, 2013, AGE, V35, P1495, DOI 10.1007/s11357-012-9453-3; Elmadfa I, 2009, ANN NUTR METAB, V55, P56, DOI 10.1159/000228996; Sakuradani E, 1999, EUR J BIOCHEM, V260, P208, DOI 10.1046/j.1432-1327.1999.00131.x; McGahon B, 1997, NEUROSCIENCE, V81, P9; Griskova I, 2005, ACTA NEUROBIOL EXP, V65, P73; Gamoh S, 2001, CLIN EXP PHARMACOL P, V28, P266, DOI 10.1046/j.1440-1681.2001.03437.x; Nishizaki Y, 2014, AM J CARDIOL, V113, P441, DOI 10.1016/j.amjcard.2013.10.011; Beck A. T., 2003, MANUAL BECK DEPRESSI; Beydoun MA, 2008, PUBLIC HEALTH NUTR, V11, P17, DOI 10.1017/S1368980007000080; Daiello L. A., ALZHEIMERS IN PRESS; FOLCH J, 1957, J BIOL CHEM, V226, P497; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gao Q, 2011, J NUTR HEALTH AGING, V15, P32, DOI 10.1007/s12603-011-0010-z; Hashimoto M., 2012, J AGING RES CLIN PRA, V1, P193; Hirayasu Y, 2000, CLIN NEUROPHYSIOL, V111, P187, DOI 10.1016/S1388-2457(99)00233-3; Hirota S, 2010, PROSTAG LEUKOTR ESS, V83, P83, DOI 10.1016/j.plefa.2010.05.003; Ishikura Y, 2009, NEUROPSYCHOBIOLOGY, V60, P73, DOI 10.1159/000236447; Ito J, 1991, Rinsho Byori, V39, P859; Kakutani S, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-241; Kobayashi M, 2001, EUR J CLIN NUTR, V55, P643, DOI 10.1038/sj.ejcn.1601194; Kotani S, 2003, NEUROSCI RES, V46, P453, DOI 10.1016/S0168-0102(03)00123-8; Mahmoudi Mohammad Jafar, 2014, J Diabetes Metab Disord, V13, P34, DOI 10.1186/2251-6581-13-34; McNamara RK, 2008, PROSTAG LEUKOTR ESS, V78, P293, DOI 10.1016/j.plefa.2008.04.001; Nilsson A, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-99; Ogura T, 2010, LIPIDS, V45, P137, DOI 10.1007/s11745-010-3386-3; Otsuka R, 2013, LIPIDS, V48, P719, DOI 10.1007/s11745-013-3763-9; POLICH J, 1990, INT J PSYCHOPHYSIOL, V9, P237, DOI 10.1016/0167-8760(90)90056-J; POLICH J, 1986, ELECTROEN CLIN NEURO, V65, P236, DOI 10.1016/0168-5597(86)90059-6; POLICH J, 1994, INT J PSYCHOPHYSIOL, V17, P25, DOI 10.1016/0167-8760(94)90052-3; SEMLITSCH HV, 1995, PHARMACOPSYCHIATRY, V28, P134, DOI 10.1055/s-2007-979605; SKLARE DA, 1984, ELECTROEN CLIN NEURO, V59, P420, DOI 10.1016/0168-5597(84)90043-1; Stough C., 2012, NEUROBIOL AGING, V33, p824el; Takahashi M, 1996, JPN J REHABIL MED, V33, P710; TAKAHASHI R, 1991, J NUTR SCI VITAMINOL, V37, P401; Tokuda H, 2014, NEUROSCI RES, V88, P58, DOI 10.1016/j.neures.2014.08.002; van de Rest O., 2008, NEUROLOGY, V71, P430, DOI DOI 10.1212/01.WNL.0000324268.45138.86; Whalley LJ, 2004, AM J CLIN NUTR, V80, P1650; YAMORI Y, 1985, J NUTR SCI VITAMINOL, V31, P417	51	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUN	2015	64	6					633	644		10.5650/jos.ess15009		12	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CJ3BX	WOS:000355359500005		
J	Sano, J; Noda, R; Watanabe, S; Aoyama, T; Sato, Y; Kayashita, J; Muto, N				Sano, Junya; Noda, Ryuji; Watanabe, Shinji; Aoyama, Toshiaki; Sato, Yukinori; Kayashita, Jun; Muto, Norio			Basic Evaluation of Gelatinous Fat to Improve Properties of Nursing Care Food	JOURNAL OF OLEO SCIENCE			English	Article						nursing care food; minced food; protein energy malnutrition (PEM); gelatinous fat	MALNUTRITION	Nursing care food, made smooth and soft by adding a substantial amount of water, has been provided to elderly people who exhibit a decline in chewing and swallowing function. However, this is associated with problems such as an increase in the volume of meals and a decrease in the nutritional value per unit weight, causing malnutrition. To resolve these issues, we aimed to develop gelatinous fat suitable for processing nursing care food. We compared several types of oil and fat including this gelatinous fat using rheology measurement and sensory evaluation. In the measurement of fat alone using a dynamic viscoelastometer, the gelatinous fat had the highest values of storage elastic modulus (G') and loss elastic modulus (G '') at the predetermined ranges of temperature and frequency. In the measurement of fat mixed with food using a creep meter, the gelatinous fat showed a significantly lower level of firmness and a higher level of cohesiveness than other types of fat. In the sensory evaluation, food processed with gelatinous fat was evaluated to be better than food processed with no addition or the addition of another type of fat in terms of softness, smoothness, low feeling of residual food, and palatability. These results suggest that the newly developed gelatinous fat is most suitable for nursing care food processing among the types of fat examined. It is expected that nursing care food processed with gelatinous fat can facilitate the consumption of food with high energy and reduce the risk of malnutrition in the elderly.	[Sano, Junya; Noda, Ryuji; Watanabe, Shinji; Aoyama, Toshiaki] Nisshin Oillio Grp Ltd, Chuo Ku, Tokyo 1048285, Japan; [Sano, Junya; Sato, Yukinori; Kayashita, Jun; Muto, Norio] Prefectural Univ Hiroshima, Grad Sch Comprehens Sci Res, Minami Ku, Hiroshima 7348558, Japan	Sano, J (reprint author), Nisshin Oillio Grp Ltd, Chuo Ku, 1-23-1 Shinkawa, Tokyo 1048285, Japan.	j-sano@nisshin-oillio.com					Devoto G, 2006, CLIN CHEM, V52, P2281, DOI 10.1373/clinchem.2006.080366; Fock RA, 2008, J NUTR SCI VITAMINOL, V54, P371, DOI 10.3177/jnsv.54.371; Fujisaki T., 2008, J JPN SOC FOOD SCI, V55, P78; Funami T., 2007, J JPN SOC BIORHEOL, V21, P16; Hada M., 2001, JPN J GERODONT, V16, P220; Higaki K, 2003, J AM OIL CHEM SOC, V80, P263, DOI 10.1007/s11746-003-0687-z; Ishihara M., 2000, J HOME ECON JPN, V51, P481; Izawa S, 2006, CLIN NUTR, V25, P962, DOI 10.1016/j.clnu.2006.05.006; Kikutani T., 2003, JPN J GERODONT, V18, P10; Kojo A., 2004, Japanese Journal of Nutrition and Dietetics, V62, P329; Kojo A., 2004, Japanese Journal of Nutrition and Dietetics, V62, P153; Kuroda R., 2004, JPN J DYS REHAB, V8, P10; Maruyama T., 2006, Journal of Japanese Society of Nutrition and Food Science, V59, P207; Nagai Harumi, 1994, Japanese Journal of Nutrition, V52, P307; Nagai H., 1991, JAPANESE J PUBLIC HL, V38, P853; Nagai Harumi, 1995, Japanese Journal of Nutrition, V53, P369; Nosaka N., 2010, J JPN SOC CLIN NUTR, V32, P52; Oogoshi H., 2007, J INTEGR STUDY DIET, V17, P288; Ooyama T, 2009, J JPN SOC FOOD SCI, V56, P14; Osuga Y., 2001, B TOYAMA COLLEGE, V36, P105; Sakai M., 2006, J JPN SOC BIORHEOL, V20, P10; Sakai M., 2001, B PREFECT U HIROSHIM, V2, P49; Sano J., 2011, B PREFECT U HIROSHIM, V6, P7; Sato K., 2005, OLEOSCIENCE, V5, P3; Sugiyama M., 2000, JPN J NUTR ASSESS, V17, P553; Takahashi J., 1987, Journal of Home Economics, Japan [Kaseigaku Zasshi], V38, P107; Takahashi T., 2008, Japanese Journal of Nutrition and Dietetics, V66, P231; Takeyama S., 2008, REP IWATE PREFECT IN, V14, P28; Wakabayashi H., 2014, J JPN SOC PARENT ENT, V29, P837; Watanabe Y, 2011, J JPN SOC FOOD SCI, V58, P51; Yagi J., 2010, REP SHIZUOKA PREFECT, V45, P109; Yamashita Y., 2004, B HIROSHIMA BUNKA GA, P15; Yamauchi T., 2008, B NAGOYA WOMENS U, V54, P89; Yoshimura M., 2004, J JAPANESE SOC MASTI, V14, P50	34	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUN	2015	64	6					653	662		10.5650/jos.ess14279		10	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CJ3BX	WOS:000355359500007		
J	Fukamachi, T; Endo, T; Yabuki, Y; Ogura, T; Misono, T; Torigoe, K; Sakai, K; Abe, M; Sakai, H				Fukamachi, Takumi; Endo, Takeshi; Yabuki, Yukinori; Ogura, Taku; Misono, Takeshi; Torigoe, Kanjiro; Sakai, Kenichi; Abe, Masahiko; Sakai, Hideki			Synthesis of Silica Nanotube Using Myelin Figure as Template and their Formation Mechanism	JOURNAL OF OLEO SCIENCE			English	Article						silica nanotube; myeline figure; sol-gel reaction; freeze fracture TEM	MESOPOROUS SILICA; GROWTH; COPOLYMER; TRIBLOCK; PHOSPHATIDYLCHOLINE; MEMBRANES; ARRAYS; TUBES	Silica nanotubes are synthesized through a sol-gel reaction of tetraethyl orthosilicate (TEOS) using myelin figures of Pluronic P123 as the structure-directing agent. The simultaneous progression of the formation of molecular assemblies that act as templates and the formation of silica frameworks though a sol-gel reaction of the silica precursor is a characteristic of this reaction system. The synthesized silica nanotubes were characterized using transmission electron microscopy (TEM), nitrogen adsorption/desorption measurements, and Fourier-transform infrared spectroscopy (FT-IR). The silica nanotubes were unilamellar with diameters of approximately 30 urn, membrane thicknesses of approximately 10 nm, and lengths exceeding a few hundred nanometers. The Brunauer-Emmett-Teller (BET) specific surface area was 589.46 m(2)/g. Silica nanotubes can also be obtained using other Pluronic surfactants that can form myelin figures. In this work, we also investigated the formation mechanism of the silica nanotubes. The typical diameter of a myelin figure is a few tens of micrometers. However, myelin figures with diameters of approximately 10 mu m can form in systems with TEOS because bifurcation is induced by minute silica nuclei that form during the initial reaction between TEOS and water. Freeze fracture TEM (FF-TEM) observations revealed the existence of myelin figures with diameters of 20 to 30 nm, which are the same size and shape as the synthesized silica nanotubes. These results indicate that bifurcation of the myelin figures is induced by the silica nuclei that form via the initial reaction of TEOS, which result in the formation of bifurcated myelin figures with diameters of similar to 10 mu m. Myelin figures with diameters of 20 to 30 nm form on the surface, and they become templates where the reaction of TEOS progresses to form silica nanotubes with diameters of approximately 30 nm.	[Fukamachi, Takumi; Endo, Takeshi; Yabuki, Yukinori; Ogura, Taku; Sakai, Kenichi; Sakai, Hideki] Tokyo Univ Sci, Fac Sci & Technol, Dept Pure & Appl Chem, Noda, Chiba 2788510, Japan; [Endo, Takeshi; Misono, Takeshi; Torigoe, Kanjiro; Sakai, Kenichi; Abe, Masahiko; Sakai, Hideki] Tokyo Univ Sci, Res Inst Sci & Technol, Noda, Chiba 2788510, Japan	Endo, T (reprint author), Tokyo Univ Sci, Fac Sci & Technol, Dept Pure & Appl Chem, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	takeendo@rs.noda.tus.ac.jp; hisakai@rs.noda.tus.ac.jp					Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548; Liang ZJ, 2004, CHEM-EUR J, V10, P4910, DOI 10.1002/chem.200400005; Yu YT, 2008, ADV FUNCT MATER, V18, P541, DOI 10.1002/adfm.200700593; Yang ZL, 2003, ANGEW CHEM INT EDIT, V42, P4201, DOI 10.1002/anie.200250808; WANKA G, 1994, MACROMOLECULES, V27, P4145, DOI 10.1021/ma00093a016; Stein A, 2000, ADV MATER, V12, P1403, DOI 10.1002/1521-4095(200010)12:19<1403::AID-ADMA1403>3.0.CO;2-X; Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i; Fan R, 2003, J AM CHEM SOC, V125, P5254, DOI 10.1021/ja034163; Lin HP, 1996, SCIENCE, V273, P765, DOI 10.1126/science.273.5276.765; Zhao DY, 2000, CHEM MATER, V12, P275, DOI 10.1021/cm9911363; Peddireddy K, 2013, LANGMUIR, V29, P15682, DOI 10.1021/la4038588; BECK S, 1992, J AM CHEM SOC, V114, P10834, DOI DOI 10.1021/JA00053A020; Brazhnik P. K., 2005, LANGMUIR, V21, P10814; Dave H, 2003, J COLLOID INTERF SCI, V264, P76, DOI 10.1016/S0021-9797(03)00319-9; Goltner G. C., 1997, ADV MATER, V9, P431; Haran M, 2002, COLLOID SURFACE A, V205, P21, DOI 10.1016/S0927-7757(01)01144-X; Inagaki S., 1993, CHEM COMMUN, V84, P680; KRESGE T, 1992, NATURE, V359, P710; Lei S, 2010, LANGMUIR, V26, P4288, DOI 10.1021/la9033707; Li M, 2008, ANGEW CHEM INT EDIT, V47, P9476, DOI 10.1002/anie.200803231; Ma J, 2014, J SOL-GEL SCI TECHN, V69, P364, DOI 10.1007/s10971-013-3228-x; MISHIMA K, 1987, BIOCHIM BIOPHYS ACTA, V904, P149, DOI 10.1016/0005-2736(87)90097-6; NAKAMURA H, 1995, ADV MATER, V7, P871, DOI 10.1002/adma.19950071013; NAKAMURA H, 1995, J AM CHEM SOC, V117, P2651, DOI 10.1021/ja00114a031; Paula J. A., 2011, CHEM-EUR J, V17, P3228; Reissig L, 2010, LANGMUIR, V26, P15192, DOI 10.1021/la102726r; Sakka S, 1988, SCI SOL GEL METHOD; SAKURAI I, 1989, BIOCHIM BIOPHYS ACTA, V985, P101, DOI 10.1016/0005-2736(89)90110-7; SAKURAI I, 1984, BIOCHIM BIOPHYS ACTA, V777, P347, DOI 10.1016/0005-2736(84)90439-5; Satishkumar C. B., 1997, J MATER RES, V12, P604; Taribagil R, 2005, J COLLOID INTERF SCI, V289, P242, DOI 10.1016/j.jcis.2005.01.004; Wang LF, 2009, J COLLOID INTERF SCI, V335, P264, DOI 10.1016/j.jcis.2009.03.091; Wu XW, 2007, CHEM MATER, V19, P1577, DOI 10.1021/cm062368m; Yu MH, 2009, CHEM LETT, V38, P442, DOI 10.1246/cl.2009.442	34	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUN	2015	64	6					663	672		10.5650/jos.ess15029		10	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CJ3BX	WOS:000355359500008		
J	Terada, S; Sekine, S; Aoyama, T				Terada, Shin; Sekine, Seiji; Aoyama, Toshiaki			Dietary Intake of Medium- and Long-chain Triacylglycerols Prevents the Progression of Hyperglycemia in Diabetic ob/ob Mice	JOURNAL OF OLEO SCIENCE			English	Article						medium-chain fatty acids; type 2 diabetes; insulin; hyperglycemia; ob/ob mouse	GASTRIC-INHIBITORY POLYPEPTIDE; FATTY-ACID-METABOLISM; INSULIN-RESISTANCE; BODY-FAT; RATS; GLUCOSE; TRIGLYCERIDES; ACCUMULATION	We examined the effects of the dietary intake of medium- and long-chain triacylglycerol (MLCT) on hyperglycemia in diabetic ob/ob mice. Six-week-old male ob/ob mice were fed a diet containing longchain triacylglycerol (LCT) or MLCT for 3 wks. During the dietary treatment, we determined the plasma glucose and insulin concentrations in the fed state once a week. Whereas the body weights did not differ between the two groups, the total intra-abdominal fat mass was significantly higher in the MLCT group compared to the LCT group. The plasma glucose levels in the freely fed state gradually increased during the 3-wk dietary treatment in the LCT but not MLCT group, although the daily food intake did not differ between the two groups. In the fed state, the MLCT group's plasma glucose was significantly lower and their insulin concentrations were significantly higher than those observed in the LCT group (p<0.01). Plasma glucose concentrations at the end of dietary treatment (3rd wk) were negatively correlated with plasma insulin concentrations (p<0.05) and tended to be inversely related to total intra-abdominal fat mass (p=0.08). These results suggest that the dietary intake of MLCT may delay the progression of hyperglycemia in ob/ob mice, possibly through the stimulation of glucose uptake in intra-abdominal fat tissue caused by enhanced insulin secretion.	[Terada, Shin] Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan; [Sekine, Seiji; Aoyama, Toshiaki] Nisshin OilliO Grp Ltd, Cent Res Lab, Yokosuka, Kanagawa 2390832, Japan	Terada, S (reprint author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, 3-8-1 Komaba, Tokyo 1538902, Japan.	terada@idaten.c.u-tokyo.ac.jp					FLATT PR, 1984, J ENDOCRINOL, V101, P249, DOI 10.1677/joe.0.1010249; BACH AC, 1982, AM J CLIN NUTR, V36, P950; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Han JR, 2007, METABOLISM, V56, P985, DOI 10.1016/j.metabol.2007.03.005; Kim W, 2008, PHARMACOL REV, V60, P470, DOI 10.1124/pr.108.000604; Masood A, 2005, J LIPID RES, V46, P2299, DOI 10.1194/jlr.D500022-JLR200; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; Aoyama Tosiaki, 2007, J Med Invest, V54, P385, DOI 10.2152/jmi.54.385; DENTON RM, 1967, BIOCHEM J, V104, P416; ECKEL RH, 1992, DIABETES, V41, P641, DOI 10.2337/diabetes.41.5.641; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRAYN KN, 1980, J LIPID RES, V21, P139; Kasai M, 2003, ASIA PAC J CLIN NUTR, V12, P151; KWASOWSKI P, 1985, BIOSCIENCE REP, V5, P701, DOI 10.1007/BF01117003; Lowry OH, 1972, FLEXIBLE SYSTEM ENZY; Noguchi O., 2002, J OLEO SCI, V51, P699; Shinohara H, 2005, BIOSCI BIOTECH BIOCH, V69, P1811, DOI 10.1271/bbb.69.1811; Shinohara H, 2006, BIOSCI BIOTECH BIOCH, V70, P2919, DOI 10.1271/bbb.60335; Takeuchi H, 2001, J NUTR SCI VITAMINOL, V47, P267; Terada S, 2012, NUTRITION, V28, P92, DOI 10.1016/j.nut.2011.04.008	20	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUN	2015	64	6					683	688		10.5650/jos.ess14287		6	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CJ3BX	WOS:000355359500010		
J	Fukuoka, T; Yoshida, S; Nakamura, J; Koitabashi, M; Sakai, H; Abe, M; Kitamoto, D; Kitamoto, H				Fukuoka, Tokuma; Yoshida, Shigenobu; Nakamura, Junichi; Koitabashi, Motoo; Sakai, Hideki; Abe, Masahiko; Kitamoto, Dai; Kitamoto, Hiroko			Application of Yeast Glycolipid Biosurfactant, Mannosylerythritol Lipid, as Agrospreaders	JOURNAL OF OLEO SCIENCE			English	Article						biosurfactant; mannosylerythritol lipid; agrochemical spreader; wetting ability; biopesticide	PSEUDOZYMA-ANTARCTICA; SURFACES; CELLS	The spreading property of mannosylerythritol lipids (MELs) was investigated in connection with our search for new application in agriculture. The wetting ability of MEL solutions for hydrophobic surfaces was evaluated based on contact angle measurements for several surfactant solutions on abiotic and biotic surfaces. The contact angle of MEL-A solution on a hydrophobic plastic surface at 100 s after placement decreased to 8.4 degrees, and those of other MEL solutions decreased more significantly compared to those of commonly-used nonionic surfactants. In addition, the contact angle of MEL solutions also dropped down to around 100 on various plant leaf surfaces. MEL solutions, in particular, efficiently spread even on poorly wettable Gramineae plant surfaces on which general nonionic surfactant solutions could not. Moreover, the wetting Ability of MEL solutions was found to be greatly affected by the structural difference in their carbohydrate configuration. Furthermore, surface pretreatment with MEL solution led to more efficient spreading and fixing of microbial cells onto plant leaf surface compared to several conventional surfactants used in this study. These results suggested that MELs have a potential to use as a natural bio-based spreading agent, particularly as agrochemical spreader for biopesticides.	[Fukuoka, Tokuma; Kitamoto, Dai] Natl Inst Adv Ind Sci & Technol, Res Inst Innovat Sustainable Chem, Tsukuba, Ibaraki 3058565, Japan; [Yoshida, Shigenobu; Koitabashi, Motoo; Kitamoto, Hiroko] Natl Inst Agroenvironm Sci, Biofunct Div, Tsukuba, Ibaraki 3058604, Japan; [Nakamura, Junichi; Sakai, Hideki; Abe, Masahiko] Tokyo Univ Sci, Fac Sci & Technol, Noda, Chiba 2788510, Japan	Kitamoto, H (reprint author), Natl Inst Agroenvironm Sci, Biofunct Div, 3-1-3 Kan Nondai, Tsukuba, Ibaraki 3058604, Japan.	kitamoto@affrc.go.jp			Science and Technology Research Promotion Program for Agriculture, Forestry, Fishers and Food Industry [25017A]	This work was partly financially supported by the Science and Technology Research Promotion Program 25017A for Agriculture, Forestry, Fishers and Food Industry.	Adamson A. W., 1997, PHYS CHEM SURFACES; Lee KS, 2008, ADV COLLOID INTERFAC, V144, P54, DOI 10.1016/j.cis.2008.08.005; Sachdev DP, 2013, APPL MICROBIOL BIOT, V97, P1005, DOI 10.1007/s00253-012-4641-8; Fukuoka T, 2008, CARBOHYD RES, V343, P555, DOI 10.1016/j.carres.2007.11.023; Morita T, 2007, APPL MICROBIOL BIOT, V74, P307, DOI 10.1007/s00253-006-0672-3; Matar OK, 2009, SOFT MATTER, V5, P3801, DOI 10.1039/b908719m; Morita T, 2010, J OLEO SCI, V59, P267, DOI 10.5650/jos.59.267; Morita T, 2009, J OLEO SCI, V58, P639, DOI 10.5650/jos.58.639; Theodorakis PE, 2014, CURR OPIN COLLOID IN, V19, P283, DOI 10.1016/j.cocis.2014.04.007; Yoshida S, 2014, APPL MICROBIOL BIOT, V98, P6419, DOI 10.1007/s00253-014-5675-x; Banat IM, 2010, APPL MICROBIOL BIOT, V87, P427, DOI 10.1007/s00253-010-2589-0; Chengara AV, 2008, ADV POLYM SCI, V218, P117, DOI 10.1007/12_2008_164; Fukuoka T, 2012, CARBOHYD RES, V351, P81, DOI 10.1016/j.carres.2012.01.019; Kawashima K., 2009, PLANT PROTECTION, V63, P233; KITAMOTO D, 1990, AGR BIOL CHEM TOKYO, V54, P37; Kitamoto D, 2009, CURR OPIN COLLOID IN, V14, P315, DOI 10.1016/j.cocis.2009.05.009; Lang S, 2002, CURR OPIN COLLOID IN, V7, P12, DOI 10.1016/S1359-0294(02)00007-9; Morita T, 2010, J OLEO SCI, V59, P451, DOI 10.5650/jos.59.451; Morita T, 2009, BIOTECHNOL APPL BIOC, V53, P39, DOI 10.1042/BA20090033; Morita T, 2013, APPL MICROBIOL BIOT, V97, P4691, DOI 10.1007/s00253-013-4858-1; Seaman D., 1982, SOLUTION BEHAVIOR SU, P1365; Taborsky V., 1992, FAO AGR SERVICES B, V96; WATANABE T, 1991, J PESTIC SCI, V16, P651	23	1	1	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUN	2015	64	6					689	695		10.5650/jos.ess15017		7	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CJ3BX	WOS:000355359500011		
J	Ishida, H; Hasegawa, H; Sato, K				Ishida, Hiroto; Hasegawa, Hiroshi; Sato, Ken-ichi			Hardware Scale and Performance Evaluation of a Compact Subsystem Modular Optical Cross Connect That Adopts Tailored Add/Drop Architecture	JOURNAL OF OPTICAL COMMUNICATIONS AND NETWORKING			English	Article						Add/drop configuration; Large scale node architecture; Optical cross-connect; Reconfigurable add/drop multiplexer; Routing and wavelength assignment; Switching, circuit	OXC	We propose novel highly scalable subsystem modular optical cross connect (OXC) architectures that use an efficient add/drop part to connect each transponder bank to a limited number of incoming/outgoing fibers. We investigate the performance and hardware scale of the proposed architectures in two add/drop configurations. Numerical evaluations prove that the proposed architectures attain almost the same routing performance as the equivalent conventional single large-scale OXC with an ideal colorless, directionless, and contentionless add/drop part, while enabling substantial hardware scale reduction.	[Ishida, Hiroto; Hasegawa, Hiroshi; Sato, Ken-ichi] Nagoya Univ, Dept Elect Engn & Comp Sci, Chikusa Ku, Nagoya, Aichi 4648603, Japan	Ishida, H (reprint author), Nagoya Univ, Dept Elect Engn & Comp Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.	h_isida@echo.nuee.nagoya-u.ac.jp			NICT; KAKENHI [26220905]	This work was partly supported by NICT (lambda-Reach Project) and KAKENHI (26220905).	Tanaka Y, 2015, OPT EXPRESS, V23, P5994, DOI 10.1364/OE.23.005994; Naruse F, 2012, J OPT COMMUN NETW, V4, pB26, DOI 10.1364/JOCN.4.000B26; Cisco Visual Networking Index, 2013, CISCO VISUAL NETWORK; Collings B., 2011, EUR C EXH OPT COMM E; Egorov R., 2013, OPT FIB COMM C NAT F; Feuer M. D., 2012, OPT FIB COMM C NAT F; Filer M., 2014, OPT FIB COMM C OFC S; Ishida H., 2014, OPT FIB COMM C NAT F; Ishida H., 2013, INT C TRANSP OPT NET; Ishii Y., 2009, P EUR C EXH OPT COMM; Iwai Y, 2013, OPT EXPRESS, V21, P478, DOI 10.1364/OE.21.000478; Iwai Y., 2012, AS COMM PHOT C ACP G; Iwai Y., 2013, OPT FIB COMM C NAT F; Jensen R., 2010, EUR C EXH OPT COMM E; Jensen R. A., 2011, OPT FIB COMM C NAT F; Kawai T., 2011, OPT FIB COMM C NAT F; Kim I., 2012, OPT FIB COMM C NAT F; Morea A., 2014, OPT FIB COMM C OFC S; Niwa T., 2012, OPT FIB COMM C NAT F; Pagnan P., 2009, PHOTONICS SWITCHING; Palacharla P., 2011, OPT FIB COMM C NAT F; Rizzelli G., 2013, OPT FIB COMM C NAT F; Sato K, 2009, J OPT COMMUN NETW, V1, pA81, DOI 10.1364/JOCN.1.000A81; Sato K., 2014, INT C OPT NETW DES M, P144; Takagi T., 2011, OPT FIB COMM C NAT F; Tanaka Y., 2014, OPT FIB COMM C NAT F; Tanaka Y., 2013, EUR C EXH OPT COMM E; Watanabe T., 2011, OPT FIB COMM C NAT F; Wellbrock G., 2013, OFC NFOEC 2013 MARK; Woodward S., 2013, OPT FIB COMM C NAT F; Younce R, 2013, J OPT COMMUN NETW, V5, pA267, DOI 10.1364/JOCN.5.00A267; Zami T., 2012, OPT FIB COMM C NAT F; Zami T., 2011, EUR C EXH OPT COMM E	33	0	0	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	1943-0620	1943-0639		J OPT COMMUN NETW	J. Opt. Commun. Netw.	JUN	2015	7	6					586	596		10.1364/JOCN.7.000586		11	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Optics; Telecommunications	Computer Science; Optics; Telecommunications	CK0ZU	WOS:000355935400009		
J	Izumi, M; Migita, K; Nakamura, M; Jiuchi, Y; Sakai, T; Yamaguchi, T; Asahara, T; Nishino, Y; Bito, S; Miyata, S; Kumagai, K; Osaki, M; Mawatari, M; Motokawa, S				Izumi, Masahiro; Migita, Kiyoshi; Nakamura, Mashio; Jiuchi, Yuka; Sakai, Tatsuya; Yamaguchi, Takayuki; Asahara, Tomihiko; Nishino, Yuichiro; Bito, Seiji; Miyata, Shigeki; Kumagai, Kenji; Osaki, Makoto; Mawatari, Masaaki; Motokawa, Satoru			Risk of Venous Thromboembolism after Total Knee Arthroplasty in Patients with Rheumatoid Arthritis	JOURNAL OF RHEUMATOLOGY			English	Article						DEEP VEIN THROMBOSIS; RHEUMATOID ARTHRITIS; THROMBOPROPHYLAXIS; TOTAL KNEE ARTHROPLASTY; VENOUS THROMBOEMBOLISM; OSTEOARTHRITIS	DEEP-VEIN THROMBOSIS; TOTAL JOINT ARTHROPLASTY; TOTAL HIP-REPLACEMENT; COMPLETE COMPRESSION ULTRASOUND; MAJOR ORTHOPEDIC-SURGERY; MOLECULAR-WEIGHT HEPARIN; PULMONARY-EMBOLISM; D-DIMER; PREVENTION; THROMBOPROPHYLAXIS	Objective. To compare the incidence of venous thromboembolism (VTE) following total knee arthroplasty (TKA) between patients with rheumatoid arthritis (RA) and those with osteoarthritis (OA). Methods. The subjects were composed of 1084 Japanese patients with OA and 204 with RA. Primary effectiveness outcomes were any deep vein thrombosis (DVT) as detected by bilateral ultrasonography up to postoperative Day 10 (POD10) and pulmonary embolism (PE) up to POD28. The main safety outcomes were bleeding and death from any cause up to POD28. Plasma D-dimer levels were measured before and at POD10 after TKA. Results. The study cohort was composed of 1288 patients from 34 hospitals. There was no death up to POD28. PE occurred in 2 patients with OA and in no patients with RA. The incidence of primary effectiveness outcome was 24.3% and 24.0% in patients with OA and RA, respectively. The incidence of major bleeding up to POD28 was 1.3% and 0.5% in patients with OA and RA, respectively. No differences in the incidence of VTE (symptomatic/asymptomatic DVT plus PE) or bleeding were noted between patients with RA and OA. D-dimer levels on POD10 were significantly higher in patients with OA compared with those with RA. Also, D-dimer levels on POD10 were significantly lower in patients receiving fondaparinux than in patients without pharmacological prophylaxis. Conclusion. Despite some differences in demographic data, patients with RA and OA have equivalent risks of VTE and bleeding following TKA.	[Izumi, Masahiro; Migita, Kiyoshi; Jiuchi, Yuka; Sakai, Tatsuya; Yamaguchi, Takayuki; Asahara, Tomihiko; Nishino, Yuichiro; Kumagai, Kenji; Motokawa, Satoru] Japanese Natl Hosp Org NHO, Evidence Based Med EBM Study Grp, Tokyo, Japan; [Izumi, Masahiro; Migita, Kiyoshi; Jiuchi, Yuka; Sakai, Tatsuya; Yamaguchi, Takayuki; Asahara, Tomihiko; Nishino, Yuichiro; Kumagai, Kenji; Motokawa, Satoru] Japanese Study Prevent & Actual Situat Venous Thr, Tokyo, Japan; [Bito, Seiji] NHO Tokyo Med Ctr, Div Clin Epidemiol, Tokyo, Japan; [Nakamura, Mashio] Mie Univ, Dept Clin Cardiovasc Res, Grad Sch Med, Tsu, Mie 514, Japan; [Miyata, Shigeki] Natl Cerebral & Cardiovasc Ctr, Div Transfus Med, Osaka, Japan; [Osaki, Makoto] Nagasaki Univ Hosp, Dept Orthoped Surg, Nagasaki, Japan; [Mawatari, Masaaki] Saga Univ Hosp, Dept Orthoped Surg, Saga, Japan	Migita, K (reprint author), NHO Nagasaki Med Ctr, Clin Res Ctr, Kubara 2-1001-1, Omura 8568652, Japan.	migita@nagasaki-mc.com			NHO (multicenter clinical studies for evidenced-based medicine)	Supported by a grant from the NHO (multicenter clinical studies for evidenced-based medicine).	Kang JH, 2010, RHEUMATOLOGY, V49, P1409, DOI 10.1093/rheumatology/keq054; Stein PD, 2004, ANN INTERN MED, V140, P589; Kim YH, 2002, J BONE JOINT SURG BR, V84B, P566, DOI 10.1302/0301-620X.84B4.12330; Lieberman JR, 2013, J BONE JOINT SURG AM, V95A, P1801, DOI 10.2106/JBJS.L.01328; Kim SC, 2013, ARTHRIT CARE RES, V65, P1600, DOI 10.1002/acr.22039; WHITE RH, 1990, J GEN INTERN MED, V5, P304, DOI 10.1007/BF02600396; Schellong SM, 2007, J THROMB HAEMOST, V5, P1431, DOI 10.1111/j.1538-7836.2007.02570.x; Turpie AGG, 2002, ARCH INTERN MED, V162, P1833, DOI 10.1001/archinte.162.16.1833; Schellong SM, 2004, CURR OPIN PULM MED, V10, P350, DOI 10.1097/01.mcp.0000136402.24828.0e; Nurmohamed MT, 1999, ANN RHEUM DIS, V58, P392, DOI 10.1136/ard.58.7.392; Nurmohamed MT, 2001, ANN RHEUM DIS, V60, P905, DOI 10.1136/ard.60.10.905; Yasunaga H, 2009, J ORTHOP SCI, V14, P10, DOI 10.1007/s00776-008-1294-7; Niimi R, 2012, THROMB RES, V130, P759, DOI 10.1016/j.thromres.2011.11.046; Warwick D, 1998, J BONE JOINT SURG AM, V80A, P1158; Husted H, 2010, ACTA ORTHOP, V81, P599, DOI 10.3109/17453674.2010.525196; Chung WS, 2014, ANN RHEUM DIS, V73, P1774, DOI 10.1136/annrheumdis-2013-203380; White RH, 1998, ARCH INTERN MED, V158, P1525, DOI 10.1001/archinte.158.14.1525; Pitto RP, 2004, J BONE JOINT SURG BR, V86B, P639, DOI 10.1302/0301-620X.86B5.14763; Niki Y, 2010, J ORTHOP SCI, V15, P57, DOI 10.1007/s00776-009-1410-3; Ravi B, 2012, ARTHRITIS RHEUM-US, V64, P3839, DOI 10.1002/art.37690; Kory PD, 2011, CHEST, V139, P538, DOI 10.1378/chest.10-1479; Kanchanabat B, 2011, BRIT J SURG, V98, P1356, DOI 10.1002/bjs.7589; Choi HK, 2013, ANN RHEUM DIS, V72, P1182, DOI 10.1136/annrheumdis-2012-201669; Raskob GE, 2012, J BONE JOINT SURG BR, V94B, P257, DOI 10.1302/0301-620X.94B2.27850; van den Oever IAM, 2014, ANN RHEUM DIS, V73, P954, DOI 10.1136/annrheumdis-2013-204767; Colwell CW, 2009, ORTHOPEDICS, V32, P67, DOI 10.3928/01477447-20091103-51; White RH, 2002, CURR OPIN PULM MED, V8, P365, DOI 10.1097/01.MCP.0000020326.82739.3A; WILSON NV, 1992, J BONE JOINT SURG BR, V74, P50; Schwarz T, 2002, CLIN APPL THROMB-HEM, V8, P45, DOI 10.1177/107602960200800106; Bates SM, 2012, CHEST, V141, pE351S, DOI 10.1378/chest.11-2299; Chandrasekaran S, 2009, ANZ J SURG, V79, P526, DOI 10.1111/j.1445-2197.2009.04982.x; Falck-Ytter Yngve, 2012, Chest, V141, pe278S, DOI 10.1378/chest.11-2404; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Giles Jon T, 2006, Nat Clin Pract Rheumatol, V2, P320, DOI 10.1038/ncprheum0178; Januel JM, 2012, JAMA-J AM MED ASSOC, V307, P294, DOI 10.1001/jama.2011.2029; Migita K, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4616; Motokawa S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-22; Nakao Shigetaka, 2010, J Med Invest, V57, P146; Petitou M, 2002, SEMIN THROMB HEMOST, V28, P393, DOI 10.1055/s-2002-34309; Ravi B, 2014, ARTHRITIS RHEUMATOL, V66, P254, DOI 10.1002/art.38231; van Heereveld HAEM, 2001, ANN RHEUM DIS, V60, P974, DOI 10.1136/ard.60.10.974; Yi SX, 2014, ARCH ORTHOP TRAUM SU, V134, P1469, DOI 10.1007/s00402-014-2056-y	42	0	0	J RHEUMATOL PUBL CO	TORONTO	365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA	0315-162X	1499-2752		J RHEUMATOL	J. Rheumatol.	JUN	2015	42	6					928	934		10.3899/jrheum.140768		7	Rheumatology	Rheumatology	CJ5QO	WOS:000355543300005		
J	Suzuki, T; Iwamoto, N; Yamasaki, S; Nishino, A; Nakashima, Y; Horai, Y; Kawashiri, S; Ichinose, K; Arima, K; Tamai, M; Nakamura, H; Origuchi, T; Miyamoto, C; Osaki, M; Ohyama, K; Kuroda, N; Kawakami, A				Suzuki, Takahisa; Iwamoto, Naoki; Yamasaki, Satoshi; Nishino, Ayako; Nakashima, Yoshikazu; Horai, Yoshiro; Kawashiri, Shin-ya; Ichinose, Kunihiro; Arima, Kazuhiko; Tamai, Mami; Nakamura, Hideki; Origuchi, Tomoki; Miyamoto, Chikara; Osaki, Makoto; Ohyama, Kaname; Kuroda, Naotaka; Kawakami, Atsushi			Upregulation of Thrombospondin 1 Expression in Synovial Tissues and Plasma of Rheumatoid Arthritis: Role of Transforming Growth Factor-beta 1 toward Fibroblast-like Synovial Cells	JOURNAL OF RHEUMATOLOGY			English	Article						RHEUMATOID ARTHRITIS; FIBROBLAST-LIKE SYNOVIAL CELL; SYNOVITIS; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR-B1; BIOMARKER	GROWTH-FACTOR-BETA; ANGIOGENESIS; APOPTOSIS; PATHWAYS; RECEPTOR	Objective. To investigate the role of thrombospondin 1 (TSP-1) in RA. Methods. Expression of TSP-1 in synovial tissues was determined by immunohistochemistry. Expression of TSP-1 in rheumatoid fibroblast-like synovial cells (FLS) was investigated by quantitative real-time PCR and ELISA. Correlations among the plasma TSP-1 and other variables in patients with RA were examined. Results. Expression of TSP-1 was increased in rheumatoid synovial tissues. Transforming growth factor-beta 1 (TGF-beta 1) clearly increased TSP-1 expression in FLS on both mRNA and protein levels. Changes in plasma TSP-1 were associated with those in 28-joint Disease Activity Score-erythrocyte sedimentation rate and plasma TGF-beta 1. Conclusion. TSP-1 might be critically involved in the disease process of RA through the TGF-beta 1/ TSP-1 axis.	[Suzuki, Takahisa; Iwamoto, Naoki; Nishino, Ayako; Nakashima, Yoshikazu; Horai, Yoshiro; Kawashiri, Shin-ya; Ichinose, Kunihiro; Nakamura, Hideki; Kawakami, Atsushi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Immunol & Rheumatol, Nagasaki 8528501, Japan; [Kawashiri, Shin-ya; Arima, Kazuhiko] Nagasaki Univ, Grad Sch Biomed Sci, Dept Publ Hlth, Nagasaki 8528501, Japan; [Origuchi, Tomoki] Nagasaki Univ, Grad Sch Biomed Sci, Dept Hlth Sci, Nagasaki 8528501, Japan; [Miyamoto, Chikara] Nagasaki Univ, Grad Sch Biomed Sci, Dept Orthoped Surg, Nagasaki 8528501, Japan; [Ohyama, Kaname] Nagasaki Univ, Grad Sch Biomed Sci, Dept Environm & Pharmaceut Sci, Nagasaki 8528501, Japan; [Yamasaki, Satoshi] Hiroshima Univ, Dept Clin Immunol & Rheumatol, Hiroshima, Japan	Iwamoto, N (reprint author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Immunol & Rheumatol, Unit Translat Med, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.	naoki-iwa@nagasaki-u.ac.jp			Ministry of Health, Labor, and Welfare, Japan	Supported in part by a grant from the Ministry of Health, Labor, and Welfare, Japan.	Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI 10.1136/ard.2010.138461; Grimbert P, 2006, J IMMUNOL, V177, P3534; Wang JG, 2012, ARTHRITIS RHEUM-US, V64, P993, DOI 10.1002/art.33425; LAWLER J, 1986, BLOOD, V67, P1197; Lu T, 2007, P NATL ACAD SCI USA, V104, P4365, DOI 10.1073/pnas.0700118104; Han GW, 2012, INT J BIOL SCI, V8, P228, DOI 10.7150/ijbs.8.228; Ishinaga H, 2009, BIOCHEM J, V417, P583, DOI 10.1042/BJ20080781; Kawakami A, 1996, ARTHRITIS RHEUM, V39, P1267, DOI 10.1002/art.1780390802; Koch AE, 1998, CLIN IMMUNOL IMMUNOP, V86, P199, DOI 10.1006/clin.1997.4480; Li YZ, 2013, CELL MOL IMMUNOL, V10, P506, DOI 10.1038/cmi.2013.32; Miyashita T, 2004, CLIN EXP IMMUNOL, V137, P430, DOI 10.1111/j.1365-2249.2004.02534.x; Nakamura H, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-140; Ohyama K, 2012, ANN RHEUM DIS, V71, P1916, DOI 10.1136/annrheumdis-2012-201305; Okada A, 2012, CLIN EXP RHEUMATOL, V30, P332; Rico MC, 2008, TRANSL RES, V152, P95, DOI 10.1016/j.trsl.2008.06.002; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; Suchard SJ, 1996, J CELL PHYSIOL, V168, P217, DOI 10.1002/(SICI)1097-4652(199607)168:1<217::AID-JCP26>3.0.CO;2-2	17	0	0	J RHEUMATOL PUBL CO	TORONTO	365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA	0315-162X	1499-2752		J RHEUMATOL	J. Rheumatol.	JUN	2015	42	6					943	947		10.3899/jrheum.141292		5	Rheumatology	Rheumatology	CJ5QO	WOS:000355543300007		
J	Hirano, K; Imagama, S; Matsuyama, Y; Kawakami, N; Yukawa, Y; Kato, F; Hachiya, Y; Kanemura, T; Kamiya, M; Deguchi, M; Ito, Z; Wakao, N; Ando, K; Tauchi, R; Muramoto, A; Ishiguro, N				Hirano, Kenichi; Imagama, Shiro; Matsuyama, Yukihiro; Kawakami, Noriaki; Yukawa, Yasutsugu; Kato, Fumihiko; Hachiya, Yudo; Kanemura, Tokumi; Kamiya, Mitsuhiro; Deguchi, Masao; Ito, Zenya; Wakao, Norimitsu; Ando, Kei; Tauchi, Ryoji; Muramoto, Akio; Ishiguro, Naoki			Surgically Treated Cases of Lumbar Spondylolysis and Isthmic Spondylolisthesis A Multicenter Study	JOURNAL OF SPINAL DISORDERS & TECHNIQUES			English	Article							MULTIPLE-LEVEL SPONDYLOLYSIS; ILIOLUMBAR LIGAMENT; LUMBOSACRAL JUNCTION; FOLLOW-UP; POPULATION; STABILITY; ADULTS; SPINE	Study Design: Prospective database study. Objectives: To grasp the characteristics of surgically treated cases with lumbar spondylolysis or isthmic spondylolisthesis. Summary of Background Data: A detailed analysis of surgically treated cases with spondylolysis or isthmic spondylolisthesis has never been reported. An epidemiological study in Japan conducted on 2000 subjects found the incidence of lumbar spondylolysis in the Japanese general population (population-based study) to be 5.9% (males: 7.9%, females: 3.9%). Among 124 vertebrae with spondylolysis, there were 0.8% L2 lesions, 3.2% L3 lesions, 5.6% L4 lesions, and 90.3% L5 lesions, including 5 cases (4.3%) with multiple-level lesions. Methods: We have been registering surgically treated spine cases in our database since 2000. From this database, we prospectively collected cases with lumbar spondylolysis or isthmic spondylolisthesis that were treated surgically between January 2000 and December 2009. We determined the age at surgery, sex, and vertebral level of spondylolysis. Results: Of the 564 spondylolysis patients treated surgically, 66.8% were male and 33.2% were female. The mean age at surgery was 52.5 years (range, 13-84 y). There were 585 vertebrae with spondylolysis including 21 cases (3.7%) with multiple-level lesions. L5 spondylolysis affected 432 vertebrae and was the most common location (73.8%), followed by 125 L4 lesions (21.4%), 24 L3 lesions (4.1%), and 2 L2 lesions (0.7%). Conclusions: The percentage of L4 lesions in our study was significantly higher and of L5 lesions was significantly lower than those lesions' percentages in the population-based study. L4 spondylolysis may be more unstable or cause clinical symptoms more frequently leading to more surgical intervention. The percentage of multiple-level spondylolysis was similar between the 2 studies, suggesting these patients respond relatively well to conservative treatment. The male/female ratio was 2:1 in both studies, indicating that males and females require surgery at a similar frequency.	[Hirano, Kenichi; Imagama, Shiro; Ito, Zenya; Ando, Kei; Tauchi, Ryoji; Muramoto, Akio; Ishiguro, Naoki] Nagoya Univ, Grad Sch Med, Dept Orthopaed Surg, Nagoya, Aichi 4668560, Japan; [Matsuyama, Yukihiro] Hamamatsu Med Univ, Dept Orthopaed Surg, Shizuoka, Japan; [Kawakami, Noriaki] Meijo Hosp, Dept Orthopaed Surg, Nagoya, Aichi, Japan; [Yukawa, Yasutsugu; Kato, Fumihiko] Chubu Rosai Hosp, Dept Orthopaed Surg, Minato Ku, Nagoya, Aichi, Japan; [Hachiya, Yudo] Hachiya Orthopaed Hosp, Nagoya, Aichi, Japan; [Kanemura, Tokumi] Konan Kosei Hosp, Dept Orthopaed Surg, Konan, Aichi, Japan; [Kamiya, Mitsuhiro; Wakao, Norimitsu] Aichi Med Univ, Dept Orthopaed Surg, Nagakute, Aichi, Japan; [Deguchi, Masao] Nagano Red Cross Hosp, Dept Orthopaed Surg, Nagano, Japan	Imagama, S (reprint author), Nagoya Univ, Grad Sch Med, Dept Orthopaed Surg, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668560, Japan.	imagama@med.nagoya-u.ac.jp					Kalichman L, 2009, SPINE, V34, P199, DOI 10.1097/BRS.0b013e31818edcfd; RAVICHANDRAN G, 1980, SPINE, V5, P552, DOI 10.1097/00007632-198011000-00011; ROSENBERG NJ, 1975, J BONE JOINT SURG AM, VA 57, P467; Sakai T, 2010, J ORTHOP SCI, V15, P281, DOI 10.1007/s00776-010-1454-4; Al-Sebai MW, 1999, EUR SPINE J, V8, P75, DOI 10.1007/s005860050130; Beutler WJ, 2003, SPINE, V28, P1027, DOI 10.1097/00007632-200305150-00014; OHMORI K, 1995, J BONE JOINT SURG BR, V77, P771; LEONG JCY, 1987, SPINE, V12, P669, DOI 10.1097/00007632-198709000-00005; YAMAMOTO I, 1990, SPINE, V15, P1138, DOI 10.1097/00007632-199011010-00010; Hu SS, 2008, J BONE JOINT SURG AM, V90A, P656; LUK KDK, 1986, J BONE JOINT SURG BR, V68, P197; WILTSE LL, 1975, J BONE JOINT SURG AM, VA 57, P17; Sakai T, 2009, SPINE, V34, P2346, DOI 10.1097/BRS.0b013e3181b4abbe; Belfi LM, 2006, SPINE, V31, pE907, DOI 10.1097/01.brs.0000245947.31473.0a; Chang JH, 2001, J FORMOS MED ASSOC, V100, P497; CHOW DHK, 1989, SPINE, V14, P611, DOI 10.1097/00007632-198906000-00013; EINGORN D, 1985, SPINE, V10, P250, DOI 10.1097/00007632-198504000-00010; GRANTHAM SA, 1975, J BONE JOINT SURG AM, V57, P713; GROBLER LJ, 1994, SPINE, V19, P222, DOI 10.1097/00007632-199401001-00018; JACKSON A M, 1978, Spine, V3, P260, DOI 10.1097/00007632-197809000-00012; Lauerman WC, 1996, JAAOS, V4, P201; LIBSON E, 1982, INT ORTHOP, V6, P259; Mays S, 2006, AM J PHYS ANTHROPOL, V131, P352, DOI 10.1002/ajpa.20447; NEWMAN PH, 1976, CLIN ORTHOP RELAT R, P116; Ogawa H, 2007, J SPINAL DISORD TECH, V20, P521, DOI 10.1097/BSD.0b013e3180335c1f; ROCHE MB, 1951, ANAT REC, V109, P233, DOI 10.1002/ar.1091090207; SARASTE H, 1987, J PEDIATR ORTHOPED, V7, P631; Sonne-Holm S, 2007, EUR SPINE J, V16, P821, DOI 10.1007/s00586-006-0250-5	28	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1536-0652	1539-2465		J SPINAL DISORD TECH	J. Spinal Disord. Tech.	JUN	2015	28	5					193	197		10.1097/BSD.0b013e31827f4321		5	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CJ7LA	WOS:000355675300007		
J	Iwata, T; Miyamoto, K; Hioki, A; Fushimi, K; Ohno, T; Shimizu, K				Iwata, Takahiro; Miyamoto, Kei; Hioki, Akira; Fushimi, Kazunari; Ohno, Takatoshi; Shimizu, Katsuji			Morphologic Changes in Contralateral Lumbar Foramen in Unilateral Cantilever Transforaminal Lumbar Interbody Fusion Using Kidney-type Intervertebral Spacers	JOURNAL OF SPINAL DISORDERS & TECHNIQUES			English	Article							FORAMINAL STENOSIS; TLIF	Study Design: A retrospective study of 58 patients undergoing cantilever transforaminal lumbar interbody fusion (c-TLIF). Objectives: To evaluate morphologic changes in the intervertebral foramen (IVF) on the side contralateral to spacer insertion in patients undergoing c-TLIF using plain x-ray films and computed tomography scan. Summary of Background Data: The morphologic changes in the contralateral lumbar foramen in c-TLIF using unilateral insertion of spacers have not been well studied. Materials and Methods: Fifty-eight consecutive patients with lumbar dysplastic changes or degenerative disk diseases underwent c-TLIF using 96 kidney-type spacers with local bone grafts. Radiographic findings (sagittal disk angle), computed tomography scan findings (coronal disk angle, disk height, foraminal height (FH), foraminal width, and cross-sectional area of IVF in contralateral lumbar foramen) were compared between preoperative period and 6 months after surgery. The correlations between contralateral lumbar foraminal dimensions and disk height, sagittal disk angle, and coronal disk angle were analyzed. Results: After c-TLIF, sagittal angle, disk height, FH, foraminal width, and cross-sectional area of the IVF were significantly increased. Increase in posterior disk height showed a positive correlation with increases in FH, foraminal width, and cross-sectional area of IVF (r=0.235-0.511). However, the increase in sagittal disk angle showed a negative correlation with changes in foraminal width and cross-sectional area of IVF (r=-0.256 to -0.206). Conclusions: Lumbar foraminal dimensions on the side contralateral to spacer insertion increased significantly after c-TLIF, suggesting that c-TLIF enables indirect decompression of the contralateral nerve root. Although increase in posterior disk height was shown to be an important factor to increase contralateral foraminal size, segmental lordosis was a risk factor for a decrease in contralateral foraminal size.	[Iwata, Takahiro] Ibi Kousei Hosp, Dept Orthopaed Surg, Gifu, Japan; [Iwata, Takahiro; Miyamoto, Kei; Hioki, Akira; Fushimi, Kazunari; Ohno, Takatoshi; Shimizu, Katsuji] Gifu Univ, Grad Sch Med, Dept Orthopaed Surg, Gifu 5011194, Japan; [Miyamoto, Kei] Gifu Univ, Grad Sch Med, Dept Reconstruct Surg Spine Bone & Joint, Gifu 5011194, Japan	Miyamoto, K (reprint author), Gifu Univ, Grad Sch Med, Dept Reconstruct Surg Spine Bone & Joint, 1-1 Yanagido, Gifu 5011194, Japan.	kei@bg8.so-net.ne.jp					Jenis LG, 2000, SPINE, V25, P389, DOI 10.1097/00007632-200002010-00022; Anand N, 2006, SPINE, V31, pE748, DOI 10.1097/01.brs.0000240211.23617.ae; HASEGAWA T, 1995, J BONE JOINT SURG AM, V77A, P32; Cinotti G, 2002, SPINE, V27, P223, DOI 10.1097/00007632-200202010-00002; Umehara S, 2000, SPINE, V25, P1617, DOI 10.1097/00007632-200007010-00004; Yan DL, 2008, EUR SPINE J, V17, P1311, DOI 10.1007/s00586-008-0739-1; Fukuta S, 2011, J SPINAL DISORD TECH, V24, P189, DOI 10.1097/BSD.0b013e3181e9f249; Daniel K, 2008, 54 ANN M ORTH RES SO; Fujiwara A, 2001, SPINE, V26, P876, DOI 10.1097/00007632-200104150-00010; GRUBB SA, 1988, SPINE, V13, P241, DOI 10.1097/00007632-198803000-00004; Harms J G, 1998, Oper Orthop Traumatol, V10, P90, DOI 10.1007/s00064-006-0112-7; Hioki A, 2011, YONSEI MED J, V52, P314, DOI 10.3349/ymj.2011.52.2.314; Hioki A, 2011, J SPINAL DISORD TECH, V24, P93, DOI 10.1097/BSD.0b013e3181dd611f; Hioki Akira, 2005, Spine J, V5, P600, DOI 10.1016/j.spinee.2005.04.001; Hioki A, 2010, SPINE, V35, P995, DOI 10.1097/BRS.0b013e3181bb8188; Hunt Travis, 2007, Eur Spine J, V16 Suppl 3, P311, DOI 10.1007/s00586-007-0387-x; Kikuike K, 2011, 8 COMB C SPIN PED SE	17	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1536-0652	1539-2465		J SPINAL DISORD TECH	J. Spinal Disord. Tech.	JUN	2015	28	5					E270	E276		10.1097/BSD.0b013e318286bb14		7	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CJ7LG	WOS:000355676000004		
J	Miwa, S; Yokogawa, A; Kobayashi, T; Nishimura, T; Igarashi, K; Inatani, H; Tsuchiya, H				Miwa, Shinji; Yokogawa, Akio; Kobayashi, Tadayoshi; Nishimura, Tatsuya; Igarashi, Kentaro; Inatani, Hiroyuki; Tsuchiya, Hiroyuki			Risk Factors of Recurrent Lumbar Disk Herniation A Single Center Study and Review of the Literature	JOURNAL OF SPINAL DISORDERS & TECHNIQUES			English	Review							LOW-BACK-PAIN; INTERVERTEBRAL-DISK; SMOKING-CESSATION; CIGARETTE-SMOKING; SURGERY; COMPLICATIONS; FAILURE; DEGENERATION; REOPERATION; DISKECTOMY	Background: The recurrence of lumbar disk herniation (LDH) is a major problem in the treatment of LDH. The purpose of this study was to investigate the risk factors for recurrent LDH. Methods: Between April 2005 and March 2008, 298 patients with LDH, who underwent surgical treatment, were enrolled in this study. The patients were divided into a nonrecurrent group (N group) and a recurrent group (R group). We compared their clinical parameters including age, sex, body mass index, smoking, alcohol, sports activity, occupational lifting, and occupational driving. The relationships between the variables and recurrent LDH were evaluated by univariate analysis and multiple logistic regression analysis. Results: The N group had 266 patients (89.3%) and the R group had 32 patients (10.7%). Univariate analysis showed that current smoking (P < 0.001) and occupational lifting (P=0.02) significantly correlated with recurrent LDH. Multivariate analysis showed that current smoking significantly related with recurrent LDH (OR, 3.47; 95% CI, 1.55-7.80; P=0.003). Conclusions: Our study suggests that smoking cessation and restraining from lifting may significantly decrease the incidence of recurrent LDH.	[Miwa, Shinji; Yokogawa, Akio; Kobayashi, Tadayoshi; Nishimura, Tatsuya; Igarashi, Kentaro; Inatani, Hiroyuki] Saiseikai Kanazawa Hosp, Dept Orthoped Surg, Kanazawa, Ishikawa 9200353, Japan; [Tsuchiya, Hiroyuki] Kanazawa Univ, Dept Orthoped Surg, Kanazawa, Ishikawa, Japan	Miwa, S (reprint author), Saiseikai Kanazawa Hosp, Dept Orthoped Surg, Ni 13-6 Akatsuchi Machi, Kanazawa, Ishikawa 9200353, Japan.	smiwa001@yahoo.co.jp					BATTIE MC, 1991, SPINE, V16, P1015, DOI 10.1097/00007632-199109000-00001; Cinotti G, 1998, J BONE JOINT SURG BR, V80B, P825, DOI 10.1302/0301-620X.80B5.8540; Moller AM, 2003, J BONE JOINT SURG BR, V85B, P178, DOI 10.1302/0301-620X.85B2.13717; LAW JD, 1978, J NEUROSURG, V48, P259, DOI 10.3171/jns.1978.48.2.0259; Carragee EJ, 2003, J BONE JOINT SURG AM, V85A, P102; Padubidri AN, 2001, PLAST RECONSTR SURG, V107, P342, DOI 10.1097/00006534-200102000-00007; Van Nieuwenhuyse A, 2004, OCCUP MED-OXFORD, V54, P513, DOI 10.1093/occmed/kqh091; Sorensen LT, 2003, ANN SURG, V238, P1, DOI 10.1097/01.SLA.0000074980.39700.31; Little CP, 2006, J HAND SURG-BRIT EUR, V31B, P252, DOI 10.1016/j.jhsb.2005.12.010; Sorensen LT, 1999, BRIT J SURG, V86, P927, DOI 10.1046/j.1365-2168.1999.01165.x; Yildiz D, 2004, TOXICON, V43, P619, DOI 10.1016/j.toxicon.2004.01.017; Marras WS, 2001, SPINE, V26, P2566, DOI 10.1097/00007632-200112010-00009; Kim JM, 2007, MINIM INVAS NEUROSUR, V50, P82, DOI 10.1055/s-2007-982504; Suk KS, 2001, SPINE, V26, P672, DOI 10.1097/00007632-200103150-00024; KELSEY JL, 1984, SPINE, V9, P608, DOI 10.1097/00007632-198409000-00012; [Anonymous], 1999, CLIN ORTHOP RELAT R, DOI 10.1097/00003086-199908000-00024; FANDINO J, 1993, ACTA NEUROCHIR, V122, P102, DOI 10.1007/BF01446994; Hangai M, 2008, SPINE J, V8, P732, DOI 10.1016/j.spinee.2007.07.392; Connolly E S, 1992, Clin Neurosurg, V39, P211; CROCK HV, 1976, J BONE JOINT SURG BR, V58, P193; Examination Committee of Criteria for Obesity Disease' in Japan, 2000, J JPN SOC STUDY OBES, V6, P18; Gill CS, 2006, J ORTHOP RES, V24, P2141, DOI 10.1002/jor.20234; GREENWOOD J, 1952, J NEUROSURG, V9, P15, DOI 10.3171/jns.1952.9.1.0015; Jozsa L, 1997, STRUCTURE METABOLISM, V69; Keyl W, 1980, REZIDIVE NACH LUMBAL, P70; KROLL SS, 1994, PLAST RECONSTR SURG, V94, P637, DOI 10.1097/00006534-199410000-00011; Kuri M, 2005, ANESTHESIOLOGY, V102, P892, DOI 10.1097/00000542-200505000-00005; MATSUI H, 1992, SPINE, V17, P1323, DOI 10.1097/00007632-199211000-00011; Mills E, 2011, AM J MED, V124, P144, DOI 10.1016/j.amjmed.2010.09.013; Morton HJV, 1944, LANCET, V1, P368; PHEASANT HC, 1975, ORTHOP CLIN N AM, V6, P319; Saberi H, 2009, J SPINAL DISORD TECH, V22, P507, DOI 10.1097/BSD.0b013e3181927051; Shamim MS, 2010, WORLD NEUROSURG, V74, P611, DOI 10.1016/j.wneu.2010.06.016; Silverstein P, 1992, AM J MED, V93, P22; Spangfort E V, 1972, Acta Orthop Scand Suppl, V142, P1; Swartz KR, 2003, NEUROSURG FOCUS, V15, P10; WILLIAMS R W, 1978, Spine, V3, P175	37	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1536-0652	1539-2465		J SPINAL DISORD TECH	J. Spinal Disord. Tech.	JUN	2015	28	5					E265	E269		10.1097/BSD.0b013e31828215b3		5	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CJ7LG	WOS:000355676000003		
J	Sumiyoshi, M; Satomi, J; Kitazato, KT; Yagi, K; Shimada, K; Kurashiki, Y; Korai, M; Miyamoto, T; Suzue, R; Kuwayama, K; Nagahiro, S				Sumiyoshi, Manabu; Satomi, Junichiro; Kitazato, Keiko T.; Yagi, Kenji; Shimada, Kenji; Kurashiki, Yoshitaka; Korai, Masaaki; Miyamoto, Takeshi; Suzue, Ryoko; Kuwayama, Kazuyuki; Nagahiro, Shinji			PPAR gamma-Dependent and -Independent Inhibition of the HMGB1/TLR9 Pathway by Eicosapentaenoic Acid Attenuates Ischemic Brain Damage in Ovariectomized Rats	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Eicosapentaenoic acid; PPAR gamma; HMGB1; RAGE; toll-like receptors; brain ischemia; ovariectomy	GROUP BOX 1; FOCAL CEREBRAL-ISCHEMIA; OOPHORECTOMIZED RATS; RECEPTOR; STROKE; RAGE; NEUROPROTECTION; ACTIVATION; INFARCTION; BIOMARKERS	High mobility group box 1 (HMGB1) elevation after cerebral ischemia activates inflammatory pathways via receptors such as the receptor for advanced glycation end products (RAGE) and toll-like receptors (TLRs) and leads to brain damage. Eicosapentaenoic acid (EPA), a peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist, attenuates postischemic inflammation and brain damage in male animals. However, postischemic HMGB1 signaling and the effects of EPA on ovariectomized (OVX+) rats remain unclear. We hypothesized that EPA attenuates brain damage in OVX+ rats via the inhibition of HMGB1 signaling in a PPAR gamma-dependent manner. Seven-week-old female Sprague-Dawley rats were divided into 3 groups; nonovariectomized (OVX-) rats and EPA-treated and EPA-untreated OVX+ rats before cerebral ischemia induction. Another set of EPA-treated OVX+ rats was injected with the PPAR gamma inhibitor GW9662. OVX+ decreased the messenger RNA level of PPAR gamma and increased that of HMGB1, RAGE, TLR9, and tumor necrosis factor alpha (TNF alpha) in parallel with ischemic brain damage. EPA restored the PPAR gamma expression, downregulated the HMGB1 signal-related molecules, and attenuated the ischemic brain damage. Neither OVX+ nor EPA affected the expression of TLR2 or TLR4. Interestingly, GW9662 partially abrogated the EPA-induced neuro-protection and the downregulation of RAGE and TLR9. In contrast, GW9662 did not affect HMGB1 or TNF alpha. These results suggest that EPA exerts PPAR gamma-dependent and PPAR gamma-independent effects on postischemic HMGB1/TLR9 pathway. The cortical infarct volume exacerbated by OVX+ is associated with the upregulation of the HMGB1/TLR9 pathway. Suppression of this pathway may help to limit ischemic brain damage in postmenopausal women.	[Sumiyoshi, Manabu; Satomi, Junichiro; Kitazato, Keiko T.; Yagi, Kenji; Shimada, Kenji; Kurashiki, Yoshitaka; Korai, Masaaki; Miyamoto, Takeshi; Suzue, Ryoko; Kuwayama, Kazuyuki; Nagahiro, Shinji] Univ Tokushima, Grad Sch, Dept Neurosurg, Inst Hlth Biosci, Tokushima 7708503, Japan	Sumiyoshi, M (reprint author), Univ Tokushima, Grad Sch, Dept Neurosurg, Inst Hlth Biosci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	mansumiyoshi@yahoo.co.jp			Ministry of Education, Science, Sports, and Culture of Japan [C24592132]	This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan (C24592132).	Agnello D, 2002, CYTOKINE, V18, P231, DOI 10.1006/cyto.2002.0890; Hayakawa K, 2012, P NATL ACAD SCI USA, V109, P7505, DOI 10.1073/pnas.1121146109; Beagley KW, 2003, FEMS IMMUNOL MED MIC, V38, P13, DOI 10.1016/S0928-8244(03)00202-5; Leung PY, 2012, STROKE, V43, P1383, DOI 10.1161/STROKEAHA.111.641522; Ueda M, 2013, BRAIN RES, V1519, P95, DOI 10.1016/j.brainres.2013.04.046; Stevens SL, 2008, J CEREBR BLOOD F MET, V28, P1040, DOI 10.1038/sj.jcbfm.9600606; Schulze J, 2013, STROKE, V44, P246, DOI 10.1161/STROKEAHA.112.676072; Yagi K, 2009, STROKE, V40, P626, DOI 10.1161/STROKEAHA.108.520262; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Draper E, 2011, J NUTR BIOCHEM, V22, P784, DOI 10.1016/j.jnutbio.2010.06.009; Sekikawa A, 2011, STROKE, V42, P2538, DOI 10.1161/STROKEAHA.110.613042; Brea D, 2011, CLIN IMMUNOL, V139, P193, DOI 10.1016/j.clim.2011.02.001; Wang LN, 2010, NEUROSCI LETT, V471, P152, DOI 10.1016/j.neulet.2010.01.030; Yang QW, 2010, J CEREBR BLOOD F MET, V30, P243, DOI 10.1038/jcbfm.2009.202; Liu H, 2004, BRAIN RES, V1025, P43, DOI 10.1016/j.brainres.2004.07.071; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Zhang L, 2012, ARTERIOSCL THROM VAS, V32, P1856, DOI 10.1161/ATVBAHA.112.252619; Tanaka K, 2008, STROKE, V39, P2052, DOI 10.1161/STROKEAHA.107.509455; LONGA EZ, 1989, STROKE, V20, P84; Berger JS, 2012, STROKE, V43, P958, DOI 10.1161/STROKEAHA.111.641324; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1011/j.1471-4159.2006.03758.x; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Clark RB, 2000, J IMMUNOL, V164, P1364; Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086; Chadli FK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061109; Kinouchi T, 2012, STROKE, V43, P478, DOI 10.1161/STROKEAHA.111.618926; Lalancette-Hebert M, 2011, STROKE, V42, P2903, DOI 10.1161/STROKEAHA.111.620856; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; O'Connor KA, 2003, CYTOKINE, V24, P254, DOI 10.1016/j.cyto.2003.08.001; Persky Rebecca W, 2010, Curr Cardiol Rep, V12, P6, DOI 10.1007/s11886-009-0080-2; Roberts BJ, 2013, EXP MOL PATHOL, V94, P58, DOI 10.1016/j.yexmp.2012.06.005; Shimada K, 2011, HYPERTENSION, V57, P1161, DOI 10.1161/HYPERTENSIONAHA.110.167650; Ulu A, 2013, J CARDIOVASC PHARM, V62, P285, DOI 10.1097/FJC.0b013e318298e460; Wang YC, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-134; Yan SF, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S146239940900101X	37	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	JUN	2015	24	6					1187	1195		10.1016/j.jstrokecerebrovasdis.2015.01.009		9	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CJ2TT	WOS:000355338200022		
J	Isho, T; Tashiro, H; Usuda, S				Isho, Takuya; Tashiro, Hideyuki; Usuda, Shigeru			Accelerometry-Based Gait Characteristics Evaluated Using a Smartphone and Their Association with Fall Risk in People with Chronic Stroke	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Accelerometry; accidental falls; cerebrovascular disorders; gait; postural balance; walking	EVALUATION SYSTEMS TEST; MINI-BESTEST; OLDER-ADULTS; WALKING; BALANCE; REHABILITATION; COMMUNITY; RELIABILITY; VALIDITY; INDIVIDUALS	Background: The smartphone, which contains inertial sensors, is currently available and affordable device and has the potential to provide a self-assessment tool for health management. The aims of this study were to use a smartphone to record trunk acceleration during walking and to compare accelerometry variables between post-stroke subjects with and without a history of falling. Methods: This cross-sectional study was conducted in 2 day care centers for elderly adults. Twenty-four community-dwelling adults with chronic stroke (mean age, 71.6 +/- 9.7 years; mean time since stroke, 68.5 +/- 38.7 months) were enrolled. Acceleration of the trunk during walking was recorded in the anteroposterior and mediolateral directions and quantified using the autocorrelation coefficient, harmonic ratio, and interstride variability (coefficient of variation of root mean square acceleration). Fall history in the past 12 months was obtained by self-report. Results: Eleven participants (45.8%) reported at least one fall in the past 12 months and were classified as fallers. Fallers exhibited significantly higher interstride variability of mediolateral trunk acceleration than nonfallers. In the logistic regression analysis, interstride variability of mediolateral trunk acceleration was significantly associated with fall history (adjusted odds ratio, 1.462; 95% confidence interval, 1.009-2.120). The area under the receiver operating characteristic curve for interstride variability of mediolateral trunk acceleration to discriminate fallers from nonfallers was .745 (95% confidence interval, .527-.963). Conclusions: The results suggest that quantitative gait assessment using a smartphone can provide detailed and objective information about subtle changes in the gait pattern of stroke subjects at risk of falling.	[Isho, Takuya] Natl Hosp Org Takasaki Gen Med Ctr, Dept Rehabil, Takasaki, Gumma 3700829, Japan; [Tashiro, Hideyuki] Saitama Cooperat Hosp, Dept Rehabil, Kawaguchi, Saitama, Japan; [Usuda, Shigeru] Gunma Univ Grad Sch Hlth Sci, Dept Rehabil Sci, Maebashi, Gumma, Japan	Isho, T (reprint author), Natl Hosp Org Takasaki Gen Med Ctr, Dept Rehabil, 36 Takamatsu Cho, Takasaki, Gumma 3700829, Japan.	isho.tak@gmail.com					Lamb SE, 2003, STROKE, V34, P494, DOI 10.1161/01.STR.0000053444.00582.B7; Mizuike C, 2009, GAIT POSTURE, V30, P60, DOI 10.1016/j.gaitpost.2009.02.017; Belgen B, 2006, ARCH PHYS MED REHAB, V87, P554, DOI 10.1016/j.apmr.2005.12.027; Kavanagh JJ, 2008, GAIT POSTURE, V28, P1, DOI 10.1016/j.gaitpost.2007.10.010; Langhorne P, 2000, STROKE, V31, P1223; Harris JE, 2005, PHYS THER, V85, P150; Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053; Watanabe Y, 2005, INT J REHABIL RES, V28, P149, DOI 10.1097/00004356-200506000-00008; Balasubramanian CK, 2009, GAIT POSTURE, V29, P408, DOI 10.1016/j.gaitpost.2008.10.061; Higashi Y, 2008, IEEE ENG MED BIOL, V27, P38, DOI 10.1109/MEMB.2008.919494; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433; Nishiguchi S, 2012, TELEMED E-HEALTH, V18, P292, DOI 10.1089/tmj.2011.0132; Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x; Franchignoni F, 2010, J REHABIL MED, V42, P323, DOI 10.2340/16501977-0537; Menz HB, 2003, GAIT POSTURE, V18, P35, DOI 10.1016/S0966-6362(02)00159-5; Moe-Nilssen R, 2004, J BIOMECH, V37, P121, DOI 10.1016/S0021-9290(03)00233-1; Weerdesteyn V, 2008, J REHABIL RES DEV, V45, P1195, DOI 10.1682/JRRD.2007.09.0145; Tsang CSL, 2013, PHYS THER, V93, P1102, DOI 10.2522/ptj.20120454; Flansbjer UB, 2005, J REHABIL MED, V37, P75, DOI 10.1080/16501970410017215; Andersson AG, 2006, J REHABIL MED, V38, P186, DOI 10.1080/16501970500478023; Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893; Mackintosh SF, 2006, ARCH PHYS MED REHAB, V87, P1583, DOI 10.1016/j.apmr.2006.09.004; Iosa M, 2012, J REHABIL RES DEV, V49, P439, DOI 10.1682/JRRD.2011.03.0057; Maki BE, 1997, J AM GERIATR SOC, V45, P313; Hyndman D, 2003, DISABIL REHABIL, V25, P817, DOI 10.1080/0963828031000122221; Zijlstra W, 2003, GAIT POSTURE, V18, P1, DOI 10.1016/S0966-6362(02)00190-X; Blum L, 2008, PHYS THER, V88, P559, DOI 10.2522/ptj.20070205; BERG K, 1989, Physiotherapy Canada, V41, P304; Boonsinsukh R, 2011, TOP STROKE REHABIL, V18, P633, DOI 10.1310/tsr18s01-633; Boonsinsukh R, 2009, ARCH PHYS MED REHAB, V90, P919, DOI 10.1016/j.apmr.2008.12.022; Brunnstrom S, 1966, Phys Ther, V46, P357; De Bujanda Eva, 2004, J Stroke Cerebrovasc Dis, V13, P58, DOI 10.1016/j.jstrokecerebrovasdis.2004.02.006; Chino N, 1996, FUNCTIONAL EVALUATIO, P19; Dennis MS, 2002, STROKE, V33, P728, DOI 10.1161/hs0302.103621; Dodd KJ, 1998, CLIN BIOMECH, V13, P371, DOI 10.1016/S0268-0033(98)00101-6; FOREMAN MD, 1987, NURS RES, V36, P216; FORSTER A, 1995, BRIT MED J, V311, P83; Gibson MJ, 1990, IMPROVING HLTH OLDER; Haga H, 1996, JAPANESE J PUBLIC HL, V43, P983; Hausdorff Jeffrey M, 2005, J Neuroeng Rehabil, V2, P19, DOI 10.1186/1743-0003-2-19; Mudge S, 2007, PHYSIOTHERAPY, V93, P189, DOI 10.1016/j.physio.2006.12.010; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142; Yamada M, 2012, RHEUMATOL INT, V32, P3869, DOI 10.1007/s00296-011-2283-2	43	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	JUN	2015	24	6					1305	1311		10.1016/j.jstrokecerebrovasdis.2015.02.004		7	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CJ2TT	WOS:000355338200040		
J	Maeshima, S; Okazaki, H; Okamoto, S; Mizuno, S; Asano, N; Maeda, H; Masaki, M; Matsuo, H; Tsunoda, T; Sonoda, S				Maeshima, Shinichiro; Okazaki, Hideto; Okamoto, Sayaka; Mizuno, Shiho; Asano, Naoki; Maeda, Hirofumi; Masaki, Mitsuko; Matsuo, Hiroshi; Tsunoda, Tetsuya; Sonoda, Shigeru			A Comparison of Knee-Ankle-Foot Orthoses with Either Metal Struts or an Adjustable Posterior Strut in Hemiplegic Stroke Patients	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Adjustable posterior strut orthoses; knee-ankle-foot orthoses; stroke; hemiplegia	REHABILITATION	Background: We investigated differences in factors affecting judgments regarding the creation of new adjustable posterior strut knee-ankle-foot orthoses (APS-KAFO) and knee-ankle-foot orthoses with metal struts (traditional KAFO) for hemiplegic stroke patients for whom KAFO were created in rehabilitation wards. Methods: Subjects were 50 patients with hemiplegia due to new-onset stroke (cerebral infarction: n = 25, cerebral hemorrhage: n = 25) who were prescribed KAFO. Patient ages ranged from 36 to 90 years, and the mean duration from stroke onset to hospitalization was 28.8 +/- 13.8 days. Neurologic symptoms, cognitive function, activities of daily living, duration from hospitalization to orthosis creation, hospitalization duration, walking ability at discharge, outcome after discharge, and so forth were compared. Results: Fourteen patients were prescribed APS-KAFO, and 36 were prescribed traditional KAFO. Those prescribed APS-KAFO had somewhat milder neurologic symptoms and cognitive dysfunction and a shorter hospitalization duration than those prescribed traditional KAFO. Patients prescribed APS-KAFO also had a higher score and efficiency on functional independence measure at admission and discharge. Walking independence at discharge was seen in 8 of the 14 patients for whom APS-KAFO were created and 8 of the 36 patients for whom traditional KAFO were created. Conclusions: APS-KAFO was chosen for patients with a high level of activity in the ward and with a higher likelihood of acquiring walking ability using APS-AFO at discharge, whereas traditional KAFO tended to be chosen for patients with relatively severe symptoms who were not expected to acquire practical walking ability.	[Maeshima, Shinichiro; Okazaki, Hideto; Okamoto, Sayaka; Mizuno, Shiho; Asano, Naoki; Maeda, Hirofumi; Masaki, Mitsuko; Matsuo, Hiroshi; Tsunoda, Tetsuya; Sonoda, Shigeru] Fujita Hlth Univ, Sch Med, Dept Rehabil Med 2, Tsu, Mie, Japan	Maeshima, S (reprint author), Fujita Hlth Univ Nanakuri Sanat, Sch Med, Dept Rehabil Med 2, 424-1 Oodori Cho, Tsu, Mie 5141295, Japan.	shinichiromaeshima@gmail.com			"Research on Measures for Intractable Diseases'' Project from Ministry of Health, Labour and Welfare	This work was supported by "Research on Measures for Intractable Diseases'' Project 2014: matching fund subsidy from Ministry of Health, Labour and Welfare.	Hesse S, 1999, STROKE, V30, P1855; Wang RY, 2005, CLIN REHABIL, V19, P37, DOI 10.1191/0269215505cr797oa; [Anonymous], 1990, DAT MAN SERV UN DAT; COTE R, 1986, STROKE, V17, P731; Folstein MF, 1975, J PSYCHIATR RES, V12, P182; Fujii S, 1935, JIKKEN IHO, V21, P1811; Hirano Y, 2012, EUR NEUROL, V68, P221, DOI 10.1159/000338478; Ishigami S, 1986, B JAP SOC PROSTHET O, V2, P41; Maeshima S, 2003, AM J PHYS MED REHAB, V82, P456, DOI 10.1097/01.PHM.0000069195.87219.E0; Maeshima S, 2013, NEUROL SCI, V34, P1765, DOI 10.1007/s10072-013-1330-z; Mizuno M, 2005, B JAP SOC PROSTHET O, V21, P225; Nishio D, 2010, JPN J STROKE, V32, P86; Sawada K, 2013, J CLIN REHABIL TOKYO, V22, P224; Shinohara Y, 2011, J STROKE CEREBROVASC, V20, pS145, DOI 10.1016/j.jstrokecerebrovasdis.2011.05.014; Yamanaka Takashi, 2004, Top Stroke Rehabil, V11, P6	15	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	JUN	2015	24	6					1312	1316		10.1016/j.jstrokecerebrovasdis.2015.02.003		5	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CJ2TT	WOS:000355338200041		
J	Katano, H; Mase, M; Nishikawa, Y; Yamada, K				Katano, Hiroyuki; Mase, Mitsuhito; Nishikawa, Yusuke; Yamada, Kazuo			Calcified Carotid Plaques Show Double Symptomatic Peaks According to Agatston Calcium Score	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Carotid stenosis; carotid plaque; calcification; calcium score; volume score; Hounsfield value	CORONARY-ARTERY CALCIUM; VASCULAR CALCIFICATION; ATHEROSCLEROTIC PLAQUE; COMPUTED-TOMOGRAPHY; CT ANGIOGRAPHY; STENOSIS; RISK; STROKE; HEART; ENDARTERECTOMY	Background: The precise mechanism of carotid calcification formation and its clinical significance including the difference in outcomes compared with coronary artery have not been clearly elucidated yet. We applied the calcium score for analyzing carotid plaque calcification in focus on its relationship with symptoms and discuss the difference in transitional patterns and the clinical outcome in comparison with calcified coronary plaques. Methods: Multidetector row computed tomography angiography was performed preoperatively to determine the Agatston calcium score, volume score, and Hounsfield values for a total of 330 carotid arteries from 194 patients. Analysis focused on the relation of "the symptomatic rate'' to calcium score, volume score, and Hounsfield value as well as the characteristics of calcified plaques and coexisting diseases. The symptomatic rate of carotid artery plaques in each range of the index was calculated as the percentage of the number of carotid arteries with plaques, which elicited symptoms of the contralateral limbs or the ipsilateral retina to the whole number of carotid arteries with plaques within the range. Results: Calcified carotids with low symptomatic rate (<40%) tended to have calcification with significantly high calcium scores, high volume scores and mean/maximum Hounsfield values, high circularities, outer positions, positive remodeling, and carotid bulb/common carotid locations by univariate analysis, whereas high maximum Hounsfield value, high circularity, and outer position of calcification were significant independent predictors of low-symptomatic calcified carotid plaques by multivariate logistic regression analysis. When analyzed by calcium score, the rates for symptomatic carotids showed double peaks at calcium scores around 200-400 and 600-800 with a dip at 400-600. Significant independent predictors of low symptomatic carotid artery were high maximum Hounsfield value (odds ratio [OR], 5.70; P = .005), calcification encircling the carotid perimeter (OR, 7.18; P = .005), and the calcium location in the common carotid artery (OR, 6.62; P = .006) in comparing groups with low (0-400) and medium (400-600) calcium scores, whereas a high volume score (OR, .01; P = .003) alone was a significant independent determinant in the comparison between groups with high (600-1000) and medium calcium scores. Conclusions: Symptomatic rates of carotid plaque calcification were demonstrated to show double peaks with increasing calcium score and represent different features. Assessment of the 2 calcium-score parts might be helpful for appropriate comprehension of symptomatology and the complex process of carotid plaque calcification. We report a hypothesis for the mechanisms of the 2 different sections.	[Katano, Hiroyuki; Mase, Mitsuhito; Nishikawa, Yusuke; Yamada, Kazuo] Nagoya City Univ, Grad Sch Med Sci, Dept Neurosurg, Mizuho Ku, Nagoya, Aichi 4678601, Japan; [Katano, Hiroyuki] Nagoya City Univ, Grad Sch Med Sci, Dept Med informat & Integrat Med, Nagoya, Aichi 4678601, Japan	Katano, H (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Neurosurg, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	katano@med.nagoya-cu.ac.jp					AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827; Nandalur KR, 2006, AM J ROENTGENOL, V186, P547, DOI 10.2214/AJR.04.1216; Ehara S, 2004, CIRCULATION, V110, P3424, DOI 10.1161/01.CIR.0000148131.41425.E9; Wahlgren CM, 2009, CEREBROVASC DIS, V27, P193, DOI 10.1159/000189204; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; Nandalur KR, 2007, STROKE, V38, P935, DOI 10.1161/01.STR.0000257995.74834.92; Abedin M, 2004, ARTERIOSCL THROM VAS, V24, P1161, DOI 10.1161/01.ATV.0000133194.94939.42; Hermann DM, 2013, STROKE, V44, P1008, DOI 10.1161/STROKEAHA.111.678078; Proudfoot D, 2000, CIRC RES, V87, P1055; Polonsky TS, 2010, JAMA-J AM MED ASSOC, V303, P1610, DOI 10.1001/jama.2010.461; Detrano R, 2008, NEW ENGL J MED, V358, P1336, DOI 10.1056/NEJMoa072100; Nicoll R, 2013, INT J CARDIOL, V167, P322, DOI 10.1016/j.ijcard.2012.06.110; Ewence AE, 2008, CIRC RES, V103, pE28, DOI 10.1161/CIRCRESAHA.108.181305; Polak JF, 2013, J AM SOC ECHOCARDIOG, V26, P548, DOI 10.1016/j.echo.2013.02.009; Shaalan WE, 2004, J VASC SURG, V40, P262, DOI 10.1016/j.jvs.2004.04.025; Cohen GI, 2013, JACC-CARDIOVASC IMAG, V6, P1160, DOI 10.1016/j.jcmg.2013.06.007; Motoyama S, 2007, J AM COLL CARDIOL, V50, P319, DOI 10.1016/j.jacc.2007.03.044; Kwee RM, 2010, J VASC SURG, V51, P1015, DOI 10.1016/j.jvs.2009.08.072; de Weert TT, 2009, AM J NEURORADIOL, V30, P177, DOI 10.3174/ajnr.A1301; Executive committee for the asymptomatic carotid atherosclerosis study, 1995, JAMA-J AM MED ASSOC, V273, P1421; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; Hamirani YS, 2010, ATHEROSCLEROSIS, V211, P141, DOI 10.1016/j.atherosclerosis.2010.01.020; Katano H, 2007, STROKE, V38, P3040, DOI 10.1161/STROKEAHA.107.490581; Katano H, 2014, J STROKE CEREBROVASC, V23, P148, DOI 10.1016/j.jstrokecerebrovasdis.2012.11.019; Katano H, 2010, WORLD NEUROSURG, V73, P147, DOI 10.1016/j.surneu.2009.02.015; Kim BJ, 2010, CEREBROVASC DIS, V30, P93, DOI 10.1159/000314711; Lee KB, 2012, ATHEROSCLEROSIS, V223, P160, DOI 10.1016/j.atherosclerosis.2012.05.012; Li ZY, 2007, CEREBROVASC DIS, V24, P452, DOI 10.1159/000108436; McKinney A, 2005, NEURORADIOLOGY, V47, P1, DOI 10.1007/s00234-004-1301-4; Miura Toshiyasu, 2011, Cerebrovasc Dis Extra, V1, P54, DOI 10.1159/000328645; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Petretta M, 2012, ATHEROSCLEROSIS, V223, P95, DOI 10.1016/j.atherosclerosis.2012.01.032; Petretta M, 2012, INT J CARDIOVAS IMAG, V28, P1547, DOI 10.1007/s10554-011-9948-5; Prabhakaran Shyam, 2007, Atherosclerosis, V195, pe197, DOI 10.1016/j.atherosclerosis.2007.03.044; Virmani Renu, 2006, Neurosurgery, V59, pS219; Wagenknecht LE, 2007, AM J EPIDEMIOL, V166, P340, DOI 10.1093/aje/kwm091; Wu MT, 2013, CALCIFIED TISSUE INT, V93, P365, DOI 10.1007/s00223-013-9712-z; Yamada S, 2014, EUR J RADIOL, V83, P384, DOI 10.1016/j.ejrad.2013.10.011	38	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	JUN	2015	24	6					1341	1350		10.1016/j.jstrokecerebrovasdis.2015.02.010		10	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CJ2TT	WOS:000355338200046		
J	Saito, T; Kawamura, Y; Sato, N; Kano, K; Takahashi, K; Asanome, A; Sawada, J; Katayama, T; Hasebe, N				Saito, Tsukasa; Kawamura, Yuichiro; Sato, Nobuyuki; Kano, Kohei; Takahashi, Kae; Asanome, Asuka; Sawada, Jun; Katayama, Takayuki; Hasebe, Naoyuki			Non-Vitamin K Antagonist Oral Anticoagulants Do Not Increase Cerebral Microbleeds	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						NOAC; warfarin; cerebral microbleeds; atrial fibrillation	ATRIAL-FIBRILLATION; STROKE; WARFARIN; DABIGATRAN; RISK; HEMORRHAGE; MR	Background: Atrial fibrillation (AF) is a cardiac arrhythmia that frequently induces ischemic strokes. Nowadays, non-vitamin K antagonist oral anticoagulants (NOACs) have come into widespread use for cardiogenic embolism prevention in place of warfarin. Recently, cerebral microbleeds (CMBs) have been noticed for their potential implication in cerebral small vessel disease. We hypothesized that NOACs do not have an unfavorable influence over cerebral small vessels and investigated whether NOACs increase CMBs in AF patients in a prospective manner. Methods: We performed baseline magnetic resonance imaging (MRI) examinations on the 69 enrolled AF patients and re-examined second round of MRI 1 year later. The enrolled patients continued the same anticoagulation therapy during the meantime. Results: CMBs did not develop in the 23 patients with NOACs for 1 year. Nine patients with antiplatelets also did not develop CMBs. On the other hand, 3 of 21 patients continued on warfarin and 3 of 9 with warfarin and antiplatelets had CMBs. When divided into 2 groups according to whether the CMBs developed, significant differences in the incidence of using NOACs were observed between the 2 groups (P = .02). A multivariate regression analysis showed that warfarin was independently related to the new development of CMBs (hazard ratio, 10.75; 95% confidence interval, 1.22-94.99; P = .03). Conclusions: This is the first report to clarify that NOACs do not increase CMBs in AF patients longitudinally in 1 year. Further consideration will be continued with a much longer follow-up in large samples.	[Saito, Tsukasa; Kawamura, Yuichiro; Sato, Nobuyuki; Kano, Kohei; Takahashi, Kae; Asanome, Asuka; Sawada, Jun; Katayama, Takayuki; Hasebe, Naoyuki] Asahikawa Med Univ, Dept Internal Med, Cardiovasc Resp & Neurol Div, Asahikawa, Hokkaido 0788510, Japan	Saito, T (reprint author), Asahikawa Med Univ, Dept Internal Med, Cardiovasc Resp & Neurol Div, Midorigaoka Higashi 2-1-1-1, Asahikawa, Hokkaido 0788510, Japan.	tsukasa@asahikawa-med.ac.jp					Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Shoamanesh A, 2011, CEREBROVASC DIS, V32, P528, DOI 10.1159/000331466; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; Toyoda K, 2008, STROKE, V39, P1740, DOI 10.1161/STROKEAHA.107.504993; Ovbiagele B, 2010, ARCH NEUROL-CHICAGO, V67, P45, DOI 10.1001/archneurol.2009.310; Viswanathan A, 2006, STROKE, V37, P550, DOI 10.1161/01.STR.0000199847.96188.12; Offenbacher H, 1996, AM J NEURORADIOL, V17, P573; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747; Komori M, 2014, CIRC J, V78, P1335, DOI 10.1253/circj.CJ-13-1534; Olesen JB, 2012, THROMB HAEMOSTASIS, V107, P1172, DOI 10.1160/TH12-03-0175; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Camm AJ, 2012, EUR HEART J, V33, P2729; COLE FM, 1968, NEUROLOGY, V18, P255; Mason PK, 2012, AM J MED, V125, P603, DOI DOI 10.1016/J.AMJMED.2011.09.030; Saito T, 2014, J STROKE CEREBROVASC, V23, P1616, DOI 10.1016/j.jstrokecerebrovasdis.2014.01.005; Song TJ, 2014, NEUROLOGY, V83, P1308, DOI 10.1212/WNL.0000000000000862; Vernooij MW, 2008, NEUROLOGY, V70, P1208, DOI 10.1212/01.wnl.0000307750.41970.d9	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	JUN	2015	24	6					1373	1377		10.1016/j.jstrokecerebrovasdis.2015.02.018		5	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CJ2TT	WOS:000355338200050		
J	Tomita, H; Hagii, J; Metoki, N; Saito, S; Shiroto, H; Hitomi, H; Kamada, T; Seino, S; Takahashi, K; Sasaki, S; Yasujima, M; Okumura, K				Tomita, Hirofumi; Hagii, Joji; Metoki, Norifumi; Saito, Shin; Shiroto, Hiroshi; Hitomi, Hiroyasu; Kamada, Takaatsu; Seino, Satoshi; Takahashi, Koki; Sasaki, Satoko; Yasujima, Minoru; Okumura, Ken			Severity and Functional Outcome of Patients with Cardioembolic Stroke Occurring during Non-vitamin K Antagonist Oral Anticoagulant Treatment	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Cardioembolic stroke; non-vitamin K antagonist oral anticoagulant; warfarin; atrial fibrillation	NONVALVULAR ATRIAL-FIBRILLATION; J-RHYTHM REGISTRY; JAPANESE PATIENTS; ISCHEMIC-STROKE; WARFARIN; RIVAROXABAN; INTENSITY; VALIDATION; DABIGATRAN; APIXABAN	Background: Severity and functional outcome of patients with cardioembolic stroke (CE) occurring during non-vitamin K antagonist oral anticoagulant (NOAC) treatment remain uncertain. Methods: The consecutive 355 CE patients within 48 hours after onset and with modified Rankin Scale (mRS) score of 1 or less before onset were studied. Of all, 262 patients were treated with no anticoagulants (non-AC), 63 with warfarin below therapeutic range of prothrombin time-international normalized ratio (PT-INR) on admission (PT-INR,1.6 [WF-Lo]), 16 with warfarin within therapeutic range (PT-INR >= 1.6 [WF-Tp]), and 14 with NOACs (9 dabigatran and 5 rivaroxaban [NOAC-DR]). We compared severity and functional outcome of CE patients among these 4 groups, especially focusing on patients during NOAC treatment. Results: Stroke severity on admission, assessed by the National Institutes of Health Stroke Scale, was lower in WF-Tp (median, 5 [1-15]) and NOAC-DR (5 [3-6]) than in non-AC (11 [5-19]) and WF-Lo (12 [5-19]; P = .006). Functional outcome at discharge, assessed by mRS, was favorable in WF-Tp (median, 1 [0-4]) and NOAC-DR (1 [1-2]) compared with that in non-AC (2 [1-4]) and WF-Lo (3 [1-5]; P = .02), and ratios of the patients with mRS score of 1 or less were 63% and 64% versus 31% and 33%, respectively (P = .005). Multivariate analysis also showed a favorable functional outcome at discharge in WF-Tp and NOAC-DR groups. Drug management was likely associated with NOAC-associated CE. Conclusions: Stroke severity and functional outcome of CE patients treated with warfarin within therapeutic range and with NOACs are similar to each other, and are more favorable than those with no anticoagulants and with warfarin below therapeutic range.	[Tomita, Hirofumi; Okumura, Ken] Hirosaki Univ, Dept Cardiol, Grad Sch Med, Hirosaki, Aomori 0368562, Japan; [Hagii, Joji; Metoki, Norifumi; Saito, Shin; Shiroto, Hiroshi; Hitomi, Hiroyasu; Kamada, Takaatsu; Seino, Satoshi; Takahashi, Koki; Sasaki, Satoko; Yasujima, Minoru] Hirosaki Univ, Grad Sch Med, Hirosaki Stroke & Rehabil Ctr, Hirosaki, Aomori 0368562, Japan; [Okumura, Ken] Hirosaki Univ, Grad Sch Med, Dept Hypertens & Stroke Med, Hirosaki, Aomori 0368562, Japan	Okumura, K (reprint author), Hirosaki Univ, Dept Cardiol, Grad Sch Med, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	okumura@hirosaki-u.ac.jp			Bayer Healthcare; Boehringer Ingelheim; Daiichi-Sankyo	H.T. received research funding from Bayer Healthcare; J.H. received research funding from Bayer Healthcare, and Speakers' Bureau/Honorarium from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb, and Pfizer; N.M. received Speakers' Bureau/Honorarium from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb, and Pfizer; M.Y. received Speakers' Bureau/Honorarium from Bristol-Myers Squibb and Pfizer; K.O. received research funding from Boehringer Ingelheim, Bayer Healthcare, and Daiichi-Sankyo and Speakers' Bureau/Honorarium from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb, Pfizer, and Eisai; the other authors have no disclosure.	Adams Jr HP, 1993, ARTERIOSCLER THROMB, V24, P35, DOI DOI 10.1161/01.STR.24.1.35; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Nakamura A, 2013, STROKE, V44, P3239, DOI 10.1161/STROKEAHA.113.002523; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0; Hagii J, 2014, STROKE, V45, P2805, DOI 10.1161/STROKEAHA.114.006661; Camm AJ, 2010, EUR HEART J, V31, P2369, DOI 10.1093/eurheartj/ehq278; Okumura K, 2014, CIRC J, V78, P1593, DOI 10.1253/circj.CJ-14-0144; Shore S, 2014, AM HEART J, V167, P810, DOI 10.1016/j.ahj.2014.03.023; [Anonymous], 2010, CIRC J, V74, P2479; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Lip GYH, 2014, CHEST, V145, P1177, DOI 10.1378/chest.13-2951; Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907; Inoue H, 2013, CIRC J, V77, P2264, DOI 10.1253/circj.CJ-13-0290; [Anonymous], 2005, JPN J STROKE, V26, P327; O'Donnell M, 2006, LANCET NEUROL, V5, P749, DOI 10.1016/S1474-4422(06)70536-1; Varin R, 2013, THROMB RES, V131, pE100, DOI 10.1016/j.thromres.2012.11.029; Hylek EM, 2014, J AM COLL CARDIOL, V63, P2141, DOI 10.1016/j.jacc.2014.02.549; Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913; Stollberger C, 2014, NEUROL NEUROCHIR POL, V48, P136, DOI 10.1016/j.pjnns.2014.03.001; Yamashita T, 2015, J CARDIOL, V65, P175, DOI 10.1016/j.jjcc.2014.07.013	22	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	JUN	2015	24	6					1430	1437		10.1016/j.jstrokecerebrovasdis.2015.03.004		8	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CJ2TT	WOS:000355338200058		
J	Kobayashi, M; Tanaka, R; Yamashiro, K; Ueno, Y; Kato, E; Miura, S; Daida, H; Hattori, N				Kobayashi, Manami; Tanaka, Ryota; Yamashiro, Kazuo; Ueno, Yuji; Kato, Etsuro; Miura, Seiji; Daida, Hiroyuki; Hattori, Nobutaka			Pre-existing Mobile Cardiac Thrombus and the Risk of Early Recurrent Embolism after Intravenous Thrombolysis: A Case Report	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Mobile cardiac thrombus; acute ischemic stroke; thrombolysis; tPA; early recurrence	MYOCARDIAL-INFARCTION; STROKE; THERAPY	Background: Early recurrence of an embolism is rarely observed in patients with stroke treated with intravenous thrombolysis. Pre-existing cardiac thrombus is thought as a risk factor for recurrent embolism, although the relationship remains unclear. Methods: The present patient was a 30-year-old man with acute ischemic stroke. Transthoracic echocardiography performed before thrombolysis demonstrated an intraventricular mobile thrombus, and the patient was treated with intravenous thrombolysis 183 minutes after the onset of stroke. During thrombolysis, he suffered from a peripheral artery embolism, without further signs of neurologic deterioration. Repeated transthoracic echocardiography showed the disappearance of the intraventricular thrombus. However, follow-up magnetic resonance imaging disclosed new ischemic lesions at the splenium of the corpus callosum, and body computed tomography showed infarction of the spleen and kidney. The peripheral artery embolism improved spontaneously without further evidence of recurrent embolism. Results: This is the first report to provide findings of an intracardiac mobile thrombus before thrombolysis and to demonstrate the acceleration of detachment of the thrombus during thrombolysis. Conclusions: Because there are currently no guidelines for the use of intravenous thrombolysis for acute ischemic stroke associated with a pre-existing intracardiac thrombus with respect to the efficacy and safety, physicians should pay special attention to similar cases.	[Kobayashi, Manami; Tanaka, Ryota; Yamashiro, Kazuo; Ueno, Yuji; Hattori, Nobutaka] Juntendo Univ, Sch Med, Dept Neurol, Tokyo 1130033, Japan; [Kato, Etsuro; Miura, Seiji; Daida, Hiroyuki] Juntendo Univ, Sch Med, Dept Cardiol, Tokyo 1130033, Japan	Tanaka, R (reprint author), Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1130033, Japan.	r_tanaka@juntendo.ac.jp					Derex L, 2001, NEUROLOGY, V57, P2122; BAUTISTA RED, 1995, STROKE, V26, P324; Chang MCK, 2002, ECHOCARDIOGR-J CARD, V19, P139, DOI 10.1046/j.1540-8175.2002.00139.x; Gomez-Beldarrain M, 2006, NEUROLOGY, V67, P1096, DOI 10.1212/01.wnl.0000237320.18214.6c; YASAKA M, 1994, ANGIOLOGY, V45, P481, DOI 10.1177/000331979404500611	5	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	JUN	2015	24	6					E161	E163		10.1016/j.jstrokecerebrovasdis.2015.03.001		3	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CJ2TT	WOS:000355338200010		
J	Matsuo, K; Uozumi, Y; Miyamoto, H; Tatsumi, S; Kohmura, E				Matsuo, Kazuya; Uozumi, Yoichi; Miyamoto, Hirohito; Tatsumi, Shotaro; Kohmura, Eiji			Varicella-Zoster Vasculitis Presenting with Cerebellar Hemorrhage	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Varicella zoster; vasculitis; hemorrhagic stroke; encephalitis	VIRUS; ANTEROGRADE; INNERVATION; GANGLION	Background: Varicella zoster virus (VZV) is known as one of the rare, but important, causes of both ischemic and hemorrhagic stroke. Most previously reported VZV-related hemorrhagic stroke and cerebral vasculitis are associated with anterior circulation because VZV spreads from trigeminal ganglia to the anterior circulation of Willis. The present study presents a patient with cerebellar hemorrhage, who was diagnosed with VZV encephalitis and vasculitis of the posterior inferior cerebellar artery. Case Report: A 75-year-old man with stupor was admitted to our hospital. Computed tomography revealed right intracerebellar hemorrhage, and magnetic resonance imaging revealed multiple high-intense signals throughout the brainstem and temporal lobe on fluid attenuation inversion recovery, suggestive of encephalitis. Cerebral angiography revealed stenosis of left posterior inferior cerebellar artery. Based on cerebrospinal fluid analysis, including anti-VZV IgG antibody and VZV DNA polymerase chain reaction, the patient was diagnosed with VZV encephalitis, vasculitis, and cerebellar hemorrhage. Conclusions: Both cerebral vasculitis and hemorrhagic stroke due to VZV can occur in the vertebrobasilar system. VZV may enter the central nervous system not only from trigeminal ganglia but also from other pathways. We should be aware that a VZV infection could cause cerebral vasculitis and hemorrhagic stroke in the vertebrobasilar system and in anterior circulation.	[Matsuo, Kazuya; Uozumi, Yoichi; Miyamoto, Hirohito; Tatsumi, Shotaro] Hirohata Steel Mem Hosp, Dept Neurosurg, Himeji, Hyogo 6711122, Japan; [Kohmura, Eiji] Kobe Univ, Grad Sch Med, Dept Neurosurg, Kobe, Hyogo 657, Japan	Matsuo, K (reprint author), Hirohata Steel Mem Hosp, Dept Neurosurg, Hirohata Ku, 3-1 Yumesaki Cho, Himeji, Hyogo 6711122, Japan.	vol5@gmail.com					FUKUMOTO S, 1986, STROKE, V17, P1024; Kang JH, 2009, STROKE, V40, P3443, DOI 10.1161/STROKEAHA.109.562017; Gilden DH, 2000, NEW ENGL J MED, V342, P635, DOI 10.1056/NEJM200003023420906; Nagel MA, 2008, NEUROLOGY, V70, P853, DOI 10.1212/01.wnl.0000304747.38502.e8; Baek W, 2012, ARCH NEUROL-CHICAGO, V69, P1193, DOI 10.1001/archneurol.2011.3741; ARBAB MAR, 1988, BRAIN RES, V445, P175, DOI 10.1016/0006-8993(88)91090-6; Bhayani N, 2008, CLIN INFECT DIS, V47, pE1, DOI 10.1086/588842; Gonzalez-Suarez I, 2014, J NEUROL SCI, V338, P34, DOI 10.1016/j.jns.2014.01.009; SAITO K, 1989, STROKE, V20, P524; ZHANG QJ, 1993, NEUROSURGERY, V32, P993	10	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	JUN	2015	24	6					E153	E155		10.1016/j.jstrokecerebrovasdis.2015.03.003		3	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CJ2TT	WOS:000355338200008		
J	Miki, Y; Fujioka, M; Taoka, T; Tanaka, H; Chitoku, S; Matsuyama, T; Tanaka, S				Miki, Yusuke; Fujioka, Masayuki; Taoka, Toshiaki; Tanaka, Hiroaki; Chitoku, Shiro; Matsuyama, Takeshi; Tanaka, Shigeko			Utility of High-b-Value Diffusion-Weighted Magnetic Resonance Imaging in Evaluating Reversible Medial Longitudinal Fasciculus Syndrome Caused by Acute Brainstem Ischemia	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						MLF syndrome; brainstem; stroke; high-b-value DWI; MRI	CARDIAC-ARREST; STROKE; MRI; HYPERINTENSITY; CAUDOPUTAMEN; PERFUSION; IMAGES	Background: Medial longitudinal fasciculus (MLF) syndrome refers to a gaze disorder characterized by impaired adduction on the ipsilateral side to the injured MLF, with dissociated nystagmus of the contralateral abducting eye. The most common cause of the MLF syndrome is ischemic stroke. However, acute ischemic change in the MLF may be undetectable even on diffusion-weighted magnetic resonance imaging (DW-MRI) partly because of its small size and specific brainstem location. Case Report: Herein, we present the first reported case of MLF syndrome in which, compared with the standard-b-value DWI, a higher b-value DWI revealed more clearly a small infarction in the dorsal pons in the acute stage. Conclusions: We suggest that high-b-value DWI can be a useful diagnostic method for patients with MLF syndrome caused by possible brainstem ischemia and thus supportive for deciding the optimal treatment for such patients.	[Miki, Yusuke; Fujioka, Masayuki; Tanaka, Hiroaki; Chitoku, Shiro; Matsuyama, Takeshi] Osaka Wakakusa Dai ichi Hosp, Stroke Ctr, Dept Neurosurg, Osaka, Japan; [Taoka, Toshiaki] Nara Med Univ, Dept Radiol, Nara, Japan; [Tanaka, Shigeko] Osaka Saiseikai Senri Hosp, Dept Radiol, Suita, Osaka 5650862, Japan	Fujioka, M (reprint author), Osaka Saiseikai Senri Hosp, Dept Neurosurg, 1-1-6 Tsukumodai, Suita, Osaka 5650862, Japan.	mfujioka_2000_99@yahoo.co.jp			JSPS KAKENHI [26462170]	The contribution of M.F. to this work was partly supported by JSPS KAKENHI, grant number: 26462170.	Fujioka M, 2000, CEREBROVASC DIS, V10, P2, DOI 10.1159/000016018; Cihangiroglu M, 2011, EUR J RADIOL, V78, P75, DOI 10.1016/j.ejrad.2009.10.011; LEBIHAN D, 1986, RADIOLOGY, V161, P401; Oppenheim C, 2000, AM J NEURORADIOL, V21, P1434; Chalela JA, 2007, LANCET, V369, P293, DOI 10.1016/S0140-6736(07)60151-2; Sylaja PN, 2008, STROKE, V39, P1898, DOI 10.1161/STROKEAHA.107.497453; VANSWIETEN JC, 1988, STROKE, V19, P604; Fujioka M, 2003, ANN NEUROL, V54, P732, DOI 10.1002/ana.10751; Le Bihan D, 2006, J MAGN RESON IMAGING, V24, P478, DOI 10.1002/jmri.20683; Fujioka M, 1999, STROKE, V30, P1043; Fujioka M, 1997, STROKE, V28, P584; Fujioka M, 2013, J STROKE CEREBROVASC, V22, P1428, DOI 10.1016/j.jstrokecerebrovasdis.2012.12.009; Etgen T, 2004, EUR NEUROL, V52, P145, DOI 10.1159/000081623; Frohman TC, 2008, NEUROLOGY, V70, pE57, DOI 10.1212/01.wnl.0000310640.37810.b3; FUJIOKA M, 1994, STROKE, V25, P2091; Fujioka M, 1999, STROKE, V30, P1038; Kim HJ, 2005, AM J NEURORADIOL, V26, P208; Lettau M, 2013, J NEURORADIOLOGY, V40, P149, DOI 10.1016/j.neurad.2012.08.007	18	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	JUN	2015	24	6					E157	E159		10.1016/j.jstrokecerebrovasdis.2015.03.002		3	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CJ2TT	WOS:000355338200009		
J	Tominaga, S; Hirai, K; Horiuchi, T				Tominaga, Shoji; Hirai, Keita; Horiuchi, Takahiko			Estimation of bispectral Donaldson matrices of fluorescent objects by using two illuminant projections	JOURNAL OF THE OPTICAL SOCIETY OF AMERICA A-OPTICS IMAGE SCIENCE AND VISION			English	Article							SAMPLES; COLORIMETRY; COMPONENTS; SEPARATION	This paper proposes a method for estimating the bispectral Donaldson matrices of fluorescent objects by using only two illuminant projections with continuous spectral power distributions. The Donaldson matrix represents the spectral radiance factor consisting of the sum of two components: a reflected radiance factor and a luminescent radiance factor. First, we describe the spectral characteristics of the observed matrix and model the matrix so that the luminescent radiance factor is separable into the emission and excitation wavelength components. We make no assumption as to the spectral shapes of any components, but derive a physical model that is useful for predicting the excitation spectral component from the reflected radiance component. An algorithm is developed to estimate the entire elements of the Donaldson matrix based on only two sets of spectral sensor outputs under two different illuminants. We suggest that the difference between the observed reflected radiance factors under the two different illuminants is not caused by the reflected radiance component, but only the luminescent radiance component. The algorithm is a sequential estimation of three radiance components of luminescent excitation, luminescent emission, and reflection. The feasibility of the proposed method is confirmed in experiments using a variety of fluorescent samples. The estimation accuracy is evaluated numerically in root-mean squared error and the color difference under the assumption of a viewing illuminant. An optimal selection of the illuminant pair is shown based on a simulation experiment using blackbody radiators with different color temperatures. (C) 2015 Optical Society of America	[Tominaga, Shoji; Hirai, Keita; Horiuchi, Takahiko] Chiba Univ, Grad Sch Adv Integrat Sci, Div Informat Sci, Chiba 2638522, Japan	Tominaga, S (reprint author), Chiba Univ, Grad Sch Adv Integrat Sci, Div Informat Sci, Chiba 2638522, Japan.	shoji@faculty.chiba-u.jp			 [23300066];  [25540063]	Grants-in-Aid for Scientific Research, Japan (23300066, 25540063).	ALLEN E, 1973, APPL OPTICS, V12, P289, DOI 10.1364/AO.12.000289; WRIGHTON MS, 1974, J PHYS CHEM-US, V78, P2229, DOI 10.1021/j100615a009; ASTM, 2001, E215301 ASTM INT; ASTM, 2000, E214703 ASTM INT; BILLMEYER FW, 1980, COLOR RES APPL, V5, P156, DOI 10.1002/col.5080050309; Choyke PL, 2012, IEEE J SEL TOP QUANT, V18, P1140, DOI 10.1109/JSTQE.2011.2164900; CIE, 2007, 1822007 CIE; DONALDSON R, 1954, BRIT J APPL PHYS, V5, P210, DOI 10.1088/0508-3443/5/6/303; Grum F., 1977, TAPPI ANN M, P54; Holopaine S., 2009, THESIS HELSINKI U TE, P166; Ishida H, 2010, COORDIN CHEM REV, V254, P2449, DOI 10.1016/j.ccr.2010.04.006; Lakowicz J. R., 2006, PRINCIPLES FLUORESCE; MINATO H, 1985, COLOR RES APPL, V10, P84, DOI 10.1002/col.5080100206; MINATO H, 1983, COLOR RES APPL, V8, P238, DOI 10.1002/col.5080080410; Mohammadi M., 2009, THESIS CF CARLSON CT; Mutanen J., 2004, THESIS U JOENSUU, P45; Schieber F., 2001, P HUMAN FACTORS ERGO, V45, P1324; Tominaga S, 2002, P IEEE, V90, P42, DOI 10.1109/5.982404; Tominaga S., 2013, P COL VIS COMP S CVC, P1; Tominaga S., 2011, PROC CIC19, P352; Wyszecki G., 1982, COLOR SCI CONCEPTS M; Zhang C, 2013, IEEE T PATTERN ANAL, V35, P2866, DOI 10.1109/TPAMI.2012.255; Zwinkels J, 2008, SPRINGER SER FLUORES, V05, P163, DOI 10.1007/4243_2008_034	23	0	0	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	1084-7529	1520-8532		J OPT SOC AM A	J. Opt. Soc. Am. A-Opt. Image Sci. Vis.	JUN	2015	32	6					1068	1078		10.1364/JOSAA.32.001068		11	Optics	Optics	CJ6VM	WOS:000355633300008		
J	Mori, K; Takara, H; Kawanishi, S				Mori, Kunihiko; Takara, Hidehiko; Kawanishi, Satoki			Analysis and design of supercontinuum pulse generation in a single-mode optical fiber (vol 18, pg 1780, 2001)	JOURNAL OF THE OPTICAL SOCIETY OF AMERICA B-OPTICAL PHYSICS			English	Correction									[Mori, Kunihiko; Takara, Hidehiko; Kawanishi, Satoki] NTT Corp, NTT Network Innovat Labs, Yokosuka, Kanagawa 2390847, Japan	Mori, K (reprint author), NTT Corp, NTT Network Innovat Labs, 1-1 Hikari No Oka, Yokosuka, Kanagawa 2390847, Japan.	mori.kunihiko@lab.ntt.co.jp					Mori K, 2001, J OPT SOC AM B, V18, P1780, DOI 10.1364/JOSAB.18.001780	1	0	0	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	0740-3224	1520-8540		J OPT SOC AM B	J. Opt. Soc. Am. B-Opt. Phys.	JUN	2015	32	6					1174	1175		10.1364/JOSAB.32.001174		2	Optics	Optics	CJ6VE	WOS:000355632200022		
J	Das, RM; Chatterjee, S; Iwasaki, M; Nakajima, T				Das, Rakesh Mohan; Chatterjee, Souvik; Iwasaki, Masahiko; Nakajima, Takashi			Ionization efficiency of Doppler-broadened atoms by transform-limited and broadband nanosecond pulses: one-photon resonant two-photon ionization of muoniums	JOURNAL OF THE OPTICAL SOCIETY OF AMERICA B-OPTICAL PHYSICS			English	Article							MULTIPHOTON IONIZATION; MASS-SPECTROMETRY; SELECTIVE IONIZATION; SPIN ROTATION; LINE-SHAPES; SPECTROSCOPY; SCHEME; STATES; INTERFERENCE; EXCITATION	We theoretically study the ionization efficiency of Doppler-broadened atoms through a one-photon resonant two-photon ionization process using nanosecond pump and ionizing laser pulses. Under the presence of significant (> tens of GHz) Doppler broadening, the bandwidth of the transform-limited nanosecond pump pulse is far smaller than the Doppler width, and the use of the broadband nanosecond pulse rather than the transform-limited nanosecond pulse seems to be much more efficient to pump and eventually ionize atoms. It turns out, however, that the transform-limited nanosecond pump pulse with sufficient high intensity can outperform the broadband nanosecond pump pulse in the high intensity regime for the ionizing pulse, at which the other broadening mechanisms because of the strong pump and fast ionization play more important roles than the bandwidth of the pump pulse. Using a set of density matrix equations, we present specific numerical results for muoniums (mu(+)e(-)) with enormous Doppler widths (80 and 230 GHz), which support the above argument. (C) 2015 Optical Society of America	[Das, Rakesh Mohan; Chatterjee, Souvik; Nakajima, Takashi] Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan; [Iwasaki, Masahiko] RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	Nakajima, T (reprint author), Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan.	nakajima@iae.kyoto-u.ac.jp	Iwasaki, Faculty of Science/M-8433-2014	Iwasaki, Faculty of Science/0000-0002-3460-9469	Ministry of Education, Culture, Sports, Science and Technology	Ministry of Education, Culture, Sports, Science and Technology.	HARRIS SE, 1989, PHYS REV LETT, V62, P1033, DOI 10.1103/PhysRevLett.62.1033; Bergmann K, 1998, REV MOD PHYS, V70, P1003, DOI 10.1103/RevModPhys.70.1003; BOLLER KJ, 1991, PHYS REV LETT, V66, P2593, DOI 10.1103/PhysRevLett.66.2593; deReotier PD, 1997, J PHYS-CONDENS MAT, V9, P9113; ZOLLER P, 1979, J PHYS B-AT MOL OPT, V12, pL547, DOI 10.1088/0022-3700/12/18/003; HURST GS, 1979, REV MOD PHYS, V51, P767, DOI 10.1103/RevModPhys.51.767; Bakule P, 2003, SPECTROCHIM ACTA B, V58, P1019, DOI 10.1016/S0584-8547(03)00062-4; BAYFIELD JE, 1974, PHYS REV LETT, V33, P258, DOI 10.1103/PhysRevLett.33.258; BEBB HB, 1966, PHYS REV, V143, P1, DOI 10.1103/PhysRev.143.1; Beer G. A., 2014, PROG THEOR EXP PHYS, V2014; Bushaw BA, 2000, SPECTROCHIM ACTA B, V55, P1679, DOI 10.1016/S0584-8547(00)00269-X; DAI BN, 1986, PHYS REV A, V34, P3954, DOI 10.1103/PhysRevA.34.3954; Deng L, 2012, OPT EXPRESS, V20, P17566, DOI 10.1364/OE.20.017566; DIXIT SN, 1980, PHYS REV A, V21, P1289, DOI 10.1103/PhysRevA.21.1289; FEAREY BL, 1990, J OPT SOC AM B, V7, P3, DOI 10.1364/JOSAB.7.000003; Gomonai AI, 2003, J PHYS B-AT MOL OPT, V36, P4155, DOI 10.1088/0953-4075/36/20/009; GONTIER Y, 1979, PHYS REV A, V19, P264, DOI 10.1103/PhysRevA.19.264; GRISCHKOWSKY D, 1976, PHYS REV A, V14, P802, DOI 10.1103/PhysRevA.14.802; Jayasekharan T, 1996, J OPT SOC AM B, V13, P641, DOI 10.1364/JOSAB.13.000641; LAMBROPO.P, 1974, PHYS REV A, V9, P1992, DOI 10.1103/PhysRevA.9.1992; LEVENSON MD, 1974, PHYS REV LETT, V32, P645, DOI 10.1103/PhysRevLett.32.645; Levine J, 2012, SPECTROCHIM ACTA B, V69, P61, DOI 10.1016/j.sab.2012.02.001; MAINFRAY G, 1991, REP PROG PHYS, V54, P1333, DOI 10.1088/0034-4885/54/10/002; NAGAMIYA S, 1975, PHYS REV LETT, V35, P308, DOI 10.1103/PhysRevLett.35.308; Nakajima T, 2010, OPT EXPRESS, V18, P27468, DOI 10.1364/OE.18.027468; Nakajima T, 2012, J OPT SOC AM B, V29, P2420, DOI 10.1364/JOSAB.29.002420; Podshivalov AA, 1999, SPECTROCHIM ACTA B, V54, P1793, DOI 10.1016/S0584-8547(99)00112-3; Rodriguez VD, 2011, J PHYS B-AT MOL OPT, V44, DOI 10.1088/0953-4075/44/12/125603; SALOUR MM, 1977, PHYS REV LETT, V38, P757, DOI 10.1103/PhysRevLett.38.757; Sankari M, 2008, J OPT SOC AM B, V25, P1820, DOI 10.1364/JOSAB.25.001820; Shore B W, 2011, MANIPULATING QUANTUM	31	0	0	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	0740-3224	1520-8540		J OPT SOC AM B	J. Opt. Soc. Am. B-Opt. Phys.	JUN	2015	32	6					1237	1244		10.1364/JOSAB.32.001237		8	Optics	Optics	CJ6VE	WOS:000355632200031		
J	Sato, T; Makino, S; Ishizaka, Y; Fujisawa, T; Saitoh, K				Sato, Takanori; Makino, Shuntaro; Ishizaka, Yuhei; Fujisawa, Takeshi; Saitoh, Kunimasa			A rigorous definition of nonlinear parameter gamma and effective area A(eff) for photonic crystal optical waveguides	JOURNAL OF THE OPTICAL SOCIETY OF AMERICA B-OPTICAL PHYSICS			English	Article							SELF-PHASE-MODULATION; SLOW-LIGHT; SILICON; ENHANCEMENT	A rigorous definition of nonlinear parameter gamma for high-index-contrast (HIC) periodic optical waveguides, such as photonic crystal (PC) optical waveguides, is proposed. The definition is fully vectorial, and approximations assumed in previous works are unnecessary. The gamma values calculated by the proposed definition are compared with those obtained by previous definitions, the rigorous nonlinear mode solver, and measured values for weakly guiding optical fibers, HIC Si-nanowire waveguides, and PC waveguides. It is demonstrated that the gamma values calculated by proposed definition agree well with those of the rigorous nonlinear mode solver and experiments for all three waveguides, showing the validity of the definition. (C) 2015 Optical Society of America	[Sato, Takanori; Makino, Shuntaro; Ishizaka, Yuhei; Fujisawa, Takeshi; Saitoh, Kunimasa] Hokkaido Univ, Grad Sch Informat Sci & Technol, Kita Ku, Sapporo, Hokkaido 0600814, Japan	Sato, T (reprint author), Hokkaido Univ, Grad Sch Informat Sci & Technol, Kita Ku, North 14,West 9, Sapporo, Hokkaido 0600814, Japan.	tsato@icp.ist.hokudai.ac.jp					Agrawal G. P., 2012, NONLINEAR FIBER OPTI; Shinkawa M, 2011, OPT EXPRESS, V19, P22208, DOI 10.1364/OE.19.022208; Leuthold J, 2010, NAT PHOTONICS, V4, P535, DOI [10.1038/NPHOTON.2010.185, 10.1038/nphoton.2010.185]; Sato T, 2014, J LIGHTWAVE TECHNOL, V32, P4011, DOI 10.1109/JLT.2014.2344731; Monat C, 2010, IEEE J SEL TOP QUANT, V16, P344, DOI 10.1109/JSTQE.2009.2033019; Boyraz O, 2004, OPT EXPRESS, V12, P829, DOI 10.1364/OPEX.12.000829; Koos C, 2007, OPT EXPRESS, V15, P5976, DOI 10.1364/OE.15.005976; Dulkeith E, 2006, OPT EXPRESS, V14, P5524, DOI 10.1364/OE.14.005524; Jacobsen RS, 2006, NATURE, V441, P199, DOI 10.1038/nature04706; Husko C, 2009, OPT EXPRESS, V17, P22442, DOI 10.1364/OE.17.022442; Brosi JM, 2008, OPT EXPRESS, V16, P4177, DOI 10.1364/OE.16.004177; STOLEN RH, 1978, PHYS REV A, V17, P1448, DOI 10.1103/PhysRevA.17.1448; Notomi M, 2010, REP PROG PHYS, V73, DOI 10.1088/0034-4885/73/9/096501; Foster MA, 2008, OPT EXPRESS, V16, P1300, DOI 10.1364/OE.16.001300; Broderick NGR, 2000, PHYS REV LETT, V84, P4345, DOI 10.1103/PhysRevLett.84.4345; McMillan JF, 2010, OPT EXPRESS, V18, P15484, DOI 10.1364/OE.18.015484; Suzuki K, 2009, OPT EXPRESS, V17, P22393, DOI 10.1364/OE.17.022393; Boskovic A, 1996, OPT LETT, V21, P1966, DOI 10.1364/OL.21.001966; Fujisawa T, 2006, IEEE PHOTONIC TECH L, V18, P1530, DOI 10.1109/LPT.2006.877593; Krauss TF, 2007, J PHYS D APPL PHYS, V40, P2666, DOI 10.1088/0022-3727/40/9/S07; Matsuda N, 2011, OPT EXPRESS, V19, P19861, DOI 10.1364/OE.19.019861; Monat C, 2009, OPT EXPRESS, V17, P2944, DOI 10.1364/OE.17.002944; Tsang HK, 2008, SEMICOND SCI TECH, V23, DOI 10.1088/0268-1242/23/6/064007; Makino S, 2013, IEEE PHOTONICS J, V5, DOI 10.1109/JPHOT.2013.2246557; Ebnali-Heidari M, 2009, OPT EXPRESS, V17, P18340, DOI 10.1364/OE.17.018340; Lin Q, 2007, OPT EXPRESS, V15, P16604, DOI 10.1364/OE.15.016604; Buckley S, 2013, APPL PHYS LETT, V103, DOI 10.1063/1.4833545; Sato T, 2014, 2014 OPTOELECTRONICS AND COMMUNICATIONS CONFERENCE AND AUSTRALIAN CONFERENCE ON OPTICAL FIBRE TECHNOLOGY (OECC/ACOFT 2014), P673; Suzuki K, 2010, OPT EXPRESS, V18, P26675, DOI 10.1364/OE.18.026675; Foresi JS, 1997, NATURE, V390, P143	30	1	1	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	0740-3224	1520-8540		J OPT SOC AM B	J. Opt. Soc. Am. B-Opt. Phys.	JUN	2015	32	6					1245	1251		10.1364/JOSAB.32.001245		7	Optics	Optics	CJ6VE	WOS:000355632200032		
J	Honda, K; Okamura, Y; Nishimura, Y; Uchita, S; Yuzaki, M; Kaneko, M; Yamamoto, N; Kubo, T; Akasaka, T				Honda, Kentaro; Okamura, Yoshitaka; Nishimura, Yoshiharu; Uchita, Shunji; Yuzaki, Mitsuru; Kaneko, Masahiro; Yamamoto, Nobuko; Kubo, Takashi; Akasaka, Takashi			Graft flow assessment using a transit time flow meter in fractional flow reserve-guided coronary artery bypass surgery	JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY			English	Article						FFR-guided coronary surgery; TTFM	ADENOSINE; STENOSIS; PATENCY	Objective: To evaluate the relationship between preoperative severity of coronary stenosis occurring with fractional flow reserve (FFR), and the intraoperative bypass graft flow pattern. Methods: In all, 72 patients were enrolled in this retrospective study. The FFR value of the left anterior descending artery was evaluated, and data on "in situ" bypass grafting from the internal thoracic artery to the left anterior descending artery were assessed. Patients were divided into 3 groups according to preoperative FFR values (Group S: FFR < 0.70; group M: 0.70 <= FFR< 0.75; and group N: FFR >= 0.75). Results: In groups S, M, and N, respectively, mean graft flow was 24.7 +/- 10.6 mL/minute, 19.2 +/- 14.0mL/minute, and 16.0 +/- 9.7mLmL/minute; pulsatility indexwas 2.35 +/- 0.6, 3.02 +/- 1.1, and 5.51 +/- 8.20; and number of patients with systolic reverse flow was 3 (6.8%), 5 (35.7%), and 4 (28.6%). Significant differences were observed in graft flow (P = .009), pulsatility index (P = .038), and proportion of systolic reverse flow (P = .023) among the 3 groups. In all patients, graft patency was confirmed with intraoperative fluorescence imaging; postoperative graft patency was confirmed with multislice computed tomography or coronary angiography in 69 patients (follow-up interval: 213 days). Early graft failure occurred in 1 patient. Conclusions: As coronary stenosis severity increased, graft flow increased, pulsatility index decreased, and proportion of patients with systolic reverse flow increased. In mild coronary artery stenosis, the chance of flow competition between the native coronary artery and the bypass graft increased.	[Honda, Kentaro; Okamura, Yoshitaka; Nishimura, Yoshiharu; Uchita, Shunji; Yuzaki, Mitsuru; Kaneko, Masahiro; Yamamoto, Nobuko] Wakayama Med Univ, Dept Thorac & Cardiovasc Surg, Wakayama, Japan; [Kubo, Takashi; Akasaka, Takashi] Wakayama Med Univ, Dept Cardiovasc Med, Wakayama, Japan	Honda, K (reprint author), Dept Thorac & Cardiovasc Surg, 811-1 Kimiidera, Wakayama 6410012, Japan.	honda-k@wakayama-med.ac.jp					De Bruyne B, 2003, CIRCULATION, V107, P1877, DOI 10.1161/01.CIR.0000061950.24940.88; Pijls NHJ, 2007, J AM COLL CARDIOL, V49, P2105, DOI 10.1016/j.jacc.2007.01.087; Kieser TM, 2010, EUR J CARDIO-THORAC, V38, P155, DOI 10.1016/j.ejcts.2010.01.026; Seo MK, 2012, CIRC-CARDIOVASC INTE, V5, P401, DOI 10.1161/CIRCINTERVENTIONS.111.965392; Botman CJ, 2007, ANN THORAC SURG, V83, P2093, DOI 10.1016/j.athoracsur.2007.01.027; Tokuda Y, 2008, ANN THORAC SURG, V86, P532, DOI 10.1016/j.athoracsur.2008.04.023; De Bruyne B, 2014, NEW ENGL J MED, V371, P1208, DOI 10.1056/NEJMoa1408758; Wijns W, 2010, EUR HEART J, V31, P2501, DOI 10.1093/eurheartj/ehq277; D'Ancona G, 2001, INTRAOPERATIVE GRAFT; Giammarco Di, 2006, J THORAC CARDIOVASC, V132, P468; KITAMURA S, 1992, ANN THORAC SURG, V53, P156; Leong DK, 2005, ANN THORAC SURG, V79, P857; Leong DKH, 2005, ANN THORAC SURG, V79, P854, DOI 10.1016/j.athorascur.2004.06.010; Marshall MV, 2010, OPEN SURG ONCOL J, V2, P12, DOI DOI 10.2174/1876504101002010012; Rubens FD, 2002, HEART SURG FORUM, V5, P141	15	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-5223	1097-685X		J THORAC CARDIOV SUR	J. Thorac. Cardiovasc. Surg.	JUN	2015	149	6					1622	1628		10.1016/j.jtcvs.2015.02.050		7	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	CJ8HI	WOS:000355740400053		
J	Dohi, M; Doi, K; Yaku, H				Dohi, Masahiro; Doi, Kiyoshi; Yaku, Hitoshi			Early stenosis of an aortic porcine bioprosthesis due to thrombosis: Case report and literature review	JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY			English	Editorial Material							VALVE-REPLACEMENT; POSITION; RISK; ANTICOAGULATION; THERAPY; PATIENT		[Dohi, Masahiro; Doi, Kiyoshi; Yaku, Hitoshi] Kyoto Prefectural Univ Med, Dept Cardiovasc Surg, Kyoto 6028566, Japan	Dohi, M (reprint author), Kyoto Prefectural Univ Med, Dept Cardiovasc Surg, Kamikyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	masad@koto.kpu-m.ac.jp					Achouh P, 2011, ANN THORAC SURG, V91, pE90, DOI 10.1016/j.athoracsur.2011.01.099; AMIDI M, 1990, ANN THORAC SURG, V49, P471; DIAMANT M, 1994, NEW ENGL J MED, V330, P1906, DOI 10.1056/NEJM199406303302618; Puvimanasinghe JPA, 2001, CIRCULATION, V103, P1535; BACIEWICZ PA, 1990, ANN THORAC SURG, V50, P817; Nishimura RA, 2014, J THORAC CARDIOV SUR, V148, pE1, DOI 10.1016/j.jtcvs.2014.05.014; JULIARD JM, 1993, CLIN CARDIOL, V16, P152; Ohnaka M, 2010, ANN THORAC SURG, V89, P2032, DOI 10.1016/j.athoracsur.2009.10.032; Brown ML, 2012, J THORAC CARDIOV SUR, V144, P108, DOI 10.1016/j.jtcvs.2011.05.032; Jander N, 2012, AM J CARDIOL, V109, P257, DOI 10.1016/j.amjcard.2011.08.038; HERAS M, 1995, J AM COLL CARDIOL, V25, P1111, DOI 10.1016/0735-1097(94)00563-6; Jander N, 2013, EUR HEART J, V34, P1357, DOI 10.1093/eurheartj/ehs323; Merie C, 2012, JAMA-J AM MED ASSOC, V308, P2118, DOI 10.1001/jama.2012.54506; Jamieson WRE, 2011, J THORAC CARDIOV SUR, V141, P1449, DOI 10.1016/j.jtcvs.2010.05.055; Edmond JJ, 2004, J HEART VALVE DIS, V13, P525; Efthymiou CA, 2013, J CARDIAC SURG, V28, P723, DOI 10.1111/jocs.12181; GHARAGOZLOO F, 1993, MAYO CLIN PROC, V68, P703; Lawton JS, 2009, J THORAC CARDIOV SUR, V137, P1556, DOI 10.1016/j.jtcvs.2008.06.042; Lehmann S, 2007, J HEART VALVE DIS, V16, P641; Mestres CA, 2000, ASIAN CARDIOVASC THO, V8, P50; Mylotte D, 2014, EUR HEART J; Peeceeyen S, 2012, J THORAC CARDIOV SUR, V143, pE13, DOI 10.1016/j.jtcvs.2011.10.041; Pislaru SV, 2014, EUR J CARDIOTHORAC S	23	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-5223	1097-685X		J THORAC CARDIOV SUR	J. Thorac. Cardiovasc. Surg.	JUN	2015	149	6					E83	U368		10.1016/j.jtcvs.2015.02.039		4	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	CJ8HI	WOS:000355740400001		
J	Rosilio, C; Nebout, M; Imbert, V; Griessinger, E; Neffati, Z; Benadiba, J; Hagenbeek, T; Spits, H; Reverso, J; Ambrosetti, D; Michiels, JF; Bailly-Maitre, B; Endou, H; Wempe, M; Peyron, JF				Rosilio, C.; Nebout, M.; Imbert, V.; Griessinger, E.; Neffati, Z.; Benadiba, J.; Hagenbeek, T.; Spits, H.; Reverso, J.; Ambrosetti, D.; Michiels, J-F; Bailly-Maitre, B.; Endou, H.; Wempe, Mf; Peyron, J-F			L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia	LEUKEMIA			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; CD98 EXPRESSION; ER STRESS; CANCER; MECHANISMS; MALIGNANCIES; METABOLISM; INHIBITOR; PROGNOSIS	The altered metabolism of cancer cells is a treasure trove to discover new antitumoral strategies. The gene (SLC7A5) encoding system L amino-acid transporter 1 (LAT1) is overexpressed in murine lymphoma cells generated via T-cell deletion of the pten tumor suppressor, and also in human T-cell acute lymphoblastic leukemia (T-ALL)/lymphoma (T-LL) cells. We show here that a potent and LAT1 selective inhibitor (JPH203) decreased leukemic cell viability and proliferation, and induced transient autophagy followed by apoptosis. JPH203 could also alter the in vivo growth of luciferase-expressing-tPTEN -/- cells xenografted into nude mice. In contrast, JPH203 was nontoxic to normal murine thymocytes and human peripheral blood lymphocytes. JPH203 interfered with constitutive activation of mTORC1 and Akt, decreased expression of c-myc and triggered an unfolded protein response mediated by the C/EBP homologous protein (CHOP) transcription factor associated with cell death. A JPH203-resistant tPTEN -/- clone appeared CHOP induction deficient. We also demonstrate that targeting LAT1 may be an efficient broad spectrum adjuvant approach to treat deadly T-cell malignancies as the molecule synergized with rapamycin, dexamethasone, doxorubicin, velcade and L-asparaginase to alter leukemic cell viability.	[Rosilio, C.; Nebout, M.; Imbert, V.; Griessinger, E.; Neffati, Z.; Benadiba, J.; Peyron, J-F] UMR INSERM U1065 UNS, Ctr Mediterranee Med Mol C3M, Equipe Inflammat Canc Cellules Souches Canc, Nice, France; [Rosilio, C.; Nebout, M.; Imbert, V.; Griessinger, E.; Neffati, Z.; Benadiba, J.; Peyron, J-F] Univ Nice Sophia Antipolis, UFR Med, Fac Med, F-06189 Nice, France; [Benadiba, J.; Peyron, J-F] Ctr Hosp Univ Nice, Serv Oncol Pediat, Hop Archet, Nice, France; [Hagenbeek, T.] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; [Spits, H.] Acad Med Ctr, Tytgat Inst Intestinal & Liver Res, Amsterdam, Netherlands; [Reverso, J.; Ambrosetti, D.; Michiels, J-F] Ctr Hosp Univ Nice, Lab Cent Anat & Cytol Pathol, Hop Archet, Nice, France; [Bailly-Maitre, B.] INSERM, U1065, Ctr Mediterraneen Med Mol C3M, Equipe Complicat hepatiques obesite, Nice, France; [Endou, H.] Kyorin Univ, Dept Pharmacol & Toxicol, Tokyo, Japan; [Endou, H.] J Pharm Co Ltd, Yokohama, Kanagawa, Japan; [Wempe, Mf] Univ Colorado, Anschutz Med Campus, Sch Pharm, Med Chem Core Facility, Aurora, CO USA	Peyron, JF (reprint author), UMR INSERM U1065 UNS, Ctr Mediterraneen Med Mol C3M, 151 Route Ginestiere BP 2 3194, F-06204 Nice, France.	peyron@unice.fr			Centre Mediterraneen de Medecine Moleculaire (C3M); La Ligue Nationale Contre le Cancer; La Fondation de France; Benjamin Delessert Institute; AFEF/Aptalis; SFD/MSD	We are sincerely grateful to Ms Cendrine Dubaud regarding her expertise to maintain the mouse strains and assistance to generate the tPTEN - / - KO mice. We also thank the C3M Imaging Core Facility (Microscopy and Imaging Platform Cote d'Azur) and C3M animal room facility. Furthermore, we express thanks to: Ms Chimene Morillon (Affymetrix analysis assistance); Dr Bernard Mari (transcriptomic result discussions) Dr Chloe Feral for discussion about CD98; Dr Marilyne Poiree, Professor Vahid Asnafi and Ms Amelie Trincand for proving primary T-ALL samples and clinical information; Dr Marie Beneteau (statistical analysis advice); Rodolphe Pontier-Bress (small animal imaging assistance). The Centre Mediterraneen de Medecine Moleculaire (C3M) provided the financial support to perform the current research. CR is a PhD fellowship recipient via La Ligue Nationale Contre le Cancer and EG is supported by a fellowship from La Fondation de France. The Centre Mediterraneen de Medecine Moleculaire (C3M) provided the financial support to perform the current research. BB-M thanks the Benjamin Delessert Institute, AFEF/Aptalis and SFD/MSD for their support.	Yanagida O, 2001, BBA-BIOMEMBRANES, V1514, P291, DOI 10.1016/S0005-2736(01)00384-4; Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Puissant A, 2010, CELL CYCLE, V9, P3470, DOI 10.4161/cc.9.17.13048; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Yanagisawa N, 2012, J CLIN PATHOL, V65, P1019, DOI 10.1136/jclinpath-2012-200826; Feral CC, 2005, P NATL ACAD SCI USA, V102, P355, DOI 10.1073/pnas.0404852102; Ichinoe M, 2011, PATHOL INT, V61, P281, DOI 10.1111/j.1440-1827.2011.02650.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091; Hagenbeek TJ, 2008, LEUKEMIA, V22, P608, DOI 10.1038/sj.leu.2405056; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Hagenbeek TJ, 2004, J EXP MED, V200, P883, DOI 10.1084/jem.20040495; Kobayashi H, 2005, J SURG ONCOL, V90, P233, DOI 10.1002/jso.20257; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Kaira K, 2008, CANCER SCI, V99, P2380, DOI 10.1111/j.1349-7006.2008.00969.x; Nawashiro H, 2006, INT J CANCER, V119, P484, DOI 10.1002/ijc.21866; Furuya M, 2012, CANCER SCI, V103, P382, DOI 10.1111/j.1349-7006.2011.02151.x; Guo W, 2008, NATURE, V453, P529, DOI 10.1038/nature06933; Sakata T, 2009, PATHOL INT, V59, P7, DOI 10.1111/j.1440-1827.2008.02319.x; Suraweera A, 2012, MOL CELL, V48, P242, DOI 10.1016/j.molcel.2012.08.003; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Zhao WL, 2010, LEUKEMIA, V24, P13, DOI 10.1038/leu.2009.223; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Boulter E, 2013, J EXP MED, V210, P173, DOI 10.1084/jem.20121651; Bulus N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040026; Cheson BD, 2009, CURR OPIN HEMATOL, V16, P299, DOI 10.1097/MOH.0b013e32832ad69a; Hayashi K, 2013, J IMMUNOL, V191, P4080, DOI 10.4049/jimmunol.1300923; Kaira K, 2007, CLIN CANCER RES, V13, P6369, DOI 10.1158/1078-0432.CCR-07-1294; Oda K, 2010, CANCER SCI, V101, P173, DOI 10.1111/j.1349-7006.2009.01386.x; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Rosilio C, 2013, CANCER LETT, V336, P114, DOI [10.1016/j.canlet.2013.04.015, 10.1016/j.canlet2013.04.015]; Vandewynckel YP, 2013, ANTICANCER RES, V33, P4683; Wempe MF, 2012, DRUG METAB PHARMACOK, V27, P155, DOI 10.2133/dmpk.DMPK-11-RG-091	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0887-6924	1476-5551		LEUKEMIA	Leukemia	JUN	2015	29	6					1253	1266		10.1038/leu.2014.338		14	Oncology; Hematology	Oncology; Hematology	CJ6PE	WOS:000355615000004		
J	Kinpara, S; Ito, S; Takahata, T; Saitoh, Y; Hasegawa, A; Kijiyama, M; Utsunomiya, A; Masuda, M; Miyazaki, Y; Matsuoka, M; Nakamura, M; Yamaoka, S; Masuda, T; Kannagi, M				Kinpara, S.; Ito, S.; Takahata, T.; Saitoh, Y.; Hasegawa, A.; Kijiyama, M.; Utsunomiya, A.; Masuda, M.; Miyazaki, Y.; Matsuoka, M.; Nakamura, M.; Yamaoka, S.; Masuda, T.; Kannagi, M.			Involvement of double-stranded RNA-dependent protein kinase and antisense viral RNA in the constitutive NF kappa B activation in adult T-cell leukemia/lymphoma cells	LEUKEMIA			English	Letter							VIRUS TYPE-1; LEUKEMIA-CELLS; I REX; PKR; SUPPRESSES; PATHWAY; ELEMENT; HTLV-1		[Kinpara, S.; Ito, S.; Takahata, T.; Hasegawa, A.; Kijiyama, M.; Masuda, T.; Kannagi, M.] Tokyo Med & Dent Univ, Dept Immunotherapeut, Tokyo, Japan; [Saitoh, Y.; Yamaoka, S.] Tokyo Med & Dent Univ, Dept Mol Virol, Tokyo, Japan; [Utsunomiya, A.] Imamura Bun In Hosp, Dept Hematol, Kagoshima, Japan; [Masuda, M.] Univ Ryukyus Hosp, Ctr Canc, Nakagami District, Okinawa, Japan; [Miyazaki, Y.] Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Nagasaki 852, Japan; [Matsuoka, M.] Kyoto Univ, Inst Virus Res, Kyoto 606, Japan; [Nakamura, M.] Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo, Japan	Kinpara, S (reprint author), Tokyo Med & Dent Univ, Dept Immunotherapeut, Tokyo, Japan.	kann.impt@tmd.ac.jp; kann.impt@tmd.ac.jp		Matsuoka, Masao/0000-0002-0473-754X			AHMED YF, 1990, GENE DEV, V4, P1014, DOI 10.1101/gad.4.6.1014; Mesnard JM, 2006, BLOOD, V108, P3979, DOI 10.1182/blood-2006-03-007732; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015; Anderson E, 2008, BIOCHEMISTRY-US, V47, P4887, DOI 10.1021/bi702211j; Mori N, 1999, BLOOD, V93, P2360; Saitoh Y, 2008, BLOOD, V111, P5118, DOI 10.1182/blood-2007-09-110635; Zhao T, 2009, BLOOD, V113, P2755, DOI 10.1182/blood-2008-06-161729; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; Kinpara S, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-52; Cachat A, 2013, J VIROL, V87, P13386, DOI 10.1128/JVI.02758-13; Melamed A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003271; MORDECHAI E, 1995, VIROLOGY, V206, P913, DOI 10.1006/viro.1995.1014; Shimizu T, 2003, FEBS LETT, V539, P73, DOI 10.1016/S0014-5793(03)00200-X; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000	15	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0887-6924	1476-5551		LEUKEMIA	Leukemia	JUN	2015	29	6					1425	1429		10.1038/leu.2015.1		6	Oncology; Hematology	Oncology; Hematology	CJ6PE	WOS:000355615000021		
J	Nishio, M; Horiike, A; Murakami, H; Yamamoto, N; Kaneda, H; Nakagawa, K; Horinouchi, H; Nagashima, M; Sekiguchi, M; Tamura, T				Nishio, Makoto; Horiike, Atsushi; Murakami, Haruyasu; Yamamoto, Nobuyuki; Kaneda, Hiroyasu; Nakagawa, Kazuhiko; Horinouchi, Hidehito; Nagashima, Masaki; Sekiguchi, Masaru; Tamura, Tomohide			Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer	LUNG CANCER			English	Article						Patritumab; Erlotinib; Human epidermal growth factor receptor (HER3); Non-small cell lung cancer; Gefitinib failure	ADVANCED SOLID TUMORS; MONOCLONAL-ANTIBODY; BREAST CARCINOMAS; III TRIAL; EXPRESSION; HER3; CETUXIMAB; THERAPY; RESISTANCE; GEFITINIB	Objectives: Human epidermal growth factor receptor 3 (HER3) is a key dimerization partner for HER family members and is associated with resistance to other HER family receptor-targeted therapeutics. This study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287), a fully human anti-HER3 monoclonal antibody, in combination with erlotinib, an epidermal growth factor receptor-tyrosine kinase inhibitor in patients with previously treated advanced non-small cell lung cancer (NSCLC). Patients and methods: This study enrolled patients with stage IIIB/IV NSCLC with Eastern Cooperative Oncology Group performance status 0-1, life expectancy >3 months and who had progressed after at least one prior course of chemotherapy (excluding erlotinib). This open-label study included two parts: dose escalation (Part 1) and dose expansion (Part 2). In Part 1, patients received intravenous patritumab 9 or 18 mg/kg every 3 weeks in addition to per-oral erlotinib 150 mg/day daily. In Part 2, patients received the recommended dose of patritumab as determined in Part 1. Adverse event rates, pharmacokinetics and tumor responses were determined. Results: Twenty-four Japanese patients received patritumab at 9 mg/kg (n = 3) or 18 mg/kg (n = 21), and erlotinib. No dose-limiting toxicities were reported, indicating the maximum-tolerated dose was not reached. The most frequent adverse events were gastrointestinal or skin toxicities, which were generally mild and manageable. Patritumab pharmacokinetics were similar to those reported in previous studies. The median progression-free survival (95% confidence interval) was 44.0(22.0-133.0) days for the EGFR wild-type group (n = 9) and 107.0(74.0-224.0) days for the EGFR-activating mutation group (n = 13). Evaluation of biomarkers by immunohistochemical analysis did not indicate a relationship between efficacy and HER3 expression in tumor tissues. Conclusion: Patritumab in combination with erlotinib was well tolerated and the efficacy of the combination was encouraging, especially in patients where prior gefitinib treatment failed. (C) 2015 The Authors. Published by Elsevier Ireland Ltd.	[Nishio, Makoto; Horiike, Atsushi] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Koto Ku, Tokyo 1358550, Japan; [Murakami, Haruyasu; Yamamoto, Nobuyuki] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka 4118777, Japan; [Kaneda, Hiroyasu; Nakagawa, Kazuhiko] Kinki Univ, Fac Med, Dept Med Oncol, Osakasayama, Osaka 5898511, Japan; [Horinouchi, Hidehito] Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo 1040045, Japan; [Nagashima, Masaki; Sekiguchi, Masaru] Daiichi Sankyo Co Ltd, Clin Dev Dept 2, Shinagawa Ku, Tokyo 1408710, Japan	Nishio, M (reprint author), Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	mnishio@jfcr.or.jp; atsushi.horiike@jfcr.or.jp; ha.murakami@scchr.jp; nbyamamo@wakayama-med.ac.jp; kaneda_h@dotd.med.kindai.ac.jp; nakagawa@med.kindai.ac.jp; hhorinou@ncc.go.jp; nagashima.masaki.ns@daiichisankyo.co.jp; sekiguchi.masaru.f3@daiichisankyo.co.jp; tamuratomohide@gmail.com			Daiichi Sankyo	This study was funded by Daiichi Sankyo. The study sponsor contributed to the design of the study, was involved in the collection, analysis and interpretation of data, in the writing of the manuscript, and in the decision to submit the manuscript for publication.	van der Horst EH, 2005, INT J CANCER, V115, P519, DOI 10.1002/ijc.20867; Tanner B, 2006, J CLIN ONCOL, V24, P4317, DOI 10.1200/JCO.2005.04.8397; PinkasKramarski R, 1996, EMBO J, V15, P2452; Kawaguchi T, 2014, J CLIN ONCOL, V32, P1902, DOI 10.1200/JCO.2013.52.4694; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Muller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388; Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9; Yi ES, 1997, MODERN PATHOL, V10, P142; Friess H, 1995, CLIN CANCER RES, V1, P1413; Kubota K, 2008, J THORAC ONCOL, V3, P1439, DOI 10.1097/JTO.0b013e31818d6702; Cho BC, 2007, J CLIN ONCOL, V25, P2528, DOI 10.1200/JCO.2006.10.4166; Narayan M, 2009, CANCER RES, V69, P2191, DOI 10.1158/0008-5472.CAN-08-1056; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; LoRusso P, 2013, CLIN CANCER RES, V19, P3078, DOI 10.1158/1078-0432.CCR-12-3051; Campbell MR, 2010, CLIN CANCER RES, V16, P1373, DOI 10.1158/1078-0432.CCR-09-1218; Katakami N, 2013, J CLIN ONCOL, V31, P3335, DOI 10.1200/JCO.2012.45.0981; Bieche I, 2003, INT J CANCER, V106, P758, DOI 10.1002/ijc.11273; Eisenhauer EA, 2014, JAPANESE VERSION 1 0; Freeman D, 2009, AACR EORTC M; Garassino MC, 2013, LANCET ONCOL, V14, P981, DOI 10.1016/S1470-2045(13)70310-3; Janjigian YY, 2011, 14 WORLD C LUNG CANC; Kawakami H, 2014, ONCOTARGET, V5, P11847; Naidu R, 1998, BRIT J CANCER, V78, P1385, DOI 10.1038/bjc.1998.689; National Cancer Institute, 2014, COMM TERM CRIT ADV E; Ranson M, 2013, J THORAC ONCOL, V8, pMO21; Soria JC, 2013, J THORAC ONCOL, V8; Treder M, 2008, EJC SUPPL, V6, P99, DOI 10.1016/S1359-6349(08)72243-2; Treder M., 2008, AACR M, pLB; Wakui H, 2014, CANCER CHEMOTH PHARM, V73, P511, DOI 10.1007/s00280-014-2375-2	32	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0169-5002	1872-8332		LUNG CANCER	Lung Cancer	JUN	2015	88	3					275	281		10.1016/j.lungcan.2015.03.010		7	Oncology; Respiratory System	Oncology; Respiratory System	CJ7WU	WOS:000355711900006		
J	Osugi, J; Yamaura, T; Muto, S; Okabe, N; Matsumura, Y; Hoshino, M; Higuchi, M; Suzuki, H; Gotoh, M				Osugi, Jun; Yamaura, Takumi; Muto, Satoshi; Okabe, Naoyuki; Matsumura, Yuki; Hoshino, Mika; Higuchi, Mitunori; Suzuki, Hiroyuki; Gotoh, Mitsukazu			Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer	LUNG CANCER			English	Article						Glucose transporter-1; ATP-citrate lyase; Non-small cell lung cancer; Prognosis	POSITRON-EMISSION-TOMOGRAPHY; FATTY-ACID SYNTHASE; MESSENGER-RNA; CELL-GROWTH; GLUT1; METABOLISM; STAGE; CARCINOMAS; HYPOXIA; ADENOCARCINOMA	Objective: Metabolic alternations are deemed a hallmark of cancer cells. Among many metabolic pathways, glycolysis and lipogenesis are essential metabolic processes in cancer cells. In this study, we examined the prognostic impact of the combined expression of glycolysis-related glucose transporter 1 (GLUT1) and ATP-citrate lyase (ACLY), which are important molecules in lipogenesis, in patients with non-small cell lung cancer (NSCLC). Materials and methods: GLUT1 and ACLY expression in 134 NSCLC specimens were determined by immunohistochemistry using a tissue microarray (TMA). We examined the overall survival of patients with GLUT1-, ACLY- or GLUT + ACLY-positive expression using Kaplan-Meier analysis. We analyzed the prognostic impact of combined GLUT1 and ACLY expression according to lymph node status using multivariate Cox analysis. Results: Patients with GLUT1- or ACLY-positive expression exhibited poorer overall survival compared with GLUT1- or ACLY-negative patients. GLUT1-positive/ACLY-positive expression status was associated with the worst overall survival, in contrast with GLUT1 negative/ACLY-negative expression status, which was correlated with the best overall survival (P = 0.003). GLUT1-positive/ACLY-positive expression was significantly correlated with poor prognosis in node-negative but not in node-positive patients. Multivariate Cox analysis indicated combined expression of GLUT1 and ACLY was an independent prognostic factor for overall survival in node-negative patients with NSCLC (P = 0.049). Conclusion: These results suggest that the combined expression of GLUT1 and ACLY could be a more valuable prognostic factor than their individual expression in node-negative patients with NSCLC. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Osugi, Jun; Yamaura, Takumi; Muto, Satoshi; Okabe, Naoyuki; Matsumura, Yuki; Hoshino, Mika; Higuchi, Mitunori; Suzuki, Hiroyuki; Gotoh, Mitsukazu] Fukushima Med Univ, Sch Med, Dept Regenerat Surg, Fukushima 9601295, Japan	Suzuki, H (reprint author), Fukushima Med Univ, Sch Med, Dept Regenerat Surg, 1 Hikarigaoka, Fukushima 9601295, Japan.	hiro@fmu.ac.jp					Sakashita M, 2001, EUR J CANCER, V37, P204, DOI 10.1016/S0959-8049(00)00371-3; Camp RL, 2000, LAB INVEST, V80, P1943, DOI 10.1038/labinvest.3780204; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Mashima T, 2009, BRIT J CANCER, V100, P1369, DOI 10.1038/sj.bjc.6605007; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Zaidi N, 2012, CANCER RES, V72, P3709, DOI 10.1158/0008-5472.CAN-11-4112; Furuta E, 2010, BBA-REV CANCER, V1805, P141, DOI 10.1016/j.bbcan.2010.01.005; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Berghmans T, 2008, J THORAC ONCOL, V3, P6, DOI 10.1097/JTO.0b013e31815e6d6b; Yohena T, 2009, J THORAC ONCOL, V4, P284, DOI 10.1097/JTO.0b013e31819852d5; Lin RT, 2013, MOL CELL, V51, P506, DOI 10.1016/j.molcel.2013.07.002; Migita T, 2009, J NATL CANCER I, V101, P519, DOI 10.1093/jnci/djp030; Sawabata N, 2011, J THORAC ONCOL, V6, P1229, DOI 10.1097/JTO.0b013e318219aae2; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; MEDES G, 1953, CANCER RES, V13, P27; Cerfolio RJ, 2005, J THORAC CARDIOV SUR, V130, P151, DOI 10.1016/j.jtcvs.2004.11.007; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Meijer TWH, 2012, LUNG CANCER, V76, P316, DOI 10.1016/j.lungcan.2011.11.006; Andersen S, 2011, LUNG CANCER, V72, P294, DOI 10.1016/j.lungcan.2010.10.006; Brahimi-Horn MC, 2007, CURR OPIN CELL BIOL, V19, P223, DOI 10.1016/j.ceb.2007.02.003; Sasaki H, 2012, MOL MED REP, V5, P599, DOI 10.3892/mmr.2011.736; Minami K, 2002, LUNG CANCER-J IASLC, V38, P51, DOI 10.1016/S0169-5002(02)00108-3; Moellering RE, 2008, CLIN EXP METASTAS, V25, P411, DOI 10.1007/s10585-008-9145-7; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Zu XY, 2012, RECENT PAT ANTI-CANC, V7, P154; Kaira K, 2014, LUNG CANCER, V83, P197, DOI 10.1016/j.lungcan.2013.11.025; Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235; Furuta E, 2008, CANCER RES, V68, P10003; Grover-McKay M, 1998, Pathol Oncol Res, V4, P115; Hunter A, 2006, APOPTOSIS, V11, P1727, DOI 10.1007/s10495-006-9789-1; Maki Y, 2013, ONCOL REP, V29, P133, DOI 10.3892/or.2012.2087; Raiser M, 2008, P NATL ACAD SCI USA, V105, P17807; Vans A, 2002, CANCER RES, V62, P2625; Yahagi N, 2005, EUR J CANCER, V41, P1316, DOI 10.1016/j.ejca.2004.12.037	35	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0169-5002	1872-8332		LUNG CANCER	Lung Cancer	JUN	2015	88	3					310	318		10.1016/j.lungcan.2015.03.004		9	Oncology; Respiratory System	Oncology; Respiratory System	CJ7WU	WOS:000355711900011		
J	Yoneshima, Y; Okamoto, I; Takano, T; Enokizu, A; Iwama, E; Harada, T; Takayama, K; Nakanishi, Y				Yoneshima, Yasuto; Okamoto, Isamu; Takano, Tomotsugu; Enokizu, Aimi; Iwama, Eiji; Harada, Taishi; Takayama, Koichi; Nakanishi, Yoichi			Successful treatment with alectinib after crizotinib-induced esophageal ulceration	LUNG CANCER			English	Article						Alectinib; Crizotinib; Esophageal ulceration; Anaplastic lymphoma kinase (ALK); Non-small-cell lung cancer (NSCLC)	CELL LUNG-CANCER; ADVERSE-EVENT; CH5424802	Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Yoneshima, Yasuto; Okamoto, Isamu; Takano, Tomotsugu; Enokizu, Aimi; Iwama, Eiji; Harada, Taishi; Takayama, Koichi; Nakanishi, Yoichi] Kyushu Univ Hosp, Res Inst Dis Chest, Grad Sch Med Sci, Fukuoka 8128582, Japan; [Okamoto, Isamu; Nakanishi, Yoichi] Kyushu Univ Hosp, Ctr Clin & Translat Res, Fukuoka 8128582, Japan; [Iwama, Eiji] Kyushu Univ Hosp, Fac Med Sci, Dept Comprehens Clin Oncol, Fukuoka 8128582, Japan	Okamoto, I (reprint author), Kyushu Univ Hosp, Ctr Clin & Translat Res, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	okamotoi@kokyu.med.kyushu-u.ac.jp					Camidge DR, 2012, LANCET ONCOL, V13, P1011, DOI 10.1016/S1470-2045(12)70344-3; Park J, 2013, LUNG CANCER, V81, P495, DOI 10.1016/j.lungcan.2013.06.017; Seto T, 2013, LANCET ONCOL, V14, P590, DOI 10.1016/S1470-2045(13)70142-6; Srivastava N, 2013, J THORAC ONCOL, V8, pE23, DOI 10.1097/JTO.0b013e31827e2451; Sakamoto H, 2011, CANCER CELL, V19, P679, DOI 10.1016/j.ccr.2011.04.004; Baatar D, 2002, AM J PATHOL, V160, P963, DOI 10.1016/S0002-9440(10)64918-8; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI 10.1056/NEJMoa1408440	8	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0169-5002	1872-8332		LUNG CANCER	Lung Cancer	JUN	2015	88	3					349	351		10.1016/j.lungcan.2015.03.012		3	Oncology; Respiratory System	Oncology; Respiratory System	CJ7WU	WOS:000355711900017		
J	Ryu, J; Jung, SH; Sim, JH; Lee, HI; Sohn, D				Ryu, Jungju; Jung, Seo-Hyun; Sim, Jae Hyun; Lee, Hyung-il; Sohn, Daewon			Clustering and Dissolution of Triazole Branched Poly(ethyl methylacrylate)	MACROMOLECULAR CHEMISTRY AND PHYSICS			English	Article						clusters; dissolution; dynamic light scattering; small angle neutron scattering; thermoresponsive polymer	TEMPERATURE IONIC LIQUID; BLOCK-COPOLYMERS; OXIDE) SOLUTIONS; PHASE-BEHAVIOR; AGGREGATION; SCATTERING; PARTICLES; SYSTEMS; CHAIN; PH	The solution properties of the multiresponsive polymer P1 (poly(2-((3-(1-(2-(dimethylamino)ethyl)-1H-1,2,3-triazol-4-yl)propanoyl)oxy)ethyl methacrylate) are studied by small angle neutron scattering (SANS) and dynamic light scattering (DLS). The P1 solution exhibits a phase transition above certain temperatures and cloud points following dissolution through the incubation at room temperature. SANS and DLS studies show that P1 forms clusters via hydrophobic interactions, which are weakened by continued incubation. The temperature dependent cluster formation is explained by hydrophobic adsorption and shrinking behavior as a function of hydrodynamic radius, correlation lengths, and Porod exponents. The weak clustering and solution property are discussed on the basis of Flory theory. Taken together, the results here indicate that time-dependent dissolution of P1 leads to a weakly hydrophobic structure.	[Ryu, Jungju; Sohn, Daewon] Hanyang Univ, Inst Nat Sci, Dept Chem & Res, Seoul 133791, South Korea; [Jung, Seo-Hyun] Korea Res Inst Chem Technol, Res Ctr Green Fine Chem, Ulsan 681802, South Korea; [Sim, Jae Hyun] Kyushu Univ, Dept Appl Chem, Fukuoka 8190395, Japan; [Lee, Hyung-il] Univ Ulsan, Dept Chem, Ulsan 680749, South Korea	Sohn, D (reprint author), Hanyang Univ, Inst Nat Sci, Dept Chem & Res, Seoul 133791, South Korea.	dsohn@hanyang.ac.kr			National Research Foundation of Korea (NRF) - Korea government (MSIP) [2012M2A2A6035933]	This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (2012M2A2A6035933). The authors are grateful to Dr. Tae-Gyu Shin and Dr. Eunjoo Shin of the Korea Atomic Energy Research Institute for their help with operating the SANS instruments at HANARO.	Yamamoto S, 2008, MACROMOLECULES, V41, P7013, DOI 10.1021/ma8011366; Li Y, 2006, ANGEW CHEM INT EDIT, V45, P5792, DOI 10.1002/anie.200602168; Fuller JM, 2013, J AM CHEM SOC, V135, P8947, DOI 10.1021/ja402019c; Kodiyath R, 2013, POLYMER, V54, P1150, DOI 10.1016/j.polymer.2012.12.031; Wang G, 2004, MACROMOLECULES, V37, P8911, DOI 10.1021/ma048416a; Triolo A, 2006, J PHYS CHEM B, V110, P1513, DOI 10.1021/jp056383a; Kline SR, 2006, J APPL CRYSTALLOGR, V39, P895, DOI 10.1107/S0021889806035059; Kratz K, 2001, POLYMER, V42, P6631, DOI 10.1016/S0032-3861(01)00099-4; Hua F, 2004, NANO LETT, V4, P823, DOI 10.1021/nl0498031; Kato T, 2002, SCIENCE, V295, P2414, DOI 10.1126/science.1070967; Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047; Hansson P, 2001, LANGMUIR, V17, P4167, DOI 10.1021/la010390i; Jung SH, 2011, MACROMOLECULES, V44, P1628, DOI 10.1021/ma102751p; Kulkarni S, 2006, BIOMACROMOLECULES, V7, P2736, DOI 10.1021/bm060186f; Glazer PJ, 2013, ADV FUNCT MATER, V23, P2964, DOI 10.1002/adfm.201203212; Kurzbach D, 2013, J AM CHEM SOC, V135, P11299, DOI 10.1021/ja4047872; Lee HI, 2010, PROG POLYM SCI, V35, P24, DOI 10.1016/j.progpolymsci.2009.11.002; Bouyer F, 2001, LANGMUIR, V17, P5225, DOI 10.1021/la010548z; Hammouda B, 2002, MACROMOLECULES, V35, P8578, DOI 10.1021/ma011657n; Aggeli A, 2003, J AM CHEM SOC, V125, P9619, DOI 10.1021/ja021047i; Wu C, 1998, PHYS REV LETT, V80, P4092, DOI 10.1103/PhysRevLett.80.4092; Kim M, 2004, J PHYS CHEM B, V108, P8269, DOI 10.1021/jp0492725; Hammouda B, 2004, MACROMOLECULES, V37, P6932, DOI 10.1021/ma049623d; Hammouda B, 2007, J POLYM SCI POL PHYS, V45, P2196, DOI 10.1002/polb.21221; Jeong B, 1997, NATURE, V388, P860; Lee HI, 2007, ANGEW CHEM INT EDIT, V46, P2453, DOI 10.1002/anie.200604278; Berne B.J., 2000, DYNAMIC LIGHT SCATTE; Costa LT, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2192777; Fujii K, 2011, POLYMER, V52, P1589, DOI 10.1016/j.polymer.2011.01.037; Ho DL, 2003, J POLYM SCI POL PHYS, V41, P135, DOI 10.1002/polb.10340; Jung SH, 2012, POLYM CHEM-UK, V3, P1002, DOI 10.1039/c2py00559j; Kim M, 2003, MACROMOLECULES, V36, P9986, DOI 10.1021/ma0346714; Meier-Koll A, 2012, LANGMUIR, V28, P8791, DOI 10.1021/la3015332; Mishra V, 2014, MACROMOL RAPID COMM, V35, P442, DOI 10.1002/marc.201300585; Mishra V, 2014, POLYM CHEM-UK, V5, P2411, DOI 10.1039/c3py01648j; Polverari M, 1996, J PHYS CHEM-US, V100, P13687, DOI 10.1021/jp960215o; Roe R. J., 2000, METHODS XRAY NEUTRON; Rostami A, 2013, MACROMOLECULES, V46, P6439, DOI 10.1021/ma401263q; Rubinstein M., 2003, POYMER PHYS; Ueki T, 2007, J PHYS CHEM B, V111, P4750, DOI 10.1021/jp0670900; WONG PZ, 1985, PHYS REV B, V32, P7417, DOI 10.1103/PhysRevB.32.7417; Yuan GC, 2006, MACROMOLECULES, V39, P3642, DOI 10.1021/ma060060a	42	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1022-1352	1521-3935		MACROMOL CHEM PHYS	Macromol. Chem. Phys.	JUN	2015	216	11					1251	1259		10.1002/macp.201400621		9	Polymer Science	Polymer Science	CJ7SM	WOS:000355699600012		
J	Hyun, J; Lee, CW; Kimura, Y				Hyun, Jungyub; Lee, Chan Woo; Kimura, Yoshiharu			Synthesis of Novel Hyper-Branched Polymers From Trimethoxysilyl-Terminated Polylactides and Their Utilization for Modification of Poly(l-Lactide) Materials	MACROMOLECULAR MATERIALS AND ENGINEERING			English	Article						hydrolytic polycondensation; hyper-branched polymer; polymer blend; silyl-terminated poly(lactide)s; stereocomplex	ENANTIOMERIC POLY(LACTIC ACID)S; RING-OPENING POLYMERIZATION; STEREOCOMPLEX FORMATION; MECHANICAL-PROPERTIES; NANOCOMPOSITES; FILMS; COPOLYMERS; MORPHOLOGY; CAST	Silyl-terminated oligomers of poly(l-lactide) (mSi-PLLA) and poly(d-lactide) (mSi-PDLA) were synthesized by hydrosilylation of allyl-terminated derivatives. They were readily hydrolyzed into hyper-branched polymers having particulate morphology. When a mSi-PDLA oligomer was blended with a PLLA sample (52.5kDa) in 1-10wt.-% by solution casting, small cross-linked particles with stereocomplex form were generated and distributed homogenously in the PLLA matrix, and by which the homo-chiral crystallization of PLLA was efficiently suppressed. When another mSi-PLLA oligomer was blended with PLLA, the cross-linked particles formed from mSi-PLLA were amorphous and distributed inhomogeneously. It was, therefore, indicated that the hydrolytic polycondensation of mSi-PDLA and mSi-PLLA was induced during the film casting, changing the inner structure and properties of the blend films with PLLA.	[Hyun, Jungyub; Kimura, Yoshiharu] Kyoto Inst Technol, Dept Biobased Mat Sci, Kyoto 6068585, Japan; [Lee, Chan Woo] Hoseo Univ, Dept Innovat Ind Technol, Asan 336795, Chungnam, South Korea	Kimura, Y (reprint author), Kyoto Inst Technol, Dept Biobased Mat Sci, Hashigami Cho, Kyoto 6068585, Japan.	ykimura@kit.ac.jp					Goffin AL, 2007, EUR POLYM J, V43, P4103, DOI 10.1016/j.eurpolymj.2007.07.041; Fukushima K, 2008, BIOMACROMOLECULES, V9, P3051, DOI 10.1021/bm800526k; Wang HS, 2012, THERMOCHIM ACTA, V527, P40, DOI 10.1016/j.tca.2011.10.004; IKADA Y, 1987, MACROMOLECULES, V20, P904, DOI 10.1021/ma00170a034; Hoglund A, 2010, BIOMACROMOLECULES, V11, P277, DOI 10.1021/bm901157h; Liu DY, 2010, EXPRESS POLYM LETT, V4, P26, DOI 10.3144/expresspolymlett.2010.5; Quynh TM, 2007, EUR POLYM J, V43, P1779, DOI 10.1016/j.eurpolymj.2007.03.007; Ray SS, 2003, MACROMOL MATER ENG, V288, P936, DOI 10.1002/mame.200300156; Masutani K, 2012, MACROMOL CHEM PHYS, V213, P695, DOI 10.1002/macp.201100683; Tsuji H, 1999, POLYMER, V40, P6699, DOI 10.1016/S0032-3861(99)00004-X; TSUJI H, 1991, MACROMOLECULES, V24, P5651, DOI 10.1021/ma00020a026; Mahboobeh E, 2010, J APPL POLYM SCI, V118, P1077, DOI 10.1002/app.32461; Deng XM, 2001, BIOMATERIALS, V22, P2867, DOI 10.1016/S0142-9612(01)00031-X; Hirata M, 2013, BIOMACROMOLECULES, V14, P2154, DOI 10.1021/bm400228x; Huang JW, 2009, J APPL POLYM SCI, V112, P1688, DOI 10.1002/app.29616; Kimura Y., 2013, BIOBASED POLYM HDB R; Nakajima H, 2011, BIOMACROMOLECULES, V12, P4036, DOI 10.1021/bm2010388; Sankaraiah S, 2008, MACROMOLECULES, V41, P6195, DOI 10.1021/ma8003345; Zhang XJ, 2011, J APPL POLYM SCI, V122, P296, DOI 10.1002/app.34059	19	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1438-7492	1439-2054		MACROMOL MATER ENG	Macromol. Mater. Eng.	JUN	2015	300	6					650	660		10.1002/mame.201400429		11	Materials Science, Multidisciplinary; Polymer Science	Materials Science; Polymer Science	CJ8JP	WOS:000355746600007		
J	Miller, MJ; Miwa, T; Mochioka, N; Watanabe, S; Yamada, Y; Fukuba, T; Tsukamoto, K				Miller, Michael J.; Miwa, Tetsuya; Mochioka, Noritaka; Watanabe, Shun; Yamada, Yoshiaki; Fukuba, Tatsuhiro; Tsukamoto, Katsumi			Now you see me, now you don't: observation of a squid hiding in its ink trail	MARINE BIODIVERSITY			English	Editorial Material							CEPHALOPODA		[Miller, Michael J.] Univ Tokyo, Atmosphere & Ocean Res Inst, Chiba, Japan; [Miwa, Tetsuya; Fukuba, Tatsuhiro] Japan Agcy Marine Earth Sci & Technol, Yokosuka, Kanagawa, Japan; [Mochioka, Noritaka] Kyushu Univ, Fac Agr, Fukuoka 812, Japan; [Watanabe, Shun; Tsukamoto, Katsumi] Nihon Univ, Bioresource Sci, Tokyo, Kanagawa 102, Japan; [Yamada, Yoshiaki] IRAGO Inst, Tahara, Aichi, Japan	Miller, MJ (reprint author), Univ Tokyo, Atmosphere & Ocean Res Inst, Chiba, Japan.	miller@aori.u-tokyo.ac.jp					Derby CD, 2007, BIOL BULL-US, V213, P274; Zeidberg LD, 2004, J EXP BIOL, V207, P4195, DOI 10.1242/jeb.01276; Hunt JC, 2000, J MAR BIOL ASSOC UK, V80, P873, DOI 10.1017/S002531540000285X; Bush SL, 2007, MAR BIOL, V152, P485, DOI 10.1007/s00227-007-0684-2; Wood JB, 2010, J EXP MAR BIOL ECOL, V388, P20, DOI 10.1016/j.jembe.2010.03.010	5	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1867-1616	1867-1624		MAR BIODIVERS	Mar. Biodivers.	JUN	2015	45	2					149	150		10.1007/s12526-014-0249-9		2	Biodiversity Conservation; Marine & Freshwater Biology	Biodiversity & Conservation; Marine & Freshwater Biology	CJ8LV	WOS:000355753700006		
J	Kajihara, H; Nishi, E; Kawabata, M; Kohtsuka, H; Uyeno, D				Kajihara, Hiroshi; Nishi, Eijiroh; Kawabata, Michiyo; Kohtsuka, Hisanori; Uyeno, Daisuke			Records of the poorly known ribbon worm Nipponnemertes ogumai (Nemertea: Monostilifera) and its phylogenetic position	MARINE BIODIVERSITY			English	Article						Hoplonemertea; Cratenemertidae; Caridea; Decapoda; DNA barcoding	RIBOSOMAL DNA-SEQUENCES; OXIDASE SUBUNIT-I; PHYLUM NEMERTEA; MOLECULAR PHYLOGENY; INVERTEBRATES; HOPLONEMERTEA; MORPHOLOGY; CRUSTACEA; PRIMERS; BIOLOGY	Recent records of the occurrence of a little-known ribbon worm, Nipponnemertes ogumai (Yamaoka 1947), along the Pacific coast of Honshu, Japan, are summarized with a map of known distribution. Photographs of the worm in its living state are provided, with brief descriptions of external morphology and behavior. Sequences of the nuclear 18S rDNA (1,785 bp) and 28S rDNA (2,215 bp), as well as the mitochondrial 16S rDNA (452 bp) and cytochrome c oxidase subunit I (COI) gene (621 bp) were determined. Preliminary maximum-likelihood phylogenetic analyses were performed together with some other congeners, viz., N. bimaculata (Coe 1901), N. pulchra (Johnston 1837), N. punctatula (Coe 1905), and two unidentified forms, for which sequences were available in the public databases. In the resulting tree, N. ogumai was nested within the congeners, consolidating the previous alteration of the generic placement of the species from Amphiporus Ehrenberg (1828-1831), to Nipponnemertes Friedrich 1968. A contaminated cytochrome c oxidase subunit I (COI) sequence implied that N. ogumai may feed on caridean shrimps.	[Kajihara, Hiroshi] Hokkaido Univ, Fac Sci, Sapporo, Hokkaido 0600810, Japan; [Nishi, Eijiroh] Yokohama Natl Univ, Coll Educ & Human Sci, Yokohama, Kanagawa 2408501, Japan; [Kawabata, Michiyo; Kohtsuka, Hisanori] Univ Tokyo, Misaki Marine Biol Stn, Miura, Kanagawa 2380225, Japan; [Uyeno, Daisuke] Univ Florida, Florida Museum Nat Hist, Gainesville, FL 32611 USA	Kajihara, H (reprint author), Hokkaido Univ, Fac Sci, Sapporo, Hokkaido 0600810, Japan.	kazi@mail.sci.hokudai.ac.jp; enishi@ynu.ac.jp; michiyo@mmbs.s.u-tokyo.ac.jp; kohtsuka@mmbs.s.u-tokyo.ac.jp; daisuke.uyeno@gmail.com		Nishi, Eijiroh/0000-0002-7608-2263	JSPS KAKENHI [16770059, 25650133, 23370038]	We are thankful to Mamoru Sekifuji (Misaki Marine Biological Station, University of Tokyo) for giving M. Kawabata and H. Kohtsuka an opportunity to collect material; to Shushi Abukawa (Hokkaido University) for his help in the molecular work; to Tomoyuki Komai (CBM) for specimen loan; to Gonzalo Giribet (Harvard University) and Per Sundberg (University of Gothenburg) for the information about the specimens included in our molecular analyses; and to Juan Junoy (University of Alcala) and an anonymous reviewer for their constructive comments on the manuscript. This study was partially supported by JSPS KAKENHI Grant Numbers 16770059, 25650133, and 23370038 to H. Kajihara.	Abildgaard PC, 1806, ZOOLOGIA DANICA SEU, V4, P25; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Chen HX, 2009, GENE, V442, P8, DOI 10.1016/j.gene.2009.04.015; BOOM R, 1990, J CLIN MICROBIOL, V28, P495; MCDERMOTT JJ, 1993, HYDROBIOLOGIA, V266, P15, DOI 10.1007/BF00013356; Briggs JC, 2012, J BIOGEOGR, V39, P12, DOI 10.1111/j.1365-2699.2011.02613.x; Thollesson M, 2003, P ROY SOC B-BIOL SCI, V270, P407, DOI 10.1098/rspb.2002.2254; Folmer O., 1994, Molecular Marine Biology and Biotechnology, V3, P294; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Robe LJ, 2012, ZOOL SCI, V29, P714, DOI 10.2108/zsj.29.714; Andrade SCS, 2012, CLADISTICS, V28, P141, DOI 10.1111/j.1096-0031.2011.00376.x; Geller J, 2013, MOL ECOL RESOUR, V13, P851, DOI 10.1111/1755-0998.12138; Sundberg P, 2003, ZOOL SCR, V32, P279, DOI 10.1046/j.1463-6409.2002.00032.x; LITTLEWOOD DTJ, 1994, MOL PHYLOGENET EVOL, V3, P221, DOI 10.1006/mpev.1994.1024; Chen HX, 2011, MOL BIOL REP, V38, P4509, DOI 10.1007/s11033-010-0582-4; Edgecombe GD, 2006, INVERTEBR SYST, V20, P503, DOI 10.1071/IS05044; Whiting MF, 1997, SYST BIOL, V46, P1; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Strand M, 2005, BIOL J LINN SOC, V86, P201, DOI 10.1111/j.1095-8312.2005.00535.x; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Bate C. S., 1862, CATALOGUE SPECIMENS; BERG G, 1972, Zoologica Scripta, V1, P211, DOI 10.1111/j.1463-6409.1972.tb00580.x; BRUNBERG LISE, 1964, OPHELIA, V1, P77; Coe W. R, 1901, P WASH ACAD SCI, V3, P1; Coe WR, 1905, B MUS COMP ZOOL HARV, V47, P1; COE WESLEY R., 1936, ZOOLOGICA, V21, P97; Crandall FB, 2002, CHECKLIST NEMERTEAN; Crandall FB, 2001, HYDROBIOLOGIA, V456, P175, DOI 10.1023/A:1013054022264; de Quatrefages A, 1846, ANN SCI NATURELLES 3, V6, P173; Dendy A, 1892, P ROYAL SOC VICTORIA, V4, P85; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Ehrenberg C. G., 1828, SYMBOLAE PHYSICAE SE, P53; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.2307/2408678; FRIEDRICH H, 1968, Zoologischer Anzeiger, V180, P33; Gibson R, 2013, WORDL NEMERTEA DATAB; Iwata F., 1954, Journal of the Faculty of Science Hokkaido University Zoology, V11, P126; Johnston G, 1837, MAGAZINE ZOOLOGY BOT, V1, P529; Johnston G, 1828, ZOOLOGICAL J, V3, P486; Kajihara H, 2007, ZOOL SCI, V24, P287, DOI 10.2108/zsj.24.287; KANNEWORFF EBBE, 1966, OPHELIA, V3, P183; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kroyer H, 1845, NATURHISTORISK TID 2, V1, P283; Kroyer H., 1845, NAATURHISTORISK TIDS, V1, P403; Kroyer H., 1845, NATURHISTORISK TIDSS, V1, P453; Liljeborg W, 1855, OFVERS VETENSK AKAD, V12, P117; MCDERMOTT JJ, 1984, OPHELIA, V23, P1; McDermott John J., 1997, Hydrobiologia, V365, P251, DOI 10.1023/A:1003114117397; Muller OF, 1774, VERMIUM TERRESTRIU 2, V1; Okuda S, 1965, NEW ILLUSTRATED ENCY, V1, P399; Pallas P. S., 1766, MISCELLANEA ZOOLOGIC; Paluzmbi S, 1991, SIMPLE FOOLS GUIDE P; Passamaneck Y, 2006, MOL PHYLOGENET EVOL, V40, P20, DOI 10.1016/j.ympev.2006.02.001; Plaisance L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025026; Podsiadlowski L, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-364; Riser NW, 1998, NEW ZEAL J ZOOL, V25, P287; Schwendinger PJ, 2005, INVERTEBR SYST, V19, P297, DOI 10.1071/IS05023; Sundberg P, 2009, BIOL J LINN SOC, V98, P556; Suzuki A, 2013, RINKAIJISSHU GA HAJI; Tavare S., 1986, SOME MATH QUESTIONS, P57; von Graff L, 1879, MORPH JB, V5, P430; Wheeler J. F. G., 1940, Journal of the Linnean Society London, V41, P20; WHEELER J. F. G., 1934, DISCOVERY REPTS [GOV DEPEND FALKLAND IS], V9, P215; Yamada Kazuyuki, 2009, Bulletin of the Biogeographical Society of Japan, V64, P189; Yamaguchi S, 2003, MAR BIOL, V143, P23, DOI 10.1007/s00227-003-1062-3; Yamaoka Teiichi, 2005, Publications of the Seto Marine Biological Laboratory, V40, P141; Yamaoka T, 1947, ILLUSTRATED ENCY FAU, P1468; Yamasaki H, 2013, MOL PHYLOGENET EVOL, V67, P303, DOI 10.1016/j.ympev.2013.02.016	67	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1867-1616	1867-1624		MAR BIODIVERS	Mar. Biodivers.	JUN	2015	45	2					175	182		10.1007/s12526-014-0252-1		8	Biodiversity Conservation; Marine & Freshwater Biology	Biodiversity & Conservation; Marine & Freshwater Biology	CJ8LV	WOS:000355753700012		
J	Kawasaki, T; Matsuda, T				Kawasaki, Tomoya; Matsuda, Takuma			Containerization of bulk trades: A case study of US-Asia wood pulp transport	MARITIME ECONOMICS & LOGISTICS			English	Article						bulk carriers; container vessels; modal choice; wood pulp; East Asia; United States		Containerization of bulk cargo has gradually emerged in recent decades, particularly along the US-East Asia trade route (China, Japan and South Korea). One of the background factors in the emergence of this phenomenon is an imbalance between eastbound and westbound container cargo movements along this route. Nonetheless, the factors that affect containerization have not yet been identified. We conduct an empirical analysis to understand how shippers choose transport modes, depending on the prevailing economic conditions. We aim to reveal the critical factors in choosing bulk carriers versus container vessels in hauling wood pulp, a bulk commodity that ships from the United States to East Asia. Our results can assist shippers and shipping companies in securing the most advantageous transport mode. Our main finding is that the effect of economic factors on the transport mode decision differs among the three East Asian countries. The Japan route is mostly subject to economic factors. Economic factors other than freight rates have no significant effect on the South Korea route. In the case of China, none of the economic factors was identified as being of great importance. Hence, in the latter case, rational decision making, based on prevailing economic conditions, might not take place when choosing the transport mode.	[Kawasaki, Tomoya] Nihon Univ, Coll Sci & Technol, Funabashi, Chiba 2748501, Japan; [Matsuda, Takuma] Japan Maritime Ctr, Planning & Res Dept, Chiyoda Ku, Tokyo 1020083, Japan	Kawasaki, T (reprint author), Nihon Univ, Coll Sci & Technol, 744-7-24-1 Narashino Dai, Funabashi, Chiba 2748501, Japan.	kawasaki.tomoya@nihon-u.ac.jp; t-matsuda@jpmac.or.jp			Japan Society for the Promotion of Science [24330138]	We thank Associate Professor Hiroshi Gunji and two anonymous reviewers for their helpful comments on this research. This research was supported by a Grant-in-Aid for Scientific Research B (24330138) from the Japan Society for the Promotion of Science.	Reinhart CM, 2011, AM ECON REV, V101, P1676, DOI 10.1257/aer.101.5.1676; Ben Akiva M., 1985, DISCRETE CHOICE ANAL; Christopher M., 2010, LOGISTICS SUPPLY CHA; Maritime Bureau of Japan, 2012, MAR REP 2012; Masui S., 2010, BOOK OF METAL SCRAP; Matsuda T., 2013, J JAPAN SOC LOGISTIC, V47, P65; McFadden D., 1974, J PUBLIC ECON, V3, P303, DOI DOI 10.1016/0047-2727(74)90003-6; Mongelluzzo B., 2007, J COMMERCE, V8, P12; Seabrook J., 2008, NEW YORKER, P48; Stopford M., 2009, MARITIME EC; Szamosszegi A., 2011, ANAL STATE OWNED ENT; USA Trade Online, 2014, FOR TRAD DAT PROD; Watanabe T., 2008, TECHNICAL NOTES NAT, P467; Wilson W. W., 2009, UGPTI DEP PUBL, V203	14	0	0	PALGRAVE MACMILLAN LTD	BASINGSTOKE	BRUNEL RD BLDG, HOUNDMILLS, BASINGSTOKE RG21 6XS, HANTS, ENGLAND	1479-2931	1479-294X		MARIT ECON LOGIST	Marit. Econ. Logist.	JUN	2015	17	2					179	197		10.1057/mel.2014.16		19	Transportation	Transportation	CJ3GL	WOS:000355371300004		
J	Mizuta, Y; Shimomura, T				Mizuta, Yoshihiro; Shimomura, Tetsu			Weighted Morrey spaces of variable exponent and Riesz potentials	MATHEMATISCHE NACHRICHTEN			English	Article						Maximal function; Riesz potentials; Sobolev's inequality; Trudinger's inequality; Morrey spaces of variable exponent; weights; 31B15; 46E30	SOBOLEV EMBEDDINGS; LEBESGUE SPACES; MAXIMAL OPERATOR; GENERALIZED LEBESGUE; NORM INEQUALITIES; BOUNDEDNESS; EQUATIONS	We prove weighted inequalities for the Hardy-Littlewood maximal operator on weighted Morrey spaces Lp(),(Rn;) of variable exponent. As an application of the boundedness of the maximal operator, we establish weighted Sobolev's inequality for Riesz potentials. We are also concerned with weighted Trudinger's inequality for Riesz potentials.	[Mizuta, Yoshihiro] Hiroshima Inst Technol, Dept Mech Syst Engn, Saeki Ku, Hiroshima 7315193, Japan; [Shimomura, Tetsu] Hiroshima Univ, Grad Sch Educ, Dept Math, Higashihiroshima, Japan	Shimomura, T (reprint author), Hiroshima Univ, Grad Sch Educ, Dept Math, Higashihiroshima, Japan.	y.mizuta.5x@it-hiroshima.ac.jp; tshimo@hiroshima-u.ac.jp					Cruz-Uribe D, 2004, ANN ACAD SCI FENN-M, V29, P247; HEDBERG LI, 1972, P AM MATH SOC, V36, P505, DOI 10.2307/2039187; Morrey CB, 1938, T AM MATH SOC, V43, P126, DOI 10.2307/1989904; Samko NG, 2007, J MATH ANAL APPL, V335, P560, DOI 10.1016/j.jmaa.2007.01.091; Cruz-Uribe D, 2006, ANN ACAD SCI FENN-M, V31, P239; ADAMS DR, 1975, DUKE MATH J, V42, P765, DOI 10.1215/S0012-7094-75-04265-9; Acerbi E, 2002, ARCH RATION MECH AN, V164, P213, DOI 10.1007/s00205-002-0208-7; Acerbi E, 2005, J REINE ANGEW MATH, V584, P117; Hasto PA, 2009, MATH RES LETT, V16, P263; Diening L, 2004, MATH INEQUAL APPL, V7, P245; Chen YM, 2006, SIAM J APPL MATH, V66, P1383, DOI 10.1137/050624522; Almeida A, 2008, GEORGIAN MATH J, V15, P195; Komori Y, 2009, MATH NACHR, V282, P219, DOI 10.1002/mana.200610733; Cruz-Uribe D, 2011, FRACT CALC APPL ANAL, V14, P361, DOI 10.2478/s13540-011-0023-7; Guliyev VS, 2010, MATH SCAND, V107, P285; Bendahmane M, 2009, NONLINEAR ANAL-THEOR, V70, P567, DOI 10.1016/j.na.2007.12.027; Capone C., 2007, REV MAT IBEROAM, V23, P743; Chiarenza F., 1987, REND MAT, V7, P273; Cruz-Uribe D, 2012, J MATH ANAL APPL, V394, P744, DOI 10.1016/j.jmaa.2012.04.044; Dai GW, 2009, NONLINEAR ANAL-THEOR, V71, P1133, DOI 10.1016/j.na.2008.11.037; Diening L, 2011, LECT NOTES MATH, V2017, P1, DOI 10.1007/978-3-642-18363-8; Diening L, 2004, MATH NACHR, V268, P31, DOI 10.1002/mana.200310157; Fiorcnza A., 2013, APPL NUMERICAL HARMO; Futamura T, 2006, MATH NACHR, V279, P1463, DOI 10.1002/mana.200410432; Garcia-Cuerva J., 1985, WEIGHTED NORM INEQUA; Harjulehto P, 2006, MATH Z, V254, P591, DOI 10.1007/s00209-006-0960-8; Hasto P., PREPRINT; Heinonen Juha, 2001, LECT ANAL METRIC SPA; Kokilashvili V, 2004, REV MAT IBEROAM, V20, P493; Mizuta Y, 2011, COMPLEX VAR ELLIPTIC, V56, P671, DOI 10.1080/17476933.2010.504837; Mizuta Y, 2012, J MATH ANAL APPL, V388, P86, DOI 10.1016/j.jmaa.2011.10.055; Mizuta Y., 1996, POTENTIAL THEORY EUC; Mizuta Y, 2012, REV MAT COMPLUT, V25, P413, DOI 10.1007/s13163-011-0074-7; Mizuta Y, 2008, J MATH SOC JPN, V60, P583, DOI 10.2969/jmsj/06020583; MUCKENHO.B, 1972, T AM MATH SOC, V165, P207, DOI 10.2307/1995882; NAKAI E, 1994, MATH NACHR, V166, P95, DOI 10.1002/mana.19941660108; Peetre J., 1969, J FUNCT ANAL, V4, P71, DOI 10.1016/0022-1236(69)90022-6; Ruzicka M., 2000, ELECTRORHEOLOGICAL F; Stein E., 1970, SINGULAR INTEGRALS D	39	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0025-584X	1522-2616		MATH NACHR	Math. Nachr.	JUN	2015	288	8-9					984	1002		10.1002/mana.201400032		19	Mathematics	Mathematics	CJ8JB	WOS:000355745100011		
J	Nunokawa, M; Sokol, J				Nunokawa, Mamoru; Sokol, Janusz			On order of strongly starlikeness in the class of uniformly convex functions	MATHEMATISCHE NACHRICHTEN			English	Article						Analytic; univalent; convex; starlike; strongly starlike; uniformly convex; order of strongly starlikeness; 30C45; 30C55		In this paper we consider the order of strongly starlikeness in the classes uniformly convex functions.	[Nunokawa, Mamoru] Gunma Univ, Chiba 2600808, Japan; [Sokol, Janusz] Rzeszow Univ Technol, Dept Math, PL-35959 Rzeszow, Poland	Sokol, J (reprint author), Rzeszow Univ Technol, Dept Math, Al Powstancow Warszawy 12, PL-35959 Rzeszow, Poland.	mamoru_nuno@doctor.nifty.jp; jsokol@prz.edu.pl					RONNING F, 1993, P AM MATH SOC, V118, P189, DOI 10.2307/2160026; BRANNAN DA, 1969, J LONDON MATH SOC, V1, P431; Goodman A. W., 1991, ANN POL MATH, V56, P87; Kana S., 1998, FOLIA SCI U TECH RES, V22, P65; Kanas S, 1999, J COMPUT APPL MATH, V105, P327, DOI 10.1016/S0377-0427(99)00018-7; Kanas S., 2000, REV ROUMAINE MATH PU, V45, P647; Kanas S, 2000, INTEGR TRANSF SPEC F, V9, P121, DOI 10.1080/10652460008819249; Lecko A, 2003, J COMPUT APPL MATH, V155, P383; Ma W., 1993, ANN POL MATH, V3, P275; Ma W., 1992, ANN POL MATH, V2, P165; Miller S. S., 1997, COMPLEX VAR, V33, P217, DOI 10.1080/17476939708815024; Mocanu P.T., 2000, SERIES MONOGRAPHS TX, V225; NUNOKAWA M, 1993, P JPN ACAD A-MATH, V69, P234; NUNOKAWA M, 1992, P JPN ACAD A-MATH, V68, P152; ROnning F., 1991, ANN U M CURIE SKLO A, V45, P117; ROnning F., 1994, COMPLEX VARIABLES, V24, P233, DOI 10.1080/17476939408814715; Soko J., 1993, FOLIA SCI U TECH RES, V28, P35; Soko J., 2011, COMPUT MATH APPL, V62, P7433; Stankiewicz J, 1966, ANN U M CURIE SKLO A, V20, P59; Winiowska-Wajnryb A., 2013, ANN POL MATH, V108, P11; Winiowska-Wajnryb A., 2009, APPL MATH COMPUT, V215, P2634	21	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0025-584X	1522-2616		MATH NACHR	Math. Nachr.	JUN	2015	288	8-9					1003	1008		10.1002/mana.201400091		6	Mathematics	Mathematics	CJ8JB	WOS:000355745100012		
J	Fanciulli, PP; Mercati, D; Machida, R; Dallai, R				Fanciulli, Pietro Paolo; Mercati, David; Machida, Ryuichiro; Dallai, Romano			Spermiogenesis and sperm ultrastructure of Machilontus sp (Insecta: Archaeognatha) with phylogenetic consideration	MICRON			English	Article						Insect spermiogenesis; Insect ultrastructure; Insect phylogeny; Electron microscopy	ZYGENTOMA	The sperm structure of the jumping bristletail Machilontus sp has been described. The species shares several sperm characteristics with other genera of the same order Archaeognatha. During late spermiogenesis the spermatid bends at half of its length with the two limbs closely apposed within the same plasma membrane. The sperm has a helicoidal bi-layered acrosome with a filamentous perforatorium and a long nucleus. The elongated flagellum consists of an axoneme with 9 accessory microtubules external to the 9+2, two rows of conventional mitochondria and two accessory bodies. The accessory bodies are located lateral to the axoneme and are probably responsible for the shifting of the accessory tubules in two opposite groups of 5 and 4 tubules, respectively. These sperm characteristics represent common traits of all Archaeognatha. (C) 2015 Elsevier Ltd. All rights reserved.	[Fanciulli, Pietro Paolo; Mercati, David; Dallai, Romano] Univ Siena, Dept Life Sci, I-53100 Siena, Italy; [Machida, Ryuichiro] Univ Tsukuba, Sugadaira Montane Res Ctr, Nagano 3862204, Japan	Dallai, R (reprint author), Univ Siena, Dept Life Sci, Via A Moro 2, I-53100 Siena, Italy.	romano.dallai@unisi.it					Kjer KM, 2004, SYST BIOL, V53, P506, DOI 10.1080/10635150490445922; Dallai R, 2002, ACTA ZOOL-STOCKHOLM, V83, P245, DOI 10.1046/j.1463-6395.2002.00118.x; Dallai R, 2014, ARTHROPOD STRUCT DEV, V43, P257, DOI 10.1016/j.asd.2014.04.002; Misof B, 2014, SCIENCE, V346, P763, DOI 10.1126/science.1257570; Blanke A, 2015, SYST ENTOMOL, V40, P357, DOI 10.1111/syen.12107; DALLAI R, 1990, J STRUCT BIOL, V103, P164, DOI 10.1016/1047-8477(90)90020-D; DALLAI R, 1992, ACTA ZOOL-STOCKHOLM, V73, P109; Dallai R, 2001, TISSUE CELL, V33, P596, DOI 10.1054/tice.2001.0214; DALLAI R, 1972, Monitore Zoologico Italiano, V6, P37; DALLAI R, 1993, J SUBMICR CYTOL PATH, V25, P499; Dallai R, 2011, ARTHROPOD STRUCT DEV, V40, P77, DOI 10.1016/j.asd.2010.08.001; DALLAI R, 1999, FUNCTION PHYLOGENETI, P333; Dallai R, 2004, TISSUE CELL, V36, P233, DOI 10.1016/j.tice.2004.03.002; Frati F., 2009, SPERM MOL EVOLUTION, P115; Giribet G, 2004, ORG DIVERS EVOL, V4, P319, DOI 10.1016/j.ode.2004.05.001; KRISTENSEN NP, 1981, ANNU REV ENTOMOL, V26, P135, DOI 10.1146/annurev.en.26.010181.001031; Kristensen N. P., 1998, Arthropod relationships., P281; ROSATI F, 1976, International Journal of Insect Morphology and Embryology, V5, P223, DOI 10.1016/0020-7322(76)90007-6; WINGSTRAND K G, 1973, Acta Zoologica (Stockholm), V54, P31	19	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0968-4328			MICRON	Micron	JUN	2015	73						47	53		10.1016/j.micron.2015.03.011		7	Microscopy	Microscopy	CJ7WE	WOS:000355710300007		
J	Wang, DJ; Ho, L; Faith, J; Ono, K; Janle, EM; Lachcik, PJ; Cooper, BR; Jannasch, AH; D'Arcy, BR; Williams, BA; Ferruzzi, MG; Levine, S; Zhao, W; Dubner, L; Pasinetti, GM				Wang, Dongjie; Ho, Lap; Faith, Jeremiah; Ono, Kenjiro; Janle, Elsa M.; Lachcik, Pamela J.; Cooper, Bruce R.; Jannasch, Amber H.; D'Arcy, Bruce R.; Williams, Barbara A.; Ferruzzi, Mario G.; Levine, Samara; Zhao, Wei; Dubner, Lauren; Pasinetti, Giulio M.			Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer's disease -amyloid oligomerization	MOLECULAR NUTRITION & FOOD RESEARCH			English	Article						-Amyloid; Bioavailability; Grape seed polyphenol extract; Phenolic metabolites; Proanthocyanidins	GRAPE SEED EXTRACT; BETA-PROTEIN; IN-VITRO; URINARY-EXCRETION; MOUSE MODEL; PROANTHOCYANIDIN METABOLITES; COLONIC METABOLISM; CHLOROGENIC ACID; BLOOD-PRESSURE; RING-FISSION	ScopeGrape seed polyphenol extract (GSPE) is receiving increasing attention for its potential preventative and therapeutic roles in Alzheimer's disease (AD) and other age-related neurodegenerative disorders. The intestinal microbiota is known to actively convert many dietary polyphenols, including GSPE, to phenolic acids. There is limited information on the bioavailability and bioactivity of GSPE-derived phenolic acid in the brain. Methods and resultsWe orally administered GSPE to rats and investigated the bioavailability of 12 phenolic acids known to be generated by microbiota metabolism of anthocyanidins. GSPE treatment significantly increased the content of two of the phenolic acids in the brain: 3-hydroxybenzoic acid and 3-(3-hydroxyphenyl)propionic acid, resulting in the brain accumulations of the two phenolic acids at micromolar concentrations. We also provided evidence that 3-hydroxybenzoic acid and 3-(3 '-hydroxyphenyl)propionic acid potently interfere with the assembly of -amyloid peptides into neurotoxic -amyloid aggregates that play key roles in AD pathogenesis. ConclusionOur observation suggests important contribution of the intestinal microbiota to the protective activities of GSPE (as well as other polyphenol preparations) in AD. Outcomes from our studies support future preclinical and clinical investigations exploring the potential contributions of the intestinal microbiota in protecting against the onset/progression of AD and other neurodegenerative conditions.	[Wang, Dongjie; Williams, Barbara A.] Univ Queensland, ARC Ctr Excellence Plant Cell Walls, Ctr Nutr & Food Sci, Brisbane, Qld, Australia; [Ho, Lap; Levine, Samara; Zhao, Wei; Dubner, Lauren; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Faith, Jeremiah] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Ono, Kenjiro] Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol & Aging, Kanazawa, Ishikawa, Japan; [Janle, Elsa M.; Lachcik, Pamela J.; Ferruzzi, Mario G.] Purdue Univ, Dept Nutr Sci, W Lafayette, IN 47907 USA; [Cooper, Bruce R.; Jannasch, Amber H.] Purdue Univ, Bindley Biosci Ctr, W Lafayette, IN 47907 USA; [D'Arcy, Bruce R.] Univ Queensland, Sch Agr & Food Sci, Brisbane, Qld, Australia; [Ferruzzi, Mario G.] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA; [Pasinetti, Giulio M.] James J Peter Vet Affairs Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY USA	Pasinetti, GM (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu			NIH/NCCAM [P01AT004511-01]; Endeavour International Postgraduate Research Scholarship (IPRS) - Australia government; Graduate School International Travel Award (GSITA) from The University of Queensland; Career Scientist Award in the Research and Development unit	The GSPE sample used in this study was generously provided by Polyphenolics (Madera, CA). Funding was provided by NIH/NCCAM grant P01AT004511-01 (to GMP) and by the Endeavour International Postgraduate Research Scholarship (IPRS), awarded by Australia government, and the Graduate School International Travel Award (GSITA) from The University of Queensland. This material is the result of work supported in part with resources and the use of facilities at the James J. Peters Veterans Affairs Medical Center, Bronx, NY. In addition, Dr. Pasinetti holds a Career Scientist Award in the Research and Development unit and is the Director of the Basic and Biomedical Research and Training Program, GRECC, James J. Peters Veterans Affairs Medical Center. We also acknowledge that the contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. GMP and LH disclose financial interest as inventors of a patent for use of GSPE for the treatment of neurodegenerative diseases (Patent number, US 8,747,924 B2).	Agarwal C, 2000, CLIN CANCER RES, V6, P2921; Tavares L, 2013, EUR J NUTR, V52, P225, DOI 10.1007/s00394-012-0307-7; Rechner AR, 2001, FREE RADICAL BIO MED, V30, P1213, DOI 10.1016/S0891-5849(01)00506-8; Prior RL, 2010, J AGR FOOD CHEM, V58, P3940, DOI 10.1021/jf9028392; Power SE, 2014, BRIT J NUTR, V111, P387, DOI 10.1017/S0007114513002560; Monagas M, 2010, FOOD FUNCT, V1, P233, DOI 10.1039/c0fo00132e; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Aura Anna-Marja, 2008, Phytochemistry Reviews, V7, P407, DOI 10.1007/s11101-008-9095-3; Gao K, 2006, J NUTR, V136, P52; Lotito SB, 2006, FREE RADICAL BIO MED, V41, P1727, DOI 10.1016/j.freeradbiomed.2006.04.033; Cueva C, 2013, FEMS MICROBIOL ECOL, V83, P792, DOI 10.1111/1574-6941.12037; Hasslauer I, 2010, MOL NUTR FOOD RES, V54, P1546, DOI 10.1002/mnfr.201000003; Keppler K, 2005, BIOORGAN MED CHEM, V13, P5195, DOI 10.1016/j.bmc.2005.05.003; Deprez S, 2000, J NUTR, V130, P2733; Clabough Erin B. D., 2013, Yale Journal of Biology and Medicine, V86, P217; Serafim TL, 2011, CHEM RES TOXICOL, V24, P763, DOI 10.1021/tx200126r; Gonthier MP, 2003, J NUTR, V133, P461; Wang DJ, 2013, J SCI FOOD AGR, V93, P276, DOI 10.1002/jsfa.5753; Urpi-Sarda M, 2009, J CHROMATOGR A, V1216, P7258, DOI 10.1016/j.chroma.2009.07.058; Feng WY, 2006, CURR DRUG METAB, V7, P755; Virmani A, 2013, MOL NEUROBIOL, V48, P353, DOI 10.1007/s12035-013-8498-3; Ono K, 2008, J BIOL CHEM, V283, P32176, DOI 10.1074/jbc.M806154200; Aura AM, 2002, J AGR FOOD CHEM, V50, P1725, DOI 10.1021/jf0108056; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Unno T, 2003, J AGR FOOD CHEM, V51, P6893, DOI 10.1021/jf034578e; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Baba S, 2001, J AGR FOOD CHEM, V49, P6050, DOI 10.1021/jf010965h; Magrone T, 2012, CURR PHARM DESIGN, V18, P34, DOI 10.2174/138161212798919057; Sato M, 2001, FREE RADICAL BIO MED, V31, P729, DOI 10.1016/S0891-5849(01)00626-8; Gonthier MP, 2003, FREE RADICAL BIO MED, V35, P837, DOI 10.1016/S0891-5849(03)00394-0; Gonthier MP, 2003, J NUTR, V133, P1853; Ferruzzi MG, 2009, J ALZHEIMERS DIS, V18, P113, DOI 10.3233/JAD-2009-1135; Bitan G, 2005, AMYLOID, V12, P88, DOI 10.1080/13506120500106958; Teplow DB, 2006, METHOD ENZYMOL, V413, P20, DOI 10.1016/S0076-6879(06)13002-5; Prasain JK, 2009, PHYTOMEDICINE, V16, P233, DOI 10.1016/j.phymed.2008.08.006; Wang J, 2008, J NEUROSCI, V28, P6388, DOI 10.1523/JNEUROSCI.0364-08.2008; Santa-Maria I, 2012, NEUROBIOL AGING, V33, P2072, DOI 10.1016/j.neurobiolaging.2011.09.027; Ward NC, 2005, J HYPERTENS, V23, P427, DOI 10.1097/00004872-200502000-00026; Saura-Calixto F, 2010, MOL NUTR FOOD RES, V54, P939, DOI 10.1002/mnfr.200900276; Tsang C, 2005, BRIT J NUTR, V94, P170, DOI 10.1079/BJN20051480; Ho L, 2010, EXPERT REV PROTEOMIC, V7, P579, DOI [10.1586/epr.10.69, 10.1586/EPR.10.69]; Olthof MR, 2003, J NUTR, V133, P1806; Wang J, 2010, J ALZHEIMERS DIS, V22, P653, DOI 10.3233/JAD-2010-101074; Manach C, 2004, AM J CLIN NUTR, V79, P727; Cui JD, 2014, CRIT REV BIOTECHNOL, V34, P258, DOI 10.3109/07388551.2013.791660; Aura AM, 2008, PHYTOCHEM LETT, V1, P18, DOI 10.1016/j.phytol.2007.12.001; Wang LQ, 2001, CHEM PHARM BULL, V49, P1640, DOI 10.1248/cpb.49.1640; Singletary KW, 2001, NUTR CANCER, V39, P252, DOI 10.1207/S15327914nc392_15; Appeldoorn MM, 2009, J AGR FOOD CHEM, V57, P1084, DOI 10.1021/jf803059z; Duyckaerts C, 2013, REV NEUROL-FRANCE, V169, P825, DOI 10.1016/j.neurol.2013.07.018; Sano A, 2003, BIOSCI BIOTECH BIOCH, V67, P1140, DOI 10.1271/bbb.67.1140; Cimini A, 2013, J CELL BIOCHEM, V114, P2209, DOI 10.1002/jcb.24548; Rechner AR, 2004, FREE RADICAL BIO MED, V36, P212, DOI 10.1016/j.freeradbiomed.2003.09.022; Wang J, 2012, J NEUROSCI, V32, P5144, DOI 10.1523/JNEUROSCI.6437-11.2012; Leifert WR, 2008, NUTR RES, V28, P729, DOI [10.1016/j.nutres.2008.08.007, 10.1016/j.nutres.2008.09.001]; Faria A, 2011, FOOD FUNCT, V2, P39, DOI 10.1039/c0fo00100g; Wang YJ, 2009, NEUROTOX RES, V15, P3, DOI 10.1007/s12640-009-9000-x; Basli A., 2012, OXID MED CELL LONGEV, V2012, P1; Calani L, 2012, J CLIN GASTROENTEROL, V46, pS95, DOI 10.1097/MCG.0b013e318264e82b; Dimakopoulos Aristotelis C., 2005, Current Alzheimer Research, V2, P19, DOI 10.2174/1567205052772795; Dinicola S, 2010, BRIT J NUTR, V104, P824, DOI 10.1017/S0007114510001522; Du Y, 2008, EUR J PHARMACOL, V591, P96, DOI 10.1016/j.ejphar.2008.06.068; Hwang IK, 2004, LIFE SCI, V75, P1989, DOI 10.1016/j.lfs.2004.05.013; Kim Bong-Soo, 2013, Pediatr Gastroenterol Hepatol Nutr, V16, P71, DOI 10.5223/pghn.2013.16.2.71; Kim H, 2004, J NUTR, V134, p3445S; Lin YH, 2012, MICROB CELL FACT, V11, DOI 10.1186/1475-2859-11-42; Nakamura Y, 2003, J AGR FOOD CHEM, V51, P7215, DOI 10.1021/jf030250+; Ras RT, 2013, BRIT J NUTR, V110, P2234, DOI 10.1017/S000711451300161X; Scalbert A, 2000, J NUTR, V130, p2073S; Sivaprakasapillai B, 2009, METABOLISM, V58, P1743, DOI 10.1016/j.metabol.2009.05.030; Smid SD, 2012, FOOD FUNCT, V3, P1242, DOI 10.1039/c2fo30075c; Wang J, 2013, MOL NUTR FOOD RES, V57, P2091, DOI 10.1002/mnfr.201300230; Ward NC, 2004, J AGR FOOD CHEM, V52, P5545, DOI 10.1021/jf049404r; Wu C., 2009, MOL NUTR FOOD RES S1, V53, pS76	74	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1613-4125	1613-4133		MOL NUTR FOOD RES	Mol. Nutr. Food Res.	JUN	2015	59	6					1025	1040		10.1002/mnfr.201400544		16	Food Science & Technology	Food Science & Technology	CJ8JD	WOS:000355745400002		
J	Nishikawa, K; Iwaya, K; Kinoshita, M; Fujiwara, Y; Akao, M; Sonoda, M; Thiruppathi, S; Suzuki, T; Hiroi, S; Seki, S; Sakamoto, T				Nishikawa, Kahoko; Iwaya, Keiichi; Kinoshita, Manabu; Fujiwara, Yoko; Akao, Mai; Sonoda, Mariko; Thiruppathi, Suresh; Suzuki, Takayoshi; Hiroi, Sadayuki; Seki, Shuhji; Sakamoto, Toshihisa			Resveratrol increases CD68(+) Kupffer cells colocalized with adipose differentiation-related protein and ameliorates high-fat-diet-induced fatty liver in mice	MOLECULAR NUTRITION & FOOD RESEARCH			English	Article						Fatty liver; Kupffer cells; Lipid droplets; Lipid metabolism; Resveratrol	LOW-DENSITY-LIPOPROTEIN; PAT FAMILY PROTEINS; HUMAN MACROPHAGES; LIPID-ACCUMULATION; HEPATIC STEATOSIS; TRIGLYCERIDE STORAGE; THP-1 MACROPHAGES; OXIDATIVE STRESS; MESSENGER-RNA; TNF-ALPHA	ScopeResveratrol reportedly improves fatty liver. This study purposed to elucidate the effect of resveratrol on fatty liver in mice fed a high-fat (HF) diet, and to investigate the role of liver macrophages (Kupffer cells). Methods and resultsC57BL/6 mice were divided into three groups, receiving either a control diet, HF diet (50% fat), or HF supplemented with 0.2% resveratrol (HF + res) diet, for 8 weeks. Compared with the HF group, the HF + res group exhibited markedly attenuated fatty liver, and reduced lipid droplets (LDs) in hepatocytes. Proteomic analysis demonstrated that the most downregulated protein in the livers of the HF + res group was adipose differentiation-related protein (ADFP), which is a major constituent of LDs and reflects lipid accumulation in cells. The HF + res group exhibited greatly increased numbers of CD68(+) Kupffer cells with phagocytic activity. Immunohistochemistry showed that several CD68(+) Kupffer cells were colocalized with ADFP immunoreaction in the HF + res group. Additionally, the HF + res group demonstrated markedly decreased TNF-alpha production, which confirmed by both liver mononuclear cells stimulated by LPS in vitro and in situ hybridization analysis, compared with the HF group. ConclusionResveratrol ameliorated fatty liver and increased CD68-positive Kupffer cells with downregulating ADFP expression.	[Nishikawa, Kahoko; Sakamoto, Toshihisa] Chuo Univ, Fac Commerce, Tokyo 112, Japan; [Iwaya, Keiichi] Natl Def Med Coll, Dept Basic Pathol, Saitama, Japan; [Kinoshita, Manabu; Seki, Shuhji] Natl Def Med Coll, Dept Immunol & Microbiol, Saitama, Japan; [Fujiwara, Yoko; Akao, Mai; Sonoda, Mariko] Ochanomizu Univ, Dept Food & Nutr Sci, Grad Sch Humanities & Sci, Tokyo 112, Japan; [Thiruppathi, Suresh; Suzuki, Takayoshi] Natl Inst Hlth Sci, Div Mol Target & Gene Therapy Prod, Tokyo, Japan; [Hiroi, Sadayuki] Natl Def Med Coll, Dept Lab Med, Saitama, Japan	Nishikawa, K (reprint author), Natl Def Med Coll, Dept Traumatol & Crit Care Med, Saitama, Japan.	knishika@ndmc.ac.jp			JSPS [25504021, 24590457]; National Cancer Center for Research and Development Fund [23-A-11]	We thank Mr. Naoto Suzuki for his assistance with the preparation of the tissue slices and Dr. Takahiro Nakamura for his help to statistical analysis. This work was supported by JSPS Grants-in-Aid for Scientific Research (C) 25504021 and (C) 24590457, and in part by the National Cancer Center for Research and Development Fund (23-A-11).	Ahn J, 2008, J HEPATOL, V49, P1019, DOI 10.1016/j.jhep.2008.08.012; Poulsen MM, 2012, NUTR RES, V32, P701, DOI 10.1016/j.nutres.2012.08.004; Kinoshita M, 2010, J HEPATOL, V53, P903, DOI 10.1016/j.jhep.2010.04.037; Shindler KS, 2010, J NEURO-OPHTHALMOL, V30, P328, DOI 10.1097/WNO.0b013e3181f7f833; Polyzos SA, 2013, METABOLISM, V62, P121, DOI 10.1016/j.metabol.2012.06.007; De Taeye BM, 2007, AM J PHYSIOL-ENDOC M, V293, pE713, DOI 10.1152/ajpendo.00194.2007; Shiozaki M, 2011, HISTOCHEM CELL BIOL, V136, P475, DOI 10.1007/s00418-011-0847-6; Toklu HZ, 2010, J PHARM PHARMACOL, V62, P1784, DOI 10.1111/j.2042-7158.2010.01197.x; Park SJ, 2012, CELL, V148, P421, DOI 10.1016/j.cell.2012.01.017; Ikarashi M, 2013, J LEUKOCYTE BIOL, V94, P1325, DOI 10.1189/jlb.0313144; Chang BHJ, 2006, MOL CELL BIOL, V26, P1063, DOI 10.1128/MCB.26.3.1063-1076.2006; Larigauderie G, 2006, FEBS J, V273, P3498, DOI 10.1111/j.1742-4658.2006.05357.x; Robenek H, 2005, J LIPID RES, V46, P1331, DOI 10.1194/jlr.M400323-JLR200; Kasdallah-Grissa A, 2007, LIFE SCI, V80, P1033, DOI 10.1016/j.lfs.2006.11.044; Tome-Carneiro J, 2012, AM J CARDIOL, V110, P356, DOI 10.1016/j.amjcard.2012.03.030; Seki S, 2000, IMMUNOL REV, V174, P35, DOI 10.1034/j.1600-0528.2002.017404.x; Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002; Robenek H, 2006, J CELL SCI, V119, P4215, DOI 10.1242/jcs.03191; Mak KM, 2008, ALCOHOL CLIN EXP RES, V32, P683, DOI 10.1111/j.1530-0277.2008.00624.x; Shang J, 2008, ACTA PHARMACOL SIN, V29, P698, DOI 10.1111/j.1745-7254.2008.00807.x; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; Larigauderie G, 2004, ARTERIOSCL THROM VAS, V24, P504, DOI 10.1161/01.ATV.0000115638.27381.97; Tunali-Akbay T, 2010, J PHARM PHARM SCI, V13, P303; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Li C, 2010, NEUROCHEM INT, V56, P495, DOI 10.1016/j.neuint.2009.12.009; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Andrade JMO, 2014, NUTRITION, V30, P915, DOI 10.1016/j.nut.2013.11.016; Gomez-Zorita S, 2012, BRIT J NUTR, V107, P202, DOI 10.1017/S0007114511002753; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Davies LC, 2013, NAT IMMUNOL, V14, P986, DOI 10.1038/ni.2705; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Buechler C, 2001, BBA-MOL CELL BIOL L, V1532, P97, DOI 10.1016/S1388-1981(01)00121-4; Bujanda L, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-40; Chen FL, 2010, MOL CELL BIOCHEM, V337, P193, DOI 10.1007/s11010-009-0299-7; Faghihzadeh F, 2014, NUTR RES, V34, P837, DOI 10.1016/j.nutres.2014.09.005; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hiroi S, 2003, DIAGN CYTOPATHOL, V29, P212, DOI 10.1002/dc.10352; Kawabata T, 2008, HEPATOLOGY, V48, P1586, DOI 10.1002/hep.22489; Larigauderie G, 2006, ATHEROSCLEROSIS, V189, P142, DOI 10.1016/j.atherosclerosis.2005.12.016; Lefkowitch JH, 2002, MODERN PATHOL, V15, P699, DOI 10.1097/01.MP.0000019579.30842.96; Liu QN, 2010, ACTA BIOCH BIOPH SIN, V42, P635, DOI 10.1093/abbs/gmq070; Nakashima H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0049339; Nishikawa K, 2014, FEBS OPEN BIO, V4, P179, DOI 10.1016/j.fob.2014.02.005; Ristig M, 2005, AIDS PATIENT CARE ST, V19, P356, DOI 10.1089/apc.2005.19.356; Robenek H, 2005, J BIOL CHEM, V280, P26330, DOI 10.1074/jbc.M413312200; Shono S, 2011, SHOCK, V36, P484, DOI 10.1097/SHK.0b013e31822dc6e4; Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200; Wan JH, 2014, HEPATOLOGY, V59, P130, DOI 10.1002/hep.26607; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5	49	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1613-4125	1613-4133		MOL NUTR FOOD RES	Mol. Nutr. Food Res.	JUN	2015	59	6					1155	1170		10.1002/mnfr.201400564		16	Food Science & Technology	Food Science & Technology	CJ8JD	WOS:000355745400013		
J	Kannawadi, A; Mandelbaum, R; Lackner, C				Kannawadi, Arun; Mandelbaum, Rachel; Lackner, Claire			The impact of cosmic variance on simulating weak lensing surveys	MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY			English	Article						gravitational lensing: weak; galaxies: evolution; large-scale structure of Universe	GALAXY LUMINOSITY FUNCTION; COSMOLOGICAL PARAMETER CONSTRAINTS; DIGITAL SKY SURVEY; SHAPE MEASUREMENT; SHEAR MEASUREMENT; IMAGE-ANALYSIS; NOISE BIAS; EVOLUTION; CHALLENGE; DENSITY	Upcoming weak lensing surveys will survey large cosmological volumes to measure the growth of cosmological structure with time and thereby constrain dark energy. One major systematic uncertainty in this process is the calibration of the weak lensing shape distortions, or shears. Most upcoming surveys plan to test several aspects of their shear estimation algorithms using sophisticated image simulations that include realistic galaxy populations based on high-resolution data from the Hubble Space Telescope (HST). However, existing data sets from the HST cover very small cosmological volumes, so cosmic variance could cause the galaxy populations in them to be atypical. A narrow redshift slice from such surveys could be dominated by a single large overdensity or underdensity. In that case, the morphology-density relation could alter the local galaxy populations and yield an incorrect calibration of shear estimates as a function of redshift. We directly test this scenario using the COSMOS survey, the largest-area HST survey to date, and show how the statistical distributions of galaxy shapes and morphological parameters (e.g. Sersic n) are influenced by redshift-dependent cosmic variance. The typical variation in rms ellipticity due to environmental effects is 5 per cent (absolute, not relative) for redshift bins of width Delta z = 0.05, which could result in uncertain shear calibration at the 1 per cent level. We conclude that the cosmic variance effects are large enough to exceed the systematic error budget of future surveys, but can be mitigated with careful choice of training data set and sufficiently large redshift binning.	[Kannawadi, Arun; Mandelbaum, Rachel] Carnegie Mellon Univ, McWilliams Ctr Cosmol, Pittsburgh, PA 15217 USA; [Lackner, Claire] Univ Tokyo, Todai Inst Adv Study, Kavli Inst Phys & Math Universe WPI, Kashiwa, Chiba 2778583, Japan	Kannawadi, A (reprint author), Carnegie Mellon Univ, McWilliams Ctr Cosmol, Pittsburgh, PA 15217 USA.	arunkannawadi@cmu.edu	Mandelbaum, Rachel/N-8955-2014	Mandelbaum, Rachel/0000-0003-2271-1527	NASA ROSES [12-EUCLID12-0004]; NASA through Space Telescope Science Institute [HST-AR-12857.01-A]; NASA [NAS5-26555]; Alfred P. Sloan Research Fellowship; World Premier International Research Center Initiative (WPI), MEXT, Japan	The authors would like to thank Thomas Kitching, Henk Hoekstra, Tim Schrabback and the anonymous referee for their helpful comments on this work. AK and RM acknowledge the support of NASA ROSES 12-EUCLID12-0004, and programme HST-AR-12857.01-A, provided by NASA through a grant from the Space Telescope Science Institute, which is operated by the Association of Universities for Research in Astronomy, Incorporated, under NASA contract NAS5-26555. RM acknowledges the support of an Alfred P. Sloan Research Fellowship. Kavli IPMU is supported by World Premier International Research Center Initiative (WPI), MEXT, Japan. We thank Alexie Leauthaud for many useful discussions.	Albrecht A., 2006, ASTROPH0609591; Viola M, 2014, MON NOT R ASTRON SOC, V439, P1909, DOI 10.1093/mnras/stu071; Refregier A, 2012, MON NOT R ASTRON SOC, V425, P1951, DOI 10.1111/j.1365-2966.2012.21483.x; Bruzual G, 2003, MON NOT R ASTRON SOC, V344, P1000, DOI 10.1046/j.1365-8711.2003.06897.x; Bartelmann M, 2001, PHYS REP, V340, P291, DOI 10.1016/S0370-1573(00)00082-X; Kriek M, 2009, ASTROPHYS J, V700, P221, DOI 10.1088/0004-637X/700/1/221; Coil AL, 2004, ASTROPHYS J, V617, P765, DOI 10.1086/425676; Melchior P, 2012, MON NOT R ASTRON SOC, V424, P2757, DOI 10.1111/j.1365-2966.2012.21381.x; Bernstein GM, 2014, MON NOT R ASTRON SOC, V438, P1880, DOI 10.1093/mnras/stt2326; Mandelbaum R, 2013, MON NOT R ASTRON SOC, V432, P1544, DOI 10.1093/mnras/stt572; Voigt LM, 2010, MON NOT R ASTRON SOC, V404, P458, DOI 10.1111/j.1365-2966.2010.16300.x; Bundy K, 2006, ASTROPHYS J, V651, P120, DOI 10.1086/507456; Melchior P, 2010, ASTRON ASTROPHYS, V510, DOI 10.1051/0004-6361/200912785; Willmer CNA, 2006, ASTROPHYS J, V647, P853, DOI 10.1086/505455; Ilbert O, 2009, ASTROPHYS J, V690, P1236, DOI 10.1088/0004-637X/690/2/1236; Bridle S, 2010, MON NOT R ASTRON SOC, V405, P2044, DOI 10.1111/j.1365-2966.2010.16598.x; Lackner CN, 2012, MON NOT R ASTRON SOC, V421, P2277, DOI 10.1111/j.1365-2966.2012.20450.x; Bernstein GM, 2002, ASTRON J, V123, P583, DOI 10.1086/338085; Kovac K, 2010, ASTROPHYS J, V708, P505, DOI 10.1088/0004-637X/708/1/505; Koekemoer AM, 2007, ASTROPHYS J SUPPL S, V172, P196, DOI 10.1086/520086; Newman JA, 2015, ASTROPART PHYS, V63, P81, DOI 10.1016/j.astropartphys.2014.06.007; Leauthaud A, 2007, ASTROPHYS J SUPPL S, V172, P219, DOI 10.1086/516598; Miller L, 2007, MON NOT R ASTRON SOC, V382, P315, DOI 10.1111/j.1365-2966.2007.12363.x; van der Wel A, 2010, ASTROPHYS J, V714, P1779, DOI 10.1088/0004-637X/714/2/1779; van Daalen MP, 2011, MON NOT R ASTRON SOC, V415, P3649, DOI 10.1111/j.1365-2966.2011.18981.x; Semboloni E, 2011, MON NOT R ASTRON SOC, V417, P2020, DOI 10.1111/j.1365-2966.2011.19385.x; Kacprzak T, 2012, MON NOT R ASTRON SOC, V427, P2711, DOI 10.1111/j.1365-2966.2012.21622.x; Scoville N, 2007, ASTROPHYS J SUPPL S, V172, P1, DOI 10.1086/516585; Wolf C, 2003, ASTRON ASTROPHYS, V401, P73, DOI 10.1051/0004-6361:20021513; Weinberg DH, 2013, PHYS REP, V530, P87, DOI 10.1016/j.physrep.2013.05.001; De Propris R, 2014, MON NOT R ASTRON SOC, V444, P2200, DOI 10.1093/mnras/stu1452; Faber SM, 2007, ASTROPHYS J, V665, P265, DOI 10.1086/519294; Blanton MR, 2003, ASTROPHYS J, V592, P819, DOI 10.1086/375776; Kitching TD, 2008, MON NOT R ASTRON SOC, V390, P149, DOI 10.1111/j.1365-2966.2008.13628.x; Bernstein GM, 2010, MON NOT R ASTRON SOC, V406, P2793, DOI 10.1111/j.1365-2966.2010.16883.x; Carollo C. M., 2014, ARXIV14021172; Chabrier G, 2003, PUBL ASTRON SOC PAC, V115, P763, DOI 10.1086/376392; de Jong J. T. A., 2013, MESSENGER, V154, P44; Giallongo E, 2005, ASTROPHYS J, V622, P116, DOI 10.1086/427819; Green J., 2012, ARXIV12084012; Heymans C, 2013, MON NOT R ASTRON SOC, V432, P2433, DOI 10.1093/mnras/stt601; Hirata C, 2003, MON NOT R ASTRON SOC, V343, P459, DOI 10.1046/j.1365-8711.2003.06683.x; Jee MJ, 2013, ASTROPHYS J, V765, DOI 10.1088/0004-637X/765/1/74; Kaiser N, 2010, PROC SPIE, V7733, DOI 10.1117/12.859188; Kitching TD, 2012, MON NOT R ASTRON SOC, V423, P3163, DOI 10.1111/j.1365-2966.2012.21095.x; Laureijs R., 2011, ARXIV11103193; Leauthaud A, 2010, ASTROPHYS J, V709, P97, DOI 10.1088/0004-637X/709/1/97; Lin H, 1999, ASTROPHYS J, V518, P533, DOI 10.1086/307297; LSST Science Collaboration et al, 2009, ARXIV09120201 LSST S; Mandelbaum R, 2014, ASTROPHYS J SUPPL S, V212, DOI 10.1088/0067-0049/212/1/5; Mandelbaum R, 2012, MON NOT R ASTRON SOC, V420, P1518, DOI 10.1111/j.1365-2966.2011.20138.x; Miller L, 2013, MON NOT R ASTRON SOC, V429, P2858, DOI 10.1093/mnras/sts454; Miyazaki S, 2006, P SOC PHOTO-OPT INS, V6269, pB2690, DOI 10.1117/12.672739; Rowe B., 2014, ARXIV14077676; Schrabback T, 2010, ASTRON ASTROPHYS, V516, DOI 10.1051/0004-6361/200913577; Semboloni E, 2013, MON NOT R ASTRON SOC, V432, P2385, DOI 10.1093/mnras/stt602; The Dark Energy Survey Collaboration, 2005, ASTROPH0510346 DARK; Tomczak AR, 2014, ASTROPHYS J, V783, DOI 10.1088/0004-637X/783/2/85; Troxel M. A., 2014, ARXIV14076990; Voigt LM, 2012, MON NOT R ASTRON SOC, V421, P1385, DOI 10.1111/j.1365-2966.2011.20395.x	60	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-8711	1365-2966		MON NOT R ASTRON SOC	Mon. Not. Roy. Astron. Soc.	JUN 1	2015	449	4					3597	3612		10.1093/mnras/stv520		16	Astronomy & Astrophysics	Astronomy & Astrophysics	CJ2VE	WOS:000355342000025		
J	Asai, H; Lee, U; Yoshida, S				Asai, Hidetaka; Lee, Umin; Yoshida, Shijun			Non-radial oscillations of the magnetized rotating stars with purely toroidal magnetic fields	MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY			English	Article						stars: magnetic field; stars: neutron; stars: oscillations	QUASI-PERIODIC OSCILLATIONS; SOFT GAMMA REPEATERS; X-RAY OSCILLATIONS; NEUTRON-STARS; MAGNETOELASTIC OSCILLATIONS; RELATIVISTIC MODELS; ISENTROPIC STARS; 2004 HYPERFLARE; GIANT-FLARE; SGR 1806-20	We calculate non-axisymmetric oscillations of uniformly rotating polytropes magnetized with a purely toroidal magnetic field, taking account of the effects of the deformation due to the magnetic field. As for rotation, we consider only the effects of Coriolis force on the oscillation modes, ignoring those of the centrifugal force, that is, of the rotational deformation of the star. Since separation of variables is not possible for the oscillation of rotating magnetized stars, we employ finite series expansions for the perturbations using spherical harmonic functions. We calculate magnetically modified normal modes such as g-, f-, p-, r-, and inertial modes. In the lowest order, the frequency shifts produced by the magnetic field scale with the square of the characteristic Alfven frequency. As a measure of the effects of the magnetic field, we calculate the proportionality constant for the frequency shifts for various oscillation modes. We find that the effects of the deformation are significant for high frequency modes such as f- and p-modes but unimportant for low-frequency modes such as g-, r-, and inertial modes.	[Asai, Hidetaka; Lee, Umin; Yoshida, Shijun] Tohoku Univ, Astron Inst, Sendai, Miyagi 9808578, Japan	Asai, H (reprint author), Tohoku Univ, Astron Inst, Sendai, Miyagi 9808578, Japan.	hasai@astr.tohoku.ac.jp; lee@astr.tohoku.ac.jp; yoshida@astr.tohoku.ac.jp			JSPS [24540245]	This work was supported in part by a Grant-in-Aid for Scientific Research from JSPS (No. 24540245).	Levin Y, 2006, MON NOT R ASTRON SOC, V368, pL35, DOI 10.1111/j.1745-3933.2006.00155.x; Glampedakis K, 2006, MON NOT R ASTRON SOC, V371, pL74, DOI 10.1111/j.1745-3933.2006.00211.x; Lee U, 2007, MON NOT R ASTRON SOC, V374, P1015, DOI 10.1111/j.1365-2966.2006.11214.x; Glampedakis K, 2011, MON NOT R ASTRON SOC, V410, P805, DOI 10.1111/j.1365-2966.2010.17484.x; Kotake K, 2006, REP PROG PHYS, V69, P971, DOI 10.1088/0034-4885/69/4/R03; Braithwaite J, 2004, NATURE, V431, P819, DOI 10.1038/nature02934; Lander SK, 2010, MON NOT R ASTRON SOC, V405, P318, DOI 10.1111/j.1365-2966.2010.16435.x; Gabler M, 2012, MON NOT R ASTRON SOC, V421, P2054, DOI 10.1111/j.1365-2966.2012.20454.x; Colaiuda A, 2008, MON NOT R ASTRON SOC, V385, P2080, DOI 10.1111/j.1365-2966.2008.12966.x; Colaiuda A, 2011, MON NOT R ASTRON SOC, V414, P3014, DOI 10.1111/j.1365-2966.2011.18602.x; Lockitch KH, 1999, ASTROPHYS J, V521, P764, DOI 10.1086/307580; Levin Y, 2007, MON NOT R ASTRON SOC, V377, P159, DOI 10.1111/j.1365-2966.2007.11582.x; Strohmayer TE, 2005, ASTROPHYS J, V632, pL111, DOI 10.1086/497911; Arras P, 2004, ASTROPHYS J, V608, pL49, DOI 10.1086/422337; Sotani H, 2008, MON NOT R ASTRON SOC, V385, pL5, DOI 10.1111/j.1745-3933.2007.00420.x; van Hoven M, 2012, MON NOT R ASTRON SOC, V420, P3035, DOI 10.1111/j.1365-2966.2011.20177.x; Lander SK, 2011, MON NOT R ASTRON SOC, V412, P1730, DOI 10.1111/j.1365-2966.2010.18009.x; Gabler M, 2011, MON NOT R ASTRON SOC, V410, pL37, DOI 10.1111/j.1745-3933.2010.00974.x; Passamonti A, 2013, MON NOT R ASTRON SOC, V429, P767, DOI 10.1093/mnras/sts372; Gabler M, 2013, MON NOT R ASTRON SOC, V430, P1811, DOI 10.1093/mnras/sts721; Israel GL, 2005, ASTROPHYS J, V628, pL53, DOI 10.1086/432615; THOMPSON C, 1993, ASTROPHYS J, V408, P194, DOI 10.1086/172580; Watts AL, 2006, ASTROPHYS J, V637, pL117, DOI 10.1086/500735; Passamonti A, 2014, MON NOT R ASTRON SOC, V438, P156, DOI 10.1093/mnras/stt2134; Sotani H, 2007, MON NOT R ASTRON SOC, V375, P261, DOI 10.1111/j.1365-2966.2006.11304.x; Cerda-Duran P, 2009, MON NOT R ASTRON SOC, V397, P1607, DOI 10.1111/j.1365-2966.2009.15056.x; Thompson C, 2002, ASTROPHYS J, V574, P332, DOI 10.1086/340586; Ciolfi R, 2009, MON NOT R ASTRON SOC, V397, P913, DOI 10.1111/j.1365-2966.2009.14990.x; Andersson N, 2009, MON NOT R ASTRON SOC, V396, P894, DOI 10.1111/j.1365-2966.2009.14734.x; Colaiuda A, 2012, MON NOT R ASTRON SOC, V423, P811, DOI 10.1111/j.1365-2966.2012.20919.x; Thompson C, 1996, ASTROPHYS J, V473, P322, DOI 10.1086/178147; Sotani H, 2008, MON NOT R ASTRON SOC, V385, P2161, DOI 10.1111/j.1365-2966.2008.12977.x; Strohmayer TE, 2006, ASTROPHYS J, V653, P593, DOI 10.1086/508703; Lee U, 2008, MON NOT R ASTRON SOC, V385, P2069, DOI 10.1111/j.1365-2966.2008.12965.x; van Hoven M, 2011, MON NOT R ASTRON SOC, V410, P1036, DOI 10.1111/j.1365-2966.2010.17499.x; Frieben J, 2012, MON NOT R ASTRON SOC, V427, P3406, DOI 10.1111/j.1365-2966.2012.22027.x; Asai H, 2014, ASTROPHYS J, V790, DOI 10.1088/0004-637X/790/1/66; Ciolfi R, 2012, ASTROPHYS J, V760, DOI 10.1088/0004-637X/760/1/1; Duncan RC, 1998, ASTROPHYS J, V498, pL45, DOI 10.1086/311303; Gabler M., 2013, PHYS REV LETT, P111; Goedbloed H., 2004, PRINCIPLES MAGNETOHY; Goosens M., 1979, ASTRON ASTROPHYS, V123, P147; Hambaryan V, 2011, ASTRON ASTROPHYS, V528, DOI 10.1051/0004-6361/201015273; Huppenkothen D, 2014, ASTROPHYS J, V787, DOI 10.1088/0004-637X/787/2/128; Kiuchi K, 2011, ASTRON ASTROPHYS, V532, DOI 10.1051/0004-6361/201016242; Kiuchi K, 2008, PHYS REV D, V78, DOI 10.1103/PhysRevD.78.044045; Lander SK, 2011, MON NOT R ASTRON SOC, V412, P1394, DOI 10.1111/j.1365-2966.2010.17998.x; Lasky PD, 2011, ASTROPHYS J LETT, V735, DOI 10.1088/2041-8205/735/1/L20; Lee U, 2005, MON NOT R ASTRON SOC, V357, P97, DOI 10.1111/j.1365-2966.2004.08614.x; LEE U, 1993, ASTROPHYS J, V405, P359, DOI 10.1086/172368; Mathis S, 2012, ASTRON ASTROPHYS, V540, DOI 10.1051/0004-6361/201118322; Mathis S, 2011, ASTRON ASTROPHYS, V526, DOI 10.1051/0004-6361/201015571; Mereghetti S, 2008, ASTRON ASTROPHYS REV, V15, P225, DOI 10.1007/s00159-008-0011-Z; MIKETINA.MJ, 1973, ASTROPHYS SPACE SCI, V22, P413, DOI 10.1007/BF00647435; Morsink SM, 2002, ASTROPHYS J, V574, P908, DOI 10.1086/341190; Piro AL, 2005, ASTROPHYS J, V634, pL153, DOI 10.1086/499049; SAIO H, 1981, ASTROPHYS J, V244, P299, DOI 10.1086/158708; Unno W., 1989, NONRADIAL OSCILLATIO; Watts A. L., 2011, ARXIV11110514V1; Woods P. M., 2006, COMPACT STELLAR XRAY, V39, P547; Yoshida S, 2006, ASTROPHYS J SUPPL S, V164, P156, DOI 10.1086/501050; Yoshida S., 2000, APJS, V120, P353; Yoshida S, 2006, ASTROPHYS J, V651, P462, DOI 10.1086/507513; Yoshida S, 2000, ASTROPHYS J, V529, P997, DOI 10.1086/308312	64	2	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-8711	1365-2966		MON NOT R ASTRON SOC	Mon. Not. Roy. Astron. Soc.	JUN 1	2015	449	4					3620	3634		10.1093/mnras/stv538		15	Astronomy & Astrophysics	Astronomy & Astrophysics	CJ2VE	WOS:000355342000027		
J	Pettitt, AR; Dobbs, CL; Acreman, DM; Bate, MR				Pettitt, Alex R.; Dobbs, Clare L.; Acreman, David M.; Bate, Matthew R.			The morphology of the Milky Way - II. Reconstructing CO maps from disc galaxies with live stellar distributions	MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY			English	Article						hydrodynamics; radiative transfer; ISM: structure; Galaxy: kinematics and dynamics; Galaxy: structure; galaxies: spiral	SMOOTHED PARTICLE HYDRODYNAMICS; INDUCED SPIRAL STRUCTURE; MOLECULAR CLOUDS; STAR-FORMATION; INTERSTELLAR-MEDIUM; INNER GALAXY; GALACTIC BAR; GAS-DYNAMICS; GRAND DESIGN; ARMS	The arm structure of the Milky Way remains somewhat of an unknown, with observational studies hindered by our location within the Galactic disc. In the work presented here, we use smoothed particle hydrodynamics and radiative transfer to create synthetic longitude-velocity observations. Our aim is to reverse engineer a top-down map of the Galaxy by comparing synthetic longitude-velocity maps to those observed. We set up a system of N-body particles to represent the disc and bulge, allowing for dynamic creation of spiral features. Interstellar gas, and the molecular content, is evolved alongside the stellar system. A 3D-radiative transfer code is then used to compare the models to observational data. The resulting models display arm features that are a good reproduction of many of the observed emission structures of the Milky Way. These arms however are dynamic and transient, allowing for a wide range of morphologies not possible with standard density wave theory. The best-fitting models are a much better match than previous work using fixed potentials. They favour a four-armed model with a pitch angle of approximately 20 degrees, though with a pattern speed that decreases with increasing Galactic radius. Inner bars are lacking, however, which appear required to fully reproduce the central molecular zone.	[Pettitt, Alex R.] Hokkaido Univ, Dept Phys, Fac Sci, Sapporo, Hokkaido 0600810, Japan; [Pettitt, Alex R.; Dobbs, Clare L.; Acreman, David M.; Bate, Matthew R.] Univ Exeter, Sch Phys & Astron, Exeter EX4 4QL, Devon, England	Pettitt, AR (reprint author), Hokkaido Univ, Dept Phys, Fac Sci, Sapporo, Hokkaido 0600810, Japan.	alex@astro1.sci.hokudai.ac.jp			STFC; Large Facilities Capital Fund of BIS; University of Exeter Supercomputer, a DiRAC Facility; University of Exeter; MEXT; European Research Council	We thank an anonymous referee, whose comments and suggestions improved the paper. We are grateful to Jim Pringle and Daniel Price for helpful comments. We thank Tom Dame for providing access to the CO longitude-velocity data. The calculations for this paper were performed on the DiRAC Complexity machine, jointly funded by STFC and the Large Facilities Capital Fund of BIS, and the University of Exeter Supercomputer, a DiRAC Facility jointly funded by STFC, the Large Facilities Capital Fund of BIS and the University of Exeter. ARP was supported by an STFC-funded postgraduate studentship while performing this work and is currently supported by a MEXT grant. CLD acknowledges funding from the European Research Council for the FP7 ERC starting grant project LOCALSTAR. Figures showing SPH density were rendered using SPLASH (Price 2007).	Glover SCO, 2007, ASTROPHYS J SUPPL S, V169, P239, DOI 10.1086/512238; Price DJ, 2007, MON NOT R ASTRON SOC, V374, P1347, DOI 10.1111/j.1365-2966.2006.11241.x; LIN CC, 1964, ASTROPHYS J, V140, P646, DOI 10.1086/147955; Steiman-Cameron TY, 2010, ASTROPHYS J, V722, P1460, DOI 10.1088/0004-637X/722/2/1460; Efremov YN, 2011, ASTRON REP+, V55, P108, DOI 10.1134/S1063772911020016; Pettitt AR, 2014, MON NOT R ASTRON SOC, V444, P919, DOI 10.1093/mnras/stu1075; CASWELL JL, 1987, ASTRON ASTROPHYS, V171, P261; Renaud F, 2013, MON NOT R ASTRON SOC, V436, P1836, DOI 10.1093/mnras/stt1698; Strasser ST, 2007, ASTRON J, V134, P2252, DOI 10.1086/522794; Grand RJJ, 2012, MON NOT R ASTRON SOC, V426, P167, DOI 10.1111/j.1365-2966.2012.21733.x; Kalberla PMW, 2005, ASTRON ASTROPHYS, V440, P775, DOI 10.1051/0004-6361:20041864; Amaral LH, 1997, MON NOT R ASTRON SOC, V286, P885; Sormani MC, 2015, MON NOT R ASTRON SOC, V446, P4186, DOI 10.1093/mnras/stu2316; Hammersley PL, 2000, MON NOT R ASTRON SOC, V317, pL45, DOI 10.1046/j.1365-8711.2000.03858.x; Francis C, 2012, MON NOT R ASTRON SOC, V422, P1283, DOI 10.1111/j.1365-2966.2012.20693.x; BATE MR, 1995, MON NOT R ASTRON SOC, V277, P362; Meidt SE, 2008, ASTROPHYS J, V688, P224, DOI 10.1086/591516; TAYLOR JH, 1993, ASTROPHYS J, V411, P674, DOI 10.1086/172870; Dobbs CL, 2010, MON NOT R ASTRON SOC, V403, P625, DOI 10.1111/j.1365-2966.2009.16161.x; SPARKE LS, 1987, MON NOT R ASTRON SOC, V225, P653; BENZ W, 1990, ASTROPHYS J, V348, P647, DOI 10.1086/168273; Navarro JF, 1996, ASTROPHYS J, V462, P563, DOI 10.1086/177173; Jackson JM, 2006, ASTROPHYS J SUPPL S, V163, P145, DOI 10.1086/500091; Struck C, 2011, MON NOT R ASTRON SOC, V414, P2498, DOI 10.1111/j.1365-2966.2011.18568.x; Drimmel R, 2001, ASTROPHYS J, V556, P181, DOI 10.1086/321556; Churchwell E, 2009, PUBL ASTRON SOC PAC, V121, P213, DOI 10.1086/597811; Baba J, 2010, PUBL ASTRON SOC JPN, V62, P1413; Dias WS, 2005, ASTROPHYS J, V629, P825, DOI 10.1086/431456; Athanassoula E, 2013, MON NOT R ASTRON SOC, V429, P1949, DOI 10.1093/mnras/sts452; Hou LG, 2009, ASTRON ASTROPHYS, V499, P473, DOI 10.1051/0004-6361/200809692; Dame TM, 2001, ASTROPHYS J, V547, P792, DOI 10.1086/318388; BLITZ L, 1991, ASTROPHYS J, V379, P631, DOI 10.1086/170535; Binney J, 1997, MON NOT R ASTRON SOC, V288, P365; Sewilo M, 2004, ASTROPHYS J SUPPL S, V154, P553, DOI 10.1086/423247; Benjamin RA, 2005, ASTROPHYS J, V630, pL149, DOI 10.1086/491785; Shen JT, 2010, ASTROPHYS J LETT, V720, pL72, DOI 10.1088/2041-8205/720/1/L72; SELLWOOD JA, 1984, ASTROPHYS J, V282, P61, DOI 10.1086/162176; Baba J, 2009, ASTROPHYS J, V706, P471, DOI 10.1088/0004-637X/706/1/471; Baba J, 2013, ASTROPHYS J, V763, DOI 10.1088/0004-637X/763/1/46; Benjamin R. A., 2008, ASP C SER, V387, P375; Binney J., 1987, GALACTIC DYNAMICS; BRAINE J, 1993, ASTRON ASTROPHYS, V280, P451; CARLBERG RG, 1985, ASTROPHYS J, V298, P486, DOI 10.1086/163634; Clarke C, 2006, MON NOT R ASTRON SOC, V371, P530, DOI 10.1111/j.1365-2966.2006.10597.x; COHEN RS, 1980, ASTROPHYS J, V239, pL53, DOI 10.1086/183290; Combes F., 1995, GALAXIES COSMOLOGY; D'Onghia E, 2013, ASTROPHYS J, V766, DOI 10.1088/0004-637X/766/1/34; Dobbs C., 2014, PASA, V31, P35; Drimmel R, 2000, ASTRON ASTROPHYS, V358, pL13; ELMEGREEN BG, 1993, ASTRON ASTROPHYS, V272, P37; Elmegreen D. M., 1985, P IAU S, V106, P255; Englmaier P, 1999, MON NOT R ASTRON SOC, V304, P512, DOI 10.1046/j.1365-8711.1999.02280.x; Fujii MS, 2011, ASTROPHYS J, V730, DOI 10.1088/0004-637X/730/2/109; Fux R, 1999, ASTRON ASTROPHYS, V345, P787; GEORGELIN YM, 1976, ASTRON ASTROPHYS, V49, P57; Gerhard O, 2002, ASTR SOC P, V273, P73; Gerhard O., 2011, MEM SOC ASTRON ITA S, V18, P185; Gomez G. C., 2004, APJ, V615, P758; Grand RJJ, 2013, ASTRON ASTROPHYS, V553, DOI 10.1051/0004-6361/201321308; Harries TJ, 2000, MON NOT R ASTRON SOC, V315, P722, DOI 10.1046/j.1365-8711.2000.03505.x; HERNQUIST L, 1993, ASTROPHYS J SUPPL S, V86, P389, DOI 10.1086/191784; Khoperskov SA, 2013, MON NOT R ASTRON SOC, V428, P2311, DOI 10.1093/mnras/sts195; Levine ES, 2006, SCIENCE, V312, P1773, DOI 10.1126/science.1128455; Liszt H. S., 1985, P IAU S, V106, P2; Martos M., 2004, Monthly Notices of the Royal Astronomical Society, V350, DOI 10.1111/j.1365-2966.2004.07850.x; McClure-Griffiths NM, 2012, ASTROPHYS J SUPPL S, V199, DOI 10.1088/0067-0049/199/1/12; Pineda JL, 2013, ASTRON ASTROPHYS, V554, DOI 10.1051/0004-6361/201321188; Price DJ, 2007, PUBL ASTRON SOC AUST, V24, P159, DOI 10.1071/AS07022; Reid MJ, 2009, ASTROPHYS J, V700, P137, DOI 10.1088/0004-637X/700/1/137; Roca-Fabrega S, 2013, MON NOT R ASTRON SOC, V432, P2878, DOI 10.1093/mnras/stt643; Rodriguez-Fernandez NJ, 2008, ASTRON ASTROPHYS, V489, P115, DOI 10.1051/0004-6361:200809644; Russeil D, 2003, ASTRON ASTROPHYS, V397, P133, DOI 10.1051/0004-6361:20021504; Salo H, 2000, MON NOT R ASTRON SOC, V319, P377, DOI 10.1046/j.1365-8711.2000.03650.x; Sellwood JA, 2011, MON NOT R ASTRON SOC, V410, P1637, DOI 10.1111/j.1365-2966.2010.17545.x; Sellwood J. A., 1988, MNRAS, V231, p25P; Sofue Y, 2012, PUBL ASTRON SOC JPN, V64; Speights JC, 2012, ASTROPHYS J, V752, DOI 10.1088/0004-637X/752/1/52; TOOMRE A, 1972, ASTROPHYS J, V178, P623, DOI 10.1086/151823; TOOMRE A, 1964, ASTROPHYS J, V139, P1217, DOI 10.1086/147861; Toomre A., 1981, STRUCTURE EVOLUTION, P111; Vallee JP, 2005, ASTRON J, V130, P569, DOI 10.1086/431744; Wada K., 2011, P IAU S, V270, P363; Weaver H, 1970, P IAU S, V38, P126; WEILAND JL, 1994, ASTROPHYS J, V425, pL81, DOI 10.1086/187315; Xu Y, 2013, ASTROPHYS J, V769, DOI 10.1088/0004-637X/769/1/15	85	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-8711	1365-2966		MON NOT R ASTRON SOC	Mon. Not. Roy. Astron. Soc.	JUN 1	2015	449	4					3911	3926		10.1093/mnras/stv600		16	Astronomy & Astrophysics	Astronomy & Astrophysics	CJ2VE	WOS:000355342000045		
J	Fasano, G; Poggianti, BM; Bettoni, D; D'Onofrio, M; Dressler, A; Vulcani, B; Moretti, A; Gullieuszik, M; Fritz, J; Omizzolo, A; Cava, A; Couch, WJ; Ramella, M; Biviano, A				Fasano, G.; Poggianti, B. M.; Bettoni, D.; D'Onofrio, M.; Dressler, A.; Vulcani, B.; Moretti, A.; Gullieuszik, M.; Fritz, J.; Omizzolo, A.; Cava, A.; Couch, W. J.; Ramella, M.; Biviano, A.			Morphological fractions of galaxies in WINGS clusters: revisiting the morphology-density paradigm	MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY			English	Article						galaxies: clusters: general; galaxies: evolution; galaxies: general; galaxies: structure	SCALE-INDEPENDENT METHOD; HUBBLE-SPACE-TELESCOPE; DIGITAL SKY SURVEY; NEARBY CLUSTERS; COSMOS FIELD; DATA RELEASE; EVOLUTION; MASS; ENVIRONMENT; PHOTOMETRY	We present the morphology-density and morphology-radius relations (T-Sigma and T-R, respectively) obtained from the WIde-field Nearby Galaxy-cluster Survey (WINGS) data base of galaxies in nearby clusters. Aiming to achieve the best statistics, we exploit the whole sample of galaxies brighter than M-V = -19.5 (5504 objects), stacking up the 76 clusters of the WINGS survey altogether. Using this global cluster sample, we find that the T-Sigma relation holds only in the inner cluster regions (R < 1/3 R-200), while the T-R relation keeps almost unchanged over the whole range of local density. A couple of tests and two sets of numerical simulations support the robustness of these results against the effects of the limited cluster area coverage of the WINGS imaging. The above mentioned results hold for all cluster masses (X-ray luminosity and velocity dispersion) and all galaxy stellar masses (M-*). The strength of the T-Sigma relation (where present) increases with increasing M-*, while this effect is not found for the T-R relation. Noticeably, the absence/presence of subclustering determines the presence/absence of the T-Sigma relation outside the inner cluster regions, leading us to the general conclusion that the link between morphology and local density is preserved just in dynamically evolved regions. We hypothesize that some mechanism of morphological broadening/redistribution operates in the intermediate/outer regions of substructured ('non-relaxed') clusters, producing a strong weakening of the T-Sigma relation.	[Fasano, G.; Poggianti, B. M.; Bettoni, D.; Moretti, A.; Gullieuszik, M.; Omizzolo, A.] Osserv Astron Padova, INAF, I-35122 Padua, Italy; [D'Onofrio, M.] Univ Padua, Dip Fis & Astron G Galilei, I-35122 Padua, Italy; [Dressler, A.] Observ Carnegie Inst Washington, Pasadena, CA 91101 USA; [Vulcani, B.] Univ Tokyo, Todai Inst Adv Study, Kavli Inst Phys & Math Univ WPI, Kashiwa, Chiba 2778582, Japan; [Fritz, J.] UNAM, CRyA, Morelia 58089, Michoacan, Mexico; [Fritz, J.] Univ Ghent, Sterrenkundig Observ, B-9000 Ghent, Belgium; [Omizzolo, A.] Specola Vaticana, I-00120 Stato Citta Del Vaticano, Italy; [Cava, A.] Univ Geneva, Observ Geneve, CH-1290 Versoix, Switzerland; [Couch, W. J.] Swinburne Univ Technol, Ctr Astrophys, Hawthorn, Vic 3122, Australia; [Ramella, M.; Biviano, A.] Osserv Astron Trieste, INAF, I-34131 Trieste, Italy	Fasano, G (reprint author), Osserv Astron Padova, INAF, Vicolo Osservatorio 5, I-35122 Padua, Italy.	giovanni.fasano@oapd.inaf.it		Bettoni, Daniela/0000-0002-4158-6496; Fasano, Giovanni/0000-0002-5660-1054; Gullieuszik, Marco/0000-0002-7296-9780; Ramella, Massimo/0000-0001-5446-4749; Moretti, Alessia/0000-0002-1688-482X	PRIN/MIUR [2009L2J4MN]; INAF/PRIN; World Premier International Research Center Initiative (WPI), MEXT, Japan; Kakenhi from the Japan Society for the Promotion of Science (JSPS) [26870140]	We acknowledge partial financial support by contract PRIN/MIUR 2009: 'Dynamics and Stellar Populations of Superdense Galaxies' (Code: 2009L2J4MN) and by INAF/PRIN 2011: 'Galaxy Evolution with the VLT Survey Telescope (VST)'.; BV was supported by the World Premier International Research Center Initiative (WPI), MEXT, Japan, and by the Kakenhi Grant-in-Aid for Young Scientists (B)(26870140) from the Japan Society for the Promotion of Science (JSPS).	Calvi R, 2011, MON NOT R ASTRON SOC, V416, P727, DOI 10.1111/j.1365-2966.2011.19088.x; Poggianti BM, 2009, ASTROPHYS J LETT, V697, pL137, DOI 10.1088/0004-637X/697/2/L137; Treu T, 2003, ASTROPHYS J, V591, P53, DOI 10.1086/375314; Bell EF, 2001, ASTROPHYS J, V550, P212, DOI 10.1086/319728; Van der Wel A, 2007, ASTROPHYS J, V670, P206, DOI 10.1086/521783; Hubble E, 1931, ASTROPHYS J, V74, P43, DOI 10.1086/143323; Cappellari M, 2011, MON NOT R ASTRON SOC, V416, P1680, DOI 10.1111/j.1365-2966.2011.18600.x; Goto T, 2003, MON NOT R ASTRON SOC, V346, P601, DOI 10.1046/j.1365-2966.2003.07114.x; Lintott C, 2011, MON NOT R ASTRON SOC, V410, P166, DOI 10.1111/j.1365-2966.2010.17432.x; Holden BP, 2007, ASTROPHYS J, V670, P190, DOI 10.1086/521777; Fritz J, 2007, ASTRON ASTROPHYS, V470, P137, DOI 10.1051/0004-6361:20077097; Fasano G, 2012, MON NOT R ASTRON SOC, V420, P926, DOI 10.1111/j.1365-2966.2011.19798.x; SPITZER L, 1951, ASTROPHYS J, V113, P413, DOI 10.1086/145406; POSTMAN M, 1984, ASTROPHYS J, V281, P95, DOI 10.1086/162078; Scoville N, 2007, ASTROPHYS J SUPPL S, V172, P38, DOI 10.1086/516580; Fasano G, 2006, ASTRON ASTROPHYS, V445, P805, DOI 10.1051/0004-6361:20053816; Schlegel DJ, 1998, ASTROPHYS J, V500, P525, DOI 10.1086/305772; Capak P, 2007, ASTROPHYS J SUPPL S, V172, P284, DOI 10.1086/518424; Ramella M, 2007, ASTRON ASTROPHYS, V470, P39, DOI 10.1051/0004-6361:20077245; Helsdon SF, 2003, MON NOT R ASTRON SOC, V339, pL29, DOI 10.1046/j.1365-8711.2003.06300.x; Varela J, 2009, ASTRON ASTROPHYS, V497, P667, DOI 10.1051/0004-6361/200809876; Berta S, 2006, ASTRON ASTROPHYS, V451, P881, DOI 10.1051/0004-6361:20054548; Calvi R, 2012, MON NOT R ASTRON SOC, V419, pL14, DOI 10.1111/j.1745-3933.2011.01168.x; Bamford SP, 2009, MON NOT R ASTRON SOC, V393, P1324, DOI 10.1111/j.1365-2966.2008.14252.x; Tasca LAM, 2009, ASTRON ASTROPHYS, V503, P379, DOI 10.1051/0004-6361/200912213; Finn RA, 2005, ASTROPHYS J, V630, P206, DOI 10.1086/431642; Wilman DJ, 2009, ASTROPHYS J, V692, P298, DOI 10.1088/0004-637X/692/1/298; Driver SP, 2005, MON NOT R ASTRON SOC, V360, P81, DOI 10.1111/j.1365-2966.2005.08990.x; Ebeling H, 1996, MON NOT R ASTRON SOC, V281, P799; Lilly SJ, 2007, ASTROPHYS J SUPPL S, V172, P70, DOI 10.1086/516589; WHITMORE BC, 1993, ASTROPHYS J, V407, P489, DOI 10.1086/172531; Valentinuzzi T, 2009, ASTRON ASTROPHYS, V501, P851, DOI 10.1051/0004-6361/200811051; Ebeling H, 1998, MON NOT R ASTRON SOC, V301, P881, DOI 10.1046/j.1365-8711.1998.01949.x; Ebeling H, 2000, MON NOT R ASTRON SOC, V318, P333; Cava A, 2009, ASTRON ASTROPHYS, V495, P707, DOI 10.1051/0004-6361:200810997; Bezanson R., 2012, APJ, V745, P179; BHAVSAR SP, 1981, ASTROPHYS J, V246, pL5, DOI 10.1086/183542; D'Onofrio M., 2014, ASTRON ASTROPHYS, V572, P87; de Vaucouleurs G., 1991, 3 REFERENCE CATALOGU; Desai V, 2007, ASTROPHYS J, V660, P1151, DOI 10.1086/513310; DESOUZA RE, 1982, ASTROPHYS J, V263, P557, DOI 10.1086/160526; Dressler A, 1997, ASTROPHYS J, V490, P577, DOI 10.1086/304890; DRESSLER A, 1980, ASTROPHYS J, V236, P351, DOI 10.1086/157753; EVRARD AE, 1990, ASTROPHYS J, V365, P13, DOI 10.1086/169454; Fasano G, 2000, ASTROPHYS J, V542, P673, DOI 10.1086/317047; Fritz J., 2011, ASTRON ASTROPHYS, V526, P45; Fukugita M, 2007, ASTRON J, V134, P579, DOI 10.1086/518962; Kroupa P, 2001, MON NOT R ASTRON SOC, V322, P231, DOI 10.1046/j.1365-8711.2001.04022.x; Liske J., 2003, MNRAS, V344, P370; Moretti A, 2014, ASTRON ASTROPHYS, V564, DOI 10.1051/0004-6361/201323098; MORGAN WW, 1961, P NATL ACAD SCI USA, V47, P905, DOI 10.1073/pnas.47.7.905; Nuijten MJHM, 2005, ASTROPHYS J, V626, pL77, DOI 10.1086/431755; OEMLER A, 1974, ASTROPHYS J, V194, P1, DOI 10.1086/153216; Oesch PA, 2010, ASTROPHYS J LETT, V714, pL47, DOI 10.1088/2041-8205/714/1/L47; PEEBLES PJE, 1993, PRINCIPLES PHYS COSM; Peng YJ, 2010, ASTROPHYS J, V721, P193, DOI 10.1088/0004-637X/721/1/193; Pisani A, 1996, MON NOT R ASTRON SOC, V278, P697; PISANI A, 1993, MON NOT R ASTRON SOC, V265, P706; Poggianti BM, 1997, ASTRON ASTROPHYS SUP, V122, P399, DOI 10.1051/aas:1997142; Postman M, 2005, ASTROPHYS J, V623, P721, DOI 10.1086/428881; Smith G, 2005, FILM COMMENT, V41, P78; Thomas T, 2006, ASTRON ASTROPHYS, V446, P31, DOI 10.1051/0004-6361:20053661; van der Wel A., 2008, APJ, V675, pL13; Vulcani B, 2012, MON NOT R ASTRON SOC, V420, P1481, DOI 10.1111/j.1365-2966.2011.20135.x; Vulcani B, 2011, MON NOT R ASTRON SOC, V413, P921, DOI 10.1111/j.1365-2966.2010.18182.x; WHITMORE BC, 1995, ASTR SOC P, V70, P41; WHITMORE BC, 1991, ASTROPHYS J, V367, P64, DOI 10.1086/169602; Zeldovich Y.B., 1999, COSMOLOGICAL PHYS, V11, P381	68	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-8711	1365-2966		MON NOT R ASTRON SOC	Mon. Not. Roy. Astron. Soc.	JUN 1	2015	449	4					3927	3944		10.1093/mnras/stv500		18	Astronomy & Astrophysics	Astronomy & Astrophysics	CJ2VE	WOS:000355342000046		
J	Zha, ZJ; Liu, Y; Satoh, S; Yu, XG; Lienhart, R				Zha, Zheng-Jun; Liu, Yan; Satoh, Shin'ichi; Yu, Xinguo; Lienhart, Rainer			Guest editorial: selected papers from ICIMCS 2012	MULTIMEDIA SYSTEMS			English	Editorial Material									[Zha, Zheng-Jun] Chinese Acad Sci, Hefei Inst Intelligent Machines, Hefei, Peoples R China; [Liu, Yan] Hong Kong Polytech Univ, Hong Kong, Hong Kong, Peoples R China; [Satoh, Shin'ichi] Natl Inst Informat, Tokyo, Japan; [Yu, Xinguo] Cent China Normal Univ, Wuhan, Peoples R China; [Lienhart, Rainer] Univ Augsburg, D-86159 Augsburg, Germany	Zha, ZJ (reprint author), Chinese Acad Sci, Hefei Inst Intelligent Machines, Hefei, Peoples R China.	junzzustc@gmail.com; csyliu@comp.polyu.edu.hk; satoh@nii.ac.jp; xgyu@mail.ccnu.edu.cn; Rainer.Lienhart@informatik.uni-augsburg.de						0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-4962	1432-1882		MULTIMEDIA SYST	Multimedia Syst.	JUN	2015	21	3			SI		243	244		10.1007/s00530-015-0461-x		2	Computer Science, Information Systems; Computer Science, Theory & Methods	Computer Science	CJ9HN	WOS:000355813200001		
J	Kume, K; Deguchi, K; Ikeda, K; Takata, T; Kokudo, Y; Kamada, M; Touge, T; Takahashi, T; Kanbayashi, T; Masaki, T				Kume, Kodai; Deguchi, Kazushi; Ikeda, Kazuyo; Takata, Tadayuki; Kokudo, Yohei; Kamada, Masaki; Touge, Tetsuo; Takahashi, Toshiyuki; Kanbayashi, Takashi; Masaki, Tsutomu			Neuromyelitis optica spectrum disorder presenting with repeated hypersomnia due to involvement of the hypothalamus and hypothalamus-amygdala linkage	MULTIPLE SCLEROSIS JOURNAL			English	Article						Neuromyelitis optica spectrum disorder; aquaporin 4; orexin; hypersomnia; hypothalamus; amygdala	ENCEPHALITIS; NARCOLEPSY; PATIENT; LESIONS; SLEEP	We report the case of a 46-year-old Japanese woman with neuromyelitis optica spectrum disorder presenting with repeated hypersomnia accompanied by decreased CSF orexin level. First episode associated with hypothalamic-pituitary dysfunction showed bilateral hypothalamic lesions that can cause secondary damage to the orexin neurons. The second episode associated with impaired memory showed a left temporal lesion involving the amygdala. The mechanism remains unknown, but the reduced blood flow in the hypothalamus ipsilateral to the amygdala lesion suggested trans-synaptic hypothalamic dysfunction secondary to the impaired amygdala. A temporal lesion involving the amygdala and hypothalamus could be responsible for hypersomnia due to neuromyelitis optica spectrum disorder.	[Kume, Kodai; Deguchi, Kazushi; Takata, Tadayuki; Kokudo, Yohei; Masaki, Tsutomu] Kagawa Univ, Dept Gastroenterol & Neurol, Fac Med, Miki, Kagawa, Japan; [Ikeda, Kazuyo; Kamada, Masaki] Kagawa Univ, Dept Neurol Intractable Dis Res, Fac Med, Miki, Kagawa, Japan; [Touge, Tetsuo] Kagawa Univ, Dept Hlth Sci, Fac Med, Miki, Kagawa, Japan; [Takahashi, Toshiyuki] Tohoku Univ, Dept Neurol, Grad Sch Med, Sendai, Miyagi 980, Japan; [Takahashi, Toshiyuki] Yonezawa Natl Hosp, Dept Neurol, Yonezawa, Yamagata, Japan; [Kanbayashi, Takashi] Akita Univ, Sch Med, Dept Psychiat, Akita 010, Japan	Deguchi, K (reprint author), Kagawa Univ, Dept Gastroenterol & Neurol, Fac Med, 1750-1 Ikenobe, Miki, Kagawa, Japan.	kdeguchi@med.kagawa-u.ac.jp					Kim W, 2010, MULT SCLER J, V16, P1229, DOI 10.1177/1352458510376640; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Tang XD, 2005, SLEEP, V28, P923; Bisetti A, 2006, NEUROSCIENCE, V142, P999, DOI 10.1016/j.neuroscience.2006.07.018; Kanbayashi T, 2011, CURR NEUROL NEUROSCI, V11, P235, DOI 10.1007/s11910-011-0178-y; Benca RM, 2000, BRAIN RES, V879, P130, DOI 10.1016/S0006-8993(00)02761-X; Landolfi JC, 2003, NEURO-ONCOLOGY, V5, P214, DOI 10.1215/S1152.8517.02.00046.7; ONOFRJ M, 1992, J NEUROL NEUROSUR PS, V55, P852, DOI 10.1136/jnnp.55.9.852; Overeem S, 2004, NEUROLOGY, V62, P138; Suzuki K, 2012, ARCH NEUROL-CHICAGO, V69, P1355, DOI 10.1001/archneurol.2012.300	10	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1352-4585	1477-0970		MULT SCLER J	Mult. Scler. J.	JUN	2015	21	7					960	962		10.1177/1352458515569100		3	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CJ3WH	WOS:000355414500017		
J	Mori, K; Iwanaga, M				Mori, Kazuma; Iwanaga, Makoto			GENERAL REWARD SENSITIVITY PREDICTS INTENSITY OF MUSIC-EVOKED CHILLS	MUSIC PERCEPTION			English	Article						emotion; musical chill; individual difference; behavioral activation system; reward responsiveness	BEHAVIORAL ACTIVATION; NUCLEUS-ACCUMBENS; EMOTION; EXPERIENCE; RESPONSES; ANTICIPATION; PERSONALITY; INHIBITION; PLEASURE; STIMULI	CHILLS (GOOSE BUMPS OR SHIVERS) EVOKED BY listening to one's favorite music are an indicator of a rewarding experience. The current study examined the relationship between individual differences in general reward sensitivity and music-evoked chills. To assess this relationship, we measured the three subscales of the behavioral activation system (BAS) and the frequency and intensity of music-evoked chills in a large-sample survey (Study 1) and a psychophysiological experiment (Study 2). One result observed in both studies was that people with high BAS reward responsiveness experienced more intense chills from music. Moreover, the results showed that the experience of chills induced highly pleasurable emotions and psychophysiological arousal. The present study suggests that general reward sensitivity is a predictor of music-evoked chills. Although music is just a sequence of tones and not clearly related to survival value, music could create a rewarding experience partially similar to other rewarding actions or events.	[Mori, Kazuma] Natl Inst Adv Ind Sci & Technol, Tsukuba, Japan; [Iwanaga, Makoto] Hiroshima Univ, Hiroshima, Japan	Mori, K (reprint author), Natl Agr & Food Res Org, Natl Food Res Inst, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.	kazumamori@affrc.go.jp					Bradley MM, 2000, PSYCHOPHYSIOLOGY, V37, P204, DOI 10.1017/S0048577200990012; Bradley MM, 2001, EMOTION, V1, P276, DOI 10.1037//1528-3542.1.3.276; Salimpoor VN, 2011, NAT NEUROSCI, V14, P257, DOI 10.1038/nn.2726; Salimpoor VN, 2013, PSYCHOL AESTHET CREA, V7, P62, DOI 10.1037/a0031819; Guhn M, 2007, MUSIC PERCEPT, V24, P473, DOI 10.1525/MP.2007.24.5.473; Menon V, 2005, NEUROIMAGE, V28, P175, DOI 10.1016/j.neuroimage.2005.05.053; Brown S, 2004, NEUROREPORT, V15, P2033, DOI 10.1097/00001756-200409150-00008; Panksepp J, 1995, MUSIC PERCEPT, V13, P171; Knutson B, 2001, J Neurosci, V21, pRC159; Benedek M, 2011, BIOL PSYCHOL, V86, P320, DOI 10.1016/j.biopsycho.2010.12.012; Koelsch S, 2006, HUM BRAIN MAPP, V27, P239, DOI 10.1002/hbm.20180; Nusbaum EC, 2011, SOC PSYCHOL PERS SCI, V2, P199, DOI 10.1177/1948550610386810; Kuhn S, 2012, NEUROIMAGE, V61, P289, DOI 10.1016/j.neuroimage.2012.02.065; CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975; CARVER CS, 1994, J PERS SOC PSYCHOL, V67, P319, DOI 10.1037/0022-3514.67.2.319; Gable SL, 2000, J PERS SOC PSYCHOL, V78, P1135, DOI 10.1037//0022-3514.78.6.1135; LITLE P, 1986, PERS INDIV DIFFER, V7, P575, DOI 10.1016/0191-8869(86)90136-4; Boucsein W, 2012, PSYCHOPHYSIOLOGY, V49, P1017, DOI 10.1111/j.1469-8986.2012.01384.x; Schubert E, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00837; Sescousse G, 2013, NEUROSCI BIOBEHAV R, V37, P681, DOI 10.1016/j.neubiorev.2013.02.002; Mas-Herrero E, 2014, CURR BIOL, V24, P699, DOI 10.1016/j.cub.2014.01.068; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; Sabatinelli D, 2007, J NEUROPHYSIOL, V98, P1374, DOI 10.1152/jn.00230.2007; Grewe O, 2007, MUSIC PERCEPT, V24, P297, DOI 10.1525/MP.2007.24.3.297; Balconi M, 2012, MOTIV EMOTION, V36, P218, DOI 10.1007/s11031-011-9244-7; Mas-Herrero E, 2013, MUSIC PERCEPT, V31, P118, DOI 10.1525/MP.2013.31.2.118; McCrae RR, 2007, MOTIV EMOTION, V31, P5, DOI 10.1007/s11031-007-9053-1; GOLDSTEIN A, 1980, PHYSIOL PSYCHOL, V8, P126; Grewe O, 2009, MUSIC PERCEPT, V27, P61, DOI 10.1525/MP.2009.27.1.61; Silvia PJ, 2011, PSYCHOL AESTHET CREA, V5, P208, DOI 10.1037/a0021914; Costa P. T., 1985, NEO PERSONALITY INVE; DAWSON R. M., 2007, HDB PSYCHOPHYSIOLOGY, P159; Gough H. G., 1983, ADJECTIVE CHECK LIST; Gray J. A., 1981, MODEL PERSONALITY, P246, DOI DOI 10.1007/978-3-642-67783-0_8; Huron D., 2010, HDB MUSIC EMOTION TH, P575; Koelsch S, 2014, NAT REV NEUROSCI, V15, P170, DOI 10.1038/nrn3666; Mori K, 2014, INT J PSYCHOPHYSIOL, V93, P220, DOI 10.1016/j.ijpsycho.2014.05.001; Rickard N. S., 2004, PSYCHOL MUSIC, V32, P371, DOI DOI 10.1177/0305735604046096; Salimpoor VN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007487; Sloboda J. A., 1991, PSYCHOL MUSIC, V19, P110, DOI DOI 10.1177/0305735691192002; Sokolov E. N., 1963, PERCEPTION CONDITION; Takahashi Y., 2007, JAPANESE J PERSONALI, V15, P276, DOI [10.2132/personality.15.276, DOI 10.2132/PERSONALITY.15.276]; Wada S, 1996, JPN J PSYCHOL, V67, P61	43	1	1	UNIV CALIFORNIA PRESS	OAKLAND	155 GRAND AVE, SUITE 400, OAKLAND, CA 94612-3758 USA	0730-7829			MUSIC PERCEPT	Music Percept.	JUN	2015	32	5					484	492		10.1525/MP.2015.32.5.484		9	Music; Psychology, Experimental	Music; Psychology	CK0KJ	WOS:000355893800004		
J	Ochiai, T; Shimomoto, K				Ochiai, Tadashi; Shimomoto, Kazuma			BERTINI THEOREM FOR NORMALITY ON LOCAL RINGS IN MIXED CHARACTERISTIC (APPLICATIONS TO CHARACTERISTIC IDEALS)	NAGOYA MATHEMATICAL JOURNAL			English	Article								In this article, we prove a strong version of the local Bertini theorem for normality on local rings in mixed characteristic. The main result asserts that a generic hyperplane section of a normal, Cohen-Macaulay, and complete local domain of dimension at least 3 is normal. Applications include the study of characteristic ideals attached to torsion modules over normal domains, which is fundamental in the study of Euler system theory, Iwasawa's main conjectures, and the deformation theory of Galois representations.	[Ochiai, Tadashi] Osaka Univ, Grad Sch Sci, Osaka 5600043, Japan; [Shimomoto, Kazuma] Meiji Univ, Sch Sci & Technol, Dept Math, Tama Ku, Kawasaki, Kanagawa 2148571, Japan	Ochiai, T (reprint author), Osaka Univ, Grad Sch Sci, 1-1 Machikaneyama, Osaka 5600043, Japan.	ochiai@math.sci.osaka-u.ac.jp; shimomotokazuma@gmail.com			Sumitomo Foundation;  [24654004];  [25800028]	The authors thank the anonymous referees for reading the manuscript carefully. The second author thanks Professor Trivedi for explaining the proof of Lemma 1.2 in [4]. The first author's work was partially supported by Grant-in-Aid for Challenging Exploratory Research (24654004) and by the Sumitomo Foundation. The second author's work was partially supported by Grant-in-Aid for Young Scientists (B) 25800028.	HARTSHORNE R, 1980, MATH ANN, V254, P121, DOI 10.1007/BF01467074; EISENBUD D, 1973, J ALGEBRA, V27, P278, DOI 10.1016/0021-8693(73)90106-3; GRECO S, 1976, NAGOYA MATH J, V60, P139; Skinner C, 2014, INVENT MATH, V195, P1, DOI 10.1007/s00222-013-0448-1; FLENNER H, 1977, MATH ANN, V229, P97, DOI 10.1007/BF01351596; Bruns W., 1993, CAMBRIDGE STUDIES AD, V39; Flach M., 2004, CONT MATH, V358, P79, DOI 10.1090/conm/358/06537; Fresnel J., 2004, PROGR MATH, V218, DOI [10.1007/978-1-4612-0041-3, DOI 10.1007/978-1-4612-0041-3.(2337)]; Grothendieck A., 1968, SEM GEOM ALG DUBOIS; GROTHENDIECK A., 1965, PUBL MATH-PARIS, V24; Kunz E., 1986, ADV LECT MATH, DOI [10.1007/978-3-663-14074-0, DOI 10.1007/978-3-663-14074-0]; Matsumura H., 1986, CAMBRIDGE STUD ADV M, V8; Neukirch J., 2000, GRUND MATH WISS, V323; Northcott D. G., 1976, CAMBRIDGE TRACTS MAT, V71; Ochiai T., SPECIALIZATION UNPUB; Ochiai T, 2005, ANN I FOURIER, V55, P113; Serre J-P, 1979, GRAD TEXTS MATH, V67; SWAN RG, 1967, MATH Z, V102, P318, DOI 10.1007/BF01110912; Trivedi V., 1994, COMMUN ALGEBRA, V22, P823, DOI 10.1080/00927879408824878	19	0	0	DUKE UNIV PRESS	DURHAM	905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA	0027-7630	2152-6842		NAGOYA MATH J	Nagoya Math. J.	JUN	2015	218						125	173		10.1215/00277630-2891620		49	Mathematics	Mathematics	CJ3LD	WOS:000355384400005		
J	Kim, J; Lee, J; Hamada, S; Murata, S; Park, SH				Kim, Junghoon; Lee, Junwye; Hamada, Shogo; Murata, Satoshi; Park, Sung Ha			Self-replication of DNA rings	NATURE NANOTECHNOLOGY			English	Article							CELLULAR-AUTOMATA; REPRODUCING MACHINES; CRYSTALLIZATION; NANOTECHNOLOGY; NANOSTRUCTURES; INFORMATION	Biology provides numerous examples of self-replicating machines, but artificially engineering such complex systems remains a formidable challenge. In particular, although simple artificial self-replicating systems including wooden blocks(1,2), magnetic systems(3,4), modular robots(5,6) and synthetic molecular systems(7-9) have been devised, such kinematic self-replicators(10) are rare compared with examples of theoretical cellular selfreplication(11-18). One of the principal reasons for this is the amount of complexity that arises when you try to incorporate self-replication into a physical medium(19). In this regard, DNA is a prime candidate material for constructing self-replicating systems due to its ability to self-assemble through molecular recognition(20). Here, we show that DNA T-motifs, which self-assemble into ring structures(21,22), can be designed to self-replicate through toehold-mediated strand displacement reactions(23,24). The inherent design of these rings allows the population dynamics of the systems to be controlled. We also analyse the replication scheme within a universal framework of self-replication(25) and derive a quantitative metric of the self-replicability of the rings.	[Kim, Junghoon; Park, Sung Ha] Sungkyunkwan Univ, Dept Phys, Suwon 440746, South Korea; [Lee, Junwye; Park, Sung Ha] Sungkyunkwan Univ, Sungkyunkwan Adv Inst Nanotechnol SAINT, Suwon 440746, South Korea; [Hamada, Shogo; Murata, Satoshi] Tohoku Univ, Grad Sch Engn, Dept Bioengn & Robot, Sendai, Miyagi 9808579, Japan	Park, SH (reprint author), Sungkyunkwan Univ, Dept Phys, Suwon 440746, South Korea.	sunghapark@skku.edu			National Research Foundation of Korea - Korean government (Ministry of Science, ICT and Future Planning) [2012R1A2A2A01005985, 2014R1A2A1A11053213, 2012M3A7B4049801]; Japanese government (Ministry of Education, Culture, Sports, Science and Technology) [22220001/24104005, 23800006/24104005]; National Research Foundation of Korea - Korean government (Ministry of Education) [2012R1A2A2A01005985, 2014R1A2A1A11053213, 2012M3A7B4049801]	The authors thank J. Kim and A. Tandon for discussions and technical assistance with DNA extraction. S.H.P. was supported by the National Research Foundation of Korea (grants 2012R1A2A2A01005985, 2014R1A2A1A11053213 and 2012M3A7B4049801), funded by the Korean government (Ministry of Science, ICT and Future Planning and Ministry of Education). S. M. and S. H. were supported by Grant-in-aid for Scientific Research grants (nos. 22220001/24104005 and 23800006/24104005, respectively) from the Japanese government (Ministry of Education, Culture, Sports, Science and Technology).	Adams B, 2003, LECT NOTES ARTIF INT, V2801, P1; PENROSE LS, 1957, NATURE, V179, P1183, DOI 10.1038/1791183a0; Zhang DY, 2007, SCIENCE, V318, P1121, DOI 10.1126/science.1148532; Nykypanchuk D, 2008, NATURE, V451, P549, DOI 10.1038/nature06560; Wang T, 2011, NATURE, V478, P225, DOI 10.1038/nature10500; Guo PX, 2010, NAT NANOTECHNOL, V5, P833, DOI [10.1038/nnano.2010.231, 10.1038/NNANO.2010.231]; Lincoln TA, 2009, SCIENCE, V323, P1229, DOI 10.1126/science.1167856; Seeman NC, 2010, ANNU REV BIOCHEM, V79, P65, DOI 10.1146/annurev-biochem-060308-102244; Schulman R, 2012, P NATL ACAD SCI USA, V109, P6405, DOI 10.1073/pnas.1117813109; Yurke B, 2000, NATURE, V406, P605; Zhang DY, 2011, NAT CHEM, V3, P103, DOI [10.1038/nchem.957, 10.1038/NCHEM.957]; Hamada S, 2009, ANGEW CHEM INT EDIT, V48, P6820, DOI 10.1002/anie.200902662; Griffith S, 2005, NATURE, V437, P636, DOI 10.1038/437636a; Klavins E, 2007, IEEE CONTR SYST MAG, V27, P43, DOI 10.1109/MCS.2007.384126; Park SY, 2008, NATURE, V451, P553, DOI 10.1038/nature06508; Zykov V, 2005, NATURE, V435, P163, DOI 10.1038/435163a; BYL J, 1989, PHYSICA D, V34, P295, DOI 10.1016/0167-2789(89)90242-X; Chandran H, 2012, J R SOC INTERFACE, V9, P1637, DOI 10.1098/rsif.2011.0819; Chou HH, 1997, PHYSICA D, V110, P252, DOI 10.1016/S0167-2789(97)00132-2; Codd E F, 1968, CELLULAR AUTOMATA; Hosokawa Kazuo, 1994, Artificial Life, V1, P413, DOI 10.1162/artl.1994.1.4.413; LANGTON CG, 1984, PHYSICA D, V10, P135, DOI 10.1016/0167-2789(84)90256-2; Lee J, 2012, SMALL, V8, P374, DOI 10.1002/smll.201101561; Lohn J. D., 1997, IEEE Transactions on Evolutionary Computation, V1, DOI 10.1109/4235.661547; Merkle R. C., 2004, KINEMATIC SELF REPLI; PENROSE LS, 1958, ANN HUM GENET, V23, P59, DOI 10.1111/j.1469-1809.1958.tb01442.x; PENROSE LS, 1959, SCI AM, V200, P105; REGGIA JA, 1993, SCIENCE, V259, P1282, DOI 10.1126/science.259.5099.1282; Tomita K, 2002, PHYSICA D, V171, P197, DOI 10.1016/S0167-2789(02)00601-2; von Neumann J., 1966, THEORY SELF REPRODUC, P31	30	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1748-3387	1748-3395		NAT NANOTECHNOL	Nat. Nanotechnol.	JUN	2015	10	6					528	U102		10.1038/NNANO.2015.87		7	Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science & Technology - Other Topics; Materials Science	CJ6RC	WOS:000355620000015		
J	Cui, X; Lee, GH; Kim, YD; Arefe, G; Huang, PY; Lee, CH; Chenet, DA; Zhang, X; Wang, L; Ye, F; Pizzocchero, F; Jessen, BS; Watanabe, K; Taniguchi, T; Muller, DA; Low, T; Kim, P; Hone, J				Cui, Xu; Lee, Gwan-Hyoung; Kim, Young Duck; Arefe, Ghidewon; Huang, Pinshane Y.; Lee, Chul-Ho; Chenet, Daniel A.; Zhang, Xian; Wang, Lei; Ye, Fan; Pizzocchero, Filippo; Jessen, Bjarke S.; Watanabe, Kenji; Taniguchi, Takashi; Muller, David A.; Low, Tony; Kim, Philip; Hone, James			Multi-terminal transport measurements of MoS2 using a van der Waals heterostructure device platform	NATURE NANOTECHNOLOGY			English	Article							MONOLAYER MOLYBDENUM-DISULFIDE; 2-DIMENSIONAL ATOMIC CRYSTALS; SINGLE-LAYER MOS2; ELECTRONIC-PROPERTIES; VALLEY POLARIZATION; BILAYER MOS2; TRANSISTORS; CONTACTS; MOBILITY; DEFECT	Atomically thin two-dimensional semiconductors such as MoS2 hold great promise for electrical, optical and mechanical devices and display novel physical phenomena. However, the electron mobility of mono-and few-layer MoS2 has so far been substantially below theoretically predicted limits, which has hampered efforts to observe its intrinsic quantum transport behaviours. Potential sources of disorder and scattering include defects such as sulphur vacancies in the MoS2 itself as well as extrinsic sources such as charged impurities and remote optical phonons from oxide dielectrics. To reduce extrinsic scattering, we have developed here a van der Waals heterostructure device platform where MoS2 layers are fully encapsulated within hexagonal boron nitride and electrically contacted in a multi-terminal geometry using gate-tunable graphene electrodes. Magneto-transport measurements show dramatic improvements in performance, including a record-high Hall mobility reaching 34,000 cm(2) V-1 s(-1) for six-layer MoS2 at low temperature, confirming that low-temperature performance in previous studies was limited by extrinsic interfacial impurities rather than bulk defects in the MoS2. We also observed Shubnikov-de Haas oscillations in high-mobility monolayer and few-layer MoS2. Modelling of potential scattering sources and quantum lifetime analysis indicate that a combination of short-range and long-range interfacial scattering limits the low-temperature mobility of MoS2.	[Cui, Xu; Kim, Young Duck; Arefe, Ghidewon; Chenet, Daniel A.; Zhang, Xian; Wang, Lei; Hone, James] Columbia Univ, Dept Mech Engn, New York, NY 10027 USA; [Lee, Gwan-Hyoung] Yonsei Univ, Dept Mat Sci & Engn, Seoul 120749, South Korea; [Huang, Pinshane Y.; Muller, David A.] Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; [Lee, Chul-Ho] Korea Univ, KU KIST Grad Sch Converging Sci & Technol, Seoul 136701, South Korea; [Ye, Fan] Columbia Univ, Dept Mat Sci & Engn, New York, NY 10027 USA; [Pizzocchero, Filippo; Jessen, Bjarke S.] Tech Univ Denmark, DTU Nanotech, Ctr Nanostruct Graphene, DK-2800 Lyngby, Denmark; [Watanabe, Kenji; Taniguchi, Takashi] Natl Inst Mat Sci, Tsukuba, Ibaraki 3050044, Japan; [Muller, David A.] Kavli Inst Cornell Nanoscale Sci, Ithaca, NY 14853 USA; [Low, Tony] Univ Minnesota, Dept Elect & Comp Engn, Minneapolis, MN 55455 USA; [Kim, Philip] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	Lee, GH (reprint author), Yonsei Univ, Dept Mat Sci & Engn, Seoul 120749, South Korea.	gwanlee@yonsei.ac.kr; jh2228@columbia.edu	Muller, David/A-7745-2010; WATANABE, Kenji/H-2825-2011	Muller, David/0000-0003-4129-0473; WATANABE, Kenji/0000-0003-3701-8119	US National Science Foundation (NSF) [DMR-1122594]; NSF MRSEC programme through Columbia in the Center for Precision Assembly of Superstratic and Superatomic Solids [DMR-1420634]; FAME Center, one of six centres of STARnet, a Semiconductor Research Corporation programme - MARCO; DARPA; Basic Science Research Program through the National Research Foundation (NRF) - Korean government Ministry of Science, ICT and Future Planning [NRF-2014R1A1A1004632]; Yonsei University Future-Leading Research Initiative; NSF Graduate Research Fellowship Program [DGE-0707428]; Cornell Center for Materials Research NSF MRSEC programme [DMR-1120296]; Basic Science Research Program through the National Research Foundation (NRF) - Korean Government Ministry of Education [NRF-2014R1A1A2055112]; Korea Institute of Science and Technology Institutional Program [2Z04490]; Center for Nanostructured Graphene (CNG); Danish National Research Foundation [DNRF58]; Elemental Strategy Initiative; JSPS [262480621, 25106006]	This research was supported by the US National Science Foundation (NSF, DMR-1122594), the NSF MRSEC programme through Columbia in the Center for Precision Assembly of Superstratic and Superatomic Solids (DMR-1420634) and in part by the FAME Center, one of six centres of STARnet, a Semiconductor Research Corporation programme sponsored by MARCO and DARPA. G-H.L. was supported by the Basic Science Research Program (NRF-2014R1A1A1004632) through the National Research Foundation (NRF) funded by the Korean government Ministry of Science, ICT and Future Planning, and in part by the Yonsei University Future-Leading Research Initiative of 2014. P.Y.H. acknowledges support from the NSF Graduate Research Fellowship Program under grant DGE-0707428. Additional support was provided through funding and shared facilities via the Cornell Center for Materials Research NSF MRSEC programme (DMR-1120296). C.-H.L. was supported by Basic Science Research Program (NRF-2014R1A1A2055112) through the National Research Foundation (NRF) funded by the Korean Government Ministry of Education, and in part by the Korea Institute of Science and Technology Institutional Program (2Z04490). F.P. and B.S.J. acknowledge support from the Center for Nanostructured Graphene (CNG), which is funded by the Danish National Research Foundation (Project DNRF58). K.W. and T.T. acknowledge support from the Elemental Strategy Initiative conducted by MEXT, Japan. T.T. acknowledges support from a Grant-in-Aid for Scientific Research (grant no. 262480621) and Innovative Areas 'NanoInformatics' (grant no. 25106006) from JSPS. The high magnetic field measurements were performed at NHMFL. The authors thank A. Suslov, B.J. Pullum, J. Billings and T. Murphy for assistance with the experiments at NHMFL.	Kaasbjerg K, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.115317; Wang H, 2012, NANO LETT, V12, P4674, DOI 10.1021/nl302015v; Lee CH, 2014, NAT NANOTECHNOL, V9, P676, DOI [10.1038/nnano.2014.150, 10.1038/NNANO.2014.150]; Baugher BWH, 2013, NANO LETT, V13, P4212, DOI 10.1021/nl401916s; Yu LL, 2014, NANO LETT, V14, P3055, DOI 10.1021/nl404795z; Ma N, 2014, PHYS REV X, V4, DOI 10.1103/PhysRevX.4.011043; Radisavljevic B, 2011, NAT NANOTECHNOL, V6, P147, DOI [10.1038/nnano.2010.279, 10.1038/NNANO.2010.279]; Novoselov KS, 2005, P NATL ACAD SCI USA, V102, P10451, DOI 10.1073/pnas.0502848102; Yoon J, 2013, SMALL, V9, P3295, DOI 10.1002/smll.201300134; Bao WZ, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4789365; Lee C, 2010, ACS NANO, V4, P2695, DOI 10.1021/nn1003937; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Haigh SJ, 2012, NAT MATER, V11, P764, DOI [10.1038/nmat3386, 10.1038/NMAT3386]; Das S, 2013, NANO LETT, V13, P100, DOI 10.1021/nl303583v; Britnell L, 2013, SCIENCE, V340, P1311, DOI 10.1126/science.1235547; STERN F, 1967, PHYS REV, V163, P816, DOI 10.1103/PhysRev.163.816; Kretinin AV, 2014, NANO LETT, V14, P3270, DOI 10.1021/nl5006542; ANDO T, 1982, REV MOD PHYS, V54, P437, DOI 10.1103/RevModPhys.54.437; Wang L, 2013, SCIENCE, V342, P614, DOI 10.1126/science.1244358; Xiao D, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.196802; Qiu H, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.3696045; Schmidt H, 2014, NANO LETT, V14, P1909, DOI 10.1021/nl4046922; Chen JH, 2008, NAT NANOTECHNOL, V3, P206, DOI 10.1038/nnano.2008.58; Li XD, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.115418; Mak KF, 2012, NAT NANOTECHNOL, V7, P494, DOI [10.1038/nnano.2012.96, 10.1038/NNANO.2012.96]; Mak KF, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.136805; van der Zande AM, 2013, NAT MATER, V12, P554, DOI [10.1038/nmat3633, 10.1038/NMAT3633]; Neal AT, 2013, ACS NANO, V7, P7077, DOI 10.1021/nn402377g; Das S, 2013, NANO LETT, V13, P3396, DOI 10.1021/nl401831u; Mak KF, 2014, SCIENCE, V344, P1489, DOI 10.1126/science.1250140; Radisavljevic B, 2013, NAT MATER, V12, P815, DOI [10.1038/nmat3687, 10.1038/NMAT3687]; Kappera R, 2014, NAT MATER, V13, P1128, DOI [10.1038/nmat4080, 10.1038/NMAT4080]; Guo Y, 2014, ACS NANO, V8, P7771, DOI 10.1021/nn503152r; Liu GB, 2013, PHYS REV B, V88, DOI 10.1103/PhysRevB.88.085433; Liu H, 2012, ACS NANO, V6, P8563, DOI 10.1021/nn303513c; Sundaram RS, 2013, NANO LETT, V13, P1416, DOI 10.1021/nl400516a; Zeng HL, 2012, NAT NANOTECHNOL, V7, P490, DOI [10.1038/nnano.2012.95, 10.1038/NNANO.2012.95]; Choi M., 2013, NATURE COMMUN, V4, P1642; Du YC, 2014, APL MATER, V2, DOI 10.1063/1.4894198; Fivaz R., 1967, PHYS REV, V163; Jiang T, 2014, NAT NANOTECHNOL, V9, P825, DOI [10.1038/nnano.2014.176, 10.1038/NNANO.2014.176]; Kappera R, 2014, APL MATER, V2, DOI [10.1063/1.4896077, 10.1063/14896077]; Kim S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2018; Lee G. H., 2013, ACS NANO, V7, P7931; Liu H., 2013, ACS NANO, V8, P1031; Qiu H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3642; Roy T., 2014, ACS NANO, V8, P6256; Sarma D., 2011, REV MOD PHYS, V83, P407; Yu ZH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6290; Zhu W., 2014, NATURE COMMUN, V5, P3078	50	19	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1748-3387	1748-3395		NAT NANOTECHNOL	Nat. Nanotechnol.	JUN	2015	10	6					534	540		10.1038/NNANO.2015.70		7	Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science & Technology - Other Topics; Materials Science	CJ6RC	WOS:000355620000016		
J	Yamamoto, K; Okada, Y; Suzuki, A; Kochi, Y				Yamamoto, Kazuhiko; Okada, Yukinori; Suzuki, Akari; Kochi, Yuta			Genetics of rheumatoid arthritis in Asia-present and future	NATURE REVIEWS RHEUMATOLOGY			English	Article							JAPANESE POPULATION; RISK LOCI; ASSOCIATION; SUSCEPTIBILITY; HLA-DRB1; DISEASE; VARIANTS; HLA-DRB1-ASTERISK-0901; ALLELE	Genome-wide association studies (GWAS) have uncovered numerous susceptibility genes for rheumatoid arthritis (RA) in patients of European, Asian and other ethnic ancestries. Although previous transethnic GWAS meta-analyses enabled the identification of several novel loci, the genetic heterogeneity observed in the PADI4 and PTPN22 genes suggests that ethnic variation should be considered. In addition, the effects of genetic polymorphisms on gene expression profiles are important when assessing the association of genetic information with disease pathogenesis and will influence the development of personalized medicine. Gene expression is controlled by epigenetic modifications, which in turn can be affected by environmental stimuli. Altogether, genetic and epigenetic information of Asian populations will contribute considerably to future rheumatology research.	[Yamamoto, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo 1130033, Japan; [Yamamoto, Kazuhiko; Suzuki, Akari; Kochi, Yuta] RIKEN, Ctr Integrated Med Sci, Lab Autoimmune Dis, Yokohama, Kanagawa 2300045, Japan; [Okada, Yukinori] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Human Genet & Dis Divers, Tokyo 1138510, Japan	Yamamoto, K (reprint author), Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo 1130033, Japan.	yamamoto-tky@umin.ac.jp					Raychaudhuri S, 2012, NAT GENET, V44, P291, DOI 10.1038/ng.1076; Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582; Stahl EA, 2012, NAT GENET, V44, P483, DOI 10.1038/ng.2232; Lee HS, 2004, ARTHRITIS RHEUM, V50, P3468, DOI 10.1002/art.20608; Kong KF, 2002, AUTOIMMUNITY, V35, P235, DOI 10.1080/08916930290024179; Smolen JS, 2010, ANN RHEUM DIS, V69, P631, DOI 10.1136/ard.2009.123919; Kurreeman FAS, 2012, AM J HUM GENET, V90, P524, DOI 10.1016/j.ajhg.2012.01.010; Kochi Y, 2011, ANN RHEUM DIS, V70, P512, DOI 10.1136/ard.2010.130526; Barreiro LB, 2010, NAT REV GENET, V11, P17, DOI 10.1038/nrg2698; Shimane K, 2013, RHEUMATOLOGY, V52, P1172, DOI 10.1093/rheumatology/kes427; Trynka G, 2013, NAT GENET, V45, P124, DOI 10.1038/ng.2504; Wakitani S, 1998, SCAND J RHEUMATOL, V27, P381; Lee JC, 2013, CELL, V155, P57, DOI 10.1016/j.cell.2013.08.034; Mori M, 2005, J HUM GENET, V50, P264, DOI 10.1007/s10038-005-0246-8; Plenge RM, 2013, NAT REV DRUG DISCOV, V12, P581, DOI 10.1038/nrd4051; Dubois PCA, 2010, NAT GENET, V42, P295, DOI 10.1038/ng.543; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Scally SW, 2013, J EXP MED, V210, P2569, DOI 10.1084/jem.20131241; Jiang L, 2014, ARTHRITIS RHEUMATOL, V66, P1121, DOI 10.1002/art.38353; Bengsch B, 2012, J IMMUNOL, V188, P5438, DOI 10.4049/jimmunol.1103801; Okada Y, 2012, NAT GENET, V44, P511, DOI 10.1038/ng.2231; Cavagna L, 2013, BIOMED RES INT, DOI 10.1155/2013/759760; Freed BM, 2011, ARTHRITIS RHEUM-US, V63, P3733, DOI 10.1002/art.30636; Jiang YX, 2013, HUM HERED, V76, P28, DOI 10.1159/000353270; Kochi Y, 2004, ARTHRITIS RHEUM, V50, P63, DOI 10.1002/art.11366; Marigorta UM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003566; Myouzen K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002949; National Institutes of Health, 2014, CATALOG PUBLISHED GE; Okada Y, 2010, ANN RHEUM DIS, V69, P1569, DOI 10.1136/ard.2009.118018; Okada Y, 2014, HUM MOL GENET, V23, P6916, DOI 10.1093/hmg/ddu387; Ramos PS, 2014, AUTOIMMUNE DIS, V2014; Suzuki A., 2003, NAT GENET, V34, P365	32	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1759-4790	1759-4804		NAT REV RHEUMATOL	Nat. Rev. Rheumatol.	JUN	2015	11	6					375	379		10.1038/nrrheum.2015.7		5	Rheumatology	Rheumatology	CJ5TX	WOS:000355554300010		
J	Gutmanas, A; Adams, PD; Bardiaux, B; Berman, HM; Case, DA; Fogh, RH; Guntert, P; Hendrickx, PMS; Herrmann, T; Kleywegt, GJ; Kobayashi, N; Lange, OF; Markley, JL; Montelione, GT; Nilges, M; Ragan, TJ; Schwieters, CD; Tejero, R; Ulrich, EL; Velankar, S; Vranken-, WF; Wedell, JR; Westbrook, J; Wishart, DS; Vuister, GW				Gutmanas, Aleksandras; Adams, Paul D.; Bardiaux, Benjamin; Berman, Helen M.; Case, David A.; Fogh, Rasmus H.; Guentert, Peter; Hendrickx, Pieter M. S.; Herrmann, Torsten; Kleywegt, Gerard J.; Kobayashi, Naohiro; Lange, Oliver F.; Markley, John L.; Montelione, Gaetano T.; Nilges, Michael; Ragan, Timothy J.; Schwieters, Charles D.; Tejero, Roberto; Ulrich, Eldon L.; Velankar, Sameer; Vranken-, Wim F.; Wedell, Jonathan R.; Westbrook, John; Wishart, David S.; Vuister, Geerten W.			NMR Exchange Format: a unified and open standard for representation of NMR restraint data	NATURE STRUCTURAL & MOLECULAR BIOLOGY			English	Letter							PROTEIN DATA-BANK; WWPDB; FILE		[Gutmanas, Aleksandras; Hendrickx, Pieter M. S.; Kleywegt, Gerard J.; Velankar, Sameer] European Bioinformat Inst, European Mol Biol Lab, Protein Data Bank Europe, Cambridge, England; [Adams, Paul D.] Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA USA; [Bardiaux, Benjamin; Nilges, Michael] Inst Pasteur, Unite Bioinformat Struct, Dept Biol Struct & Chim, Paris, France; [Bardiaux, Benjamin; Nilges, Michael] CNRS, Unite Mixte Rech 3528, Paris, France; [Berman, Helen M.; Case, David A.; Westbrook, John] Rutgers State Univ, Ctr Integrat Prote Res, Dept Chem & Chem Biol, Piscataway, NJ USA; [Fogh, Rasmus H.; Ragan, Timothy J.; Vuister, Geerten W.] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; [Guentert, Peter] Goethe Univ Frankfurt, Frankfurt Inst Adv Studies, Inst Biophys Chem, D-60054 Frankfurt, Germany; [Guentert, Peter] Tokyo Metropolitan Univ, Grad Sch Sci & Engn, Tokyo 158, Japan; [Guentert, Peter] ETH, Phys Chem, Zurich, Switzerland; [Herrmann, Torsten] Ecole Normale Super Lyon, Ctr Resonance Magnet Nucl Tres Hauts Champs, Villeurbanne, France; [Herrmann, Torsten] CNRS, Unite Mixte Rech 5280, Inst Sci Analyt, Villeurbanne, France; [Kobayashi, Naohiro] Osaka Univ, Inst Prot Res, Osaka, Japan; [Lange, Oliver F.] Tech Univ Munich, Biomol NMR, Munich Ctr Integrated Prot Sci, Dept Chem, Garching, Germany; [Markley, John L.; Ulrich, Eldon L.] Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA; [Montelione, Gaetano T.] Rutgers State Univ, Dept Mol Biol & Biochem, Ctr Adv Biotechnol & Med, Piscataway, NJ USA; [Montelione, Gaetano T.] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Biochem & Mol Biol, Piscataway, NJ 08854 USA; [Schwieters, Charles D.] NIH, Div Computat Biosci, Ctr Informat Technol, Bethesda, MD 20892 USA; [Tejero, Roberto] Univ Valencia, Dept Quim Fis, Valencia, Spain; [Vranken-, Wim F.] Vlaams Inst Biotechnol, Struct Biol Res Ctr, Brussels, Belgium; [Vranken-, Wim F.] Vrije Univ Brussel, Struct Biol Brussels, Brussels, Belgium; [Vranken-, Wim F.] Univ Libre Bruxelles, Vrije Univ Brussel, Interuniv Inst Bioinformat Brussels, Brussels, Belgium; [Wishart, David S.] Univ Alberta, Dept Comp Sci, Edmonton, AB, Canada; [Wishart, David S.] Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada	Vuister, GW (reprint author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.	gutmanas@ebi.ac.uk; gv29@le.ac.uk	Nilges, Michael/E-4803-2011; Fachbereich14, Dekanat/C-8553-2015; Herrmann, Torsten/B-9978-2008	Nilges, Michael/0000-0002-1451-8092; 			BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Ulrich EL, 2008, NUCLEIC ACIDS RES, V36, pD402, DOI 10.1093/nar/gkm957; Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449; Berman H, 2007, NUCLEIC ACIDS RES, V35, pD301, DOI 10.1093/nar/gkl971; Doreleijers JF, 2009, J BIOMOL NMR, V45, P389, DOI 10.1007/s10858-009-9378-z; HALL SR, 1991, J CHEM INF COMP SCI, V31, P326, DOI 10.1021/ci00002a020; Markley John L, 2003, Methods Biochem Anal, V44, P89; Montelione GT, 2013, STRUCTURE, V21, P1563, DOI 10.1016/j.str.2013.07.021; Tejero R, 2013, J BIOMOL NMR, V56, P337, DOI 10.1007/s10858-013-9753-7	9	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1545-9993	1545-9985		NAT STRUCT MOL BIOL	Nat. Struct. Mol. Biol.	JUN	2015	22	6					433	434				2	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CJ6RI	WOS:000355620600001		
J	Xiao, YL; Ma, BY; McElheny, D; Parthasarathy, S; Long, F; Hoshi, M; Nussinov, R; Ishii, Y				Xiao, Yiling; Ma, Buyong; McElheny, Dan; Parthasarathy, Sudhakar; Long, Fei; Hoshi, Minako; Nussinov, Ruth; Ishii, Yoshitaka			A beta(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease	NATURE STRUCTURAL & MOLECULAR BIOLOGY			English	Article							SOLID-STATE NMR; NUCLEAR-MAGNETIC-RESONANCE; BETA-SHEET STRUCTURES; A-BETA; EXPERIMENTAL CONSTRAINTS; PROTEIN BACKBONE; ROTATING SOLIDS; CHEMICAL-SHIFTS; MODEL; POLYMORPHISM	Increasing evidence has suggested that formation and propagation of misfolded aggregates of 42-residue human amyloid beta(A beta(1-42)), rather than of the more abundant A beta(1-40), provokes the Alzheimer's disease cascade. However, structural details of misfolded A beta(1-42) have remained elusive. Here we present the atomic model of an A beta(1-42) amyloid fibril, from solid-state NMR (ssNMR) data. It displays triple parallel-beta-sheet segments that differ from reported structures of A beta(1-40) fibrils. Remarkably, A beta(1-40) is incompatible with the triple-beta-motif, because seeding with A beta(1-42) fibrils does not promote conversion of monomeric A beta(1-40) into fibrils via cross-replication. ssNMR experiments suggest that C-terminal Ala42, absent in A beta(1-40), forms a salt bridge with Lys28 to create a self-recognition molecular switch that excludes A beta(1-40). The results provide insight into the A beta(1-42)-selective self-replicating amyloid-propagation machinery in early-stage Alzheimer's disease.	[Xiao, Yiling; McElheny, Dan; Parthasarathy, Sudhakar; Long, Fei; Ishii, Yoshitaka] Univ Illinois, Dept Chem, Chicago, IL 60607 USA; [Ma, Buyong; Nussinov, Ruth] NCI, Canc & Inflammat Program, Leidos Biomed Res, Frederick, MD 21701 USA; [Hoshi, Minako] Inst Biomed Res & Innovat, Kobe, Hyogo, Japan; [Hoshi, Minako] Kyoto Univ, Dept Anat & Dev Biol, Grad Sch Med, Kyoto, Japan; [Nussinov, Ruth] Tel Aviv Univ, Sackler Inst Mol Med, Dept Human Genet & Mol Med, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Ishii, Yoshitaka] Univ Illinois, Struct Biol Ctr, Chicago, IL USA	Ishii, Y (reprint author), Univ Illinois, Dept Chem, Chicago, IL 60607 USA.	yishii@uic.edu	Ishii, Yoshitaka/F-4558-2014		US National Institutes of Health (NIH) RO1 program [GM 098033]; Alzheimer's Association Investigator-Initiated Research Grant (IIRG) [08-91256]; federal funds from the Frederick National Laboratory for Cancer Research, NIH [HHSN261200800001E]; Intramural Research Program of the NIH, Frederick National Laboratory, Center for Cancer Research	This work was supported primarily by the US National Institutes of Health (NIH) RO1 program (GM 098033) and by an Alzheimer's Association Investigator-Initiated Research Grant (IIRG) (08-91256) to Y.I. This project has been funded in part with federal funds from the Frederick National Laboratory for Cancer Research, NIH, under contract HHSN261200800001E, to B.M. and R.N. This research was supported in part by the Intramural Research Program of the NIH, Frederick National Laboratory, Center for Cancer Research, to B.M. and R.N. The content of this publication does not necessarily reflect the views or policies of the US Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government. MD simulations to generate initial structural models were performed at the high-performance computational facilities of the Biowulf PC/Linux cluster at the NIH (http://biowulf.nih.gov/). Y.I. is grateful to S. Chimon, C. Jones and N. Wickramasinghe for their initial efforts in the preparation of A beta(1-42) fibrils at the University of Illinois at Chicago.	Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Shen Y, 2013, J BIOMOL NMR, V56, P227, DOI 10.1007/s10858-013-9741-y; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; Jaroniec CP, 2001, J AM CHEM SOC, V123, P3507, DOI 10.1021/ja003266e; Bertini I, 2011, J AM CHEM SOC, V133, P16013, DOI 10.1021/ja2035859; Han B, 2011, J BIOMOL NMR, V50, P43, DOI 10.1007/s10858-011-9478-4; Sarkar B, 2014, ANGEW CHEM INT EDIT, V53, P6888, DOI 10.1002/anie.201402636; Lange A, 2006, NATURE, V440, P959, DOI 10.1038/nature04649; Fawzi NL, 2011, NATURE, V480, P268, DOI 10.1038/nature10577; Ma BY, 2002, P NATL ACAD SCI USA, V99, P14126, DOI 10.1073/pnas.212206899; Graff-Radford NR, 2007, ARCH NEUROL-CHICAGO, V64, P354, DOI 10.1001/archneur.64.3.354; Paravastu AK, 2008, P NATL ACAD SCI USA, V105, P18349, DOI 10.1073/pnas.0806270105; Lu JX, 2013, CELL, V154, P1257, DOI 10.1016/j.cell.2013.08.035; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Stohr J, 2012, P NATL ACAD SCI USA, V109, P11025, DOI 10.1073/pnas.1206555109; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; van Oijen M, 2006, LANCET NEUROL, V5, P655, DOI 10.1016/S1474-4422(06)70501-4; Hyung SJ, 2013, P NATL ACAD SCI USA, V110, P3743, DOI 10.1073/pnas.1220326110; Olofsson A, 2006, J BIOL CHEM, V281, P477, DOI 10.1074/jbc.M508962200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Noguchi A, 2009, J BIOL CHEM, V284, P32895, DOI 10.1074/jbc.M109.000208; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Bernstein SL, 2009, NAT CHEM, V1, P326, DOI [10.1038/nchem.247, 10.1038/NCHEM.247]; Takegoshi K, 2003, J CHEM PHYS, V118, P2325, DOI 10.1063/1.1534105; Jones EM, 2005, CELL, V121, P63, DOI 10.1016/j.cell.2005.01.034; Ahmed M, 2010, NAT STRUCT MOL BIOL, V17, P561, DOI 10.1038/nsmb.1799; Ma BY, 2011, J BIOL CHEM, V286, P34244, DOI 10.1074/jbc.M111.241141; Lopez del Amo JM, 2012, ANGEW CHEM INT EDIT, V51, P6136, DOI 10.1002/anie.201200965; Loquet A, 2012, NATURE, V486, P276, DOI 10.1038/nature11079; Masuda Y, 2009, CHEMBIOCHEM, V10, P287, DOI 10.1002/cbic.200800411; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Heinig M, 2004, NUCLEIC ACIDS RES, V32, pW500, DOI 10.1093/nar/gkh429; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Schmidt M, 2009, P NATL ACAD SCI USA, V106, P19813, DOI 10.1073/pnas.0905007106; Petkova AT, 2006, BIOCHEMISTRY-US, V45, P498, DOI 10.1021/bi051952q; Chimon S, 2005, J AM CHEM SOC, V127, P13472, DOI 10.1021/ja0540391; De Strooper B, 2007, EMBO REP, V8, P141, DOI 10.1038/sj.embor.7400897; Chimon S, 2007, NAT STRUCT MOL BIOL, V14, P1157, DOI 10.1038/nsmb1345; Wasmer C, 2008, SCIENCE, V319, P1523, DOI 10.1126/science.1151839; Stohr J, 2014, P NATL ACAD SCI USA, V111, P10329, DOI 10.1073/pnas.1408968111; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; GULLION T, 1990, J MAGN RESON, V89, P479, DOI 10.1016/0022-2364(90)90331-3; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; Kajava AV, 2010, FASEB J, V24, P1311, DOI 10.1096/fj.09-145979; Luhrs T, 2005, P NATL ACAD SCI USA, V102, P17342, DOI 10.1073/pnas.0506723102; Tsui V, 2000, J AM CHEM SOC, V122, P2489, DOI 10.1021/ja9939385; Cady SD, 2010, NATURE, V463, P689, DOI 10.1038/nature08722; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; Kodali R, 2007, CURR OPIN STRUC BIOL, V17, P48, DOI 10.1016/j.sbi.2007.01.007; O'Nuallain B, 2005, BIOCHEMISTRY-US, V44, P12709, DOI 10.1021/bi050927h; Antzutkin ON, 2002, BIOCHEMISTRY-US, V41, P15436, DOI 10.1021/bi0204185; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013; Luheshi LM, 2007, PLOS BIOL, V5, P2493, DOI 10.1371/journal.pbio.0050290; Murakami K, 2003, J BIOL CHEM, V278, P46179, DOI 10.1074/jbc.M301874200; Pauwels K, 2012, J BIOL CHEM, V287, P5650, DOI 10.1074/jbc.M111.264473	57	8	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1545-9993	1545-9985		NAT STRUCT MOL BIOL	Nat. Struct. Mol. Biol.	JUN	2015	22	6					499	U97		10.1038/nsmb.2991		9	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CJ6RI	WOS:000355620600013		
J	Kobayashi, M; Fujimaki, T; Mihara, B; Ohira, T				Kobayashi, Masahito; Fujimaki, Takamitsu; Mihara, Ban; Ohira, Takayuki			Repetitive Transcranial Magnetic Stimulation Once a Week Induces Sustainable Long-Term Relief of Central Poststroke Pain	NEUROMODULATION			English	Article						Central poststroke pain; thalamic pain; transcranial magnetic stimulation	MOTOR CORTEX STIMULATION; INTRACTABLE DEAFFERENTATION PAIN; NEUROPATHIC PAIN; ELECTRICAL-STIMULATION; CORTICAL EXCITABILITY; SPINAL-CORD; HEMORRHAGE; DEPRESSION; REDUCTION; EFFICACY	ObjectiveCentral poststroke pain is a serious problem for some patients after stroke. Repetitive transcranial magnetic stimulation (rTMS) has been reported to relieve poststroke pain but its efficacy is still controversial. We tested the possibility that rTMS, when applied once a week, would induce sustainable relief of poststroke pain. Materials and MethodsEighteen patients with central poststroke pain were included in this study. rTMS (10 trains of 10-sec 5Hz-rTMS) was delivered over the primary motor cortex on the affected side. The rTMS session was repeated once a week for 12 weeks, and for six patients the intervention was continued for one year. The degree of the pain was assessed before each weekly rTMS session to evaluate sustainable effects. ResultsThe effects of the rTMS reached a plateau at the eighth week. At the 12th week, the rTMS was effective in 61.1% of the patients; 5 of the 18 patients showed more than 70% reduction based on a visual analog scale, 6 patients showed 40-69% reduction, and 7 remained at a pain reduction level of less than 40%. When patients were divided into two groups with or without severe dysesthesia, it was found that eight patients with severe dysesthesia showed less pain relief than those without. In the six patients who continued rTMS for one year, the pain relief effects also were sustained. ConclusionAlthough this was an open-label study without a control group, our findings suggest that rTMS of the primary motor cortex, when maintained once a week, could help to relieve poststroke pain.	[Kobayashi, Masahito; Fujimaki, Takamitsu] Saitama Med Univ, Dept Neurosurg, Moroyama, Saitama 3500495, Japan; [Kobayashi, Masahito; Mihara, Ban] Mihara Mem Hosp, Inst Brain & BloodVessels, Dept Neurol, Saitama, Japan; [Ohira, Takayuki] Keio Univ Sch Med, Dept Neurosurg, Saitama, Japan	Kobayashi, M (reprint author), Saitama Med Univ, Dept Neurosurg, 38 Morohongo, Moroyama, Saitama 3500495, Japan.	mkob@saitama-med.ac.jp			JSPS KAKENHI [23592105]	This work was partly supported by JSPS KAKENHI Grant Number 23592105.	Rasche D, 2006, PAIN, V121, P43, DOI 10.1016/j.pain.2005.12.006; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Wolter T, 2012, NEUROMODULATION, V15, P13, DOI 10.1111/j.1525-1403.2011.00410.x; Hirayama A, 2006, PAIN, V122, P22, DOI 10.1016/j.pain.2005.12.001; Hansson P, 2004, EUR J NEUROL, V11, P22, DOI 10.1111/j.1471-0552.2004.00793.x; Goto T, 2008, PAIN, V140, P509, DOI 10.1016/j.pain.2008.10.009; Siebner HR, 1999, NEUROLOGY, V52, P529; Hosomi K, 2008, CLIN NEUROPHYSIOL, V119, P993, DOI 10.1016/j.clinph.2007.12.022; Lefaucheur JP, 2001, NEUROREPORT, V12, P2963, DOI 10.1097/00001756-200109170-00041; Lefaucheur JP, 2008, CLIN NEUROPHYSIOL, V119, P2179, DOI 10.1016/j.clinph.2008.07.007; Saitoh Y, 2007, J NEUROSURG, V107, P555, DOI 10.3171/JNS-07/09/0555; George MS, 1997, AM J PSYCHIAT, V154, P1752; KWAK R, 1983, STROKE, V14, P493; Khedr EM, 2005, J NEUROL NEUROSUR PS, V76, P833, DOI 10.1136/jnnp.2004.055806; Pascual-Leone A, 1998, J CLIN NEUROPHYSIOL, V15, P333, DOI 10.1097/00004691-199807000-00005; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Garcia-Larrea L, 1999, PAIN, V83, P259; Hosomi K, 2013, PAIN, V154, P1352, DOI 10.1016/j.pain.2013.04.017; Nguyen JP, 1999, PAIN, V82, P245, DOI 10.1016/S0304-3959(99)00062-7; Khedr EM, 2003, EUR J NEUROL, V10, P567, DOI 10.1046/j.1468-1331.2003.00649.x; Kumar B, 2009, ANESTH ANALG, V108, P1645, DOI 10.1213/ane.0b013e31819d644c; Baron JC, 2004, CEREBROVASC DIS, V18, P260, DOI 10.1159/000080293; Geller V, 1997, PROG NEURO-PSYCHOPH, V21, P105, DOI 10.1016/S0278-5846(96)00161-3; Hannibal KE, 2014, PHYS THER, V94, P1816, DOI 10.2522/ptj.20130597; Hasan M, 2014, NEUROMODULATION, V17, P731, DOI 10.1111/ner.12198; JUVELA S, 1995, ARCH NEUROL-CHICAGO, V52, P1193; Katayama Y, 1998, J NEUROSURG, V89, P585, DOI 10.3171/jns.1998.89.4.0585; Kishima H, 2007, J NEUROSURG, V107, P43, DOI 10.3171/JNS-07/07/0043; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Mylius V, 2013, NEUROIMAGE, V78, P224, DOI 10.1016/j.neuroimage.2013.03.061; Ohn SH, 2012, NEUROREHAB NEURAL RE, V26, P344, DOI 10.1177/1545968311423110; Pagano RL, 2012, PAIN, V153, P2359, DOI 10.1016/j.pain.2012.08.002; Pleger B, 2004, NEUROSCI LETT, V356, P87, DOI 10.1016/j.neulet.2003.11.037; Rollnik JD, 2000, NEUROREPORT, V11, P4013, DOI 10.1097/00001756-200012180-00022; Saitoh Y, 2000, J NEUROSURG, V92, P150, DOI 10.3171/jns.2000.92.1.0150; Saitoh Y, 2007, ACTA NEUROCHIR SUPPL, V97, P51; Saitoh Y, 2006, ACT NEUR S, V99, P57, DOI 10.1007/978-3-211-35205-2_11; Tsubokawa T, 1991, Acta Neurochir Suppl (Wien), V52, P137; TSUBOKAWA T, 1993, J NEUROSURG, V78, P393, DOI 10.3171/jns.1993.78.3.0393; Wassermann EM, 1996, ELECTROENCEPHALOGR C, V108, P1	40	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	JUN	2015	18	4					249	254		10.1111/ner.12301		6	Medicine, Research & Experimental; Clinical Neurology	Research & Experimental Medicine; Neurosciences & Neurology	CJ6WE	WOS:000355635100002		
J	Tan, CB; Shichinohe, H; Abumiya, T; Nakayama, N; Kazumata, K; Hokari, M; Hamauchi, S; Houkin, K				Tan, Chengbo; Shichinohe, Hideo; Abumiya, Takeo; Nakayama, Naoki; Kazumata, Ken; Hokari, Masaaki; Hamauchi, Shuji; Houkin, Kiyohiro			Short-, middle- and long-term safety of superparamagnetic iron oxide-labeled allogeneic bone marrow stromal cell transplantation in rat model of lacunar infarction	NEUROPATHOLOGY			English	Article						bone marrow stromal cell; cell tracking; lacunar stroke; regenerative medicine; superparamagnetic iron oxide	MESENCHYMAL STEM-CELLS; ENDOTHELIAL-LIKE CELLS; IN-VIVO; ENHANCES RECOVERY; CEREBRAL INFARCT; ISCHEMIC-STROKE; BRAIN; INJURY; MICROGLIA; TRACKING	Recently, both basic and clinical studies demonstrated that bone marrow stromal cell (BMSC) transplantation therapy can promote functional recovery of patients with CNS disorders. A non-invasive method for cell tracking using MRI and superparamagnetic iron oxide (SPIO)-based labeling agents has been applied to elucidate the behavior of transplanted cells. However, the long-term safety of SPIO-labeled BMSCs still remains unclear. The aim of this study was to investigate the short-, middle- and long-term safety of the SPIO-labeled allogeneic BMSC transplantation. For this purpose, BMSCs were isolated from transgenic rats expressing green fluorescent protein (GFP) and were labeled with SPIO. The Na/K ATPase pump inhibitor ouabain or vehicle was stereotactically injected into the right striatum of wild-type rats to induce a lacunar lesion (n=22). Seven days after the insult, either BMSCs or SPIO solution were stereotactically injected into the left striatum. A 7.0-Tesla MRI was performed to serially monitor the behavior of BMSCs in the host brain. The animals were sacrificed after 7 days (n=7), 6 weeks (n=6) or 10 months (n=9) after the transplantation. MRI demonstrated that BMSCs migrated to the damage area through the corpus callosum. Histological analysis showed that activated microglia were present around the bolus of donor cells 7 days after the allogeneic cell transplantation, although an immunosuppressive drug was administered. The SPIO-labeled BMSCs resided and started to proliferate around the route of the cell transplantation. Within 6 weeks, large numbers of SPIO-labeled BMSCs reached the lacunar infarction area from the transplantation region through the corpus callosum. Some SPIO nanoparticles were phagocytized by microglia. After 10 months, the number of SPIO-positive cells was lower compared with the 7-day and 6-week groups. There was no tumorigenesis or severe injury observed in any of the animals. These findings suggest that BMSCs are safe after cell transplantation for the treatment of stroke.	[Tan, Chengbo; Shichinohe, Hideo; Abumiya, Takeo; Nakayama, Naoki; Kazumata, Ken; Hokari, Masaaki; Hamauchi, Shuji; Houkin, Kiyohiro] Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Sapporo, Hokkaido 0608638, Japan	Shichinohe, H (reprint author), Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, N15W7, Sapporo, Hokkaido 0608638, Japan.	hshichi@med.hokudai.ac.jp					Bulte JWM, 2009, AM J ROENTGENOL, V193, P314, DOI 10.2214/AJR.09.3107; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Kraitchman DL, 2003, CIRCULATION, V107, P2290, DOI 10.1161/01.CIR.0000070931.62772.4E; McCormack DR, 2011, LASER SURG MED, V43, P333, DOI 10.1002/lsm.21060; Kosaka N, 2010, NANOMEDICINE-UK, V5, P765, DOI [10.2217/nnm.10.49, 10.2217/NNM.10.49]; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Savitz SI, 2011, STROKE, V42, P825, DOI 10.1161/STROKEAHA.110.601914; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhao SY, 2014, J SURG RES, V191, P290, DOI 10.1016/j.jss.2014.03.064; Tamama K, 2008, STEM CELLS DEV, V17, P897, DOI 10.1089/scd.2007.0155; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Garcon G, 2001, CANCER LETT, V167, P7, DOI 10.1016/S0304-3835(01)00474-8; Kuroda S, 2013, ACTA NEUROBIOL EXP, V73, P57; He T, 2014, CURR GENE THER, V14, P136; Liu JW, 2007, J THROMB HAEMOST, V5, P826, DOI 10.1111/j.1538-7836.2007.02381.x; Taylor A, 2012, CHEM SOC REV, V41, P2707, DOI 10.1039/c2cs35031a; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Tang Y, 2014, CELL DEATH DIFFER, V21, P369, DOI 10.1038/cdd.2013.159; Grossmann R, 2002, GLIA, V37, P229, DOI 10.1002/glia.10031; Irons H, 2004, CELL TRANSPLANT, V13, P283, DOI 10.3727/000000004783983990; Ito M, 2011, TRANSL STROKE RES, V2, P294, DOI 10.1007/s12975-011-0098-9; Janowski M, 2008, J NEUROL SCI, V273, P40, DOI 10.1016/j.jns.2008.06.019; Kawabori M, 2014, METAB BRAIN DIS, P12; Kawabori M, 2013, NEUROPATHOLOGY, V33, P140, DOI 10.1111/j.1440-1789.2012.01335.x; Kuroda S, 2011, J Stem Cells Regen Med, V7, P2; Miyamoto M, 2013, J NUCL MED, V54, P145, DOI 10.2967/jnumed.112.109017; Shichinohe H, 2012, TRANSL STROKE RES, V3, P99, DOI 10.1007/s12975-011-0138-5; Shichinohe H, 2014, NEUROREHAB NEURAL RE, P10; Shichinohe H, 2013, ACTA NEUROBIOL EXP, V73, P354; van der Stelt M, 2001, J NEUROSCI, V21, P8765; Veldhuis WB, 2003, J CEREBR BLOOD F MET, V23, P62, DOI 10.1097/01.WCB.0000039287.37737.50; Wang Yi-Xiang J, 2011, Quant Imaging Med Surg, V1, P35, DOI 10.3978/j.issn.2223-4292.2011.08.03; Xu HS, 2014, EUR REV MED PHARMACO, V18, P520; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031; Zhen-Zhou C, 2008, CYTOTHERAPY, V10, P611, DOI 10.1080/14653240802317621	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	JUN	2015	35	3					197	208		10.1111/neup.12180		12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CJ7LY	WOS:000355678100001		
J	Inose, Y; Kato, Y; Kitagawa, K; Uchiyama, S; Shibata, N				Inose, Yuri; Kato, Yoichiro; Kitagawa, Kazuo; Uchiyama, Shinichiro; Shibata, Noriyuki			Activated microglia in ischemic stroke penumbra upregulate MCP-1 and CCR2 expression in response to lysophosphatidylcholine derived from adjacent neurons and astrocytes	NEUROPATHOLOGY			English	Article						ischemic penumbra; lysophophatidylcholine; MCP-1; microglia; phospholipase A(2)	CENTRAL-NERVOUS-SYSTEM; CYTOSOLIC PHOSPHOLIPASE A(2); FOCAL CEREBRAL-ISCHEMIA; SMOOTH-MUSCLE CELLS; LESION VOLUME; NEURODEGENERATIVE DISEASES; ENDOTHELIAL-CELLS; P2X(7) RECEPTORS; GENE-EXPRESSION; ARTERY STROKE	In acute stage of ischemic stroke, the surrounding zone of fresh infarcts is termed penumbra, where microglia are activated in response to damaged cell-derived proinflammatory mediators. Rescuing penumbra by regulating inflammatory activity would minimize infarct volume, which positively correlates with functional outcome. To elucidate mechanisms by which inflammation occurs in penumbra, we performed immunohistochemical investigations using autopsied human brains affected by acute, subacute and chronic stages of cerebral infarction as well as cell culture experiments using a murine microglia-derived cell line (BV-2). In penumbra of fresh infarcts, immunoreactivity for secretory phospholipase A(2) group X (sPLA(2)-X), which is responsible for the production and release of the proinflammatory mediator lysophosphatidylcholine (LPC), was intensely detected in neurons and astrocytes. Furthermore, immunoreactivities for the LPC receptors G protein-coupled receptor 132 (G2A) and P2X purinoreceptor 7 (P2X7R), as well as the CC chemokine monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2, were detectable in activated microglia. Prior to cell culture experiments, it was confirmed that BV-2 cells were immunoreactive for ionized Ca2+-binding adaptor molecule 1 (Iba1), G2A, P2X7R, MCP-1 and CCR2. Reverse transcription-quantitative polymerase chain reaction analysis revealed that MCP-1 and CCR2 mRNA expression levels were significantly increased by LPC stimulation. The LPC-driven increase in MCP-1 transcripts was lowered by blockade of G2A or P2X7R or by inhibition of Rho-associated protein kinase (ROCK) or inhibitor of B kinase. The LPC-driven increase in CCR2 transcripts was lowered by blockade of G2A or P2X7R or by inhibition of ROCK, phosphatidylinositide 3-kinanse, extracellular signal-regulated kinase kinase, or p38 mitogen-activated protein kinase. The present results provide in vivo and in vitro evidence that in acute stage of ischemic stroke, the sPLA(2)-X enzyme product LPC is released from neurons and astrocytes and stimulates penumbra microglia via G2A and P2X7R, thereby exerting the MCP-1/CCR2-mediated neurotoxicity through distinct cell-signaling pathways.	[Inose, Yuri] Tokyo Womens Med Univ, Grad Sch Med, Tokyo 1628666, Japan; [Inose, Yuri; Kato, Yoichiro; Shibata, Noriyuki] Tokyo Womens Med Univ, Dept Pathol, Tokyo 1628666, Japan; [Inose, Yuri; Kitagawa, Kazuo; Uchiyama, Shinichiro] Tokyo Womens Med Univ, Dept Neurol, Tokyo 1628666, Japan; [Uchiyama, Shinichiro] Int Univ Hlth & Welfare, Clin Res Ctr Med, Tokyo, Japan; [Uchiyama, Shinichiro] Sanno Hosp, Ctr Brain & Cerebral Vessels, Tokyo, Japan; [Uchiyama, Shinichiro] Sanno Med Ctr, Tokyo, Japan	Shibata, N (reprint author), Tokyo Womens Med Univ, Dept Pathol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	shibatan@research.twmu.ac.jp					Ancuta P, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-403; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Zhang J, 2012, BRAIN RES, V1471, P129, DOI 10.1016/j.brainres.2012.06.031; Adibhatla RM, 2006, FREE RADICAL BIO MED, V40, P376, DOI 10.1016/j.freeradbiomed.2005.08.044; Lee YB, 2002, J NEUROSCI RES, V69, P94, DOI 10.1002/jnr.10253; Skaper SD, 2006, GLIA, V54, P234, DOI 10.1002/glia.20379; Yagami T, 2014, MOL NEUROBIOL, V49, P863, DOI 10.1007/s12035-013-8565-9; Shieh CH, 2014, GLIA, V62, P592, DOI 10.1002/glia.22628; Bose S, 2013, ARCH PHARM RES, V36, P1039, DOI 10.1007/s12272-013-0161-z; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Sun GY, 2010, NEUROMOL MED, V12, P133, DOI 10.1007/s12017-009-8092-z; Amantea D, 2009, FEBS J, V276, P13, DOI 10.1111/j.1742-4658.2008.06766.x; Pelisek J, 2012, ARCH IMMUNOL THER EX, V60, P431, DOI 10.1007/s00005-012-0192-z; Suzumura A, 2013, CURR PROTEIN PEPT SC, V14, P16; Kaushal V, 2008, J NEUROSCI, V28, P2221, DOI 10.1523/JNEUROSCI.5643-07.2008; Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200; Kabarowski JH, 2009, PROSTAG OTH LIPID M, V89, P73, DOI 10.1016/j.prostaglandins.2009.04.007; Sheikh AM, 2009, GLIA, V57, P898, DOI 10.1002/glia.20815; Farooqui AA, 2006, PHARMACOL REV, V58, P591, DOI 10.1124/pr.58.3.7; Heiss WD, 2012, ANN NY ACAD SCI, V1268, P26, DOI 10.1111/j.1749-6632.2012.06668.x; Skaper SD, 2010, FASEB J, V24, P337, DOI 10.1096/fj.09-138883; Arsene D, 2011, ROM J MORPHOL EMBRYO, V52, P29; Benitez S, 2004, ATHEROSCLEROSIS, V177, P299, DOI 10.1016/j.atherosclerosis.2004.07.027; Cui QH, 2013, NEURAL REGEN RES, V8, P1180, DOI 10.3969/j.issn.1673-5374.2013.13.003; Davis S, 2013, INT J STROKE, V8, P2, DOI 10.1111/ijs.12185; delsZoppo G., 2000, BRAIN PATHOL, V10, P95; Ding WG, 2011, J MOL CELL CARDIOL, V50, P58, DOI 10.1016/j.yjmcc.2010.10.006; Etemad S, 2012, J NEUROSCI METH, V209, P79, DOI 10.1016/j.jneumeth.2012.05.025; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; Ferrer I, 2008, GREENFIELDS NEUROPAT, V1, P180; Grol MW, 2012, AM J PHYSIOL-ENDOC M, V302, pE561, DOI 10.1152/ajpendo.00209.2011; GRUSS HJ, 1994, J IMMUNOL, V153, P4907; Hasegawa H, 2011, BIOCHEM BIOPH RES CO, V415, P526, DOI 10.1016/j.bbrc.2011.10.119; Hinojosa AE, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-77; Hoda MN, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-21; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Jing Q, 2000, CIRC RES, V87, P52; Li JZ, 2013, INT J MOL MED, V31, P493, DOI 10.3892/ijmm.2012.1211; Michel AD, 2007, BRIT J PHARMACOL, V152, P523, DOI 10.1038/sj.bjp.0707417; Rong JX, 2002, ARTERIOSCL THROM VAS, V22, P1617, DOI 10.1161/01.ATV.0000035408.93749.71; Schiemanck SK, 2004, STROKE, V35, pE319; Schiemanck SK, 2005, RESTOR NEUROL NEUROS, V23, P257; Schiemanck SK, 2005, NEUROREHAB NEURAL RE, V19, P133, DOI 10.1177/154596830501900207; Schilling M, 2009, BRAIN RES, V1289, P79, DOI 10.1016/j.brainres.2009.06.054; Takenouchi T, 2007, J NEUROCHEM, V102, P1518, DOI 10.1111/j.1471-4159.2007.04570.x; Vesterinen Hanna M, 2013, Syst Rev, V2, P33, DOI 10.1186/2046-4053-2-33; Wang WY, 2010, CARDIOVASC RES, V85, P845, DOI 10.1093/cvr/cvp367; Yamakawa T, 2002, ARTERIOSCL THROM VAS, V22, P752, DOI 10.1161/01.ATV.0000015903.02749.71	49	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	JUN	2015	35	3					209	223		10.1111/neup.12182		15	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CJ7LY	WOS:000355678100002		
J	Oyanagi, K; Yamazaki, M; Hashimoto, T; Asakawa, M; Wakabayashi, K; Takahashi, H				Oyanagi, Kiyomitsu; Yamazaki, Mineo; Hashimoto, Tomoyo; Asakawa, Mika; Wakabayashi, Koichi; Takahashi, Hitoshi			Hippocampal sclerosis in the parkinsonism-dementia complex of Guam: quantitative examination of neurons, neurofibrillary tangles, and TDP-43 immunoreactivity in CA1	NEUROPATHOLOGY			English	Article						CA1; hippocampal sclerosis; neurofibrillary tangle; Parkinsonism-dementia complex; TDP-43	AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; PROGRESSIVE SUPRANUCLEAR PALSY; PATHOLOGICAL FEATURES; ALZHEIMERS-DISEASE; ENDEMIC DISEASE; TAU; BRAINS; INCLUSIONS; EPILEPSY	The cornu ammonis 1 (CA1) area in the hippocampus of the parkinsonism-dementia complex (PDC) of Guam was examined quantitatively with special references to the number of neurons, intraneuronal (i) and extracellular (e) neurofibirillary tangles (NFTs), and TDP-43 (43-kDa trans-activation-responsive region DNA-binding protein)-immunopositive structures, in 24 Chamorro patients with PDC of Guam and seven control Chamorro Guamanians (both groups having no ischemic or anoxic complications). The results were that: (i) in the patients with mildly involved PDC, total numbers of neurons, iNFTs and eNFTs were almost the same as those of neurons of controls; (ii) in patients severely involved, total numbers of neurons, iNFTs and eNFTs decreased markedly; (iii) the decrease of the number of pyramidal neurons in CA1 with positive nuclear TDP-43 was intimately correlated with the decrease in total neuron numbers; (iv) whereas the numbers of neurons and TDP-43-immunopositive intracytoplasmic aggregation in the CA1 area were inversely correlated; and (v) depression of nuclear TDP-43 immuonostainability was not affected by the presence or absence of NFTs. In conclusion, hippocampal sclerosis exists in PDC; there is a possibility of elimination of eNFTs which appeared in the CA1 in patients with PDC and loss of the neurons correlates with disappearance of nuclear TDP-43, but not with appearance of intraneurocytoplasmic TDP-43 aggregation or iNFTs.	[Oyanagi, Kiyomitsu; Hashimoto, Tomoyo; Asakawa, Mika] Shinshu Univ, Sch Med, Dept Brain Dis Res, Matsumoto, Nagano 3908621, Japan; [Yamazaki, Mineo] Chiba Hokusoh Hosp, Nippon Med Sch, Dept Neurol, Chiba, Japan; [Hashimoto, Tomoyo] Univ Occupat & Environm Hlth, Dept Neurol, Kitakyushu, Fukuoka 807, Japan; [Wakabayashi, Koichi] Hirosaki Univ, Grad Sch Med, Dept Neuropathol, Hirosaki, Aomori, Japan; [Takahashi, Hitoshi] Niigata Univ, Dept Pathol, Brain Res Inst, Niigata, Niigata, Japan	Oyanagi, K (reprint author), Shinshu Univ, Sch Med, Dept Brain Dis Res, Div Neuropathol, Asahi 3-1-1, Matsumoto, Nagano 3908621, Japan.	k123ysm@shinshu-u.ac.jp			Japan Foundation for Neuroscience and Mental Health; Brain Research Institute, Niigata University, Niigata, Japan [2503]	The authors thank Professor Y. Ihara, Doshisha University, Kyoto Japan, Professor P. Davies and Professor S.-H. Yen, Mayo Clinic Jacksonville, Florida, USA, Dr. Masato Hasegawa, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, for their generously giving us antibodies. The authors are indebted to Professor Charles Duyckaerts, La SalPetriere Hospital, Paris, France, for his suggestion on morphometry, and Dr. Sachiko Takahama, Shinshu University, Nagano, Japan, for her help in statistical analysis, Ms. Emiko Kawakami, Tokyo Metropolitan Institute for Medical Science, Tokyo, Japan, Dr. Kwang-Ming Chen, Guam, USA and Dr. Eiji Yamada, Department of Pathology, Hikone City Hospital, Shiga, Japan, for their cooperation in propelling this research. This work was supported in part by grants from the Japan Foundation for Neuroscience and Mental Health (to KO), and the Collaborative Research Project of the Brain Research Institute, Niigata University, Niigata, Japan (#2503) to KO.	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Cairns NJ, 2007, ACTA NEUROPATHOL, V114, P5, DOI 10.1007/s00401-007-0237-2; Higashi S, 2007, BRAIN RES, V1184, P284, DOI 10.1016/j.brainres.2007.09.048; CRAS P, 1995, ACTA NEUROPATHOL, V89, P291; Hasegawa M, 2008, ANN NEUROL, V64, P60, DOI 10.1002/ana.21425; Blumcke I, 2002, BRAIN PATHOL, V12, P199; Geser F, 2008, ACTA NEUROPATHOL, V115, P133, DOI 10.1007/s00401-007-0257-y; Anamizu Y, 2005, ACTA NEUROPATHOL, V109, P457, DOI 10.1007/s00401-004-0971-7; Hasegawa M, 2007, BRAIN, V130, P1386, DOI 10.1093/brain/awm065; Johnson BS, 2008, P NATL ACAD SCI USA, V105, P6439, DOI 10.1073/pnas.0802082105; DICKSON DW, 1992, ACTA NEUROPATHOL, V84, P596; Nelson PT, 2013, ACTA NEUROPATHOL, V126, P161, DOI 10.1007/s00401-013-1154-1; Seelaar H, 2007, BRAIN, V130, P1375, DOI 10.1093/brain/awm024; Mackenzie IRA, 2011, ACTA NEUROPATHOL, V122, P111, DOI 10.1007/s00401-011-0845-8; DICKSON DW, 1990, LAB INVEST, V63, P87; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Bobinski M, 1998, BRAIN RES, V799, P156, DOI 10.1016/S0006-8993(98)00441-7; Morsch R, 1999, J NEUROPATH EXP NEUR, V58, P188, DOI 10.1097/00005072-199902000-00008; Neumann M, 2009, ACTA NEUROPATHOL, V117, P137, DOI 10.1007/s00401-008-0477-9; Schwab C, 1998, ACTA NEUROPATHOL, V96, P409; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; HIRANO A, 1961, BRAIN, V84, P662, DOI 10.1093/brain/84.4.662; Oyanagi K, 2001, J NEUROPATH EXP NEUR, V60, P393; Nishihira Y, 2008, ACTA NEUROPATHOL, V116, P169, DOI 10.1007/s00401-008-0385-z; Arai N, 2007, NEUROPATHOLOGY, V27, P594, DOI 10.1111/j.1440-1789.2007.00811.x; Hatanpaa KJ, 2014, J NEUROPATH EXP NEUR, V73, P136, DOI [10.1097/OPX.0000000000000170, 10.1097/NEN.0000000000000037]; HIRANO A, 1962, ARCH NEUROL-CHICAGO, V7, P227; HIRANO A, 1961, BRAIN, V84, P642, DOI 10.1093/brain/84.4.642; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; Mikossy J, 2008, ACTA NEUROPATHOL, V116, P625; OYANAGI K, 1994, ACTA NEUROPATHOL, V88, P122; Oyanagi K., 2011, NEURODEGENERATION MO, P171; OYANAGI K, 1994, ACTA NEUROPATHOL, V88, P405; Oyanagi K, 1997, J NEUROPATH EXP NEUR, V56, P308, DOI 10.1097/00005072-199703000-00010; Parent A, 1996, CARPENTERS HUMAN NEU, P744; Schwab C, 1999, NEUROBIOL AGING, V20, P57, DOI 10.1016/S0197-4580(99)00005-6; Schwab C, 1997, ACTA NEUROPATHOL, V93, P87; Sephton CF, 2012, BIOL CHEM, V393, P589, DOI 10.1515/hsz-2012-0115; SIEDLAK SL, 1991, J HISTOCHEM CYTOCHEM, V39, P899; Sumi H, 2009, J NEUROPATH EXP NEUR, V68, P37, DOI 10.1097/NEN.0b013e3181919cb5; Yamazaki M, 2005, J NEUROPATH EXP NEUR, V64, P839, DOI 10.1097/01.jnen.0000182977.79483.89; Yamazaki M, 2000, J NEUROPATH EXP NEUR, V59, P585	42	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	JUN	2015	35	3					224	235		10.1111/neup.12185		12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CJ7LY	WOS:000355678100003		
J	Shioya, A; Saito, Y; Arima, K; Kakuta, Y; Yuzuriha, T; Tanaka, N; Murayama, S; Tamaoka, A				Shioya, Ayako; Saito, Yuko; Arima, Kunimasa; Kakuta, Yukio; Yuzuriha, Takefumi; Tanaka, Noriko; Murayama, Shigeo; Tamaoka, Akira			Neurodegenerative changes in patients with clinical history of bipolar disorders	NEUROPATHOLOGY			English	Article						argyrophilic grain; chronic traumatic encephalopathy; lithium carbonate; mood disorder; tau	ARGYROPHILIC GRAIN DISEASE; LEWY BODY DISEASE; CEREBRAL-CORTEX; LITHIUM; TAUOPATHY; DEMENTIA; SCHIZOPHRENIA; DEPRESSION; PATHOLOGY; BODIES	Neurodegeneration in bipolar disorder (BPD) is poorly understood. Therefore, the current study was designed to assess the immunohistochemical changes in neurodegenerative markers in patients with BPD. Eleven consecutive autopsy cases diagnosed with BPD were analyzed. Sections were obtained from archival paraffin blocks of representative areas and stained using conventional methods, as well as immunostained with several antibodies to screen for neurodegenerative diseases. Age- and non-argyrophilic grains (AGs) degeneration matched controls were selected for each case. Clinical information was retrospectively collected from medical charts. All patients were men, and the average age of death was 70 years. Neuropathological diagnoses included dementia with grains (2), argyrophilic grain disease (2), corticobasal degeneration (CBD, 1), Lewy body disease (1), hypoxic encephalopathy (1) and cerebral infarction (1). All cases showed AGs to various degrees. Three patients died in their 50s; one demonstrated dementia with Lewy bodies, while the other two showed abundant AGs in the thalamus and amygdala. Of the three patients who died in their 60s, one showed AGs preferentially in the thalamus and amygdala, while the others demonstrated limbic predominance. The patients who died in/after their 70s demonstrated AGs similar to controls, except for the patient with CBD. Our data provides potentiality that neurodegenerative diseases may be an underlying pathology in certain cases of BPD.	[Shioya, Ayako; Saito, Yuko] Natl Ctr Neurol & Psychiat, Natl Ctr Hosp, Dept Pathol & Lab Med, Tokyo 1878551, Japan; [Arima, Kunimasa] Natl Ctr Neurol & Psychiat, Natl Ctr Hosp, Dept Psychiat, Tokyo 1878551, Japan; [Tanaka, Noriko] Natl Ctr Global Hlth & Med, Ctr Clin Sci, Dept Clin Res & Informat, Biostat Sect, Tokyo, Japan; [Murayama, Shigeo] Tokyo Metropolitan Inst Gerontol, Brain Bank Aging Res, Tokyo, Japan; [Shioya, Ayako; Tamaoka, Akira] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Neurol, Tsukuba, Ibaraki 305, Japan; [Kakuta, Yukio] Yokohama Rosai Hosp, Dept Pathol, Yokohama, Kanagawa, Japan; [Yuzuriha, Takefumi] Hizen Psychiat Ctr, Dept Psychiat, Saga, Japan	Saito, Y (reprint author), Natl Ctr Neurol & Psychiat, Natl Ctr Hosp, Dept Pathol & Lab Med, 4-1-1 Ogawahigashi Chou, Tokyo 1878551, Japan.	yukosm@ncnp.go.jp			Japanese Bureau of Health, Labor, and Welfare; Ministry of Education, Science, and Technology; Health and Labour Sciences Research Grant, "Research on Applying Health Technology," from the Japanese Ministry of Health, Labor and Welfare; Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP [25-7]	The authors thank Mr. Nobuo Kuninaka, Ms. Yoko Tanaka, Mr. Naoo Aikyo, Ms. Mieko Harada, Ms. Yuki Kimura and Ms. Nobuko Naoi for technical support. This study was supported by Grants-in-Aid from the Japanese Bureau of Health, Labor, and Welfare (Y.S. & S.M.) and the Ministry of Education, Science, and Technology (Y.S. & S.M.), Health and Labour Sciences Research Grant, "Research on Applying Health Technology," from the Japanese Ministry of Health, Labor and Welfare (Y.S.& S.M.) and by an Intramural Research Grant (25-7) for Neurological and Psychiatric Disorders of NCNP (Y.S.).	Prickaerts J, 2006, J NEUROSCI, V26, P9022, DOI 10.1523/JNEUROSCI.5216-05.2006; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Dickson DW, 2002, J NEUROPATH EXP NEUR, V61, P935; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; Townsend J, 2012, BIPOLAR DISORD, V14, P326, DOI 10.1111/j.1399-5618.2012.01021.x; Togo T, 2002, J NEUROPATH EXP NEUR, V61, P547; Kato T, 2007, PSYCHIAT CLIN NEUROS, V61, P3, DOI 10.1111/j.1440-1819.2007.01604.x; Saito Y, 2003, J NEUROPATH EXP NEUR, V62, P644; Dixon JF, 1998, P NATL ACAD SCI USA, V95, P8363, DOI 10.1073/pnas.95.14.8363; Saito Y, 2004, J NEUROPATH EXP NEUR, V63, P911; KOSAKA K, 1984, CLIN NEUROPATHOL, V3, P185; Shimada K, 2012, NEUROBIOL DIS, V46, P101, DOI 10.1016/j.nbd.2011.12.050; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Fumimura Y, 2007, J NEUROPATH EXP NEUR, V66, P354, DOI 10.1097/nen.0b013e3180517454; Dokucu ME, 2005, NEUROPSYCHOPHARMACOL, V30, P2216, DOI 10.1038/sj.npp.1300764; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; BRAAK H, 1987, NEUROSCI LETT, V76, P124, DOI 10.1016/0304-3940(87)90204-7; Belmaker RH, 2004, NEW ENGL J MED, V351, P476, DOI 10.1056/NEJMra035354; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hatsuta H, 2007, NEUROPATHOLOGY, V27, P191; Ikeda K, 2000, CLIN NEUROPATHOL, V19, P278; Jellinger KA, 2009, ACTA NEUROPATHOL, V117, P423, DOI 10.1007/s00401-009-0492-5; Manji HK, 1999, BIOL PSYCHIAT, V46, P929, DOI 10.1016/S0006-3223(99)00165-1; Massot O, 1999, NEUROPSYCHOPHARMACOL, V21, P530, DOI 10.1016/S0893-133X(99)00042-1; Nagao S, 2014, EUR ARCH PSY CLIN N, V264, P317, DOI 10.1007/s00406-013-0472-6; Tolnay M, 1997, ACTA NEUROPATHOL, V93, P477	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	JUN	2015	35	3					245	253		10.1111/neup.12191		9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CJ7LY	WOS:000355678100005		
J	Maekawa, A; Kohashi, K; Yamada, Y; Nakamizo, A; Yoshimoto, K; Mizoguchi, M; Iwaki, T; Oda, Y				Maekawa, Akira; Kohashi, Kenichi; Yamada, Yuichi; Nakamizo, Akira; Yoshimoto, Koji; Mizoguchi, Masahiro; Iwaki, Toru; Oda, Yoshinao			A case of intracranial solitary fibrous tumor/hemangiopericytoma with dedifferentiated component	NEUROPATHOLOGY			English	Article						dedifferentiation; fusion gene transcripts; hemangiopericytoma; NAB2-STAT6; solitary fibrous tumor	TUMORS; MDM2; PROGRESSION; LIPOSARCOMA; CDK4; P53	We report the case of a 51-year-old Japanese man with an intracranial dedifferentiated solitary fibrous tumor/hemangiopericytoma (SFT/HPC) identified morphologically and immunohistochemically, comprised of a typical SFT/HPC with a high-grade pleomorphic component. NAB2-STAT6 fusion transcripts were detected by reverse transcriptase polymerase chain reaction in both the conventional and high-grade components. The tumor cells in both components showed the nuclear expression of STAT6 protein, indicating the diagnostic value of these examinations. Intracranial dedifferentiated SFT/HPC is a very rare but important differential diagnosis in intracranial pleomorphic tumors.	[Maekawa, Akira; Kohashi, Kenichi; Yamada, Yuichi; Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka 8128582, Japan; [Maekawa, Akira] Kyushu Univ, Grad Sch Med Sci, Dept Orthoped Surg, Fukuoka 8128582, Japan; [Yoshimoto, Koji; Mizoguchi, Masahiro] Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka 8128582, Japan; [Iwaki, Toru] Kyushu Univ, Grad Sch Med Sci, Dept Neuropathol, Fukuoka 8128582, Japan; [Nakamizo, Akira] Steel Mem Yawata Hosp, Stroke Ctr, Fukuoka, Japan	Oda, Y (reprint author), Kyushu Univ, Dept Anat Pathol, Pathol Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	oda@surgpath.med.kyushu-u.ac.jp					Mosquera JM, 2009, AM J SURG PATHOL, V33, P1314; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; Schweizer L, 2013, ACTA NEUROPATHOL, V125, P651, DOI 10.1007/s00401-013-1117-6; Tihan T, 2003, ARCH PATHOL LAB MED, V127, P432; Oda Y, 2000, MODERN PATHOL, V13, P994, DOI 10.1038/modpathol.3880180; Henricks WH, 1997, AM J SURG PATHOL, V21, P271, DOI 10.1097/00000478-199703000-00002; Morimitsu Y, 2000, APMIS, V108, P617, DOI 10.1034/j.1600-0463.2000.d01-105.x; Aleixo PB, 2009, J CLIN PATHOL, V62, P1127, DOI 10.1136/jcp.2009.070201; Brimo F, 2008, HISTOPATHOLOGY, V52, P892, DOI 10.1111/j.1365-2559.2008.03030.x; Gianitte C, 2007, WHO CLASSIFICATION T, P178; Kurisaki-Arakawa A, 2014, VIRCHOWS ARCH, V465, P615, DOI 10.1007/s00428-014-1625-3; Masuda Y, 2014, INT J CLIN EXP PATHO, V7, P386; Moritani S, 2011, PATHOL INT, V61, P143, DOI 10.1111/j.1440-1827.2010.02627.x; Naobumi T, 2013, ARCH PATHOL LAB MED, V137, P632; Ng HK, 2000, J NEUROSURG, V93, P490, DOI 10.3171/jns.2000.93.3.0490	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	JUN	2015	35	3					260	265		10.1111/neup.12181		6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CJ7LY	WOS:000355678100007		
J	Miyahara, H; Itonaga, T; Maeda, T; Izumi, T; Ihara, K				Miyahara, Hiroaki; Itonaga, Tomoyo; Maeda, Tomoki; Izumi, Tatsuro; Ihara, Kenji			Overexpression of p53 but not Rb in the cytoplasm of neurons and small vessels in an autopsy of a patient with Cockayne syndrome	NEUROPATHOLOGY			English	Article						aging; Cockayne syndrome; p53; progeria; Rb; senescence	REPAIR DISORDERS; PROTEIN; SENESCENCE; PARC; RNA	Cockayne syndrome presents senescence-like changes starting in early infancy; however, the mechanism of premature aging remains unclear. In an autopsy of a 23-year-old woman with Cockayne syndrome, we evaluated the correlation between Cockayne pathology and the expression patterns of the senescence-associated proteins p53 and Rb. Neuropathological findings in this case revealed basal ganglia calcification, tigroid leukodystrophy, bizarre reactive astrocytes, severe cerebellar atrophy with loss of Purkinje cells, and arteriolar/neuronal calcifications in the hypothalamus. Multiple arteriolar calcifications and sclerotic changes were seen in the central nervous system and kidney, but the endothelium of the aorta and coronary arteries remained intact appropriately for the individual's age without any finding of arteriosclerosis. Overexpression of p53 protein was confirmed in the cytoplasm of neurons in the basal ganglia, thalamus, hypothalamus, hippocampus and cerebellum, of arteriolar endothelial cells of the cerebrum and renal glomerular capillaries, and of cutaneous epithelial cells. The distribution of p53 overexpression was coincident with that of pathological alteration, such as neuronal loss, calcification and atrophy. High expression of p53 was localized in the cytoplasm, not in the nucleus. In contrast to p53, Rb was not expressed in any senescence lesion. In terms of senescence, distinct differences are found among organs in a patient with Cockayne syndrome. This segmental progeria differs from natural aging, and implicates p53 overexpression in the etiology of CS.	[Miyahara, Hiroaki; Itonaga, Tomoyo; Maeda, Tomoki; Izumi, Tatsuro; Ihara, Kenji] Oita Univ, Fac Med, Dept Pediat, Oita 8795593, Japan	Miyahara, H (reprint author), Oita Univ, Fac Med, Dept Pediat, 1-1 Idaigaoka, Oita 8795593, Japan.	hmiya@oita-u.ac.jp					Andressoo JO, 2006, CELL CYCLE, V5, P2886, DOI 10.4161/cc.5.24.3565; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Rapin I, 2006, J CHILD NEUROL, V21, P991, DOI 10.2310/7010.2006.00088; Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Latini P, 2011, CELL CYCLE, V10, P3719, DOI 10.4161/cc.10.21.17905; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Minamino T, 2009, NAT MED, V15, P1082, DOI 10.1038/nm.2014; Bakhanashvili M, 2008, J MOL MED-JMM, V86, P75, DOI 10.1007/s00109-007-0247-5; Chen J, 2006, AM J PHYSIOL-HEART C, V290, pH1575, DOI 10.1152/ajpheart.00364.2005; COCKAYNE EA, 1946, ARCH DIS CHILD, V21, P52; Cockayne E A, 1936, Arch Dis Child, V11, P1; Derech-Haim S, 2012, CELL CYCLE, V11, P1400, DOI 10.4161/cc.19812; Frontini M, 2012, AGING-US, V4, P89; van der Pluijm I, 2007, PLOS BIOL, V5, P23, DOI 10.1371/journal.pbio.0050002; Hasty P, 2013, PATHOBIOL A IN PRESS, V3, DOI [10.3402/pba.v3i0.22702, DOI 10.3402/PBA.V3I0.22702]; Hayashi M, 2012, NEUROPATHOLOGY, V32, P113, DOI 10.1111/j.1440-1789.2011.01241.x; Inoue T, 1997, INTERNAL MED, V36, P565; Kastan MB, 2003, CELL, V112, P1, DOI 10.1016/S0092-8674(02)01281-3; Kennedy BK, 2014, ADV EXP MED BIOL, V773, P127, DOI 10.1007/978-1-4899-8032-8_6; Kohji T, 1998, NEUROSCI LETT, V243, P133, DOI 10.1016/S0304-3940(98)00109-8; Lake RJ, 2011, J BIOL CHEM, V286, P34951, DOI 10.1074/jbc.M111.252643; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; Okoshi Y, 2014, BRAIN DEV-JPN, V36, P907, DOI 10.1016/j.braindev.2014.01.004; Puzianowska-Kuznicka M, 2005, INT J BIOCHEM CELL B, V37, P947, DOI 10.1016/j.biocel.2004.10.011; Talluri S, 2014, CELL CYCLE, V13, P641, DOI 10.4161/cc.27527; TROELSTRA C, 1992, GENOMICS, V12, P745, DOI 10.1016/0888-7543(92)90304-B; Weidenheim KM, 2009, MECH AGEING DEV, V130, P619, DOI 10.1016/j.mad.2009.07.006; Wilson DM, 2013, MECH AGEING DEV, V134, P159, DOI 10.1016/j.mad.2013.04.002	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	JUN	2015	35	3					266	272		10.1111/neup.12183		7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CJ7LY	WOS:000355678100008		
J	Adachi, T; Kitayama, M; Nakano, T; Adachi, Y; Kato, S; Nakashima, K				Adachi, Tadashi; Kitayama, Michio; Nakano, Toshiya; Adachi, Yoshiki; Kato, Shinsuke; Nakashima, Kenji			Autopsy case of spinocerebellar ataxia type 31 with severe dementia at the terminal stage	NEUROPATHOLOGY			English	Article						autosomal dominant; dementia; pathology; SCA31; tau	DOMINANT CEREBELLAR-ATAXIA; ALZHEIMERS-DISEASE; NEUROPATHOLOGIC ASSESSMENT; PATHOLOGY; CONSORTIUM; TAUOPATHY; REPEAT; BRAIN; JAPAN; AD	Spinocerebellar ataxia type 31 (SCA31) is an autosomal dominant cerebellar ataxia commonly observed in Japan. However, few neuropathological examinations have been conducted. Here we report the case of a 76-year-old Japanese male SCA31 patient. He noticed dysarthria and difficulty walking at 65 years old. His symptoms subsequently deteriorated, although he could still walk with assistance at 70 years. At 73 years, when he could no longer walk, he was admitted to our hospital. He showed severe limb and truncal ataxia. His father and older brother had shown the same symptoms. Brain magnetic resonance imaging showed cerebellar atrophy of the anterior lobe and white matter hyperintensities. He was diagnosed with SCA31 by genetic analysis. Gradually, his cognitive functions and ability to communicate declined. He died of respiratory failure at the age of 76. Neuropathological examination revealed severe Purkinje cell loss that was accentuated in the anterior lobe of the cerebellum. Furthermore, the remaining Purkinje cells showed abnormal processes (that is, halo-like amorphous materials), as has been reported previously. Severe deposition of hyperphosphorylated tau-positive neurites, many senile plaques and amyloid angiopathy were observed in the neocortex. Our findings suggest that in SCA31, accelerated tau and amyloid pathology in the neocortex might induce dementia at the terminal stage.	[Adachi, Tadashi; Kitayama, Michio; Nakano, Toshiya; Nakashima, Kenji] Tottori Univ, Fac Med, Dept Brain & Neurosci, Div Neurol, Yonago, Tottori 6838504, Japan; [Adachi, Yoshiki] Natl Hosp Org, Matsue Med Ctr, Dept Neurol, Matsue, Shimane, Japan; [Kato, Shinsuke] Tottori Univ, Dept Neuropathol, Fac Med, Yonago, Tottori 6838504, Japan	Adachi, T (reprint author), Tottori Univ, Fac Med, Dept Brain & Neurosci, Div Neurol, 36-1 Nishi Chou, Yonago, Tottori 6838504, Japan.	adachi.neuro@gmail.com			Research Committee for Ataxic Disease, the Ministry of Health, Labour, and Welfare of Japan	The authors thank Ms. Sachi Kurimasa for her technical support. The authors also thank all the members of the Department of Neurology, Tottori University. This work was supported by Grants-in Aid from the Research Committee for Ataxic Disease, the Ministry of Health, Labour, and Welfare of Japan (K.N.).	Owada K, 2005, NEUROLOGY, V65, P629, DOI 10.1212/01.wnl.0000173065.75680.e2; Niimi Y, 2013, NEUROPATHOLOGY, V33, P600, DOI 10.1111/neup.12032; Schmahmann JD, 2004, J NEUROPSYCH CLIN N, V16, P367, DOI 10.1176/appi.neuropsych.16.3.367; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239; MIRRA SS, 1991, NEUROLOGY, V41, P479; Saito Y, 2004, J NEUROPATH EXP NEUR, V63, P911; Alafuzoff I, 2008, BRAIN PATHOL, V18, P484, DOI 10.1111/j.1750-3639.2008.00147.x; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Thal DR, 2002, NEUROLOGY, V58, P1791; Basri R, 2007, J HUM GENET, V52, P848, DOI 10.1007/s10038-007-0182-x; Caillet-Boudin ML, 2014, FRONT MOL NEUROSCI, V6, DOI [10.3389/fnmol.2013.00057, 10.3389/fnmo1.2013.00057]; Fujioka S, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-14; Hayashi M, 2007, ACTA NEUROL SCAND, V116, P123, DOI 10.1111/j.1600-0404.2007.00815.x; Hirano A, 1976, Trans Am Neurol Assoc, V101, P87; Ishikawa K, 2005, AM J HUM GENET, V77, P280, DOI 10.1086/432518; Ishikawa K, 2010, NEUROPATHOLOGY; Ishikawa K, 2011, NEUROLOGY, V77, P1853, DOI 10.1212/WNL.0b013e3182377e3a; Nozaki H, 2007, MOVEMENT DISORD, V22, P857, DOI 10.1002/mds.21443; Sato N, 2009, AM J HUM GENET, V85, P544, DOI 10.1016/j.ajhg.2009.09.019; Shintaku M, 2009, NEUROPATHOLOGY, V29, P285, DOI 10.1111/j.1440-1789.2008.00947.x	21	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	JUN	2015	35	3					273	279		10.1111/neup.12184		7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CJ7LY	WOS:000355678100009		
J	Kondo, D; Hino, H; Shibuya, K; Fujisawa, K; Kosaka, K; Hirayasu, Y; Yamamoto, R; Kasanuki, K; Minegishi, M; Sato, K; Hosokawa, M; Arai, T; Arai, H; Iseki, E				Kondo, Daizo; Hino, Hiroaki; Shibuya, Katsuhiko; Fujisawa, Koshiro; Kosaka, Kenji; Hirayasu, Yoshio; Yamamoto, Ryoko; Kasanuki, Koji; Minegishi, Michiko; Sato, Kiyoshi; Hosokawa, Masato; Arai, Tetsuaki; Arai, Heii; Iseki, Eizo			An autopsied case of corticobasal degeneration showing severe cerebral atrophy over a protracted disease course of 16 years	NEUROPATHOLOGY			English	Article						abnormal tau structure; corticobasal degeneration; long-survival course; severe white matter degeneration; tau isoform	PROGRESSIVE SUPRANUCLEAR PALSY; FRONTOTEMPORAL DEMENTIA; TAU; TAUOPATHY; ASTROCYTES; CRITERIA; VARIANT; BRAINS	The patient was a 72-year-old Japanese woman. At the age of 57, she started having difficulty performing daily work and developed agraphia. She also exhibited restlessness and loss of interest, and began to speak less. Thereafter, stereotypical behavior, gait disturbance and dysphagia were noted. CT scan demonstrated left-dominant frontal and temporal lobe atrophy. She died at the age of 72, about 16 years after the onset of symptoms. Neuropathologically, the brain weighed 867g, and showed remarkable cerebral atrophy with degeneration of the white matter, predominantly in the left dorsal frontal lobe and anterior temporal lobe. Microscopically, severe neuronal loss and gliosis with rarefaction were found in the cerebral cortex, and severe destruction of myelin and axons was observed in the cerebral white matter. Moderate neuronal loss with gliosis was also found in the pallidum and substantia nigra. Gallyas-Braak staining and tau immunostaining revealed pretangle neurons, NFTs, ballooned neurons and astrocytic plaques in the cerebral cortex, subcortical nuclei and brainstem, and argyrophilic threads and coiled bodies in the subcortical white matter. Tau isoform-specific immunostaining revealed that most tau-immunoreactive structures were positive for 4-repeat (4R) tau, but some of the NFTs were positive for 3-repeat (3R) tau in the cerebral neocortex. Immunoblotting demonstrated an accumulation of 4R tau in the cerebral cortex and subcortical white matter. The patient was pathologically diagnosed as having corticobasal degeneration. Her long survival course likely accounts for the severe white matter degeneration and accumulation of 3R tau in NFTs.	[Kondo, Daizo; Yamamoto, Ryoko; Kasanuki, Koji; Minegishi, Michiko; Sato, Kiyoshi; Iseki, Eizo] Juntendo Univ, Sch Med, Juntendo Tokyo Koto Geriatr Med Ctr, PET CT Dementia Res Ctr,Koto Ku, Tokyo 1360075, Japan; [Yamamoto, Ryoko; Kasanuki, Koji; Arai, Heii; Iseki, Eizo] Juntendo Univ, Sch Med, Dept Psychiat, Tokyo 1360075, Japan; [Kondo, Daizo; Kosaka, Kenji; Hirayasu, Yoshio] Yokohama City Univ, Sch Med, Dept Psychiat, Yokohama, Kanagawa 232, Japan; [Hino, Hiroaki; Shibuya, Katsuhiko; Fujisawa, Koshiro; Kosaka, Kenji] Yokohama Hoyu Hosp, Dept Psychiat, Yokohama, Kanagawa, Japan; [Hosokawa, Masato; Arai, Tetsuaki] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 305, Japan	Iseki, E (reprint author), Juntendo Univ, Sch Med, Juntendo Tokyo Koto Geriatr Med Ctr, PET CT Dementia Res Ctr,Koto Ku, 3-3-20 Shinsuna, Tokyo 1360075, Japan.	iseki@juntendo.gmc.ac.jp					Josephs KA, 2011, ACTA NEUROPATHOL, V122, P137, DOI 10.1007/s00401-011-0839-6; Lee SE, 2011, ANN NEUROL, V70, P327, DOI 10.1002/ana.22424; Armstrong MJ, 2013, NEUROLOGY, V80, P496, DOI 10.1212/WNL.0b013e31827f0fd1; Dickson DW, 2002, J NEUROPATH EXP NEUR, V61, P935; Uchihara T, 2011, BRAIN PATHOL, V21, P180, DOI 10.1111/j.1750-3639.2010.00433.x; Togo T, 2002, J NEUROPATH EXP NEUR, V61, P547; Ling HL, 2010, BRAIN, V133, P2045, DOI 10.1093/brain/awq123; Boeve BF, 2003, ANN NEUROL, V54, pS15, DOI 10.1002/ana.10570; Saito Y, 2003, J NEUROPATH EXP NEUR, V62, P644; Tan CF, 2005, ACTA NEUROPATHOL, V109, P329, DOI 10.1007/s00401-004-0933-0; GIBB WRG, 1989, BRAIN, V112, P1171, DOI 10.1093/brain/112.5.1171; de Silva R, 2003, NEUROPATH APPL NEURO, V29, P288, DOI 10.1046/j.1365-2990.2003.00463.x; Wakabayashi K, 2004, NEUROPATHOLOGY, V24, P79, DOI 10.1111/j.1440-1789.2003.00543.x; Kouri N, 2011, NAT REV NEUROL, V7, P263, DOI 10.1038/nrneurol.2011.43; Boeve BF, 2011, J MOL NEUROSCI, V45, P350, DOI 10.1007/s12031-011-9624-1; REBEIZ JJ, 1968, ARCH NEUROL-CHICAGO, V18, P20; Arai T, 2001, NEUROREPORT, V12, P935, DOI 10.1097/00001756-200104170-00014; Cairns NJ, 2010, NEUROLOGY, V74, P354, DOI 10.1212/WNL.0b013e3181ce5dd6; Dickson D, 2003, NEURODEGENERATION MO, P115; Homma Taku, 2013, Brain Nerve, V65, P887; IKEDA K, 1994, NEUROSCI LETT, V174, P157, DOI 10.1016/0304-3940(94)90010-8; Iseki E, 2006, NEUROSCI LETT, V405, P29, DOI 10.1016/j.neulet.2006.06.036; Mizuno Y, 2002, ACTA NEUROPATHOL, V103, P288, DOI 10.1007/s004010100460; Ohara S, 2002, NEUROSCI LETT, V330, P84, DOI 10.1016/S0304-3940(02)00616-X; Tsutiya K, 2005, CLIN NEUROSCI, V23, P262; Wakabayashi K, 2006, NEUROPATHOLOGY, V26, P66, DOI 10.1111/j.1440-1789.2006.00635.x; Yoshida Mari, 2013, Brain Nerve, V65, P1445; Zhang W, 2009, NEUROPATHOLOGY, V29, P720, DOI 10.1111/j.1440-1789.2009.01012.x	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	JUN	2015	35	3					280	288		10.1111/neup.12188		9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CJ7LY	WOS:000355678100010		
J	Sumi-Akamaru, H; Beck, G; Kato, S; Mochizuki, H				Sumi-Akamaru, Hisae; Beck, Goichi; Kato, Shinsuke; Mochizuki, Hideki			Neuroaxonal dystrophy in PLA2G6 knockout mice	NEUROPATHOLOGY			English	Review						calcium independent phospholipaseA(2) (iPLA(2)); infantile neuroaxonal dystrophy (INAD); membrane; mitochondria; PLA2G6	PHOSPHOLIPASE A(2); DOCOSAHEXAENOIC ACID; PHENOTYPIC SPECTRUM; BRAIN; MOUSE; PARKINSONISM; DEFICIENCY; MUTATION; MODEL; MITOCHONDRIA	The PLA2G6 gene encodes group VIA calcium-independent phospholipase A(2) (iPLA(2)), which belongs to the PLA(2) superfamily that hydrolyses the sn-2 ester bond in phospholipids. In the nervous system, iPLA(2) is essential for remodeling membrane phospholipids in axons and synapses. Mutated PLA2G6 causes PLA2G6-associated neurodegeneration (PLAN) including infantile neuroaxonal dystrophy (INAD) and adult-onset dystonia-parkinsonism (PARK14), which have unique clinical phenotypes. In the PLA2G6 knockout (KO) mouse, which is an excellent PLAN model, specific membrane degeneration takes place in neurons and their axons, and this is followed by axonal spheroid formation. These pathological findings are similar to those in PLAN. This review details the evidence that membrane degeneration of mitochondria and axon terminals is a precursor to spheroid formation in this disease model. From a young age before the onset, many mitochondria with damaged inner membranes appear in PLA2G6KO mouse neurons. These injured mitochondria move anterogradely within the axons, increasing in the distal axons. As membrane degeneration progresses, the collapse of the double membrane of mitochondria accompanies axonal injury near impaired mitochondria. At the axon terminals, the membranes of the presynapses expand irregularly from a young age. Over time, the presynaptic membrane ruptures, causing axon terminal degeneration. Although these processes occur in different degenerating membranes, both contain tubulovesicular structures, which are a specific ultrastructural marker of INAD. This indicates that two unique types of membrane degeneration underlie PLAN pathology. We have shown a new pathological mechanism whereby axons degenerate due to defective maintenance and rupture of both the inner mitochondrial and presynaptic membranes. This degeneration mechanism could possibly clarify the pathologies of PLAN, Parkinson disease and neurodegeneration with iron accumulation (NBIA), which are assumed to be due to the primary degeneration of axons.	[Sumi-Akamaru, Hisae; Beck, Goichi; Mochizuki, Hideki] Osaka Univ, Grad Sch Med, Dept Neurol, Suita, Osaka 5650871, Japan; [Kato, Shinsuke] Tottori Univ, Fac Med, Dept Brain & Neurosci, Div Neuropathol, Yonago, Tottori 683, Japan	Sumi-Akamaru, H (reprint author), Osaka Univ, Grad Sch Med, Dept Neurol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	hasumi@neurol.med.osaka-u.ac.jp			Japan Society for the Promotion of Science (JSPS)	This work was supported by Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (JSPS) (HS, GB).	Shindou H, 2013, J BIOCHEM, V154, P21, DOI 10.1093/jb/mvt048; Morgan NV, 2006, NAT GENET, V38, P752, DOI 10.1038/ng1826; Beck G, 2011, J NEUROSCI, V31, P11411, DOI 10.1523/JNEUROSCI.0345-11.2011; Kiebish MA, 2008, J NEUROCHEM, V106, P299, DOI 10.1111/j.1471-4159.2008.05383.x; Malik I, 2008, AM J PATHOL, V172, P406, DOI 10.2353/ajpath.2008.070823; Seleznev K, 2006, J BIOL CHEM, V281, P22275, DOI 10.1074/jbc.M604330200; Kurian MA, 2008, NEUROLOGY, V70, P1623, DOI 10.1212/01.wnl.0000310986.48286.8e; Hishikawa D, 2014, J LIPID RES, V55, P799, DOI 10.1194/jlr.R046094; Yoshino H, 2010, NEUROLOGY, V75, P1356, DOI 10.1212/WNL.0b013e3181f73649; Paisan-Ruiz C, 2009, ANN NEUROL, V65, P19, DOI 10.1002/ana.21415; Shinzawa K, 2008, J NEUROSCI, V28, P2212, DOI 10.1523/JNEUROSCI.4354-07.2008; Murakami M, 2011, PROG LIPID RES, V50, P152, DOI 10.1016/j.plipres.2010.12.001; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Green JT, 2008, J LIPID RES, V49, P939, DOI 10.1194/jlr.R700017-JLR200; Cheon Y, 2012, BBA-MOL CELL BIOL L, V1821, P1278, DOI 10.1016/j.bbalip.2012.02.003; Gregory A, 2008, NEUROLOGY, V71, P1402, DOI 10.1212/01.wnl.0000327094.67726.28; Paisan-Ruiz C, 2012, NEUROBIOL AGING, V33, P814, DOI 10.1016/j.neurobiolaging.2010.05.009; COWEN D, 1963, J NEUROPATH EXP NEUR, V22, P175, DOI 10.1097/00005072-196304000-00001; Burke JE, 2009, J LIPID RES, V50, pS237, DOI 10.1194/jlr.R800033-JLR200; Paradies G, 2014, BBA-BIOENERGETICS, V1837, P408, DOI 10.1016/j.bbabio.2013.10.006; Wada H, 2009, AM J PATHOL, V175, P2257, DOI 10.2353/ajpath.2009.090343; Khateeb S, 2006, AM J HUM GENET, V79, P942, DOI 10.1086/508572; Liu W, 2011, FREE RADICAL BIO MED, V50, P166, DOI 10.1016/j.freeradbiomed.2010.10.709; Blanchard H, 2014, NEUROCHEM RES, V39, P1522, DOI 10.1007/s11064-014-1342-y; Crompton D, 2010, MOL GENET METAB, V100, P207, DOI 10.1016/j.ymgme.2010.02.009; desLeon GA, 1985, ACTA NEUROPATHOL, V66, P89; DUNCAN C, 1970, NEUROLOGY, V20, P1024; Engel LA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012897; Glynn P, 2013, BBA-MOL CELL BIOL L, V1831, P633, DOI 10.1016/j.bbalip.2012.07.023; HEDLEYWH.ET, 1968, NEUROLOGY, V18, P891; Ong WY, 2005, J NEUROCYTOL, V34, P447, DOI 10.1007/s11068-006-8730-4; Riku Yuichi, 2013, Acta Neuropathol Commun, V1, P12, DOI 10.1186/2051-5960-1-12; Salih MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076831; Seitelberger F, 1952, P 1 INT C NEUR, V3, P323; Shi CH, 2011, NEUROLOGY, V77, P75, DOI 10.1212/WNL.0b013e318221acd3; Wada H, 2013, HISTOL HISTOPATHOL, V28, P965; WILLIAMSON K, 1982, ANN NEUROL, V11, P335, DOI 10.1002/ana.410110403; Zhao ZS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026991	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	JUN	2015	35	3					289	302		10.1111/neup.12202		14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CJ7LY	WOS:000355678100011		
J	Goda, T				Goda, Takashi			Fast construction of higher order digital nets for numerical integration in weighted Sobolev spaces	NUMERICAL ALGORITHMS			English	Article						Quasi-Monte Carlo; Numerical integration; Higher order digital nets; Weighted Sobolev spaces	QUASI-MONTE CARLO; POLYNOMIAL LATTICE RULES; ARBITRARY HIGH-ORDER; HIGH-DIMENSIONAL INTEGRATION; BY-COMPONENT CONSTRUCTION; MULTIVARIATE INTEGRATION; SMOOTH FUNCTIONS; LOW-DISCREPANCY; HILBERT-SPACES; ALGORITHMS	Higher order digital nets are special classes of point sets for quasi-Monte Carlo rules which achieve the optimal convergence rate for numerical integration of smooth functions. An explicit construction of higher order digital nets was proposed by Dick, which is based on digitally interlacing in a certain way the components of classical digital nets whose number of components is a multiple ds of the dimension s. In this paper we give a fast computer search algorithm to find good classical digital nets suitable for interlaced components by using polynomial lattice point sets. We consider certain weighted Sobolev spaces of smoothness of arbitrarily high order, and derive an upper bound on the mean square worst-case error for digitally shifted higher order digital nets. Employing this upper bound as a quality criterion, we prove that the component-by-component construction can be used efficiently to find good polynomial lattice point sets suitable for interlaced components. Through this approach we are able to get some tractability results under certain conditions on the weights. Fast construction using the fast Fourier transform requires the construction cost of operations using O(N) memory, where N is the number of points and s is the dimension. This implies a significant reduction in the construction cost as compared to higher order polynomial lattice point sets. Numerical experiments confirm that the performance of our constructed point sets often outperforms those of higher order digital nets with Sobol' sequences and Niederreiter-Xing sequences used for interlaced components, indicating the usefulness of our algorithm.	Univ Tokyo, Grad Sch Engn, Bunkyo Ku, Tokyo 1138656, Japan	Goda, T (reprint author), Univ Tokyo, Grad Sch Engn, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	goda@frcer.t.u-tokyo.ac.jp			 [24-4020]	This work was supported by Grant-in-Aid for JSPS Fellows No. 24-4020.	Abramowitz M., 1971, HDB MATH FUNCTIONS; Sloan IH, 1998, J COMPLEXITY, V14, P1, DOI 10.1006/jcom.1997.0463; Dick J, 2013, ACTA NUMER, V22, P133, DOI 10.1017/S0962492913000044; Joe S, 2003, ACM T MATH SOFTWARE, V29, P49, DOI 10.1145/641876.641879; Dick J, 2007, SIAM J NUMER ANAL, V45, P2141, DOI 10.1137/060658916; Novak E, 2008, EMS TRACTS MATH, V6, P1, DOI 10.4171/026; Nuyens D, 2006, MATH COMPUT, V75, P903, DOI 10.1090/S0025-5718-06-01785-6; Owen AB, 1997, ANN STAT, V25, P1541; Baldeaux J, 2012, NUMER ALGORITHMS, V59, P403, DOI 10.1007/s11075-011-9497-y; Walsh JL, 1923, AM J MATH, V45, P5, DOI 10.2307/2387224; Dick J, 2008, SIAM J NUMER ANAL, V46, P1519, DOI 10.1137/060666639; Baldeaux J, 2009, CONSTR APPROX, V30, P495, DOI 10.1007/s00365-009-9074-y; Baldeaux J, 2011, J COMPLEXITY, V27, P281, DOI 10.1016/j.jco.2010.06.002; Chrestenson H. E., 1955, PAC J MATH, V5, P17; Cools R, 2006, SIAM J SCI COMPUT, V28, P2162, DOI 10.1137/06065074X; Dick J., 2010, DIGITAL NETS SEQUENC; Dick J, 2005, J COMPLEXITY, V21, P149, DOI 10.1016/j.jco.2004.07.003; Dick J, 2011, ANN STAT, V39, P1372, DOI 10.1214/11-AOS880; Dick J, 2007, J COMPLEXITY, V23, P436, DOI 10.1016/j.jco.2007.02.001; FAURE H, 1982, ACTA ARITH, V41, P337; Goda T, CONSTRUCTING G UNPUB; Hickernell FJ, 2002, MONTE CARLO AND QUASI-MONTE CARLO METHODS 2000, P274; Kuo FY, 2011, ANZIAM J, V53, P1, DOI 10.1017/S1446181112000077; Lemieux C, 2009, SPRINGER SER STAT, P1, DOI 10.1007/978-0-387-78165-5_1; Niederreiter H., 2001, LONDON MATH SOC LECT, V285; NIEDERREITER H, 1988, J NUMBER THEORY, V30, P51, DOI 10.1016/0022-314X(88)90025-X; Niederreiter H., 1992, CBMS NSF SERIES APPL, V63; NIEDERREITER H, 1992, CZECH MATH J, V42, P143; Novak E, 2010, EMS TRACTS MATH, V12, P1, DOI 10.4171/084; Nuyens D., 2006, MONTE CARLO QUASIMON, P373, DOI DOI 10.1007/3-540-31186-6; Owen A. B., 1995, LECT NOTES STAT, V106, P299; Pirsic G, 2002, MONTE CARLO AND QUASI-MONTE CARLO METHODS 2000, P434; Sharygin I.F., 1963, ZH VYCH MAT MAT FIZ, V3, P370; Sloan I. H., 1994, LATTICE METHODS MULT; Sobol' I. M., 1967, Zhurnal Vychislitel'noi Matematiki i Matematicheskoi Fiziki, V7	35	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1017-1398	1572-9265		NUMER ALGORITHMS	Numer. Algorithms	JUN	2015	69	2					357	396		10.1007/s11075-014-9902-4		40	Mathematics, Applied	Mathematics	CJ1DB	WOS:000355221100008		
J	Asada, K; Eguchi, S; Tsunekawa, A; Tsuji, M; Itahashi, S; Katou, H				Asada, Kei; Eguchi, Sadao; Tsunekawa, Ayumi; Tsuji, Masaki; Itahashi, Sunao; Katou, Hidetaka			Predicting nitrogen leaching with the modified LEACHM model: validation in soils receiving long-term application of animal manure composts	NUTRIENT CYCLING IN AGROECOSYSTEMS			English	Article						Crop-livestock production; Groundwater quality; Nutrient management; Rothamsted Carbon Model; Scenario analysis	DYNAMICS; TRANSFORMATIONS; MINERALIZATION; TEMPERATURE; CYCLES; JAPAN	A variety of process-based models have been developed for predicting nitrogen (N) dynamics in agro-ecosystem; however, no reliable models have been validated for N leaching from soils receiving a long-term application of different types of animal manure composts. The Leaching Estimation and Chemistry Model (LEACHM) was recently modified by incorporating the basic structure of Rothamsted Carbon Model for extending its ability to describe soil organic matter decomposition and subsequent N leaching in soils rich in organic matter. We evaluate the applicability of the modified LEACHM in cropped Yellow soils receiving 10-year application of cattle or swine manure compost in addition to chemical fertilizers, where high-frequency field monitoring data of soil water contents, soil N contents and leachate N concentrations were available for the last 3 years. Particular attention was paid to determine all input parameters from independent measurements, parameterization from known soil properties or databases without optimisation to fit the measured field data. The model reasonably predicted temporal changes in the soil NH4-N and NO3-N contents, and inorganic N concentrations in the leachate as well as their differences due to different manure compost/chemical fertilizer applications. The simulations of leached N concentration yielded a Willmott index of agreement (IA) of 0.62-0.68, with those for soil moisture, soil nitrate content and crop N uptake all within an acceptable IA range. In view of the good performance without site-specific calibrations, the modified LEACHM appears to be a valuable tool for predicting N leaching from cropped soils receiving long-term manure compost applications.	[Asada, Kei; Eguchi, Sadao; Itahashi, Sunao; Katou, Hidetaka] Natl Inst Agroenvironm Sci, Tsukuba, Ibaraki 3058604, Japan; [Tsunekawa, Ayumi; Tsuji, Masaki] Aichi Agr Res Ctr, Nagakute, Aichi 4801193, Japan	Asada, K (reprint author), Natl Inst Agroenvironm Sci, Kannondai 3-1-3, Tsukuba, Ibaraki 3058604, Japan.	keiasada@affrc.go.jp			Ministry of Agriculture, Forestry and Fisheries, Japan	This work was funded by the Ministry of Agriculture, Forestry and Fisheries, Japan through a research project entitled 'Development of technologies for mitigation and adaptation to climate change in Agriculture, Forestry and Fisheries'. Discussion with Dr. N. Toride and Mr. D. Chen is gratefully acknowledged. We also thank Dr. S. Yoshikawa for helpful comments on the manuscript. We are grateful to anonymous reviewers for constructive comments to for improving the manuscript.	Allen R. G., 1998, 56 FAO; Wieder WR, 2013, NAT CLIM CHANGE, V3, P909, DOI [10.1038/nclimate1951, 10.1038/NCLIMATE1951]; Chalhoub M, 2013, SOIL BIOL BIOCHEM, V65, P144, DOI 10.1016/j.soilbio.2013.05.023; HUTSON JL, 1991, SOIL USE MANAGE, V7, P74, DOI 10.1111/j.1475-2743.1991.tb00853.x; Austin AT, 2004, OECOLOGIA, V141, P221, DOI 10.1007/s00442-004-1519-1; Gerke HH, 1999, PLANT SOIL, V213, P75, DOI 10.1023/A:1004452515423; Falloon P, 1998, SOIL BIOL BIOCHEM, V30, P1207, DOI 10.1016/S0038-0717(97)00256-3; Obara Hiroshi, 2011, Bulletin of the National Institute of Agro-Environmental Sciences, V29, P1; Kuwagata Tsuneo, 2011, Journal of Agricultural Meteorology, V67, P297, DOI 10.2480/agrmet.67.4.9; Doltra J, 2011, EUR J AGRON, V34, P83, DOI 10.1016/j.eja.2010.11.002; Davidson EA, 2009, NAT GEOSCI, V2, P659, DOI 10.1038/NGEO608; Maeda M, 2003, ENVIRON POLLUT, V121, P477, DOI 10.1016/S0269-7491(02)00233-6; Cookson WR, 2002, SOIL BIOL BIOCHEM, V34, P1401, DOI 10.1016/S0038-0717(02)00083-4; JOHNSSON H, 1987, AGR ECOSYST ENVIRON, V18, P333, DOI 10.1016/0167-8809(87)90099-5; Bouwman L, 2013, P NATL ACAD SCI USA, V110, P20882, DOI 10.1073/pnas.1012878108; VANGENUCHTEN MT, 1980, SOIL SCI SOC AM J, V44, P892; Asada K, 2013, PLANT SOIL, V373, P609, DOI 10.1007/s11104-013-1809-7; Bleken MA, 2009, EUR J AGRON, V30, P283, DOI 10.1016/j.eja.2009.01.001; Clark K, 2009, SOIL BIOL BIOCHEM, V41, P348, DOI 10.1016/j.soilbio.2008.11.009; Coleman K, 1996, NATO ASI SERIES 1, V38, P237; Doltra J, 2010, AGR WATER MANAGE, V97, P277, DOI 10.1016/j.agwat.2009.09.019; Eguchi S, 2011, P ASA CSSA SSSA INT; Hara Y, 2000, SOIL SCI PLANT NUTR, V46, P683; Hutson JL, 2003, DEP CROP SOIL SCI RE; IUSS Working Group WRB, 2006, WORLD SOIL RES REP, V103; Iwate Agricultural Research Centre (IARC), 2007, RES RES UPL FIELD NO; Japanese Standards Association, 2009, JIS HDB; Kusano S, 1995, AGR TECHNOLOGY SOIL; Long GQ, 2012, AGR ECOSYST ENVIRON, V146, P73, DOI 10.1016/j.agee.2011.10.013; Ma L., 2011, METHODS INTRO SYSTEM, V2, P1; Malone RW, 2007, GEODERMA, V140, P310, DOI 10.1016/j.geoderma.2007.04.014; Nendel C, 2007, J PLANT NUTR SOIL SC, V170, P598, DOI 10.1002/jpln.200725102; Ogawa K, 1988, RES B HOKKAIDO NATL, V149, P57; Owa N, 1996, NEW MOVEMENT EFFECTI, P1; Reynolds WD, 2002, METHODS SOIL ANAL 4, V5, P797; Shaffer MJ, 2001, MODELING CARBON NITR, P55; Syswerda SP, 2012, AGR ECOSYST ENVIRON, V149, P10, DOI 10.1016/j.agee.2011.12.007; Tabuchi T, 1985, JAPAN J WATER POLLUT, V8, P486; Topp GC, 2002, SSSA BOOK SER, V5, P417; Tsunekawa A, 2013, RES B AICHI AGR RES, V45, P1; Ueyama H, 2008, B NAT AGR RES ORG W, V7, P145; van Genuchten MT, 1991, 600291065 EPA USDAAR; van Kessel C, 2009, J ENVIRON QUAL, V38, P393, DOI 10.2134/jeq2008.0277; Whalen JK, 2001, BIOL FERT SOILS, V34, P334, DOI 10.1007/s003740100416; WILLMOTT CJ, 1982, B AM METEOROL SOC, V63, P1309, DOI 10.1175/1520-0477(1982)063<1309:SCOTEO>2.0.CO;2	45	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1385-1314	1573-0867		NUTR CYCL AGROECOSYS	Nutr. Cycl. Agroecosyst.	JUN	2015	102	2					209	225		10.1007/s10705-015-9690-9		17	Soil Science	Agriculture	CJ9JG	WOS:000355817800004		
J	Nomiya, T; Akamatsu, H; Harada, M; Ota, I; Hagiwara, Y; Ichikawa, M; Miwa, M; Mizutani, M; Kato, T; Nagaoka, A; Tomita, Y; Nemoto, K				Nomiya, Takuma; Akamatsu, Hiroko; Harada, Mayumi; Ota, Ibuki; Hagiwara, Yasuhito; Ichikawa, Mayumi; Miwa, Misako; Mizutani, Masaomi; Kato, Tomoyuki; Nagaoka, Akira; Tomita, Yoshihiko; Nemoto, Kenji			Modified simultaneous integrated boost radiotherapy for large retroperitoneal malignant tumor: A case report	ONCOLOGY LETTERS			English	Article						retroperitoneal neoplasm; clinical trial; radiotherapy; technique	INTENSITY-MODULATED RADIOTHERAPY; OF-THE-LITERATURE; MUCINOUS ADENOCARCINOMA; MANAGEMENT; SARCOMA	The current study reports the case of a large retroperitoneal tumor treated with modified simultaneous integrated boost (SIB) radiotherapy. A 45-year-old female presented to the emergency department complaining of left abdominal pain and fever. A computed tomography scan detected a retroperitoneal tumor of 12x16x16 cm, and a biopsy revealed a poorly-differentiated adenocarcinoma. The patient was diagnosed with a large adenocarcinoma originating from the left ureter, with no distant metastasis. Due to the patient's poor physical condition, surgery was not recommended, and the patient was referred to the Department of Radiation Oncology (Yamagata University Hospital, Yamagata, Japan). Modified SIB radiotherapy was administered following the acquisition of written consent from the patient. The.total irradiation dose to the center of the tumor and to the surrounding healthy tissue was similar to 96 Gy/33 fractions and <60 Gy133 fractions, respectively. At the end of the radio-therapeutic course, the tumor volume was reduced by >= 80%, and the residual tumor was surgically resected. As a result of the resection, a complete pathological response was confirmed; the patient has been recurrence-free for >3 years with no complications. Modified SIB radiotherapy may be safely administered, with favorable outcomes. Complete recovery can be achieved with this technique, even in a patient with a large radioresistant tumor.	[Nomiya, Takuma; Harada, Mayumi] Natl Inst Radiol Sci, Res Ctr Hosp Charged Particle Therapy, Chiba 2638555, Japan; [Akamatsu, Hiroko; Ota, Ibuki; Hagiwara, Yasuhito; Ichikawa, Mayumi; Miwa, Misako; Nemoto, Kenji] Yamagata Univ Hosp, Dept Radiat Oncol, Yamagata 9909585, Japan; [Mizutani, Masaomi] Yamagata Univ Hosp, Dept Surg, Yamagata 9909585, Japan; [Kato, Tomoyuki; Nagaoka, Akira; Tomita, Yoshihiko] Yamagata Univ Hosp, Dept Urol, Yamagata 9909585, Japan	Nomiya, T (reprint author), Natl Inst Radiol Sci, Res Ctr Hosp Charged Particle Therapy, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.	t_nomiya@nirs.go.jp					Gatcombe HG, 2004, J SURG ONCOL, V86, P107, DOI 10.1002/jso.20043; Cho KH, 2010, INT J RADIAT ONCOL, V78, P390, DOI 10.1016/j.ijrobp.2009.08.029; Tambo M, 2007, INT J UROL, V14, P785, DOI 10.1111/j.1442-2042.2007.01839.x; Strauss DC, 2011, ANN ROY COLL SURG, V93, P275, DOI 10.1308/003588411X571944; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Thomas DM, 2009, EXPERT REV ANTICANC, V9, P1145, DOI [10.1586/era.09.77, 10.1586/ERA.09.77]; Buse S, 2006, BJU INT, V98, P969, DOI 10.1111/j.1464-410X.2006.06418.x; Clark J A, 1996, Oncology (Williston Park), V10, P1867; Clark MA, 2005, NEW ENGL J MED, V353, P701, DOI 10.1056/NEJMra041866; Cupp JS, 2013, J REPROD MED, V58, P85; Ghosal SR, 2013, INDIAN J SURG, V75, pS33, DOI 10.1007/s12262-011-0294-6; Jiang HP, 2011, ONCOL LETT, V2, P633, DOI 10.3892/ol.2011.319; Joiner MC, 2004, INT J RADIAT ONCOL, V58, P871, DOI 10.1016/j.ijrobp.2003.10.036; Kattepura S, 2008, PEDIATR SURG INT, V24, P1083, DOI 10.1007/s00383-008-2216-7; Li ZW, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-96; Menenakos Charalambos, 2007, World J Surg Oncol, V5, P45, DOI 10.1186/1477-7819-5-45; National Comprehensive Cancer Network, 2014, OCC PRIM VERS 3 2014; National Comprehensive Cancer Network, NONH LYMPH VERS 2 20; Nomiya T, 2014, CLIN BREAST CANC; Nomiya T, 2014, WORLD J GASTROENTERO, V20, P18480, DOI 10.3748/wjg.v20.i48.18480; Peponi E, 2010, STRAHLENTHER ONKOL, V186, P135, DOI 10.1007/s00066-010-2048-y; Spinelli C, 2013, Case Rep Oncol, V6, P616, DOI 10.1159/000357424; Strauss DC, 2010, BRIT J SURG, V97, P698, DOI 10.1002/bjs.6994; STUSCHKE M, 1992, INT J RADIAT ONCOL, V24, P119; Tasdemir Arzu, 2012, JOP, V13, P304; Van Roggen J F, 2000, Sarcoma, V4, P17, DOI 10.1155/S1357714X00000049; Yadav R, 2013, MALAY J PATHOL, V35, P95; Zerrweck-López Carlos, 2009, Cir Cir, V77, P397	28	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	JUN	2015	9	6					2520	2524		10.3892/ol.2015.3095		5	Oncology	Oncology	CJ4ZS	WOS:000355497800015		
J	Hirai, F; Seto, T; Inamasu, E; Shimokawa, M; Toyokawa, G; Yoshida, T; Nosaki, K; Takenaka, T; Yamaguchi, M; Takenoyama, M; Ichinose, Y				Hirai, Fumihiko; Seto, Takashi; Inamasu, Eiko; Shimokawa, Mototsugu; Toyokawa, Gouji; Yoshida, Tsukihisa; Nosaki, Kaname; Takenaka, Tomoyoshi; Yamaguchi, Masafumi; Takenoyama, Mitsuhiro; Ichinose, Yukito			Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer	ONCOLOGY LETTERS			English	Article						non-squamous non-small cell lung cancer; 15 mg/kg bevacizumab plus cisplatin/pemetrexed	CISPLATIN PLUS GEMCITABINE; PHASE-III TRIAL; ENDOTHELIAL GROWTH-FACTOR; 1ST-LINE CHEMOTHERAPY; THYMIDYLATE SYNTHASE; PEMETREXED PLUS; DOUBLE-BLIND; CARBOPLATIN; PACLITAXEL; METASTASES	The aim of the present study was to retrospectively evaluate the feasibility of cisplatin/pemetrexed/bevacizumab (CPB) therapy at a bevacizumab (BEV) dose of 15 mg/kg as a first-line chemotherapeutic strategy for patients with advanced non-squamous non-small cell lung cancer (NSCLC). A total of 31 consecutive patients with non-squamous NSCLC were treated with first-line chemotherapy of CPB at a BEV dose of 15 mg/kg at the National Kyushu Cancer Center (Fukuoka, Japan) between November 2009 and December 2011. Clinical characteristics, response rate (RR), progression-free survival (PFS) time, overall survival (OS) time and adverse events were retrospectively analyzed. The 31 patients exhibited a male:female ratio of 21:10 and a median age of 60 years (range, 38-76 years). In total, 5 patients were of clinical stage III and 26 patients were of stage IV, 15 had a performance status of 0 and 16 had a performance status of 1, and 29 patients were diagnosed with adenocarcinoma and 2 were diagnosed with adenosquamous carcinoma. The EGFR mutation status was positive (exon 19 deletion), wild-type and unknown in 3, 21 and 7 patients, respectively. A total of 28 patients (90.3%) received a minimum of four courses of CPB therapy. Hematological toxicities classified as grade III or higher included neutropenia (29.0%), anemia (3.2%) and thrombocytopenia (3.2%), however, no severe non-hematological toxicities were observed. Additionally, 22 patients (71.0%) exhibited a partial response and 9 (29.0%) exhibited stable disease, resulting in a RR of 71.0% [95% confidence interval (CI), 41-74]. The median PFS and OS times were 8.4 months (95% CI, 7.9-9.0) and 28.5 months (95% CI, 26.4-30.6), respectively. Therefore, CPB therapy at a BEV dose of 15 mg/kg appears to be a feasible treatment strategy for patients with advanced non-squamous NSCLC.	[Hirai, Fumihiko; Seto, Takashi; Inamasu, Eiko; Toyokawa, Gouji; Yoshida, Tsukihisa; Nosaki, Kaname; Takenaka, Tomoyoshi; Yamaguchi, Masafumi; Takenoyama, Mitsuhiro; Ichinose, Yukito] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka 8111395, Japan; [Shimokawa, Mototsugu; Ichinose, Yukito] Kyushu Natl Canc Ctr, Clin Res Inst, Fukuoka, Fukuoka 8111395, Japan	Seto, T (reprint author), Kyushu Natl Canc Ctr, Dept Thorac Oncol, Minami Ku, 3-1-1 Notame, Fukuoka, Fukuoka 8111395, Japan.	tseto@nk-cc.go.jp					Reck M, 2009, J CLIN ONCOL, V27, P1227, DOI 10.1200/JCO.2007.14.5466; TAYLOR EC, 1992, J MED CHEM, V35, P4450, DOI 10.1021/jm00101a023; Mok TSK, 2011, ASIA-PAC J CLIN ONCO, V7, P4, DOI 10.1111/j.1743-7563.2011.01397.x; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Seto T, 2006, LUNG CANCER-J IASLC, V53, P91, DOI 10.1016/j.lungcan.2006.02.009; Ciuleanu T, 2009, LANCET, V374, P1432, DOI 10.1016/S0140-6736(09)61497-5; Gray R, 2009, J CLIN ONCOL, V27, P4966, DOI 10.1200/JCO.2008.21.6630; Gronberg BH, 2009, J CLIN ONCOL, V27, P3217, DOI 10.1200/JCO.2008.20.9114; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Paz-Ares L, 2012, LANCET ONCOL, V13, P247, DOI 10.1016/S1470-2045(12)70063-3; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Shih C, 1998, ADV ENZYME REGUL, V38, P135; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Schultz RM, 1999, ANTICANCER RES, V19, P437; Besse B, 2010, CLIN CANCER RES, V16, P269, DOI 10.1158/1078-0432.CCR-09-2439; Ohe Y, 2007, ANN ONCOL, V18, P317, DOI 10.1093/annonc/mdl377; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Niho S, 2012, LUNG CANCER, V76, P362, DOI 10.1016/j.lungcan.2011.12.005; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Barlesi F, 2011, ANN ONCOL, V22, P2466, DOI 10.1093/annonc/mdr003; Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721; Clement-Duchene C, 2010, J THORAC ONCOL, V5, P1821, DOI 10.1097/JTO.0b013e3181f1d23c; William WN, 2010, CANCER-AM CANCER SOC, V116, P2401, DOI 10.1002/cncr.24996	27	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	JUN	2015	9	6					2577	2582		10.3892/ol.2015.3086		6	Oncology	Oncology	CJ4ZS	WOS:000355497800024		
J	Otowa, Y; Nakamura, T; Takiguchi, G; Urakawa, N; Ishida, R; Imanishi, T; Suzuki, S; Tanaka, K; Kuroda, D; Kakeji, Y				Otowa, Yasunori; Nakamura, Tetsu; Takiguchi, Gosuke; Urakawa, Naoki; Ishida, Ryo; Imanishi, Tatsuya; Suzuki, Satoshi; Tanaka, Kenichi; Kuroda, Daisuke; Kakeji, Yoshihiro			Successful treatment of quintuple primary cancer, including esophageal cancer: A case report	ONCOLOGY LETTERS			English	Article						esophageal cancer; head and neck cancer; multiple cancer	NECK-CANCER; HEAD; ENDOSCOPY; SURGERY; JAPAN	The present study reports the rare case of a patient with quintuple primary cancer that underwent systematic treatment, including surgical intervention. A 63-year-old male patient was initially diagnosed with primary esophageal cancer and hypopharyngeal cancer. The patient underwent total pharyngolaryngoesophagectomy using a thoracoscopic method and reconstruction using the free jejunal flap and gastric tube and was subsequently administered adjuvant chemotherapy (80 mg/m(2) intravenously on day 1, cisplatin; 800 mg/m(2) continuous intravenous administration on days 1-5, 5-fluorouracil). At 66 years old, the patient was diagnosed with left maxillary sinus cancer and underwent chemoradiotherapy (four 100 mg/m(2) arterial cisplatin injections; 70 Gy/35 f radiotherapy, 2 Gy per day over 35 days). At 68 years old, the patient was diagnosed with gastric tube cancer and underwent gastric tube resection followed by pedicled jejunum flap reconstruction. At 69 years old, the patient was diagnosed with tongue cancer and underwent resection and reconstruction of the tongue by pectoralis major myocutaneous flap. Six years subsequent to the primary surgery, the patient remains alive, without metastasis of the lesions. To the best of our knowledge, the present study is the first report of a patient that underwent a curative procedure for the treatment of five primary multiple cancers in five organs, including esophageal cancer.	[Otowa, Yasunori; Nakamura, Tetsu; Takiguchi, Gosuke; Urakawa, Naoki; Ishida, Ryo; Imanishi, Tatsuya; Suzuki, Satoshi; Tanaka, Kenichi; Kakeji, Yoshihiro] Kobe Univ, Grad Sch Med, Div Gastrointestinal Surg, Dept Surg, Kobe, Hyogo 6500017, Japan; [Kuroda, Daisuke] Kita Harima Med Ctr, Dept Surg, Ono, Hyogo, Japan	Otowa, Y (reprint author), Kobe Univ, Grad Sch Med, Div Gastrointestinal Surg, Dept Surg,Chuo Ku, 7-5-2 Kusunoki Chou, Kobe, Hyogo 6500017, Japan.	otoway@med.kobe-u.ac.jp					American Cancer Society, 2015, CANC FACTS FIG 2015; Morita M, 2008, SURGERY, V143, P499, DOI 10.1016/j.surg.2007.12.007; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Cercato MC, 2008, ANTICANCER RES, V28, P2953; Okabayashi K, 2014, SURG TODAY, V44, P405, DOI 10.1007/s00595-013-0591-8; Pohl H, 2010, CANCER EPIDEM BIOMAR, V19, P1468, DOI 10.1158/1055-9965.EPI-10-0012; Baan R, 2007, LANCET ONCOL, V8, P292, DOI 10.1016/S1470-2045(07)70099-2; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Belcher R, 2014, J SURG ONCOL, V110, P551, DOI 10.1002/jso.23724; Chuang SC, 2008, CANCER EPIDEM BIOMAR, V17, P1543, DOI 10.1158/1055-9965.EPI-07-2876; Urbano MTG, 2004, BRIT J RADIOL, V77, P88, DOI 10.1259/bjr/84246820; Morita M, 2013, ANN SURG ONCOL, V20, P2434, DOI 10.1245/s10434-013-2875-z; Nonaka S, 2010, J GASTROEN HEPATOL, V25, P264, DOI 10.1111/j.1440-1746.2009.05993.x; Ries LAG, 2006, SEER CANC STAT REV 1; Sabesan A, 2014, SURG ONCOL; Sobin LH, 2002, INT UNION CANC TNM C, V6th, P60; SUGIMACHI K, 1988, ANN SURG, V208, P179, DOI 10.1097/00000658-198808000-00008; Tachimori Y, 2014, ESOPHAGUS-TOKYO, V11, P21, DOI 10.1007/s10388-013-0393-5; VANDERHOOP RG, 1990, CANCER, V66, P1697, DOI 10.1002/1097-0142(19901015)66:8<1697::AID-CNCR2820660808>3.0.CO;2-G; WEAVER A, 1979, SURGERY, V86, P493	20	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	JUN	2015	9	6					2583	2585		10.3892/ol.2015.3082		3	Oncology	Oncology	CJ4ZS	WOS:000355497800025		
J	Furuse, H; Yasuhara, R; Hiraga, K				Furuse, Hiroaki; Yasuhara, Ryo; Hiraga, Keijiro			Thermo-optic effects of ceramic TGG in the 300-500 K temperature range	OPTICAL MATERIALS EXPRESS			English	Article							TERBIUM GALLIUM GARNET; THERMALLY-INDUCED DEPOLARIZATION; HIGH AVERAGE POWER; FARADAY ISOLATOR; LASER-RADIATION; CRYSTAL; YAG; BIREFRINGENCE; REDUCTION; EXPANSION	The thermal expansion coefficient a and the thermo-optic coefficient dn/dT were measured using a He-Ne laser (lambda = 632.8 nm) between 300 K and 500 K for ceramic and single-crystal terbium gallium garnet ( TGG). For ceramic TGG, the experimental values of a and dn/dT at 300 K were 7.0 x 10(-6) K-1 and 17.5 x 10(-6) K-1, respectively. We proposed fitting relations regarding the temperature dependence of a and dn/dT. Both a and dn/dT increased with temperature, and the temperature dependencies for ceramic TGG were in agreement with those of single-crystal TGG with < 111 > orientation. We then evaluated thermally induced depolarization for an average laser power of 1 kW. The depolarization was evaluated to be larger than 0.01 at room temperature. Moreover, we simulated the thermal lens focal length and found that the temperature dependence is very slight compared to its dependence on the beam radius. (C) 2015 Optical Society of America	[Furuse, Hiroaki; Hiraga, Keijiro] Kitami Inst Technol, Kitami, Hokkaido 0908507, Japan; [Yasuhara, Ryo] Natl Inst Fus Sci, Toki, Gifu 5095292, Japan	Furuse, H (reprint author), Kitami Inst Technol, 165 Koen Cho, Kitami, Hokkaido 0908507, Japan.	furuse@mail.kitami-it.ac.jp			NIFS Collaboration Research program [NIFS13KBAH006]; CASIO Science Promotion Foundation	This work was performed with the support and under the auspices of the NIFS Collaboration Research program (NIFS13KBAH006). This work was also supported in part by the CASIO Science Promotion Foundation.	Khazanov EA, 1999, IEEE J QUANTUM ELECT, V35, P1116, DOI 10.1109/3.777210; Goncalves-Novo T, 2013, OPT EXPRESS, V21, P855, DOI 10.1364/OE.21.000855; Khazanov E, 2002, APPL OPTICS, V41, P483, DOI 10.1364/AO.41.000483; Yasuhara R, 2007, OPT EXPRESS, V15, P11255, DOI 10.1364/OE.15.011255; Shoji I, 2002, OPT LETT, V27, P234, DOI 10.1364/OL.27.000234; Snetkov IL, 2013, OPT EXPRESS, V21, P21254, DOI 10.1364/OE.21.021254; Kagan MA, 2004, APPL OPTICS, V43, P6030, DOI 10.1364/AO.43.006030; Banerjee S, 2012, OPT LETT, V37, P2175, DOI 10.1364/OL.37.002175; Yoshida H, 2011, OPT EXPRESS, V19, P15181, DOI 10.1364/OE.19.015181; Tsunekane M, 2010, IEEE J QUANTUM ELECT, V46, P277, DOI 10.1109/JQE.2009.2030967; Yasuhara R, 2014, OPT LETT, V39, P1145, DOI 10.1364/OL.39.001145; Yasuhara R, 2013, OPT LETT, V38, P1751, DOI 10.1364/OL.38.001751; Shoji I, 2002, APPL PHYS LETT, V80, P3048, DOI 10.1063/1.1475365; Sato Y, 2014, OPT MATER EXPRESS, V4, P876, DOI 10.1364/OME.4.000876; Furuse H, 2014, OPT MATER EXPRESS, V4, P1794, DOI 10.1364/OME.4.001794; FOSTER JD, 1968, APPL OPTICS, V7, P2428, DOI 10.1364/AO.7.002428; Furuse H, 2011, OPT EXPRESS, V19, P2448, DOI 10.1364/OE.19.002448; Mukhin I, 2009, OPT EXPRESS, V17, P5496, DOI 10.1364/OE.17.005496; RAJA MYA, 1995, APPL PHYS LETT, V67, P2123, DOI 10.1063/1.114740; Snetkov Ilya, 2011, Opt Express, V19, P6366, DOI 10.1364/OE.19.006366; Snetkov IL, 2014, OPT EXPRESS, V22, P4144, DOI 10.1364/OE.22.004144; Soloviev AA, 2012, QUANTUM ELECTRON+, V42, P367, DOI 10.1070/QE2012v042n04ABEH014817; Starobor A, 2014, OPT MATER EXPRESS, V4, P2127, DOI 10.1364/OME.4.002127; Starobor AV, 2014, IEEE J QUANTUM ELECT, V50, P749, DOI 10.1109/JQE.2014.2339230; Tokita S, 2014, OPT MATER EXPRESS, V4, P2122, DOI 10.1364/OME.4.002122; Yasuhara R, 2013, OPT EXPRESS, V21, P31443, DOI 10.1364/OE.21.031443; Yasuhara R, 2014, APPL PHYS LETT, V105, DOI 10.1063/1.4904461; Yasuhara Ryo, 2007, Review of Laser Engineering, V35	28	0	0	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	2159-3930			OPT MATER EXPRESS	Opt. Mater. Express	JUN 1	2015	5	6					1266	1273		10.1364/OME.5.001266		8	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CJ6TP	WOS:000355627100003		
J	Headland, D; Thurgood, P; Stavrevski, D; Withayachumnankul, W; Abbott, D; Bhaskaran, M; Sriram, S				Headland, Daniel; Thurgood, Peter; Stavrevski, Daniel; Withayachumnankul, Withawat; Abbott, Derek; Bhaskaran, Madhu; Sriram, Sharath			Doped polymer for low-loss dielectric material in the terahertz range	OPTICAL MATERIALS EXPRESS			English	Article							TIME-DOMAIN SPECTROSCOPY; HIGH-REFRACTIVE-INDEX; FREQUENCIES; METAMATERIALS; REFLECTARRAY; ALUMINA	The dielectric properties of an elastomeric polymer are modified with the inclusion of dopants, with the aim of reducing dielectric loss in the terahertz range. Polydimethylsiloxane (PDMS) is selected as the host polymer, and micro/nano-particle powders of either alumina or polytetrafluoroethylene (PTFE) are employed as dopants. Composite samples are prepared, and characterised with terahertz time-domain spectroscopy (THz-TDS). The samples exhibit significantly reduced dielectric loss, with a maximum reduction of 15.3% in loss tangent reported for a sample that is 40% PTFE by mass. Results are found to have reasonable agreement with the Lichtenecker logarithmic mixture formula, and any deviation can be accounted for by agglomeration of dopant micro/nano-particles. The new dielectric composites are promising for devising efficient micro-structure components at terahertz frequencies. (C) 2015 Optical Society of America	[Headland, Daniel; Withayachumnankul, Withawat; Abbott, Derek] Univ Adelaide, Sch Elect & Elect Engn, Adelaide, SA 5005, Australia; [Thurgood, Peter; Stavrevski, Daniel; Withayachumnankul, Withawat; Bhaskaran, Madhu; Sriram, Sharath] RMIT Univ, Funct Mat & Microsyst Res Grp, Melbourne, Vic 3001, Australia; [Withayachumnankul, Withawat] Tokyo Inst Technol, Interdisciplinary Grad Sch Sci & Engn, Meguro Ku, Tokyo 1528552, Japan	Headland, D (reprint author), Univ Adelaide, Sch Elect & Elect Engn, Adelaide, SA 5005, Australia.	daniel.headland@adelaide.edu.au; sharath.sriram@gmail.com	Bhaskaran, Madhu/C-6201-2011; Sriram, Sharath/C-6200-2011	Bhaskaran, Madhu/0000-0003-4319-1081; Sriram, Sharath/0000-0002-8365-7504			Wietzke S, 2007, POLYM TEST, V26, P614, DOI 10.1016/j.polymertesting.2007.03.002; Simpkin R, 2010, IEEE T MICROW THEORY, V58, P545, DOI 10.1109/TMTT.2010.2040406; Tao H, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.241103; Jin YS, 2006, J KOREAN PHYS SOC, V49, P513; Li JN, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4773238; PEELEN JGJ, 1974, J APPL PHYS, V45, P216, DOI 10.1063/1.1662961; Ung BSY, 2013, IEEE T THZ SCI TECHN, V3, P216, DOI 10.1109/TTHZ.2013.2241427; Choi M, 2011, NATURE, V470, P369, DOI 10.1038/nature09776; LOOYENGA H, 1965, PHYSICA, V31, P401, DOI 10.1016/0031-8914(65)90045-5; Jansen C, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3341309; Niu TM, 2014, OPT EXPRESS, V22, P16148, DOI 10.1364/OE.22.016148; Scheller M, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/6/065415; Lotters JC, 1997, J MICROMECH MICROENG, V7, P145, DOI 10.1088/0960-1317/7/3/017; Niu TM, 2013, OPT EXPRESS, V21, P2875, DOI 10.1364/OE.21.002875; Han NR, 2011, OPT EXPRESS, V19, P6990, DOI 10.1364/OE.19.006990; Grady NK, 2013, SCIENCE, V340, P1304, DOI 10.1126/science.1235399; Haskal ZJ, 1997, RADIOLOGY, V205, P682; Ung B, 2011, J OPT SOC AM B, V28, P917, DOI 10.1364/JOSAB.28.000917; Chenoweth K, 2005, J AM CHEM SOC, V127, P7192, DOI 10.1021/ja050980t; Berdel K, 2005, IEEE T MICROW THEORY, V53, P1266, DOI 10.1109/TMTT.2005.845752; Iwaszczuk K, 2012, OPT EXPRESS, V20, P635, DOI 10.1364/OE.20.000635; Cheng YZ, 2014, APPL PHYS LETT, V105, DOI 10.1063/1.4901272; Cunningham P.D., 2011, J APPL PHYS, V109; Garnett JCM, 1904, P R SOC LONDON, V73, P443, DOI 10.1098/rspl.1904.0058; Giles R. H., 1993, P 4 INT S SPAC THZ T, V124; Hernandez-Serrano AI, 2014, APPL OPTICS, V53, P7872, DOI 10.1364/AO.53.007872; Khodasevych IE, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.3665180; Li M, 2010, ACTA MECH SOLIDA SIN, V23, P592; Nelson CT, 2007, PLASMA SOURCES SCI T, V16, P813, DOI 10.1088/0963-0252/16/4/017; Sihvola A, 2001, J ELECTROMAGNET WAVE, V15, P715, DOI 10.1163/156939301X00968; Takami Y, 1997, J BIOMED MATER RES, V36, P381, DOI 10.1002/(SICI)1097-4636(19970905)36:3<381::AID-JBM12>3.0.CO;2-H; Tang Q., 2013, P SPIE TERAHERTZ ULT, V8585; Tanoto H, 2013, INT J THZ SCI TECHNO, V6, P1; Tao H., 2008, ARXIV08080454; Walia S, 2015, APPL PHYS REV, V2, DOI 10.1063/1.4913751; Withayachumnankul W, 2014, J INFRARED MILLIM TE, V35, P610, DOI 10.1007/s10762-013-0042-z; Yahiaoui R, 2014, J OPTICS-UK, V16, DOI 10.1088/2040-8978/16/9/094014	37	0	0	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	2159-3930			OPT MATER EXPRESS	Opt. Mater. Express	JUN 1	2015	5	6					1373	1380		10.1364/OME.5.001373		8	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CJ6TP	WOS:000355627100016		
J	Yamane, T; Terasawa, T				Yamane, Takeshi; Terasawa, Tsuneo			Background level in extreme-UV dark-field image for mask blank inspection	OPTICAL REVIEW			English	Article						Extreme UV; Dark field; Mask; Inspection; Multilayer; Surface roughness; Speckle noise	DEFECTS	The background level (BGL) in an extreme-UV (EUV) dark-field image for EUV mask blank inspection was analyzed. The background refers to the light scattered by the multilayer roughness of the mask blank, and the variation in the BGL is attributed to random and fixed factors. We found that the BGL variation due to the fixed factor could be successfully reproduced by simulation using surface information obtained by atomic force microscope measurement with the assumption of a multilayer roughness structure. This means that the fixed factor contributing to the BGL variation was found to be speckle noise due to the multilayer roughness. Moreover, this reproduction procedure was found to be valuable for estimating the multilayer roughness structure up to several layers below the surface.	[Yamane, Takeshi; Terasawa, Tsuneo] EUVL Infrastruct Dev Ctr Inc EIDEC, Tsukuba, Ibaraki 3058569, Japan	Yamane, T (reprint author), EUVL Infrastruct Dev Ctr Inc EIDEC, Tsukuba, Ibaraki 3058569, Japan.	takeshi.yamane@eidec.co.jp			New Energy and Industrial Technology Development Organization (NEDO); Ministry of Economy, Trade and Industry (METI) of Japan	This work was supported by New Energy and Industrial Technology Development Organization (NEDO) and the Ministry of Economy, Trade and Industry (METI) of Japan. Mask blank observation with the HVM prototype ABI tool was performed by Lasertec Corporation.	Gullikson EM, 2004, P SOC PHOTO-OPT INS, V5374, P791, DOI 10.1117/12.558816; Clifford C. H., 2009, P SOC PHOTO-OPT INS, V7488; Goldberg KA, 2006, J VAC SCI TECHNOL B, V24, P2824, DOI 10.1116/1.2375085; Gullikson EM, 1999, P SOC PHOTO-OPT INS, V3676, P717, DOI 10.1117/12.351162; Tchikoulaeva A, 2013, PROC SPIE, V8679, DOI 10.1117/12.2011776; Terasawa T, 2009, PROC SPIE, V7271, DOI 10.1117/12.813602; Tezuka Y, 2006, JPN J APPL PHYS 1, V45, P5359, DOI 10.1143/JJAP.45.5359; Tomie T., 2005, United States Patent, Patent No. [6,954,266, 6954266]; Tomie T, 2003, P SOC PHOTO-OPT INS, V5038, P41, DOI 10.1117/12.482811; van der Walle P, 2012, PROC SPIE, V8522, DOI 10.1117/12.2006408; Yamane T, 2012, PROC SPIE, V8522, DOI 10.1117/12.964965; Yamane T, 2012, PROC SPIE, V8441, DOI 10.1117/12.978628	12	0	0	OPTICAL SOC JAPAN	TOKYO	KUDAN-KITA BLDG 5F, 1-12-3, KUDAN-KITA CHIYODA-KU, TOKYO, 102, JAPAN	1340-6000	1349-9432		OPT REV	Opt. Rev.	JUN	2015	22	3					402	409		10.1007/s10043-015-0083-8		8	Optics	Optics	CJ6JG	WOS:000355599500003		
J	Fujita, K; Egami, C				Fujita, Kohei; Egami, Chikara			Measurement of inhomogeneous absorptive organic media with polarization interferometric confocal microscope	OPTICAL REVIEW			English	Article						Inhomogeneous organic media; Confocal microscope; Optical anisotropy; Ellipsometry; Birefringence	REFRACTIVE-INDEXES; FILMS; ANISOTROPY	Polarization interferometric confocal microscope has been developed for high-precision measurement, especially for inhomogeneous organic media doped with nonlinear chromophores. The microscope has a novel contrast-enhancing technique: suppressing the background electric field with polarization interferometer. With this technique, the microscope has allowed optical anisotropy detection in a submicron area (400 nm x 400 nm), even with a low-cost and low-power continuous-wave (CW) laser light source. In particular, the microscope clearly distinguishes between isotropic and anisotropic regions. According to polarization interferometric ellipsometry, the microscope produces inspection images showing planer distribution of the optical parameter directly.	[Fujita, Kohei; Egami, Chikara] Shizuoka Univ, Fac Engn, Naka Ku, Hamamatsu, Shizuoka 4328561, Japan	Fujita, K (reprint author), Shizuoka Univ, Fac Engn, Naka Ku, 3-5-1 Johoku, Hamamatsu, Shizuoka 4328561, Japan.	f0330133@ipc.shizuoka.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	This work has been supported in part by a grant in aid for fundamental scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Kuhn JR, 2001, BIOPHYS J, V80, P972; Nielsen MMB, 2013, LANGMUIR, V29, P1525, DOI 10.1021/la3046675; Fang GJ, 2011, LANGMUIR, V27, P10407, DOI 10.1021/la201306a; Fronk M, 2014, J MOL STRUCT, V1073, P82, DOI 10.1016/j.molstruc.2014.05.001; Fujita K., 2014, ADV COND MATTER PHYS, V2014; Hinrichs K, 2013, J PHYS CHEM C, V117, P13557, DOI 10.1021/jp401576r; Kasetty S, 2010, J FORENSIC SCI, V55, P779, DOI 10.1111/j.1556-4029.2010.01363.x; Kedzierski J, 2014, OPTO-ELECTRON REV, V22, P162, DOI 10.2478/s11772-014-0196-9; Nitanai E, 1996, OPT ENG, V35, P900, DOI 10.1117/1.600637; Sehnem AL, 2013, CHEM PHYS LETT, V588, P150, DOI 10.1016/j.cplett.2013.09.073; Shiga Y, 2012, APPL OPTICS, V51, P2847, DOI 10.1364/AO.51.002847	11	0	0	OPTICAL SOC JAPAN	TOKYO	KUDAN-KITA BLDG 5F, 1-12-3, KUDAN-KITA CHIYODA-KU, TOKYO, 102, JAPAN	1340-6000	1349-9432		OPT REV	Opt. Rev.	JUN	2015	22	3					410	414		10.1007/s10043-015-0076-7		5	Optics	Optics	CJ6JG	WOS:000355599500004		
J	Tahara, T; Kaku, T; Arai, Y				Tahara, Tatsuki; Kaku, Toru; Arai, Yasuhiko			Single-shot multiwavelength phase unwrapping using a single reference beam and a monochromatic image sensor	OPTICAL REVIEW			English	Article						Phase unwrapping; Digital holography; Interferometry; Holography	SHIFTING DIGITAL HOLOGRAPHY; INTERFEROMETRY; MICROSCOPY	We propose single-shot multiwavelength phase unwrapping using a single reference beam and a monochromatic image sensor. A single beam containing multiple wavelengths passes through a reference arm and acts as reference waves. Multiple-wavelength information is multiplexed in the space domain on the monochromatic image sensor and is separated in the spatial frequency domain by utilizing the spatial frequency difference of interference fringes at multiple wavelengths. From a single hologram, multiwavelength phase unwrapping is conducted and an unwrapped phase image is obtained. Both transmission and reflective single-shot multiwavelength digital holography systems using a monochromatic image sensor can be constructed with a simple optical setup employing the proposed technique. Single-shot multiwavelength phase unwrapping by the proposed technique is numerically simulated and experimentally demonstrated.	[Tahara, Tatsuki; Kaku, Toru; Arai, Yasuhiko] Kansai Univ, Fac Engn Sci, Suita, Osaka 5648680, Japan	Tahara, T (reprint author), Kansai Univ, Fac Engn Sci, Yamatecho 3-3-35, Suita, Osaka 5648680, Japan.	tahara@kansai-u.ac.jp			Research Foundation for Opt-Science and Technology; Murata Science Foundation; Research Foundation of Tokyo Institute of Technology; Okawa Foundation; Japan Society for the Promotion of Science (JSPS) [25886014]; MEXT	This study was partially supported by The Research Foundation for Opt-Science and Technology, The Murata Science Foundation, The Research Foundation of Tokyo Institute of Technology, The Okawa Foundation, Grant-in-Aid for Research Activity Start-up 25886014 from Japan Society for the Promotion of Science (JSPS), and the MEXT-Supported Program for the Strategic Research Foundation at Private Universities.	Gass J, 2003, OPT LETT, V28, P1141, DOI 10.1364/OL.28.001141; Yamaguchi I, 2002, OPT LETT, V27, P1108, DOI 10.1364/OL.27.001108; Frauel Y, 2006, P IEEE, V94, P636, DOI 10.1109/JPROC.2006.870704; Kuhn J, 2007, OPT EXPRESS, V15, P7231, DOI 10.1364/OE.15.007231; Yamaguchi I, 2001, OPT REV, V8, P85, DOI 10.1007/s10043-001-0085-6; Watanabe E, 2013, OPT LETT, V38, P1319, DOI 10.1364/OL.38.001319; TAKEDA M, 1982, J OPT SOC AM, V72, P156, DOI 10.1364/JOSA.72.000156; LEITH EN, 1962, J OPT SOC AM, V52, P1123, DOI 10.1364/JOSA.52.001123; GOODMAN JW, 1967, APPL PHYS LETT, V11, P77, DOI 10.1063/1.1755043; Takaki Y, 1999, APPL OPTICS, V38, P4990, DOI 10.1364/AO.38.004990; GABOR D, 1948, NATURE, V161, P777, DOI 10.1038/161777a0; Murata S, 2000, OPT LASER TECHNOL, V32, P567, DOI 10.1016/S0030-3992(00)00088-8; Kubota T, 2007, OPT EXPRESS, V15, P14348, DOI 10.1364/OE.15.014348; ITOH K, 1982, APPL OPTICS, V21, P2470, DOI 10.1364/AO.21.002470; Lue N., 2012, APPL PHYS LETT, V101; Wada A, 2008, APPL OPTICS, V47, P2053, DOI 10.1364/AO.47.002053; Yokota M, 2010, OPT REV, V17, P166, DOI 10.1007/s10043-010-0029-0	17	0	0	OPTICAL SOC JAPAN	TOKYO	KUDAN-KITA BLDG 5F, 1-12-3, KUDAN-KITA CHIYODA-KU, TOKYO, 102, JAPAN	1340-6000	1349-9432		OPT REV	Opt. Rev.	JUN	2015	22	3					415	421		10.1007/s10043-015-0072-y		7	Optics	Optics	CJ6JG	WOS:000355599500005		
J	Mochizuki, K; Oosumi, K; Koizumi, F; Shinohara, Y; Tagaya, A; Koike, Y				Mochizuki, Keiichi; Oosumi, Kazumasa; Koizumi, Fumiaki; Shinohara, Yoshinori; Tagaya, Akihiro; Koike, Yasuhiro			Distribution angle control of a light-emitting diode downlight lens with high color uniformity using a scattering polymer	OPTICAL REVIEW			English	Article						LED; Downlight lens; LED lighting; Highly scattered optical transmission polymer; Mie scattering theory; Illuminance distribution; Color uniformity		We have proposed a light-emitting diode (LED) downlight lens that is made of a highly scattered optical transmission (HSOT) polymer. The HSOT polymer contains optimized heterogeneous structures that produce homogeneously scattered light with forward directivity. The full width at half maximum of the illuminance distribution angle can be increased from 16.7 degrees to 37.9 degrees as the concentration of the scattering particles in the HSOT polymer LED downlight lenses of identical shape is increased from 0.015 to 0.100 wt%. The colors in an illuminated area are highly uniform, which is not discernible by the human eye, with a high output efficiency greater than 85 %.	[Mochizuki, Keiichi; Oosumi, Kazumasa; Koizumi, Fumiaki; Shinohara, Yoshinori] Nittho Kogaku KK, Suwa, Nagano 3920021, Japan; [Mochizuki, Keiichi; Tagaya, Akihiro; Koike, Yasuhiro] Keio Univ, Keio Photon Res Inst, Kawasaki, Kanagawa 2120032, Japan	Mochizuki, K (reprint author), Nittho Kogaku KK, Suwa, Nagano 3920021, Japan.	kmochizuki@nittohkogaku.co.jp			Japan Society for the Promotion of Science (JSPS) through its "Funding Program for World-Leading Innovation R&D on Science and Technology (FIRST Program)"	This research is supported by the Japan Society for the Promotion of Science (JSPS) through its "Funding Program for World-Leading Innovation R&D on Science and Technology (FIRST Program)".	Tagaya A, 2002, JPN J APPL PHYS 1, V41, P2241, DOI 10.1143/JJAP.41.2241; [Anonymous], 2011, C81055 JIS; Bredemeier K., 2005, ISAL 2005 S DARMST U, P1030; Japan LED Association, 2011, LED LIGHT HDB, P127	4	1	1	OPTICAL SOC JAPAN	TOKYO	KUDAN-KITA BLDG 5F, 1-12-3, KUDAN-KITA CHIYODA-KU, TOKYO, 102, JAPAN	1340-6000	1349-9432		OPT REV	Opt. Rev.	JUN	2015	22	3					422	426		10.1007/s10043-015-0085-6		5	Optics	Optics	CJ6JG	WOS:000355599500006		
J	Matsuoka, J; Koga, T; Suetake, N; Uchino, E				Matsuoka, Jyohei; Koga, Takanori; Suetake, Noriaki; Uchino, Eiji			Switching non-local median filter	OPTICAL REVIEW			English	Article						Random-valued impulse noise; Noise detector; Switching median filter; Non-local median filter		This paper describes a novel image filtering method for removal of random-valued impulse noise superimposed on grayscale images. Generally, it is well known that switching-type median filters are effective for impulse noise removal. In this paper, we propose a more sophisticated switching-type impulse noise removal method in terms of detail-preserving performance. Specifically, the noise detector of the proposed method finds out noise-corrupted pixels by focusing attention on the difference between the value of a pixel of interest (POI) and the median of its neighboring pixel values, and on the POI's isolation tendency from the surrounding pixels. Furthermore, the removal of the detected noise is performed by the newly proposed median filter based on nonlocal processing, which has superior detail-preservation capability compared to the conventional median filter. The effectiveness and the validity of the proposed method are verified by some experiments using natural grayscale images.	[Matsuoka, Jyohei; Suetake, Noriaki; Uchino, Eiji] Yamaguchi Univ, Yamaguchi 7538512, Japan; [Koga, Takanori] Tokuyama Coll, Natl Inst Technol, Gakuendai, Shunan 7458585, Japan; [Uchino, Eiji] Yamaguchi Univ, Fuzzy Log Syst Inst, Iizuka, Fukuoka 8200067, Japan	Suetake, N (reprint author), Yamaguchi Univ, 1677-1 Yoshida, Yamaguchi 7538512, Japan.	u005wa@yamaguchi-u.ac.jp; koga@tokuyama.ac.jp; suetake@sci.yamaguchi-u.ac.jp; uchino@yamaguchi-u.ac.jp					Wu J, 2014, SIGNAL IMAGE VIDEO P, V8, P349, DOI 10.1007/s11760-012-0297-1; Chaudhury KN, 2012, IEEE SIGNAL PROC LET, V19, P745, DOI 10.1109/LSP.2012.2217329; Takeda H, 2007, IEEE T IMAGE PROCESS, V16, P349, DOI 10.1109/TIP.2006.888330; Tasdizen T, 2009, IEEE T IMAGE PROCESS, V18, P2649, DOI 10.1109/TIP.2009.2028259; Dabov K, 2007, IEEE T IMAGE PROCESS, V16, P2080, DOI 10.1109/TIP.2007.901238; DONOHO DL, 1995, IEEE T INFORM THEORY, V41, P613, DOI 10.1109/18.382009; SUN T, 1994, PATTERN RECOGN LETT, V15, P341, DOI 10.1016/0167-8655(94)90082-5; Azuma D., 2011, IEICE TECH REP SIP, V111, P67; Buades A., 2005, IEEE COMP SOC C COMP, V2, P66; Hashimoto Y., 2000, IEICE T FUND ELECTR, VJ83-A, P361; Heidarzadeh A., 2007, 9 INT S SIGN PROC IT, P1; Jacquin A., 1997, Proceedings DCC '97. Data Compression Conference (Cat. No.97TB100108), DOI 10.1109/DCC.1997.581986; Matsui S., 2009, 9 AS C COMP VIS, P213; Orchard J., 2008, 15 IEEE INT C IM PRO, P1732; RONSE C, 1990, SIGNAL PROCESS, V21, P129, DOI 10.1016/0165-1684(90)90046-2; Sakauchi M., 1984, ITEJ TECHNICAL REPOR, V8, P7; Tomasi C, 1998, SIXTH INTERNATIONAL CONFERENCE ON COMPUTER VISION, P839, DOI 10.1109/ICCV.1998.710815; Tukey JW, 1974, C REC EASCON 74, P673; Wang Z, 2004, IEEE T IMAGE PROCESS, V13, P600, DOI 10.1109/TIP.2003.819861	19	0	0	OPTICAL SOC JAPAN	TOKYO	KUDAN-KITA BLDG 5F, 1-12-3, KUDAN-KITA CHIYODA-KU, TOKYO, 102, JAPAN	1340-6000	1349-9432		OPT REV	Opt. Rev.	JUN	2015	22	3					448	458		10.1007/s10043-015-0081-x		11	Optics	Optics	CJ6JG	WOS:000355599500010		
J	Shinoda, K; Watanabe, A; Hasegawa, M; Kato, S				Shinoda, Kazuma; Watanabe, Aya; Hasegawa, Madoka; Kato, Shigeo			Multispectral information hiding in RGB image using bit-plane-based watermarking and its application	OPTICAL REVIEW			English	Article						Multispectral image; Spectral estimation; Digital watermarking; Image compression; JPEG2000	SPECTRAL REFLECTANCE; SYSTEM	Although it was expected that multispectral images would be implemented in many applications, such as remote sensing and medical imaging, their use has not been widely diffused in these fields. The development of a compact multispectral camera and display will be needed for practical use, but the format compatibility between multispectral and RGB images is also important for reducing the introduction cost and having high usability. We propose a method of embedding the spectral information into an RGB image by watermarking. The RGB image is calculated from the multispectral image, and then, the original multispectral image is estimated from the RGB image using Wiener estimation. The residual data between the original and the estimated multispectral image are compressed and embedded in the lower bit planes of the RGB image. The experimental results show that, as compared with Wiener estimation, the proposed method leads to more than a 10 dB gain in the peak signal-to-noise ratio of the reconstructed multispectral image, while there are almost no significant perceptual differences in the watermarked RGB image.	[Shinoda, Kazuma; Hasegawa, Madoka; Kato, Shigeo] Utsunomiya Univ, Grad Sch Engn, Utsunomiya, Tochigi 3218585, Japan; [Watanabe, Aya] Utsunomiya Univ, Fac Engn, Utsunomiya, Tochigi 3218585, Japan	Shinoda, K (reprint author), Utsunomiya Univ, Grad Sch Engn, 7-1-2 Yoto, Utsunomiya, Tochigi 3218585, Japan.	shinoda@is.utsunomiya-u.ac.jp			JSPS KAKENHI [25870676]	This work was supported by JSPS KAKENHI Grant Number 25870676. We would like to thank Masahiro Yamaguchi at the Tokyo Institute of Technology for providing the test images used in our experiments.	[Anonymous], 2011, JASPER SOFTWARE VERS; [Anonymous], 2002, T801ISOIEC ITUT; [Anonymous], 1999, 6196621 IEC; Haneishi H, 2000, APPL OPTICS, V39, P6621, DOI 10.1364/AO.39.006621; [Anonymous], 1999, 10526CIE ISO; CIE, 1932, COMM INT ECL P; Fukuda Hiroyuki, 2005, Proceedings of the SPIE - The International Society for Optical Engineering, V5667, DOI 10.1117/12.592533; Hill B, 2000, P SOC PHOTO-OPT INS, V3963, P2; Keusen T, 1996, J IMAGING SCI TECHN, V40, P510; Murakami Y, 2013, COLOR RES APPL, V38, P120, DOI 10.1002/col.20729; Shen HL, 2008, APPL OPTICS, V47, P2494, DOI 10.1364/AO.47.002494; Shinoda K, 2011, J ELECTRON IMAGING, V20, DOI 10.1117/1.3574104; Shinoda K., 2015, MULTISPECTR IN PRESS; Stigell P, 2007, Pattern Recognition and Image Analysis, V17, DOI 10.1134/S1054661807020101; Takamura S., 2004, Journal of the Institute of Image Electronics Engineers of Japan, V33; Yamaguchi M, 2008, J IMAGING SCI TECHN, V52, DOI 10.2352/J.ImagingSci.Technol.(2008)52:1(010201); Yu SS, 2006, OPT REV, V13, P346, DOI 10.1007/s10043-006-0346-5	17	0	0	OPTICAL SOC JAPAN	TOKYO	KUDAN-KITA BLDG 5F, 1-12-3, KUDAN-KITA CHIYODA-KU, TOKYO, 102, JAPAN	1340-6000	1349-9432		OPT REV	Opt. Rev.	JUN	2015	22	3					469	476		10.1007/s10043-015-0082-9		8	Optics	Optics	CJ6JG	WOS:000355599500012		
J	Ismail, I; Quang, NT; Matsuura, M; Sharif, GM; Kishi, N				Ismail, Irneza; Quang Nguyen-The; Matsuura, Motoharu; Sharif, Gazi Mohammad; Kishi, Naoto			Wide range operation of an all-optical NRZ-DPSK-to-RZ-DPSK regenerative waveform-wavelength conversion with flexible width-tunability	OPTICAL REVIEW			English	Article						Regenerative waveform-wavelength conversion; Four wave-mixing (FWM); Width-tunability; Differential phase-shift keying (DPSK); Non-return-to-zero (NRZ); Return-to-zero (RZ)	PULSEWIDTH TUNABILITY; SINGLE SOA; FIBER; WDM; TRANSMISSION; COMPRESSION; PERFORMANCE; GENERATION; NETWORKS; SIGNAL	For the first time, we demonstrated a wide range operation of an all-optical non-return-to-zero (NRZ)-differential-phase-shift-keying (DPSK)-to-return-to-zero (RZ)-DPSK waveform-wavelength conversion with flexible picosecond width-tunablity and regenerative functionality. The scheme is based on a Raman amplifier soliton compressor (RASC) and a fiber-based four-wave mixing (FWM) AND-gate. In the first demonstration, we demonstrated waveform-wavelength conversion of a 10-Gb/s DPSK signal without input signal degradation over 54-nm input-output wavelength ranges. The measurement results of the converted RZ-DPSK signal are pedestal-free, and its converted pulse width from 13.0 to 2.87-ps can be adjusted by tuning the Raman pump power between 0.20 and 0.90 W. An investigation of the regenerative waveform-wavelength conversion is further conducted at different Raman pump power settings over 40-km standard single-mode fibers without dispersion compensation. Error-free operation with a low power penalty less than -1.95 dB is obtained for the RZ-DPSK regenerated converted signal.	[Ismail, Irneza; Quang Nguyen-The; Matsuura, Motoharu; Sharif, Gazi Mohammad; Kishi, Naoto] Univ Electrocommun, Dept Commun Engn & Informat, Chofu, Tokyo 1828585, Japan	Ismail, I (reprint author), Univ Electrocommun, Dept Commun Engn & Informat, Chofu, Tokyo 1828585, Japan.	irneza@uec.ac.jp			JSPS KAKENHI [24360148]	This work was partly supported by JSPS KAKENHI Grant Number 24360148.	Agrawal G. P., 1995, NONLINEAR FIBER OPTI, P145; Devgan P, 2006, J LIGHTWAVE TECHNOL, V24, P3677, DOI 10.1109/JLT.2006.882244; Matsumoto M, 2012, IEEE J SEL TOP QUANT, V18, P738, DOI 10.1109/JSTQE.2011.2136331; Norte D, 1996, J LIGHTWAVE TECHNOL, V14, P1170, DOI 10.1109/50.511619; CHERNIKOV SV, 1992, ELECTRON LETT, V28, P1842, DOI 10.1049/el:19921175; Yu Y, 2011, OPT EXPRESS, V19, P14720, DOI 10.1364/OE.19.014720; Wang J, 2009, IEEE J QUANTUM ELECT, V45, P195, DOI 10.1109/JQE.2008.2010798; Tan HN, 2008, OPT EXPRESS, V16, P19063, DOI 10.1364/OE.16.019063; CHERNIKOV SV, 1994, ELECTRON LETT, V30, P433, DOI 10.1049/el:19940262; Xu C, 2003, IEEE PHOTONIC TECH L, V15, P617, DOI 10.1109/LPT.2003.809317; Sambo N, 2012, IEEE COMMUN MAG, V50, P66, DOI 10.1109/MCOM.2012.6194384; Parmigiani F, 2012, IEEE J SEL TOP QUANT, V18, P689, DOI 10.1109/JSTQE.2011.2126040; Argyris A, 2003, ELECTRON LETT, V39, P230, DOI 10.1049/el:20030094; Boerner C, 2003, ELECTRON LETT, V39, P1071, DOI 10.1049/el:20030674; Bogris A, 2003, J LIGHTWAVE TECHNOL, V21, P1892, DOI [10.1109/JLT.2003.814390, 10.1109/JTL.2003.814390]; Contestabile G., 2008, P OPT FIB COMM C NAT, pOMN2; Hu H, 2012, MICROW OPT TECHN LET, V54, P2172, DOI 10.1002/mop.27034; Inoue T, 2006, J LIGHTWAVE TECHNOL, V24, P2510, DOI 10.1109/JLT.2006.874650; Ismail I., 2014, P AS COMM PHOT C ACP; Jiang Z, 2005, IEEE PHOTONIC TECH L, V17, P2733, DOI 10.1109/LPT.2005.858077; Lei GKP, 2011, ELECTRON LETT, V47, P808, DOI 10.1049/el.2011.1132; Lu GW, 2009, ELECTRON LETT, V45, P221, DOI 10.1049/el:20092990; Matsuura M, 2005, OPT EXPRESS, V13, P10010, DOI 10.1364/OPEX.13.010010; Matsuura M, 2009, IEEE PHOTONIC TECH L, V21, P572, DOI 10.1109/LPT.2009.2014968; Nakazawa M., 2010, ULTRAHIGH SPEED OPTI; Nguyen-The Q., 2011, IEICE T ELECTRON, VE94-C, P1160; NORTE D, 1995, IEEE PHOTONIC TECH L, V7, P1354, DOI 10.1109/68.473496; Satobayashi H., 2002, P IEEE LEOS SUMM TOP, pWF3; Sharif GM, 2014, IEICE T ELECTRON, VE97C, P755, DOI 10.1587/transele.E97.C.755; Stern T. E., 2009, MULTIWAVELENGTH OPTI, P230; Weber H. G., 2006, J LIGHTWAVE TECHNOL, V24, P4617; Xu C, 2004, IEEE J SEL TOP QUANT, V10, P281, DOI 10.1109/JSTQE.2004.827835; Yan L., 2012, J LIGHTWAVE TECHNOL, V30, P1760; Yan LS, 2005, J LIGHTWAVE TECHNOL, V23, P1063, DOI 10.1109/JLT.2004.839983; Yu Y., 2008, P C LAS EL QUANT EL; Yu Y., 2010, P C LAS EL QUANT EL	36	0	0	OPTICAL SOC JAPAN	TOKYO	KUDAN-KITA BLDG 5F, 1-12-3, KUDAN-KITA CHIYODA-KU, TOKYO, 102, JAPAN	1340-6000	1349-9432		OPT REV	Opt. Rev.	JUN	2015	22	3					489	495		10.1007/s10043-015-0089-2		7	Optics	Optics	CJ6JG	WOS:000355599500015		
J	Saito, H; Manago, N; Kuriyama, K; Kuze, H				Saito, Hayato; Manago, Naohiro; Kuriyama, Kenji; Kuze, Hiroaki			Near-infrared open-path measurement of CO2 concentration in the urban atmosphere	OPTICS LETTERS			English	Article							DIOXIDE	Average concentration of carbon dioxide (CO2) has been measured over a path length of 5.1 km in the lower troposphere by the method of differential optical absorption spectroscopy (DOAS) using a near-infrared light source based on amplified spontaneous emission. The analysis of CO2 absorption intensity around 1575 nm observed during 10 days over the Chiba city area has revealed that the CO2 concentration varied in the range of around 360-450 ppmv, with presumable influence of air mass advection from nearby industrial facilities. In addition, a good correlation has been found in relative humidity values between the DOAS and meteorological station data. As a whole, the present result indicates the usefulness of such a DOAS approach for measuring the concentration of CO2 averaged over an optical path of a few kilometers in the lower troposphere. (C) 2015 Optical Society of America	[Saito, Hayato; Manago, Naohiro; Kuze, Hiroaki] Chiba Univ, Ctr Environm Remote Sensing CEReS, Inage Ku, Chiba 2638522, Japan; [Kuriyama, Kenji] Shizuoka Univ, Fac Engn, Naka Ku, Hamamatsu, Shizuoka 4328561, Japan	Saito, H (reprint author), Chiba Univ, Ctr Environm Remote Sensing CEReS, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.	haya_saito@chiba-u.jp					Buchwitz M, 2005, ATMOS CHEM PHYS, V5, P941; Sakaizawa D, 2009, APPL OPTICS, V48, P748, DOI 10.1364/AO.48.000748; DANSGAARD W, 1964, TELLUS, V16, P436; JENKINSON DS, 1991, NATURE, V351, P304, DOI 10.1038/351304a0; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431; Rothman LS, 2013, J QUANT SPECTROSC RA, V130, P4, DOI 10.1016/j.jqsrt.2013.07.002; Masarie KA, 2001, J GEOPHYS RES-ATMOS, V106, P20445, DOI 10.1029/2000JD000023; Berglund M, 2011, PURE APPL CHEM, V83, P397, DOI 10.1351/PAC-REP-10-06-02; Yokota T, 2009, SOLA, V5, P160, DOI 10.2151/sola.2009-041; BACASTOW RB, 1985, J GEOPHYS RES-ATMOS, V90, P10529, DOI 10.1029/JD090iD06p10529; Inoue M, 2013, ATMOS CHEM PHYS, V13, P9771, DOI 10.5194/acp-13-9771-2013; Kambe Y, 2012, J ENVIRON MONITOR, V14, P944, DOI 10.1039/c2em10625f; Kern C, 2006, APPL OPTICS, V45, P2077, DOI 10.1364/AO.45.002077; Mahalov A, 2010, LASER PHOTONICS REV, V4, P144, DOI 10.1002/lpor.200910002; Matsueda H., 2008, PAP METEOROL GEOPHYS, V59, P1, DOI DOI 10.2467/MRIPAPERS.59.1; Platt U, 2008, PHYS EARTH SPACE ENV, P1, DOI 10.1007/978-3-540-75776-4_1; Saito H., 2014, OPEN J AIR POLLUT, V3, P20; Satho M., 2008, J COMPUT PHYS, V227, P3486; Somekawa T, 2011, OPT LETT, V36, P4782, DOI 10.1364/OL.36.004782	19	0	0	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	0146-9592	1539-4794		OPT LETT	Opt. Lett.	JUN 1	2015	40	11					2568	2571		10.1364/OL.40.002568		4	Optics	Optics	CJ6UP	WOS:000355630200033		
J	Nakamura, T; Sonoda, S; Yamamoto, T; Adachi, S				Nakamura, Toshihiro; Sonoda, Shohei; Yamamoto, Taisei; Adachi, Sadao			Discrete-mode ZnO microparticle random laser	OPTICS LETTERS			English	Article							RANDOM-MEDIA; LIGHT	A random laser incorporating irregular-shaped ZnO microparticles exhibits a small number of lasing lines with stable lasing intensities and negligibly low background emission. This unique feature is in direct contrast to that observed for a conventional ZnO nanoparticle film random laser. Gain competition between the discrete laser modes also occurs in this microparticle random laser. These lasing characteristics are because of the intra-particle confinement of the laser cavity modes in each ZnO microparticle. (C) 2015 Optical Society of America	[Nakamura, Toshihiro; Sonoda, Shohei; Adachi, Sadao] Gunma Univ, Grad Sch Sci & Technol, Kiryu, Gunma 3768515, Japan; [Yamamoto, Taisei] HakusuiTech Co Ltd, Osaka 5310072, Japan	Nakamura, T (reprint author), Gunma Univ, Grad Sch Sci & Technol, Kiryu, Gunma 3768515, Japan.	nakamura@el.gunma-u.ac.jp	Nakamura, Toshihiro/A-5517-2012				Cao H, 2003, PHYS REV B, V67, DOI [10.1103/PhysRevB.67.161101, 10.1103/PhysRevB.161101]; Nakamura T, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.205103; Noginov MA, 2004, LASER PHYS LETT, V1, P291, DOI 10.1002/lapl.200410068; Nakamura T, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.125324; El-Dardiry RGS, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.043830; Cao H, 1999, PHYS REV LETT, V82, P2278, DOI 10.1103/PhysRevLett.82.2278; Wiersma DS, 2008, NAT PHYS, V4, P359, DOI 10.1038/nphys971; Fujiwara H, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4792349; Takahashi T, 2009, OPT LETT, V34, P3923, DOI 10.1364/OL.34.003923; Klingshirn C, 2007, PHYS STATUS SOLIDI B, V244, P3027, DOI 10.1002/pssb.200743072; Chu S, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3012579; Cao H, 2003, WAVE RANDOM MEDIA, V13, pR1, DOI 10.1088/0959-7174/13/3/201; Cao H, 2000, PHYS REV LETT, V84, P5584, DOI 10.1103/PhysRevLett.84.5584; Li YP, 2013, J APPL PHYS, V113, DOI 10.1063/1.4808445; Noginov M A, 2005, SOLID STATE RANDOM L	15	1	1	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	0146-9592	1539-4794		OPT LETT	Opt. Lett.	JUN 1	2015	40	11					2661	2664		10.1364/OL.40.002661		4	Optics	Optics	CJ6UP	WOS:000355630200057		
J	Ikehara, K				Ikehara, Kenji			Introduction for the Proceedings of Origins 2014	ORIGINS OF LIFE AND EVOLUTION OF BIOSPHERES			English	Editorial Material						Origins 2014; Origin of life; Evolution of life			Open Univ Japan, Chiba, Japan	Ikehara, K (reprint author), Open Univ Japan, Chiba, Japan.	ikehara@cc.nara-wu.ac.jp						0	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0169-6149	1573-0875		ORIGINS LIFE EVOL B	Orig. Life Evol. Biosph.	JUN	2015	45	1-2			SI		3	4		10.1007/s11084-015-9433-6		2	Biology	Life Sciences & Biomedicine - Other Topics	CJ9KC	WOS:000355820100001		
J	Kojo, S				Kojo, Shosuke			S-Isovaline Contained in Meteorites, Induces Enantiomeric Excess in D,L-glutamic Acid During Recrystallization	ORIGINS OF LIFE AND EVOLUTION OF BIOSPHERES			English	Article; Proceedings Paper	Conference on Origins of Life and Evolution of Biospheres (OLEB)	JUL 06-11, 2014	Nara, JAPAN			Asparagine; Enantiomeric excess; Glutamic acid; Isovaline; Homochirality; Meteorite	AMINO-ACIDS; D,L-AMINO ACIDS; ORIGIN; CRYSTALLIZATION; D,L-ASPARAGINE; AMPLIFICATION; BIOSPHERE	S-Isovaline (S-Iva: 6.7 mmol) and D,L-glutamic acid (Glu: 2 mmol) were dissolved in 10 ml of hot water, and the resulting solution was divided in 5 vessels. After recrystallization, the crystals were collected from each vessel, and the enantiomeric excess (ee) of Glu was determined with chemical derivatization using 1-fluoro-2,4-dinitrophenyl- 5-L-leucinamide followed by high-performance liquid chromatography. Ten crystallizations provided all D-rich Glu with ee values of 2.69 % +/- 0.81 % (mean +/- standard deviation), and those using R-Iva provided all L-rich Glu with ee values of 6.24 % +/- 2.20 %. Five recrystallizations of D,L-Glu alone provided ee values of 0.474 % +/- 0.33 %. The differences among these three ee values were statistically significant, showing that S-Iva, which was present in meteorites caused a significant induction of ee in this physiological amino acid. This is the first outcome that S-Iva induced ee changes in a physiological amino acid. S-Iva did not induce any ee changes in D,L-asparagine, leucine, valine, methionine, phenylalanine, tryptophan, glutamine, tyrosine, aspartic acid, or histidine under similar recrystallizations.	Open Univ Japan, Wakaba Ku, Mihama Ku, Chiba 2618586, Japan	Kojo, S (reprint author), Open Univ Japan, Wakaba Ku, Mihama Ku, Chiba 2618586, Japan.	kojo@ouj.ac.jp					Glavin DP, 2009, P NATL ACAD SCI USA, V106, P5487, DOI 10.1073/pnas.0811618106; Pizzarello S, 2006, ACCOUNTS CHEM RES, V39, P231, DOI 10.1021/ar050049f; Burton AS, 2013, METEORIT PLANET SCI, V48, P390, DOI 10.1111/maps.12063; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; Fujii K, 1997, ANAL CHEM, V69, P5146, DOI 10.1021/ac970289b; Glavin DP, 2012, METEORIT PLANET SCI, V47, P1347, DOI 10.1111/j.1945-5100.2012.01400.x; SOAI K, 1995, NATURE, V378, P767, DOI 10.1038/378767a0; Pizzarello S, 2003, GEOCHIM COSMOCHIM AC, V67, P1589, DOI 10.1016/S0016-7037(00)01283-8; Breslow R, 2006, P NATL ACAD SCI USA, V103, P12979, DOI 10.1073/pnas.0605863103; Avalos M, 2004, ORIGINS LIFE EVOL B, V34, P391, DOI 10.1023/B:ORIG.0000029886.32034.f3; Kojo S, 2001, CHEM COMMUN, P1980, DOI 10.1039/b105663h; Kojo S, 2004, CHEM COMMUN, P2146, DOI 10.1039/b409941a; Kojo S, 2010, SYMMETRY-BASEL, V2, P1022, DOI 10.3390/sym2021022	13	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0169-6149	1573-0875		ORIGINS LIFE EVOL B	Orig. Life Evol. Biosph.	JUN	2015	45	1-2			SI		85	91		10.1007/s11084-015-9407-8		7	Biology	Life Sciences & Biomedicine - Other Topics	CJ9KC	WOS:000355820100010		
J	Munegumi, T				Munegumi, Toratane			Aldolase as a Chirality Intersection of L-Amino Acids and D-Sugars	ORIGINS OF LIFE AND EVOLUTION OF BIOSPHERES			English	Article; Proceedings Paper	Conference on Origins of Life and Evolution of Biospheres (OLEB)	JUL 06-11, 2014	Nara, JAPAN			Aldolase; Metabolism; L-amino acid; D-sugar; Chirality	FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE; AMINOACYLATION	Aldolase plays an important role in glycolysis and gluconeogenesis to produce D-fructose-1,6-bisphosphate (D-FBP) from dihydroxyacetone phosphate (DHP) and D-glyceraldehyde-3-phosphate (D-GAP). This reaction is stereoselective and retains the D-GAP 2R configuration and yields D-FBP (with the configuration: 3S, 4S, 5R). The 3- and 4-position carbons are the newly formed chiral carbons because the 5-position carbon of D-FBP comes from the 2-position of D-GAP. Although four diastereomeric products, (3S, 4R, 5R), (3R, 4R, 5R), (3R, 4S, 5R), (3S, 4S, 5R), are expected in the nonenzymatic reaction, only the (3S, 4S, 5R) diastereomer (D-FBP) is obtained. Therefore, the chirality in the 3- and 4-positions is induced by the chirality of the enzyme composed of L-amino acid residues. D-Glucose-6-phosphate (D-G6P), which is generated from D-FBP in the gluconeogenesis pathway, produces D-ribose-5-phosphate (D-R5P) in the pentose phosphate pathway. D-R5P is converted to PRPP (5-phosphoribosyl-alpha-pyrophosphate), which is used for the de novo synthesis of nucleotides. Ribonucleic acid (RNA) uses the nucleotides as building blocks. The configurations of the 4R-carbon and of the 3S-carbon are retained. The stereochemical structure of RNA is based on 3S as well as 4R (D). The consideration above suggests that aldolase is a key enzyme that determines the 3S configuration in D-R5P. It is thus a chirality intersection between amino acids and sugars, because the sugar chirality is determined by the chiral environment of an L-amino acid protein, aldolase, to produce D-FBP.	Naruto Univ Educ, Naruto, Tokushima 7728502, Japan	Munegumi, T (reprint author), Naruto Univ Educ, Naruto, Tokushima 7728502, Japan.	tmunegumi@naruto-u.ac.jp					Lorentzen E, 2004, BIOCHEM SOC T, V32, P259, DOI 10.1042/BST0320259; Stewart JJP, 2007, J MOL MODEL, V13, P1173, DOI 10.1007/s00894-007-0233-4; Tamura K, 2004, SCIENCE, V305, P1253, DOI 10.1126/science.1099141; Say RF, 2010, NATURE, V464, P1077, DOI 10.1038/nature08884; Siebers B, 2001, J BIOL CHEM, V276, P28710, DOI 10.1074/jbc.M103447200; Andreeva A, 2008, NUCLEIC ACIDS RES, V36, pD419, DOI 10.1093/nar/gkm993; Dalby A, 1999, PROTEIN SCI, V8, P291; Pizzarello S, 2004, SCIENCE, V303, P1151, DOI 10.1126/science.1093057; Avalos M, 1998, CHEM REV, V98, P2381; Breslow R, 2010, ORIGINS LIFE EVOL B, V40, P11, DOI 10.1007/s11084-009-9179-0; Imanaka H, 2002, J BIOSCI BIOENG, V94, P237, DOI 10.1263/jbb.94.237; Munegumi T, 2003, CHIRALITY, V15, pS108, DOI 10.1002/chir.10256; Palyi G, 2004, PROGR BIOL CHIRALITY, P429; Pavlov VA, 2014, CURR ORG CHEM, V18, P93, DOI 10.2174/13852728113179990033; PROFY AT, 1984, J MOL EVOL, V20, P147, DOI 10.1007/BF02257375; Ronimus Ron S., 2003, Archaea, V1, P199, DOI 10.1155/2003/162593; Smith MB, 2007, MARCHS ADV ORGANIC C, P194; Voet D., 2011, BIOCHEMISTRY; WEBER AL, 1987, J MOL EVOL, V25, P7, DOI 10.1007/BF02100034	19	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0169-6149	1573-0875		ORIGINS LIFE EVOL B	Orig. Life Evol. Biosph.	JUN	2015	45	1-2			SI		173	182		10.1007/s11084-015-9415-8		10	Biology	Life Sciences & Biomedicine - Other Topics	CJ9KC	WOS:000355820100018		
J	Oda, A; Fukuyoshi, S				Oda, Akifumi; Fukuyoshi, Shuichi			Predicting Three-Dimensional Conformations of Peptides Constructed of Only Glycine, Alanine, Aspartic Acid, and Valine	ORIGINS OF LIFE AND EVOLUTION OF BIOSPHERES			English	Article; Proceedings Paper	Conference on Origins of Life and Evolution of Biospheres (OLEB)	JUL 06-11, 2014	Nara, JAPAN			GADV hypothesis; Protein structure prediction; Secondary structure formation; Replica-exchange molecular dynamics simulation	MOLECULAR-DYNAMICS; PROTEIN-STRUCTURE; GENETIC-CODE; AMINO-ACIDS; HYPOTHESIS; LIFE; ATMOSPHERES; IRRADIATION; EVOLUTION; ORIGIN	The GADV hypothesis is a form of the protein world hypothesis, which suggests that life originated from proteins (Lacey et al. 1999; Ikehara 2002; Andras 2006). In the GADV hypothesis, life is thought to have originated from primitive proteins constructed of only glycine, alanine, aspartic acid, and valine ([GADV]-proteins). In this study, the three-dimensional (3D) conformations of randomly generated short [GADV]-peptides were computationally investigated using replica-exchange molecular dynamics (REMD) simulations (Sugita and Okamoto 1999). Because the peptides used in this study consisted of only 20 residues each, they could not form certain 3D structures. However, the conformational tendencies of the peptides were elucidated by analyzing the conformational ensembles generated by REMD simulations. The results indicate that secondary structures can be formed in several randomly generated [GADV]-peptides. A long helical structure was found in one of the hydrophobic peptides, supporting the conjecture of the GADV hypothesis that many peptides aggregated to form peptide multimers with enzymatic activity in the primordial soup. In addition, these results indicate that REMD simulations can be used for the structural investigation of short peptides.	[Oda, Akifumi; Fukuyoshi, Shuichi] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Kanazawa, Ishikawa 9201192, Japan; [Oda, Akifumi] Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Oda, A (reprint author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	oda@p.kanazawa-u.ac.jp	Fukuyoshi, Shuichi/D-8388-2015				Ajay, 1995, J MED CHEM, V38, P4953; Andras P, 2006, VIVA ORIGINO, V34, P40; Ferris JP, 1996, NATURE, V381, P59, DOI 10.1038/381059a0; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Ikehara K, 2002, J MOL EVOL, V54, P530, DOI 10.1007/s00239-001-0053-6; Imai E, 1999, SCIENCE, V283, P831, DOI 10.1126/science.283.5403.831; Yamaotsu N, 2008, BIOL PHARM BULL, V31, P1552, DOI 10.1248/bpb.31.1552; CRICK FHC, 1957, P NATL ACAD SCI USA, V43, P416, DOI 10.1073/pnas.43.5.416; Oda A, 2009, J COMPUT CHEM, V30, P2728, DOI 10.1002/jcc.21299; Palm K, 1997, PHARMACEUT RES, V14, P568, DOI 10.1023/A:1012188625088; Vekey K, 1996, RAPID COMMUN MASS SP, V10, P911, DOI 10.1002/(SICI)1097-0231(19960610)10:8<911::AID-RCM593>3.0.CO;2-7; Ikehara K, 2005, CHEM REC, V5, P107, DOI 10.1002/tcr.20037; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; Xu D, 2012, PROTEINS, V80, P1715, DOI 10.1002/prot.24065; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; Kobayashi K, 1998, ORIGINS LIFE EVOL B, V28, P155, DOI 10.1023/A:1006561217063; Nguyen H, 2013, J CHEM THEORY COMPUT, V9, P2020, DOI 10.1021/ct3010485; Sugita Y, 1999, CHEM PHYS LETT, V314, P141, DOI 10.1016/S0009-2614(99)01123-9; Lonnberg H, 2011, ORG BIOMOL CHEM, V9, P1687, DOI 10.1039/c0ob00486c; Case D., 2012, AMBER 12; Case DA, 2005, RE AMBER VALUE SALTC; Dyson F., 1985, ORIGIN OF LIFE; Futamura Y, 2005, VIVA ORIGINO, V33, P269; Huang C, 2002, DMS; Ikebe J, 2007, PROTEIN SCI, V16, P1596, DOI 10.1110/ps.062721907; Ikehara K, 2009, INT J MOL SCI, V10, P1525, DOI 10.3390/ijms10041525; Ikehara K, 2002, J BIOSCIENCES, V27, P165, DOI 10.1007/BF02703773; Jin L, 2000, J BIOL CHEM, V275, P27238; Jordan IK, 2005, NATURE, V433, P633, DOI 10.1038/nature03306; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kobayashi K, 2010, ASTROBIOLOGY EMERGEN, P175; Kobayashi K, 1999, ADV SPACE RES, V24, P461, DOI 10.1016/S0273-1177(99)00088-5; Lacey JC, 1999, CHEMTRACTS BIOCH MOL, V12, P398; Mongan J, 2007, J CHEM THEORY COMPUT, V3, P156, DOI 10.1021/ct600085e; Oba T, 2005, ORIGINS LIFE EVOL B, V35, P447, DOI 10.1007/s11084-005-3519-5; Oda A, 2013, J COMPUT AIDED CHEM, V14, P23, DOI [10.2751/jcac.14.23, DOI 10.2751/JCAC.14.23]; Oda A, 2011, J CHROMATOGR B, V879, P3337, DOI 10.1016/j.jchromb.2011.08.011; Oshima T, 2011, VIVA ORIGINO, V39, P45; SCHLESINGER G, 1983, J MOL EVOL, V19, P376, DOI 10.1007/BF02101642; Takahashi J, 1999, APPL PHYS LETT, V74, P877, DOI 10.1063/1.123396; van der Gulik P, 2009, J THEOR BIOL, V261, P531, DOI 10.1016/j.jtbi.2009.09.004; ZUCKERKA.E, 1971, J MOL BIOL, V59, P473, DOI 10.1016/0022-2836(71)90311-1	42	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0169-6149	1573-0875		ORIGINS LIFE EVOL B	Orig. Life Evol. Biosph.	JUN	2015	45	1-2			SI		183	193		10.1007/s11084-015-9418-5		11	Biology	Life Sciences & Biomedicine - Other Topics	CJ9KC	WOS:000355820100019		
J	Okochi, K; Mieno, T; Kondo, K; Hasegawa, S; Kurosawa, K				Okochi, Kazuki; Mieno, Tetsu; Kondo, Kazuhiko; Hasegawa, Sunao; Kurosawa, Kosuke			Possibility of Production of Amino Acids by Impact Reaction Using a Light-Gas Gun as a Simulation of Asteroid Impacts	ORIGINS OF LIFE AND EVOLUTION OF BIOSPHERES			English	Article; Proceedings Paper	Conference on Origins of Life and Evolution of Biospheres (OLEB)	JUL 06-11, 2014	Nara, JAPAN			Titan; Impact reaction; Amino acid; HPLC; FTIR; LD-ToF-MS	MURCHISON METEORITE; ATMOSPHERE; CARBON	In order to investigate impact production of carbonaceous products by asteroids on Titan and other satellites and planets, simulation experiments were carried out using a 2-stage light gas gun. A small polycarbonate or metal bullet with about 6.5 km/s was injected into a pressurized target chamber filled with 1 atm of nitrogen gas, to collide with a ice + iron target or an iron target or a ice + hexane + iron target. After the impact, black soot including fine particles was deposited on the chamber wall. The soot was carefully collected and analyzed by High Performance Liquid Chromatography (HPLC), Fourier Transform Infrared Spectroscopy (FT-IR), and Laser Desorption Time-of-Flight Mass Spectrometry (LD-ToF-MS). As a result of the HPLC analysis, about 0.04-8 pmol of glycine, and a lesser amount of alanine were found in the samples when the ice + hexane + iron target was used. In case of the ice + iron target and the iron target, less amino acids were produced. The identification of the amino acids was also supported by FTIR and LD-ToF-MS analysis.	[Okochi, Kazuki; Mieno, Tetsu; Kondo, Kazuhiko] Shizuoka Univ, Dept Phys, Suruga Ku, Shizuoka 4228529, Japan; [Mieno, Tetsu] Shizuoka Univ, Grad Sch Sci & Technol, Suruga Ku, Shizuoka 4228529, Japan; [Hasegawa, Sunao] Japan Aerosp Explorat Agcy, Inst Space & Astronaut Sci, Chuo Ku, Sagamihara, Kanagawa 2525210, Japan; [Kurosawa, Kosuke] Chiba Inst Technol, Planetary Explorat Res Ctr, Narashino, Chiba 2750016, Japan	Okochi, K (reprint author), Shizuoka Univ, Dept Phys, Suruga Ku, 836 Oya, Shizuoka 4228529, Japan.	sptmien@ipc.shizuoka.ac.jp	Kurosawa, Kosuke/N-2291-2015	Kurosawa, Kosuke/0000-0003-4965-4585			Akabori S, 1955, KAGAKU, V25, P54; KUNDE VG, 1981, NATURE, V292, P686, DOI 10.1038/292686a0; Atreya SK, 2009, TITAN FROM CASSINI-HUYGENS, P177, DOI 10.1007/978-1-4020-9215-2_7; HANEL R, 1981, SCIENCE, V212, P192, DOI 10.1126/science.212.4491.192; Kurosawa K, 2013, ORIGINS LIFE EVOL B, V43, P221, DOI 10.1007/s11084-013-9339-0; ZHAO MX, 1989, NATURE, V339, P463, DOI 10.1038/339463a0; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; Furukawa Y, 2009, NAT GEOSCI, V2, P62, DOI 10.1038/NGEO383; Engel MH, 1997, NATURE, V389, P265, DOI 10.1038/38460; Beghin C, 2009, PLANET SPACE SCI, V57, P1872, DOI 10.1016/j.pss.2009.04.006; CHANG JY, 1981, BIOCHEM J, V199, P547; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; CRONIN JR, 1985, GEOCHIM COSMOCHIM AC, V49, P2259, DOI 10.1016/0016-7037(85)90226-1; Irvine WM, 1989, ORIGIN EVOLUTION PLA, P3; Israel G, 2005, NATURE, V438, P796, DOI 10.1038/nature04349; KASTING JF, 1990, ORIGINS LIFE EVOL B, V20, P199, DOI 10.1007/BF01808105; KVENVOLD.K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; McKay CP, 1997, SCIENCE, V276, P390, DOI 10.1126/science.276.5311.390; Mieno T, 2008, APPL PHYS EXPRESS, V1; Poch O, 2012, PLANET SPACE SCI, V61, P114, DOI 10.1016/j.pss.2011.04.009; Sato Y, 2010, BUNSEKI KAGAKU, V59, P823, DOI 10.2116/bunsekikagaku.59.823; SCHLESINGER G, 1983, J MOL EVOL, V19, P376, DOI 10.1007/BF02101642; Shibasaki M, 2008, ORG REACTIONS, V70, P1; Strecker A, 1850, LIEBIGS ANN CHEM, V75, P27; Taniuchi T, 2013, ANAL SCI, V29, P777	25	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0169-6149	1573-0875		ORIGINS LIFE EVOL B	Orig. Life Evol. Biosph.	JUN	2015	45	1-2			SI		195	205		10.1007/s11084-015-9419-4		11	Biology	Life Sciences & Biomedicine - Other Topics	CJ9KC	WOS:000355820100020		
J	Tabata, M; Yano, H; Kawai, H; Imai, E; Kawaguchi, Y; Hashimoto, H; Yamagishi, A				Tabata, Makoto; Yano, Hajime; Kawai, Hideyuki; Imai, Eiichi; Kawaguchi, Yuko; Hashimoto, Hirofumi; Yamagishi, Akihiko			Silica Aerogel for Capturing Intact Interplanetary Dust Particles for the Tanpopo Experiment	ORIGINS OF LIFE AND EVOLUTION OF BIOSPHERES			English	Article; Proceedings Paper	Conference on Origins of Life and Evolution of Biospheres (OLEB)	JUL 06-11, 2014	Nara, JAPAN			Silica aerogel; Cosmic dust; International Space Station; Astrobiology; Tanpopo		In this paper, we report the progress in developing a silica-aerogel-based cosmic dust capture panel for use in the Tanpopo experiment on the International Space Station (ISS). Previous studies revealed that ultralow-density silica aerogel tiles, comprising two layers with densities of 0.01 and 0.03 g/cm(3) developed using our production technique, were suitable for achieving the scientific objectives of the astrobiological mission. A special density configuration (i.e., box framing) aerogel with a holder was designed to construct the capture panels. Qualification tests for an engineering model of the capture panel as an instrument aboard the ISS were successful. Sixty box-framing aerogel tiles were manufactured in a contamination-controlled environment.	[Tabata, Makoto; Kawai, Hideyuki] Chiba Univ, Dept Phys, Chiba 2638522, Japan; [Tabata, Makoto; Yano, Hajime; Kawaguchi, Yuko; Hashimoto, Hirofumi] Japan Aerosp Explorat Agcy JAXA, Inst Space & Astronaut Sci ISAS, Sagamihara, Kanagawa 2525210, Japan; [Imai, Eiichi] Nagaoka Univ Technol, Dept Bioengn, Nagaoka, Niigata 9402188, Japan; [Yamagishi, Akihiko] Tokyo Univ Pharm & Life Sci, Dept Appl Life Sci, Hachioji, Tokyo 1920392, Japan	Tabata, M (reprint author), Chiba Univ, Dept Phys, Chiba 2638522, Japan.	makoto@hepburn.s.chiba-u.ac.jp		Tabata, Makoto/0000-0001-6138-1028			ADACHI I, 1995, NUCL INSTRUM METH A, V355, P390, DOI 10.1016/0168-9002(94)01119-2; Brownlee D, 2006, SCIENCE, V314, P1711, DOI 10.1126/science.1135840; TSOU P, 1995, J NON-CRYST SOLIDS, V186, P415, DOI 10.1016/0022-3093(95)00065-8; YOKOGAWA H, 1995, J NON-CRYST SOLIDS, V186, P23, DOI 10.1016/0022-3093(95)00086-0; Tabata M, 2010, NUCL INSTRUM METH A, V623, P339, DOI 10.1016/j.nima.2010.02.241; Burchell MJ, 2006, ANNU REV EARTH PL SC, V34, P385, DOI 10.1146/annurev.earth.34.031405.124939; Kawaguchi Y, 2014, ORIGINS LIFE EVOL B, V44, P43, DOI 10.1007/s11084-014-9361-x; Noguchi T, 2011, EARTH PLANET SC LETT, V309, P198, DOI 10.1016/j.epsl.2011.06.032; Ogata Y, 2013, 2013R51P ISTS; Sumiyoshi T, 1998, J NON-CRYST SOLIDS, V225, P369, DOI 10.1016/S0022-3093(98)00057-X; Tabata M., 2011, BIOL SCI SPACE, V25, P7; Tabata M, 2005, IEEE NUCL SCI CONF R, P816; Tabata M, 2012, NUCL INSTRUM METH A, V668, P64, DOI 10.1016/j.nima.2011.12.017; Tabata M, 2014, T JSASS AEROSPACE TE; Yamagishi A, 2009, T JAPAN SOC AERONAUT; Yamagishi A, 2007, BIOL SCI SPACE, V21, P67, DOI 10.2187/bss.21.67	16	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0169-6149	1573-0875		ORIGINS LIFE EVOL B	Orig. Life Evol. Biosph.	JUN	2015	45	1-2			SI		225	229		10.1007/s11084-015-9423-8		5	Biology	Life Sciences & Biomedicine - Other Topics	CJ9KC	WOS:000355820100023		
J	Hasegawa, T; Tanakura, M; Takeda, D; Sakakibara, A; Akashi, M; Minamikawa, T; Komori, T				Hasegawa, Takumi; Tanakura, Makiko; Takeda, Daisuke; Sakakibara, Akiko; Akashi, Masaya; Minamikawa, Tsutomu; Komori, Takahide			Risk Factors Associated with Distant Metastasis in Patients with Oral Squamous Cell Carcinoma	OTOLARYNGOLOGY-HEAD AND NECK SURGERY			English	Article						distant metastasis; oral squamous cell carcinoma; risk factor; oral cancer	LOCALLY ADVANCED HEAD; NECK-CANCER PATIENTS; CISPLATIN PLUS FLUOROURACIL; COOPERATIVE-ONCOLOGY-GROUP; PULMONARY METASTASES; PREDICTIVE FACTORS; PROGNOSTIC-FACTORS; HISTOLOGIC GRADE; RANDOMIZED-TRIAL; PHASE-II	Objective The purpose of this study was to retrospectively evaluate the incidence of distant metastasis (DM) after curative surgical treatment and assess the multivariate relationships among various risk factors for DM in patients with oral squamous cell carcinoma (OSCC). Study Design Case series with chart review. Setting Tertiary referral center. Subjects and Methods The medical records of all patients with OSCC without DM who underwent curative surgery with or without postoperative adjuvant chemoradiation between January 2001 and February 2014 at our institution were retrospectively reviewed. There were a total of 451 patients, including 271 men and 180 women, with a mean age of 65.9 13.5 years. Results Of these patients, 30 (6.7%) developed DM. During the follow-up period, the 5-year overall survival rate was 76.2%. Sites of DM comprised the lungs (80.0%), skin (13.3%), liver (10.0%), bone (6.7%), and brain (3.3%). We found the T classification and N classification as well as the histologic grade to be significant risk factors associated with the development of DM in the univariate analysis only (P = .003), whereas locoregional failure (odds ratio [OR], 4.03), multiple lymph node metastases (more than 4 positive nodes; OR, 3.32) and positive extracapsular spread (OR, 3.06) were identified to be significant risk factors associated with the development of DM in the multivariate analysis. Conclusion We demonstrated multivariate relationships among various risk factors for DM in OSCC patients. Clinicians should consider these risk factors and pay special attention to detecting DM early during the postoperative management of OSCC patients with these risk factors.	[Hasegawa, Takumi; Tanakura, Makiko; Takeda, Daisuke; Sakakibara, Akiko; Akashi, Masaya; Minamikawa, Tsutomu; Komori, Takahide] Kobe Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Kobe, Hyogo 6500017, Japan	Hasegawa, T (reprint author), Kobe Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	hasetaku@med.kobe-u.ac.jp					Garavello W, 2006, ARCH OTOLARYNGOL, V132, P762, DOI 10.1001/archotol.132.7.762; Myers JN, 2001, CANCER, V92, P3030, DOI 10.1002/1097-0142(20011215)92:12<3030::AID-CNCR10148>3.0.CO;2-P; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; Leon X, 2000, HEAD NECK-J SCI SPEC, V22, P680, DOI 10.1002/1097-0347(200010)22:7<680::AID-HED7>3.0.CO;2-J; CALHOUN KH, 1994, LARYNGOSCOPE, V104, P1199; Ferlito A, 2001, ORL J OTO-RHINO-LARY, V63, P202, DOI 10.1159/000055740; Forastiere AA, 2001, J CLIN ONCOL, V19, P1088; LARAMORE GE, 1992, INT J RADIAT ONCOL, V23, P705; Liao CT, 2008, ANN SURG ONCOL, V15, P915, DOI 10.1245/s10434-007-9761-5; Baselga J, 2005, J CLIN ONCOL, V23, P5568, DOI 10.1200/JCO.2005.07.119; Bachaud JM, 1996, INT J RADIAT ONCOL, V36, P999, DOI 10.1016/S0360-3016(96)00430-0; Li X, 2009, EJSO-EUR J SURG ONC, V35, P1348, DOI 10.1016/j.ejso.2009.06.010; Gibson MK, 2005, J CLIN ONCOL, V23, P3562, DOI 10.1200/JCO.2005.01.057; Chen TC, 2013, ORAL ONCOL, V49, P367, DOI 10.1016/j.oraloncology.2012.10.006; STELL PM, 1990, BRIT J CANCER, V61, P311; Jerjes W, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-9; FORASTIERE AA, 1992, J CLIN ONCOL, V10, P1245; Rose BS, 2011, J CLIN ONCOL, V29, P3503, DOI 10.1200/JCO.2011.35.7301; Fortin A, 2001, J CLIN ONCOL, V19, P4107; O-charoenrat P, 2003, ORAL ONCOL, V39, P386, DOI 10.1016/S1368-8375(02)00142-2; JACOBS C, 1992, J CLIN ONCOL, V10, P257; Kademani D, 2005, J ORAL MAXIL SURG, V63, P1599, DOI 10.1016/j.joms.2005.07.011; Shingaki S, 1996, J ORAL MAXIL SURG, V54, P853, DOI 10.1016/S0278-2391(96)90535-2; Bernier J, 2005, HEAD NECK-J SCI SPEC, V27, P843, DOI 10.1002/hed.20279; FINLEY RK, 1992, AM J SURG, V164, P594, DOI 10.1016/S0002-9610(05)80714-7; HONG WK, 1985, CANCER, V56, P1242, DOI 10.1002/1097-0142(19850915)56:6<1242::AID-CNCR2820560603>3.0.CO;2-Z; Huang CG, 2014, J CLIN VIROL, V61, P230, DOI 10.1016/j.jcv.2014.07.007; Kowalski LP, 2005, ORAL ONCOL, V41, P534, DOI 10.1016/j.oraloncology.2005.01.012; Liao CT, 2007, CANCER, V110, P1501, DOI 10.1002/cncr.22959; Lim JY, 2010, ORAL ONCOL, V46, P504, DOI 10.1016/j.oraloncology.2010.02.005; Lim YC, 2007, LARYNGOSCOPE, V117, P1576, DOI 10.1097/MLG.0b013e318093ee2b; MAZER TM, 1988, AM J SURG, V156, P238, DOI 10.1016/S0002-9610(88)80282-4; Nibu K, 1997, AM J OTOLARYNG, V18, P391, DOI 10.1016/S0196-0709(97)90059-4; Yuen APW, 2002, HEAD NECK-J SCI SPEC, V24, P513, DOI 10.1002/hed.10094; Shiono S, 2009, ANN THORAC SURG, V88, P856, DOI 10.1016/j.athoracsur.2009.04.040; SLOTMAN GJ, 1984, CANCER, V54, P2009, DOI 10.1002/1097-0142(19841101)54:9<2009::AID-CNCR2820540938>3.0.CO;2-3; Sumioka S, 2013, J ORAL MAXIL SURG, V71, P1291, DOI 10.1016/j.joms.2012.12.023; Troell RJ, LARYNGOSCOPE, V105, P247; Wedman J, 1996, HEAD NECK-J SCI SPEC, V18, P311	39	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0194-5998	1097-6817		OTOLARYNG HEAD NECK	Otolaryngol. Head Neck Surg.	JUN	2015	152	6					1053	1060		10.1177/0194599815580980		8	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	CJ7QJ	WOS:000355692300016		
J	Roberts, GS				Roberts, Glenda S.			RETURN: Nationalizing Transnational Mobility in Asia.	PACIFIC AFFAIRS			English	Book Review									[Roberts, Glenda S.] Waseda Univ, Tokyo, Japan	Roberts, GS (reprint author), Waseda Univ, Tokyo, Japan.						Biao Xiang, 2013, RETURN NATL TRANSNAT	1	0	0	PACIFIC AFFAIRS UNIV BRITISH COLUMBIA	VANCOUVER	#164-1855 WEST MALL, VANCOUVER, BC V6T 1Z2, CANADA	0030-851X	1715-3379		PAC AFF	Pac. Aff.	JUN	2015	88	2					259	261				3	Area Studies	Area Studies	CJ7YC	WOS:000355715300006		
J	Debnar, M				Debnar, Milos			JAPANESE PERCEPTIONS OF FOREIGNERS.	PACIFIC AFFAIRS			English	Book Review									[Debnar, Milos] Doshisha Univ, Kyoto 602, Japan	Debnar, M (reprint author), Doshisha Univ, Kyoto 602, Japan.						TANABE S, 2013, JAPANESE PERCEPTIONS	1	0	0	PACIFIC AFFAIRS UNIV BRITISH COLUMBIA	VANCOUVER	#164-1855 WEST MALL, VANCOUVER, BC V6T 1Z2, CANADA	0030-851X	1715-3379		PAC AFF	Pac. Aff.	JUN	2015	88	2					310	312				3	Area Studies	Area Studies	CJ7YC	WOS:000355715300031		
J	Maeda, E				Maeda, Eriko			DILEMMAS OF ADULTHOOD: Japanese Women and the Nuances of Long-Term Resistance.	PACIFIC AFFAIRS			English	Book Review									[Maeda, Eriko] Univ Hyogo, Himeji, Hyogo 6712201, Japan	Maeda, E (reprint author), Univ Hyogo, Himeji, Hyogo 6712201, Japan.						ROSENBERGER N, 2013, DILEMMAS ADULTHOOD J	1	0	0	PACIFIC AFFAIRS UNIV BRITISH COLUMBIA	VANCOUVER	#164-1855 WEST MALL, VANCOUVER, BC V6T 1Z2, CANADA	0030-851X	1715-3379		PAC AFF	Pac. Aff.	JUN	2015	88	2					312	314				3	Area Studies	Area Studies	CJ7YC	WOS:000355715300032		
J	Narita, K; Hu, DL; Asano, K; Nakane, A				Narita, Kouji; Hu, Dong-Liang; Asano, Krisana; Nakane, Akio			Vaccination with non-toxic mutant toxic shock syndrome toxin-1 induces IL-17-dependent protection against Staphylococcus aureus infection	PATHOGENS AND DISEASE			English	Article						Staphylococcus aureus; TSST-1; vaccination; Th17; chemokine	DELTA-T-CELLS; MICE; RESISTANT; MODEL; INTERLEUKIN-17A; INFLAMMATION; PROTEIN	Toxic shock syndrome toxin-1 (TSST-1) is one of superantigens produced by Staphylococcus aureus. We have previously demonstrated that vaccination with non-toxic mutant TSST-1 (mTSST-1) develops host protection to lethal S. aureus infection in mice. However, the detailed mechanism underlying this protection is necessary to elucidate because the passive transfer of antibodies against TSST-1 fails to provide complete protection against S. aureus infection. In this study, the results showed that interleukin-17A (IL-17A)-producing cells were increased in the spleen cells of mTSST-1-vaccinated mice. The main source of IL-17A in mTSST-1-vaccinated mice was T-helper 17 (Th17) cells. The protective effect of vaccination was induced when the vaccinated wild type but not IL-17A-deficient mice were challenged with S. aureus. Gene expression of chemokines, CCL2 and CXCL1, and infiltration of neutrophils and macrophages were increased in spleens and livers of vaccinated mice after infection. The IL-17A-dependent immune response was TSST-1 specific because TSST-1-deficient S. aureus failed to induce the response. The present study suggests that mTSST-1 vaccination is able to provide the IL-17A-dependent host defense against S. aureus infection which promotes chemokine-mediated infiltration of phagocytes into the infectious foci.	[Narita, Kouji; Hu, Dong-Liang; Asano, Krisana; Nakane, Akio] Hirosaki Univ, Grad Sch Med, Dept Microbiol & Immunol, Hirosaki, Aomori 0368562, Japan; [Narita, Kouji] Hirosaki Univ, Grad Sch Med, Inst Anim Experimentat, Hirosaki, Aomori 0368562, Japan; [Hu, Dong-Liang] Kitasato Univ, Sch Vet Med, Lab Zoonoses, Towada, Aomori 0348628, Japan	Nakane, A (reprint author), Hirosaki Univ, Grad Sch Med, Dept Microbiol & Immunol, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	a27k03n0@hirosaki-u.ac.jp			JSPS KAKENHI [23390100]	This study was supported by JSPS KAKENHI grant number 23390100 and grant for Hirosaki University Institutional Research.	Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; Thurlow LR, 2011, J IMMUNOL, V186, P6585, DOI 10.4049/jimmunol.1002794; NAKANE A, 1995, INFECT IMMUN, V63, P1165; Gaffen SL, 2008, CYTOKINE, V43, P402, DOI 10.1016/j.cyto.2008.07.017; Klein E, 2007, EMERG INFECT DIS, V13, P1840, DOI 10.3201/eid1312.070629; Zaraket H, 2007, MICROBIOL IMMUNOL, V51, P171; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; BONVENTRE PF, 1995, INFECT IMMUN, V63, P509; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212; STILES BG, 1995, INFECT IMMUN, V63, P1229; Hu DL, 2003, J INFECT DIS, V188, P743, DOI 10.1086/377308; Curtis MM, 2009, IMMUNOLOGY, V126, P177, DOI 10.1111/j.1365-2567.2008.03017.x; Jeyaseelan S, 2004, INFECT IMMUN, V72, P7247, DOI 10.1128/IAI.72.12.7247-7256.2004; Murphy AG, 2014, J IMMUNOL, V192, P3697, DOI 10.4049/jimmunol.1303420; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; Narita K, 2010, INFECT IMMUN, V78, P4234, DOI 10.1128/IAI.00447-10; Asano K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113018; BONVENTRE PF, 1993, INFECT IMMUN, V61, P793; Cheng P, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-38; Dieli F, 2003, J IMMUNOL, V170, P463; Henningsson L, 2010, INFECT IMMUN, V78, P3783, DOI 10.1128/IAI.00385-10; Hobden JA, 1997, INFECT IMMUN, V65, P2754; Hu DL, 2008, J MED MICROBIOL, V57, P1106, DOI 10.1099/jmm.0.2008/002790-0; Ikejima S, 2005, DIABETES, V54, P182, DOI 10.2337/diabetes.54.1.182; Lin L, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000703; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Molne L, 2000, INFECT IMMUN, V68, P6162, DOI 10.1128/IAI.68.11.6162-6167.2000; Narita K, 2008, FEMS IMMUNOL MED MIC, V52, P389, DOI 10.1111/j.1574-695X.2008.00384.x; Piao Chuncheng, 2005, Microbiol Immunol, V49, P959; RASHEED JK, 1985, INFECT IMMUN, V47, P598; Tekstra J, 1999, CLIN EXP IMMUNOL, V117, P489	33	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	2049-632X			PATHOG DIS	Pathog. Dis.	JUN	2015	73	4							ftv023	10.1093/femspd/ftv023		10	Immunology; Infectious Diseases; Microbiology	Immunology; Infectious Diseases; Microbiology	CJ2OC	WOS:000355323300012		
J	Yamaguchi, Y; Kurita-Ochiai, T; Kobayashi, R; Suzuki, T; Ando, T				Yamaguchi, Yohei; Kurita-Ochiai, Tomoko; Kobayashi, Ryoki; Suzuki, Toshihiko; Ando, Tomohiro			Activation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated atherosclerosis	PATHOGENS AND DISEASE			English	Article						Porphyromonas gingivalis; atherosclerosis; NLRP3 inflammasome	SPONTANEOUSLY HYPERLIPIDEMIC MICE; OUTER-MEMBRANE PROTEIN; ENDOTHELIAL-CELLS; DISEASE; GINGIPAINS; EXPRESSION; INFECTION; IMMUNIZATION; RECOGNITION; RECEPTORS	Porphyromonas gingivalis has been shown to accelerate atherosclerotic lesion development in hyperlipidemic animals. Atherosclerosis is a disease characterized by inflammation of the arterial wall. Recent studies have suggested that the NLRP3 inflammasome plays an important role in the development of vascular inflammation and atherosclerosis. Herein, we investigated a possible association between the inflammasome in atherosclerosis and periodontal disease induced by P. gingivalis infection using apolipoprotein E-deficient, spontaneously hyperlipidemic (Apoeshl) mice. Oral infection with wild-type (WT) P. gingivalis significantly increased the area of aortic sinus covered with atherosclerotic plaque and alveolar bone loss, compared with KDP136 (gingipain-null mutant) or KDP150 (FimA-deficient mutant) challenge. WT challenge also increased IL-1 beta, IL-18 and TNF-alpha production in peritoneal macrophages, and gingival or aortic gene expression of Nod-like receptor family, pyrin domain containing 3 (NLRP3), pro-IL-1 beta, pro-IL-18 and pro-caspase-1. Porphyromonas gingivalis genomic DNA was detected more in the aorta, gingival tissue, liver and spleen of WT-challenged mice than those in KDP136-or KDP150-challenged mice. We conclude that WT P. gingivalis activates innate immune cells through the NLRP3 inflammasome compared with KDP136 or KDP150. The NLRP3 inflammasome may play a critical role in periodontal disease and atherosclerosis induced by P. gingivalis challenge through sustained inflammation.	[Yamaguchi, Yohei; Ando, Tomohiro] Tokyo Womens Med Univ, Sch Med, Dept Oral & Maxillofacial Surg, Tokyo 1628666, Japan; [Kurita-Ochiai, Tomoko; Kobayashi, Ryoki] Nihon Univ, Sch Dent Matsudo, Dept Microbiol & Immunol, Matsudo, Chiba 2718587, Japan; [Suzuki, Toshihiko] Univ Ryukyus, Grad Sch Med, Dept Mol Bacteriol & Immunol, Okinawa 9030215, Japan	Kurita-Ochiai, T (reprint author), Nihon Univ, Sch Dent Matsudo, Dept Microbiol & Immunol, 2-870-1 Sakaecho Nishi, Matsudo, Chiba 2718587, Japan.	ochiai.tomoko@nihon-u.ac.jp			Japan Society for the Promotion of Science [26463145]; 'Strategic Research Base Development' Program (Japan [MEXT]) for Private Universities of the Ministry of Education, Culture, Sports, Science and Technology, Japan [S1001024, 3107]; Nihon University	This study was supported by Grants-in-Aid for Scientific Research (26463145) from the Japan Society for the Promotion of Science, 'Strategic Research Base Development' Program (Japan [MEXT], 2010-2014 [S1001024]) for Private Universities of the Ministry of Education, Culture, Sports, Science and Technology, Japan (3107), and through the Nihon University Multidisciplinary Research Grant for 2014.	Ather JL, 2011, J IMMUNOL, V187, P64, DOI 10.4049/jimmunol.1100500; Bostanci N, 2012, FEMS MICROBIOL LETT, V333, P1, DOI 10.1111/j.1574-6968.2012.02579.x; Koizumi Y, 2008, INFECT IMMUN, V76, P2958, DOI 10.1128/IAI.01572-07; Gibson FC, 2004, CIRCULATION, V109, P2801, DOI 10.1161/01.CIR.0000129769.17895.F0; Park E, 2014, INFECT IMMUN, V82, P112, DOI 10.1128/IAI.00862-13; Wada K, 2010, J PHARMACOL SCI, V113, P115, DOI 10.1254/jphs.09R22FM; De Nardo D, 2011, TRENDS IMMUNOL, V32, P373, DOI 10.1016/j.it.2011.05.004; Pontillo A, 2013, REPROD SCI, V20, P563, DOI 10.1177/1933719112459240; Socransky SS, 1998, J CLIN PERIODONTOL, V25, P134, DOI 10.1111/j.1600-051X.1998.tb02419.x; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Hajishengallis G, 2004, IMMUNOL INVEST, V33, P157, DOI 10.1081/IMM-120030917; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Konopka L, 2012, J PERIODONTAL RES, V47, P681, DOI 10.1111/j.1600-0765.2012.01480.x; Zhang T, 2010, FEMS IMMUNOL MED MIC, V59, P143, DOI 10.1111/j.1574-695X.2010.00674.x; Darveau RP, 2012, J DENT RES, V91, P816, DOI 10.1177/0022034512453589; Martinon F, 2004, CURR BIOL, V14, P1929, DOI 10.1016/j.cub.2004.10.027; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Fitzpatrick RE, 2009, J INNATE IMMUN, V1, P109, DOI 10.1159/000181145; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Epstein SE, 1999, CIRCULATION, V100, pE20; Taniguchi A, 2003, METABOLISM, V52, P142, DOI 10.1053/meta.2003.50001; Chiu B, 1999, AM HEART J, V138, pS534, DOI 10.1016/S0002-8703(99)70294-2; Petrasek J, 2012, J CLIN INVEST, V122, P3476, DOI 10.1172/JCI60777; Miyamoto T, 2006, INFECT IMMUN, V74, P1376, DOI 10.1128/IAI.74.2.1376-1380.2006; Jain S, 2013, INFECT IMMUN, V81, P1277, DOI 10.1128/IAI.01036-12; Becker CE, 2007, SEMIN IMMUNOPATHOL, V29, P239, DOI 10.1007/s00281-007-0081-4; Zheng F, 2014, MEDIAT INFLAMM, DOI 10.1155/2014/507208; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Wang M, 2009, ORAL MICROBIOL IMMUN, V24, P478, DOI 10.1111/j.1399-302X.2009.00545.x; Kummer JA, 2007, J HISTOCHEM CYTOCHEM, V55, P443, DOI 10.1369/jhc.6A7101.2006; Lourbakos A, 2001, BLOOD, V97, P3790, DOI 10.1182/blood.V97.12.3790; Kaushik R, 2011, J PERIODONTOL, V82, P1353, DOI 10.1902/jop.2011.100472; Hajishengallis G, 2011, CELL HOST MICROBE, V10, P497, DOI 10.1016/j.chom.2011.10.006; Blair P, 2009, CIRC RES, V104, P346, DOI 10.1161/CIRCRESAHA.108.185785; Braddock M, 2004, NAT REV DRUG DISCOV, V3, P1, DOI 10.1038/nrd1342; Huck O, 2015, INNATE IMMUN-LONDON, V21, P65, DOI 10.1177/1753425914523459; Kato T, 2007, FEMS MICROBIOL LETT, V273, P96, DOI 10.1111/j.1574-6968.2007.00779.x; Matsushima Y, 2001, J Atheroscler Thromb, V8, P71; Momoi F, 2008, INFECT IMMUN, V76, P2777, DOI 10.1128/IAI.01502-07; Sambri V, 2004, J CLIN MICROBIOL, V42, P4914, DOI 10.1128/JCM.42.10.4914-4915.2004; Zheng F, 2013, HEART LUNG CIRC, V22, P746, DOI 10.1016/j.hlc.2013.01.012	41	2	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	2049-632X			PATHOG DIS	Pathog. Dis.	JUN	2015	73	4							ftv011	10.1093/femspd/ftv011		8	Immunology; Infectious Diseases; Microbiology	Immunology; Infectious Diseases; Microbiology	CJ2OC	WOS:000355323300004		
J	Yazawa, T				Yazawa, Takuya			Recent advances in histogenesis research of lung neuroendocrine cancers: Evidence obtained from functional analyses of primitive neural/neuroendocrine cell-specific transcription factors	PATHOLOGY INTERNATIONAL			English	Review						ASCL1; carcinoid; class III; IV POU; histogenesis; large cell neuroendocrine carcinoma; lung; NeuroD1; REST; small cell carcinoma; TTF1	GENE-EXPRESSION PROFILES; COMBINED CARCINOID-TUMOR; CHROMOGRANIN-A; NONSMALL CELL; FACTOR BRN-2; NULL MICE; HOMOLOG 1; FACTOR-I; DIFFERENTIATION; MUTATIONS	Small cell carcinoma (SmCC) and large cell neuroendocrine carcinoma (LENEC) are categorized as neuroendocrine cancers (NECs) of the lung and have extremely poor prognoses. The lack of an effective therapeutic strategy against SmCC and LCNEC is a serious issue. Because the regulation of the cellular phenotype is complicated by the actions of various transcription factors, investigations into the function of neural/neuroendocrine cell-specific transcription factors are important for elucidating the cellular characteristics and histogenesis of SmCC and LCNEC and for establishing innovative therapeutic strategies against them. In this review, the functions of ASCL1, NeuroD1, REST, TTF1, and class III/IV POU, that are specifically and highly expressed in lung NECs, are introduced. These transcription factors transactivate and/or transrepress various genes and are involved in neural progenitor phenotyping, neuroendocrine and stem cell marker expression, and epithelial-to-mesenchymal transition. Based on the evidence that certain carcinoids express ASCL1, NeuroD1, TTF1, and class III/IV POU and that lung NECs can develop from non-NE cells/non-NEC cells, the relationships among lung NECs, carcinoid tumors, and non-NECs are discussed. Finally, a model of the histogenesis of lung NECs in view of similarities in the expression of primitive neural/neuroendocrine cell-specific transcription factors is proposed.	[Yazawa, Takuya] Chiba Univ, Grad Sch Med, Dept Diagnost Pathol, Chiba, Chiba 2608670, Japan	Yazawa, T (reprint author), Chiba Univ, Grad Sch Med, Dept Diagnost Pathol, Chuo Ku, 1-8-1 Inohana, Chiba, Chiba 2608670, Japan.	tkyazawatkyazawa@gmail.com			Ministry of Education, Culture, Sports, Science, and Technology of Japan	The author was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. Takuya Yazawa was the winner of The Japanese Society of Pathology; Pathology Research Award in 2013.	Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Rossi G, 2005, J CLIN ONCOL, V23, P8774, DOI 10.1200/JCO.2005.02.8233; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Varghese AM, 2014, J THORAC ONCOL, V9, P892, DOI 10.1097/JTO.0000000000000142; Marchetti A, 2008, HUM MUTAT, V29, P609, DOI 10.1002/humu.20707; Fujiwara T, 2012, LUNG CANCER, V75, P119, DOI 10.1016/j.lungcan.2011.05.028; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Song H, 2012, P NATL ACAD SCI USA, V109, P17531, DOI 10.1073/pnas.1207238109; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Kreisler A, 2010, ONCOGENE, V29, P5828, DOI 10.1038/onc.2010.321; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Nana-Sinkam SP, 2013, CHEST, V143, pE30, DOI 10.1378/chest.12-2346; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; Pennesi ME, 2003, J NEUROSCI, V23, P453; Jones MH, 2004, LANCET, V363, P775, DOI 10.1016/S0140-6736(04)15693-6; Hiroshima K, 2006, MODERN PATHOL, V19, P1358, DOI 10.1038/modpathol.3800659; Malecki MT, 1999, NAT GENET, V23, P323; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Saito RA, 2009, CANCER RES, V69, P2783, DOI 10.1158/0008-5472.CAN-08-3490; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; Hamanaka W, 2014, HUM PATHOL, V45, P1045, DOI 10.1016/j.humpath.2014.01.001; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Kashiwagi K, 2012, PATHOL INT, V62, P232, DOI 10.1111/j.1440-1827.2011.02781.x; Coulson JM, 2000, CANCER RES, V60, P1840; Morinaga R, 2007, LUNG CANCER, V58, P411, DOI 10.1016/j.lungcan.2007.05.014; Jiang TY, 2009, CANCER RES, V69, P845, DOI 10.1158/0008-5472.CAN-08-2762; Nakatani Y, 2004, AM J SURG PATHOL, V28, P921, DOI 10.1097/00000478-200407000-00012; Oshiro Y, 2004, AM J ROENTGENOL, V182, P87; La Rosa S, 2013, HUM PATHOL, V44, P1391, DOI 10.1016/j.humpath.2012.11.013; Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; Nishikawa E, 2011, CANCER RES, V71, P6165, DOI 10.1158/0008-5472.CAN-11-1020; Dominguez MH, 2013, CEREB CORTEX, V23, P2632, DOI 10.1093/cercor/bhs252; Yazawa T, 1999, J PATHOL, V187, P191, DOI 10.1002/(SICI)1096-9896(199901)187:2<191::AID-PATH206>3.0.CO;2-3; Osada H, 2008, CANCER RES, V68, P1647, DOI 10.1158/0008-5472.CAN-07-5039; Fischer B, 2007, CANCER TREAT REV, V33, P391, DOI 10.1016/j.ctrv.2007.01.006; Ito T, 2000, DEVELOPMENT, V127, P3913; Kim WY, 2001, DEVELOPMENT, V128, P417; Zakowski MF, 2006, NEW ENGL J MED, V355, P213, DOI 10.1056/NEJMc053610; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Negrini S, 2013, TRENDS CELL BIOL, V23, P289, DOI 10.1016/j.tcb.2013.01.006; Hosono Y, 2012, EMBO J, V31, P481, DOI 10.1038/emboj.2011.416; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Anbazhagan R, 1999, CANCER RES, V59, P5119; Bari MF, 2014, HISTOPATHOLOGY, V64, P547, DOI 10.1111/his.12278; Bery A, 2014, CEREB CORTEX, V24, P2822, DOI 10.1093/cercor/bht126; Brambilla E, 2004, WHO CLASSIFICATION T, P45; Canaff L, 1998, ENDOCRINOLOGY, V139, P1184, DOI 10.1210/en.139.3.1184; Cobrinik D, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-72; D'Adda T, 2008, MODERN PATHOL, V21, P414, DOI 10.1038/modpathol.3801014; Debelenko LV, 2000, GENE CHROMOSOME CANC, V28, P58, DOI 10.1002/(SICI)1098-2264(200005)28:1<58::AID-GCC7>3.0.CO;2-2; Endo T, 2014, PATHOL INT, V64, P365, DOI 10.1111/pin.12183; Fellegara G, 2008, VIRCHOWS ARCH, V453, P107, DOI 10.1007/s00428-008-0620-y; Fisseler-Eckhoff Annette, 2012, Cancers (Basel), V4, P777, DOI 10.3390/cancers4030777; Folpe AL, 1999, MODERN PATHOL, V12, P5; Gandhi Leena, 2006, J Natl Compr Canc Netw, V4, P631; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Huang J, 2002, ARCH PATHOL LAB MED, V126, P437; Huang Z, 2012, FEBS LETT, V586, P1602, DOI 10.1016/j.febslet.2012.04.052; Ishii J, 2014, PATHOL INT, V64, P415, DOI 10.1111/pin.12198; Li Y, 2012, AM J RESP CELL MOL, V47, P768, DOI 10.1165/rcmb.2012-0027OC; Lietz M, 2003, EUR J BIOCHEM, V270, P2, DOI 10.1046/j.1432-1033.2003.03360.x; Malik KF, 1997, MOL BRAIN RES, V45, P99, DOI 10.1016/S0169-328X(96)00238-0; Morita S, 2013, AM J SURG PATHOL, V37, P924, DOI 10.1097/PAS.0b013e31827e1e83; Murase T, 2003, HUM PATHOL, V34, P1178, DOI 10.1053/S0046-8177(03)00466-0; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; Owens CL, 2011, INT J SURG PATHOL, V19, P273, DOI 10.1177/1066896910397883; Rapa I, 2008, MODERN PATHOL, V21, P700, DOI 10.1038/modpathol.2008.39; Righi L, 2012, VIRCHOWS ARCH, V460, P415, DOI 10.1007/s00428-012-1223-1; Rindi G, 2010, WHO CLASSIFICATION T, V3, P13; Sakaeda M, 2013, LAB INVEST, V93, P408, DOI 10.1038/labinvest.2013.2; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; Sen F, 1998, LUNG CANCER-J IASLC, V21, P53, DOI 10.1016/S0169-5002(98)00042-7; Seo S, 2007, EMBO J, V26, P5093, DOI 10.1038/sj.emboj.7601923; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Snyder AJ, 2004, P NATL ACAD SCI USA, V101, P4471; Southerland KD, 2011, CANCER CELL, V19, P754; Travis W., 2004, WHO CLASSIFICATION T, P31; Travis WD, 2010, ANN ONCOL          S, V7, pvii65; Travis WD, 1999, WHO HISTOLOGIC TYPIN, V3rd, P32; Travis WD, 2004, WHO CLASSIFICATION T, P19; vansMeerbeeck JP, 2011, LANCET, V378, P1741; Wagner PL, 2009, AM J CLIN PATHOL, V131, P376, DOI 10.1309/AJCPYNPFL56POZQY; World Health Organization, 1981, HIST TYP BREAST TUM, P19; Yazawa T, 2009, AM J PATHOL, V175, P976, DOI 10.2353/ajpath.2009.081004; Yazawa T, 2002, AM J PATHOL, V161, P291, DOI 10.1016/S0002-9440(10)64181-8	86	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2015	65	6					277	285		10.1111/pin.12267		9	Pathology	Pathology	CJ7CJ	WOS:000355651400001		
J	Hattori, Y; Yoshida, A; Yoshida, M; Takahashi, M; Tsuta, K				Hattori, Yukinori; Yoshida, Akihiko; Yoshida, Masayuki; Takahashi, Masahide; Tsuta, Koji			Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung	PATHOLOGY INTERNATIONAL			English	Article						androgen receptor; breast carcinoma; estrogen receptor; GATA3; gross cystic disease fluid protein-15; immunohistochemistry; lung carcinoma; mammaglobin; metastasis; progesterone receptor	UROTHELIAL CARCINOMA; EXPRESSION; CANCER; TUMORS; ESTROGEN; DISEASE; MAMMARY; UTILITY; MAMMAGLOBIN; PULMONARY	Differentiating metastatic breast carcinoma in the lungs from primary lung tumors and mesotheliomas is important for determining prognosis and treatment. We evaluated novel breast specific markers, androgen receptor (AR) and GATA binding protein 3 (GATA3) immunohistostaining, for this differential, and compare to other traditional markers. The specimens comprised 33 metastatic breast carcinomas to the lung, 566 primary lung tumors (170 adenocarcinomas, 157 squamous cell carcinomas, 31 pleomorphic carcinomas, 115 large cell neuroendocrine carcinomas, 43 small cell carcinomas, and 49 typical carcinoids) and 42 malignant mesotheliomas. They were analyzed by immunohistochemistry using antibodies to AR, GATA3, estrogen receptor (ER), progesterone receptor (PgR), mammaglobin, gross cystic disease fluid protein-15 (GCDFP-15). Of the metastatic breast carcinomas, immunohistostaining of AR, GATA3, ER, PgR, mammaglobin, GCDFP-15 were positive in 27 cases (81.8%), 24 cases (72.7%), 26 cases (78.8%), 13 cases (39.4%), 12 cases (36.4%), 9 cases (27.3%), respectively. Of primary lung tumors and mesotheliomas, staining of AR, GATA3, ER, PgR, mammaglobin, GCDFP-15 were positive in 18 cases (3%), 3 cases (0.5%), 4 cases (0.7%), 2 cases (0.3%), 0 case (0%), 2 cases (0.3%), respectively. Immunohistochemistry of AR and GATA3 are reliable for differentiating metastatic breast carcinoma from primary lung tumors and mesotheliomas.	[Hattori, Yukinori; Yoshida, Akihiko; Yoshida, Masayuki; Tsuta, Koji] Natl Canc Ctr, Div Pathol & Clin Labs, Tokyo 1040045, Japan; [Hattori, Yukinori; Takahashi, Masahide] Nagoya Univ, Grad Sch Med, Dept Pathol, Nagoya, Aichi 4648601, Japan	Tsuta, K (reprint author), Natl Canc Ctr, Div Pathol & Clin Labs, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	ktsuta@ncc.go.jp					Matsumoto T, 2013, ANNU REV PHYSIOL, V75, P201, DOI 10.1146/annurev-physiol-030212-183656; YANG ZY, 1994, MOL CELL BIOL, V14, P2201; Liegl B, 2005, MODERN PATHOL, V18, P1283, DOI 10.1038/modpathol.3800437; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Nasser SM, 2003, AM J CLIN PATHOL, V119, P801, DOI 10.1309/RVTP1G0Q727WJUQD; Bhargava R, 2007, AM J CLIN PATHOL, V127, P103, DOI 10.1309/TDP92PQLDE2HLEET; Collins LC, 2011, MODERN PATHOL, V24, P924, DOI 10.1038/modpathol.2011.54; Wei S, 2009, APPL IMMUNOHISTO M M, V17, P393, DOI 10.1097/PAI.0b013e31819faa07; Liu HY, 2012, AM J CLIN PATHOL, V138, P57, DOI 10.1309/AJCP5UAFMSA9ZQBZ; Ogawa Y, 2008, INT J CLIN ONCOL, V13, P431, DOI 10.1007/s10147-008-0770-6; Mimae T, 2011, CANCER-AM CANCER SOC, V117, P4396, DOI 10.1002/cncr.26061; Moinfar F, 2003, CANCER, V98, P703, DOI 10.1002/cncr.11532; MCDONALD ML, 1994, ANN THORAC SURG, V58, P1599; Chang A, 2012, AM J SURG PATHOL, V36, P1472, DOI 10.1097/PAS.0b013e318260cde7; Downes MR, 2013, J CLIN PATHOL, V66, P779, DOI 10.1136/jclinpath-2013-201586; Takeda Y, 2008, ARCH PATHOL LAB MED, V132, P239, DOI 10.1043/1543-2165(2008)132[239:AOEPOB]2.0.CO;2; Niemeier LA, 2010, MODERN PATHOL, V23, P205, DOI 10.1038/modpathol.2009.159; Yang M, 2010, MODERN PATHOL, V23, P654, DOI 10.1038/modpathol.2010.38; Ordonez NG, 2013, ADV ANAT PATHOL, V20, P352, DOI 10.1097/PAP.0b013e3182a28a68; Cimino-Mathews A, 2012, HUM PATHOL, V43, P1003, DOI 10.1016/j.humpath.2011.08.007; Cimino-Mathews A, 2013, HUM PATHOL, V44, P1341, DOI 10.1016/j.humpath.2012.11.003; Gong Y, 2011, CANCER-AM CANCER SOC, V117, P705, DOI 10.1002/cncr.25506; Gonzalez LO, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-149; Lakhani SR, 2012, WHO CLASSIFICATION T; Mikkonen L, 2010, MOL CELL ENDOCRINOL, V317, P14, DOI 10.1016/j.mce.2009.12.022; Shidham VB, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-34; So JS, 2013, MODERN PATHOL, V26, P1365, DOI 10.1038/modpathol.2013.76; Suzuki T, 2010, MED MOL MORPHOL, V43, P75, DOI 10.1007/s00795-010-0494-3; Travis W, 2004, PATHOLOGY GENETICS T; Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223	30	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2015	65	6					286	292		10.1111/pin.12278		7	Pathology	Pathology	CJ7CJ	WOS:000355651400002		
J	Shiino, S; Tsuda, H; Yoshida, M; Jimbo, K; Asaga, S; Hojo, T; Kinoshita, T				Shiino, Sho; Tsuda, Hitoshi; Yoshida, Masayuki; Jimbo, Kenjiro; Asaga, Sota; Hojo, Takashi; Kinoshita, Takayuki			Intraductal papillomas on core biopsy can be upgraded to malignancy on subsequent excisional biopsy regardless of the presence of atypical features	PATHOLOGY INTERNATIONAL			English	Article						breast cancer; core needle biopsy; intraductal papilloma; surgical excision; upgrade; World Health Organization (WHO) classification	NEEDLE-BIOPSY; PAPILLARY LESIONS; BREAST-CARCINOMA; MANAGEMENT; ULTRASOUND; RISK	Intraductal papillary lesions of the breast constitute a heterogeneous entity, including benign intraductal papilloma (IDP) with or without atypia and malignant papillary carcinoma. Differentiating between these diagnoses can be challenging. We re-evaluated core biopsy specimens that were diagnosed as IDP and the corresponding surgical excision specimens, and assessed the potential risk for the diagnosis to be modified to malignancy based on excision. By sorting the pathology database of the National Cancer Center Hospital, Tokyo, we identified 146 core biopsy cases that were histologically diagnosed as IDP between 1997 and 2013. The re-evaluated diagnosis was IDP without atypia in 79 (54%) patients, IDP with atypia in 66 (45%), and ductal carcinoma in situ (DCIS) in 1 (1%). Among the 34 patients (23%) who underwent surgical excision subsequent to core biopsy, histological diagnosis was upgraded to carcinoma, excluding lobular carcinoma in situ (LCIS), in 14 (41%) cases, including 4 (33%) of 12 IDPs without atypia and 10 (45%) of 22 IDPs with atypia. Complete surgical excision should be kept in mind for all IDPs diagnosed on core biopsy, not only IDPs with atypia but IDPs without atypia, especially when clinical or imaging diagnosis findings cannot rule out the possibility of malignancy, because papillary lesions comprise a variety of morphological appearances.	[Shiino, Sho; Jimbo, Kenjiro; Asaga, Sota; Hojo, Takashi; Kinoshita, Takayuki] Natl Canc Ctr, Breast Surg Div, Tokyo, Japan; [Tsuda, Hitoshi; Yoshida, Masayuki] Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo, Japan; [Tsuda, Hitoshi] Natl Def Med Coll, Dept Basic Pathol, Tokorozawa, Saitama 3598513, Japan	Tsuda, H (reprint author), Natl Def Med Coll, Dept Basic Pathol, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	htsuda@ndmc.ac.jp			Cancer Research and Development Fund from National Cancer Center, Japan [26-A-4]	This study was supported in part by the Cancer Research and Development Fund from National Cancer Center, Japan (26-A-4).	Collins LC, 2008, HISTOPATHOLOGY, V52, P20, DOI 10.1111/j.1365-2559.2007.02898.x; Sydnor MK, 2007, RADIOLOGY, V242, P58, DOI 10.1148/radiol.2421031988; Agoff SN, 2004, AM J CLIN PATHOL, V122, P440, DOI 10.1309/NAPJMB0GXKJC6PTH; Puglisi F, 2003, ONCOLOGY-BASEL, V65, P311, DOI 10.1159/000074643; Ueng SH, 2009, ARCH PATHOL LAB MED, V133, P893, DOI 10.1043/1543-2165-133.6.893; Ahmadiyeh N, 2009, ANN SURG ONCOL, V16, P2264, DOI 10.1245/s10434-009-0534-1; Rizzo M, 2008, ANN SURG ONCOL, V15, P1040, DOI 10.1245/s10434-007-9780-2; Lu QH, 2012, ANZ J SURG, V82, P168, DOI 10.1111/j.1445-2197.2011.05969.x; Ashkenazi I, 2007, AM J SURG, V194, P183, DOI 10.1016/j.amjsurg.2006.11.028; Cyr AE, 2011, ANN SURG ONCOL, V18, P946, DOI 10.1245/s10434-010-1403-7; Jaffer S, 2009, CANCER, V115, P2837, DOI 10.1002/cncr.24321; O'Malley F, 2012, WHO CLASSIFICATION T, V4th, P100; Page DL, 1996, CANCER, V78, P258, DOI 10.1002/(SICI)1097-0142(19960715)78:2<258::AID-CNCR11>3.0.CO;2-V; Renshaw AA, 2004, AM J CLIN PATHOL, V122, P217, DOI 10.1309/K1BNJXETEY3H06UL; Richter-Ehrenstein C, 2011, BREAST, V20, P501, DOI 10.1016/j.breast.2011.05.004; Tavassoli FA, 1999, PATHOLOGY BREAST	16	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2015	65	6					293	300		10.1111/pin.12285		8	Pathology	Pathology	CJ7CJ	WOS:000355651400003		
J	Ono, M; Tsuda, H; Kobayashi, T; Takeshita, F; Takahashi, RU; Tamura, K; Akashi-Tanaka, S; Moriya, T; Yamasaki, T; Kinoshita, T; Yamamoto, J; Fujiwara, Y; Ochiya, T				Ono, Makiko; Tsuda, Hitoshi; Kobayashi, Takayuki; Takeshita, Fumitaka; Takahashi, Ryou-u; Tamura, Kenji; Akashi-Tanaka, Sadako; Moriya, Tomoyuki; Yamasaki, Tamio; Kinoshita, Takayuki; Yamamoto, Junji; Fujiwara, Yasuhiro; Ochiya, Takahiro			The expression and clinical significance of ribophorin II (RPN2) in human breast cancer	PATHOLOGY INTERNATIONAL			English	Article						breast cancer; cancer stem cell; p53; ribophorin II	MOLECULAR SUBTYPES; METASTASIS; INVASION; PATTERNS; FEATURES; TUMORS	Ribophorin II (RPN2), part of the N-oligosaccharyltransferase complex, is highly expressed in breast cancer stem cells and is associated with tumor metastasis through interaction with mutant p53. The clinicopathological implication of RPN2 expression is undetermined. We examined immunohistochemically the expression levels of RPN2 and p53 in primary breast cancer tissues surgically resected from 218 patients. The correlations of RPN2 expression with the intrinsic subtype defined by hormone receptors (HRs) and HER2, clinicopathological parameters, p53 expression, and patients' clinical outcomes were examined. RPN2 was positive in 139 (64%), and the incidence of RPN2 expression was higher in the triple-negative breast cancer (TNBC) (HR-/HER2-) (65%) and HER2-enriched (HR-/HER2+) subtype (95%) than in the luminal A-like (HR+/HER2-) subtype (58%) (P = 0.0009). RPN2 expression was also correlated with p53 nuclear accumulation (P = 0.04). The RPN2-positive/p53-positive patient group showed significantly poorer prognosis than the RPN2-negative group for disease-free survival (P = 0.05) and for overall survival (P = 0.02). By multivariate analyses, the combination of RPN2 and p53 was not an independent prognostic factor. RPN2 expression was correlated with clinically aggressive features of breast cancer. These data support the further clinical application of anti-RPN2 therapy and the development of personalized medicine.	[Ono, Makiko; Takeshita, Fumitaka; Takahashi, Ryou-u; Ochiya, Takahiro] Natl Canc Ctr, Res Inst, Div Mol & Cellular Med, Tokyo 1040045, Japan; [Tsuda, Hitoshi] Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo, Japan; [Tamura, Kenji; Akashi-Tanaka, Sadako; Kinoshita, Takayuki; Fujiwara, Yasuhiro] Natl Canc Ctr, Breast & Med Oncol Div, Tokyo, Japan; [Tsuda, Hitoshi; Kobayashi, Takayuki] Natl Def Med Coll, Dept Basic Pathol, Saitama, Japan; [Moriya, Tomoyuki; Yamasaki, Tamio; Yamamoto, Junji] Natl Def Med Coll, Dept Surg, Saitama, Japan	Ochiya, T (reprint author), Natl Canc Ctr, Res Inst, Div Mol & Cellular Med, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	tochiya@ncc.go.jp			National Cancer Center Research and Development Fund; Japan Society for Promotion of Science (KAKENHI)	The present work was supported in part by the National Cancer Center Research and Development Fund and a grant-in-aid for Scientific Research from Japan Society for Promotion of Science (KAKENHI). The authors are thankful to Sachiko Miura, M.T., and Chizu Kina, M.T., for technical assistance.	Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Honma K, 2008, NAT MED, V14, P939, DOI 10.1038/nm.1858; Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756; Allred DC, 1998, MODERN PATHOL, V11, P155; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Ono M, 2012, BREAST CANCER RES TR, V132, P793, DOI 10.1007/s10549-011-1554-7; Center for Cancer Control and Information Services, 2009, J VITAL STAT JAPAN M; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Kobayashi T, 2010, BREAST CANCER RES TR, V123, P733, DOI 10.1007/s10549-009-0672-y; O'Shaughnessy J, 2014, J CLIN ONCOL, V32, P3840, DOI 10.1200/JCO.2014.55.2984; Ono M, 2012, STEM CELLS CANC STEM, V4, P249; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Takahashi RU, 2013, SCI REP, V3, P1; Takahashi Ryou-U, 2011, Cancers (Basel), V3, P1311, DOI 10.3390/cancers3011311	23	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2015	65	6					301	308		10.1111/pin.12297		8	Pathology	Pathology	CJ7CJ	WOS:000355651400004		
J	Saito, T; Kondo, C; Shitara, K; Ito, Y; Saito, N; Ikehara, Y; Yatabe, Y; Yamamichi, K; Tanaka, H; Nakanishi, H				Saito, Takuya; Kondo, Chihiro; Shitara, Kohei; Ito, Yuichi; Saito, Noriko; Ikehara, Yuzuru; Yatabe, Yasushi; Yamamichi, Keigo; Tanaka, Hideo; Nakanishi, Hayao			Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case	PATHOLOGY INTERNATIONAL			English	Article						drug resistance; gastric cancer; HER2 gene amplification; intratumoral heterogeneity; metastases; trastuzumab	IN-SITU HYBRIDIZATION; CELL-LINES; LIVER METASTASIS; BREAST-CANCER; TRASTUZUMAB; AMPLIFICATION; CHEMOTHERAPY; SENSITIVITY; CARCINOMA; ERBB2	Intratumoral heterogeneity of HER2 expression in the metastatic foci of HER2-positive advanced gastric cancer remains unclear. In this study, we compared HER2 expression between primary and metastatic tumors in HER2-positive three autopsied cases and one resected case with multiple organ metastases by immunohistochemistry (IHC) and dual color in situ hybridization (DISH). All four cases judged positive (IHC3+) at the primary tumor tissues showed varying HER2 gene amplification (GA) status. One homogeneously HER2-positive autopsied case (Case 1) and one intratumorally heterogeneous positive resected case (Case 2) with high GA showed a homogeneous positive staining pattern in all the metastatic foci. One heterogeneously HER2-positive autopsied case (Case 3) with low GA showed a partially heterogeneous HER2 staining pattern in all the metastatic foci. In contrast, one heterogeneously HER2-positive autopsied case (Case 4) with equivocal GA showed a completely heterogeneous HER2 staining pattern in the metastatic foci. These results indicate that HER2-positive gastric cancers with low to high GA at the primary tumor show substantially homogeneous HER2 overexpression in the metastatic foci, whereas HER2-positive gastric cancers with equivocal GA expressed HER2 heterogeneously within the metastatic tumor, suggesting that metastatic foci of the latter HER2-positive cases would be potentially resistant to trastuzumab.	[Saito, Takuya; Tanaka, Hideo] Nagoya Univ, Grad Sch Med, Program Hlth & Community Med, Dept Epidemiol, Nagoya, Aichi 4648601, Japan; [Kondo, Chihiro] Japanese Red Cross Nagoya Daiichi Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan; [Ito, Yuichi] Aichi Canc Ctr, Cent Hosp, Dept Gastroenterol Surg, Nagoya, Aichi 464, Japan; [Yatabe, Yasushi] Aichi Canc Ctr, Cent Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 464, Japan; [Saito, Noriko] Aichi Canc Ctr, Res Inst, Div Oncol Pathol, Nagoya, Aichi 464, Japan; [Shitara, Kohei] Natl Canc Ctr, Hosp East, Dept Gastrointestinal Oncol, Chiba, Japan; [Ikehara, Yuzuru] Natl Inst Adv Ind Sci & Technol, Res Ctr Med Glycosci, Mol Med Team, Tsukuba, Japan; [Yamamichi, Keigo] Osaka Saiseikai Izuo Hosp, Dept Surg, Osaka, Japan; [Nakanishi, Hayao] Aichi Hosp, Aichi Canc Ctr, Lab Pathol & Clin Res, Okazaki, Aichi 4440011, Japan	Nakanishi, H (reprint author), Aichi Hosp, Aichi Canc Ctr, Lab Pathol & Clin Res, 18 Kuriyada Kakemachi, Okazaki, Aichi 4440011, Japan.	hnakanis@aichi-cc.jp			Ministry of Education, Science, Sports, Culture and Technology, Japan	We thank Ms. M. Yoshimura and N. Shibata for their expert technical assistance. This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, Culture and Technology, Japan.	Nashimoto A, 2013, GASTRIC CANCER, V16, P1, DOI 10.1007/s10120-012-0163-4; Tajiri R, 2014, HUM PATHOL, V45, P725, DOI 10.1016/j.humpath.2013.11.004; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Lee HE, 2013, EUR J CANCER, V49, P1448, DOI 10.1016/j.ejca.2012.10.018; Sawaki A, 2012, GASTRIC CANCER, V15, P313, DOI 10.1007/s10120-011-0118-1; Bozzetti C, 2011, BRIT J CANCER, V104, P1372, DOI 10.1038/bjc.2011.121; Kataoka Y, 2013, GASTRIC CANCER, V16, P84, DOI 10.1007/s10120-012-0150-9; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Carlsson J, 2004, BRIT J CANCER, V90, P2344, DOI 10.1038/sj.bjc.6601881; Ohtsu A, 2008, J GASTROENTEROL, V43, P256, DOI 10.1007/s00535-008-2177-6; Kim MA, 2011, HISTOPATHOLOGY, V59, P822, DOI 10.1111/j.1365-2559.2011.04012.x; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Yokoyama H, 2006, BRIT J CANCER, V95, P1504, DOI 10.1038/sj.bjc.6603459; Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x; Kim KC, 2011, ANN SURG ONCOL, V18, P2833, DOI 10.1245/s10434-011-1695-2; Wang T, 2014, HUM PATHOL, V45, P970, DOI 10.1016/j.humpath.2013.12.010; Bang YJ, 2010, LANCET, V376, P687, DOI 10.1016/S0140-6736(10)61121-X; Eto K, 2015, INT J CANCER, V136, P1537, DOI 10.1002/ijc.29168; Gao FF, 2014, AM J CLIN PATHOL, V141, P102, DOI 10.1309/AJCP6CXS8OSRHXIR; Ieni A, 2014, INT J MOL SCI, V15, P22331, DOI 10.3390/ijms151222331; Kochi M, 2013, DIAGN PATHOL; Nakanishi H, 2005, CLIN EXP METASTAS, V22, P137, DOI 10.1007/s10585-005-6526-z; Oshima Y, 2014, GASTRIC CANCER, V17, P450, DOI 10.1007/s10120-013-0290-6; Saito T, 2014, GASTRIC CANC; Shimoyama S., 2014, MOL CLIN ONCOL, V2, P175	25	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2015	65	6					309	317		10.1111/pin.12290		9	Pathology	Pathology	CJ7CJ	WOS:000355651400005		
J	Hida, T; Hamasaki, M; Matsumoto, S; Abe, S; Takakura, K; Hiroshima, K; Nabeshima, K				Hida, Tomoyuki; Hamasaki, Makoto; Matsumoto, Shinji; Abe, Sosei; Takakura, Koji; Hiroshima, Kenzo; Nabeshima, Kazuki			Diffuse intrapulmonary malignant mesothelioma presenting with miliary pulmonary nodules: A case report	PATHOLOGY INTERNATIONAL			English	Article						diffuse intrapulmonary malignant mesothelioma; DIMM; epithelioid; miliary mesothelioma; p16FISH	PLEURAL MESOTHELIOMA; LUNG ADENOCARCINOMA; ASSOCIATION; METASTASES; MUTATIONS; SURVIVAL; DISEASE	A 67-year-old male with a history of asbestos exposure presented with fever, cough, and dyspnea and was found to have diffuse granular shadowing in both lungs, right pleural effusion, and hilar and mediastinal lymphadenopathy upon chest computed tomography. For definitive diagnosis, a thoracoscopic lung biopsy was performed. Intraoperative findings showed no remarkable macroscopic changes in the visceral and parietal pleura, although a high level of hyaluronic acid in the pleural effusion was noted. Histological findings showed proliferation of atypical cells with round-to-oval nuclei, prominent nucleoli, and eosinophilic cytoplasms. These cells were arranged into sheets or tubules and were located predominantly in the lung parenchyma. Lymphovascular invasion was conspicuous. Immunohistochemically, tumor cells were positive for calretinin, D2-40, and CK5/6, focally positive for Ber-EP4, but negative for WT-1, TTF-1, CEA, and MOC31. Fluorescence in situ hybridization for the tumor suppressor p16 revealed homozygous deletion in the tumor cells. Therefore, we diagnosed the tumor as diffuse intrapulmonary malignant mesothelioma (DIMM). The patient had a poor response to chemotherapy and died 1 year after diagnosis. Although rare, DIMM should be considered when patients present with multiple, tiny intrapulmonary nodules, regardless of macroscopic pleural changes. Furthermore, this is the first report on p16 status in DIMM.	[Hida, Tomoyuki; Hamasaki, Makoto; Matsumoto, Shinji; Abe, Sosei; Nabeshima, Kazuki] Fukuoka Univ Hosp, Dept Pathol, Fukuoka, Fukuoka 8140180, Japan; [Takakura, Koji] Ohmuta Natl Hosp, Dept Resp Med, Natl Hosp Org, Fukuoka, Japan; [Hiroshima, Kenzo] Tokyo Womens Med Univ, Dept Pathol, Yachiyo Med Ctr, Yachiyo, Japan	Nabeshima, K (reprint author), Fukuoka Univ Hosp, Dept Pathol, Jonan ku, 7-45-1 Nanakuma, Fukuoka, Fukuoka 8140180, Japan.	kaznabes@fukuoka-u.ac.jp					Deutsch M, 2007, AM J CLIN ONCOL-CANC, V30, P294, DOI 10.1097/01.coc.0000256102.40842.78; Purek L, 2011, J THORAC ONCOL, V6, P1753, DOI 10.1097/JTO.0b013e31822e295a; Chiosea S, 2008, MODERN PATHOL, V21, P742, DOI 10.1038/modpathol.2008.45; Teta MJ, 2007, CANCER, V109, P1432, DOI 10.1002/cncr.22526; Zucali PA, 2011, CANCER TREAT REV, V37, P543, DOI 10.1016/j.ctrv.2011.01.001; Mezzapelle R, 2013, BRIT J CANCER, V108, P1743, DOI 10.1038/bjc.2013.130; Milano MT, 2010, J THORAC ONCOL, V5, P1841, DOI 10.1097/JTO.0b013e3181f1cf2b; Togashi Y, 2011, CANCER-AM CANCER SOC, V117, P819, DOI 10.1002/cncr.25618; Husain AN, 2013, ARCH PATHOL LAB MED, V137, P647, DOI 10.5858/arpa.2012-0214-OA; Gemba K, 2013, ACTA ONCOL, V52, P803, DOI 10.3109/0284186X.2012.709948; HUNCHAREK M, 1994, CHEST, V106, P605, DOI 10.1378/chest.106.2.605; Iwakawa R, 2008, CLIN CANCER RES, V14, P3746, DOI 10.1158/1078-0432.CCR-07-4552; Larsen BT, 2013, AM J SURG PATHOL, V37, P1555, DOI 10.1097/PAS.0b013e3182910c82; Livasy Chad A, 2003, Ann Diagn Pathol, V7, P249, DOI 10.1016/S1092-9134(03)00071-6; MUSK AW, 1991, AUST NZ J MED, V21, P460, DOI 10.1111/j.1445-5994.1991.tb01355.x; Nind NR, 2003, HISTOPATHOLOGY, V42, P150, DOI 10.1046/j.1365-2559.2003.01555.x; Raoof S, 2006, CHEST, V129, P805, DOI 10.1378/chest.129.3.805; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Rubins JB, 2009, CHEST, V135, P578, DOI 10.1378/chest.07-3002; URI AJ, 1988, CHEST, V93, P433, DOI 10.1378/chest.93.2.433	20	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2015	65	6					318	323		10.1111/pin.12282		6	Pathology	Pathology	CJ7CJ	WOS:000355651400006		
J	Kimura, M; Maenishi, O; Enoki, E; Chikugo, T; Umeyama, T; Ohno, H; Miyazaki, Y				Kimura, Masatomo; Maenishi, Osamu; Enoki, Eisuke; Chikugo, Takaaki; Umeyama, Takashi; Ohno, Hideaki; Miyazaki, Yoshitsugu			Aspergillus fungal ball in central cavity of a pulmonary cryptococcal nodal lesion	PATHOLOGY INTERNATIONAL			English	Letter									[Kimura, Masatomo; Maenishi, Osamu; Enoki, Eisuke; Chikugo, Takaaki] Kinki Univ, Fac Med, Dept Pathol, Osaka, Japan; [Umeyama, Takashi; Ohno, Hideaki; Miyazaki, Yoshitsugu] Natl Inst Infect Dis, Dept Chemotherapy & Mycoses, Tokyo, Japan; [Ohno, Hideaki] Saitama Med Univ, Dept Infect Dis & Infect Control, Saitama Med Ctr, Kawagoe, Saitama, Japan	Kimura, M (reprint author), Kinki Univ, Fac Med, Dept Pathol, Osaka, Japan.						Enoki E, 2012, PATHOL INT, V62, P574, DOI 10.1111/j.1440-1827.2012.02839.x; Fukuzawa M, 1995, VIRCHOWS ARCH, V427, P407; Hara Hiromichi, 2004, Nihon Kokyuki Gakkai Zasshi, V42, P854; Khayhan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072222; Lin Chih-Ming, 2006, J Infect, V53, pe55, DOI 10.1016/j.jinf.2005.10.017; Makino Y, 2014, INTERNAL MED, V53, P2737, DOI 10.2169/internalmedicine.53.2973; ROSENHEIM SH, 1975, AM REV RESPIR DIS, V111, P549; SAROSI GA, 1971, AM REV RESPIR DIS, V104, P581; SCHWARZ J, 1961, AM J MED, V31, P692, DOI 10.1016/0002-9343(61)90153-X	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2015	65	6					329	331		10.1111/pin.12266		3	Pathology	Pathology	CJ7CJ	WOS:000355651400008		
J	Noma, D; Morohoshi, T; Adachi, H; Natsume, I; Ookouchi, M; Tsuura, Y; Tsuboi, M; Masuda, M				Noma, Daisuke; Morohoshi, Takao; Adachi, Hiroyuki; Natsume, Ichirou; Ookouchi, Minoru; Tsuura, Yukio; Tsuboi, Masahiro; Masuda, Munetaka			A resected case of combined small cell lung carcinoma with carcinosarcoma	PATHOLOGY INTERNATIONAL			English	Letter									[Noma, Daisuke; Morohoshi, Takao; Adachi, Hiroyuki] Yokosuka Kyousai Hosp, Dept Gen Thorac Surg, Yokosuka, Kanagawa, Japan; [Natsume, Ichirou; Ookouchi, Minoru] Yokosuka Kyousai Hosp, Dept Internal Med, Yokosuka, Kanagawa, Japan; [Tsuura, Yukio] Yokosuka Kyousai Hosp, Dept Pathol, Yokosuka, Kanagawa, Japan; [Tsuboi, Masahiro] Natl Canc Ctr, East Hosp, Dept Gen Thorac Surg, Kashiwa, Chiba, Japan; [Masuda, Munetaka] Yokohama City Univ, Dept Surg Therapeut, Yokohama, Kanagawa 232, Japan	Noma, D (reprint author), Yokosuka Kyousai Hosp, Dept Gen Thorac Surg, Yokosuka, Kanagawa, Japan.						TRAVIS WD, 1995, CANCER, V75, P191, DOI 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y; Hamai K, 2010, JJLC, V50, P15; HEREMANS A, 1989, ACTA CLIN BELG, V44, P110; Koss MN, 1999, AM J SURG PATHOL, V23, P1514, DOI 10.1097/00000478-199912000-00009; MOORE TC, 1961, SURGERY, V50, P886; SARMA DP, 1982, J SURG ONCOL, V19, P216, DOI 10.1002/jso.2930190408; Takayama Y, 2010, JJOLC, V50, P151; Travis WD, 1999, WHO CLASSIFICATION T	8	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2015	65	6					332	334		10.1111/pin.12269		3	Pathology	Pathology	CJ7CJ	WOS:000355651400009		
J	Aishima, S; Tanaka, Y; Kubo, Y; Shirabe, K; Maehara, Y; Oda, Y				Aishima, Shinichi; Tanaka, Yuki; Kubo, Yuichiro; Shirabe, Ken; Maehara, Yoshihiko; Oda, Yoshinao			Bile duct adenoma should not be designated as a reactive process Reply	PATHOLOGY INTERNATIONAL			English	Letter									[Aishima, Shinichi] Saga Univ, Fac Med, Dept Pathol & Microbiol, Saga 840, Japan; [Tanaka, Yuki; Kubo, Yuichiro; Oda, Yoshinao] Kyushu Univ, Grad Sch Med, Anat Pathol, Fukuoka 812, Japan; [Shirabe, Ken; Maehara, Yoshihiko] Kyushu Univ, Grad Sch Med, Surg & Sci, Fukuoka 812, Japan	Aishima, S (reprint author), Saga Univ, Fac Med, Dept Pathol & Microbiol, Saga 840, Japan.						Aishima S, 2014, PATHOL INT, V64, P551, DOI 10.1111/pin.12209; Goeppert B, 2014, MODERN PATHOL, V27, P1028, DOI 10.1038/modpathol.2013.206; Pujals A, 2015, PATHOL INT, V65, P338, DOI 10.1111/pin.12273; Pujals A, 2015, HISTOPATHOLOGY, V67, P562, DOI 10.1111/his.12674; Pujals A, 2015, HEPATOLOGY, V61, P403, DOI 10.1002/hep.27133	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUN	2015	65	6					339	339		10.1111/pin.12307		1	Pathology	Pathology	CJ7CJ	WOS:000355651400012		
J	Yamada, H; Nishida, Y; Maihara, T; Sa'adah, N; Harahap, NHF; Nurputra, DK; Rochmah, MA; Nishimura, N; Saito, T; Kubo, Y; Saito, K; Nishio, H				Yamada, Hiroyuki; Nishida, Yoshinobu; Maihara, Toshiro; Sa'adah, Nihayatus; Harahap, Nur Hmna Fatimah; Nurputra, Dian Kesumapramudya; Rochmah, Mawaddah Ar; Nishimura, Noriyuki; Saito, Toshio; Kubo, Yuji; Saito, Kayoko; Nishio, Hisahide			Two Japanese Patients With SMA Type 1 Suggest that Axonal-SMN May Not Modify the Disease Severity	PEDIATRIC NEUROLOGY			English	Article						spinal muscular atrophy; full-length SMN1; C-terminal domain; axonal-SMN	SPINAL MUSCULAR-ATROPHY; MOTOR-NEURON GENE; SURVIVAL; PROTEIN; MUTATIONS	BACKGROUND: Spinal muscular atrophy is caused by survival motor neuron gene SMN1 mutations. SMN1 produces a full-length SMN1 protein isoform encoded by exons 1-7, and an axonal-SMN protein isoform encoded by exons 1-3 and intron 3. The axonal-SMN protein is expressed only in the embryonic period and plays a significant role in axonal growth. However, there has been no report on contribution of axonal-SMN to spinal muscular atrophy severity until now. PATIENTS: Two Japanese boys with spinal muscular atrophy type 1 in our study presented with generalized muscle weakness and respiratory insufficiency soon after birth and required an artificial ventilator from early infancy. Patient 1 was compound heterozygous for two SMN1 mutations, whole-gene deletion, and an intragenic mutation (c.819_820insT). He retained one copy of SMN1 producing the N-terminal part of SMN1 including axonal-SMN. On the other hand, patient 2 was homozygous for SMN1 deletion. Both of them showed the same copy number of spinal muscular atrophy modifying genes, NAIP and SMN2. These findings suggested that the C-terminal domain of full-length SMN1 determined the severity, irrespective of presence or absence of axonal-SMN expression. CONCLUSION: In patient 1, the C-terminal domain of full-length SMN1 determined spinal muscular atrophy severity, rather than the axonal-SMN, one copy of which could be present and intact. The presence or absence of axonal-SMN may not impact disease severity in spinal muscular atrophy type 1 patients.	[Yamada, Hiroyuki; Nishida, Yoshinobu; Maihara, Toshiro] Hyogo Prefectural Tsukaguchi Hosp, Dept Pediat, Amagasaki, Hyogo, Japan; [Yamada, Hiroyuki] Toyooka Publ Hosp, Dept Pediat, Toyooka, Hyogo, Japan; [Sa'adah, Nihayatus; Harahap, Nur Hmna Fatimah; Nurputra, Dian Kesumapramudya; Rochmah, Mawaddah Ar; Nishimura, Noriyuki; Nishio, Hisahide] Kobe Univ, Grad Sch Med, Dept Community Med & Social Hlth Care, Kobe, Hyogo 6500017, Japan; [Nishimura, Noriyuki; Nishio, Hisahide] Kobe Univ, Grad Sch Med, Dept Pediat, Kobe, Hyogo 6500017, Japan; [Saito, Toshio] Natl Hosp Org, Toneyama Natl Hosp, Dept Neurol, Div Child Neurol, Toyonaka, Osaka, Japan; [Kubo, Yuji; Saito, Kayoko] Tokyo Womens Med Univ, Inst Med Genet, Tokyo, Japan	Nishio, H (reprint author), Kobe Univ, Grad Sch Med, Dept Community Med & Social Healthcare Sci, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	nishio@med.kobe-u.ac.jp			Research Committee of Spinal Muscular Atrophy [H22-NANCHI-IPPAN-012]; Ministry of Education, Culture, Sports, Science and Technology of Japan [25461549]	This study was supported in part by Grants-in-Aid provided from the Research Committee of Spinal Muscular Atrophy (Research Project Number:H22-NANCHI-IPPAN-012), and the Ministry of Education, Culture, Sports, Science and Technology of Japan (Research Project Number: 25461549).	LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Feldkotter M, 2002, AM J HUM GENET, V70, P358, DOI 10.1086/338627; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Wirth B, 2000, HUM MUTAT, V15, P228, DOI 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Kotani T, 2007, J NEUROL, V254, P624, DOI 10.1007/s00415-006-0410-x; Locatelli D, 2012, J NEUROCHEM, V121, P465, DOI 10.1111/j.1471-4159.2012.07689.x; Munsat L, 1992, NEUROMUSCULAR DISORD, V2, P423; Setola V, 2007, P NATL ACAD SCI USA, V104, P1959, DOI 10.1073/pnas.0610660104; Yamamoto T, 2014, BRAIN DEV-JPN, V36, P914, DOI 10.1016/j.braindev.2013.11.009; Zhang HLL, 2003, J NEUROSCI, V23, P6627	11	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	JUN	2015	52	6					638	641		10.1016/j.pediatrneurol.2015.02.023		4	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CJ5ZJ	WOS:000355572500011		
J	Chong, PF; Matsukura, M; Kira, R				Chong, Pin Fee; Matsukura, Masaru; Kira, Ryutaro			Water Immersion-Induced Skin Wrinkling Test in Complex Regional Pain Syndrome	PEDIATRIC NEUROLOGY			English	Editorial Material									[Chong, Pin Fee; Matsukura, Masaru; Kira, Ryutaro] Fukuoka Childrens Hosp, Dept Pediat Neurol, Fukuoka 8100017, Japan	Chong, PF (reprint author), Fukuoka Childrens Hosp, Dept Pediat Neurol, Higashi Ku, 5-1-1 Kashii Teriha, Fukuoka 8100017, Japan.	chong.p.f@fcho.jp					Marinus J, 2011, LANCET NEUROL, V10, P637, DOI 10.1016/S1474-4422(11)70106-5; Borchers AT, 2014, AUTOIMMUN REV, V13, P242, DOI 10.1016/j.autrev.2013.10.006; Wilder-Smith EPV, 2004, CLIN AUTON RES, V14, P125, DOI 10.1007/s10286-004-0172-4	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	JUN	2015	52	6					649	650		10.1016/j.pediatrneurol.2015.02.022		2	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CJ5ZJ	WOS:000355572500014		
J	Wang, YQ; Li, R; Wu, X; Zhu, F; Takata, Y; Zhang, Z; Zhang, MQ; Li, SQ; Qu, WM				Wang, Yi-Qun; Li, Rui; Wu, Xu; Zhu, Fen; Takata, Yohko; Zhang, Ze; Zhang, Meng-Qi; Li, Shan-Qun; Qu, Wei-Min			Fasting activated histaminergic neurons and enhanced arousal effect of caffeine in mice	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Caffeine; EEG; Fasted; H1R; Wakefulness	FOOD-ANTICIPATORY ACTIVITY; EYE-MOVEMENT SLEEP; ADENOSINE RECEPTORS; H-1 RECEPTORS; OREXIN; BEHAVIOR; SYSTEM; BRAIN; HYPOTHALAMUS; WAKEFULNESS	Caffeine, a popular psychoactive compound, promotes wakefulness via blocking adenosine A(2A) receptors in the shell of the nucleus accumbens, which projects to the arousal histaminergic tuberomammillary nucleus (TMN). The TMN controls several behaviors such as wakefulness and feeding. Fasting has been reported to activate the TMN histaminergic neurons to increase arousal. Therefore, we propose that caffeine may promote greater arousal under fasting rather than normal feeding conditions. In the current study, locomotor activity recording, electroencephalogram (EEG) and electromyogram recording and c-Fos expression were used in wild type (WT) and histamine H-1 receptor (H1R) knockout (KO) mice to investigate the arousal effects of caffeine under fasting conditions. Caffeine (15 mg/kg) enhanced locomotor activity in fasted mice for 5 h, but only did so for 3 h in normally fed animals. Pretreatment with the FliR antagonist pyrilamine abolished caffeine-induced stimulation on locomotor activity in fasted mice. EEG recordings confirmed that caffeine-induced wakefulness for 3 h in fed WT mice, and for 5 h in fasted ones. A stimulatory effect of caffeine was not observed in fasted H1R KO mice. Furthermore, c-Fos expression was increased in the TMN under fasting conditions. These results indicate that caffeine had greater wakefulness-promoting effects in fasted mice through the mediation of H1R. (C) 2015 Elsevier Inc. All rights reserved.	[Wang, Yi-Qun; Li, Rui; Qu, Wei-Min] Fudan Univ, Sch Basic Med Sci, Dept Pharmacol, Shanghai 200032, Peoples R China; [Wang, Yi-Qun; Li, Rui; Qu, Wei-Min] Fudan Univ, Sch Basic Med Sci, Shanghai Key Lab Bioact Small Mol, Shanghai 200032, Peoples R China; [Li, Rui; Wu, Xu; Zhu, Fen; Li, Shan-Qun] Fudan Univ, Zhongshan Hosp, Dept Resp Med, Shanghai 200433, Peoples R China; [Li, Rui; Wu, Xu; Zhu, Fen; Li, Shan-Qun] Fudan Univ, Zhongshan Hosp, Clin Ctr Sleep Breathing Disorder & Snoring, Shanghai 200433, Peoples R China; [Takata, Yohko] Univ Tsukuba, IIIS, Int Inst Integrat Sleep Med WPI, Ibaraki, Japan; [Zhang, Ze; Qu, Wei-Min] Fudan Univ, Shanghai Med Coll, Inst Brain Sci, Shanghai 200433, Peoples R China; [Zhang, Meng-Qi] Fudan Univ, Sch Basic Med Sci, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China	Wang, YQ (reprint author), Fudan Univ, Sch Basic Med Sci, Dept Pharmacol, Shanghai 200032, Peoples R China.	yiqunwang@fudan.edu.cn; li.shanqun@zs-hospital.sh.cn; quweimin@fudan.edu.cn			National Natural Science Foundation of China [J1210041, 31171010, 31171049, 31121061, 31271164, 31471064, 81420108015]; National Basic Research Program of China [2011CB711000, 2015CB856401, 2009ZX09303-006]; Fundamental Research Funds for the Central Universities [10FX041]; key laboratory program of the Education Commission of Shanghai Municipality [ZDSYS14005]; Shanghai Committee of Science and Technology [13140903100, 14JC1400900, 13dz2260700]; Shanghai Leading Academic Discipline Project [B119]; Programs Foundation of Ministry of Education of China [20110071110033]	The authors thank Dr Zhi-Li Huang (Department of Pharmacology, School of Basic Medical Sciences, Fudan University) for his comments and help in the preparation of the manuscript. This study was supported in part by grants-in-aid for scientific research from the National Natural Science Foundation of China (J1210041, 31171010, 31171049, 31121061, 31271164, 31471064, 81420108015), the National Basic Research Program of China (2011CB711000, 2015CB856401, 2009ZX09303-006), the Fundamental Research Funds for the Central Universities (10FX041), a key laboratory program of the Education Commission of Shanghai Municipality (ZDSYS14005), the Shanghai Committee of Science and Technology (13140903100, 14JC1400900, 13dz2260700), the Shanghai Leading Academic Discipline Project (B119), PhD, and the Programs Foundation of Ministry of Education of China (20110071110033).	Qu WM, 2010, J NEUROSCI, V30, P4382, DOI 10.1523/JNEUROSCI.4936-09.2010; Huang ZL, 2006, P NATL ACAD SCI USA, V103, P4687, DOI 10.1073/pnas.0600451103; Inoue I, 1996, P NATL ACAD SCI USA, V93, P13316, DOI 10.1073/pnas.93.23.13316; Liu YY, 2012, J BIOL RHYTHM, V27, P398, DOI 10.1177/0748730412455913; Akiyama M, 2004, EUR J NEUROSCI, V20, P3054, DOI 10.1111/j.1460-9568.2004.03749.x; Diano S, 2003, ENDOCRINOLOGY, V144, P3774, DOI 10.1210/en.2003-0274; Valdes JL, 2010, EUR J NEUROSCI, V31, P2073, DOI 10.1111/j.1460-9568.2010.07241.x; Panula P, 2013, NAT REV NEUROSCI, V14, P472, DOI 10.1038/nrn3526; Sakurai T, 1999, REGUL PEPTIDES, V85, P25, DOI 10.1016/S0167-0115(99)00076-2; Brown RE, 2002, J NEUROSCI, V22, P8850; Wang YQ, 2012, J NEUROCHEM, V120, P314, DOI 10.1111/j.1471-4159.2011.07558.x; Fredholm BB, 2011, PHARMACOL REV, V63, P1, DOI 10.1124/pr.110.003285; Lazarus M, 2011, J NEUROSCI, V31, P10067, DOI 10.1523/JNEUROSCI.6730-10.2011; Huang ZL, 2001, P NATL ACAD SCI USA, V98, P9965, DOI 10.1073/pnas.181330998; Huang ZL, 2005, NAT NEUROSCI, V8, P858, DOI 10.1038/nn1491; Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983; PANULA P, 1989, NEUROSCIENCE, V28, P585, DOI 10.1016/0306-4522(89)90007-9; Fredholm BB, 2005, INT REV NEUROBIOL, V63, P191, DOI 10.1016/S0074-7742(05)63007-3; Huang ZL, 2014, INT REV NEUROBIOL, V119, P349, DOI 10.1016/B978-0-12-801022-8.00014-3; LIN JS, 1988, NEUROPHARMACOLOGY, V27, P111, DOI 10.1016/0028-3908(88)90159-1; Masaki T, 2007, MINI-REV MED CHEM, V7, P821; MONTI JM, 1986, J NEURAL TRANSM, V66, P1, DOI 10.1007/BF01262953; Sakurai T, 2003, CURR OPIN CLIN NUTR, V6, P353, DOI 10.1097/01.mco.0000078995.96795.91; Sakurai T, 2014, NAT REV NEUROSCI, V15, P719, DOI 10.1038/nrn3837; Tokunaga S, 2009, BIOL PHARM BULL, V32, P51; Valdes JL, 2005, EUR J NEUROSCI, V21, P1931, DOI 10.1111/j.1460-9568.2005.04013.x; Vanni-Mercier G, 2003, BEHAV BRAIN RES, V144, P227, DOI 10.1016/S0166-4328(03)00091-3; Wang YQ, 2015, PHARMACOL BIOCHEM BE, V129, P56, DOI 10.1016/j.pbb.2014.12.002; Zhang JP, 2013, FRONT NEUROANAT, V7, DOI 10.3389/fnana.2013.00043	29	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	JUN	2015	133						164	173		10.1016/j.pbb.2015.04.003		10	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	CK0GF	WOS:000355883000019		
J	Nishizawa, A; Seto, N				Nishizawa, Atsushi; Seto, Naoki			Search for an emission line of a gravitational wave background	PHYSICAL REVIEW D			English	Article							RADIATION	In light of the history of research on an electromagnetic wave spectrum, a sharp emission line of gravitational wave background (GWB) would be an interesting observational target. Here we study an efficient method to detect a line GWB by correlating data of multiple ground-based detectors. We find that the width of frequency bin for coarse graining is a critical parameter, and, with the commonly used value 0.25 Hz, the signal-to-noise ratio could be decreased by up to a factor of 6.6, compared with a finer width of 0.02 Hz. By reanalyzing the existing data with a smaller bin width, we might detect a precious line signal from the early Universe.	[Nishizawa, Atsushi] CALTECH, Theoret Astrophys 350 17, Pasadena, CA 91125 USA; [Seto, Naoki] Kyoto Univ, Dept Phys, Kyoto 6068502, Japan	Nishizawa, A (reprint author), CALTECH, Theoret Astrophys 350 17, Pasadena, CA 91125 USA.	anishi@caltech.edu			JSPS Postdoctoral Fellowships for Research Abroad; JSPS [24540269]; MEXT [24103006]	A. N. is supported by JSPS Postdoctoral Fellowships for Research Abroad. N. S. is supported by JSPS (24540269) and MEXT (24103006).	Aasi J, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.231101; Abadie J, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.271102; Aghanim N, 2014, ASTRON ASTROPHYS, V571, DOI 10.1051/0004-6361/201321556; Nishizawa A, 2009, PHYS REV D, V79, DOI 10.1103/PhysRevD.79.082002; Seto N, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.151101; Allen B, 1997, PHYS REV D, V56, P545, DOI 10.1103/PhysRevD.56.545; Allen B, 1999, PHYS REV D, V59, DOI 10.1103/PhysRevD.59.102001; FLANAGAN EE, 1993, PHYS REV D, V48, P2389, DOI 10.1103/PhysRevD.48.2389; Grojean C, 2007, PHYS REV D, V75, DOI 10.1103/PhysRevD.75.043507; Punturo M, 2010, CLASSICAL QUANT GRAV, V27, DOI 10.1088/0264-9381/27/8/084007; Damour T, 2005, PHYS REV D, V71, DOI 10.1103/PhysRevD.71.063510; Turner MS, 1997, PHYS REV D, V55, pR435, DOI 10.1103/PhysRevD.55.R435; CHRISTENSEN N, 1992, PHYS REV D, V46, P5250, DOI 10.1103/PhysRevD.46.5250; Nishizawa A, 2014, PHYS REV D, V89, DOI 10.1103/PhysRevD.89.063541; Boyle LA, 2008, PHYS REV D, V78, DOI 10.1103/PhysRevD.78.043531; Abbott B, 2007, PHYS REV D, V76, DOI 10.1103/PhysRevD.76.082003; KAMIONKOWSKI M, 1994, PHYS REV D, V49, P2837, DOI 10.1103/PhysRevD.49.2837; Smith TL, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.021301; CHODOS A, 1980, PHYS REV D, V21, P2167, DOI 10.1103/PhysRevD.21.2167; Easther R, 2006, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2006/04/010; Gumrukcuoglu AE, 2012, CLASSICAL QUANT GRAV, V29, DOI 10.1088/0264-9381/29/23/235026; Fenu E, 2009, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2009/10/005; LISA Study Team, 1998, LISA PREPH REP; Maggiore M., 2000, Physics Reports, V331, DOI 10.1016/S0370-1573(99)00102-7; Nakayama K, 2008, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2008/06/020; Prince TA, 2002, PHYS REV D, V66, DOI 10.1103/PhysRevD.66.122002; Sathyaprakash BS, 2009, LIVING REV RELATIV, V12; Seahra SS, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.121302; Seoane P. A., ARXIV13055720 ELISA; Watanabe Y, 2006, PHYS REV D, V73, DOI 10.1103/PhysRevD.73.123515	30	2	2	AMER PHYSICAL SOC	COLLEGE PK	ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA	1550-7998	1550-2368		PHYS REV D	Phys. Rev. D	JUN 1	2015	91	12							122001	10.1103/PhysRevD.91.122001		6	Astronomy & Astrophysics; Physics, Particles & Fields	Astronomy & Astrophysics; Physics	CJ3VW	WOS:000355413300002		
J	Ishikawa, H; Yoshida, M; Nawa, K; Jeong, M; Kramer, S; Horvatic, M; Berthier, C; Takigawa, M; Akaki, M; Miyake, A; Tokunaga, M; Kindo, K; Yamaura, J; Okamoto, Y; Hiroi, Z				Ishikawa, H.; Yoshida, M.; Nawa, K.; Jeong, M.; Kraemer, S.; Horvatic, M.; Berthier, C.; Takigawa, M.; Akaki, M.; Miyake, A.; Tokunaga, M.; Kindo, K.; Yamaura, J.; Okamoto, Y.; Hiroi, Z.			One-Third Magnetization Plateau with a Preceding Novel Phase in Volborthite	PHYSICAL REVIEW LETTERS			English	Article							KAGOME HEISENBERG-ANTIFERROMAGNET; LIQUIDS; CHAINS; STATES; FIELD	We have synthesized high-quality single crystals of volborthite, a seemingly distorted kagome antiferromagnet, and carried out high-field magnetization measurements up to 74 T and V-51 NMR measurements up to 30 T. An extremely wide 1/3 magnetization plateau appears above 28 T and continues over 74 T at 1.4 K, which has not been observed in previous studies using polycrystalline samples. NMR spectra reveal an incommensurate order (most likely a spin-density wave order) below 22 T and a simple spin structure in the plateau phase. Moreover, a novel intermediate phase is found between 23 and 26 T, where the magnetization varies linearly with magnetic field and the NMR spectra indicate an inhomogeneous distribution of the internal magnetic field. This sequence of phases in volborthite bears a striking similarity to those of frustrated spin chains with a ferromagnetic nearest-neighbor coupling J(1) competing with an antiferromagnetic next-nearest-neighbor coupling J(2)	[Ishikawa, H.; Yoshida, M.; Nawa, K.; Takigawa, M.; Akaki, M.; Miyake, A.; Tokunaga, M.; Kindo, K.; Okamoto, Y.; Hiroi, Z.] Univ Tokyo, Inst Solid State Phys, Kashiwa, Chiba 2778581, Japan; [Jeong, M.; Kraemer, S.; Horvatic, M.; Berthier, C.] UPS, CNRS, LNCMI, UJF,UPR3228, F-38042 Grenoble 9, France; [Jeong, M.; Kraemer, S.; Horvatic, M.; Berthier, C.] INSA, F-38042 Grenoble 9, France; [Yamaura, J.] Tokyo Inst Technol, Mat Res Ctr Element Strategy, Yokohama, Kanagawa 2268503, Japan; [Okamoto, Y.] Nagoya Univ, Dept Appl Phys, Nagoya, Aichi 4648603, Japan	Ishikawa, H (reprint author), Univ Tokyo, Inst Solid State Phys, Kashiwa, Chiba 2778581, Japan.		Tokunaga, Masashi/C-6821-2014	Tokunaga, Masashi/0000-0002-1401-9381	Japan Society for the Promotion of Science (JSPS KAKENHI) [14J07886]; Program for Leading Graduate Schools (MERIT); MEXT Japan [26800176, 25287083]; EuroMagNET II network under the EU Contract [228043]	We are grateful to O. Janson for helpful discussion. H. I. was supported by research fellowship of Japan Society for the Promotion of Science (JSPS KAKENHI Grant No. 14J07886) and its Program for Leading Graduate Schools (MERIT). Synchrotron radiation experiments were performed at BL-8A in KEK-PF (Proposal No. 2013S2002). This work was partly supported by a Grant-in-Aid for Scientific Research (No. 26800176 and No. 25287083) and Elements Strategy Initiative from MEXT Japan and EuroMagNET II network under the EU Contract No. 228043.	Mizuno Y, 1998, PHYS REV B, V57, P5326, DOI 10.1103/PhysRevB.57.5326; Jiang HC, 2012, NAT PHYS, V8, P902, DOI 10.1038/NPHYS2465; Helton JS, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.107204; Okamoto Y, 2009, J PHYS SOC JPN, V78, DOI 10.1143/JPSJ.78.033701; Hikihara T, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.144404; Mendels P, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.077204; Hiroi Z, 2001, J PHYS SOC JPN, V70, P3377, DOI 10.1143/JPSJ.70.3377; Schnyder AP, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.174420; Svistov LE, 2011, JETP LETT+, V93, P21, DOI 10.1134/S0021364011010073; Yoshida H, 2009, J PHYS SOC JPN, V78, DOI 10.1143/JPSJ.78.043704; Yoshida H, 2012, J MATER CHEM, V22, P18793, DOI 10.1039/c2jm32250a; Yan SM, 2011, SCIENCE, V332, P1173, DOI 10.1126/science.1201080; Heidrich-Meisner F, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.020403; Iqbal Y, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.060405; CHUBUKOV AV, 1991, PHYS REV B, V44, P4693, DOI 10.1103/PhysRevB.44.4693; Capponi S, 2013, PHYS REV B, V88, DOI 10.1103/PhysRevB.88.144416; Singh RRP, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.180407; Depenbrock S, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.067201; Yoshida M, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.077207; Shores MP, 2005, J AM CHEM SOC, V127, P13462, DOI 10.1021/ja053891p; Hida K, 2001, J PHYS SOC JPN, V70, P3673, DOI 10.1143/JPSJ.70.3673; Apel W, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/14/145255; Balents L, 2010, NATURE, V464, P199, DOI 10.1038/nature08917; Bert F, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.087203; Buttgen N, 2014, PHYS REV B, V90, DOI 10.1103/PhysRevB.90.134401; Cabra D. C., ARXIVCONDMAT0312119; Fukaya A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.207603; Ishikawa H, 2012, ACTA CRYSTALLOGR C, V68, pI41, DOI 10.1107/S010827011202536X; Janson O, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.104434; Kaneko R, 2010, J PHYS SOC JPN, V79, DOI 10.1143/JPSJ.79.073708; Kindo K, 2010, J LOW TEMP PHYS, V159, P381, DOI 10.1007/s10909-009-0153-z; Kohno Y., COMMUNICATION; Lacroix C, 2011, INTRO FRUSTRATED MAG; LAFONTAINE MA, 1990, J SOLID STATE CHEM, V85, P220, DOI 10.1016/S0022-4596(05)80078-7; Masuda H, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.057201; Nilsen GJ, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.172401; Nishimoto S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3287; Ohta H, 2009, J PHYS CONF SER, V145, DOI 10.1088/1742-6596/145/1/012010; Okamoto Y, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.180407; Sindzingre P., ARXIV07074264; Sudan J, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.140402; Wang F, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.094421; Yamashita S, 2010, J PHYS SOC JPN, V79, DOI 10.1143/JPSJ.79.083710; Yavors'kii T, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.064430; Yoshida H, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1875; Yoshida M, 2012, J PHYS SOC JPN, V81, DOI 10.1143/JPSJ.81.024703; Yoshida M, 2013, J PHYS SOC JPN, V82, DOI 10.7566/JPSJ.82.013702; Yoshida M., UNPUB; Yoshida M, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.020410	49	3	3	AMER PHYSICAL SOC	COLLEGE PK	ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA	0031-9007	1079-7114		PHYS REV LETT	Phys. Rev. Lett.	JUN 1	2015	114	22							227202	10.1103/PhysRevLett.114.227202		5	Physics, Multidisciplinary	Physics	CJ3SN	WOS:000355404300005		
J	Kishikawa, A; Ashour, A; Zhu, QC; Yasuda, M; Ishikawa, H; Shimizu, K				Kishikawa, Asuka; Ashour, Ahmed; Zhu, Qinchang; Yasuda, Midori; Ishikawa, Hiroya; Shimizu, Kuniyoshi			Multiple Biological Effects of Olive Oil By-products such as Leaves, Stems, Flowers, Olive Milled Waste, Fruit Pulp, and Seeds of the Olive Plant on Skin	PHYTOTHERAPY RESEARCH			English	Article						Olive (Olea europaea L; ) by-products; antioxidant activity; antibacterial activity; anti-melanogenesis activity; anti-allergic activity; collagen-production-promoting activity	OLEA-EUROPAEA; PHENOLIC-COMPOUNDS; DIFFERENT PARTS; EXTRACTS; MICE; VARIETIES; EXPOSURE; CELLS	As olive oil production increases, so does the amount of olive oil by-products, which can cause environmental problems. Thus, new ways to utilize the by-products are needed. In the present study, five bioactive characteristics of olive oil by-products were assessed, namely their antioxidant, anti-bacterial, anti-melanogenesis, anti-allergic, and collagen-production-promoting activities. First, the extracts of leaves (May and October), stems (May and October), flowers, olive milled waste, fruit pulp and seeds were prepared using two safe solvents, ethanol and water. According to HPLC and LC/MS analysis and Folin-Ciocalteu assay, the ethanol extracts of the leaves (May and October), stems (May and October) and flowers contained oleuropein, and the ethanol extract of the stems showed the highest total phenol content. Oleuropein may contribute to the antioxidant and anti-melanogenesis activities of the leaves, stems, and flowers. However, other active compounds or synergistic effects present in the ethanol extracts are also likely to contribute to the anti-bacterial activity of the leaves and flowers, the anti-melanogenesis activity of some parts, the anti-allergic activity of olive milled waste, and the collagen-production-promoting activity of the leaves, stems, olive milled waste and fruit pulp. This study provides evidence that the by-products of olive oil have the potential to be further developed and used in the skin care industry. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Kishikawa, Asuka; Zhu, Qinchang; Shimizu, Kuniyoshi] Kyushu Univ, Dept Agroenvironm Sci, Fac Agr, Fukuoka 8128581, Japan; [Ashour, Ahmed] Mansoura Univ, Dept Pharmacognosy, Fac Pharm, Mansoura, Egypt; [Yasuda, Midori] Nishikyushu Univ, Dept Hlth & Nutr Sci, Saga 8428585, Japan; [Ishikawa, Hiroya] Fukuoka Womens Univ, Int Coll Arts & Sci, Fukuoka 8138529, Japan	Ishikawa, H (reprint author), Fukuoka Womens Univ, Int Coll Arts & Sci, Fukuoka 8138529, Japan.	ishikawa@fwu.ac.jp; shimizu@agr.kyushu-u.ac.jp			Olive Japan Co., Ltd.	The authors are very grateful to Olive Japan Co., Ltd., for its support of this research.	Rafehi H, 2012, GENES NUTR, V7, P343, DOI 10.1007/s12263-011-0249-3; Aburjai T, 2003, PHYTOTHER RES, V17, P987, DOI 10.1002/ptr.1363; Tanaka A, 2014, MOLECULES, V19, P8238, DOI 10.3390/molecules19068238; Ikawati Z, 2001, J ETHNOPHARMACOL, V75, P249, DOI 10.1016/S0378-8741(01)00201-X; Dao JH, 2009, ANAL BIOCHEM, V384, P213, DOI 10.1016/j.ab.2008.09.052; Ghanbari R, 2012, INT J MOL SCI, V13, P3291, DOI 10.3390/ijms13033291; Miller LS, 2011, NAT REV IMMUNOL, V11, P505, DOI 10.1038/nri3010; Romero C, 2002, EUR FOOD RES TECHNOL, V215, P489, DOI 10.1007/s00217-002-0619-6; Mira A, 2013, J ETHNOPHARMACOL, V148, P980, DOI 10.1016/j.jep.2013.06.008; Sato A, 2014, J AGR FOOD CHEM, V62, P7787, DOI 10.1021/jf502151b; Arung TE, 2007, CHEM BIODIVERS, V4, P2166; Arung TE, 2010, FOOD CHEM, V124, P1024; Brahmi F, 2013, IND CROP PROD, V49, P256, DOI 10.1016/j.indcrop.2013.04.042; Budiyanto A, 2000, CARCINOGENESIS, V21, P2085, DOI 10.1093/carcin/21.11.2085; Decorps J, 2014, AGEING RES REV, V13, P90, DOI 10.1016/j.arr.2013.12.003; Giner E, 2013, J NAT PROD, V76, P1113, DOI 10.1021/np400175b; Ha JY, 2009, FOOD SCI BIOTECHNOL, V18, P1193; Klen TJ, 2012, FOOD SCI TECHNOL, V49, P267; McGrath JA, 2012, BRIT J DERMATOL, V166, P9, DOI 10.1111/j.1365-2133.2012.10860.x; Mijatovic SA, 2010, INT J CANCER, V128, P1955; Sumiyoshi M, 2010, PHYTOTHER RES, V24, P995, DOI 10.1002/ptr.3048; Thaipong K, 2006, J FOOD COMPOS ANAL, V19, P669, DOI 10.1016/j.jfca.2006.01.003; Yamauchi K, 2013, J NAT MED-TOKYO, V67, P369, DOI 10.1007/s11418-012-0672-9	23	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0951-418X	1099-1573		PHYTOTHER RES	Phytother. Res.	JUN	2015	29	6					877	886		10.1002/ptr.5326		10	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ9SQ	WOS:000355843200013		
J	Iwatake, M; Okamoto, K; Tanaka, T; Tsukuba, T				Iwatake, Mayumi; Okamoto, Kuniaki; Tanaka, Takashi; Tsukuba, Takayuki			Castalagin Exerts Inhibitory Effects on Osteoclastogenesis Through Blocking a Broad Range of Signaling Pathways with Low Cytotoxicity	PHYTOTHERAPY RESEARCH			English	Article						osteoclasts; castalagin; NFATc1; RANKL	NF-KAPPA-B; FACTOR RECEPTOR; DIFFERENTIATION; RANKL; ACTIVATION; KINASE; PHOSPHORYLATION; ELLAGITANNIN; CELLS	Castalagin is a rare plant polyphenol that is classified as a hydrolyzable tannin. Although it has antioxidant, antitumorigenic, and leishmanicidal effects, the utility of castalagin against bone diseases remain to be elucidated. Here, we investigated the effects of castalagin on the differentiation of osteoclasts (OCLs), multinucleated bone-resorbing cells. After stimulation with receptor activator of nuclear factor kappa-B ligand (RANKL), the formation of OCLs from bone marrow-derived macrophages was significantly inhibited by castalagin even at 1M. However, castalagin displayed little cytotoxicity at a higher concentration of 50M. The effects of castalagin on intracellular signaling during OCL differentiation showed that castalagin suppresses RANKL-stimulated phosphorylation of major signaling pathways including protein kinase B (Akt), extracellular signal-regulated kinase, Jun N-terminal kinase, p38 mitogen-activated protein kinases, and inhibitor of nuclear factor kappa B alpha. Moreover, following castalagin treatment, the protein levels of nuclear factor of activated T-cells, cytoplasmic 1, a master regulator for OCL differentiation, and NF-B were decreased. Thus, castalagin exerts inhibitory effects on osteoclastogenesis through blockage of a broad range of signaling pathways, but has low cytotoxicity. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Iwatake, Mayumi; Okamoto, Kuniaki; Tsukuba, Takayuki] Nagasaki Univ, Div Dent Pharmacol, Grad Sch Biomed Sci, Nagasaki 8528588, Japan; [Tanaka, Takashi] Nagasaki Univ, Div Nat Prod Chem, Grad Sch Biomed Sci, Nagasaki 8528521, Japan	Tsukuba, T (reprint author), Nagasaki Univ, Div Dent Pharmacol, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	tsuta@nagasaki-u.ac.jp			Ministry of Education, Science, and Culture of Japan	We thank Dr Kazuhisa Nishishita for providing recombinant RANKL and Dr Eiko Sakai for the useful comments. This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan (T.T.).	Shuaibu MN, 2008, PARASITOL RES, V103, P1333, DOI 10.1007/s00436-008-1137-7; Vivas N, 2004, J AGR FOOD CHEM, V52, P2073, DOI 10.1021/jf030460m; Park EK, 2004, BIOCHEM BIOPH RES CO, V325, P1472, DOI 10.1016/j.bbrc.2004.10.197; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Hager TJ, 2008, J AGR FOOD CHEM, V56, P661, DOI 10.1021/jf071990b; Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Sakai E, 2013, J PHARMACOL SCI, V121, P288, DOI 10.1254/jphs.12243FP; Kamiya T, 1998, J BIOCHEM-TOKYO, V123, P752; Zhang YH, 2001, J BIOL CHEM, V276, P563; Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372; Fridrich D, 2008, J AGR FOOD CHEM, V56, P3010, DOI 10.1021/jf073427z; Fumimoto R, 2012, J PHARMACOL SCI, V118, P479, DOI 10.1254/jphs.11212FP; Has H, 2004, EXP CELL RES, V301, P119; Hes B, 2013, BIOORG MED CHEM LETT, V23, P630; Hus JP, 2008, EUR J PHARMACOL, V580, P70; Lees NK, 2005, BLOOD, V106, P852; Narahara S, 2012, CELL TISSUE RES, V348, P81, DOI 10.1007/s00441-012-1325-8	20	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0951-418X	1099-1573		PHYTOTHER RES	Phytother. Res.	JUN	2015	29	6					917	924		10.1002/ptr.5333		8	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ9SQ	WOS:000355843200018		
J	Kim, JS; Lee, J; Lee, CH; Woo, SY; Kang, H; Seo, SG; Kim, SH				Kim, Ji-Seong; Lee, Jeongeun; Lee, Chan-hui; Woo, Su Young; Kang, Hoduck; Seo, Sang-Gyu; Kim, Sun-Hyung			Activation of Pathogenesis-related Genes by the Rhizobacterium, Bacillus sp JS, Which Induces Systemic Resistance in Tobacco Plants	PLANT PATHOLOGY JOURNAL			English	Article						antifungal activities; disease resistance; plant growth promoting rhizobacteria	FLUORESCENT PSEUDOMONADS; DEFENSE RESPONSES; SWEET-POTATO; CELL-WALL; BIOCONTROL; PROTEINS; GROWTH; ARABIDOPSIS; RHIZOSPHERE; PEROXIDASE	Plant growth promoting rhizobacteria (PGPR) are known to confer disease resistance to plants. Bacillus sp. JS demonstrated antifungal activities against five fungal pathogens in in vitro assays. To verify whether the volatiles of Bacillus sp. JS confer disease resistance, tobacco leaves pre-treated with the volatiles were damaged by the fungal pathogen, Rhizoctonia solani and oomycete Phytophthora nicotianae. Pre-treated tobacco leaves had smaller lesion than the control plant leaves. In pathogenesis-related (PR) gene expression analysis, volatiles of Bacillus sp. JS caused the up-regulation of PR-2 encoding beta-1,3-glucanase and acidic PR-3 encoding chitinase. Expression of acidic PR-4 encoding chitinase and acidic PR-9 encoding peroxidase increased gradually after exposure of the volatiles to Bacillus sp. JS. Basic PR-14 encoding lipid transfer protein was also increased. However, PR-1 genes, as markers of salicylic acid (SA) induced resistance, were not expressed. These results suggested that the volatiles of Bacillus sp. JS confer disease resistance against fungal and oomycete pathogens through PR genes expression.	[Kim, Ji-Seong; Lee, Jeongeun] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; [Lee, Chan-hui] Kyung Hee Univ, Grad Sch Biotechnol, Yongin 446701, South Korea; [Kim, Ji-Seong; Lee, Jeongeun; Woo, Su Young; Seo, Sang-Gyu; Kim, Sun-Hyung] Univ Seoul, Dept Environm Hort, Seoul 130743, South Korea; [Kang, Hoduck] Dongguk Univ, Dept Biol & Environm Sci, Seoul 100715, South Korea	Kim, SH (reprint author), Univ Seoul, Dept Environm Hort, Seoul 130743, South Korea.	mongal@uos.ac.kr			Forest Science & Technology Projects, Forest Service [S211214L030210]; Advanced Production Technology Development Program, Ministry of Agriculture, Food and Rural Affairs, Republic of Korea [1100345]	This work was supported by a grant (Code # S211214L030210) from Forest Science & Technology Projects, Forest Service and by Advanced Production Technology Development Program, Ministry of Agriculture, Food and Rural Affairs (Code # 1100345), Republic of Korea.	Agrios G. N., 2005, PLANT PATHOLOGY; Raupach GS, 1996, PLANT DIS, V80, P891; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; Ligon JM, 2000, PEST MANAG SCI, V56, P688, DOI 10.1002/1526-4998(200008)56:8<688::AID-PS186>3.3.CO;2-M; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Pieterse CMJ, 1998, PLANT CELL, V10, P1571, DOI 10.1105/tpc.10.9.1571; Sels J, 2008, PLANT PHYSIOL BIOCH, V46, P941, DOI 10.1016/j.plaphy.2008.06.011; Ryu CM, 2004, PLANT PHYSIOL, V134, P1017, DOI 10.1104/pp.103.026583; Kim SH, 2005, BIOTECHNOL LETT, V27, P1841, DOI 10.1007/s10529-005-3891-2; Passardi F, 2004, TRENDS PLANT SCI, V9, P534, DOI 10.1016/j.tplants.2004.09.002; Yedidia I, 1999, APPL ENVIRON MICROB, V65, P1061; Vespermann A, 2007, APPL ENVIRON MICROB, V73, P5639, DOI 10.1128/AEM.01078-07; Haas D, 2005, NAT REV MICROBIOL, V3, P307, DOI 10.1038/nrmicro1129; van Loon LC, 2006, ANNU REV PHYTOPATHOL, V44, P135, DOI 10.1146/annurev.phyto.44.070505.143425; Raaijmakers JM, 2002, ANTON LEEUW INT J G, V81, P537, DOI 10.1023/A:1020501420831; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; Park KS, 2000, BIOL CONTROL, V18, P2, DOI 10.1006/bcon.2000.0815; Shibuya N, 2001, PHYSIOL MOL PLANT P, V59, P223, DOI 10.1006/pmpp.2001.0364; Adams DJ, 2004, MICROBIOL-SGM, V150, P2029, DOI 10.1099/mic.0.26980-0; Whipps JM, 2001, J EXP BOT, V52, P487; DEFAGO G, 1993, PLANT PATHOL, V42, P311, DOI 10.1111/j.1365-3059.1993.tb01506.x; DUIJFF BJ, 1994, BIOCONTROL SCI TECHN, V4, P279, DOI 10.1080/09583159409355336; Kim YH, 2008, PLANTA, V227, P867, DOI 10.1007/s00425-007-0663-3; LAGRIMINI LM, 1987, P NATL ACAD SCI USA, V84, P7542, DOI 10.1073/pnas.84.21.7542; MAUCH F, 1988, PLANT PHYSIOL, V88, P936, DOI 10.1104/pp.88.3.936; Moyne AL, 2004, FEMS MICROBIOL LETT, V234, P43, DOI 10.1016/j.femsle.2004.03.011; Nielsen TH, 2002, APPL ENVIRON MICROB, V68, P3416, DOI 10.1128/AEM.68.7.3416-3423.2002; Sharifi-Tehrani A, 1998, EUR J PLANT PATHOL, V104, P631, DOI 10.1023/A:1008672104562; Song JY, 2012, J BACTERIOL, V194, P3760, DOI 10.1128/JB.00676-12	29	0	0	KOREAN SOC PLANT PATHOLOGY	SUWON	NATIONAL INST AGRICULTURAL SCIENCE & TECHNOLOGY, PLANT PATHOLOGY DIVISION, SUWON, 441-707, SOUTH KOREA	1598-2254	2093-9280		PLANT PATHOLOGY J	Plant Pathol. J.	JUN	2015	31	2					195	201		10.5423/PPJ.NT.11.2014.0122		7	Agriculture, Multidisciplinary; Plant Sciences	Agriculture; Plant Sciences	CJ5AF	WOS:000355499100013		
J	Blatter, H; Greve, R				Blatter, Heinz; Greve, Ralf			Comparison and verification of enthalpy schemes for polythermal glaciers and ice sheets with a one-dimensional model	POLAR SCIENCE			English	Article						Glacier; Ice sheet; Polythermal ice; Modeling; Enthalpy method	STORGLACIAREN; FORMULATION; SWEDEN; COLD	The enthalpy method for the thermodynamics of polythermal glaciers and ice sheets is tested and verified by a one-dimensional problem (parallel-sided slab). The enthalpy method alone does not include explicitly the transition conditions at the coldetemperate transition surface (CTS) that separates the upper cold from the lower temperate layer. However, these conditions are important for correctly determining the position of the CTS. For the numerical solution of the polythermal slab problem, we consider a two-layer front-tracking scheme as well as three different one-layer schemes (conventional one-layer scheme, one-layer melting CTS scheme, one-layer freezing CTS scheme). Computed steady-state temperature and water-content profiles are verified with exact solutions, and transient solutions computed by the one-layer schemes are compared with those of the two-layer scheme, considered to be a reliable reference. While the conventional one-layer scheme (that does not include the transition conditions at the CTS) can produce correct solutions for melting conditions at the CTS, it is more reliable to enforce the transition conditions explicitly. For freezing conditions, it is imperative to enforce them because the conventional one-layer scheme cannot handle the associated discontinuities. The suggested numerical schemes are suitable for implementation in three-dimensional glacier and icesheet models. (C) 2015 Elsevier B.V. and NIPR. All rights reserved.	[Blatter, Heinz; Greve, Ralf] Hokkaido Univ, Inst Low Temp Sci, Kita Ku, Sapporo, Hokkaido 0600819, Japan; [Blatter, Heinz] Swiss Fed Inst Technol, Inst Atmospher & Climate Sci, CH-8092 Zurich, Switzerland	Greve, R (reprint author), Hokkaido Univ, Inst Low Temp Sci, Kita Ku, Kita 19,Nishi 8, Sapporo, Hokkaido 0600819, Japan.	greve@lowtem.hokudai.ac.jp	Greve, Ralf/G-2336-2010	Greve, Ralf/0000-0002-1341-4777	Invitation Fellowship for Research in Japan of the Japan Society for the Promotion of Science (JSPS) [L13525]; JSPS [22244058]	We thank F. Saito, A. Aschwanden, E. Bueler and T. Kleiner for helpful discussions. Comments by two anonymous reviewers and the scientific editor, T. Kameda, helped to improve the manuscript. H.B. was supported by an Invitation Fellowship for Research in Japan (No. L13525) of the Japan Society for the Promotion of Science (JSPS). R.G. was supported by a JSPS Grant-in-Aid for Scientific Research A (No. 22244058).	Greve R, 1997, PHILOS T R SOC A, V355, P921, DOI 10.1098/rsta.1997.0050; FOWLER AC, 1978, PROC R SOC LON SER-A, V363, P217, DOI 10.1098/rspa.1978.0165; Dash JG, 2006, REV MOD PHYS, V78, P695, DOI 10.1103/RevModPhys.78.695; Aschwanden A, 2012, J GLACIOL, V58, P441, DOI 10.3189/2012JoG11J088; Sato T, 2012, ANN GLACIOL, V53, P221, DOI 10.3189/2012AoG60A042; Aschwanden A, 2005, J GEOPHYS RES-EARTH, V110, DOI 10.1029/2005JF000328; BLATTER H, 1991, J GLACIOL, V37, P261; Duval P., 1977, INT ASS HYDROLOGICAL, V118, P29; FOWLER AC, 1984, GEOPHYS ASTRO FLUID, V28, P99, DOI 10.1080/03091928408222846; Greve R, 2009, ADV GEOPHYS ENV MECH, P1, DOI 10.1007/978-3-642-03415-2_1; Greve R, 2013, ANN GLACIOL, V54, P209, DOI 10.3189/2013AoG63A085; HUTTER K, 1982, GEOPHYS ASTRO FLUID, V21, P201, DOI 10.1080/03091928208209013; HUTTER K, 1993, J GLACIOL, V39, P65; Kleiner T, 2015, CRYOSPHERE, V9, P217, DOI 10.5194/tc-9-217-2015; Pettersson R, 2007, J GLACIOL, V53, P99, DOI 10.3189/172756507781833974	15	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1873-9652	1876-4428		POLAR SCI	Polar Sci.	JUN	2015	9	2					196	207		10.1016/j.polar.2015.04.001		12	Ecology; Geosciences, Multidisciplinary	Environmental Sciences & Ecology; Geology	CJ6WJ	WOS:000355635600002		
J	Matsuno, T; Nogi, Y; Seama, N				Matsuno, Tetsuo; Nogi, Yoshifumi; Seama, Nobukazu			Electrical resistivity structure under the western Cosmonauts Sea at the continental margin of East Antarctica inferred via a marine magnetotelluric experiment	POLAR SCIENCE			English	Article						Electrical resistivity structure; Marine magnetotellurics; Offshore East Antarctica; Gondwana breakup; Continental margin	LUTZOW-HOLM BAY; UPPER-MANTLE; LITHOSPHERIC EXTENSION; PASSIVE MARGINS; AURORAL-ZONE; CONDUCTIVITY; BREAKUP; FLOOR; CONVECTION; GONDWANA	The western Cosmonauts Sea, off the coast of East Antarctica, was a site of rifting of the Gondwana supercontinent and subsequent early seafloor spreading. To improve our understanding of the breakup of Gondwana, we conducted a marine magnetotelluric experiment to determine the electrical resistivity structure within the uppermost several hundred kilometers beneath the western Cosmonauts Sea. Magnetotelluric response functions at two sites, obtained after considering possible influences of non-plane magnetic field sources, suggest that these responses include distortions by topographic variations and conductive anomalies around the observation sites. Three-dimensional forward modeling confirmed that these distortions due to topographic variations and a thin (similar to 2-km thick) conductive layer immediately under the sites (mostly sediments) are severe. Furthermore, three-dimensional forward modeling to investigate the resistivity structure at deeper depths revealed an upper resistive layer (similar to 300 Omega-m), with a thickness of <100 km, and an underlying conductive half-space (similar to 10 Omega-m). The upper resistive layer and the underlying conductive structure most likely represent dry and water/melt-rich oceanic upper mantle, respectively. The upper resistive layer may be thinner than anticipated under the old seafloor of the study area (likely >90 Ma), and may suggest a conductive anomaly in the upper mantle produced by mantle convection and/or upwelling. (C) 2015 Elsevier B.V. and NIPR. All rights reserved.	[Matsuno, Tetsuo] Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, Tokyo 1130032, Japan; [Nogi, Yoshifumi] Grad Univ Adv Studies Sokendai, Natl Inst Polar Res, Tachikawa, Tokyo 1908518, Japan; [Nogi, Yoshifumi] Grad Univ Adv Studies Sokendai, Dept Polar Res, Tachikawa, Tokyo 1908518, Japan; [Seama, Nobukazu] Kobe Univ, Dept Earth & Planetary Sci, Nada Ku, Kobe, Hyogo 6578501, Japan	Matsuno, T (reprint author), Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	tmatsuno@eri.u-tokyo.ac.jp			National Institute of Polar Research (NIPR) under the Ministry of Education, Culture, Sports, Science and Technology; NIPR [KP-7]	We thank the captain and crew of the Icebreaker Shirase 5002 of the 47th Japanese Antarctic Research Expedition (JARE-47) for the deployment/recovery of the OBEMS. We also thank Kazuya Kitada for the operation of the experiment and Koichi Okada for the preliminary data analysis. Two anonymous reviewers provided helpful comments that improved the manuscript. This research is a part of the Science Program of JARE, supported by the National Institute of Polar Research (NIPR) under the Ministry of Education, Culture, Sports, Science and Technology. This work was also supported by NIPR through Project Research no. KP-7. The AE index data were provided by the World Data Center for Geomagnetism at Kyoto University. The GMT software (Wessel and Smith, 1998) was used for creating the figures.	Amante C., 2009, NGDC24 NOAA NESDIS, P1, DOI DOI 10.7289/V5C8276M; MCKENZIE D, 1978, EARTH PLANET SC LETT, V40, P25, DOI 10.1016/0012-821X(78)90071-7; LEPICHON X, 1981, J GEOPHYS RES, V86, P3708, DOI 10.1029/JB086iB05p03708; Chave AD, 2004, GEOPHYS J INT, V157, P988, DOI 10.1111/j.1365-246X.2004.02203.x; Pulkkinen A, 2006, J GEOPHYS RES-SPACE, V111, DOI 10.1029/2005JA011294; Baba K, 2010, PHYS EARTH PLANET IN, V183, P44, DOI 10.1016/j.pepi.2010.09.010; Constable S, 2009, GEOPHYS J INT, V176, P431, DOI 10.1111/j.1365-246X.2008.03975.x; Key K, 2011, PHYS EARTH PLANET IN, V184, P194, DOI 10.1016/j.pepi.2010.11.008; Baba K, 2013, GEOCHEM GEOPHY GEOSY, V14, P4969, DOI 10.1002/2013GC004997; Karato S, 1998, EARTH PLANET SC LETT, V157, P193, DOI 10.1016/S0012-821X(98)00034-X; Huismans RS, 2008, GEOLOGY, V36, P163, DOI 10.1130/G24231A.1; STOREY BC, 1995, NATURE, V377, P301, DOI 10.1038/377301a0; Lucazeau F, 2008, NAT GEOSCI, V1, P854, DOI 10.1038/ngeo359; MARESCHAL M, 1986, SURV GEOPHYS, V8, P261, DOI 10.1007/BF01904062; GAMBLE TD, 1979, GEOPHYSICS, V44, P53, DOI 10.1190/1.1440923; Finlay CC, 2010, GEOPHYS J INT, V183, P1216, DOI 10.1111/j.1365-246X.2010.04804.x; NORTON IO, 1979, J GEOPHYS RES, V84, P6803, DOI 10.1029/JB084iB12p06803; King SD, 1998, EARTH PLANET SC LETT, V160, P289, DOI 10.1016/S0012-821X(98)00089-2; LISTER GS, 1986, GEOLOGY, V14, P246, DOI 10.1130/0091-7613(1986)14<246:DFATEO>2.0.CO;2; Evans RL, 2005, NATURE, V437, P249, DOI 10.1038/nature04014; Archie G., 1942, J PET TECH, V5, P1; Armitage JJ, 2013, J GEOPHYS RES-SOL EA, V118, P1817, DOI 10.1002/jgrb.50097; Baba K, 2005, SURV GEOPHYS, V26, P701, DOI 10.1007/s10712-005-1831-2; Baba K, 2002, GEOPHYS J INT, V150, P392, DOI 10.1046/j.1365-246X.2002.01673.x; Baranov A, 2013, TECTONOPHYSICS, V609, P299, DOI 10.1016/j.tecto.2012.12.023; Becker K., 1994, P OCEAN DRILL PROGRA, V139, P613; BERGH HW, 1977, NATURE, V269, P686, DOI 10.1038/269686a0; BUCK WR, 1986, EARTH PLANET SC LETT, V77, P362; Fuji-ta K, 2004, GEOPHYS J INT, V157, P79, DOI 10.1111/j.1365-246X.2004.02165.x; Garcia X, 1997, J GEOMAGN GEOELECTR, V49, P1451; GLOVER PWJ, 1995, SURV GEOPHYS, V16, P5, DOI 10.1007/BF00682710; Hiroi Y., 1983, E ANTARCTICA ANTARCT, P32; Hiroi Y., 1991, GEOLOGICAL EVOLUTION, P83; Jokat W, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL045117; Jokat W, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001802; Jones AG, 2002, EARTH PLANETS SPACE, V54, P443; Jones AG, 2001, NATURE, V409, P331, DOI 10.1038/35053053; Kanao M., 2011, INT J GEOPHYS; Kanao M, 1997, TECTONOPHYSICS, V270, P43, DOI 10.1016/S0040-1951(96)00207-7; Lawver L. A., 1992, ANTARCT RES SER, V56, P7; Lezaeta P, 2007, PHYS EARTH PLANET IN, V164, P21, DOI 10.1016/j.pepi.2007.05.002; Matsuno T, 2010, GEOCHEM GEOPHY GEOSY, V11, DOI 10.1029/2010GC003101; NOBES DC, 1986, GEOPHYS J INT, V86, P289, DOI 10.1111/j.1365-246X.1986.tb03830.x; Nogi Y, 2013, PRECAMBRIAN RES, V234, P279, DOI 10.1016/j.precamres.2013.02.008; Nogi Y, 2004, MAR GEOPHYS RES, V25, P221, DOI 10.1007/s11001-005-1317-0; PELTIER WR, 1971, CAN J EARTH SCI, V8, P338, DOI 10.1139/e71-034; Ritzwoller MH, 2001, J GEOPHYS RES-SOL EA, V106, P30645, DOI 10.1029/2001JB000179; Roeser H. A., 1996, WEDDELL SEA TECTONIC, V108, P243; SHIRAISHI K, 1994, J GEOL, V102, P47; Simon K, 2009, GEOPHYS J INT, V176, P327, DOI 10.1111/j.1365-246X.2008.03891.x; Solli K, 2008, MAR GEOPHYS RES, V29, P51, DOI 10.1007/s11001-008-9045-x; Stagg HMJ, 2004, MAR GEOPHYS RES, V25, P183, DOI 10.1007/s11001-005-1316-1; Viljanen A., 2012, MAGNETOTELLURIC METH, P96; WESSEL P, 1998, EOS T AGU, V0079; Worzewski T, 2012, GEOPHYS J INT, V189, P357, DOI 10.1111/j.1365-246X.2012.05385.x	55	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1873-9652	1876-4428		POLAR SCI	Polar Sci.	JUN	2015	9	2					221	234		10.1016/j.polar.2015.03.001		14	Ecology; Geosciences, Multidisciplinary	Environmental Sciences & Ecology; Geology	CJ6WJ	WOS:000355635600004		
J	Nakagawa, Y; Ichikawa, H; Kitamura, M; Nishino, Y; Taniguchi, A				Nakagawa, Yoshizumi; Ichikawa, Hideaki; Kitamura, Mitsuaki; Nishino, Yasuto; Taniguchi, Akira			Copepod community succession during warm season in Lagoon Notoro-ko, northeastern Hokkaido, Japan	POLAR SCIENCE			English	Article						Lagoon Notoro-ko; Okhotsk Sea; Copepod community; Paracalanus parvus; Pseudocalanus newmani	CENTROPAGES-ABDOMINALIS; PLANKTONIC COPEPODS; PSEUDOCALANUS	Lagoon Notoro-ko, located on the northeastern coast of Hokkaido, Japan, and connected to the Okhotsk Sea by a humanmade channel, is strongly influenced by local hydrography, as water masses in the lagoon are seasonally influenced by the Soya Warm Current and the East Sakhalin Current. We here report on the succession of copepod communities during the warm season in relation to water mass exchange. Copepods were categorized into four seasonal communities (spring/early-summer, mid-summer, late-summer/fall, and early-winter) via a cluster analysis based on Bray-Curtis similarities. Spring/earlysummer and early-winter communities were characterized by the temperate-boreal calanoid Pseudocalanus newmani, comprising 34.9%-77.6% of the total abundance of copepods during times of low temperature/salinity, as influenced by the prevailing East Sakhalin Current. Late-summer/fall communities were characterized by the neritic warm-water calanoid Paracalanus parvus s.l., comprising 63.9%-96.3% of the total abundance, as influenced by the Soya Warm Current. Midsummer communities comprised approximately equal abundances of P. parvus, Eurytemora herdmani, Scolecithricella minor, and Centropages abdominalis (12.8%-28.2%); this community is transitional between those of the spring/earlysummer and late-summer/fall. Copepod community succession in Lagoon Notoro-ko can be largely explained by seasonal changes in water masses. (C) 2015 Elsevier B.V. and NIPR. All rights reserved.	[Nakagawa, Yoshizumi; Ichikawa, Hideaki; Nishino, Yasuto] Tokyo Univ Agr, Fac Bioind, Abashiri, Hokkaido 0992493, Japan; [Nakagawa, Yoshizumi; Kitamura, Mitsuaki] Tokyo Univ Agr, Grad Sch Bioind, Abashiri, Hokkaido 0992493, Japan; [Taniguchi, Akira] Sanyo Technomarine Inc, Chuoh City, Tokyo 1030012, Japan	Nakagawa, Y (reprint author), Tokyo Univ Agr, Fac Bioind, 196 Yasaka, Abashiri, Hokkaido 0992493, Japan.	y4nakaga@bioindustry.nodai.ac.jp					Mackas DL, 1999, PROG OCEANOGR, V43, P335, DOI 10.1016/S0079-6611(99)00012-9; Liang D, 1996, MAR BIOL, V124, P527, DOI 10.1007/BF00351034; MCLAREN IA, 1989, CAN J ZOOL, V67, P552; FROST BW, 1989, CAN J ZOOL, V67, P525; WELSCHMEYER NA, 1994, LIMNOL OCEANOGR, V39, P1985; Anraku M., 1954, Bulletin of the Faculty of Fisheries Hokkaido, V4, P249; Aota M., 1979, NOTE COAST OCEANOGR, V17, P1; Arima D, 2014, CRUSTACEANA, V87, P364, DOI 10.1163/15685403-00003287; Asami H., 1995, JPN SCI REP HOKKAIDO, V49, P17; Asami H., 2010, PICES SCI REP, V36, P233; Brodskii K. A., 1950, VESLONOGIE RACHKI CA; CLARKE KR, 1993, AUST J ECOL, V18, P117, DOI 10.1111/j.1442-9993.1993.tb00438.x; Clarke K.R., 2001, CHANGE MARINE COMMUN; Hattori H., 1990, P HOKKAIDO TOKAI U S, V18, P115; Heron G. A., 1964, Crustaceana, V7, P199, DOI 10.1163/156854064X00155; HIRAKAWA K, 1986, CRUSTACEANA, V51, P296, DOI 10.1163/156854086X00467; Imada K., 1995, SCI REP HOKKAIDO FIS, V49, P17; Kanno Yasuji, 1993, Bulletin of the Faculty of Fisheries Hokkaido University, V44, P158; Kas'yan V.V., 2004, RUSS J MAR BIOL, V30, P87, DOI 10.1023/B:RUMB.0000025984.39048.d4; Kitamura M., 2014, ECOENGINEERING, V26, P89; Kurata N., 1987, SCI REP HOKKAIDO FIS, V29, P17; Liang Dong, 1994, Bulletin of Plankton Society of Japan, V41, P131; MINODQ T, 1971, Memoirs of the Faculty of Fisheries Hokkaido University, V18, P1; Mori T., 1964, PELAGIC COPEPODA NEI; Morioka Y., 1976, Bulletin Japan Sea reg Fish Res Lab, VNo. 27, P91; Nishihama Y., 1994, FISHERY JAPANESE SCA; Nishino Y., 2014, ECOENGINEERING, V26, P3; Ohtsuka S., 1997, ILLUSTRATED GUIDE MA, P649; Takizawa T., 1982, J OCEANOGR SOC JPN, V38, P281, DOI 10.1007/BF02114532; VERVOORT W., 1965, ATLANTIDE REP SCI RESULTS DANISH EXP COAST TROP WEST AFR, V8, P9; Vervoort W., 1963, Atlantide Report, V7, P77; Yamaguchi Atsushi, 1999, Plankton Biology and Ecology, V46, P54; Yamaguchi Atsushi, 1998, Plankton Biology and Ecology, V45, P183; Yamaguchi Atsushi, 1997, Bulletin of Plankton Society of Japan, V44, P11	34	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1873-9652	1876-4428		POLAR SCI	Polar Sci.	JUN	2015	9	2					249	257		10.1016/j.polar.2015.02.001		9	Ecology; Geosciences, Multidisciplinary	Environmental Sciences & Ecology; Geology	CJ6WJ	WOS:000355635600006		
J	Nakatsubo, T; Uchida, M; Sasaki, A; Kondo, M; Yoshitake, S; Kanda, H				Nakatsubo, Takayuki; Uchida, Masaki; Sasaki, Akiko; Kondo, Miyuki; Yoshitake, Shinpei; Kanda, Hiroshi			Carbon accumulation rate of peatland in the High Arctic, Svalbard: Implications for carbon sequestration	POLAR SCIENCE			English	Article						Carbon accumulation; C-14 dating; High Arctic; Moss tundra; Peatland; Svalbard	GLACIER FORELAND; NY-ALESUND; PHOTOSYNTHETIC CHARACTERISTICS; VEGETATION; ECOSYSTEM; CLIMATE; STOCKS	Moss tundra that accumulates a thick peat layer is one of the most important ecosystems in the High Arctic, Svalbard. The importance of this ecosystem for carbon sequestration was estimated from the apparent rates of carbon accumulation based on the C-14 age and amount of peat in the active layer. The study site at Stuphallet, Brogger Peninsula, northwestern Svalbard was covered with a thick peat layer dominated by moss species such as Calliergon richardsonii, Paludella squarrosa, Tomenthypnum nitens, and Warnstorfia exannulata. The average thickness of the active layer (brown moss and peat) was approximately 28 cm in 1 August 2011. The calibrated (cal) age of peat from the bottom of the active layer (20-30 cm below the peatland surface) ranged from 81 to 701 cal yr BP (median value of 2s range). Based on the total carbon (4.5-9.2 kg C m(-2)), the apparent rate of carbon accumulation in the active layer was 9.0-19.2 (g C m(-2) yr(-1)), which is similar to or greater than the net ecosystem production or net primary production reported for other vegetation types in this area. Our data suggest that moss tundra plays an important role in carbon sequestration in this area. (C) 2015 Elsevier B.V. and NIPR. All rights reserved.	[Nakatsubo, Takayuki; Sasaki, Akiko] Hiroshima Univ, Grad Sch Biosphere Sci, Dept Environm Dynam & Management, Higashihiroshima 7398521, Japan; [Uchida, Masaki; Kanda, Hiroshi] Natl Inst Polar Res, Tachikawa, Tokyo 1908518, Japan; [Uchida, Masaki] Grad Univ Adv, Studies SOKENDAI, Dept Polar Sci, Tachikawa, Tokyo 1908518, Japan; [Kondo, Miyuki] Natl Inst Environm Studies, Tsukuba, Ibaraki 3058506, Japan; [Yoshitake, Shinpei] Gifu Univ, River Basin Res Ctr, Takayama Field Stn, Takayama 5060815, Japan	Nakatsubo, T (reprint author), Hiroshima Univ, Grad Sch Biosphere Sci, Dept Environm Dynam & Management, 1-7-1 Kagamiyama, Higashihiroshima 7398521, Japan.	kuyakat@hiroshima-u.ac.jp			Japan Society for the Promotion of Science (JSPS) [20405010, 24405009]	We thank Mr. Sumihisa Matsuyama of the Geo Science Laboratory for his helpful suggestions during this study. This study was partly supported by Grants-in-Aid for Scientific Research (No. 20405010 and No. 24405009) from the Japan Society for the Promotion of Science (JSPS).	Yoshitake S, 2010, NEW PHYTOL, V186, P451, DOI 10.1111/j.1469-8137.2010.03180.x; Muraoka H, 2002, CAN J BOT, V80, P1193, DOI [10.1139/B02-108, 10.1139/b02-108]; Uchida M, 2002, ARCT ANTARCT ALP RES, V34, P287, DOI 10.2307/1552486; Yu ZC, 2012, BIOGEOSCIENCES, V9, P4071, DOI 10.5194/bg-9-4071-2012; Charman DJ, 2013, BIOGEOSCIENCES, V10, P929, DOI 10.5194/bg-10-929-2013; Nakatsubo T, 2005, J PLANT RES, V118, P173, DOI 10.1007/s10265-005-0211-9; Ping CL, 2008, NAT GEOSCI, V1, P615, DOI 10.1038/ngeo284; JOHNSON LC, 1991, OIKOS, V61, P234, DOI 10.2307/3545341; ELVEBAKK A, 1994, J VEG SCI, V5, P791, DOI 10.2307/3236194; Clymo RS, 1998, OIKOS, V81, P368, DOI 10.2307/3547057; IPCC, 2013, CLIM CHANG 2013 PHYS; Loisel J, 2013, J GEOPHYS RES-BIOGEO, V118, P41, DOI 10.1029/2012JG001978; Longton RE, 1988, BIOL POLAR BRYOPHYTE; Muraoka H, 2008, J PLANT RES, V121, P137, DOI 10.1007/s10265-007-0134-8; OVENDEN L, 1990, QUATERNARY RES, V33, P377, DOI 10.1016/0033-5894(90)90063-Q; POST WM, 1982, NATURE, V298, P156, DOI 10.1038/298156a0; Rozema J, 2006, PLANT ECOL, V182, P155, DOI 10.1007/s11258-005-9024-0; Tarnocai C, 2009, GLOBAL BIOGEOCHEM CY, V23, DOI 10.1029/2008GB003327; Uchida M, 2006, POLAR RES, V25, P39, DOI 10.1111/j.1751-8369.2006.tb00149.x; Vanderpuye AW, 2002, J VEG SCI, V13, P875, DOI 10.1658/1100-9233(2002)013[0875:PCAEGO]2.0.CO;2; Vardy SR, 2000, HOLOCENE, V10, P273, DOI 10.1191/095968300671749538; Yoshitake S, 2011, POLAR SCI, V5, P391, DOI 10.1016/j.polar.2011.03.002	22	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1873-9652	1876-4428		POLAR SCI	Polar Sci.	JUN	2015	9	2					267	275		10.1016/j.polar.2014.12.002		9	Ecology; Geosciences, Multidisciplinary	Environmental Sciences & Ecology; Geology	CJ6WJ	WOS:000355635600008		
J	Kotani, M; Dohi, H; Kimura, H; Muraoka, K; Kaji, H				Kotani, Marina; Dohi, Hidehiko; Kimura, Hideaki; Muraoka, Kiyoshige; Kaji, Hironori			Distribution ratio of carbon black in polyisobutyrene/polyisoprene rubber blends using high-resolution solid-state C-13 NMR	POLYMER JOURNAL			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; FILLER DISTRIBUTION; MODULUS REINFORCEMENT; ELASTOMER COMPOSITES; POLYBUTADIENE BLENDS; AFM; MORPHOLOGY; SBR; RELAXATION; H-1-NMR	We attempted to estimate the distribution ratio of carbon black (CB) in blends of polyisobutyrene rubber and polyisoprene rubber using high-resolution solid-state C-13 nuclear magnetic resonance (NMR). Our NMR analysis revealed that, in polyisobutyrene rubber/polyisoprene rubber/CB composites, CB more easily distributes in polyisoprene rubber than in polyisobutyrene rubber. We found that more than 70% of CB is distributed into the polyisoprene rubber phase. The sum of the amounts of CB in both the polyisobutyrene rubber and polyisoprene rubber phases estimated by our method using C-13 NMR closely corresponds with the amount of CB originally added to the compound, verifying the validity of the NMR method. Further, we observed the distribution of CB in polyisobutyrene/polyisoprene rubber blends using transmission electron microscopy and the Carbon-Black-Gel method, which can only be used for unvulcanized rubber blends, for comparison. The results obtained using these three methods show similar tendencies, which confirms the accuracy of this method of using C-13 NMR to determine CB distribution in rubber blends.	[Kotani, Marina; Dohi, Hidehiko; Kimura, Hideaki] Sumitomo Rubber Ind Ltd, Res & Dev HQ, Chem Anal Ctr, Kobe, Hyogo 6510071, Japan; [Muraoka, Kiyoshige] Sumitomo Rubber Ind Ltd, Mat Res & Dev HQ, Mat Dept 1, Kobe, Hyogo 6510071, Japan; [Kaji, Hironori] Kyoto Univ, Inst Chem Res, Kyoto 606, Japan	Kotani, M (reprint author), Sumitomo Rubber Ind Ltd, Res & Dev HQ, Chuo Ku, 2-1-1 Tsutsui Cho, Kobe, Hyogo 6510071, Japan.	m-kotani.az@srigroup.co.jp; kaji@scl.kyoto-u.ac.jp					Kotani M, 2007, MACROMOLECULES, V40, P9451, DOI 10.1021/ma702104w; ZIEGEL KD, 1973, J APPL POLYM SCI, V17, P1119, DOI 10.1002/app.1973.070170410; HESS WM, 1985, RUBBER CHEM TECHNOL, V58, P350, DOI 10.5254/1.3536071; Karasek L, 1996, J MATER SCI, V31, P281, DOI 10.1007/BF01139141; Kluppel M, 1999, RUBBER CHEM TECHNOL, V72, P91; Litvinov VM, 1999, MACROMOLECULES, V32, P8476, DOI 10.1021/ma9910080; HESS WM, 1977, RUBBER CHEM TECHNOL, V50, P301, DOI 10.5254/1.3535145; Jeon IH, 2003, RUBBER CHEM TECHNOL, V76, P1, DOI 10.5254/1.3547733; Callan J. E., 1971, RUBBER CHEM TECHNOL, V44, P814, DOI DOI 10.5254/1.3544796; COTTEN GR, 1988, KAUT GUMMI KUNSTST, V41, P54; COTTEN GR, 1988, RUBBER CHEM TECHNOL, V61, P609, DOI 10.5254/1.3536207; Datta S., 2013, HDB SCI TECHNOLOGY R, P547; FOUCHE PM, 1989, PLAST RUB PROC APPL, V12, P227; Galuska AA, 1997, SURF INTERFACE ANAL, V25, P418; Hess W. M., 1967, RUBBER CHEM TECHNOL, V40, P371, DOI 10.5254/1.3539053; Hu WG, 2007, RUBBER CHEM TECHNOL, V80, P1, DOI 10.5254/1.3548166; Kunizawa T., 2009, JAPAN SOC COMPOS MAT, V35, P157; Leisen J, 1999, RUBBER CHEM TECHNOL, V72, P1, DOI 10.5254/1.3538790; MAITI S, 1992, RUBBER CHEM TECHNOL, V65, P293, DOI 10.5254/1.3538612; MASSIE JM, 1993, RUBBER CHEM TECHNOL, V66, P276, DOI 10.5254/1.3538311; McBrierty V. J., 1997, EUROFILLERS 97, P67; Naitoh S., 1976, NIPPON GOMU KYOKAISH, V49, P476; Naitoh S., 1997, NIPPON GOMU KYOKAISH, V70, P632; Payne A. R., 1970, COMPOSITES, V1, P203, DOI DOI 10.1016/0010-4361(70)90005-4; Portal J, 2009, POLYM ENG SCI, V49, P1544, DOI 10.1002/pen.21376; Railsback H. E., 1958, RUBBER PLAST AGE, V39, P867; SIMON G, 1989, POLYM BULL, V21, P475; Sirisinha C, 2001, J APPL POLYM SCI, V81, P3198, DOI 10.1002/app.1773; Tsou AH, 2002, KAUT GUMMI KUNSTST, V55, P382; Wang CC, 2005, RUBBER CHEM TECHNOL, V78, P17, DOI 10.5254/1.3547869; ZIEGEL KD, 1973, J APPL POLYM SCI, V17, P1133, DOI 10.1002/app.1973.070170411	31	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0032-3896	1349-0540		POLYM J	Polym. J.	JUN	2015	47	6					422	427		10.1038/pj.2015.3		6	Polymer Science	Polymer Science	CJ8IU	WOS:000355744300003		
J	Shudo, Y; Izumi, A; Takeuchi, T; Nakao, T; Shibayama, M				Shudo, Yasuyuki; Izumi, Atsushi; Takeuchi, Takeshi; Nakao, Toshio; Shibayama, Mitsuhiro			Dynamic light scattering study of the curing mechanisms of novolac-type phenolic resins	POLYMER JOURNAL			English	Article							X-RAY-SCATTERING; CROSS-LINK INHOMOGENEITY; SMALL-ANGLE NEUTRON; ELECTRON-MICROSCOPY; CASCADE THEORY; GEL FORMATION; SPECTROSCOPY; HEXAMETHYLENETETRAMINE; POLYMERS; GELATION	The curing behavior of a novolac resin (NV) cured with hexamethylenetetramine (HMTA), as well as the influence of an excess amount of HMTA on the curing reaction, were investigated by dynamic light scattering and gel permeation chromatography. A two-roll mixing mill process was applied to control the curing reaction degree. The dependence of the number of mixing times on the weight-average molecular weight (M-w) and hydrodynamic radius (R-h) of NV differed significantly with the HMTA amount. A larger quantity of HMTA resulted in faster growth and larger R-h and M-w values. The relationship between M-w and R-h for NV in tetrahydrofuran indicates two different polymer-growth mechanisms irrespective of the excess amount of HMTA (that is, power-law and subsequent deviation corresponding to the chain extension and intermolecular reactions between larger molecules, respectively). These results suggest that structural differences governing the mechanical properties of phenolic resins are initiated in the pregel stage, followed by noticeable differences in the mechanical properties during the subsequent curing process.	[Shudo, Yasuyuki; Nakao, Toshio; Shibayama, Mitsuhiro] Univ Tokyo, Inst Solid State Phys, Neutron Sci Lab, Chiba, Japan; [Shudo, Yasuyuki; Izumi, Atsushi; Takeuchi, Takeshi] Sumitomo Bakelite Co Ltd, Kobe, Hyogo 6512241, Japan	Shudo, Y (reprint author), Sumitomo Bakelite Co Ltd, Corp R&D Ctr, Nishi Ku, 1-1-5 Murotani, Kobe, Hyogo 6512241, Japan.	yshudo@sumibe.co.jp; sibayama@issp.u-tokyo.ac.jp	Shibayama, Mitsuhiro/E-1646-2015; 	Shibayama, Mitsuhiro/0000-0002-8683-5070; Izumi, Atsushi/0000-0001-8213-7032			Zhang XQ, 1997, POLYMER, V38, P5835, DOI 10.1016/S0032-3861(97)00141-9; Shibayama M, 2006, POLYMER, V47, P6446, DOI 10.1016/j.polymer.2006.06.060; Izumi A, 2012, SOFT MATTER, V8, P8438, DOI 10.1039/c2sm26072g; Markovic S, 2001, J APPL POLYM SCI, V81, P1902, DOI 10.1002/app.1623.abs; de Medeiros ES, 2003, J APPL POLYM SCI, V90, P1678, DOI 10.1002/app.12838; Stockmayer WH, 1943, J CHEM PHYS, V11, P45, DOI 10.1063/1.1723803; Shibayama M, 1998, MACROMOL CHEM PHYSIC, V199, P1; KATOVIC Z, 1985, IND ENG CHEM PROD RD, V24, P179, DOI 10.1021/i300018a001; Nomoto M, 2010, J MOL STRUCT, V976, P419, DOI 10.1016/j.molstruc.2010.04.018; Shibayama M, 2002, B CHEM SOC JPN, V75, P641, DOI 10.1246/bcsj.75.641; Izumi A, 2012, SOFT MATTER, V8, P5283, DOI 10.1039/c2sm25067e; ARANGUREN MI, 1984, IND ENG CHEM PROD RD, V23, P370, DOI 10.1021/i300015a009; Izumi A, 2013, SOFT MATTER, V9, P4188, DOI 10.1039/c3sm27438a; Yarovsky I, 2002, POLYMER, V43, P963, DOI 10.1016/S0032-3861(01)00634-6; LOONEY MG, 1995, AUST J CHEM, V48, P323; Baekeland L. H., 1907, USA, Patent, Patent No. 942699; BORRAJO J, 1982, POLYMER, V23, P263, DOI 10.1016/0032-3861(82)90312-3; Carotenuto G, 1999, J APPL POLYM SCI, V74, P2703, DOI 10.1002/(SICI)1097-4628(19991209)74:11<2703::AID-APP18>3.0.CO;2-M; Chen WJ, 1998, POLYMER, V39, P2867, DOI 10.1016/S0032-3861(97)00595-8; Dominguez JC, 2010, THERMOCHIM ACTA, V498, P39, DOI 10.1016/j.tca.2009.09.010; Drumm M. F., 1972, STEP GROWTH POLYM, V3, P157; Gardziella A., 1999, PHENOLIC RESINS CHEM; Izumi A, 2011, J POLYM SCI POL CHEM, V49, P4941, DOI 10.1002/pola.24948; Izumi A, 2015, POLYMER, V59, P226, DOI 10.1016/j.polymer.2015.01.018; Izumi A, 2011, POLYMER, V52, P4355, DOI 10.1016/j.polymer.2011.06.059; Nakao T, 2002, MACROMOLECULES, V35, P5649, DOI 10.1021/ma011704b; Nakao T, 2006, MACROMOLECULES, V39, P6643, DOI 10.1021/ma052686r; Nomoto M., 2006, J NETWORK POLYM JPN, V27, P210; Pascault J.-P., 2002, THERMOSETTING POLYM; Pilato L, 2010, PHENOLIC RESINS: A CENTURY OF PROGRESS, P1, DOI 10.1007/978-3-642-04714-5; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; Shibayama M, 2005, POLYMER, V46, P2381, DOI 10.1016/j.polymer.2005.01.018; SOJKA SA, 1981, MACROMOLECULES, V14, P1539, DOI 10.1021/ma50006a076; Wohlfarth C., 1996, OPTICAL CONSTANTS B; Yamagishi T., 1999, KOBUNSHI KAKO JPN, V34, P178; Yamagishi TA, 1996, ANGEW MAKROMOL CHEM, V240, P181, DOI 10.1002/apmc.1996.052400116; Yaws C. L., 1995, HDB VISCOSITY; Yoonessi M, 2008, CARBON, V46, P577, DOI 10.1016/j.carbon.2008.01.003	38	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0032-3896	1349-0540		POLYM J	Polym. J.	JUN	2015	47	6					428	433		10.1038/pj.2015.15		6	Polymer Science	Polymer Science	CJ8IU	WOS:000355744300004		
J	Nakao, A; Fujiki, M				Nakao, Ayako; Fujiki, Michiya			Visualizing spontaneous physisorption of non-charged pi-conjugated polymers onto neutral surfaces of spherical silica in nonpolar solvents	POLYMER JOURNAL			English	Article							TRANSFER RADICAL POLYMERIZATION; STRUCTURAL-CHARACTERIZATION; HYBRID MATERIALS; ADSORPTION; FILMS; POLYFLUORENE; TEMPERATURE; MONOLAYERS; MOBILITY; BRUSHES	In this study, we demonstrated that the non-charged p-conjugative polymeric fluorophore poly(di-n-octylfluorene; PF8) spontaneously physisorbs onto the neutral surface of mu m-sized spherical silica (SiO2) in suspension within several hours at room temperature using chloroform, benzene, toluene and carbon tetrachloride as solvents. This process was observed by photoluminescence and photoluminescence excitation spectra, as well as observation with the naked eye. The level-off amount of physisorption was controlled by the choice of dispersion solvent and physisorption time. Surprisingly, the highest fraction (51-56%) of beta-phase was spontaneously deposited at the surface without thermal treatment. Similarly, two other non-charged p-conjugated polymers (i.e., poly[(9,9-dioctyl-fluorenyl-2,7-diyl)-alt-bithiophene]; PF8T2) and poly[ 2-methoxy-5-(2-ethylhexyloxy)1,4- phenylenevinylene]; MEH-PPV) spontaneously physisorbed onto surfaces of several mu m-sized SiO2, Al2O3, ZnO and TiO2 (anatase and rutile) particles in chloroform over several hours. Attractive van der Waals interactions between these non-charged polymers and ceramics are assumed to be the driving force for spontaneous solution-phase physisorption. Our experimental results may provide an alternative approach that enables hybridization of various pi-conjugative polymers with ceramics in addition to the conventional chemisorption and physisorption approaches (i.e., grafting-from, grafting-to and layer-by-layer deposition due to Coulombic forces).	[Nakao, Ayako; Fujiki, Michiya] Nara Inst Sci & Technol, Grad Sch Mat Sci, Ikoma, Nara 6300192, Japan	Fujiki, M (reprint author), Nara Inst Sci & Technol, Grad Sch Mat Sci, 8916-5 Takayama, Ikoma, Nara 6300192, Japan.	fujikim@ms.naist.jp			Japan Science Society; NAIST Presidential Special Fund; JSPS KAKENHI [22350052]	AN acknowledges financial support from the Sasakawa Scientific Research Grant from the Japan Science Society and the NAIST Presidential Special Fund. MF is grateful for the Grants-in-Aid from JSPS KAKENHI (22350052). We thank Jun-ichi Kikuchi, Tsuyoshi Ando and Hironari Kamikubo for stimulating discussions and encouragement. We also wish to thank Takashi Matsuda for the valuable suggestion of PF8 and Noritake Koike for assistance with FE-SEM observations. The Toa-Gosei Co. and Micron Co. kindly donated spherical silica and Al<INF>2</INF>O<INF>3</INF>, respectively.	Tanaka K, 2009, J PHYS CHEM B, V113, P4571, DOI 10.1021/jp810370f; Ejaz M, 1998, MACROMOLECULES, V31, P5934, DOI 10.1021/ma980240n; Evans RC, 2012, CHEM COMMUN, V48, P3742, DOI 10.1039/c2cc18022g; Pyun J, 2001, CHEM MATER, V13, P3436, DOI 10.1021/cm011065j; Kajiyama T, 1997, MACROMOLECULES, V30, P280, DOI 10.1021/ma960582y; Tsubokawa N, 2007, POLYM J, V39, P983, DOI 10.1295/polymj.PJ2007035; Zhao B, 2000, PROG POLYM SCI, V25, P677, DOI 10.1016/S0079-6700(00)00012-5; Zhou F, 2006, PHYS CHEM CHEM PHYS, V8, P3815, DOI 10.1039/b606415a; Grell M, 1999, MACROMOLECULES, V32, P5810, DOI 10.1021/ma990741o; Bucur CB, 2006, J AM CHEM SOC, V128, P13690, DOI 10.1021/ja064532c; PORTER MD, 1987, J AM CHEM SOC, V109, P3559, DOI 10.1021/ja00246a011; Grell M, 1998, ACTA POLYM, V49, P439, DOI 10.1002/(SICI)1521-4044(199808)49:8<439::AID-APOL439>3.0.CO;2-A; Sirringhaus H, 1999, NATURE, V401, P685, DOI 10.1038/44359; Liu CF, 2013, MACROMOLECULES, V46, P3025, DOI 10.1021/ma400010f; Matyjaszewski K, 2001, CHEM REV, V101, P2921, DOI 10.1021/cr940534g; LVOV Y, 1993, LANGMUIR, V9, P481, DOI 10.1021/la00026a020; SAGIV J, 1980, J AM CHEM SOC, V102, P92, DOI 10.1021/ja00521a016; Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232; Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004; Knaapila M, 2006, MACROMOLECULES, V39, P6505, DOI 10.1021/ma060886c; Dabrowski A, 2001, ADV COLLOID INTERFAC, V93, P135, DOI 10.1016/S0001-8686(00)00082-8; Park MK, 2001, LANGMUIR, V17, P7670, DOI 10.1021/la011006k; LVOV Y, 1995, J AM CHEM SOC, V117, P6117, DOI 10.1021/ja00127a026; Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023; KUMAR A, 1993, APPL PHYS LETT, V63, P2002, DOI 10.1063/1.110628; Caruso F, 1998, SCIENCE, V282, P1111, DOI 10.1126/science.282.5391.1111; Yamamoto K, 2007, POLYM J, V39, P1, DOI 10.1295/polymj.PJ2006128; BERNDT P, 1992, LANGMUIR, V8, P2486, DOI 10.1021/la00046a022; BOYER TH, 1969, PHYS REV, V180, P19, DOI 10.1103/PhysRev.180.19; Brust M., 1994, J CHEM SOC CHEM COMM, P1801; Butt H-J, 2006, PHYS CHEM INTERFACES; Cone CW, 2011, J PHYS CHEM B, V115, P12380, DOI 10.1021/jp2061078; Ertl G., 1991, SCIENCE, V254, P1751; Guo GQ, 2004, CHEM COMMUN, P276, DOI 10.1039/b310985b; Hansen C.M., 1967, 3 DIMENSIONAL SOLUBI; HARTMANN U, 1991, PHYS REV B, V43, P2404, DOI 10.1103/PhysRevB.43.2404; Inoue R, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.031802; Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1; Jones R. A. L., 1999, POLYM SURFACE INTERF; KITCHENER JA, 1957, PROC R SOC LON SER-A, V242, P403, DOI 10.1098/rspa.1957.0184; KOTOV NA, 1995, J PHYS CHEM-US, V99, P13065, DOI 10.1021/j100035a005; Mizukami M., 2006, J SURF SCI NANOTECH, V4, P244; Netzer N., 1983, J AM CHEM SOC, V105, P674; Parfitt G., 1983, ADSORPTION SOLUTION; Park JW, 2011, CHEM COMMUN, V47, P4860, DOI 10.1039/c1cc00038a; Riddick J.A., 1986, ORGANIC SOLVENTS PHY, VII; Satomi N, 1999, MACROMOLECULES, V32, P4474, DOI 10.1021/ma981850q; Wu LB, 2004, MACROMOLECULES, V37, P6183, DOI 10.1021/ma0494535	48	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0032-3896	1349-0540		POLYM J	Polym. J.	JUN	2015	47	6					434	442		10.1038/pj.2015.14		9	Polymer Science	Polymer Science	CJ8IU	WOS:000355744300005		
J	Kawano, S; Kida, T; Miyawaki, K; Fukuda, Y; Kato, E; Nakano, T; Akashi, M				Kawano, Shintaro; Kida, Toshiyuki; Miyawaki, Kazuhiro; Fukuda, Yasunori; Kato, Eiichi; Nakano, Takeshi; Akashi, Mitsuru			Adsorption capability of urethane-crosslinked heptakis(2,6-di-O-methyl)-beta-cyclodextrin polymers toward polychlorobiphenyls in nonpolar organic media	POLYMER JOURNAL			English	Article							POLYCHLORINATED-BIPHENYLS PCBS; BETA-CYCLODEXTRIN; INSULATING OIL; AROMATIC-COMPOUNDS; REMOVAL; SORPTION; WATER; TRANSFORMERS; ADSORBENTS; COPOLYMERS	Urethane-crosslinked beta-cyclodextrin polymers are prepared by crosslinking heptakis(2,6-di-O-methyl)-beta-cyclodextrin (DM-beta-CD) with various diisocyanate linkers, such as 4,4'-methylenebis(phenyl isocyanate) (MDI), 1,4-phenylene diisocyanate (PDI) and hexamethylene diisocyanate (HMDI), in DMF. Among these polymers, MDI- and PDI-crosslinked polymers have high adsorption capabilities toward polychlorobiphenyls (PCBs), such as tetra, penta and hexachlorobiphenyl, in isooctane. Toward hexachlorobiphenyl in insulating oil, the adsorption capability of the MDI-crosslinked polymer increases with the adsorption temperature. In addition, using acetone as a washing solvent gives the highest recovery percentage of the PCB from the PCB-adsorbed polymer.	[Kawano, Shintaro; Kida, Toshiyuki; Nakano, Takeshi; Akashi, Mitsuru] Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan; [Miyawaki, Kazuhiro; Fukuda, Yasunori; Kato, Eiichi] NEOS Co Ltd, Konan, Shiga, Japan	Akashi, M (reprint author), Osaka Univ, Grad Sch Engn, Dept Appl Chem, 2-1 Yamada Oka, Suita, Osaka 5650871, Japan.	akashi@chem.eng.osaka-u.ac.jp			Funding Program for Next Generation World-Leading Researchers [GR067]; Japan Society of the Promotion of Science [25288081]; Japan Science and Technology Agency (JST)	This work was partially supported by the Funding Program for Next Generation World-Leading Researchers (GR067), a Grant-in-Aid for Scientific Research (No. 25288081) from the Japan Society of the Promotion of Science and the Risk-Taking Fund for Technology Development from the Japan Science and Technology Agency (JST).	Kaya D, 2013, INT BIODETER BIODEGR, V83, P41, DOI 10.1016/j.ibiod.2013.04.003; Crini G, 1998, J APPL POLYM SCI, V68, P1973, DOI 10.1002/(SICI)1097-4628(19980620)68:12<1973::AID-APP11>3.3.CO;2-R; Bhaskar M, 2004, ANAL CHIM ACTA, V509, P39, DOI 10.1016/j.aca.2003.12.015; Rouse TO, 1998, IEEE ELECTR INSUL M, V14, P6, DOI 10.1109/57.675572; SAFE SH, 1994, CRIT REV TOXICOL, V24, P87, DOI 10.3109/10408449409049308; Kida T, 2013, J AM CHEM SOC, V135, P3371, DOI 10.1021/ja312367k; Kawano S, 2014, ENVIRON SCI TECHNOL, V48, P8094, DOI 10.1021/es501243v; Wilson LD, 2011, MATERIALS, V4, P1528, DOI 10.3390/ma4091528; Takasuga T, 2005, ARCH ENVIRON CON TOX, V49, P385, DOI 10.1007/s00244-004-0209-7; Kelly BC, 2007, SCIENCE, V317, P236, DOI 10.1126/science.1138275; Yamasaki H, 2006, J CHEM TECHNOL BIOT, V81, P1271, DOI 10.1002/jctb.1545; Crini G, 2002, J SEP SCI, V25, P789, DOI 10.1002/1615-9314(20020901)25:13<789::AID-JSSC789>3.0.CO;2-J; Garcia-Zubiri IX, 2009, J COLLOID INTERF SCI, V337, P11, DOI 10.1016/j.jcis.2009.04.071; Szejtli J, 1998, CHEM REV, V98, P1743, DOI 10.1021/cr970022c; Kida T, 2009, ORG LETT, V11, P5282, DOI 10.1021/ol902239e; Wilson LD, 2011, J COLLOID INTERF SCI, V357, P215, DOI 10.1016/j.jcis.2011.01.081; Chen CY, 2007, BIORESOURCE TECHNOL, V98, P2578, DOI 10.1016/j.biortech.2006.09.009; Bibby A, 2003, GREEN CHEM, V5, P15, DOI 10.1039/b209251b; GUSTAFSO.CG, 1970, ENVIRON SCI TECHNOL, V4, P814, DOI 10.1021/es60045a008; Kanbe H, 2001, WASTE MANAGE, V21, P371, DOI 10.1016/S0956-053X(00)00089-1; Kawano S, 2013, CHEM LETT, V42, P392, DOI 10.1246/cl.121239; Kawano S., 2012, P DIOX 2012 INT S HA, P1194; Kida T, 2011, ORG LETT, V13, P4570, DOI 10.1021/ol2017627; Kida T, 2008, ANAL CHEM, V80, P317, DOI 10.1021/ac071509g; Ma M, 1999, CHEM MATER, V11, P872, DOI 10.1021/cm981090y; Mahamed M. H., 2012, CARBOHYD POLYM, V87, P1241; Mohamed MH, 2011, J COLLOID INTERF SCI, V356, P217, DOI 10.1016/j.jcis.2010.11.002; Murai S, 1998, ENVIRON SCI TECHNOL, V32, P782, DOI 10.1021/es970463d; RISEBROUGH RW, 1968, NATURE, V220, P1098, DOI 10.1038/2201098a0; Seok J, 2005, J HAZARD MATER, V124, P133, DOI 10.1016/j.hazmat.2005.04.035; Wilson LD, 2012, J COLLOID INTERF SCI, V387, P250, DOI 10.1016/j.jcis.2012.07.092	31	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0032-3896	1349-0540		POLYM J	Polym. J.	JUN	2015	47	6					443	448		10.1038/pj.2015.13		6	Polymer Science	Polymer Science	CJ8IU	WOS:000355744300006		
J	Mishima, S; Okada, T; Sakai, T; Kiyono, R; Haeiwa, T				Mishima, Shozi; Okada, Tomohiko; Sakai, Toshio; Kiyono, Ryutaro; Haeiwa, Tetsuji			Preparation of porous thin-film polymethylsiloxane microparticles in a W/O emulsion system	POLYMER JOURNAL			English	Article							HOLLOW SILICA MICROSPHERES; SOLID ACID CATALYSIS; CORE-SHELL PARTICLES; MICROEMULSION SYSTEM; DENSE SILICA; SPHERES; FABRICATION; ADSORPTION; OXIDATION	Porous thin-film polymethylsiloxane microparticles have been prepared successfully from octyltrichlorosilane and methyltrichlorosilane in (water/oil) W/O emulsion systems by using several oil phases and changing the amount of the silanes or of the surfactant Span 60. Hollow microspheres of various shell thicknesses (120-180 nm) and high surface area were prepared by using four types of nonpolar solvents as the oil phase of the W/O emulsion system. The diameter of the spheres can also be controlled (1-1.6 mu m) by using different oil phases. The results of thermal analysis, nitrogen adsorption isotherm, infrared spectra and X-ray diffraction data showed that hollow microspheres of amorphous polymethylsiloxane with high surface area (360-385 m(2)g(-1)) can be obtained by heating the spheres in air at 673 K; the polymethylsiloxane microspheres become nonporous silica particles after calcination at 873 K for 3 h. Cup-shape microparticles of polymethylsiloxane with nano-order thickness (20-120 nm) were prepared by reducing the amount of silanes in the mixture. Small hollow particles were prepared by replacing a portion of the octyltrichlorosilane with Span 60.	[Mishima, Shozi; Okada, Tomohiko; Sakai, Toshio; Kiyono, Ryutaro] Shinshu Univ, Fac Engn, Dept Chem & Mat Engn, Nagano 3808553, Japan; [Haeiwa, Tetsuji] Shinshu Univ, Fac Engn, Dept Informat Technol, Nagano 3808553, Japan	Mishima, S (reprint author), Shinshu Univ, Fac Engn, Dept Chem & Mat Engn, Wakasato 4-17-1, Nagano 3808553, Japan.	smisima@shinshu-u.ac.jp	Okada, Tomohiko/O-2266-2014	Okada, Tomohiko/0000-0002-9361-7004	Iketani Science and Technology Foundation	We are grateful for the financial support from the Iketani Science and Technology Foundation.	Zoldesi CI, 2005, ADV MATER, V17, P924, DOI 10.1002/adma.200401183; Kang SZ, 2012, MATER RES BULL, V47, P3065, DOI 10.1016/j.materresbull.2012.08.046; Chung CJ, 2008, J AM CERAM SOC, V91, P3074, DOI 10.1111/j.1551-2916.2008.02414.x; Smith RDL, 2014, CHEM MATER, V26, P1654, DOI 10.1021/cm4041715; Fujiwara M, 2004, CHEM MATER, V16, P5420, DOI 10.1021/cm048804r; Ghindes-Azaria L, 2012, J PHYS CHEM C, V116, P7442, DOI 10.1021/jp212524f; Tseng WJ, 2013, CERAM INT, V39, P3779, DOI 10.1016/j.ceramint.2012.10.217; Zhang SG, 2009, MATER LETT, V63, P258, DOI 10.1016/j.matlet.2008.10.004; Zoldesi CI, 2006, LANGMUIR, V22, P4343, DOI 10.1021/la060101w; Ren N, 2007, J CATAL, V251, P182, DOI 10.1016/j.jcat.2007.07.009; Park JH, 2003, J COLLOID INTERF SCI, V266, P107, DOI 10.1016/S0021-9797(03)00645-3; Mishima S, 2002, CHEM LETT, P1092, DOI 10.1246/cl.2002.1092; Bian YR, 2013, SURF INTERFACE ANAL, V45, P1317, DOI 10.1002/sia.5272; Fan HT, 2011, MATER LETT, V65, P1811, DOI 10.1016/j.matlet.2011.03.045; Fu XY, 2011, COLLOID SURFACE A, V380, P241, DOI 10.1016/j.colsurfa.2011.02.025; Guizard C, 2009, CATAL TODAY, V146, P367, DOI 10.1016/j.cattod.2009.05.012; Han X, 2013, MATER RES BULL, V48, P3717, DOI 10.1016/j.materresbull.2013.05.117; Lamic-Humblot AF, 2013, THIN SOLID FILMS, V527, P96, DOI 10.1016/j.tsf.2012.11.096; Li WJ, 2002, CHEM COMMUN, P2434, DOI 10.1039/b206020e; Liu SQ, 2011, MATER LETT, V65, P2083, DOI 10.1016/j.matlet.2011.04.005; Okada T, 2011, CHEM LETT, V40, P106, DOI 10.1246/cl.2011.106; Okada T, 2014, IND ENG CHEM RES, V53, P8759, DOI 10.1021/ie500588j; Okada T, 2009, CHEM LETT, V38, P32, DOI 10.1246/cl.2009.32; Okada T, 2014, ACS CATAL, V4, P73, DOI 10.1021/cs400923q; Okada T, 2014, J MATER CHEM A, V2, P5751, DOI 10.1039/c3ta15405j; Song LY, 2005, CHEM LETT, V34, P1314, DOI 10.1246/cl.2005.1314; Tao HX, 2013, J SOLID STATE CHEM, V200, P179, DOI 10.1016/j.jssc.2013.01.045; Wang L, 2012, MICROPOR MESOPOR MAT, V163, P243, DOI 10.1016/j.micromeso.2012.06.032; Xiong CR, 2005, MICROPOR MESOPOR MAT, V86, P14, DOI 10.1016/j.micromeso.2005.05.052; Yang LM, 2006, MICROPOR MESOPOR MAT, V94, P269, DOI 10.1016/j.micromeso.2006.03.048; Yue NL, 2011, INORG CHEM COMMUN, V14, P1233, DOI 10.1016/j.inoche.2011.04.029	31	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0032-3896	1349-0540		POLYM J	Polym. J.	JUN	2015	47	6					449	455		10.1038/pj.2015.16		7	Polymer Science	Polymer Science	CJ8IU	WOS:000355744300007		
J	Matsuhira, T; Osaki, S				Matsuhira, Takashi; Osaki, Shigeyoshi			Molecular weight of Nephila clavata spider silk	POLYMER JOURNAL			English	Article							CLAVIPES DRAGLINE SILK; CONSERVED C-TERMINI; IRRADIATION; FIBERS	The molecular weight of Nephila clavata spider silk was determined to be ca. 600 kDa, under unreduced conditions, corresponding to its natural state, using the sodium dodecyl sulfate polyacrylamide gel electrophoresis method and a protein marker with a maximum molecular weight of 500 kDa. The addition of 2-mercaptoethanol into the spider silk solution decreased the molecular weight from ca. 600 kDa to ca. 270 kDa. Such a dramatic decrease in the molecular weight was ascribed to the presence of 2-mercaptoethanol as a reductant. This finding indicates the possibility that the reduction process cleaved the disulfide bonds formed between the spider silk proteins and then drastically decreased the molecular weight from ca. 600 to ca. 270 kDa. These results suggest that N. clavata spider silk proteins might consist of two proteins with a molecular weight of ca. 270 kDa that are crosslinked by disulfide bonds and exist as a dimer of ca. 600 kDa.	[Matsuhira, Takashi] Nara Med Univ, Dept Chem, Kashihara, Nara 6348521, Japan; [Osaki, Shigeyoshi] Nara Med Univ, Dept Dermatol, Kashihara, Nara 6348521, Japan	Osaki, S (reprint author), Nara Med Univ, Dept Dermatol, Kashihara, Nara 6348521, Japan.	s-osaki@naramed-u.ac.jp					Hakimi O, 2007, COMPOS PART B-ENG, V38, P324, DOI 10.1016/j.compositesb.2006.06.012; Hedhammar M, 2008, BIOCHEMISTRY-US, V47, P3407, DOI 10.1021/bi702432y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ittah S, 2007, BIOMACROMOLECULES, V8, P2768, DOI 10.1021/bm7004559; Vollrath F, 2001, NATURE, V410, P541, DOI 10.1038/35069000; Sponner A, 2005, BIOCHEMISTRY-US, V44, P4727, DOI 10.1021/bi047671k; Sponner A, 2005, BIOCHEM BIOPH RES CO, V338, P897, DOI 10.1016/j.bbrc.2005.10.048; Sponner A, 2004, BIOMACROMOLECULES, V5, P840, DOI 10.1021/bm034378b; WORK RW, 1982, TEXT RES J, V52, P349, DOI 10.1177/004051758205200508; Lazaris A, 2002, SCIENCE, V295, P472, DOI 10.1126/science.1065780; Vollrath F, 1999, INT J BIOL MACROMOL, V24, P81, DOI 10.1016/S0141-8130(98)00076-2; Aitken CE, 2008, BIOPHYS J, V94, P1826, DOI 10.1529/biophysj.107.117689; Osaki S, 1996, NATURE, V384, P419, DOI 10.1038/384419a0; GOSLINE JM, 1984, NATURE, V309, P551, DOI 10.1038/309551a0; JACKSON C, 1995, MACROMOLECULES, V28, P5975, DOI 10.1021/ma00121a042; Kuhbier JW, 2011, J BIOMED MATER RES B, V97B, P381, DOI 10.1002/jbm.b.31825; MARSHALL I, 1953, T FARADAY SOC, V49, P67, DOI 10.1039/tf9534900067; Matsuhira T, 2013, POLYM J, V45, P1167, DOI 10.1038/pj.2013.41; Mello C. M., 1994, SILK POLYM MAT SCI B, P67; Osaki S, 2002, POLYM J, V34, P25, DOI 10.1295/polymj.34.25; Osaki S, 2004, POLYM J, V36, P657, DOI 10.1295/polymj.36.657; Osaki S, 2004, POLYM J, V36, P623, DOI 10.1295/polymj.36.623; Osaki Shigeyoshi, 1994, Acta Arachnologica, V43, P1, DOI 10.2476/asjaa.43.1; Osaki S, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.154301; Osaki S, 2011, POLYM J, V43, P200, DOI 10.1038/pj.2010.119; Osaki S., 1989, ACTA ARACHNOL, V7, P69; Osaki Shigeyoshi, 1997, Acta Arachnologica, V46, P1, DOI 10.2476/asjaa.46.1; Yokota R., 1990, KOBUNSHI, V39, P371	28	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0032-3896	1349-0540		POLYM J	Polym. J.	JUN	2015	47	6					456	459		10.1038/pj.2015.10		4	Polymer Science	Polymer Science	CJ8IU	WOS:000355744300008		
J	Takemura, K; Ajiro, H; Fujiwara, T; Akashi, M				Takemura, Kazuya; Ajiro, Hiroharu; Fujiwara, Tomoko; Akashi, Mitsuru			A novel substrate for testosterone: biodegradable and biocompatible oil gel	POLYMER JOURNAL			English	Article							BONE DEFECTS; DRUG-DELIVERY; STEREOCOMPLEX; ACID); TEMPERATURE; RELEASE; POLYLACTIDE; FABRICATION; COPOLYMERS; HYDROGELS	The androgen testosterone is less expensive than bone morphogenetic proteins and has been shown to effectively repair bone fractures. However, testosterone is lipophilic and insoluble in water, making it difficult to load into hydrogels, which are common drug carriers. In this study, we prepared a novel oil gel composed of poly(L-lactide) and a poly(trimethylene carbonate) derivative and studied the release of testosterone from the gel. Dimethyl sulfoxide and dimethyl carbonate, which are organic solvents with relatively low toxicities, were used as dispersion media. The oil gel in dimethyl sulfoxide released testosterone faster than that in dimethyl carbonate. In addition, the dimethyl carbonate oil gel was vacuum-dried to reduce the gel porosity and thus slow testosterone release. Therefore, oil gel is a promising substrate for lipophilic drugs, including testosterone.	[Takemura, Kazuya; Ajiro, Hiroharu; Akashi, Mitsuru] Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan; [Ajiro, Hiroharu; Akashi, Mitsuru] Osaka Univ, Ctr Adv Med Engn & Informat, Suita, Osaka 5650871, Japan; [Fujiwara, Tomoko] Univ Memphis, Dept Chem, Memphis, TN 38152 USA	Akashi, M (reprint author), Osaka Univ, Grad Sch Engn, Dept Appl Chem, 2-1 Yamada Oka, Suita, Osaka 5650871, Japan.	akashi@chem.eng.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology [23225004]; MEXT project 'Creating Hybrid Organs of the Future' at Osaka University	This work was supported by a Grant-in-Aid for Scientific Research (S) from the Ministry of Education, Culture, Sports, Science and Technology (23225004) and by the MEXT project 'Creating Hybrid Organs of the Future' at Osaka University. We are grateful to Drs T Kida, M Matsusaki and T Akagi for fruitful discussions.	Vintiloiu A, 2008, J CONTROL RELEASE, V125, P179, DOI 10.1016/j.jconrel.2007.09.014; Ajiro H, 2012, MACROMOLECULES, V45, P2668, DOI 10.1021/ma300183t; Ende MTA, 1997, J CONTROL RELEASE, V48, P47; Miller MA, 2011, INT ORTHOP, V35, P599, DOI 10.1007/s00264-010-1013-9; Diab T, 2012, J MECH BEHAV BIOMED, V11, P123, DOI 10.1016/j.jmbbm.2011.11.007; Fitzpatrick SD, 2012, EXPERT REV MED DEVIC, V9, P339, DOI [10.1586/erd.12.24, 10.1586/ERD.12.24]; Akagi T, 2012, ANGEW CHEM INT EDIT, V51, P5493, DOI 10.1002/anie.201201586; Pang XA, 2010, BIOTECHNOL J, V5, P1125, DOI 10.1002/biot.201000135; Kondo K, 2010, J AM CHEM SOC, V132, P8236, DOI 10.1021/ja1020537; Basak S, 2012, J MATER CHEM, V22, P11658, DOI 10.1039/c2jm30711a; Akagi T, 2014, LANGMUIR, V30, P1669, DOI 10.1021/la404162h; Zhang C, 2013, J APPL POLYM SCI, V130, P3800, DOI 10.1002/app.39646; Okamura Y, 2013, ADV MATER, V25, P545, DOI 10.1002/adma.201202851; Kim SH, 2011, BIOMATERIALS, V32, P5505, DOI 10.1016/j.biomaterials.2011.04.017; Tsuge T, 2010, POLYM DEGRAD STABIL, V95, P1345, DOI 10.1016/j.polymdegradstab.2010.01.028; Costa D, 2011, LANGMUIR, V27, P13780, DOI 10.1021/la2026285; Chu TMG, 2007, BIOMATERIALS, V28, P459, DOI 10.1016/j.biomaterials.2006.09.004; Lutolf MR, 2003, NAT BIOTECHNOL, V21, P513, DOI 10.1038/nbt818; Cheng BH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070234; Chu H, 2013, CHEM LETT, V42, P74, DOI 10.1246/cl.2013.74; Dargaville BL, 2011, BIOMACROMOLECULES, V12, P3856, DOI 10.1021/bm201291e; Floerkemeier T., 2012, ORTHOP REV PAVIA, V4, pe13; GONG JP, 1991, MACROMOLECULES, V24, P6582, DOI 10.1021/ma00025a006; Kim YH, 2013, J POROUS MAT, V20, P303, DOI 10.1007/s10934-012-9599-5; Ninawe PR, 2011, BIOTECHNOL PROGR, V27, P1442, DOI 10.1002/btpr.632; Ridha H, 2011, J RECONSTR MICROSURG, V27, P383, DOI 10.1055/s-0031-1281520; Takemura K, 2014, RSC ADV, V4, P33462, DOI 10.1039/c4ra05341a; Tokuyama H, 2010, EUR POLYM J, V46, P277, DOI 10.1016/j.eurpolymj.2009.10.016; Zhu Y, 2013, POLYM J, V45, P560, DOI 10.1038/pj.2012.174	29	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0032-3896	1349-0540		POLYM J	Polym. J.	JUN	2015	47	6					460	463		10.1038/pj.2015.17		4	Polymer Science	Polymer Science	CJ8IU	WOS:000355744300009		
J	Yamada, S; Sanada, Y; Tamura, A; Yui, N; Sakurai, K				Yamada, Shimpei; Sanada, Yusuke; Tamura, Atsushi; Yui, Nobuhiko; Sakurai, Kazuo			Chain architecture and flexibility of alpha-cyclodextrin/PEG polyrotaxanes in dilute solutions	POLYMER JOURNAL			English	Article							SCHIZOPHYLLUM-COMMUNE POLYSACCHARIDE; LIGHT-SCATTERING; WORMLIKE CHAINS; TRIPLE HELIX; DRUG-CARRIER; NECKLACE		[Yamada, Shimpei; Sanada, Yusuke; Sakurai, Kazuo] Univ Kitakyushu, Dept Chem & Biochem, Kitakyushu, Fukuoka 8080135, Japan; [Tamura, Atsushi; Yui, Nobuhiko] Tokyo Med & Dent Univ, Dept Organ Biomat, Inst Biomat & Bioengn, Tokyo, Japan	Sakurai, K (reprint author), Univ Kitakyushu, Dept Chem & Biochem, 1-1 Hibikino, Kitakyushu, Fukuoka 8080135, Japan.	sakurai@kitakyu-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan [23107004, 2306]	A part of this work was financially supported by the Grant-in-Aid for Scientific Research (No. 23107004) on Innovative Areas 'Nanomedicine Molecular Science' (No. 2306) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan. All SAXS measurements were performed at SPring-8 40B2(2014A1268).	KRATKY O, 1949, RECL TRAV CHIM PAY B, V68, P1106; Tamura A, 2013, BIOMATERIALS, V34, P2480, DOI 10.1016/j.biomaterials.2012.12.006; Mendichi R, 2002, BIOCONJUGATE CHEM, V13, P1253, DOI 10.1021/bc025522d; Schultz A, 2012, J AM CHEM SOC, V134, P7672, DOI 10.1021/ja303177v; Shigekawa H, 2000, J AM CHEM SOC, V122, P5411, DOI 10.1021/ja000037j; Harada A, 2009, CHEM REV, V109, P5974, DOI 10.1021/cr9000622; YANAKI T, 1980, MACROMOLECULES, V13, P1462, DOI 10.1021/ma60078a019; HARADA A, 1992, NATURE, V356, P325, DOI 10.1038/356325a0; Fleury G, 2005, SOFT MATTER, V1, P378, DOI 10.1039/b510331b; KASHIWAGI Y, 1981, MACROMOLECULES, V14, P1220, DOI 10.1021/ma50006a016; Kienberger F., 2000, Single Molecules, V1, DOI 10.1002/1438-5171(200006)1:2<123::AID-SIMO123>3.3.CO;2-V; Mayumi K, 2008, MACROMOLECULES, V41, P6480, DOI 10.1021/ma801021g; Nakamura Y, 2004, J POLYM SCI POL PHYS, V42, P1398, DOI 10.1002/polb.20026; Naruse K, 2009, J PHYS CHEM B, V113, P10222, DOI 10.1021/jp9019415; Okamoto N, 1996, MACROMOLECULES, V29, P2878, DOI 10.1021/ma951451k; Ooya T, 1997, J BIOMAT SCI-POLYM E, V8, P437, DOI 10.1163/156856297X00371; Ribeiro W, 2007, LANGMUIR, V23, P7014, DOI 10.1021/la700269k; Terao K, 1999, MACROMOLECULES, V32, P711, DOI 10.1021/ma9816517; Yamakawa H., 1971, MODERN THEORY POLYM; YAMAKAWA H, 1974, MACROMOLECULES, V7, P649, DOI 10.1021/ma60041a020	20	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0032-3896	1349-0540		POLYM J	Polym. J.	JUN	2015	47	6					464	467		10.1038/pj.2015.18		4	Polymer Science	Polymer Science	CJ8IU	WOS:000355744300010		
J	Kumura, H				Kumura, Hironori			Exit radii of submanifolds from cylindrical domains in warped product manifolds	PROCEEDINGS OF THE ROYAL SOCIETY OF EDINBURGH SECTION A-MATHEMATICS			English	Article							CONJECTURES; IMMERSIONS; CURVATURE	Let U-B(p(0);rho 1) x (f) MV be a cylindrically bounded domain in a warped product manifold (M) over bar := MB x (f) M-V and let M be an isometrically immersed submanifold in (M) over bar. The purpose of this paper is to provide explicit radii of the geodesic balls of M which first exit from UB(p(0);rho 1) x (f) M-V for the case in which the mean curvature of M is sufficiently small and the lower bound of the Ricci curvature of M does not diverge to -infinity too rapidly at infinity.	Shizuoka Univ, Dept Math, Shizuoka 4228529, Japan	Kumura, H (reprint author), Shizuoka Univ, Dept Math, Shizuoka 4228529, Japan.	smhkumu@ipc.shizuoka.ac.jp					Alias L. J., 2010, PREPRINT; Nadirashvili N, 1996, INVENT MATH, V126, P457, DOI 10.1007/s002220050106; OMORI H, 1967, J MATH SOC JPN, V19, P205; Collin P, 1999, B SCI MATH, V123, P563, DOI 10.1016/S0007-4497(99)00113-X; JORGE L, 1981, AM J MATH, V103, P711, DOI 10.2307/2374048; JORGE LPD, 1981, MATH Z, V178, P77, DOI 10.1007/BF01218372; KASUE A, 1984, LECT NOTES MATH, V1090, P1; Kasue A., 1984, ADV STUD PURE MATH, V3, P333; Martin F, 2000, MICH MATH J, V47, P499, DOI 10.1307/mmj/1030132591; Zhou DT, 1996, ARCH MATH, V67, P50, DOI 10.1007/BF01196166	10	0	0	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	0308-2105	1473-7124		P ROY SOC EDINB A	Proc. R. Soc. Edinb. Sect. A-Math.	JUN	2015	145	3					559	569		10.1017/S0308210512000534		11	Mathematics, Applied; Mathematics	Mathematics	CJ9DQ	WOS:000355803100006		
J	Tanaka, H; Harauma, A; Takimoto, M; Moriguchi, T				Tanaka, Hideko; Harauma, Akiko; Takimoto, Mao; Moriguchi, Toru			Association between very long chain fatty acids in the meibomian gland and dry eye resulting from n-3 fatty acid deficiency	PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS			English	Article						Meibomian gland; Very long chain fatty acid; Branched chain fatty acid; GC-MS; 4,4-dimethyloxazoline; Picolinyl ester	MASS-SPECTROMETRY; PICOLINYL ESTERS; PERMEABILITY BARRIER; STRUCTURAL-ANALYSIS; METHYL-ESTERS; HUMAN MEIBUM; DERIVATIVES; LIPIDS; RETINA; ELOVL4	In our previously study, we reported lower tear volume in with an n-3 fatty acid deficient mice and that the docosahexaenoic acid and total n-3 fatty acid levels in these mice are significantly reduced in the meibomian gland, which secretes an oily tear product. Furthermore, we noted very long chain fatty acids (>= 25 carbons) in the meibomian gland. To verify the detailed mechanism of the low tear volume in the n-3 fatty acid-deficient mice, we identified the very long chain fatty adds in the meibomian gland, measured the fatty acid composition in the tear product. Very long chain fatty acids were found to exist as monoesters. In particular, very long chain fatty acids with 25-29 carbons existed for the most part as iso or anteiso branched-chain fatty acids. n-3 fatty acid deficiency was decreased the amount of meibum secretion from meibomian gland without change of fatty acid composition. These results suggest that the n-3 fatty acid deficiency causes the enhancement of evaporation of tear film by reducing oily tear secretion along with the decrease of meibomian gland function. (C) 2015 Elsevier Ltd. All rights reserved.	[Tanaka, Hideko; Harauma, Akiko; Moriguchi, Toru] Azabu Univ, Sch Life & Environm Sci, Lab Funct Anal Marine Mat, Sagamihara, Kanagawa 2525201, Japan; [Takimoto, Mao; Moriguchi, Toru] Azabu Univ, Sch Life & Environm Sci, Dept Food & Life Sci, Lab Food & Nutr Sci,Chuo Ku, Sagamihara, Kanagawa 2525201, Japan	Moriguchi, T (reprint author), Azabu Univ, Sch Life & Environm Sci, Dept Food & Life Sci, Lab Food & Nutr Sci,Chuo Ku, 1-17-71 Fuchinobe, Sagamihara, Kanagawa 2525201, Japan.	moriguchi@azabu-u.ac.jp			Nippon Suisan Kaisha Ltd., Tokyo, Japan	This work was supported by a grant from Nippon Suisan Kaisha Ltd., Tokyo, Japan. We would like to thank Mr. Hisamatsu of Lecturer (Laboratory of Environmental analysis, Department of Enviromental Science, School of Life and Environmental Science, Azabu University) for technical support on the GC MS facility.	Nguyen CTO, 2008, INVEST OPHTH VIS SCI, V49, P3586, DOI 10.1167/iovs.08-1735; Moriguchi T, 2000, J NEUROCHEM, V75, P2563, DOI 10.1046/j.1471-4159.2000.0752563.x; Masood A, 2005, J LIPID RES, V46, P2299, DOI 10.1194/jlr.D500022-JLR200; Harvey DJ, 1998, MOL BIOTECHNOL, V10, P251, DOI 10.1007/BF02740846; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Butovich IA, 2007, J LIPID RES, V48, P2220, DOI 10.1194/jlr.M700237-JLR200; LEPAGE G, 1986, J LIPID RES, V27, P114; Fedorova I, 2006, PROSTAG LEUKOTR ESS, V75, P271, DOI 10.1016/j.plefa.2006.07.006; Christie WW, 1998, LIPIDS, V33, P343, DOI 10.1007/s11745-998-0214-x; Destaillats F, 2002, J AM OIL CHEM SOC, V79, P253, DOI 10.1007/s11746-002-0469-7; Berdeaux O, 2010, J CHROMATOGR A, V1217, P7738, DOI 10.1016/j.chroma.2010.10.039; Butovich IA, 2009, J LIPID RES, V50, P501, DOI 10.1194/jlr.M800426-JLR200; Cameron DJ, 2007, INT J BIOL SCI, V3, P111; Dobson G, 1996, TRAC-TREND ANAL CHEM, V15, P130, DOI 10.1016/0165-9936(95)00111-5; Dubois N, 2006, EUR J LIPID SCI TECH, V108, P28, DOI 10.1002/ejlt.200501217; Harauma A, 2014, PROSTAG LEUKOTR ESS, V90, P207, DOI 10.1016/j.plefa.2014.02.005; Harauma A, 2011, LIPIDS, V46, P409, DOI 10.1007/s11745-010-3523-z; Igor A., 2010, STEROIDS, V75, P726; Moriguchi T, 2001, J LIPID RES, V42, P419; Morita Masashi, 2008, Seikagaku, V80, P434; Ran-Ressler RR, 2012, J LIPID RES, V53, P195, DOI 10.1194/jlr.D020651; Sassa T, 2013, MOL CELL BIOL, V33, P2787, DOI 10.1128/MCB.00192-13; Vasireddy V, 2007, HUM MOL GENET, V16, P471, DOI 10.1093/hmg/ddl480; Weisinger HS, 2002, LIPIDS, V37, P759, DOI 10.1007/s11745-002-0958-3; YU QT, 1988, LIPIDS, V23, P804, DOI 10.1007/BF02536225	25	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0952-3278	1532-2823		PROSTAG LEUKOTR ESS	Prostaglandins Leukot. Essent. Fatty Acids	JUN	2015	97						1	6		10.1016/j.plefa.2015.02.004		6	Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism	CJ7VH	WOS:000355707900001		
J	Iwashita, K; Inoue, N; Handa, A; Shiraki, K				Iwashita, Kazuki; Inoue, Naoto; Handa, Akihiro; Shiraki, Kentaro			Thermal Aggregation of Hen Egg White Proteins in the Presence of Salts	PROTEIN JOURNAL			English	Article						Hen egg white proteins; Thermal aggregation; Hofmeister series; High concentration; Crowding	PROTEOMIC ANALYSIS; HOFMEISTER SERIES; SOLUTION ADDITIVES; CROWDING AGENTS; AMINO-ACIDS; LYSOZYME; ARGININE; INACTIVATION; WATER; ENVIRONMENT	Hen egg white contains more than 40 kinds of proteins with concentrations reaching 100 mg/mL. Highly concentrated protein mixtures are common in the food industry, but the effects of a crowded environment containing salts on protein stability and aggregation have only been investigated using pure protein solutions. Here, we investigated the thermal aggregation of hen egg white protein (EWP) at various concentrations in the presence of inorganic salts by solubility measurements and SDS-PAGE. EWP at 1 mg/mL formed aggregates with increasing temperature above 55 A degrees C; the aggregation temperatures increased in the presence of inorganic salt with the Hofmeister series. Namely, the chaotrope 0.5 M NaSCN completely suppressed the thermal aggregation of 1 mg/mL EWP. As the protein concentration increased, NaSCN unexpectedly enhanced the protein aggregation; the aggregation temperature of 10 and 100 mg/mL EWP solutions were dramatically decreased at 62 and 47 A degrees C, respectively. This decrease in aggregation temperatures due to the chaotrope was described by the excluded volume effect, based on a comparative experiment using Ficoll 70 as a neutral crowder. By contrast, the kosmotrope Na2SO4 did not affect the aggregation temperature at concentrations from 1 to 100 mg/mL EWPs. The unexpected fact that a chaotrope rather enhanced the protein aggregation at high concentration provides new insight into the aggregation phenomena with the Hofmeister effect as well as the crude state of highly concentrated proteins.	[Iwashita, Kazuki; Inoue, Naoto; Shiraki, Kentaro] Univ Tsukuba, Fac Pure & Appl Sci, Tsukuba, Ibaraki 3058573, Japan; [Handa, Akihiro] Kewpie Corp, Inst Technol, R&D Div, Chofu, Tokyo 1820002, Japan	Shiraki, K (reprint author), Univ Tsukuba, Fac Pure & Appl Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058573, Japan.	shiraki@bk.tsukuba.ac.jp			Tsukuba University	We thank Dr. Eisuke Takai for helpful discussion. This study was supported financially by Tsukuba University.	YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Wang YQ, 2012, J PHYS CHEM LETT, V3, P2703, DOI 10.1021/jz3010915; Ellis RJ, 2003, NATURE, V425, P27, DOI 10.1038/425027a; Wang YQ, 2010, J AM CHEM SOC, V132, P9392, DOI 10.1021/ja102296k; Hirano A, 2007, PROTEIN J, V26, P423, DOI 10.1007/s10930-007-9082-3; Tomita S, 2011, BIOPOLYMERS, V95, P695, DOI 10.1002/bip.21637; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Zhang YJ, 2006, CURR OPIN CHEM BIOL, V10, P658, DOI 10.1016/j.cbpa.2006.09.020; Chebotareva NA, 2004, BIOCHEMISTRY-MOSCOW+, V69, P1239, DOI 10.1007/s10541-005-0070-y; Perham M, 2007, FEBS LETT, V581, P5065, DOI 10.1016/j.febslet.2007.09.049; Pegram LM, 2008, CHEM PHYS LETT, V467, P1, DOI 10.1016/j.cplett.2008.10.090; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; Jungwirth P, 2014, NAT CHEM, V6, P261, DOI 10.1038/nchem.1899; LIN MY, 1989, NATURE, V339, P360, DOI 10.1038/339360a0; Handa A, 1998, J FOOD SCI, V63, P403, DOI 10.1111/j.1365-2621.1998.tb15752.x; Zhang YJ, 2009, P NATL ACAD SCI USA, V106, P15249, DOI 10.1073/pnas.0907616106; MINE Y, 1990, J AGR FOOD CHEM, V38, P2122, DOI 10.1021/jf00102a004; Okanojo M, 2005, J BIOSCI BIOENG, V100, P556, DOI 10.1263/jbb.100.556; Kunz W, 2010, CURR OPIN COLLOID IN, V15, P34, DOI 10.1016/j.cocis.2009.11.008; Abeyrathne EDNS, 2013, POULTRY SCI, V92, P3292, DOI 10.3382/ps.2013-03391; Arakawa T, 2014, CURR PROTEIN PEPT SC, V15, P608; Nihonyanagi S, 2014, J AM CHEM SOC, V136, P6155, DOI 10.1021/ja412952y; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; Schwierz N, 2010, LANGMUIR, V26, P7370, DOI 10.1021/la904397v; Hirano A, 2008, J BIOCHEM, V144, P363, DOI 10.1093/jb/mvn078; Qiu N, 2012, J AGR FOOD CHEM, V60, P7746, DOI 10.1021/jf302100m; Homouz D, 2008, P NATL ACAD SCI USA, V105, P11754, DOI 10.1073/pnas.0803672105; Schwierz N, 2013, LANGMUIR, V29, P2602, DOI 10.1021/la303924e; Mann K, 2007, PROTEOMICS, V7, P3558, DOI 10.1002/pmic.200700397; Lo Nostro P, 2012, CHEM REV, V112, P2286, DOI 10.1021/cr200271j; Kudou M, 2003, EUR J BIOCHEM, V270, P4547, DOI 10.1046/j.1432-1033.2003.03850.x; Qiu N, 2012, J PROTEOMICS, V75, P1895, DOI 10.1016/j.jprot.2011.12.037; Pegram LM, 2007, J PHYS CHEM B, V111, P5411, DOI 10.1021/jp070245z; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Sun YX, 2002, J AGR FOOD CHEM, V50, P1636, DOI 10.1021/jf0109975; Breydo L, 2014, BBA-PROTEINS PROTEOM, V1844, P346, DOI 10.1016/j.bbapap.2013.11.004; Kunz W, 2004, CURR OPIN COLLOID IN, V9, P19, DOI 10.1016/j.cocis.2004.05.005; Kozer N, 2004, J MOL BIOL, V336, P763, DOI 10.1016/j.jmb.2003.12.008; Guerin-Dubiard C, 2006, J AGR FOOD CHEM, V54, P3901, DOI 10.1021/jf0529969; Shiraki K, 2002, J BIOCHEM, V132, P591; Rao Q, 2012, J AGR FOOD CHEM, V60, P10625, DOI 10.1021/jf302402k; Ariki R, 2011, J BIOCHEM, V149, P389, DOI 10.1093/jb/mvr004; Bostroem M, 2011, LANGMUIR, V27, P9504, DOI 10.1021/la202023r; Croguennec T, 2002, FOOD ENG PHYS PROP, V67, P606; Hamada H, 2008, BIOTECHNOL PROGR, V24, P436, DOI 10.1021/bp070350q; Hamada H, 2007, J BIOTECHNOL, V130, P153, DOI 10.1016/j.jbiotec.2007.03.003; Ito L, 2010, ACTA CRYSTALLOGR F, V66, P744, DOI 10.1107/S1744309110013710; Lopez-Leon T, 2008, J PHYS CHEM C, V112, P16061; Markossian KA, 2009, INT J MOL SCI, V10, P1314, DOI 10.3390/ijms10031314; Matsuoka T, 2009, BIOTECHNOL PROGR, V25, P1515, DOI 10.1002/btpr.245; Rivas German, 2004, EMBO Reports, V5, P23, DOI 10.1038/sj.embor.7400056; Sanfelice D, 2012, J PHYS-CONDENS MAT, V24, DOI 10.1088/0953-8984/24/24/244107; Sarkar Mohona, 2013, Biophysical Reviews, V5, DOI 10.1007/s12551-013-0104-4; Shiraki K, 2004, EUR J BIOCHEM, V271, P3242, DOI 10.1111/j.1432-1033.2004.04257.x; Tomita S, 2012, BIOTECHNOL BIOENG, V109, P2543, DOI 10.1002/bit.24531; Wang J, 2014, EUPA OPEN PROTEOMICS, V2, P38	56	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1572-3887	1573-4943		PROTEIN J	Protein J.	JUN	2015	34	3					212	219		10.1007/s10930-015-9612-3		8	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CJ6VW	WOS:000355634300006		
J	Inoue, Y				Inoue, Yuichi			Sleep-related eating disorder and its associated conditions	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Review						circadian rhythm; hypnotics; night eating syndrome; parasomnia; sleep-related eating disorder	RESTLESS-LEGS-SYNDROME; PLACEBO-CONTROLLED TRIAL; GENERAL-POPULATION; CIRCADIAN RHYTHMICITY; GLUCOSE-UTILIZATION; CASE SERIES; ZDF RATS; PREVALENCE; TOPIRAMATE; BEHAVIORS	Sleep-related eating disorder (SRED) is a condition characterized by recurrent episodes of eating at the transition from night-time sleep to arousal. SRED patients describe eating in an out-of-control manner with preference for high-caloric foods and sometimes with inedible or toxic items. Level of consciousness during SRED episodes ranges from partial consciousness to dense unawareness typical of somnambulistic episodes. SRED is sometimes associated with psychotropic medication, in particular sedative hypnotics, and other sleep disorders, including parasomnias, narcolepsy, and restless legs syndrome. Night eating syndrome (NES) is another important condition in the disordered night-time eating spectrum showing hyperphagia episodes at full arousal from nocturnal sleep without accompanying amnesia. NES could be considered an abnormality in the circadian rhythm of meal timing with a normal circadian timing of sleep onset. The two conditions often overlap and possibly share a common pathophysiology. Studies have suggested that central nervous system serotonin modulation may lead to an effective treatment of NES, while the anti-seizure medication topiramate may be an effective SRED treatment.	[Inoue, Yuichi] Tokyo Med Univ, Dept Somnol, Tokyo 1600023, Japan; [Inoue, Yuichi] Neuropsychiat Res Inst, Tokyo, Japan	Inoue, Y (reprint author), Tokyo Med Univ, Shinjuku Ku, 6-1-1 Shinjuku, Tokyo 1600023, Japan.	inoue@somnology.com			JSPS KAKENHI [25515009]	This work was supported by JSPS KAKENHI Grant Number 25515009. The author has nothing to disclose.	American Academy of Sleep Medicine, 2014, INT CLASS SLEEP DIS, P240; Winkelman JW, 2003, SLEEP MED, V4, P243, DOI 10.1016/S1389-9457(03)00060-1; O'Reardon JP, 2006, AM J PSYCHIAT, V163, P893, DOI 10.1176/appi.ajp.163.5.893; Allison KC, 2013, EAT BEHAV, V14, P199, DOI 10.1016/j.eatbeh.2013.02.001; Bass J, 2012, NATURE, V491, P348, DOI 10.1038/nature11704; Smink FRE, 2012, CURR PSYCHIAT REP, V14, P406, DOI 10.1007/s11920-012-0282-y; VANCAUTER E, 1991, J CLIN INVEST, V88, P934, DOI 10.1172/JCI115396; Brion A, 2012, SLEEP MED, V13, P1094, DOI 10.1016/j.sleep.2012.06.012; MAQUET P, 1990, BRAIN RES, V513, P136, DOI 10.1016/0006-8993(90)91099-3; Birketvedt GS, 1999, JAMA-J AM MED ASSOC, V282, P657, DOI 10.1001/jama.282.7.657; Howell MJ, 2012, J CLIN SLEEP MED, V8, P413, DOI 10.5664/jcsm.2036; Tsai MJ, 2007, CLIN TOXICOL, V45, P179, DOI 10.1080/15563650600956741; Shapira NA, 2000, J CLIN PSYCHIAT, V61, P368; Dolder CR, 2008, CNS DRUGS, V22, P1021, DOI 10.2165/0023210-200822120-00005; McElroy SL, 2009, CNS DRUGS, V23, P139, DOI 10.2165/00023210-200923020-00004; Parrino L, 2006, SLEEP MED REV, V10, P267, DOI 10.1016/j.smrv.2005.12.004; BOYLE PJ, 1994, J CLIN INVEST, V93, P529, DOI 10.1172/JCI117003; Vinai P, 2012, SLEEP MED, V13, P686, DOI 10.1016/j.sleep.2011.11.017; Ferrari AJ, 2013, PSYCHOL MED, V43, P471, DOI 10.1017/S0033291712001511; Paquet V, 2002, J CLIN PSYCHIAT, V63, P597; Vetrugno R, 2006, SLEEP, V29, P949; Howell MJ, 2009, SLEEP MED REV, V13, P23, DOI 10.1016/j.smrv.2008.07.005; Manni R, 1997, SLEEP, V20, P734; Berger K, 2004, ARCH INTERN MED, V164, P196, DOI 10.1001/archinte.164.2.196; VanCauter E, 1997, ENDOCR REV, V18, P716, DOI 10.1210/er.18.5.716; SCHENCK CH, 1993, SLEEP, V16, P457; Yang ST, 2009, ENDOCRINOLOGY, V150, P2153, DOI 10.1210/en.2008-0705; Friedman S, 2002, AM J PSYCHIAT, V159, P875, DOI 10.1176/appi.ajp.159.5.875; Bello NT, 2010, PHARMACOL BIOCHEM BE, V97, P25, DOI 10.1016/j.pbb.2010.04.016; Lam SP, 2008, J CLIN PSYCHIAT, V69, P1374; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Nomura T, 2008, MOVEMENT DISORD, V23, P2363, DOI 10.1002/mds.22274; Allen RP, 2005, ARCH INTERN MED, V165, P1286, DOI 10.1001/archinte.165.11.1286; O'Reardon JP, 2004, OBES RES, V12, P1789, DOI 10.1038/oby.2004.222; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Goel N, 2009, J BIOL RHYTHM, V24, P85, DOI 10.1177/0748730408328914; Rogers NL, 2006, SLEEP, V29, P814; Simon C, 1998, J CLIN ENDOCR METAB, V83, P1893, DOI 10.1210/jc.83.6.1893; Roth T, 2013, J CLIN SLEEP MED, V9, P955, DOI 10.5664/jcsm.3004; Winkelman JW, 1998, J CLIN PSYCHIAT, V59, P14, DOI 10.4088/JCP.v59n0104; Pilon M, 2008, NEUROLOGY, V70, P2284, DOI 10.1212/01.wnl.0000304082.49839.86; Chiang Ambrose, 2008, J Clin Sleep Med, V4, P155; De Ocampo Joel, 2002, Sleep Med, V3, P525, DOI 10.1016/S1389-9457(02)00137-5; desZwaan M, 2006, INT J EAT DISORDER, V39, P224; Dzaja A, 2004, AM J PHYSIOL-ENDOC M, V286, pE963, DOI 10.1152/ajpendo.00527.2003; Gluck ME, 2001, OBES RES, V9, P264, DOI 10.1038/oby.2001.31; Gupta M., 1991, SLEEP RES, V20, P182; Heathman JC, 2014, J CLIN PSYCHOPHARM, V34, P658, DOI 10.1097/JCP.0000000000000198; Hwang TJ, 2010, J CLIN PSYCHIAT, V71, P1331, DOI 10.4088/JCP.09m05083bro; Lam SP, 2009, AUST NZ J PSYCHIAT, V43, P426, DOI 10.1080/00048670902817703; Lecendreux M, 2003, MOL PSYCHIATR, V8, P114, DOI 10.1038/sj.mp.4001203; Liang Y, 2005, DIABETES OBES METAB, V7, P360, DOI 10.1111/j.1463-1326.2004.00403.x; Lu ML, 2004, J CLIN PSYCHIAT, V65, P273; Milano W, 2013, CASE REP MED, V2013; Molina SM, 2010, J CLIN PSYCHIAT, V71, P210, DOI 10.4088/JCP.09l05364bro; Morgenthaler Timothy I, 2002, Sleep Med, V3, P323, DOI 10.1016/S1389-9457(02)00007-2; NADEL C, 1981, BRIT J PSYCHIAT, V139, P79; Najjar M., 2007, J CLIN SLEEP MED, V3, P637; NECKELMANN D, 1993, SLEEP, V16, P467; Oguchi Y, 2010, JPN J PSYCHIAT TREAT, V25, P1509; O' Reardon JP, 2005, CNS DRUGS, V19, P997, DOI 10.2165/00023210-200519120-00003; Palaia V, 2011, SLEEP, V34, P1365, DOI 10.5665/SLEEP.1280; Paulus W, 2007, MOVEMENT DISORD, V22, pS431, DOI 10.1002/mds.21824; Provini F, 2009, MOVEMENT DISORD, V24, P871, DOI 10.1002/mds.22460; Provini F, 2008, SLEEP MED, V9, P903, DOI 10.1016/j.sleep.2007.10.021; Provini F, 2005, EUR J NEUROL, V12, P432, DOI 10.1111/j.1468-1331.2005.01017.x; Rand CSW, 1997, INT J EAT DISORDER, V22, P65; Schenck C., 2006, PARADOX LOST MIDNIGH; SCHENCK CH, 1991, SLEEP, V14, P419; Schenck CH, 2005, SLEEP, V28, pA259; SCHENCK CH, 1994, INT J EAT DISORDER, V15, P343; Tsai JH, 2013, SLEEP, V36, P197, DOI 10.5665/sleep.2372; Vander Wal Jillon S, 2012, J Clin Psychopharmacol, V32, P341, DOI 10.1097/JCP.0b013e318254239b; Wallace Douglas McKay, 2011, J Clin Sleep Med, V7, P310, DOI 10.5664/JCSM.1082; WHYTE J, 1990, INT J EAT DISORDER, V9, P577, DOI 10.1002/1098-108X(199009)9:5<577::AID-EAT2260090514>3.0.CO;2-C; Wilkes JJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE617, DOI 10.1152/ajpendo.00437.2004; Winkelman JW, 2006, SLEEP, V29, P876; Winkelman JW, 1997, SLEEP RES, V26, P31; Winkelman John W, 2011, Handb Clin Neurol, V98, P577, DOI 10.1016/B978-0-444-52006-7.00037-X; Winkelman JW, 2006, J CLIN PSYCHIAT, V67, P1729; Winkelman JW, 1999, PSYCHOL MED, V29, P1461, DOI 10.1017/S0033291799008272	81	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUN	2015	69	6					309	320		10.1111/pcn.12263		12	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CJ8IS	WOS:000355744100001		
J	Watanabe, N; Furukawa, TA; Shimodera, S; Katsuki, F; Fujita, H; Sasaki, M; Sado, M; Perlis, ML				Watanabe, Norio; Furukawa, Toshiaki A.; Shimodera, Shinji; Katsuki, Fujika; Fujita, Hirokazu; Sasaki, Megumi; Sado, Mitsuhiro; Perlis, Michael L.			Cost-effectiveness of cognitive behavioral therapy for insomnia comorbid with depression: Analysis of a randomized controlled trial	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article						behavior therapy; cost-benefit analysis; depressive disorder; resource allocation; sleep initiation and maintenance disorders	PRIMARY-CARE; PSYCHOLOGICAL TREATMENT; PSYCHOTHERAPY; SYMPTOMS; DISORDER	AimAlthough the efficacy of cognitive behavioral therapy for insomnia has been confirmed, dissemination depends on the balance of benefits and costs. This study aimed to examine the cost-effectiveness of cognitive behavioral therapy for insomnia consisting of four weekly individual sessions. MethodsWe conducted a 4-week randomized controlled trial with a 4-week follow up in outpatient clinics in Japan. Thirty-seven patients diagnosed as having major depressive disorder according to DSM-IV and suffering from chronic insomnia were randomized to receive either treatment as usual (TAU) alone or TAU plus cognitive behavioral therapy for insomnia. Effectiveness was evaluated as quality-adjusted life years (QALY) over 8 weeks' time, estimated by bootstrapping of the observed total scores of the Hamilton Depression Rating Scale. Direct medical costs for cognitive behavioral therapy for insomnia and TAU were also evaluated. We calculated the incremental cost-effectiveness ratio. ResultsOver the 8 weeks of the study, the group receiving cognitive behavioral therapy for insomnia plus TAU had significantly higher QALY (P=0.002) than the TAU-alone group with an incremental value of 0.019 (SD 0.006), and had non-significantly higher costs with an incremental value of 254 (SD 203) USD in direct costs. The incremental cost-effectiveness ratio was 13678 USD (95% confidence interval: -5691 to 71316). Adding cognitive behavioral therapy for insomnia demonstrated an approximately 95% chance of gaining one more QALY if a decision-maker was willing to pay 60000 USD, and approximately 90% for 40000 USD. ConclusionAdding cognitive behavioral therapy for insomnia is highly likely to be cost-effective for patients with residual insomnia and concomitant depression.	[Watanabe, Norio] Natl Ctr Neurol & Psychiat, Dept Clin Epidemiol, Translat Med Ctr, Kodaira, Tokyo 1878551, Japan; [Sado, Mitsuhiro] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan; [Watanabe, Norio] Nagoya City Univ, Grad Sch Med Sci, Dept Psychiat & Cognit Behav Med, Nagoya, Aichi, Japan; [Katsuki, Fujika] Nagoya City Univ, Sch Nursing, Dept Psychiat & Mental Hlth Nursing, Nagoya, Aichi, Japan; [Furukawa, Toshiaki A.] Kyoto Univ, Grad Sch Med, Sch Publ Hlth, Dept Hlth Promot & Human Behav, Kyoto, Japan; [Furukawa, Toshiaki A.] Kyoto Univ, Grad Sch Med, Sch Publ Hlth, Dept Clin Epidemiol, Kyoto, Japan; [Shimodera, Shinji; Fujita, Hirokazu] Kochi Univ, Dept Neuropsychiat, Kochi Med Sch, Kochi 780, Japan; [Sasaki, Megumi] Japan Adv Inst Sci & Technol, Hlth Care Ctr, Nomi, Ishikawa, Japan; [Perlis, Michael L.] Univ Penn, Dept Psychiat, Behav Sleep Med Program, Philadelphia, PA 19104 USA	Watanabe, N (reprint author), Natl Ctr Neurol & Psychiat, Dept Clin Epidemiol, Translat Med Ctr, 4-1-1 Ogawa Higashi, Kodaira, Tokyo 1878551, Japan.	noriow@ncnp.go.jp			Ministry of Health, Labor and Welfare, Japan [19230201]; Intramural Research Grant for Neurological and Psychiatric Disorders of National Center of Neurology and Psychiatry, Japan [25-8]	This study was funded by a Grant-in-Aid for Scientific Research (No. 19230201) from the Ministry of Health, Labor and Welfare, Japan, and an Intramural Research Grant (25-8) for Neurological and Psychiatric Disorders of National Center of Neurology and Psychiatry, Japan. The authors have no conflicts of interests to declare that may be affected by the publication of this article.	Pyne JM, 2007, MED CARE, V45, P357, DOI 10.1097/01.mlr.0000256971.81184.aa; Morin CM, 2009, JAMA-J AM MED ASSOC, V301, P2005, DOI 10.1001/jama.2009.682; Fenwick E, 2005, BRIT J PSYCHIAT, V187, P106, DOI 10.1192/bjp.187.2.106; Lave JR, 1998, ARCH GEN PSYCHIAT, V55, P645, DOI 10.1001/archpsyc.55.7.645; Watanabe N, 2011, J CLIN PSYCHIAT, V72, P1651, DOI 10.4088/JCP.10m06130gry; Daley M, 2009, SLEEP, V32, P55; Manber R, 2008, SLEEP, V31, P489; McCrone P, 2004, BRIT J PSYCHIAT, V185, P55, DOI 10.1192/bjp.185.1.55; Simon GE, 2009, ARCH GEN PSYCHIAT, V66, P1081, DOI 10.1001/archgenpsychiatry.2009.123; Furukawa TA, 2007, J CLIN PSYCHOPHARM, V27, P531, DOI 10.1097/JCP.0b013e31814f30b1; Araya R, 2006, AM J PSYCHIAT, V163, P1379, DOI 10.1176/appi.ajp.163.8.1379; Sunderajan P, 2010, CNS SPECTRUMS, V15, P394; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Morgan K, 2003, J PSYCHOSOM RES, V54, P21, DOI 10.1016/S0022-3999(02)00569-X; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Bennett KJ, 1996, QUALITY LIFE PHARMAC, P253; Carney CE, 2007, J CLIN PSYCHIAT, V68, P254; Furukawa T, 2003, GRID HAMD 17; Kaltenthaler E, 2002, Health Technol Assess, V6, P1; Montgomery P, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003161; Morgan K, 2004, HEALTH TECHNOL ASSES, V8, pIII; Morin CM, 2004, INSOMNIA CLIN GUIDE; Munezawa T, 2009, JAP J PSYCHIAT TREAT, V24, P219; Perlis ML, 2005, COGNITIVE BEHAV TREA; Sado M, 2011, SEISHIN SHIKKAN NO S; Sapin Christophe, 2004, Health Qual Life Outcomes, V2, P20, DOI 10.1186/1477-7525-2-20; The WHO Collaborating Centre for Drug Statistics Methodology, 2009, ATC DDD DEF DAIL DOS; Watanabe N, 2013, PSYCHOTHER PSYCHOSOM, V82, P401, DOI 10.1159/000353174	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUN	2015	69	6					335	343		10.1111/pcn.12237		9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CJ8IS	WOS:000355744100003		
J	Ota, M; Noda, T; Sato, N; Hattori, K; Hori, H; Sasayama, D; Teraishi, T; Nagashima, A; Obu, S; Higuchi, T; Kunugi, H				Ota, Miho; Noda, Takamasa; Sato, Noriko; Hattori, Kotaro; Hori, Hiroaki; Sasayama, Daimei; Teraishi, Toshiya; Nagashima, Anna; Obu, Satoko; Higuchi, Teruhiko; Kunugi, Hiroshi			White matter abnormalities in major depressive disorder with melancholic and atypical features: A diffusion tensor imaging study	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article						atypical features; diffusion tensor imaging; major depressive disorder; melancholic features; tract-based spatial statistics	INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; HIPPOCAMPAL VOLUME; DSM-IV; INTEGRITY; EPIDEMIOLOGY; LOCALIZATION; ORGANIZATION; METAANALYSIS; VALIDATION; SYMPTOMS	AimThe DSM-IV recognizes some subtypes of major depressive disorder (MDD). It is known that the effectiveness of antidepressants differs among the MDD subtypes, and thus the differentiation of the subtypes is important. However, little is known as to structural brain changes in MDD with atypical features (aMDD) in comparison with MDD with melancholic features (mMDD), which prompted us to examine possible differences in white matter integrity assessed with diffusion tensor imaging (DTI) between these two subtypes. MethodsSubjects were 21 patients with mMDD, 24 with aMDD, and 37 age- and sex-matched healthy volunteers whose DTI data were obtained by 1.5 tesla magnetic resonance imaging. We compared fractional anisotropy and mean diffusivity value derived from DTI data on a voxel-by-voxel basis among the two diagnostic groups and healthy subjects. ResultsThere were significant decreases of fractional anisotropy and increases of mean diffusivity in patients with MDD compared with healthy subjects in the corpus callosum, inferior fronto-occipital fasciculus, and left superior longitudinal fasciculus. However, we detected no significant difference in any brain region between mMDD and aMDD. ConclusionOur results suggest that patients with MDD had reduced white matter integrity in some regions; however, there was no major difference between aMDD and mMDD.	[Ota, Miho; Hattori, Kotaro; Hori, Hiroaki; Sasayama, Daimei; Teraishi, Toshiya; Nagashima, Anna; Obu, Satoko; Kunugi, Hiroshi] Natl Ctr Hosp Neurol & Psychiat, Dept Mental Disorder Res, Natl Inst Neurosci, Tokyo, Japan; [Higuchi, Teruhiko] Natl Ctr Hosp Neurol & Psychiat, Natl Ctr Neurol & Psychiat, Tokyo, Japan; [Noda, Takamasa] Natl Ctr Hosp Neurol & Psychiat, Dept Psychiat, Tokyo, Japan; [Sato, Noriko] Natl Ctr Hosp Neurol & Psychiat, Dept Radiol, Tokyo, Japan	Ota, M (reprint author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Disorder Res, 4-1-1 Ogawa Higashi, Kodaira, Tokyo 1878502, Japan.	ota@ncnp.go.jp			Health and Labor Sciences Research Grant (Comprehensive Research on Disability, Health, and Welfare); Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP [24-11]; CREST grant from JST; 'Understanding of Molecular and Environmental Bases for Brain Health' program	This study was supported by a Health and Labor Sciences Research Grant (Comprehensive Research on Disability, Health, and Welfare) (to M.O. and H.K.), an Intramural Research Grant (24-11) for Neurological and Psychiatric Disorders of NCNP (to M.O. and H.K.), by a CREST grant from JST (to H.K.), and by funds from the 'Understanding of Molecular and Environmental Bases for Brain Health' program carried out under the Strategic Research Program for Brain Sciences by the Ministry of Education, Culture, Sports, Science and Technology of Japan (to H.K.). All authors declare that they have no conflicts of interest.	Alves GS, 2012, PSYCHIAT RES-NEUROIM, V203, P194, DOI 10.1016/j.pscychresns.2011.12.006; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andrade L, 2003, INT J METH PSYCH RES, V12, P3, DOI 10.1002/mpr.138; Levitan RD, 1997, AM J PSYCHIAT, V154, P934; Catani M, 2002, NEUROIMAGE, V17, P77, DOI 10.1006/nimg.2002.1136; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Sexton CE, 2009, BIOL PSYCHIAT, V66, P814, DOI 10.1016/j.biopsych.2009.05.024; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Otsubo T, 2005, PSYCHIAT CLIN NEUROS, V59, P517, DOI 10.1111/j.1440-1819.2005.01408.x; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Rusch BD, 2001, BIOL PSYCHIAT, V50, P960, DOI 10.1016/S0006-3223(01)01248-3; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Sheline YI, 2003, BIOL PSYCHIAT, V54, P338, DOI 10.1016/S0006-3223(03)00347-0; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Juruena MF, 2007, REV BRAS PSIQUIATR, V29, pS19, DOI 10.1590/S1516-44462007000500005; Campbell S, 2004, AM J PSYCHIAT, V161, P598, DOI 10.1176/appi.ajp.161.4.598; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Guo WB, 2012, NEUROSCI LETT, V522, P139, DOI 10.1016/j.neulet.2012.06.027; Mukherjee P, 2008, AM J NEURORADIOL, V29, P843, DOI 10.3174/ajnr.A1052; Han KM, 2014, J AFFECT DISORDERS, V155, P42, DOI 10.1016/j.jad.2013.10.021; Angst J, 2007, ACTA PSYCHIAT SCAND, V115, P72, DOI 10.1111/j.1600-0447.2007.00965.x; Posternak MA, 2002, ARCH GEN PSYCHIAT, V59, P70, DOI 10.1001/archpsyc.59.1.70; Zhu XL, 2011, BRAIN RES, V1369, P223, DOI 10.1016/j.brainres.2010.10.104; Korgaonkar MS, 2011, HUM BRAIN MAPP, V32, P2161, DOI 10.1002/hbm.21178; Thase ME, 2009, NEUROPSYCHOPHARMACOL, V34, P2633, DOI 10.1038/npp.2009.100; Phillips ML, 2003, BIOL PSYCHIAT, V54, P515, DOI 10.1016/S0006-3223(03)00171-9; Gold PW, 2002, MOL PSYCHIATR, V7, P254, DOI 10.1038/sj/mp/4001032; Clark L, 2009, ANNU REV NEUROSCI, V32, P57, DOI 10.1146/annurev.neuro.31.060407.125618; Thase ME, 2007, J CLIN PSYCHIAT, V68, P11; Lavretsky H, 2005, J CLIN PSYCHIAT, V66, P964; Greenberg DL, 2008, PSYCHIAT RES-NEUROIM, V163, P126, DOI 10.1016/j.pscychresns.2007.12.009; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Nobuhara K, 2004, NEUROPSYCHOBIOLOGY, V50, P48, DOI 10.1159/000077941; ASNIS GM, 1995, AM J PSYCHIAT, V152, P31; Baumeister H, 2012, J AFFECT DISORDERS, V139, P126, DOI DOI 10.1016/J.JAD.2011.07.015; Choi KS, 2014, NEUROPSYCHOPHARMACOL, V39, P1332, DOI 10.1038/npp.2013.345; Ffytche DH, 2005, PHILOS T ROY SOC B, V360, P767, DOI 10.1098/rstb.2005.1621; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Inagaki A., 2006, JPN J CLIN PSYCHOPHA, V9, P1443; Kieseppa T, 2010, J AFFECT DISORDERS, V120, P240, DOI 10.1016/j.jad.2009.04.023; Korgaonkar MS, 2014, BIOL PSYCHIAT, V76, P567, DOI 10.1016/j.biopsych.2014.02.018; Murphy Melissa L, 2011, Biol Mood Anxiety Disord, V1, P3, DOI 10.1186/2045-5380-1-3; Pae CU, 2009, CNS DRUGS, V23, P1023, DOI 10.2165/11310990-000000000-00000; Posternak MA, 2003, HARVARD REV PSYCHIAT, V11, P1, DOI 10.1080/10673220303941; Zuo NM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037561	45	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUN	2015	69	6					360	368		10.1111/pcn.12255		9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CJ8IS	WOS:000355744100006		
J	Oka, M; Kubota, T; Tsubaki, H; Yamauchi, K				Oka, Mayumi; Kubota, Takafumi; Tsubaki, Hiroe; Yamauchi, Keita			Analysis of impact of geographic characteristics on suicide rate and visualization of result with Geographic Information System	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article						community; geographic characteristics; protective factors for suicide; risk factors for suicide; suicide	SOCIAL SUPPORT; MENTAL-HEALTH; DEPRESSION; MORTALITY; JAPAN	AimThe aim of our study was to understand the geographic characteristics of Japanese communities and the impact of these characteristics on suicide rates. MethodsWe calculated the standardized mortality ratio from suicide statistics of 3318 municipalities from 1972 to 2002. Correlation analysis, multi-regression analysis and generalized additive model were used to find the relation between topographic and climatic variables and suicide rate. We visualized the relation between geographic characteristics and suicide rate on the map of Wakayama Prefecture, using the Geographic Information System. ResultsOur study showed that the geographic characteristics of each community are related with its suicide rate. The strongest factor among the geographic characteristics to increase the suicide rate was the slope of the habitable land. ConclusionsIt is necessary to take the characteristics of each community into consideration when we work out measures of suicide prevention. Visualization of the findings on the local map should be helpful to promote understanding of problems and to share the information among various parties in charge of suicide prevention.	[Oka, Mayumi] Wakayama Med Univ, Sch Hlth & Nursing Sci, Wakayama, Wakayama 6410011, Japan; [Kubota, Takafumi] Tama Univ, Sch Management & Informat Sci, Tokyo, Japan; [Tsubaki, Hiroe] Inst Stat Math, Tokyo, Japan; [Yamauchi, Keita] Keio Univ, Fac Nursing & Med Care, Keio, Kanagawa, Japan	Oka, M (reprint author), Wakayama Med Univ, Sch Hlth & Nursing Sci, 580 Mikazura, Wakayama, Wakayama 6410011, Japan.	okamayu@gmail.com					Ajdacic-Gross V, 2010, SOC SCI MED, V71, P657, DOI 10.1016/j.socscimed.2010.05.030; Berry HL, 2010, INT J PUBLIC HEALTH, V55, P123, DOI 10.1007/s00038-009-0112-0; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; Brusilovskiy E, 2012, SOC SCI MED, V74, P1591, DOI 10.1016/j.socscimed.2012.01.033; King CA, 2008, ARCH SUICIDE RES, V12, P181, DOI 10.1080/13811110802101203; Poudel-Tandukar K, 2011, J PSYCHIATR RES, V45, P1545, DOI 10.1016/j.jpsychires.2011.07.009; Kapusta ND, 2010, PSYCHIAT SERV, V61, P1198, DOI 10.1176/appi.ps.61.12.1198; Brenner B, 2011, HIGH ALT MED BIOL, V12, P31, DOI 10.1089/ham.2010.1058; Cabinet Office of Japan, 2012, WHIT PAP SUIC PREV; DelMastro K, 2011, J AFFECT DISORDERS, V129, P376, DOI 10.1016/j.jad.2010.10.001; Egashira K, 1987, CLIN PSYCHIATR, V7, P735; Egashira KAK, 1990, JPN J BIOMETEOROL, V4, P3; Gary Faye A, 2005, Online J Issues Nurs, V10, P6; Gruebner O, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-177; Haggarty J, 2010, RURAL REMOTE HEALTH, V10, P37; Haws CA, 2009, MED HYPOTHESES, V73, P587, DOI 10.1016/j.mehy.2009.05.040; Hooghe M, 2011, SUICIDE LIFE-THREAT, V41, P453, DOI 10.1111/j.1943-278X.2011.00047.x; Inoue K, 2009, J ST MARIANNA MED I, V8, P7; Johnson LA, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-7; Kelleher MJ, 1997, IRISH MED J, V90, P262; LASKER JN, 1994, SOC SCI MED, V39, P53, DOI 10.1016/0277-9536(94)90165-1; Mazza JJ, 1998, SUICIDE LIFE-THREAT, V28, P358; National Police Agency of Japan, 2012, TRAFF ACC FAT; New Zealand Ministry of Health, 2005, SUIC PREV REV EV RIS; Oka M, 2012, J HLTH WELF STAT, P1; Oka M, 2012, JAPANESE B SOCIAL PS, V21, P167; Oka M, 2011, JPN B SOC PSYCHIAT, V7, P213; Oka M, 2010, JPN B SOC PSYCHIAT, V7, P199; Oka M, 2012, JAPANESE J COMMUNITY, V15, P136; Ono Y, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-315; Scottish Government Social Research, 2008, RISK PROT FACT SUIC; Shimai S, 2010, B MINAMIKYUSHU U, V4, P43; Takahashi S, 1989, RES PRACT FORENSIC M, V12, P323; Tondo L, 2006, J CLIN PSYCHIAT, V67, P517; Toshiharu F, 2009, REGIONAL STAT SUICID; WHO, 2011, SUIC PREV; World Health Organization, 2000, PREV SUIC RES COUNS; World Health Organization, 2000, PREV SUIC RES TEACH	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUN	2015	69	6					375	382		10.1111/pcn.12254		8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CJ8IS	WOS:000355744100008		
J	Takeuchi, D; Ono, T; Wada, Y				Takeuchi, Daisuke; Ono, Toshiyuki; Wada, Yuji			Case of neuroleptic malignant syndrome with diffuse neurofibrillary tangles with calcification	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Letter									[Takeuchi, Daisuke; Ono, Toshiyuki] Tsuruga Onsen Hosp, Dept Psychiat, Tsuruga, Fukui, Japan; [Wada, Yuji] Univ Fukui, Dept Neuropsychiat, Fac Med Sci, Fukui, Japan	Takeuchi, D (reprint author), Tsuruga Onsen Hosp, Dept Psychiat, Tsuruga, Fukui, Japan.	turugaoh@poem.ocn.ne.jp					Manyam BV, 2005, PARKINSONISM RELAT D, V11, P73, DOI 10.1016/j.parkreldis.2004.12.001; Habuchi C, 2011, J NEUROL SCI, V301, P77, DOI 10.1016/j.jns.2010.10.021	2	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUN	2015	69	6					383	384		10.1111/pcn.12246		2	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CJ8IS	WOS:000355744100010		
J	Kakisaka, Y; Fujikawa, M; Hino-Fukuyo, N				Kakisaka, Yosuke; Fujikawa, Mayu; Hino-Fukuyo, Naomi			Clinical diagnosis of rabies in a patient with schizophrenia	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Letter									[Kakisaka, Yosuke; Fujikawa, Mayu] Tohoku Univ, Grad Sch Med, Dept Epileptol, Sendai, Miyagi 980, Japan; [Kakisaka, Yosuke; Hino-Fukuyo, Naomi] Tohoku Univ, Grad Sch Med, Dept Pediat, Sendai, Miyagi 980, Japan	Kakisaka, Y (reprint author), Tohoku Univ, Grad Sch Med, Dept Epileptol, Sendai, Miyagi 980, Japan.	kakisuke@mui.biglobe.ne.jp					desWet JS., 1980, S AFR MED J, V58, P297; SCHNEIDER LS, 1985, PSYCHOSOMATICS, V26, P338	2	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUN	2015	69	6					385	385		10.1111/pcn.12285		1	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CJ8IS	WOS:000355744100012		
J	Umezawa, S; Fujisawa, D; Fujimori, M; Ogawa, A; Matsushima, E; Miyashita, M				Umezawa, Shino; Fujisawa, Daisuke; Fujimori, Maiko; Ogawa, Asao; Matsushima, Eisuke; Miyashita, Mitsunori			Prevalence, associated factors and source of support concerning supportive care needs among Japanese cancer survivors	PSYCHO-ONCOLOGY			English	Article						cancer; oncology; cancer survivor; supportive care needs; source of support	BREAST-CANCER; LUNG-CANCER; VERSION; HEALTH; TRENDS	BackgroundThe current study aimed to describe cancer survivors' supportive care needs in Japan, to identify associated factors of unmet needs, and to describe the source of support that are preferred and actually used by cancer survivors. MethodsUsing a web-based questionnaire, we examined unmet supportive needs and its associated factors among 628 adult Japanese cancer survivors. The questionnaire comprised 16 items representing five domains (medical-psychological, financial, social-spiritual, sexual, and physical needs). ResultsPrevalence of unmet need ranged from 5 to 18%, depending on different domains. The prevalence was high in medical-psychological and financial domains and relatively low in physical and sexual domains. Poor performance status, psychiatric morbidity and low income status were associated with unmet needs of most domains. Most cancer survivors preferred and actually sought support from their family and friends. Financial needs were preferred to be provided by non-medical professionals. Call for peer support was intense, especially for medical-psychological, social-spiritual, and sexual needs; however, peer support was not well-provided. ConclusionsThis study illustrated characteristics of Japanese cancer survivors who are likely to have unmet needs. The study demonstrated need for expanded involvement of non-medical professionals and peer support, especially in the domains of medical-psychological, social-spiritual, financial and sexual needs. Copyright (c) 2014 John Wiley & Sons, Ltd.	[Umezawa, Shino; Fujisawa, Daisuke; Fujimori, Maiko; Ogawa, Asao] Natl Canc Ctr Hosp East, Psychooncol Div, Kashiwa, Chiba 2778577, Japan; [Umezawa, Shino; Matsushima, Eisuke] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Div Comprehens Patient Care, Sect Liaison Psychiat & Palliat Med, Tokyo, Japan; [Fujisawa, Daisuke] Massachusetts Gen Hosp, Ctr Psychiat Oncol & Behav Sci, Boston, MA 02114 USA; [Fujisawa, Daisuke] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan; [Fujimori, Maiko] Natl Ctr Neurol Psychiat, Ctr Suicide Prevent, Natl Inst Mental Hlth, Tokyo, Japan; [Miyashita, Mitsunori] Tohoku Univ, Grad Sch Med, Div Palliat Nursing, Hlth Sci, Sendai, Miyagi 980, Japan	Fujisawa, D (reprint author), Natl Canc Ctr Hosp East, Psychooncol Div, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	dai_fujisawa@yahoo.co.jp			Japanese Ministry of Health Labor and Welfare [H22-005]	The authors thank Professor Yosuke Uchitomi (Okayama University) and Justin Eusebio (Massachusetts General Hospital) for their helpful comments. This work was supported by the Grant-in-Aid from Japanese Ministry of Health Labor and Welfare [grant number H22-005].	Harrison JD, 2009, SUPPORT CARE CANCER, V17, P1117, DOI 10.1007/s00520-009-0615-5; Stanton AL, 2012, J CLIN ONCOL, V30, P1215, DOI 10.1200/JCO.2011.39.7406; Sanders SL, 2010, PSYCHO-ONCOLOGY, V19, P480, DOI 10.1002/pon.1577; Okuyama T, 2009, PSYCHO-ONCOL, V18, P1003, DOI 10.1002/pon.1482; Sanson-Fisher R, 2000, CANCER, V88, P226, DOI 10.1002/(SICI)1097-0142(20000101)88:1<226::AID-CNCR30>3.0.CO;2-P; Katanoda K, 2013, JPN J CLIN ONCOL, V43, P492, DOI 10.1093/jjco/hyt038; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Boyes A, 2009, J EVAL CLIN PRACT, V15, P602, DOI 10.1111/j.1365-2753.2008.01057.x; Armes J, 2009, J CLIN ONCOL, V27, P6172, DOI 10.1200/JCO.2009.22.5151; Zebrack B, 2009, SUPPORT CARE CANCER, V17, P349, DOI 10.1007/s00520-008-0469-2; Feuerstein M, 2010, J CANCER SURVIV, V4, P415, DOI 10.1007/s11764-010-0154-6; Ream E, 2008, BRIT J CANCER, V98, P1903, DOI 10.1038/sj.bjc.6604406; Furukawa TA, 2008, INT J METH PSYCH RES, V17, P152, DOI 10.1002/mpr.257; Ferrell BR, 1995, QUAL LIFE RES, V4, P523, DOI 10.1007/BF00634747; Hodgkinson K, 2007, PSYCHO-ONCOL, V16, P796, DOI 10.1002/pon.1137; Endo C, 2008, JPN J CLIN ONCOL, V38, P653, DOI 10.1093/jjco/hyn088; Zebrack BJ, 2013, CANCER-AM CANCER SOC, V119, P201, DOI 10.1002/cncr.27713; Harrison SE, 2011, J CLIN ONCOL, V29, P2091, DOI 10.1200/JCO.2010.32.5167; Akechi T, 2011, PSYCHO-ONCOLOGY, V20, P497, DOI 10.1002/pon.1757; Lam WWT, 2011, BREAST CANCER RES TR, V130, P531, DOI 10.1007/s10549-011-1592-1; Mehnert A, 2011, CRIT REV ONCOL HEMAT, V77, P109, DOI 10.1016/j.critrevonc.2010.01.004; Boyes A, 2012, BMC CANC, V12, P150; DAHLEM NW, 1991, J CLIN PSYCHOL, V47, P756, DOI 10.1002/1097-4679(199111)47:6<756::AID-JCLP2270470605>3.0.CO;2-L; Fielding R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065099; Fujisawa D, 2010, SUPPORT CARE CANCER, V18, P1393, DOI 10.1007/s00520-009-0761-9; Fujisawa D, 2013, ANN REPORT CLIN CANC, P41; Fujisawa D, 2014, SUPPORT CARE CANCER, V22, P3125, DOI 10.1007/s00520-014-2284-2; Japanese Ministry of Health Labor and Welfare, CANC CONTR MEAS; Jefford M, 2012, BR CANC, V108, P14; Kawakami S, 2014, JPN J CANC CHEMOTHER, V41, P31; Matsuda A, 2013, JPN J CLIN ONCOL, V44, P388; McDowell ME, 2010, PSYCHO-ONCOLOGY, V19, P508, DOI 10.1002/pon.1604; Mehnert A, 2013, CANCER-AM CANCER SOC, V119, P2151, DOI 10.1002/cncr.28067; Morita T, 2000, PSYCHO-ONCOL, V9, P164, DOI 10.1002/(SICI)1099-1611(200003/04)9:2<164::AID-PON447>3.0.CO;2-S; Ohnuki-Tierney E., 1984, ILLNESS CULTURE CONT, P51, DOI 10.1017/CBO9780511621772.003; Takahashi M, 2006, J CLIN ONCOL, V24, P5763, DOI 10.1200/JCO.2006.06.9146; Takahashi M, SURVEY MED TREATMENT; Takahashi M, 2008, PSYCHO-ONCOL, V17, P901, DOI 10.1002/pon.1297; Yamaguchi K., 2004, VIEWS 7885 PEOPLE WH	39	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1057-9249	1099-1611		PSYCHO-ONCOLOGY	Psycho-Oncol.	JUN	2015	24	6					635	642		10.1002/pon.3702		8	Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical	Oncology; Psychology; Biomedical Social Sciences	CK1HN	WOS:000355958000003		
J	Yuan, KH; Tian, YB; Yanagihara, H				Yuan, Ke-Hai; Tian, Yubin; Yanagihara, Hirokazu			Empirical Correction to the Likelihood Ratio Statistic for Structural Equation Modeling with Many Variables	PSYCHOMETRIKA			English	Article						Bartlett correction; Bayesian information criterion; maximum likelihood; type I errors	COVARIANCE STRUCTURE-ANALYSIS; GOODNESS-OF-FIT; CONFIRMATORY FACTOR-ANALYSIS; SAMPLE-SIZE; TESTS; INDEXES; MATRICES; ERROR; NONCENTRALITY; SPECIFICATION	Survey data typically contain many variables. Structural equation modeling (SEM) is commonly used in analyzing such data. The most widely used statistic for evaluating the adequacy of a SEM model is T (ML), a slight modification to the likelihood ratio statistic. Under normality assumption, T (ML) approximately follows a chi-square distribution when the number of observations (N) is large and the number of items or variables (p) is small. However, in practice, p can be rather large while N is always limited due to not having enough participants. Even with a relatively large N, empirical results show that T (ML) rejects the correct model too often when p is not too small. Various corrections to T (ML) have been proposed, but they are mostly heuristic. Following the principle of the Bartlett correction, this paper proposes an empirical approach to correct T (ML) so that the mean of the resulting statistic approximately equals the degrees of freedom of the nominal chi-square distribution. Results show that empirically corrected statistics follow the nominal chi-square distribution much more closely than previously proposed corrections to T (ML), and they control type I errors reasonably well whenever Na parts per thousand yenmax(50,2p). The formulations of the empirically corrected statistics are further used to predict type I errors of T (ML) as reported in the literature, and they perform well.	[Yuan, Ke-Hai] Univ Notre Dame, Notre Dame, IN 46556 USA; [Tian, Yubin] Beijing Inst Technol, Beijing, Peoples R China; [Yanagihara, Hirokazu] Hiroshima Univ, Hiroshima 730, Japan	Yuan, KH (reprint author), Univ Notre Dame, Dept Psychol, Notre Dame, IN 46556 USA.	kyuan@nd.edu			National Natural Science Foundation of China [31271116]; Ministry of Education, Science, Sports, and Culture of Japan [22650058]	The research was supported in part by a grant from the National Natural Science Foundation of China (31271116), and in part by a grant from the Ministry of Education, Science, Sports, and Culture of Japan (22650058).	SATORRA A, 1990, COMPUT STAT DATA AN, V10, P235, DOI 10.1016/0167-9473(90)90004-2; Curran PJ, 1996, PSYCHOL METHODS, V1, P16, DOI 10.1037/1082-989X.1.1.16; Fujikoshi Y, 2000, J MULTIVARIATE ANAL, V72, P249, DOI 10.1006/jmva.1999.1854; MCDONALD RP, 1990, PSYCHOL BULL, V107, P247, DOI 10.1037//0033-2909.107.2.247; Yuan KH, 2003, BRIT J MATH STAT PSY, V56, P93, DOI 10.1348/000711003321645368; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037//0033-2909.88.3.588; Herzog W, 2009, STRUCT EQU MODELING, V16, P1, DOI 10.1080/10705510802561279; Moshagen M, 2012, STRUCT EQU MODELING, V19, P86, DOI 10.1080/10705511.2012.634724; JORESKOG KG, 1969, PSYCHOMETRIKA, V34, P183, DOI 10.1007/BF02289343; Yuan KH, 1998, BRIT J MATH STAT PSY, V51, P289; MacCallum RC, 2000, ANNU REV PSYCHOL, V51, P201, DOI 10.1146/annurev.psych.51.1.201; Schott JR, 2007, COMPUT STAT DATA AN, V51, P6535, DOI 10.1016/j.csda.2007.03.004; Yuan KH, 2005, MULTIVAR BEHAV RES, V40, P115, DOI 10.1207/s15327906mbr4001_5; Yuan KH, 1999, STAT SINICA, V9, P831; Yuan KH, 1999, J EDUC BEHAV STAT, V24, P225; Browne MW, 2002, PSYCHOL METHODS, V7, P403, DOI 10.1037//1082-989X.7.4.403; Yuan KH, 2008, COMPUT STAT DATA AN, V52, P4842, DOI 10.1016/j.csda.2008.03.030; ANDERSON JC, 1984, PSYCHOMETRIKA, V49, P155, DOI 10.1007/BF02294170; Bentler PM, 1999, MULTIVAR BEHAV RES, V34, P181, DOI 10.1207/S15327906Mb340203; BOX GEP, 1949, BIOMETRIKA, V36, P317, DOI 10.2307/2332671; HU LT, 1992, PSYCHOL BULL, V112, P351, DOI 10.1037/0033-2909.112.2.351; SORBOM D, 1989, PSYCHOMETRIKA, V54, P371, DOI 10.1007/BF02294623; Fan XT, 1999, STRUCT EQU MODELING, V6, P56, DOI 10.1080/10705519909540119; BERAN R, 1988, J AM STAT ASSOC, V83, P687, DOI 10.2307/2289292; WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526; ANDERSON JC, 1988, PSYCHOL BULL, V103, P411, DOI 10.1037/0033-2909.103.3.411; LAWLEY DN, 1956, BIOMETRIKA, V43, P295, DOI 10.2307/2332908; AMEMIYA Y, 1990, ANN STAT, V18, P1453, DOI 10.1214/aos/1176347760; Fouladi RT, 2000, STRUCT EQU MODELING, V7, P356, DOI 10.1207/S15328007SEM0703_2; MARDIA KV, 1970, BIOMETRIKA, V57, P519, DOI 10.2307/2334770; Nevitt J, 2004, MULTIVAR BEHAV RES, V39, P439, DOI 10.1207/S15327906MBR3903_3; Srivastava MS, 2010, J MULTIVARIATE ANAL, V101, P1319, DOI 10.1016/j.jmva.2009.12.010; BARTLETT MS, 1951, BIOMETRIKA, V38, P337, DOI 10.2307/2332580; BARNDORFFNIELSEN OE, 1988, BIOMETRIKA, V75, P374, DOI 10.1093/biomet/75.2.374; Bartlett MS, 1937, PROC R SOC LON SER-A, V160, P0268, DOI 10.1098/rspa.1937.0109; BARTLETT MS, 1954, J ROY STAT SOC B, V16, P296; Bentler P., 2008, EQS 6 STRUCTURAL EQU; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; Bollen KA, 1993, TESTING STRUCTURAL E, P111; Boomsma A., 1982, SYSTEMS INDIRECT OBS, V1, P149; Casella G., 2002, STAT INFERENCE; Efron B., 1993, INTRO BOOTSTRAP; Evans M., 2000, STAT DISTRIBUTIONS; GEWEKE JF, 1980, J AM STAT ASSOC, V75, P133, DOI 10.2307/2287400; Hall P., 1992, BOOTSTRAP EDGEWORTH; Herzog W, 2007, STRUCT EQU MODELING, V14, P361; Hinkley D.V., 1974, THEORETICAL STAT; Holzinger K. J., 1939, SUPPLEMENTARY ED MON, V48; ICHIKAWA M, 1995, PSYCHOMETRIKA, V60, P77, DOI 10.1007/BF02294430; KANO Y, 1992, STAT PROBABIL LETT, V15, P21, DOI 10.1016/0167-7152(92)90279-E; Maxwell A. E., 1971, FACTOR ANAL STAT MET; Mooijaart A., 1991, STAT NEERL, V45, P159, DOI DOI 10.1111/J.1467-9574.1991.TB01301.X; Ogasawara Haruhiko, 2010, American Journal of Mathematical and Management Sciences, V30; Okada K, 2007, JPN J EDUC PSYCHOL, V55, P382; Satorra A, 1994, LATENT VARIABLES ANA, P399; Swain A. J., 1975, THESIS U ADELAIDE AU; WAKAKI H, 1990, J MULTIVARIATE ANAL, V32, P313, DOI 10.1016/0047-259X(90)90089-Z; Yuan KH, 2002, BRIT J MATH STAT PSY, V55, P41, DOI 10.1348/000711002159699; Yung Y. F., 1996, ADV STRUCTURAL EQUAT, P195; Yung Y.-F., 1999, STAT STRATEGIES SMAL, P81	60	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0033-3123	1860-0980		PSYCHOMETRIKA	Psychometrika	JUN	2015	80	2					379	405		10.1007/s11336-013-9386-5		27	Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods; Psychology, Mathematical	Mathematics; Mathematical Methods In Social Sciences; Psychology	CJ9VD	WOS:000355850400006		
J	Okubo, T; Mayekawa, S				Okubo, Tomoya; Mayekawa, Shin-ichi			Modeling Viewpoint Shifts in Probabilistic Choice	PSYCHOMETRIKA			English	Article						viewpoint shift; vector model; latent class model; multidimensional scaling model; decision theory	INTRANSITIVE PREFERENCES; SPATIAL REPRESENTATION; COMPARATIVE JUDGMENT; MAXIMUM-LIKELIHOOD; UTILITY THEORIES; VECTOR MODEL; RISKY CHOICE; TRANSITIVITY; RATINGS	A number of mathematical models for overcoming intransitive choice have been proposed and tested in the literature of decision theory. This article presents the development of a new stochastic choice model based on multidimensional scaling. This allows decision-makers to have multiple viewpoints, whereas current multidimensional scaling models are based on the assumption that a subject or group of subjects has only one viewpoint. The implication of our model is that subjects make an intransitive choice because they are able to shift their viewpoint. This paper also presents the maximum likelihood estimation of the proposed model, and reanalyzes Tversky's gamble experiment data.	[Okubo, Tomoya] Natl Ctr Univ Entrance Examinat, Tokyo 1538501, Japan; [Mayekawa, Shin-ichi] Tokyo Inst Technol, Tokyo, Japan	Okubo, T (reprint author), Natl Ctr Univ Entrance Examinat, Meguro Ku, 2-19-23 Komaba, Tokyo 1538501, Japan.	okubo@rd.dnc.ac.jp					Agresti A., 2002, CATEGORICAL DATA ANA; Akaike H., 1973, P 2 INT S INF THEOR, P267; Anderson E. B., 1980, DISCRETE STAT MODELS; TVERSKY A, 1969, PSYCHOL REV, V76, P31, DOI 10.1037/h0026750; Loomes G, 2002, J RISK UNCERTAINTY, V24, P103, DOI 10.1023/A:1014094209265; DESARBO WS, 1991, PSYCHOMETRIKA, V56, P121, DOI 10.1007/BF02294590; HARLESS DW, 1994, ECONOMETRICA, V62, P1251, DOI 10.2307/2951749; CHINTAGUNTA PK, 1994, J MARKETING RES, V31, P304, DOI 10.2307/3152201; DESARBO WS, 1989, PSYCHOMETRIKA, V54, P105, DOI 10.1007/BF02294452; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1; HEY JD, 1994, ECONOMETRICA, V62, P1291, DOI 10.2307/2951750; ANDERSEN EB, 1973, BRIT J MATH STAT PSY, V26, P31; Birnbaum MH, 1999, ORGAN BEHAV HUM DEC, V77, P44, DOI 10.1006/obhd.1998.2816; Regenwetter M, 2011, PSYCHOL REV, V118, P42, DOI 10.1037/a0021150; Thurstone LL, 1927, PSYCHOL REV, V34, P273, DOI 10.1037/h0070288; BUSEMEYER JR, 1993, PSYCHOL REV, V100, P432, DOI 10.1037/0033-295X.100.3.432; DESOETE G, 1993, J CLASSIF, V10, P195; Regenwetter M, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00148; DESARBO WS, 1986, APPL PSYCH MEAS, V10, P79, DOI 10.1177/014662168601000107; IVERSON G, 1985, MATH SOC SCI, V10, P131, DOI 10.1016/0165-4896(85)90031-9; Loomes G, 1998, ECONOMICA, V65, P581, DOI 10.1111/1468-0335.00147; BENNETT JF, 1960, PSYCHOMETRIKA, V25, P27, DOI 10.1007/BF02288932; Birnbaum MH, 2007, ORGAN BEHAV HUM DEC, V104, P96, DOI 10.1016/j.obhdp.2007.02.001; BOCKENHOLT U, 1991, PSYCHOMETRIKA, V56, P699, DOI 10.1007/BF02294500; BUDESCU DV, 1987, ORGAN BEHAV HUM DEC, V39, P184, DOI 10.1016/0749-5978(87)90037-9; Carroll J. D., 1972, MULTIDIMENSIONAL SCA, V1, P105; Davis-Stober CP, 2012, J MATH PSYCHOL, V56, P86, DOI 10.1016/j.jmp.2012.01.003; DeSarbo WS, 2009, COMPUT STAT DATA AN, V53, P3217, DOI 10.1016/j.csda.2008.04.011; DESOETE G, 1993, PSYCHOMETRIKA, V58, P545; Gaul W., 1986, APPLIED STOCHASTIC M, V2, P202; GOODMAN LA, 1979, PSYCHOMETRIKA, V44, P123, DOI 10.1007/BF02293792; LOOMES G, 1995, EUR ECON REV, V39, P641, DOI 10.1016/0014-2921(94)00071-7; Montgomery H., 1977, DECISION MAKING CHAN, P347; SCHEFFE H, 1952, J AM STAT ASSOC, V47, P381, DOI 10.2307/2281310; SLATER P, 1960, BRIT J STATIST PSYCH, V13, P119; TAKANE Y, 1980, JPN PSYCHOL RES, V22, P188; Takane Y, 1998, JPN PSYCHOL RES, V40, P31, DOI 10.1111/1468-5884.00072; Tsai RC, 2006, J MATH PSYCHOL, V50, P1, DOI 10.1016/j.jmp.2005.11.004; Tsai RC, 2008, J MATH PSYCHOL, V52, P10, DOI 10.1016/j.jmp.2007.09.004; Tucker L. R., 1960, PSYCHOL SCALING THEO, P155; van der Heijden P. G. M., 2003, P SCI MOD 30 ANN M I, P348; Winsberg S, 2002, APPL STOCH MODEL BUS, V18, P391, DOI 10.1002/asmb.467	42	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0033-3123	1860-0980		PSYCHOMETRIKA	Psychometrika	JUN	2015	80	2					412	427		10.1007/s11336-013-9392-7		16	Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods; Psychology, Mathematical	Mathematics; Mathematical Methods In Social Sciences; Psychology	CJ9VD	WOS:000355850400008		
J	Ito, T				Ito, Tetsuya			ACTIONS OF THE N-STRAND BRAID GROUPS ON THE FREE GROUP OF RANK N WHICH ARE SIMILAR TO THE ARTIN REPRESENTATION	QUARTERLY JOURNAL OF MATHEMATICS			English	Article							AUTOMORPHISMS; INVARIANTS; LINKS	We classify an action of the n-strand braid group on the free group of rank n, which is similar to the Artin representation in the sense that the ith generator sigma(i) of B-n acts so that it fixes all free generators x(j) except j = i, i + 1. We determine all such representations and discuss knot invariants coming from such representations.	Kyoto Univ, Math Sci Res Inst, Sakyo Ku, Kyoto, Japan	Ito, T (reprint author), Kyoto Univ, Math Sci Res Inst, Sakyo Ku, Kyoto, Japan.	tetitoh@kurims.kyoto-u.ac.jp			JSPS [25887030]	T.I. was partially supported by the JSPS Grant-in-Aid for Research Activity start-up, Grant Number 25887030.	Birman J. S., 1974, ANN MATH STUDIES, V82; Carter S., 2003, T AM MATH SOC, V355, P3947; Crisp J, 2005, PAC J MATH, V221, P1; Dehornoy P., 2008, MATH SURVEYS MONOGRA, V148; Ito T, 2012, J MATH SOC JPN, V64, P1147, DOI 10.2969/jmsj/06441147; Ito T, 2013, J PURE APPL ALGEBRA, V217, P1754, DOI 10.1016/j.jpaa.2012.12.010; Meskin S., 1974, LECT NOTES MATH, V372, P494; Shpilrain V, 2001, INT J ALGEBR COMPUT, V11, P773, DOI 10.1142/S0218196701000760; WADA M, 1992, TOPOLOGY, V31, P399, DOI 10.1016/0040-9383(92)90029-H	9	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0033-5606	1464-3847		Q J MATH	Q. J. Math.	JUN	2015	66	2					563	581		10.1093/qmath/hau033		19	Mathematics	Mathematics	CK0ZG	WOS:000355933800010		
J	Sasaki, T; Yoshida, H; Aoyama, S; Kobayashi, T; Takagi, I; Moriyama, H				Sasaki, Takayuki; Yoshida, Hatsumi; Aoyama, Shunsuke; Kobayashi, Taishi; Takagi, Ikuji; Moriyama, Hirotake			Discrete fragment model for apparent formation constants of actinide ions with humic substances	RADIOCHIMICA ACTA			English	Article						Actinides; Humic substances; Formation constant; Metal ions; Model	TERNARY AQUEOUS SYSTEM; COMPLEX-FORMATION; METAL-IONS; SOLID-PHASE; BINDING; ACID; PU(IV); CARBOXYLATES; SOLUBILITY; PARAMETERS	A semi-empirical thermodynamic model was applied to estimate the apparent formation constants of actinide ions, i.e., Th(IV), Pu(IV) and Np(V), with humic substances (HSs), including humic and fulvic acids, over awide range of solution conditions, i.e., pH, ionic strength, and HS and metal concentrations. The hypothetical HSs consist of humic and fulvic acids with nine types of simple organic ligands, which include aromatic and aliphatic carboxyl groups and phenol groups, as binding sites. The abundance of each binding site in the hypothetical HSs was determined via afitting analysis using an acid-dissociation dataset for several HSs. To determine the apparent formation constant of a given metal ion with HSs, 54 specific binding sites were considered, including nine monodentate sites (1 : 1 metal/ligand complexes) and 45 bidentate sites (1 : 2 metal/ligand complexes). The formation constant of each monodentate binding was determined from the experimental data, while those of the bidentate bindings were determined by considering two monodentate bindings and the chelating effect, for which one of the adjustable parameters was introduced in the model. Introduction of the other parameter, which is related to the fraction of monodentate to bidentate sites (i.e., the heterogeneity), afforded the parameter values with good correlation with the apparent formation constant data. The present model with adjusted parameter values well reproduced the experimental apparent complex formation constants for actinide ion interaction with HSs in awide range of solution conditions except for those obtained at trace concentrations.	[Sasaki, Takayuki; Yoshida, Hatsumi; Aoyama, Shunsuke; Kobayashi, Taishi; Takagi, Ikuji] Kyoto Univ, Dept Nucl Engn, Nishikyo Ku, Kyoto 6158540, Japan; [Moriyama, Hirotake] Kyoto Univ, Inst Res Reactor, Kumatori, Osaka 5900494, Japan	Sasaki, T (reprint author), Kyoto Univ, Dept Nucl Engn, Nishikyo Ku, Kyoto Daigaku Katsura C3, Kyoto 6158540, Japan.	sasaki@nucleng.kyoto-u.ac.jp			 [24360393]	This work was supported by Grant-in-Aid for Scientific Research (B) 24360393.	Abbt-Braun G, 2004, AQUAT SCI, V66, P151, DOI 10.1007/s00027-004-0711-z; Allard B., 1997, OECD PUBLICATIONS; MARCUS Y, 1988, CHEM REV, V88, P1475, DOI 10.1021/cr00090a003; KIM JI, 1990, FRESEN J ANAL CHEM, V338, P245, DOI 10.1007/BF00323017; Tipping E, 1998, AQUAT GEOCHEM, V4, P3, DOI 10.1023/A:1009627214459; SCHULTEN HR, 1993, NATURWISSENSCHAFTEN, V80, P29, DOI 10.1007/BF01139754; CHOPPIN GR, 1983, RADIOCHIM ACTA, V32, P43; Milne CJ, 2001, ENVIRON SCI TECHNOL, V35, P2049, DOI 10.1021/es000123j; Schmeide K, 2003, INORG CHIM ACTA, V351, P133, DOI 10.1016/S0020-1693(03)00184-1; Milne CJ, 2003, ENVIRON SCI TECHNOL, V37, P958, DOI 10.1021/es0258879; Tipping E, 2011, ENVIRON CHEM, V8, P225, DOI 10.1071/EN11016; MOULIN V, 1992, RADIOCHIM ACTA, V58-9, P179; Marsac R, 2014, GEOCHIM COSMOCHIM AC, V131, P290, DOI 10.1016/j.gca.2014.01.039; Carbonaro RF, 2007, GEOCHIM COSMOCHIM AC, V71, P3958, DOI 10.1016/j.gca.2007.06.005; Guillaumont R., 2003, CHEM THERMODYNAMICS, V5; Kim JI, 1996, RADIOCHIM ACTA, V73, P5; Kobayashi T, 2011, J NUCL SCI TECHNOL, V48, P993, DOI 10.3327/jnst.48.993; Kobayashi T, 2009, RADIOCHIM ACTA, V97, P237, DOI 10.1524/ract.2009.1603; MORIYAMA H, 1995, MATER RES SOC SYMP P, V353, P1129; Muller K, 2013, RADIOCHIM ACTA, V101, P1, DOI 10.1524/ract.2013.1992; Neck V, 2000, RADIOCHIM ACTA, V88, P815, DOI 10.1524/ract.2000.88.9-11.815; Rand M., 2008, CHEM THERMODYNAMICS, V11; Sasaki T, 2012, RADIOCHIM ACTA, V100, P737, DOI 10.1524/ract.2012.1944; Sasaki T, 2005, J NUCL SCI TECHNOL, V42, P724, DOI 10.3327/jnst.42.724; Sasaki T, 2008, J NUCL SCI TECHNOL, V45, P718, DOI 10.3327/jnst.45.718; Sasaki T., 2012, AM J ANAL CHEM, V3, P462; Sasaki T., 2006, RECENT ADV ACTINIDE; Sasaki T, 2009, RADIOCHIM ACTA, V97, P193, DOI 10.1524/ract.2009.1594; Sasaki T, 2008, RADIOCHIM ACTA, V96, P799, DOI 10.1524/ract.2008.1523; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; Smith R. M., 2003, NIST CRITICALLY SELE; Steelink C., 1985, HUMIC SUBSTANCES SOI; Stockdale A, 2011, J ENVIRON MONITOR, V13, P2946, DOI 10.1039/c1em10407a; Szabo G, 2010, RADIOCHIM ACTA, V98, P13, DOI 10.1524/ract.2010.1683; Tochiyama O, 2004, RADIOCHIM ACTA, V92, P559, DOI 10.1524/ract.92.9.559.54996	35	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0033-8230			RADIOCHIM ACTA	Radiochim. Acta	JUN	2015	103	6					411	421		10.1515/ract-2014-2296		11	Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CJ6SP	WOS:000355624200002		
J	Shultz, J				Shultz, John			EXPERIMENTAL BUDDHISM: INNOVATION AND ACTIVISM IN CONTEMPORARY JAPAN.	RELIGIOUS STUDIES REVIEW			English	Book Review									[Shultz, John] Kansai Gaidai Univ, Hirakata, Osaka, Japan	Shultz, J (reprint author), Kansai Gaidai Univ, Hirakata, Osaka, Japan.						NELSON JK, 2013, EXPT BUDDHISM INNOVA	1	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0319-485X	1748-0922		RELIG STUD REV	Relig. Stud. Rev.	JUN	2015	41	2					91	91		10.1111/rsr.12222		1	Religion	Religion	CJ9PP	WOS:000355835000124		
J	Shultz, JA				Shultz, John A.			BONES OF CONTENTION: ANIMALS AND RELIGION IN CONTEMPORARY JAPAN.	RELIGIOUS STUDIES REVIEW			English	Book Review									[Shultz, John A.] Kansai Gaidai Univ, Hirakata, Osaka, Japan	Shultz, JA (reprint author), Kansai Gaidai Univ, Hirakata, Osaka, Japan.						AMBROS BR, 2012, BONES CONTENTION ANI	1	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0319-485X	1748-0922		RELIG STUD REV	Relig. Stud. Rev.	JUN	2015	41	2					91	91		10.1111/rsr.12221		1	Religion	Religion	CJ9PP	WOS:000355835000123		
J	Mori, C; Yabuuchi, A; Ezoe, K; Murata, N; Takayama, Y; Okimura, T; Uchiyama, K; Takakura, K; Abe, H; Wada, K; Okuno, T; Kobayashi, T; Kato, K				Mori, Chiemi; Yabuuchi, Akiko; Ezoe, Kenji; Murata, Nana; Takayama, Yuko; Okimura, Tadashi; Uchiyama, Kazuo; Takakura, Kei; Abe, Hiroyuki; Wada, Keiko; Okuno, Takashi; Kobayashi, Tamotsu; Kato, Keiichi			Hydroxypropyl cellulose as an option for supplementation of cryoprotectant solutions for embryo vitrification in human assisted reproductive technologies	REPRODUCTIVE BIOMEDICINE ONLINE			English	Article						embryo; Cryotop (R); hydroxypropyl cellulose; vitrification	OOCYTE VITRIFICATION; BOVINE OOCYTES; CRYOPRESERVATION; METAANALYSIS; OUTCOMES; PROGRESS; CYCLES; TRIAL; STAGE	Hydroxypropyl cellulose (HPC) was investigated as a replacement for serum substitute supplement (SSS) for use in cryoprotectant solutions for embryo vitrification. Mouse blastocysts from inbred (n = 1056), hybrid (n = 128) strains, and 121 vitrified blastocysts donated by infertile patients (n = 102) were used. Mouse and human blastocysts, with or without zona pellucida, were vitrified and warmed in either 1% or 5% HPC or in 5% or 20% SSS-supplemented media using the Cryotop (Kitazato BioPharma Co. Ltd, Fuji, Japan) method, and the survival and oxygen consumption rates were assessed. Viscosity of each vitrification solution was compared. Survival rates of mouse hybrid blastocysts and human zona pellucida-intact blastocysts were comparable among the groups. Mouse and human zona pellucida-free blastocysts, which normally exhibit poor cryoresistance, showed significantly higher survival rates in 5% HPC than 5% SSS (P < 0.05). The 5% HPC-supplemented vitrification solution showed a significantly higher viscosity (P < 0.05). The blastocysts were easily detached from the Cryotop strip during warming when HPC-supplemented vitrification solution was used. The oxygen consumption rates were similar between non-vitrified and 5% HPC groups. The results suggest possible use of HPC for supplementation of cryoprotectant solutions and provide useful information to improve vitrification protocols. (C) 2015 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.	[Mori, Chiemi; Yabuuchi, Akiko; Ezoe, Kenji; Murata, Nana; Takayama, Yuko; Okimura, Tadashi; Uchiyama, Kazuo; Wada, Keiko; Okuno, Takashi; Kobayashi, Tamotsu; Kato, Keiichi] Kato Ladies Clin, Shinjuku Ku, Tokyo 1600023, Japan; [Takakura, Kei; Abe, Hiroyuki] Yamagata Univ, Grad Sch Sci & Engn, Yonezawa, Yamagata 9928510, Japan	Yabuuchi, A (reprint author), Kato Ladies Clin, Shinjuku Ku, 7-20-3 Nishishinjuku, Tokyo 1600023, Japan.	a-yabuuchi@towako-kato.com; k-kato@towako.net					Maheshwari A, 2012, FERTIL STERIL, V98, P368, DOI 10.1016/j.fertnstert.2012.05.019; Cobo A, 2010, HUM REPROD, V25, P2239, DOI 10.1093/humrep/deq146; Shiku H, 2001, ANAL CHEM, V73, P3751, DOI 10.1021/ac010339j; Cobo A, 2012, FERTIL STERIL, V98, P1138, DOI 10.1016/j.fertnstert.2012.07.1107; Kato O, 2012, EUR J OBSTET GYN R B, V161, P46, DOI 10.1016/j.ejogrb.2011.12.005; Roque M, 2013, FERTIL STERIL, V99, P156, DOI 10.1016/j.fertnstert.2012.09.003; Boyer P, 2013, GYNECOL OBSTET FERTI, V41, P551, DOI 10.1016/j.gyobfe.2013.07.021; Meintjes M, 2009, HUM REPROD, V24, P782, DOI 10.1093/humrep/den396; Checura CM, 2007, THERIOGENOLOGY, V67, P919, DOI 10.1016/j.theriogenology.2006.09.044; Forman EJ, 2012, FERTIL STERIL, V98, P644, DOI 10.1016/j.fertnstert.2012.04.028; Vajta G, 2013, REPROD FERT DEVELOP, V25, P719, DOI 10.1071/RD12118; Abe H, 2003, J REPROD DEVELOP, V49, P193; Gosden R, 2011, FERTIL STERIL, V96, P264, DOI 10.1016/j.fertnstert.2011.06.029; Saragusty J, 2011, REPRODUCTION, V141, P1, DOI 10.1530/REP-10-0236; Escriba MJ, 2010, FERTIL STERIL, V93, P669, DOI 10.1016/j.fertnstert.2009.08.041; Horvath G, 2006, THERIOGENOLOGY, V66, P1026, DOI 10.1016/j.theriogenology.2006.03.004; Kuleshova LL, 2001, CRYOBIOLOGY, V43, P21, DOI 10.1006/cryo.2001.2335; Morato R, 2011, CRYOBIOLOGY, V63, P240, DOI 10.1016/j.cryobiol.2011.09.002; Mori C., 2009, 46 ANN M SOC CRYOB C; Shaw JM, 1997, CRYOBIOLOGY, V35, P219, DOI 10.1006/cryo.1997.2043; Valbuena D, 2012, FERTIL STERIL, V97, P209, DOI 10.1016/j.fertnstert.2011.10.008	21	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1472-6483	1472-6491		REPROD BIOMED ONLINE	Reprod. Biomed. Online	JUN	2015	30	6					613	621		10.1016/j.rbmo.2015.02.004		9	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	CJ5UN	WOS:000355556800008		
J	Nakashizuka, H; Shimada, H; Hattori, T; Noguchi, T; Kokubo, N; Yuzawa, M				Nakashizuka, Hiroyuki; Shimada, Hiroyuki; Hattori, Takayuki; Noguchi, Takayasu; Kokubo, Naomi; Yuzawa, Mitsuko			VITRECTOMY USING 0.025% POVIDONE-IODINE IN BALANCED SALT SOLUTION PLUS FOR THE TREATMENT OF POSTOPERATIVE ENDOPHTHALMITIS	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Article							STAPHYLOCOCCUS-EPIDERMIDIS; FUNGAL ENDOPHTHALMITIS; INTRAVITREAL INJECTION; RABBIT EYES; EFFICACY; FLUOROQUINOLONES; GLUTATHIONE; IRRIGATION; MODEL	Purpose: To investigate the bactericidal effect of 0.025% povidone-iodine in Balanced Salt Solution PLUS (0.025% PI-BSS PLUS) and its use in vitrectomy for postoperative endophthalmitis. Methods: First, an experimental laboratory model using Staphylococcus aureus was used to evaluate the bactericidal effect of PI-BSS PLUS. Next, in a case series of 4 eyes with postoperative endophthalmitis, vitrectomy using 0.025% PI-BSS PLUS as irrigation solution was conducted, followed by postoperative intravitreal and intravenous antibiotics. Results: In in vitro study, PI at concentrations of 0.01% and above in BSS PLUS exhibited marked bactericidal effect after 15 seconds of exposure. Bactericidal effect of 0.025% PI-BSS PLUS was maintained at room temperature storage for 15 minutes but was attenuated after 30 minutes. Among 4 eyes that underwent vitrectomy using 0.025% PI-BSS PLUS, coagulase-negative Staphylococcus sp. was isolated in 1 eye at the beginning but not at completion of surgery. In all four eyes, endophthalmitis was resolved with no adverse events. Ocular toxicity was not observed. Conclusion: The 0.025% PI-BSS PLUS is bactericidal and nontoxic when used as irrigation solution in vitrectomy. In 4 cases of postoperative endophthalmitis, vitrectomy using 0.025% PI-BSS PLUS followed by postoperative antibiotics resolved endophthalmitis.	[Nakashizuka, Hiroyuki; Shimada, Hiroyuki; Hattori, Takayuki; Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo 1018309, Japan; [Noguchi, Takayasu; Kokubo, Naomi] Sagami Res Labs, Kawasaki, Kanagawa, Japan	Shimada, H (reprint author), Nihon Univ, Dept Ophthalmol, Surugadai Hosp, Chiyoda Ku, 1-8-13 Surugadai Kanda, Tokyo 1018309, Japan.	sshimada@olive.ocn.ne.jp					Shimada H, 2011, AM J OPHTHALMOL, V151, P11, DOI 10.1016/j.ajo.2010.07.002; Sheyman AT, 2013, JAMA OPHTHALMOL, V131, P864, DOI 10.1001/jamaophthalmol.2013.88; Mikosz CA, 2014, EMERG INFECT DIS, V20, P248, DOI 10.3201/eid2002.131257; Shimada H, 2013, GRAEF ARCH CLIN EXP, V251, P1885, DOI 10.1007/s00417-013-2274-y; AGUILAR HE, 1995, RETINA-J RET VIT DIS, V15, P428; Schimel AM, 2013, AM J OPHTHALMOL, V156, P50, DOI 10.1016/j.ajo.2013.01.027; ZAMORA JL, 1986, AM J SURG, V151, P400, DOI 10.1016/0002-9610(86)90477-0; Kobayashi T, 2011, JPN J OPHTHALMOL, V55, P547, DOI 10.1007/s10384-011-0062-y; Bonowitz A, 2001, J DRUG TARGET, V9, P75; Brozou CG, 2009, OPHTHAL RES, V41, P181, DOI 10.1159/000217721; Callegan MC, 2009, ADV THER, V26, P447, DOI 10.1007/s12325-009-0018-5; Clement C, 2011, INVEST OPHTH VIS SCI, V52, P339, DOI 10.1167/iovs.10-5944; Hyon JY, 2009, J CATARACT REFR SURG, V35, P1609, DOI 10.1016/j.jcrs.2009.04.036; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Naor J, 2001, J Cataract Refract Surg, V27, P941, DOI 10.1016/S0886-3350(00)00750-1; Oduwole KO, 2010, J ORTHOP RES, V28, P1252, DOI 10.1002/jor.21110; Pathengay A, 2011, RETINA-J RET VIT DIS, V31, P1806, DOI 10.1097/IAE.0b013e31820f4b9d; Rikimaru T, 2002, INT J TUBERC LUNG D, V6, P763; Shimada H, 2013, RETINA-J RET VIT DIS, V33, P143, DOI 10.1097/IAE.0b013e318261a6ce; Trost LW, 2007, J OCUL PHARMACOL TH, V23, P70, DOI 10.1089/jop.2006.0076; VANDENBROEK PJ, 1982, ANTIMICROB AGENTS CH, V22, P593; WHITACRE MM, 1990, CURR EYE RES, V9, P725, DOI 10.3109/02713689008999567; WINKLER BS, 1991, INVEST OPHTH VIS SCI, V32, P2840	23	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0275-004X	1539-2864		RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	JUN	2015	35	6					1087	1094		10.1097/IAE.0000000000000634		8	Ophthalmology	Ophthalmology	CJ7KJ	WOS:000355673600006		
J	Guan, LJ; Ohtsuka, J; Okai, M; Miyakawa, T; Mase, T; Zhi, YH; Hou, F; Ito, N; Iwasaki, A; Yasohara, Y; Tanokura, M				Guan, Li-Jun; Ohtsuka, Jun; Okai, Masahiko; Miyakawa, Takuya; Mase, Tomoko; Zhi, Yuehua; Hou, Feng; Ito, Noriyuki; Iwasaki, Akira; Yasohara, Yoshihiko; Tanokura, Masaru			A new target region for changing the substrate specificity of amine transaminases	SCIENTIFIC REPORTS			English	Article							PROSTATIC HYPERPLASIA; ASPERGILLUS-FUMIGATUS; ASYMMETRIC-SYNTHESIS; MICROBIAL SYNTHESIS; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURES; CHIRAL AMINES; AMINOTRANSFERASES; RECOGNITION; SITAGLIPTIN	(R)-stereospecific amine transaminases (R-ATAs) are important biocatalysts for the production of (R)-amine compounds in a strict stereospecific manner. An improved R-ATA, ATA-117-Rd11, was successfully engineered for the manufacture of sitagliptin, a widely used therapeutic agent for type-2 diabetes. The effects of the individual mutations, however, have not yet been demonstrated due to the lack of experimentally determined structural information. Here we describe three crystal structures of the first isolated R-ATA, its G136F mutant and engineered ATA-117-Rd11, which indicated that the mutation introduced into the 136th residue altered the conformation of a loop next to the active site, resulting in a substrate-binding site with drastically modified volume, shape, and surface properties, to accommodate the large pro-sitagliptin ketone. Our findings provide a detailed explanation of the previously reported molecular engineering of ATA-117-Rd11 and propose that the loop near the active site is a new target for the rational design to change the substrate specificity of ATAs.	[Guan, Li-Jun; Ohtsuka, Jun; Okai, Masahiko; Miyakawa, Takuya; Mase, Tomoko; Zhi, Yuehua; Hou, Feng; Tanokura, Masaru] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; [Okai, Masahiko] Tokyo Univ Marine Sci & Technol, Dept Ocean Sci, Minato Ku, Tokyo 1088477, Japan; [Ito, Noriyuki; Yasohara, Yoshihiko] Kaneka Corp, Biotechnol Dev Labs, Takasago, Hyogo 6768688, Japan; [Iwasaki, Akira] Kaneka Corp, QOL Div, Res & Dev Grp, Takasago, Hyogo 6768688, Japan	Tanokura, M (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	amtanok@mail.ecc.u-tokyo.ac.jp	OKAI, Masahiko/O-1925-2014		Platform for Drug Discovery, Informatics, and Structural Life Science of the Ministry of Education, Culture, Sports, Science, and Technology, Japan	The synchrotron-radiation experiments were performed on beamlines BL5A and NW12A at the Photon Factory, Tsukuba, Japan (Proposal No. 2013G163). We thank the beamline staffs at the Photon Factory for their kind help in collecting the data. This work was supported in part by the Platform for Drug Discovery, Informatics, and Structural Life Science of the Ministry of Education, Culture, Sports, Science, and Technology, Japan.	Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Hohne M, 2010, NAT CHEM BIOL, V6, P807, DOI [10.1038/nchembio.447, 10.1038/NCHEMBIO.447]; Schatzle S, 2011, ADV SYNTH CATAL, V353, P2439, DOI 10.1002/adsc.201100435; Aschner P, 2006, DIABETES CARE, V29, P2632, DOI 10.2337/dc06-0703; Cazzola M, 2005, EXPERT OPIN INV DRUG, V14, P775, DOI 10.1517/13543784.14.7.775; Chen C, 2008, CURR MED CHEM, V15, P2173, DOI 10.2174/092986708785747625; Celniker G, 2013, ISR J CHEM, V53, P199, DOI 10.1002/ijch.201200096; Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589; Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314; Desai AA, 2011, ANGEW CHEM INT EDIT, V50, P1974, DOI 10.1002/anie.201007051; Humble MS, 2012, FEBS J, V279, P779, DOI 10.1111/j.1742-4658.2012.08468.x; Sayer C, 2014, FEBS J, V281, P2240, DOI 10.1111/febs.12778; Steffen-Munsberg F, 2013, CHEMCATCHEM, V5, P154, DOI 10.1002/cctc.201200545; Hirotsu K, 2005, CHEM REC, V5, P160, DOI 10.1002/tcr.20042; Taylor PP, 1998, TRENDS BIOTECHNOL, V16, P412, DOI 10.1016/S0167-7799(98)01240-2; Cowtan K, 2006, ACTA CRYSTALLOGR D, V62, P1002, DOI 10.1107/S0907444906022116; Thomsen M, 2014, ACTA CRYSTALLOGR D, V70, P1086, DOI 10.1107/S1399004714001084; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Savile CK, 2010, SCIENCE, V329, P305, DOI 10.1126/science.1188934; Iwasaki A, 2012, APPL MICROBIOL BIOT, V93, P1563, DOI 10.1007/s00253-011-3580-0; Shin JS, 2002, J ORG CHEM, V67, P2848, DOI 10.1021/jo016115i; Bornscheuer UT, 2012, NATURE, V485, P185, DOI 10.1038/nature11117; Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633; Ashkenazy H, 2010, NUCLEIC ACIDS RES, V38, pW529, DOI 10.1093/nar/gkq399; Cohen SX, 2004, ACTA CRYSTALLOGR D, V60, P2222, DOI 10.1107/S0907444904027556; Erickson B, 2011, SCIENCE, V333, P1254, DOI 10.1126/science.1211066; Hohn M, 2009, CHEMCATCHEM, V1, P42, DOI 10.1002/cctc.200900110; Iwasaki A, 2006, APPL MICROBIOL BIOT, V69, P499, DOI 10.1007/s00253-005-0002-1; Iwasaki A, 2003, BIOTECHNOL LETT, V25, P1843, DOI 10.1023/A:1026229610628; Lyskowski A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087350; Midelfort K. S., 2012, PROTEIN ENG DES SEL, V26, P25; Savile C., 2010, World Intellectual Property Organization patent, Patent No. [WO 2010/099501, 2010099501]; Sayer C, 2013, ACTA CRYSTALLOGR D, V69, P564, DOI 10.1107/S0907444912051670; Schilit S, 2009, CLIN THER, V31, P2489, DOI 10.1016/j.clinthera.2009.11.024; Schulman CC, 2001, J UROLOGY, V166, P1358, DOI 10.1016/S0022-5347(05)65769-2; Skalden L, 2015, FEBS J, V282, P407, DOI 10.1111/febs.13149; Yamada Y., 2002, United States patent, Patent No. [US 6,344,351, 6344351]; Yamada Y., 2007, United States patent, Patent No. [US 7,169,592, 7169592]	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 1	2015	5								10753	10.1038/srep10753		11	Multidisciplinary Sciences	Science & Technology - Other Topics	CJ6KT	WOS:000355603400001		
J	Mohideen, SS; Yamasaki, Y; Omata, Y; Tsuda, L; Yoshiike, Y				Mohideen, Sahabudeen Sheik; Yamasaki, Yasutoyo; Omata, Yasuhiro; Tsuda, Leo; Yoshiike, Yuji			Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies	SCIENTIFIC REPORTS			English	Article							AGGREGATION INHIBITOR THERAPY; MUSHROOM BODY NEURONS; TAU-AGGREGATION; METHYLENE-BLUE; DROSOPHILA-MELANOGASTER; ALZHEIMERS-DISEASE; IN-VITRO; MEMORY; DYES; NEURODEGENERATION	Methylene blue (MB) inhibits the aggregation of tau, a main constituent of neurofibrillary tangles. However, MB's mode of action in vivo is not fully understood. MB treatment reduced the amount of sarkosyl-insoluble tau in Drosophila that express human wild-type tau. MB concurrently ameliorated the climbing deficits of transgenic tau flies to a limited extent and diminished the climbing activity of wild-type flies. MB also decreased the survival rate of wild-type flies. Based on its photosensitive efficacies, we surmised that singlet oxygen generated through MB under light might contribute to both the beneficial and toxic effects of MB in vivo. We identified rose bengal (RB) that suppressed tau accumulation and ameliorated the behavioral deficits to a lesser extent than MB. Unlike MB, RB did not reduce the survival rate of flies. Our findings indicate that singlet oxygen generators with little toxicity may be suitable drug candidates for treating tauopathies.	[Mohideen, Sahabudeen Sheik; Yoshiike, Yuji] Natl Ctr Geriatr & Gerontol, Ctr Dev Adv Med Dementia, Alzheimers Dis Project Team, Obu, Aichi 4748511, Japan; [Yamasaki, Yasutoyo] Natl Ctr Geriatr & Gerontol, Ctr Dev Adv Med Dementia, Dept Drug Discovery, Obu, Aichi 4748511, Japan; [Omata, Yasuhiro] Nagoya Univ, Grad Sch Med, Dept Occupat & Environm Hlth, Showa Ku, Nagoya, Aichi 4668550, Japan; [Tsuda, Leo] Natl Ctr Geriatr & Gerontol, Ctr Dev Adv Med Dementia, Anim Models Aging, Obu, Aichi 4748511, Japan	Yoshiike, Y (reprint author), Natl Ctr Geriatr & Gerontol, Ctr Dev Adv Med Dementia, Alzheimers Dis Project Team, 7-430 Morioka, Obu, Aichi 4748511, Japan.	yyoshiik@ncgg.go.jp			National Center for Geriatrics and Gerontology Institutional Grants [23-38, 26-31]; Japan Foundation for Aging and Health [58]; Translational Research Network Program at Nagoya University [A18]	We thank Drs. Akihiko Takashima, Masataka Sugimoto, and Michihiro Hashimoto, and the members of "AD salon" for fruitful discussions. We thank Mrs. Yukako Tsuchiya for assistance with the fly experiments. This work was supported by National Center for Geriatrics and Gerontology Institutional Grants 23-38 and 26-31, and grants from the Japan Foundation for Aging and Health No. 58 and the Translational Research Network Program at Nagoya University A18 to Y. Yoshiike.	Akalal DBG, 2006, LEARN MEMORY, V13, P659, DOI 10.1101/lm.221206; Braak H, 1991, BRAIN PATHOL, V1, P213, DOI 10.1111/j.1750-3639.1991.tb00661.x; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Takashima A, 2013, J ALZHEIMERS DIS, V37, P565, DOI 10.3233/JAD-130653; BRAND AH, 1993, DEVELOPMENT, V118, P401; KHAN AU, 1979, P NATL ACAD SCI USA, V76, P6047, DOI 10.1073/pnas.76.12.6047; Lira-De Leon KI, 2013, J ALZHEIMERS DIS, V35, P319, DOI 10.3233/JAD-121765; Ja WW, 2007, P NATL ACAD SCI USA, V104, P8253, DOI 10.1073/pnas.0702726104; Kosmidis S, 2010, J NEUROSCI, V30, P464, DOI 10.1523/JNEUROSCI.1490-09.2010; Stack C, 2014, HUM MOL GENET, V23, P3716, DOI 10.1093/hmg/ddu080; Desideri E, 2012, AUTOPHAGY, V8, P1769, DOI 10.4161/auto.22037; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Crowe A, 2013, J BIOL CHEM, V288, P11024, DOI 10.1074/jbc.M112.436006; FOOTE CS, 1968, J AM CHEM SOC, V90, P6233, DOI 10.1021/ja01024a061; Akoury E, 2013, ANGEW CHEM INT EDIT, V52, P3511, DOI 10.1002/anie.201208290; Krishnan N, 2012, NEUROBIOL DIS, V45, P1129, DOI 10.1016/j.nbd.2011.12.034; Congdon EE, 2012, AUTOPHAGY, V8, P609, DOI 10.4161/auto.19048; Riha PD, 2005, EUR J PHARMACOL, V511, P151, DOI 10.1016/j.ejphar.2005.02.001; Davies J, 2007, GUT, V56, P155, DOI 10.1136/gut.2006.107300; Boyle RW, 1996, PHOTOCHEM PHOTOBIOL, V64, P469, DOI 10.1111/j.1751-1097.1996.tb03093.x; Wischik CM, 1996, P NATL ACAD SCI USA, V93, P11213, DOI 10.1073/pnas.93.20.11213; Jinwal UK, 2009, J NEUROSCI, V29, P12079, DOI 10.1523/JNEUROSCI.3345-09.2009; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Hohn A, 2013, J PROTEOMICS, V92, P132, DOI 10.1016/j.jprot.2013.01.004; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Mershin A, 2004, LEARN MEMORY, V11, P277, DOI 10.1101/lm.70804; Wischik CM, 2014, BIOCHEM PHARMACOL, V88, P529, DOI 10.1016/j.bcp.2013.12.008; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Wischik C, 2009, J NUTR HEALTH AGING, V13, P367, DOI 10.1007/s12603-009-0046-5; Baddeley TC, 2015, J PHARMACOL EXP THER, V352, P110, DOI 10.1124/jpet.114.219352; Bruchey A. K., 2008, AM J PHARM TOXICOL, V3, P72; BURROWS GE, 1984, J VET PHARMACOL THER, V7, P225, DOI 10.1111/j.1365-2885.1984.tb00904.x; Clifton 2nd J., 2003, AM J THER, V10, P289; GARVIN RT, 1969, SCIENCE, V164, P583, DOI 10.1126/science.164.3879.583; Gistelinck M., 2012, INT J ALZHEIMERS DIS, V2012, DOI DOI 10.1155/2012/970980; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; HIASA Y, 1988, JPN J CANCER RES, V79, P314; HIRSCH J, 1959, J COMP PHYSIOL PSYCH, V52, P304, DOI 10.1037/h0043498; Hosokawa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052389; MASSIE HR, 1993, MECH AGEING DEV, V68, P175, DOI 10.1016/0047-6374(93)90149-L; Miyata Y, 2012, CHEM BIOL, V19, P1391, DOI 10.1016/j.chembiol.2012.07.026; MOSTELLER RD, 1987, NEW ENGL J MED, V317, P1098; O'Leary JC, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-45; PITTENDR.CS, 1972, P NATL ACAD SCI USA, V69, P1537, DOI 10.1073/pnas.69.6.1537; Rakshit K, 2013, EXP GERONTOL, V48, P1260, DOI 10.1016/j.exger.2013.07.013; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Yoshiike Y, 2012, AGING CELL, V11, P51, DOI 10.1111/j.1474-9726.2011.00756.x	47	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 1	2015	5								10821	10.1038/srep10821		14	Multidisciplinary Sciences	Science & Technology - Other Topics	CJ6LT	WOS:000355606000002		
J	Shinzawa, M; Konno, H; Qin, JW; Akiyama, N; Miyauchi, M; Ohashi, H; Miyamoto-Sato, E; Yanagawa, H; Akiyama, T; Inoue, J				Shinzawa, Miho; Konno, Hiroyasu; Qin, Junwen; Akiyama, Nobuko; Miyauchi, Maki; Ohashi, Hiroyuki; Miyamoto-Sato, Etsuko; Yanagawa, Hiroshi; Akiyama, Taishin; Inoue, Jun-ichiro			Catalytic subunits of the phosphatase calcineurin interact with NF-kappa B-inducing kinase (NIK) and attenuate NIK-dependent gene expression	SCIENTIFIC REPORTS			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; TUMOR-NECROSIS-FACTOR; IN-VITRO; NEGATIVE FEEDBACK; MULTIPLE-MYELOMA; NF-KAPPA-B2 P100; ACTIVATION; PATHWAY; TRANSCRIPTION; MUTATION	Nuclear factor (NF)-kappa B-inducing kinase (NIK) is a serine/ threonine kinase that activates NF-kappa B pathways, thereby regulating a wide variety of immune systems. Aberrant NIK activation causes tumor malignancy, suggesting a requirement for precise regulation of NIK activity. To explore novel interacting proteins of NIK, we performed in vitro virus screening and identified the catalytic subunit A alpha isoform of serine/ threonine phosphatase calcineurin (CnA alpha) as a novel NIK-interacting protein. The interaction of NIK with CnAa in living cells was confirmed by co-immunoprecipitation. Calcineurin catalytic subunit A beta isoform (CnA alpha) also bound to NIK. Experiments using domain deletion mutants suggested that CnAa and CnA beta interact with both the kinase domain and C-terminal region of NIK. Moreover, the phosphatase domain of CnA alpha is responsible for the interaction with NIK. Intriguingly, we found that TRAF(3), a critical regulator of NIK activity, also binds to CnA alpha and CnA beta. Depletion of CnA alpha and CnA beta significantly enhanced lymphotoxin-beta receptor (Lt beta R)-mediated expression of the NIK-dependent gene Spi-B and activation of RelA and RelB, suggesting that CnA alpha and CnA beta attenuate NF-kappa B activation mediated by Lt beta R-NIK signaling. Overall, these findings suggest a possible role of CnA alpha and CnA beta in modifying NIK functions.	[Shinzawa, Miho; Konno, Hiroyasu; Qin, Junwen; Akiyama, Nobuko; Miyauchi, Maki; Ohashi, Hiroyuki; Akiyama, Taishin; Inoue, Jun-ichiro] Univ Tokyo, Inst Med Sci, Div Cell & Mol Biol, Minato Ku, Tokyo, Japan; [Qin, Junwen] Jinan Univ, Minist Sci & Technol, Minist Educ & Int Base Collaborat Sci & Technol, Dept Dev & Regenerat Biol,Key Lab Regenerat Med, Guangzhou, Guangdong, Peoples R China; [Ohashi, Hiroyuki; Miyamoto-Sato, Etsuko] Univ Tokyo, Inst Med Sci, Div Interactome Med Sci, Minato Ku, Tokyo, Japan; [Miyamoto-Sato, Etsuko] Tokyo Univ Sci, Res Inst Biomed Sci, Div Mol Biol, Noda, Chiba 278, Japan; [Yanagawa, Hiroshi] Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Yokohama, Kanagawa 223, Japan	Akiyama, T (reprint author), Univ Tokyo, Inst Med Sci, Div Cell & Mol Biol, Minato Ku, Tokyo, Japan.	taishin@ims.u-tokyo.ac.jp; jun-i@ims.u-tokyo.ac.jp			Japanese Society for the Promotion of Science; grants for Priority Area Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Genome Network Project from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Initiative for Global Research Network on Infectious Diseases; Ministry of Education, Culture, Sports, Science, and Technology of Japan	This work was supported by a grant from the Japanese Society for the Promotion of Science (T.A.), grants for Priority Area Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (J.I.), a grant from Grant-in-Aid for challenging Exploratory Research (T. A.), This work was also supported by Genome Network Project from the Ministry of Education, Culture, Sports, Science and Technology of Japan (J.I.) and contract research funding from the Japan Initiative for Global Research Network on Infectious Diseases (J. I.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Akiyama N, 2014, J EXP MED, V211, P2425, DOI 10.1084/jem.20141207; Akiyama T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00278; Nemoto N, 1997, FEBS LETT, V414, P405, DOI 10.1016/S0014-5793(97)01026-0; Lovas A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-606; Palkowitsch L, 2011, J BIOL CHEM, V286, P7522, DOI 10.1074/jbc.M110.155895; Inoue J, 2007, CANCER SCI, V98, P268, DOI 10.1111/j.1349-7006.2007.00389.x; Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676; Kang YJ, 2007, J IMMUNOL, V179, P4598; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600-065X.2011.01088.x; Cyster JG, 2000, IMMUNOL REV, V176, P181; Morris GP, 2012, NAT IMMUNOL, V13, P121, DOI 10.1038/ni.2190; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Frischbutter S, 2011, EUR J IMMUNOL, V41, P2349, DOI 10.1002/eji.201041052; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Li HM, 2011, TRENDS CELL BIOL, V21, P91, DOI 10.1016/j.tcb.2010.09.011; Rusnak F, 2000, PHYSIOL REV, V80, P1483; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Thu YM, 2010, CYTOKINE GROWTH F R, V21, P213, DOI 10.1016/j.cytogfr.2010.06.002; Enzler T, 2006, IMMUNITY, V25, P403, DOI 10.1016/j.immuni.2006.07.010; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Britanova LV, 2008, BIOCHEM BIOPH RES CO, V365, P583, DOI 10.1016/j.bbrc.2007.10.200; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Chin RK, 2003, NAT IMMUNOL, V4, P1121, DOI 10.1038/ni982; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Shinzawa M, 2011, BIOCHEM BIOPH RES CO, V414, P773, DOI 10.1016/j.bbrc.2011.10.001; Lin X, 1998, MOL CELL BIOL, V18, P5899; Miyamoto-Sato E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009289; Miyamoto-Sato E, 2005, GENOME RES, V15, P710, DOI 10.1101/gr.3510505; Razani B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000778; Akiyama T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095992; Yamaguchi N, 2013, SCI REP-UK, V3, DOI 10.1038/srep02568	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 1	2015	5								10758	10.1038/srep10758		12	Multidisciplinary Sciences	Science & Technology - Other Topics	CJ6KX	WOS:000355603800001		
J	Simakov, SK; Kouchi, A; Mel'nik, NN; Scribano, V; Kimura, Y; Hama, T; Suzuki, N; Saito, H; Yoshizawa, T				Simakov, S. K.; Kouchi, A.; Mel'nik, N. N.; Scribano, V.; Kimura, Y.; Hama, T.; Suzuki, N.; Saito, H.; Yoshizawa, T.			Nanodiamond Finding in the Hyblean Shallow Mantle Xenoliths	SCIENTIFIC REPORTS			English	Article							DIAMOND FORMATION; GABBROIC XENOLITHS; METAMORPHIC ROCKS; FLUID; HYDROCARBONS; OPHIOLITE; GRAPHITE; GENESIS; SYSTEM; CARBON	Most of Earth's diamonds are connected with deep-seated mantle rocks; however, in recent years, mu m-sized diamonds have been found in shallower metamorphic rocks, and the process of shallow-seated diamond formation has become a hotly debated topic. Nanodiamonds occur mainly in chondrite meteorites associated with organic matter and water. They can be synthesized in the stability field of graphite from organic compounds under hydrothermal conditions. Similar physicochemical conditions occur in serpentinite-hosted hydrothermal systems. Herein, we report the first finding of nanodiamonds, primarily of 6 and 10 nm, in Hyblean asphaltene-bearing serpentinite xenoliths (Sicily, Italy). The discovery was made by electron microscopy observations coupled with Raman spectroscopy analyses. The finding reveals new aspects of carbon speciation and diamond formation in shallow crustal settings. Nanodiamonds can grow during the hydrothermal alteration of ultramafic rocks, as well as during the lithogenesis of sediments bearing organic matter.	[Kouchi, A.; Kimura, Y.; Hama, T.] Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan; [Mel'nik, N. N.] Russian Acad Sci, PN Lebedev Phys Inst, Moscow 119991, Russia; [Scribano, V.] Univ Catania, Dept Biol Geol & Environm Sci, I-95129 Catania, Italy; [Suzuki, N.] Hokkaido Univ, Fac Sci, Dept Nat Hist Sci, Sapporo, Hokkaido 0600810, Japan; [Saito, H.] Hokkaido Univ, Creat Res Inst, Res Div JAPEX Earth Energy Frontier, Sapporo, Hokkaido 0010021, Japan; [Yoshizawa, T.] Hokkaido Univ, Creat Res Inst, Open Facil Div, Equipment Management Ctr, Sapporo, Hokkaido 0010021, Japan	Simakov, SK (reprint author), Harchenko 19-A-7H, St Petersburg 194100, Russia.	simakov1957@yandex.ru	HAMA, Tetsuya/A-9766-2012; Suzuki, Noriyuki/B-5694-2012; Melnik, Nikolay/E-5666-2014	HAMA, Tetsuya/0000-0002-4991-4044; Melnik, Nikolay/0000-0002-7058-0333	RFBR [14-02-00436]; Progettidi Ricerca di Ateneo; Universita di Catania; Japanese Ministry of Education, Culture, Sports, Science and Technology	We wish to thank F. Manuella, T. Miyazaki and Sh. Maruyama for analytical facilities of TEM in Tohoku University for their stimulating discussions, comments and help. This work was partly supported by RFBR No 14-02-00436, Progettidi Ricerca di Ateneo, area 04 of Universita di Catania (V.S.) and Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (A.K., Y.K. and T.H.). The analysis of Raman was carried out with in Via Reflex at the Open Facility, Hokkaido University Sousei Hall.	McCollom TM, 2013, REV MINERAL GEOCHEM, V75, P467, DOI 10.2138/rmg.2013.75.15; BADZIAG P, 1990, NATURE, V343, P244, DOI 10.1038/343244a0; Konn C, 2009, CHEM GEOL, V258, P299, DOI 10.1016/j.chemgeo.2008.10.034; Russell SS, 1996, METORIT PLANET SCI, V31, P343; Yang JS, 2015, GONDWANA RES, V27, P459, DOI 10.1016/j.gr.2014.07.004; Dahl JE, 2003, SCIENCE, V299, P96, DOI 10.1126/science.1078239; Evans BW, 2004, INT GEOL REV, V46, P479, DOI 10.2747/0020-6814.46.6.479; Etiope G, 2013, CHEM GEOL, V347, P161, DOI 10.1016/j.chemgeo.2013.04.003; Bauschlicher CW, 2007, ASTROPHYS J, V671, P458, DOI 10.1086/522683; Capelli M., 1995, CAPELLI M, Patent No. US 5,417,953; Ciliberto E, 2009, CHEM GEOL, V258, P258, DOI 10.1016/j.chemgeo.2008.10.029; Frost R.B., 1985, J PETROL, V26, P31; Jiang Q, 2000, J PHYS-CONDENS MAT, V12, P5623, DOI 10.1088/0953-8984/12/26/309; Klein F, 2009, J PETROL, V50, P37, DOI 10.1093/petrology/egn071; KOUCHI A, 2005, ASTROPHYS J 2, V626, pL12; Manuella FC, 2013, J GEODYN, V66, P92, DOI 10.1016/j.jog.2013.02.006; Manuella FC, 2013, MINERAL MAG, V77, P3163, DOI 10.1180/minmag.2013.077.8.10; Nakano H, 2002, P JPN ACAD B-PHYS, V78, P277, DOI 10.2183/pjab.78.277; Pechnikov VA, 2008, EUR J MINERAL, V20, P395, DOI 10.1127/0935-1221/2008/0020-1813; Rudenko A.P., 1993, RUSS CHEM REV, V62, P87, DOI 10.1070/RC1993v062n02ABEH000007; Scire S, 2011, LITHOS, V125, P956, DOI 10.1016/j.lithos.2011.05.011; Scribano V, 2006, MINER PETROL, V86, P63, DOI 10.1007/s00710-005-0092-6; Scribano V, 2006, OFIOLITI, V31, P161; Simakov SK, 2010, J MATER RES, V25, P2336, DOI 10.1557/JMR.2010.0303; Simakov SK, 2008, DOKL EARTH SCI, V421, P835, DOI 10.1134/S1028334X08050280; SOBOLEV NV, 1990, NATURE, V343, P742, DOI 10.1038/343742a0; Sommer AP, 2008, CRYST GROWTH DES, V8, P2628, DOI 10.1021/cg8005037; Suiting I, 2009, J VOLCANOL GEOTH RES, V186, P361, DOI 10.1016/j.jvolgeores.2009.07.013; TIELENS AGGM, 1987, ASTROPHYS J 2, V319, pL10; Tissot B. P., 1978, PETROLEUM FORMATION; Zhang C, 2010, COMPUT GEOSCI-UK, V36, P569, DOI 10.1016/j.cageo.2009.05.008	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 1	2015	5								10765	10.1038/srep10765		8	Multidisciplinary Sciences	Science & Technology - Other Topics	CJ6KY	WOS:000355603900001		
J	Tanimoto, N; Sothilingam, V; Kondo, M; Biel, M; Humphries, P; Seeliger, MW				Tanimoto, Naoyuki; Sothilingam, Vithiyanjali; Kondo, Mineo; Biel, Martin; Humphries, Peter; Seeliger, Mathias W.			Electroretinographic assessment of rod- and cone-mediated bipolar cell pathways using flicker stimuli in mice	SCIENTIFIC REPORTS			English	Article							TARGETED DISRUPTION; MOUSE MODEL; VISION; ERG; LACKING; RETINA; SINE; GENE	Mouse full-field electroretinograms (ERGs) are dominated by responses of photoreceptors and depolarizing (ON-) bipolar cells, but not much of hyperpolarizing (OFF-) bipolar cells under conventional recording conditions. Here we investigate a novel ERG protocol in mice for functional assessment of the major ON-and OFF- bipolar cell pathways using flicker stimuli for a high luminance with varying frequency up to 30 Hz. Wild- type (WT) and functionally specific transgenic mice (Cnga3(-/-), no cone photoreceptor function; rho(-/-), no rod photoreceptor function; mGluR6(-/-), no ON-bipolar cell function) were examined. The Cnga3(-/-) flicker ERG was similar to the WT flicker ERG at very low stimulus frequencies, whereas ERGs were comparable between WT and rho(-/-) mice at 5 Hz and above. Between 5 and 15 Hz, ERGs in mGluR6(-/-) mice differed in configuration and amplitude from those in WT and rho(-/-) mice; in contrast, response amplitudes above 15 Hz were comparable among WT, rho(-/-) and mGluR6(-/-) mice. In summary, we found three frequency ranges with these conditions that are dominated by activity in the rod pathways (below 5 Hz), cone ON-pathway (between 5 and 15 Hz), and cone OFF-pathway (above 15 Hz) that enables a quick overview of the functionality of the major bipolar cell pathways.	[Tanimoto, Naoyuki; Sothilingam, Vithiyanjali; Seeliger, Mathias W.] Univ Tubingen, Ctr Ophthalmol, Inst Ophthalm Res, Div Ocular Neurodegenerat, D-72076 Tubingen, Germany; [Kondo, Mineo] Mie Univ, Grad Sch Med, Dept Ophthalmol, Tsu, Mie 5148507, Japan; [Biel, Martin] Univ Munich, CIPSM, Ctr Integrated Prot Sci Munich, D-81377 Munich, Germany; [Biel, Martin] Univ Munich, Dept Pharm, Ctr Drug Res, D-81377 Munich, Germany; [Humphries, Peter] Univ Dublin Trinity Coll, Smurfit Inst Genet, Ocular Genet Unit, Dublin 2, Ireland	Tanimoto, N (reprint author), Univ Tubingen, Ctr Ophthalmol, Inst Ophthalm Res, Div Ocular Neurodegenerat, Schleichstr 4-3, D-72076 Tubingen, Germany.	naoyuki.tanimoto@med.uni-tuebingen.de	Biel, Martin/G-1175-2014	Biel, Martin/0000-0002-9974-3052	Deutsche Forschungsgemeinschaft (DFG) [KFO134-Se837/5-2, Se837/6-2]; Ministry of Education, Culture, Sports, Science and Technology of Japan [20592603]	We thank Pia Lacroix and Gudrun Utz for technical assistance, Shigetada Nakanishi (Osaka Bioscience Institute, Japan) for providing the mGluR6 knockout mouse line, and Daniel L. Rathbun for critical reading of the manuscript. This work was supported by the Deutsche Forschungsgemeinschaft (DFG, grants KFO134-Se837/5-2 and Se837/6-2); and Grant-in-Aid for Scientific Research C (# 20592603) from Ministry of Education, Culture, Sports, Science and Technology of Japan (http://www.jsps.go.jp/).	Marmor MF, 2004, DOC OPHTHALMOL, V108, P107, DOI 10.1023/B:DOOP.0000036793.44912.45; Jaissle GB, 2001, INVEST OPHTH VIS SCI, V42, P506; Schmitt U, 2009, NEUROSCIENCE, V162, P234, DOI 10.1016/j.neuroscience.2009.04.046; Samardzija M, 2009, HUM MOL GENET, V18, P1266, DOI 10.1093/hmg/ddp026; Biel M, 1999, P NATL ACAD SCI USA, V96, P7553, DOI 10.1073/pnas.96.13.7553; MASU M, 1995, CELL, V80, P757, DOI 10.1016/0092-8674(95)90354-2; Shirato S, 2008, EXP EYE RES, V86, P914, DOI 10.1016/j.exer.2008.03.008; Wassle H, 2004, NAT REV NEUROSCI, V5, P747, DOI 10.1038/nrn1497; Pardue MT, 1998, INVEST OPHTH VIS SCI, V39, P2443; Krishna VR, 2002, J NEUROPHYSIOL, V87, P42; Sharma S, 2005, VISUAL NEUROSCI, V22, P631, DOI 10.1017/S0952523805225129; Tsukamoto Y, 2001, J NEUROSCI, V21, P8616; Tanimoto N, 2009, FRONT BIOSCI, V14, P2730, DOI 10.2741/4009; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; Frishman L. J., 2011, ADLERS PHYSL EYE, P480; Kondo M, 2002, INVEST OPHTH VIS SCI, V43, P2500; Kondo M, 2001, INVEST OPHTH VIS SCI, V42, P305; Marmor M. F., 1989, ARCH OPHTHALMOL-CHIC, V107, P16; McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7; Pardue MT, 2014, DOC OPHTHALMOL, V128, P77, DOI 10.1007/s10633-013-9424-8; Sahaboglu A., 2010, PLOS ONE, V5; Seeliger M. W., 2011, NAT COMMUN, V2, P532; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; Tanimoto Naoyuki, 2013, Methods Mol Biol, V935, P69, DOI 10.1007/978-1-62703-080-9_4; Tsukamoto Y, 2007, J NEUROSCI, V27, P6261, DOI 10.1523/JNEUROSCI.5646-06-2007	25	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 1	2015	5								10731	10.1038/srep10731		7	Multidisciplinary Sciences	Science & Technology - Other Topics	CJ6KK	WOS:000355602500001		
J	Yaginuma, S; Nakajima, C; Kaneko, N; Yokoyama, Y; Nakayama, KS				Yaginuma, S.; Nakajima, C.; Kaneko, N.; Yokoyama, Y.; Nakayama, K. S.			Log-normal diameter distribution of Pd-based metallic glass droplet and wire	SCIENTIFIC REPORTS			English	Article							SUPERCOOLED LIQUID; ATOMIZATION; NANOWIRES; ALLOY; STATE; HAIR	We have studied the formation of Pd42.5Cu30Ni7.5P20 metallic glass droplets and wires in the gas atomization process. We demonstrate that the sizes of droplets and wires can be distinguished by the Ohnesorge number (O-h), which is the proportion of the spinnability to the capillary instability, and the diameter distributions follow a log-normal distribution function, implying cascade fragmentation. For droplets, the number significantly increases at O-h < 1 but the diameter gradually decreases. For wires, the number greatly increases at O-h > 1 while the diameter steadies below 400 nm. Further, the wire diameter is quadrupled at O-h = 16 due to the high viscosity which suppresses both capillary breakup and ligament elongation.	[Yaginuma, S.; Nakajima, C.; Kaneko, N.; Nakayama, K. S.] Tohoku Univ, WPI Adv Inst Mat Res, Sendai, Miyagi 9808577, Japan; [Kaneko, N.] Dexerials Corp, Tagajo, Sakuragi 9850842, Japan; [Yokoyama, Y.] Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan	Nakayama, KS (reprint author), Tohoku Univ, WPI Adv Inst Mat Res, Sendai, Miyagi 9808577, Japan.	kojisn@wpi-aimr.tohoku.ac.jp	Nakayama, Koji/E-5053-2012		JSPS [25286019, 26870058]; JST A-STEP [H25 S II-463]; WPI Fusion Research Program	We thank O. Haruyama for providing Pd-based metallic glass, H. Kato, Y. Yamazaki, and T. Nakamura for stimulating discussions, and R. Kumashiro and K. Saito for technical assistance. This work has been partly supported by JSPS Grant-in-Aid for Scientific Research (B) # 25286019, Young Scientists (B) # 26870058, JST A-STEP #H25 S II-463, and WPI Fusion Research Program.	Kumar G, 2009, NATURE, V457, P868, DOI 10.1038/nature07718; Nakayama KS, 2010, ADV MATER, V22, P872, DOI 10.1002/adma.200902295; Schroers J, 2008, ACTA MATER, V56, P471, DOI 10.1016/j.actamat.2007.10.008; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; Nakayama KS, 2012, NANO LETT, V12, P2404, DOI 10.1021/nl3003864; McKinley GH, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3663616; Haruyama O, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.064201; Schroers J, 2010, ADV MATER, V22, P1566, DOI 10.1002/adma.200902776; Carmo M, 2011, ACS NANO, V5, P2979, DOI 10.1021/nn200033c; Kumar G, 2011, ADV MATER, V23, P461, DOI 10.1002/adma.201002148; Eggers J, 2008, REP PROG PHYS, V71, DOI 10.1088/0034-4885/71/3/036601; Nakayama KS, 2008, NANO LETT, V8, P516, DOI 10.1021/nl0727462; Nishiyama N, 2002, APPL PHYS LETT, V80, P568, DOI 10.1063/1.1445475; Babinsky E, 2002, PROG ENERG COMBUST, V28, P303, DOI 10.1016/S0360-1285(02)00004-7; Bayvel L., 1993, LIQUID ATOMIZATION; German RM, 1994, POWDER METALLURGY SC; Kolmogorov A. N., 1941, DOKL AKAD NAUK SSSR, V31, P99; Nakayama KS, 2014, APPL PHYS LETT, V105, DOI 10.1063/1.4902147; Nishi T, 2004, MATER TRANS, V45, P2584, DOI 10.2320/matertrans.45.2584; Nukiyama S., 1939, T SOC MECH ENG JPN, V5, P62; Rimbert N, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.056316; SHIMOZURU D, 1994, B VOLCANOL, V56, P217, DOI 10.1007/BF00279606; Villermaux E, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/125; Villermaux E, 2012, CR MECANIQUE, V340, P555, DOI 10.1016/j.crme.2012.06.003; Villermaux E, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.074501; Zheng B, 2011, HANDBOOK OF ATOMIZATION AND SPRAYS: THEORY AND APPLICATIONS, P837, DOI 10.1007/978-1-4419-7264-4_36	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 1	2015	5								10711	10.1038/srep10711		8	Multidisciplinary Sciences	Science & Technology - Other Topics	CJ6JW	WOS:000355601100001		
J	Tuttle, KM; Martinez, SA; Schramm, EC; Takebayashi, Y; Seo, M; Steber, CM				Tuttle, Keiko M.; Martinez, Shantel A.; Schramm, Elizabeth C.; Takebayashi, Yumiko; Seo, Mitsunori; Steber, Camille M.			Grain dormancy loss is associated with changes in ABA and GA sensitivity and hormone accumulation in bread wheat, Triticum aestivum (L.)	SEED SCIENCE RESEARCH			English	Article						abscisic acid; afterripening; cold stratification; dormancy; gibberellin; pre-harvest sprouting; Triticum aestivum	WHITE WINTER-WHEAT; SEED DORMANCY; ABSCISIC-ACID; ARABIDOPSIS-THALIANA; SPROUTING-RESISTANT; SPRING WHEAT; GIBBERELLIN BIOSYNTHESIS; INSENSITIVE MUTANTS; IMPOSED DORMANCY; LOW-TEMPERATURE	Knowledge about the hormonal control of grain dormancy and dormancy loss is essential in wheat, because low grain dormancy at maturity is associated with the problem of pre-harvest sprouting (PHS) when cool and rainy conditions occur before harvest. Low GA (gibberellin A) hormone sensitivity and high ABA (abscisic acid) sensitivity were associated with higher wheat grain dormancy and PHS tolerance. Grains of two PHS-tolerant cultivars were very dormant at maturity, and insensitive to GA stimulation of germination. More PHS-susceptible cultivars were less sensitive to ABA inhibition of germination, and were either more GA sensitive or germinated efficiently without GA at maturity. As grain dormancy was lost through dry afterripening or cold imbibition, grains first gained GA sensitivity and then lost ABA sensitivity. These changes in GA and ABA sensitivity can serve as landmarks defining stages of dormancy loss that cannot be discerned without hormone treatment. These dormancy stages can be used to compare different cultivars, seed lots and studies. Previous work showed that wheat afterripening is associated with decreasing ABA levels in imbibing seeds. Wheat grain dormancy loss through cold imbibition also led to decreased endogenous ABA levels, suggesting that reduced ABA signalling is a general mechanism triggering dormancy loss.	[Tuttle, Keiko M.; Martinez, Shantel A.; Schramm, Elizabeth C.; Steber, Camille M.] Washington State Univ, Dept Crop & Soil Sci, Mol Plant Sci, Pullman, WA 99164 USA; [Takebayashi, Yumiko; Seo, Mitsunori] RIKEN, Ctr Sustainable Resource Sci, Yokohama, Kanagawa 2300045, Japan; [Steber, Camille M.] Washington State Univ, USDA ARS, Physiol & Dis Res Unit, Wheat Genet Qual, Pullman, WA 99164 USA	Steber, CM (reprint author), Washington State Univ, Dept Crop & Soil Sci, Mol Plant Sci, Pullman, WA 99164 USA.	csteber@wsu.edu	Seo, Mitsunori/N-9603-2015		National Science Foundation's East Asia and Pacific Summer Institute Award [1209878]; Japanese Society for Promotion of Science Summer Internship Award; Washington Grain Commission; US Department of Agriculture-Agricultural Research Service	This research was supported by the National Science Foundation's East Asia and Pacific Summer Institute Award (1209878 to K.M.T.), the Japanese Society for the Promotion of Science Summer Internship Award (to K.M.T. and M.S.), the Washington Grain Commission and the US Department of Agriculture-Agricultural Research Service (to C.M.S.).	Baskin JM, 2004, SEED SCI RES, V14, P1, DOI 10.1079/SSR2003150; Gao F, 2012, PLANT BIOTECHNOL J, V10, P465, DOI 10.1111/j.1467-7652.2012.00682.x; KING RW, 1984, AUST J AGR RES, V35, P327, DOI 10.1071/AR9840327; Kucera B, 2005, SEED SCI RES, V15, P281, DOI 10.1079/SSR2005218; DERKX MPM, 1993, PHYSIOL PLANTARUM, V89, P360, DOI 10.1034/j.1399-3054.1993.890218.x; ANDERSON JA, 1993, CROP SCI, V33, P453; Spielmeyer W, 2004, THEOR APPL GENET, V109, P847, DOI 10.1007/s00122-004-1689-6; Hedden P, 1997, ANNU REV PLANT PHYS, V48, P431, DOI 10.1146/annurev.arplant.48.1.431; Himi E, 2011, THEOR APPL GENET, V122, P1561, DOI 10.1007/s00122-011-1555-2; Yamauchi Y, 2004, PLANT CELL, V16, P367, DOI 10.1105/tpc.018143; Ariizumi T, 2013, PLANT PHYSIOL, V162, P2125, DOI 10.1104/pp.113.219451; Kobayashi F, 2008, J PLANT PHYSIOL, V165, P224, DOI 10.1016/j.jplph.2006.11.004; Himi E, 2002, J EXP BOT, V53, P1569, DOI 10.1093/jxb/erf005; Jacobsen JV, 2002, PHYSIOL PLANTARUM, V115, P428, DOI 10.1034/j.1399-3054.2002.1150313.x; Flintham JE, 2000, SEED SCI RES, V10, P43; Steber CM, 1998, GENETICS, V149, P509; Nakamura S, 2011, PLANT CELL, V23, P3215, DOI 10.1105/tpc.111.088492; WALKERSIMMONS M, 1988, PLANT CELL ENVIRON, V11, P769, DOI 10.1111/j.1365-3040.1988.tb01161.x; Barrero JM, 2010, PLANT J, V61, P611, DOI 10.1111/j.1365-313X.2009.04088.x; Schramm EC, 2013, THEOR APPL GENET, V126, P791, DOI 10.1007/s00122-012-2018-0; Warner RL, 2000, SEED SCI RES, V10, P51; Rikiishi K, 2010, J CEREAL SCI, V51, P292, DOI 10.1016/j.jcs.2010.01.003; Jacobsen JV, 2013, PLANTA, V238, P121, DOI 10.1007/s00425-013-1878-0; Finkelstein R, 2008, ANNU REV PLANT BIOL, V59, P387, DOI 10.1146/annurev.arplant.59.032607.092740; PATERSON AH, 1989, CAN J PLANT SCI, V69, P681; Schramm EC, 2012, EUPHYTICA, V188, P35, DOI 10.1007/s10681-012-0669-1; Kushiro T, 2004, EMBO J, V23, P1647, DOI 10.1038/sj.emboj.7600121; WALKERSIMMONS M, 1987, PLANT PHYSIOL, V84, P61, DOI 10.1104/pp.84.1.61; Hori K, 2010, THEOR APPL GENET, V120, P1547, DOI 10.1007/s00122-010-1275-z; Millar AA, 2006, PLANT J, V45, P942, DOI 10.1111/j.1365-313X.2006.02659.x; Appleford NEJ, 2007, J EXP BOT, V58, P3213, DOI 10.1093/jxb/erm166; Fang J, 2008, PLANT J, V54, P177, DOI 10.1111/j.1365-313X.2008.03411.x; KARSSEN CM, 1983, PLANTA, V157, P158, DOI 10.1007/BF00393650; Sears RG, 1997, CROP SCI, V37, P1010; MORRIS CF, 1991, PLANT PHYSIOL, V95, P814, DOI 10.1104/pp.95.3.814; Yoshimoto K, 2009, PLANT CELL, V21, P2914, DOI 10.1105/tpc.109.068635; Barrero JM, 2009, PLANT PHYSIOL, V150, P1006, DOI 10.1104/pp.109.137901; Appleford NEJ, 2006, PLANTA, V223, P568, DOI 10.1007/s00425-005-0104-0; Benech-Arnold RL, 1999, SEED SCI RES, V9, P39; BEWLEY J. D., 2013, SEEDS PHYSL DEV GERM; Black M, 1994, SEEDS PHYSL DEV GERM; Campbell K.G., 2013, J PLANT REGIST, V7, P81; Carter AH, 2014, J PLANT REGIST, V8, P273, DOI 10.3198/jpr2013.12.0074crc; Cereal Variety Testing, 2013, W WASHINGTON VARIETY; Debeaujon I., 2007, SEED DEV DORMANCY GE, V27, P25; DePauw RM, 2012, EUPHYTICA, V188, P7, DOI 10.1007/s10681-011-0611-y; MIYAMOTO TAKAO, 1958, AGRON JOUR, V50, P733; Gerjets T, 2010, J EXP BOT, V61, P597, DOI 10.1093/jxb/erp329; HEYNE E. G., 1959, Agronomy Journal, V51, P689; Jacobsen J. V., 1987, Plant hormones and their role in plant growth and development, P164; Jones SS, 2001, CROP SCI, V41, P2006; Jones SS, 2010, J PLANT REGIST, V4, P137, DOI 10.3198/jpr2009.06.0306crc; Karssen C. M., 1986, Plant growth substances 1985. Proceedings of the 12th international conference on plant growth substances., P315; Kawakami N, 1997, J EXP BOT, V48, P1415, DOI 10.1093/jxb/48.7.1415; King RW, 2000, EUPHYTICA, V112, P157, DOI 10.1023/A:1003832031695; Li C.D., 2004, J FUNCTIONAL INTEGRA, V4, P84; Liu AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056570; MCCAIG TN, 1992, CROP SCI, V32, P19; McMaster G. J., 1976, Cereal Research Communications, V4, P251; MORRIS CF, 1989, PLANT PHYSIOL, V90, P643, DOI 10.1104/pp.90.2.643; MORRIS CF, 1989, CROP SCI, V29, P246; NODA K, 1994, PLANT BREEDING, V113, P53, DOI 10.1111/j.1439-0523.1994.tb00701.x; Nyachiro JM, 2002, EUPHYTICA, V126, P123, DOI 10.1023/A:1019694800066; RADLEY M, 1967, PLANTA, V75, P164, DOI 10.1007/BF00387132; Ringlund K., 1992, PREHARVEST SPROUTING, P3; Rodriguez M.V., 2015, SEED SCI RE IN PRESS; Rodriguez V.M., 2001, AGRON J, V93, P1071; Schramm EC, 2010, PLANT SCI, V179, P620, DOI 10.1016/j.plantsci.2010.06.004; Syngenta, 2011, SY OV NEW SOFT WHIT; WAHL TI, 1993, PRE-HARVEST SPROUTING IN CEREALS 1992, P10; WestBred, 2014, WEB ARR HARD RED WIN; Wilkinson MD, 2002, EUPHYTICA, V126, P27, DOI 10.1023/A:1019627807335; Zemetra RS, 2003, CROP SCI, V43, P1884	73	0	0	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	0960-2585	1475-2735		SEED SCI RES	Seed Sci. Res.	JUN	2015	25	2			SI		179	193		10.1017/S0960258515000057		15	Plant Sciences	Plant Sciences	CK0SE	WOS:000355914400011		
J	Kondo, T; Narita, M; Phartyal, SS; Hidayati, SN; Walck, JL; Baskin, JM; Baskin, CC				Kondo, Tetsuya; Narita, Mizuki; Phartyal, Shyam S.; Hidayati, Siti N.; Walck, Jeffrey L.; Baskin, Jerry M.; Baskin, Carol C.			Morphophysiological dormancy in seeds of Convallaria keiskei and a proposal to recognize two types of double dormancy in seed dormancy classification	SEED SCIENCE RESEARCH			English	Article						Convallaria keiskei; deep simple double morphophysiological dormancy; double dormancy; embryo growth; epigeal germination; hypogeal germination; Trillium camschatcense	LIFE-HISTORY MONOGRAPHS; JAPANESE PLANTS; GERMINATION; TRILLIACEAE; BREAKING	Convallaria majalis has double dormancy and hypogeal germination, but no information is available on embryo growth or on the effects of light and gibberellic acid (GA(3)) on germination in this genus. Therefore, we investigated embryo growth and other germination features in seeds of Convallaria keiskei and compared the data with those of Trillium camschatcense in another study. Until now, in seeds with double dormancy, embryo growth and germination (epigeal) have been studied in detail only for seeds of Trillium camschatcense. Phenology of embryo growth and emergence of cotyledonary petiole/root (hereafter root) and shoot in seeds of Convallaria keiskei were monitored outdoors. Effects of temperature, light and GA(3) on embryo growth and root and shoot emergence were tested under laboratory conditions. Roots emerged the first spring following seed dispersal in autumn. The embryo grew soon after root emergence, and germination was hypogeal. Seeds with an emerged root formed buds from which a shoot (leaf) emerged above ground during the second spring. Alternating temperatures and light had negative effects on root emergence, and GA(3) did not substitute for cold stratification in root emergence. Seeds of Convallaria keiskei have double dormancy, but it differs from that in Trillium camschatcense. Based on differences in embryo growth before (Trillium camschatcense) versus after (Convallaria keiskei) root emergence, and on epigeal (Trillium camschatcense) versus hypogeal (Convallaria keiskei) germination, we suggest that two types of deep simple double morphophysiological dormancy (MPD) be recognized. Since embryo growth in Convallaria keiskei does not fit the standard definition of MPD, we propose to expand this definition.	[Kondo, Tetsuya; Narita, Mizuki] Hokkaido Univ, Grad Sch Agr, Sapporo, Hokkaido 0608589, Japan; [Phartyal, Shyam S.] HNB Garhwal Cent Univ, Dept Forestry & Nat Resources, Srinagar 246174, Garhwal, India; [Hidayati, Siti N.; Walck, Jeffrey L.] Middle Tennessee State Univ, Dept Biol, Evolut & Ecol Grp, Murfreesboro, TN 37132 USA; [Baskin, Jerry M.; Baskin, Carol C.] Univ Kentucky, Dept Biol, Lexington, KY 40506 USA; [Baskin, Carol C.] Univ Kentucky, Dept Plant & Soil Sci, Lexington, KY 40546 USA	Kondo, T (reprint author), Hokkaido Univ, Grad Sch Agr, Sapporo, Hokkaido 0608589, Japan.	kondo@res.agr.hokudai.ac.jp			JSPS (Japan Society for the Promotion of Science) KAKENHI [23580028]	This work was supported by JSPS (Japan Society for the Promotion of Science) KAKENHI Grant Number 23580028.	KAUL RB, 1978, AQUAT BOT, V5, P139, DOI 10.1016/0304-3770(78)90057-8; Suzuki K, 2010, PLANT SPEC BIOL, V25, P231, DOI 10.1111/j.1442-1984.2010.00295.x; Ohara M, 2006, PLANT SPEC BIOL, V21, P119, DOI 10.1111/j.1442-1984.2006.00157.x; Kondo T, 2011, AM J BOT, V98, P215, DOI 10.3732/ajb.1000151; Takagi H, 2001, J JPN SOC HORTIC SCI, V70, P416; WHIGHAM D, 1974, AM MIDL NAT, V91, P343, DOI 10.2307/2424326; Ohara M, 2005, PLANT SPEC BIOL, V20, P75, DOI 10.1111/j.1442-1984.2005.00126.x; Takagi H, 2001, J JPN SOC HORTIC SCI, V70, P424; Baskin CC, 2009, INT J PLANT SCI, V170, P174, DOI 10.1086/595283; Barton L. V., 1942, CONTRIBUTIONS BOYCE, V12, P277; Barton Lela V., 1944, CONTR BOYCE THOMPSON INST, V13, P259; Baskin CC, 2014, SEEDS: ECOLOGY, BIOGEOGRAPHY, AND EVOLUTION OF DORMANCY AND GERMINATION, 2ND EDITION, P1; Bewley J. D., 1994, SEEDS PHYSL DEV GERM; Boyd L, 1932, T P BOT SOC EDINBURG, V31, P1; Chien CT, 2011, ANN BOT-LONDON, V108, P13, DOI 10.1093/aob/mcr096; Gyer J. F, 1997, COMB P INT PLANT PRO, V47, P499; Japan Meteorological Agency, 2011, CLIM STAT NORM 1981; Kondo T., 2002, J JAPANESE SOC REVEG, V28, P330; MacDougal D. T, 1901, TORREYA, V1, P2; Ohwi J, 1983, NEW FLORA OF JAPAN; Pickett F.L., 1913, P INDIANA ACAD SCI, V1913, P125; PLATT RB, 1951, ECOL MONOGR, V21, P269, DOI 10.2307/1948652; Rennert R. J., 1902, B TORREY BOT CLUB, V29, P37, DOI 10.2307/2478848; Tillich H.-J, 1995, MONOCOTYLEDONS SYSTE, P303; Tillich HJ, 2007, ANN BOT-LONDON, V100, P1413, DOI 10.1093/aob/mcm238	25	1	1	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	0960-2585	1475-2735		SEED SCI RES	Seed Sci. Res.	JUN	2015	25	2			SI		210	220		10.1017/S0960258515000136		11	Plant Sciences	Plant Sciences	CK0SE	WOS:000355914400014		
J	Satoh, K; Wagatsuma, K				Satoh, Kozue; Wagatsuma, Kazuaki			Comparative study on contribution of charge-transfer collision to excitations of iron ion between argon radio-frequency inductively-coupled plasma and nitrogen microwave induced plasma	SPECTROCHIMICA ACTA PART B-ATOMIC SPECTROSCOPY			English	Article						Microwave induced plasma; Okamoto-cavity; Boltzmann plot; Excitation mechanism; Iron ionic line	ATOMIC-EMISSION-SPECTROMETRY; GLOW-DISCHARGE PLASMAS; OXYGEN MIXED-GAS; ATMOSPHERIC-PRESSURE; OKAMOTO-CAVITY; ANALYTICAL PERFORMANCE; BOLTZMANN DISTRIBUTION; HELIUM; LINES; TEMPERATURE	This paper describes an ionization/excitation phenomenon of singly-ionized iron occurring in an Okamoto-cavity microwave induced plasma (MIP) as well as an argon radio-frequency inductively-coupled plasma (ICP), by comparing the Boltzmann distribution among iron ionic lines (Fe II) having a wide range of the excitation energy from 4.76 to 9.01 eV. It indicated in both the plasmas that plots of Fe II lines having lower excitation energies (4.76 to 5.88 eV) were fitted on each linear relationship, implying that their excitations were caused by a dominant thermal process such as collision with energetic electron. However, Fe II lines having higher excitation energies (more than 7.55 eV) had a different behavior from each other. In the ICP, Boltzmann plots of Fe II lines assigned to the higher excited levels also followed the normal Boltzmann relationship among the low-lying excited levels, even including a deviation from it in particular excited levels having an excitation energy of ca. 7.8 eV. This deviation can be attributed to a charge-transfer collision with argon ion, which results in the overpopulation of these excited levels, but the contribution is small. On the other hand, the distribution of the high-lying excited levels was non-thermal in the Okamoto-cavity MIP, which did not follow the normal Boltzmann relationship among the low-lying excited levels. A probable reason for the non-thermal characteristics in the MIP is that a charge-transfer collision with nitrogen molecule ion having many vibrational/rotational levels could work for populating the 3d(6)4p (3d(5)4s4p) excited levels of iron ion broadly over an energy range of 7.6-9.0 eV, while collisional excitation by energetic electron would occur insufficiently to excite these high-energy levels. (C) 2015 Elsevier B.V. All rights reserved.	[Satoh, Kozue; Wagatsuma, Kazuaki] Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan	Wagatsuma, K (reprint author), Tohoku Univ, Inst Mat Res, Katahira 2-1-1, Sendai, Miyagi 9808577, Japan.	wagatuma@imr.tohoku.ac.jp	Wagatsuma, Kazuaki/B-3079-2012		Ministry of Education, Science, Sports and Culture of Japan [26281044]	This work was performed with advice of Professor Y. Okamoto under the Inter-University Cooperative Research Program of the Institute for Materials Research, Tohoku University. The spectrometer system was modified under the support of a Grant-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan (No. 26281044).	GOLDWASSER A, 1986, SPECTROCHIM ACTA B, V41, P725, DOI 10.1016/0584-8547(86)80087-8; OKAMOTO Y, 1991, ANAL SCI, V7, P283, DOI 10.2116/analsci.7.283; Ohata M, 1998, J ANAL ATOM SPECTROM, V13, P447, DOI 10.1039/a707117e; BEENAKKER CIM, 1976, SPECTROCHIM ACTA B, V31, P483, DOI 10.1016/0584-8547(76)80047-X; Arai Y, 2013, ISIJ INT, V53, P1993, DOI 10.2355/isijinternational.53.1993; Boumans P. W. J. M., 1986, THEORY SPECTROCHEMIC, P124; Broekaert J. A. C., 2001, ANAL ATOMIC SPECTROM, P234; CAUGHLIN BL, 1984, SPECTROCHIM ACTA B, V39, P1583, DOI 10.1016/0584-8547(84)80188-3; Chan GCY, 2004, SPECTROCHIM ACTA B, V59, P1007, DOI 10.1016/j.sab.2004.05.008; Duffendack OS, 1929, PHYS REV, V34, P35, DOI 10.1103/PhysRev.34.35; Farnsworth PB, 1999, SPECTROCHIM ACTA B, V54, P2143, DOI 10.1016/S0584-8547(99)00151-2; Fuhr J. R., 1988, J PHYS CHEM DATA, V17, P13; FURUTA N, 1982, SPECTROCHIM ACTA B, V37, P53, DOI 10.1016/0584-8547(82)80008-6; Gaydon A. G., 1968, DISSOCIATION ENERGIE, V3rd; Herzberg G., 1945, ATOMIC SPECTRA ATOMI, P229; HUBERT J, 1979, SPECTROCHIM ACTA B, V34, P1, DOI 10.1016/0584-8547(79)80016-6; Kanehisa G, 2007, TETSU TO HAGANE, V93, P121; KITAGAWA K, 1992, J ANAL ATOM SPECTROM, V7, P1207, DOI 10.1039/ja9920701207; KORNBLUM GR, 1982, SPECTROCHIM ACTA B, V37, P83, DOI 10.1016/0584-8547(82)80012-8; Maeda T, 2004, MICROCHEM J, V76, P53, DOI 10.1016/j.microc.2003.11.010; Maeda T, 2005, SPECTROCHIM ACTA B, V60, P81, DOI 10.1016/j.sab.2004.10.011; Ogura K, 1997, APPL SPECTROSC, V51, P1496, DOI 10.1366/0003702971938984; OKAMOTO Y, 1990, JPN J APPL PHYS 2, V29, pL670, DOI 10.1143/JJAP.29.L670; Pearse R. W. B., 1976, IDENTIFICATION MOL S; RAAIJMAKERS IJMM, 1983, SPECTROCHIM ACTA B, V38, P697, DOI 10.1016/0584-8547(83)80170-0; Sagar J., 1985, J PHYS CHEM REF DATA, V14, P407; Sato S, 2014, ANAL SCI, V30, P237; SCHRAM DC, 1983, SPECTROCHIM ACTA B, V38, P1545, DOI 10.1016/0584-8547(83)80015-9; STEERS EBM, 1993, J ANAL ATOM SPECTROM, V8, P309, DOI 10.1039/ja9930800309; STEERS EBM, 1987, J ANAL ATOM SPECTROM, V2, P239, DOI 10.1039/ja9870200239; UCHIDA H, 1981, SPECTROCHIM ACTA B, V36, P711, DOI 10.1016/0584-8547(81)80122-X; Von Engel A, 1965, IONIZED GASES; Wagatsuma K, 2009, ISIJ INT, V49, P1184; WAGATSUMA K, 1987, SPECTROCHIM ACTA B, V42, P523, DOI 10.1016/0584-8547(87)80031-9; Wagatsuma K, 2009, ANAL BIOANAL CHEM, V393, P2067, DOI 10.1007/s00216-009-2700-5; WAGATSUMA K, 1988, ANAL CHEM, V60, P702, DOI 10.1021/ac00158a022; Wagatsuma K, 2005, SPECTROCHIM ACTA B, V60, P1538, DOI 10.1016/j.sab.2005.10.004; WAGATSUMA K, 1991, SPECTROCHIM ACTA B, V46, P269, DOI 10.1016/0584-8547(91)80028-2; Wagatsuma K, 2005, APPL SPECTROSC REV, V40, P229, DOI 10.1081/ASR-200054372; Yamada H, 2001, APPL SPECTROSC, V55, P114, DOI 10.1366/0003702011951623; Zhang L, 2012, SPECTROCHIM ACTA B, V67, P24, DOI 10.1016/j.sab.2011.12.005; Zhang L, 2011, SPECTROCHIM ACTA B, V66, P785, DOI 10.1016/j.sab.2011.10.002; Zhang ZN, 2002, J ANAL ATOM SPECTROM, V17, P699, DOI 10.1039/b202777c	43	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0584-8547			SPECTROCHIM ACTA B	Spectroc. Acta Pt. B-Atom. Spectr.	JUN 1	2015	108						21	27		10.1016/j.sab.2015.03.015		7	Spectroscopy	Spectroscopy	CJ3CG	WOS:000355360400004		
J	Komiyama, KM; Guo, BY; Zughbi, H; Zulli, P; Yu, AB				Komiyama, Keisuke Matthew; Guo, Bao-Yu; Zughbi, Habib; Zulli, Paul; Yu, Ai-Bing			Numerical Analysis of Titanium Compounds in Blast Furnace Hearth During Titania Addition	STEEL RESEARCH INTERNATIONAL			English	Article						thermodynamics; iron making; phase change; refractory; erosion	HEAT-TRANSFER; FLOW; CAMPAIGN; METAL; MODEL	The longevity of an iron making blast furnace is largely limited by the erosion of hearth refractory. The addition of titanium (Ti)-bearing materials into the furnace may promote so-called Ti-rich scaffolds along the damaged hearth lining. A Computational Fluid Dynamics model is used to investigate the complex transport phenomena associated with the formation and dissolution of solid particles. Based on the modeling results, the isotherm of the equilibrium temperature of the incoming hot metal solution can be used as an indicator for the extent and phase of Ti compounds. It is proposed that the particles can be managed by controlling the location of this isotherm. This can be conducted by either (a) altering the Ti dosage and concentration or (b) altering the hot metal pool temperature. The effects of these parameters on the solids holdup along the hearth refractory linings are investigated. The equilibrium isotherm concept may provide a more suitable way to control the location of Ti-based particles for furnace operators.	[Komiyama, Keisuke Matthew; Guo, Bao-Yu] Univ New S Wales, Sch Mat Sci & Engn, Lab Simulat & Modelling Particulate Syst, Sydney, NSW 2052, Australia; [Guo, Bao-Yu; Yu, Ai-Bing] Monash Univ, Dept Chem Engn, Clayton, Vic 3800, Australia; [Zughbi, Habib; Zulli, Paul] BlueScope, Port Kembla, NSW 2505, Australia	Komiyama, KM (reprint author), Sumitomo Heavy Ind Ltd, Technol Res Ctr, 19 Natsushima Cho, Yokosuka, Kanagawa 2378555, Japan.	baoyu@unsw.edu.au	Yu, Aibing/A-6054-2008	Yu, Aibing/0000-0002-5139-0657	BlueScope; Australian Research Council; National Computational Merit Allocation Scheme	This work is supported by BlueScope and the Australian Research Council. Computational resources are supported through the National Computational Merit Allocation Scheme.	Panjkovic V, 2002, IRONMAK STEELMAK, V29, P390, DOI 10.1179/030192302225005187; NARITA K, 1977, T IRON STEEL I JPN, V17, P459; Silva SN, 2005, IRONMAK STEELMAK, V32, P459, DOI 10.1179/174328105X48160; Guo BY, 2008, ISIJ INT, V48, P1676; ANSYS Inc, 2010, ANSYS CFX REL 13 0 H; Bergsma D, 2001, IRONM CONF PROC, V60, P297; Eto B., 1957, TETSU TO HAGANE, V43, P211; Guo BY, 2010, METALL MATER TRANS B, V41, P876, DOI 10.1007/s11663-010-9384-2; Hisada K., 1964, TETSU TO HAGANE, V50, P1616; Jomoto Y., 1965, TETSU TO HAGANE, V51, P1713; Komiyama KM, 2014, METALL MATER TRANS B, V45, P1895, DOI 10.1007/s11663-014-0099-7; Korthas B., 2007, TECHNICAL STEEL RES; Kurunov IF, 2007, METALLURGIST+, V51, P7, DOI 10.1007/s11015-007-0002-8; Kurunov IF, 2006, METALLURGIST+, V50, P605, DOI 10.1007/s11015-006-0131-5; Li Y, 2001, ISIJ INT, V41, P1417, DOI 10.2355/isijinternational.41.1417	15	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1611-3683	1869-344X		STEEL RES INT	Steel Res. Int.	JUN	2015	86	6			SI		592	603		10.1002/srin.201400305		12	Metallurgy & Metallurgical Engineering	Metallurgy & Metallurgical Engineering	CJ6UK	WOS:000355629500001		
J	Yang, J; Cui, YR; Wang, L; Sasaki, Y; Zhang, JQ; Ostrovski, O; Kashiwaya, Y				Yang, Jian; Cui, Yaru; Wang, Lin; Sasaki, Yasushi; Zhang, Jianqiang; Ostrovski, Oleg; Kashiwaya, Yoshiaki			In-Situ Study of Crystallization Behavior of a Mold Flux Using Single and Double Hot Thermocouple Technique	STEEL RESEARCH INTERNATIONAL			English	Article						crystallization; mold flux; hot thermocouple technique; TTT diagram; CCT diagram	RADIATIVE HEAT-TRANSFER; CASTING MOLD; SLAG; STEEL; SOLIDIFICATION; SURFACE	In this study, crystallization behavior of an industrial mold flux was investigated using both single hot thermocouple technique (SHTT) and double hot thermocouple technique (DHTT). Continuous cooling transformation (CCT) and time-temperature transformation (TTT) diagrams were constructed using SHTT. The critical cooling rate in continuous cooling process was determined as 7 degrees Cs-1 above which a glassy phase was formed. The TTT diagram showed two noses at approximately 1000 and 1075 degrees C. Phase identification carried out using X-ray diffraction (XRD) revealed that dicalcium silicate (Ca2SiO4) was the major phase at both 950 and 1100 degrees C, together with minor precipitates of Na2CaSi3O8 and Ca2MgSi2O7 whose concentrations were relatively higher at 950 degrees C. Cuspidine (Ca4Si2O7F2) was also identified by XRD at 950 degrees C. Crystallization kinetics was analyzed using Johnson-Mehl-Avrami-Kolmogorov equation. DHTT was used to simulate the temperature gradient between copper mold and strand in the continuous casting mold. Glassy phase was formed quickly near the cold side when it was quenched from 1500 to 800 degrees C. Crystals started to precipitate in the glassy region after 48s. Then major part of the glassy region was gradually transformed to crystalline phase and the crystals subsequently grew to the liquid region. A steady three-layer state was reached after 360s.	[Yang, Jian; Cui, Yaru; Wang, Lin; Sasaki, Yasushi; Zhang, Jianqiang; Ostrovski, Oleg] Univ New S Wales, Sch Mat Sci & Engn, Sydney, NSW 2052, Australia; [Cui, Yaru] Xian Univ Architecture & Technol, Sch Met Engn, Xian 710055, Peoples R China; [Kashiwaya, Yoshiaki] Kyoto Univ, Dept Energy Sci & Technol, Sakyo Ku, Kyoto 6068501, Japan	Zhang, JQ (reprint author), Univ New S Wales, Sch Mat Sci & Engn, Sydney, NSW 2052, Australia.	j.q.zhang@unsw.edu.au			Baosteel through the Baosteel-Australia Joint Research Centre; Abel Metal Services; Australian Research Council (ARC) [LP130100773]	This project was financially supported by Baosteel through the Baosteel-Australia Joint Research Centre, Abel Metal Services, and Australian Research Council (ARC Linkage Project LP130100773). Technical support from Dr. Chen Zhang and Mr. Dexiang Cai at Baosteel Research Institute (R&D Centre) is highly appreciated.	Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Mills KC, 2003, ISIJ INT, V43, P1479, DOI 10.2355/isijinternational.43.1479; Ryu HG, 2010, ISIJ INT, V50, P1142, DOI 10.2355/isijinternational.50.1142; Zhou LJ, 2012, METALL MATER TRANS B, V43, P925, DOI 10.1007/s11663-012-9669-8; Kashiwaya Y, 1998, ISIJ INT, V38, P357, DOI 10.2355/isijinternational.38.357; Meng YA, 2003, METALL MATER TRANS B, V34, P707, DOI 10.1007/s11663-003-0041-x; Zhou LJ, 2012, METALL MATER TRANS B, V43, P354, DOI 10.1007/s11663-011-9591-5; Wang WL, 2011, ISIJ INT, V51, P1838; Ozawa S, 2006, ISIJ INT, V46, P413, DOI 10.2355/isijinternational.46.413; Kashiwaya Y, 1998, ISIJ INT, V38, P348, DOI 10.2355/isijinternational.38.348; Li J, 2012, ISIJ INT, V52, P2220, DOI 10.2355/isijinternational.52.2220; Tsutsumi K, 1999, ISIJ INT, V39, P1150, DOI 10.2355/isijinternational.39.1150; Nakada H, 2006, ISIJ INT, V46, P441, DOI 10.2355/isijinternational.46.441; Zhou LJ, 2013, METALL MATER TRANS B, V44, P1264, DOI 10.1007/s11663-013-9864-2; Wang WL, 2010, MET MATER INT, V16, P913, DOI 10.1007/s12540-010-1209-y; Wang WL, 2005, ISIJ INT, V45, P1864, DOI 10.2355/isijinternational.45.1864; Bothma JA, 2007, IRONMAK STEELMAK, V34, P513, DOI [10.1179/174328107X203912, 10.1179/174328207X203922]; Cho JW, 2001, J NON-CRYST SOLIDS, V282, P110, DOI 10.1016/S0022-3093(01)00333-7; He SP, 2009, INT J MIN MET MATER, V16, P261; Kawamoto M, 1997, ISIJ INT, V37, P134, DOI 10.2355/isijinternational.37.134; Orrling C., 2000, IRON STEELMAKER, V20, P53; Porter D. A., 1992, PHASE TRANSFORMATION; Nakamori T, 1996, ISIJ INT, V36, P179, DOI 10.2355/isijinternational.36.179; Wang W, 2010, STEEL RES INT, V81, P446, DOI 10.1002/srin.201000009; YAMAUCHI A, 1993, ISIJ INT, V33, P140, DOI 10.2355/isijinternational.33.140; Zhang ZT, 2011, J IRON STEEL RES INT, V18, P31, DOI 10.1016/S1006-706X(11)60061-7	26	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1611-3683	1869-344X		STEEL RES INT	Steel Res. Int.	JUN	2015	86	6			SI		636	643		10.1002/srin.201400346		8	Metallurgy & Metallurgical Engineering	Metallurgy & Metallurgical Engineering	CJ6UK	WOS:000355629500006		
J	Nobel-Jorgensen, M; Aage, N; Christiansen, AN; Igarashi, T; B'rentzen, JA; Sigmund, O				Nobel-Jorgensen, Morten; Aage, Niels; Christiansen, Asger Nyman; Igarashi, Takeo; B'rentzen, J. Andreas; Sigmund, Ole			3D interactive topology optimization on hand-held devices	STRUCTURAL AND MULTIDISCIPLINARY OPTIMIZATION			English	Article						Interactive; Topology optimization; Smartphones; Tablets		This educational paper describes the implementation aspects, user interface design considerations and work-flow potential of the recently published TopOpt 3D App. The app solves the standard minimum compliance problem in 3D and allows the user to change design settings interactively at any point in time during the optimization. Apart from its educational nature, the app may point towards future ways of performing industrial design. Instead of the usual geometrize, then model and optimize approach, the geometry now automatically adapts to the varying boundary and loading conditions. The app is freely available for iOS at Apple's App Store and at http://www.topopt.dtu.dk/TopOpt3D for Windows and OSX.	[Nobel-Jorgensen, Morten; Christiansen, Asger Nyman; B'rentzen, J. Andreas] Tech Univ Denmark, Dept Appl Math & Comp Sci, DK-2800 Lyngby, Denmark; [Igarashi, Takeo] Univ Tokyo, Dept Comp Sci, Bunkyo Ku, Tokyo, Japan; [Aage, Niels; Sigmund, Ole] Tech Univ Denmark, Dept Mech Engn, Solid Mech, DK-2800 Lyngby, Denmark	Nobel-Jorgensen, M (reprint author), Tech Univ Denmark, Dept Appl Math & Comp Sci, Asmussens Alle,B-305, DK-2800 Lyngby, Denmark.	mono@dtu.dk		Aage, Niels/0000-0002-3042-0036	Villum foundation	The authors gratefully acknowledge the support from the Villum foundation through the NextTop project. The authors would also like to extend their gratitude to the members of the DTU-TopOpt group for their invaluable input on the design and testing of the TopOpt 3D App.	Aage N, 2013, STRUCT MULTIDISCIP O, V47, P1, DOI 10.1007/s00158-012-0827-z; Aage N, 2015, STRUCT MULTIDISCIP O, V51, P565, DOI 10.1007/s00158-014-1157-0; Amir O, 2014, STRUCT MULTIDISCIP O, V49, P815, DOI 10.1007/s00158-013-1015-5; BENDSOE MP, 1988, COMPUT METHOD APPL M, V71, P197, DOI 10.1016/0045-7825(88)90086-2; Sigmund O, 2001, STRUCT MULTIDISCIP O, V21, P120; BendsOe M. P., 2003, TOPOLOGY OPTIMIZATIO; Bowman D., 2004, 3D USER INTERFACES T; Davis T, 2014, SUITE SPARSE SUITE S; Dyn N, 2001, INNOV APPL MATH, P135; Khan A, 2008, I3D 2008: SYMPOSIUM ON INTERACTIVE 3D GRAPHICS AND GAMES, PROCEEDINGS, P17; Lorensen W. E., 1987, COMPUT GRAPH, V21, P163, DOI DOI 10.1145/37402.37422; Sigmund O, 2013, STRUCT MULTIDISCIP O, V48, P1031, DOI 10.1007/s00158-013-0978-6; Miller R.B., 1968, P AFIPS FALL JOINT C, P267; Nguyen TH, 2010, STRUCT MULTIDISCIP O, V41, P525, DOI 10.1007/s00158-009-0443-8; Nielsen J., 1994, USABILITY ENG; Nielsen Jacob, 1993, USABILITY ENG; Rooney B, 2011, WALL STREET J IPAD 2; Tcherniak D, 2001, STRUCT MULTIDISCIP O, V22, P179; Tognazzini B, 2014, 1 PRINCIPLES INTERAC	19	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1615-147X	1615-1488		STRUCT MULTIDISCIP O	Struct. Multidiscip. Optim.	JUN	2015	51	6					1385	1391		10.1007/s00158-014-1214-8		7	Computer Science, Interdisciplinary Applications; Engineering, Multidisciplinary; Mechanics	Computer Science; Engineering; Mechanics	CJ8NY	WOS:000355761000013		
J	Taniguchi, M; Shimamura, T; Todo, S; Furukawa, H				Taniguchi, Masahiko; Shimamura, Tsuyoshi; Todo, Satoru; Furukawa, Hiroyuki			Small-for-size syndrome in living-donor liver transplantation using a left lobe graft	SURGERY TODAY			English	Review						Small-for-size syndrome; Living-donor liver transplantation; Left lobe graft	INTRAGRAFT GENE-EXPRESSION; SINGLE-CENTER EXPERIENCE; PORTAL-HYPERTENSION; PORTACAVAL-SHUNT; INFLOW MODULATION; WEIGHT RATIO; VEIN RECONSTRUCTION; BUFFER RESPONSE; RISK-FACTORS; HEPATITIS-C	In living-donor liver transplantation with a left lobe graft, which can reduce the burden on the donor compared to right lobe graft, the main problem is small-for-size (SFS) syndrome. SFS syndrome is a multifactorial disease that includes aspects related to the graft size, graft quality, recipient factors and even technical issues. The main pathophysiology of SFS syndrome is the sinusoidal microcirculatory disturbance induced by shear stress, which is caused by excessive portal inflow into the smaller graft. The donor age, the presence of steatosis of the graft and a poor recipient status are all risk factors for SFS syndrome. To resolve SFS syndrome, portal inflow modulation, splenectomy, splenic artery modulation and outflow modulation have been developed. It is important to establish strict criteria for managing SFS syndrome. Using pharmacological interventions and/or therapeutic approaches that promote liver regeneration could increase the adequate outcomes in SFS liver transplantation. Left lobe liver transplantation could be adopted in Western countries to help resolve the organ shortage.	[Taniguchi, Masahiko; Furukawa, Hiroyuki] Asahikawa Med Coll, Dept Surg, Div Gastroenterol & Gen Surg, Asahikawa, Hokkaido 0788510, Japan; [Shimamura, Tsuyoshi] Hokkaido Univ Hosp, Div Organ Transplantat, Sapporo, Hokkaido 060, Japan; [Todo, Satoru] St Marys Hosp, Res Inst, Kurume, Fukuoka, Japan	Taniguchi, M (reprint author), Asahikawa Med Coll, Dept Surg, Div Gastroenterol & Gen Surg, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	tonny@isis.ocn.ne.jp					Troisi R, 2005, AM J TRANSPLANT, V5, P1397, DOI 10.1111/j.1600-6143.2005.00850.x; Ben-Haim M, 2001, LIVER TRANSPLANT, V7, P948, DOI 10.1053/jlts.2001.29033; Troisi RI, 2013, AM J TRANSPLANT, V13, P2472, DOI 10.1111/ajt.12362; Roll GR, 2013, LIVER TRANSPLANT, V19, P472, DOI 10.1002/lt.23608; Schoen JM, 2001, NITRIC OXIDE-BIOL CH, V5, P453, DOI 10.1006/niox.2001.0373; Yang ZF, 2004, J IMMUNOL, V173, P2507; Busquets J, 2001, TRANSPLANTATION, V71, P1765, DOI 10.1097/00007890-200106270-00011; Hayashi M, 1999, TRANSPLANT P, V31, P403, DOI 10.1016/S0041-1345(98)01679-0; Cheah YL, 2013, LIVER TRANSPLANT, V19, P499, DOI 10.1002/lt.23575; Man K, 2003, ANN SURG, V237, P256, DOI 10.1097/00000658-200302000-00015; Fishbein TM, 1997, TRANSPLANTATION, V64, P248, DOI 10.1097/00007890-199707270-00012; Tian YH, 2011, HEPATOLOGY, V53, P253, DOI 10.1002/hep.23960; Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024; Spitzer AL, 2010, LIVER TRANSPLANT, V16, P874, DOI 10.1002/lt.22085; Smyrniotis V, 2002, TRANSPLANT INT, V15, P355, DOI 10.1007/s00147-002-0425-x; Hill MJ, 2009, LIVER TRANSPLANT, V15, P1056, DOI 10.1002/lt.21846; Umeda Y, 2008, TRANSPLANTATION, V86, P673, DOI 10.1097/TP.0b013e318181e02d; Humar A, 2009, LIVER TRANSPLANT, V15, P163, DOI 10.1002/lt.21636; Lake JR, 2005, AM J TRANSPLANT, V5, P549, DOI 10.1111/j.1600-6143.2005.00741.x; Selzner M, 2009, LIVER TRANSPLANT, V15, P1776, DOI 10.1002/lt.21955; Ferrero A, 2007, WORLD J SURG, V31, P1643, DOI 10.1007/s00268-007-9123-2; Morioka D, 2007, ANN SURG, V245, P315, DOI 10.1097/01.sla.0000236600.24667.a4; Gruttadauria S, 2007, CLIN TRANSPLANT, V21, P761, DOI 10.1111/j.1399-0012.2007.00735.x; Moon JI, 2010, LIVER TRANSPLANT, V16, P864, DOI 10.1002/lt.22094; Boillot O, 2002, LANCET, V359, P406, DOI 10.1016/S0140-6736(02)07593-1; Soejima Y, 2012, AM J TRANSPLANT, V12, P1877, DOI 10.1111/j.1600-6143.2012.04022.x; Schindl MJ, 2005, GUT, V54, P289, DOI 10.1136/gut.2004.046524; Yamada T, 2008, AM J TRANSPLANT, V8, P847, DOI 10.1111/j.1600-6143.2007.02144.x; Ishizaki Y, 2012, LIVER TRANSPLANT, V18, P305, DOI 10.1002/lt.22440; Li JJ, 2010, TRANSPL INT, V23, P924, DOI 10.1111/j.1432-2277.2010.01058.x; Kawasaki S, 1998, ANN SURG, V227, P269, DOI 10.1097/00000658-199802000-00017; Dahm F, 2005, AM J TRANSPLANT, V5, P2605, DOI 10.1111/j.1600-6143.2005.01081.x; Sainz-Barriga M, 2011, LIVER TRANSPLANT, V17, P836, DOI 10.1002/lt.22295; Urahashi T, 2012, EXP CLIN TRANSPLANT, V10, P350, DOI 10.6002/ect.2012.0075; Busuttil RW, 2003, LIVER TRANSPLANT, V9, P651, DOI 10.1053/jlts.2003.50105; Vauthey JN, 2000, SURGERY, V127, P512, DOI 10.1067/msy.2000.105294; Botha JF, 2010, LIVER TRANSPLANT, V16, P649, DOI 10.1002/lt.22043; Bogetti D, 2004, CLIN TRANSPLANT, V18, P222, DOI 10.1046/j.1399-0012.2003.00146.x; Boillot O, 2013, CLIN TRANSPLANT, V27, P571, DOI 10.1111/ctr.12162; Botha JF, 2009, LIVER TRANSPLANT, V15, P1671, DOI 10.1002/lt.21944; Chang TH, 2004, TRANSPLANTATION, V77, P22, DOI 10.1097/01.TP.0000089234.93366.6D; Cui YY, 2012, TRANSPLANTATION, V94, P687, DOI 10.1097/TP.0b013e3182633478; Demetris AJ, 2006, AM J SURG PATHOL, V30, P986, DOI 10.1097/00000478-200608000-00009; Glanemann M, 2005, EUR SURG RES, V37, P335, DOI 10.1159/000090333; Guo L, 2004, AM J TRANSPLANT, V4, P879, DOI 10.1111/j.1600-6143.2004.00444.x; Hessheimer AJ, 2011, ANN SURG, V253, P1201, DOI 10.1097/SLA.0b013e3181ffb2d7; Ikegami T, 2012, J AM COLL SURGEONS, V214, pE53, DOI 10.1016/j.jamcollsurg.2012.02.016; Ikegami T, 2008, TRANSPL P, V40, P1471, DOI 10.1016/j.transproceed.2008.02.084; Kaido T, 2011, TRANSPL P, V43, P2391, DOI 10.1016/j.transproceed.2011.05.037; Kelly DM, 2009, LIVER TRANSPLANT, V15, P1448, DOI 10.1002/lt.21863; Kishi Y, 2005, CLIN TRANSPLANT, V19, P769, DOI 10.1111/j.1399-0012.2005.00419.x; Konishi N, 2008, AM J TRANSPLANT, V8, P170, DOI 10.1111/j.1600-6143.2007.02037.x; LAUTT WW, 1985, AM J PHYSIOL, V248, pH331; Lei JY, 2012, HEPATO-GASTROENTEROL, V59, P1491, DOI 10.5754/hge11634; Li HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074081; Lo CM, 1996, TRANSPLANTATION, V62, P696, DOI 10.1097/00007890-199609150-00029; Makuuchi M, 2003, TRANSPLANTATION, V75, pS23, DOI 10.1097/01.TP.0000046617.21019.17; Man K, 2004, ANN SURG, V240, P159, DOI 10.1097/01.sla.0000129673.13552.e0; Man K, 2001, ARCH SURG-CHICAGO, V136, P280, DOI 10.1001/archsurg.136.3.280; Man K, 2003, LIVER TRANSPLANT, V9, P425, DOI 10.1053/jlts.2003.50066; Masetti M, 2004, AM J TRANSPLANT, V4, P1713, DOI 10.1111/j.1600-6143.2004.00548.x; Morioka D, 2003, LIVER TRANSPLANT, V9, P79, DOI 10.1053/jlts.2003.36845; Onoe T, 2013, TRANSPLANTATION, V95, P1521, DOI 10.1097/TP.0b013e31829150a4; Oura T, 2008, AM J TRANSPLANT, V8, P250, DOI 10.1111/j.1600-6143.2007.02045.x; Ozden I, 2007, EXP CLIN TRANSPLANT, V5, P686; Palmes D, 2003, LIVER TRANSPLANT, V9, P929, DOI 10.1053/jlts.2003.50191; Palmes D, 2005, VIRCHOWS ARCH, V447, P731, DOI 10.1007/s00428-005-0006-3; Ren YS, 2012, HEPATOB PANCREAT DIS, V11, P60, DOI 10.1016/S1499-3872(11)60126-4; Samimi F, 1998, DIGEST DIS SCI, V43, P1931, DOI 10.1023/A:1018822206580; Sato Y, 2010, TRANSPLANTATION, V90, P1200, DOI 10.1097/TP.0b013e3181fa93e0; Shimamura T, 2001, TRANSPLANT P, V33, P1331, DOI 10.1016/S0041-1345(00)02496-9; Soejima Y, 2003, TRANSPLANTATION, V76, P344, DOI 10.1097/01.TP.0000071205.52835.A4; Soejima Y, 2003, LIVER TRANSPLANT, V9, P581, DOI 10.1053/jlts.2003.50114; Soejima Y, 2006, AM J TRANSPLANT, V6, P1004, DOI 10.1111/j.1600-6143.2006.01284.x; Suehiro T, 2005, TRANSPLANTATION, V80, P964, DOI 10.1097/01.tp.0000173776.66867.f5; Sugawara Y, 2003, TRANSPLANTATION, V75, pS20, DOI 10.1097/01.TP.0000046616.76542.DF; Tang LM, 2007, TRANSPLANT INT, V20, P93, DOI 10.1111/j.1432-2277.2006.00394.x; Taniguchi M, 2007, LIVER TRANSPLANT, V13, P932, DOI 10.1002/lt.21080; Trotter JF, 2002, NEW ENGL J MED, V346, P1074, DOI 10.1056/NEJMra011629; WANG XD, 1994, EUR J SURG, V160, P153; WANG XD, 1993, EUR J SURG, V159, P343; Xiao L, 2012, LIVER TRANSPLANT, V18, P1118, DOI 10.1002/lt.23457; Xu MQ, 2004, WORLD J GASTROENTERO, V10, P573; Yagi S, 2012, EUR SURG RES, V48, P163, DOI 10.1159/000338622; Yagi S, 2011, J SURG RES, V167, pE375, DOI 10.1016/j.jss.2010.12.040; Yagi S, 2005, LIVER TRANSPLANT, V11, P68, DOI 10.1002/lt.20317; Yamanaka K, 2013, J SURG RES, V183, P391, DOI 10.1016/j.jss.2012.11.033; Yamauchi Y, 2010, HEPATO-GASTROENTEROL, V57, P813; Yang ZF, 2004, LIVER TRANSPLANT, V10, P784, DOI 10.1002/lt.20142; Yang ZF, 2004, AM J TRANSPLANT, V4, P196, DOI 10.1046/j.1600-6143.2003.00313.x; Yi NJ, 2009, LIVER TRANSPLANT, V15, P496, DOI 10.1002/lt.21606; Yoshida R, 2008, WORLD J SURG, V32, P2419, DOI 10.1007/s00268-008-9715-5; Yoshizumi T, 2008, TRANSPL INT, V21, P833, DOI 10.1111/j.1432-2277.2008.00678.x; Zhong Z, 2005, GASTROENTEROLOGY, V129, P652, DOI [10.1053/j.gastro.2005.05.060, 10.1016/j.gastro.2005.05.060]	94	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					663	671		10.1007/s00595-014-0945-x		9	Surgery	Surgery	CJ6KW	WOS:000355603700001		
J	Sawa, Y				Sawa, Yoshiki			Current status of third-generation implantable left ventricular assist devices in Japan, Duraheart and HeartWare	SURGERY TODAY			English	Review						Left ventricular assist device; Mechanical circulatory support; Bridge to transplantation	CARDIAC TRANSPLANTATION; CIRCULATORY SUPPORT; MYOCARDIAL RECOVERY; CENTRIFUGAL PUMP; BRIDGE; EXPERIENCE; SYSTEM; FAILURE; CHILDREN; DESTINATION	Recently, left ventricular assist devices (LVADs) have become a viable therapeutic approach as a bridge to cardiac transplantation, as well as destination therapy or as part of the bridge to recovery. In Japan, paracorporeal pneumatic devices are the only choice for such therapy, as implantable LVADs are not yet generally available due to device lag, which represents a serious problem in this field. Clinical trials of four different continuous-flow pumps, both axial and centrifugal flow types, were completed at about the same time, and two of those devices, DuraHeart and EVAHEART, have already been approved for use in Japan. Thus, reports of advanced treatment for severe heart failure with these devices are expected. The DuraHeart (Terumo Heart, Ann Arbor, MI, USA) and another device named the HeartWare (HeartWare Inc, Miami Lakes, FL, USA) are so-called third-generation devices, as they have achieved miniaturization and improvements in performance from the use of magnetic levitation. Based on our experiences from both clinical research and experimental use, we herein discuss the DuraHeart and HeartWare devices, with a focus on the clinical outcomes and management strategies. Because of the long waiting period for heart transplantation in Japan, these two devices are considered to have important roles in the near future for the treatment of severe heart failure, and a comprehensive strategy for LVAD therapy including such third-generation implantable devices is expected.	Osaka Univ, Grad Sch Med, Dept Cardiovasc Surg, Suita, Osaka 5650871, Japan	Sawa, Y (reprint author), Osaka Univ, Grad Sch Med, Dept Cardiovasc Surg, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	sawa@surg1.med.osaka-u.ac.jp					Cassidy J, 2013, J HEART LUNG TRANSPL, V32, P1101, DOI 10.1016/j.healun.2013.08.003; Kirklin JK, 2008, J HEART LUNG TRANSPL, V27, P1065, DOI 10.1016/j.healun.2008.07.021; Slaughter MS, 2013, J HEART LUNG TRANSPL, V32, P675, DOI 10.1016/j.healun.2013.04.004; Saito S, 2011, J HEART LUNG TRANSPL, V30, P475, DOI 10.1016/j.healun.2010.11.013; Strueber M, 2010, J THORAC CARDIOV SUR, V140, P936, DOI 10.1016/j.jtcvs.2010.04.007; Wieselthaler GM, 2010, J HEART LUNG TRANSPL, V29, P1218, DOI 10.1016/j.healun.2010.05.016; Eghtesady P, 2013, CIRCULATION, V128, pS24, DOI 10.1161/CIRCULATIONAHA.112.000446; Sakaguchi T, 2013, CIRC J, V77, P1736, DOI 10.1253/circj.CJ-12-1410; Nurozler F, 2001, ANN THORAC SURG, V71, P614, DOI 10.1016/S0003-4975(00)01444-2; Miera O, 2011, ANN THORAC SURG, V91, P1256, DOI 10.1016/j.athoracsur.2010.12.013; Yoshioka D, 2012, CIRC J, V76, P372, DOI 10.1253/circj.CJ-11-0833; Catanese KA, 1996, ANN THORAC SURG, V62, P646, DOI 10.1016/S0003-4975(96)00456-0; Craig Michael L, 2011, Curr Heart Fail Rep, V8, P65, DOI 10.1007/s11897-010-0043-3; FARRAR DJ, 1988, NEW ENGL J MED, V318, P333, DOI 10.1056/NEJM198802113180601; Hrobowski Tara, 2013, Curr Heart Fail Rep, V10, P101, DOI 10.1007/s11897-012-0123-7; Krabatsch T, 2011, CIRCULATION, V124, pS179, DOI 10.1161/CIRCULATIONAHA.110.011502; Loforte A, 2010, J HEART LUNG TRANSPL, V29, P1443, DOI 10.1016/j.healun.2010.07.012; Matsumiya G, 2009, CIRC J, V73, P1386; MCCARTHY PM, 1991, J THORAC CARDIOV SUR, V102, P578; MCCARTHY PM, 1994, CIRCULATION, V90, P83; Morita S, 2011, CIRC J, V75, P53, DOI 10.1253/circj.CJ-10-1143; Morshuis M, 2009, EUR J CARDIO-THORAC, V35, P1020, DOI 10.1016/j.ejcts.2008.12.033; Neragi-Miandoab S, 2012, SURG TODAY, V42, P917, DOI 10.1007/s00595-012-0256-z; Nishinaka T, 2006, CIRC J, V70, P1421, DOI 10.1253/circj.70.1421; Nojiir C, 2000, ASAIO J, V46, P117, DOI 10.1097/00002480-200001000-00027; PENNOCK JL, 1986, J THORAC CARDIOV SUR, V92, P994; PHILLIPS SJ, 1973, J THORAC CARDIOV SUR, V65, P471; PIERCE WS, 1974, ANN SURG, V180, P418, DOI 10.1097/00000658-197410000-00006; Saito S, 2012, J HEART LUNG TRANSPL, V31, P858, DOI 10.1016/j.healun.2012.03.002; Saito S, 2009, J ARTIF ORGANS, V12, P27, DOI 10.1007/s10047-009-0448-5; Stevenson LW, 2004, CIRCULATION, V110, P975, DOI 10.1161/01.CIR.0000139862.48167.23; Ueno T, 2012, CIRC J, V76, P752, DOI 10.1253/circj.CJ-11-1001; Wood C, 2008, J HEART LUNG TRANSPL, V27, P695, DOI 10.1016/j.healun.2008.03.007; Yamazaki Kenji, 2002, Jpn J Thorac Cardiovasc Surg, V50, P461, DOI 10.1007/BF02919636; Yoshitake I, 2009, ARTIF ORGANS, V33, P763, DOI 10.1111/j.1525-1594.2009.00902.x	35	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					672	681		10.1007/s00595-014-0957-6		10	Surgery	Surgery	CJ6KW	WOS:000355603700002		
J	Ariizumi, S; Yamamoto, M				Ariizumi, Shun-ichi; Yamamoto, Masakazu			Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis	SURGERY TODAY			English	Review						Intrahepatic cholangiocarcinoma; Cholangiolocellular carcinoma; Cirrhosis	B-VIRUS-INFECTION; COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA; PRIMARY LIVER-CANCER; C VIRUS; RISK-FACTORS; UNITED-STATES; SURGICAL OUTCOMES; CLINICOPATHOLOGICAL CHARACTERISTICS; EXTRAHEPATIC CHOLANGIOCARCINOMA; PERIPHERAL CHOLANGIOCARCINOMA	Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer. Cirrhosis and chronic viral hepatitis are known to be important risk factors for ICC, especially the mass-forming (MF) type of ICC at the periphery of the liver. Cholangiolocellular carcinoma (CoCC) is a rare type of primary liver cancer, which is thought to originate from hepatic progenitor or stem cells. CoCC often exhibits the similar MF type at the periphery of the liver, as ICC, and CoCC is also associated with cirrhosis or chronic viral hepatitis. Better survival rates after surgery have been reported for ICC patients with chronic viral hepatitis than for those without chronic viral hepatitis, although survival rates did not differ significantly in relation to cirrhosis. On the other hand, patients with CoCC had better surgical results than those with MF-type ICC. This review summarizes the clinical characteristics and surgical outcomes of ICC and CoCC associated with cirrhosis or chronic viral hepatitis.	[Ariizumi, Shun-ichi; Yamamoto, Masakazu] Tokyo Womens Med Univ, Dept Surg, Inst Gastroenterol, Shinjuku Ku, Tokyo 1620054, Japan	Ariizumi, S (reprint author), Tokyo Womens Med Univ, Dept Surg, Inst Gastroenterol, Shinjuku Ku, Kawada 8-1, Tokyo 1620054, Japan.	ariizumi@ige.twmu.ac.jp; yamamoto@ige.twmu.ac.jp					Aishima S, 2007, AM J SURG PATHOL, V31, P1059, DOI 10.1097/PAS.0b013e31802b34b6; Patel T, 2001, HEPATOLOGY, V33, P1353, DOI 10.1053/jhep.2001.25087; Lee TY, 2008, AM J GASTROENTEROL, V103, P1716, DOI 10.1111/j.1572-0241.2008.01796.x; TOMIMATSU M, 1993, CANCER, V72, P683, DOI 10.1002/1097-0142(19930801)72:3<683::AID-CNCR2820720310>3.0.CO;2-C; Theise ND, 2003, HISTOPATHOLOGY, V43, P263, DOI 10.1046/j.1365-2559.2003.01707.x; Nakanuma Y, 2012, AM J SURG PATHOL, V36, P1629, DOI 10.1097/PAS.0b013e31826e0249; Spear BT, 1999, SEMIN CANCER BIOL, V9, P109, DOI 10.1006/scbi.1998.0087; KLATSKIN G, 1965, AM J MED, V38, P241, DOI 10.1016/0002-9343(65)90178-6; Hai S, 2005, DIGEST SURG, V22, P432, DOI 10.1159/000091446; Okabayashi T, 2001, CANCER, V92, P2374, DOI 10.1002/1097-0142(20011101)92:9<2374::AID-CNCR1585>3.0.CO;2-L; Zhou HB, 2010, EUR J CANCER, V46, P1056, DOI 10.1016/j.ejca.2010.02.005; Lee CH, 2009, BRIT J CANCER, V100, P1765, DOI 10.1038/sj.bjc.6605063; Welzel TM, 2007, CLIN GASTROENTEROL H, V5, P1221, DOI 10.1016/j.cgh.2007.05-020; Nakagawa T, 2005, WORLD J SURG, V29, P728, DOI 10.1007/s00268-005-7761-9; Roskams TA, 2004, HEPATOLOGY, V39, P1739, DOI 10.1002/hep.20130; Komuta M, 2008, HEPATOLOGY, V47, P1544, DOI 10.1002/hep.22238; Patel T, 2011, NAT REV GASTRO HEPAT, V8, P189, DOI 10.1038/nrgastro.2011.20; Yamamoto S, 2004, CANCER SCI, V95, P592, DOI 10.1111/j.1349-7006.2004.tb02492.x; El-Serag HB, 2009, HEPATOLOGY, V49, P116, DOI 10.1002/hep.22606; Shimada K, 2009, SURGERY, V145, P411, DOI 10.1016/j.surg.2008.11.010; Kobayashi M, 2000, CANCER, V88, P2471, DOI 10.1002/1097-0142(20000601)88:11<2471::AID-CNCR7>3.0.CO;2-T; Palmer WC, 2012, J HEPATOL, V57, P69, DOI 10.1016/j.jhep.2012.02.022; Robles R, 2004, ANN SURG, V239, P265, DOI 10.1097/01.sla.0000108702.45715.81; Endo I, 2008, ANN SURG, V248, P84, DOI 10.1097/SLA.0b013e318176c4d3; Roskams T, 2010, CLIN LIVER DIS, V14, P705, DOI 10.1016/j.cld.2010.08.003; Welzel TM, 2011, HEPATOLOGY, V54, P463, DOI 10.1002/hep.24397; Donato F, 2001, CANCER CAUSE CONTROL, V12, P959, DOI 10.1023/A:1013747228572; Rimola J, 2009, HEPATOLOGY, V50, P791, DOI 10.1002/hep.23071; BROOME U, 1995, HEPATOLOGY, V22, P1404, DOI 10.1016/0270-9139(95)90144-2; Nathan H, 2009, ANN SURG ONCOL, V16, P14, DOI 10.1245/s10434-008-0180-z; Vilana R, 2010, HEPATOLOGY, V51, P2020, DOI 10.1002/hep.23600; Yamamoto M, 2011, SURG TODAY, V41, P896, DOI 10.1007/s00595-011-4517-z; Motosugi U, 2009, J COMPUT ASSIST TOMO, V33, P682, DOI 10.1097/RCT.0b013e318195400c; Tsuchiya A, 2011, CANCER LETT, V309, P95, DOI 10.1016/j.canlet.2011.05.021; Yamamoto M, 1998, CANCER, V82, P2145, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2145::AID-CNCR8>3.3.CO;2-9; Shiota K, 2001, ONCOL REP, V8, P263; Welzel TM, 2006, J NATL CANCER I, V98, P873, DOI 10.1093/jnci/djj234; Meyer CG, 2000, TRANSPLANTATION, V69, P1633; Shaib YH, 2005, GASTROENTEROLOGY, V128, P620, DOI 10.1053/j.gastro.2004.12.048; Zhou YM, 2008, WORLD J GASTROENTERO, V14, P632, DOI 10.3748/wjg.14.632; Shin HR, 2010, CANCER SCI, V101, P579, DOI 10.1111/j.1349-7006.2009.01458.x; Songsivilai S, 1996, T ROY SOC TROP MED H, V90, P505, DOI 10.1016/S0035-9203(96)90296-5; Ariizumi SI, 2011, J SURG ONCOL, V104, P130, DOI 10.1002/jso.21917; Welzel TM, 2007, INT J CANCER, V120, P638, DOI 10.1002/ijc.22283; Ghali P, 2005, LIVER TRANSPLANT, V11, P1412, DOI 10.1002/lt.20512; Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889; STEINER PE, 1959, CANCER, V12, P753, DOI 10.1002/1097-0142(195907/08)12:4<753::AID-CNCR2820120420>3.0.CO;2-L; Khan SA, 2005, LANCET, V366, P1303, DOI 10.1016/S0140-6736(05)67530-7; Yano Y, 2003, JPN J CLIN ONCOL, V33, P283, DOI 10.1093/jjco/hyg056; Ishikawa K, 2007, ONCOLOGIST, V12, P320, DOI 10.1634/theoncologist.12-3-320; Shin HR, 1996, INT J EPIDEMIOL, V25, P933, DOI 10.1093/ije/25.5.933; Ariizumi S, 2012, ANN SURG ONCOL, V19, P1628, DOI 10.1245/s10434-011-2150-0; Ariizumi S, 2014, ANN SURG ONCOL, V21, P451, DOI 10.1245/s10434-014-3582-0; Bosman FT, 2010, WHO CLASSIFICATION T, P225; Callea F, 1993, J Surg Oncol Suppl, V3, P131; Edge SB, 2009, AM JOINT COMMITTEE C; Ishii T, 2005, EXP CELL RES, V309, P68, DOI 10.1016/j.yexer.2005.05.028; Ishii T, 2010, CANCER LETT, V294, P25, DOI 10.1016/j.canlet.2010.01.019; Komuta M, 2012, HEPATOLOGY, V55, P1876, DOI 10.1002/hep.25595; Kozaka K, 2007, HISTOPATHOLOGY, V51, P390, DOI 10.1111/j.1365-2559.2007.02735.x; Li YY, 2011, J GASTROINTEST SURG, V15, P608, DOI 10.1007/s11605-011-1419-8; Liu RQ, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-99; Luo X, 2014, J GASTROINTEST SURG, P7; Maeno S, 2012, J HEPATO-BIL-PAN SCI, V19, P289, DOI 10.1007/s00534-011-0483-5; Nakano M., 2004, TAN TO SUI, V25, P343; Nakanuma Y, 2000, WHO CLASSIFICATION T; Nakanuma Y, 1994, PRIMARY LIVER CANC J, P39; Nakanuma Yasuni, 2010, World J Hepatol, V2, P419, DOI 10.4254/wjh.v2.i12.419; Nanashima A, 2008, J SURG ONCOL, V98, P535, DOI 10.1002/jso.21142; Shen WF, 2009, WORLD J GASTROENTERO, V15, P5976, DOI 10.3748/wjg.15.5976; Shimada K, 2007, WORLD J SURG, V31, P2016, DOI 10.1007/s00268-007-9194-0; Su CH, 1997, BRIT J SURG, V84, P969, DOI 10.1002/bjs.1800840717; Tao L-T, 2009, LIVER INT, V30, P215, DOI DOI 10.1111/J.1478-3231.2009.02149.X; The Liver Cancer Study Group of Japan, 2009, GEN RUL CLIN PATH ST; Uchiyama K, 2010, J HEPATOBILIARY PANC; Wu ZF, 2013, J VIRAL HEPATITIS, V20, P306, DOI 10.1111/jvh.12005; Yamamoto M, 2004, J SURG ONCOL, V87, P80, DOI 10.1002/jso.20091; Yamamoto M, 1998, J SURG ONCOL, V69, P162, DOI 10.1002/(SICI)1096-9098(199811)69:3<162::AID-JSO8>3.0.CO;2-L; Yamasaki Susumu, 2003, J Hepatobiliary Pancreat Surg, V10, P288, DOI 10.1007/s00534-002-0732-8; Zhang L, 2010, J SURG ONCOL, V101, P233, DOI 10.1002/jso.21488; Zhou HB, 2011, WORLD J GASTROENTERO, V17, P1292, DOI 10.3748/wjg.v17.i10.1292	81	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					682	687		10.1007/s00595-014-1031-0		6	Surgery	Surgery	CJ6KW	WOS:000355603700003		
J	Unno, N; Yamamoto, N; Inuzuka, K; Mano, Y; Sano, M; Saito, T; Sugisawa, R; Katahashi, K; Konno, H				Unno, Naoki; Yamamoto, Naoto; Inuzuka, Kazunori; Mano, Yuuki; Sano, Masaki; Saito, Takaaki; Sugisawa, Ryota; Katahashi, Kazuto; Konno, Hiroyuki			Early outcomes of iliac branch grafts in the endovascular repair of abdominal aortic aneurysms with concomitant bilateral common iliac artery aneurysms at a Japanese institution	SURGERY TODAY			English	Article						Abdominal aortic aneurysm; Bilateral common iliac artery aneurysm; Iliac branch device; Hypogastric artery	ISCHEMIC COMPLICATIONS; AORTOILIAC ANEURYSMS; BLOOD-FLOW; EMBOLIZATION; EXPERIENCE; ENDOGRAFT; OCCLUSION; DEVICE; PENILE; EVAR	Purpose Endovascular aneurysm repair (EVAR) is used to treat abdominal aortic aneurysms (AAAs) with bilateral common iliac artery aneurysms (CIAAs), and an interruption of the bilateral internal iliac arteries (IIAs) is often needed, which may cause postoperative ischemic complications. An iliac branch device (IBD) has thus been introduced as an endovascular technique to preserve the IIA flow. This study aimed to evaluate the technical feasibility and short-term results of using an IBD when treating AAA with bilateral CIAAs in a Japanese institution, where IBD use has still not been approved by the government. Methods EVAR was performed using an IBD in six patients at high risk for open repair of an AAA with bilateral CIAAs. Results Advanta V12 stent grafts were successfully placed in the IIA, bridging between the IIA and the IBD side branch from the contralateral iliac artery. Subsequently, EVAR was performed as usual. The technical success rate was 100 %. At the most recent follow-up (mean follow-up period, 14.2 months), all IBDs were patent. No patients complained of buttock claudication or ischemic colitis. Conclusions The implantation of an IBD during EVAR is technically feasible in Japanese AAA patients with bilateral CIAAs, and may be a viable method to avoid pelvic ischemic complications, such as intractable buttock claudication.	[Unno, Naoki; Yamamoto, Naoto; Inuzuka, Kazunori; Mano, Yuuki; Sano, Masaki; Saito, Takaaki; Sugisawa, Ryota; Katahashi, Kazuto; Konno, Hiroyuki] Hamamatsu Univ Sch Med, Dept Surg 2, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan	Unno, N (reprint author), Hamamatsu Univ Sch Med, Dept Surg 2, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	unno@hama-med.ac.jp					Abraham CZ, 2003, J ENDOVASC THER, V10, P203, DOI 10.1583/1545-1550(2003)010<0203:AMMSFE>2.0.CO;2; Razavi MK, 2000, J VASC INTERV RADIOL, V11, P561, DOI 10.1016/S1051-0443(07)61606-6; Lin PH, 2002, J VASC SURG, V36, P500, DOI 10.1067/mva.2002.127350; Moll FL, 2011, EUR J VASC ENDOVASC, V41, pS1, DOI 10.1016/j.ejvs.2010.09.011; Wong S, 2013, J VASC SURG, V58, P861, DOI 10.1016/j.jvs.2013.02.033; Maldonado TS, 2004, J VASC SURG, V40, P703, DOI 10.1016/j.jvs.2004.07.032; Cheng SWK, 2004, J ENDOVASC THER, V11, P605, DOI 10.1583/04-1268R.1; Parlani G, 2012, EUR J VASC ENDOVASC, V43, P287, DOI 10.1016/j.ejvs.2011.12.011; Unno N, 2006, J VASC SURG, V44, P1170, DOI 10.1016/j.jvs.2006.08.011; Yano OJ, 2001, J VASC SURG, V34, P204, DOI 10.1067/mva.2001.115380; Greenhalgh RM, 2004, LANCET, V364, P843, DOI 10.1016/S0140-6736(04)16979-1; Karch LA, 2000, J VASC SURG, V32, P676, DOI 10.1067/mva.2000.109750; Verzini F, 2009, J VASC SURG, V49, P1154, DOI 10.1016/j.jvs.2008.11.100; Bratby MJ, 2008, CARDIOVASC INTER RAD, V31, P246, DOI 10.1007/s00270-007-9203-6; Handa Nobuhiro, 2012, Ann Vasc Dis, V5, P172, DOI 10.3400/avd.oa.12.00010; Inuzuka K, 2006, EUR J VASC ENDOVASC, V31, P359, DOI 10.1016/j.ejvs.2005.09.019; Karthikesalingam A, 2012, EUR J VASC ENDOVASC, V39, P285; Marin ML, 2004, J VASC SURG, V40, P709; Serracino-Inglott F, 2007, J VASC SURG, V46, P211, DOI 10.1016/j.jvs.2007.03.040; Unno N, 2006, SURG TODAY, V36, P257, DOI 10.1007/s00595-005-3139-8; Unno Naoki, 2013, Ann Vasc Dis, V6, P642, DOI 10.3400/avd.cr.13-00047	21	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					688	694		10.1007/s00595-014-0927-z		7	Surgery	Surgery	CJ6KW	WOS:000355603700004		
J	Matsuoka, T; Sonobe, M; Date, H				Matsuoka, Takahisa; Sonobe, Makoto; Date, Hiroshi			Intraoperative fine-needle aspiration biopsy (FNA) for lung cancer: diagnostic value and risk of pleural dissemination	SURGERY TODAY			English	Article						Lung cancer; Intraoperative FNA; VATS	AIR-EMBOLISM; IMPLANTATION METASTASIS; PNEUMOTHORAX; LESIONS; CYTODIAGNOSIS; COMPLICATION; RECURRENCE; TUMORS; TRACT; CELLS	Purpose Intraoperative fine-needle aspiration biopsy (FNA) is one of the most important diagnostic tools for undiagnosed lung nodules suspected of being lung cancer; however, the sensitivity and safety of FNA, including the risk of intrapleural dissemination of cancer cells, have not been established. Methods Between 2006 and 2008, 324 patients underwent lung resection for cancers located in the lung periphery. Intraoperative FNA for definite diagnosis was performed immediately after thoracotomy in 147 (45.4 %) of these patients, but not in the other 177. Results A diagnosis of lung cancer was obtained by the intraoperative FNA in 124 (84.4 %) of the 147 patients. During a median follow-up of 55 months, pleural dissemination or malignant effusion ipsilateral to the operated side as the first recurrent site occurred in 11 (7.4%) of the 147 patients who underwent the needle biopsy and 10 (5.6 %) of the 177 patients who did not. This difference was not significant (P = 0.5046). Conclusion Intraoperative FNA was safe and useful for the diagnosis of peripheral lung cancer and did not increase the risk of pleural dissemination in this series.	[Matsuoka, Takahisa] Natl Hosp Org Himeji Med Ctr, Dept Thorac Surg, Himeji, Hyogo 6708520, Japan; [Matsuoka, Takahisa; Sonobe, Makoto; Date, Hiroshi] Kyoto Univ, Dept Thorac Surg, Grad Sch Med, Kyoto, Japan	Matsuoka, T (reprint author), Natl Hosp Org Himeji Med Ctr, Dept Thorac Surg, 68 Honmachi, Himeji, Hyogo 6708520, Japan.	matsuoka1971114@yahoo.co.jp					DECARO LF, 1983, J THORAC CARDIOV SUR, V85, P404; Schreiber G, 2003, CHEST, V123, p115S, DOI 10.1378/chest.123.1_suppl.115S; VORAVUD N, 1992, CHEST, V102, P313, DOI 10.1378/chest.102.1.313; Inoue M, 2011, ANN THORAC SURG, V91, P1066, DOI 10.1016/j.athoracsur.2010.12.032; Chakrabarti B, 2009, RESP MED, V103, P449, DOI 10.1016/j.rmed.2008.09.010; Tomiyama N, 2006, EUR J RADIOL, V59, P60, DOI 10.1016/j.ejrad.2006.02.001; Yoshikawa T, 2000, JPN J CLIN ONCOL, V30, P450, DOI 10.1093/jjco/hyd120; Yeow KM, 2004, CHEST, V126, P748, DOI 10.1378/chest.126.3.748; Geraghty PR, 2003, RADIOLOGY, V229, P475, DOI 10.1148/radiol.2291020499; Mansour A, 2005, CARDIOVASC INTER RAD, V28, P131, DOI 10.1007/s00270-004-0118-1; MCCARTHY WJ, 1980, ANN THORAC SURG, V30, P24; Lattin G, 2006, J VASC INTERV RADIOL, V17, P1355, DOI 10.1097/01.RVI.0000231949.35479.89; Matsuguma H, 2005, ANN THORAC SURG, V80, P2026, DOI 10.1016/j.athoracsur.2005.06.074; BERGER RL, 1972, J THORAC CARDIOV SUR, V63, P430; Capellari JO, 1994, ACTA CYTOL, V38, P707; Christensen ES, 1978, DANISH MED B, V25, P82; FERRUCCI JT, 1979, RADIOLOGY, V130, P345; FREISE G, 1967, DIS CHEST, V52, P485; Hiraki T, 2007, CHEST, V132, P684, DOI 10.1378/chest.06-3030; Ishikawa Y, 2009, ANN THORAC SURG, V87, P1622, DOI 10.1016/j.athoracsur.2008.08.035; Kara M, 2001, EUR J CARDIO-THORAC, V20, P868, DOI 10.1016/S1010-7940(01)00866-1; Kim JH, 2003, EUR J CARDIO-THORAC, V23, P8; Laspas F, 2008, J MED IMAG RADIAT ON, V52, P458, DOI 10.1111/j.1440-1673.2008.01990.x; REDWOOD N, 1989, THORAX, V44, P826, DOI 10.1136/thx.44.10.826; Sano Y, 2009, CANCER, V115, P5526, DOI 10.1002/cncr.24620; Sawabata N, 2000, CHEST, V118, P936, DOI 10.1378/chest.118.4.936; SEYFER AE, 1989, ANN THORAC SURG, V48, P284; TERADA Y, 1990, CHEST, V98, P1156, DOI 10.1378/chest.98.5.1156	28	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					695	699		10.1007/s00595-014-1029-7		5	Surgery	Surgery	CJ6KW	WOS:000355603700005		
J	Numata, M; Hasuo, K; Hara, K; Maezawa, Y; Kazama, K; Inari, H; Takata, K; Jin, Y; Yukawa, N; Oshima, T; Rino, Y; Taguri, M; Masuda, M				Numata, Masakatsu; Hasuo, Kimiatsu; Hara, Kentaro; Maezawa, Yukio; Kazama, Keisuke; Inari, Hitoshi; Takata, Ken; Jin, Yasuyuki; Yukawa, Norio; Oshima, Takashi; Rino, Yasushi; Taguri, Masataka; Masuda, Munetaka			A propensity score-matching analysis comparing the oncological outcomes of laparoscopic and open surgery in patients with Stage I/II colon and upper rectal cancers	SURGERY TODAY			English	Article						Colorectal cancer; Laparoscopic surgery; Propensity-matching analysis; Long-term outcomes	RANDOMIZED CONTROLLED-TRIAL; COLORECTAL-CANCER; OPEN COLECTOMY; BIAS REDUCTION; CLASICC TRIAL; IMMUNOSUPPRESSION; RESECTION; HELPER	Purpose Previous studies from Western countries have shown similar survival outcomes after both open and laparoscopic resections. In Japan, radical D3 dissections performed by open resection have been routinely performed for >= T2- or >= N1-stage cancers, and relatively favorable survival outcomes were obtained. This study compared the survival in patients with Stage I/II colon and upper rectal cancers undergoing laparoscopic and open resection. Methods A total of 145 patients were initially enrolled. Propensity score matching was applied to assemble a study cohort. D2 lymph node dissection for T1 cancer and D3 for >= T2-and >= N1-stage cancers were applied. The primary outcome measure was the disease-free survival; the cancer-specific and overall survival rates were secondary outcomes. Results A total of 64 patients were matched for the analysis. The length of hospitalization, postoperative complication rates, number of lymph nodes removed and surgical margins were similar between the groups. The disease-free survival following laparoscopic surgery was better than that following open surgery, but the difference was not statistically significant. Neither the cancer-specific nor overall survival rates following laparoscopic surgery were inferior to those associated with open surgery. Conclusions The outcomes of the laparoscopic approach were comparable to those for open surgeries accompanied by radical lymph node dissection.	[Numata, Masakatsu; Hasuo, Kimiatsu; Hara, Kentaro; Maezawa, Yukio; Kazama, Keisuke; Inari, Hitoshi; Takata, Ken; Jin, Yasuyuki] Japanese Red Cross Hadano Hosp, Dept Surg, Hadano, Kanagawa 2570017, Japan; [Yukawa, Norio; Oshima, Takashi; Rino, Yasushi; Masuda, Munetaka] Yokohama City Univ, Dept Surg, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; [Taguri, Masataka] Yokohama City Univ, Dept Biostat & Epidemiol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Numata, M (reprint author), Japanese Red Cross Hadano Hosp, Dept Surg, 1-1 Tatenodai, Hadano, Kanagawa 2570017, Japan.	masakatsunumata@hotmail.co.jp					Allemani C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003055; Alnasser M, 2013, SURG ENDOSC, V28, P49; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Decker D, 1996, SURGERY, V119, P316, DOI 10.1016/S0039-6060(96)80118-8; Coleman MP, 2008, LANCET ONCOL, V9, P730, DOI [10.1016/S1470-2045(08)70179-7, 10.1016/S470-2045(08)70179-7]; Watanabe M, 2003, SURG ENDOSC, V17, P1274, DOI 10.1007/s00464-002-8822-x; Watanabe T, 2012, INT J CLIN ONCOL, V17, P1, DOI 10.1007/s10147-011-0315-2; Green BL, 2013, BRIT J SURG, V100, P75, DOI 10.1002/bjs.8945; Shawki S, 2009, SURG ENDOSC, V23, P2321, DOI 10.1007/s00464-009-0329-2; Da Costa ML, 1998, BRIT J SURG, V85, P1439; Hasegawa H, 2003, SURG ENDOSC, V17, P636, DOI 10.1007/s00464-002-8516-4; Delgado S, 2001, DIS COLON RECTUM, V44, P638, DOI 10.1007/BF02234558; Lacy AM, 2002, LANCET, V359, P2224, DOI 10.1016/S0140-6736(02)09290-5; Vittimberga FJ, 1998, ANN SURG, V227, P326, DOI 10.1097/00000658-199803000-00003; Silber JH, 2001, MED CARE, V39, P1048, DOI 10.1097/00005650-200110000-00003; Guillou PJ, 2005, LANCET, V365, P1718, DOI 10.1016/S0140-6736(05)66545-2; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; BERENDS FJ, 1994, LANCET, V344, P58, DOI 10.1016/S0140-6736(94)91079-0; Buunen M, 2009, LANCET ONCOL, V10, P44, DOI DOI 10.1016/S1470-2045(08)70310-3; COLE WH, 1985, J SURG ONCOL, V30, P139; Fleshman JW, 1996, DIS COLON RECTUM, V39, pS53, DOI 10.1007/BF02053806; Fox JP, 2012, J GASTROINTEST SURG, V16, P2112, DOI 10.1007/s11605-012-2018-z; HANSBROUGH JF, 1984, AM J SURG, V148, P303, DOI 10.1016/0002-9610(84)90459-8; Jacobs M, 1991, Surg Laparosc Endosc, V1, P144; Kye BH, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-89; Nelson H, 2004, NEW ENGL J MED, V350, P2050; SCHOLEFIELD JH, 1995, BRIT J SURG, V82, P745, DOI 10.1002/bjs.1800820609; SCHOLEFIELD JH, 1992, LANCET, V340, P1101, DOI 10.1016/0140-6736(92)93124-6; Schwenk W, 2005, COCHRANE DB SYST REV, V3; Bonjer HJ, 2005, LANCET ONCOL, V6, P477, DOI 10.1016/S1470-2045(05)70221-7; Vukasin P, 1996, DIS COLON RECTUM, V39, pS20, DOI 10.1007/BF02053801	31	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					700	707		10.1007/s00595-014-0954-9		8	Surgery	Surgery	CJ6KW	WOS:000355603700006		
J	Oishi, K; Sakaguchi, T; Baba, S; Suzuki, S; Konno, H				Oishi, Kosuke; Sakaguchi, Takanori; Baba, Satoshi; Suzuki, Shohachi; Konno, Hiroyuki			Macrophage density and macrophage colony-stimulating factor expression predict the postoperative prognosis in patients with intrahepatic cholangiocarcinoma	SURGERY TODAY			English	Article						Intrahepatic cholangiocarcinoma; Macrophage density; Macrophage colony-stimulating factor; Hepatectomy	TUMOR-ASSOCIATED MACROPHAGES; HEPATOCELLULAR-CARCINOMA; POOR-PROGNOSIS; CANCER PATIENTS; CSF-1 RECEPTOR; RISK-FACTORS; SURVIVAL; GROWTH; RESECTION; POLARIZATION	Purposes Macrophages are included in the stromal compartments in various neoplasms, and their behavior against tumors is diverse. The aim of this study was to examine the role of tumor-infiltrating macrophages and their main regulator, macrophage colony-stimulating factor (M-CSF), in intrahepatic cholangiocarcinoma (ICC). Methods Macrophage density and M-CSF expression in 39 resected ICC specimens were immunohistochemically evaluated in the central and peripheral areas of tumors, which were defined as fields more than and within 500 mu m from the invasive front, respectively. The number of CD68-positive macrophages was counted using an image-analyzing software program. The relationship between these results and other clinicopathological factors and the postoperative prognosis were evaluated. Results Sporadic M-CSF expression in cancer cells around the peripheral area was observed in fourteen patients. M-CSF-positive ICCs showed a higher macrophage density in the tumor-peripheral area than did M-CSF-negative ICCs. M-CSF expression and higher macrophage density in the tumor-peripheral area were related to a better postoperative prognosis, whereas a higher macrophage density in the central area was one of the significant risk factors for a poor prognosis in a univariate analysis. Conclusion Tumor-peripheral macrophage infiltration, presumably dependent on M-CSF, and M-CSF-independent tumor-central macrophage infiltration are predictive factors for better and worse postoperative prognosis in ICC patients, respectively. The tumor microenvironment, such as the presence of hypoxia, may affect the behavior of infiltrating macrophages in ICC.	[Oishi, Kosuke; Sakaguchi, Takanori; Konno, Hiroyuki] Hamamatsu Univ Sch Med, Dept Surg 2, Hamamatsu, Shizuoka 4313192, Japan; [Oishi, Kosuke] Kikugawa City Hosp, Kikugawa 4390022, Japan; [Baba, Satoshi] Hamamatsu Univ Sch Med, Fac Pathol, Hamamatsu, Shizuoka 4313192, Japan; [Suzuki, Shohachi] Iwata City Hosp, Dept Surg, Iwata 4388550, Japan	Oishi, K (reprint author), Kikugawa City Hosp, 1632 Higashiyokochi, Kikugawa 4390022, Japan.	roadster484@yahoo.co.jp					Forssell J, 2007, CLIN CANCER RES, V13, P1472, DOI 10.1158/1078-0432.CCR-06-2073; Beck AH, 2009, CLIN CANCER RES, V15, P778, DOI 10.1158/1078-0432.CCR-08-1283; Fujii H, 2008, RADIOTHER ONCOL, V86, P354, DOI 10.1016/j.radonc.2007.11.020; Ohno S, 2003, ANTICANCER RES, V23, P5015; Welzel TM, 2007, CLIN GASTROENTEROL H, V5, P1221, DOI 10.1016/j.cgh.2007.05-020; Gatto M, 2010, EUR REV MED PHARMACO, V14, P363; Takeda N, 2010, GENE DEV, V24, P491, DOI 10.1101/gad.1881410; Laoui D, 2011, INT J DEV BIOL, V55, P861, DOI 10.1387/ijdb.113371dl; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Hasita H, 2010, CANCER SCI, V101, P1913, DOI 10.1111/j.1349-7006.2010.01614.x; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Ding T, 2009, HUM PATHOL, V40, P381, DOI 10.1016/j.humpath.2008.08.011; Menke J, 2012, CANCER RES, V72, P187, DOI 10.1158/0008-5472.CAN-11-1232; Zhu XD, 2008, J CLIN ONCOL, V26, P2707, DOI 10.1200/JCO.2007.15.6521; Fang HY, 2009, BLOOD, V114, P844, DOI 10.1182/blood-2008-12-195941; Zhang BC, 2011, CLINICS, V66, P1879, DOI 10.1590/S1807-59322011001100006; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Ohno S, 2004, ANTICANCER RES, V24, P3335; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Ikai I, 2007, HEPATOL RES, V37, P676, DOI 10.1111/j.1872-034X.2007.00119.x; Aharinejad S, 2004, CANCER RES, V64, P5378, DOI 10.1158/0008-5472.CAN-04-0961; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Imtiyaz HZ, 2010, J CLIN INVEST, V120, P2699, DOI 10.1172/JCI39506; Li YW, 2009, J CANCER RES CLIN, V135, P439, DOI 10.1007/s00432-008-0469-0; Eubank TD, 2009, CANCER RES, V69, P2133, DOI 10.1158/0008-5472.CAN-08-1405; Niino D, 2010, PATHOL INT, V60, P278, DOI 10.1111/j.1440-1827.2010.02514.x; Elbarghati L, 2008, IMMUNOBIOLOGY, V213, P899, DOI 10.1016/j.imbio.2008.07.016; Bij GJ, 2008, CANC LETT, V262, P77; Fiona J, 2004, TRENDS CELL BIOL, V14, P628; Liver Cancer Study Group of J, 1990, ANN SURG, V211, P277; Ma JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-112; MASON RP, 1994, INT J RADIAT ONCOL, V29, P95; Mroczko B, 2007, CLIN CHIM ACTA, V380, P208, DOI 10.1016/j.cca.2007.02.037; Sobin LH, 2002, TNM CLASSIFICATION M, V6th, P114; Toy EP, 2001, GYNECOL ONCOL, V80, P194, DOI 10.1006/gyno.2000.6070; Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025	37	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					715	722		10.1007/s00595-014-0989-y		8	Surgery	Surgery	CJ6KW	WOS:000355603700008		
J	Nojiri, T; Inoue, M; Takeuchi, Y; Maeda, H; Shintani, Y; Sawabata, N; Hamasaki, T; Okumura, M				Nojiri, Takashi; Inoue, Masayoshi; Takeuchi, Yukiyasu; Maeda, Hajime; Shintani, Yasushi; Sawabata, Noriyoshi; Hamasaki, Toshimitsu; Okumura, Meinoshin			Impact of cardiopulmonary complications of lung cancer surgery on long-term outcomes	SURGERY TODAY			English	Article						Lung cancer surgery; Postoperative complications; Long-term outcome	BRAIN NATRIURETIC PEPTIDE; VENTRICULAR DIASTOLIC DYSFUNCTION; PULMONARY-HYPERTENSION; ATRIAL-FIBRILLATION; HEART-FAILURE; COPD; PREDICTOR; RESECTION; MARKER; TRIAL	Purpose The impact of postoperative cardiopulmonary complications on long-term outcomes has not been established. We investigated the effects of acute postoperative cardiopulmonary complications not only on cancer recurrence, but also on cardiovascular or respiratory events in the chronic phase after lung cancer surgery. Methods From a prospective single-institution database of 496 consecutive patients, who underwent lung cancer surgery between August, 2008 and December, 2011, medical records, including information about cardiovascular or respiratory events and cancer recurrence in the chronic phase (>6 months) after surgery, were analyzed retrospectively. Results were compared between patients with vs. those without postoperative cardiopulmonary complications in the acute phase. Results Postoperative cardiopulmonary complications were identified in 90 (20 %) patients. There were significantly more cardiovascular or respiratory events in the chronic phase after lung cancer surgery in the patients who had suffered postoperative cardiopulmonary complications in the acute phase than in those who had not (23 vs. 5 %; p < 0.0001). Conclusions Postoperative cardiopulmonary complications in the acute phase were associated with a higher incidence of cardiovascular or respiratory events in the chronic phase after lung cancer surgery.	[Nojiri, Takashi; Inoue, Masayoshi; Shintani, Yasushi; Sawabata, Noriyoshi; Okumura, Meinoshin] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Suita, Osaka 5650871, Japan; [Nojiri, Takashi] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biochem, Suita, Osaka, Japan; [Takeuchi, Yukiyasu; Maeda, Hajime] Natl Hosp Org Toneyama Hosp, Dept Gen Thorac Surg, Toyonaka, Osaka, Japan; [Hamasaki, Toshimitsu] Osaka Univ, Grad Sch Med, Dept Biomed Stat, Suita, Osaka 5650871, Japan	Nojiri, T (reprint author), Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Yamadaoka 2-2,L5, Suita, Osaka 5650871, Japan.	nojirit@thoracic.med.osaka-u.ac.jp	Hamasaki, Toshimitsu/N-3851-2015	Hamasaki, Toshimitsu/0000-0002-4928-1160			LOUIE EK, 1995, CIRCULATION, V92, P819; Tsang TSM, 2002, J AM COLL CARDIOL, V40, P1636, DOI 10.1016/S0735-1097(02)02373-2; Boffa DJ, 2008, J THORAC CARDIOV SUR, V135, P247, DOI 10.1016/j.jtcvs.2007.07.060; Nishikimi T, 1996, HYPERTENSION, V28, P22; Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073; Curkendall SM, 2006, ANN EPIDEMIOL, V16, P63, DOI 10.1016/j.annepidem.2005.04.008; Reesink HJ, 2007, ANN THORAC SURG, V84, P537, DOI 10.1016/j.athoracsur.2007.04.006; Suzuki M, 2002, HYPERTENS RES, V25, P669; Stolz D, 2008, CHEST, V133, P1088, DOI 10.1378/chest.07-1959; Nojiri T, 2011, ANN THORAC SURG, V92, P1051, DOI 10.1016/j.athoracsur.2011.03.085; Ledwidge M, 2013, JAMA-J AM MED ASSOC, V310, P66, DOI 10.1001/jama.2013.7588; Allen MS, 2006, ANN THORAC SURG, V81, P1013, DOI 10.1016/j.athoracsur.2005.06.066; Nagaya N, 1998, J AM COLL CARDIOL, V31, P202, DOI 10.1016/S0735-1097(97)00452-X; Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043; Barr RG, 2010, NEW ENGL J MED, V362, P217, DOI 10.1056/NEJMoa0808836; Birim O, 2006, J THORAC CARDIOV SUR, V132, P491, DOI 10.1016/j.jtcvs.2006.04.010; Goto T, 2010, AM J CARDIOL, V106, P87, DOI 10.1016/j.amjcard.2010.01.372; Inoue Y, 2009, INTERNAL MED, V48, P503, DOI 10.2169/internalmedicine.48.1701; Lubien E, 2002, CIRCULATION, V105, P595, DOI 10.1161/hc0502.103010; Win T, 2005, EUR RESPIR J, V25, P594, DOI 10.1183/09031936.05.00077504	20	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					740	745		10.1007/s00595-014-1032-z		6	Surgery	Surgery	CJ6KW	WOS:000355603700011		
J	Tokumitsu, Y; Yoshino, S; Iida, M; Yoshimura, K; Ueno, T; Hazama, S; Oka, M				Tokumitsu, Yukio; Yoshino, Shigefumi; Iida, Michihisa; Yoshimura, Kiyoshi; Ueno, Tomio; Hazama, Shoichi; Oka, Masaaki			Intraoperative dissemination during gastrectomy for gastric cancer associated with serosal invasion	SURGERY TODAY			English	Article						Gastric cancer; Dissemination; Cytology	PERITONEAL-LAVAGE CYTOLOGY; PROGNOSTIC-SIGNIFICANCE; CURATIVE RESECTION; WASHING CYTOLOGY; CARCINOMA; METASTASIS; CELLS; STRATEGY	Purpose Free cancer cells shed from the serosal surface of gastric cancer result in peritoneal dissemination. The aim of this study was to clarify the extent of tumor cell implantation due to surgical manipulation during gastrectomy. Methods The participants comprised 34 patients who underwent curative gastrectomy for gastric cancer with macroscopic serosal invasion. Two types of cytology were obtained from each patient: (1) cytology from the wound dressing material that covered the serosal invasion area during the operation (Covering Cy), and (2) cytology of the intraperitoneal wash samples (Lavage Cy). Result Thirteen patients showed no serosal invasion histopathologically, and all of these patients had negative results for both Lavage Cy and Covering Cy. Among the 21 patients with histopathologically confirmed serosal invasion, six had positive results for both Lavage Cy and Covering Cy, three showed positive findings for Covering Cy alone, one had positive Lavage Cy alone and 11 patients had negative results for both Lavage Cy and Covering Cy. Disseminated recurrence developed in 10 patients. Seven of the nine patients with positive Covering Cy developed disseminated recurrence, compared to three of 12 patients with negative Covering Cy. Positive Covering Cy findings were significantly associated with disseminated recurrence (p < 0.05). Conclusion We demonstrated that the intraoperative dissemination of gastric cancer can occur during gastrectomy.	[Tokumitsu, Yukio; Yoshino, Shigefumi; Iida, Michihisa; Yoshimura, Kiyoshi; Ueno, Tomio; Hazama, Shoichi; Oka, Masaaki] Yamaguchi Univ, Grad Sch Medicene, Dept Digest Surg & Surg Oncol, Ube, Yamaguchi 7558505, Japan	Tokumitsu, Y (reprint author), Yamaguchi Univ, Grad Sch Medicene, Dept Digest Surg & Surg Oncol, 1-1-1 Minamikogushi, Ube, Yamaguchi 7558505, Japan.	yukio790604@gmail.com; 2geka-1@po.cc.yamaguchi-u.ac.jp					ABE S, 1995, J SURG ONCOL, V59, P226, DOI 10.1002/jso.2930590405; Lee SE, 2009, J AM COLL SURGEONS, V209, P461, DOI 10.1016/j.jamcollsurg.2009.06.001; Wu CC, 1997, J AM COLL SURGEONS, V184, P611; Fukagawa T, 2010, WORLD J SURG, V34, P563, DOI 10.1007/s00268-009-0355-1; Fujiwara Y, 2007, GASTRIC CANCER, V10, P197, DOI 10.1007/s10120-007-0436-5; Bando E, 1999, AM J SURG, V178, P256, DOI 10.1016/S0002-9610(99)00162-2; Mezhir JJ, 2010, ANN SURG ONCOL, V17, P3173, DOI 10.1245/s10434-010-1183-0; Li JK, 2005, WORLD J GASTROENTERO, V11, P7374; Marutsuka T, 2003, CLIN CANCER RES, V9, P678; Lee SD, 2012, BRIT J SURG, V99, P397, DOI 10.1002/bjs.7812; Cetin B, 2005, SURG TODAY, V35, P919, DOI 10.1007/s00595-005-3057-9; Hayes N, 1999, BRIT J CANCER, V79, P520, DOI 10.1038/sj.bjc.6690081; Bentrem D, 2005, ANN SURG ONCOL, V12, P347, DOI 10.1245/ASO.2005.03.065; Han TS, 2011, ANN SURG ONCOL, V18, P2818, DOI 10.1245/s10434-011-1620-8; Glehen O, 2010, ANN SURG ONCOL, V17, P2370, DOI 10.1245/s10434-010-1039-7; Homma Y, 2010, ANN SURG ONCOL, V17, P455, DOI 10.1245/s10434-009-0764-2; Suzuki T, 1999, SEMIN SURG ONCOL, V17, P103, DOI 10.1002/(SICI)1098-2388(199909)17:2<103::AID-SSU4>3.0.CO;2-Q; Schauer M, 2011, EUR J MED RES, V16, P29; Huang BJ, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-57; Jeong O, 2011, WORLD J SURG, V35, P2252, DOI 10.1007/s00268-011-1197-1; KORENAGA D, 1994, J SURG ONCOL, V55, P250, DOI 10.1002/jso.2930550410; Mori N, 2000, BRIT J CANCER, V83, P1026, DOI 10.1054/bjoc.2000.1408; Oh CA, 2012, J SURG ONCOL, V105, P393, DOI 10.1002/jso.22091; SOOSAY GN, 1991, J PATHOL, V163, P299, DOI 10.1002/path.1711630406; Yasuda K, 2007, HEPATO-GASTROENTEROL, V54, P2028	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					746	751		10.1007/s00595-014-1005-2		6	Surgery	Surgery	CJ6KW	WOS:000355603700012		
J	Kashihara, H; Shimada, M; Kurita, N; Iwata, T; Sato, H; Yoshikawa, K; Miyatani, T; Takasu, C; Matsumoto, N				Kashihara, Hideya; Shimada, Mitsuo; Kurita, Nobuhiro; Iwata, Takashi; Sato, Hirohiko; Yoshikawa, Kozo; Miyatani, Tomohiko; Takasu, Chie; Matsumoto, Noriko			Protein kinase C iota is a new prognostic factor in gastric cancer	SURGERY TODAY			English	Article						Protein kinase C iota (PKC iota); Gastric cancer; Vascular endothelial cell growth factor (VEGF); Extracellular signal-regulated kinase (ERK)	PKC-IOTA; MUTATIONS; CARCINOMA; ONCOGENE; TUMORS	Purposes Protein kinase C iota (PKC iota) is an important oncogenic K-ras effector, and its expression is correlated with tumor angiogenesis. The role of PKC iota in gastric cancer remains unclear. The aim of this study was to clarify the role of PKC iota in gastric cancer. Methods Twenty-eight patients with gastric cancer who underwent gastrectomy were enrolled in this study. The expression of PKC iota mRNA was determined, as were the clinicopathological factors. The patients were divided into PKC iota high and low expression groups. The 5-year survival rate, ERK mRNA level and VEGF mRNA level were compared between the two groups. The prognostic factors were investigated by a multivariate analysis. Results High expression of PKC iota was observed to be associated with a lack of differentiation, tumor invasion >= muscularis propria <=, stage III and IV disease and peritoneal dissemination. The 5-year survival rate in the PKC iota high group was lower than that in the PKC iota low group. The multivariate analysis revealed that a high expression level of PKC iota was an independent prognostic factor. The expression levels of ERK and VEGF in the PKC iota high group were higher than those in the PKC iota low group. Conclusion Our results indicate that PKC iota is correlated with tumor progression and angiogenesis. PKC iota may be a new prognostic factor for gastric cancer.	[Kashihara, Hideya; Shimada, Mitsuo; Kurita, Nobuhiro; Iwata, Takashi; Sato, Hirohiko; Yoshikawa, Kozo; Miyatani, Tomohiko; Takasu, Chie; Matsumoto, Noriko] Univ Tokushima, Grad Sch, Dept Surg, Inst Hlth Biosci, Tokushima 7708503, Japan	Kashihara, H (reprint author), Univ Tokushima, Grad Sch, Dept Surg, Inst Hlth Biosci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	kashihara@clin.med.tokushima-u.ac.jp					Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200; Hiyama T, 2002, INT J CANCER, V97, P562, DOI 10.1002/ijc.1644; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Yang YL, 2008, GENE CHROMOSOME CANC, V47, P127, DOI 10.1002/gcc.20514; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; van Grieken NCT, 2013, BRIT J CANCER, V108, P1495, DOI 10.1038/bjc.2013.109; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429; Spitaler M, 2004, NAT IMMUNOL, V5, P785, DOI 10.1038/ni1097; Liu SG, 2011, MOL CANCER RES, V9, P390, DOI 10.1158/1541-7786.MCR-10-0359; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Arber N, 2000, GASTROENTEROLOGY, V118, P1045, DOI 10.1016/S0016-5085(00)70357-X; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Atmaca A, 2011, ONCOLOGY-BASEL, V80, P130, DOI 10.1159/000329063; Billadeau Daniel D, 2006, Int J Gastrointest Cancer, V37, P110, DOI 10.1007/s12029-007-0011-7; Cooper GM, 1995, ONCOGENES, P222; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Japanese Gastric Cancer Association, 2010, JAP CLASS GASTR CARC, V14th; Poole AAW, 2004, TRENDS PHARMACOL SCI, V25, P528, DOI 10.1016/j.tips.2004.08.006; Regala RP, 2009, CANCER RES, V69, P7603, DOI 10.1158/0008-5472.CAN-09-2066; Scotti ML, 2010, CANCER RES, V70, P2064, DOI 10.1158/0008-5472.CAN-09-2684; SOH K, 1993, JPN J CANCER RES, V84, P388; Tahara E., 1993, CANC RES CLIN ONCOL, V119, P265; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	28	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					759	764		10.1007/s00595-014-1010-5		6	Surgery	Surgery	CJ6KW	WOS:000355603700014		
J	Matsuda, M; Amemiya, H; Hosomura, N; Ogiku, M; Fujii, H				Matsuda, Masanori; Amemiya, Hidetake; Hosomura, Naohiro; Ogiku, Masahito; Fujii, Hideki			Hepatic resection for hepatocellular carcinoma in a patient with situs ambiguous with polysplenia: report of a case	SURGERY TODAY			English	Article						Hepatocellular carcinoma; Polysplenia; Situs ambiguous; Heterotaxia; Anatomical hepatic resection	PREDUODENAL PORTAL-VEIN; INVERSUS TOTALIS; GASTRIC-CANCER; ANOMALIES; PANCREAS; STOMACH	We report a case of successful resection of hepatocellular carcinoma (HCC) in a patient with situs ambiguous with polysplenia (PS), a rare congenital anomaly. A 62-year-old Japanese man was admitted to our hospital for investigation and treatment of a hepatic tumor. Imaging studies revealed two HCCs, 2.5 and 0.7 cm in diameter, in the anterior section and segment 3 of the reversed liver, respectively. He also had multiple spleens in the right side of the abdomen, right side of the stomach, and duodenum, as well as azygous continuation of the inferior vena cava (IVC) with absence of the retro-hepatic IVC, a truncated pancreas, rare variation of the hepatic artery, and dextrocardia. We performed anterior sectionectomy of the liver and partial resection of segment 3. We found only two previous reports of HCC in patients with situs ambiguous with PS, but our patient is the first to have undergone anatomical hepatic resection of the reversed liver. Accurate anatomical assessment is essential during surgery on such patients.	[Matsuda, Masanori; Amemiya, Hidetake; Hosomura, Naohiro; Ogiku, Masahito; Fujii, Hideki] Yamanashi Univ, Sch Med, Dept Surg 1, Chuo Ku, Kofu, Yamanashi 4093898, Japan	Matsuda, M (reprint author), Yamanashi Univ, Sch Med, Dept Surg 1, Chuo Ku, 1110 Shimokato, Kofu, Yamanashi 4093898, Japan.	masam@yamanashi.ac.jp					PEOPLES WM, 1983, PEDIATR CARDIOL, V4, P129, DOI 10.1007/BF02076338; Iwamura T, 2001, J CLIN GASTROENTEROL, V33, P148, DOI 10.1097/00004836-200108000-00012; Fulcher AS, 2002, RADIOGRAPHICS, V22, P1439, DOI 10.1148/rg.226025016; Applegate KE, 1999, RADIOGRAPHICS, V19, P837; Byun JR, 2010, DIGEST ENDOSC, V22, P322, DOI 10.1111/j.1443-1661.2010.01024.x; Chirica M, 2005, GASTROEN CLIN BIOL, V29, P456, DOI 10.1016/S0399-8320(05)80816-4; Choi MG, 2012, SURG LAPARO ENDO PER, V22, pE15, DOI 10.1097/SLE.0b013e31823c948e; CURRAN JG, 1987, BRIT J RADIOL, V60, P929; Ghosh S, 2009, AM J ROENTGENOL, V193, P1107, DOI 10.2214/AJR.09.2411; HIROHATA S, 1985, ARCH INTERN MED, V145, P1134, DOI 10.1001/archinte.145.6.1134; Li T, 2007, LIVER INT, V27, P1430, DOI 10.1111/j.1478-3231.2007.01597.x; Low JP, 2011, BRIT J RADIOL, V84, pE217, DOI 10.1259/bjr/27680217; Matsuda M, 2001, J Hepatobiliary Pancreat Surg, V8, P353, DOI 10.1007/s005340170008; MATSUSUE S, 1984, JPN J SURG, V14, P394, DOI 10.1007/BF02469547; Mimatsu K, 2012, SURG RADIOL ANAT, V34, P179, DOI 10.1007/s00276-011-0894-7; Park SS, 2005, DIGEST LIVER DIS, V37, P799, DOI 10.1016/j.dld.2005.02.013; Sugimachi Keishi, 2008, Case Rep Gastroenterol, V2, P76, DOI 10.1159/000118830; Tawfik AM, 2013, SURG RADIOL ANAT, V2013, P19; Tsutsumi R, 2007, SURG TODAY, V37, P676, DOI 10.1007/s00595-006-3445-9; WINERMURAM HT, 1989, RADIOL CLIN N AM, V27, P1147	20	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					765	771		10.1007/s00595-014-0997-y		7	Surgery	Surgery	CJ6KW	WOS:000355603700015		
J	Kawasaki, R; Miyamoto, N; Oki, H; Okada, T; Yamaguchi, M; Gomi, T; Higashino, T; Washio, T; Maruta, T; Sugimura, K; Sugimoto, K				Kawasaki, Ryota; Miyamoto, Naokazu; Oki, Haruka; Okada, Takuya; Yamaguchi, Masato; Gomi, Takashi; Higashino, Takanori; Washio, Tetsuo; Maruta, Tsutomu; Sugimura, Kazuro; Sugimoto, Koji			Flow-preserved coil embolization using a side-holed indwelling catheter for common hepatic artery pseudoaneurysm: report of three cases	SURGERY TODAY			English	Article						Visceral artery; Pseudoaneurysm; Embolization; Indwelling catheter; Coil	ENDOVASCULAR TREATMENT; LIVER METASTASES; STENT-GRAFTS; ANEURYSMS; PANCREATICODUODENECTOMY; MANAGEMENT; INFUSION	We report three cases of hepatic artery pseudoaneurysm, which were all treated successfully using a combination of coil embolization and a side-holed 5F indwelling catheter for maintaining minimal hepatic artery blood flow with exclusion of the pseudoaneurysm. The tip of an infusion catheter was placed in the right hepatic artery and a side hole was positioned at the celiac axis. Coil embolization was then performed from the proper to the common hepatic artery using detachable coils. Hemostasis was achieved in all patients, with a final angiogram showing the hepatic arteries through the indwelling catheter. One major hepatic infarction and one focal liver abscess caused by reflux cholangitis manifested on postoperative days (PODs) 11 and 87, respectively. All patients survived and the indwelling catheter was removed on POD 136-382 without complication.	[Kawasaki, Ryota; Miyamoto, Naokazu; Oki, Haruka] Hyogo Brain & Heart Ctr, Dept Radiol, Himeji, Hyogo 6700981, Japan; [Okada, Takuya; Yamaguchi, Masato; Sugimura, Kazuro; Sugimoto, Koji] Kobe Univ, Dept Radiol, Grad Sch Med, Chuo Ku, Kobe, Hyogo 657, Japan; [Okada, Takuya; Yamaguchi, Masato; Sugimura, Kazuro; Sugimoto, Koji] Kobe Univ, Ctr Endovasc Therapy, Grad Sch Med, Chuo Ku, Kobe, Hyogo 657, Japan; [Gomi, Takashi] Himeji Med Ctr, Dept Surg, Himeji, Hyogo, Japan; [Higashino, Takanori; Washio, Tetsuo; Maruta, Tsutomu] Himeji Med Ctr, Dept Radiol, Himeji, Hyogo, Japan	Kawasaki, R (reprint author), Hyogo Brain & Heart Ctr, Dept Radiol, 520 Saisho Ko, Himeji, Hyogo 6700981, Japan.	kawaryo1999@yahoo.co.jp					Hur S, 2011, J VASC INTERV RADIOL, V22, P294, DOI 10.1016/j.jvir.2010.11.020; Miura F, 2009, J HEPATO-BILIARY-PAN, V16, P56, DOI 10.1007/s00534-008-0012-3; Fujii Y, 2007, J GASTROINTEST SURG, V11, P432, DOI 10.1007/s11605-006-0076-9; Song HH, 2010, J VASC INTERV RADIOL, V21, P1508, DOI 10.1016/j.jvir.2010.05.022; Arai Y, 1997, CANCER CHEMOTH PHARM, V40, P526, DOI 10.1007/s002800050697; Ikeda O, 2010, CARDIOVASC INTER RAD, V33, P1128, DOI 10.1007/s00270-010-9973-0; Lagana D, 2006, EUR J RADIOL, V59, P104, DOI 10.1016/j.ejrad.2006.02.004; Larson RA, 2002, J VASC SURG, V36, P1260, DOI 10.1067/mva.2002.129645; Loffroy R, 2010, EUR J VASC ENDOVASC, V40, P209, DOI 10.1016/j.ejvs.2010.03.009; Moukaddam H, 2007, J VASC INTERV RADIOL, V18, P897, DOI 10.1016/j.jvir.2007.04.032; Narumi S, 2007, HEPATO-GASTROENTEROL, V54, P2152; Rossi M, 2008, CARDIOVASC INTER RAD, V31, P36, DOI 10.1007/s00270-007-9167-6; ROUGIER P, 1992, J CLIN ONCOL, V10, P1112; Sasaki K, 2009, SURG TODAY, V39, P68, DOI 10.1007/s00595-008-3775-x	14	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					772	776		10.1007/s00595-014-0976-3		5	Surgery	Surgery	CJ6KW	WOS:000355603700016		
J	Ito, M; Matsumoto, S; Takayama, T; Wakatsuki, K; Tanaka, T; Migita, K; Nakajima, Y				Ito, Masahiro; Matsumoto, Sohei; Takayama, Tomoyoshi; Wakatsuki, Kohei; Tanaka, Tetsuya; Migita, Kazuhiro; Nakajima, Yoshiyuki			Cronkhite-Canada syndrome associated with esophageal and gastric cancers: report of a case	SURGERY TODAY			English	Article						Cronkhite-Canada syndrome; Esophageal cancer; Gastric cancer; Multiple primary cancers	GASTROINTESTINAL POLYPOSIS	Cronkhite-Canada Syndrome (CCS) is a rare non-inherited gastrointestinal polyposis syndrome with characteristic ectodermal changes. We report an extremely unusual case of CCS associated with primary esophageal and gastric cancers. A 74-year-old Japanese man with symptoms of anorexia and diarrhea was found to have primary esophageal and gastric cancers, as well as multiple gastric and colonic polyps. Based on the physical findings of onychodystrophy and alopecia, we diagnosed CCS. Because of his age and nutritional status, we decided to perform total gastrectomy for gastric cancer and chemoradiotherapy for esophageal cancer, upon completion of which the patient was started on steroid therapy for the CCS. After 1 week of steroid therapy, the patient's watery diarrhea improved. We recommend that for patients with CCS, the therapeutic strategy be carefully considered based on the patient's nutritional status, the severity of the CCS, and the extent of gastrointestinal cancer.	[Ito, Masahiro; Matsumoto, Sohei; Takayama, Tomoyoshi; Wakatsuki, Kohei; Tanaka, Tetsuya; Migita, Kazuhiro; Nakajima, Yoshiyuki] Nara Med Univ, Dept Surg, Kashihara, Nara 6348522, Japan	Ito, M (reprint author), Nara Med Univ, Dept Surg, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	mito@naramed-u.ac.jp					CRONKHITE LW, 1955, NEW ENGL J MED, V252, P1011, DOI 10.1056/NEJM195506162522401; Matsunou H, 1996, CANCER, V77, P1998, DOI 10.1002/(SICI)1097-0142(19960515)77:10<1998::AID-CNCR6>3.0.CO;2-D; Egawa T, 2000, GASTRIC CANCER, V3, P156, DOI 10.1007/PL00011711; Goto A, 1986, J JPN SOC CANC THER, V41, P1597; Hushida S, 1994, J JPN SURG ASS, V55, P2854; KANEKO Y, 1991, JPN J CLIN ONCOL, V21, P194; Karasawa H, 2009, GASTRIC CANCER, V12, P113, DOI 10.1007/s10120-009-0506-y; Konishi T, 1998, J JPN SURG ASS, V59, P2801; MURAI N, 1993, SURG TODAY, V23, P825; Murata I, 2000, J GASTROENTEROL, V35, P706, DOI 10.1007/s005350070051; Nakamura Y, 1979, STOMACH INTESTINE, V14, P1217; NONOMURA A, 1980, ACTA PATHOL JAPON, V30, P825; Sagara K, 1983, J GASTROENTEROL, V18, P260; Tanaka Y, 2012, J JPN SURG ASS, V73, P847; UCHIDA Y, 1986, Stomach and Intestine (Tokyo), V21, P559; Ward EM, 2002, ALIMENT PHARM THERAP, V16, P333, DOI 10.1046/j.1365-2036.2002.01172.x; Watanabe T, 1999, GASTROINTEST ENDOSC, V50, P688, DOI 10.1016/S0016-5107(99)80022-4; Watari J, 2001, DIGEST ENDOSC, V23, P319; Yamaguchi K, 2001, SURG TODAY, V31, P521; Yokoyama S, 1983, STOMACH INTESTINE, V18, P981; Yokoyama T, 2003, J JPN SURG ASS, V64, P3052	21	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					777	782		10.1007/s00595-014-0977-2		6	Surgery	Surgery	CJ6KW	WOS:000355603700017		
J	Tanioka, T; Matsumoto, S; Takahashi, S; Ueki, S; Takahashi, M; Ichihara, S				Tanioka, Toshiro; Matsumoto, Satoru; Takahashi, Shusaku; Ueki, Shinya; Takahashi, Masahiro; Ichihara, Shin			Laparoscopic distal gastrectomy for pyloric stenosis caused by heterotopic glands in a young female: report of a case	SURGERY TODAY			English	Article						Heterotopic glands; Pyloric stenosis; Laparoscopic distal gastrectomy	GASTRIC-MUCOSA; OBSTRUCTION; STOMACH	A 17-year-old female was referred to our hospital with worsening dietary intake and abdominal bloating. She had epigastric fullness, but no abdominal pain. Gastrointestinal endoscopy revealed food residue and pyloric stenosis. A contrast-enhanced radiograph also showed pyloric stenosis, and gastrografin was not passed well through her pylorus. Computed tomography revealed similar findings. The biopsy results indicated hyperplasia of the gastric glands. The patient was diagnosed with a benign lesion, and underwent endoscopic balloon dilation several times. However, her stenosis worsened and we decided to perform surgery. In consideration of the cosmetic outcome, we performed laparoscopic distal gastrectomy. The postoperative course was good, and the patient was discharged on postoperative day 10. The final diagnosis was pyloric stenosis caused by heterotopic glands. No malignant lesions were found. Since gastric stenosis caused by heterotopic glands has not been reported previously, we consider this to be a very rare case.	[Tanioka, Toshiro; Matsumoto, Satoru; Takahashi, Shusaku; Ueki, Shinya; Takahashi, Masahiro] JA Sapporo Kosei Hosp, Dept Surg, Chuo Ku, Sapporo, Hokkaido 0600033, Japan; [Ichihara, Shin] JA Sapporo Kosei Hosp, Dept Pathol, Chuo Ku, Sapporo, Hokkaido 0600033, Japan	Tanioka, T (reprint author), JA Sapporo Kosei Hosp, Dept Surg, Chuo Ku, N3,E8, Sapporo, Hokkaido 0600033, Japan.	t-tanioka@umin.ac.jp					Amy Noffsinger CMF-P, 2008, GASTROINTESTINAL DIS; Tanpowpong P, 2011, DIS ESOPHAGUS, V24, pE32, DOI 10.1111/j.1442-2050.2011.01192.x; Atik F A, 1998, Rev Assoc Med Bras, V44, P340; DERKSEN EJ, 1989, NETH J SURG, V41, P35; Fenoglio-Preiser CM., 2008, GASTROINTESTINAL PAT; IWANAGA T, 1975, CANCER, V36, P606, DOI 10.1002/1097-0142(197508)36:2<606::AID-CNCR2820360243>3.0.CO;2-V; LODGE JPA, 1987, BRIT J RADIOL, V60, P710; Matsuoka M, 1995, GASTROENTEROL ENDOSC, P767; Ohira S, 2002, I TO CHYO, P233; POWELL RW, 1988, J PEDIATR SURG, V23, P632, DOI 10.1016/S0022-3468(88)80633-X; Watanabe H, 1990, HISTOLOGICAL TYPING; WOLFF M, 1971, AM J CLIN PATHOL, V55, P604; YAMAGIWA H, 1979, ACTA PATHOL JAPON, V29, P347	13	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					783	786		10.1007/s00595-014-0962-9		4	Surgery	Surgery	CJ6KW	WOS:000355603700018		
J	Miyo, M; Takemasa, I; Mokutani, Y; Uemura, M; Nishimura, J; Hata, T; Mizushima, T; Yamamoto, H; Doki, Y; Mori, M				Miyo, Masaaki; Takemasa, Ichiro; Mokutani, Yukako; Uemura, Mamoru; Nishimura, Junichi; Hata, Taishi; Mizushima, Tsunekazu; Yamamoto, Hirofumi; Doki, Yuichiro; Mori, Masaki			Single-incision laparoscopic rectopexy (Wells) with simultaneous sigmoidectomy in a case of complete rectal prolapse and a sigmoid tumor: report of a case	SURGERY TODAY			English	Article						Wells; Single-incision; Laparoscopy; Rectal prolapse; Polyp	SURGERY; RESECTION; CANCER; TRIAL	Recently, the technique of single-incision laparoscopic surgery for colorectal disease has rapidly disseminated in association with improvements in instrumentation and procedures, offering a less invasive procedure and excellent cosmetic results. We herein present the case of a 74-year-old female who suffered complete rectal prolapse with a pedunculated polyp (20 mm) in the sigmoid colon; the stalk of the polyp was too thick to perform endoscopic mucosal resection, which is associated with a high risk of bleeding. The patient was successfully managed using single-incision laparoscopic rectopexy (Wells) with simultaneous sigmoidectomy, a procedure that has not been reported in the literature to date. There were no perioperative complications. The patient's constipation caused by the rectal prolapse improved, and no recurrence was observed for 2 months after the operation. This case emphasizes that complete rectal prolapse is a benign disease occurring in elderly patients that is well suited to treatment with minimally invasive single-incision laparoscopic surgery.	[Miyo, Masaaki; Takemasa, Ichiro; Mokutani, Yukako; Uemura, Mamoru; Nishimura, Junichi; Hata, Taishi; Mizushima, Tsunekazu; Yamamoto, Hirofumi; Doki, Yuichiro; Mori, Masaki] Osaka Univ, Grad Sch Med Osaka, Dept Surg Gastroenterol, Suita, Osaka 5650871, Japan	Miyo, M (reprint author), Osaka Univ, Grad Sch Med Osaka, Dept Surg Gastroenterol, 2-2,E-2, Suita, Osaka 5650871, Japan.	phantommasa0905@yahoo.co.jp; itakemasa@gesurg.med.osaka-u.ac.jp	Nishimura, Junichi/K-8390-2015	Nishimura, Junichi/0000-0001-8220-3423			Adair J, 2011, AM J SURG, V202, P243, DOI 10.1016/j.amjsurg.2010.08.034; Gutt CN, 2004, SURG ENDOSC, V18, P898, DOI 10.1007/s00464-003-9233-3; Solomon MJ, 2002, BRIT J SURG, V89, P35, DOI 10.1046/j.0007-1323.2001.01957.x; Takemasa I, 2014, SURG ENDOSC, V28, P1110, DOI 10.1007/s00464-013-3284-x; Bergamaschi R, 2003, SURG LAPARO ENDO PER, V13, P374, DOI 10.1097/00129689-200312000-00005; Chand M, 2011, BRIT J SURG, V98, P166, DOI 10.1002/bjs.7379; HASSAON HM, 1971, AM J OBSTET GYNECOL, V110, P886; HENRY LG, 1994, SURG LAPAROSC ENDOSC, V4, P357; Himpens J, 1999, SURG ENDOSC-ULTRAS, V13, P139, DOI 10.1007/s004649900923; HUBER FT, 1995, WORLD J SURG, V19, P138; Takao Y, 2007, SURG THER, V96, P167; Takemasa I, 2010, SURG ENDOSC, V24, P2321, DOI 10.1007/s00464-010-0948-7; Williams JG, 2012, CONT COLOPROCTOLOGY, P421; Yamamoto S, 2013, ANN SURG, V258, P283, DOI 10.1097/SLA.0b013e318283669c	14	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	JUN	2015	45	6					793	798		10.1007/s00595-014-0963-8		6	Surgery	Surgery	CJ6KW	WOS:000355603700020		
J	Yamaguchi, M; Ichinose, Y; Shimamatsu, S; Yoshida, T; Toyokawa, G; Nosaki, K; Hirai, F; Seto, T; Takenoyama, M				Yamaguchi, Masafumi; Ichinose, Yukito; Shimamatsu, Shinichiro; Yoshida, Tsukihisa; Toyokawa, Gouji; Nosaki, Kaname; Hirai, Fumihiko; Seto, Takashi; Takenoyama, Mitsuhiro			Preoperative concurrent chemoradiotherapy followed by extrapleural pneumonectomy for patients with non-small cell lung cancer with malignant pleural effusion and/or pleural nodules: Ten-year results of a prematurely terminated single institute phase II trial	SURGICAL ONCOLOGY-OXFORD			English	Review						Non-small cell lung cancer; Malignant pleural effusion and/or pleural nodules; UFT and cisplatin; Hemithorax radiation; Extrapleural pneumonectomy	HYPOTONIC CISPLATIN TREATMENT; LAVAGE CYTOLOGY; CARCINOMATOUS PLEURITIS; PLUS CISPLATIN; THORACOTOMY; DISSEMINATION; MESOTHELIOMA; CHEMOTHERAPY; METAANALYSIS; PROGNOSIS	Background: Malignant pleural effusion and/or pleural nodules are a final stage of disease extension of non-small cell lung cancer (NSCLC), which is currently classified as M1a-Stage IV disease. The role of surgery, especially extrapleural pneumonectomy (EPP) for local disease control and its impact on the survival of patients remains uncertain. Patients and methods: This single institute phase II trial was performed from March 1997 to March July 2004 to assess the effects of induction concurrent chemoradiotherapy (CRT) using a pro-drug of 5-FU, uracil-tegafur (UFT (R), Taiho Pharmaceutical Co., Ltd, Tokyo, Japan), plus cisplatin concurrently with 40 Gy hemithorax radiation followed by EPP. Intraoperative hypotonic cisplatin treatment in the pleural cavity before resection of the pericardium and diaphragm was performed. The primary endpoint of this study was the overall survival (OS), and the secondary endpoint was the disease-free survival (DFS), safety, response to the induction CRT, local disease control period in the affected thorax and the type of disease recurrence. Results: This trial was prematurely terminated because of the slow registration pace. During the study period, 11 patients were enrolled. There were five males and six females, with a median age of 55 (36 -64) years. All patients had adenocarcinoma. All patients received the planned induction CRT. Five patients achieved a partial response and five achieved stable disease, and one patient could not be evaluated. One patient underwent exploratory thoracotomy due to unresectable chest wall invasion, and nine patients (81.8%) underwent EPP. No perioperative deaths were encountered. The median follow-up time was matured at 32.1 (range 15.0-100) months. The one-, three-and five-year DFS rates were 77.8% (95% CI: 50.6-100%), 11.1% and 11.1% (95% CI: 95% CI: 0-31.7%), respectively. The one-, three-and five-year OS rates were 100.0%, 33.3% (95% CI: 2.5-64.1%) and 22.2% (95% CI: 0.0-49.4%), respectively. Recurrence developed in eight of nine patients who underwent EPP (88.9%). All first recurrent sites were distant regions, and no ipsilateral local recurrence was identified. Conclusion: The trimodality treatment used in this trial appears to be a choice of treatment for highly selected patients. However, the impact on the survival of NSCLC patients with malignant pleural effusion and/or pleural nodules still remains uncertain given the small number of patients enrolled in the study. (C) 2015 Elsevier Ltd. All rights reserved.	[Yamaguchi, Masafumi; Ichinose, Yukito; Shimamatsu, Shinichiro; Yoshida, Tsukihisa; Toyokawa, Gouji; Nosaki, Kaname; Hirai, Fumihiko; Seto, Takashi; Takenoyama, Mitsuhiro] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Minami Ku, Fukuoka 8111395, Japan	Yamaguchi, M (reprint author), Kyushu Natl Canc Ctr, Dept Thorac Oncol, Minami Ku, 3-1-1 Notame, Fukuoka 8111395, Japan.	yamaguchi.m@nk-cc.go.jp					Seto T, 2006, BRIT J CANCER, V95, P717, DOI 10.1038/sj.bjc.6603319; Krug LM, 2009, J CLIN ONCOL, V27, P3007, DOI 10.1200/JCO.2008.20.3943; Van Schil PE, 2010, EUR RESPIR J, V36, P1362, DOI 10.1183/09031936.00039510; Fujita A, 2001, CHEST, V119, P340, DOI 10.1378/chest.119.2.340; Fukuse T, 2001, LUNG CANCER-J IASLC, V34, P75, DOI 10.1016/S0169-5002(01)00228-8; Ichinose Y, 2002, J THORAC CARDIOV SUR, V123, P695, DOI 10.1067/mtc.2002.120712; Ichinose Y, 2004, CLIN CANCER RES, V10, P4369, DOI 10.1158/1078-0432.CCR-04-0143; Ichinose Y, 2000, SURG TODAY, V30, P1062; Lim E, 2010, J THORAC CARDIOV SUR, V139, P1441, DOI 10.1016/j.jtcvs.2009.05.048; National Cancer Institute. Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E; Burdett S, 2008, J CLIN ONCOL, V26, P4617, DOI 10.1200/JCO.2008.17.7162; Ohta Y, 2000, ANN THORAC SURG, V69, P1025, DOI 10.1016/S0003-4975(99)01579-9; Okada M, 2003, J THORAC CARDIOV SUR, V126, P1911, DOI 10.1016/S0022-5223(03)00715-3; Sawabata N, 2002, ANN THORAC SURG, V73, P412, DOI 10.1016/S0003-4975(01)03426-9; Shimizu J, 1996, J SURG ONCOL, V61, P1, DOI 10.1002/(SICI)1096-9098(199601)61:1<1::AID-JSO1>3.0.CO;2-H; Sobin LH, 2009, TNM CLASSIFICATION M; Sobin LH, 2002, TNM CLASSIFICATION M; Travis WD, 1999, INT HISTOLOGICAL CLA, V3rd	18	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0960-7404	1879-3320		SURG ONCOL	Surg. Oncol.-Oxf.	JUN	2015	24	2					78	83		10.1016/j.suronc.2015.02.004		6	Oncology; Surgery	Oncology; Surgery	CJ7MI	WOS:000355679200004		
J	Hiwa, S; Nishioka, M; Hiroyasu, T; Miki, M				Hiwa, Satoru; Nishioka, Masashi; Hiroyasu, Tomoyuki; Miki, Mitsunori			Novel search scheme for multi-objective evolutionary algorithms to obtain well-approximated and widely spread Pareto solutions	SWARM AND EVOLUTIONARY COMPUTATION			English	Article						Evolutionary algorithm; Reference point-based algorithm; Distributed cooperation scheme; Multi-objective optimization	OPTIMIZATION; MOEA/D; DECOMPOSITION	In multi-objective optimization, the quality of Pareto-optimal solutions is evaluated by the efficiency of the optimal front (proximity), uniformity, and spread. This paper introduces a novel search scheme for multi-objective evolutionary algorithms (MOEAs), whose solutions demonstrate improved proximity and spread metrics. Our proposed scheme comprises two search phases with different search objectives. The first phase uses a reference-point-based approach to improve proximity; the second phase adopts a distributed-cooperation scheme (DC-scheme) to broaden the range of solutions. We experimentally investigate the effectiveness of our proposed scheme on the walking fish group (WFG) test suite of scalable multi-objective problems. Finally, we show the applicability of the proposed scheme to various types of MOEAs. (C) 2015 Elsevier B.V. All rights reserved.		Hiwa, S (reprint author), 1-3 Tatara Miyakodani, Kyotanabe, Kyoto, Japan.	hiwa1983@gmail.com					Deb K, 2006, GECCO 2006: GENETIC AND EVOLUTIONARY COMPUTATION CONFERENCE, VOL 1 AND 2, P635; Bandyopadhyay S, 2008, IEEE T EVOLUT COMPUT, V12, P269, DOI 10.1109/TEVC.2007.900837; Bradstreet L, 2008, IEEE T EVOLUT COMPUT, V12, P714, DOI 10.1109/TEVC.2008.919001; NELDER JA, 1965, COMPUT J, V7, P308; Bosman PAN, 2012, IEEE T EVOLUT COMPUT, V16, P51, DOI 10.1109/TEVC.2010.2051445; Li H, 2009, IEEE T EVOLUT COMPUT, V13, P284, DOI 10.1109/TEVC.2008.925798; Huband S, 2006, IEEE T EVOLUT COMPUT, V10, P477, DOI 10.1109/TEVC.2005.861417; Durillo JJ, 2011, ADV ENG SOFTW, V42, P760, DOI 10.1016/j.advengsoft.2011.05.014; Zhang QF, 2007, IEEE T EVOLUT COMPUT, V11, P712, DOI 10.1109/TEVC.2007.892759; Molina J, 2009, EUR J OPER RES, V197, P685, DOI 10.1016/j.ejor.2008.07.015; Paquete L, 2003, LECT NOTES COMPUT SC, V2632, P479; Ishibuchi H, 2009, IEEE SYS MAN CYBERN, P1758, DOI 10.1109/ICSMC.2009.5346628; Zitzler E, 2003, IEEE T EVOLUT COMPUT, V7, P117, DOI 10.1109/TEVC.2003.810758; Bradstreet L., 2007, COMP INT MULT DEC MA, P382; Chankong V., 1983, N HOLLAND SERIES SYS; Chiang TC, 2011, IEEE C EVOL COMPUTAT, P1473; Deb K, 2000, 200001 KANGAL IND I; Deb K., 1995, Complex Systems, V9; Dubois-Lacoste J., 2013, STUDIES COMPUTATIONA, V434, P97; Goldberg D. E., 1989, GENETIC ALGORITHMS S; Hiwa S., 2012, 2012 Joint 6th International Conference on Soft Computing and Intelligent Systems (SCIS 2012) and 13th International Symposium on Advanced Intelligent Systems (ISIS 2012), DOI 10.1109/SCIS-ISIS.2012.6505242; Huang V. L., 2007, TECHNICAL REPORT; Ishibuchi H, 2004, LECT NOTES COMPUT SC, V3102, P1259; Jaimes AL, 2005, IEEE C EVOL COMPUTAT, P2294; Knowles J., 2005, Proceedings. 5th International Conference on Intelligent Systems Design and Applications; Knowles J. D., 2006, 214 TIK ETH ZUR COMP; Kukkonen S., 2006, IEEE C EV COMP, P2002; Li H, 2006, LECT NOTES COMPUT SC, V4193, P583; Martinez S. Zapotecas, 2011, P 13 ANN C GEN EV CO, P69; Martinez S.Z., 2012, INNOV FOOD SCI EMERG, P1; Mohammadi M.N.O. Asad, 2012, P 2012 IEEE WORLD C, P1150; Nguyen TT, 2012, SWARM EVOL COMPUT, V6, P1, DOI 10.1016/j.swevo.2012.05.001; Okuda T., 2002, ADV NATURE INSPIRED, P25; Tan Y. Yan, 2012, COMPUT OPER RES; Tanese R., 1989, P 3 INT C GEN ALG IC, P434; Wickramasinghe U. K., 2008, P 10 ANN C GEN EV CO, P745, DOI 10.1145/1389095.1389237; Zitzler E, 2001, 103 TIK ETH SWISS FE	37	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	2210-6502	2210-6510		SWARM EVOL COMPUT	Swarm Evol. Comput.	JUN	2015	22						30	46		10.1016/j.swevo.2015.01.004		17	Computer Science, Artificial Intelligence; Computer Science, Theory & Methods	Computer Science	CK0HB	WOS:000355885200003		
J	McKinley, IG; Kawamura, H; Hardie, SML; Klein, E; Beattie, TM				McKinley, Ian G.; Kawamura, Hideki; Hardie, Susie M. L.; Klein, Elizaveta; Beattie, Tara M.			Key natural analogue input required to build a safety case for direct disposal of spent nuclear fuel in Japan	SWISS JOURNAL OF GEOSCIENCES			English	Article						Deep geological disposal; Steel corrosion; Canister failure; Redox buffering; Radiolysis; Realistic assessment	ROCK	Natural analogues have been previously used to support the safety case for direct disposal of spent nuclear fuel, but the focus of such work was very dependent on the key barriers of specific national disposal concepts. Investigations of the feasibility of such disposal in Japan are at an early stage but, nevertheless, it is clear that building a robust safety case will be very challenging and would benefit from focused support from natural analogue studies-both in terms of developing/testing required models and, as importantly, presenting safety arguments to a wide range of stakeholders. This paper identifies key analogues that support both longevity and spread of failure times of massive steel overpacks, the effectiveness of buffering of radiolytic oxidants and the chemical and physical mechanisms retarding release of radionuclides from the engineered barriers. It is concluded that, for countries like Japan where performance needs to be assessed as realistically as possible, natural analogues can complement the existing laboratory and theoretical knowledge base and contribute towards development of a robust safety case.	[McKinley, Ian G.; Hardie, Susie M. L.; Klein, Elizaveta] MCM Consulting, CH-5405 Baden, Switzerland; [Kawamura, Hideki] Obayashi Corp, Nucl Facil Div, Minato Ku, Tokyo 1088502, Japan; [Beattie, Tara M.] MCM Consulting, Orchard St Business Ctr, Bristol BS1 5EH, Avon, England	McKinley, IG (reprint author), MCM Consulting, Tafernstr 11, CH-5405 Baden, Switzerland.	ian.mckinley@mcm-international.ch; susie.hardie@mcm-international.ch					Akagawa F, 2006, GEOCHEM-EXPLOR ENV A, V6, P49, DOI 10.1144/1467-7873/05-085; Alexander W.R., 1994, 9110 NTB; Sadiq R, 2004, RELIAB ENG SYST SAFE, V86, P1, DOI 10.1016/j.ress.2003.12.007; Mennecart T, 2004, RADIOCHIM ACTA, V92, P611, DOI 10.1524/ract.92.9.611.55010; Alexander WR, 2015, SWISS J GEOSCI, V108, P75, DOI 10.1007/s00015-015-0187-y; Mazurek M, 2008, PHYS CHEM EARTH, V33, pS95, DOI 10.1016/j.pce.2008.10.046; Cabral AR, 2011, CHEM ERDE-GEOCHEM, V71, P297, DOI 10.1016/j.chemer.2011.02.004; COUTURE RA, 1983, NUCL CHEM WASTE MAN, V4, P301, DOI 10.1016/0191-815X(83)90055-4; Gridrod P, 1993, J CONTAM HYDROL, V13, P167; Hallberg R. O, 1987, WASTE MANAGEMENT SER, VEUR 11037, P135; JNC, 2000, TN1410 JNC; Johnson A. B., 1980, PNL3198; Laucht S. L, 2011, THESIS U NEWCASTLE A, P301; MacKenzie A.B., 1991, 9025 NTB; Marcos N, 1996, 199615 POS; Masuda S, 2004, NUCL ENG INT, V49, P26; McKinley I.G., 2012, P SCI BAS NUCL WAST, P281; McKinley I.G., 2009, VOLCANIC TECTONIC HA, P548, DOI 10.1017/CBO9780511635380.025; Miyahara K., 2009, P SCI BAS NUCL WAST, P177; Motamedi M, 1996, FEMS MICROBIOL LETT, V141, P83; MURPHY WM, 1994, NUCLEAR SCIENCE AND TECHNOLOGY, P219; Nagra, 2002, 0205 NTB; Reijonen HM, 2015, SWISS J GEOSCI, V108, P101, DOI 10.1007/s00015-015-0185-0; West J. M., 2002, ENCY ENV MICROBIOLOG, P2661; Yoshikawa H., 2003, P 9 INT C ENV REM RA	25	0	0	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1661-8726	1661-8734		SWISS J GEOSCI	Swiss J. Geosci.	JUN	2015	108	1					147	154		10.1007/s00015-015-0186-z		8	Geosciences, Multidisciplinary; Paleontology	Geology; Paleontology	CJ7GN	WOS:000355662800011		
J	Bayliffe, FH; Steven, A; Ando, K; Shipman, M				Bayliffe, Frances H.; Steven, Alan; Ando, Kaori; Shipman, Michael			Sodium Amide Induced Cyclization of 2-Iodoprop-2-enylamines: Application to the Synthesis of 1-Aryl-2-methyleneaziridines	SYNLETT			English	Article						aziridines; cyclization; aminocyclopropanes; DFT calculations; vinylic S(N)2	RADICAL REARRANGEMENT REACTIONS; PALLADIUM-CATALYZED REACTION; MULTICOMPONENT REACTIONS; 1,3-DISUBSTITUTED PROPANONES; SUBSTITUTED PIPERIDINES; 4-COMPONENT REACTION; ANNULATION REACTIONS; RAPID GENERATION; BETA-LACTAMS; METHYLENEAZIRIDINES	The effect of the halogen on the rate of sodium amide induced cyclization of 2-haloprop-2-enylamines to methyleneaziridines is studied. Using DFT calculations and competition experiments, it is shown to proceed faster using iodide-based substrates. A practical route to 1-aryl-2-methyleneaziridines is devised based on these observations and their further rearrangement to cyclopropanimines explored.	[Bayliffe, Frances H.; Shipman, Michael] Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England; [Steven, Alan] AstraZeneca Pharmaceut Dev, Macclesfield SK10 2NA, Cheshire, England; [Ando, Kaori] Gifu Univ, Dept Chem, Fac Engn, Gifu 5011193, Japan	Shipman, M (reprint author), Univ Warwick, Dept Chem, Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.	m.shipman@warwick.ac.uk			Engineering and Physical Sciences Research Council; AstraZeneca	This work was financially supported by the Engineering and Physical Sciences Research Council and AstraZeneca.	ALPER H, 1987, TETRAHEDRON LETT, V28, P3237, DOI 10.1016/S0040-4039(00)95481-9; Tehrani KA, 2009, CURR ORG CHEM, V13, P854; de Nanteuil F, 2014, J AM CHEM SOC, V136, P6239, DOI 10.1021/ja5024578; Boralsky LA, 2011, ORG LETT, V13, P1924, DOI 10.1021/ol2002418; Cariou CCA, 2008, J ORG CHEM, V73, P9762, DOI 10.1021/jo801664g; Adams CS, 2012, J AM CHEM SOC, V134, P10807, DOI 10.1021/ja304859w; de Nanteuil F, 2013, ORG LETT, V15, P3738, DOI 10.1021/ol401616a; Montagne C, 2006, TETRAHEDRON LETT, V47, P9207, DOI 10.1016/j.tetlet.2006.10.135; Takahashi H, 2014, ORG LETT, V16, P1192, DOI 10.1021/ol500062a; Pan B, 2013, CHEM COMMUN, V49, P5073, DOI 10.1039/c3cc41061g; BINGHAM EM, 1975, J ORG CHEM, V40, P224, DOI 10.1021/jo00890a016; BOTTINI AT, 1957, J AM CHEM SOC, V79, P1462, DOI 10.1021/ja01563a051; BOTTINI AT, 1963, J ORG CHEM, V28, P3241, DOI 10.1021/jo01046a525; ETTLINGER MG, 1956, CHEM IND-LONDON, P166; Griffin K, 2012, ORG BIOMOL CHEM, V10, P1032, DOI 10.1039/c1ob06578e; Hayes JF, 2002, J ORG CHEM, V67, P935, DOI 10.1021/jo016164v; Ince J, 1996, TETRAHEDRON, V52, P7037, DOI 10.1016/0040-4020(96)00308-0; Ishikawa S, 2013, ANGEW CHEM INT EDIT, V52, P10060, DOI 10.1002/anie.201304720; Ismailov VM, 2009, RUSS J ORG CHEM+, V45, P1250, DOI 10.1134/S1070428009080247; Kathriarachchi KKADS, 2007, TETRAHEDRON LETT, V48, P2267, DOI 10.1016/j.tetlet.2007.01.170; Margathe JF, 2005, ORG LETT, V7, P4987, DOI 10.1021/ol051953a; Miyamura S, 2015, ANGEW CHEM INT EDIT, V54, P846, DOI 10.1002/anie.201409186; Mumford PM, 2009, J ORG CHEM, V74, P3573, DOI 10.1021/jo9004958; Oh Byoung Ho, 2004, Journal of Organic Chemistry, V69, P2856, DOI 10.1021/jo035739g; Oh BH, 2002, TETRAHEDRON LETT, V43, P9625, DOI 10.1016/S0040-4039(02)02410-3; POLLARD CB, 1951, J AM CHEM SOC, V73, P2925, DOI 10.1021/ja01150a145; Prevost N, 2001, ORG LETT, V3, P2383, DOI 10.1021/ol016194k; Prevost N, 2002, TETRAHEDRON, V58, P7165, DOI 10.1016/S0040-4020(02)00730-5; Prie G, 2004, ANGEW CHEM INT EDIT, V43, P6517, DOI 10.1002/anie.200461084; QUAST H, 1973, ANGEW CHEM INT EDIT, V12, P414, DOI 10.1002/anie.197304141; Rigoli JW, 2014, ORG LETT, V16, P1696, DOI 10.1021/ol5003576; Rigoli JW, 2013, ORG LETT, V15, P290, DOI 10.1021/ol303167n; Robertson J, 2010, ORG BIOMOL CHEM, V8, P3060, DOI 10.1039/c003693e; Serrano E, 2014, SYNLETT, V25, P2285, DOI 10.1055/s-0034-1378512; Shiers JJ, 2006, CHEM COMMUN, P649, DOI 10.1039/b516192d; Shiers JJ, 2004, J AM CHEM SOC, V126, P6868, DOI 10.1021/ja0482684; Shipman M, 2006, SYNLETT, P3205, DOI 10.1055/s-2006-951566; Siriwardana AI, 2004, J AM CHEM SOC, V126, P13898, DOI 10.1021/ja0455401; Stoll AH, 2010, J AM CHEM SOC, V132, P2108, DOI 10.1021/ja908538t; Takahashi H, 2013, EUR J ORG CHEM, P40, DOI 10.1002/ejoc.201201305; Takasu K, 2002, J ORG CHEM, V67, P6001, DOI 10.1021/jo0258397; Valenta P, 2010, J AM CHEM SOC, V132, P14179, DOI 10.1021/ja105435y; WIJNBERG JBPA, 1981, SYNTHESIS-STUTTGART, P901; Yudin A. K., 2006, AZIRIDINES EXPOXIDES	44	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0936-5214	1437-2096		SYNLETT	Synlett	JUN	2015	26	10					1371	1374		10.1055/s-0034-1380521		4	Chemistry, Organic	Chemistry	CJ7SD	WOS:000355698400011		
J	Agata, R; Iwamoto, T; Nakagawa, N; Isozaki, K; Hatakeyama, T; Takaya, H; Nakamura, M				Agata, Ryosuke; Iwamoto, Takahiro; Nakagawa, Naohisa; Isozaki, Katsuhiro; Hatakeyama, Takuji; Takaya, Hikaru; Nakamura, Masaharu			Iron Fluoride/N-Heterocyclic Carbene Catalyzed Cross Coupling between Deactivated Aryl Chlorides and Alkyl Grignard Reagents with or without beta-Hydrogens	SYNTHESIS-STUTTGART			English	Article						C-C bond formation; cross coupling; iron fluoride; N-heterocyclic carbene; aryl chloride	HALIDES; REACTIVITY; TOSYLATES; CHEMISTRY; ALKENYLATION; COMPLEXES	High-yielding cross-coupling reactions of various combinations of aryl chlorides and alkyl Grignard reagents have been developed by using an iron(III) fluoride/1,3-bis(2,6-diisopropylphenyl)imidazolin-2-ylidene (SIPr) catalyst composite. The iron(III) fluoride/SIPr-catalyzed aryl-alkyl coupling demonstrates unprecedented scope for both aryl chlorides and alkyl Grignard reagents, thus enabling the first efficient coupling of electron-rich (deactivated) aryl chlorides with alkyl Grignard reagents without -hydrogens. The present reaction is also effective for diverse alkyl Grignard reagents such as (trimethylsilyl)methyl, primary, and secondary alkyl Grignard reagents.	[Agata, Ryosuke; Iwamoto, Takahiro; Nakagawa, Naohisa; Isozaki, Katsuhiro; Hatakeyama, Takuji; Takaya, Hikaru; Nakamura, Masaharu] Kyoto Univ, Inst Chem Res, Int Res Ctr Elements Sci, Kyoto 6110011, Japan; [Agata, Ryosuke; Iwamoto, Takahiro; Nakagawa, Naohisa; Isozaki, Katsuhiro; Takaya, Hikaru; Nakamura, Masaharu] Kyoto Univ, Grad Sch Engn, Dept Energy & Hydrocarbon Chem, Nishikyo Ku, Kyoto 6158510, Japan; [Iwamoto, Takahiro] CRESTJapan Sci & Technol Agcy JST, Kawaguchi, Saitama 3320012, Japan; [Hatakeyama, Takuji] Kyoto Univ, Elements Strategy Initiat Catalysts & Batteries, Nishikyo Ku, Kyoto 6158520, Japan	Nakamura, M (reprint author), Kyoto Univ, Inst Chem Res, Int Res Ctr Elements Sci, Kyoto 6110011, Japan.	masaharu@scl.kyoto-u.ac.jp			Japan Society for the Promotion of Science (JSPS) through the 'Funding Program for Next-Generation World-Leading Researchers (NEXT Program); Council for Science and Technology Policy (CSTP); Japan Science and Technology Agency (JST); Core Research for Evolutional Science and Technology Program [CREST 1102545]; MEXT program 'Elements Strategy Initiative to Form Core Research Center'	This work was supported by the Japan Society for the Promotion of Science (JSPS) through the 'Funding Program for Next-Generation World-Leading Researchers (NEXT Program),' initiated by the Council for Science and Technology Policy (CSTP) and supported in part by the Japan Science and Technology Agency (JST), the Core Research for Evolutional Science and Technology (CREST 1102545) Program, and MEXT program 'Elements Strategy Initiative to Form Core Research Center.' T.I. and K.I. also thank RIKEN for the provision of beam time in SPring-8 (BL14B2: 2014B1907 and 2014B1654).	Agrawal T, 2013, ORG LETT, V15, P96, DOI 10.1021/ol303130j; Agrawal T, 2014, ORG LETT, V16, P5080, DOI 10.1021/ol5024344; ALEANDRI LE, 1995, CHEM MATER, V7, P1153, DOI 10.1021/cm00054a015; Hatakeyama T, 2007, J AM CHEM SOC, V129, P9844, DOI 10.1021/ja0730841; Riener K, 2014, CHEM REV, V114, P5215, DOI 10.1021/cr4006439; Takaya H, 2015, B CHEM SOC JPN, V88, P410, DOI 10.1246/bcsj.20140376; Nicolaou KC, 2005, ANGEW CHEM INT EDIT, V44, P4442, DOI 10.1002/anie.200500368; Ingleson MJ, 2012, CHEM COMMUN, V48, P3579, DOI 10.1039/c2cc18021a; Furstner A, 2008, J AM CHEM SOC, V130, P8773, DOI 10.1021/ja801466t; Furstner A, 2006, ANGEW CHEM INT EDIT, V45, P440, DOI 10.1002/anie.200502859; Malhotra S, 2013, ORG LETT, V15, P3698, DOI 10.1021/ol401508u; Ghorai SK, 2012, ORG LETT, V14, P1066, DOI 10.1021/ol2031729; Cahiez G, 1998, SYNTHESIS-STUTTGART, P1199; Hatakeyama T, 2009, J AM CHEM SOC, V131, P11949, DOI 10.1021/ja9039289; Bezier D, 2013, ADV SYNTH CATAL, V355, P19, DOI 10.1002/adsc.201200666; Silberstein AL, 2012, ORG LETT, V14, P3796, DOI 10.1021/ol301681z; Bogdanovic B, 2000, ANGEW CHEM INT EDIT, V39, P4610, DOI 10.1002/1521-3773(20001215)39:24<4610::AID-ANIE4610>3.0.CO;2-O; Nakamura M, 2004, J AM CHEM SOC, V126, P3686, DOI 10.1021/ja049744t; Kawamura S, 2012, CHEM COMMUN, V48, P9376, DOI 10.1039/c2cc34185a; Furstner A, 2002, ANGEW CHEM INT EDIT, V41, P609; Barreiro EJ, 2011, CHEM REV, V111, P5215, DOI 10.1021/cr200060g; Hocek M, 2003, J ORG CHEM, V68, P5773, DOI 10.1021/jo034351i; Banno T, 2002, J ORGANOMET CHEM, V653, P288, DOI 10.1016/S0022-328X(02)01165-8; Scheiper B, 2004, J ORG CHEM, V69, P3943, DOI 10.1021/jo0498866; Daifuku SL, 2014, J AM CHEM SOC, V136, P9132, DOI 10.1021/ja503596m; Jana R, 2011, CHEM REV, V111, P1417, DOI 10.1021/cr100327p; Czaplik WM, 2009, CHEMSUSCHEM, V2, P396, DOI 10.1002/cssc.200900055; Yamamoto E, 2012, J AM CHEM SOC, V134, P19997, DOI 10.1021/ja309578k; Hatakeyama T, 2011, CHEM LETT, V40, P1030, DOI 10.1246/cl.2011.1030; TAMURA M, 1971, J AM CHEM SOC, V93, P1487, DOI 10.1021/ja00735a030; Schonherr H, 2013, ANGEW CHEM INT EDIT, V52, P12256, DOI 10.1002/anie.201303207; Bedford RB, 2006, J ORG CHEM, V71, P1104, DOI 10.1021/jo052250+; Hatakeyama T, 2010, J AM CHEM SOC, V132, P10674, DOI 10.1021/ja103973a; Furstner A, 2002, J AM CHEM SOC, V124, P13856, DOI 10.1021/ja027190t; Chemler SR, 2001, ANGEW CHEM INT EDIT, V40, P4544, DOI 10.1002/1521-3773(20011217)40:24<4544::AID-ANIE4544>3.0.CO;2-N; Nakamura E, 2011, NAT MATER, V10, P158, DOI 10.1038/nmat2969; Bedford RB, 2009, CHEM COMMUN, P600, DOI 10.1039/b818961g; Brase S., 2014, METAL CATALYZED CROS, P995; Cahiez G, 1996, PURE APPL CHEM, V68, P53, DOI 10.1351/pac199668010053; Furstner A., 2005, ORG SYNTH, V81, P33; Hegedus L.S., 2010, TRANSITION METALS SY; Nakamura E., 2014, ORG REACTIONS, V83, P1, DOI DOI 10.1002/0471264180.OR083.01; Nakamura M, 2005, SYNLETT, P1794, DOI 10.1055/s-2005-871541; NEUMANN SM, 1975, J ORG CHEM, V40, P599, DOI 10.1021/jo00893a013; Perry MC, 2012, TETRAHEDRON LETT, V53, P4436, DOI 10.1016/j.tetlet.2012.06.048; Rushworth PJ, 2013, J ORG CHEM, V78, P9517, DOI 10.1021/jo4016612; Sherry BD, 2008, ACCOUNTS CHEM RES, V41, P1500, DOI 10.1021/ar800039x; Siedlaczek G, 1998, CATAL LETT, V55, P67, DOI 10.1023/A:1019026711011; Tamao K., 1991, COMPREHENSIVE ORGANI, V3, P435	49	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0039-7881	1437-210X		SYNTHESIS-STUTTGART	Synthesis	JUN	2015	47	12					1733	1740		10.1055/s-0034-1380361		8	Chemistry, Organic	Chemistry	CJ7SP	WOS:000355700000007		
J	Kobori, Y; Suzuki, K; Iwahata, T; Shin, T; Sato, R; Nishio, K; Yagi, H; Arai, G; Soh, S; Okada, H				Kobori, Yoshitomo; Suzuki, Keisuke; Iwahata, Toshiyuki; Shin, Takeshi; Sato, Ryo; Nishio, Kojiro; Yagi, Hiroshi; Arai, Gaku; Soh, Shigehiro; Okada, Hiroshi			Induction of spermatogenesis by rhFSH for azoospermia due to spermatogenic dysfunction with maturation arrest: five case series	SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE			English	Article						Azoospermia; maturation arrest; recombinant human follicle-stimulating hormone; spermatogenesis	FOLLICLE-STIMULATING-HORMONE; TESTICULAR SPERM EXTRACTION; MALE-FACTOR INFERTILITY; NONOBSTRUCTIVE AZOOSPERMIA; GONADOTROPIN TREATMENT; RECOMBINANT FSH; MEN	When sperm cannot be retrieved from the testes of patients with azoospermia due to spermatogenic dysfunction (ASD), there is no rational way for the patient to become a biological father. We investigated the possibility of inducing spermatogenesis in such patients by hormonal therapy with recombinant human follicle-stimulating hormone (rhFSH) alone. Twenty-six ASD patients who could not obtain spermatozoa by microdissection testicular sperm extraction (micro-TESE) were confirmed to have arrested spermatogenesis at the late stage of maturation arrest. They were subsequently treated with 75-150 IU two times/week rhFSH alone for 12 months. The primary endpoint was the appearance of sperm in ejaculate, and we followed the patients to determine the outcome of inseminating their partners. After rhFSH treatment, mature spermatozoa were found in the ejaculate in five of 26 (19.2%) patients, all of whom showed histology of non-uniform type maturation arrest. Intracytoplasmic sperm injection of the mature spermatozoa resulted in two ongoing clinical pregnancies (insemination success rate, 40.0%). Recombinant human follicle-stimulating hormone treatment can be used as an advanced assisted reproductive technology to improve spermatogenesis in some azoospermic patients with maturation arrest of spermatogenesis and is a potential treatment option after unsuccessful micro-TESE.	[Kobori, Yoshitomo; Suzuki, Keisuke; Iwahata, Toshiyuki; Shin, Takeshi; Sato, Ryo; Nishio, Kojiro; Yagi, Hiroshi; Arai, Gaku; Soh, Shigehiro; Okada, Hiroshi] Dokkyo Med Univ, Dept Urol, Koshigaya Hosp, Koshigaya, Saitama 3438555, Japan	Kobori, Y (reprint author), Dokkyo Med Univ, Dept Urol, Koshigaya Hosp, Koshigaya, Saitama 3438555, Japan.	ykobori@dokkyomed.ac.jp					Shiraishi K, 2012, HUM REPROD, V27, P331, DOI 10.1093/humrep/der404; Nieschlag E, 1999, CLIN ENDOCRINOL, V51, P139, DOI 10.1046/j.1365-2265.1999.00846.x; Singh J, 1996, J ANDROL, V17, P382; Okada H, 2002, J UROLOGY, V168, P1063, DOI 10.1097/01.ju.0000025397.03586.c4; Hung AJ, 2007, J UROLOGY, V178, P608, DOI 10.1016/j.juro.2007.03.125; Sato T, 2011, NATURE, V471, P504, DOI 10.1038/nature09850; Efesoy O, 2009, J ANDROL, V30, P679, DOI 10.2164/jandrol.108.007278; Kottler ML, 2010, EUR J ENDOCRINOL, V162, P633, DOI 10.1530/EJE-09-0648; Paradisi R, 2006, FERTIL STERIL, V86, P728, DOI 10.1016/j.fertnstert.2006.02.087; Sarrate Z., 2009, JOVE-J VIS EXP, V31, P1405; Selman H, 2006, FERTIL STERIL, V86, P466, DOI 10.1016/j.fertnstert.2005.12.055; Yao L, 2011, STEM CELL REV REP, V7, P714, DOI 10.1007/s12015-011-9236-8	12	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1939-6368	1939-6376		SYST BIOL REPROD MED	Syst. Biol. Reprod. Med.	JUN	2015	61	3					168	170		10.3109/19396368.2015.1024897		3	Andrology; Reproductive Biology	Endocrinology & Metabolism; Reproductive Biology	CJ7XY	WOS:000355714900006		
J	Matsuo, H				Matsuo, Hidenori			Message From the President of the Japanese Society for Apheresis	THERAPEUTIC APHERESIS AND DIALYSIS			English	Editorial Material									Japanese Soc Apheresis, Karuizawa, Nagano, Japan	Matsuo, H (reprint author), Japanese Soc Apheresis, Karuizawa, Nagano, Japan.	hidenori@kawatana.hosp.go.jp						0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1744-9979	1744-9987		THER APHER DIAL	Ther. Apher. Dial.	JUN	2015	19	3					199	200		10.1111/1744-9987.12321		2	Hematology; Urology & Nephrology	Hematology; Urology & Nephrology	CJ6UN	WOS:000355629900001		
J	Wakasugi, M; Kazama, JJ; Narita, I				Wakasugi, Minako; Kazama, Junichiro James; Narita, Ichiei			Anticipated Increase in the Number of Patients Who Require Dialysis Treatment Among the Aging Population of Japan	THERAPEUTIC APHERESIS AND DIALYSIS			English	Article						Aging; Dialysis; Epidemiology; Incidence; Population projection	CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; GENERAL-POPULATION; PREVENTION; MORTALITY	The aging population is anticipated to have a large impact on the number of incident dialysis patients, as the risk of end-stage kidney disease increases with age. This study aimed to examine trends in the sex- and age-specific incidence rates of dialysis between 2008 and 2012, and to assess the impact of population aging on the number of incident dialysis patients over the next decade in Japan. Incidence was calculated using published data and Japan's population statistics. The 2012 incidence was extrapolated, and projected future demographic changes within the Japanese population were used to estimate the number of incident dialysis patients in 2020 and 2025. As a general trend, the sex- and age-specific incidence rates of dialysis decreased gradually between 2008 and 2012, except among men aged 80 years. The total number of incident dialysis patients was projected to increase by 12.8% from 36590 in 2012 to 41270 in 2025. Greater increases were observed in the oldest age group (85 years). In 2025, the number of incident dialysis patients in this group was projected to increase by 92.6% in men and 62.2% in women. This study shows the number of patients who initiate dialysis treatment is projected to increase over the next decade in Japan due to aging of the population. Effective strategies are needed to offset the challenges faced by the aging population, with a particular focus on octogenarians and older, given the notable proportion of patients requiring dialysis treatment in the future.	[Wakasugi, Minako] Niigata Univ Grad Sch Med & Dent Sci, Ctr Interorgan Commun Res, Niigata, Japan; [Narita, Ichiei] Niigata Univ Grad Sch Med & Dent Sci, Div Clin Nephrol & Rheumatol, Niigata, Japan; [Kazama, Junichiro James] Niigata Univ Med & Dent Hosp, Div Blood Purificat Therapy, Niigata, Japan	Wakasugi, M (reprint author), 1-757 Asahimachi,Chuo Ku, Niigata 9518510, Japan.	minakowa@med.niigata-u.ac.jp		Wakasugi, Minako/0000-0003-1555-7736			Wakasugi M, 2013, HYPERTENS RES, V36, P328, DOI 10.1038/hr.2012.186; Nakai S, 2012, THER APHER DIAL, V16, P483, DOI 10.1111/j.1744-9987.2012.01143.x; Irie F, 2006, KIDNEY INT, V69, P1264, DOI 10.1038/sj.ki.5000284; Nakai S, 2010, THER APHER DIAL, V14, P505, DOI 10.1111/j.1744-9987.2010.00893.x; Nakai S, 2012, THER APHER DIAL, V16, P11, DOI 10.1111/j.1744-9987.2011.01050.x; Nakai S, 2013, THER APHER DIAL, V17, P567, DOI 10.1111/1744-9987.12147; Lopez-Vargas PA, 2013, NEPHROLOGY, V18, P592, DOI 10.1111/nep.12119; Chang A, 2013, AM J KIDNEY DIS, V62, P267, DOI 10.1053/j.ajkd.2013.02.363; Hata J, 2013, CIRCULATION, V128, P1198, DOI 10.1161/CIRCULATIONAHA.113.002424; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; ANZDATA, 2013, 36 ANZDATA; Chen N, 2010, NEPHROLOGY, V15, P31, DOI 10.1111/j.1440-1797.2010.01309.x; Department of Population Dynamics Research National Institute of Population and Social Security Research, 2012, POP PROJ JAP JAN 201; Ministry of Health Labour and Welfare, 2014, LIF EXP 2012 STAT AB; Ministry of Health Labour and Welfare, 2014, ANN HLTH LAB LAB WEL; Nakai S, 2014, NIHON TOSEKI IGAKKAI, V47, P1; Noordzij Marlies, 2014, Clin Kidney J, V7, P227, DOI 10.1093/ckj/sfu007; Statistics Bureau Ministry of Internal Affairs and Communications, CURR POP EST OCT 1 2; Statistics Bureau Ministry of Internal Affairs and Communications, 2012, CURR POP EST OCT 1 2; The Renal Association UK Renal Registry, 2013, 16 REN ASS UK REN RE; Tonelli M, 2014, NEPHROL DIAL TRANSPL, V29, P221, DOI 10.1093/ndt/gft519; USRDS United States Renal Data System, 2013, ANN DAT REP; Wakasugi M, 2013, THER APHER DIAL, V17, P298, DOI 10.1111/j.1744-9987.2012.01144.x; Wakasugi M, 2014, THER APHER DIAL, V18, P162, DOI 10.1111/1744-9987.12074; World Health Organisation, 2012, GOOD HLTH ADDS LIF Y; Yamagata K, 2014, CLIN EXP NEPHROL, DOI [10.1007/510157-014-0978-x, DOI 10.1007/510157-014-0978-X]	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1744-9979	1744-9987		THER APHER DIAL	Ther. Apher. Dial.	JUN	2015	19	3					201	206		10.1111/1744-9987.12266		6	Hematology; Urology & Nephrology	Hematology; Urology & Nephrology	CJ6UN	WOS:000355629900002		
J	Hamanoue, S; Hoshino, J; Suwabe, T; Marui, Y; Ueno, T; Kikuchi, K; Hazue, R; Mise, K; Kawada, M; Imafuku, A; Hayami, N; Sumida, K; Hiramatsu, R; Hasegawa, E; Sawa, N; Takaichi, K; Ubara, Y				Hamanoue, Satoshi; Hoshino, Junichi; Suwabe, Tatsuya; Marui, Yuji; Ueno, Toshiharu; Kikuchi, Koichi; Hazue, Ryo; Mise, Koki; Kawada, Masahiro; Imafuku, Aya; Hayami, Noriko; Sumida, Keiichi; Hiramatsu, Rikako; Hasegawa, Eiko; Sawa, Naoki; Takaichi, Kennmei; Ubara, Yoshifumi			Peritoneal Dialysis is Limited by Kidney and Liver Volume in Autosomal Dominant Polycystic Kidney Disease	THERAPEUTIC APHERESIS AND DIALYSIS			English	Article						Autosomal dominant polycystic kidney disease; Kidney volume; Liver volume; Peritoneal dialysis; Transcatheter renal artery embolization	TRANSCATHETER ARTERIAL EMBOLIZATION; RENAL REPLACEMENT THERAPY	We evaluated the influence of kidney volume (KV) and liver volume (LV) on continuation of peritoneal dialysis (PD) in patients with autosomal dominant polycystic kidney disease (PKD). Twenty-two PKD patients on PD were retrospectively investigated after being divided into two groups. Group 1 comprised 15 patients who started PD at our hospital and group 2 was composed of seven patients referred from other hospitals for treatment of renomegaly by transcatheter arterial embolization (TAE) at 47.1 +/- 21.8 months after commencing PD. In group 1, KV for both kidneys (mean +/- SD) was 2787 +/- 1945mL (range: 1043 to 6816mL), LV was 2198 +/- 1139mL (1005 to 4116mL), and the total organ volume (TV=KV+LV) was 4985 +/- 1815mL (2320 to 8912mL). In the patient with the largest TV from group 1 (KV of 6816mL, TV of 8912mL, and TV/BMI ratio of 426, PD was stopped due to dialysate leakage. However, dialysate leakage did not occur in the other 14 patients (TV7963mL and TV/BMI ratio of 353 at the start of PD). In group 2, KV was 5822 +/- 1597mL (3832 to 8862mL), LV was 1776 +/- 519mL (1271 to 2671mL), and TV was 7597 +/- 1431mL (5505 to 10358) before TAE. Leakage of dialysate did not occur with a mean infusion volume of 1530 +/- 370mL (1000mL to 2000mL), even after renomegaly and hepatomegaly progressed to the maximum TV/BMI ratio of 359. Six patients from the two groups developed new abdominal hernias at 36 +/- 5 months (6-55 months) after starting PD. These findings suggest that performance of PD may be limited by renomegaly and hepatomegaly in patients with PKD.	[Hamanoue, Satoshi; Hoshino, Junichi; Suwabe, Tatsuya; Marui, Yuji; Ueno, Toshiharu; Kikuchi, Koichi; Hazue, Ryo; Mise, Koki; Kawada, Masahiro; Imafuku, Aya; Hayami, Noriko; Sumida, Keiichi; Hiramatsu, Rikako; Hasegawa, Eiko; Sawa, Naoki; Takaichi, Kennmei; Ubara, Yoshifumi] Toranomon Gen Hosp, Nephrol Ctr, Tokyo 1058470, Japan; [Takaichi, Kennmei; Ubara, Yoshifumi] Toranomon Gen Hosp, Okinaka Mem Inst Med Res, Tokyo 1058470, Japan	Ubara, Y (reprint author), Toranomon Gen Hosp, Nephrol Ctr, Tokyo 1058470, Japan.	ubara@toranomon.gr.jp			Okinaka Memorial Institute for Medical Research	This study was funded by the Okinaka Memorial Institute for Medical Research.	SINGH S, 1991, NEPHRON, V57, P40; Ubara Y, 2002, AM J KIDNEY DIS, V39, P571, DOI 10.1053/ajkd.2002.31407; FLETCHER S, 1994, NEPHROL DIAL TRANSPL, V9, P832; Hadimeri H, 1998, PERITON DIALYSIS INT, V18, P429; Del Peso G, 2003, PERITON DIALYSIS INT, V23, P249; Takei R, 2007, AM J KIDNEY DIS, V49, P744, DOI 10.1053/j.ajkd.2007.03.018; Li L, 2011, AM J KIDNEY DIS, V57, P903, DOI 10.1053/j.ajkd.2011.01.019; Kumar S, 2008, KIDNEY INT, V74, P946, DOI 10.1038/ki.2008.352; De Vecchi AF, 2003, PERITON DIALYSIS INT, V22, P82; GRAHAM AN, 1986, NEW ZEAL MED J, V99, P491; Toyohara T, 2011, AM J KIDNEY DIS, V58, P860, DOI 10.1053/j.ajkd.2011.07.008; Ubara Y, 2006, THER APHER DIAL, V10, P333, DOI 10.1111/j.1744-9987.2006.00386.x	12	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1744-9979	1744-9987		THER APHER DIAL	Ther. Apher. Dial.	JUN	2015	19	3					207	211		10.1111/1744-9987.12272		5	Hematology; Urology & Nephrology	Hematology; Urology & Nephrology	CJ6UN	WOS:000355629900003		
J	Kono, K; Nishida, Y; Moriyama, Y; Taoka, M; Sato, T				Kono, Kenichi; Nishida, Yusuke; Moriyama, Yoshihumi; Taoka, Masahiro; Sato, Takashi			Validating the Absolute Reliability of a Fat Free Mass Estimate Equation in Hemodialysis Patients Using Near-Infrared Spectroscopy	THERAPEUTIC APHERESIS AND DIALYSIS			English	Article						Dry weight; Fat free mass; Hemodialysis; Near-infrared spectroscopy; Reliability	X-RAY ABSORPTIOMETRY; NUTRITIONAL RISK INDEX; BODY-COMPOSITION; BIOELECTRICAL-IMPEDANCE; OLDER MEN; SARCOPENIA; MORTALITY; MUSCLE; INTERACTANCE; PREDICTOR	The assessment of nutritional states using fat free mass (FFM) measured with near-infrared spectroscopy (NIRS) is clinically useful. This measurement should incorporate the patient's post-dialysis weight (dry weight), in order to exclude the effects of any change in water mass. We therefore used NIRS to investigate the regression, independent variables, and absolute reliability of FFM in dry weight. The study included 47 outpatients from the hemodialysis unit. Body weight was measured before dialysis, and FFM was measured using NIRS before and after dialysis treatment. Multiple regression analysis was used to estimate the FFM in dry weight as the dependent variable. The measured FFM before dialysis treatment (Mw-FFM), and the difference between measured and dry weight (Mw-Dw) were independent variables. We performed Bland-Altman analysis to detect errors between the statistically estimated FFM and the measured FFM after dialysis treatment. The multiple regression equation to estimate the FFM in dry weight was: Dw-FFM=0.038+(0.984xMw-FFM)+(-0.571x[Mw-Dw]); R-2=0.99). There was no systematic bias between the estimated and the measured values of FFM in dry weight. Using NIRS, FFM in dry weight can be calculated by an equation including FFM in measured weight and the difference between the measured weight and the dry weight.	[Kono, Kenichi] Aichi Med Univ, Dept Rehabil, Kiyosu City, Aichi 4521931, Japan; [Nishida, Yusuke] Seirei Christopher Univ, Dept Rehabil, Hamamatsu, Shizuoka, Japan; [Moriyama, Yoshihumi] Nagoya Kyoritsu Hosp, Wellness Ctr, Nagoya, Aichi, Japan; [Taoka, Masahiro; Sato, Takashi] Meiko Kyoritsu Clin, Hemodialysis Ctr, Nagoya, Aichi, Japan	Kono, K (reprint author), Aichi Med Univ, Dept Rehabil, 519 Ichiba, Kiyosu City, Aichi 4521931, Japan.	kohno@yuai.ac.jp					Abrahamsen B, 1996, AM J CLIN NUTR, V63, P80; CONWAY JM, 1984, AM J CLIN NUTR, V40, P1123; Kalantar-Zadeh K, 2006, AM J CLIN NUTR, V83, P202; Kalantar-Zadeh K, 2004, AM J CLIN NUTR, V80, P299; Goodpaster BH, 2006, J GERONTOL A-BIOL, V61, P1059; Carrero JJ, 2013, J RENAL NUTR, V23, P77, DOI 10.1053/j.jrn.2013.01.001; Delmonico MJ, 2007, J AM GERIATR SOC, V55, P769, DOI 10.1111/j.1532-5415.2007.01140.x; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Yamada K, 2008, AM J CLIN NUTR, V87, P106; Schutz Y, 2002, INT J OBESITY, V26, P953, DOI 10.1038/sj.ijo.0802037; Flakoll PJ, 2004, JPEN-PARENTER ENTER, V28, P13, DOI 10.1177/014860710402800113; Beberashvili I, 2013, CLIN J AM SOC NEPHRO, V8, P443, DOI 10.2215/CJN.04980512; Eknoyan G, 2000, AM J KIDNEY DIS, V35, pS1, DOI 10.1053/ajkd.2000.35s1; Fahal IH, 2014, NEPHROL DIAL TRANSPL, V29, P1655, DOI 10.1093/ndt/gft070; FORMICA C, 1993, OSTEOPOROSIS INT, V3, P192, DOI 10.1007/BF01623675; Kalantar-Zadeh K, 1999, NEPHROL DIAL TRANSPL, V14, P169, DOI 10.1093/ndt/14.1.169; Krause KE, 2012, GAIT POSTURE, V35, P180, DOI 10.1016/j.gaitpost.2011.09.003; Levine JA, 2000, J APPL PHYSIOL, V88, P452; Panichi V, 2014, J NEPHROL, V27, P193, DOI 10.1007/s40620-013-0033-0; Park JH, 2012, THER APHER DIAL, V16, P121, DOI 10.1111/j.1744-9987.2011.01046.x; SAWAI S, 1990, Japanese Journal of Physical Fitness and Sports Medicine, V39, P155; Takahashi H, 2014, J CARDIOL, V64, P32, DOI 10.1016/j.jjcc.2013.10.018; Yoshida D, 2012, GERIATR GERONTOL INT, V12, P652, DOI 10.1111/j.1447-0594.2011.00834.x	23	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1744-9979	1744-9987		THER APHER DIAL	Ther. Apher. Dial.	JUN	2015	19	3					220	224		10.1111/1744-9987.12283		5	Hematology; Urology & Nephrology	Hematology; Urology & Nephrology	CJ6UN	WOS:000355629900005		
J	Akizawa, T; Akiba, T; Hirakata, H; Kinugasa, E; Tominaga, Y; Fukagawa, M; Yokoyama, K; Zhang, WY; Linde, PG; Suzuki, M				Akizawa, Tadao; Akiba, Takashi; Hirakata, Hideki; Kinugasa, Eriko; Tominaga, Yoshihiro; Fukagawa, Masafumi; Yokoyama, Keitaro; Zhang, Wuyan; Linde, Peter G.; Suzuki, Masashi			Comparison of Paricalcitol With Maxacalcitol Injection in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism	THERAPEUTIC APHERESIS AND DIALYSIS			English	Article						Chronic Kidney Disease; Maxacalcitol; Paricalcitol; Secondary Hyperparathyroidism; Vitamin D	PARATHYROID-HORMONE SECRETION; VITAMIN-D; 1,25-DIHYDROXY-22-OXAVITAMIN D-3; SUPPRESSION; CALCITRIOL; RECEPTOR	Secondary hyperparathyroidism (SHPT) is one of the major complications of chronic kidney disease (CKD) and is associated with elevated serum intact parathyroid hormone (iPTH). Calcitriol, a non-selective vitamin D receptor agonist (VDRA) that suppresses iPTH is used for SHPT treatment, but its use is frequently complicated by hypercalcemia. Paricalcitol, a selective VDRA, demonstrated efficacy in iPTH suppression compared to maxacalcitol in a Phase 2 study (M11-609) in Japanese subjects. The current larger Phase 3 study (M11-517), evaluated the efficacy of intravenous paricalcitol injection compared to intravenous maxacalcitol injection with respect to iPTH and calcium control using a non-inferiority primary endpoint. In this double-blind, double-dummy, parallel-group study, eligible Japanese CKD subjects with SHPT on hemodialysis were randomized 1:1 to receive intravenous paricalcitol or intravenous maxacalcitol injections for 12 weeks. Dynamic allocation of subjects on the basis of screening iPTH levels was used to ensure equal distribution of subjects with iPTH<500pg/mL and 500pg/mL into the two treatment groups. 255 subjects were randomized to receive paricalcitol (N=127) or maxacalcitol (N=128). Primary efficacy analysis indicated that 27.7% in the paricalcitol group vs. 30.5% in the maxacalcitol group (95% CI -14.34% to 8.79%, P=0.353) achieved target iPTH in the last 3 weeks without hypercalcemia during treatment, failing to achieve the non-inferiority margin of -5% that was set based upon agreement with the PMDA. Both intravenous paricalcitol and maxacalcitol were effective in reducing iPTH and provided similar safety profiles; however, non-inferiority for paricalcitol vs. maxacalcitol was not demonstrated.	[Akizawa, Tadao] Showa Univ Sch Med, Tokyo, Japan; [Akiba, Takashi] Tokyo Womens Med Univ, Tokyo, Japan; [Yokoyama, Keitaro] Jikei Univ Sch Med, Tokyo, Japan; [Hirakata, Hideki] Japanese Red Cross Fukuoka Hosp, Fukuoka, Japan; [Kinugasa, Eriko] Showa Univ Northern Yokohama Hosp, Yokohama, Kanagawa, Japan; [Tominaga, Yoshihiro] Nagoya Daini Red Cross Hosp, Nagoya, Aichi, Japan; [Fukagawa, Masafumi] Tokai Univ Sch Med, Isehara, Kanagawa, Japan; [Suzuki, Masashi] Shinrakuen Hosp, Niigata, Japan; [Zhang, Wuyan] AbbVie, Clin Stat, N Chicago, IL USA; [Linde, Peter G.] AbbVie, Renal Clin Dev, N Chicago, IL USA	Akizawa, T (reprint author), Showa Univ Sch Med, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	akizawa@med.showa-u.ac.jp			AbbVie	AbbVie provided funding for the M11-609 and M11-517 studies and was involved in the study design, study execution, collection, analysis and interpretation of data, and in writing, reviewing and approval of the report. We thank all investigators that were involved with studies M11-517 and M11-609. We thank Yoshihiko Ueki, an employee of AbbVie Japan, for critically reviewing the manuscript. All authors had access to study results, and the lead author vouches for the accuracy and completeness of the data reported. The lead author had the final decision to submit the publication. The study was overseen by a data review committee. Medical writing support was provided by Adebusola Ajibade, PhD, of AbbVie.	Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523-1755.2003.00878.x; Rodriguez M, 2005, AM J PHYSIOL-RENAL, V288, pF253, DOI 10.1152/ajprenal.00302.2004; Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058; BROWN AJ, 1989, J CLIN INVEST, V84, P728, DOI 10.1172/JCI114229; Andress D, 2007, DRUGS, V67, P1999; Brown AJ, 2002, NEPHROL DIAL TRANSPL, V17, P10; Hirata M, 2002, NEPHROL DIAL TRANSPL, V17, P41; Kinugasa E, 2002, NEPHROL DIAL TRANSPL, V17, P20; Sprague SM, 2001, AM J KIDNEY DIS, V38, pS51, DOI 10.1053/ajkd.2001.28110; Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536	10	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1744-9979	1744-9987		THER APHER DIAL	Ther. Apher. Dial.	JUN	2015	19	3					225	234		10.1111/1744-9987.12242		10	Hematology; Urology & Nephrology	Hematology; Urology & Nephrology	CJ6UN	WOS:000355629900006		
J	Shoji, T; Marubayashi, S; Shigematsu, T; Iseki, K; Tsubakihara, Y				Shoji, Tetsuo; Marubayashi, Seiji; Shigematsu, Takashi; Iseki, Kunitoshi; Tsubakihara, Yoshiharu		Comm Renal Data Registry; Japanese Soc Dialysis Therapy	Use of Vitamin D Receptor Activator, Incident Cardiovascular Disease and Death in a Cohort of Hemodialysis Patients	THERAPEUTIC APHERESIS AND DIALYSIS			English	Article						Chronic kidney disease mineral bone disorder; Fatality; Hemodialysis; Incident cardiovascular disease; Mortality; Phosphate binders; Vitamin D	CHRONIC KIDNEY-DISEASE; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY CALCIFICATION; LONG-TERM PROGNOSIS; DIALYSIS PATIENTS; PARATHYROID-HORMONE; PRACTICE PATTERNS; MORTALITY RISK; SERUM-CALCIUM; 1,25-DIHYDROXYVITAMIN D-3	The use of vitamin D receptor activators (VDRAs) is an independent predictor of a lower risk of death from cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). We examined whether the use of VDRAs and other CKD-mineral bone disorder (MBD)-related factors are associated with incident CVD or death after CVD in hemodialysis patients. This is a historical cohort study of 37690 prevalent hemodialysis patients without previous history of CVD at the end of 2004 extracted from a nationwide registry in Japan. The key exposure was the use of VDRAs, and the outcomes were incident CVD (myocardial infarction, cerebral infarction, cerebral hemorrhage, and sudden death) and death after CVD during the 1-year follow-up. VDRAs were used in 57% of the subjects at baseline. We identified 2433 patients with incident CVD and 397 deaths after the events. In multivariate logistic regression models, independent predictors of incident CVD were non-use of VDRA, higher intact PTH, non-use of calcium-based phosphate-binder, and non-use of non-calcium-based phosphate binder. Risk of death after CVD was not significantly associated with VDRA, whereas it was lower in those with lower corrected calcium, and the risk was higher in those with higher phosphate and in non-users of calcium-based phosphate binders. The use of VDRAs was associated with a lower risk of incident CVD but not with death after CVD in this large cohort of hemodialysis patients. The CKD-MBD-related predictors of poor outcomes are associated with the risk of incident CVD, the risk of death after CVD, or both.	[Shoji, Tetsuo] Osaka City Univ Grad Sch Med, Dept Geriatr & Vasc Med, Osaka 5458585, Japan; [Shoji, Tetsuo; Marubayashi, Seiji; Shigematsu, Takashi; Iseki, Kunitoshi; Tsubakihara, Yoshiharu] Japanese Soc Dialysis Therapy, Comm Renal Data Registry, Tokyo, Japan	Shoji, T (reprint author), Osaka City Univ Grad Sch Med, Dept Geriatr & Vasc Med, Osaka 5458585, Japan.	t-shoji@med.osaka-cu.ac.jp			Chugai; Kyowa Hakko Kirin; Bayer; Teijin Pharma; Astellas; Daiich-Sankyo; Asahi Kasei Pharma; Otsuka; Kyowa Medex	Seiji Marubayashi: No potential conflict of interest to disclose. Takashi Shigematsu: Research grant from Chugai, Kyowa Hakko Kirin, Bayer, Teijin Pharma, and Astellas. Honorarium from Chugai, Kyowa Hakko Kirin, Bayer, Teijin Pharma, and Astellas. Kunitoshi Iseki: Research grant from Chugai, Daiich-Sankyo, Kyowa Hakko Kirin, Bayer and Teijin Pharma. Advisory Committee of Astra Zeneka and Kyowa Hakko Kirin. Yoshiharu Tsubakihara: Endowed chair from Baxter and Chugai. Research grant from Asahi Kasei Pharma, Otsuka, and Kyowa Medex. Honoraria for lecturing from Chugai, Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, and Torii.	Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Tentori F, 2009, NEPHROL DIAL TRANSPL, V24, P963, DOI 10.1093/ndt/gfn592; Palmer SC, 2011, JAMA-J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308; Wolf M, 2007, KIDNEY INT, V72, P1004, DOI 10.1038/sj.ki.5002451; Lopes AA, 2012, AM J KIDNEY DIS, V60, P90, DOI 10.1053/j.ajkd.2011.12.025; Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414; Naves-Diaz M, 2008, KIDNEY INT, V74, P1070, DOI 10.1038/ki.2008.343; [Anonymous], 2008, THER APHER DIAL, V12, P514; London GM, 2005, CURR OPIN NEPHROL HY, V14, P525, DOI 10.1097/01.mnh.0000168336.67499.c0; Drechsler C, 2010, EUR HEART J, V31, P2253, DOI 10.1093/eurheartj/ehq246; Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020; Iseki K, 2000, AM J KIDNEY DIS, V36, P820, DOI 10.1053/ajkd.2000.17676; Nakai S, 2008, THER APHER DIAL, V12, P49, DOI 10.1111/j.1744-9987.2007.00540.x; Jamal SA, 2013, LANCET, V382, P1268, DOI 10.1016/S0140-6736(13)60897-1; Lim K, 2012, CIRCULATION, V125, P2243, DOI 10.1161/CIRCULATIONAHA.111.053405; Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573; Fukuda D, 2006, HEART, V92, P759, DOI 10.1136/hrt.2005.067934; Iseki K, 2000, NEPHROL DIAL TRANSPL, V15, P1808, DOI 10.1093/ndt/15.11.1808; MASSRY SG, 1979, CLIN NEPHROL, V11, P181; Wang L, 2006, J AM COLL CARDIOL, V48, P1018, DOI 10.1016/j.jacc.2006.04.089; Xiang W, 2005, AM J PHYSIOL-ENDOC M, V288, pE125, DOI 10.1152/ajpendo.00224.2004; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; KAUTZKYWILLER A, 1995, KIDNEY INT, V47, P200, DOI 10.1038/ki.1995.24; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; Isakova T, 2009, J AM SOC NEPHROL, V20, P388, DOI 10.1681/ASN.2008060609; Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122; Herzog CA, 1998, NEW ENGL J MED, V339, P799, DOI 10.1056/NEJM199809173391203; Beddhu S, 2004, J AM SOC NEPHROL, V15, P733, DOI 10.1097/01.ASN.0000113319.57131.28; Melamed ML, 2006, KIDNEY INT, V70, P351, DOI 10.1038/sj.ki.5001542; Shoji T, 2004, NEPHROL DIAL TRANSPL, V19, P179, DOI 10.1093/ndt/gfg513; Shoji T, 2011, CLIN J AM SOC NEPHRO, V6, P1112, DOI 10.2215/CJN.09961110; DEGOULET P, 1982, NEPHRON, V31, P103, DOI 10.1159/000182627; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Li YC, 2002, J CLIN INVEST, V110, P229, DOI 10.1172/JCI200215219; Taniguchi M, 2013, THER APHER DIAL, V17, P221, DOI 10.1111/1744-9987.12030; Braunlin W, 2002, KIDNEY INT, V62, P611, DOI 10.1046/j.1523-1755.2002.00459.x; Caliskan Y, 2010, NEPHROL DIAL TRANSPL, V25, P2685, DOI 10.1093/ndt/gfq113; Cannata-Andía Jorge B, 2013, Kidney Int, V84, P998, DOI 10.1038/ki.2013.185; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; KLAHR S, 1986, ANNU REV MED, V37, P71; Manenti L, 2010, KIDNEY INT, V78, P1187, DOI 10.1038/ki.2010.357; Nakai S, 2006, THER APHER DIAL, V10, P476, DOI 10.1111/j.1744-9987.2006.00440.x; Nishizawa Y, 2001, AM J KIDNEY DIS, V38, pS4, DOI 10.1053/ajkd.2001.27380; Park JW, 2011, AM J NEPHROL, V34, P77, DOI 10.1159/000329081; Shoji T, 2005, INTERNAL MED, V44, P179, DOI 10.2169/internalmedicine.44.179; Shoji T, 2006, THER APHER DIAL, V10, P305, DOI 10.1111/j.1744-9987.2006.00382.x; Smith GL, 2008, J AM SOC NEPHROL, V19, P141, DOI 10.1681/ASN.2007050554; Son BK, 2008, J ATHEROSCLER THROMB, V15, P63; SUEMATSU Y, 1995, J CELL PHYSIOL, V165, P547, DOI 10.1002/jcp.1041650313; TABATA T, 1986, J CLIN ENDOCR METAB, V63, P1218	51	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1744-9979	1744-9987		THER APHER DIAL	Ther. Apher. Dial.	JUN	2015	19	3					235	244		10.1111/1744-9987.12274		10	Hematology; Urology & Nephrology	Hematology; Urology & Nephrology	CJ6UN	WOS:000355629900007		
J	Irifuku, T; Naito, T; Ogawa, T; Shimizu, Y; Maeoka, Y; Masaki, T				Irifuku, Taisuke; Naito, Takayuki; Ogawa, Takahiko; Shimizu, Yuka; Maeoka, Yujiro; Masaki, Takao			Hemodialysis Immediately After Cardiac Catheterization Is a Risk Factor for Intradialytic Hypotension	THERAPEUTIC APHERESIS AND DIALYSIS			English	Article						Cardiac catheterization; Coronary stenosis; Hemodialysis; Intradialytic hypotension; Myocardial stunning	BLOOD-PRESSURE; RENAL-FAILURE; MORTALITY; DYSFUNCTION; RELAXATION; ADENOSINE; FALL	Many hemodialysis clinicians have noticed that patients frequently develop intradialytic hypotension (IDH) immediately after cardiac catheterization (CC). However, precise data about the incidence of IDH immediately after CC are scarce. This study involved a single-center, retrospective, cross-sectional design. We reviewed the medical records of all HD patients who underwent CC between January 2009 and March 2012 at Hiroshima Prefectural Hospital. IDH was defined as a fall of systolic blood pressure of more than 20mmHg or a fall of mean blood pressure of more than 10mmHg, with symptoms according to the K/DOQI criteria. Data on a total of 112 patients were obtained: 64 patients commenced HD immediately after CC (IA group) and 48 patients underwent HD on the day after CC (ND group). The overall incidence of IDH was 34% (38/112). The incidence of IDH was significantly higher in the IA group than in the ND group (27/64, 42% vs. 11/48, 23%; P<0.05). Multivariate logistic regression analysis showed that IA (odds ratio, 5.39; 95% confidence interval, 1.76 to 16.49; P<0.01), coronary stenosis (odds ratio, 4.16; 95% confidence interval, 1.49 to 11.64; P<0.05) were independently associated with IDH. This study revealed that HD immediately after CC is associated with a higher incidence of IDH. Clinicians should consider that HD following CC be scheduled for the next day, especially in patients with coronary stenosis.	[Irifuku, Taisuke; Masaki, Takao] Hiroshima Univ Hosp, Dept Nephrol, Hiroshima, Japan; [Naito, Takayuki; Ogawa, Takahiko; Shimizu, Yuka; Maeoka, Yujiro] Hiroshima Prefectural Hosp, Ctr Kidney Dis, Hiroshima, Japan	Naito, T (reprint author), 1-2-3 Kasumi, Hiroshima 7348551, Japan.	t.irifuku@gmail.com					Wong PCY, 2012, INT J CARDIOL, V158, P186, DOI 10.1016/j.ijcard.2011.06.115; van der Sande FM, 2000, NEPHROL DIAL TRANSPL, V15, P1746, DOI 10.1093/ndt/15.11.1746; Pflueger A, 2000, MAYO CLIN PROC, V75, P1275; Shoji T, 2004, KIDNEY INT, V66, P1212, DOI 10.1111/j.1523-1755.2004.00812.x; Burton JO, 2009, CLIN J AM SOC NEPHRO, V4, P914, DOI 10.2215/CJN.03900808; Inrig JK, 2007, KIDNEY INT, V71, P454, DOI 10.1038/sj.ki.5002077; Breidthardt T, 2012, CLIN J AM SOC NEPHRO, V7, P1285, DOI 10.2215/CJN.00460112; Dasselaar JJ, 2009, NEPHROL DIAL TRANSPL, V24, P604, DOI 10.1093/ndt/gfn501; Davenport A, 2008, KIDNEY INT, V73, P759, DOI 10.1038/sj.ki.5002745; HENDERSON LW, 1980, KIDNEY INT, V17, P571, DOI 10.1038/ki.1980.67; Henderson LW, 2012, SEMIN DIALYSIS, V25, P320, DOI 10.1111/j.1525-139X.2012.01068.x; Kalantar-Zadeh K, 2003, KIDNEY INT, V63, P793, DOI 10.1046/j.1523-1755.2003.00803.x; McIntyre CW, 2008, CLIN J AM SOC NEPHRO, V3, P19, DOI 10.2215/CJN.03170707; Boon D, 2004, NEPHRON CLIN PRACT, V96, P82, DOI 10.1159/000076745; BRAUNWALD E, 1982, CIRCULATION, V66, P1146; Breidthardt T, 2011, REV CARDIOVASC MED, V12, P13, DOI 10.3909/ricm0585; Chang MH, 2001, AM J NEPHROL, V21, P357, DOI 10.1159/000046274; COLLINS P, 1993, CIRCULATION, V87, P80; Coresh J, 1998, J AM SOC NEPHROL, V9, pS; Foley R N, 1998, J Am Soc Nephrol, V9, pS16; HERLIHY JT, 1976, AM J PHYSIOL, V230, P1239; Matsukawa T, 1998, AM J PHYSIOL, V275, pR160; Pecovnik-Balon B, 2005, THER APHER DIAL, V9, P208, DOI 10.1111/j.1774-9987.2005.00255.x; Yamamoto K, 2012, THER APHER DIAL, V16, P219, DOI 10.1111/j.1744-9987.2011.01053.x	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1744-9979	1744-9987		THER APHER DIAL	Ther. Apher. Dial.	JUN	2015	19	3					245	249		10.1111/1744-9987.12252		5	Hematology; Urology & Nephrology	Hematology; Urology & Nephrology	CJ6UN	WOS:000355629900008		
J	Suzuki, T; Muto, S; Miyata, Y; Maeda, T; Odate, T; Shimanaka, K; Kusano, E				Suzuki, Takao; Muto, Shigeaki; Miyata, Yukio; Maeda, Takao; Odate, Takayuki; Shimanaka, Kimio; Kusano, Eiji			Characterization of the Cation-Binding Capacity of a Potassium-Adsorption Filter Used in Red Blood Cell Transfusion	THERAPEUTIC APHERESIS AND DIALYSIS			English	Article						Extracellular potassium; Resin filter; Sodium polystyrene sulfonate resin; Stored irradiated red blood cells	SODIUM POLYSTYRENE SULFONATE; EXCHANGE RESIN; RENAL-FAILURE; IN-VITRO; HYPERKALEMIA; REDUCTION; UNITS; BAGS	A K+-adsorption filter was developed to exchange K+ in the supernatant of stored irradiated red blood cells with Na+. To date, however, the filter's adsorption capacity for K+ has not been fully evaluated. Therefore, we characterized the cation-binding capacity of this filter. Artificial solutions containing various cations were continuously passed through the filter in 30mL of sodium polystyrene sulfonate at 10mL/min using an infusion pump at room temperature. The cation concentrations were measured before and during filtration. When a single solution containing K+, Li+, H+, Mg2+, Ca2+, or Al3+ was continuously passed through the filter, the filter adsorbed K+ and the other cations in exchange for Na+ in direct proportion to the valence number. The order of affinity for cation adsorption to the filter was Ca2+>Mg2+>K+>H+>Li+. In K+-saturated conditions, the filter also adsorbed Na+. After complete adsorption of these cations on the filter, their concentration in the effluent increased in a sigmoidal manner over time. Cations that were bound to the filter were released if a second cation was passed through the filter, despite the different affinities of the two cations. The ability of the filter to bind cations, especially K+, should be helpful when it is used for red blood cell transfusion at the bedside. The filter may also be useful to gain a better understanding of the pharmacological properties of sodium polystyrene sulfonate.	[Suzuki, Takao; Maeda, Takao; Odate, Takayuki; Shimanaka, Kimio] Jichi Med Univ, Dept Clin Engn, Shimotsuke, Tochigi, Japan; [Muto, Shigeaki; Miyata, Yukio; Kusano, Eiji] Jichi Med Univ, Div Nephrol, Dept Internal Med, Shimotsuke, Tochigi, Japan	Muto, S (reprint author), Jichi Med Univ, Div Nephrol, Dept Internal Med, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	smuto@jichi.ac.jp			Japan Society for the Promotion of Science	We wish to thank Kawasumi Laboratories, Inc. (Tokyo, Japan) for providing the K<SUP>+</SUP>-adsorption filters. This work was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science. Part of this work has been presented at the Annual Meeting of the American Society of Nephrology in Philadelphia, PA, in 2008. We have no conflict of interest to declare.	Smith HM, 2008, ANESTH ANALG, V106, P1062, DOI [10.1213/ane.0b013e318164f03d, 10.1213/ane.0b013618164f03d]; Yamada C, 2010, TRANSFUSION, V50, P1926, DOI 10.1111/j.1537-2995.2010.02742.x; Cid J, 2008, TRANSFUSION, V48, P1966, DOI 10.1111/j.1537-2995.2008.01776.x; O'Leary MF, 2011, TRANSFUSION, V51, P955, DOI 10.1111/j.1537-2995.2010.02935.x; Mukherjee S, 2010, INDIAN J MED RES, V132, P715; BERLYNE GM, 1966, LANCET, V1, P167; Baliarsingh S, 2014, TRANSFUSION MED, V24, P45, DOI 10.1111/tme.12086; Bansal I, 2007, TRANSFUSION, V47, P248, DOI 10.1111/j.1537-2995.2007.01095.x; BELANGER DR, 1992, ANN EMERG MED, V21, P1312, DOI 10.1016/S0196-0644(05)81893-1; BERLYNE GM, 1967, ISRAEL J MED SCI, V3, P45; Evans BM, 1953, LANCET, V2, P791; Inaba S, 2000, TRANSFUSION, V40, P1469, DOI 10.1046/j.1537-2995.2000.40121469.x; INABA S, 1994, LANCET, V343, P1223, DOI 10.1016/S0140-6736(94)92430-9; Inaba S, 1996, JPN J TRANSFUS MED, V42, P218; Ng Y Y, 1990, J Formos Med Assoc, V89, P399; Permutit Co. Ltd, 1951, LEAFL ION EXCH RES; RAMIREZ AM, 1987, TRANSFUSION, V27, P444, DOI 10.1046/j.1537-2995.1987.27587320546.x; SCHEER L, 1961, NEW ENGL J MED, V264, P115, DOI 10.1056/NEJM196101192640303; THORP JA, 1990, AM J OBSTET GYNECOL, V163, P607; WATLING SM, 1995, AM J EMERG MED, V13, P294, DOI 10.1016/0735-6757(95)90202-3; Westphal-Varghese B, 2007, TRANSFUSION MED, V17, P89, DOI 10.1111/j.1365-3148.2007.00732.x	21	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1744-9979	1744-9987		THER APHER DIAL	Ther. Apher. Dial.	JUN	2015	19	3					288	295		10.1111/1744-9987.12278		8	Hematology; Urology & Nephrology	Hematology; Urology & Nephrology	CJ6UN	WOS:000355629900014		
J	Nakatsuka, M; Yoshida, R; Ishibashi, Y				Nakatsuka, Mineo; Yoshida, Ryochi; Ishibashi, Yoshitaka			New Method of Dialysate Drainage Flow Analysis: An Implication for Automated Peritoneal Dialysis Prescription	THERAPEUTIC APHERESIS AND DIALYSIS			English	Letter									[Nakatsuka, Mineo; Yoshida, Ryochi; Ishibashi, Yoshitaka] Japanese Red Cross Med Ctr, Dept Nephrol, Tokyo, Japan	Nakatsuka, M (reprint author), Japanese Red Cross Med Ctr, Dept Nephrol, Tokyo, Japan.	hiromaekikaku@gmail.com					BRANDES JC, 1995, AM J KIDNEY DIS, V25, P603, DOI 10.1016/0272-6386(95)90131-0	1	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1744-9979	1744-9987		THER APHER DIAL	Ther. Apher. Dial.	JUN	2015	19	3					299	299		10.1111/1744-9987.12251		1	Hematology; Urology & Nephrology	Hematology; Urology & Nephrology	CJ6UN	WOS:000355629900016		
J	Hasegawa, J; Wakai, S; Shirakawa, H				Hasegawa, Jumpei; Wakai, Sachiko; Shirakawa, Hiroki			Juvenile Slow Progressive Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Diagnosed After Kidney Transplantation: A Case Report	THERAPEUTIC APHERESIS AND DIALYSIS			English	Letter									[Hasegawa, Jumpei; Wakai, Sachiko] Ohkubo Hosp, Dept Nephrol, Tokyo, Japan; [Shirakawa, Hiroki] Ohkubo Hosp, Dept Urol, Tokyo, Japan	Hasegawa, J (reprint author), Ohkubo Hosp, Dept Nephrol, Tokyo, Japan.	sachiko_wakai@tokyo-hmt.jp					Gardner-Medwin JMM, 2002, LANCET, V360, P1197, DOI 10.1016/S0140-6736(02)11279-7; Gong DH, 2013, THER APHER DIAL, V17, P93, DOI 10.1111/j.1744-9987.2012.01107.x; Lane Suzanne E, 2005, Curr Rheumatol Rep, V7, P270, DOI 10.1007/s11926-005-0036-5; Lau D, 2012, NEPHROLOGY, V17, P16, DOI 10.1111/j.1440-1797.2012.01586.x	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1744-9979	1744-9987		THER APHER DIAL	Ther. Apher. Dial.	JUN	2015	19	3					303	304		10.1111/1744-9987.12249		2	Hematology; Urology & Nephrology	Hematology; Urology & Nephrology	CJ6UN	WOS:000355629900019		
J	Takahashi, S; Uekita, H; Kato, T; Inoue, K; Domon, T				Takahashi, Shigeru; Uekita, Hiroki; Kato, Tsuyoshi; Inoue, Kiichiro; Domon, Takanori			Growth of rat parotid glands is inhibited by liquid diet feeding	TISSUE & CELL			English	Article						Liquid diet; Growth; Parotid gland; Acinar cell; Cell proliferation; Apoptosis	SALIVARY-GLANDS; ACINAR-CELLS; DUCT LIGATION; BITE FORCE; APOPTOSIS; SECRETION; ATROPHY; MICE; PARASYMPATHECTOMY; OBSTRUCTION	This study investigated how liquid diet feeding affects the growth of parotid glands. We weaned 21-day-old rats and thereafter fed them a pellet diet (control group) or a liquid diet (experimental group) for 0, 1, 2, 4, or 8 weeks. Their parotid glands were excised, weighed, examined, and tested for 5-bromo-2'-deoxyuridine (BrdU) and cleaved caspase-3 (Casp-3) as markers of proliferation and apoptosis, respectively. Parotid gland weights were consistently smaller in experimental animals than in controls. Morphometrical analysis showed that control group acinar cells increased in area during the experiment, but experimental group acinar cells were almost unchanged. Labeling indices of BrdU in acinar cells in both groups declined during the experiment, but were consistently lower in the experimental group than in controls. Casp-3-positive acinar cells were rare in both groups, which consistently express significantly similar Casp-3 levels. Ultrastructurally, terminal portions of the experimental parotid glands consisted of a few acinar cells that were smaller than those in controls. Control acinar cells showed mitotic figures within short experimental periods, but not in experimental glands. These observations indicate that liquid diet feeding inhibits growth of parotid glands in growing rats through suppression of growth and proliferation of individual acinar cells, but not through apoptosis. (C) 2015 Elsevier Ltd. All rights reserved.	[Takahashi, Shigeru; Uekita, Hiroki; Kato, Tsuyoshi; Inoue, Kiichiro; Domon, Takanori] Hokkaido Univ, Grad Sch Dent Med, Dept Oral Funct Anat, Kita Ku, Sapporo, Hokkaido 0608586, Japan	Takahashi, S (reprint author), Hokkaido Univ, Grad Sch Dent Med, Dept Oral Funct Anat, Kita Ku, Kita 13,Nishi 7, Sapporo, Hokkaido 0608586, Japan.	tshigeru@den.hokudai.ac.jp	Takahashi, Shigeru/A-4804-2012				ABE K, 1995, ARCH HISTOL CYTOL, V58, P221, DOI 10.1679/aohc.58.221; Carpenter GH, 2005, J NEUROIMMUNOL, V160, P4, DOI 10.1016/j.jneuroim.2004.10.020; Ohira A, 2012, INT J PAEDIATR DENT, V22, P146, DOI 10.1111/j.1365-263X.2011.01162.x; Scott J, 1999, J DENT RES, V78, P1711; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; Harrison JD, 2001, J ORAL PATHOL MED, V30, P29, DOI 10.1034/j.1600-0714.2001.300105.x; Miehe B, 1999, ANN ANAT, V181, P37, DOI 10.1016/S0940-9602(99)80084-3; Kiliaridis S, 1999, AM J ORTHOD DENTOFAC, V116, P121, DOI 10.1016/S0889-5406(99)70207-6; CHISHOLM DM, 1995, VIRCHOWS ARCH, V427, P181; HALL HD, 1964, P SOC EXP BIOL MED, V117, P789; HAND AR, 1981, ARCH ORAL BIOL, V26, P369, DOI 10.1016/0003-9969(81)90032-7; HARRISON JD, 1976, J PATHOL, V118, P245, DOI 10.1002/path.1711180407; ITO G, 1988, ANAT ANZEIGER, V165, P151; JOHNSON DA, 1982, J NUTR, V112, P175; Kato T., 2015, MED PRIN PR IN PRESS, V24; KILIARIDIS S, 1988, ARCH ORAL BIOL, V33, P187, DOI 10.1016/0003-9969(88)90044-1; Kurahashi M, 1999, ARCH ORAL BIOL, V44, P1013, DOI 10.1016/S0003-9969(99)00099-0; Leal Soraya Coelho, 2003, Braz Dent J, V14, P172, DOI 10.1590/S0103-64402003000300006; Maki K, 2001, Int J Paediatr Dent, V11, P281, DOI 10.1046/j.1365-263X.2001.00298.x; Murakami K, 2007, AM J CLIN NUTR, V86, P206; Nakamura K., 1997, JPN J ORAL BIOL, V39, P655; POAT JA, 1982, J AUTON PHARMACOL, V2, P79, DOI 10.1111/j.1474-8673.1982.tb00472.x; SCOTT J, 1991, ARCH ORAL BIOL, V36, P855, DOI 10.1016/0003-9969(91)90035-S; SCOTT J, 1990, ARCH ORAL BIOL, V35, P509, DOI 10.1016/0003-9969(90)90080-T; Suzuki H, 2005, METABOLISM, V54, P1593, DOI 10.1016/j.metabol.2005.06.006; Takahashi S, 2012, J MOL HISTOL, V43, P761, DOI 10.1007/s10735-012-9442-y; Takahashi S, 2014, TISSUE CELL, V46, P136, DOI [10.1016/j.tice.2014.01.001, 10.1016/j.tice.2013.12.001]; Tsuchiya M, 2014, LIFE SCI, V103, P8, DOI 10.1016/j.lfs.2014.03.022; WALKER NI, 1987, J PATHOL, V153, P333, DOI 10.1002/path.1711530407; WALKER NI, 1987, AM J PATHOL, V126, P439; WATT DG, 1951, AM J ORTHOD DENTOFAC, V37, P895, DOI 10.1016/0002-9416(51)90101-7; WILBORN WH, 1970, Z ZELLFORSCH MIK ANA, V103, P1, DOI 10.1007/BF00335396; Yamanaka R, 2009, J ORAL REHABIL, V36, P584, DOI 10.1111/j.1365-2842.2009.01971.x	33	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0040-8166			TISSUE CELL	Tissue Cell	JUN	2015	47	3					336	341		10.1016/j.tice.2015.04.003		6	Anatomy & Morphology; Cell Biology	Anatomy & Morphology; Cell Biology	CJ5UT	WOS:000355557700013		
J	Kon, R; Ikarashi, N; Hayakawa, A; Haga, Y; Fueki, A; Kusunoki, Y; Tajima, M; Ochiai, W; Machida, Y; Sugiyama, K				Kon, Risako; Ikarashi, Nobutomo; Hayakawa, Akio; Haga, Yusuke; Fueki, Aika; Kusunoki, Yoshiki; Tajima, Masataka; Ochiai, Wataru; Machida, Yoshiaki; Sugiyama, Kiyoshi			Morphine-Induced Constipation Develops With Increased Aquaporin-3 Expression in the Colon via Increased Serotonin Secretion	TOXICOLOGICAL SCIENCES			English	Article						aquaporin-3; morphine; constipation; serotonin; fluoxetine	VASOACTIVE INTESTINAL PEPTIDE; RAT GASTROINTESTINAL-TRACT; ADVANCED CANCER-PATIENTS; EPITHELIAL-CELL LINE; WATER CHANNEL; MAGNESIUM-SULFATE; EXCHANGE ACTIVITY; PALLIATIVE CARE; DISTAL COLON; 5-HYDROXYTRYPTAMINE	Aquaporin-3 (AQP3) is a water channel that is predominantly expressed in the colon, where it plays a critical role in the regulation of fecal water content. This study investigated the role of AQP3 in the colon in morphine-induced constipation. AQP3 expression levels in the colon were analyzed after oral morphine administration to rats. The degree of constipation was analyzed after the combined administration of HgCl2 (AQP3 inhibitor) or fluoxetine (5-HT reuptake transporter [SERT] inhibitor) and morphine. The mechanism by which morphine increased AQP3 expression was examined in HT-29 cells. AQP3 expression levels in rat colon were increased during morphine-induced constipation. The combination of HgCl2 and morphine improved morphine-induced constipation. Treatment with morphine in HT-29 cells did not change AQP3 expression. However, 5-HT treatment significantly increased the AQP3 expression level and the nuclear translocation of peroxisome proliferator-activated receptor gamma (PPAR gamma) 1 h after treatment. Pretreatment with fluoxetine significantly suppressed these increases. Fluoxetine pretreatment suppressed the development of morphine-induced constipation and the associated increase in AQP3 expression in the colon. The results suggest that morphine increases the AQP3 expression level in the colon, which promotes water absorption from the luminal side to the vascular side and causes constipation. This study also showed that morphine-induced 5-HT secreted from the colon was taken into cells by SERT and activated PPAR gamma, which subsequently increased AQP3 expression levels.	[Kon, Risako; Ikarashi, Nobutomo; Hayakawa, Akio; Haga, Yusuke; Fueki, Aika; Kusunoki, Yoshiki; Tajima, Masataka; Ochiai, Wataru; Sugiyama, Kiyoshi] Hoshi Univ, Dept Clin Pharmacokinet, Tokyo 1428501, Japan; [Machida, Yoshiaki] Hoshi Univ, Div Appl Pharmaceut Educ & Res, Tokyo 1428501, Japan	Sugiyama, K (reprint author), Hoshi Univ, Dept Clin Pharmacokinet, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	sugiyama@hoshi.ac.jp			Japan Society for the Promotion of Science [25860195]; Takeda Science Foundation	Grant-in-Aid for Young Scientists (B) from the Japan Society for the Promotion of Science (No. 25860195) and the Takeda Science Foundation.	Magro F, 2007, LIFE SCI, V81, P560, DOI 10.1016/j.lfs.2007.06.024; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Ikarashi N, 2012, BIOL PHARM BULL, V35, P957; Kon R, 2014, J ETHNOPHARMACOL, V152, P190, DOI 10.1016/j.jep.2013.12.055; Hendriks G, 2004, J BIOL CHEM, V279, P2975, DOI 10.1074/jbc.M310767200; Larkin PJ, 2008, PALLIATIVE MED, V22, P796, DOI 10.1177/0269216308096908; Ma TH, 1999, J PHYSIOL-LONDON, V517, P317, DOI 10.1111/j.1469-7793.1999.0317t.x; Itoh A, 2003, J GASTROEN HEPATOL, V18, P203, DOI 10.1046/j.1440-1746.2003.02949.x; ORTIZ J, 1992, BRIT J PHARMACOL, V105, P941; Baumgarten R, 1998, J AM SOC NEPHROL, V9, P1553; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; PHILLIPS SF, 1973, J LAB CLIN MED, V81, P733; King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469; Swegle JM, 2006, AM FAM PHYSICIAN, V74, P1347; Herndon CM, 2002, PHARMACOTHERAPY, V22, P240, DOI 10.1592/phco.22.3.240.33552; Waku T, 2010, EMBO J, V29, P3395, DOI 10.1038/emboj.2010.197; Ikarashi N, 2012, EUR J PHARM SCI, V45, P73, DOI 10.1016/j.ejps.2011.10.024; Coates MD, 2004, GASTROENTEROLOGY, V126, P1657, DOI 10.1053/j.gastro.2004.03.013; Koyama Y, 1999, AM J PHYSIOL-CELL PH, V276, pC621; MANARA L, 1986, J PHARMACOL EXP THER, V237, P945; Loo DDF, 2002, J PHYSIOL-LONDON, V542, P53, DOI 10.1113/jphysiol.2002.018713; Mancini I, 1998, SUPPORT CARE CANCER, V6, P356, DOI 10.1007/s005200050177; Iversen L, 2000, MOL PSYCHIATR, V5, P357, DOI 10.1038/sj.mp.4000728; Jiang YJ, 2011, EXP DERMATOL, V20, P595, DOI 10.1111/j.1600-0625.2011.01269.x; Camilleri M, 2011, AM J GASTROENTEROL, V106, P835, DOI 10.1038/ajg.2011.30; DeLuca A, 1996, PHARMACOL THERAPEUT, V69, P103, DOI 10.1016/0163-7258(95)02053-5; Wade PR, 1996, J NEUROSCI, V16, P2352; Ataee R, 2010, J CANCER RES CLIN, V136, P1461, DOI 10.1007/s00432-010-0801-3; BEUBLER E, 1990, GASTROENTEROLOGY, V99, P83; BURKS TF, 1973, J PHARMACOL EXP THER, V185, P530; BURKS TF, 1967, J PHARMACOL EXP THER, V156, P267; DUPONT C, 1980, EUR J CLIN INVEST, V10, P67, DOI 10.1111/j.1365-2362.1980.tb00012.x; Gallardo P, 2001, AM J PHYSIOL-GASTR L, V281, pG856; Gill RK, 2005, GASTROENTEROLOGY, V128, P962, DOI 10.1053/j.gastro.2005.02.01; Hoffman M, 1997, CANCER INVEST, V15, P542, DOI 10.3109/07357909709047595; Ikarashi N, 2011, LIFE SCI, V88, P194, DOI 10.1016/j.lfs.2010.11.013; Ikarashi N, 2011, BIOL PHARM BULL, V34, P238, DOI 10.1248/bpb.34.238; Ikarashi N, 2011, AM J PHYSIOL-GASTR L, V301, pG887, DOI 10.1152/ajpgi.00286.2011; Itoh A, 2004, INT J MOL MED, V14, P621; KAUFMAN PN, 1988, GASTROENTEROLOGY, V94, P1351; Kim M, 2001, J CLIN INVEST, V108, P1051, DOI 10.1172/JCI12467; KUO CK, 1991, J PHARMACOBIO-DYNAM, V14, P187; Kuramoto H, 2007, ARCH HISTOL CYTOL, V70, P235, DOI 10.1679/aohc.70.235; Kuwahara M, 1997, BIOCHEMISTRY-US, V36, P13973, DOI 10.1021/bi9711442; LABURTHE M, 1978, P NATL ACAD SCI USA, V75, P2772, DOI 10.1073/pnas.75.6.2772; Matsuzaki Toshiyuki, 2004, Medical Electron Microscopy, V37, P71; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; Mercadante S, 2006, EUR J PAIN, V10, P153, DOI 10.1016/j.ejpain.2005.02.006; RACKE K, 1991, PHARMACOL RES, V23, P13, DOI 10.1016/S1043-6618(05)80101-X; Saksena S, 2005, J BIOL CHEM, V280, P11859, DOI 10.1074/jbc.M411553200; SAWE J, 1985, BRIT J CLIN PHARMACO, V19, P495; Silberstein C, 1999, BRAZ J MED BIOL RES, V32, P1303, DOI 10.1590/S0100-879X1999001000018; Spector DA, 2002, AM J PHYSIOL-RENAL, V282, pF1034, DOI 10.1152/ajprenal.00136.2001; Stepulak A, 2008, CANCER BIOL THER, V7, P1685; Umenishi F, 2005, BIOCHEM BIOPH RES CO, V338, P1593, DOI 10.1016/j.bbrc.2005.10.127; Vanegas G, 1998, CANCER NURS, V21, P289, DOI 10.1097/00002820-199808000-00011; YUE QY, 1990, PHARMACOL TOXICOL, V66, P221	58	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1096-6080	1096-0929		TOXICOL SCI	Toxicol. Sci.	JUN	2015	145	2					337	347		10.1093/toxsci/kfv055		11	Toxicology	Toxicology	CJ7GS	WOS:000355663300011		
J	Aikyo, Y; Kobayashi, Y; Akashi, T; Ishiwatari, M				Aikyo, Yutaka; Kobayashi, Yuki; Akashi, Tomohiko; Ishiwatari, Makoto			Feasibility Study of Airbag Concept Applicable to Motorcycles Without Sufficient Reaction Structure	TRAFFIC INJURY PREVENTION			English	Article						safety; motorcycle; car-to-car; crash testing; airbag; protection		Objectives: An airbag system for motorcycle applications was developed and marketed in 2006 followed by many research projects on the system. In the airbag system, the bag should be supported during the kinetic energy-absorbing period of a rider in a collision. The previously developed system employed a configuration in which motorcycle structures support the airbag, such as a gauge unit and/or a steering structure. The supporting structure functions to receive the reaction force to hold the airbag during a crash to properly absorb the rider's kinetic energy. However, the previous system requires a larger area for this reaction structure and is applicable only to the motorcycles that can provide that area. To overcome this limitation, we propose an airbag system employing another concept. In this concept, the airbag does not use its vehicle structures as a reaction structure but uses the structures of an opposing vehicle, such as doors and/or pillars of an opposing vehicle. In this project, we aim to verify the effectiveness of the proposed system when installed in a motorcycle that cannot provide a larger area for the reaction structure. Methods: In the system with this concept, it is assumed that the occupant protection performance is largely affected depending on impact configurations. Accordingly, full-scale motorcycle-to-car crash tests using 125cm(3) scooter-type models with and without the proposed system were conducted in various impact configurations. The 7 impact configurations specified in ISO 13232 were selected as the test configurations. Injury variables and injury indices of head, neck, chest, and abdomen were evaluated with the motorcyclist dummy. Results: Injury variables and indices obtained from the crash tests with the airbag were compared to those of the baseline tests. In 2 impact configurations, the airbags were supported by the side structures of the opposing vehicle and performed to reduce the injury variable of head and/or chest compared to that of the baseline test. Conclusion: Through the crash tests, beneficial protection effects of the airbag system were confirmed in particular impact configurations. No significant risk for the occupant due to the airbag was observed in the conducted crash tests. It was concluded that the proposed airbag system has feasibility to reduce rider injury in a collision of a motorcycle without sufficient reaction structure.	[Aikyo, Yutaka; Kobayashi, Yuki; Akashi, Tomohiko; Ishiwatari, Makoto] Honda Res & Dev Co Ltd, Motorcycle R&D Ctr, Asaka, Saitama 3518555, Japan	Aikyo, Y (reprint author), Honda Res & Dev Co Ltd, Motorcycle R&D Ctr, 3-15-1 Senzui, Asaka, Saitama 3518555, Japan.	yutaka.aikyo@mail.a.rd.honda.co.jp					Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Institute for Traffic Accident Research and Data Analysis, TRAFF ACC DAT 1997 2; International Organization for Standardization, 2012, 13232 ISO, V2nd; International Organization for Standardization, 2005, 13232 ISO, V2nd; Kanbe S, 2007, 20 INT TECHN C ENH S; Kuroe T, 2005, 19 INT TECHN C ENH S; Kuroe T, 2004, 5 INT MOT C IFZ SEPT	7	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.	JUN 1	2015	16			1	SI		S148	S152		10.1080/15389588.2015.1016156		5	Public, Environmental & Occupational Health; Transportation	Public, Environmental & Occupational Health; Transportation	CJ3SQ	WOS:000355404600020		
J	Antona-Makoshi, J; Eliasson, E; Davidsson, J; Ejima, S; Ono, K				Antona-Makoshi, Jacobo; Eliasson, Erik; Davidsson, Johan; Ejima, Susumu; Ono, Koshiro			Effect of Aging on Brain Injury Prediction in Rotational Head Trauma-A Parameter Study with a Rat Finite Element Model	TRAFFIC INJURY PREVENTION			English	Article						traumatic brain injury (TBI); acute subdural hematoma (ASDH); age; finite element method; diffuse axonal injuries (DAI)	AGE-RELATED-CHANGES; SUBDURAL-HEMATOMA; LIPID-COMPOSITION; CRITERIA; GENDER; IMPACT	Objective: The aim of this study was to investigate the possible effects of age-related intracranial changes on the potential outcome of diffuse axonal injuries and acute subdural hematoma under rotational head loading. Methods: A simulation-based parametric study was conducted using an updated and validated finite element model of a rat head. The validation included a comparison of predicted brain cortex sliding with respect to the skull. Further, model material properties were modified to account for aging; predicted tissue strains were compared with experimental data in which groups of rats in 2 different lifecycle stages, young adult and mature adult, were subjected to rotational trauma. For the parameter study, 2 age-dependent factors-brain volume and region-specific brain material properties-were implemented into the model. The models young adult and old age were subjected to several injurious and subinjurious sagittal plane rotational acceleration levels. Results: Sequential analysis of the simulated trauma progression indicates that an increase in acute subdural hematoma injury risk indicator occurs at an early stage of the trauma, whereas an increase in diffuse axonal injury risk indicators occurs at a later stage. Tissue stiffening from young adult to mature adult rats produced an increase in strain-based thresholds accompanied by a wider spread of strain distribution toward the rear part of the brain, consistent with rotational trauma experiments with young adult and mature adult rats. Young adult to old age brain tissue softening and brain atrophy resulted in an increase in diffuse axonal injuries and acute subdural hematoma injury risk indicators, respectively. Conclusions: The findings presented in this study suggest that age-specific injury thresholds should be developed to enable the development of superior restraint systems for the elderly. The findings also motivate other further studies on age-dependency of head trauma.	[Antona-Makoshi, Jacobo; Eliasson, Erik; Davidsson, Johan] Chalmers, S-41296 Gothenburg, Sweden; [Antona-Makoshi, Jacobo; Ejima, Susumu; Ono, Koshiro] Japan Automot Res Inst, Tsukuba, Ibaraki, Japan	Antona-Makoshi, J (reprint author), 2530 Karima, Tsukuba, Ibaraki 3050822, Japan.	ajacobo@jari.or.jp			Japan Society for the Promotion of Science (JSPS) Summer Program; Japan Automobile Research Institute (JARI); Chalmers University Areas of Advance within Transport, Sweden	Funding for this research was provided by the Japan Society for the Promotion of Science (JSPS) Summer Program, the Japan Automobile Research Institute (JARI), and Chalmers University Areas of Advance within Transport, Sweden.	Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Xu J, 2000, AM J NEURORADIOL, V21, P112; Sack I, 2009, NEUROIMAGE, V46, P652, DOI 10.1016/j.neuroimage.2009.02.040; Takhounts EG, 2008, STAPP CAR C, V52, P1; Chen JCT, 2000, NEUROSURG CLIN N AM, V11, P399; Fox NC, 2004, LANCET, V363, P392, DOI 10.1016/S0140-6736(04)15441-X; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; SVENNERHOLM L, 1994, J NEUROCHEM, V63, P1802; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Antona-Makoshi J, 2014, INT J AUTOMOT ENG, V5, P31; Antona-Makoshi J, 2013, INT RES COUNC BIOM I; Bener A, 2010, BRAIN INJURY, V24, P74, DOI 10.3109/02699050903508192; Bruns John Jr., 2003, Epilepsia, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CAMERON TP, 1982, LAB ANIM SCI, V32, P495; Davidsson J, 2011, FRONTIERS NEUROTRAUM, V2, P1; Davidsson J, 2009, INT RES COUNC BIOM I; Davidsson J, 2015, FRONTIERS NEUR UNPUB; Elkin BS, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000164; Elkin BS, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025386; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Kameyama M, 2008, NEUROTRAUMATOLOGY, V31, P46; Kimpara H, 2006, STAPP CAR CRASH J, V50, P27; Lamy M, 2009, INT RES COUNC BIOM I; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Matsumae M, 1996, J NEUROSURG, V84, P982, DOI 10.3171/jns.1996.84.6.0982; McElhaney JH, 1976, HDB HUMAN TOLERANCE; Meaney DF, 1993, ASME WAM, V25, P169; Meaney DF, 1991, THESIS U PENNSYLVANI; ROUSER G, 1968, LIPIDS, V3, P284, DOI 10.1007/BF02531202; Sawauchi S, 2007, NEUROL SURG TOKYO, V35, P665; Sengupta Pallav, 2013, Int J Prev Med, V4, P624; Takhounts EG, 2003, STAPP CAR CRASH J, V47, P107; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; UN, 2012, WORLD POP PROSP 2012; World Health Organization, 2012, GLOB PLAN DEC ACT RO; Yanaoka T, 2013, INT RES COUNC BIOM I; Zhang L, 2001, Stapp Car Crash J, V45, P369	40	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.	JUN 1	2015	16			1	SI		S91	S99		10.1080/15389588.2015.1021416		9	Public, Environmental & Occupational Health; Transportation	Public, Environmental & Occupational Health; Transportation	CJ3SQ	WOS:000355404600013		
J	Antona-Makoshi, J; Yamamoto, Y; Kato, R; Sato, F; Ejima, S; Dokko, Y; Yasuki, T				Antona-Makoshi, Jacobo; Yamamoto, Yoshihiro; Kato, Ryosuke; Sato, Fusako; Ejima, Susumu; Dokko, Yasuhiro; Yasuki, Tsuyoshi			Age-Dependent Factors Affecting Thoracic Response: A Finite Element Study Focused on Japanese Elderly Occupants	TRAFFIC INJURY PREVENTION			English	Article						elderly; front impact; safety; chest injury		Objectives: The ultimate goal of this research is to reduce thoracic injuries due to traffic crashes, especially in the elderly. The specific objective is to develop and validate a full-body finite element model under 2 distinct settings that account for factors relevant for thoracic fragility of elderly: one setting representative of an average size male and one representative of an average size Japanese elderly male. Methods: A new thorax finite element model was developed from medical images of a 71-year-old average Japanese male elderly size (161cm, 60kg) postmortem human subject (PMHS). The model was validated at component and assembled levels against original series of published test data obtained from the same elderly specimen. The model was completed with extremities and head of a model previously developed. The rib cage and the thoracic flesh materials were assigned age-dependent properties and the model geometry was scaled up to simulate a 50th percentile male. Thereafter, the model was validated against existing biomechanical data for younger and elderly subjects, including hub-to-thorax impacts and frontal impact sled PMHS test data. Finally, a parametric study was conducted with the new models to understand the effect of size and aging factors on thoracic response and risk of rib fractures. Results: The model behaved in agreement with tabletop test experiments in intact, denuded, and eviscerated tissue conditions. In frontal impact sled conditions, the model showed good 3-dimensional head and spine kinematics, as well as rib cage multipoint deflections. When properties representative of an aging person were simulated, both the rib cage deformation and the predicted number of rib fractures increased. The effects of age factors such as rib cortical thickness, mechanical properties, and failure thresholds on the model responses were consistent with the literature. Aged and thereby softened flesh reduced load transfer between ribs; the coupling of the rib cage was reduced. Aged costal cartilage increased the severity of the diagonal belt loading sustained by the lower loaded rib cage. Conclusions: When age-specific parameters were implemented in a finite element (FE) model of the thorax, the rib cage kinematics and thorax injury risk increased. When the effect of size was isolated, 2 factors, in addition to rib material properties, were found to be important: flesh and costal cartilage properties. These 2 were identified to affect rib cage deformation mechanisms and may potentially increase the risk of rib fractures.	[Antona-Makoshi, Jacobo; Yamamoto, Yoshihiro; Kato, Ryosuke; Sato, Fusako; Ejima, Susumu] Japan Automobile Res Inst, Tsukuba, Ibaraki 3050822, Japan; [Dokko, Yasuhiro; Yasuki, Tsuyoshi] Japan Automobile Manufacturers Assoc, Tokyo, Japan	Antona-Makoshi, J (reprint author), Japan Automobile Res Inst, 2530 Karima, Tsukuba, Ibaraki 3050822, Japan.	ajacobo@jari.or.jp					Mendoza-Vazquez M, 2013, INT J CRASHWORTHINES, V18, P516, DOI 10.1080/13588265.2013.815019; BURSTEIN AH, 1976, J BONE JOINT SURG AM, V58, P82; STEIN ID, 1976, CALC TISS RES, V20, P61, DOI 10.1007/BF02546398; Shaw G, 2009, STAPP CAR CRASH JO, V53, P1; Ash JH, 2012, IRCOBI C; Carroll J, 2010, IRCOBI C; Davidsson J, 2014, IRCOBI C; Dokko Y, 2011, JSAE ANN C; Dokko Y, 2009, 2009010396 SAE; Ejima S, 2014, C COMP ENG SCI; Forman JL, 2009, THESIS U VIRGINIA; Hamzah M, 2013, IRCOBI C; Hayamizu N, 2003, JSME MIE TOK BRANCH, P94; Ito O, 2009, 2009010381 SAE; Japanese Police, 2013, ANN REP ROAD TRAFF F; Kato R, 2014, JSAE ANN C; Kemper AR, 2005, 2005222010 SAE; Kent R, 2005, IRCOBI C; Kroell CK, 1974, 741187 SAE; Lebarbe M, 2012, IRCOBI C; Lemmen P, 2013, ESV C; Lemmen P, 2012, IRCOBI C; Marieb E.N., 2010, HUMAN ANATOMY PHYSL; McElhaney JH, 1976, HDB HUM TOL; Perz R, 2013, IRCOBI C; Research Institute of Human Engineering Quality of Life (HQL), 2008, JAP BOD SIZ DAT BOOK; Rhule Heather H, 2002, Stapp Car Crash J, V46, P477; Salzar R, 2014, JSAE ANN C; Sato F, 2013, IRCOBI C; Shaw G, 2010, INT P IRCOBI C; Subit D, 2014, SHEAR LOADING COSTAL; Subit D, 2014, P JSAE ANN C; United Nations, 2012, WORLD POP PROSP 2012; Wang S, 2013, JSAE ANN C FOR; Yaguchi M, 2011, P ESV C; Yamada H., 1970, STRENGTH BIOL MAT; Zama Y, 2010, P JSAE ANN C	37	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.	JUN 1	2015	16			1	SI		S66	S74		10.1080/15389588.2015.1014552		9	Public, Environmental & Occupational Health; Transportation	Public, Environmental & Occupational Health; Transportation	CJ3SQ	WOS:000355404600010		
J	Iwamoto, M; Nakahira, Y; Kimpara, H				Iwamoto, Masami; Nakahira, Yuko; Kimpara, Hideyuki			Development and Validation of the Total HUman Model for Safety (THUMS) Toward Further Understanding of Occupant Injury Mechanisms in Precrash and During Crash	TRAFFIC INJURY PREVENTION			English	Article						biofidelity; finite elements; occupant kinematics; muscle activation; injury outcome; modeling	MUSCLE; SPINE; CONTRACTIONS; EXTENSION; RESPONSES; FLEXION; FORCES; ADULTS; ELBOW	Objective: Active safety devices such as automatic emergency brake (AEB) and precrash seat belt have the potential to accomplish further reduction in the number of the fatalities due to automotive accidents. However, their effectiveness should be investigated by more accurate estimations of their interaction with human bodies. Computational human body models are suitable for investigation, especially considering muscular tone effects on occupant motions and injury outcomes. However, the conventional modeling approaches such as multibody models and detailed finite element (FE) models have advantages and disadvantages in computational costs and injury predictions considering muscular tone effects. The objective of this study is to develop and validate a human body FE model with whole body muscles, which can be used for the detailed investigation of interaction between human bodies and vehicular structures including some safety devices precrash and during a crash with relatively low computational costs. Methods: In this study, we developed a human body FE model called THUMS (Total HUman Model for Safety) with a body size of 50th percentile adult male (AM50) and a sitting posture. The model has anatomical structures of bones, ligaments, muscles, brain, and internal organs. The total number of elements is 281,260, which would realize relatively low computational costs. Deformable material models were assigned to all body parts. The muscle-tendon complexes were modeled by truss elements with Hill-type muscle material and seat belt elements with tension-only material. The THUMS was validated against 35 series of cadaver or volunteer test data on frontal, lateral, and rear impacts. Model validations for 15 series of cadaver test data associated with frontal impacts are presented in this article. The THUMS with a vehicle sled model was applied to investigate effects of muscle activations on occupant kinematics and injury outcomes in specific frontal impact situations with AEB. Results and Conclusions: In the validations using 5 series of cadaver test data, force-time curves predicted by the THUMS were quantitatively evaluated using correlation and analysis (CORA), which showed good or acceptable agreement with cadaver test data in most cases. The investigation of muscular effects showed that muscle activation levels and timing had significant effects on occupant kinematics and injury outcomes. Although further studies on accident injury reconstruction are needed, the THUMS has the potential for predictions of occupant kinematics and injury outcomes considering muscular tone effects with relatively low computational costs.	[Iwamoto, Masami; Nakahira, Yuko; Kimpara, Hideyuki] Toyota Cent Res & Dev Labs Inc, Nagakute, Aichi 4801192, Japan	Iwamoto, M (reprint author), Toyota Cent Res & Dev Labs Inc, 41-1 Yokomichi, Nagakute, Aichi 4801192, Japan.	iwamoto@mosk.tytlabs.co.jp					AMIS AA, 1980, J BIOMECH, V13, P825, DOI 10.1016/0021-9290(80)90170-0; Thelen DG, 2003, J BIOMECH ENG-T ASME, V125, P70, DOI 10.1115/1.1531112; Anderson DE, 2007, J BIOMECH, V40, P3105, DOI 10.1016/j.jbiomech.2007.03.022; PANJABI MM, 1976, J BONE JOINT SURG AM, V58, P642; Arbogast KB, 2009, STAPP CAR CRASH JO, V53, P329; SCHULTZ AB, 1979, J BIOMECH ENG-T ASME, V101, P46; Buchanan TS, 1998, J BIOMECH ENG-T ASME, V120, P634, DOI 10.1115/1.2834755; Bendjellal F, 1984, APR BIOMECHANICAL DA; Dibb AT, 2013, TRAFFIC INJ PREV, V14, pS116, DOI 10.1080/15389588.2013.806795; Gans C, 1982, EXERCISE SPORT SCI R, V10, P106; Hardy W N, 2001, Stapp Car Crash J, V45, P1; Iwamoto M, 2000, Stapp Car Crash J, V44, P281; Iwamoto Masami, 2012, Stapp Car Crash J, V56, P231; Kent Richard, 2004, Stapp Car Crash J, V48, P495; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; MURRAY MP, 1980, PHYS THER, V60, P412; Osth J, 2012, TRAFFIC INJ PREV, V13, P265, DOI 10.1080/15389588.2011.649437; Rupp JD, 2008, STAPP CAR C, V52, P421; Schneider L.W., 1983, DEV ANTHROPOMETRICAL; VANEIJDEN TMGJ, 1987, ACTA ANAT, V129, P310; Winters J, 1990, MULTIPLE MUSCLE SYST, P69; Yamada H., 1970, STRENGTH BIOL MAT	22	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.	JUN 1	2015	16			1	SI		S36	S48		10.1080/15389588.2015.1015000		13	Public, Environmental & Occupational Health; Transportation	Public, Environmental & Occupational Health; Transportation	CJ3SQ	WOS:000355404600007		
J	Guo, Y; Li, P; Yuyama, N; Tan, LB; Fu, YC; Zhu, ZF; Liu, FX; Sun, CQ; Cai, HW				Guo, Yan; Li, Pan; Yuyama, Nana; Tan, Lubin; Fu, Yongcai; Zhu, Zuofeng; Liu, Fengxia; Sun, Chuanqing; Cai, Hongwei			Identification of Quantitative Trait Locus for Seed Dormancy and Expression Analysis of Four Dormancy-Related Genes in Sorghum	TROPICAL PLANT BIOLOGY			English	Article						Sorghum; Seed dormancy; QTL; Gene homologs; Gene expression	RICE ORYZA-SATIVA; PREHARVEST SPROUTING RESISTANCE; NATURAL ALLELIC VARIATION; CONTRASTING DORMANCY; INBRED LINES; LINKAGE MAPS; QTL ANALYSIS; MAIZE VP1; L.; ARABIDOPSIS	Seed dormancy is an important trait during the domestication of major crops. Dormant seeds are unable to germinate under conditions normally suitable for non-dormant seeds. Quantitative trait loci (QTLs) and genes affecting seed dormancy in sorghum remain largely unknown. To identify the genomic regions controlling seed dormancy in sorghum, we produced two F-2 segregating populations from two crosses between a deep dormant weedy line B140 (as the female parent) and two weak dormant grain lines CK60B and MS138B (as the male parents). A genetic linkage map of the B140/CK60B population was constructed with 216 simple sequence repeat (SSR) markers spanning 1710.3 cM. One QTL on chromosome 4 and two QTLs on chromosome 7 were identified in the B140/CK60B population. They accounted for 17.9 to 24.9% of the phenotypic variance using a simple interval mapping method. The QTL on chromosome 4 was verified in another F-2 mapping population (MS138B/B140). To understand the mechanism of dormancy, we conducted an expression analysis of four sorghum genes encoding homologs of dormancy genes of other plant species: Vp1 (maize), DOG1 (Arabidopsis), qSD12 and Sdr4 (rice). We demonstrated that there were clear differences in the expression level of all these four genes between the two parental lines with different seed dormancy level, and their expression were also tissue-specific with the expression levels of qSD12 low throughout all growth stages and tissues in B140. Our findings will help to define the genetic mechanism of seed dormancy in sorghum, and the identified QTLs may be useful biomarker for selection in sorghum improvement programs.	[Guo, Yan; Li, Pan; Tan, Lubin; Fu, Yongcai; Zhu, Zuofeng; Liu, Fengxia; Sun, Chuanqing; Cai, Hongwei] China Agr Univ, Coll Agron & Biotechnol, Dept Plant Genet & Breeding, Beijing 100193, Peoples R China; [Guo, Yan; Li, Pan; Tan, Lubin; Fu, Yongcai; Zhu, Zuofeng; Liu, Fengxia; Sun, Chuanqing] Minist Agr, Beijing Key Lab Crop Genet Improvement & Genome, Beijing 100193, Peoples R China; [Yuyama, Nana; Cai, Hongwei] Japan Grassland Agr & Forage Seed Assoc, Forage Crop Res Inst, Nasushiobara, Tochigi 3292742, Japan	Cai, HW (reprint author), China Agr Univ, Coll Agron & Biotechnol, Dept Plant Genet & Breeding, 2 Yuanmingyuan West Rd, Beijing 100193, Peoples R China.	caihw@cau.edu.cn					Baskin JM, 2004, SEED SCI RES, V14, P1, DOI 10.1079/SSR2003150; Perez-Flores L, 2003, J EXP BOT, V54, P2071, DOI 10.1093/jxb/erg233; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; Gu XY, 2010, PLANT MOL BIOL, V73, P97, DOI 10.1007/s11103-009-9555-1; Gu XY, 2011, GENETICS, V189, P1515, DOI 10.1534/genetics.111.131169; Rodriguez MV, 2009, ANN BOT-LONDON, V104, P975, DOI 10.1093/aob/mcp184; Bentsink L, 2006, P NATL ACAD SCI USA, V103, P17042, DOI 10.1073/pnas.0607877103; Rodriguez MV, 2012, PLANT CELL PHYSIOL, V53, P64, DOI 10.1093/pcp/pcr154; Hori K, 2007, THEOR APPL GENET, V115, P869, DOI 10.1007/s00122-007-0620-3; Gu XY, 2008, GENETICS, V179, P2263, DOI 10.1534/genetics.108.092007; Voorrips RE, 2002, J HERED, V93, P77, DOI 10.1093/jhered/93.1.77; Manly KF, 2001, MAMM GENOME, V12, P930, DOI 10.1007/s00335-001-1016-3; VanderSchaar W, 1997, HEREDITY, V79, P190, DOI 10.1038/hdy.1997.142; Cai HW, 2000, THEOR APPL GENET, V100, P840, DOI 10.1007/s001220051360; Rampling LR, 2001, AUST J AGR RES, V52, P1131, DOI 10.1071/AR01027; Yonemaru J, 2009, DNA RES, V16, P187, DOI 10.1093/dnares/dsp005; Gu XY, 2004, GENETICS, V166, P1503, DOI 10.1534/genetics.166.3.1503; Alonso-Blanco C, 2003, GENETICS, V164, P711; Wan JM, 2006, PLANT SCI, V170, P786, DOI 10.1016/j.plantsci.2005.11.011; Li ML, 2009, MOL BREEDING, V24, P41, DOI 10.1007/s11032-009-9270-2; He P, 2001, CROP SCI, V41, P1240; Clerkx EJM, 2004, PLANT PHYSIOL, V135, P432, DOI 10.1104/pp.103.036814; Li CD, 2003, AUST J AGR RES, V54, P1303, DOI 10.1071/AR02210; HATTORI T, 1994, PLANT MOL BIOL, V24, P805, DOI 10.1007/BF00029862; Fang J, 2008, PLANT J, V54, P177, DOI 10.1111/j.1365-313X.2008.03411.x; Sugimoto K, 2010, P NATL ACAD SCI USA, V107, P5792, DOI 10.1073/pnas.0911965107; Gao W, 2003, THEOR APPL GENET, V107, P552, DOI 10.1007/s00122-003-1281-5; Schuelke M, 2000, NAT BIOTECHNOL, V18, P233, DOI 10.1038/72708; Brown E, 1948, USDA TECH B; Carrari F, 2001, PLANT MOL BIOL, V45, P631, DOI 10.1023/A:1010648420669; Chavan JK, 1984, NUTR PROCESSING QUAL; GRITTON ET, 1963, AGRON J, V55, P169; Gu XY, 2005, THEOR APPL GENET, V110, P1108, DOI 10.1007/s00122-005-1939-2; HARRIS HB, 1970, AGRON J, V62, P835; Heng Y, 2010, PLANT SCI, V179, P612; Jiang Ling, 2003, Acta Genetica Sinica, V30, P453; Kosambi D. D., 1944, ANN EUGENICS, V12, P172; Li BL, 1997, TRENDS PLANT SCI, V2, P384, DOI 10.1016/S1360-1385(97)90053-4; Lijavetzky D, 2000, EUPHYTICA, V112, P125, DOI 10.1023/A:1003823829878; Lin SY, 1998, THEOR APPL GENET, V96, P997, DOI 10.1007/s001220050831; Lullien-Pellerin V, 2001, EUR J BIOCHEM, V268, P5705, DOI 10.1046/j.0014-2956.2001.02416.x; McCouch SR, 1997, RICE GENET NEWSLETT, V14, P11, DOI DOI 10.1007/S10681-005-0449-2; Nair GV, 1965, INDIAN J AGR SCI, V35, P234; Prada D, 2004, THEOR APPL GENET, V109, P62, DOI 10.1007/s00122-004-1608-x; Quinby J. R., 1970, Sorghum production and utilization., P73; RINGLUND K, 1993, PRE-HARVEST SPROUTING IN CEREALS 1992, P3; Sugimoto K, 2013, PLANT AN GEN 21 C PL; Wan J, 1997, CROP SCI, V37, P1759; Wu YH, 2012, DERMATOL SIN, V30, P1, DOI 10.1016/j.dsi.2012.02.004	49	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1935-9756	1935-9764		TROP PLANT BIOL	Trop. Plant Biol.	JUN	2015	8	1-2					9	18		10.1007/s12042-015-9146-z		10	Plant Sciences	Plant Sciences	CJ8CV	WOS:000355728000002		
J	Murata, S; Warigaya, K; Matsuzaki, I; Itonaga, M; Shimizu, Y; Shuto, M				Murata, Shin-ichi; Warigaya, Kenji; Matsuzaki, Ibu; Itonaga, Masahiro; Shimizu, Yuki; Shuto, Masayo			Microtubule-organizing center-mediated nuclear polarity in various normal and neoplastic human tissues	VIRCHOWS ARCHIV			English	Article						Nuclear polarity; Microtubule-organizing center; Centrosome; Gamma-tubulin; Pericentrin	CELL POLARIZATION; CENTROSOME; ASSOCIATION; MECHANISMS; MEMBRANE; PROTEIN; COMPLEX; MTOC	Nuclear polarity is characterized by intracytoplasmic nuclear positioning and alignment in the tissue. The mechanisms responsible for maintaining nuclear polarity in normal cells and its disturbance in neoplastic cells are not understood. We studied microtubule-organizing center (MTOC) positioning-mediated nuclear polarity in various normal and neoplastic human tissues, as well as in cultured cells. To visualize the MTOC in cells, gamma-tubulin and pericentrin were immunohistochemically stained by fluorescence and non-fluorescence methods. Position of MTOC in normal and neoplastic tissue was assessed by spatial relationship with nucleus and apico-basal axis. We found MTOC positioning to be related to morphogenesis in various normal and neoplastic human tissues, as well as in cultured cells. MTOC positions were different between two-dimensional cultured isolated cells and three-dimensional cultured gland-formed cells. The MTOC position was specific depending on the cell type in the tissue structure. In particular, glandular and urothelial epithelium had a strong relationship with preservation of nuclear polarity and MTOC positioning. Carcinoma cells showed an irregular position or absence of the MTOC depending on poorer differentiation and higher grade of carcinomas. In conclusion, the position of the MTOC affects regulation of nuclear polarity and morphogenesis of normal and pathological tissue structure.	[Murata, Shin-ichi; Warigaya, Kenji; Matsuzaki, Ibu; Itonaga, Masahiro; Shimizu, Yuki] Wakayama Med Univ, Dept Human Pathol, Wakayama 6418509, Japan; [Shuto, Masayo] Saitama Med Univ, Sch Med Technol & Hlth, Fac Hlth & Med Care, Int Med Ctr, Saitama, Japan	Murata, S (reprint author), Wakayama Med Univ, Dept Human Pathol, 811-1 Kimiidera, Wakayama 6418509, Japan.	smurata@wakayama-med.ac.jp			Japan Society for the Promotion of Science [23590412]; Wakayama Medical University	The current study was supported by following funding sources; (1) Grant-in-Aid for Scientific Research C (23590412), supported by Japan Society for the Promotion of Science; and (2) Grant for Specific Research (2012, 2013, and 2014), sponsored by Wakayama Medical University.	Bartolini F, 2006, J CELL SCI, V119, P4155, DOI 10.1242/jcs.03227; Reinsch S, 1998, J CELL SCI, V111, P2283; Feldman JL, 2012, CURR BIOL, V22, P575, DOI 10.1016/j.cub.2012.02.044; Salpingidou G, 2007, J CELL BIOL, V178, P897, DOI 10.1083/jcb.200702026; Roux KJ, 2009, P NATL ACAD SCI USA, V106, P2194, DOI 10.1073/pnas.0808602106; Xiang X, 2012, CURR BIOL, V22, pR496, DOI 10.1016/j.cub.2012.04.044; Chabin-Brion K, 2001, MOL BIOL CELL, V12, P2047; Dupin I, 2011, INT J BIOCHEM CELL B, V43, P1698, DOI 10.1016/j.biocel.2011.09.004; Crisp M, 2006, J CELL BIOL, V172, P41, DOI 10.1083/jcb.200509124; Jones C, 2008, NAT GENET, V40, P69, DOI 10.1038/ng.2007.54; Hale CM, 2011, J CELL SCI, V124, P4267, DOI 10.1242/jcs.091231; Burakov AV, 2013, CELL BIOL INT, V37, P95, DOI 10.1002/cbin.10016; Tang N, 2012, J CELL SCI, V125, P4951, DOI 10.1242/jcs.038083; Gundersen GG, 2013, CELL, V152, P1376, DOI 10.1016/j.cell.2013.02.031; Kayser G, 2005, VIRCHOWS ARCH, V447, P61, DOI 10.1007/s00428-004-1191-1; Nakashima Y, 2011, HISTOPATHOLOGY, V59, P841, DOI 10.1111/j.1365-2559.2011.04035.x; Niu DF, 2009, VIRCHOWS ARCH, V455, P149, DOI 10.1007/s00428-009-0802-2; Oriolo AS, 2007, MOL BIOL CELL, V18, P781, DOI 10.1091/mbc.E06-03-0201; Petersen J. L., 1993, Pathology Research and Practice, V189, P780; Rodríguez-Fraticelli Alejo E, 2013, Small GTPases, V4, P136, DOI 10.4161/sgtp.24303; Urbani L, 1999, CURR BIOL, V9, pR315; Zhang YH, 2012, J BIOL CHEM, V287, P17746, DOI 10.1074/jbc.M112.358143	22	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2015	466	6					625	635		10.1007/s00428-015-1744-5		11	Pathology	Pathology	CK0ZH	WOS:000355933900003		
J	Ueno, H; Shinto, E; Hashiguchi, Y; Shimazaki, H; Kajiwara, Y; Sueyama, T; Yamamoto, J; Hase, K				Ueno, Hideki; Shinto, Eiji; Hashiguchi, Yojiro; Shimazaki, Hideyuki; Kajiwara, Yoshiki; Sueyama, Takahiro; Yamamoto, Junji; Hase, Kazuo			In rectal cancer, the type of desmoplastic response after preoperative chemoradiotherapy is associated with prognosis	VIRCHOWS ARCHIV			English	Article						Rectal cancer; Desmoplastic reaction; Fibrotic cancer stroma; Chemoradiation	EPITHELIAL-MESENCHYMAL TRANSITION; PATHOLOGICAL COMPLETE RESPONSE; COLORECTAL-CANCER; NEOADJUVANT CHEMORADIOTHERAPY; HISTOLOGICAL CATEGORIZATION; TUMOR-REGRESSION; STEM-CELLS; RADIOTHERAPY; STROMA; CHEMOTHERAPY	Although the essential contribution of the desmoplastic reaction (DR) to aggressive tumor behavior is increasingly recognized, its prognostic value has not been investigated in rectal cancer after preoperative chemoradiotherapy. We retrospectively analyzed 101 consecutive patients with rectal cancer treated with short-course chemoradiotherapy followed by surgery (2001-2007). The DR in the resected primary tumor was pathologically classified into three patterns on the basis of products of cancer-associated fibroblasts (CAFs): mature (multilayered fibrotic), intermediate (keloid-like hyalinized), and immature (mostly myxoid). We classified 46 tumors as mature, 30 as intermediate, and 25 as immature DR. In addition, immunostaining of CD8(+) and FoxP3(+) cells was performed to characterize the immune response accompanying DR. Mature DR correlated with higher density of CD8(+) and FoxP3(+) cells in both resected surgical and pretreatment biopsy specimens. A significant association with DR category was observed for T stage, lymphatic invasion, and venous invasion (P <= 0.0001-0.0006). Mature DR was significantly associated with higher grade of pathological response (P=0.0350). The 5-year disease-free survival (DFS) rates were 82, 72, and 47 % for mature, intermediate, and immature DR, respectively (P=0.0055). On multivariate analysis, DR category and ypN were independently predictive of DFS. The pattern of the DR in rectal cancers after chemoradiotherapy treatment might have a prognostic value, as it likely reflects pretreatment desmoplastic environment.	[Ueno, Hideki; Shinto, Eiji; Kajiwara, Yoshiki; Sueyama, Takahiro; Yamamoto, Junji; Hase, Kazuo] Natl Def Med Coll, Dept Surg, Tokorozawa, Saitama 3598513, Japan; [Hashiguchi, Yojiro] Teikyo Univ, Dept Surg, Tokyo 173, Japan; [Shimazaki, Hideyuki] Natl Def Med Coll Hosp, Dept Lab Med, Tokorozawa, Saitama, Japan	Ueno, H (reprint author), Natl Def Med Coll, Dept Surg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	ueno@ndmc.ac.jp			Japan Society for the Promotion of Science (JSPS)	This study was supported by a Grant-in-Aid for Scientific Research (C) by Japan Society for the Promotion of Science (JSPS).	JASS JR, 1986, J CLIN PATHOL, V39, P585, DOI 10.1136/jcp.39.6.585; Dhadda AS, 2011, EUR J CANCER, V47, P1138, DOI 10.1016/j.ejca.2010.12.006; Tsai CJ, 2011, CANCER-AM CANCER SOC, V117, P3713, DOI 10.1002/cncr.25973; Allen M, 2011, J PATHOL, V223, P162, DOI 10.1002/path.2803; Bouzourene H, 2002, CANCER, V94, P1121, DOI 10.1002/cncr.10327; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Kim CW, 2011, ANN SURG ONCOL, V18, P3271, DOI 10.1245/s10434-011-1740-1; Trakarnsanga A, 2013, ANN SURG ONCOL, V20, P1179, DOI 10.1245/s10434-012-2722-7; Ueno H, 2004, GUT, V53, P581, DOI 10.1136/gut.2003.028365; Tabachnyk M, 2012, ORAL ONCOL, V48, P594, DOI 10.1016/j.oraloncology.2012.01.024; Perez RO, 2009, DIS COLON RECTUM, V52, P1137, DOI 10.1007/DCR.0b013e31819ef76b; Roh MS, 2009, J CLIN ONCOL, V27, P5124, DOI 10.1200/JCO.2009.22.0467; Bosset JF, 2006, NEW ENGL J MED, V355, P1114, DOI 10.1056/NEJMoa060829; Ropponen KM, 1997, J PATHOL, V182, P318, DOI 10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6; Radisky DC, 2008, CELL STEM CELL, V2, P511, DOI 10.1016/j.stem.2008.05.007; Lee YC, 2013, DIS COLON RECTUM, V56, P1093, DOI 10.1097/DCR.0b013e318298e36b; Gerard JP, 2006, J CLIN ONCOL, V24, P4620, DOI 10.1200/JCO.2006.06.7629; Yeo SG, 2010, ANN SURG, V252, P998, DOI 10.1097/SLA.0b013e3181f3f1b1; Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694; Ashley N, 2013, CANCER LETT, V338, P120, DOI 10.1016/j.canlet.2012.04.016; Mei Z, 2014, BRIT J CANCER, V110, P1595, DOI 10.1038/bjc.2014.46; Chargari C, 2013, DRUG RESIST UPDATE, V16, P10, DOI 10.1016/j.drup.2013.01.001; Hodkinson PS, 2007, INT J RADIAT BIOL, V83, P733, DOI 10.1080/09553000701570204; Japanese Society for Cancer of the Colon and Rectum, 2009, JAP CLASS COL CARC; Kim TH, 2009, INT J RADIAT ONCOL, V77, P1158; Kojima M, 2009, PATHOL INT, V59, P857, DOI 10.1111/j.1440-1827.2009.02464.x; Lee JH, 2012, ANN SURG ONCOL, V19, P1213, DOI 10.1245/s10434-011-2062-z; Lieubeau B, 1999, INT J CANCER, V81, P629, DOI 10.1002/(SICI)1097-0215(19990517)81:4<629::AID-IJC20>3.0.CO;2-8; Miyashita M, 2014, BREAST CANCER RES TR, V148, P525, DOI 10.1007/s10549-014-3197-y; Persiani R, 2014, BRIT J SURG, V101, P133, DOI 10.1002/bjs.9341; Shinto E, 2011, DIS COLON RECTUM, V54, P1098, DOI 10.1097/DCR.0b013e3182218155; Shinto E, 2014, ANN SURG ONCOL S, V3, P414; Suarez J, 2007, COLORECTAL DIS, V10, P563; Ueno H, 2014, BRIT J CANCER, V111, P2082, DOI 10.1038/bjc.2014.509; Ueno H, 2014, ANN SURG ONCOL; Ueno H, 2002, HISTOPATHOLOGY, V40, P327, DOI 10.1046/j.1365-2559.2002.01376.x	36	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2015	466	6					655	663		10.1007/s00428-015-1756-1		9	Pathology	Pathology	CK0ZH	WOS:000355933900006		
J	Hosoda, W; Sasaki, E; Murakami, Y; Yamao, K; Shimizu, Y; Yatabe, Y				Hosoda, Waki; Sasaki, Eiichi; Murakami, Yoshiko; Yamao, Kenji; Shimizu, Yasuhiro; Yatabe, Yasushi			GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas	VIRCHOWS ARCHIV			English	Article						Pancreas; GNAS; KRAS; Mucinous; Tubular; IPMN-associated adenocarcinoma	STIMULATORY G-PROTEIN; DUCTAL ADENOCARCINOMAS; ACTIVATING MUTATION; INTESTINAL PATHWAY; LUNG-CANCER; ALPHA-CHAIN; TUMORS; DISTINCT; IPMN; GS	In contrast to pancreatic ductal adenocarcinomas (PDAs), intraductal papillary mucinous neoplasms (IPMNs) frequently harbour GNAS mutations. To characterise GNAS-mutated pancreatic carcinomas, we examined mutations of GNAS and KRAS in 290 pancreatic adenocarcinomas and 77 pancreatic intraepithelial neoplasias (PanINs). In 64% (39/61) of IPMNs and 37 % (11/30) of IPMN-associated adenocarcinomas, a GNAS mutation was found. GNAS mutations were frequent (78 %, 7/9) in mucinous carcinomas, with or without associated IPMN. In contrast, GNAS mutations were rarely observed in PDAs (1 %, 1/88) and PanINs (3 %, 2/77), and not at all in mucinous cystic neoplasms (MCNs) (0/10), neuroendocrine neoplasms (0/52), acinar cell neoplasms (0/16), serous cystadenomas (0/10), and solid-pseudopapillary neoplasms (0/14). We found GNAS mutations in 55/91 IPMNs with or without associated invasive carcinoma, solely in intestinal-type (78 %, 21/27) and gastric-type (62 %, 34/55) IPMNs. Of the IPMN-associated adenocarcinomas, mucinous-subtype tumours harboured GNAS mutations more frequently (83 %, 5/6) than tubular-subtype tumours (25 %, 6/24) (p=0.02). We separately analysed GNAS in the adenocarcinoma and the IPMN component in the IPMN-associated adenocarcinomas. In all mucinous-subtype tumours, the two components exhibited identical genotypes. In contrast, the two components in 8 of 24 tubular-subtype tumours exhibited different genotypes, indicating intratumour heterogeneity. In conclusion, mucinous carcinomas with or without associated IPMN as well as IPMNs frequently harbour a GNAS mutation, reinforcing the notion that these constitute a spectrum of pancreatic tumours. Clinically and pathologically, these tumours are associated, but GNAS mutation sheds further light on this spectrum.	[Hosoda, Waki; Sasaki, Eiichi; Murakami, Yoshiko; Yatabe, Yasushi] Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan; [Yamao, Kenji] Aichi Canc Ctr Hosp, Dept Gastroenterol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; [Shimizu, Yasuhiro] Aichi Canc Ctr Hosp, Dept Gastrointestinal Surg, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Yatabe, Y (reprint author), Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Kanokoden 1-1, Nagoya, Aichi 4648681, Japan.	yyatabe@aichi-cc.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [B-25293090]	The authors thank Chieko Yamada, Noriko Shibata, Ayako Nonaka, and Motoko Nimura for their excellent technical assistance with the molecular genetics. This work was supported in part by a Grant-in-Aid (B-25293090) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Yatabe Y, 2006, J MOL DIAGN, V8, P335, DOI 10.2353/jmoldx.2006.050104; Basturk O, 2010, AM J SURG PATHOL, V34, P364, DOI 10.1097/PAS.0b013e3181cf8bb6; Yamaguchi K, 2011, PANCREAS, V40, P571, DOI 10.1097/MPA.0b013e318215010c; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Matsubara A, 2013, J PATHOL, V229, P579, DOI 10.1002/path.4153; Delaney D, 2009, MODERN PATHOL, V22, P718, DOI 10.1038/modpathol.2009.32; Hosoda W, 2010, PATHOL INT, V60, P358, DOI 10.1111/j.1440-1827.2010.02527.x; Koh YX, 2014, ANN SURG ONCOL, V21, P2782, DOI 10.1245/s10434-014-3639-0; Pao W, 2007, CLIN CANCER RES, V13, P4954, DOI 10.1158/1078-0432.CCR-07-1387; Adsay NV, 2004, AM J SURG PATHOL, V28, P839, DOI 10.1097/00000478-200407000-00001; Nishikawa G, 2013, BRIT J CANCER, V108, P951, DOI 10.1038/bjc.2013.47; Amato E, 2014, J PATHOL, V233, P217, DOI 10.1002/path.4344; Okamoto S, 2000, VIRCHOWS ARCH, V437, P133, DOI 10.1007/s004280000217; Hong SM, 2011, ARCH PATHOL LAB MED, V135, P716, DOI 10.1043/2010-0566-RA.1; Ueki T, 2000, CANCER RES, V60, P1835; Furukawa T, 2005, VIRCHOWS ARCH, V447, P794, DOI 10.1007/s00428-005-0039-7; Weinstein LS, 2004, ENDOCRINOLOGY, V145, P5459, DOI 10.1210/en.2004-0865; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Mino-Kenudson M, 2011, GUT, V60, P1712, DOI 10.1136/gut.2010.232272; Tanaka M, 2012, PANCREATOLOGY, V12, P183, DOI 10.1016/j.pan.2012.04.004; Poultsides GA, 2010, ANN SURG, V251, P470, DOI 10.1097/SLA.0b013e3181cf8a19; Matsuno S, 2004, PANCREAS, V28, P219, DOI 10.1097/00006676-200404000-00002; House MG, 2003, CARCINOGENESIS, V24, P193, DOI 10.1093/carcin/24.2.193; Grutzmann R, 2010, ONCOLOGIST, V15, P1294, DOI 10.1634/theoncologist.2010-0151; Bosman FT, 2010, WHO CLASSIFICATION T; BOURNE HR, 1989, PROTEINS, V6, P222, DOI 10.1002/prot.340060304; Dal Molin M, 2013, ANN SURG ONCOL, V20, P3802, DOI [10.1245/s10434-013-3096-1, DOI 10.1245/S10434-013-3096-1]; Fragoso MCBV, 1998, J CLIN ENDOCR METAB, V83, P2074; Furukawa T, 2011, SCI REP-UK, V1, DOI 10.1038/srep00161; Iacobuzio-Donahue CA, 2000, AM J PATHOL, V157, P755, DOI 10.1016/S0002-9440(10)64589-0; Ideno N, 2013, ANN SURG, V258, P141, DOI 10.1097/SLA.0b013e31828cd008; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Matsubara A, 2014, AM J SURG PATHOL, V38, P370, DOI 10.1097/PAS.0000000000000093; Sasaki M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081706; Seidel G, 2002, AM J SURG PATHOL, V26, P56, DOI 10.1097/00000478-200201000-00006; Tsai JH, 2013, AM J SURG PATHOL, V37, P1862, DOI 10.1097/PAS.0b013e3182986bb5; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Wilson CH, 2010, ONCOGENE, V29, P4567, DOI 10.1038/onc.2010.202; Wu J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002543; Yamada M, 2012, J PATHOL, V228, P113, DOI 10.1002/path.4012	41	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2015	466	6					665	674		10.1007/s00428-015-1751-6		10	Pathology	Pathology	CK0ZH	WOS:000355933900007		
J	Nguyen, TT; Hachisuga, T; Urabe, R; Kurita, T; Kagami, S; Kawagoe, T; Shimajiri, S; Nabeshima, K				Thuy Thi Nguyen; Hachisuga, Toru; Urabe, Rie; Kurita, Tomoko; Kagami, Seiji; Kawagoe, Toshinori; Shimajiri, Shohei; Nabeshima, Kazuki			Significance of p53 expression in background endometrium in endometrial carcinoma	VIRCHOWS ARCHIV			English	Article						Endometrial cancer; Immunohistochemistry; p53 signature; Lynch syndrome; Estrogen receptor; Ki-67	SEROUS CARCINOGENESIS; ESTROGEN-RECEPTOR; LYNCH SYNDROME; CANCER; ADENOCARCINOMAS; OVARIAN; WOMEN; IMMUNOHISTOCHEMISTRY; IDENTIFICATION; PROGRESSION	The p53 signature (p53S) has been proposed to be a marker of the earliest phase of development of endometrial serous carcinoma. We examined the presence of p53S in the background endometrium in cases of endometrial carcinoma. From a series of 351 endometrial carcinomas, 225 (64.1 %) lesions, for which slides of the adjacent noncancerous endometrium were available for review, were included. Expression of estrogen receptor (ER)-alpha, Ki-67, and p53 in the adjacent endometrium was studied by immunohistochemistry. The p53S was defined as the presence of morphologically benign endometrial epithelial cells with moderate to strong intensity of p53 immunostaining. Of the 225 noncancerous endometrium samples, 34 consisted of hyperplastic and 191 of non-hyperplastic endometrium. A p53S was found in 22 cases (mean age 64.2 years), 2 in hyperplastic, and 20 in non-hyperplastic background endometrium. All p53S-positive cases also expressed ER-alpha; their median Ki-67 labeling index (LI) was 4.0 % (range 0.0 to 21.0 %). The two cases with hyperplastic p53S-positive background endometrium were in association with a grade 1 endometrioid tumor in a premenopausal woman with Lynch syndrome. Of the 152 cases of endometrioid adenocarcinomas with non-hyperplastic endometrium, 12 (8 %) were p53S positive, none of which associated with EIC. Of the 21 cases of serous carcinoma, five (24 %) were p53S positive, 4 of which (19 %) associated with EIC while in 5 others (24 %) EIC was found without p53S. Of three clear cell adenocarcinomas, none were p53S positive while two contained EIC without p53S. Of 15 carcinosarcomas, 3 (20 %) were p53S positive, all of which with EIC while 6 others (40 %) were associated with EIC but without p53S. Of the 8 non-endometrioid tumors with p53S, 7 (88 %) were associated with EIC. p53S is thought to be associated with precancerous lesions of non-endometrioid tumors, including carcinosarcomas.	[Thuy Thi Nguyen; Hachisuga, Toru; Urabe, Rie; Kurita, Tomoko; Kagami, Seiji; Kawagoe, Toshinori] Univ Occupat & Environm Hlth, Dept Obstet & Gynecol, Sch Med, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; [Shimajiri, Shohei] Univ Occupat & Environm Hlth, Dept Pathol & Cell Biol, Sch Med, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; [Nabeshima, Kazuki] Fukuoka Univ, Sch Med, Dept Pathol, Jonan Ku, Fukuoka 8140180, Japan	Hachisuga, T (reprint author), Univ Occupat & Environm Hlth, Dept Obstet & Gynecol, Sch Med, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	duongthanhthuy1182@gmail.com; thachisu@med.uoeh-u.ac.jp; urarie@med.uoeh-u.ac.jp; t-kurita@med.uoeh-u.ac.jp; s-kagami@med.uoeh-u.ac.jp; t-kawa@med.uoeh-u.ac.jp; shohei-s@med.uoeh-u.ac.jp; kaznabes@fukuoka-u.ac.jp					Folkins AK, 2008, GYNECOL ONCOL, V109, P168, DOI 10.1016/j.ygyno.2008.01.012; Comin CE, 2007, AM J SURG PATHOL, V31, P1139, DOI 10.1097/PAS.0b013e318033e7a8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Steinke V, 2014, INT J CANCER, V135, P69, DOI 10.1002/ijc.28650; Kuhn E, 2012, JNCI-J NATL CANCER I, V104, P1503, DOI 10.1093/jnci/djs345; Yemelyanova A, 2009, AM J SURG PATHOL, V33, P1504, DOI 10.1097/PAS.0b013e3181ac35f5; Schlosshauer PW, 2002, MODERN PATHOL, V15, P1032, DOI 10.1097/01.MP.0000028573.34289.04; Zorn KK, 2005, CLIN CANCER RES, V11, P6422, DOI 10.1158/1078-0432.CCR-05.0508; Matsuo K, 2014, GYNECOL ONCOL, V133, P473, DOI 10.1016/j.ygyno.2014.03.563; Mutter GL, 2014, CANCER RES, V74, P2796, DOI 10.1158/0008-5472.CAN-14-0108; Han CP, 2009, MODERN PATHOL, V22, P797, DOI 10.1038/modpathol.2009.31; Zhang LP, 2011, AM J SURG PATHOL, V35, P868, DOI 10.1097/PAS.0b013e318219c6f9; Nenutil R, 2005, J PATHOL, V207, P251, DOI 10.1002/path.1838; Lu KH, 2013, FAM CANCER, V12, P273, DOI 10.1007/s10689-013-9664-5; Crum CP, 2012, INT J GYNECOL CANCER, V22, pS29, DOI 10.1097/IGC.0b013e31824d7269; Ellenson LH, 2011, BLAUSTEINS PATHOLOGY, P394, DOI 10.1007/978-1-4419-0489-8_9; Jarboe EA, 2009, MODERN PATHOL, V22, P345, DOI 10.1038/modpathol.2008.197; Koi C, 2015, MENOPAUSE, V22, P104, DOI [10.1097/GME.0000000000000265, 10.1097/gme.0000000000000265]; Maia H, 2004, BJOG-INT J OBSTET GY, V111, P1242, DOI 10.1111/j.1471-0528.2004.00406.x; Seifert M, 2006, J MOL HISTOL, V37, P301, DOI 10.1007/s10735-006-9062-5; Zhang X, 2009, AM J PATHOL, V174, P2000, DOI 10.2353/ajpath.2009.081085; Zheng WX, 2011, AM J SURG PATHOL, V35, pE1, DOI 10.1097/PAS.0b013e318202772e	22	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUN	2015	466	6					695	702		10.1007/s00428-015-1752-5		8	Pathology	Pathology	CK0ZH	WOS:000355933900010		
J	Nakashima, Y; Uno, Y; Kawai, N; Sato, T; Yokoya, N				Nakashima, Yuta; Uno, Yusuke; Kawai, Norihiko; Sato, Tomokazu; Yokoya, Naokazu			AR image generation using view-dependent geometry modification and texture mapping	VIRTUAL REALITY			English	Article						View-dependent geometry modification; View-dependent texture mapping; Augmented reality; Free-viewpoint image generation		Augmented reality (AR) applications often require virtualized real objects, i.e., virtual objects that are built based on real objects and rendered from an arbitrary viewpoint. In this paper, we propose a method for real object virtualization and AR image generation based on view-dependent geometry modification and texture mapping. The proposed method is a hybrid of model- and image-based rendering techniques that uses multiple input images of the real object as well as the object's three-dimensional (3D) model obtained by an automatic 3D reconstruction technique. Even with state-of-the-art technology, the reconstructed 3D model's accuracy can be insufficient, resulting in such visual artifacts as false object boundaries. The proposed method generates a depth map from a 3D model of a virtualized real object and expands its region in the depth map to remove the false object boundaries. Since such expansion reveals the background pixels in the input images, which is particularly undesirable for AR applications, we preliminarily extract object regions and use them for texture mapping. With our GPU implementation for real-time AR image generation, we experimentally demonstrated that using expanded geometry reduces the number of required input images and maintains visual quality.	[Nakashima, Yuta; Uno, Yusuke; Kawai, Norihiko; Sato, Tomokazu; Yokoya, Naokazu] Nara Inst Sci & Technol NAIST, Nara 6300192, Japan	Nakashima, Y (reprint author), Nara Inst Sci & Technol NAIST, 8916-5 Takayama Cho, Nara 6300192, Japan.	n-yuta@is.naist.jp; yusuke-u@is.naist.jp; norihi-k@is.naist.jp; tomoka-s@is.naist.jp; yokoya@is.naist.jp			Japan Society for the Promotion of Science KAKENHI . [23240024]	This work is partly supported by the Japan Society for the Promotion of Science KAKENHI No. 23240024.	Furukawa Y, 2010, PROC CVPR IEEE, P1434, DOI 10.1109/CVPR.2010.5539802; Wu CC, 2013, 2013 INTERNATIONAL CONFERENCE ON 3D VISION (3DV 2013), P127, DOI 10.1109/3DV.2013.25; Buehler C, 2001, COMP GRAPH, P425; Davis A, 2012, COMPUT GRAPH FORUM, V31, P305, DOI 10.1111/j.1467-8659.2012.03009.x; Azuma RT, 1997, PRESENCE-TELEOP VIRT, V6, P355; Rother C, 2004, ACM T GRAPHIC, V23, P309, DOI 10.1145/1015706.1015720; Kolev K, 2012, IEEE T PATTERN ANAL, V34, P493, DOI 10.1109/TPAMI.2011.150; Bastian JW, 2010, P INT S MIX AUGM REA, P199; Chaurasia G, 2013, ACM T GRAPHIC, V32, DOI 10.1145/2487228.2487238; Debevec Paul, 1998, P 9 EUR WORKSH REND, P105; Gortler S. J., 1996, P SIGGRAPH 96, P43, DOI DOI 10.1145/237170.237200; Irani M, 2002, LECT NOTES COMPUT SC, V2351, P883; Jancosek Michal, 2011, P CVPR, P3121; Kato H., 1999, Proceedings 2nd IEEE and ACM International Workshop on Augmented Reality (IWAR'99), DOI 10.1109/IWAR.1999.803809; Klein G., 2007, P IEEE ACM INT S MIX, V6, P225; Levoy M., 1996, Computer Graphics Proceedings. SIGGRAPH '96, DOI 10.1145/237170.237199; Metaio GmbH, MET SDK; NVIDIA Developer Zone, CONJUGATEGRADIENTUM; Renka RJ, 1997, ACM T MATH SOFTWARE, V23, P416, DOI 10.1145/275323.275329; Seitz S., 2006, P IEEE C COMP VIS PA, P519, DOI [DOI 10.1109/CVPR.2006.19, 10.1109/CVPR.2006.19]; Wu C., 2007, SIFTGPU GPU IMPLEMEN; Wu C., 2011, VISUALSFM VISUAL STR	22	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1359-4338	1434-9957		VIRTUAL REAL-LONDON	Virtual Real.	JUN	2015	19	2					83	94		10.1007/s10055-015-0259-3		12	Computer Science, Interdisciplinary Applications; Computer Science, Software Engineering; Imaging Science & Photographic Technology	Computer Science; Imaging Science & Photographic Technology	CJ9MO	WOS:000355826700002		
J	Ito, K; Kuroda, T; Saito, K; Wada, A				Ito, Kosuke; Kuroda, Tohru; Saito, Kazuo; Wada, Akiyoshi			Forecasting a Large Number of Tropical Cyclone Intensities around Japan Using a High-Resolution Atmosphere-Ocean Coupled Model	WEATHER AND FORECASTING			English	Article							SEA EXCHANGE COEFFICIENTS; WESTERN NORTH PACIFIC; HURRICANE; PREDICTION; CLIMATE	This work quantifies the benefits of using a high-resolution atmosphere-ocean coupled model in tropical cyclone (TC) intensity forecasts in the vicinity of Japan. To do so, a large number of high-resolution calculations were performed by running the Japan Meteorological Agency (JMA) nonhydrostatic atmospheric mesoscale model (AMSM) and atmosphere-ocean coupled mesoscale model (CMSM). A total of 281 3-day forecasts were compiled for 34 TCs from April 2009 to September 2012 for each model. The performance of these models is compared with the JMA global atmospheric spectral model (GSM) that is used for the operational TC intensity guidance. The TC intensities are better predicted by CMSM than the other models. The improvement rates in CMSM relative to GSM and AMSM generally increase with increasing forecast time (FT). CMSM is better than GSM and AMSM by 27.4% and 21.3% at FT = 48 h in terms of minimum sea level pressure, respectively. Regarding the maximum wind speed, CMSM is better than GSM and AMSM by 12.8% and 19.5% at FT = 48 h, respectively. This is due to smaller initial intensity errors and sea surface cooling consistent with in situ observations that suppress erroneous TC intensification. Thus, a high-resolution coupled model is promising for TC intensity prediction in the area surrounding Japan, where most of the TCs are in a decay stage. In contrast, coupling to the upper-ocean model yields only a negligible difference in the TC track forecast skill on average.	[Ito, Kosuke; Kuroda, Tohru; Saito, Kazuo] Japan Agcy Marine Earth Sci & Technol, Yokohama, Kanagawa, Japan; [Ito, Kosuke; Kuroda, Tohru; Saito, Kazuo; Wada, Akiyoshi] Meteorol Res Inst, Tsukuba, Ibaraki 305, Japan	Ito, K (reprint author), Univ Ryukyus, Dept Phys & Earth Sci, 1 Sembaru, Nishihara, Okinawa 9030213, Japan.	itokosk@sci.u-ryukyu.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology (MEXT) through the Strategic Programs for Innovative Research (SPIRE); MEXT KAKENHI [25106708]	We thank Drs. Y. Sato, S. Ishizaki, Y. Honda, T. Tsuyuki, H. Seko, F. Kimura, and T. Tokioka for providing useful comments. This work was supported by the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) through the Strategic Programs for Innovative Research (SPIRE). AW was supported by MEXT KAKENHI Grant 25106708. All of the results were obtained using the K computer at the RIKEN Advanced Institute for Computational Science (Proposals hp120282, hp130012, and hp140220).	Oouchi K, 2006, J METEOROL SOC JPN, V84, P259, DOI 10.2151/jmsj.84.259; Yau MK, 2004, MON WEATHER REV, V132, P1410, DOI 10.1175/1520-0493(2004)132<1410:AMNSOH>2.0.CO;2; Nakanishi M, 2004, BOUND-LAY METEOROL, V112, P1, DOI 10.1023/B:BOUN.0000020164.04146.98; Wang Y, 2004, METEOROL ATMOS PHYS, V87, P257, DOI 10.1007/s00703-003-0055-6; Davis C, 2008, MON WEATHER REV, V136, P1990, DOI 10.1175/2007MWR2085.1; Bender MA, 2007, MON WEATHER REV, V135, P3965, DOI 10.1175/2007MWR2032.1; Walsh KJE, 2007, J CLIMATE, V20, P2307, DOI 10.1175/JCLI4074.1; Franklin JL, 2003, WEATHER FORECAST, V18, P32, DOI 10.1175/1520-0434(2003)018<0032:GDWPIH>2.0.CO;2; Wada A, 2010, SOLA, V6A, P13, DOI 10.2151/sola.6A-004; Lloyd ID, 2011, J CLIMATE, V24, P1138, DOI 10.1175/2010JCLI3763.1; PRICE JF, 1983, J PHYS OCEANOGR, V13, P949, DOI 10.1175/1520-0485(1983)013<0949:IWWOAM>2.0.CO;2; Lin II, 2008, MON WEATHER REV, V136, P3288, DOI 10.1175/2008MWR2277.1; Yablonsky RM, 2009, MON WEATHER REV, V137, P4410, DOI 10.1175/2009MWR2863.1; Emanuel K, 2004, J ATMOS SCI, V61, P843, DOI 10.1175/1520-0469(2004)061<0843:ECOTCI>2.0.CO;2; BELJAARS ACM, 1991, J APPL METEOROL, V30, P327, DOI 10.1175/1520-0450(1991)030<0327:FPOLSF>2.0.CO;2; Saito K, 2006, MON WEATHER REV, V134, P1266, DOI 10.1175/MWR3120.1; Bryan GH, 2009, MON WEATHER REV, V137, P1770, DOI 10.1175/2008MWR2709.1; PRICE JF, 1986, J GEOPHYS RES-OCEANS, V91, P8411, DOI 10.1029/JC091iC07p08411; Jacob SD, 2000, J PHYS OCEANOGR, V30, P1407, DOI 10.1175/1520-0485(2000)030<1407:TOMLRT>2.0.CO;2; Ito K, 2011, J ATMOS SCI, V68, P2250, DOI 10.1175/JAS-D-10-05022.1; Manganello JV, 2012, J CLIMATE, V25, P3867, DOI 10.1175/JCLI-D-11-00346.1; PRICE JF, 1994, J PHYS OCEANOGR, V24, P233, DOI 10.1175/1520-0485(1994)024<0233:FSRTAM>2.0.CO;2; Antonov J., 2010, SALINITY, V2; GINIS I, 1995, J PHYS OCEANOGR, V25, P1218, DOI 10.1175/1520-0485(1995)025<1218:HGDACA>2.0.CO;2; Honda Y., 2009, RES ACTIVITIES ATMOS, P0111; Ikawa M., 1991, 28 MRI; Ito K, 2013, J METEOROL SOC JPN, V91, P337, DOI 10.2151/jmsj.2013-307; Ito K, 2010, SOLA, V6, P13, DOI 10.2151/sola.2010-004; Japan Meteorological Agency, 2014, NUM WEATH PRED JAP M; Japan Meteorological Agency, 2013, ANN REP ACT RSMC TOK; Kosaka Y., 2010, RES ACTIVITIES ATMOS, P0121; Kurihara Y., 2006, WEATHER B, V73, P1; Lin II, 2005, MON WEATHER REV, V133, P2635, DOI 10.1175/MWR3005.1; Locarnini R., 2010, TEMPERATURE, V1, P68; National Hurricane Center, 2013, NAT HURR CTR FOR VER; Nishijima Kazuyoshi, 2012, Hydrological Research Letters, V6, DOI 10.3178/HRL.6.23; PRICE JF, 1981, J PHYS OCEANOGR, V11, P153, DOI 10.1175/1520-0485(1981)011<0153:UORTAH>2.0.CO;2; Saito K., 2012, ATMOSPHERIC MODEL AP, P85, DOI [DOI 10.5772/35368, dx.doi.org/10.5772/35368]; Sakai R., 2005, RES ACTIVITIES ATMOS, P27; Shay L. K., 2010, GLOBAL PERSPECTIVES, V4, P93, DOI DOI 10.1142/9789814293488_0003; Wada A., 2007, PAP METEOROL GEOPHYS, V58, P103, DOI 10.2467/mripapers.58.103; Wada A, 2013, ADV METEOROL, DOI 10.1155/2013/859810; Yu H, 2013, WEATHER FORECAST, V28, P353, DOI 10.1175/WAF-D-11-00100.1	43	2	2	AMER METEOROLOGICAL SOC	BOSTON	45 BEACON ST, BOSTON, MA 02108-3693 USA	0882-8156	1520-0434		WEATHER FORECAST	Weather Forecast.	JUN	2015	30	3					793	808		10.1175/WAF-D-14-00034.1		16	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	CJ7FG	WOS:000355659300018		
J	Mongkol, R; Chavasiri, W; Ishida, M; Matsuda, K; Morimoto, M				Mongkol, Rachsawan; Chavasiri, Warinthorn; Ishida, Miki; Matsuda, Kazuhiko; Morimoto, Masanori			Phytotoxic and antiphytopathogenic compounds from Thai Alpinia galanga (L.) Willd. rhizomes	WEED BIOLOGY AND MANAGEMENT			English	Article						1-acetoxychavicol acetate; Alpinia galanga; antiphytopathogenic agent; phytotoxicity	STRUCTURAL REQUIREMENTS; HIGHER-PLANTS; PHENYLPROPANOIDS; CONSTITUENTS; EXTRACTS	The management of weeds and diseases that are caused by phytopathogenic fungi is important for preventing the loss of agricultural products. The aim of the present study was to identify phytotoxic and antiphytopathogenic agents from the Thai Alpinia galanga rhizome. Extracts of the dried rhizomes of A.galanga (Zingiberaceae) were separated and tested for phytotoxic activity against lettuce (Lactuca sativa L. cv. Great Lakes) and Italian ryegrass (Lolium multiflorum Lam. cv. Wasefudou) and for antiphytopathogenic activity against Alternaria porri, Colletotrichum gloeosporioides, Fusarium oxysporum and Phytophthora nicotianae. 1-Acetoxychavicol acetate (1) was identified as one of the main components, together with trans-p-coumaryl acetate (3) and trans-p-acetoxycinnamyl acetate (2). 1-Acetoxychavicol acetate (1) was solvolyzed with 2% EtOH to yield trans-p-coumaryl ethyl ether (6), trans-p-coumaryl acetate (3) and trans-p-coumaryl alcohol (5). 1-Acetoxychavicol acetate (1) completely inhibited the root growth of the lettuce seedlings at 50gmL(-1), but had a weaker inhibitory effect on the growth of Italian ryegrass. 1-Acetoxychavicol acetate also inhibited the growth of P.nicotianae and A.porri, with minimum inhibition concentration values of 15.6 and 31.5gmL(-1), respectively. The plant growth-inhibitory activity and fungal growth-inhibitory activity of trans-p-coumaryl acetate (3), trans-p-coumaryl ethyl ether, trans-p-coumaryl alcohol (5) and trans-p-acetoxycinnamyl acetate (2) were lower than those of 1-acetoxychavicol acetate. A structure-activity relationship suggested that the strong phytotoxic and antiphytopathogenic activity of 1-acetoxychavicol acetate relied on the 1-acetoxyl group.	[Mongkol, Rachsawan] Chulalongkorn Univ, Dept Chem, Fac Sci, Program Biotechnol, Bangkok, Thailand; [Chavasiri, Warinthorn] Chulalongkorn Univ, Dept Chem, Nat Prod Res Unit, Fac Sci, Bangkok, Thailand; [Mongkol, Rachsawan; Ishida, Miki; Matsuda, Kazuhiko; Morimoto, Masanori] Kinki Univ, Sch Agr, Dept Agr Chem, Nara, Nara 6318505, Japan	Morimoto, M (reprint author), Kinki Univ, Sch Agr, Dept Agr Chem, 3327-204 Nakamachi, Nara, Nara 6318505, Japan.	masanori@nara.kindai.ac.jp			office of the Higher Education Commission, Bangkok, Thailand; Graduate School, Chulalongkorn University, Bangkok, Thailand; Chulalongkorn University [RES 560530183-FW]	We would like to thank the office of the Higher Education Commission, Bangkok, Thailand, for supporting this study with a grant under the program "Strategic Scholarships for Frontier Research Network" for the Ph.D. Program of the Thai Doctoral degree. In addition, the support of the Graduate School, Chulalongkorn University, Bangkok, Thailand, and project RES 560530183-FW from Chulalongkorn University was greatly appreciated.	Agrios G. N., 2004, PLANT PATHOLOGY; Tian J, 2011, INT J FOOD MICROBIOL, V145, P464, DOI 10.1016/j.ijfoodmicro.2011.01.023; Khattak S, 2005, FITOTERAPIA, V76, P254, DOI 10.1016/j.fitote.12.012; Matsuda H, 2003, BIOORG MED CHEM LETT, V13, P3197, DOI 10.1016/S0960-894X(03)00710-8; Colbach N, 2013, J AGR SCI, V151, P229, DOI 10.1017/S0021859612000159; Costa TR, 2000, J ETHNOPHARMACOL, V72, P111, DOI 10.1016/S0378-8741(00)00214-2; BENNER JP, 1993, PESTIC SCI, V39, P95, DOI 10.1002/ps.2780390202; Butkhup L., 2011, Research Journal of Medicinal Plant, V5, P254, DOI 10.3923/rjmp.2011.254.265; Chandel B. S., 2009, Indian Journal of Entomology, V71, P203; Chukanhom Kanit, 2005, Biocontrol Science, V10, P105; Finney D.J., 1952, PROBIT ANAL; Fukaki H, 2007, INT REV CYTOL, V256, P111, DOI 10.1016/S0074-7696(07)56004-3; Inderjit, 2001, PERSPECT PLANT ECOL, V4, P3; Kiuchi Fumiyuki, 2002, Natural Medicines, V56, P64; Lee CC, 2005, J ETHNOPHARMACOL, V100, P237, DOI 10.1016/j.jep.2005.01.064; Leem JY, 1999, FEBS LETT, V442, P53, DOI 10.1016/S0014-5793(98)01614-7; Matsuda H, 2003, EUR J PHARMACOL, V471, P59, DOI 10.1016/S0014-2999(03)01785-0; MITSUI S, 1976, CHEM PHARM BULL, V24, P2377; NORO T, 1988, CHEM PHARM BULL, V36, P244; Oonmetta-aree J., 2006, LWT - Food Science and Technology, V39, P1214, DOI 10.1016/j.lwt.2005.06.015; Sukhirun N, 2011, J ECON ENTOMOL, V104, P1534, DOI 10.1603/EC11080; Trakranrungsie N, 2008, RES VET SCI, V84, P80, DOI 10.1016/j.r-vsc.2007.03.006; Yamsakul P., 2009, Proceedings of the 47th Kasetsart University Annual Conference, Kasetsart, 17-20 March, 2009. Subject: Veterinary Medicine, P208; Yang XG, 1999, J AGR FOOD CHEM, V47, P1657, DOI 10.1021/jf9808224; Yasuhara T, 2009, BIOORG MED CHEM LETT, V19, P2944, DOI 10.1016/j.bmcl.2009.04.065	25	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1444-6162	1445-6664		WEED BIOL MANAG	Weed Biol. Manag.	JUN	2015	15	2					87	93		10.1111/wbm.12071		7	Agronomy; Plant Sciences	Agriculture; Plant Sciences	CJ7EW	WOS:000355658200004		
J	Takeuchi, K; Uneyama, H				Takeuchi, Koji; Uneyama, Hisayuki			Frontier of Gastrointestinal Taste and Nutrient Sensor Research: Search for Potential Drug Target Foreword	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Editorial Material									[Takeuchi, Koji] Kyoto Pharmaceut Univ, Yamashina Ku, Kyoto 6078414, Japan; [Takeuchi, Koji] Gen Inc Assoc, Kyoto Res Ctr Gastrointestinal Dis, Nakagyo Ku, Kyoto 6048017, Japan; [Uneyama, Hisayuki] Ajinomoto Co Inc, Inst Innovat, Kawasaki Ku, Kawasaki, Kanagawa 2108681, Japan	Uneyama, H (reprint author), Kyoto Pharmaceut Univ, Yamashina Ku, 5 Nakauchi Cho, Kyoto 6078414, Japan.	hisayuki_uneyama@ajinomoto.com					Amagase K, 2015, YAKUGAKU ZASSHI, V135, P779, DOI 10.1248/yakushi.14-00250-3; Iwatsuki K, 2012, J PHARMACOL SCI, V118, P123, DOI 10.1254/jphs.11R08CP; Hirasawa A, 2015, YAKUGAKU ZASSHI, V135, P769; Kokrashvili Z, 2014, BRIT J NUTR, V111, pS23, DOI 10.1017/S0007114513002262; Mizuta E, 2015, YAKUGAKU ZASSHI, V135, P789, DOI 10.1248/yakushi.14-00250-5; Nomura M, 2015, YAKUGAKU ZASSHI, V135, P763, DOI 10.1248/yakushi.14-00250-1; Satoh S., 2015, YAKUGAKU ZASSHI, V135, P783; Uneyama Hisayuki, 2004, Nihon Yakurigaku Zasshi, V124, P210; Uneyama H., 2013, GI RES, V21, P99; Uneyama H, 2013, JPN J TASTE SMELL RE, V20, P121	10	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUN	2015	135	6					761	762				2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LT	WOS:000355386200001		
J	Nomura, M; Kawahara, Y				Nomura, Masatoshi; Kawahara, Yuta			Role of the Sweet Taste Receptor in Glucose Metabolism: No Sweets for Diabetes?	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						type 2 diabetes; taste receptor type 1 member 2; gastrointestinal tract; neuroendocrine cell; knock-in mouse; lacZ	PEPTIDE-1 SECRETION	Type 2 diabetes is closely associated with our daily diets and has become a global health problem with increasing number of patients. Maintaining energy homeostasis is essentially required for the treatment of diabetes. Energy metabolism starts with taking in a meal. Nutrients including amino acids, fatty acids and glucose in the digest have been shown to act on the neuroendocrine cells in the gastrointestinal (GI) tract, and thereby play important roles in energy homeostasis. Therefore, the GI tract is now recognized as a sensor system for nutrient signals. Taste receptor type 1 member 2 (T1R2) is known to function as a co-receptor with T1R3 to detect sweet chemicals in the taste buds. It has been proposed that the T1R2/T1R3 receptor complex acts as sweet sensor in the intestine, and plays a pivotal role in sensing sugars and maintaining glucose homeostasis through incretin secretion. To clarify the physiological roles of T1R2 in glucose homeostasis, T1r2-lacZ knock-in/knock-out mice were generated. We found lacZ gene expression in the GI tract where T1r3 expression has been reported. Interestingly, the T1r2-lacZ knock-in mice showed impaired glucose tolerance on oral glucose challenge but not on intraperitoneal injection. However, the fasting glucose level in T1r2-lacZ knock-in mice was comparable to that in wild type mice. These results suggest an important role of the sweet taste receptor system in the intestine when stimulated by glucose. Therefore, the roles of T1R2 will be presented and the mechanism for metabolic homeostasis will be discussed.	[Nomura, Masatoshi; Kawahara, Yuta] Kyushu Univ, Dept Med & Bioregulatory Sci, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan	Nomura, M (reprint author), Kyushu Univ, Dept Med & Bioregulatory Sci, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nomura@med.kyushu-u.ac.jp					Anini Y, 2003, DIABETES, V52, P252; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Thomas C, 2009, CELL METAB, V10, P167, DOI 10.1016/j.cmet.2009.08.001; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Margolskee RF, 2007, P NATL ACAD SCI USA, V104, P15075, DOI 10.1073/pnas.0706678104; Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054; Farilla L, 2002, ENDOCRINOLOGY, V143, P4397, DOI 10.1210/en.2002-220405; TURNER RC, 1995, DIABETES, V44, P1249; Iwatsuki K, 2010, BIOCHEM BIOPH RES CO, V402, P495, DOI 10.1016/j.bbrc.2010.10.057	9	1	1	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUN	2015	135	6					763	767				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LT	WOS:000355386200002		
J	Hirasawa, A				Hirasawa, Akira			Free Fatty Acid Receptor Family: A New Therapeutic Target for Metabolic Diseases	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						free fatty acid receptor 4; GPR120; fatty acid receptor; G protein-coupled receptor (GPCR); FFAR1; GPR40	STIMULATED INSULIN-SECRETION; PROTEIN-COUPLED RECEPTOR; PANCREATIC BETA-CELLS; DOCKING SIMULATION; GLUCOSE-TOLERANCE; 4 FFA4/GPR120; HUMAN ISLETS; GPR40; GPR120; RAT	Free fatty acids (FFAs) are not only essential nutritional components but they also act as signaling molecules in various physiological processes. A strategy to deorphanize G-protein-coupled receptors (GPCRs) identified a series of receptors for FFAs that play significant roles in nutrition regulation. In this free fatty acid receptor family, FFAR1 (GPR40) and FFAR4 (GPR120) are activated by long-chain FFAs. FFAR1 regulates insulin secretion in pancreatic,beta-cells, whereas FFAR4 promotes the secretion of glucagon-like peptide-1 (GLP-1) in the intestine, and also acts as a lipid sensor in adipose tissue to sense dietary fat and control energy balance. In this review, we discuss recent advances in the pharmacological characterization of FFAR1 and FFAR4, and we present a summary of current understandings of their physiological roles and their potential as drug targets.	[Hirasawa, Akira] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genom Drug Discovery Sci, Sakyo Ku, Kyoto 6068501, Japan; [Hirasawa, Akira] Tokyo Womens Med Univ, Inst Integrated Med Sci, Shinjuku Ku, Tokyo 1628666, Japan	Hirasawa, A (reprint author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genom Drug Discovery Sci, Sakyo Ku, 46-29 Yoshida Shimo Adachi Cho, Kyoto 6068501, Japan.	akira_h@pharm.kyoto-u.ac.jp					Vettor R, 2008, J CLIN ENDOCR METAB, V93, P3541, DOI 10.1210/jc.2007-2680; Ichimura A, 2012, NATURE, V483, P350, DOI 10.1038/nature10798; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Tanaka T, 2008, N-S ARCH PHARMACOL, V377, P523, DOI 10.1007/s00210-007-0200-8; Stoddart LA, 2008, PHARMACOL REV, V60, P405, DOI 10.1124/pr.108.00802; Kotarsky K, 2003, BIOCHEM BIOPH RES CO, V301, P406, DOI 10.1016/S0006-291X(02)03064-4; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Sun Q, 2010, MOL PHARMACOL, V78, P804, DOI 10.1124/mol.110.066324; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Dobbins RL, 1998, DIABETES, V47, P1613, DOI 10.2337/diabetes.47.10.1613; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Hu H, 2009, BIOCHEM BIOPH RES CO, V390, P557, DOI 10.1016/j.bbrc.2009.10.004; Oh DY, 2014, NAT MED, V20, P942, DOI 10.1038/nm.3614; Nagasumi K, 2009, DIABETES, V58, P1067, DOI 10.2337/db08-1233; Srivastava A, 2014, NATURE, V513, P124, DOI 10.1038/nature13494; Taneera J, 2012, CELL METAB, V16, P122, DOI 10.1016/j.cmet.2012.06.006; Briscoe CP, 2006, BRIT J PHARMACOL, V148, P619, DOI 10.1038/sj.bjp.0706770; Hudson BD, 2014, J BIOL CHEM, V289, P20345, DOI 10.1074/jbc.M114.561449; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Fukunaga S, 2006, LIFE SCI, V80, P17, DOI 10.1016/j.lfs.2006.08.022; Hudson BD, 2013, MOL PHARMACOL, V84, P710, DOI 10.1124/mol.113.087783; Hara T, 2009, MOL PHARMACOL, V75, P85, DOI 10.1124/mol.108.052225; Shah BP, 2012, AM J PHYSIOL-CELL PH, V302, pC210, DOI 10.1152/ajpcell.00209.2011; Catchen JM, 2009, GENOME RES, V19, P1497, DOI 10.1101/gr.090480.108; Miyauchi S, 2009, N-S ARCH PHARMACOL, V379, P427, DOI 10.1007/s00210-008-0390-8; Hamid YH, 2005, DIABETIC MED, V22, P74, DOI 10.1111/j.1464-5491.2005.01505.x; Humphries PS, 2009, BIOORG MED CHEM LETT, V19, P2400, DOI 10.1016/j.bmcl.2009.03.082; Remely M, 2014, GENE, V537, P85, DOI 10.1016/j.gene.2013.11.081; Fujiwara K, 2005, AM J PHYSIOL-ENDOC M, V289, pE670, DOI 10.1152/ajpendo.00035.2005; Halder S, 2013, EXPERT OPIN THER PAT, V23, P1581, DOI 10.1517/13543776.2013.842977; Stein DT, 1996, J CLIN INVEST, V97, P2728, DOI 10.1172/JCI118727; Katsuma S, 2005, J BIOL CHEM, V280, P19507, DOI 10.1074/jbc.M412385200; Feng DD, 2006, ENDOCRINOLOGY, V147, P674, DOI 10.1210/en.2005-0225; Kimura I, 2011, P NATL ACAD SCI USA, V108, P8030, DOI 10.1073/pnas.1016088108; Suzuki T, 2008, J MED CHEM, V51, P7640, DOI 10.1021/jm800970b; Hara T, 2009, N-S ARCH PHARMACOL, V380, P247, DOI 10.1007/s00210-009-0425-9; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Dobbins RL, 1998, J CLIN INVEST, V101, P2370, DOI 10.1172/JCI1813; Ogawa T, 2005, METABOLISM, V54, P296, DOI 10.1016/j.metabol.2004.09.008; Sasaki S, 2011, J MED CHEM, V54, P1365, DOI 10.1021/jm101405t; Davenport AP, 2013, BRIT J PHARMACOL, V170, P693, DOI 10.1111/bph.12339; Garrido DM, 2006, BIOORG MED CHEM LETT, V16, P1840, DOI 10.1016/j.bmcl.2006.01.007; Gravena C, 2002, J ENDOCRINOL, V173, P73, DOI 10.1677/joe.0.1730073; Louet JF, 2001, BIOCHEM J, V354, P189, DOI 10.1042/0264-6021:3540189; Matsumura S, 2007, BIOMED RES-TOKYO, V28, P49, DOI 10.2220/biomedres.28.49; Sauer LA, 2000, CANCER RES, V60, P5289; Steneberg Par, 2005, Cell Metabolism, V1, P245, DOI 10.1016/j.cmet.2005.03.007; Suckow AT, 2014, J BIOL CHEM, V289, P15751, DOI 10.1074/jbc.M114.568683; Takeuchi M, 2013, BRIT J PHARMACOL, V168, P1570, DOI 10.1111/j.1476-5381.2012.02052.x; Zhang XD, 2010, BIOMED PHARMACOTHER, V64, P647, DOI 10.1016/j.biopha.2010.06.008	51	2	3	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUN	2015	135	6					769	777				9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LT	WOS:000355386200003		
J	Amagase, K; Nakamura, E; Kato, S; Takeuchi, K				Amagase, Kikuko; Nakamura, Eiji; Kato, Shinichi; Takeuchi, Koji			Glutamate as a Potential Protective Drug in the Gastrointestinal Mucosa	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						monosodium glutamate; loxoprofen; small intestinal lesion; healing-promoting action	NSAID-INDUCED ENTEROPATHY; ENDOTHELIAL GROWTH-FACTOR; SMALL-INTESTINAL LESIONS; NITRIC-OXIDE SYNTHASE; MONOSODIUM GLUTAMATE; GASTRIC-ULCERS; EP4 RECEPTORS; UP-REGULATION; INDOMETHACIN; INDUCTION	Monosodium glutamate (MSG) is known to provide the umami taste in the food. We have recently reported that glutamate has the potential to protect the small intestine against non-steroidal anti-inflammatory drugs (NSAIDs) -induced lesions in rats. In this paper, we examined this protective effect using sodium loxoprofen, one of the NSAIDs frequently used in Asian countries, to determine whether MSG accelerates the healing of loxoprofen-induced small intestinal lesions in rats. Loxoprofen at 60 mg/kg caused hemorrhagic lesions in the small intestine, mainly in the jejunum and ileum. These lesions spontaneously healed within 7 days, but this healing process was delayed by repeated administration of loxoprofen at low doses (10, 30 mg/kg) for 5 d after lesion induction. The healing-impairment action of loxoprofen was accompanied by the down-regulation of vascular endothelium-derived growth factor (VEGF) expression and an angiogenic response. The impaired healing caused by loxoprofen was significantly restored by co-treatment with a diet containing 5% MSG for 5 d, accompanied by the enhancement of VEGF expression and angiogenesis. We suggest that daily intake of MSG not only protects the small intestine against NSAIDs-induced damage but also exerts healing-promoting effects on these lesions.	[Amagase, Kikuko; Kato, Shinichi; Takeuchi, Koji] Kyoto Pharmaceut Univ, Dept Pharmacol & Expt Therapeut, Div Pathol Sci, Yamashina Ku, Kyoto 6078414, Japan; [Nakamura, Eiji] Ajinomoto Co Inc, Frontier Res Labs, Inst Innovat, Kawasaki Ku, Kawasaki, Kanagawa 2108681, Japan; [Takeuchi, Koji] Gen Inc Assoc, Kyoto Res Ctr Gastrointestinal Dis, Nakagyo Ku, Kyoto 6048017, Japan	Amagase, K (reprint author), Kyoto Pharmaceut Univ, Dept Pharmacol & Expt Therapeut, Div Pathol Sci, Yamashina Ku, 5 Nakauchi Cho, Kyoto 6078414, Japan.	amagase@mb.kyoto-phu.ac.jp					Akiba Y, 2011, DIGESTION, V83, P25, DOI 10.1159/000323401; Akiba Y, 2009, AM J PHYSIOL-GASTR L, V297, pG781, DOI 10.1152/ajpgi.90605.2008; San Gabriel AM, 2007, FEBS LETT, V581, P1119, DOI 10.1016/j.febslet.2007.02.016; Takeuchi K, 2010, J GASTROEN HEPATOL, V25, pS67, DOI 10.1111/j.1440-1746.2010.06222.x; Tarnawski AS, 2005, DIGEST DIS SCI, V50, pS24, DOI 10.1007/s10620-005-2803-6; WHITTLE BJR, 1995, BRIT J PHARMACOL, V116, P2286; Uneyama H, 2006, AM J PHYSIOL-GASTR L, V291, pG1163, DOI 10.1152/ajpgi.00587.2005; Amagase K, 2014, CURR PHARM DESIGN, V20, P2783, DOI 10.2174/13816128113199990579; Amagase K, 2012, J PHARMACOL SCI, V118, P131, DOI 10.1254/jphs.11R03FM; Majima M, 2000, BRIT J PHARMACOL, V130, P641, DOI 10.1038/sj.bjp.0703327; Amagase K, 2010, J PHARMACOL SCI, V112, P25, DOI 10.1254/jphs.09R11FM; Hatazawa R, 2006, J PHARMACOL EXP THER, V318, P691, DOI 10.1124/jpet.106.103994; Hatazawa R, 2007, AM J PHYSIOL-GASTR L, V293, pG788, DOI 10.1152/ajpgi.00131.2007; Jones MK, 2001, GASTROENTEROLOGY, V121, P1040, DOI 10.1053/gast.2001.29308; Kojo A., 2010, GASTROENTEROLOGY S1, V138, pS704; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; Nakamura E, 2002, AM J PHYSIOL-GASTR L, V283, pG1264, DOI 10.1152/ajpgi.00235.2002; Takeuchi K., 2012, CELL TISSUE INJURY C; Takeuchi K, 2006, DIGEST DIS SCI, V51, P1250, DOI 10.1007/s10620-006-8045-4; Tarnawski A., 1990, J CLIN GASTROENTEROL, V12, P148	20	1	1	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUN	2015	135	6					779	782				4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LT	WOS:000355386200004		
J	Kuriwada-Satoh, S; Sasano, T				Kuriwada-Satoh, Shizuko; Sasano, Takashi			New Remedy for Dry Mouth Using the Gustatory-Salivary Reflex	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						dry mouth; elderly; umami taste; minor salivary gland; gustatory-salivary reflex	HYPOGEUSIA; FLOW	Patients with dry mouth are increasing in Japan due to the country's super-aging society and stressful modern society. Dry mouth affects quality of life, including difficulty with speech or swallowing, and also causes aspiration pneumonia and, respiratory infection. Moreover, dry mouth closely relates to taste dysfunction, resulting in malnutrition, a common risk of nursing care in the elderly. Against these backgrounds, dry mouth has recently been a target of social concern. Drugs for dry mouth such as M3, a muscarinic agonist, have been widely used: however, these drugs have serious side effects, such as vomiting, sweating and/or digestive disorders. We examined the gustatory-salivary reflex to explore a remedy for dry mouth. We have demonstrated that umami stimulation increases saliva from both minor- and major salivary-glands, and that the effect is longer-lasting than with the other four basic tastes. Stimulating the umami response could therefore be a safe and useful remedy for dry mouth.	[Kuriwada-Satoh, Shizuko; Sasano, Takashi] Tohoku Univ, Grad Sch Dent, Div Oral Diag, Dept Oral Med & Surg,Aoba Ku, Sendai, Miyagi 9808575, Japan	Kuriwada-Satoh, S (reprint author), Tohoku Univ, Grad Sch Dent, Div Oral Diag, Dept Oral Med & Surg,Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	kuri-shu@dent.tohoku.ac.jp					Hodson NA, 2006, PHYSIOL BEHAV, V89, P711, DOI 10.1016/j.physbeh.2006.08.011; BACKSTROM I, 1995, ORAL ONCOL, V31B, P253; Sasano T, 2010, BIOL PHARM BULL, V33, P1791, DOI 10.1248/bpb.33.1791; Satoh-Kuriwada S, 2009, J HEALTH SCI, V55, P689, DOI 10.1248/jhs.55.689; NARHI TO, 1994, J DENT RES, V73, P20, DOI 10.1177/00220345940730010301; Sasano T, 2014, CURR PHARM DESIGN, V20, P2750, DOI 10.2174/13816128113199990577; Satoh-Kuriwada S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095177; Satoh-Kuriwada S., 2012, J NUTR FOOD SCI, DOI [10.4172/2155-9600.S10-003, DOI 10.4172/2155-9600.S10-003]; Satoh-Kuriwada S, 2012, ARCH ORAL BIOL, V57, P1121, DOI 10.1016/j.archoralbio.2012.05.007; Shoji N, 2003, ARCH ORAL BIOL, V48, P761, DOI 10.1016/S0003-9969(03)00157-2; Sreebny L. M., 2010, DRY MOUTH MALEVOLENT, P37; van Nieuw Amerongen A., 2010, DRY MOUTH MALEVOLENT, P10	12	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUN	2015	135	6					783	787				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LT	WOS:000355386200005		
J	Mizuta, E				Mizuta, Einosuke			Impact of Taste Sensitivity on Lifestyle-related Diseases	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						taste sensitivity; eating habit; life-style related disease; cardiovascular disease	GENE; PSEUDOGENIZATION; SODIUM; LEPTIN	Individual taste sensitivity affects one's eating habits, and could thus play a role in the development of lifestyle-related diseases, such as obesity, hypertension and dyslipidemia. However, only a handful of studies have been conducted to investigate these associations. Therefore, we performed taste sensitivity tests on approximately 250 patients with lifestyle-related diseases who were undergoing outpatient treatment at the Department of Internal Medicine, or received a health check-up in order to examine the associations of individual taste sensitivity with their eating habits and lifestyle-related diseases. Our findings showed that sensitivity to sweet or salt taste was significantly lower in patients with cardiovascular diseases, and sensitivity to umami taste was significantly lower in obese patients. These findings suggest that taste sensitivity disorders may be linked not only to eating habits and lifestyle-related diseases, but also to the onset of cardiovascular diseases. Many of the drugs used in the treatment of lifestyle-related diseases and cardiovascular diseases, including antihypertensive agents, statins, fibrates, and allopurinol, are known to form zinc chelates and thereby possibly cause drug-induced taste disorders. Focusing on individual taste sensitivity to improve or maintain intake levels may become a new target for drug development in the areas of lifestyle-related and cardiovascular diseases.	Sanin Rosai Hosp, Dept Cardiol, Yonago, Tottori 6838605, Japan	Mizuta, E (reprint author), Sanin Rosai Hosp, Dept Cardiol, Kaike Shinden 1-8-1, Yonago, Tottori 6838605, Japan.	einosuke@kc4.so-net.ne.jp					Zhao HB, 2010, MOL BIOL EVOL, V27, P2642, DOI 10.1093/molbev/msq152; Kawai K, 2000, P NATL ACAD SCI USA, V97, P11044, DOI 10.1073/pnas.190066697; Tanaka T, 2002, J HUM HYPERTENS, V16, P97, DOI 10.1038/sj/jhh/1001307; Murakoshi N, 2013, CIRC J, V77, P2419, DOI 10.1253/circj.CJ-13-1129; FALK E, 1995, CIRCULATION, V92, P657; Pepino MY, 2010, OBESITY, V18, P959, DOI 10.1038/oby.2009.493; Jang HJ, 2007, P NATL ACAD SCI USA, V104, P15069, DOI 10.1073/pnas.0706890104; Li X, 2005, PLOS GENET, V1, P27, DOI 10.1371/journal.pgen.0010003; Zhao HB, 2010, MOL BIOL EVOL, V27, P2669, DOI 10.1093/molbev/msq153; Kusaba T, 2009, KIDNEY INT, V76, P638, DOI 10.1038/ki.2009.214; Mizuta E, 2008, HYPERTENS RES, V31, P1069, DOI 10.1291/hypres.31.1069; Ross R, 1999, NEW ENGL J MED, V340, P115	12	1	1	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUN	2015	135	6					789	792				4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LT	WOS:000355386200006		
J	Nojiri, S				Nojiri, Shuko			Bias and Confounding: Pharmacoepidemiological Study Using Administrative Database	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						bias; confounding factor; database; epidemiology; pharmacoepidemiology	MARGINAL STRUCTURAL MODELS; NESTED CASE-CONTROL; ACUTE MYOCARDIAL-INFARCTION; PROPENSITY SCORE METHODS; IMMORTAL TIME BIAS; INSTRUMENTAL VARIABLES; EPIDEMIOLOGIC RESEARCH; CAUSAL INFERENCE; COMORBIDITY SCORES; PROTOPATHIC BIAS	The provision of health care frequently creates digitalized data such as hospital-based electronic data, medication prescription records, and claims data collectively termed "administrative database research". The data source and analytical opportunities for study create risks that can lead to misinterpretation or bias the results. This review serves as an introduction to the concept of bias and confounding to help researchers conduct methodologically sound pharmacoepidemiologic research projects using administrative databases. Beyond general considerations for observational study, there are several unique issues related to database research that should be addressed. The risks of uninterpretable or biased results can be minimized by: providing a robust description of the data tables used; focusing on why and how they were created; measuring and reporting the accuracy of diagnostic and procedural codes used; and properly accounting for any time-dependent nature of variables. The hallmark of good research is rigorously careful analysis and interpretation. The promise for value of real world evidence using databases in medical decision making must be balanced against concerns related to observational inherited limitations for bias and confounding. Researchers should aim to avoid bias in the design of a study, adjust for confounding, and discuss the effects of residual bias on the results.	Juntendo Clin Res Support Ctr, Bunkyo Ku, Tokyo 1138421, Japan	Nojiri, S (reprint author), Juntendo Clin Res Support Ctr, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	s-nojiri@juntendo.ac.jp					Amari S., 2002, TAHENRYO KAISEKI NO; Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324; Delaney JA, 2009, STAT METHODS MED RES, V18, P53, DOI 10.1177/0962280208092346; ROOS LL, 1993, MED CARE, V31, P201, DOI 10.1097/00005650-199303000-00002; Stukel TA, 2007, JAMA-J AM MED ASSOC, V297, P278, DOI 10.1001/jama.297.3.278; Schneeweiss S, 2005, J CLIN EPIDEMIOL, V58, P323, DOI 10.1016/j.jclinepi.2004.10.012; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Sturmer T, 2006, J CLIN EPIDEMIOL, V59, P437, DOI 10.1016/j.jclinepi.2005.07.004; Nakhai-Pour HR, 2011, CAN MED ASSOC J, V183, P1713, DOI 10.1503/cmaj.110454; Hernan MA, 2006, EPIDEMIOLOGY, V17, P360, DOI 10.1097/01.ede.0000222409.00878.37; Daniel RM, 2013, STAT MED, V32, P1584, DOI 10.1002/sim.5686; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; Shrank WH, 2011, J GEN INTERN MED, V26, P546, DOI 10.1007/s11606-010-1609-1; Stricker BHC, 2010, EUR J EPIDEMIOL, V25, P245, DOI 10.1007/s10654-010-9451-7; Brookhart MA, 2006, EPIDEMIOLOGY, V17, P268, DOI 10.1097/01.ede.0000193606.58671.c5; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144; Suissa S, 2007, NAT CLIN PRACT RHEUM, V3, P725, DOI 10.1038/ncprheum0652; ROBINS JM, 1992, EPIDEMIOLOGY, V3, P319, DOI 10.1097/00001648-199207000-00007; Sorensen HT, 1996, INT J EPIDEMIOL, V25, P435, DOI 10.1093/ije/25.2.435; DRAKE C, 1993, BIOMETRICS, V49, P1231, DOI 10.2307/2532266; Walker AM, 1996, EPIDEMIOLOGY, V7, P335; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Motheral B, 2003, VALUE HEALTH, V6, P90, DOI 10.1046/j.1524-4733.2003.00242.x; ERNSTER VL, 1994, PREV MED, V23, P587, DOI 10.1006/pmed.1994.1093; Platt RW, 2012, EUR J EPIDEMIOL, V27, P77, DOI 10.1007/s10654-011-9637-7; Tamim H, 2007, PHARMACOEPIDEM DR S, V16, P250, DOI 10.1002/pds.1360; Shwartz M, 1996, MED CARE, V34, P767, DOI 10.1097/00005650-199608000-00005; Austin PC, 2005, STAT MED, V24, P1563, DOI 10.1002/sim.2053; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Ali MS, 2013, EUR J EPIDEMIOL, V28, P291, DOI 10.1007/s10654-013-9766-2; Vellinga A, 2010, J ANTIMICROB CHEMOTH, V65, P1514, DOI 10.1093/jac/dkq149; Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008; Cole SR, 2003, AM J EPIDEMIOL, V158, P687, DOI 10.1093/aje/kwg206; Wilchesky M, 2004, J CLIN EPIDEMIOL, V57, P131, DOI 10.1016/S0895-4356(03)00246-4; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Schneeweiss S, 2000, INT J EPIDEMIOL, V29, P891, DOI 10.1093/ije/29.5.891; Benchimol EI, 2011, J CLIN EPIDEMIOL, V64, P821, DOI 10.1016/j.jclinepi.2010.10.006; van Walraven C, 2012, J CLIN EPIDEMIOL, V65, P126, DOI 10.1016/j.jclinepi.2011.08.002; Greenland S, 2000, INT J EPIDEMIOL, V29, P722, DOI 10.1093/ije/29.4.722; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; Shah BR, 2005, J CLIN EPIDEMIOL, V58, P550, DOI 10.1016/j.jclinepi.2004.10.016; Hall GC, 2012, PHARMACOEPIDEM DR S, V21, P1, DOI 10.1002/pds.2229; Suissa S, 2007, PHARMACOEPIDEM DR S, V16, P241, DOI 10.1002/pds.1357; HORWITZ RI, 1980, AM J MED, V68, P255, DOI 10.1016/0002-9343(80)90363-0; Martens EP, 2006, EPIDEMIOLOGY, V17, P260, DOI 10.1097/01.ede.0000215160.88317.cb; Austin PC, 2001, CAN J PUBLIC HEALTH, V92, P150; BENNETT CL, 1991, CANCER, V67, P2633, DOI 10.1002/1097-0142(19910515)67:10<2633::AID-CNCR2820671039>3.0.CO;2-9; Berzuini Carlo, 2012, CAUSALITY STAT PERSP; Brookhart MA, 2010, MED CARE, V48, pS114, DOI 10.1097/MLR.0b013e3181dbebe3; Carnahan RM, 2012, PHARMACOEPIDEM DR S, V21, P90, DOI 10.1002/pds.2318; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Choi B. C. K., 2000, ENCY EPIDEMIOLOGIC M, P74; Chubak J, 2012, J CLIN EPIDEMIOL, V65, P343, DOI 10.1016/j.jclinepi.2011.09.002; CLARK DA, 1973, AM J MED, V54, P563, DOI 10.1016/0002-9343(73)90114-9; Delgado-Rodriguez M., 2004, COMMUNITY HLTH, V58, P635, DOI DOI 10.1136/JECH.2003.008466; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Essebag Vidal, 2005, BMC Med Res Methodol, V5, P5, DOI 10.1186/1471-2288-5-5; Etminan M, 2004, PHARMACOTHERAPY, V24, P1105, DOI 10.1592/phco.24.13.1105.38083; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; Guo S. Y., 2009, ADV QUANTITATIVE TEC; Iezzoni LI, 1997, ANN INTERN MED, V127, P666; JACKSON R, 1992, AM J EPIDEMIOL, V136, P819; Kimura T., 2013, JPN J PHARMACOEPIDEM, V17, P135; KLEINBAUM DG, 1981, AM J EPIDEMIOL, V113, P452; Korhonen MJ, 2009, EUR J CLIN PHARMACOL, V65, P1167, DOI 10.1007/s00228-009-0701-0; Kuroki M., 2003, JPN J APPL STAT, V32, P89; LANGHOLZ B, 1994, ENVIRON HEALTH PERSP, V102, P47; LITWIN MS, 1993, J UROLOGY, V149, P84; Maclure M, 2001, EPIDEMIOLOGY, V12, P114, DOI 10.1097/00001648-200101000-00019; MESSMER BJ, 1969, LANCET, V1, P954; NAESSENS JM, 1992, MAYO CLIN PROC, V67, P1140; Nakajo K., 2014, 30 INT C PHARM THER; Nordstrom BL, 2007, PHARMACOEPIDEM DR S, V16, P289, DOI 10.1002/pds.1337; Okubo S., 2014, 30 INT C PHARM THER; RAY WA, 1989, AM J EPIDEMIOL, V129, P837; ROBINS J, 1986, MATH MODELLING, V7, P1393, DOI 10.1016/0270-0255(86)90088-6; Robins JM, 2009, CH CRC HANDB MOD STA, P553; ROOS LL, 1989, J CLIN EPIDEMIOL, V42, P1193, DOI 10.1016/0895-4356(89)90118-2; Rothman K. J., 2012, MODERN EPIDEMIOLOGY; Rothman K. J., 2012, MODERN EPIDEMIOLOGY, P258; Sato T., 2011, JPN J BIOMET, V32, pS35; Schneeweiss S, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-180; Schonberger RB, 2014, J CARDIOTHOR VASC AN, V28, P247, DOI 10.1053/j.jvca.2013.03.014; Snijders T., 1999, MULTILEVEL ANAL; Strom B. L., 2011, PHARMACOEPIDEM DR S, V5th, P158; Suissa S, 2004, EUR RESPIR J, V23, P391, DOI 10.1183/09031936.04.00062504; Tanaka I, 2013, J OSTEOPOROS, V2013; The European Network of Centres for Pharmaco epidemiology and Pharmacovigilance (ENCePP), GUID METH STAND PHAR; Twisk J., 2003, APPL LONGITUDINAL DA; van Walraven C, 2011, J CLIN EPIDEMIOL, V64, P1054, DOI 10.1016/j.jclinepi.2011.01.001	92	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUN	2015	135	6					793	808				16	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LT	WOS:000355386200007		
J	Kikuchi, C; Matsunaga, T; Suzuki, T				Kikuchi, Chigusa; Matsunaga, Tamihide; Suzuki, Tadashi			Effects of Training Students through a Program Simulating Medication Administration and Patient Instructions in Pre-training for Practical Training	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						pre-training for practical training; simulation; instructing patient; medication adherence	DRUG-THERAPY; ADHERENCE	Pharmacy school students were trained in a program simulating medication administration and giving adherence instructions. Following the training, the educational effects were evaluated. Students were separated into two groups. One group of students played the role of pharmacists and instructed simulated patients on medication adherence. Another group of students played the role of patients receiving simulated drug therapy; they were instructed on medication adherence by the students playing the role of pharmacists. The educational effects were evaluated using a questionnaire. The scores for "recognition of factors that influence medication adherence" tended to increase after the simulation, and they increased significantly after practical training. The scores for "self-evaluation of technique for instructing patients on medication adherence" increased significantly after the simulation, and they increased even more after practical training. The students' understanding of the effects on patients who were being instructed also increased significantly after the simulation, and these changes were maintained after practical training. In particular, students became more aware of the influence of pharmacists' attitudes. In practical training, the simulation training was helpful for bedside practice at hospital pharmacies and over-the-counter service at community pharmacies. Thus, the use of role play and simulated patients was an effective method for training pharmacy students to instruct patients on medication adherence.	[Kikuchi, Chigusa; Matsunaga, Tamihide; Suzuki, Tadashi] Nagoya City Univ, Dept Clin Pharm, Grad Sch Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan	Kikuchi, C (reprint author), Nagoya City Univ, Dept Clin Pharm, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.	kikuchi@phar.nagoya-cu.ac.jp					Lee JK, 2006, JAMA-J AM MED ASSOC, V296, P2563, DOI 10.1001/jama.296.21.joc60162; Krapek K, 2004, ANN PHARMACOTHER, V38, P1357, DOI 10.1345/aph.1D612; Taitel M, 2012, PATIENT PREFER ADHER, V6, P323, DOI 10.2147/PPA.S29353; Certification Board for Diabetes Educators in Japan, 2009, NIH TON JYUK GUID 20, P98; Hatae T., 2011, J JPN SOC HOSP PHARM, V47, P1033; Japan Pharmaceutical Association, 2008, CHOZ, V12th, P332; Kikuchi C, 2011, YAKUGAKU ZASSHI, V131, P477, DOI 10.1248/yakushi.131.477; Murata A, 2012, PATIENT PREFER ADHER, V6, P863, DOI 10.2147/PPA.S36295; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Saito M., 2013, JPN J SOC PHARM, V32, P54; Shibata Y., 2009, JPN J PHARM HLTH CAR, V35, P259; Terui T, 2010, PHARM MED, V28, P113; Tsuboi K, 2012, IRYOUYAKUGAKU, V38, P522	13	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUN	2015	135	6					809	820				12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LT	WOS:000355386200008		
J	Ichimura, Y; Takamatsu, H; Ideuchi, H; Oda, M; Takeda, K; Saitoh, H				Ichimura, Yuichi; Takamatsu, Hiroyuki; Ideuchi, Hideki; Oda, Masako; Takeda, Kiyotaka; Saitoh, Hiroshi			Plasma Concentrations of Anionic Uremic Toxins in Hemodialysis Patients and Their Effects on Protein Binding of Pravastatin	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						anionic uremic toxin; plasma concentration; hemodialysis patient; protein binding; indoxyl sulfate; pravastatin	HUMAN SERUM-ALBUMIN; INDOXYL SULFATE; HEPATIC-UPTAKE; FATTY-ACIDS; METABOLISM; REMOVAL; SOLUTES	Uremic toxins (UTs) accumulate in the body of hemodialysis patients. UTs often exert unfavorable effects on patients and cause significant interactions with clinically relevant drugs. In this study, we assayed plasma concentrations of three typical anionic UTs, indoxyl sulfate (IS), 3-indoleacetic acid (IA), and 3-carboxy-4-methyl-5-propyl-2-furan-propionic acid (CMPF), in 20 hemodialysis patients and 5 healthy volunteers. Moreover, the effects of these anionic UTs on the binding of pravastatin to human serum albumin (HSA) were also evaluated. CMPF concentrations in the plasma of patients were unchanged before and after dialysis (63.0 +/- 6.3 mu m and 65.1 +/- 6.7 mu m, respectively), and these values were about 5-fold greater compared with those in healthy volunteers. Although dialysis decreased the plasma IS concentration from 157.9 +/- 19.9 mu m to 103.8 +/- 13.3 mu m, the value after hemodialysis was still ca. 27-fold greater than that in healthy volunteers. IA concentrations before and after hemodialysis were almost identical to those in healthy volunteers. There were no significant differences in the plasma concentrations of the three anionic UTs between male and female patients. The magnitude of protein binding was in the order CMPF>IS>IA, indicating that hemodialysis clearance of these anionic UTs was dependent on their protein binding capacities. The ability of IS to reduce pravastatin binding to HSA was much greater than that of CMPF. The present results suggest that statins bind to site II on HSA, and that their binding is modulated by IS when elevated in hemodialysis patients.	[Ichimura, Yuichi; Takamatsu, Hiroyuki; Oda, Masako; Saitoh, Hiroshi] Hlth Sci Univ Hokkaido, Dept Pharmaceut, Sch Pharmaceut Sci, Tobetsu, Hokkaido 0610293, Japan; [Ideuchi, Hideki; Takeda, Kiyotaka] Sapporo Higashi Tokushukai Hosp, Dept Pharm, Higashi Ku, Sapporo, Hokkaido 0650033, Japan	Saitoh, H (reprint author), Hlth Sci Univ Hokkaido, Dept Pharmaceut, Sch Pharmaceut Sci, 1757 Kanazawa, Tobetsu, Hokkaido 0610293, Japan.	saitoh@hoku-iro-u.ac.jp					Tsujimoto M, 2008, THER DRUG MONIT, V30, P576, DOI 10.1097/FTD.0b013e3181838077; Duranton F, 2012, J AM SOC NEPHROL, V23, P1258, DOI 10.1681/ASN.2011121175; Niwa T, 2013, BLOOD PURIFICAT, V35, P20, DOI 10.1159/000350843; Itoh Y, 2012, ANAL BIOANAL CHEM, V403, P1841, DOI 10.1007/s00216-012-5929-3; Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x; Nakai S, 2013, THER APHER DIAL, V17, P567, DOI 10.1111/1744-9987.12147; Sakai T, 1995, BIOL PHARM BULL, V18, P1755; Dou L, 2004, KIDNEY INT, V65, P442, DOI 10.1111/j.1523-1755.2004.00399.x; NIWA T, 1994, J LAB CLIN MED, V124, P96; Neirynck N, 2013, INT UROL NEPHROL, V45, P139, DOI 10.1007/s11255-012-0258-1; Banoglu E, 2001, EUR J DRUG METAB PH, V26, P235; De Smet R, 2007, NEPHROL DIAL TRANSPL, V22, P2006, DOI 10.1093/ndt/gfm065; Iitaka M, 1998, CLIN ENDOCRINOL, V48, P739, DOI 10.1046/j.1365-2265.1998.00419.x; Imai E., 2010, JPN J CLIN DIAL, V27, P9; ISHII K, 1988, J BIOCHEM-TOKYO, V103, P836; LIM CF, 1993, J CLIN ENDOCR METAB, V76, P318, DOI 10.1210/jc.76.2.318; Lin CJ, 2012, ARCH MED RES, V43, P451, DOI [10.1016/j.arcmed.2012.08.002, 10.1016/j.aremed.2012.08.002]; Mutsaers HAM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018438; Sun H, 2004, DRUG METAB DISPOS, V32, P1239, DOI 10.1124/dmd.104.000521; Takamura N, 2007, YAKUGAKU ZASSHI, V127, P1805, DOI 10.1248/yakushi.127.1805; Takamura N, 1997, CLIN CHEM, V43, P2274; The Japanese Society for Dialysis Therapy, 2011, CLIN GUID EV TREATM; TSE FLS, 1993, J PHARM SCI, V82, P942, DOI 10.1002/jps.2600820914; Watanabe H., 2001, XENOBIO METABOL DISP, V16, P264; Watanabe H, 2012, DRUG METAB DISPOS, V40, P1423, DOI 10.1124/dmd.112.045617	25	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUN	2015	135	6					821	828				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LT	WOS:000355386200009		
J	Sugawara, T; Murakami, N; Uetake, N; Hiraki, K				Sugawara, Takafumi; Murakami, Noritaka; Uetake, Nobue; Hiraki, Kouichi			Evaluation of Antibiotics for the Treatment of Bacteremia Due to Extended-spectrum beta-Lactamase-producing Escherichia coli	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						extended-spectrum beta-lactamase; sepsis; Escherichia coli; carbapenem antibiotic; cefmetazole	THERAPY	Recently, extended-spectrum beta-lactamase (ESBL) -producing Escherichia coli has been more frequently isolated from blood specimens than in the past. In this study we investigated a panel of therapeutic agents used to treat 37 patients with ESBL-producing E. coli bacteremia. Antimicrobial agents administered as definitive therapy displayed higher efficacy rates than when empiric therapy was administered (efficacy rates, 95.7% vs. 62.5%). The success rate of carbapenem was 95.8% (23/24) in patients with ESBL-producing E. coli bacteremia. In addition, the success rate of cefmetazole against ESBL-producing E. coli sensitive to this drug was 87.5% (7/8). In conclusion, patients at high risk of infection due to ESBL-producing E. coli should be empirically treated with carbapenem antibiotics. In addition, cefmetazole may be a treatment option for patients with ESBL-producing E. coli bacteremia.	[Sugawara, Takafumi; Murakami, Noritaka; Uetake, Nobue; Hiraki, Kouichi] Hiroshima Citizens Hosp, Hiroshima City Hosp, Dept Pharm, Naka Ku, Hiroshima 7308518, Japan	Sugawara, T (reprint author), Hiroshima Citizens Hosp, Hiroshima City Hosp, Dept Pharm, Naka Ku, 7-33 Motomachi, Hiroshima 7308518, Japan.	t.as@city-hosp.naka.hiroshima.jp					Gaieski DF, 2010, CRIT CARE MED, V38, P1045, DOI 10.1097/CCM.0b013e3181cc4824; Ramphal R, 2006, CLIN INFECT DIS, V42, pS164, DOI 10.1086/500663; Paterson DL, 2004, CLIN INFECT DIS, V39, P31, DOI 10.1086/420816; Clinical and Laboratory Standards Institute (CLSI), 2012, PERF STAND ANT SUSC, P44; Doi A., 2013, INT J INFECT DIS, V17, P159; Muratani T., 2004, JPN J CHEMOTHER, V52, P556; Muratani T., 2011, KAGAKURYOUHOU NO RYO, V27, P1602; Sugawara T., 2013, J JPN SOC HOSP PHARM, V49, P153; YAMAGUCHI Y, 2009, JPN J CHEMOTHER, V57, P502; Yoshida Isamu, 2010, Jpn J Antibiot, V63, P457	10	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUN	2015	135	6					829	833				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LT	WOS:000355386200010		
J	Tomita, T; Goto, H; Yoshimura, Y; Tsubouchi, Y; Nakanishi, R; Kojima, C; Yoneshima, M; Yoshida, T; Tanaka, K; Sumiya, K; Kohda, Y				Tomita, Takashi; Goto, Hidekazu; Yoshimura, Yuya; Tsubouchi, Yoshiko; Nakanishi, Rie; Kojima, Chikako; Yoneshima, Mihoko; Yoshida, Tadashi; Tanaka, Katsuya; Sumiya, Kenji; Kohda, Yukinao			Effect of Food Thickener on Disintegration and Dissolution of Magnesium Oxide Tablets	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						food thickener; magnesium oxide; tablet; disintegration; dissolution rate		It has been reported that magnesium oxide tablets are excreted in a non-disintegrated state in the stool of patients when the tablets are administered after being immersed in a food thickener. Therefore we examined whether immersion in a food thickener affects the pharmacological effect in patients taking magnesium oxide tablets, and whether immersion affects its disintegration and solubility. The mean dosage (1705 mg/d) was higher for patients who took tablets after immersion in a food thickener than for those who took non-immersed tablets (1380 mg/d). The disintegration time and dissolution rate of the immersed tablets were lower than those of non-immersed tablets in vitro. Furthermore, components that constitute the food thickener and differences in composition concentrations differentially affect the disintegration and solubility of magnesium oxide tablets. This suggests that commercially available food thickeners are likely to be associated with changes in the degradation of magnesium oxide tablets, and they therefore should be carefully used in certain clinical situations.	[Tomita, Takashi; Goto, Hidekazu; Nakanishi, Rie; Kojima, Chikako; Yoneshima, Mihoko; Kohda, Yukinao] Hosp Bando, Dept Pharm, Bando, Ibaraki 3060515, Japan; [Yoshida, Tadashi] Hosp Bando, Dept Internal Med, Bando, Ibaraki 3060515, Japan; [Tanaka, Katsuya] Hosp Bando, Dept Psychiat, Bando, Ibaraki 3060515, Japan; [Yoshimura, Yuya; Tsubouchi, Yoshiko] Kyowa Chem Ind Co Ltd, Miki, Kagawa 7610705, Japan; [Sumiya, Kenji] Iwaki Meisei Univ, Fac Pharm, Iwaki, Fukushima 9708551, Japan; [Kohda, Yukinao] Tsukuba Int Univ, Fac Hlth Sci, Tsuchiura, Ibaraki 3000051, Japan	Tomita, T (reprint author), Hosp Bando, Dept Pharm, 411 Kutsukake, Bando, Ibaraki 3060515, Japan.	t.tomita@hpbando.jp					Deto A., 2007, B FAC HUMAN CULTURE, V2, P39; Fujitani J., 2000, YAKKYOKU, V51, P1350; Japanese Society of Dysphagia Rehabilitation, 2013, JPN J DYSPHAGIA REHA, V17, P255; Morita T., 2011, JPN J PHARM HLTH CAR, V37, P13; Nakamura M., 2012, Japanese Journal of Nutrition and Dietetics, V70, P59; Ookoshi H., 2005, MED REHABILITATION, V57, P132; Ookoshi H., 2004, JPN J CLIN NUTR, V105, P178; Yamaguchi H., 2014, 24 ANN M JAP SOC PHA, P371	8	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUN	2015	135	6					835	840				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LT	WOS:000355386200011		
J	Nakashima, K; Ishimaru, H; Fujimoto, T; Mizowaki, T; Mitarai, K; Nakashima, K; Matsuoka, Y; Uetani, M				Nakashima, Kazuaki; Ishimaru, Hideki; Fujimoto, Toshifumi; Mizowaki, Takashi; Mitarai, Kazunori; Nakashima, Kei; Matsuoka, Yohjiro; Uetani, Masataka			Diagnostic performance of CT findings for bowel ischemia and necrosis in closed-loop small-bowel obstruction	ABDOMINAL IMAGING			English	Article						Small-bowel obstruction; Closed loop; Contrast-enhanced CT; Bowel ischemia; Mesenteric artery; Mesenteric vein	INTESTINAL-OBSTRUCTION; COMPUTED-TOMOGRAPHY; HELICAL CT; DIFFERENTIATION; STRANGULATION; MANAGEMENT; AGREEMENT; ADHESIONS; SIGNS	Purpose: The aim of this study was to investigate the diagnostic performance of contrast-enhanced CT (CECT) findings for bowel ischemia and necrosis in closed-loop small-bowel obstruction (CL-SBO). Materials and Methods: Thirty-five patients with CL-SBO confirmed by laparotomy (n = 34) or multiplanar reconstruction of thin slice CT images (n = 1) were included. Based on the surgical and clinical findings, these patients were classified into three groups: necrosis group (n = 16), ischemia without necrosis group (n = 11), and no-ischemia group (n = 8). Two blinded radiologists retrospectively reviewed CECT including multiplanar reconstruction images and evaluated 12 CT findings. The sensitivity and specificity of each finding were compared among the three groups, and logistic regression analysis was performed. Results: High attenuation of the bowel wall, intraperitoneal air, reduced enhancement of the mesenteric arteries, and small-bowel feces signs showed high specificities of 100%, 100%, 89%, and 89% but low sensitivities of 31%, 25%, 44%, and 31%, respectively, for the prediction of bowel necrosis in CL-SBO. According to multivariate logistic regression analysis, reduced bowel-wall enhancement, reduced enhancement of the mesenteric veins, and a lack of engorgement of the mesenteric veins were significant for predicting bowel ischemia or necrosis (P < 0.05). Conclusions: Reduced enhancements of bowel wall and mesenteric veins were good indicators of bowel ischemia or necrosis. On the contrary, engorgement of the mesenteric veins was a predictor of a viable bowel.	[Nakashima, Kazuaki; Fujimoto, Toshifumi; Mizowaki, Takashi; Mitarai, Kazunori; Nakashima, Kei; Matsuoka, Yohjiro] Natl Nagasaki Med Ctr, Dept Radiol, Omura 8568562, Japan; [Ishimaru, Hideki; Uetani, Masataka] Nagasaki Univ, Sch Med, Dept Radiol, Nagasaki 8528501, Japan	Nakashima, K (reprint author), Natl Nagasaki Med Ctr, Dept Radiol, 2-1001-1 Kubara, Omura 8568562, Japan.	marimori@v101.vaio.ne.jp					Frager D, 1996, AM J ROENTGENOL, V166, P67; Mallo RD, 2005, J GASTROINTEST SURG, V9, P690, DOI 10.1016/j.gassur.2004.10.006; Boudiaf M, 2001, RADIOGRAPHICS, V21, P613; Silva AC, 2009, RADIOGRAPHICS, V29, P423, DOI 10.1148/rg.292085514; Sheedy SP, 2006, RADIOLOGY, V241, P729, DOI 10.1148/radiol.2413050965; Fevang BT, 2000, ANN SURG, V231, P529, DOI 10.1097/00000658-200004000-00012; Nicolaou S, 2005, AM J ROENTGENOL, V185, P1036, DOI 10.2214/AJR.04.0815; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; BALTHAZAR EJ, 1994, AM J ROENTGENOL, V162, P255; Zalcman M, 2000, AM J ROENTGENOL, V175, P1601; Ha HK, 1997, RADIOLOGY, V204, P507; Maglinte DDT, 2008, CLIN GASTROENTEROL H, V6, P130, DOI 10.1016/j.cgh.2007.11.025; Balthazar EJ, 1997, RADIOLOGY, V205, P519; Jancelewicz T, 2009, J GASTROINTEST SURG, V13, P93, DOI 10.1007/s11605-008-0610-z; BALTHAZAR EJ, 1992, RADIOLOGY, V185, P769; Furukawa A, 2001, RADIOGRAPHICS, V21, P341; Zielinski MD, 2010, WORLD J SURG, V34, P910, DOI 10.1007/s00268-010-0479-3; Assenza M, 2007, HEPATO-GASTROENTEROL, V54, P2017; Burkill GJC, 2001, CLIN RADIOL, V56, P350, DOI 10.1053/crad.2000.0655; FEDERLE MP, 1984, AM J ROENTGENOL, V142, P91; FRAGER DH, 1995, SEMIN ULTRASOUND CT, V16, P127, DOI 10.1016/0887-2171(95)90005-5; HA HK, 1993, J COMPUT ASSIST TOMO, V17, P386, DOI 10.1097/00004728-199305000-00009; Idris M, 2011, JPN J RADIOL, V30, P235; IRVIN TT, 1989, BRIT J SURG, V76, P1121, DOI 10.1002/bjs.1800761105; Kato K, 2010, JPN J RADIOL, V28, P727, DOI 10.1007/s11604-010-0500-7; LEFFALL LD, 1965, ARCH SURG-CHICAGO, V91, P592; Makita O, 1999, ABDOM IMAGING, V24, P120, DOI 10.1007/s002619900458; MAYOSMITH WW, 1995, CLIN RADIOL, V50, P765, DOI 10.1016/S0009-9260(05)83216-7; MEGIBOW AJ, 1991, RADIOLOGY, V180, P313; TAOUREL PG, 1995, AM J ROENTGENOL, V165, P1187	30	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-8925	1432-0509		ABDOM IMAGING	Abdom. Imaging	JUN	2015	40	5					1097	1103		10.1007/s00261-014-0335-2		7	Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging	Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging	CJ2TI	WOS:000355337000016		
J	Noda, Y; Kanematsu, M; Goshima, S; Kondo, H; Watanabe, H; Kawada, H; Kawai, N; Tanahashi, Y; Furui, T; Morishige, K; Bae, KT				Noda, Yoshifumi; Kanematsu, Masayuki; Goshima, Satoshi; Kondo, Hiroshi; Watanabe, Haruo; Kawada, Hiroshi; Kawai, Nobuyuki; Tanahashi, Yukichi; Furui, Tatsuro; Morishige, Ken-ichirou; Bae, Kyongtae T.			Prenatal MR imaging diagnosis of placental invasion	ABDOMINAL IMAGING			English	Article						Magnetic resonance imaging; Placental invasion; Uterine bulging; Heterogeneous signal intensity; Hypointense intraplacental band	CESAREAN DELIVERIES; PREVIA-ACCRETA; RISK-FACTORS; PERCRETA	The aim of the study was to evaluate the characteristic imaging features and performance of prenatal magnetic resonance (MR) imaging in the diagnosis of placental invasion. This retrospective study was approved by our institutional review board and written informed consent was waived. Twenty-eight patients (age range 26-39 years; mean age, 33.8 +/- A 3.1 years) with suspected placental invasion underwent prenatal MR imaging, including 7 patients with placental invasion and 21 without. Two radiologists assessed the presence of seven previously described MR imaging findings associated with placental invasion. Sensitivity, specificity, positive and negative predictive values, and accuracy were calculated. The diagnostic performance was also determined by a receiver-operating-characteristic curve analysis. Three MR imaging findings (uterine bulging, heterogeneous signal intensity in the placenta on T2-weighted images, and hypointense intraplacental bands on T2-weighted images) were significantly more common in patients with placental invasion than in those without (P = 0.020-0.023). The presence of at least two of these three imaging findings yielded a sensitivity, specificity, positive and negative predictive values, and accuracy of 100, 86, 67, 95, and 89%, respectively. The presence of at least two of the three characteristic prenatal MR imaging findings strongly supports a diagnosis of placental invasion.	[Noda, Yoshifumi; Kanematsu, Masayuki; Goshima, Satoshi; Kondo, Hiroshi; Watanabe, Haruo; Kawada, Hiroshi; Kawai, Nobuyuki; Tanahashi, Yukichi] Gifu Univ Hosp, Dept Radiol, Gifu 5011194, Japan; [Kanematsu, Masayuki] Gifu Univ Hosp, Dept Radiol Serv, Gifu 5011194, Japan; [Furui, Tatsuro; Morishige, Ken-ichirou] Gifu Univ Hosp, Dept Obstet & Gynecol, Gifu 5011194, Japan; [Bae, Kyongtae T.] Univ Pittsburgh, Dept Radiol, Med Ctr, Pittsburgh, PA 15260 USA	Kanematsu, M (reprint author), Gifu Univ Hosp, Dept Radiol, 1-1 Yanagido, Gifu 5011194, Japan.	masa_gif@yahoo.co.jp					Baughman WC, 2008, RADIOGRAPHICS, V28, P1905, DOI 10.1148/rg.287085060; Grobman WA, 2007, OBSTET GYNECOL, V110, P1249, DOI 10.1097/01.AOG.0000292082.80566.cd; Silver RM, 2006, OBSTET GYNECOL, V107, P1226, DOI 10.1097/01.AOG.0000219750.79480.84; Lam G, 2002, J SOC GYNECOL INVEST, V9, P37, DOI 10.1016/S1071-5576(01)00146-0; Miller DA, 1997, AM J OBSTET GYNECOL, V177, P210, DOI 10.1016/S0002-9378(97)70463-0; BREEN JL, 1977, OBSTET GYNECOL, V49, P43; Maldjian C, 1999, MAGN RESON IMAGING, V17, P965, DOI 10.1016/S0730-725X(99)00035-1; Wu S, 2005, AM J OBSTET GYNECOL, V192, P1458, DOI 10.1016/j.ajog.2004.12.074; Hamilton BE, 2013, PEDIATRICS, V131, P548, DOI 10.1542/peds.2012-3769; Usta IM, 2005, AM J OBSTET GYNECOL, V193, P1045, DOI 10.1016/j.ajog.2005.06.037; Lax A, 2007, MAGN RESON IMAGING, V25, P87, DOI 10.1016/j.mri.2006.10.007; Derman AY, 2011, AM J ROENTGENOL, V197, P1514, DOI 10.2214/AJR.10.5443; CLARK SL, 1985, OBSTET GYNECOL, V66, P89; FEJGIN MD, 1993, J PERINAT MED, V21, P165; Kim JA, 2004, ACTA RADIOL, V45, P692, DOI 10.1080/02841850410001114; Lau WC, 1997, EUR J OBSTET GYN R B, V74, P133, DOI 10.1016/S0301-2115(97)00090-0; Martin Joyce A, 2002, Natl Vital Stat Rep, V50, P1	17	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-8925	1432-0509		ABDOM IMAGING	Abdom. Imaging	JUN	2015	40	5					1273	1278		10.1007/s00261-014-0281-z		6	Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging	Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging	CJ2TI	WOS:000355337000037		
J	Kubo, F; Takahara, M; Yasuda, T; Katakami, N; Matsuoka, T; Shimomura, I				Kubo, Fumiyo; Takahara, Mitsuyoshi; Yasuda, Tetsuyuki; Katakami, Naoto; Matsuoka, Taka-aki; Shimomura, Iichiro			Positive conversion of GAD autoantibody in patients with presumed type 2 diabetes	ACTA DIABETOLOGICA			English	Letter						Type 2 diabetes; GAD autoantibody; Re-examination; Positive conversion			[Kubo, Fumiyo; Takahara, Mitsuyoshi; Yasuda, Tetsuyuki; Katakami, Naoto; Matsuoka, Taka-aki; Shimomura, Iichiro] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka 5650871, Japan	Takahara, M (reprint author), Osaka Univ, Grad Sch Med, Dept Metab Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	takahara@endmet.med.osaka-u.ac.jp					Hawa MI, 2013, DIABETES CARE, V36, P908, DOI 10.2337/dc12-0931; Maruyama T, 2008, J CLIN ENDOCR METAB, V93, P2115, DOI 10.1210/jc.2007-2267; Davis TME, 2005, DIABETOLOGIA, V48, P695, DOI 10.1007/s00125-005-1690-x; Mahadeb YP, 2014, ACTA DIABETOL, V51, P103, DOI 10.1007/s00592-013-0513-7	4	0	0	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	0940-5429	1432-5233		ACTA DIABETOL	Acta Diabetol.	JUN	2015	52	3					629	630		10.1007/s00592-014-0657-0		2	Endocrinology & Metabolism	Endocrinology & Metabolism	CJ1HB	WOS:000355233500024		
J	Miyazaki, M; Nakagawa, S				Miyazaki, Masamine; Nakagawa, Shinichi			Geographical variation in male calls and the effect on female response in little penguins	ACTA ETHOLOGICA			English	Article						Speciation; Species divergence; Acoustic signals; Female choice; Playback experiment	WHITE-CROWNED SPARROWS; EUDYPTULA-MINOR; BLUE PENGUINS; ZONOTRICHIA-LEUCOPHRYS; SONG DIALECTS; DISCRIMINATION; POPULATION; BEHAVIOR; BIRD; RESPONSIVENESS	We investigated the variation in male advertising calls of two subspecies of little penguins (Eudyptula minor minor and Eudyptula minor iredalei), which live in two different regions within New Zealand. We found that the call frequency in both exhalation and inhalation phrases in male advertising calls differed between the two subspecies. Further, we conducted a reciprocal playback experiment to examine how females at the two geographical locations respond to the local and non-local male calls. Females tended to approach towards their regional calls, indicating that females recognize and might prefer their local male calls. Interestingly, E. minor iredalei females responded vocally to their local calls and took a longer time when approaching, while E. minor minor females did not use any vocalization during the approach and selected their local calls within a shorter time. However, given our limited sample size, we cannot exclude the possibility that these observed differences might be due to individual differences. Thus, further research is required to evaluate whether male mating signals and female responses to the male calls have diverged between the two subspecies.	[Miyazaki, Masamine; Nakagawa, Shinichi] Univ Waikato, Dept Biol Sci, Hamilton, New Zealand	Miyazaki, M (reprint author), Tokyo City Univ, Dept Nat Sci, Fac Knowledge Engn, 1-28-1 Tamazutsumi, Tokyo 1588557, Japan.	minemiya@aol.com	Nakagawa, Shinichi/B-5571-2011	Nakagawa, Shinichi/0000-0002-7765-5182	University of Waikato	We thank Barbara and Ray Walter on Tiritiri Matangi Island and Dave Houston in Oamaru for their invaluable help during this study. We gratefully acknowledge Joseph R. Waas who provided the opportunity to pursue this study. We also thank Losia Lagisz, Masatoshi Saikawa and anonymous referees who commented on and improved the manuscript. The University of Waikato provided financial assistance. A permit to conduct research on little penguins was supplied by the Department of Conservation, New Zealand. The University of Waikato Animal Ethics Committee approved our experimental protocol.	Danner JE, 2011, AM NAT, V178, P53, DOI 10.1086/660283; WAAS JR, 1991, ANIM BEHAV, V41, P375, DOI 10.1016/S0003-3472(05)80838-3; Nelson DA, 2004, BEHAVIOUR, V141, P53, DOI 10.1163/156853904772746600; Miyazaki M, 2003, J AVIAN BIOL, V34, P229, DOI 10.1034/j.1600-048X.2003.03099.x; Nakagawa S, 2007, BIOL REV, V82, P591, DOI 10.1111/j.1469-185X.2007.00027.x; Briefer E, 2010, J THEOR BIOL, V262, P151, DOI 10.1016/j.jtbi.2009.09.020; KROODSMA DE, 1976, SCIENCE, V192, P574, DOI 10.1126/science.192.4239.574; WAAS JR, 1991, BEHAV ECOL SOCIOBIOL, V29, P139, DOI 10.1007/BF00166489; ROTHSTEIN SI, 1987, CONDOR, V89, P1, DOI 10.2307/1368756; TEMELES EJ, 1994, ANIM BEHAV, V47, P339, DOI 10.1006/anbe.1994.1047; Williams H, 2004, ANN NY ACAD SCI, V1016, P1, DOI 10.1196/annals.1298.029; Searcy WA, 1997, CONDOR, V99, P651, DOI 10.2307/1370477; Miyazaki M, 2003, IBIS, V145, P98, DOI 10.1046/j.1474-919X.2003.00126.x; BAKER MC, 1978, EVOLUTION, V32, P712, DOI 10.2307/2407487; BAKER MC, 1982, AM ZOOL, V22, P561; BAKER MC, 1981, SCIENCE, V214, P819, DOI 10.1126/science.214.4522.819; Bretagnolle V, 1998, BEHAVIOUR, V135, P1161; BROOKE MDL, 1978, ANIM BEHAV, V26, P622; Chilton G, 1996, BEHAVIOUR, V133, P173, DOI 10.1163/156853996X00107; Cohen J., 1988, STAT POWER ANAL BEHA; Crawley MJ, 2002, STAT COMPUTING INTRO; ERIKSSON D, 1986, BEHAV ECOL SOCIOBIOL, V19, P297, DOI 10.1007/BF00300645; JAMES PC, 1984, IBIS, V126, P89, DOI 10.1111/j.1474-919X.1984.tb03671.x; Jouventin P, 2000, IBIS, V142, P645, DOI 10.1111/j.1474-919X.2000.tb04464.x; Jouventin P., 1982, VISUAL VOCAL SIGNALS; Kinsky FC, 1976, REC NAT MUS WELLINGT, V3, P145; Klecka W., 1980, DISCRIMINANT ANAL; Koetz-Trowse AH, 2012, EMU, V112, P189, DOI 10.1071/MU11056; MARLER P., 1962, CONDOR, V64, P368, DOI 10.2307/1365545; MILLIGAN MM, 1971, CONDOR, V73, P208, DOI 10.2307/1365840; Miyazaki M, 2002, BEHAVIOUR, V139, P1413, DOI 10.1163/15685390260514681; Miyazaki M, 2005, J ETHOL, V23, P167, DOI 10.1007/s10164-005-0148-4; Nakagawa S, 2001, BEHAV ECOL SOCIOBIOL, V50, P180, DOI 10.1007/s002650100355; Nakagawa Shinichi, 2004, Acta Ethologica, V7, P103, DOI 10.1007/s10211-004-0095-z; R Development Core Team, 2013, R LANG ENV STAT COMP; SEARCY WA, 1981, BEHAVIOUR, V77, P152, DOI 10.1163/156853981X00202; SEARCY WA, 1990, BEHAV ECOL SOCIOBIOL, V27, P123, DOI 10.1007/BF00168455; Skierczynski M, 2010, BEHAVIOUR, V147, P333, DOI 10.1163/000579509X12549112908535; STOREY AE, 1984, BEHAVIOUR, V89, P73, DOI 10.1163/156853984X00047; WAAS JR, 1988, ANIM BEHAV, V36, P366, DOI 10.1016/S0003-3472(88)80007-1; Waas J.R., 1990, P345; Williams T., 1995, PENGUINS SPHENISCIDA; Wright TF, 2001, ETHOLOGY, V107, P111, DOI 10.1046/j.1439-0310.2001.00632.x	43	2	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0873-9749	1437-9546		ACTA ETHOL	Acta Ethol.	JUN	2015	18	2					227	234		10.1007/s10211-014-0193-5		8	Behavioral Sciences; Zoology	Behavioral Sciences; Zoology	CJ2LH	WOS:000355315700017		
J	Suzuki, O; Goto, T; Yoshino, T; Nakamura, S; Maeda, H				Suzuki, Osamu; Goto, Taiji; Yoshino, Toshiharu; Nakamura, Satoshi; Maeda, Hiroaki			The role of phosphodiesterase 4B in IL-8/LTB4-induced human neutrophil chemotaxis evaluated with a phosphodiesterase 4B inhibitor	ACTA PHARMACEUTICA			English	Article						phosphodiesterase 4B; phosphodiesterase 4D; mononuclear cells; neutrophils	CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; BLOOD MONONUCLEAR-CELLS; CYTOKINE PRODUCTION; EXPRESSION	PDE4B was previously shown to be a dominant PDE4 subtype of neutrophils. However, its physiological role in the neutrophil function has not been evaluated. In this study, the inhibitory effects of a phosphodiesterase 4B (PDE4B)selective inhibitor (compound A) and subtype non-selective PDE4 inhibitors (roflumilast and cilomilast) were evaluated in human peripheral blood cells. Compound A, roflumilast and cilomilast in a similar manner inhibited TNF-alpha production by LPS-stimulated human mononuclear cells. However, the inhibitory effect of compound A on IL-8 or LTB4-induced chemotactic response of neutrophils was modest even at the highest concentration (10 mu mol L-1), whereas roflumilast and cilomilast inhibited IL-8 or LTB4-induced neutrophil chemotaxis. Our results suggest that PDE4B does not play an important role during the chemotactic response of human neutrophils.	[Suzuki, Osamu; Maeda, Hiroaki] Daiichi Sankyo Co Ltd, Biol Res Labs 3, Tokyo 1408710, Japan; [Goto, Taiji; Yoshino, Toshiharu] Daiichi Sankyo Co Ltd, Lead Discovery & Optimizat Res Labs 2, Tokyo 1408710, Japan; [Suzuki, Osamu; Nakamura, Satoshi] Tokyo Inst Technol, Dept Bioengn, Atsugi, Kanagawa 2268501, Japan	Suzuki, O (reprint author), Daiichi Sankyo Co Ltd, Cardiovasc Metab Res Labs, Tokyo 1408710, Japan.	suzuki.osamu.g5@daiichisankyo.co.jp					Wang P, 1999, MOL PHARMACOL, V56, P170; Francis SH, 2011, PHYSIOL REV, V91, P651, DOI 10.1152/physrev.00030.2010; Suzuki O, 2013, J PHARMACOL SCI, V123, P219, DOI 10.1254/jphs.13103FP; Maurice DH, 2014, NAT REV DRUG DISCOV, V13, P290, DOI 10.1038/nrd4228; Houslay MD, 2010, TRENDS BIOCHEM SCI, V35, P91, DOI 10.1016/j.tibs.2009.09.007; Cloez-Tayarani I, 2003, INT IMMUNOL, V15, P233, DOI 10.1093/intimm/dxg027; Manning CD, 1999, BRIT J PHARMACOL, V128, P1393, DOI 10.1038/sj.bjp.0702911; Peter D, 2007, J IMMUNOL, V178, P4820; PRABHAKAR U, 1994, INT J IMMUNOPHARMACO, V16, P805, DOI 10.1016/0192-0561(94)90054-X; Vacca G, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-24; Yoshimura T, 1997, GEN PHARMACOL, V29, P633, DOI 10.1016/S0306-3623(96)00580-0	11	0	0	HRVATSKO FARMACEUTSKO DRUSTOV (HFD)-CROATION PHARMACEUTICAL SOC	ZAGREB	MASARYKOVA 2, 10000 ZAGREB, CROATIA	1330-0075	1846-9558		ACTA PHARMACEUT	Acta Pharm.	JUN	2015	65	2					191	197		10.1515/acph-2015-0016		7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ0WG	WOS:000355199400008		
J	Nobukawa, KK; Nobukawa, M; Tsuru, TG; Koyama, K				Nobukawa, K. K.; Nobukawa, M.; Tsuru, T. G.; Koyama, K.			Discovery of new X-ray sources near the unidentified gamma-ray source HESS J1841-055	ADVANCES IN SPACE RESEARCH			English	Article						X-ray; Interstellar medium; HESS J1841-055	GALACTIC PLANE; SUZAKU; PULSAR; GALAXIES; CLUSTER; REGION; RIDGE; LINE	HESS J1841-055 is a diffuse unidentified gamma-ray source with the size of similar to 1 degrees.3 x 1 degrees. No conclusive counterpart in other wavelengths has so far detected. To search for X-rays responsible for the TeV emission, the Suzaku observations were conducted, which covered a half region of the HESS source. In the soft band (0.5-2.0 keV), we discovered a diffuse emission, Suzaku J1840.2-0552, with the size of similar to 10'. Since its spectrum was fitted by an optically thin thermal plasma model, Suzaku J1840.2-0552 is likely to be a supernova remnant. We also discovered an extended source, Suzaku J1840.2-0544, in the hard band (2.0-8.0 keV) with an emission line at 6.1 keV. From the spectral feature and large interstellar absorption, this source is likely to be a cluster of galaxies behind the Galactic plane at the red-shift of similar to 0.09. The other diffuse source spatially overlaps with the SNR candidate G26.6-0.2, which shows a non-thermal dominant spectrum. Since no other candidate is found in the hard X-ray band, we infer that these largely extended sources could be possible counterparts of HESS J1841-055. (C) 2015 COSPAR. Published by Elsevier Ltd. All rights reserved.	[Nobukawa, K. K.; Nobukawa, M.; Tsuru, T. G.; Koyama, K.] Kyoto Univ, Grad Sch Sci, Dept Phys, Sakyo Ku, Kyoto 6068502, Japan; [Nobukawa, M.] Kyoto Univ, Hakubi Ctr Adv Res, Sakyo Ku, Kyoto 6068302, Japan; [Koyama, K.] Osaka Univ, Grad Sch Sci, Dept Earth & Space Sci, Toyonaka, Osaka 5600043, Japan	Nobukawa, KK (reprint author), Kyoto Univ, Grad Sch Sci, Dept Phys, Sakyo Ku, Kitashirakawa Oiwake Cho, Kyoto 6068502, Japan.	kumiko@cr.scphys.kyoto-u.ac.jp	XRAY, SUZAKU/A-1808-2009		Japan Society for the Promotion of Science for Young Scientists; JSPS; MEXT KAKENHI [24740123, 20340043, 23340047, 25109004, 24540229]	The authors thank all of the Suzaku team members for their full support of the Suzaku project. KKN is supported by Research Fellowships of Japan Society for the Promotion of Science for Young Scientists. This study was also supported by JSPS and MEXT KAKENHI Grant Nos. 24740123 (MN), 20340043, 23340047, 25109004 (TGT), and 24540229 (KK).	Acero F, 2013, ASTROPHYS J, V773, DOI 10.1088/0004-637X/773/1/77; Aharonian F, 2008, ASTRON ASTROPHYS, V477, P353, DOI 10.1051/0004-6361:20078516; WORRALL DM, 1982, ASTROPHYS J, V255, P111, DOI 10.1086/159809; Evans IN, 2010, ASTROPHYS J SUPPL S, V189, P37, DOI 10.1088/0067-0049/189/1/37; Bamba A, 2003, ASTROPHYS J, V589, P253, DOI 10.1086/374354; Bartoli B, 2013, ASTROPHYS J, V767, DOI 10.1088/0004-637X/767/2/99; Bozzo E., 2011, ASTRON ASTROPHYS, V531, P130, DOI DOI 10.1051/0004-6361/201116726.ARXIV:1106.5125; Fukazawa Y, 2000, MON NOT R ASTRON SOC, V313, P21, DOI 10.1046/j.1365-8711.2000.03204.x; Hobbs G, 2004, MON NOT R ASTRON SOC, V352, P1439, DOI 10.1111/j.1365-2966.2004.08042.x; Ishisaki Y, 2007, PUBL ASTRON SOC JPN, V59, pS113; Koyama K, 2007, PUBL ASTRON SOC JPN, V59, pS23; KOYAMA K, 1986, PUBL ASTRON SOC JPN, V38, P121; Matsushita K, 2011, ASTRON ASTROPHYS, V527, P134; Mitsuda K, 2007, PUBL ASTRON SOC JPN, V59, pS1; Negueruela I, 2006, ESA SP PUBL, V604, P165; Neronov A., 2010, GALACTIC SOURCES E 1; Nevalainen J, 2001, ASTRON ASTROPHYS, V374, P66, DOI 10.1051/0004-6361:20010649; Nobukawa KK, 2012, PUBL ASTRON SOC JPN, V64; Pletsch HJ, 2012, ASTROPHYS J LETT, V755, DOI 10.1088/2041-8205/755/1/L20; Ricci C., 2014, ASTRON ASTROPHYS, V567, P142; Romano P, 2009, MON NOT R ASTRON SOC, V399, P2021, DOI 10.1111/j.1365-2966.2009.15356.x; Serlemitsos PJ, 2007, PUBL ASTRON SOC JPN, V59, pS9; Sguera V, 2009, ASTROPHYS J, V697, P1194, DOI 10.1088/0004-637X/697/2/1194; Sguera V, 2005, ASTRON ASTROPHYS, V444, P221, DOI 10.1051/0004-6361:20053103; Takata A., PUBL ASTRON SOC JPN; Tawa N, 2008, PUBL ASTRON SOC JPN, V60, pS11; Uchiyama H, 2013, PUBL ASTRON SOC JPN, V65; Yamauchi S, 2011, PUBL ASTRON SOC JPN, V63, pS957; Yamazaki R, 2006, MON NOT R ASTRON SOC, V371, P1975, DOI 10.1111/j.1365-2966.2006.10832.x; Yasumi M., 2014, PASJ, V66, P689	30	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0273-1177	1879-1948		ADV SPACE RES	Adv. Space Res.	JUN 1	2015	55	11					2493	2499		10.1016/j.asr.2015.02.035		7	Astronomy & Astrophysics; Geosciences, Multidisciplinary; Meteorology & Atmospheric Sciences	Astronomy & Astrophysics; Geology; Meteorology & Atmospheric Sciences	CI8LU	WOS:000355024600001		
J	Niita, T; Torii, S; Akaike, Y; Asaoka, Y; Kasahara, K; Ozawa, S; Tamura, T				Niita, Tae; Torii, Shoji; Akaike, Yosui; Asaoka, Yoichi; Kasahara, Katsuaki; Ozawa, Shunsuke; Tamura, Tadahisa			Energy calibration of Calorimetric Electron Telescope (CALET) in space	ADVANCES IN SPACE RESEARCH			English	Article						Cosmic-ray electrons; Direct measurement; Detector calibration	SPECTROMETER; ESCAPE	The Calorimetric Electron Telescope (CALET) is a space experiment, currently under development by Japan in collaboration with Italy and the United States. CALET will measure the flux of cosmic ray electrons (including positrons) up to 20 TeV, gamma-rays up to 10 TeV and nuclei from Z = 1 up to 40 up to 1000 TeV during a two-year mission on the International Space Station (ISS), extendable to five years. The unique feature of CALET is its thick, fully active calorimeter that allows measurements well into the TeV energy region with excellent energy resolution (< 3%), coupled with a fine imaging upper calorimeter to accurately identify the starting point of electromagnetic showers. For continuous high performance of the detector, it is required to calibrate each detector component on orbit. We use the measured response to minimum ionizing particles for the energy calibration, taking data in a dedicated trigger mode and selecting useful events in off-line analysis. In this paper, we present on-orbit and off-line data handling methods for the energy calibration developed through beam tests at CERN-SPS and Monte Carlo simulations. (C) 2015 COSPAR. Published by Elsevier Ltd. All rights reserved.	[Niita, Tae; Torii, Shoji; Asaoka, Yoichi; Kasahara, Katsuaki; Ozawa, Shunsuke] Waseda Univ, Shinjuku Ku, Tokyo, Japan; [Akaike, Yosui] Univ Tokyo, Inst Cosm Ray Res, Tokyo 1138654, Japan; [Tamura, Tadahisa] Kanagawa Univ, Inst Phys, Yokohama, Kanagawa, Japan	Niita, T (reprint author), Waseda Univ, Shinjuku Ku, 3-4-1 Okubo, Tokyo, Japan.	many-pictures@fuji.waseda.jp			Japan Society for the Promotion of Science (JSPS) [21224006]	We sincerely thank Prof. Pier Simone Marrocchesi (Siena University) and his colleagues in Italy for contribution to the CERN beam tests. Prof. Martin Israel (Washington University in St. Louis) and Dr. Holger Motz (Waseda University) are also appreciated for careful reading of this manuscript and useful comments. The work was supported in part by Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (S), Grant No. 21224006.	Honda M, 2004, PHYS REV D, V70, DOI 10.1103/PhysRevD.70.043008; Accardo L, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.121101; Adriani O, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.201101; Aguilar M, 2002, PHYS REP, V366, P331, DOI 10.1016/S0370-1573(02)00013-3; Akaike Y., 2013, P 33 INT COSM RAY C; Cholis I, 2013, PHYS REV D, V88, DOI 10.1103/PhysRevD.88.023013; Kobayashi T, 2004, ASTROPHYS J, V601, P340, DOI 10.1086/380431; GLEESON LJ, 1968, ASTROPHYS J, V154, P1011, DOI 10.1086/149822; Barnett RM, 1996, PHYS REV D, V54, P1, DOI 10.1103/PhysRevD.54.1; Akaike Y, 2010, ADV SPACE RES, V45, P690, DOI 10.1016/j.asr.2009.11.002; Bergstrom L, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.171101; Sanuki T, 2000, ASTROPHYS J, V545, P1135, DOI 10.1086/317873; Guzik T., 2013, P 33 INT COSM RAY C; Hinton JA, 2011, ASTROPHYS J LETT, V743, DOI 10.1088/2041-8205/743/1/L7; Kasahara K., 1995, P 24 INT COSM RAY C; Kawanaka N, 2011, ASTROPHYS J, V729, DOI 10.1088/0004-637X/729/2/93; Marrocchesi P.S, 2013, P 33 INT COSM RAY C; Mertsch P, 2011, J COSMOL ASTROPART P; Roesler S, 2000, P MONTE CARLO, V71, P2000; Tamura T, 2013, P 33 INT COSM RAY C; Torii S., 2013, P 33 INT COSM RAY C; Yoshida K., 2013, P 33 INT COSM RAY C	22	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0273-1177	1879-1948		ADV SPACE RES	Adv. Space Res.	JUN 1	2015	55	11					2500	2508		10.1016/j.asr.2015.03.006		9	Astronomy & Astrophysics; Geosciences, Multidisciplinary; Meteorology & Atmospheric Sciences	Astronomy & Astrophysics; Geology; Meteorology & Atmospheric Sciences	CI8LU	WOS:000355024600002		
J	Hamada, AM; Mahrous, AM; Fathy, I; Ghamry, E; Groves, K; Yumoto, K				Hamada, A. M.; Mahrous, A. M.; Fathy, I.; Ghamry, E.; Groves, K.; Yumoto, K.			TEC variations during geomagnetic storm/substorm with Pc5/PI2 pulsation signature	ADVANCES IN SPACE RESEARCH			English	Article						Geomagnetic storm; Substorm; Magnetic pulsations; Ionospheric storm	TOTAL ELECTRON-CONTENT; LOW-LATITUDE IONOSPHERE; DISTURBANCE DYNAMO; MAGNETOSPHERIC DISTURBANCES; MAGNETIC STORM; MIDLATITUDE IONOSPHERE; EQUATORIAL REGION; PI2 PULSATIONS; BOUNDARY-LAYER; SOLAR-WIND	The electron density integral along the paths between a GPS satellite and receiver is known as Total Electron Content (TEC), and this parameter is used in studying the ionosphere behaviors. TEC can be obtained by means of many methods. A space-based radio navigation system, such as Global Positioning System (GPS), offers good opportunities for studying the ionosphere. The TEC is calculated from the group path delay and phase advance in GPS satellite signals along the slant paths connecting GPS receivers and satellites at 22,000 km. Locally, a dual frequency GPS receiver was installed in Helwan, Egypt (29.86 degrees N, 31.32 degrees E) in November 2009. Here, GPS data were analyzed to establish a daily observation of Vertical TEC in a region located near to the northern crest of the ionospheric equatorial anomaly. During a moderate geomagnetic storm, observed on 02-05 May 2010, a number of ionospheric/magnetic phenomena were observed. Also, observations for Pc5/Pi2 pulsations were recorded during the geomagnetic storm phases. These geomagnetic observations are taken from MAGDAS-magnetometer station, located at Aswan (23.59 degrees N, 32.51 degrees E). More than 10 TECU increase in the ionospheric TEC values were recorded during the daytime of 02 May, followed by a large reduction during 03 May, reference to the pre-storm conditions. This confirms the enhancement in the geomagnetic H-component peak during the storm's initial phase and its reduction during the main phase. (C) 2015 COSPAR. Published by Elsevier Ltd. All rights reserved.	[Hamada, A. M.; Mahrous, A. M.; Fathy, I.] Helwan Univ, Fac Sci, Space Weather Monitoring Ctr, Cairo, Egypt; [Ghamry, E.] NRIAG, Cairo 11421, Egypt; [Ghamry, E.] Kyung Hee Univ, Sch Space Res, Yongin 446701, Gyeonggi Do, South Korea; [Groves, K.] Boston Coll, Inst Sci Res, Boston, MA USA; [Yumoto, K.] Kyushu Univ, Int Ctr Space Weather Sci & Educ, Fukuoka 812, Japan	Hamada, AM (reprint author), Helwan Univ, Fac Sci, Space Weather Monitoring Ctr, Cairo, Egypt.	amr@helwan.edu.eg					Abdu MA, 1996, J GEOPHYS RES, V101, P26729, DOI 10.1029/96JA00321; Klimenko MV, 2012, J ATMOS SOL-TERR PHY, V90-91, P146, DOI 10.1016/j.jastp.2012.02.018; FEJER BG, 1995, GEOPHYS RES LETT, V22, P851, DOI 10.1029/95GL00390; Yumoto K, 2001, EARTH PLANETS SPACE, V53, P981; Lu G, 2008, J GEOPHYS RES-SPACE, V113, DOI 10.1029/2007JA012895; Sastri JH, 2003, J GEOPHYS RES-SPACE, V108, DOI 10.1029/2003JA009962; Kepko L, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014405; Cander LR, 2003, ANN GEOPHYS-ITALY, V46, P719; FEJER BG, 1983, GEOPHYS RES LETT, V10, P537, DOI 10.1029/GL010i007p00537; Pilipenko V, 2014, J GEOPHYS RES-SPACE, V119, P4358, DOI 10.1002/2013JA019594; Meng CI, 2004, SPACE SCI REV, V113, P41, DOI 10.1023/B:SPAC.0000042939.88548.68; SAITO T, 1969, SPACE SCI REV, V10, P319; Araujo-Pradere EA, 2002, RADIO SCI, V37, DOI 10.1029/2002RS002620; FullerRowell TJ, 1996, J GEOPHYS RES-SPACE, V101, P2343, DOI 10.1029/95JA01614; Yizengaw E, 2004, ANN GEOPHYS-GERMANY, V22, P2765; Buonsanto MJ, 1999, SPACE SCI REV, V88, P563, DOI 10.1023/A:1005107532631; NISHIDA A, 1966, ANN GEOPHYS, V22, P478; Mann IR, 1999, J GEOPHYS RES-SPACE, V104, P333, DOI 10.1029/1998JA900026; Basu S, 2007, J GEOPHYS RES-SPACE, V112, DOI 10.1029/2006JA012192; Sobral JHA, 2001, J ATMOS SOL-TERR PHY, V63, P965, DOI 10.1016/S1364-6826(00)00197-8; Balan N, 2010, J GEOPHYS RES-SPACE, V115, DOI 10.1029/2009JA014515; FULLERROWELL TJ, 1994, J GEOPHYS RES-SPACE, V99, P3893, DOI 10.1029/93JA02015; ABDU MA, 1995, J ATMOS TERR PHYS, V57, P1065, DOI 10.1016/0021-9169(94)00123-6; BLANC M, 1980, J GEOPHYS RES-SPACE, V85, P1669, DOI 10.1029/JA085iA04p01669; Astafyeva E, 2009, ANN GEOPHYS-GERMANY, V27, P1175; de Abreu AJ, 2014, ADV SPACE RES, V53, P1313, DOI 10.1016/j.asr.2014.02.011; Namgaladze AA, 2000, ANN GEOPHYS-ATM HYDR, V18, P461, DOI 10.1007/s00585-000-0461-8; BALAN N, 1991, ANN GEOPHYS, V9, P60; Basu S., 2000, GEOPHYS RES LETT, V28, P3573; Bolshakova O.V., 1995, GEOMAGN AERON, V34, P492; Burke WJ, 2000, IEEE T PLASMA SCI, V28, P1903, DOI 10.1109/27.902218; Burke WJ, 1998, GEOPHYS RES LETT, V25, P3023, DOI 10.1029/98GL00469; Cander LR, 1998, J GEOPHYS RES-SPACE, V103, P391, DOI 10.1029/97JA02418; Danilov A. D., 2001, INT J GEOMAGNETISM A, V2, P209; Danilov A.D., 1985, MORPHOL PHYS REV GEO, V25, P593; DUNLOP IS, 1994, J ATMOS TERR PHYS, V56, P667, DOI 10.1016/0021-9169(94)90106-6; ESSEX EA, 1981, J ATMOS TERR PHYS, V43, P293, DOI 10.1016/0021-9169(81)90091-X; Fejer BG, 2002, J ATMOS SOL-TERR PHY, V64, P1401, DOI 10.1016/S1364-6826(02)00103-7; FEJER BG, 1990, J GEOPHYS RES, V95, P2367, DOI 10.1029/JA095iA03p02367; FESEN CG, 1989, J GEOPHYS RES, V94, P5405, DOI 10.1029/JA094iA05p05405; Fuller-Rowell T., 1997, GEOPHYS MONOGR SER, V98, P203, DOI DOI 10.1029/GM098P0203; Fuller-Rowell TJ, 2000, ANN GEOPHYS-ATM HYDR, V18, P766, DOI 10.1007/s00585-000-0766-7; GONZALES CA, 1983, J GEOPHYS RES-SPACE, V88, P9135, DOI 10.1029/JA088iA11p09135; Henderson S., 2005, J GEOPHYS RES, V110; Ho CM, 1998, J GEOPHYS RES-SPACE, V103, P26409, DOI 10.1029/98JA01237; Horvath I, 2003, ANN GEOPHYS-GERMANY, V21, P1017; Huang CS, 2002, J GEOPHYS RES-SPACE, V107, DOI 10.1029/2001JA009025; Huang CS, 2005, J GEOPHYS RES-SPACE, V110, DOI 10.1029/2005JA011202; Jakowski N, 1999, J ATMOS SOL-TERR PHY, V61, P299, DOI 10.1016/S1364-6826(98)00130-8; Kepko L, 1999, J GEOPHYS RES-SPACE, V104, P25021, DOI 10.1029/1999JA900361; Kessel RL, 2004, ANN GEOPHYS-GERMANY, V22, P629; KIKUCHI T, 1986, J GEOPHYS RES, V91, P3101, DOI 10.1029/JA091iA03p03101; Kil H, 2003, J GEOPHYS RES-SPACE, V108, DOI 10.1029/2002JA009782; Kintner PM, 2008, GEOPHYS MONOGR SER, V181, P1, DOI 10.1029/181GM02; KIVELSON MG, 1984, PLANET SPACE SCI, V32, P1335, DOI 10.1016/0032-0633(84)90077-1; Klimenko M.V., 2011, RADIO SCI, V46; LILLEY FEM, 1973, J GEOPHYS RES, V78, P1603, DOI 10.1029/JA078i010p01603; Lu G., 1998, SUBSTORM, V4, P617; MCHARG MG, 1995, J GEOPHYS RES, V100, P19729, DOI 10.1029/94JA03054; MCPHERRO.RL, 1973, J GEOPHYS RES, V78, P3131, DOI 10.1029/JA078i016p03131; Olson JV, 1999, J GEOPHYS RES-SPACE, V104, P17499, DOI 10.1029/1999JA900086; Prolss G.W, 1995, HDB ATMOSPHERIC ELEC, V2, P195; Richmond A. D., 2003, J GEOPHYS RES, V108, pSIA5/1; SAGALYN RC, 1974, J GEOPHYS RES, V79, P4252, DOI 10.1029/JA079i028p04252; Sastri JH, 2001, J GEOPHYS RES-SPACE, V106, P29925, DOI 10.1029/2001JA900120; WALKER ADM, 1992, J GEOPHYS RES, V97, P12187, DOI 10.1029/92JA00329; YUMOTO K, 1986, J GEOPHYS-Z GEOPHYS, V60, P79; YUMOTO K, 1980, PLANET SPACE SCI, V28, P789, DOI 10.1016/0032-0633(80)90076-8; YUMOTO K, 1988, J GEOMAGN GEOELECTR, V40, P293; ZIESOLLECK CWS, 1994, J GEOPHYS RES, V99, P5817, DOI 10.1029/93JA02903	70	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0273-1177	1879-1948		ADV SPACE RES	Adv. Space Res.	JUN 1	2015	55	11					2534	2542		10.1016/j.asr.2015.02.010		9	Astronomy & Astrophysics; Geosciences, Multidisciplinary; Meteorology & Atmospheric Sciences	Astronomy & Astrophysics; Geology; Meteorology & Atmospheric Sciences	CI8LU	WOS:000355024600006		
J	Tanno, LK; Calderon, MA; Goldberg, BJ; Gayraud, J; Bircher, AJ; Casale, T; Li, J; Sanchez-Borges, M; Rosenwasser, LJ; Pawankar, R; Papadopoulos, NG; Demoly, P				Tanno, L. K.; Calderon, M. A.; Goldberg, B. J.; Gayraud, J.; Bircher, A. J.; Casale, T.; Li, J.; Sanchez-Borges, M.; Rosenwasser, L. J.; Pawankar, R.; Papadopoulos, N. G.; Demoly, P.			Constructing a classification of hypersensitivity/allergic diseases for ICD-11 by crowdsourcing the allergist community	ALLERGY			English	Article						allergic diseases; classification; hypersensitivity diseases; International Classification of Diseases; World Health Organization	HYMENOPTERA VENOM ALLERGY; CONSENSUS REPORT; INTERNATIONAL CONSENSUS; DRUG HYPERSENSITIVITY; CONTACT-DERMATITIS; POSITION PAPER; FOOD ALLERGY; DIAGNOSIS; ASTHMA; GUIDELINES	The global allergy community strongly believes that the 11th revision of the International Classification of Diseases (ICD-11) offers a unique opportunity to improve the classification and coding of hypersensitivity/allergic diseases via inclusion of a specific chapter dedicated to this disease area to facilitate epidemiological studies, as well as to evaluate the true size of the allergy epidemic. In this context, an international collaboration has decided to revise the classification of hypersensitivity/allergic diseases and to validate it for ICD-11 by crowdsourcing the allergist community. After careful comparison between ICD-10 and 11 beta phase linearization codes, we identified gaps and trade-offs allowing us to construct a classification proposal, which was sent to the European Academy of Allergy and Clinical Immunology (EAACI) sections, interest groups, executive committee as well as the World Allergy Organization (WAO), and American Academy of Allergy Asthma and Immunology (AAAAI) leaderships. The crowdsourcing process produced comments from 50 of 171 members contacted by e-mail. The classification proposal has also been discussed at face-to-face meetings with experts of EAACI sections and interest groups and presented in a number of business meetings during the 2014 EAACI annual congress in Copenhagen. As a result, a high-level complex structure of classification for hypersensitivity/allergic diseases has been constructed. The model proposed has been presented to the WHO groups in charge of the ICD revision. The international collaboration of allergy experts appreciates bilateral discussion and aims to get endorsement of their proposals for the final ICD-11.	[Tanno, L. K.] Hosp Sirio Libanes, Sao Paulo, Brazil; [Calderon, M. A.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London, England; [Goldberg, B. J.] Kaiser Permanente So Calif, Reg Allergy Immunol Lab, Los Angeles, CA USA; [Goldberg, B. J.] Int Hlth Terminol Stand Dev Org, Los Angeles, CA USA; [Gayraud, J.] Polyclin Ormeau, Tarbes, France; [Bircher, A. J.] Univ Basel Hosp, Dept Dermatol, Allergy Unit, CH-4031 Basel, Switzerland; [Casale, T.] Univ S Florida, Morsani Coll Med, Internal Med, Tampa, FL USA; [Li, J.] Mayo Clin, Div Allerg Dis, Rochester, MN USA; [Sanchez-Borges, M.] Ctr Med Docente La Trinidad, Allergy & Clin Immunol Dept, Caracas, Venezuela; [Rosenwasser, L. J.] Childrens Mercy Hosp & Clin, Div Immunol Res, Dept Pediat, Kansas City, MO USA; [Pawankar, R.] Nippon Med Sch, Div Allergy, Dept Pediat, Tokyo 113, Japan; [Papadopoulos, N. G.] Univ Manchester, Inst Human Dev, Ctr Paediat & Child Hlth, Manchester, Lancs, England; [Papadopoulos, N. G.] Univ Athens, Dept Allergy, Pediat Clin 2, Athens, Greece; [Demoly, P.] Univ Hosp Montpellier, F-34295 Montpellier, France; [Demoly, P.] Univ Paris 06, Univ Paris 04, UMR S 1136, IPLESP,Equipe EPAR, Paris, France	Demoly, P (reprint author), Univ Hosp Montpellier, Div Allergy, Dept Pulmonol, F-34295 Montpellier, France.	pascal.demoly@inserm.fr					Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Tan CH, 2014, CLIN DERMATOL, V32, P116, DOI 10.1016/j.clindermatol.2013.05.033; Muraro A, 2014, ALLERGY, V69, P1008, DOI 10.1111/all.12429; Burks AW, 2012, J ALLERGY CLIN IMMUN, V129, P906, DOI 10.1016/j.jaci.2012.02.001; Cicardi M, 2012, ALLERGY, V67, P147, DOI 10.1111/j.1398-9995.2011.02751.x; Leonardi A, 2012, ALLERGY, V67, P1327, DOI 10.1111/all.12009; Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350; Zuberbier T, 2009, ALLERGY, V64, P1417, DOI 10.1111/j.1398-9995.2009.02179.x; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Pirmohamed M, 2011, CLIN PHARMACOL THER, V89, P896, DOI 10.1038/clpt.2011.79; Bircher AJ, 2010, MED CLIN N AM, V94, P711, DOI 10.1016/j.mcna.2010.04.001; Bonini S, 2004, EYE, V18, P345, DOI 10.1038/sj.eye.6700675; Akdis CA, 2006, ALLERGY, V61, P969, DOI 10.1111/j.1398-9995.2006.01153.x; Bousquet J, 2010, ALLERGY, V65, P1212, DOI 10.1111/j.1398-9995.2010.02480.x; Papadopoulos NG, 2012, ALLERGY, V67, P976, DOI 10.1111/j.1398-9995.2012.02865.x; Roujeau JC, 2005, TOXICOLOGY, V209, P123, DOI 10.1016/j.tox.2004.12.022; Bateman ED, 2007, EUR RESPIR J, V29, P56, DOI 10.1183/09031936.00128505; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Fokkens W, 2007, RHINOLOGY, P1; Asthma, 2010, QUICK ASTHM FACTS FA; Bonitsis NG, 2011, CONTACT DERMATITIS, V64, P245, DOI 10.1111/j.1600-0536.2010.01860.x; Centers for Disease Control, 2003, VITAL HLTH STAT; Craig Timothy, 2012, World Allergy Organ J, V5, P182, DOI 10.1097/WOX.0b013e318279affa; Demoly P, 2014, ALLERGY, V69, P559, DOI 10.1111/all.12386; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; La Rosa M, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-18; Moscato G, 2014, ALLERGY, V69, P292, DOI 10.1111/all.12352; Papadopoulos Nikolaos G, 2012, Clin Transl Allergy, V2, P21, DOI 10.1186/2045-7022-2-21; Pawankar R., 2013, WAO WHITE BOOK ALLER; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Scadding Glenis, 2011, Clin Transl Allergy, V1, P2, DOI 10.1186/2045-7022-1-2; Simons F Estelle R, 2014, World Allergy Organ J, V7, P9, DOI 10.1186/1939-4551-7-9; Simpson CR, 2007, CLIN EXP ALLERGY, V37, P1586, DOI 10.1111/j.1365-2222.2007.02830.x; Soares-Weiser Karla, 2013, Clin Transl Allergy, V3, P18, DOI 10.1186/2045-7022-3-18; Tanno Luciana Kase, 2014, Clin Transl Allergy, V4, P42, DOI 10.1186/2045-7022-4-42; Tanno LK, 2012, ALLERGY, V67, P783, DOI 10.1111/j.1398-9995.2012.02829.x; The European Academy of Allergy and Clinical Immunology (EAACI), EUR DECL ALL IMM; Tu S, 2011, CONTENT MODEL ICD 11	39	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538	1398-9995		ALLERGY	Allergy	JUN	2015	70	6					609	615		10.1111/all.12604		7	Allergy; Immunology	Allergy; Immunology	CJ1LR	WOS:000355245600001		
J	Song, JS; You, JS; Jeong, SI; Yang, S; Hwang, IT; Im, YG; Baek, HS; Kim, HY; Suh, DI; Lee, HB; Izuhara, K				Song, J. -S.; You, J. -S.; Jeong, S. -I.; Yang, S.; Hwang, I. -T.; Im, Y. -G.; Baek, H. -S.; Kim, H. -Y.; Suh, D. -I.; Lee, H. -B.; Izuhara, K.			Serum periostin levels correlate with airway hyper-responsiveness to methacholine and mannitol in children with asthma	ALLERGY			English	Article						airway hyperresponsiveness; asthma; children; periostin	EXHALED NITRIC-OXIDE; 1ST 6 YEARS; CLINICAL-SIGNIFICANCE; BRONCHIAL-ASTHMA; CLUSTER-ANALYSIS; MATRIX PROTEIN; INFLAMMATION; RESPONSIVENESS; PHENOTYPES; LIFE	BackgroundPeriostin is a matricellular protein, and its synthesis in airway epithelial cells and lung fibroblasts is induced by interleukin (IL)-4 and IL-13. The significance of periostin as a biomarker of T(H)2-induced airway inflammation, and (importantly) as a measure of the response to T(H)2-targeted therapy, has recently been emphasized. We explored the relationship between periostin and airway hyperresponsiveness (AHR) in asthmatic children. MethodsThe study included 83 children aged 6-15years in an asthmatic group (n=54) and healthy controls (n=29). We measured the periostin levels in serum and performed methacholine and mannitol provocation challenges. The responses to mannitol were expressed as the provocative dose causing a 15% fall in the FEV1 (the PD15 dose). ResultsOf the 54 subjects with asthma, all had positive methacholine bronchial provocation test (BPT) results and 38 had positive mannitol BPT results. Children with asthma had significantly higher periostin levels than controls [76.0 (65.0-91.8) vs 71.0 (57.5-80.0) ng/mL; P=0.017]. Periostin levels were significantly correlated with both the methacholine PC20 and mannitol PD15 values. ConclusionSerum levels of periostin, a new biomarker induced by IL-13, were higher in asthmatic children, and were associated with AHR to methacholine and mannitol.	[Song, J. -S.; You, J. -S.; Jeong, S. -I.; Yang, S.; Hwang, I. -T.; Baek, H. -S.] Hallym Univ, Dept Pediat, Kandong Sacred Heart Hosp, Seoul, South Korea; [Im, Y. -G.] Chonnam Natl Univ, Dent Hosp, Dept Oral Med, Gwangju, South Korea; [Kim, H. -Y.] Hallym Univ, Dept Gynecol & Obstet, Kangdong Sacred Heart Hosp, Seoul, South Korea; [Suh, D. -I.] Seoul Natl Univ, Coll Med, Seoul, South Korea; [Lee, H. -B.] Hanyang Univ, Coll Med, Seoul 133791, South Korea; [Izuhara, K.] Saga Med Sch, Dept Biomol Sci, Saga, Japan	Baek, HS (reprint author), Hallym Univ, Dept Pediat, Kandong Sacred Heart Hosp, Seoul, South Korea.	paviola7@hanmail.net		Baek, Heysung/0000-0003-0297-9446	Hallym University [HURF-2013-10]	This research was supported by Hallym University Research Fund 2013 (HURF-2013-10).	American Thoracic Society; European Respiratory Society, 2005, AM J RESP CRIT CARE, V171, p912 , DOI [10.1164/rccm.200406-710ST, DOI 10.1164/RCCM.200406-7105]; Anderson SD, 2010, CHEST, V138, p25S, DOI 10.1378/chest.10-0116; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Brannan JD, 2003, EUR RESPIR J, V22, P491, DOI 10.1183/09031936.03.00113403; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI [10.1164/rccm.200711-1754OC, 10.1164/rccm.200711-17540C]; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Kuhn B, 2007, NAT MED, V13, P962, DOI 10.1038/nm1619; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Menzies D, 2007, CHEST, V131, P410, DOI 10.1378/chest.06-1335; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Hamilton DW, 2008, J CELL COMMUN SIGNAL, V2, P9, DOI 10.1007/s12079-008-0023-5; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Kii I, 2006, BIOCHEM BIOPH RES CO, V342, P766, DOI 10.1016/j.bbrc.2006.02.016; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI [10.1164/rccm.9120-11ST, 10.1164/rccm.912011ST]; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Kikuchi Y, 2008, J HISTOCHEM CYTOCHEM, V56, P753, DOI 10.1369/jhc.2008.951061; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Okamoto M, 2011, EUR RESPIR J, V37, P1119, DOI 10.1183/09031936.00059810; Kim MA, 2014, CURR OPIN ALLERGY CL, V14, P49, DOI 10.1097/ACI.0000000000000028; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Lopez-Guisa JM, 2012, J ALLERGY CLIN IMMUN, V129, P990, DOI 10.1016/j.jaci.2011.11.035; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; Dorn GW, 2007, NEW ENGL J MED, V357, P1552, DOI 10.1056/NEJMcibr074816; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; Porsbjerg C, 2008, CLIN EXP ALLERGY, V38, P43, DOI 10.1111/j.1365-2222.2007.02878.x; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972	32	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538	1398-9995		ALLERGY	Allergy	JUN	2015	70	6					674	681		10.1111/all.12599		8	Allergy; Immunology	Allergy; Immunology	CJ1LR	WOS:000355245600008		
J	Sugioka, K; Takagi, M; Sakamoto, S; Fujita, S; Ito, A; Iwata, S; Matsumura, Y; Nakagawa, M; Doi, A; Miki, Y; Yoshiyama, M; Ueda, M				Sugioka, Kenichi; Takagi, Masahiko; Sakamoto, Shinichi; Fujita, Suwako; Ito, Asahiro; Iwata, Shinichi; Matsumura, Yoshiki; Nakagawa, Masashi; Doi, Atsushi; Miki, Yukio; Yoshiyama, Minoru; Ueda, Makiko			Predictors of silent brain infarction on magnetic resonance imaging in patients with nonvalvular atrial fibrillation: A transesophageal echocardiographic study	AMERICAN HEART JOURNAL			English	Article							ASYMPTOMATIC CEREBRAL INFARCTION; SPONTANEOUS ECHO CONTRAST; THROMBOEMBOLIC RISK; ELDERLY PATIENTS; ISCHEMIC-STROKE; PREVALENCE; DIAGNOSIS; STENOSIS; CHADS(2); DISEASE	Background Silent brain infarction (SBI) is often found in patients with atrial fibrillation (AF) and may be related to cognitive decline. We investigated the predictors of SBI on brain magnetic resonance imaging (MRI) using transesophageal echocardiography (TEE) in patients with nonvalvular AF. Methods The study population consisted of 103 neurologically asymptomatic patients with nonvalvular AF who underwent TEE before transcatheter AF ablation (76 men; mean age 63 +/- 10 years). Left atrial (LA) abnormalities such as LA thrombus, spontaneous echo contrast, or abnormal LA appendage emptying velocity (<20 cm/s) and complex plaques in the aortic arch defined as large plaques >= 4 mm thickness, ulcerated plaques, or mobile plaques were evaluated by TEE. All patients were screened for SBI by brain MRI. Results Of 103 patients, 31 (30%) showed SBI on brain MRI. Most lesions were multiple (61%) and small (<15 mm) in diameter (84%). Patients with SBI had a higher prevalence of LA abnormalities (45% vs 14%; P < .001) and complex arch plaques (45% vs 7%; P < .001) compared with those without SBI. In a multivariate logistic regression analysis including age and CHADS(2) score >= 2, LA abnormalities (odds ratio 4.13; 95% CI 1.34-12.72; P = .014) and complex arch plaques (odds ratio 4.82; 95% CI 1.23-18.92; P = .024) were independent predictors of SBI. Conclusions Left atrial abnormalities and complex arch plaques detected by TEE were closely associated with the presence of SBI on brain MRI, suggesting that microembolization of small thrombi derived from the fibrillating LA or advanced aortic atherosclerotic lesions may be important causes of SBI in patients with nonvalvular AF.	[Sugioka, Kenichi; Takagi, Masahiko; Fujita, Suwako; Ito, Asahiro; Iwata, Shinichi; Matsumura, Yoshiki; Nakagawa, Masashi; Doi, Atsushi; Yoshiyama, Minoru] Osaka City Univ, Grad Sch Med, Dept Cardiovasc Med, Osaka 5458585, Japan; [Sakamoto, Shinichi; Miki, Yukio] Osaka City Univ, Grad Sch Med, Dept Radiol, Osaka 5458585, Japan; [Ueda, Makiko] Osaka City Univ, Grad Sch Med, Dept Pathol, Osaka 5458585, Japan	Sugioka, K (reprint author), Osaka City Univ, Grad Sch Med, Dept Cardiovasc Med, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	k-sugioka@med.osaka-cu.ac.jp					Zhu YC, 2011, STROKE, V42, P1140, DOI 10.1161/STROKEAHA.110.600114; Lin HJ, 1996, STROKE, V27, P1760; Zabalgoitia M, 1998, J AM COLL CARDIOL, V31, P1622, DOI 10.1016/S0735-1097(98)00146-6; Cha MJ, 2014, AM J CARDIOL, V113, P655, DOI 10.1016/j.amjcard.2013.11.011; EZEKOWITZ MD, 1995, CIRCULATION, V92, P2178; KEMPSTER PA, 1988, STROKE, V19, P955; PETERSEN P, 1987, STROKE, V18, P1098; Jorgensen HS, 1996, STROKE, V27, P1765; Rastegar R, 2003, J AM COLL CARDIOL, V41, P603, DOI 10.1016/S0735-1097(02)02898-X; Gaita F, 2013, J AM COLL CARDIOL, V62, P1990, DOI 10.1016/j.jacc.2013.05.074; Imai E, 2007, AM J KIDNEY DIS, V50, P927, DOI 10.1053/j.ajkd.2007.09.004; vanLatum JC, 1996, NEUROLOGY, V46, P159; Kim HJ, 2011, STROKE, V42, P2323, DOI 10.1161/STROKEAHA.111.616573; Teramoto T, 2007, J ATHEROSCLER THROMB, V14, P45; Pepi M, 2010, EUR J ECHOCARDIOGR, V11, P461, DOI 10.1093/ejechocard/jeq045; Chen LY, 2014, STROKE, V45, P2568, DOI 10.1161/STROKEAHA.114.005243; CASTELLO R, 1990, AM J CARDIOL, V65, P1149, DOI 10.1016/0002-9149(90)90330-4; FATKIN D, 1994, J AM COLL CARDIOL, V23, P961; Gaita F, 2010, CIRCULATION, V122, P1667, DOI 10.1161/CIRCULATIONAHA.110.937953; Kronzon I, 2006, CIRCULATION, V114, P63, DOI 10.1161/CIRCULATIONAHA.105.593418; Puwanant S, 2009, J AM COLL CARDIOL, V54, P2032, DOI 10.1016/j.jacc.2009.07.037; Sugioka K, 2011, AM J CARDIOL, V108, P1002, DOI 10.1016/j.amjcard.2011.05.036; WOLF PA, 1991, STROKE, V22, P983; Vermeer SE, 2007, LANCET NEUROL, V6, P611, DOI 10.1016/S1474-4422(07)70170-9; Kalantarian S, 2013, ANN INTERN MED, V158, P338, DOI 10.7326/0003-4819-158-5-201303050-00007; Blackshear JL, 1999, STROKE, V30, P834; CHIMOWITZ MI, 1993, STROKE, V24, P1015; FEINBERG WM, 1990, ARCH INTERN MED, V150, P2340, DOI 10.1001/archinte.150.11.2340; January CT, 2014, CIRCULATION, V130, pE199, DOI 10.1161/CIR.0000000000000041; Kimura K, 2005, J NEUROL NEUROSUR PS, V76, P679, DOI 10.1136/jnnp.2004.048827; Kobayashi A, 2012, J STROKE CEREBROVASC, V21, P310, DOI 10.1016/j.jstrokecerebrovasdis.2010.09.004; Rundek T, 1999, STROKE, V30, P2683; Seino Y, 2010, DIABETOL INT, V1, P2, DOI 10.1007/s13340-010-0006-7; Shimada JI, 2014, CIRC J, V78, P738, DOI 10.1253/circj.CJ-13-1072; Shinokawa N, 2001, CHEST, V120, P840, DOI 10.1378/chest.120.3.840; Sugioka K, 2002, STROKE, V33, P2077, DOI 10.1161/01.STR.0000021410.83049.32; Willens HJ, 2013, J AM SOC ECHOCARDIOG, V26, P175, DOI 10.1016/j.echo.2012.11.002	37	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0002-8703	1097-5330		AM HEART J	Am. Heart J.	JUN	2015	169	6					783	790		10.1016/j.ahj.2015.03.016		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ1AK	WOS:000355213300006		
J	Tanaka, F; Makita, S; Ito, T; Onoda, T; Sakata, K; Nakamura, M				Tanaka, Fumitaka; Makita, Shinji; Ito, Tomonori; Onoda, Toshiyuki; Sakata, Kiyomi; Nakamura, Motoyuki			Relationship between the seismic scale of the 2011 northeast Japan earthquake and the incidence of acute myocardial infarction: A population-based study	AMERICAN HEART JOURNAL			English	Article							HANSHIN-AWAJI EARTHQUAKE; SUDDEN CARDIAC DEATH; CARDIOVASCULAR EVENTS; MORTALITY; TRIGGERS; STRESS	Background Previous studies have reported a relationship between large earthquakes and acute coronary events, but have yielded conflicting results. On March 11, 2011, a massive magnitude 9.0 earthquake hit the northeastern coast of Japan and generated repeated aftershocks. The aim of this study is to clarify the influence of this earthquake on the risk of acute myocardial infarction (AMI) including sudden cardiac death based on the data from a population-based analysis. Methods The study subjects were residents in the northeast of Iwate prefecture, Japan. Cases corresponding to the definition of AMI according to the criteria of the World Health Organization MONICA project were registered from 4 weeks before to 8 weeks after the disaster and in the corresponding periods in 2009 and 2010. Results The relative risk of AMI was 2.03 (95% CI 1.55-2.66) for the 4-week period after the disaster compared with the corresponding periods in the preceding years. The number of events peaked within the first week after the earthquake decreased to levels seen in the preceding years and then increased again after high-magnitude aftershocks. The incidence of AMI was positively correlated with the seismic scale of the earthquake (r = 0.75, P < .01). Conclusions This population-based study suggests that the increase in AMI events after a major earthquake varies depending on the seismic scale of the initial shock and each aftershock.	[Tanaka, Fumitaka; Makita, Shinji; Ito, Tomonori; Nakamura, Motoyuki] Iwate Med Univ, Dept Internal Med, Morioka, Iwate 0208505, Japan; [Onoda, Toshiyuki; Sakata, Kiyomi] Iwate Med Univ, Dept Hyg & Prevent Med, Morioka, Iwate 0208505, Japan	Tanaka, F (reprint author), Iwate Med Univ, Dept Internal Med, 19-1 Uchimaru, Morioka, Iwate 0208505, Japan.	ftanaka@iwate-med.ac.jp			Ministry of Education, Science, and Culture of Japan, Tokyo, Japan [26461082, 26461083]; Japan Arteriosclerosis Prevention Fund, Tokyo, Japan; Takeda Science Foundation, Osaka, Japan	This research was supported, in part, by grants-in-aid from the scientific research fund of the Ministry of Education, Science, and Culture of Japan (26461082 and 26461083), Tokyo, Japan; the Japan Arteriosclerosis Prevention Fund, Tokyo, Japan; the Takeda Science Foundation, Osaka, Japan.	Chugh SS, 2004, J AM COLL CARDIOL, V44, P1268, DOI 10.1016/j.jacc.2004.06.029; Leor J, 1996, AM J CARDIOL, V77, P1230, DOI 10.1016/S0002-9149(96)00169-5; Mittleman MA, 2011, CIRCULATION, V124, P346, DOI 10.1161/CIRCULATIONAHA.110.968776; Aoki T, 2013, CIRC J, V77, P490, DOI 10.1253/circj.CJ-12-1594; Suzuki S, 1997, AM HEART J, V134, P974, DOI 10.1016/S0002-8703(97)80023-3; Brown DL, 1999, AM HEART J, V137, P830, DOI 10.1016/S0002-8703(99)70406-0; DOBSON AJ, 1991, MED J AUSTRALIA, V155, P757; Japan Meteorological Agency, 2011 PAC COAST TOH E; Japan Meteorological Agency, MON EARTHQ TSUN VOLC; Kario K, 1997, J AM COLL CARDIOL, V29, P926; KATSOUYANNI K, 1986, INT J EPIDEMIOL, V15, P326, DOI 10.1093/ije/15.3.326; KLONER RA, 1997, CALIFORNIA J AM COLL, V30, P1174; Leor J, 1996, NEW ENGL J MED, V334, P413, DOI 10.1056/NEJM199602153340701; Nakajima H, ASSESSMENT TSUNAMI F; National Police Agency of Japan, 2013, DAM SIT POL COUNT AS; Niiyama M, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000798; Ogawa K, 2000, INT J EPIDEMIOL, V29, P449, DOI 10.1093/ije/29.3.449; Sherman DG, 1976, LANCET, V23, P911; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; TRICHOPOULOS D, 1983, LANCET, V1, P441; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583; Watanabe H, 2005, JAMA-J AM MED ASSOC, V294, P305, DOI 10.1001/jama.294.3.305	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0002-8703	1097-5330		AM HEART J	Am. Heart J.	JUN	2015	169	6					861	869		10.1016/j.ahj.2015.02.007		9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ1AK	WOS:000355213300016		
J	Shinohara, A; Ikeda, M; Okuyama, H; Kobayashi, M; Funazaki, H; Mitsunaga, S; Shimizu, S; Ohno, I; Takahashi, H; Ichida, Y; Takahashi, K; Okusaka, T; Saitoh, S				Shinohara, Akira; Ikeda, Masafumi; Okuyama, Hiroyuki; Kobayashi, Misaki; Funazaki, Hideki; Mitsunaga, Shuichi; Shimizu, Satoshi; Ohno, Izumi; Takahashi, Hideaki; Ichida, Yasuhiko; Takahashi, Kunio; Okusaka, Takuji; Saitoh, Shinichiro			Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study	AMERICAN JOURNAL OF CLINICAL DERMATOLOGY			English	Article							CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER; CLINICAL-TRIALS GROUP; JAPANESE PATIENTS; RANDOMIZED-TRIAL; EGFR INHIBITORS; PHASE-III; RECEPTORS; RASH; ACNE	Background Erlotinib has been reported as being associated with a high incidence of skin toxicities such as acneiform rash, paronychia, and xerosis. Objective The aim of this study was to evaluate the efficacy of prophylactic minocycline treatment for the skin toxicities induced by erlotinib as compared with deferred minocycline treatment in patients with pancreatic cancer treated with erlotinib plus gemcitabine. Methods A total of 96 patients were studied retrospectively, of whom 44 received prophylactic minocycline between August 2012 and June 2013 and 52 received deferred minocycline treatment between August 2011 and July 2012 at the National Cancer Center Hospital East, Kashiwa, Japan. In the prophylactic minocycline group, 200 mg/day oral minocycline was prophylactically administered during the treatment period. Results The incidence rate of acneiform rash and xerosis of any grade during the first 6 weeks of treatment was significantly reduced in the prophylactic minocycline group compared with the deferred minocycline treatment group (47.7 vs. 80.8 %, p < 0.001; 2.3 vs. 19.2 %, p = 0.01). Multivariate analysis identified prophylactic minocycline as a significant independent factor associated with the incidence of acneiform rash and xerosis of any severity (odds ratio [OR] 0.16, 95 % confidence interval [CI] 0.06-0.46, p < 0.001; OR 0.11, 95 % CI 0.01-0.90, p = 0.04). Conclusion Prophylactic minocycline appears to be useful for the management of erlotinib-related acneiform rash and xerosis during chemotherapy in patients with advanced pancreatic cancer.	[Shinohara, Akira; Kobayashi, Misaki; Funazaki, Hideki; Ichida, Yasuhiko; Takahashi, Kunio; Saitoh, Shinichiro] Natl Canc Ctr Hosp East, Dept Pharm, Kashiwa, Chiba 2778577, Japan; [Ikeda, Masafumi; Okuyama, Hiroyuki; Mitsunaga, Shuichi; Shimizu, Satoshi; Ohno, Izumi; Takahashi, Hideaki] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba 2778577, Japan; [Okusaka, Takuji] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan	Ikeda, M (reprint author), Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	masikeda@east.ncc.go.jp					Li TH, 2009, TARGET ONCOL, V4, P107, DOI 10.1007/s11523-009-0114-0; Wheatley-Price P, 2008, J CLIN ONCOL, V26, P2350, DOI 10.1200/JCO.2007.15.2280; Vincent JA, 2007, DIABETES, V56, P224, DOI 10.2337/db06-0427; NANNEY LB, 1990, J INVEST DERMATOL, V94, P742, DOI 10.1111/1523-1747.ep12874601; Dreno B, 2004, EUR J DERMATOL, V14, P391; Wacker B, 2007, CLIN CANCER RES, V13, P3913, DOI 10.1158/1078-0432.CCR-06-2610; Scope A, 2007, J CLIN ONCOL, V25, P5390, DOI 10.1200/JCO.2007.12.6987; Lacouture ME, 2010, J CLIN ONCOL, V28, P1351, DOI 10.1200/JCO.2008.21.7828; Stintzing S, 2013, INT J CANCER, V132, P236, DOI 10.1002/ijc.27654; Perez-Soler R, 2004, J CLIN ONCOL, V22, P3238, DOI 10.1200/JCO.2004.11.057; Jatoi A, 2009, ONCOLOGY-BASEL, V77, P120, DOI 10.1159/000229751; Pastore S, 2005, J IMMUNOL, V174, P5047; Nakagawa K, 2012, J THORAC ONCOL, V7, P1296, DOI 10.1097/JTO.0b013e3182598abb; Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Galimont-Collen AFS, 2007, EUR J CANCER, V43, P845, DOI 10.1016/j.ejca.2006.11.016; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Lacouture ME, 2006, NAT REV CANCER, V6, P803, DOI 10.1038/nrc1970; Migliaccio A, 2006, ANN NY ACAD SCI, V1089, P194, DOI 10.1196/annals.1386.006; Okusaka T, 2011, CANCER SCI, V102, P425, DOI 10.1111/j.1349-7006.2010.01810.x; PRUZANSKI W, 1992, BIOCHEM PHARMACOL, V44, P1165, DOI 10.1016/0006-2952(92)90381-R; Shu K-Y, 2006, Br J Dermatol, V154, P191; Soulieres D, 2004, J CLIN ONCOL, V22, P3238	23	1	1	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1175-0561	1179-1888		AM J CLIN DERMATOL	Am. J. Clin. Dermatol.	JUN	2015	16	3					221	229		10.1007/s40257-015-0116-x		9	Dermatology	Dermatology	CJ0YF	WOS:000355206100008		
J	Urakawa, H; Tsukushi, S; Arai, E; Kozawa, E; Futamura, N; Ishiguro, N; Nishida, Y				Urakawa, Hiroshi; Tsukushi, Satoshi; Arai, Eisuke; Kozawa, Eiji; Futamura, Naohisa; Ishiguro, Naoki; Nishida, Yoshihiro			Association of Short Duration From Initial Symptoms to Specialist Consultation With Poor Survival in Soft-Tissue Sarcomas	AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS			English	Article						soft-tissue sarcoma; non-small round cell; specialist consultation; length of symptom; survival	PROGNOSTIC-FACTORS; MULTIVARIATE-ANALYSIS; COLORECTAL-CANCER; DIAGNOSIS; VARIABLES; DELAY; TIME; METASTASIS; RECURRENCE; INTERVAL	Introduction: The association of symptom duration with survival remains controversial in soft-tissue sarcoma (STS). Materials and Methods: We determined whether the length from initial symptoms to specialist consultation affects prognosis in STSs. We retrospectively reviewed 152 primary STS patients (with 142 non-small round cell sarcomas) who consulted our specialist hospital. The factors that affected the length of the period from the initial symptoms to specialist consultation and the length of the delay at the clinic before specialist hospital referral were investigated. The relation between the length of the period from symptom onset and overall survival was also analyzed. Results: Unplanned excision and superficial tumor were significantly associated with increasing duration from the initial symptoms to specialist hospital referral. Multivariate analysis revealed that tumors over 5 cm (P = 0.002 and 0.005) and symptoms within 6 months (P = 0.017 and 0.016) were independent poor prognostic factors of overall survival among the pretreatment factors when analyzing all and non-small round cell STSs. Conclusions: This is a first report to show the independent prognostic role of symptom duration in STSs on multivariate analysis. Considering the impact of symptom duration on survival in these heterogenous tumors, careful follow-up and consideration of treatment are necessary for patients with short symptom duration.	[Urakawa, Hiroshi] Nagoya Univ, Grad Sch, Dept Orthoped Surg, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Nagoya, Aichi 4668550, Japan	Urakawa, H (reprint author), Nagoya Univ, Grad Sch, Dept Orthoped Surg, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	urakawa@med.nagoya-u.ac.jp					Rougraff BT, 2007, CLIN ORTHOP RELAT R, P181, DOI 10.1097/BLO.0b013e3180f62608; TROJANI M, 1984, INT J CANCER, V33, P37, DOI 10.1002/ijc.2910330108; Bauer HCF, 2001, ACTA ORTHOP SCAND, V72, P150, DOI 10.1080/000164701317323408; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]; FEIN DA, 1995, INT J RADIAT ONCOL, V32, P969, DOI 10.1016/0360-3016(95)00105-8; UEDA T, 1988, CANCER, V62, P1444, DOI 10.1002/1097-0142(19881001)62:7<1444::AID-CNCR2820620733>3.0.CO;2-L; Stojadinovic A, 2002, J CLIN ONCOL, V20, P4344, DOI 10.1200/JCO.2002.07.154; Lahat G, 2008, ANN SURG ONCOL, V15, P2739, DOI 10.1245/s10434-008-9970-6; Zagars GK, 2003, CANCER, V97, P2530, DOI 10.1002/cncr.11365; Nakamura T, 2011, J SURG ONCOL, V104, P771, DOI 10.1002/jso.22006; Ferrari A, 2010, CANCER, V116, P177, DOI 10.1002/cncr.24695; Eilber FC, 2005, ANN SURG ONCOL, V12, P228, DOI 10.1245/ASO.2005.03.045; Myrdal G, 2004, THORAX, V59, P45; Arai E, 2010, CLIN ORTHOP RELAT R, V468, P3028, DOI 10.1007/s11999-010-1392-7; Bharucha S, 2005, COLORECTAL DIS, V7, P169, DOI 10.1111/j.1463-1318.2004.00743.x; CADMAN NL, 1965, CANCER, V18, P613, DOI 10.1002/1097-0142(196505)18:5<613::AID-CNCR2820180510>3.0.CO;2-V; HEISE HW, 1986, CANCER, V57, P172, DOI 10.1002/1097-0142(19860101)57:1<172::AID-CNCR2820570133>3.0.CO;2-D; Jullumstro E, 2009, EUR J CANCER, V45, P2383, DOI 10.1016/j.ejca.2009.03.014; KAWAGUCHI N, 2004, CLIN ORTHOP RELA FEB, P165, DOI DOI 10.1097/01.BLO.0000116308.86761.F5; MAGUIRE A, 1994, EUR J CANCER, V30A, P785, DOI 10.1016/0959-8049(94)90293-3; Mulcahy HE, 1997, EUR J CANCER, V33, P1461, DOI 10.1016/S0959-8049(97)00089-0; Pitchers M, 2006, BRIT J CANCER, V94, P955, DOI 10.1038/sj.bjc.6603044; ROOSER B, 1988, CANCER, V61, P817, DOI 10.1002/1097-0142(19880215)61:4<817::AID-CNCR2820610429>3.0.CO;2-9; STOTTER AT, 1990, CANCER, V65, P1119, DOI 10.1002/1097-0142(19900301)65:5<1119::AID-CNCR2820650515>3.0.CO;2-P; Tsukushi S, 2012, J SURG ONCOL, V105, P668, DOI 10.1002/jso.23025; WEISS SW, 1977, CANCER, V39, P1672, DOI 10.1002/1097-0142(197704)39:4<1672::AID-CNCR2820390442>3.0.CO;2-C	26	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0277-3732	1537-453X		AM J CLIN ONCOL-CANC	Am. J. Clin. Oncol.-Cancer Clin. Trials	JUN	2015	38	3					266	271		10.1097/COC.0b013e318295aea2		6	Oncology	Oncology	CJ0DH	WOS:000355142900006		
J	Ito, T; Hamasaki, M; Matsumoto, S; Hiroshima, K; Tsujimura, T; Kawai, T; Shimao, Y; Marutsuka, K; Moriguchi, S; Maruyama, R; Miyamoto, S; Nabeshima, K				Ito, Tomohiro; Hamasaki, Makoto; Matsumoto, Shinji; Hiroshima, Kenzo; Tsujimura, Tohru; Kawai, Toshiaki; Shimao, Yoshiya; Marutsuka, Kousuke; Moriguchi, Sayaka; Maruyama, Riruke; Miyamoto, Shingo; Nabeshima, Kazuki			p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Diffuse malignant peritoneal mesothelioma; p16; 9p21; Fluorescence in situ hybridization; Reactive mesothelial hyperplasia; Epithelial ovarian cancer	IN-SITU HYBRIDIZATION; SEROUS PAPILLARY CARCINOMA; 9P21 HOMOZYGOUS DELETION; PLEURAL MESOTHELIOMA; EFFUSION CYTOLOGY; P16; DIAGNOSIS; IMMUNOHISTOCHEMISTRY; EXPRESSION; CDKN2A	Objectives: It can be difficult to differentiate diffuse malignant peritoneal mesothelioma (DMPM) from reactive mesothelial hyperplasia (RMH) or peritoneal dissemination of gynecologic malignancies, such as epithelial ovarian cancer (EOC), which cause a large amount of ascites. Detection of the homozygous deletion of p16/CDKN2A (p16) by fluorescence in situ hybridization (FISH) is an effective adjunct in the diagnosis of malignant pleural mesothelioma. The aim of this study was to investigate the ability of the p16 FISH assay to differentiate DMPM from RMH and EOC. Methods: p16 FISH was performed in 28 DMPMs (successful in 19), 30 RMHS, and 40 EOC cases. The cutoff values of p16 FISH were more than 10% for homozygous deletion and more than 40% for heterozygous deletion. Results: According to the above criteria, nine (47.4%) of 19 successful DMPM cases were homozygous deletion positive, and three (15.8%) of 19 were heterozygous deletion positive, whereas all RMH cases were negative for the p16 deletion. In all four major histologic subtypes of EOC, neither p16 homozygous nor heterozygous deletions were detected. To differentiate DMPM from RMH or EOC, the sensitivity of the p16 homozygous deletion was 32% (9/28), and the specificity was 100%. Conclusions: Our study suggests that p16 FISH analysis is useful in differentiating DMPM from RMH and EOC when homozygous deletion is detected.	[Ito, Tomohiro; Hamasaki, Makoto; Matsumoto, Shinji; Nabeshima, Kazuki] Fukuoka Univ, Sch Med & Hosp, Dept Pathol, Fukuoka 8140180, Japan; [Ito, Tomohiro; Miyamoto, Shingo] Fukuoka Univ, Sch Med & Hosp, Dept Obstet & Gynecol, Fukuoka 8140180, Japan; [Hiroshima, Kenzo] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Pathol, Yachiyo, Japan; [Tsujimura, Tohru] Hyogo Coll Med, Dept Pathol, Nishinomiya, Hyogo, Japan; [Kawai, Toshiaki] Natl Def Med Coll, Dept Pathol & Lab Med, Tokorozawa, Saitama 359, Japan; [Shimao, Yoshiya] Miyazaki Prefectural Miyazaki Hosp, Dept Pathol, Miyazaki, Japan; [Marutsuka, Kousuke; Moriguchi, Sayaka] Miyazaki Univ, Dept Pathol, Sch Med, Miyazaki, Japan; [Maruyama, Riruke] Shimane Univ, Sch Med, Lab Surg Pathol, Izumo, Shimane, Japan	Nabeshima, K (reprint author), Fukuoka Univ, Sch Med & Hosp, Dept Pathol, Jonan Ku, 7-45-1 Nanakuma, Fukuoka 8140180, Japan.	kaznabes@fukuoka-u.ac.jp			Izumo City Supporting Cancer Research Project; Research Center for Advanced Molecular Medicine, Fukuoka University	This work was supported in part by a grant from the Research Center for Advanced Molecular Medicine, Fukuoka University, and Izumo City Supporting Cancer Research Project.	Onofre FBDM, 2008, CANCER CYTOPATHOL, V114, P204, DOI 10.1002/cncr.23413; Lopez-Rios F, 2006, CANCER RES, V66, P2970, DOI 10.1158/0008-5472/CAN-05-3907; Comin CE, 2007, AM J SURG PATHOL, V31, P1139, DOI 10.1097/PAS.0b013e318033e7a8; Clement PB, 1996, AM J SURG PATHOL, V20, P1067, DOI 10.1097/00000478-199609000-00004; Takeda M, 2010, PATHOL INT, V60, P395, DOI 10.1111/j.1440-1827.2010.02534.x; Boffetta P, 2007, ANN ONCOL, V18, P985, DOI 10.1093/annonc/mdl345; Wu D, 2013, AM J CLIN PATHOL, V139, P39, DOI 10.1309/AJCPT94JVWIHBKRD; Dacic S, 2008, VIRCHOWS ARCH, V453, P627, DOI 10.1007/s00428-008-0689-3; Baratti D, 2011, J SURG ONCOL, V103, P822, DOI 10.1002/jso.21787; Chiosea S, 2008, MODERN PATHOL, V21, P742, DOI 10.1038/modpathol.2008.45; Savic S, 2010, CHEST, V138, P137, DOI 10.1378/chest.09-1951; Monaco SE, 2011, AM J CLIN PATHOL, V135, P619, DOI 10.1309/AJCPP5R2ZJZKCLWN; Khoury T, 2009, MODERN PATHOL, V22, P1457, DOI 10.1038/modpathol.2009.117; Attanoos RL, 2003, HISTOPATHOLOGY, V43, P231, DOI 10.1046/j.1365-2559.2003.01686.x; Sugarbaker PH, 2006, EJSO, V32, P686, DOI 10.1016/j.ejso.2006.03.012; Illei PB, 2003, CANCER CYTOPATHOL, V99, P51, DOI 10.1002/cncr.10923; Ordonez NG, 2013, HUM PATHOL, V44, P1, DOI 10.1016/j.humpath.2012.05.014; DeHaan RD, 2007, HUM PATHOL, V38, P491, DOI 10.1016/j.humpath.2006.09.004; Chung CTS, 2010, J CLIN PATHOL, V63, P630, DOI 10.1136/jcp.2010.076794; Matsumoto S, 2013, CANCER CYTOPATHOL, V121, P415, DOI 10.1002/cncy.21269; Hasteh F, 2010, CANCER CYTOPATHOL, V118, P90, DOI 10.1002/cncy.20071; Attanoos RL, 2002, HISTOPATHOLOGY, V40, P237, DOI 10.1046/j.1365-2559.2002.01352.x; Bosman FT, 2010, WHO CLASSIFICATION T; CHENG JQ, 1994, CANCER RES, V54, P5547; Fujita M, 1997, INT J CANCER, V74, P148, DOI 10.1002/(SICI)1097-0215(19970422)74:2<148::AID-IJC2>3.3.CO;2-9; HATTA Y, 1995, J UROLOGY, V154, P1954, DOI 10.1016/S0022-5347(01)66833-2; Hesdorffer ME, 2008, CURR TREAT OPTION ON, V9, P180, DOI 10.1007/s11864-008-0072-2; Husain AN, 2012, ARCH PATHOL LAB MED, V136, P1; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Krasinskas AM, 2010, MODERN PATHOL, V23, P531, DOI 10.1038/modpathol.2009.186; Luo YL, 2013, PATHOL ONCOL RES, V19, P35, DOI 10.1007/s12253-012-9555-3; Mani H, 2010, INT J GYNECOL PATHOL, V29, P523, DOI 10.1097/PGP.0b013e3181e6a3ee; Musti M, 2006, CANCER GENET CYTOGEN, V170, P9, DOI 10.1016/j.jcancergencyto.2006.04.011; Prins JB, 1998, INT J CANCER, V75, P649, DOI 10.1002/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.0.CO;2-2; Sangisetty Suma L, 2012, World J Gastrointest Surg, V4, P87, DOI 10.4240/wjgs.v4.i4.87; Tavassoli F.A., 2003, WHO CLASSIFICATION T; Xio S, 1995, Oncogene, V11, P511; Yan TD, 2011, CANCER-AM CANCER SOC, V117, P1855, DOI 10.1002/cncr.25640	38	1	1	AMER SOC CLINICAL PATHOLOGY	CHICAGO	2100 W HARRISON ST, CHICAGO, IL 60612 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUN	2015	143	6					830	838		10.1309/AJCPOATJ9L4GCGDA		9	Pathology	Pathology	CJ0HN	WOS:000355156500009		
J	Kurata, T; Kanbayashi, D; Nishimura, H; Komano, J; Kase, T; Takahashi, K				Kurata, Takako; Kanbayashi, Daiki; Nishimura, Hiroshi; Komano, Jun; Kase, Tetsuo; Takahashi, Kazuo			Increased reports of measles in a low endemic region during a rubella outbreak in adult populations	AMERICAN JOURNAL OF INFECTION CONTROL			English	Article						Measles; Rubella; Outbreak; Epidemiology	PHYSICIANS	In 2013, a rubella outbreak was observed in Japan, Romania, and Poland. The outbreak in Japan was accompanied by an increase of measles reports, especially from a region where measles is highly controlled. This was attributed to the adult populations affected by this rubella outbreak, similarity of clinical signs between rubella and measles, sufficiently small impact of measles outbreaks from neighboring nations, and elimination levels of measles endemicity. Current and future concerns for measles control are discussed. Copyright (C) 2015 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.	[Kurata, Takako; Kanbayashi, Daiki; Nishimura, Hiroshi; Komano, Jun; Kase, Tetsuo; Takahashi, Kazuo] Osaka Prefectural Inst Publ Hlth, Dept Infect Dis, Osaka 537, Japan; [Komano, Jun] Natl Hosp Org, Nagoya Med Ctr, Dept Clin Lab, Nagoya, Aichi 4600001, Japan	Komano, J (reprint author), Natl Hosp Org, Nagoya Med Ctr, Naka Ku, 4-1-1 Sannomaru, Nagoya, Aichi 4600001, Japan.	komano@nnh.hosp.go.jp			Japanese Ministry of Health and Welfare [H25-Shinko-Ippan-010];  [26861351]	This work was partly supported by a grant-in-aid from the Japanese Ministry of Health and Welfare (H25-Shinko-Ippan-010) and a grant-in-aid for Young Scientists (B) (no. 26861351).	Cosgrove SE, 2005, ARCH INTERN MED, V165, P2002, DOI 10.1001/archinte.165.17.2002; Muscat M, 2014, CLIN MICROBIOL INFEC, V20, P12, DOI 10.1111/1469-0691.12584; Centers for Disease Control and Prevention (CDC), 2013, MMWR-MORBID MORTAL W, V62, P983; Tanaka-Taya K, 2013, MMWR-MORBID MORTAL W, V62, P457; Griffin D, 2007, FIELDS VIROLOGY, V5th, P1552; Janta D, 2011, EUROSURVEILLANCE, V17; Kurata T, 2014, AM J MED, V127, pE3, DOI 10.1016/j.amjmed.2013.10.015; National Institute of Infectious Disease, 2007, INFECT AGENTS SURVEI, V28, P239; National Institute of Infectious Diseases, 2014, INFECT AGENTS SURVEI, V35, P93; National Institute of Infectious Diseases, 2013, INFECT AGENTS SURVEI, V34, P21; Paradowska-Stankiewicz I, 2013, EURO SURVEILL, V18; Peter M, 2013, VACCINES, V6th, P352; Rota JS, 2011, J INFECT DIS, V204, pS559, DOI 10.1093/infdis/jir098; Woods R, 2004, BIOSECUR BIOTERROR, V2, P157, DOI 10.1089/bsp.2004.2.157; World Health Organization Western Pacific regional Office ( WHO), 2004, FIELD GUID MEASL EL; World Health Organization Western Pacific regional Office (WHO), 2013, RUB CONG RUB SYNDR C	16	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-6553	1527-3296		AM J INFECT CONTROL	Am. J. Infect. Control	JUN	2015	43	6					653	655		10.1016/j.ajic.2015.02.022		3	Public, Environmental & Occupational Health; Infectious Diseases	Public, Environmental & Occupational Health; Infectious Diseases	CJ1RI	WOS:000355261500022		
J	Amiot, C; Iyama, O; Reiten, I				Amiot, Claire; Iyama, Osamu; Reiten, Idun			STABLE CATEGORIES OF COHEN-MACAULAY MODULES AND CLUSTER CATEGORIES	AMERICAN JOURNAL OF MATHEMATICS			English	Article							CALABI-YAU ALGEBRAS; TRIANGULATED CATEGORIES; PREPROJECTIVE ALGEBRAS; CONSISTENCY CONDITIONS; SINGULARITIES; QUIVERS; REPRESENTATIONS; EQUIVALENCE; GORENSTEIN; DIMENSION	By Auslander's algebraic McKay correspondence, the stable category of Cohen-Macaulay modules over a simple singularity is triangle equivalent to the l-cluster category of the path algebra of a Dynkin quiver (i.e., the orbit category of the derived category by the action of the Auslander-Reiten translation). In this paper we give a systematic method to construct a similar, type of triangle equivalence between the stable category of Cohen-Macaulay modules over a Gorenstein isolated singularity R and the generalized (higher) cluster category of a finite dimensional algebra Lambda. The key role is played by a bimodule Calabi-Yau algebra, which is the higher Auslander algebra of R as well as the higher preprojective algebra of an extension of Lambda. As a byproduct, we give a triangle equivalence between the stable category of graded Cohen-Macaulay R-modules and the derived category of Lambda. Our main results apply in particular to a class of cyclic quotient singularities and to certain toric affine threefolds associated with dimer models.	[Amiot, Claire] Univ Grenoble 1, Inst Fourier, F-38402 St Martin Dheres, France; [Iyama, Osamu] Nagoya Univ, Grad Sch Math, Nagoya, Aichi 4648601, Japan; [Reiten, Idun] Norges Teknisk Nat Vitenskapelige Univ, Insitutt Matemat Fag, N-7491 Trondheim, Norway	Amiot, C (reprint author), Univ Grenoble 1, Inst Fourier, 100 Rue Maths, F-38402 St Martin Dheres, France.	claire.amiot@ujf-grenoble.fr; iyama@math.nagoya-u.ac.jp; idunr@math.ntnu.no			Norwegian Research Council [196600/V30]; ANR [ANR-09-BLAN-0039-02]; JSPS [21740010, 21340003, 20244001, 22224001]	Research of all authors supported by the project 196600/V30 from the Norwegian Research Council; research of the first author supported in part by the ANR project ANR-09-BLAN-0039-02; research of the second author supported by JSPS Grant-in-Aid for Scientific Research 21740010, 21340003, 20244001, and 22224001.	Amiot C, 2012, P LOND MATH SOC, V104, P513, DOI 10.1112/plms/pdr020; Amiot C, 2011, ADV MATH, V226, P3813, DOI 10.1016/j.aim.2010.10.028; Amiot C., 2008, THESIS U PARIS DIDER; Amiot C, 2014, DOC MATH, V19, P1155; Amiot C, 2007, B SOC MATH FR, V135, P435; Fomin S, 2002, J AM MATH SOC, V15, P497, DOI 10.1090/S0894-0347-01-00385-X; HERZOG J, 1978, MATH ANN, V233, P21, DOI 10.1007/BF01351494; Craw A, 2007, J ALGEBRA, V316, P514, DOI 10.1016/j.jalgebra.2007.02.014; Iyama O, 2007, ADV MATH, V210, P22, DOI 10.1016/j.aim.2006.06.002; IWANAGA Y, 1979, COMMUN ALGEBRA, V7, P393, DOI 10.1080/00927877908822356; Kajiura H, 2007, ADV MATH, V211, P327, DOI 10.1016/j.aim.2006.08.005; Bocklandt R, 2008, J PURE APPL ALGEBRA, V212, P14, DOI 10.1016/j.jpaa.2007.03.009; Buan AB, 2009, COMPOS MATH, V145, P1035, DOI 10.1112/S0010437X09003960; Keller B, 2005, DOC MATH, V10, P551; Derksen H, 2008, SEL MATH-NEW SER, V14, P59, DOI 10.1007/s00029-008-0057-9; Burban I, 2008, ADV MATH, V217, P2443, DOI 10.1016/j.aim.2007.10.007; Iyama O, 2013, MATH ANN, V356, P1065, DOI 10.1007/s00208-012-0842-9; Buan AB, 2006, ADV MATH, V204, P572, DOI 10.1016/j.aim.2005.06.003; Iyama O, 2008, AM J MATH, V130, P1087; Herschend M, 2011, COMPOS MATH, V147, P1885, DOI 10.1112/S0010437X11005367; Iyama O, 2011, ADV MATH, V226, P1, DOI 10.1016/j.aim.2010.03.004; Keller B, 2008, COMPOS MATH, V144, P1332, DOI 10.1112/S0010437X08003540; Geiss C, 2006, INVENT MATH, V165, P589, DOI 10.1007/s00222-006-0507-y; Keller B, 2011, J REINE ANGEW MATH, V654, P125, DOI 10.1515/CRELLE.2011.031; Iyama O, 2007, ADV MATH, V210, P51, DOI 10.1016/j.aim.2006.06.003; Bocklandt R, 2010, J PURE APPL ALGEBRA, V214, P1501, DOI 10.1016/j.jpaa.2009.07.013; Amiot C, 2009, ANN I FOURIER, V59, P2525; RICKARD J, 1989, J PURE APPL ALGEBRA, V61, P303, DOI 10.1016/0022-4049(89)90081-9; Keller B, 2007, ADV MATH, V211, P123, DOI 10.1016/j.aim.2006.07.013; Iyama O, 2013, ADV MATH, V244, P23, DOI 10.1016/j.aim.2013.03.013; Davison B, 2011, J ALGEBRA, V338, P1, DOI 10.1016/j.jalgebra.2011.05.005; Iyama O, 2008, INVENT MATH, V172, P117, DOI 10.1007/s00222-007-0096-4; Bocklandt R, 2012, GLASGOW MATH J, V54, P429, DOI 10.1017/S0017089512000080; Keller B, 2011, COMPOS MATH, V147, P591, DOI 10.1112/S0010437X10004902; Herschend M, 2014, ADV MATH, V252, P292, DOI 10.1016/j.aim.2013.09.023; Orlov D, 2009, PROG MATH, V270, P503, DOI 10.1007/978-0-8176-4747-6_16; AUSLANDER M, 1986, T AM MATH SOC, V293, P293, DOI 10.2307/2000282; Auslander M., 1978, LECTURE NOTES PURE A, V37, P1; Broomhead N., 2012, MEM AM MATH SOC, V215; Buchweitz R.-O., MAXIMAL COHEN UNPUB; de Thanhoffer de Volcsey L., MATH RES LE IN PRESS; GeiB C., 2007, PREPRINT; Ginzburg V., 2007, PREPRINT; Gulotta D, 2008, J HIGH ENERGY PHYS, V10, P31; Guo LY, 2011, J PURE APPL ALGEBRA, V215, P2055, DOI 10.1016/j.jpaa.2010.11.015; Happel D., 1988, LONDON MATH SOC LECT, V119; Ishii A., 2013, PREPRINT; Iyama O., 2010, STABLE CATEGORIES CO, P1338; KELLER B, 1987, CR ACAD SCI I-MATH, V305, P225; Keller B., 2008, EMS SER C REP, P467; Lenzing H, 2011, MATH Z, V268, P143, DOI 10.1007/s00209-010-0663-z; MCKAY J, 1980, P SYMP PURE MATH, V37, P183; Minamoto H, 2011, ADV MATH, V226, P4061, DOI 10.1016/j.aim.2010.11.004; Reiten I., 1989, MEM AM MATH SOC, V80; REITEN I, 1987, LECT NOTES MATH, V1273, P35; Ueda K, 2008, P AM MATH SOC, V136, P2745, DOI 10.1090/S0002-9939-08-09470-7; Yoshino Y., 1990, LONDON MATH SOC LECT, V146	57	1	1	JOHNS HOPKINS UNIV PRESS	BALTIMORE	JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA	0002-9327	1080-6377		AM J MATH	Am. J. Math.	JUN	2015	137	3					813	857				45	Mathematics	Mathematics	CJ0HF	WOS:000355155700007		
J	Kline, AD; Calof, AL; Lander, AD; Gerton, JL; Krantz, ID; Dorsett, D; Deardorff, MA; Blagowidow, N; Yokomori, K; Shirahige, K; Santos, R; Woodman, J; Megee, PC; O'Connor, JT; Egense, A; Noon, S; Belote, M; Goodban, MT; Hansen, BD; Timmons, JG; Musio, A; Ishman, SL; Bryan, Y; Wu, YN; Bettini, LR; Mehta, D; Zakari, M; Mills, JA; Srivastava, S; Haaland, RE				Kline, Antonie D.; Calof, Anne L.; Lander, Arthur D.; Gerton, Jennifer L.; Krantz, Ian D.; Dorsett, Dale; Deardorff, Matthew A.; Blagowidow, Natalie; Yokomori, Kyoko; Shirahige, Katsuhiko; Santos, Rosaysela; Woodman, Julie; Megee, Paul C.; O'Connor, Julia T.; Egense, Alena; Noon, Sarah; Belote, Maurice; Goodban, Marjorie T.; Hansen, Blake D.; Timmons, Jenni Glad; Musio, Antonio; Ishman, Stacey L.; Bryan, Yvon; Wu, Yaning; Bettini, Laura R.; Mehta, Devanshi; Zakari, Musinu; Mills, Jason A.; Srivastava, Siddharth; Haaland, Richard E.			Clinical, developmental and molecular update on Cornelia de Lange syndrome and the cohesin complex: Abstracts from the 2014 Scientific and Educational Symposium	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						de Lange syndrome; CdLS; cohesin complex; cohesinopathy; intellectual disability; mice; zebrafish; drosophila		Cornelia de Lange Syndrome (CdLS) is the most common example of disorders of the cohesin complex, or cohesinopathies. There are a myriad of clinical issues facing individuals with CdLS, particularly in the neurodevelopmental system, which also have implications for the parents and caretakers, involved professionals, therapists, and schools. Basic research in developmental and cell biology on cohesin is showing significant progress, with improved understanding of the mechanisms and the possibility of potential therapeutics. The following abstracts are presentations from the 6th Cornelia de Lange Syndrome Scientific and Educational Symposium, which took place on June 25-26, 2014, in conjunction with the Cornelia de Lange Syndrome Foundation National Meeting in Costa Mesa, CA. The Research Committee of the CdLS Foundation organizes the meeting, reviews and accepts abstracts, and subsequently disseminates the information to the families through members of the Clinical Advisory Board. In addition to the scientific and clinical discussions, there were educationally focused talks related to practical aspects of behavior and development. AMA CME credits were provided by Greater Baltimore Medical Center, Baltimore, MD. (c) 2015 Wiley Periodicals, Inc.	[Kline, Antonie D.; Blagowidow, Natalie] Greater Baltimore Med Ctr, Harvey Inst Human Genet, Baltimore, MD 21204 USA; [Calof, Anne L.] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA; [Calof, Anne L.; Lander, Arthur D.; Santos, Rosaysela] Univ Calif Irvine, Ctr Complex Biol Syst, Irvine, CA USA; [Calof, Anne L.; Lander, Arthur D.; Santos, Rosaysela] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92717 USA; [Gerton, Jennifer L.; Zakari, Musinu] Univ Kansas, Sch Med, Stowers Inst Med Res, Kansas City, MO USA; [Gerton, Jennifer L.] Univ Kansas, Sch Med, Dept Biochem & Mol Biol, Kansas City, MO USA; [Krantz, Ian D.; Deardorff, Matthew A.; Noon, Sarah; Wu, Yaning; Mehta, Devanshi; Mills, Jason A.] Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA 19104 USA; [Krantz, Ian D.; Deardorff, Matthew A.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Dorsett, Dale] St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; [Yokomori, Kyoko] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA; [Shirahige, Katsuhiko] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo, Japan; [Shirahige, Katsuhiko] Japanese Sci & Technol Agcy, CREST, Tokyo, Japan; [Woodman, Julie; Megee, Paul C.] Univ Colorado, Sch Med, Dept Biochem & Mol Genet, Denver, CO USA; [O'Connor, Julia T.] Kennedy Krieger Inst, Dept Psychiat & Behav Sci, Baltimore, MD USA; [O'Connor, Julia T.; Srivastava, Siddharth] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Egense, Alena] Univ Maryland, Med Ctr, Dept Pediat, Div Human Genet, Baltimore, MD 21201 USA; [Belote, Maurice] San Francisco State Univ, Calif Deaf Blind Serv, San Francisco, CA 94132 USA; [Goodban, Marjorie T.] Elmhurst Coll, Speech Language Pathol, Elmhurst, IL USA; [Hansen, Blake D.] Brigham Young Univ, Dept Counseling Psychol & Special Educ, Provo, UT 84602 USA; [Timmons, Jenni Glad] Univ Minnesota, Minneapolis, MN USA; [Musio, Antonio] CNR, Ist Ric Genet & Biomed, I-56100 Pisa, Italy; [Ishman, Stacey L.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Otolaryngol, Cincinnati, OH USA; [Ishman, Stacey L.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pulm Med, Cincinnati, OH USA; [Bryan, Yvon] Wake Forest Baptist Med Ctr, Dept Anesthesiol, Winston Salem, NC USA; [Bettini, Laura R.] San Gerardo Hosp, Fdn MBBM, Dept Pediat, Monza, Italy; [Haaland, Richard E.] Cornelia Lange Syndrome Fdn, Avon, CT USA	Kline, AD (reprint author), Greater Baltimore Med Ctr, Harvey Inst Human Genet, 6701 N Charles St,Suite 2326, Baltimore, MD 21204 USA.	akline@gbmc.org						0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	JUN	2015	167	6					1179	1192		10.1002/ajmg.a.37056		14	Genetics & Heredity	Genetics & Heredity	CJ1WV	WOS:000355276700003		
J	Izumi, K; Kellogg, E; Fujiki, K; Kaur, M; Tilton, RK; Noon, S; Wilkens, A; Shirahige, K; Krantz, ID				Izumi, Kosuke; Kellogg, Emily; Fujiki, Katsunori; Kaur, Maninder; Tilton, Richard K.; Noon, Sarah; Wilkens, Alisha; Shirahige, Katsuhiko; Krantz, Ian D.			Elevation of insulin-like growth factor binding protein-2 level in Pallister-Killian syndrome: Implications for the postnatal growth retardation phenotype	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						isochromosome 12p; mosaicism; growth retardation	TRANSGENIC MICE; IGF SYSTEM; GENE; OVEREXPRESSION; MUTATION	Pallister-Killian syndrome (PKS) is a multi-system developmental disorder caused by tetrasomy 12p that exhibits tissue-limited mosaicism. Probands with PKS often demonstrate a unique growth profile consisting of macrosomia at birth with deceleration of growth postnatally. We have previously demonstrated that cultured skin fibroblasts from PKS probands have significantly elevated expression of insulin-like growth factor binding protein-2 (IGFBP2). To further evaluate the role of IGFBP2 in PKS, the amount of IGFBP2 secreted from cultured skin fibroblast cell lines and serum IGFBP2 levels were measured in probands with PKS. Approximately 60% of PKS fibroblast cell lines secreted higher levels of IGFBP2 compared to control fibroblasts, although the remaining 40% of PKS samples produced comparable level of IGFBP2 to that of control fibroblasts. Serum IGFBP2 levels were also measured in PKS probands and were elevated in 40% of PKS probands. PKS probands with elevated IGFBP2 manifested with severe postnatal growth retardation. IGFBPs are the family of related proteins that bind IGFs with high affinity and are typically thought to attenuate IGF action. We suggest that elevated IGFBP2 levels might play a role in the growth retardation phenotype of PKS. (c) 2015 Wiley Periodicals, Inc.	[Izumi, Kosuke; Kellogg, Emily; Kaur, Maninder; Tilton, Richard K.; Noon, Sarah; Wilkens, Alisha; Krantz, Ian D.] Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA 19104 USA; [Izumi, Kosuke; Fujiki, Katsunori; Shirahige, Katsuhiko] Univ Tokyo, Inst Mol & Cellular Biosci, Res Ctr Epigenet Dis, Tokyo 1130032, Japan; [Tilton, Richard K.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA; [Krantz, Ian D.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	Izumi, K (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Res Ctr Epigenet Dis, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	kosukeizumi@iam.u-tokyo.ac.jp			PKS Kids family support group; Children's Hospital of Philadelphia institutional development funds; Japan Society for the Promotion of Science	Grant sponsor: PKS Kids family support group; Grant sponsor: The Children's Hospital of Philadelphia institutional development funds; Grant sponsor: Japan Society for the Promotion of Science Grant-in-Aid for Young Scientists (B).	Wheatcroft SB, 2009, TRENDS ENDOCRIN MET, V20, P153, DOI 10.1016/j.tem.2009.01.002; Wheatcroft SB, 2007, DIABETES, V56, P285, DOI 10.2337/db06-0436; Hedbacker K, 2010, CELL METAB, V11, P11, DOI 10.1016/j.cmet.2009.11.007; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; Hoeflich A, 2001, ENDOCRINOLOGY, V142, P1889, DOI 10.1210/en.142.5.1889; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; de Boer L, 2004, EUR J ENDOCRINOL, V151, P333, DOI 10.1530/eje.0.1510333; Eckstein F, 2002, ANAT EMBRYOL, V206, P139, DOI 10.1007/s00429-002-0282-5; Ester WA, 2009, J CLIN ENDOCR METAB, V94, P4717, DOI 10.1210/jc.2008-1502; Fottner C, 2008, EUR J ENDOCRINOL, V159, P317, DOI 10.1530/EJE-08-0033; Huber C, 2010, HUM MUTAT, V31, P20, DOI 10.1002/humu.21150; Izumi K, 2014, CHROMOSOME RES, V22, P453; Kaur M, 2014, PLOS ONE, V9; Maffei P, 2007, CLIN ENDOCRINOL, V66, P269, DOI 10.1111/j.1365-2265.2007.02721.x; OCRANT I, 1990, ENDOCRINOLOGY, V127, P1260; PELTOMAKI P, 1987, CLIN GENET, V31, P399; Sato H, 2006, AM J PATHOL, V169, P1550, DOI 10.2353/ajpath.2006.051068; van Duyvenvoorde HA, 2010, J CLIN ENDOCR METAB, V95, pE363, DOI 10.1210/jc.2010-0511; Walenkamp MJE, 2005, J CLIN ENDOCR METAB, V90, P2855, DOI 10.1210/jc.2004-1254; Wilkens A, 2012, AM J MED GENET A, V158A, P3002, DOI 10.1002/ajmg.a.35722; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805	21	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	JUN	2015	167	6					1268	1274		10.1002/ajmg.a.36976		7	Genetics & Heredity	Genetics & Heredity	CJ1WV	WOS:000355276700013		
J	Izumi, K; Kubota, N; Arakawa, M; Takayama, M; Harada, Y; Nakamura, T; Nishi, E; Hidaka, E				Izumi, Kosuke; Kubota, Noriko; Arakawa, Michiko; Takayama, Masayoshi; Harada, Yukiko; Nakamura, Tomohiko; Nishi, Eriko; Hidaka, Eiko			Dissecting the phenotype of supernumerary marker chromosome 20 in a patient with syndromic pierre robin sequence: Combinatorial effect of gene dosage and uniparental disomy	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						trisomy rescue; SNP array; growth retardation	ALAGILLE-SYNDROME; HUMAN JAGGED1; MOSAICISM; MUTATIONS; RESCUE; CHILD; AXONS	Clinical phenotypes in individuals with a supernumerary marker chromosome (SMC) are mainly caused by gene dosage effects due to the genes located on the SMC. An additional effect may result from uniparental disomy (UPD). Consequently, the occurrence of UPD may be a confounding factor in identifying genotype-phenotype correlations in SMC syndromes. Here, we report on a patient that illustrates this problem; the phenotype of this patient was a consequence of a combined effect of gene dosage and UPD. The proband showed facial dysmorphisms, growth retardation and developmental delay. G-band karyotype of the proband's peripheral blood showed the presence of mosaic SMC. A SNP array analysis documented maternal UPD20 and 20p duplication. It is known that maternal UPD20 causes prenatal onset growth retardation and feeding difficulties. By contrast, duplication of 20p causes facial dysmorphisms, micrognathia, cleft palate, developmental delay and vertebral anomalies. Our classification of the proband's phenotype showed a mixture of these two effects. Therefore, we suggest the routine use of genome-wide SNP array towards the detailed genotype-phenotype correlations for SMC syndromes. (c) 2015 Wiley Periodicals, Inc.	[Izumi, Kosuke; Arakawa, Michiko; Nishi, Eriko] Nagano Childrens Hosp, Div Med Genet, Azumino, Japan; [Izumi, Kosuke] Univ Tokyo, Inst Mol & Cellular Biosci, Res Ctr Epigenet Dis, Tokyo 1130032, Japan; [Kubota, Noriko; Hidaka, Eiko] Nagano Childrens Hosp, Dept Lab Med, Azumino, Japan; [Kubota, Noriko; Nakamura, Tomohiko; Nishi, Eriko; Hidaka, Eiko] Nagano Childrens Hosp, Life Sci Res Ctr, Azumino, Japan; [Takayama, Masayoshi] Nagano Red Cross Hosp, Dept Pediat, Nagano, Japan; [Harada, Yukiko] Inariyama Med Walfare Ctr, Dept Pediat, Chikuma, Japan; [Nakamura, Tomohiko] Nagano Childrens Hosp, Div Neonatol, Azumino, Japan; [Nishi, Eriko] Shinshu Univ, Grad Sch Med, Dept Med Genet, Matsumoto, Nagano 390, Japan	Izumi, K (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Res Ctr Epigenet Dis, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	kosukeizumi@iam.u-tokyo.ac.jp			Ministry of Health, Labour, and Welfare of Japan	Grant sponsor: The Ministry of Health, Labour, and Welfare of Japan.	Liehr T, 2006, CYTOGENET GENOME RES, V112, P23, DOI 10.1159/000087510; Matsui A, 2013, SCIENCE, V342, P1114, DOI 10.1126/science.1244505; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Leyva-Diaz E, 2014, CURR BIOL, V24, P494, DOI 10.1016/j.cub.2014.01.042; Robinson WP, 2005, PRENATAL DIAG, V25, P239, DOI 10.1002/pd.1121; Liehr T, 2011, J HISTOCHEM CYTOCHEM, V59, P842, DOI 10.1369/0022155411412780; Bartels I, 2003, CYTOGENET GENOME RES, V101, P103, DOI 10.1159/000074163; Bartolini L, 2013, GENE, V524, P368, DOI 10.1016/j.gene.2013.04.033; Batanian JR, 2014, AM J MED GENET A, V164, P535, DOI 10.1002/ajmg.a.36305; Bhoj EJ, 2013, 63 ANN M AM SOC HUM; Chudoba I, 1999, EUR J HUM GENET, V7, P533, DOI 10.1038/sj.ejhg.5200287; HUME RF, 1995, AM J OBSTET GYNECOL, V173, P1334, DOI 10.1016/0002-9378(95)91382-3; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Moog U, 1996, CLIN DYSMORPHOL, V5, P279; Srebniak M, 2008, PRENATAL DIAG, V28, P967, DOI 10.1002/pd.2077; Wallerstein R, 2000, PRENATAL DIAG, V20, P103, DOI 10.1002/(SICI)1097-0223(200002)20:2<103::AID-PD761>3.3.CO;2-B	16	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	JUN	2015	167	6					1289	1293		10.1002/ajmg.a.36921		5	Genetics & Heredity	Genetics & Heredity	CJ1WV	WOS:000355276700016		
J	Kuroda, Y; Ohashi, I; Naruto, T; Ida, K; Enomoto, Y; Saito, T; Nagai, J; Wada, T; Kurosawa, K				Kuroda, Yukiko; Ohashi, Ikuko; Naruto, Takuya; Ida, Kazumi; Enomoto, Yumi; Saito, Toshiyuki; Nagai, Jun-ichi; Wada, Takahito; Kurosawa, Kenji			Delineation of the KIAA2022 mutation phenotype: Two patients with X-linked intellectual disability and distinctive features	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						KIAA2022; X-linked intellectual disability; targeted sequencing; next-generation sequencing	MENTAL-RETARDATION; NEURITE OUTGROWTH; EXPRESSION; DISORDERS; GENES; BRAIN; EXOME	Next-generation sequencing has enabled the screening for a causative mutation in X-linked intellectual disability (XLID). We identified KIAA2022 mutations in two unrelated male patients by targeted sequencing. We selected 13 Japanese male patients with severe intellectual disability (ID), including four sibling patients and nine sporadic patients. Two of thirteen had a KIAA2022 mutation. Patient 1 was a 3-year-old boy. He had severe ID with autistic behavior and hypotonia. Patient 2 was a 5-year-old boy. He also had severe ID with autistic behavior, hypotonia, central hypothyroidism, and steroid-dependent nephrotic syndrome. Both patients revealed consistent distinctive features, including upswept hair, narrow forehead, downslanting eyebrows, wide palpebral fissures, long nose, hypoplastic alae nasi, open mouth, and large ears. De novo KIAA2022 mutations (p.Q705X in Patient 1, p.R322X in Patient 2) were detected by targeted sequencing and confirmed by Sanger sequencing. KIAA2022 mutations and alterations have been reported in only four families with nonsyndromic ID and epilepsy. KIAA2022 is highly expressed in the fetal and adult brain and plays a crucial role in neuronal development. These additional patients support the evidence that KIAA2022 is a causative gene for XLID. (c) 2015 Wiley Periodicals, Inc.	[Kuroda, Yukiko; Ohashi, Ikuko; Naruto, Takuya; Ida, Kazumi; Enomoto, Yumi; Kurosawa, Kenji] Kanagawa Childrens Med Ctr, Div Med Genet, Yokohama, Kanagawa 2328555, Japan; [Saito, Toshiyuki; Nagai, Jun-ichi] Kanagawa Childrens Med Ctr, Dept Clin Lab, Yokohama, Kanagawa 2328555, Japan; [Wada, Takahito] Kanagawa Childrens Med Ctr, Div Pediat Neurol, Yokohama, Kanagawa 2328555, Japan	Kuroda, Y (reprint author), Univ Tokyo, Dept Pediat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	ykodama-hok@umin.ac.jp; kkurosawa@kcmc.jp			Ministry of Health, Labour and Welfare of Japan; Intramural Research Grant [24-8]; CREST, Japan Science and Technology Agency	Grant sponsor: The Ministry of Health, Labour and Welfare of Japan; Grant sponsor: The Intramural Research Grant; Grant number: (24-8); Grant sponsor: CREST, Japan Science and Technology Agency (KK).	de Ligt J, 2012, NEW ENGL J MED, V367, P1921, DOI 10.1056/NEJMoa1206524; Tarpey PS, 2009, NAT GENET, V41, P535, DOI 10.1038/ng.367; Najmabadi H, 2011, NATURE, V478, P57, DOI 10.1038/nature10423; Van Maldergem L, 2013, HUM MOL GENET, V22, P3306, DOI 10.1093/hmg/ddt187; Lubs HA, 2012, AM J HUM GENET, V90, P579, DOI 10.1016/j.ajhg.2012.02.018; Kanasaki K, 2008, DEV BIOL, V313, P584, DOI 10.1016/j.ydbio.2007.10.047; Magome T, 2013, NEUROCHEM INT, V63, P561, DOI 10.1016/j.neuint.2013.09.011; Vissers LELM, 2010, NAT GENET, V42, P1109, DOI 10.1038/ng.712; Cantagrel V, 2004, J MED GENET, V41, P736, DOI 10.1136/jmg.2004.021626; Ishikawa T, 2012, NEUROSCIENCE, V214, P181, DOI 10.1016/j.neuroscience.2012.04.030; Kuhara T, 1997, J AM SOC NEPHROL, V8, P1679; Ljungberg P, 1996, VIRCHOWS ARCH, V428, P333; Nava C, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.102	13	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	JUN	2015	167	6					1349	1353		10.1002/ajmg.a.37002		5	Genetics & Heredity	Genetics & Heredity	CJ1WV	WOS:000355276700026		
J	Wakamatsu, N				Wakamatsu, Nobuaki			The spectrum of ZEB2 mutations causing the Mowat-Wilson syndrome in Japanese populations (vol 164, pg 1899, 2014)	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Correction									Aichi Human Serv Ctr, Inst Dev Res, Dept Genet, Kasugai, Aichi 4800392, Japan	Wakamatsu, N (reprint author), Aichi Human Serv Ctr, Inst Dev Res, Dept Genet, 713-8 Kamiya Cho, Kasugai, Aichi 4800392, Japan.	nwaka@inst-hsc.jp					WAKAMATSU N, 2014, AM J MED GENET, V164, P1899, DOI DOI 10.1002/AJMG.A.36551; Yamada Y, 2014, AM J MED GENET A, V164, P1899, DOI 10.1002/ajmg.a.36551	2	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	JUN	2015	167	6					1428	1428		10.1002/ajmg.a.36911		1	Genetics & Heredity	Genetics & Heredity	CJ1WV	WOS:000355276700046		
J	Sonoda, S; Sakamoto, T; Yamashita, T; Uchino, E; Kawano, H; Yoshihara, N; Terasaki, H; Shirasawa, M; Tomita, M; Ishibashi, T				Sonoda, Shozo; Sakamoto, Taiji; Yamashita, Takehiro; Uchino, Eisuke; Kawano, Hiroki; Yoshihara, Naoya; Terasaki, Hiroto; Shirasawa, Makoto; Tomita, Masatoshi; Ishibashi, Tatsuro			Luminal and Stromal Areas of Choroid Determined by Binarization Method of Optical Coherence Tomographic Images	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							CENTRAL SEROUS CHORIORETINOPATHY; BLOOD-FLOW REGULATION; MACULAR DEGENERATION; AXIAL LENGTH; NORMAL EYES; THICKNESS; AGE; SEX; VASCULOPATHY; RANIBIZUMAB	PURPOSE: To determine the proportion of luminal and stromal areas of normal choroids in the optical coherence tomographic (OCT) images obtained by enhanced depth imaging (EDI)-OCT. DESIGN: A prospective, masked, observational cross-sectional study. METHODS: SETTING: This study was performed at the Kagoshima University Hospital, Japan. STUDY POPULATION: One hundred and eighty right eyes of 180 healthy volunteers (106 women; mean age of 55.9 years) without ocular pathology. OBSERVATIONAL PROCEDURES: The EDI-OCT images of the posterior choroid 7500 pun from the optic disc in the horizontal plane were converted to binary images. The total cross-sectional choroidal area, luminal area, and stromal area of the choroid were measured. MAIN OUTCOME MEASURES: Correlations between clinical factors and each choroidal structure and ratio of luminal/stromal areas were determined. The correlations of each choroidal structure and the age, sex, axial length (AL), and refractive errors were calculated. RESULTS: The mean total cross-sectional choroidal area was 1.84 mm(2) (luminal area 1.21 mm(2) and stromal area 0.63 mm(2)). Multivariate analysis (standardized partial regression coefficient) showed that age (-0.723, P <.001) was significantly correlated with the reduced area of the choroid, and the correlation was greater than that for the AL (-0.408, P <.001). The ratio of luminal/ stromal area was significantly reduced in eyes with longer ALs (-0.531, P <.001), and the strength of the correlation was greater than that of age (-0.389, P <.001). CONCLUSIONS: Although both the luminal and the stromal areas decrease with increasing age and with longer ALs, the degree of decrease and areas affected were not the same. (C) 2015 by Elsevier Inc. All rights reserved.)	[Sonoda, Shozo; Sakamoto, Taiji; Yamashita, Takehiro; Uchino, Eisuke; Kawano, Hiroki; Yoshihara, Naoya; Terasaki, Hiroto; Shirasawa, Makoto; Tomita, Masatoshi] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima 890, Japan; [Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med, Dept Ophthalmol, Fukuoka 812, Japan	Sakamoto, T (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima 890, Japan.	tsakamot@m3.kufm.kagoshima-u.ac.jp			Research Committee on Chorioretinal Degeneration and Optic Atrophy, Ministry of Health, Labor, and Welfare, Tokyo, Japan; Ministry of Education, Science, and Culture of the Japanese Government, Tokyo, Japan	Funding/support: The funding organizations had no role in the design or conduct of this research. This study was done under a grant from the Research Committee on Chorioretinal Degeneration and Optic Atrophy, Ministry of Health, Labor, and Welfare, Tokyo, Japan; and a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of the Japanese Government, Tokyo, Japan. All authors attest that they meet the current ICMJE requirements to qualify as authors.	Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048; VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278; RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857; Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032; Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066; Kim M, 2014, OPTOMETRY VISION SCI, V91, P491, DOI 10.1097/OPX.0000000000000229; Lutty GA, 1997, AM J PATHOL, V151, P707; Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754; Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108; Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065; Toda N, 2012, PHARMACOL THERAPEUT, V133, P159, DOI 10.1016/j.pharmthera.2011.10.004; Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008; Ruiz-Medrano J, 2014, INVEST OPHTH VIS SCI, V55, P3532, DOI 10.1167/iovs.14-13868; Vitale S, 2009, ARCH OPHTHALMOL-CHIC, V127, P1632, DOI 10.1001/archophthalmol.2009.303; Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447; Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729; Sawada A, 2008, OPHTHALMOLOGY, V115, P363, DOI 10.1016/j.ophtha.2007.03.075; Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383; Stenmark KR, 2013, ANNU REV PHYSIOL, V75, P23, DOI 10.1146/annurev-physiol-030212-183802; Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018; Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83; Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022; Yamashita T, 2012, INVEST OPHTH VIS SCI, V53, P1102, DOI 10.1167/iovs.11-8836; Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001; Centofanti M, 2000, BRIT J OPHTHALMOL, V84, P786, DOI 10.1136/bjo.84.7.786; Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004; Bloom RI, 2010, CURR OPIN OPHTHALMOL, V21, P247, DOI 10.1097/ICU.0b013e328339f1dd; CastroCorreia J, 1995, INT OPHTHALMOL, V19, P135; De Moraes Carlos Gustavo Vasconcelos, 2009, Graefes Arch Clin Exp Ophthalmol, V247, P385, DOI 10.1007/s00417-008-0969-2; FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220; Kumar A, 2014, INVEST OPHTH VIS SCI, V55, P1787, DOI 10.1167/iovs.13-13522; Ooto S, 2010, GRAEF ARCH CLIN EXP, V248, P1077, DOI 10.1007/s00417-010-1338-5; SOBIN SS, 1992, MECH AGEING DEV, V63, P183, DOI 10.1016/0047-6374(92)90064-K; Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631; Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43	35	3	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394	1879-1891		AM J OPHTHALMOL	Am. J. Ophthalmol.	JUN	2015	159	6					1123	1131		10.1016/j.ajo.2015.03.005		9	Ophthalmology	Ophthalmology	CI9DL	WOS:000355070500016		
J	Mori, K; Gehlbach, PL; Kishi, S				Mori, Keisuke; Gehlbach, Peter L.; Kishi, Shoji			Posterior Vitreous Mobility Delineated by Tracking of Optical Coherence Tomography Images in Eyes With Idiopathic Macular Holes	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							DETACHMENT	PURPOSE: To demonstrate the,posterior vitreous mobility following eye movements in patients forming macular holes, using an optical coherence tomography (OCT) eye-tracking system. " DESIGN: Prospective consecutive interventional case series. METHODS: Twenty-four eyes of 17 consecutive patients with idiopathic macular hole and the remaining fellow eyes were recruited. Following acquisition of baseline fundus scans, all patients were instructed to perform sets of standardized full-excursion vertical and horizontal eye movements. Immediately after each set of movements an OCT scan registered to the baseline fundus image was obtained using the eye-tracking system. Three images were then overlaid using picture-editing software, thereby documenting the changing configuration of the posterior vitreous as well as its position relative to the static retinal structures. RESULTS: In patients with macular hole, 22 of 24 eyes (92%) had duplication of the posterior cortical vitreous in overlaid images. The extent of duplication (indicating mobility) was increased with increasing vitreous separation and as the stage of macular hole increased (75% in stage 0; 80% in stage 1; 100% in both stage 2 and stage 3). In all eyes in which there was a wavy configuration to the vitreous face, or in which there was a greater angle of vitreous insertion into the peripheral retina, vitreous mobility was evident on overlaid images (P = 2.7 x 10(-17) and P = 1.7 x 10(-13), respectively). CONCLUSION: By dynamically evaluating patients, we offer potential mechanistic 'insights that may further implicate mobile vitreous and associated fluid currents in the pathogenesis and progression of macular holes. (C) 2015 by Elsevier Inc. All rights reserved.)	[Mori, Keisuke] Saitama Med Univ, Dept Ophthalmol, Iruma, Saitama 3500495, Japan; [Gehlbach, Peter L.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA; [Kishi, Shoji] Gunma Univ, Sch Med, Dept Ophthalmol, Maebashi, Gumma 371, Japan	Mori, K (reprint author), Saitama Med Univ, Dept Ophthalmol, 38 Morohongo, Iruma, Saitama 3500495, Japan.	keisuke@saitama-med.ac.jp			Ministry of Education, Culture and Science in Japan [24592641]; Research to Prevent Blindness; J. Willard and Alice S. Marriott Foundation; Gale Trust	ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST and none were reported. This research was supported in part by a grant-in-aid for scientific research (24592641) from the Ministry of Education, Culture and Science in Japan (KM.), Research to Prevent Blindness, The J. Willard and Alice S. Marriott Foundation, and The Gale Trust and a generous gift from Mr Bill Wilbur (P.G.). All authors attest that they meet the current ICMJE requirements to qualify as authors.	HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; Johnson MW, 2010, AM J OPHTHALMOL, V149, P371, DOI 10.1016/j.ajo.2009.11.022; Sadda SR, 1999, ARCH OPHTHALMOL-CHIC, V117, P478; GASS JDM, 1988, ARCH OPHTHALMOL-CHIC, V106, P629; Johnson MW, 2001, ARCH OPHTHALMOL-CHIC, V119, P215; HEE MR, 1995, OPHTHALMOLOGY, V102, P748; GASS JDM, 1995, AM J OPHTHALMOL, V119, P752; Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744; SMIDDY WE, 1989, AM J OPHTHALMOL, V108, P360; Chan A, 2004, OPHTHALMOLOGY, V111, P2027, DOI 10.1016/j.ophtha.2004.05.034; GUYER DR, 1993, RETINA AND VITREOUS, P135; Mori K, 2012, OPHTHALMOLOGY, V119, P2600, DOI 10.1016/j.ophtha.2012.06.027; Mori K, 2000, OPHTHALMIC SURG LAS, V31, P203; Takahashi A, 2011, AM J OPHTHALMOL, V151, P981, DOI 10.1016/j.ajo.2011.01.011	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394	1879-1891		AM J OPHTHALMOL	Am. J. Ophthalmol.	JUN	2015	159	6					1132	1141		10.1016/j.ajo.2015.02.016		10	Ophthalmology	Ophthalmology	CI9DL	WOS:000355070500017		
J	Tomonari, H; Yagi, T; Kuninori, T; Ikemori, T; Miyawaki, S				Tomonari, Hiroshi; Yagi, Takakazu; Kuninori, Takaharu; Ikemori, Takahiro; Miyawaki, Shouichi			Replacement of a first molar and 3 second molars by the mesial inclination of 4 impacted third molars in an adult with a Class II Division 1 malocclusion	AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS			English	Article							EXTRACTION; ERUPTION; 2ND-MOLAR; PATHOLOGY; ANCHORAGE; MOVEMENT; POSITION	This case report presents the successful replacement of 1 first molar and 3 second molars by the mesial inclination of 4 impacted third molars. A woman, 23 years 6 months old, had a chief complaint of crowding of her anterior teeth and linguoclination of a second molar on the left side. The panoramic radiographic images showed that the maxillary and mandibular third molars on both sides were impacted. Root resorption on the distal surfaces of the maxillary second molars was suspected. The patient was given a diagnosis of Angle Class II Division 1 malocclusion with severe crowding of the anterior teeth and 4 impacted third molars. After we extracted the treated maxillary second premolars and the second molars on both sides, the treated mandibular second premolar and the second molar on the left side, and the root canal-filled mandibular first molar on the right side, the 4 impacted third molars were uprighted and formed part of the posterior functional occlusion. The total active treatment period was 39 months. The maxillary and mandibular third molars on both sides successfully replaced the first and second molars. The replacement of a damaged molar by an impacted third molar is a useful treatment option for using sound teeth.	[Tomonari, Hiroshi; Yagi, Takakazu; Kuninori, Takaharu; Ikemori, Takahiro; Miyawaki, Shouichi] Kagoshima Univ, Grad Sch Dent Sci, Dept Orthodont Field Dev Med Hlth Res Course, Kagoshima, Kagoshima 8908544, Japan	Miyawaki, S (reprint author), Kagoshima Univ, Grad Sch Dent Sci, Dept Orthodont, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima 8908544, Japan.	miyawaki@dent.kagoshima-u.ac.jp					De-La-Rosa-Gay C, 2006, AM J ORTHOD DENTOFAC, V129, P337, DOI 10.1016/j.ajodo.2005.11.002; Nunn ME, 2013, J DENT RES, V92, P1095, DOI 10.1177/0022034513509281; Tomonari H, 2014, J ORAL REHABIL, V41, P257, DOI 10.1111/joor.12148; Miyawaki S, 2003, AM J ORTHOD DENTOFAC, V124, P373, DOI 10.1016/S0889-5406(03)00565-1; GOORIS CGM, 1990, AM J ORTHOD DENTOFAC, V98, P161, DOI 10.1016/0889-5406(90)70010-A; Ay S, 2006, AM J ORTHOD DENTOFAC, V129, P36, DOI 10.1016/j.ajodo.2004.10.010; Battagel JM, 1998, AM J ORTHOD DENTOFAC, V113, P133, DOI 10.1016/S0889-5406(98)70285-9; Bayram M, 2009, ORAL SURG ORAL MED O, V107, pE14, DOI 10.1016/j.tripleo.2008.10.011; BISHARA SE, 1983, AM J ORTHOD DENTOFAC, V83, P131, DOI 10.1016/S0002-9416(83)90298-1; Blakey GH, 2009, J ORAL MAXIL SURG, V67, P2425, DOI 10.1016/j.joms.2008.12.064; De-la-Rosa-Gay C, 2010, AM J ORTHOD DENTOFAC, V137, P346, DOI 10.1016/j.ajodo.2008.02.026; Foster TD., 1990, TXB ORTHODONTICS; Koyama I, 2011, EUR J ORTHODONT, V33, P126, DOI 10.1093/ejo/cjq047; Livas C, 2011, AM J ORTHOD DENTOFAC, V140, P377, DOI 10.1016/j.ajodo.2010.06.026; Maeda A, 2013, AM J ORTHOD DENTOFAC, V144, P430, DOI 10.1016/j.ajodo.2012.08.032; Marciani RD, 2012, J ORAL MAXIL SURG, V70, pS15, DOI 10.1016/j.joms.2012.04.025; Orton-Gibbs S, 2001, AM J ORTHOD DENTOFAC, V119, P226, DOI 10.1067/mod.2001.111556; RICHARDS.ME, 1974, ANGLE ORTHOD, V44, P141; Ryu Y K, 1990, Taehan Chikkwa Uisa Hyophoe Chi, V28, P1069; Yun SW, 2007, AM J ORTHOD DENTOFAC, V132, P842, DOI 10.1016/j.ajodo.2006.03.029	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0889-5406	1097-6752		AM J ORTHOD DENTOFAC	Am. J. Orthod. Dentofac. Orthop.	JUN	2015	147	6					755	765		10.1016/j.ajodo.2014.05.030		11	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CJ3JB	WOS:000355378100022		
J	Ishihara, Y; Tomikawa, K; Deguchi, T; Honjo, T; Suzuki, K; Kono, T; Kuboki, T; Kamioka, H; Takashiba, S; Yamashiroi, T				Ishihara, Yoshihito; Tomikawa, Kazuya; Deguchi, Toru; Honjo, Tadashi; Suzuki, Koji; Kono, Takayuki; Kuboki, Takuo; Kamioka, Hiroshi; Takashiba, Shogo; Yamashiroi, Takashi			Interdisciplinary orthodontic treatment for a patient with generalized aggressive periodontitis: Assessment of IgG antibodies to identify type of periodontitis and correct timing of treatment	AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS			English	Article							PATHOLOGICAL TOOTH MIGRATION; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; JUVENILE PERIODONTITIS; MICROBIAL COLONIZATION; GINGIVALIS	Aggressive periodontitis is a great challenge to clinicians when providing orthodontic treatment because of the potential for progression of periodontal disease. In this article, we report the successful comprehensive orthodontic treatment of bimaxillary protrusion and severe crowding in an adult with generalized aggressive periodontitis. A woman, aged 22 years 7 months, with a chief complaint of incisal crowding was diagnosed with a skeletal Class I malocclusion associated with severe anterior crowding, possibly worsened by generalized aggressive periodontitis. In addition to a periodontal examination, a blood IgG antibody titer analysis and microbiologic examination for periodontal pathogens were used to diagnose the type of periodontal disease and determine the proper timing to initiate orthodontic treatment. The total active treatment period was 28 months, followed by periodontal prostheses and regeneration therapy. Consequently, satisfactory facial profile, occlusion, and periodontal health were maintained for at least 36 months. These results indicate that efficient screening is important for providing successful orthodontic treatment in patients with advanced periodontal disease. This report also demonstrates the diagnostic importance of blood IgG antibody titer assays and microbiologic examinations to detect periodontal pathogens.	[Ishihara, Yoshihito; Kamioka, Hiroshi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Orthodont, Okayama 7008525, Japan; [Tomikawa, Kazuya] Kyushu Univ Hosp, Div Gen Dent, Fukuoka 812, Japan; [Deguchi, Toru] Ohio State Univ, Coll Dent, Div Orthodont, Columbus, OH 43210 USA; [Honjo, Tadashi] Tottori Univ, Fac Med, Div Oral & Maxillofacial Biopathol Surg, Yonago, Tottori 683, Japan; [Suzuki, Koji; Kono, Takayuki] Okayama Univ Hosp, Dept Comprehens Dent, Okayama, Japan; [Kuboki, Takuo] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral Rehabil & Regenerat Med, Okayama 7008525, Japan; [Takashiba, Shogo] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathophysiol Periodontal Sci, Okayama 7008525, Japan; [Yamashiroi, Takashi] Osaka Univ, Dept Orthodont & Dentofacial Orthoped, Grad Sch Dent, Suita, Osaka, Japan	Ishihara, Y (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Orthodont, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008525, Japan.	ishihara@md.okayama-u.ac.jp					American Academy of Periodontology, 2000, J PERIODONTOL, V71, P867; Armitage GC, 2004, PERIODONTOL 2000, V34, P9, DOI 10.1046/j.0906-6713.2002.003421.x; Maeda H, 2003, FEMS IMMUNOL MED MIC, V39, P81, DOI 10.1016/S0928-8244(03)00224-4; Turkkahraman H, 2005, ANGLE ORTHOD, V75, P231; Maeda S, 2005, AM J ORTHOD DENTOFAC, V127, P374, DOI 10.1016/j.ajodo.2004.01.019; Armitage G C, 1999, Ann Periodontol, V4, P1, DOI 10.1902/annals.1999.4.1.1; BALENSEI.JW, 1970, J DENT RES, V49, P320, DOI 10.1177/00220345700490022101; BRAGD L, 1987, J CLIN PERIODONTOL, V14, P95, DOI 10.1111/j.1600-051X.1987.tb00949.x; Brunsvold MA, 2005, J PERIODONTOL, V76, P859, DOI 10.1902/jop.2005.76.6.859; Ishihara Y, 2013, ANGLE ORTHOD, V83, P341, DOI 10.2319/042412-343.1; Ishihara Y, 2012, AM J ORTHOD DENTOFAC, V142, P534, DOI 10.1016/j.ajodo.2011.02.029; Kokich VG, 2011, AM J ORTHOD DENTOFAC, V139, pS14, DOI 10.1016/j.ajodo.2011.01.006; Kudo C, 2012, J DENT RES, V91, P1190, DOI 10.1177/0022034512461796; MANDELL RL, 1981, J PERIODONTOL, V52, P593, DOI 10.1902/jop.1981.52.10.593; Mathews D P, 1997, Semin Orthod, V3, P21, DOI 10.1016/S1073-8746(97)80037-0; Murayama Y, 1988, Adv Dent Res, V2, P339; Nalcaci R, 2014, ANGLE ORTHOD, V84, P479, DOI 10.2319/061913-461.1; NEWMAN MG, 1976, J PERIODONTOL, V47, P373, DOI 10.1902/jop.1976.47.7.373; Okada K, 2000, CLEFT PALATE-CRAN J, V37, P318, DOI 10.1597/1545-1569(2000)037<0318:OTFAPW>2.3.CO;2; Passanezi E, 2007, AM J ORTHOD DENTOFAC, V131, P268, DOI 10.1016/j.ajodo.2005.03.025; SINCLAIR PM, 1987, ANGLE ORTHOD, V57, P271; Thilander B, 1996, Semin Orthod, V2, P55, DOI 10.1016/S1073-8746(96)80040-5; Tonetti M S, 1999, Ann Periodontol, V4, P39, DOI 10.1902/annals.1999.4.1.39; Wada K, 1981, J KANAZAWA MED U, V6, P60	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0889-5406	1097-6752		AM J ORTHOD DENTOFAC	Am. J. Orthod. Dentofac. Orthop.	JUN	2015	147	6					766	780		10.1016/j.ajodo.2014.09.022		15	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CJ3JB	WOS:000355378100023		
J	Tei, M; Wakasugi, M; Omori, T; Ueshima, S; Tori, M; Akamatsu, H				Tei, Mitsuyoshi; Wakasugi, Masaki; Omori, Takeshi; Ueshima, Shigeyuki; Tori, Masayuki; Akamatsu, Hiroki			Single-port laparoscopic colectomy is safe and feasible in patients with previous abdominal surgery	AMERICAN JOURNAL OF SURGERY			English	Article						Single-incision laparoscopic surgery; Single-port surgery; Colorectal disease; Previous abdominal surgery	SHORT-TERM OUTCOMES; COLORECTAL SURGERY; RIGHT HEMICOLECTOMY; INCISION; CANCER; MULTICENTER; OPERATIONS; RESECTION	BACKGROUND: The aim of this study was to assess the impact of previous abdominal surgery (PAS) on single-port laparoscopic colectomy (SPLC). METHODS: We studied 429 consecutive patients who underwent SPLC in our department from May 2009 to December 2013. Patients were divided into 2 groups: those with PAS (PAS group) and those with NPAS (NPAS group). Operative parameters and outcomes were analyzed between the 2 groups retrospectively. RESULTS: SPLC was performed in 152 PAS patients and 277 NPAS patients. Eight patients in the PAS group and 6 patients in the NPAS group were converted to multiport laparoscopic colectomy (5.3% vs 2.2%, respectively; P = .077). Three patients in the PAS group and 2 patients in the NPAS group had inadvertent enterotomy (2.0% vs.7%, respectively; P = .352). No patients were converted to open surgery. There were no significant differences between the 2 groups in terms of blood loss, operative time, and postoperative outcomes. CONCLUSION: Our experience has demonstrated the safety and feasibility of SPLC in patients with PAS. (C) 2015 Elsevier Inc. All rights reserved.	[Tei, Mitsuyoshi; Wakasugi, Masaki; Omori, Takeshi; Ueshima, Shigeyuki; Tori, Masayuki; Akamatsu, Hiroki] Osaka Police Hosp, Dept Surg, Tennoji Ku, Osaka, Osaka 5430035, Japan	Tei, M (reprint author), Osaka Police Hosp, Dept Surg, Tennoji Ku, 10-31 Kitayama Cho, Osaka, Osaka 5430035, Japan.	mtei@live.jp					Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Yun JA, 2013, SURG ENDOSC, V27, P2122, DOI 10.1007/s00464-012-2722-5; Champagne BJ, 2012, ANN SURG, V255, P66, DOI 10.1097/SLA.0b013e3182378442; Huscher CG, 2012, AM J SURG, V204, P115, DOI 10.1016/j.amjsurg.2011.09.005; Poon JTC, 2012, SURG ENDOSC, V26, P2729, DOI 10.1007/s00464-012-2262-z; Gonzalez IA, 2006, SURG LAPARO ENDO PER, V16, P8, DOI 10.1097/01.sle.0000202188.57537.07; Remzi FH, 2008, COLORECTAL DIS, V10, P823, DOI 10.1111/j.1463-1318.2008.01660.x; Hamel CT, 2000, SURG ENDOSC-ULTRAS, V14, P853, DOI 10.1007/s004640000218; Chen WTL, 2011, SURG ENDOSC, V25, P1887, DOI 10.1007/s00464-010-1481-4; Offodile AC, 2008, DIS COLON RECTUM, V51, P1669, DOI 10.1007/s10350-008-9278-4; Yamamoto M, 2013, DIS COLON RECTUM, V56, P336, DOI 10.1097/DCR.0b013e31827ba103; Merchant AM, 2009, DIS COLON RECTUM, V52, P1021, DOI 10.1007/DCR.0b013e3181a4fabe; Law WL, 2005, SURG ENDOSC, V19, P326, DOI 10.1007/s00464-004-8114-8; Kwag SJ, 2013, AM J SURG, V206, P320, DOI 10.1016/j.amjsurg.2012.11.007; Becker JM, 1996, J AM COLL SURGEONS, V183, P297; Bucher P, 2009, DIS COLON RECTUM, V52, P1797, DOI 10.1007/DCR.0b013e3181b551ce; Franko Jan, 2006, JSLS, V10, P169; Gaujoux S, 2012, J GASTROINTEST SURG, V16, P629, DOI 10.1007/s11605-011-1780-7; Papaconstantinou HT, 2011, SURGERY, V150, P820, DOI 10.1016/j.surg.2011.07.060; Vignali A, 2007, Tech Coloproctol, V11, P241, DOI 10.1007/s10151-007-0358-6; Wolthuis AM, 2012, COLORECTAL DIS, V14, P634, DOI 10.1111/j.1463-1318.2011.02721.x	21	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	JUN	2015	209	6					1007	1012		10.1016/j.amjsurg.2014.06.015		6	Surgery	Surgery	CI9WL	WOS:000355120700013		
J	Morita, Y; Yamaguchi, S; Ishii, T; Tashiro, J; Kondo, H; Suzuki, A; Hara, K; Koyama, I				Morita, Yohei; Yamaguchi, Shigeki; Ishii, Toshimasa; Tashiro, Jo; Kondo, Haruka; Suzuki, Asami; Hara, Kiyoka; Koyama, Isamu			Does transumbilical incision increase incisional hernia at the extraction site of laparoscopic anterior resection?	AMERICAN JOURNAL OF SURGERY			English	Article						Incisional hernia; Transumbilical incision; Laparoscopic colectomy	COLORECTAL SURGERY; COMPLICATIONS; MIDLINE; REPAIR	BACKGROUND: It is unclear whether transumbilical incision for laparoscopic colectomy has a risk of incisional hernia at the extraction site similar to left lower incision. METHODS: Consecutive patients who underwent laparoscopic sigmoid plus high and low anterior resection between August 2008 and February 2011 were included in the study. Incision for specimen extraction was changed from left lower to transumbilical incision in February 2010. The main outcome was the incidence of incisional hernia diagnosed by computed tomography. RESULTS: One hundred and eighty-six patients underwent laparoscopic anterior resection (94 transumbilical incisions and 92 left lower transverse incisions). Three percent of patients had an incisional hernia at the extraction site, and the incidence of this phenomenon was not significantly different between the 2 groups. Surgical wound infection was lower in the transumbilical incision group than in the left lower incision group. CONCLUSIONS: Extraction site for transumbilical incision may not affect the risk of incisional hernia. (C) 2015 The Authors. Published by Elsevier Inc. All rights reserved.	[Morita, Yohei; Yamaguchi, Shigeki; Ishii, Toshimasa; Tashiro, Jo; Kondo, Haruka; Suzuki, Asami; Hara, Kiyoka; Koyama, Isamu] Saitama Med Univ, Dept Surg Gastroenterol, Int Med Ctr, Saitama 13971, Japan	Morita, Y (reprint author), Saitama Med Univ, Dept Surg Gastroenterol, Int Med Ctr, 1397-1 Yamane, Saitama 13971, Japan.	y_morita@saitama-med.ac.jp					Andersen LPH, 2008, SURG ENDOSC, V22, P2026, DOI 10.1007/s00464-008-9924-x; Llaguna OH, 2010, AM J SURG, V200, P265, DOI 10.1016/j.amjsurg.2009.08.044; Sonoda T, 2009, J AM COLL SURGEONS, V208, P62, DOI 10.1016/j.jamcollsurg.2008.09.003; O'Dwyer PJ, 2003, SURG J R COLL SURG E, V1, P17; Weiss HG, 2014, ANN SURG, V259, P89, DOI 10.1097/SLA.0b013e31827b7818; deSouza A, 2011, SURG ENDOSC, V25, P1031, DOI 10.1007/s00464-010-1309-2; Samia H, 2013, AM J SURG, V205, P264, DOI 10.1016/j.amjsurg.2013.01.006; Lim SW, 2013, TECH COLOPROCTOL, V17, P59, DOI 10.1007/s10151-012-0883-9; Lee L, 2012, SURG ENDOSC, V26, P3180, DOI 10.1007/s00464-012-2311-7; Evans KK, 2012, AM SURGEON, V78, P388; Helgstrand F, 2013, J AM COLL SURGEONS, V216, P217, DOI 10.1016/j.jamcollsurg.2012.10.013; Imamura H, 2013, JPN J GASTROENTEROL, V46, P237; Nho RLH, 2012, J VISC SURG, V149, pE3, DOI 10.1016/j.jviscsurg.2012.05.004; MUDGE M, 1985, BRIT J SURG, V72, P70, DOI 10.1002/bjs.1800720127; Nieuwenhuizen J, 2008, HERNIA, V12, P223, DOI 10.1007/s10029-007-0322-4	15	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	JUN	2015	209	6					1048	1052		10.1016/j.amjsurg.2014.06.023		5	Surgery	Surgery	CI9WL	WOS:000355120700019		
J	Aoki, D; Uchida, S; Takata, T				Aoki, Daisuke; Uchida, Satoshi; Takata, Toshikazu			Star/Linear Polymer Topology Transformation Facilitated by Mechanical Linking of Polymer Chains	ANGEWANDTE CHEMIE-INTERNATIONAL EDITION			English	Article						ring-opening polymerization; rotaxanes; star polymers; structure transformation; topology	EPSILON-CAPROLACTONE; BLOCK-COPOLYMERS; STAR; ROTAXANE)S; BEHAVIOR; INITIATOR; ROP	Topology transformation of a star polymer to a linear polymer is demonstrated for the first time. A three-armed star polymer possessing a mechanical linking of two polymer chains was synthesized by the living ring-opening polymerization of -valerolactone initiated by a pseudo[2]rotaxane having three hydroxy groups as the initiator sites on the wheel component and at both axle termini. The polymerization was followed by the propagation end-capping reaction with a bulky isocyanate not only to prevent the wheel component deslippage but also to introduce the urethane moiety at the axle terminal. The resulting rotaxane-linked star polymer with a fixed rotaxane linkage based on the ammonium/crown ether interaction was subjected to N-acetylation of the ammonium moiety, which liberated the components from the interaction to move the wheel component to the urethane terminal as the interaction site, eventually affording the linear polymer. The physical property change caused by the present topology transformation was confirmed by the hydrodynamic volume and viscosity.	[Aoki, Daisuke; Uchida, Satoshi; Takata, Toshikazu] Tokyo Inst Technol, Dept Organ & Polymer Mat, Meguro Ku, Tokyo 1528552, Japan	Takata, T (reprint author), Tokyo Inst Technol, Dept Organ & Polymer Mat, Meguro Ku, 2-12-1 O Okayama, Tokyo 1528552, Japan.	ttakata@polymer.titech.ac.jp	Uchida, Satoshi/B-9501-2015	Uchida, Satoshi/0000-0002-8471-2181	ACT-C program of JST; Ministry of Education, Culture, Sports, Science and Technology, Japan [26102512, 25410125, 26886006]	This research was financially supported by the ACT-C program of JST, a Grant-in Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (No. 26102512, 25410125, 26886006).	Liu HH, 2012, J POLYM SCI POL CHEM, V50, P4705, DOI 10.1002/pola.26285; Fang L, 2009, J AM CHEM SOC, V131, P7126, DOI 10.1021/ja900859d; Jia ZF, 2006, J AM CHEM SOC, V128, P8144, DOI 10.1021/ja062314d; Lee JH, 2009, MACROMOLECULES, V42, P1392, DOI 10.1021/ma8022662; Hecht S, 2001, ANGEW CHEM INT EDIT, V40, P74, DOI 10.1002/1521-3773(20010105)40:1<74::AID-ANIE74>3.0.CO;2-C; Voit BI, 2009, CHEM REV, V109, P5924, DOI 10.1021/cr900068q; Yuan CX, 2013, J AM CHEM SOC, V135, P8842, DOI 10.1021/ja404198h; Schappacher M, 2011, J AM CHEM SOC, V133, P1630, DOI 10.1021/ja108821p; Aoshima S, 2007, J POLYM SCI POL CHEM, V45, P1801, DOI 10.1002/pola.21995; Aoshima S, 2009, CHEM REV, V109, P5245, DOI 10.1021/cr900225g; Romuald C, 2012, CHEM SCI, V3, P1851, DOI 10.1039/c2sc20072d; Aoki D, 2014, POLYM J, V46, P546, DOI 10.1038/pj.2014.22; Hoskins JN, 2009, MACROMOLECULES, V42, P6406, DOI 10.1021/ma9011076; Grayson SM, 2001, CHEM REV, V101, P3819, DOI 10.1021/cr990116h; Castro-Osma JA, 2013, MACROMOLECULES, V46, P6388, DOI 10.1021/ma401216u; Igari M, 2013, MACROMOLECULES, V46, P7303, DOI 10.1021/ma401394t; Kobatake S, 2007, NATURE, V446, P778, DOI 10.1038/nature05669; Guan ZB, 1999, SCIENCE, V283, P2059, DOI 10.1126/science.283.5410.2059; Altintas O, 2010, CHEM COMMUN, V46, P6291, DOI 10.1039/c0cc00702a; Poelma JE, 2012, ACS NANO, V6, P10845, DOI 10.1021/nn304217y; Lee JH, 2008, MACROMOLECULES, V41, P9165, DOI 10.1021/ma801429k; Floudas G, 1996, MACROMOLECULES, V29, P4142, DOI 10.1021/ma951762v; Laurent BA, 2009, CHEM SOC REV, V38, P2202, DOI 10.1039/b809916m; Aoki D, 2014, ACS MACRO LETT, V3, P324, DOI 10.1021/mz5001306; Aoki D, 2013, ACS MACRO LETT, V2, P461, DOI 10.1021/mz400197d; Deng Y, 2013, POLYM CHEM-UK, V4, P1289, DOI 10.1039/c2py20622f; Dong BT, 2010, MACROMOLECULES, V43, P8790, DOI 10.1021/ma101807y; Gibson HW, 1997, MACROMOLECULES, V30, P3711, DOI 10.1021/ma961362n; Gong CG, 1997, J AM CHEM SOC, V119, P5862, DOI 10.1021/ja970673q; Gong CG, 1997, J AM CHEM SOC, V119, P8585, DOI 10.1021/ja971385x; Hecht S., 2001, ANGEW CHEM, V113, P76, DOI 10.1002/1521-3757(20010105)113:1<76::AID-ANGE76>3.0.CO;2-F; Honda S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2585; Quirk RP, 1998, MACROMOLECULES, V31, P8016, DOI 10.1021/ma980456p; Sanda F, 2002, MACROMOLECULES, V35, P680, DOI 10.1021/ma011341f; Van Renterghem LM, 2006, MACROMOLECULES, V39, P528, DOI 10.1021/ma051846w; Wan HS, 2008, MACROMOLECULES, V41, P465, DOI 10.1021/ma071149z; Zhao Y, 2011, MACROMOLECULES, V44, P4007, DOI 10.1021/ma200691s	37	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1433-7851	1521-3773		ANGEW CHEM INT EDIT	Angew. Chem.-Int. Edit.	JUN 1	2015	54	23					6770	6774		10.1002/anie.201500578		5	Chemistry, Multidisciplinary	Chemistry	CJ2KT	WOS:000355314100013		
J	Xu, F; Xu, H; Chen, X; Wu, DC; Wu, Y; Liu, H; Gu, C; Fu, RW; Jiang, DL				Xu, Fei; Xu, Hong; Chen, Xiong; Wu, Dingcai; Wu, Yang; Liu, Hao; Gu, Cheng; Fu, Ruowen; Jiang, Donglin			Radical Covalent Organic Frameworks: A General Strategy to Immobilize Open-Accessible Polyradicals for High-Performance Capacitive Energy Storage	ANGEWANDTE CHEMIE-INTERNATIONAL EDITION			English	Article						capacitors; covalent organic frameworks; energy storage; radicals; synthesis	CLEAN ENERGY; CRYSTALLINE; SUPERCAPACITORS; HYDROGEN; FUNCTIONALIZATION; CONDUCTION; ELECTRODE	Ordered -columns and open nanochannels found in covalent organic frameworks (COFs) could render them able to store electric energy. However, the synthetic difficulty in achieving redox-active skeletons has thus far restricted their potential for energy storage. A general strategy is presented for converting a conventional COF into an outstanding platform for energy storage through post-synthetic functionalization with organic radicals. The radical frameworks with openly accessible polyradicals immobilized on the pore walls undergo rapid and reversible redox reactions, leading to capacitive energy storage with high capacitance, high-rate kinetics, and robust cycle stability. The results suggest that channel-wall functional engineering with redox-active species will be a facile and versatile strategy to explore COFs for energy storage.	[Xu, Fei; Xu, Hong; Chen, Xiong; Wu, Yang; Gu, Cheng; Jiang, Donglin] Natl Inst Nat Sci, Inst Mol Sci, Dept Mat Mol Sci, Okazaki, Aichi 4448787, Japan; [Xu, Fei; Wu, Dingcai; Liu, Hao; Fu, Ruowen] Sun Yat Sen Univ, Inst Mat Sci, Sch Chem & Chem Engn, Guangzhou 510275, Guangdong, Peoples R China	Jiang, DL (reprint author), Natl Inst Nat Sci, Inst Mol Sci, Dept Mat Mol Sci, 5-1 Higashiyama, Okazaki, Aichi 4448787, Japan.	jiang@ims.ac.jp	xu, fei/A-3049-2011; CHEN, Xiong/O-8506-2014	CHEN, Xiong/0000-0003-2878-7522	MEXT of Japan [24245030]; National Key Basic Research Program of China (973) [2014CB932402]; NSFC [51232005, 51372280, 51173213]; National Science Foundation for Excellent Young Scholars [51422307]; Guangdong Natural Science Funds for Distinguished Young Scholars project [S2013050014408]	This work was supported by a Grant-in-Aid for Scientific Research (A) (24245030) from MEXT of Japan. R.F. thanks the National Key Basic Research Program of China (973, 2014CB932402) and the NSFC (51232005). D.W. thanks the National Science Foundation for Excellent Young Scholars (No. 51422307), the NSFC (51372280 and 51173213), and the Guangdong Natural Science Funds for Distinguished Young Scholars project (S2013050014408).	Choi KM, 2014, ACS NANO, V8, P7451, DOI 10.1021/nn5027092; Simon P, 2008, NAT MATER, V7, P845, DOI 10.1038/nmat2297; Diaz R, 2012, MATER LETT, V68, P126, DOI 10.1016/j.matlet.2011.10.046; Chandra S, 2014, J AM CHEM SOC, V136, P6570, DOI 10.1021/ja502212v; Xu H, 2014, CHEM COMMUN, V50, P1292, DOI 10.1039/c3cc48813f; Calik M, 2014, J AM CHEM SOC, V136, P17802, DOI 10.1021/ja509551m; Li SL, 2013, ENERG ENVIRON SCI, V6, P1656, DOI 10.1039/c3ee40507a; Mas-Torrent M, 2012, CHEM REV, V112, P2506, DOI 10.1021/cr200233g; Li ZP, 2014, CHEM COMMUN, V50, P13825, DOI 10.1039/c4cc05665e; Doonan CJ, 2010, NAT CHEM, V2, P235, DOI [10.1038/nchem.548, 10.1038/NCHEM.548]; Feng X, 2012, CHEM SOC REV, V41, P6010, DOI 10.1039/c2cs35157a; Faust TB, 2014, RSC ADV, V4, P17498, DOI 10.1039/c4ra00958d; Furukawa H, 2009, J AM CHEM SOC, V131, P8875, DOI 10.1021/ja9015765; Rabbani MG, 2013, CHEM-EUR J, V19, P3324, DOI 10.1002/chem.201203753; Potts SV, 2011, J AM CHEM SOC, V133, P12948, DOI 10.1021/ja204548d; Chandra S, 2013, J AM CHEM SOC, V135, P17853, DOI 10.1021/ja408121p; Kovalenko I, 2010, ADV FUNCT MATER, V20, P3979, DOI 10.1002/adfm.201000906; Feng X, 2012, ANGEW CHEM INT EDIT, V51, P2618, DOI 10.1002/anie.201106203; Li LC, 2014, J AM CHEM SOC, V136, P7543, DOI 10.1021/ja5019095; DeBlase CR, 2013, J AM CHEM SOC, V135, P16821, DOI 10.1021/ja409421d; Dogru M, 2014, CHEM COMMUN, V50, P5531, DOI 10.1039/c3cc46767h; Kandambeth S, 2013, ANGEW CHEM INT EDIT, V52, P13052, DOI 10.1002/anie.201306775; Lee DY, 2012, MICROPOR MESOPOR MAT, V153, P163, DOI 10.1016/j.micromeso.2011.12.040; Bertrand GHV, 2013, P NATL ACAD SCI USA, V110, P4923, DOI 10.1073/pnas.1221824110; Wang GP, 2012, CHEM SOC REV, V41, P797, DOI 10.1039/c1cs15060j; DeBlase CR, 2015, ACS NANO, V9, P3178, DOI 10.1021/acsnano.5b00184; Stegbauer L, 2014, CHEM SCI, V5, P2789, DOI 10.1039/c4sc00016a; Bunck D. N., 2012, ANGEW CHEM, V124, P1921; Bunck DN, 2012, ANGEW CHEM INT EDIT, V51, P1885, DOI 10.1002/anie.201108462; Bunck DN, 2013, CHEM COMMUN, V49, P2457, DOI 10.1039/c3cc40358k; Fang QR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5503; Feng X., 2012, ANGEW CHEM, V124, P2672; Gao YL, 2015, NEW J CHEM, V39, P94, DOI 10.1039/c4nj01719f; Kahveci Z, 2013, CRYSTENGCOMM, V15, P1524, DOI 10.1039/c2ce26487k; Kandambeth S., 2013, ANGEW CHEM, V125, P13290; Nagai A., 2011, NAT COMMUN, DOI [10.1038/ncomms1542, DOI 10.1038/NCOMMS1542]; Xu F, 2015, SCI REP-UK, V5, DOI 10.1038/srep08225; Zanello P., 2003, INORGANIC ELECTROCHE	38	5	5	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1433-7851	1521-3773		ANGEW CHEM INT EDIT	Angew. Chem.-Int. Edit.	JUN 1	2015	54	23					6814	6818		10.1002/anie.201501706		5	Chemistry, Multidisciplinary	Chemistry	CJ2KT	WOS:000355314100022		
J	Lunkenbein, T; Girgsdies, F; Wernbacher, A; Noack, J; Auffermann, G; Yasuhara, A; Klein-Hoffmann, A; Ueda, W; Eichelbaum, M; Trunschke, A; Schlogl, R; Willinger, MG				Lunkenbein, Thomas; Girgsdies, Frank; Wernbacher, Anna; Noack, Johannes; Auffermann, Gudrun; Yasuhara, Akira; Klein-Hoffmann, Achim; Ueda, Wataru; Eichelbaum, Maik; Trunschke, Annette; Schloegl, Robert; Willinger, Marc G.			Direct Imaging of Octahedral Distortion in a Complex Molybdenum Vanadium Mixed Oxide	ANGEWANDTE CHEMIE-INTERNATIONAL EDITION			English	Article						annular bright field microscopy; bond angles; electron microscopy; light elements; transmission electron microscopy	TRANSMISSION ELECTRON-MICROSCOPY; SUB-ANGSTROM RESOLUTION; ATOMIC-RESOLUTION; GRAIN-BOUNDARIES; METAL-OXIDES; CATALYSTS; OXYGEN; PHASES; SCALE; M1	Complex Mo,V-based mixed oxides that crystallize in the orthorhombic M1-type structure are promising candidates for the selective oxidation of small alkanes. The oxygen sublattice of such a complex oxide has been studied by annular bright field scanning transmission electron microscopy. The recorded micrographs directly display the local distortion in the metal oxygen octahedra. From the degree of distortion we are able to draw conclusions on the distribution of oxidation states in the cation columns at different sites. The results are supported by X-ray diffraction and electron paramagnetic resonance measurements that provide integral details about the crystal structure and spin coupling, respectively.	[Lunkenbein, Thomas; Girgsdies, Frank; Wernbacher, Anna; Noack, Johannes; Klein-Hoffmann, Achim; Eichelbaum, Maik; Trunschke, Annette; Schloegl, Robert; Willinger, Marc G.] Max Planck Gesell, Fritz Haber Inst, Dept Inorgan Chem, D-14195 Berlin, Germany; [Auffermann, Gudrun] Max Planck Inst Chem Phys Fester Stoffe, D-01187 Dresden, Germany; [Yasuhara, Akira] JEOL Ltd, Tokyo, Japan; [Ueda, Wataru] Hokkaido Univ, Catalysis Res Ctr, Sapporo, Hokkaido 060, Japan; [Schloegl, Robert; Willinger, Marc G.] Max Planck Inst Chem Energiekonvers, D-45470 Mulheim, Germany	Willinger, MG (reprint author), Max Planck Gesell, Fritz Haber Inst, Dept Inorgan Chem, Faradayweg 4-6, D-14195 Berlin, Germany.	willinger@fhi-berlin.mpg.de			BasCat	J.N. thanks BasCat for a fellowship.	Amakawa K., 2013, ANGEW CHEM, V125, P13796; Pyrz WD, 2008, ANGEW CHEM INT EDIT, V47, P2788, DOI 10.1002/anie.200705700; Zhang ZL, 2003, SCIENCE, V302, P846, DOI 10.1126/science.1089785; Ok KM, 2006, CHEM MATER, V18, P3176, DOI 10.1021/cm0604817; KUNZ M, 1995, J SOLID STATE CHEM, V115, P395, DOI 10.1006/jssc.1995.1150; Batson PE, 2011, NAT MATER, V10, P270, DOI 10.1038/nmat2993; Batson PE, 2002, NATURE, V418, P617, DOI 10.1038/nature00972; Li X, 2014, NAT MATER, V13, P586, DOI [10.1038/nmat3964, 10.1038/NMAT3964]; Jia CL, 2008, NAT MATER, V7, P57, DOI 10.1038/nmat2080; Bjork H, 2001, ACTA CRYSTALLOGR B, V57, P759, DOI 10.1107/S0108768101014264; Yoshida K, 2006, NANOTECHNOLOGY, V17, P3944, DOI 10.1088/0957-4484/17/15/056; Jia CL, 2003, SCIENCE, V299, P870, DOI 10.1126/science.1079121; SAXTON WO, 1978, OPTIK, V49, P505; Amakawa K, 2013, ANGEW CHEM INT EDIT, V52, P13553, DOI 10.1002/anie.201306620; Haider M, 1998, NATURE, V392, P768, DOI 10.1038/33823; CANADELL E, 1990, INORG CHEM, V29, P2256, DOI 10.1021/ic00337a016; DeSanto P, 2004, Z KRISTALLOGR, V219, P152, DOI 10.1524/zkri.219.3.152.29091; Konya T, 2013, CATAL SCI TECHNOL, V3, P380, DOI 10.1039/c2cy20444d; Ishikawa S, 2013, CHEM MATER, V25, P2211, DOI 10.1021/cm400239c; Kihlborg L., 1963, NONSTOICHIOMETRIC CO, V39, P3745, DOI 10.1021/ba-1964-0039.ch003; Kirkland EJ, 2010, ADVANCED COMPUTING IN ELECTRON MICROSCOPY, SECOND ED, P1, DOI 10.1007/978-1-4419-6533-2; Kisielowski C, 2001, ULTRAMICROSCOPY, V89, P243, DOI 10.1016/S0304-3991(01)00090-0; MacLaren I, 2014, INT MATER REV, V59, P115, DOI 10.1179/1743280413Y.0000000026; Pyrz W. D., 2008, ANGEW CHEM, V120, P2830, DOI 10.1002/ange.200705700; Pyrz WD, 2010, CHEM MATER, V22, P2033, DOI 10.1021/cm100124a; Pyrz WD, 2010, P NATL ACAD SCI USA, V107, P6152, DOI 10.1073/pnas.1001239107; Urban KW, 2009, NAT MATER, V8, P260, DOI 10.1038/nmat2407	27	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1433-7851	1521-3773		ANGEW CHEM INT EDIT	Angew. Chem.-Int. Edit.	JUN 1	2015	54	23					6828	6831		10.1002/anie.201502236		4	Chemistry, Multidisciplinary	Chemistry	CJ2KT	WOS:000355314100025		
J	Mori, K; Murase, T; Fujita, M				Mori, Kazuyuki; Murase, Takashi; Fujita, Makoto			One-Step Synthesis of [16]Helicene	ANGEWANDTE CHEMIE-INTERNATIONAL EDITION			English	Article						helical structures; photocyclization; - interactions; polycyclic aromatic compounds; regioselectivity	ONE HUNDRED YEARS; STEREOSELECTIVE SYNTHESES; CIRCULAR-DICHROISM; OPTICAL-PROPERTIES; HELICAL MOLECULES; HELICENES; OCTA; PHOTOCHEMISTRY; CARBOHELICENES; PHOTOCYCLIZATION	A single-strand arylene-vinylene precursor containing four phenylene and three naphthylene units linked together with six vinylene spacers undergoes helical folding via sextuple photocyclization to give a [16]helicene core in a single step. The phenylene and naphthylene units are arranged in the precursor such that unfavorable side reactions (anthracene or benzoperylene formation) are avoided, and this is the key to the success of the one-step synthesis of [16]helicene, which is the longest [n]helicene that has been synthesized to date.	[Mori, Kazuyuki; Fujita, Makoto] Univ Tokyo, Sch Engn, Dept Appl Chem, Bunkyo Ku, Tokyo 1138656, Japan; [Murase, Takashi] Yamagata Univ, Fac Sci, Dept Mat & Biol Chem, Yamagata, Yamagata 9908560, Japan	Murase, T (reprint author), Yamagata Univ, Fac Sci, Dept Mat & Biol Chem, 1-4-12 Kojirakawa Machi, Yamagata, Yamagata 9908560, Japan.	tmurase@sci.kj.yamagata-u.ac.jp; mfujita@appchem.t.u-tokyo.ac.jp			 [24000009];  [25708008]	This research was supported by Grants-in-Aid for Specially Promoted Research (24000009) and for Young Scientists (A) (25708008).	AIHARA J, 1990, B CHEM SOC JPN, V63, P1956, DOI 10.1246/bcsj.63.1956; Gingras M, 2013, CHEM SOC REV, V42, P968, DOI 10.1039/c2cs35154d; Botek E, 2004, J CHEM PHYS, V120, P2042, DOI 10.1063/1.1635353; Rulisek L, 2007, J PHYS CHEM C, V111, P14948, DOI 10.1021/jp075129a; Gingras M, 2013, CHEM SOC REV, V42, P1007, DOI 10.1039/c2cs35111k; Furche F, 2000, J AM CHEM SOC, V122, P1717, DOI 10.1021/ja991960s; MARTIN RH, 1974, TETRAHEDRON, V30, P343, DOI 10.1016/S0040-4020(01)91468-1; Urbano A, 2013, ORG BIOMOL CHEM, V11, P699, DOI 10.1039/c2ob27108g; WOOD CS, 1964, J ORG CHEM, V29, P3373, DOI 10.1021/jo01034a059; TAMAGAWA K, 1976, J MOL STRUCT, V30, P243, DOI 10.1016/0022-2860(76)87003-2; Gingras M, 2013, CHEM SOC REV, V42, P1051, DOI 10.1039/c2cs35134j; LIU LB, 1991, J ORG CHEM, V56, P3769, DOI 10.1021/jo00012a005; MARTIN RH, 1975, TETRAHEDRON, V31, P2135, DOI 10.1016/0040-4020(75)80208-0; Jorgensen KB, 2010, MOLECULES, V15, P4334, DOI 10.3390/molecules15064334; OBENLAND S, 1975, J AM CHEM SOC, V97, P6633, DOI 10.1021/ja00856a006; Minami A, 2005, J AM CHEM SOC, V127, P6148, DOI 10.1021/ja042848j; Schulman JM, 1999, J PHYS CHEM A, V103, P6669, DOI 10.1021/jp9910587; Shen Y, 2012, CHEM REV, V112, P1463, DOI 10.1021/cr200087r; Bas G. L., 1976, CRYST STRUCT COMMUN, V5, P713; Bosanac T, 2004, ORG LETT, V6, P2321, DOI 10.1021/ol049369; Botek E, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2805395; DIETZ F, 1968, TETRAHEDRON, V24, P6845, DOI 10.1016/S0040-4020(01)96798-5; Grimme S, 1998, EUR J ORG CHEM, P1491; Hoffmann N, 2014, J PHOTOCH PHOTOBIO C, V19, P1, DOI 10.1016/j.jphotochemrev.2013.11.001; KAGAN H, 1971, TETRAHEDRON LETT, P2479; Katz T. J., 2000, ANGEW CHEM, V112, P1997, DOI 10.1002/1521-3757(20000602)112:11<1997::AID-ANGE1997>3.0.CO;2-6; Katz TJ, 2000, ANGEW CHEM INT EDIT, V39, P1921, DOI 10.1002/1521-3773(20000602)39:11<1921::AID-ANIE1921>3.0.CO;2-F; LAARHOVE.WH, 1970, TETRAHEDRON, V26, P4865, DOI 10.1016/S0040-4020(01)93139-4; Laarhoven W. H., 1984, CURR CHEM, V125, P63; Lee KY, 2004, TETRAHEDRON LETT, V45, P5977, DOI 10.1016/j.tetlet.2004.06.058; Mallory F. B., 1984, ORG REACTIONS, V30, P51; Martin R. H., 1971, SYNTHETIC COMMUN, V1, P257, DOI 10.1080/00397917108082706; MARTIN RH, 1974, ANGEW CHEM INT EDIT, V13, P649, DOI 10.1002/anie.197406491; MARTIN RH, 1969, TETRAHEDRON LETT, P3683; Martin R. H., 1974, ANGEW CHEM, V86, P727, DOI 10.1002/ange.19740862003; MARTIN RH, 1980, J CHEM RES-S, P130; MARTIN RH, 1968, TETRAHEDRON LETT, P3507; MEURER KP, 1985, TOP CURR CHEM, V127, P1; MORADPOUR A, 1975, TETRAHEDRON, V31, P2139, DOI 10.1016/0040-4020(75)80209-2; Nakai Y, 2012, J PHYS CHEM A, V116, P7372, DOI 10.1021/jp304576g; Roose J, 2013, EUR J ORG CHEM, P3223, DOI 10.1002/ejoc.201300407; Tian YH, 2008, CHEM MATER, V20, P3266, DOI 10.1021/cm702813s; Tommasini M, 2014, J CHEM THEORY COMPUT, V10, P5520, DOI 10.1021/ct500697e; Urbano A., 2003, ANGEW CHEM, V115, P4116, DOI 10.1002/ange.200301667; Urbano A, 2003, ANGEW CHEM INT EDIT, V42, P3986, DOI 10.1002/anie.200301667; WYNBERG H, 1971, ACCOUNTS CHEM RES, V4, P65, DOI 10.1021/ar50038a004	46	3	3	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1433-7851	1521-3773		ANGEW CHEM INT EDIT	Angew. Chem.-Int. Edit.	JUN 1	2015	54	23					6847	6851		10.1002/anie.201502436		5	Chemistry, Multidisciplinary	Chemistry	CJ2KT	WOS:000355314100029		
J	Kushida, T; Shuto, A; Yoshio, M; Kato, T; Yamaguchi, S				Kushida, Tomokatsu; Shuto, Ayumi; Yoshio, Masafumi; Kato, Takashi; Yamaguchi, Shigehiro			A Planarized Triphenylborane Mesogen: Discotic Liquid Crystals with Ambipolar Charge-Carrier Transport Properties	ANGEWANDTE CHEMIE-INTERNATIONAL EDITION			English	Article						boron; charge carrier transport; liquid crystals; stacking interactions; x-ray diffraction	3-COORDINATE ORGANOBORON COMPOUNDS; NONLINEAR-OPTICAL PROPERTIES; BORON-DOPED TRI(9,10-ANTHRYLENE)S; PI-ELECTRON MATERIALS; TRIVALENT BORON; SINGLE-PHOTON; 2-PHOTON-EXCITED FLUORESCENCE; OPTOELECTRONIC PROPERTIES; MOLECULAR-STRUCTURES; B-N	A discotic liquid-crystalline (LC) material, consisting of a planarized triphenylborane mesogen, was synthesized. X-ray diffraction analysis confirmed that this compound forms a hexagonal columnar LC phase with an interfacial distance of 3.57 angstrom between the discs. At ambient temperature, this boron-centered discotic liquid crystal exhibited ambipolar carrier transport properties with electron and hole mobility values of approximately 10(-3) and 3x10(-5)cm(2)V(-1)s(-1), respectively.	[Kushida, Tomokatsu; Shuto, Ayumi; Yamaguchi, Shigehiro] Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan; [Kushida, Tomokatsu; Shuto, Ayumi; Yamaguchi, Shigehiro] Nagoya Univ, Inst Transformat Biomol WPI ITbM, Chikusa Ku, Nagoya, Aichi 4648602, Japan; [Yoshio, Masafumi; Kato, Takashi] Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan	Yoshio, M (reprint author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	yoshio@chembio.t.u-tokyo.ac.jp; yamaguchi@chem.nagoya-u.ac.jp	Yamaguchi, Shigehiro/D-7120-2012		CREST, JST; Ministry of Education, Culture, Sports, Science, and Technology of Japan [24109007, 25109513]	This work was supported by CREST, JST, for S.Y. and Grants-in-Aid for Scientific Research on Innovative Area (Stimuli-responsive Chemical Species, no. 24109007 for S.Y. and no. 25109513 for M.Y.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Sergeyev S, 2007, CHEM SOC REV, V36, P1902, DOI 10.1039/b417320c; Hoffend C, 2013, TETRAHEDRON, V69, P7073, DOI 10.1016/j.tet.2013.06.036; Reus C, 2014, MACROMOLECULES, V47, P3727, DOI 10.1021/ma500518x; Liu ZQ, 2003, CHEM-EUR J, V9, P5074, DOI 10.1002/chem.200304833; Yamaguchi S, 2001, J AM CHEM SOC, V123, P11372, DOI 10.1021/ja015957w; Weber L, 2012, CHEM-EUR J, V18, P1369, DOI 10.1002/chem.201102059; Entwistle CD, 2009, J MATER CHEM, V19, P7532, DOI 10.1039/b905719f; Funahashi M, 2009, POLYM J, V41, P459, DOI 10.1295/polymj.PJ2008324; Shuto A, 2013, ORG LETT, V15, P6234, DOI 10.1021/ol403084x; Liu ZQ, 2004, ORG LETT, V6, P2933, DOI 10.1021/ol048984a; Liu ZQ, 2005, ORG LETT, V7, P5481, DOI 10.1021/ol052323b; Tanaka D, 2007, JPN J APPL PHYS 2, V46, pL117, DOI 10.1143/JJAP.46.L117; LEQUAN M, 1991, J MATER CHEM, V1, P997, DOI 10.1039/jm9910100997; Kushida T, 2013, ANGEW CHEM INT EDIT, V52, P8054, DOI 10.1002/anie.201303830; Yoshio M, 2006, J AM CHEM SOC, V128, P5570, DOI 10.1021/ja0606935; Noda T, 1998, J AM CHEM SOC, V120, P9714, DOI 10.1021/ja9817343; Hoffend C, 2012, CHEM-EUR J, V18, P15394, DOI 10.1002/chem.201202280; Entwistle CD, 2004, CHEM MATER, V16, P4574, DOI 10.1021/cm0495717; Entwistle CD, 2002, ANGEW CHEM INT EDIT, V41, P2927, DOI 10.1002/1521-3773(20020816)41:16<2927::AID-ANIE2927>3.0.CO;2-L; Iino H, 2005, OPTO-ELECTRON REV, V13, P295; Yuan Z, 2000, J SOLID STATE CHEM, V154, P5, DOI 10.1006/jssc.2000.8803; Zhou ZG, 2012, J AM CHEM SOC, V134, P4529, DOI 10.1021/ja211944q; Ji L, 2010, ORG LETT, V12, P5192, DOI 10.1021/ol102057t; Charlot M, 2005, PHYS CHEM CHEM PHYS, V7, P600, DOI 10.1039/b416605a; Funahashi M, 2007, ADV MATER, V19, P353, DOI 10.1002/adma.200602319; Kushida T, 2014, CHEM SCI, V5, P1296, DOI 10.1039/c3sc52751d; Yamaguchi S, 2002, J AM CHEM SOC, V124, P8816, DOI 10.1021/ja026689k; Wade CR, 2010, CHEM REV, V110, P3958, DOI 10.1021/cr900401a; Schaz A, 2005, LIQ CRYST, V32, P513, DOI 10.1080/02678290412331329215; Bosdet MJD, 2009, CAN J CHEM, V87, P8, DOI 10.1139/V08-110; Collings JC, 2009, CHEM-EUR J, V15, P198, DOI 10.1002/chem.200801719; Tanaka D, 2007, CHEM LETT, V36, P262, DOI 10.1246/cl.2007.262; Chen PK, 2012, ANGEW CHEM INT EDIT, V51, P7994, DOI 10.1002/anie.201203788; Caruso A, 2010, ANGEW CHEM INT EDIT, V49, P4213, DOI 10.1002/anie.201000411; Yamaguchi S, 2006, PURE APPL CHEM, V78, P1413, DOI 10.1351/pac200678071413; Liu XY, 2006, ANGEW CHEM INT EDIT, V45, P5475, DOI 10.1002/anie.200601286; Shirota Y, 2007, CHEM REV, V107, P953, DOI 10.1021/cr050143+; Branger C, 1996, J MATER CHEM, V6, P555, DOI 10.1039/jm9960600555; Matsuo K, 2014, J AM CHEM SOC, V136, P12580, DOI 10.1021/ja506980p; Mellerup SK, 2014, ORGANOMETALLICS, V33, P5483, DOI 10.1021/om500757r; YUAN Z, 1993, J ORGANOMET CHEM, V449, P27, DOI 10.1016/0022-328X(93)80103-I; Chen PK, 2011, J AM CHEM SOC, V133, P20142, DOI 10.1021/ja209602z; Jia WL, 2005, J MATER CHEM, V15, P3326, DOI 10.1039/b506840a; Percec V, 2001, J AM CHEM SOC, V123, P1302, DOI 10.1021/ja0037771; Kushida T, 2013, ORGANOMETALLICS, V32, P6654, DOI 10.1021/om400560u; Jakle F, 2010, CHEM REV, V110, P3985, DOI 10.1021/cr100026f; Yuan Z, 2006, CHEM-EUR J, V12, P2758, DOI 10.1002/chem.200501096; Kushida T, 2012, CHEM COMMUN, V48, P10715, DOI 10.1039/c2cc35874c; Shirota Y, 2000, J MATER CHEM, V10, P1, DOI 10.1039/a908130e; Branger C, 1997, CHEM PHYS LETT, V272, P265, DOI 10.1016/S0009-2614(97)88019-0; Caruso Jr A., 2010, ANGEW CHEM, V122, P4309; Chen P. K., 2012, ANGEW CHEM, V124, P8118; Entwistle C. D., 2002, ANGEW CHEM, V114, P3051, DOI 10.1002/1521-3757(20020816)114:16<3051::AID-ANGE3051>3.0.CO;2-R; Liu ZQ, 2002, CHEM COMMUN, P2900, DOI 10.1039/b207210f; Hoffend C, 2013, DALTON T, V42, P13826, DOI 10.1039/c3dt51035b; Ji L, 2014, CHEM-EUR J, V20, P13618, DOI 10.1002/chem.201402273; Jia WL, 2004, CHEM-EUR J, V10, P994, DOI 10.1002/chem.200305579; KEPLER RG, 1960, PHYS REV, V119, P1226, DOI 10.1103/PhysRev.119.1226; Kushida T., 2013, ANGEW CHEM, V125, P8212; Liu X., 2006, ANGEW CHEM, V118, P5601, DOI 10.1002/ange.200601286; Mercier L. G., 2009, ANGEW CHEM, V121, P6224; Mercier LG, 2009, ANGEW CHEM INT EDIT, V48, P6108, DOI 10.1002/anie.200902803; Reus C, 2013, J AM CHEM SOC, V135, P12892, DOI 10.1021/ja406766e; Shizu K, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3499310; Tai TB, 2013, J PHYS CHEM C, V117, P14999, DOI 10.1021/jp4049154; Wakamiya A, 2008, CHEM COMMUN, P579, DOI 10.1039/b716107g; Yin XD, 2014, ANGEW CHEM INT EDIT, V53, P9761, DOI 10.1002/anie.201403700; Yin X. D., 2014, ANGEW CHEM, V126, P9919; YUAN Z, 1990, J CHEM SOC CHEM COMM, P1489, DOI 10.1039/c39900001489	69	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1433-7851	1521-3773		ANGEW CHEM INT EDIT	Angew. Chem.-Int. Edit.	JUN 1	2015	54	23					6922	6925		10.1002/anie.201502678		4	Chemistry, Multidisciplinary	Chemistry	CJ2KT	WOS:000355314100046		
J	Ohsawa, I; Honda, D; Nagamachi, S; Hisada, A; Shimamoto, M; Inoshita, H; Mano, S; Tomino, Y				Ohsawa, Isao; Honda, Daisuke; Nagamachi, Seiji; Hisada, Atsuko; Shimamoto, Mamiko; Inoshita, Hiroyuki; Mano, Satoshi; Tomino, Yasuhiko			Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in Japan	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Article							C1 INHIBITOR DEFICIENCY; QUALITY-OF-LIFE; ACQUIRED ANGIOEDEMA; MANAGEMENT; FEATURES; REGISTRY; ATTACKS; BURDEN; EDEMA	Background: Hereditary angioedema (HAE) is a rare and potentially life-threatening condition that results from mutations in the C1 inhibitor (C1-INH). Awareness of HAE among physicians in Japan is increasing, but real-world data are lacking. Objective: To explore the clinical manifestations, diagnosis, quality of life (QOL), and treatment of Japanese patients with HAE. Methods: A 14-point survey was developed and sent to 387 physicians in Japan (March to May 2014) to gather clinical data on their HAE patients' family history, severity and frequency of attacks, QOL, and therapy use. Results: Data on 171 HAE patients were collected from 94 physicians (24.3% response rate). Of the patients, 76.6% had a family history of angioedema (AE), and 11.7% had experienced a death in the family due to an AE attack. HAE type I occurred in 99 patients (57.9%), HAE type II occurred in 9 patients (5.3%), HAE with normal C1-INH occurred in 3 patients (1.8%), and an additional 60 patients were unclassified. Mean time from initial symptoms to diagnosis was 13.8 years. Attacks that required airway management and abdominal surgery with uncertain diagnosis were observed in 9.5% and 2.9% of patients, respectively. In the past year, 21.0% of patients presented with more than 10 attacks, 21.1% were admitted to the hospital for more than 1 day, and 28.7% were absent from work or school. On-demand C1-INH concentrate and prophylactic tranexamic acid were used in approximately half of the patients (47.4% and 39.2%, respectively). Conclusion: HAE is a severe condition characterized by recurrent AE attacks. In Japan, delayed patient diagnosis and limited use of HAE-specific therapies exacerbate the burden on HAE patients. (C) 2015 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.	[Ohsawa, Isao; Honda, Daisuke; Nagamachi, Seiji; Hisada, Atsuko; Shimamoto, Mamiko; Inoshita, Hiroyuki; Mano, Satoshi; Tomino, Yasuhiko] Juntendo Univ, Fac Med, Dept Internal Med, Div Nephrol, Tokyo 1138421, Japan	Tomino, Y (reprint author), Juntendo Univ, Fac Med, Dept Internal Med, Div Nephrol,Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	yasu@juntendo.ac.jp			Japan Society for the Promotion of Science (KAKENHI) [26461493, 26460654]; CSL Behring K.K., Tokyo, Japan	This study was supported in part by grants 26461493 and 26460654 from the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI) and CSL Behring K.K., Tokyo, Japan.	Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Riedl M, 2011, ANN ALLERG ASTHMA IM, V106, P316, DOI 10.1016/j.anai.2010.12.012; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977; Vitrat-Hincky V, 2010, ALLERGY, V65, P1331, DOI 10.1111/j.1398-9995.2010.02368.x; Roche O, 2005, ANN ALLERG ASTHMA IM, V94, P498; Horiuchi T, 2012, ALLERGOL INT, V61, P559, DOI 10.2332/allergolint.12-RAI-0471; Wilson DA, 2010, ANN ALLERG ASTHMA IM, V104, P314, DOI 10.1016/j.anai.2010.01.024; Bork K, 2003, AM J MED, V114, P294, DOI 10.1016/S0002-9343(02)01526-7; Bouillet L, 2013, ANN ALLERG ASTHMA IM, V111, P290, DOI 10.1016/j.anai.2013.07.012; Lumry WR, 2010, ALLERGY ASTHMA PROC, V31, P407, DOI 10.2500/aap.2010.31.3394; Zuraw BL, 2012, ALLERGY ASTHMA PROC, V33, pS145, DOI 10.2500/aap.2012.33.3627; Lunn ML, 2010, ANN ALLERG ASTHMA IM, V104, P211, DOI 10.1016/j.anai.2009.12.004; Bork K, 2013, IMMUNOL ALLERGY CLIN, V33, P457, DOI 10.1016/j.iac.2013.07.002; Aygoren-Pursun E, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-99; Bork Konrad, 2010, Allergy Asthma Clin Immunol, V6, P15, DOI 10.1186/1710-1492-6-15; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Bouillet L, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.034; Bowen T, 2010, ALLERGY ASTHMA CL IM, V6, P1; Bygum A, 2009, BRIT J DERMATOL, V161, P1153, DOI 10.1111/j.1365-2133.2009.09366.x; Craig Timothy, 2012, World Allergy Organ J, V5, P182, DOI 10.1097/WOX.0b013e318279affa; Craig TJ, 2014, INT ARCH ALLERGY IMM, V165, P119, DOI 10.1159/000368404; Duan QL, 2009, J ALLERGY CLIN IMMUN, V123, P906, DOI 10.1016/j.jaci.2008.12.010; Farkas H, 2013, J ANGIOEDEMA, V1, P1; Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x; Iwamoto Kazumasa, 2011, Arerugi, V60, P26; Jolles S, 2014, CLIN EXP IMMUNOL, V175, P59, DOI 10.1111/cei.12159; Kurita T., 2011, Journal of Medical Sciences (Pakistan), V11, P30, DOI 10.3923/jms.2011.30.38; Ohsawa I, 2011, PHARM MED, V29, P109; Ohsawa I, 2013, BMC GASTROENTEROL, V13, P1; Ohsawa I, 2014, ALLERGOL INT, V63, P595, DOI 10.2332/allergolint.14-OA-0700; Psarros F, 2014, INT ARCH ALLERGY IMM, V164, P326, DOI 10.1159/000366276; Riedl MA, 2015, J ALLER CL IMM-PRACT, V3, P220, DOI 10.1016/j.jaip.2014.08.017; Toscani Michael, 2011, Manag Care, V20, P44; Xu YY, 2013, EUR J DERMATOL, V23, P500, DOI 10.1684/ejd.2013.2105; Yamamoto T, 2012, AM J MED SCI, V343, P210, DOI 10.1097/MAJ.0b013e31822bdb65; Zanichelli A, 2013, ALLERGY ASTHMA CL IM, V9, P1; Zuraw Bruce L, 2010, World Allergy Organ J, V3, pS25, DOI 10.1097/WOX.0b013e3181f3f21c	37	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1081-1206	1534-4436		ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	JUN	2015	114	6					492	498		10.1016/j.anai.2015.03.010		7	Allergy; Immunology	Allergy; Immunology	CJ0OV	WOS:000355177000011		
J	Tominari, S; Morita, A; Ishibashi, T; Yamazaki, T; Takao, H; Murayama, Y; Sonobe, M; Yonekura, M; Saito, N; Shiokawa, Y; Date, I; Tominaga, T; Nozaki, K; Houkin, K; Miyamoto, S; Kirino, T; Hashi, K; Nakayama, T				Tominari, Shinjiro; Morita, Akio; Ishibashi, Toshihiro; Yamazaki, Tomosato; Takao, Hiroyuki; Murayama, Yuichi; Sonobe, Makoto; Yonekura, Masahiro; Saito, Nobuhito; Shiokawa, Yoshiaki; Date, Isao; Tominaga, Teiji; Nozaki, Kazuhiko; Houkin, Kiyohiro; Miyamoto, Susumu; Kirino, Takaaki; Hashi, Kazuo; Nakayama, Takeo		Unruptured Cerebral Aneurysm Study	Prediction model for 3-year rupture risk of unruptured cerebral aneurysms in Japanese patients	ANNALS OF NEUROLOGY			English	Article							INTRACRANIAL ANEURYSMS; SUBARACHNOID HEMORRHAGE; ENDOVASCULAR TREATMENT; SACCULAR ANEURYSMS; NATURAL-HISTORY; METAANALYSIS; COHORT; PERIOD; HYPERTENSION; PREVALENCE	ObjectiveTo build a prediction model that estimates the 3-year rupture risk of unruptured saccular cerebral aneurysms. MethodsSurvival analysis was done using each aneurysm as the unit for analysis. Derivation data were from the Unruptured Cerebral Aneurysm Study (UCAS) in Japan. It consists of patients with unruptured cerebral aneurysms enrolled between 2000 and 2004 at neurosurgical departments at tertiary care hospitals in Japan. The model was presented as a scoring system, and aneurysms were classified into 4 risk grades by predicted 3-year rupture risk: I,<1%; II, 1 to 3%; III, 3 to 9%, and IV, >9%. The discrimination property and calibration plot of the model were evaluated with external validation data. They were a combination of 3 Japanese cohort studies: UCAS II, the Small Unruptured Intracranial Aneurysm Verification study, and the study at Jikei University School of Medicine. ResultsThe derivation data include 6,606 unruptured cerebral aneurysms in 5,651 patients. During the 11,482 aneurysm-year follow-up period, 107 ruptures were observed. The predictors chosen for the scoring system were patient age, sex, and hypertension, along with aneurysm size, location, and the presence of a daughter sac. The 3-year risk of rupture ranged from <1% to >15% depending on the individual characteristics of patients and aneurysms. External validation indicated good discrimination and calibration properties. InterpretationA simple scoring system that only needs easily available patient and aneurysmal information was constructed. This can be used in clinical decision making regarding management of unruptured cerebral aneurysms. Ann Neurol 2015;77:1050-1059	[Tominari, Shinjiro; Nakayama, Takeo] Kyoto Univ, Sch Publ Hlth, Dept Hlth Informat, Kyoto 6068501, Japan; [Morita, Akio] Univ Tokyo, Unruptured Cerebral Aneurysm Study Japan Coordina, Tokyo, Japan; [Morita, Akio] Nippon Med Sch, Dept Neurol Surg, Tokyo 113, Japan; [Ishibashi, Toshihiro; Takao, Hiroyuki; Murayama, Yuichi] Jikei Univ, Sch Med, Div Endovasc Neurosurg, Tokyo, Japan; [Yamazaki, Tomosato; Sonobe, Makoto] Mito Med Ctr, Natl Hosp Org, Dept Neurosurg, Ibaraki, Japan; [Yonekura, Masahiro] Nagasaki Med Ctr, Natl Hosp Org, Dept Neurosurg, Nagasaki, Japan; [Saito, Nobuhito] Univ Tokyo, Dept Neurosurg, Tokyo 113, Japan; [Shiokawa, Yoshiaki] Kyorin Univ, Sch Med, Dept Neurosurg, Tokyo, Japan; [Date, Isao] Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 700, Japan; [Tominaga, Teiji] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 980, Japan; [Nozaki, Kazuhiko] Shiga Univ Med Sci, Dept Neurosurg, Otsu, Shiga 52021, Japan; [Houkin, Kiyohiro] Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Sapporo, Hokkaido, Japan; [Miyamoto, Susumu] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan; [Kirino, Takaaki] Natl Hosp Org, Tokyo, Japan; [Hashi, Kazuo] Shinsapporo Neurosurg Hosp, Sapporo, Hokkaido, Japan	Nakayama, T (reprint author), Kyoto Univ, Sch Publ Hlth, Dept Hlth Informat, Sakyo Ku, Yoshidakonoe Cho, Kyoto 6068501, Japan.	t-nakayama@umin.ac.jp			Department of Health Informatics, Kyoto University School of Public Health	This study was funded by the research budget of the Department of Health Informatics, Kyoto University School of Public Health.	Akiyama Y, 2010, CEREBROVASC DIS, V30, P491, DOI 10.1159/000317087; Raghavan ML, 2005, J NEUROSURG, V102, P355, DOI 10.3171/jns.2005.102.2.0355; Juvela S, 2000, J NEUROSURG, V93, P379, DOI 10.3171/jns.2000.93.3.0379; Vlak MHM, 2013, J NEUROL NEUROSUR PS, V84, P619, DOI 10.1136/jnnp-2012-303783; Huang MC, 2011, STROKE, V42, P1730, DOI 10.1161/STROKEAHA.110.603803; Ujiie H, 1999, NEUROSURGERY, V45, P119, DOI 10.1097/00006123-199907000-00028; Yasui N, 1997, NEUROSURGERY, V40, P1155, DOI 10.1097/00006123-199706000-00007; Iasonos A, 2008, J CLIN ONCOL, V26, P1364, DOI 10.1200/JCO.2007.12.9791; Iwamoto H, 1999, STROKE, V30, P1390; Harada K, 2013, ACTA NEUROCHIR, V155, P2037, DOI 10.1007/s00701-013-1841-7; Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3; Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; Sonobe M, 2010, STROKE, V41, P1969, DOI 10.1161/STROKEAHA.110.585059; Raaymakers TWM, 1998, STROKE, V29, P1531; Ikeda N, 2011, LANCET, V378, P1094, DOI 10.1016/S0140-6736(11)61055-6; Nahed BV, 2005, NEUROSURGERY, V57, P676, DOI 10.1227/01.NEU.0000175549.96530.59; Ishibashi T, 2009, STROKE, V40, P313, DOI 10.1161/STROKEAHA.108.521674; Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0; Wermer MJH, 2007, STROKE, V38, P1404, DOI 10.1161/01.STR.0000260955.51401.cd; Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1; Aoki N, 2001, MED DECIS MAKING, V21, P87, DOI 10.1177/02729890122062334; Burns JD, 2009, CURR NEUROL NEUROSCI, V9, P6, DOI 10.1007/s11910-009-0002-0; Wiebers D, 1998, NEW ENGL J MED, V339, P1725; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Lindekleiv H, 2012, STROKE, V43, P1885, DOI 10.1161/STROKEAHA.112.651315; Morita A, 2011, JPN J NEUROSURG TOKY, V20, P484; Morita A, 2012, NEW ENGL J MED, V366, P2474; Naggara ON, 2010, RADIOLOGY, V256, P887, DOI 10.1148/radiol.10091982; Okamoto K, 2005, ANN EPIDEMIOL, V15, P744, DOI 10.1016/j.annepidem.2005.02.001; Rogers W, 1993, STATA TECHNICAL B, V3, P88; Steyerberg EW, 2001, STAT MED, V20, P3847, DOI 10.1002/sim.915.abs; Steyerberg EW, 2009, CLIN PREDICTION MODE; UCAS Japan, TREATM UNR CER AN; Ujiie H, 1999, NEUROSURGERY, V45, P129	34	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUN	2015	77	6					1050	1059		10.1002/ana.24400		10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CJ1GA	WOS:000355230100012		
J	Kuramitsu, Y; Tanaka, I; Wang, YF; Okada, F; Tokuda, K; Kitagawa, T; Akada, J; Nakamura, K				Kuramitsu, Yasuhiro; Tanaka, Issei; Wang, Yufeng; Okada, Futoshi; Tokuda, Kazuhiro; Kitagawa, Takao; Akada, Junko; Nakamura, Kazuyuki			Inflammation-Related Tumor Progression in Murine Fibrosarcoma Exhibited Over-expression of Sex-determining Region Y-box 2 (Sox2) Compared to Parental Regressor Cells	ANTICANCER RESEARCH			English	Article						SOX2; HSPB1; HSF1; tumor progression	HEAT-SHOCK PROTEINS; PANCREATIC-CANCER CELLS; DOWN-REGULATION; TRANSCRIPTION FACTOR-1; MOLECULAR CHAPERONES; HSP27 HSPB1; RESISTANCE; GEMCITABINE; MIGRATION; INVASION	Background/Aim: Tumor progression is one of the most serious issues to overcome cancer disease. As a model of inflammation-induced tumor progression, we used the regressive murine fibrosarcoma cell clone QR-32 and the progressive malignant clone QRsP-11, that was derived from QR-32. Heat shock protein beta-1 (Hspb1) is a molecular chaperone. Hspb1 plays roles in not only cell protection but also chemo-resistance, tumorigenicity and protection from apoptosis. In a recent study, we showed that Hspb1 was upregulated in QRsP-11 compared to QR-32. Materials and Methods: We compared the expression levels of Hspb1, Hsf1 and Sox2 in QR-32 and QRsP-11 cells by means of western blotting. Results: Hsf1, a transcription factor for Hspb1 was not increased in QRsP-11. Sex determining region Y-box 2 (Sox2) is a transcription factor, reported to interact with Hspb1. Sox2 was up-regulated in QRsP-11 compared to QR-32. Conclusion: These results suggest that Sox2-Hspb1 signaling is a possible pathway responsible to tumor progression of QRsP-11.	[Kuramitsu, Yasuhiro; Tanaka, Issei; Wang, Yufeng; Tokuda, Kazuhiro; Kitagawa, Takao; Akada, Junko; Nakamura, Kazuyuki] Yamaguchi Univ, Grad Sch Med, Dept Biochem, Ube, Yamaguchi 7558505, Japan; [Kuramitsu, Yasuhiro; Tanaka, Issei; Wang, Yufeng; Tokuda, Kazuhiro; Kitagawa, Takao; Akada, Junko; Nakamura, Kazuyuki] Yamaguchi Univ, Grad Sch Med, Dept Funct Prote, Ube, Yamaguchi 7558505, Japan; [Okada, Futoshi] Tottori Univ, Sch Med, Div Pathol Biochem, Yonago, Tottori 683, Japan; [Nakamura, Kazuyuki] Tokuyama Med Assoc Hosp, Ctr Clin Labs, Shunan, Yamaguchi, Japan	Kuramitsu, Y (reprint author), Yamaguchi Univ, Grad Sch Med, Dept Biochem & Funct Prote, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	climates@yamaguchi-u.ac.jp					Carver JA, 2003, IUBMB LIFE, V55, P661, DOI 10.1080/15216540310001640498; Mori-Iwamoto S, 2008, MOL MED REP, V1, P429; Liu KC, 2013, CELL SIGNAL, V25, P1264, DOI 10.1016/j.cellsig.2013.02.013; Xia Y, 2012, CANCER LETT, V318, P145, DOI 10.1016/j.canlet.2011.09.043; Bryantsev AL, 2007, BIOCHEM J, V407, P407, DOI 10.1042/BJ20070195; Toma-Jonik A, 2015, CELL SIGNAL, V27, P394, DOI 10.1016/j.cellsig.2014.11.029; OKADA F, 1992, BRIT J CANCER, V66, P635, DOI 10.1038/bjc.1992.329; Lou XY, 2013, OMICS, V17, P510, DOI 10.1089/omi.2013.0058; ISHIKAWA M, 1987, J NATL CANCER I, V78, P567; Nawata J, 2014, ANTICANCER RES, V34, P4807; Chou YT, 2013, STEM CELLS, V31, P2607, DOI 10.1002/stem.1518; Acunzo J, 2012, INT J BIOCHEM CELL B, V44, P1622, DOI 10.1016/j.biocel.2012.04.002; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kim J, 2013, J ORAL PATHOL MED, V42, P9, DOI 10.1111/j.1600-0714.2012.01155.x; Heimberger T, 2013, BRIT J HAEMATOL, V160, P465, DOI 10.1111/bjh.12164; Mori-Iwamoto S, 2007, INT J ONCOL, V31, P1345; Wang YF, 2014, ELECTROPHORESIS, V35, P2195, DOI 10.1002/elps.201300497; de Thonel A, 2012, INT J BIOCHEM CELL B, V44, P1593, DOI 10.1016/j.biocel.2012.06.012; Baron B, ANTICANCER IN PRESS; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; Cox JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062857; FUQUA SAW, 1994, BREAST CANCER RES TR, V32, P67, DOI 10.1007/BF00666207; Katsogiannou M, FRONT GENET, V5, P346; Katsogiannou Maria, 2014, Frontiers in Genetics, V5, P346, DOI 10.3389/fgene.2014.00346; Pavan S, 2014, INT J CANCER, V134, P1289, DOI 10.1002/ijc.28464; Takenawa T, 2013, ANTICANCER RES, V33, P153; Voll EA, 2014, ONCOTARGET, V5, P2648; Xu YM, 2012, J PROTEOME RES, V11, P2625, DOI 10.1021/pr201151a	28	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3217	3221				5	Oncology	Oncology	CJ1VW	WOS:000355273800011		
J	Hara, R; Kikuchi, H; Setoguchi, T; Miyazaki, S; Yamamoto, M; Hiramatsu, Y; Kamiya, K; Ohta, M; Baba, S; Konno, H				Hara, Ryuhei; Kikuchi, Hirotoshi; Setoguchi, Tomohiko; Miyazaki, Shinichiro; Yamamoto, Masayoshi; Hiramatsu, Yoshihiro; Kamiya, Kinji; Ohta, Manabu; Baba, Satoshi; Konno, Hiroyuki			Microarray Analysis Reveals Distinct Gene Set Profiles for Gastric and Intestinal Gastrointestinal Stromal Tumors	ANTICANCER RESEARCH			English	Article						Gastrointestinal stromal tumor; microarray; stomach; intestine; SLIT2	OF-FUNCTION MUTATIONS; TERM-FOLLOW-UP; AXON GUIDANCE; POOR-PROGNOSIS; CDC42 ACTIVITY; CELL INVASION; BETA-CATENIN; SLIT2 GENE; C-KIT; DIAGNOSIS	Aim: We sought to address the mechanisms by which intestinal gastrointestinal stromal tumors (GIST) have a markedly higher risk of recurrence than gastric GISTs. Materials and Methods: Gene expression levels were compared among six primary gastric, three intestinal and six metastatic liver GISTs using cDNA microarray. Protein levels of Slit homolog 2 (SLIT2) were analyzed by immunohisto-chemistry in 25 primary gastric and 10 intestinal GIST. Results: Intestinal GIST had gene expression profiles similar to clinically malignant and metastatic GIST. In gene set-enrichment analysis, the gene sets MITOTIC_CELL CYCLE and NEURON_DIFFERENTIATION were up-regulated and down-regulated, respectively, in intestinal GIST compared to gastric GIST. High-risk gastric GISTs and intestinal GIST, expressed similar levels of SLIT2 protein, which were lower than those of low-risk gastric GISTs. Conclusion: The gene-expression profile of intestinal GISTs was similar to that of metastatic liver GISTs. Besides higher proliferative activity, down-regulation of SLIT2 might be involved in clinically malignant phenotypes of intestinal GIST.	[Hara, Ryuhei; Kikuchi, Hirotoshi; Setoguchi, Tomohiko; Miyazaki, Shinichiro; Yamamoto, Masayoshi; Hiramatsu, Yoshihiro; Kamiya, Kinji; Konno, Hiroyuki] Hamamatsu Univ Sch Med, Dept Surg 2, Hamamatsu, Shizuoka 4313192, Japan; [Ohta, Manabu] Hamamatsu Univ Sch Med, Oncol Ctr, Hamamatsu, Shizuoka 4313192, Japan; [Baba, Satoshi] Hamamatsu Univ Sch Med, Dept Pathol, Hamamatsu, Shizuoka 4313192, Japan	Kikuchi, H (reprint author), Hamamatsu Univ Sch Med, Dept Surg 2, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	kikuchih@hama-med.ac.jp					Hasegawa T, 2002, HUM PATHOL, V33, P669, DOI 10.1053/hupa.2002.124116; Dallol A, 2003, CANCER RES, V63, P1054; Miettinen M, 2005, AM J SURG PATHOL, V29, P52, DOI 10.1097/01.pas.0000146010.92933.de; Zhao WY, 2014, INT J CLIN EXP PATHO, V7, P2298; Patil DT, 2011, ARCH PATHOL LAB MED, V135, P1298, DOI 10.5858/arpa.2011-0022-RA; Joensuu H, 2008, HUM PATHOL, V39, P1411, DOI 10.1016/j.humpath.2008.06.025; Ypsilanti AR, 2010, DEVELOPMENT, V137, P1939, DOI 10.1242/dev.044511; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Wang G, 2013, EXP CELL RES, V319, P1083, DOI 10.1016/j.yexcr.2013.02.011; Joensuu H, 2012, LANCET ONCOL, V13, P265, DOI 10.1016/S1470-2045(11)70299-6; Miettinen M, 2006, ARCH PATHOL LAB MED, V130, P1466; Yiin JJ, 2009, NEURO-ONCOLOGY, V11, P779, DOI 10.1215/15228517-2008-017; Miettinen M, 2002, HUM PATHOL, V33, P478, DOI 10.1053/hupa.2002.124123; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Miettinen M, 2006, AM J SURG PATHOL, V30, P477, DOI 10.1097/00000478-200604000-00008; Chedotal A, 2007, ADV EXP MED BIOL, V621, P65, DOI 10.1007/978-0-387-76715-4_5; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Mehlen P, 2011, NAT REV CANCER, V11, P188, DOI 10.1038/nrc3005; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Dallol A, 2002, CANCER RES, V62, P5874; Joensuu H, 2012, JAMA-J AM MED ASSOC, V307, P1265, DOI 10.1001/jama.2012.347; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S001-5085(03)01046-1; Prasad A, 2008, J BIOL CHEM, V283, P26624, DOI 10.1074/jbc.M800679200; Tseng RC, 2010, CANCER RES, V70, P543, DOI 10.1158/0008-5472.CAN-09-2084; Miettinen M, 2006, SEMIN DIAGN PATHOL, V23, P70, DOI 10.1053/j.semdp.2006.09.001; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Dunwell TL, 2009, EPIGENETICS, V4, P265; Kikuchi H, 2006, CANCER SCI, V97, P127, DOI 10.1111/j.1349-7006.2006.00154.x; Kikuchi H, 2007, CANCER SCI, V98, P1734, DOI 10.1111/j.1349-7006.2007.00592.x; Maiti GP, 2015, OR SURG OR MED OR PA, V119, P202, DOI 10.1016/j.oooo.2014.09.029; O'Leary T, 2002, HUM PATHOL, V33, P456, DOI 10.1053/hupa.2002.124120; Setoguchi T, 2011, CANCER SCI, V102, P883, DOI 10.1111/j.1349-7006.2011.01872.x; Tseng RC, 2015, J THORAC ONCOL, V10, P189, DOI 10.1097/JTO.0000000000000369; Werbowetski-Ogilvie TE, 2006, ONCOGENE, V25, P5103, DOI 10.1038/sj.onc.1209524	35	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3289	3298				10	Oncology	Oncology	CJ1VW	WOS:000355273800018		
J	Takenokuchi, M; Miyamoto, K; Saigo, K; Taniguchi, T				Takenokuchi, Mariko; Miyamoto, Kazuhide; Saigo, Katsuyasu; Taniguchi, Taizo			Bortezomib Causes ER Stress-related Death of Acute Promyelocytic Leukemia Cells Through Excessive Accumulation of PML-RARA	ANTICANCER RESEARCH			English	Article						Proteasome inhibitor; ubiquitin-proteasome system; PML-RARA; ER stress	NF-KAPPA-B; UBIQUITIN-PROTEASOME PATHWAY; OVERCOMES DRUG-RESISTANCE; ARTIFICIAL RING FINGER; MULTIPLE-MYELOMA CELLS; PROTEIN-DEGRADATION; HISTONE DEACETYLASE; INDUCED APOPTOSIS; FUSION PROTEINS; ALPHA	Background/Aim: The success of proteasome inhibitors in therapy of multiple myeloma has led to their use for other malignancies. For the proteasome inhibitor bortezomib, combination therapies with histone deacetylase inhibitors, which up-regulate ubiquitin-proteasome system (UPS)-related enzymes, produce a beneficial effect. However, the mechanisms underlying the effect of bortezomib are not completely understood. We hypothesized that bortezomib causes excessive accumulation of aberrant proteins, which augments endoplasmic reticulum (ER) stress, leading to death of malignant cells. Materials and Methods: The NB4 cell line established from a patient with acute promyelocytic leukemia (APL) expressing the promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA) fusion protein was used to assess changes in cell viability and apoptosis caused by bortezomib, as well as alterations in PML-RARA and UPS-related enzymes via western blotting and immunoprecipitation assays. Results: Bortezomib time- and dose-dependently reduced cell viability and induced apoptosis. Bortezomib significantly increased the abundance of ubiquitinated-PML-RARA (Ub-PML-RARA), ubiquitin-conjugating human enzyme 8 (UbcH8), and Ub-UbcH8, indicating that UbcH8 is the E2 ubiquitin-conjugating enzyme for PML-RARA. Moreover, UbcH8 abundance was dose-dependently increased in the culture supernatant of bortezomib-treated cells. Conclusion: UbcH8 may have a utility as a biomarker of treatment response to bortezomib in patients with APL. Furthermore, bortezomib impairs the UPS that controls normal protein homeostasis by causing excessive accumulation of PML-RARA augmenting ER stress and leading to APL cell death. The study provides a rationale for incorporating proteasome inhibitors in the treatment of diseases expressing aberrant proteins. Furthermore, monitoring of UPS-related enzymes might have use in predicting the treatment response to proteasome inhibitors and in assessing their therapeutic effects.	[Takenokuchi, Mariko; Miyamoto, Kazuhide; Saigo, Katsuyasu; Taniguchi, Taizo] Himeji Dokkyo Univ, Fac Pharmacol Sci, Himeji, Hyogo 6708524, Japan	Takenokuchi, M (reprint author), Himeji Dokkyo Univ, Fac Pharmacol Sci, 7-2-1 Kamiohno, Himeji, Hyogo 6708524, Japan.	tmariko@himeji-du.ac.jp					Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026-008-8025-1; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Hideshima T, 2001, CANCER RES, V61, P3071; Isakson P, 2010, BLOOD, V116, P2324, DOI 10.1182/blood-2010-01-261040; Xie Q, 2002, NATURE, V419, P167, DOI 10.1038/nature00998; Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200; LANOTTE M, 1991, BLOOD, V77, P1080; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Richardson PG, 2007, BLOOD, V110, P3557, DOI 10.1182/blood-2006-08-036947; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Grignani F, 1998, NATURE, V391, P815; Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2009, BLOOD, V114, P1046, DOI 10.1182/blood-2009-01-199604; Khan MM, 2004, J BIOL CHEM, V279, P11814, DOI 10.1074/jbc.M312121200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Buchwald M, 2009, CANCER LETT, V280, P160, DOI 10.1016/j.canlet.2009.02.028; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Sartore-Bianchi A, 2007, CLIN CANCER RES, V13, P5942, DOI 10.1158/1078-0432.CCR-07-0536; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Deegan S, 2013, CELL MOL LIFE SCI, V70, P2425, DOI 10.1007/s00018-012-1173-4; Matondo M, 2010, LEUKEMIA RES, V34, P498, DOI 10.1016/j.leukres.2009.09.020; Kitagawa K, 2009, CANCER SCI, V100, P1374, DOI 10.1111/j.1349-7006.2009.01196.x; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Meister S, 2007, CANCER RES, V67, P1783, DOI 10.1158/0008-5472.CAN-06-2258; Richardson PG, 2008, EXPERT REV ANTICANC, V8, P1053, DOI 10.1586/14737140.8.7.1053; Melnick A, 1999, BLOOD, V93, P3167; Lin RJ, 1998, NATURE, V391, P811; Biswas DK, 2006, J CELL PHYSIOL, V209, P645, DOI 10.1002/jcp.20785; Dai Y, 2011, BRIT J HAEMATOL, V153, P222, DOI 10.1111/j.1365-2141.2011.08591.x; Elkabetz Y, 2003, J BIOL CHEM, V278, P18922, DOI 10.1074/jbc.M.08730200; Grimwade D, 1999, BRIT J HAEMATOL, V106, P591, DOI 10.1046/j.1365-2141.1999.01501.x; Gu JL, 2012, BIOCHEM BIOPH RES CO, V420, P644, DOI 10.1016/j.bbrc.2012.03.056; Hu G, 1999, MOL CELL BIOL, V19, P724; Khan M, 2010, EXPERT REV PROTEOMIC, V7, P591, DOI [10.1586/epr.10.38, 10.1586/EPR.10.38]; Kramer OH, 2008, FASEB J, V22, P1369, DOI 10.1096/fj.06-8050com; Lo Coco F, 1999, BLOOD, V94, P12; Miyamoto K, 2014, SCI REP-UK, V4, DOI 10.1038/srep06574; Miyamoto K, 2012, J PEPT SCI, V18, P135, DOI 10.1002/psc.1426; Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961; Niewerth D, 2013, EXPERT REV ANTICANC, V13, P327, DOI [10.1586/era.13.4, 10.1586/ERA.13.4]; Takenokuchi M, 2009, J CLIN LAB ANAL, V23, P223, DOI 10.1002/jcla.20306; Uttenweiler-Joseph S, 2013, PROTEOMICS, V13, P37, DOI 10.1002/pmic.201200233; Ying HQ, 2006, CELL CYCLE, V5, P506, DOI 10.4161/cc.5.5.2515	48	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3307	3316				10	Oncology	Oncology	CJ1VW	WOS:000355273800020		
J	Tanji, N; Kikugawa, T; Ochi, T; Taguchi, S; Sato, H; Sato, T; Sugahara, T; Hamada, H; Asai, S; Matsumoto, A				Tanji, Nozomu; Kikugawa, Tadahiko; Ochi, Takashi; Taguchi, Senzo; Sato, Hideki; Sato, Takeshi; Sugahara, Takeshi; Hamada, Hitoshi; Asai, Seiji; Matsumoto, Atsushi			Circulating Cytokine Levels in Patients with Prostate Cancer: Effects of Neoadjuvant Hormonal Therapy and External-beam Radiotherapy	ANTICANCER RESEARCH			English	Article						cytokines; prostate cancer; radiotherapy; hormonal therapy	INTERLEUKIN-2 THERAPY; MARKER LESION; TUMOR; IL-2; DOGS; CARCINOMAS; REGRESSION; EFFICACY	Aim: The aim of the study was to better characterize the temporal induction of inflammatory cytokines in the serum of patients with prostate cancer (PCa) treated with radiotherapy and to ascertain the influence of hormonal therapy upon those expressions. Patients and Methods: Between May 2007 and December 2009, 30 patients with localized PCa were treated with 3-dimensional conformal external-beam radiotherapy. Fifteen patients had received neoadjuvant hormonal therapy using a leuteinizing hormone-releasing hormone (LH-RH) analog for six months prior to radiotherapy. The cytokine levels were collectively measured using a multiplex assay system. Results: Seventeen cytokines were at detectable levels throughout the blood sampling times before and during radiotherapy. Hormonal therapy for six months significantly decreased the serum levels of fibroblast growth factor-2 (FGF2) and vascular endothelial growth factor (VEGF). The levels of epidermal growth factor (EGF), granulocyte-colony stimulating factor (G-CSF), and interferon-gamma (IFN gamma) significantly increased during radiotherapy. Most cytokine levels, except for eotaxin, G-CSF, growth-related oncogene (GRO), transforming growth factor-beta (TGF beta)-1 and TGF beta 2, significantly increased during radiotherapy compared to the levels observed before radiotherapy. Conclusion: The present study revealed the influence of hormonal, and of radiation therapy on the proinflammatory cytokine levels in the sera of patients with PCa. In addition, neoadjuvant hormonal therapy amplified the radiation-induced alteration of serum cytokines. Further studies to characterize the mechanism underlying a radiation-or hormone-induced inflammatory state are, therefore, necessary.	[Tanji, Nozomu; Kikugawa, Tadahiko; Asai, Seiji] Ehime Univ, Grad Sch Med, Dept Urol, Toon, Ehime 7910295, Japan; [Ochi, Takashi; Taguchi, Senzo] Ehime Univ, Grad Sch Med, Dept Therapeut Radiol, Toon, Ehime 7910295, Japan; [Sato, Hideki; Sato, Takeshi] Ohzu City Hosp, Dept Urol, Ohzu, Ehime, Japan; [Sugahara, Takeshi; Hamada, Hitoshi] Ehime Prefectural Imabari Hosp, Dept Urol, Imabari, Ehime, Japan; [Matsumoto, Atsushi] Houshasen Daiichi Hosp, Dept Urol, Ohzu, Ehime, Japan	Tanji, N (reprint author), Ehime Univ, Grad Sch Med, Dept Urol, Toon, Ehime 7910295, Japan.	tanji@m.ehime-u.ac.jp					Nak D, 2005, J VET MED A, V52, P366, DOI 10.1111/j.1439-0442.2005.00743.x; Dingli D, 2006, NATURE, V443, P35, DOI 10.1038/443035a; Murgia C, 2006, CELL, V126, P477, DOI 10.1016/j.cell.2006.05.051; Den Otter W, 2013, ANTICANCER RES, V33, P2099; BERNSEN MR, 1993, INT J CANCER, V54, P513, DOI 10.1002/ijc.2910540326; Brooks WC, 2013, TRANSMISSIBLE VENERE; DENOTTER W, 1993, ANTICANCER RES, V13, P2453; Den Otter W, 1998, J UROLOGY, V159, P1183, DOI 10.1016/S0022-5347(01)63548-1; Den Otter W, 1999, CANCER IMMUNOL IMMUN, V48, P419; Den Otter W, 2008, CANCER IMMUNOL IMMUN, V57, P931, DOI 10.1007/s00262-008-0455-z; Den Otter W, 2015, ANTICANCER RES, V35, P713; Hill FWG, 1995, CANCER IMMUNOL IMMUN, V41, P14; Jacobs JJL, 2011, TRENDS CANC RES, V7, P1; Jacobs JJL, 2005, CANCER IMMUNOL IMMUN, V54, P792, DOI 10.1007/s00262-004-0641-6; Kutzler M, 2013, OVERVIEW CANINE TRAN; Martins MIM, RECENT ADV SMALL ANI; Mukaratirwa S., 2003, Veterinary Quarterly, V25, P101; Murchison EP, 2008, ONCOGENE, V27, P19; Nowinsky MA, 1876, J AM VET MED ASSOC, V14, P790; Purohit GN, 2009, INTERNET J VET MED, V6, DOI [10.5580/a6a, DOI 10.5580/A6A]; Rubin E, 2014, ESSENTIALS RUBINS PA, VSixth, P295; Spoormakers TJP, 2003, CANCER IMMUNOL IMMUN, V52, P179, DOI 10.1007/s00262-002-0369-0; Stewart RJE, 2006, VET REC, V159, P668; Welsh JS, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2010-0301; Woods JP, 2013, SMALL ANIMAL CLIN ON, V4th, P692; YANG TJ, 1987, J AM VET MED ASSOC, V190, P555; Ziekman PGPM, 2013, ANTICANCER RES, V33, P161	27	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3379	3391				12	Oncology	Oncology	CJ1VW	WOS:000355273800028		
J	Taniguchi, D; Harimoto, N; Takeishi, K; Itoh, S; Yamashita, Y; Ikegami, T; Yoshizumi, T; Kawanaka, H; Shirabe, K; Morodomi, Y; Tagawa, T; Okamoto, T; Maehara, Y				Taniguchi, Daisuke; Harimoto, Norifumi; Takeishi, Kazuki; Itoh, Shinji; Yamashita, Yoichi; Ikegami, Toru; Yoshizumi, Tomoharu; Kawanaka, Hirofumi; Shirabe, Ken; Morodomi, Yosuke; Tagawa, Tetsuzo; Okamoto, Tatsuro; Maehara, Yoshihiko			Liver Transplantation Followed by Pulmonary Resection Complicated with End-Stage Liver Cirrhosis: A Case Report	ANTICANCER RESEARCH			English	Article						Lung cancer; living donor liver transplantation; pulmonary resection	CANCER	Background: With the recent popularization of living-donor liver transplantation (LDLT), it has become important to provide treatment for comorbidities in recipients. We report the case of a patient who was successfully treated with LDLT, followed by left upper lobectomy for lung cancer concomitant with decompensated liver cirrhosis. Case Report: A 67-year-old female was admitted for treatment for severe liver cirrhosis. The lung cancer was identified preoperatively using computed tomography. We initially performed LDLT to improve liver function and coagulopathy; the patient was discharged postoperatively on day 39 without complication. Three months after LDLT, we performed a left upper lobectomy. Results: The patient's postoperative course was uneventful and she was discharged after 11 days. Conclusion: We conclude that an aggressive and appropriate surgical strategy, including LDLT, is an effective curative treatment in patients with controllable malignancy, concomitant with severe liver dysfunction.	[Taniguchi, Daisuke; Harimoto, Norifumi; Takeishi, Kazuki; Itoh, Shinji; Yamashita, Yoichi; Ikegami, Toru; Yoshizumi, Tomoharu; Kawanaka, Hirofumi; Shirabe, Ken; Morodomi, Yosuke; Tagawa, Tetsuzo; Okamoto, Tatsuro; Maehara, Yoshihiko] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan	Harimoto, N (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	harimoto@surg2.med.kyushu-u.ac.jp					Sawabata N, 2011, J THORAC ONCOL, V6, P1229, DOI 10.1097/JTO.0b013e318219aae2; Soejima Y, 2012, AM J TRANSPLANT, V12, P1877, DOI 10.1111/j.1600-6143.2012.04022.x; Mansour A, 1997, SURGERY, V122, P730, DOI 10.1016/S0039-6060(97)90080-5; Buell JF, 2005, TRANSPLANTATION, V80, pS254, DOI 10.1097/01.tp.0000186382.81130.ba; Murray KF, 2005, HEPATOLOGY, V41, P1407, DOI 10.1002/hep.20704; Benten D, 2008, LIVER TRANSPLANT, V14, P789, DOI 10.1002/lt.21434; Fransworth N, 2004, AM J SURG, V188, P580; Nishimura S, 2014, ANTICANCER RES, V34, P4307; The Japan Lung Cancer Society, 2010, GUID SEV OBST HEM, V7th, P1; Vallejo GH, 2005, CRIT REV ONCOL HEMAT, V56, P87, DOI 10.1016/j.critevonc.2004.12.011	10	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3411	3414				4	Oncology	Oncology	CJ1VW	WOS:000355273800032		
J	Ueda, K; Suekane, S; Nishihara, K; Ogasawara, N; Kurose, H; Hayashi, S; Chikui, K; Suyama, S; Nakiri, M; Matsuo, M; Igawa, T				Ueda, Kosuke; Suekane, Shigetaka; Nishihara, Kiyoaki; Ogasawara, Naoyuki; Kurose, Hirofumi; Hayashi, Shuichiro; Chikui, Katsuaki; Suyama, Shunsuke; Nakiri, Makoto; Matsuo, Mitsunori; Igawa, Tsukasa			Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma	ANTICANCER RESEARCH			English	Article						Renal cell carcinoma; molecular targeted therapy; prognostic factor; duration of first-line treatment	ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; C-REACTIVE PROTEIN; INTERFERON-ALPHA; PROGRESSION-FREE; CANCER; IMPACT; TRIAL; SORAFENIB; SUNITINIB	Aim: We investigated the prognostic factors associated with overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who received molecular targeted-therapies. Material and Methods: A total of 66 patients underwent molecular targeted-therapies at the Kurume University between May 2008 and April 2014. Medical records were retrieved and analyzed retrospectively. Results: The median OS was 25.9 [95% confidence interval (CI)=18.3-33.7] months. The median OS stratified by the Memorial Sloan Kettering Cancer Center risk classification was 49.3, 28.6 and 18.3 months for the favorable-, intermediate-and poor-risk groups, respectively. Univariate analyses for various factors revealed gender, pre-treatment C-reactive protein (CRP) level, best response to first-line treatment, the number of molecular targeted agents and the duration of first-line treatment with a median of 6 months, as prognostic variables. Multivariate analyses showed than two or more than three molecular targeted agents [two: hazard ratio (HR)=0.351, 95% CI=0.121-0.901; more than three: HR=0.193, 95% CI=0.069-0.495] and a duration of first-line treatment of more than 6 months (HR=0.203, 95% CI=0.078-0.498) to be independent prognostic factors. Conclusion: Our results suggest that the duration of first-line treatment with molecular targeted-therapies is the strongest prognostic factor in patients with mRCC.	[Ueda, Kosuke; Suekane, Shigetaka; Nishihara, Kiyoaki; Ogasawara, Naoyuki; Kurose, Hirofumi; Hayashi, Shuichiro; Chikui, Katsuaki; Suyama, Shunsuke; Nakiri, Makoto; Matsuo, Mitsunori; Igawa, Tsukasa] Kurume Univ, Sch Med, Dept Urol, Kurume, Fukuoka 8300011, Japan	Ueda, K (reprint author), Kurume Univ, Sch Med, Dept Urol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	ueda_kousuke@med.kurume-u.ac.jp					Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764; Chow WH, 1999, JAMA-J AM MED ASSOC, V281, P1628, DOI 10.1001/jama.281.17.1628; Heng DY, 2012, ANN ONCOL, V23, P1549, DOI 10.1093/annonc/mdr533; Beuselinck B, 2011, ANN ONCOL, V22, P794, DOI 10.1093/annonc/mdq554; Tran HT, 2012, LANCET ONCOL, V13, P827, DOI 10.1016/S1470-2045(12)70241-3; Wu Y, 2011, J CANCER RES CLIN, V137, P887, DOI 10.1007/s00432-010-0951-3; Saito K, 2009, EUR UROL, V55, P1145, DOI 10.1016/j.eururo.2008.10.012; Hegde PS, 2013, CLIN CANCER RES, V19, P929, DOI 10.1158/1078-0432.CCR-12-2535; Jonasch E, 2010, CANCER, V116, P57, DOI 10.1002/cncr.24685; Zurita AJ, 2012, ANN ONCOL, V23, P46, DOI 10.1093/annonc/mdr047; Teishima J, 2014, ONCOL LETT, V8, P881, DOI 10.3892/ol.2014.2207; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.20.1.289; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Yasuda Y, 2013, INT J CLIN ONCOL, V18, P884, DOI 10.1007/s10147-012-0454-0; Pena C, 2010, CLIN CANCER RES, V16, P4853, DOI 10.1158/1078-0432.CCR-09-3343; Patil S, 2011, ANN ONCOL, V22, P295, DOI 10.1093/annonc/mdq342; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; Busch J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-295; Ko JJ, 2014, BRIT J CANCER, V110, P1917, DOI 10.1038/bjc.2014.25; Marugame T, 2006, JPN J CLIN ONCOL, V36, P668, DOI 10.1093/jjco/hyl084; Muriel LC, 2012, INVEST NEW DRUGS, V30, P2443; Seidel C, 2012, EUR J CANCER, V48, P1023, DOI 10.1016/j.ejca.2012.02.048; Seidel C, 2013, BRIT J CANCER, V109, P2998, DOI 10.1038/bjc.2013.662; Tsavachidou-Fenner D, 2010, ANN ONCOL, V21, P1599, DOI 10.1093/annonc/mdp600; Vuky J, 2000, UROL ONCOL, V5, P249, DOI 10.1016/S1078-1439(00)00068-5	26	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3415	3421				7	Oncology	Oncology	CJ1VW	WOS:000355273800033		
J	Sonoda, K; Yahata, H; Ichinoe, A; Okugawa, K; Kaneki, E; Kawano, Y; Kenjo, H; Ohgami, T; Yagi, H; Ohga, S; Asai, K; Nakamura, K; Honda, H; Kato, K				Sonoda, Kenzo; Yahata, Hideaki; Ichinoe, Akimasa; Okugawa, Kaoru; Kaneki, Eisuke; Kawano, Yoshiaki; Kenjo, Hironori; Ohgami, Tatsuhiro; Yagi, Hiroshi; Ohga, Saiji; Asai, Kaori; Nakamura, Katsumasa; Honda, Hiroshi; Kato, Kiyoko			Retrospective Analysis of Concurrent Chemoradiation with Triweekly Cisplatin plus 5-Fluorouracil Versus Weekly Cisplatin in Cervical Cancer	ANTICANCER RESEARCH			English	Article						Cervical cancer; concurrent chemoradiation; survival	RATE INTRACAVITARY BRACHYTHERAPY; GYNECOLOGIC-ONCOLOGY-GROUP; TERM-FOLLOW-UP; UTERINE CERVIX; RADIATION-THERAPY; PELVIC RADIATION; RANDOMIZED-TRIAL; PHASE-II; CHEMORADIOTHERAPY; CARCINOMA	Background/Aim: Concurrent chemoradiation (CCRT) is the standard treatment for locally advanced cervical cancer. The purpose of the study was to compare the outcomes of triweekly cisplatin plus 5-fluorouracil and weekly cisplatin regimens. Patients and Methods: We retrospectively reviewed data from 91 patients with stage IB1-IVA cervical cancer. Results: Out of 91 patients, 48 received triweekly CCRT and 43 received weekly CCRT. For triweekly CCRT, patients received a median of two chemotherapy cycles and median total doses of cisplatin and 5-fluorouracil were 210 mg/body and 8,525 mg/body, respectively. For weekly CCRT, patients received a median of five chemotherapy cycles and the median total dose of cisplatin was 252 mg/body. No statistically significant differences in overall survival or progression-free survival were noted between the two groups. Conclusion: Both triweekly CCRT and weekly CCRT appear to have similar efficacy for cervical cancer patients, but the toxicities were better tolerable in weekly CCRT.	[Sonoda, Kenzo; Yahata, Hideaki; Ichinoe, Akimasa; Okugawa, Kaoru; Kaneki, Eisuke; Kawano, Yoshiaki; Kenjo, Hironori; Ohgami, Tatsuhiro; Yagi, Hiroshi; Kato, Kiyoko] Kyushu Univ, Dept Obstet & Gynecol, Grad Sch Med Sci, Fukuoka 8128582, Japan; [Ohga, Saiji; Asai, Kaori; Nakamura, Katsumasa; Honda, Hiroshi] Kyushu Univ, Dept Clin Radiol, Grad Sch Med Sci, Fukuoka 8128582, Japan	Sonoda, K (reprint author), Kyushu Univ, Dept Obstet & Gynecol, Grad Sch Med Sci, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	kenzo@med.kyushu-u.ac.jp					Shim SH, 2013, GYNECOL ONCOL, V128, P54, DOI 10.1016/j.ygyno.2012.09.033; Cannistra SA, 1996, NEW ENGL J MED, V334, P1030, DOI 10.1056/NEJM199604183341606; Toita T, 2012, GYNECOL ONCOL, V126, P211, DOI 10.1016/j.ygyno.2012.04.036; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; Peters WA, 2000, J CLIN ONCOL, V18, P1606; Mabuchi S, 2010, GYNECOL OBSTET INVES, V69, P224, DOI 10.1159/000273207; Green JA, 2001, LANCET, V358, P781, DOI 10.1016/S0140-6736(01)05965-7; Kirwan JM, 2003, RADIOTHER ONCOL, V68, P217, DOI 10.1016/S0167-8140(03)00197-X; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Keys HM, 1999, NEW ENGL J MED, V340, P1154, DOI 10.1056/NEJM199904153401503; Whitney CW, 1999, J CLIN ONCOL, V17, P1339; Hirakawa M, 2008, GYNECOL ONCOL, V108, P126, DOI 10.1016/j.ygyno.2007.08.091; Choi CH, 2011, INT J RADIAT ONCOL, V81, P1252, DOI 10.1016/j.ijrobp.2010.07.2006; Colombo A, 1997, TUMORI, V83, P895; Fujiwara H, 2014, INT J GYNECOL CANCER, V24, pS96, DOI 10.1097/IGC.0000000000000263; Hong Ji-Hong, 2006, Chang Gung Med J, V29, P550; Kong TW, 2012, J GYNECOL ONCOL, V23, P235, DOI 10.3802/jgo.2012.23.4.235; Kuzuya Kazuo, 2004, Int J Clin Oncol, V9, P458, DOI 10.1007/s10147-004-0452-y; Monk BJ, 1998, GYNECOL ONCOL, V71, P308, DOI 10.1006/gyno.1998.5140; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; Nagai Y, 2012, ANTICANCER RES, V32, P1475; National Cancer Institutes Clinical Announcement, 1999, CONC CHEM CERV CANC; Shibata K, 2009, EJSO-EUR J SURG ONC, V35, P768, DOI 10.1016/j.ejso.2008.07.002; Sonoda K, 2013, PATIENT SURVEILLANCE, P335; STEHMAN FB, 1993, J CLIN ONCOL, V11, P1523; Tang J, 2012, GYNECOL ONCOL, V125, P297, DOI 10.1016/j.ygyno.2012.01.033; Thomas G, 1998, GYNECOL ONCOL, V69, P137, DOI 10.1006/gyno.1998.4990; Toita T, 2012, INT J GYNECOL CANCER, V22, P1420, DOI 10.1097/IGC.0b013e3182647265; Tseng CJ, 1997, GYNECOL ONCOL, V66, P52, DOI 10.1006/gyno.1997.4721; Ushijima K, 2013, J GYNECOL ONCOL, V24, P108, DOI 10.3802/jgo.2013.24.2.108	30	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3447	3454				8	Oncology	Oncology	CJ1VW	WOS:000355273800038		
J	Kawahara, H; Watanabe, K; Enomoto, H; Tomoda, M; Akiba, T; Yanaga, K				Kawahara, Hidejiro; Watanabe, Kazuhiro; Enomoto, Hiroya; Tomoda, Mitsuhiro; Akiba, Tadashi; Yanaga, Katsuhiko			Sentinel Node Navigation Surgery for Lower Rectal Cancer	ANTICANCER RESEARCH			English	Article						Lower rectal cancer; lateral pelvic dissection; laparoscopic surgery; sentinel lymph node	MESORECTAL EXCISION; DISSECTION; CARCINOMA; RADIOTHERAPY; TRIAL	Background: Lateral pelvic lymph node metastasis is generally present in 17% of patients with T3 lower rectal cancer. However, such lymph node metastases cannot be accurately detected before surgery. Since 2001, we have performed sentinel node navigation surgery for patients with T3 lower rectal cancer considering the lymph nodes located between the vesicohypogastric fascia and the pelvic nerve plexus as the lateral sentinel lymph node (LSN). Patients and Methods: Between 2001 and 2010, 101 patients with T3 lower rectal cancer without distant metastasis or peritoneal dissemination were prospectively enrolled in the study. Patients with negative lymph nodes in the mesorectum underwent only LSN dissection in the lateral pelvic space. Patients with metastatic lymph nodes detected in the mesorectum underwent lateral pelvic lymph node dissection (LPLD). Results: Fifty-three out of the 101 patients with pathologically-negative lymph nodes in the mesorectum and a negative LSN were clinically judged as having stage. disease because no recurrence was detected in the lateral pelvic space during the three years following surgery. The other 48 patients underwent LPLD because of a positive lymph node in the mesorectum, and were further divided into two sub-groups, 40 with a negative and 8 with a positive LSN. Only the eight patients with a positive LSN also had positive lymph nodes in the lateral pelvic space. Conclusion: Patients with T3 lower rectal cancer in stage. may not require LPLD. LSN may be very useful to determine stage. disease during surgery.	[Kawahara, Hidejiro; Watanabe, Kazuhiro; Enomoto, Hiroya; Tomoda, Mitsuhiro; Akiba, Tadashi] Jikei Univ, Sch Med, Kashiwa Hosp, Dept Surg, Kashiwa, Chiba 2778567, Japan; [Yanaga, Katsuhiko] Jikei Univ, Sch Med, Dept Surg, Tokyo, Japan	Kawahara, H (reprint author), Jikei Univ, Sch Med, Kashiwa Hosp, Dept Surg, 163-1 Kashiwashita, Kashiwa, Chiba 2778567, Japan.	kawahide@jikei.ac.jp					Ueno M, 2005, BRIT J SURG, V92, P756, DOI 10.1002/bjs.4975; CEDERMARK B, 1995, CANCER, V75, P2269, DOI 10.1002/1097-0142(19950501)75:9<2269::AID-CNCR2820750913>3.0.CO;2-I; [Anonymous], 2006, JAPANESE SOC CANC CO, VSeventh; Sugihara K, 2006, DIS COLON RECTUM, V49, P1663, DOI 10.1007/s10350-006-0714-z; Martling A, 2001, CANCER, V92, P896, DOI 10.1002/1097-0142(20010815)92:4<896::AID-CNCR1398>3.0.CO;2-R; Heald RJ, 1998, SEMIN SURG ONCOL, V15, P66, DOI 10.1002/(SICI)1098-2388(199809)15:2<66::AID-SSU2>3.0.CO;2-3; MORIYA Y, 1995, EUR J CANCER, V31A, P1229, DOI 10.1016/0959-8049(95)00164-E; [Anonymous], 2009, JAP SOC CANC COL REC, VSecond; MACFARLANE JK, 1993, LANCET, V341, P457; Funahashi K, 2006, DIS COLON RECTUM, V49, pS53, DOI 10.1007/s10350-006-0659-2; HEALD RJ, 1982, BRIT J SURG, V69, P613, DOI 10.1002/bjs.1800691019; HEALD RJ, 1988, J ROY SOC MED, V81, P503; Homma Y, 2015, SURG TODAY, V44, P1084; Kawahara H, 2007, DIGEST SURG, V24, P413, DOI 10.1159/000108323; Kawahara H, 2012, HEPATO-GASTROENTEROL, V59, P116, DOI 10.5754/hge11320; MORIYA Y, 1989, DIS COLON RECTUM, V32, P307, DOI 10.1007/BF02553486; Quadros CA, 2006, ANN SURG ONCOL, V13, P1617, DOI 10.1245/s10434-006-9116-7; Sobin LH, 2002, INT UNION CANC TNM C; Surgihara K, 1996, CANCER, V78, P1871; Takahashi T, 2000, DIS COLON RECTUM, V43, pS59, DOI 10.1007/BF02237228	20	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3489	3493				5	Oncology	Oncology	CJ1VW	WOS:000355273800044		
J	Ogawa, S; Itabashi, M; Kondo, C; Momose, M; Sakai, S; Kameoka, S				Ogawa, Shimpei; Itabashi, Michio; Kondo, Chisato; Momose, Mitsuru; Sakai, Shuji; Kameoka, Shingo			Prognostic Value of Total Lesion Glycolysis Measured by F-18-FDG-PET/CT in Patients with Colorectal Cancer	ANTICANCER RESEARCH			English	Article						Total lesion glycolysis; TLG; F-18-FDG PET/CT; colorectal cancer; prognostic value	SQUAMOUS-CELL CARCINOMA; POSITRON-EMISSION-TOMOGRAPHY; STANDARDIZED UPTAKE VALUE; RADIATION-THERAPY; TUMOR VOLUME; COMPUTED-TOMOGRAPHY; PET-CT; SURVIVAL; PARAMETERS; RECURRENCE	Aim: [F-18] Fluorodeoxyglucose positron-emission tomography with computed tomography (F-18-FDG-PET/CT) was assessed regarding its utility in prediction of outcomes after curative resection of colorectal cancer. Patients and Methods: Preoperative F-18-FDG-PET/CT was performed in 325 patients with colorectal cancer. Maximum standardized uptake value (SUVmax), mean SUV (SUVmean), metabolic volume (MV), and total lesion glycolysis (TLG) were measured. Patients were divided into groups using cut-offs for overall survival (OS). F-18-FDG-PET/CT parameters and other clinicopathological factors were investigated as prognostic factors. Results: The 5-year OS rates in the low and high SUVmax, SUVmean, MV, and TLG groups were 91.4% and 87.0% (p= 0.238), 90.8% and 88.2% (p= 0.453), 91.7% and 83.8% (p= 0.006), and 92.1% and 70.1% (p= 0.001), respectively, indicating poorer outcomes in patients with high MV and TLG. In multivariate analysis, high TLG, age >= 65 years, rectal tumor location, and pN(+) were independent factors predicting a poor prognosis. Conclusion: TLG in F-18-FDG-PET/CT is a prognostic parameter for colorectal cancer after curative resection.	[Ogawa, Shimpei; Itabashi, Michio; Kameoka, Shingo] Tokyo Womens Med Univ, Sch Med, Dept Surg 2, Shinjuku Ku, Tokyo 1628666, Japan; [Kondo, Chisato; Momose, Mitsuru; Sakai, Shuji] Tokyo Womens Med Univ, Sch Med, Dept Diagnost Imaging & Nucl Med, Shinjuku Ku, Tokyo 1628666, Japan	Itabashi, M (reprint author), Tokyo Womens Med Univ, Sch Med, Dept Surg 2, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	itabashi@surg2.twmu.ac.jp					Hermans R, 1999, INT J RADIAT ONCOL, V44, P755, DOI 10.1016/S0360-3016(99)00039-5; Park GC, 2013, ANN ONCOL, V24, P208, DOI 10.1093/annonc/mds247; Moon SH, 2013, HEAD NECK-J SCI SPEC, V35, P15, DOI 10.1002/hed.22904; Hyun SH, 2010, ANN SURG ONCOL, V17, P115, DOI 10.1245/s10434-009-0719-7; Moon SH, 2013, KOREAN J RADIOL, V14, P1, DOI 10.3348/kjr.2013.14.1.1; Shum WY, 2012, ANTICANCER RES, V32, P4163; Gulec SA, 2011, EUR J NUCL MED MOL I, V38, P1289, DOI 10.1007/s00259-011-1758-4; Chan WKS, 2011, CLIN NUCL MED, V36, P1007, DOI 10.1097/RLU.0b013e31821a29a4; Chen SW, 2014, CLIN NUCL MED, V39, pE296, DOI 10.1097/RLU.0000000000000243; Edge SB, 2010, AJCC CANC STAGING MA; Herbertson RA, 2007, ANN ONCOL, V18, P1774, DOI 10.1093/annonc/mdm108; Jo HJ, 2014, CLIN NUCL MED, V39, P493, DOI 10.1097/RLU.0000000000000438; Kyoto Y, 2010, ANN NUCL MED, V24, P395, DOI 10.1007/s12149-010-0372-z; Lee JE, 2012, WORLD J GASTROENTERO, V18, P5072, DOI 10.3748/wjg.v18.i36.5072; Ljumanovic R, 2004, RADIOLOGY, V232, P440, DOI 10.1148/radiol.2322031001; Park MS, 2014, ANTICANCER RES, V34, P2551	16	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3495	3500				6	Oncology	Oncology	CJ1VW	WOS:000355273800045		
J	Ohi, M; Mori, K; Toiyama, Y; Mohri, Y; Okigami, M; Yasuda, H; Saigusa, S; Tanaka, K; Inoue, Y; Kusunoki, M				Ohi, Masaki; Mori, Koichiro; Toiyama, Yuji; Mohri, Yasuhiko; Okigami, Masato; Yasuda, Hiromi; Saigusa, Susumu; Tanaka, Koji; Inoue, Yasuhiro; Kusunoki, Masato			Preoperative Prediction of Peritoneal Metastasis in Gastric Cancer as an Indicator for Neoadjuvant Treatment	ANTICANCER RESEARCH			English	Article						Albumin; lymphocyte; gastric cancer; peritoneal metastasis	STAGING LAPAROSCOPY; PROGNOSTIC-FACTOR; LYMPHOCYTE RATIO; NEUTROPHIL; IMPROVES; CA-19-9; TUMOR; NODE; CEA	Aim: The aim of the present study was to investigate whether serum markers and clinical factors could be used for preoperative prediction of peritoneal metastasis in gastric cancer (GC) as an indicator for neoadjuvant treatment. Patients and Methods: We enrolled 493 patients with GC for whom preoperative serum tumor markers [carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9], systemic inflammatory marker C-reactive protein (CRP), host immune markers [neutrophil and lymphocyte counts and their ratio (NLR)], albumin as a nutritional marker, and objective preoperative clinical factors were available as indicators of postoperative peritoneal metastasis. Results: Specific clinical factors, including tumor size, histopathology of biopsy sample, and tumor morphology, were significantly correlated with peritoneal metastasis. CA19-9, lymphocyte count and NLR were also predictive factors for peritoneal metastasis. Multivariate analysis identified the clinical factors tumor morphology and histopathology, and laboratory markers CA19-9 and lymphocyte count as independent factors predictive for peritoneal metastasis. A combination of independent predictive factors achieved high predictive accuracy (0.882) for peritoneal metastasis preoperatively. Conclusion: A combination of specific factors is an alternative method to preoperatively discriminate patients with GC with peritoneal metastasis from those without.	[Ohi, Masaki; Mori, Koichiro; Toiyama, Yuji; Mohri, Yasuhiko; Okigami, Masato; Yasuda, Hiromi; Saigusa, Susumu; Tanaka, Koji; Inoue, Yasuhiro; Kusunoki, Masato] Mie Univ, Grad Sch Med, Inst Life Sci, Dept Gastrointestinal & Pediat Surg,Div Reparat M, Tsu, Mie 5148507, Japan	Toiyama, Y (reprint author), Mie Univ, Grad Sch Med, Inst Life Sci, Dept Gastrointestinal & Pediat Surg,Div Reparat M, Tsu, Mie 5148507, Japan.	ytoi0725@clin.medic.mie-u.ac.jp					Onate-Ocana LF, 2007, ANN SURG ONCOL, V14, P381, DOI 10.1245/s10434-006-9093-x; Sarela AI, 2006, AM J SURG, V191, P134, DOI 10.1016/j.amjsurg.2005.10.015; Halazun KJ, 2008, EJSO-EUR J SURG ONC, V34, P55, DOI 10.1016/j.ejso.2007.02.014; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Walsh Sr, 2005, J SURG ONCOL, V91, P181, DOI 10.1002/jso.20329; PETRIE HT, 1985, J IMMUNOL, V134, P230; Ishigami H, 2010, ANN ONCOL, V21, P67, DOI 10.1093/annonc/mdp260; [Anonymous], 2011, GASTRIC CANC, V14, P101; Louhimo J, 2002, ANTICANCER RES, V22, P1759; Glehen O, 2004, LANCET ONCOL, V5, P219, DOI 10.1016/S1470-2045(04)01425-1; Nozoe T, 2011, AM J SURG, V201, P186, DOI 10.1016/j.amjsurg.2010.01.030; Lai H, 2014, TUMOR BIOL, V35, P10547, DOI 10.1007/s13277-014-2355-5; Song KY, 2007, WORLD J SURG, V31, P1228, DOI 10.1007/s00268-007-9017-3; Yonemura Y, 2006, EJSO, V32, P661, DOI 10.1016/j.ejso.2006.03.007; ELHAG A, 1987, J IMMUNOL, V139, P2406; Carpelan-Holmstrom M, 2002, ANTICANCER RES, V22, P2311; Chang Cheng-Chih, 2010, Chang Gung Med J, V33, P301; Cidón Esther Uña, 2009, Clin Med Oncol, V3, P91; D'Ugo DM, 2003, J AM COLL SURGEONS, V196, P965, DOI 10.1016/S1072-7515(03)00126-1; Edge SB, 2010, AJCC CANC STAGING MA; FUJIMOTO S, 1993, ONCOLOGY, V50, P338; Fujiwara Y, 2011, ANN SURG ONCOL, V18, P3726, DOI 10.1245/s10434-011-1770-8; Hur H, 2010, J SURG ONCOL, V102, P753, DOI 10.1002/jso.21685; Hwang Gun Ick, 2004, Cancer Res Treat, V36, P178, DOI 10.4143/crt.2004.36.3.178; Kim DK, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-155; Nakayama Y, 2014, SURG TODAY, V44, P2146, DOI 10.1007/s00595-014-0917-1; Ozkan E, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-75; Polat E, 2014, PAK J MED SCI, V30, P145, DOI 10.12669/pjms.301.3968; Seevaratnam R, 2012, GASTRIC CANCER, V15, pS3, DOI 10.1007/s10120-011-0069-6; Wang Z, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-19; Yamashita H, 2010, WORLD J SURG, V34, P2399, DOI 10.1007/s00268-010-0703-1; Zahorec R, 2001, Bratisl Lek Listy, V102, P5	32	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3511	3518				8	Oncology	Oncology	CJ1VW	WOS:000355273800047		
J	Shimokawa, M; Itoh, S; Ikegami, T; Takeishi, K; Harimoto, N; Yamashita, YI; Yoshizumi, T; Kawanaka, H; Shirabe, K; Maehara, Y				Shimokawa, Masahiro; Itoh, Shinji; Ikegami, Toru; Takeishi, Kazuki; Harimoto, Norifumi; Yamashita, Yo-Ich; Yoshizumi, Tomoharu; Kawanaka, Hirofumi; Shirabe, Ken; Maehara, Yoshihiko			Local Therapy Improvement of Outcome in a Patient with Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Case Report	ANTICANCER RESEARCH			English	Article						hepatocellular carcinoma; living donor liver transplantation; microsatellite analysis; case report	PROGNOSIS	We describe a very rare case of recurrent hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT). A 47-year-old female underwent LDLT for HCC within Milan criteria, receiving a left liver lobe from her 38-year-old husband with an incompatible blood type. Thirty months after LDLT, however, enhanced computed tomography (CT) showed a tumor in her left adrenal gland; after another six months, enhanced CT and positron-emission tomography detected a frontal head bone tumor; enhanced CT performed 54 months after LDLT revealed a recurrent HCC in the liver graft. Each of these three tumors was surgically resected. Two months after hepatic partial resection, an enhanced CT showed another HCC in her liver graft, which was treated with local ablation therapy. One year after the last ablation treatment, the recipient is doing well without evidence of recurrence. At the time of detection of each of these tumors, the patient's serum concentration of hepatitis B virus surface antigen was elevated. Pathological examination showed that the resected tumors were moderately differentiated HCCs. Genotyping by microsatellite analysis confirmed their origin to be metastases of the primary HCC.	[Shimokawa, Masahiro; Itoh, Shinji; Ikegami, Toru; Takeishi, Kazuki; Harimoto, Norifumi; Yamashita, Yo-Ich; Yoshizumi, Tomoharu; Kawanaka, Hirofumi; Shirabe, Ken; Maehara, Yoshihiko] Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Fukuoka 8128582, Japan	Itoh, S (reprint author), Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	itoshin@surg2.med.kyushu-u.ac.jp					Taketomi A, 2010, ANN SURG ONCOL, V17, P2283, DOI 10.1245/s10434-010-0999-y; Welker MW, 2013, TRANSPL INT, V26, P109, DOI 10.1111/j.1432-2277.2012.01562.x; Roh YN, 2014, CLIN TRANSPLANT, V28, P141, DOI 10.1111/ctr.12286; Roayaie S, 2004, LIVER TRANSPLANT, V10, P534, DOI 10.1002/lt.20128; Taketomi A, 2010, ANN SURG ONCOL, V17, P2740, DOI 10.1245/s10434-010-1076-2; Mazzaferro V, 2011, LIVER TRANSPLANT, V17, pS44, DOI 10.1002/lt.22365; Gomez-Martin C, 2012, LIVER TRANSPLANT, V18, P45, DOI 10.1002/lt.22434; Kornberg A, 2010, EJSO-EUR J SURG ONC, V36, P275, DOI 10.1016/j.ejso.2009.10.001; Kneuertz PJ, 2012, J GASTROINTEST SURG, V16, P874, DOI 10.1007/s11605-011-1710-8; Morita K, 2009, LIVER TRANSPLANT, V15, P1412, DOI 10.1002/lt.21894	10	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3525	3529				5	Oncology	Oncology	CJ1VW	WOS:000355273800049		
J	Kaneko, M; Sasaki, S; Ishimaru, K; Terai, E; Nakayama, H; Watanabe, T				Kaneko, Manabu; Sasaki, Shin; Ishimaru, Kazuhiro; Terai, Emi; Nakayama, Hiroshi; Watanabe, Toshiyuki			The Impact of Perioperative Allogeneic Blood Transfusion on Survival in Elderly Patients with Colorectal Cancer	ANTICANCER RESEARCH			English	Article						Blood transfusion; colorectal cancer; TRIM; immunosenescence	REGULATORY T-CELLS; POSTOPERATIVE INFECTION; METAANALYSIS; IMMUNOSENESCENCE; RECURRENCE; MANAGEMENT; PROGNOSIS; SURGERY	Background: The relationship between perioperative allogeneic blood transfusion (ABT) and survival following curative surgery for colorectal cancer (CRC) in elderly patients has not been elucidated to date. Patients and Methods: The cases of 108 patients aged 75 years or more who underwent curative surgery for CRC between 2004 and 2011 were retrospectively reviewed. The association between perioperative ABT requirements and other clinicopathological variables was examined. Subsequently, perioperative ABT was compared with other variables concerning overall survival (OS) by univariate and multivariate analyses. Results: Tumor depth, lymph node metastasis and hemoglobin levels were significantly associated with perioperative ABT. Transfused patients had significantly worse OS compared to non-transfused patients. In the multivariate analysis, perioperative ABT (hazard ratio= 3.16, 95% confidence interval= 1.11-8.98, p= 0.031) was the only independent indicator of OS. Conclusion: Perioperative ABT was significantly associated with increased mortality in elderly patients with CRC.	[Kaneko, Manabu; Sasaki, Shin; Ishimaru, Kazuhiro; Terai, Emi; Nakayama, Hiroshi; Watanabe, Toshiyuki] Omori Red Cross Hosp, Dept Surg, Tokyo 1438527, Japan	Kaneko, M (reprint author), Omori Red Cross Hosp, Dept Surg, Ota Ku, 4-30-1 Chuo, Tokyo 1438527, Japan.	m.kaneko@fancy.ocn.ne.jp					Amato A, 2006, COCHRANE DB SYST REV, DOI 10.1002/1465158.CD005033.pub2; VANTWUYVER E, 1991, NEW ENGL J MED, V325, P1210, DOI 10.1056/NEJM199110243251704; Gilliss BM, 2011, ANESTHESIOLOGY, V115, P635, DOI 10.1097/ALN.0b013e31822a22d9; Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x; Qiu MZ, 2010, TUMOR BIOL, V31, P633, DOI 10.1007/s13277-010-0079-8; BURROWS L, 1982, LANCET, V2, P662; Vamvakas EC, 2002, TRANSFUS MED REV, V16, P144, DOI 10.1053/tmrv.2002.31463; Yao HS, 2008, WORLD J SURG, V32, P2038, DOI 10.1007/s00268-008-9675-9; McElhaney JE, 2009, CURR OPIN IMMUNOL, V21, P418, DOI 10.1016/j.coi.2009.05.023; Li LQ, 2013, CLIN IMMUNOL, V148, P246, DOI 10.1016/j.clim.2013.05.003; Jagger A, 2014, GERONTOLOGY, V60, P130, DOI 10.1159/000355303; Acheson AG, 2012, ANN SURG, V256, P235, DOI 10.1097/SLA.0b013e31825b35d5; Munoz M, 2014, WORLD J GASTROENTERO, V20, P1972, DOI 10.3748/wjg.v20.i8.1972; Berezina TL, 2002, J SURG RES, V102, P6, DOI 10.1006/jsre.2001.6306; Gruver AL, 2007, J PATHOL, V211, P144, DOI 10.1002/path.2104; Carson JL, 2012, ANN INTERN MED, V157, P49, DOI 10.7326/0003-4819-157-1-201206190-00429; Baumgartner JM, 2009, J AM COLL SURGEONS, V208, P110, DOI 10.1016/j.jamcollsurg.2008.08.012; Donnelly P K, 1991, Transfus Med, V1, P217, DOI 10.1111/j.1365-3148.1991.tb00036.x; Guo JR, 2014, ASIAN PAC J CANCER P, V15, P467, DOI 10.7314/APJCP.2014.15.1.467; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064261; Long MY, 2014, INT J CLIN EXP MED, V15, P2889; Luan HX, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-34; Mishima Y, 2014, TRANSFUS APHER SCI; OKSANEN K, 1993, BRIT J HAEMATOL, V84, P639, DOI 10.1111/j.1365-2141.1993.tb03140.x; Sobin LH, 2009, INT UNION CANC UICC; Tsuno NH, 2013, TRANSFUS APHER SCI, V49, P673, DOI 10.1016/j.transci.2013.02.002; WOOLLEY AL, 1992, ANN OTO RHINOL LARYN, V101, P724; Zhen Li, 2012, J Surg Oncol, V105, P371, DOI 10.1002/jso.22032	30	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3553	3558				6	Oncology	Oncology	CJ1VW	WOS:000355273800053		
J	Shida, A; Futawatari, N; Fukuyama, T; Ichiki, Y; Takahashi, Y; Nishi, Y; Kobayashi, N; Yamazaki, H; Watanabe, M				Shida, Akiko; Futawatari, Nobue; Fukuyama, Takashi; Ichiki, Yoshinobu; Takahashi, Yoshihito; Nishi, Yatsushi; Kobayashi, Noritada; Yamazaki, Hitoshi; Watanabe, Masahiko			Frequent High Expression of Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1) in Gastric Cancer	ANTICANCER RESEARCH			English	Article						Kita-kyushu lung cancer antigen-1; KK-LC-1; cancer/testis antigen; gastric cancer	CYTOLYTIC T-LYMPHOCYTES; GENE; IDENTIFICATION; CARCINOMAS; MELANOMA	Background: The tumor-associated antigen Kita-Kyushu lung cancer antigen-1 (KK-LC-1) has been reported as not being expressed in normal tissues, except for the testis, and in the setting of non-small cell lung cancer. The present study demonstrated that KK-LC-1 is expressed in gastric cancer. Materials and Methods: We analyzed the expression of KK-LC-1 and cancer/testis antigens (CTAs) in surgical specimens of 49 gastric carcinomas. The expression of KK-LC-1 and CTAs was assessed using reverse transcription-polymerase chain reaction. Results: KK-LC-1 expression was observed in gastric carcinomas. The number of lesions with expression of KK-LC-1, Melanoma antigen gene encoding-A1 (MAGE-A1), MAGE-A3 and New York Esophageal squamous cell carcinoma-1 (NY-ESO-1) was 40 (81.6%), 17 (34.7%), 22 (44.9%) and 8 (16.3%) out of the 49 specimens, respectively. Conclusion: KK-LC-1 should be categorized as a CTA. The frequency of KK-LC-1 expression was higher than that of the other CTAs. KK-LC-1 might be a useful target for immunotherapy and in diagnosis of gastric cancer.	[Shida, Akiko; Futawatari, Nobue; Takahashi, Yoshihito; Nishi, Yatsushi] Kitasato Univ, Med Ctr, Div Surg, Saitama 3648501, Japan; [Fukuyama, Takashi; Kobayashi, Noritada] Kitasato Univ, Med Ctr, Div Biomed Res, Saitama 3648501, Japan; [Yamazaki, Hitoshi] Kitasato Univ, Med Ctr, Div Pathol, Saitama 3648501, Japan; [Ichiki, Yoshinobu] Univ Occupat & Environm Hlth, Sch Med, Dept Surg 2, Kitakyushu, Fukuoka 807, Japan; [Shida, Akiko; Futawatari, Nobue; Watanabe, Masahiko] Kitasato Univ, Div Surg, Sagamihara, Kanagawa 228, Japan	Fukuyama, T (reprint author), Kitasato Univ, Med Ctr, Div Biomed Res, 6-100 Arai, Saitama 3648501, Japan.	fukuyam@insti.kitasato-u.ac.jp					Nakamura Y, 2007, ANN SURG ONCOL, V14, P885, DOI 10.1245/s10434-006-9121-x; Fukuyama T, 2006, CANCER RES, V66, P4922, DOI 10.1158/0008-5472.CAN-05-3840; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Mashino K, 2001, BRIT J CANCER, V85, P713, DOI 10.1054/bjoc.2001.1974; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Shigematsu Y, 2010, LUNG CANCER, V68, P105, DOI 10.1016/j.lungcan.2009.05.010; Ogata K, 2011, ANN SURG ONCOL, V18, P1195, DOI 10.1245/s10434-010-1399-z; Ichiki Y, 2004, J IMMUNOL, V172, P4844; Mori M, 1997, TRANSPLANTATION, V64, P1017, DOI 10.1097/00007890-199710150-00014; Breckpot K, 2004, J IMMUNOL, V172, P2232; Bolli M, 2005, INT J CANCER, V115, P960, DOI 10.1002/ijc.20953; Benlalam H, 2003, J IMMUNOL, V171, P6283; Corbiere V, 2004, TISSUE ANTIGENS, V63, P453, DOI 10.1111/j.0001-2815.2004.00203.x; Fukuyama T, 2012, TUMOR BIOL, V33, P1881, DOI 10.1007/s13277-012-0448-6; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Kim YM, 2001, J KOREAN MED SCI, V16, P62; Sharma A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028217; Takenoyama M, 2006, INT J CANCER, V118, P1992, DOI 10.1002/ijc.21594; Tanaka H, 1996, Clin Transpl, P139; Wang Yu, 2004, Cancer Immun, V4, P11	20	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3575	3579				5	Oncology	Oncology	CJ1VW	WOS:000355273800058		
J	Fujii, T; Yajima, R; Tatsuki, H; Suto, T; Morita, H; Tsutsumi, S; Kuwano, H				Fujii, Takaaki; Yajima, Reina; Tatsuki, Hironori; Suto, Toshinaga; Morita, Hiroki; Tsutsumi, Soichi; Kuwano, Hiroyuki			Significance of Lymphatic Invasion Combined with Size of Primary Tumor for Predicting Sentinel Lymph Node Metastasis in Patients with Breast Cancer	ANTICANCER RESEARCH			English	Article						Lymphatic invasion; tumor size; breast cancer; lymph node metastasis; sentinel node	LYMPHOVASCULAR INVASION; EXTRACAPSULAR INVASION; VASCULAR INVASION; PROGNOSTIC VALUE; BIOPSY; IMPACT	Background/Aim: Lymphatic invasion (ly) may mainly reflect the selective affinity of breast cancer cells for lymph nodes. We conducted the present study to investigate whether the presence of lymphatic invasion is a predictor of sentinel lymph node (SLN) metastasis in clinically node-negative breast cancer. Patients and Methods: We retrospectively evaluated the cases of 202 consecutive female patients with clinically node-negative primary breast cancer who underwent a radical breast operation with SLN biopsy. We examined the relationship between SLN metastasis and the significance of clinicopathological factors, including lymphatic invasion. Results: Among the 202 patients, 49 (24.3%) had SLN metastasis. The univariate and multivariate analyses revealed that the size of the tumor and lymphatic invasion were independent risk factors for SLN metastasis. Among the 96 patients who were ly-negative and had a tumor size of less than 20 mm, only 5 (5.2%) had 1-2 metastases within the SLN. Among the 34 patients who were ly-negative and had a tumor size of less than 10 mm, there were no patients with SLN metastasis. Conclusion: Our results suggest that the presence of lymphatic invasion combined with the size of the primary cancer could be considered a strong risk factor for SLN metastasis in clinically node-negative breast cancer, and patients with a tumor size of less than 20 mm and clinically node-negative breast cancer may avoid axillary lymph node dissection after SLN biopsy. There is also a possibility that SLN biopsy could be unnecessary for patients with clinically node-negative breast cancer who are ly-negative and have a tumor size of less than 10 mm.	[Fujii, Takaaki; Yajima, Reina; Tatsuki, Hironori; Suto, Toshinaga; Morita, Hiroki; Tsutsumi, Soichi; Kuwano, Hiroyuki] Gunma Univ, Dept Gen Surg Sci, Grad Sch Med, Maebashi, Gunma 3718511, Japan	Fujii, T (reprint author), Gunma Univ, Dept Gen Surg Sci, Grad Sch Med, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan.	ftakaaki@gunma-u.ac.jp					Achen MG, 2009, ANN NY ACAD SCI, V1131, P225; Veronesi U, 1997, LANCET, V349, P1864, DOI 10.1016/S0140-6736(97)01004-0; Rakha EA, 2012, CANCER-AM CANCER SOC, V118, P3670, DOI 10.1002/cncr.26711; Allred DC, 1998, MODERN PATHOL, V11, P155; Fujii T, 2014, ANTICANCER RES, V34, P1255; Braun M, 2008, BREAST CANCER RES TR, V112, P503, DOI 10.1007/s10549-007-9875-2; Krag D, 1998, NEW ENGL J MED, V339, P941, DOI 10.1056/NEJM199810013391401; Cornwell LB, 2011, AM SURGEON, V77, P874; Bundred NJ, 2015, NAT REV CLIN ONCOL, V12, P51; Clarke D, 2001, WORLD J SURG, V25, P819; Ejlertsen B, 2009, J NATL CANCER I, V101, P729, DOI 10.1093/jnci/djp090; Fujii T, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-216; Fujii T, 2014, ANTICANCER RES, V34, P3147; Fujii T, 2010, WORLD J SURG, V34, P544, DOI 10.1007/s00268-009-0389-4; Fujii T, 2014, INT SURG, V99, P305, DOI 10.9738/INTSURG-D-13-00012.1; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; Royton D, 2009, J PATHOL, V217, P608; Woo CS, 2002, AM J SURG, V184, P337, DOI 10.1016/S0002-9610(02)00950-9; Yajima R, 2015, ANN SURG ONCOL, V22, P52, DOI 10.1245/s10434-014-3941-x	19	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3581	3584				4	Oncology	Oncology	CJ1VW	WOS:000355273800059		
J	Kato, M; Onishi, H; Furugaki, K; Yunotani, S; Matsumoto, K; Tsuruta, N; Nakamura, K; Katano, M				Kato, Masato; Onishi, Hideya; Furugaki, Kouichi; Yunotani, Seiji; Matsumoto, Kotaro; Tsuruta, Nobuko; Nakamura, Katsuya; Katano, Mitsuo			New Approach to Complete Video-assisted Thoracoscopic Lobectomy in T2 and T3 Non-Small Cell Lung Cancer	ANTICANCER RESEARCH			English	Article						VATS; T2 and T3; non-small cell lung cancer	THORACIC-SURGERY; FEASIBILITY	Complete video-assisted thoracoscopic surgery (c-VATS) for lung cancer is minimally invasive because of the small incision required. c-VATS has recently become a standard procedure for treatment of stage IA/IB lung cancer. However, a long thoracic incision or extensive costal rib resection is required in patients with large lung tumors. We herein introduce an improved VATS lobectomy procedure for patients with T2 and T3 lung cancer. In this technique, resected tissue is removed through a small upper abdominal midline incision below the xiphoid through the retrosternal-extraperitoneal pathway. Five patients who underwent this new procedure were compared against 10 control patients who underwent hybrid VATS lobectomy. Significantly fewer patients who underwent c-VATS lobectomy complained of severe postoperative pain; however, there was no significant difference in the postoperative hospital stay between the two groups. The present study demonstrates that c-VATS lobectomy can be performed with minimal operative pain and without need for a long thoracic incision or extensive rib resection, even in patients with large lung tumors (T2 and T3). These results suggest that the indications for c-VATS lobectomy in patients with T2 and T3 non-small cell lung cancer can be expanded by implementation of our approach, which involves removal of the freed lobe through an abdominal incision.	[Kato, Masato; Furugaki, Kouichi; Yunotani, Seiji] Karatsu Red Cross Hosp, Dept Surg, Karatsu, Saga, Japan; [Onishi, Hideya; Katano, Mitsuo] Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Fukuoka 8128502, Japan; [Nakamura, Katsuya] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 8128502, Japan; [Matsumoto, Kotaro] Hamanomachi Hosp, Dept Surg, Fukuoka, Japan; [Tsuruta, Nobuko] Hamanomachi Hosp, Dept Resp Med, Fukuoka, Japan	Onishi, H (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Fukuoka 8128502, Japan.	ohnishi@surg1.med.kyushu-u.ac.jp					LEWIS RJ, 1992, ANN THORAC SURG, V54, P80; McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078; Kato M, 2014, ANTICANCER RES, V34, P3053; Cao C, 2013, EUR J CARDIO-THORAC, V44, P849, DOI 10.1093/ejcts/ezt406; Demmy TL, 2010, ANN THORAC SURG, V89, pS2142, DOI 10.1016/j.athoracsur.2010.02.110; Japan Lung Cancer Society, 2010, 7 ED GEN RUL CLIN PA; Kato M, 2012, ANTICANCER RES, V32, P5099; Milone L, 2011, SURG ENDOSC, V25, P2731, DOI 10.1007/s00464-011-1613-5; Roviaro G, 1992, Surg Laparosc Endosc, V2, P244; Shao WL, 2014, CHINESE J CANCER RES, V26, P418, DOI 10.3978/j.issn.1000-9604.2014.08.05; Watanabe A, 2009, EUR J CARDIO-THORAC, V35, P775, DOI 10.1016/j.ejcts.2009.01.013	11	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3585	3589				5	Oncology	Oncology	CJ1VW	WOS:000355273800060		
J	Ohga, S; Nakamura, K; Shioyama, Y; Sasaki, T; Yamaguchi, T; Yoshitake, T; Terashima, K; Asai, K; Matsumoto, K; Honda, H				Ohga, Saiji; Nakamura, Katsumasa; Shioyama, Yoshiyuki; Sasaki, Tomonari; Yamaguchi, Toshihiro; Yoshitake, Tadamasa; Terashima, Kotaro; Asai, Kaori; Matsumoto, Keiji; Honda, Hiroshi			Treatment Outcome of Radiotherapy for Localized Primary Ocular Adnexal MALT Lymphoma - Prognostic Effect of the AJCC Tumor-Node-Metastasis Clinical Staging System	ANTICANCER RESEARCH			English	Article						Primary ocular adnexal MALT lymphoma; AJCC TNM clinical staging system; radiotherapy	B-CELL LYMPHOMA; RADIATION-THERAPY; RESPONSE CRITERIA; ORBITAL LYMPHOMA; MARGINAL ZONE; TISSUE; CANCER; COMMITTEE; DISEASE	Aim: To analyze the treatment outcome of radiotherapy for localized primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (POAML) and evaluate the prognostic effect of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) clinical staging system for POAML. Patients and Methods: Seventy-three patients with Ann Arbor stage IE POAML who were treated with radiotherapy alone were analyzed. T-Factor based on the AJCC staging system was T1 in 28, T2 in 33 and T3 in 12 patients. Results: Out of nine patients with relapse, six had distant and three had contralateral ocular adnexal relapse. One patient died of lymphoma progression. The 5-year local control and progression-free survival (PFS) rates were 100% and 81.5%, respectively. T-Factor was not significantly associated with PFS. Conclusion: Radiotherapy achieved excellent local control and survival rates for stage IE POAML. The AJCC TNM clinical staging system was not significantly predictive for PFS of stage IE POAML.	[Ohga, Saiji; Nakamura, Katsumasa; Sasaki, Tomonari; Yamaguchi, Toshihiro; Yoshitake, Tadamasa; Terashima, Kotaro; Asai, Kaori; Matsumoto, Keiji; Honda, Hiroshi] Kyushu Univ, Grad Sch Med Sci, Dept Clin Radiol, Fukuoka 812, Japan; [Shioyama, Yoshiyuki] Kyushu Int Heavy Ion Beam Canc Treatment Ctr, Saga, Japan	Ohga, S (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Clin Radiol, Fukuoka 812, Japan.	saiji@radiol.med.kyushu-u.ac.jp					Hashimoto N, 2012, INT J RADIAT ONCOL, V82, P1509, DOI 10.1016/j.ijrobp.2011.04.052; Graue GF, 2013, EUR J OPHTHALMOL, V23, P344, DOI 10.5301/ejo.5000224; Tanimoto K, 2006, ANN ONCOL, V17, P135, DOI 10.1093/annonc/mdj025; Cheson BD, 1999, J CLIN ONCOL, V17, P1244; ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3; Son SH, 2010, INT J RADIAT ONCOL, V77, P86, DOI 10.1016/j.ijrobp.2009.04.018; Stafford SL, 2001, RADIOTHER ONCOL, V59, P139, DOI 10.1016/S0167-8140(00)00328-5; [Anonymous], 2009, NIH PUBLICATION, V09-7473; Nam H, 2009, RADIOTHER ONCOL, V90, P236, DOI 10.1016/j.radonc.2008.09.011; Ferry JA, 2007, AM J SURG PATHOL, V31, P170, DOI 10.1097/01.pas.0000213350.49767.46; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; CARBONE PP, 1971, CANCER RES, V31, P1860; Uno T, 2003, CANCER, V98, P865, DOI 10.1002/cncr.11539; Aronow ME, 2013, OPHTHALMOLOGY, V120, P1915, DOI 10.1016/j.ophtha.2013.02.003; Bayraktar S, 2010, BRIT J HAEMATOL, V152, P144; Coupland SE, 2009, ARCH PATHOL LAB MED, V133, P1262, DOI 10.1043/1543-2165-133.8.1262; Ejima Y, 2006, RADIOTHER ONCOL, V78, P6, DOI 10.1016/j.radonc.2005.11.005; Goda JS, 2011, INT J RADIAT ONCOL, V81, P659; Harada K, 2014, INT J RADIAT ONCOL, V88, P650, DOI 10.1016/j.ijrobp.2013.11.235; Johnson TE, 1999, OPHTHALMIC PLAST REC, V15, P171, DOI 10.1097/00002341-199905000-00006; Le QT, 2002, INT J RADIAT ONCOL, V52, P657, DOI 10.1016/S0360-3016(01)02729-8; Lister TA, 1989, J CLIN ONCOL, V7, P630; Martinet S, 2003, INT J RADIAT ONCOL, V55, P892, DOI 10.1016/S0360-3016(02)04159-7; McKelvie PA, 2001, CLIN EXP OPHTHALMOL, V29, P387, DOI 10.1046/j.1442-9071.2001.d01-18.x; Yoshitake T, 2013, ANTICANCER RES, V33, P5649; Smiljanic M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0722-5; Tsang RW, SEMINARS RAD ONCOLOG, V17, P198; Woo Jung-Min, 2006, Korean J Ophthalmol, V20, P7	28	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUN	2015	35	6					3591	3597				7	Oncology	Oncology	CJ1VW	WOS:000355273800061		
J	Hori, K; Ohara, Y; Ishikawa, M; Nakatani, H				Hori, Katsutoshi; Ohara, Yuki; Ishikawa, Masahito; Nakatani, Hajime			Effectiveness of direct immobilization of bacterial cells onto material surfaces using the bacterionanofiber protein AtaA	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						Immobilization; Adhesion; Bacterionanofiber; Trimeric autotransporter adhesin	SOLVENT 2-PHASE SYSTEM; ACINETOBACTER-SP TOL-5; BIOFILM REACTORS; MICROBIAL-CELLS; WATER; INDIGO; APPENDAGES; PARTICLES; CATALYSTS; ADHESINS	The bacterionanofiber protein AtaA, a member of the trimeric autotransporter adhesin family found in Acinetobacter sp. Tol 5, is responsible for the nonspecific, high adhesiveness and autoagglutination of this strain. Previously, we introduced the ataA gene into the nonadhesive Acinetobacter strain ST-550, which conferred high adhesiveness to this strain, immobilized its cells, and improved indigo productivity due to enhanced tolerance to the toxic substrate. In this study, we again demonstrated the effectiveness of this new microbial immobilization method using AtaA in a number of conditions. AtaA enabled the effective immobilization of growing, resting, and lyophilized cells of a type strain of Acinetobacter, ADP1, which is also intrinsically nonadhesive, onto the surface of several kinds of support ranging from artificial to natural materials and from hydrophobic polyurethane to hydrophilic glass. Immobilization with AtaA enabled exclusive cell growth in the support space and only a few cells existed in the bulk medium. Immobilization of resting cells drastically increased cell concentration, depending on the support material; dry cells of approximately 110 g/L could be immobilized onto glass wool. Finally, we demonstrated that ADP1 cells immobilized on polyurethane foam can undergo at least 10 repetitive reactions without inactivation during a 5-h period. Even after drying and storing for 3 days, the immobilized cells showed enzymatic activity and an ester hydrolysis reaction was repeated by simply transferring the support with the cells into a fresh reaction buffer.	[Hori, Katsutoshi; Ohara, Yuki; Ishikawa, Masahito; Nakatani, Hajime] Nagoya Univ, Grad Sch Engn, Dept Biotechnol, Chikusa Ku, Nagoya, Aichi 4648603, Japan	Hori, K (reprint author), Nagoya Univ, Grad Sch Engn, Dept Biotechnol, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.	khori@nubio.nagoya-u.ac.jp			Japan Science and Technology Agency through the "Precursory Research for Embryonic Science and Technology Program"; Japan Society for the Promotion of Science through the "Funding Program for Next Generation World-Leading Researchers (NEXT Program)"; Council for Science and Technology Policy in Japan	This work was supported by grants from the Japan Science and Technology Agency through the "Precursory Research for Embryonic Science and Technology Program" and by the Japan Society for the Promotion of Science through the "Funding Program for Next Generation World-Leading Researchers (NEXT Program)," initiated by the Council for Science and Technology Policy in Japan.	Hoiczyk E, 2000, EMBO J, V19, P5989, DOI 10.1093/emboj/19.22.5989; Rosche B, 2009, TRENDS BIOTECHNOL, V27, P636, DOI 10.1016/j.tibtech.2009.08.001; Urbance SE, 2004, APPL MICROBIOL BIOT, V65, P664, DOI 10.1007/s00253-004-1634-2; Ban K, 2002, J MOL CATAL B-ENZYM, V17, P157, DOI 10.1016/S1381-1177(02)00023-1; Feng Q, 2012, BIORESOURCE TECHNOL, V117, P201, DOI 10.1016/j.biortech.2012.04.076; Doukyu N, 2003, APPL MICROBIOL BIOT, V60, P720, DOI 10.1007/s00253-002-1187-1; de Carvalho CCCR, 2011, BIOTECHNOL ADV, V29, P75, DOI 10.1016/j.biotechadv.2010.09.001; Guo WS, 2010, BIORESOURCE TECHNOL, V101, P1435, DOI 10.1016/j.biortech.2009.05.062; Gross R, 2007, BIOTECHNOL BIOENG, V98, P1123, DOI 10.1002/bit.21547; Pollard DJ, 2007, TRENDS BIOTECHNOL, V25, P66, DOI 10.1016/j.tibtech.2006.12.005; Cheng KC, 2011, APPL MICROBIOL BIOT, V90, P921, DOI 10.1007/s00253-011-3151-4; Linke D, 2006, TRENDS MICROBIOL, V14, P264, DOI 10.1016/j.tim.2006.04.005; Cassidy MB, 1996, J IND MICROBIOL, V16, P79, DOI 10.1007/BF01570068; Xing XH, 2000, BIOCHEM ENG J, V5, P29, DOI 10.1016/S1369-703X(99)00056-X; Cheng KC, 2010, APPL MICROBIOL BIOT, V87, P445, DOI 10.1007/s00253-010-2622-3; Doukyu N, 2002, APPL MICROBIOL BIOT, V58, P543, DOI 10.1007/s00253-001-0919-y; Qureshi N, 2005, MICROB CELL FACT, V4, DOI 10.1186/1475-2859-4-24; Halan B, 2012, TRENDS BIOTECHNOL, V30, P453, DOI 10.1016/j.tibtech.2012.05.003; Gross R, 2010, BIOTECHNOL BIOENG, V105, P705, DOI 10.1002/bit.22584; DERVAKOS GA, 1991, BIOTECHNOL ADV, V9, P559, DOI 10.1016/0734-9750(91)90733-C; Carballeira JD, 2009, BIOTECHNOL ADV, V27, P686, DOI 10.1016/j.biotechadv.2009.05.001; Holland HL, 1998, CURR OPIN CHEM BIOL, V2, P77, DOI 10.1016/S1367-5931(98)80039-2; Hori K, 2001, J CHEM ENG JPN, V34, P1120, DOI 10.1252/jcej.34.1120; Hori K, 2011, J BIOSCI BIOENG, V111, P31, DOI 10.1016/j.jbiosc.2010.08.009; Ishii S, 2008, J BIOSCI BIOENG, V105, P20, DOI 10.1263/jbb.105.20; Ishii SI, 2006, BIOSCI BIOTECH BIOCH, V70, P2635, DOI 10.1271/bbb.602336; Ishikawa M, 2012, J BIOSCI BIOENG, V113, P719, DOI 10.1016/j.jbiosc.2012.01.011; Ishikawa M, 2014, BIOTECHNOL BIOENG, V111, P16, DOI 10.1002/bit.25012; Ishikawa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048830; Junter GA, 2004, BIOTECHNOL ADV, V22, P633, DOI 10.1016/j.biotechadv.2004.06.003; KOK RG, 1993, J GEN MICROBIOL, V139, P2329; Nguyen TT, 2010, BIORESOURCE TECHNOL, V101, P1416, DOI 10.1016/j.biortech.2009.07.081; Watanabe H, 2008, J BIOSCI BIOENG, V106, P226, DOI 10.1263/jbb.106.226	33	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	JUN	2015	99	12					5025	5032		10.1007/s00253-015-6554-9		8	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CJ0ZA	WOS:000355208900007		
J	Tani, Y; Miyake, R; Yukami, R; Dekishima, Y; China, H; Saito, S; Kawabata, H; Mihara, H				Tani, Yasushi; Miyake, Ryoma; Yukami, Ryoichi; Dekishima, Yasumasa; China, Hideyasu; Saito, Shigeki; Kawabata, Hiroshi; Mihara, Hisaaki			Functional expression of L-lysine alpha-oxidase from Scomber japonicus in Escherichia coli for one-pot synthesis of L-pipecolic acid from DL-lysine	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						L-Lysine alpha-oxidase; L-Pipecolic acid; One-pot synthesis; Stereoselective synthesis; Delta(1)-Piperideine-2-carboxylic acid	ROCKFISH SEBASTES-SCHLEGELI; SUBTILIS GLUCOSE-DEHYDROGENASE; APOPTOSIS-INDUCING PROTEIN; AMINO-ACID; PSEUDOMONAS-PUTIDA; BACILLUS-SUBTILIS; ENZYMATIC-SYNTHESIS; SKIN MUCUS; IN-VITRO; REDUCTASE	l-Pipecolic acid is a key component of biologically active molecules and a pharmaceutically important chiral building block. It can be stereoselectively produced from l-lysine by a two-step bioconversion involving l-lysine alpha-oxidase and a dagger(1)-piperideine-2-carboxylae (Pip2C) reductase. In this study, we focused on an l-lysine alpha-oxidase from Scomber japonicus that was originally identified as an apoptosis-inducing protein (AIP) and applied the enzyme to one-pot fermentation of l-pipecolic acid in Escherichia coli. A synthetic gene coding for an AIP was expressed in E. coli, and the recombinant enzyme was purified and characterized. The purified enzyme was determined to be a homodimer with a molecular mass of 133.9 kDa. The enzyme essentially exhibited the same substrate specificity as the native enzyme. Optimal temperature and pH for the enzymatic reaction were 70 A degrees C and 7.4, respectively. The enzyme was stable below 60 A degrees C and at a pH range of 5.5-7.5 but was markedly inhibited by Co2+. To establish a one-pot fermentation system for the synthesis of optically pure l-pipecolic acid from dl-lysine, an E. coli strain carrying a plasmid encoding AIP, Pip2C reductase from Pseudomonas putida, lysine racemase from P. putida, and glucose dehydrogenase from Bacillus subtilis was constructed. The one-pot process produced 45.1 g/L of l-pipecolic acid (87.4 % yield from dl-lysine) after a 46-h reaction with high optical purity (> 99.9 % enantiomeric excess).	[Tani, Yasushi; Yukami, Ryoichi; China, Hideyasu; Saito, Shigeki; Mihara, Hisaaki] Ritsumeikan Univ, Dept Biotechnol, Coll Life Sci, Kusatsu, Shiga 5258577, Japan; [Tani, Yasushi; China, Hideyasu; Saito, Shigeki] Ritsumeikan Univ, Ritsumeikan Global Innovat Res Org, Kusatsu, Shiga 5258577, Japan; [Miyake, Ryoma; Dekishima, Yasumasa; Kawabata, Hiroshi] Mitsubishi Chem Grp Sci & Technol Res Ctr Inc, Yokohama, Kanagawa 2278502, Japan; [Miyake, Ryoma; Dekishima, Yasumasa; Kawabata, Hiroshi] API Corp, Yokohama, Kanagawa 2278502, Japan	Mihara, H (reprint author), Ritsumeikan Univ, Dept Biotechnol, Coll Life Sci, Kusatsu, Shiga 5258577, Japan.	mihara@fc.ritsumei.ac.jp			Ritsumeikan Global Innovation Research Organization (R-GIRO), Ritsumeikan University	This work was supported in part by a research grant (to H. M.) from the Ritsumeikan Global Innovation Research Organization (R-GIRO), Ritsumeikan University.	AKETA K, 1976, CHEM PHARM BULL, V24, P621; Job V, 2002, J BIOL CHEM, V277, P6985, DOI 10.1074/jbc.M111095200; Goto M, 2005, J BIOL CHEM, V280, P40875, DOI 10.1074/jbc.M507399200; Morimoto Y, 2014, J BIOSCI BIOENG, V117, P147, DOI 10.1016/j.jbiosc.2013.07.005; Nagashima Y, 2009, COMP BIOCHEM PHYS B, V154, P55, DOI 10.1016/j.cbpb.2009.05.006; Mihara H, 2005, FEBS J, V272, P1117, DOI 10.1111/j.1742-4658.2004.04541.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Muramatsu H, 2005, J BIOL CHEM, V280, P5329; Fujii T, 2002, BIOSCI BIOTECH BIOCH, V66, P622; KIKUMOTO R, 1984, BIOCHEMISTRY-US, V23, P85, DOI 10.1021/bi00296a014; TANAKA H, 1987, J AM CHEM SOC, V109, P5031, DOI 10.1021/ja00250a050; Gatto GJ, 2006, J AM CHEM SOC, V128, P3838, DOI 10.1021/ja0587603; Germann UA, 1997, ANTI-CANCER DRUG, V8, P125, DOI 10.1097/00001813-199702000-00004; Ginesta X, 2002, TETRAHEDRON LETT, V43, P779, DOI 10.1016/S0040-4039(01)02271-7; FUJITA Y, 1977, J BACTERIOL, V132, P282; Boger DL, 1996, J AM CHEM SOC, V118, P1629, DOI 10.1021/ja952799y; KUSAKABE H, 1980, J BIOL CHEM, V255, P976; Weigelt S, 2012, CHEM-EUR J, V18, P478, DOI 10.1002/chem.201102134; CLEVENSTINE EC, 1979, BIOCHEMISTRY-US, V18, P3663, DOI 10.1021/bi00584a004; Pollegioni L, 2013, APPL MICROBIOL BIOT, V97, P9323, DOI 10.1007/s00253-013-5230-1; Macheroux P, 1999, METH MOL B, V131, P1; Muramatsu H, 2006, BIOSCI BIOTECH BIOCH, V70, P2296, DOI 10.1271/bbb.60125; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Asada K, 2012, WO-patent, Patent No. [2012029819A1, 2012029819]; Atanas DR, 2013, J BACTERIOL, V195, P5016, DOI [10.1128/JB.00761-13, DOI 10.1128/JB.00761-13]; Calmes M, 2003, TETRAHEDRON-ASYMMETR, V14, P1685, DOI 10.1016/S0957-4166(03)00304-5; Chang MY, 2006, HETEROCYCLES, V68, P2365; Eichhorn E, 1997, TETRAHEDRON-ASYMMETR, V8, P2533, DOI 10.1016/S0957-4166(97)00256-5; Ekenstam TBA, 1987, US patent, Patent No. [US4695576A, 4695576]; FLYNN GA, 1987, J AM CHEM SOC, V109, P7914, DOI 10.1021/ja00259a068; Fujii T, 2002, BIOSCI BIOTECH BIOCH, V66, P1981; Hamilton GS, 2002, J MED CHEM, V45, P3549, DOI 10.1021/jm010556c; Jung SK, 2000, J IMMUNOL, V165, P1491; Kasai K, 2010, FEBS J, V277, P453, DOI 10.1111/j.1742-4658.2009.07497.x; Khaw LE, 1998, J BACTERIOL, V180, P809; Kitani Y, 2013, DEV COMP IMMUNOL, V39, P456, DOI 10.1016/j.dci.2012.12.008; Kitani Y, 2007, FEBS J, V274, P125, DOI 10.1111/j.1742-4658.2006.05570.x; Kitani Y, 2007, FISH SHELLFISH IMMUN, V23, P1178, DOI 10.1016/j.fsi.2007.04.005; LAMPEL KA, 1986, J BACTERIOL, V166, P238; Martin J, 2009, EUR J ORG CHEM, P5414, DOI 10.1002/ejoc.200900726; Murakawa M, 2001, CELL DEATH DIFFER, V8, P298, DOI 10.1038/sj.cdd.4400811; NAKATSUKA M, 1990, J AM CHEM SOC, V112, P5583, DOI 10.1021/ja00170a024; Picaud S, 2007, PROTEIN EXPRES PURIF, V51, P71, DOI 10.1016/j.pep.2006.06.025; RAMALEY RF, 1983, J BIOL CHEM, V258, P2558; Rogers LMA, 2003, TETRAHEDRON LETT, V44, P3047, DOI 10.1016/S0040-4039(03)00557-4; Sandee D, 2005, BIOTECHNOL BIOENG, V91, P418, DOI 10.1002/bit.20524; TAKAYAMA S, 1984, AGR BIOL CHEM TOKYO, V48, P839; Watanabe LA, 2005, TETRAHEDRON-ASYMMETR, V16, P903, DOI 10.1016/j.tetasy.2005.01.017; Yasuda M, 2006, TETRAHEDRON-ASYMMETR, V17, P1775, DOI 10.1016/j.tetasy.2006.07.005	49	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	JUN	2015	99	12					5045	5054		10.1007/s00253-014-6308-0		10	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CJ0ZA	WOS:000355208900009		
J	Shimizu, K; Kon, M; Tanimura, Y; Hanaoka, Y; Kimura, F; Akama, T; Kono, I				Shimizu, Kazuhiro; Kon, Michihiro; Tanimura, Yuko; Hanaoka, Yukichi; Kimura, Fuminori; Akama, Takao; Kono, Ichiro			Coenzyme Q10 supplementation downregulates the increase of monocytes expressing toll-like receptor 4 in response to 6-day intensive training in kendo athletes	APPLIED PHYSIOLOGY NUTRITION AND METABOLISM			English	Article						ubiquinone; antioxidant; inflammation; immune function; lymphocyte; CD28; exercise	OXIDATIVE STRESS; STRENUOUS EXERCISE; Q(10) SUPPLEMENTATION; CELL SUBPOPULATIONS; BLOOD MONOCYTES; CD28 EXPRESSION; TNF-ALPHA; IN-VITRO; HUMANS; PLASMA	This study examined changes in toll-like receptor 4 (TLR-4)-expressing monocytes and lymphocyte subpopulations in response to continuous intensive exercise training in athletes, as well as the effect of coenzyme Q10 (CoQ10) supplementation on these changes. Eighteen male elite kendo athletes in Japan were randomly assigned to a CoQ10-supplementation group (n = 9) or a placebo-supplementation group (n = 9) using a double-blind method. Subjects in the CoQ10 group took 300 mg CoQ10 per day for 20 days. Subjects in the placebo group took the same dosage of placebo. All subjects practiced kendo 5.5 h per day for 6 consecutive days during the study period. Blood samples were collected 2 weeks before training, on the first day (day 1), third day (day 3), and fifth day of training (day 5), and 1 week after the training period (post-training) to ascertain TLR-4(+)/CD14(+) monocyte and lymphocyte subpopulations (CD3(+), CD4(+), CD8(+), CD28(+)/CD4(+), CD28(+)/CD8(+), and CD56(+)/CD3(-) cells) using flow cytometry analysis. The group x time interaction for TLR-4(+)/CD14(+) cells did not reach significance (p = 0.08). Within the CoQ10 group, the absolute number of TLR-4(+)/CD14(+) cells was significantly higher only at day 5. The placebo group showed a significant increase in the absolute number of TLR-4(+)/CD14(+) cells at day 3, day 5, and post-training (p < 0.05). There was no significant group x time interaction for any lymphocyte subpopulation. CD3(+), CD8(+), and CD56(+)/CD3(-) cells were significantly reduced at day 3 in both groups (p < 0.05). In conclusion, CoQ10 supplementation might downregulate the increase of TLR-4-expressing monocytes in response to continuous strenuous exercise training in kendo athletes.	[Shimizu, Kazuhiro] Japan Inst Sports Sci, Dept Sport Sci, Kita Ku, Tokyo 1150056, Japan; [Kon, Michihiro] Chukyo Univ, Sch Int Liberal Studies, Showa Ku, Nagoya, Aichi 4668666, Japan; [Tanimura, Yuko] Aichi Toho Univ, Fac Human Studies, Meitou Ku, Nagoya, Aichi 4658515, Japan; [Hanaoka, Yukichi; Kimura, Fuminori; Kono, Ichiro] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan; [Akama, Takao] Waseda Univ, Fac Sport Sci, Tokorozawa, Saitama 3591192, Japan	Shimizu, K (reprint author), Japan Inst Sports Sci, Dept Sport Sci, Kita Ku, 3-15-1 Nishigaoka, Tokyo 1150056, Japan.	kazuhiro.shimizu@jpnsport.go.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [25750358]	We thank all those who participated in this study, and we thank Kaneka Corp. for the generous gift of CoQ10. This study was supported by a Grant-in-Aid for Science Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (25750358 to K.S.).	Schmelzer C, 2009, J CLIN BIOCHEM NUTR, V44, P62, DOI 10.3164/jcbn.08-182; Gul I, 2011, J SPORT MED PHYS FIT, V51, P305; Booth S, 2010, EUR J APPL PHYSIOL, V110, P1259, DOI 10.1007/s00421-010-1616-2; Turner JE, 2011, J APPL PHYSIOL, V111, P206, DOI 10.1152/japplphysiol.00051.2011; Powers KA, 2006, J EXP MED, V203, P1951, DOI 10.1084/jem.20060913; Zhang YP, 2013, NEUROBIOL DIS, V58, P169, DOI 10.1016/j.nbd.2013.05.003; Lancaster GI, 2005, J PHYSIOL-LONDON, V563, P945, DOI 10.1116/jphysiol.2004.081224; Diaz-Castro J, 2012, EUR J NUTR, V51, P791, DOI 10.1007/s00394-011-0257-5; Ryan KA, 2004, INFECT IMMUN, V72, P2123, DOI 10.1128/IAI.72.4.2123.2130.2004; Bryl E, 2001, J IMMUNOL, V167, P3231; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Imai H, 2002, JPN J PHYSIOL, V52, P135, DOI 10.2170/jjphysiol.52.135; JENKINS MK, 1991, J IMMUNOL, V147, P2461; Stewart LK, 2005, BRAIN BEHAV IMMUN, V19, P389, DOI 10.1016/j.bbi.2005.04.003; Bruunsgaard H, 1999, LIFE SCI, V65, P2623, DOI 10.1016/S0024-3205(99)00531-7; Ikematsu H, 2006, REGUL TOXICOL PHARM, V44, P212, DOI 10.1016/j.yrtph.2005.12.002; Shimizu K, 2008, EXERC IMMUNOL REV, V14, P24; Renshaw M, 2002, J IMMUNOL, V169, P4697; Oliveira M, 2010, EUR J APPL PHYSIOL, V109, P251, DOI 10.1007/s00421-009-1350-9; Macdonald J, 2003, BRIT J ANAESTH, V90, P221, DOI 10.1093/bja/aeg034; Kon M, 2008, BRIT J NUTR, V100, P903, DOI 10.1017/S0007114508926544; Gleeson M, 2006, EXERC IMMUNOL REV, V12, P34; Ostman B, 2012, NUTRITION, V28, P403, DOI 10.1016/j.nut.2011.07.010; Shimizu K, 2011, J STRENGTH COND RES, V25, P1943, DOI 10.1519/JSC.0b013e3181e4f9c6; Simpson RJ, 2009, BRAIN BEHAV IMMUN, V23, P232, DOI 10.1016/j.bbi.2008.09.013; BATTINO M, 1991, ANAL CHIM ACTA, V255, P367, DOI 10.1016/0003-2670(91)80070-A; Beck JM, 2003, J IMMUNOL, V171, P1969; Cohen J, 1988, STAT POWER ANAL BEHA, P75; Dlugosz A, 2004, INT UROL NEPHROL, V36, P253, DOI 10.1023/B:UROL.0000034652.88578.a8; Fernandez-Gonzalo R, 2012, J APPL PHYSIOL, V112, P2011, DOI 10.1152/japplphysiol.01499.2011; Hessel E, 2000, CLIN CHIM ACTA, V298, P145, DOI 10.1016/S0009-8981(00)00295-3; Kreher Jeffrey B, 2012, Sports Health, V4, P128; Ma SB, 2003, EXP GERONTOL, V38, P1109, DOI 10.1016/S0531-5565(03)00166-9; Nickel T, 2012, EUR J APPL PHYSIOL, V112, P1699, DOI 10.1007/s00421-011-2140-8; Novoselova EG, 2009, EUR J PHARMACOL, V615, P234, DOI 10.1016/j.ejphar.2009.05.004; Ogura Y, 2008, AM J PHYSIOL-REG I, V294, pR1600, DOI 10.1152/ajpregu.00581.2007; Shimizu K, 2011, J STRENGTH COND RES, V25, P2565, DOI 10.1519/JSC.0b013e3181fc5e67; Tanskanen M, 2010, J SPORT SCI, V28, P309, DOI 10.1080/02640410903473844; THOMAS JR, 1991, RES Q EXERCISE SPORT, V62, P344; Tran MT, 2001, PHARMACOTHERAPY, V21, P797, DOI 10.1592/phco.21.9.797.34564; Zhou J, 2005, IMMUNOLOGY, V114, P522, DOI 10.1111/j.1365-2567.2004.02112.x; Zhou M, 1999, J CARDIOVASC SURG, V40, P355	43	0	0	CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS	OTTAWA	65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA	1715-5312	1715-5320		APPL PHYSIOL NUTR ME	Appl. Physiol. Nutr. Metab.	JUN	2015	40	6					575	581		10.1139/apnm-2014-0556		7	Nutrition & Dietetics; Physiology; Sport Sciences	Nutrition & Dietetics; Physiology; Sport Sciences	CJ2PT	WOS:000355327700006		
J	Negron-Mendoza, A; Uribe, RM; Ramos-Bernal, S; Camargo-Raya, C; Gomez-Vidales, V; Kobayashi, K				Negron-Mendoza, Alicia; Uribe, Roberto M.; Ramos-Bernal, Sergio; Camargo-Raya, Claudia; Gomez-Vidales, Virginia; Kobayashi, Kensei			Calcium carbonate as a possible dosimeter for high irradiation doses	APPLIED RADIATION AND ISOTOPES			English	Article						Calcium carbonate; EPR; Dose effect; High-energy ionizing radiation	SINGLE-CRYSTAL CALCITE; PARAMAGNETIC-RESONANCE; THERMAL-BEHAVIOR; ESR-SIGNALS; SPECTRA; HYDROXYAPATITE; APATITES; DEFECTS; CENTERS; LI2CO3	The aim of this work is to analyze the interactions of 5 MeV electron beam radiation and a 290 MeV/u Carbon beam with calcium carbonate (powder) at 298 K and at different irradiation doses, for the potential use of calcium carbonate as a high-dose dosimeter. The irradiation doses with the electron beam were from 0.015 to 9 MGy, and with Carbon beam from 1.5 kGy to 8 kGy. High-energy radiation induces the formation of free radicals in solid calcium carbonate that can be detected and measured by electron paramagnetic resonance (EPR). An increase of the EPR response for some of the free radicals produced in the sample was observed as a function of the irradiation dose. These measurements are reproducible; the preparation of the sample is simple and inexpensive; and the signal is stable for several months. The response curves show that the dosimeter tends to saturate at 10 MGy. Based on these properties, we propose this chemical compound as a high-dose dosimeter, mainly for electron irradiation. (C) 2014 Elsevier Ltd. All rights reserved.	[Negron-Mendoza, Alicia; Ramos-Bernal, Sergio; Camargo-Raya, Claudia] Univ Nacl Autonoma Mexico, Inst Ciencias Nucl, Mexico City 04510, DF, Mexico; [Uribe, Roberto M.] Kent State Univ, Coll Technol, Kent, OH 44242 USA; [Gomez-Vidales, Virginia] Univ Nacl Autonoma Mexico, Inst Quim, Mexico City 04510, DF, Mexico; [Kobayashi, Kensei] Yokohama Natl Univ, Yokohama, Kanagawa, Japan	Negron-Mendoza, A (reprint author), Univ Nacl Autonoma Mexico, Inst Ciencias Nucl, Mexico City 04510, DF, Mexico.	negron@nucleares.unam.mx			PAPIIT [IN110513]; CONACyT [168579/11]	This work was supported by PAPIIT Grant no. IN110513 and the CONACyT Grant no. 168579/11. We thank to the staff of the NEO Beam facility in Northeast Ohio. USA and the heavy ion irradiation source at NIRS at Chiba, Japan for their support in the preparation and irradiation of the samples. We thank to the reviewers for their comments.	ALBARRAN G, 1994, RADIAT PHYS CHEM, V43, P307, DOI 10.1016/0969-806X(94)90017-5; BARABAS M, 1992, QUATERNARY SCI REV, V11, P173, DOI 10.1016/0277-3791(92)90060-L; SERWAY RA, 1967, J CHEM PHYS, V46, P1949, DOI 10.1063/1.1840958; Seletchi ED, 2007, ROM J PHYS, V52, P657; Vorona IP, 2013, PHYS SOLID STATE+, V55, P2543, DOI 10.1134/S1063783413120329; Herrera E, 2005, APPL RADIAT ISOTOPES, V63, P241, DOI 10.1016/j.apradiso.2005.02.010; BAHAIN JJ, 1994, QUATERNARY SCI REV, V13, P671, DOI 10.1016/0277-3791(94)90096-5; BARABAS M, 1989, APPL RADIAT ISOTOPES, V40, P1105; Callens F, 1998, APPL MAGN RESON, V14, P235; Debuyst R., 1993, APPL RADIAT ISOTOPES, V44, P241; Gilinskaya LG, 2005, INORG MATER+, V41, P503, DOI 10.1007/s10789-005-0158-1; Jacobs C., 1989, RAD ISOTOPES, V40, P1147; MCMILLAN JA, 1968, J CHEM PHYS, V48, P467, DOI 10.1063/1.1667947; Miller A., 2009, 2791 NATL PHYS LAB P, V2791, P1; Murali S, 2001, APPL RADIAT ISOTOPES, V55, P253, DOI 10.1016/S0969-8043(01)00043-4; Murata T, 1996, APPL RADIAT ISOTOPES, V47, P1527, DOI 10.1016/S0969-8043(96)00193-5; Nagabhushana H, 2008, SPECTROCHIM ACTA A, V71, P1070, DOI [10.1016/j.saa.2008.03.003, 10.1016/j.saa.2009.03.003]; Nokhrin SM, 2006, AM MINERAL, V91, P1425, DOI 10.2138/am.2006.2142; Pabst S., 2010, 11 GSI PNIMR, V11, P379; Romanyukha A., 2011, CONCEPTS TRENDS MED, P1345; Rudko VV, 2010, IOP CONF SER-MAT SCI, V15, DOI 10.1088/1757-899X/15/1/012032; Urena-Nunez F, 2009, RADIAT EFF DEFECT S, V164, P240, DOI 10.1080/10420150802271498	22	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0969-8043			APPL RADIAT ISOTOPES	Appl. Radiat. Isot.	JUN	2015	100						55	59		10.1016/j.apradiso.2014.11.024		5	Chemistry, Inorganic & Nuclear; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	Chemistry; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	CJ4ZT	WOS:000355497900012		
J	Farwig, R; Nakatsuka, T; Taniuchi, Y				Farwig, Reinhard; Nakatsuka, Tomoyuki; Taniuchi, Yasushi			Existence of solutions on the whole time axis to the Navier-Stokes equations with precompact range in L (3)	ARCHIV DER MATHEMATIK			English	Article						Navier-Stokes equations; Global in time mild solutions; Existence; Precompact range condition; Unbounded domains	PERIODIC-SOLUTIONS; UNBOUNDED-DOMAINS; EXTERIOR DOMAINS; APERTURE DOMAIN; UNIQUENESS; SPACES; SEMIGROUP; BOUNDARY; OPERATOR; FLOW	We present an existence theorem of mild solutions on the whole time axis to the Navier-Stokes equations in unbounded domains having precompact range in if the external force is small and has precompact range in some function space. In our forthcoming paper [7] we proved the uniqueness of such solutions.	[Farwig, Reinhard] Tech Univ Darmstadt, Int Res Training Grp Darmstadt Tokyo IRTG 1529, D-64289 Darmstadt, Germany; [Nakatsuka, Tomoyuki] Nagoya Univ, Grad Sch Math, Nagoya, Aichi 4648602, Japan; [Taniuchi, Yasushi] Shinshu Univ, Dept Math Sci, Matsumoto, Nagano 3908621, Japan	Farwig, R (reprint author), Tech Univ Darmstadt, Int Res Training Grp Darmstadt Tokyo IRTG 1529, D-64289 Darmstadt, Germany.	farwig@mathematik.tu-darmstadt.de; m09033b@math.nagoya-u.ac.jp; taniuchi@math.shinshu-u.ac.jp			IRTG 1529 Darmstadt-Tokyo; Japan Society for the Promotion of Science. [25002702, 23540194]	The first and second authors greatly acknowledge the support by IRTG 1529 Darmstadt-Tokyo. The second and third authors are supported in part by a Grant-in-Aid for JSPS Fellows No. 25002702 and by a Grant-in-Aid for Scientific Research(C) No. 23540194, respectively, from the Japan Society for the Promotion of Science.	Abe T., 2003, J MATH FLUID MECH, V5, P245; GIGA Y, 1981, MATH Z, V178, P297, DOI 10.1007/BF01214869; Kang K, 2012, COMMUN PART DIFF EQ, V37, P1717, DOI 10.1080/03605302.2012.708082; Yamazaki M, 2000, MATH ANN, V317, P635, DOI 10.1007/PL00004418; BORCHERS W, 1988, MATH ANN, V282, P139, DOI 10.1007/BF01457017; BORCHERS W, 1987, MATH Z, V196, P415, DOI 10.1007/BF01200362; Corduneanu C., 1989, ALMOST PERIODIC FUNC; Crispo F, 2008, MATH METHOD APPL SCI, V31, P249, DOI 10.1002/mma.903; Deimling K., 1985, NONLINEAR FUNCTIONAL; Farwig R., 1996, ANALYSIS, V16, P1; Farwig R., 2013, 2675 TU DARMST FACHB; Farwig R., 2010, ANN U FERRARA SEZ 7, V56, P249; Farwig R, 2011, J EVOL EQU, V11, P485, DOI 10.1007/s00028-010-0098-3; FARWIG R, 1994, MATH NACHR, V170, P53; Galdi GP, 2004, ARCH RATION MECH AN, V172, P363, DOI 10.1007/s00205-004-0306-9; IWASHITA H, 1989, MATH ANN, V285, P265, DOI 10.1007/BF01443518; Kozono H, 1996, TOHOKU MATH J, V48, P33, DOI 10.2748/tmj/1178225411; Kubo T, 2005, MATH METHOD APPL SCI, V28, P1341, DOI 10.1002/mma.618; Kubo T., 2004, QUAD MAT, V15, P149; Kubo T, 2007, J MATH SOC JPN, V59, P837, DOI 10.2969/jmsj/05930837; Maremonti P., 1991, RIC MAT, V40, P81; Maremonti P., 1999, J MATH SCI, V233, p[141, 719], DOI 10.1007/BF02366850; MAREMONTI P, 1991, NONLINEARITY, V4, P503, DOI 10.1088/0951-7715/4/2/013; Nakatsuka T, 2012, NONLINEAR ANAL-THEOR, V75, P3457, DOI 10.1016/j.na.2011.12.032; SALVI R, 1995, NAVIER-STOKES EQUATIONS AND RELATED NONLINEAR PROBLEMS, P63; Shibata Y., 2003, QUAD SEM MAT BRESCIA, V01; Simader C.G., 1992, SERIES ADV MATH APPL, V11, P1; Taniuchi Y, 2009, MATH Z, V261, P597, DOI 10.1007/s00209-008-0341-6; UKAI S, 1987, COMMUN PUR APPL MATH, V40, P611, DOI 10.1002/cpa.3160400506	29	1	1	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	0003-889X	1420-8938		ARCH MATH	Arch. Math.	JUN	2015	104	6					539	550		10.1007/s00013-015-0772-3		12	Mathematics	Mathematics	CJ0ZC	WOS:000355209200006		
J	Yoshida, Y; Ogata, A; Kang, SJ; Ebina, K; Shi, KR; Nojima, S; Kimura, T; Ito, D; Morimoto, K; Nishide, M; Hosokawa, T; Hirano, T; Shima, Y; Narazaki, M; Tsuboi, H; Saeki, Y; Tomita, T; Tanaka, T; Kumanogoh, A				Yoshida, Yuji; Ogata, Atsushi; Kang, Sujin; Ebina, Kousuke; Shi, Kenrin; Nojima, Satoshi; Kimura, Tetsuya; Ito, Daisuke; Morimoto, Keiko; Nishide, Masayuki; Hosokawa, Takashi; Hirano, Toru; Shima, Yoshihito; Narazaki, Masashi; Tsuboi, Hideki; Saeki, Yukihiko; Tomita, Tetsuya; Tanaka, Toshio; Kumanogoh, Atsushi			Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production Pathogenic and Therapeutic Implications	ARTHRITIS & RHEUMATOLOGY			English	Article							IMMUNE-SYSTEM; SURFACE EXPRESSION; DISEASE-ACTIVITY; B-CELL; RECEPTOR; ROLES; CD100; ACTIVATION; RESPONSES; CANCER	Objective. Semaphorin 4D (Sema4D)/CD100 has pleiotropic roles in immune activation, angiogenesis, bone metabolism, and neural development. We undertook this study to investigate the role of Sema4D in rheumatoid arthritis (RA). Methods. Soluble Sema4D (sSema4D) levels in serum and synovial fluid were analyzed by enzyme-linked immunosorbent assay. Cell surface expression and transcripts of Sema4D were analyzed in peripheral blood cells from RA patients, and immunohistochemical staining of Sema4D was performed in RA synovium. Generation of sSema4D was evaluated in an ADAMTS-4-treated monocytic cell line (THP-1 cells). The efficacy of anti-Sema4D antibody was evaluated in mice with collagen-induced arthritis (CIA). Results. Levels of sSema4D were elevated in both serum and synovial fluid from RA patients, and disease activity markers were correlated with serum sSema4D levels. Sema4D-expressing cells also accumulated in RA synovium. Cell surface levels of Sema4D on CD3+ and CD14+ cells from RA patients were reduced, although levels of Sema4D transcripts were unchanged. In addition, ADAMTS-4 cleaved cell surface Sema4D to generate sSema4D in THP-1 cells. Soluble Sema4D induced tumor necrosis factor (TNF) and interleukin-6 (IL-6) production from CD14+ monocytes. IL-6 and TNF induced ADAMTS-4 expression in synovial cells. Treatment with an anti-Sema4D antibody suppressed arthritis and reduced proinflammatory cytokine production in CIA. Conclusion. A positive feedback loop involving sSema4D/IL-6 and TNF/ADAMTS-4 may contribute to the pathogenesis of RA. The inhibition of arthritis by anti-Sema4D antibody suggests that Sema4D represents a potential therapeutic target for RA.	[Yoshida, Yuji; Ogata, Atsushi; Kang, Sujin; Ebina, Kousuke; Shi, Kenrin; Nojima, Satoshi; Kimura, Tetsuya; Ito, Daisuke; Morimoto, Keiko; Nishide, Masayuki; Hosokawa, Takashi; Hirano, Toru; Shima, Yoshihito; Narazaki, Masashi; Tomita, Tetsuya; Tanaka, Toshio; Kumanogoh, Atsushi] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Suita, Osaka 5650871, Japan; [Shi, Kenrin] Osaka Univ Hosp, Osaka 553, Japan; [Tsuboi, Hideki; Saeki, Yukihiko] Natl Hosp Org, Osaka Minami Med Ctr, Osaka, Japan	Ogata, A (reprint author), Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	ogata@imed3.med.osaka			Ministry of Education, Culture, Sports, Science, and Technology of Japan; Japan Society for the Promotion of Science (JSPS KAKENHI grant) [25460495]; Ministry of Health, Labor, and Welfare; Core Research for Evolutionary Science and Technology (CREST) grant from the Japan Science and Technology Agency	Supported by research grants and Center of Innovation program (COI-STREAM) grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS KAKENHI grant 25460495 to Dr. Ogata), grants-in-aid from the Ministry of Health, Labor, and Welfare (to Dr. Kumanogoh), and a Core Research for Evolutionary Science and Technology (CREST) grant from the Japan Science and Technology Agency (to Dr. Kumanogoh).	Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000; Burrage PS, 2006, FRONT BIOSCI, V11, P529, DOI 10.2741/1817; Sierra JR, 2008, J EXP MED, V205, P1673, DOI 10.1084/jem.20072602; Elhabazi A, 2001, J IMMUNOL, V166, P4341; Mou PP, 2013, BLOOD, V121, P4221, DOI 10.1182/blood-2012-11-470609; Zhou YP, 2008, TRENDS BIOCHEM SCI, V33, P161, DOI 10.1016/j.tibs.2008.01.006; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Kumanogoh A, 2013, NAT REV IMMUNOL, V13, P802, DOI 10.1038/nri3545; Okuno T, 2010, J IMMUNOL, V184, P1499, DOI 10.4049/jimmunol.0903302; BOUGERET C, 1992, J IMMUNOL, V148, P318; Shi W, 2000, IMMUNITY, V13, P633, DOI 10.1016/S1074-7613(00)00063-7; Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115; Kumanogoh A, 2000, IMMUNITY, V13, P621, DOI 10.1016/S1074-7613(00)00062-5; Tian Y, 2013, AM J PATHOL, V182, P2310, DOI 10.1016/j.ajpath.2013.02.037; Ogura H, 2008, IMMUNITY, V29, P628, DOI 10.1016/j.immuni.2008.07.018; Lin EA, 2010, PROTEIN CELL, V1, P33, DOI 10.1007/s13238-010-0002-5; Holmdahl R, 2014, EUR J IMMUNOL, V44, P1593, DOI 10.1002/eji.201444486; Vadasz Z, 2010, AUTOIMMUN REV, V9, P825, DOI 10.1016/j.autrev.2010.07.014; Nagase H, 2003, ARTHRITIS RES THER, V5, P94, DOI 10.1186/ar630; Cessak G, 2014, PHARMACOL REP, V66, P836, DOI 10.1016/j.pharep.2014.05.004; Negishi-Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489; Takamatsu H, 2012, TRENDS IMMUNOL, V33, P127, DOI 10.1016/j.it.2012.01.008; Gu CH, 2013, EXP CELL RES, V319, P1306, DOI 10.1016/j.yexcr.2013.02.003; Ishida I, 2003, INT IMMUNOL, V15, P1027, DOI 10.1093/intimm/dxg098; Xie G, 2013, ARTHRITIS RHEUM-US, V65, P2457, DOI 10.1002/art.38036; Zhao W, 2014, ARTHRITIS RHEUMATOL, V66, P2355, DOI 10.1002/art.38696; Zhu L, 2007, P NATL ACAD SCI USA, V104, P1621, DOI 10.1073/pnas.0606344104; Elhabazi A, 2003, CRIT REV IMMUNOL, V23, P65, DOI 10.1615/CritRevImmunol.v23.i12.40; Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001; Catalano A, 2010, J IMMUNOL, V185, P6373, DOI 10.4049/jimmunol.0903527; Wang XS, 2001, BLOOD, V97, P3498, DOI 10.1182/blood.V97.11.3498; Rehman M, 2013, SEMIN CELL DEV BIOL, V24, P179, DOI 10.1016/j.semcdb.2012.10.005; Gras C, 2014, ARTHRITIS RHEUMATOL, V66, P1461, DOI 10.1002/art.38425; Nakatsuji Y, 2012, J IMMUNOL, V188, P4858, DOI 10.4049/jimmunol.1102023; Kumanogoh A, 2003, J CELL SCI, V116, P3463, DOI 10.1242/jcs.00674; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Ji JD, 2009, RHEUMATOL INT, V29, P727, DOI 10.1007/s00296-009-0852-4; Kochi Y, 2014, BIOCHEM BIOPH RES CO, V452, P254, DOI 10.1016/j.bbrc.2014.07.085; Kolodkin AL, 1996, TRENDS CELL BIOL, V6, P15, DOI 10.1016/0962-8924(96)81033-6; Kumanogoh A, 2001, TRENDS IMMUNOL, V22, P670, DOI 10.1016/S1471-4906(01)02087-7; Okamoto K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3323; Patnaik A, 2014, J CLIN ONCOL S, V32, p5s; Rizzolio S, 2007, CELL ADHES MIGR, V1, DOI 10.4161/cam.1.2.4570; Semerano L, 2011, JOINT BONE SPINE, V78, P118, DOI 10.1016/j.jbspin.2010.06.004; Vadasz Z, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3881; vansGestel AM, 1996, ARTHRITIS RHEUM, V39, P34; Williams-Skipp C, 2009, ARTHRITIS RHEUM, V60, P408, DOI 10.1002/art.24260; Yeh ETH, 2004, CIRCULATION, V109, P11, DOI 10.1161/01.CIR.0000129507.12719.80; Yoshida Y, 2014, BIOMED RES INT, V2014; Zhang YS, 2013, CELL MOL IMMUNOL, V10, P97, DOI 10.1038/cmi.2012.65	50	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2326-5191	2326-5205		ARTHRITIS RHEUMATOL	Arthritis Rheumatol.	JUN	2015	67	6					1481	1490		10.1002/art.39086		10	Rheumatology	Rheumatology	CJ2QA	WOS:000355328400011		
J	Takatori, H; Kawashima, H; Matsuki, A; Meguro, K; Tanaka, S; Iwamoto, T; Sanayama, Y; Nishikawa, N; Tamachi, T; Ikeda, K; Suto, A; Suzuki, K; Kagami, S; Hirose, K; Kubo, M; Hori, S; Nakajima, H				Takatori, Hiroaki; Kawashima, Hirotoshi; Matsuki, Ayako; Meguro, Kazuyuki; Tanaka, Shigeru; Iwamoto, Taro; Sanayama, Yoshie; Nishikawa, Natsuko; Tamachi, Tomohiro; Ikeda, Kei; Suto, Akira; Suzuki, Kotaro; Kagami, Shin-ichiro; Hirose, Koichi; Kubo, Masato; Hori, Shohei; Nakajima, Hiroshi			Helios Enhances Treg Cell Function in Cooperation With FoxP3	ARTHRITIS & RHEUMATOLOGY			English	Article							REGULATORY T-CELLS; RHEUMATOID-ARTHRITIS; DNA MICROARRAY; TH17 CELLS; IKAROS; DIFFERENTIATION; GENE; INTERLEUKIN-6; EXPRESSION; RECEPTOR	Objective. Helios+FoxP3+CD4+ (Helios+) Treg cells are believed to be involved in the regulation of various autoimmune diseases; however, the regulatory mechanisms underlying the development of Helios+ Treg cells remain uncertain. This study was undertaken to elucidate the regulatory mechanisms of Helios expression in CD4+ T cells and its roles in transforming growth factor beta (TGF)-induced Treg cell function. Methods. We examined the expression of Helios in CD4+ T cells in patients with rheumatoid arthritis by DNA microarray analysis before and after treatment with biologic agents. We also examined the effect of interleukin-6 (IL-6) and TGF beta on Helios expression in CD4+ T cells in humans and mice. The effect of forced expression of Helios on murine induced Treg cell function was also examined. The role of FoxP3 in the induction and function of Helios was assessed by using CD4+ T cells from FoxP3-deficient scurfy mice. Results. Tocilizumab, but not tumor necrosis factor (TNF) inhibitors or abatacept, increased Helios expression in CD4+ T cells in patients with a good response. IL-6 inhibited the TGF beta-induced development of Helios+ induced Treg cells in both humans and mice. Both cell-intrinsic FoxP3 expression and TGF beta signaling were required for Helios induction in murine induced Treg cells. The forced expression of Helios enhanced the expression of various Treg cell-related molecules and the suppressive function in murine induced Treg cells. Helios-mediated enhancement of the suppressive function of induced Treg cells was obvious in FoxP3-sufficient CD4+ T cells but not in FoxP3-deficient CD4+ T cells. Conclusion. Our findings indicate that Helios enhances induced Treg cell function in cooperation with FoxP3.	[Takatori, Hiroaki; Kawashima, Hirotoshi; Matsuki, Ayako; Meguro, Kazuyuki; Tanaka, Shigeru; Iwamoto, Taro; Sanayama, Yoshie; Nishikawa, Natsuko; Tamachi, Tomohiro; Ikeda, Kei; Suto, Akira; Suzuki, Kotaro; Kagami, Shin-ichiro; Hirose, Koichi; Nakajima, Hiroshi] Chiba Univ, Grad Sch Med, Chiba, Chiba 2608670, Japan; [Kubo, Masato] Tokyo Univ Sci, Noda, Chiba 278, Japan; [Hori, Shohei] RIKEN, Yokohama Inst, Yokohama, Kanagawa, Japan	Takatori, H (reprint author), Chiba Univ, Grad Sch Med, Dept Allergy & Clin Immunol, 1-8-1 Inohana, Chiba, Chiba 2608670, Japan.	takatorih@faculty.chiba-u.jp; nakajimh@faculty.chiba-u.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT); MEXT Global COE Program (Chiba University Global Center for Education and Research in Immune System Regulation and Treatment); Health and Labor Sciences Research Grant on Allergic Disease and Immunology from the Ministry of Health, Labor, and Welfare of Japan; Uehara Memorial Foundation, Japan; Chugai Pharmaceutical; Bristol-Myers Squibb; Mitsubishi Tanabe Pharma	Supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT), the MEXT Global COE Program (Chiba University Global Center for Education and Research in Immune System Regulation and Treatment), a Health and Labor Sciences Research Grant on Allergic Disease and Immunology from the Ministry of Health, Labor, and Welfare of Japan, and funding from the Uehara Memorial Foundation, Japan.; Dr. Nakajima has received research grants from Chugai Pharmaceutical, Bristol-Myers Squibb, and Mitsubishi Tanabe Pharma.	Akimova T, 2011, PLOS ONE, V6; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; Du WT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056209; Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391; Rebollo A, 2003, IMMUNOL CELL BIOL, V81, P171, DOI 10.1046/j.1440-1711.2003.01159.x; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Tanaka T, 2012, ANNU REV PHARMACOL, V52, P199, DOI 10.1146/annurev-pharmtox-010611-134715; Kawashima H, 2013, J IMMUNOL, V191, P3614, DOI 10.4049/jimmunol.1300509; Gottschalk RA, 2012, J IMMUNOL, V188, P976, DOI 10.4049/jimmunol.1102964; Merkenschlager M, 2010, FEBS LETT, V584, P4910, DOI 10.1016/j.febslet.2010.09.042; Getnet D, 2010, MOL IMMUNOL, V47, P1595, DOI 10.1016/j.molimm.2010.02.001; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; Ju JH, 2012, ARTHRITIS RHEUM-US, V64, P3543, DOI 10.1002/art.34601; Samson M, 2012, ARTHRITIS RHEUM-US, V64, P2499, DOI 10.1002/art.34477; Golding A, 2013, ARTHRITIS RHEUM-US, V65, P2898, DOI 10.1002/art.38119; Hiramatsu Y, 2010, J LEUKOCYTE BIOL, V87, P703, DOI 10.1189/jlb.0909639; Sugimoto N, 2006, INT IMMUNOL, V18, P1197, DOI 10.1093/intimm/dx1060; Kim YC, 2012, BLOOD, V119, P2810, DOI 10.1182/blood-2011-09-377895; Pan F, 2009, SCIENCE, V325, P1142, DOI 10.1126/science.1176077; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Takatori H, 2008, MOD RHEUMATOL, V18, P533, DOI 10.1007/s10165-008-0099-z; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; John LB, 2011, MOL IMMUNOL, V48, P1272, DOI 10.1016/j.molimm.2011.03.006; Alexander T, 2013, ANN RHEUM DIS, V72, P1549, DOI 10.1136/annrheumdis-2012-202216; Wells G, 2009, ANN RHEUM DIS, V68, P954, DOI 10.1136/ard.2007.084459; Wojno EDT, 2011, J IMMUNOL, V187, P266, DOI 10.4049/jimmunol.1004182; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Miyao T, 2012, IMMUNITY, V36, P262, DOI 10.1016/j.immuni.2011.12.012; Huber M, 2008, INT IMMUNOL, V20, P223, DOI 10.1093/intimm/dxm139; Cai Q, 2009, J IMMUNOL, V183, P2303, DOI 10.4049/jimmunol.0901407; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Baine I, 2012, J IMMUNOL, V190, P1008; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; McGovern JL, 2012, ARTHRITIS RHEUM-US, V64, P3129, DOI 10.1002/art.34565; Saito Y, 2014, ARTHRITIS RHEUMATOL, V66, P1185, DOI 10.1002/art.38324; Sanayama Y, 2014, ARTHRITIS RHEUMATOL, V66, P1421, DOI 10.1002/art.38400; Tanaka S, 2014, J EXP MED, V211, P1857, DOI 10.1084/jem.20130791; Xu WH, 2012, J CLIN IMMUNOL, V32, P975, DOI 10.1007/s10875-012-9685-0; Zabransky DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034547	42	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2326-5191	2326-5205		ARTHRITIS RHEUMATOL	Arthritis Rheumatol.	JUN	2015	67	6					1491	1502		10.1002/art.39091		12	Rheumatology	Rheumatology	CJ2QA	WOS:000355328400012		
J	Chijiiwa, M; Mochizuki, S; Kimura, T; Abe, H; Tanaka, Y; Fujii, Y; Shimizu, H; Enomoto, H; Toyama, Y; Okada, Y				Chijiiwa, Miyuki; Mochizuki, Satsuki; Kimura, Tokuhiro; Abe, Hitoshi; Tanaka, Yukie; Fujii, Yutaka; Shimizu, Hidenori; Enomoto, Hiroyuki; Toyama, Yoshiaki; Okada, Yasunori			CCN1 (Cyr61) Is Overexpressed in Human Osteoarthritic Cartilage and Inhibits ADAMTS-4 (Aggrecanase 1) Activity	ARTHRITIS & RHEUMATOLOGY			English	Article							IMMEDIATE-EARLY GENE; CALCIUM PENTOSAN POLYSULFATE; C-TERMINAL DOMAIN; MATRICELLULAR PROTEINS; ARTICULAR CHONDROCYTES; EMBRYONIC-DEVELOPMENT; NONCATALYTIC DOMAINS; THERAPEUTIC TARGETS; TGF-BETA; EXPRESSION	Objective. ADAMTS-4, also called aggrecanase 1, is considered to play a key role in aggrecan degradation in human osteoarthritic (OA) cartilage, but information about regulators of ADAMTS-4 aggrecanase activity remains limited. We undertook this study to search for molecules that modulate ADAMTS-4 activity. Methods. Molecules copurified with ADAMTS-4 from ADAMTS-4-transfected chondrocytic cells were sequenced by nanoscale liquid chromatography tandem mass spectrometry. Binding activity was determined by immunoprecipitation and solid-phase binding assay. Effects on ADAMTS-4 activity were examined by aggrecan digestion assay. Expression of the binding molecule in OA cartilage and chondrocytes was examined by immunohistochemistry and reverse transcription-polymerase chain reaction. Results. We identified CCN1 (Cyr61) as an ADAMTS-4-binding protein and showed specific binding to the ADAMTS-4 cysteine-rich domain. Aggrecanase activity of ADAMTS-4 was inhibited by interaction with CCN1. Expression of messenger RNA for CCN1 was significantly higher in human OA cartilage than in normal cartilage. CCN1 was immunolocalized to chondrocytes in OA cartilage, showing direct correlations of immunoreactivity with the Mankin score of cartilage lesions and chondrocyte cloning. CCN1 and ADAMTS-4 were commonly coexpressed in clustered chondrocytes. CCN1 expression in OA chondrocytes was down-regulated by interleukin-1 (IL-1) and up-regulated by transforming growth factor (TGF). ADAMTS-4 expression was induced by treatment with IL-1 or TGF, but aggrecanase activity was detected only under stimulation with IL-1. TGF-treated chondrocytes exhibited aggrecanase activity when CCN1 expression was knocked down. Conclusion. Our findings provide the first evidence that CCN1 suppresses ADAMTS-4 activity and that CCN1 overexpression is directly correlated with chondrocyte cloning in OA cartilage. Our results suggest that the TGF/CCN1 axis plays a role in chondrocyte cluster formation through inhibition of ADAMTS-4.	[Chijiiwa, Miyuki; Mochizuki, Satsuki; Abe, Hitoshi; Shimizu, Hidenori; Enomoto, Hiroyuki; Toyama, Yoshiaki; Okada, Yasunori] Keio Univ, Sch Med, Tokyo 1600016, Japan; [Kimura, Tokuhiro] Yamaguchi Univ, Grad Sch Med, Ube, Yamaguchi, Japan; [Tanaka, Yukie; Fujii, Yutaka] Univ Fukui, Sch Med, Fukui 910, Japan	Okada, Y (reprint author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1600016, Japan.	okada@z6.keio.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan	Supported by the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Grant-in-Aid for Scientific Research [C] to Dr. Mochizuki and Grant-in-Aid for Scientific Research [A] to Dr. Okada).	Takeda S, 2012, BBA-PROTEINS PROTEOM, V1824, P164, DOI 10.1016/j.bbapap.2011.04.009; Fushimi K, 2008, J BIOL CHEM, V283, P6706, DOI 10.1074/jbc.M708647200; Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018-011-0778-3; Kurtis MS, 2003, ARTHRITIS RHEUM, V48, P110, DOI 10.1002/art.10704; Lotz MK, 2010, ARTHRITIS RHEUM-US, V62, P2206, DOI 10.1002/art.27528; Wu LH, 2012, CURR PHARM DESIGN, V18, P3293; Naito S, 2007, PATHOL INT, V57, P703, DOI 10.1111/j.1440-1827.2007.02167.x; Hashimoto G, 2001, FEBS LETT, V494, P192, DOI 10.1016/S0014-5793(01)02323-7; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Troeberg L, 2008, FASEB J, V22, P3515, DOI 10.1096/fj.08-112680; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569; Holbourn KP, 2008, TRENDS BIOCHEM SCI, V33, P461, DOI 10.1016/j.tibs.2008.07.006; Akiyama M, 2009, P NATL ACAD SCI USA, V106, P19274, DOI 10.1073/pnas.0909755106; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Enomoto H, 2003, AM J PATHOL, V162, P171, DOI 10.1016/S0002-9440(10)63808-4; Plaas A, 2011, OSTEOARTHR CARTILAGE, V19, P1081, DOI 10.1016/j.joca.2011.05.003; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; Fosang AJ, 2008, NAT CLIN PRACT RHEUM, V4, P420, DOI 10.1038/ncprheum0841; Yamanishi Y, 2002, J IMMUNOL, V168, P1405; Yatabe T, 2009, ANN RHEUM DIS, V68, P1051, DOI 10.1136/ard.2007.086884; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502; van der Kraan PM, 2012, CELL TISSUE RES, V347, P257, DOI 10.1007/s00441-011-1194-6; Gendron C, 2007, J BIOL CHEM, V282, P18294, DOI 10.1074/jbc.M701523200; Yamaai T, 2005, J BONE MINER METAB, V23, P280, DOI 10.1007/s00774-004-0600-5; Chen CC, 2009, INT J BIOCHEM CELL B, V41, P771, DOI 10.1016/j.biocel.2008.07.025; MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; Azai C, 2011, BBA-BIOENERGETICS, V1807, P803, DOI 10.1016/j.bbabio.2011.03.007; Fujita Y, 2006, ARTHRITIS RHEUM, V54, P3233, DOI 10.1002/art.22140; Guillon-Munos A, 2011, J BIOL CHEM, V286, P25505, DOI 10.1074/jbc.M110.213231; Hashimoto G, 2004, J BIOL CHEM, V279, P32483, DOI 10.1074/jbc.M314216200; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; LOESER RF, 1995, EXP CELL RES, V217, P248, DOI 10.1006/excr.1995.1084; Moritani N.H., 2005, CELL COMMUN SIGNAL, V3, P6, DOI 10.1186/1478-811X-3-6; Okada Y., 2013, KELLEYS TXB RHEUMATO, V9th, P97; Okubo M, 2011, ARTHRITIS RHEUM-US, V63, P3000, DOI 10.1002/art.30482; Powell AJ, 2007, ARTHRITIS RHEUM, V56, P3010, DOI 10.1002/art.22818; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Takizawa M, 2008, FEBS LETT, V582, P2945, DOI 10.1016/j.febslet.2008.07.036; Wayne GJ, 2007, J BIOL CHEM, V282, P20991, DOI 10.1074/jbc.M610721200; Yokoyama T, 2004, CLIN EXP METASTAS, V21, P223, DOI 10.1023/B:CLIN.0000037704.72028.72	44	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2326-5191	2326-5205		ARTHRITIS RHEUMATOL	Arthritis Rheumatol.	JUN	2015	67	6					1557	1567		10.1002/art.39078		11	Rheumatology	Rheumatology	CJ2QA	WOS:000355328400018		
J	Battula, KK; Nappanveettil, G; Nakanishi, S; Kuramoto, T; Friedman, JM; Kalashikam, RR				Battula, Kiran Kumar; Nappanveettil, Giridharan; Nakanishi, Satoshi; Kuramoto, Takashi; Friedman, Jeffry M.; Kalashikam, Rajender Rao			Genetic Relatedness of WNIN and WNIN/Ob with Major Rat Strains in Biomedical Research	BIOCHEMICAL GENETICS			English	Article						Disease models; Obesity; Microsatellite markers; Phylogeny; Rat	OBESE MUTANT RATS; LABORATORY RAT; LEPTIN; GENOME; PHYLOGENETICS; RESISTANCE; MARKERS; DISEASE; MODEL	WNIN (Wistar/NIN) is an inbred rat strain maintained at National Institute of Nutrition (NIN) for more than 90 years, and WNIN/Ob is an obese mutant originated from it. To determine their genetic relatedness with major rat strains in biomedical research, they were genotyped at various marker loci. The recently identified markers for albino and hooded mutations which clustered all the known albino rats into a single lineage also included WNIN and WNIN/Ob rats. Genotyping using microsatellite DNA markers and phylogenetic analysis with 49 different rat strains suggested that WNIN shares a common ancestor with many Wistar originated strains. Fst estimates and Fischer's exact test suggest that WNIN rats differed significantly from all other strains tested. WNIN/Ob though shows hyper-leptinemia, like Zucker fatty rat, did not share the Zucker fatty rat mutation. The above analyses suggest WNIN as a highly differentiated rat strain and WNIN/Ob a novel obese mutant evolved from it.	[Battula, Kiran Kumar; Nappanveettil, Giridharan; Kalashikam, Rajender Rao] Natl Inst Nutr, Natl Ctr Lab Anim Sci, Mol Genet Lab, Hyderabad 500007, Andhra Pradesh, India; [Nakanishi, Satoshi; Kuramoto, Takashi] Kyoto Univ, Inst Lab Anim, Grad Sch Med, Kyoto, Japan; [Friedman, Jeffry M.] Rockefeller Univ, Howard Hughes Med Inst, Mol Genet Lab, New York, NY 10065 USA	Kalashikam, RR (reprint author), Natl Inst Nutr, Natl Ctr Lab Anim Sci, Mol Genet Lab, Hyderabad 500007, Andhra Pradesh, India.	rkrajender@yahoo.com			Indian Council of Medical Research (ICMR), Government of India; National Institutes of Health (NIH), USA; Rockefeller University, NY, USA; ICMR, INDIA; National Institutes of Health, USA [63/2/INDO-US/2005-RHN]	Authors acknowledge the Indian Council of Medical Research (ICMR), Government of India, National Institutes of Health (NIH), USA, Rockefeller University, NY, USA, for the research fund. We thank lab members of Dr. Friedman, Rockefeller University and lab members of Dr. Takashi, Kyoto University for extending their help in genetic analysis of WNIN rats. Authors also thank the Director, National Institute of Nutrition for the support in this work. The work was funded by ICMR, INDIA and National Institutes of Health, USA (No. 63/2/INDO-US/2005-RHN). The funding agencies have no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Albuquerque D, 2015, MOL GENET GENOM 0308; NEI M, 1978, GENETICS, V89, P583; Sainz N, 2015, METABOLISM, V64, P35, DOI 10.1016/j.metabol.2014.10.015; Wauman J, 2011, FRONT BIOSCI-LANDMRK, V16, P2771, DOI 10.2741/3885; Shimoyama M, 2015, NUCLEIC ACIDS RES, V43, pD743, DOI 10.1093/nar/gku1026; Atanur SS, 2013, CELL, V154, P691, DOI 10.1016/j.cell.2013.06.040; Aitman TJ, 2008, NAT GENET, V40, P516, DOI 10.1038/ng.147; Bandaru P, 2011, VACCINE, V29, P3038, DOI 10.1016/j.vaccine.2011.01.107; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Rousset F, 2008, MOL ECOL RESOUR, V8, P103, DOI 10.1111/j.1471-8286.2007.01931.x; Beermann F, 2004, MAMM GENOME, V15, P749, DOI 10.1007/s00335-04-4002-8; Canzian F, 1997, GENOME RES, V7, P262, DOI 10.1101/gr.7.3.262; Dwinell MR, 2011, MAMM GENOME, V22, P466, DOI 10.1007/s00335-011-9346-2; Felsenstein J, 2009, PHYLIP PHYLOGENY INF; Festing MFW, 1993, INT INDEX LAB ANIMAL, V6th, P186; Ginter E, 2014, BRATISL MED J, V115, P527, DOI 10.4149/BLL_2014_102; GIRIDHARAN N, 1996, SCAND J LAB ANIM SCI, V23, P131; Harishankar N, 2011, INDIAN J MED RES, V134, P330; Harishankar N, 2011, ISRN ENDOCRINOL, V2011; Kalashikam RR, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-25; Kalashikam RR, 2013, PLOS ONE, V81; Kiran KB, 2007, BIOCHEM GENET, V45, P77, DOI 10.1007/s10528-006-9064-8; Kuramoto T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043059; Leibel RL, 1997, J BIOL CHEM, V272, P31937, DOI 10.1074/jbc.272.51.31937; Lifshitz Fima, 2014, Pediatr Endocrinol Rev, V12, P17; Lindesy JR, 2006, LAB RAT, P33; Lutz T.A., 2012, CURR PROTOC PHARM, DOI DOI 10.1002/0471141755.PH0561S58; Mashimo T, 2009, CURR PHARM BIOTECHNO, V10, P214; Miller Mark P, 1997, MAMM GENOME, V14, P61; Reddy GB, 2009, INVEST OPHTH VIS SCI, V50, P3456, DOI 10.1167/iovs.08-2498; Schutz Y, 2014, OBESITY FACTS, V7, P15, DOI 10.1159/000357846; SERIKAWA T, 1992, GENETICS, V131, P701; Swinburn BA, 2011, LANCET, V27, P804, DOI DOI 10.1016/S0140-6736(11)60813-1; Szpirer C, 2012, GENOME MAPPING GENOM, P217; Thomas MA, 2003, MAMM GENOME, V14, P61, DOI 10.1007/s00335-002-2204-5; Watanabe TK, 1999, NAT GENET, V22, P27, DOI 10.1038/8737	36	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0006-2928	1573-4927		BIOCHEM GENET	Biochem. Genet.	JUN	2015	53	4-6					132	140		10.1007/s10528-015-9679-8		9	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	CJ2LN	WOS:000355316400006		
J	Yan, LM; Wang, CZ; Lin, B; Liu, JJ; Liu, DW; Hou, R; Wang, YF; Gao, LL; Zhang, SL; Iwamori, M				Yan, Limei; Wang, Changzhi; Lin, Bei; Liu, Juanjuan; Liu, Dawo; Hou, Rui; Wang, Yifei; Gao, Lili; Zhang, Shulan; Iwamori, Masao			Lewis y enhances CAM-DR in ovarian cancer cells by activating the FAK signaling pathway and upregulating Bcl-2/Bcl-XL expression	BIOCHIMIE			English	Article						Lewis y; CAM-DR; Integrin alpha 5 beta 1; FAK signaling pathway; Bcl-2	RMG-I CELLS; ALPHA-1,2-FUCOSYL-TRANSFERASE GENE; MULTIDRUG-RESISTANCE; INTEGRIN EXPRESSION; CARCINOMA-CELLS; ADHESION; APOPTOSIS; ANTIGEN; LINE; PROMOTES	Oligosaccharides on the surface of adhesion molecules may contribute to the process of CAM-DR. To investigate the role of the Lewis y antigen in this process, we established a cell adhesion model mediated by the integrin alpha 5 beta 1-FN interaction in the ovarian cancer cell line, RMG-1-hFUT, which highly expresses Lewis y by transfection with alpha 1,2-fucosyltransferase into RMG-1 cells. Our results indicate that the rates of carboplatin-induced apoptosis and necrosis are reduced in FN-adhered tumor cells, and carboplatin resistance is significantly decreased in the presence of anti-Lewis y antibody. CAM-DR in tumor cells has been correlated with elevated expression of the nuclear anti-apoptotic proteins Bcl-2 and Bcl-XL. Lewis y promotes the expression of the Bcl-2 and Bcl-X-L genes by activating the focal adhesion kinase signaling pathway and accelerating their transcription. Thus, Lewis y leads to inhibition of apoptosis and enhancement of CAM-DR by activation of the FAK signaling pathway and upregulation of Bcl-2/Bcl-X-L expression in ovarian cancer cell lines. (C) 2015 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.	[Yan, Limei; Lin, Bei; Liu, Juanjuan; Liu, Dawo; Hou, Rui; Gao, Lili; Zhang, Shulan] China Med Univ, Shengjing Hosp Affiliated, Dept Obstet & Gynecol, Shenyang 110004, Peoples R China; [Wang, Changzhi] Shantou Univ, Dept Obstet & Gynecol, Coll Med, Shantou 515000, Peoples R China; [Wang, Yifei] Dalian Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Dalian 116027, Peoples R China; [Iwamori, Masao] Kinki Univ, Fac Sci & Technol, Dept Biochem, Higashiosaka, Osaka 5778502, Japan	Lin, B (reprint author), 36 Sanhao St, Shenyang 110004, Peoples R China.	linbei88@hotmail.com			National Natural Science Foundation of China [30170980, 30571958, 30872757, 81072118]; Educational Department Doctor Projects Fund [20070159023]; Key Laboratory Project of Liaoning Province Education Office [2008S247]; Free Researchers' Plan of Shengjing Hospital [200807]; Science Committee Foundation of Shenyang City, China [F10-14-9-9-52]; Abbott Laboratories [ABT-737, ABT-737E]	This work was supported by grants from the National Natural Science Foundation of China (No. 30170980, 30571958, 30872757, and 81072118), Educational Department Doctor Projects Fund (No. 20070159023), Key Laboratory Project of Liaoning Province Education Office (No. 2008S247), Free Researchers' Plan of Shengjing Hospital (No. 200807), Science Committee Foundation of Shenyang City, China (No. F10-14-9-9-52), ABT-737 and ABT-737E were provided by Abbott Laboratories.	Goupille C, 2000, GLYCOBIOLOGY, V10, P375, DOI 10.1093/glycob/10.4.375; Taylor ST, 2000, J NATL CANCER I, V92, P18, DOI 10.1093/jnci/92.1.18; Yan LM, 2010, BIOCHIMIE, V92, P852, DOI 10.1016/j.biochi.2010.02.012; Yang XWH, 2010, CANCER RES, V70, P2256, DOI 10.1158/0008-5472.CAN-09-4032; Damiano JS, 1999, BLOOD, V93, P1658; Li FF, 2010, INT J MOL SCI, V11, P3748, DOI 10.3390/ijms11103748; Rout UK, 2004, DEV BIOL, V268, P135, DOI 10.1016/j.ydbio.2003.12.010; Wang SE, 2009, CANCER RES, V69, P475, DOI 10.1158/0008-5472.CAN-08-2649; Xing H, 2008, APOPTOSIS, V13, P213, DOI 10.1007/s10495-007-0158-5; Liang Y, 2001, EUR J CANCER, V37, P1041, DOI 10.1016/S0959-8049(01)00086-7; KIM YS, 1986, CANCER RES, V46, P5985; Madjd Z, 2005, BREAST CANCER RES, V7, pR780, DOI 10.1186/bcr1305); Liu JJ, 2010, ONCOL REP, V23, P833, DOI 10.3892/or_00000705; Cowell LN, 2006, ONCOGENE, V25, P7597, DOI 10.1038/sj.onc.1209747; Shtil AA, 2005, INT REV CYTOL, V246, P1, DOI 10.1016/S0074-7696(05)46001-5; Le XF, 2005, J BIOL CHEM, V280, P2092, DOI 10.1074/jbc.M403080200; Nakahara S, 2003, MOL CANCER THER, V2, P1207; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; Huang Y, 2006, CANCER LETT, V239, P168, DOI 10.1016/j.canlet.2005.07.032; Bast RC, 2010, NAT REV CLIN ONCOL, V7, P559, DOI 10.1038/nrclinonc.2010.152; Chhieng DC, 2003, HUM PATHOL, V34, P1016, DOI 10.1053/S0046-8177(03)00355-1; Cong JP, 2010, PROG BIOCHEM BIOPHYS, V37, P175, DOI 10.3724/SP.J.1206.2009.00459; Diao B., 2008, J MOD ONCOL, V16, P335; Ganapathi R, 1996, MOL PHARMACOL, V50, P243; Gao LL, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-15; Gao Lili, 2011, J EXP CLIN CANC RES, V30, P7; Guo Hong-Yan, 2004, Zhonghua Fu Chan Ke Za Zhi, V39, P750; Haider J, 2005, CLIN CANCER RES, V11, P8829; Hao Ying Ying, 2008, Fen Zi Xi Bao Sheng Wu Xue Bao, V41, P435; Hazlehurst LA, 2006, CANCER RES, V66, P2338, DOI 10.1158/0008-5472.CAN-05-3256; Huanwen Wu, 2009, Mol Cancer, V8, P125, DOI 10.1186/1476-4598-8-125; Iwamori M, 2005, CANCER SCI, V96, P26, DOI 10.1111/j.1349-7006.2005.00005.x; Iwamori M, 2007, J BIOCHEM, V141, P309, DOI 10.1093/jb/mvm031; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; Kudo T., 2007, MOL CANCER, V6, P1; Li Fei-fei, 2008, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V24, P267; Li QR, 2010, INT J GYNECOL CANCER, V20, P1482, DOI 10.1111/IGC.0b013e3181ea7ecb; Liu JJ, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-154; Liu Q, 2009, ZHONGGUO YI XUE KE X, V31, P481; Lopez-Ferrer A, 2000, GUT, V47, P349, DOI 10.1136/gut.47.3.349; Lu JG, 2009, EUR ARCH OTO-RHINO-L, V266, P89, DOI 10.1007/s00405-008-0675-z; Mahadevan D, 2005, CURR CANCER DRUG TAR, V5, P445, DOI 10.2174/1568009054863609; Mariotti M, 2009, CANCER LETT, V273, P155, DOI 10.1016/j.canlet.2008.08.017; Maubant S, 2002, INT J CANCER, V97, P186, DOI 10.1002/ijc.1600; Scheltema JMW, 1997, J CANCER RES CLIN, V123, P546, DOI 10.1007/s004320050103; Witham J, 2007, CLIN CANCER RES, V13, P7191, DOI 10.1158/1078-0432.CCR-07-0362; Wu Xiao-hua, 2004, Zhonghua Fu Chan Ke Za Zhi, V39, P112; Yan LM, 2010, INT J MOL SCI, V11, P4441, DOI 10.3390/ijms11114441; Zhao Y, 2008, PROG BIOCHEM BIOPHYS, V35, P1175; Zhu Lian-Cheng, 2008, Ai Zheng, V27, P934	51	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0300-9084	1638-6183		BIOCHIMIE	Biochimie	JUN	2015	113						17	25		10.1016/j.biochi.2015.01.013		9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CJ2XQ	WOS:000355348400003		
J	Ariga, H				Ariga, Hiroyoshi			Common Mechanisms of Onset of Cancer and Neurodegenerative Diseases	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Review						c-Myc; DJ-1; Myc-Modulator 1 (MM-1); cancer; Parkinson's disease; neurodegenerative disease	FAMILIAL PARKINSONS-DISEASE; DOMINANT RETINITIS-PIGMENTOSA; SQUAMOUS-CELL CARCINOMA; C-MYC GENE; P53 TRANSCRIPTIONAL ACTIVITY; OXIDATIVE STRESS; DNA-REPLICATION; BINDING-PROTEIN; DJ-1 PROTEIN; PROTEOMIC ANALYSIS	Onset of cancer and neurodegenerative disease occurs by abnormal cell growth and neuronal cell death, respectively, and the number of patients with both diseases has been increasing in parallel with an increase in mean lifetime, especially in developed countries. Although both diseases are sporadic, about 10% of the diseases are genetically inherited, and analyses of such familial forms of gene products have contributed to an understanding of the molecular mechanisms underlying the onset and pathogenesis of these diseases. I have been working on c-myc, a protooncogene, for a long time and identified various c-Myc-binding proteins that play roles in c-Myc-derived tumorigenesis. Among these proteins, some proteins have been found to be also responsible for the onset of neurodegenerative diseases, including Parkinson's disease, retinitis pigmentosa and cerebellar atrophy. In this review, I summarize our findings indicating the common mechanisms of onset between cancer and neurodegenerative diseases, with a focus on genes such as DJ-1 and Myc-Modulator 1 (MM-1) and signaling pathways that contribute to the onset and pathogenesis of cancer and neurodegenerative diseases.	Hokkaido Univ, Fac Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Ariga, H (reprint author), Hokkaido Univ, Fac Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	hiro@pharm.hokudai.ac.jp					Abd El Atti RM, 2013, DIAGN PATHOL, V8, P126; Abdel-Salam OME, 2014, CNS NEUROL DISORD-DR, V13, P1485; Abe A, 2013, J BIOL CHEM, V288, P27764, DOI 10.1074/jbc.M113.476358; Akazawa YO, 2010, NEUROSCI LETT, V483, P201, DOI 10.1016/j.neulet.2010.08.007; An CN, 2011, FERTIL STERIL, V96, P19, DOI 10.1016/j.fertnstert.2011.04.048; Shinbo YM, 2005, INT J ONCOL, V26, P641; Thomas KJ, 2011, HUM MOL GENET, V20, P40, DOI 10.1093/hmg/ddq430; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Yokota T, 2003, BIOCHEM BIOPH RES CO, V312, P1342, DOI 10.1016/j.bbrc.2003.11.056; Zhang L, 2005, HUM MOL GENET, V14, P2063, DOI 10.1093/hmg/ddi211; Mullett SJ, 2009, NEUROBIOL DIS, V33, P28, DOI 10.1016/j.nbd.2008.09.013; Camilleri A, 2014, CNS NEUROSCI THER, V20, P591, DOI 10.1111/cns.12264; Devic I, 2011, BRAIN, V134, DOI 10.1093/brain/awr015; Fan J, 2008, FEBS LETT, V582, P1151, DOI 10.1016/j.febslet.2008.03.003; Choi J, 2006, J BIOL CHEM, V281, P10816, DOI 10.1074/jbc.M509079200; Giusti L, 2008, J PROTEOME RES, V7, P4079, DOI 10.1021/pr8000404; Zhou WB, 2006, J MOL BIOL, V356, P1036, DOI 10.1016/j.imb.2005.12.030; Zhou WB, 2005, J BIOL CHEM, V280, P43150, DOI 10.1074/jbc.M507124200; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Kato I, 2013, MOL CELL BIOL, V33, P340, DOI 10.1128/MCB.01350-12; Ishikawa S, 2010, J BIOL CHEM, V285, P39718, DOI 10.1074/jbc.M110.137034; Wilson MA, 2011, ANTIOXID REDOX SIGN, V15, P111, DOI 10.1089/ars.2010.3481; Sekito A, 2006, FREE RADICAL RES, V40, P155, DOI 10.1080/10715760500456847; Melle C, 2007, CLIN CHEM, V53, P629, DOI 10.1373/clinchem.2006.079194; Allard L, 2005, CLIN CHEM, V51, P2043, DOI 10.1373/clinchem.2005.053942; Bandopadhyay R, 2004, BRAIN, V127, P420, DOI 10.1093/brain/awh054; Srisomsap C, 2002, PROTEOMICS, V2, P706, DOI 10.1002/1615-9861(200206)2:6<706::AID-PROT706>3.0.CO;2-E; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Bai J, 2012, MOL BIOL REP, V39, P2697, DOI 10.1007/s11033-011-1024-7; Hayashi T, 2009, BIOCHEM BIOPH RES CO, V390, P667, DOI 10.1016/j.bbrc.2009.10.025; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Fujioka Y, 2001, J BIOL CHEM, V276, P45137, DOI 10.1074/jbc.M106127200; He XY, 2011, J DIGEST DIS, V12, P131, DOI 10.1111/j.1751-2980.2011.00488.x; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Kim JH, 2013, NEUROBIOL DIS, V60, P1, DOI 10.1016/j.nbd.2013.08.007; Wang XL, 2012, J NEUROCHEM, V121, P830, DOI 10.1111/j.1471-4159.2012.07734.x; Clements CM, 2006, P NATL ACAD SCI USA, V103, P15091, DOI 10.1073/pnas.0607260103; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Sabo A, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014191; Kawate T, 2013, BREAST CANCER RES TR, V139, P51, DOI 10.1007/s10549-013-2523-0; Chen J, 2010, HUM MOL GENET, V19, P2395, DOI 10.1093/hmg/ddq113; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; Takahashi-Niki K, 2004, BIOCHEM BIOPH RES CO, V320, P389, DOI 10.1016/j.bbrc.2004.05.187; Yanagisawa D, 2008, J CEREBR BLOOD F MET, V28, P563, DOI 10.1038/sj.jcbfm.9600553; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Kinumi T, 2004, BIOCHEM BIOPH RES CO, V317, P722, DOI 10.1016/j.bbrc.2004.03.110; Keen TJ, 2002, EUR J HUM GENET, V10, P245, DOI 10.1038/sj/ejhg/5200797; Yanagida T, 2009, OXID MED CELL LONGEV, V2, P36; Niki T, 2003, MOL CANCER RES, V1, P247; Yasuda T, 2013, BIOCHEM BIOPH RES CO, V436, P289, DOI 10.1016/j.bbrc.2013.05.095; Kusnadi EP, 2015, GENE, V556, P27, DOI 10.1016/j.gene.2014.11.010; Yanagida T, 2009, J PHARMACOL SCI, V109, P463, DOI 10.1254/jphs.08323SC; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Girotto S, 2014, J BIOL CHEM, V289, P10887, DOI 10.1074/jbc.M113.535112; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Takano M, 2014, BRAIN RES, V1542, P186, DOI 10.1016/j.brainres.2013.10.034; Miyazawa M, 2011, J BIOL CHEM, V286, P19191, DOI 10.1074/jbc.M110.216259; Zhong N, 2008, HUM MOL GENET, V17, P3357, DOI 10.1093/hmg/ddn230; Junn E, 2005, P NATL ACAD SCI USA, V102, P9691, DOI 10.1073/pnas.0409635102; Sakono M, 2008, FEBS J, V275, P5982, DOI 10.1111/j.1742-4658.2008.06727.x; Malhotra D, 2008, AM J RESP CRIT CARE, V178, P592, DOI 10.1164/rccm.200803-380OC; HANN SR, 1984, MOL CELL BIOL, V4, P2486; Nuytemans K, 2010, HUM MUTAT, V31, P763, DOI 10.1002/humu.21277; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pna.1133288100; Miyazaki S, 2008, J NEUROCHEM, V105, P2418, DOI 10.1111/j.1471-4159.2008.05327.x; Jain D, 2012, J MOL CELL BIOL, V4, P221, DOI 10.1093/jmcb/mjs025; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Malaud E, 2014, ATHEROSCLEROSIS, V233, P551, DOI 10.1016/j.atherosclerosis.2013.12.019; Gao H, 2012, J MOL BIOL, V423, P232, DOI 10.1016/j.jmb.2012.06.034; Waragai M, 2007, NEUROSCI LETT, V425, P18, DOI 10.1016/j.neulet.2007.08.010; Le Naour F, 2001, CLIN CANCER RES, V7, P3328; Maita C, 2008, NEUROSCI LETT, V431, P86, DOI 10.1016/j.neulet.2007.11.027; Yuen HF, 2008, CANCER EPIDEM BIOMAR, V17, P3593, DOI 10.1158/1055-9965.EPI-08-0214; Diolaiti D, 2015, BBA-GENE REGUL MECH, V1849, P484, DOI 10.1016/j.bbagrm.2014.05.016; Koide-Yoshida S, 2007, INT J MOL MED, V19, P885; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Segura-Aguilar J, 2014, J NEUROCHEM, V129, P898, DOI 10.1111/jnc.12686; Li HM, 2005, FREE RADICAL RES, V39, P1091, DOI 10.1080/10715760500260348; Aleyasin H, 2007, P NATL ACAD SCI USA, V104, P18748, DOI 10.1073/pnas.0709379104; Cuevas S, 2012, HYPERTENSION, V59, P446, DOI 10.1161/HYPERTENSIONAHA.111.185744; Tsuchiya B, 2012, HISTOPATHOLOGY, V61, P69, DOI 10.1111/j.1365-2559.2012.04202.x; Klawitter J, 2013, CARDIOVASC RES, V97, P66, DOI 10.1093/cvr/cvs302; Fan J, 2008, J BIOL CHEM, V283, P4022, DOI 10.1074/jbc.M707176200; Arnouk H, 2009, PROTEOM CLIN APPL, V3, P516, DOI 10.1002/prca.200800068; Billia F, 2013, P NATL ACAD SCI USA, V110, P6085, DOI 10.1073/pnas.1303444110; Tashiro E, 2013, J BIOL CHEM, V288, P19958, DOI 10.1074/jbc.M113.477984; Waak J, 2009, J BIOL CHEM, V284, P14245, DOI 10.1074/jbc.M806902200; Lee Y, 2011, J BIOL CHEM, V286, P726, DOI 10.1074/jbc.M110.177352; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Maita H, 2005, EXP CELL RES, V302, P61, DOI 10.1016/j.yexcr.2004.08.022; Morelli M, 2014, INT J GYNECOL CANCER, V24, P649, DOI 10.1097/IGC.0000000000000102; Wang ZQ, 2011, ANN NEUROL, V70, P591, DOI 10.1002/ana.22514; Inden M, 2006, NEUROBIOL DIS, V24, P144, DOI 10.1016/j.nbd.2006.06.004; Li Y, 2013, INT J MED SCI, V10, P1689, DOI 10.7150/ijms.7292; Collins AR, 2009, CIRC RES, V104, pe42, DOI 10.1161/CIRCRESAHA.108.188771; Satou A, 2001, J BIOL CHEM, V276, P46562, DOI 10.1074/jbc.M104937200; Kim YC, 2010, FEBS LETT, V584, P3891, DOI 10.1016/j.febslet.2010.08.010; Shiizaki Shigeru, 2013, Advances in Biological Regulation, V53, P135, DOI 10.1016/j.jbior.2012.09.006; Kim YC, 2009, INT J ONCOL, V35, P1331, DOI 10.3892/ijo_00000451; Kahle PJ, 2009, FREE RADICAL BIO MED, V47, P1354, DOI 10.1016/j.freeradbiomed.2009.08.003; Tillman JE, 2007, CANCER RES, V67, P4630, DOI 10.1158/0008-5472.CAN-06-4556; Lee H, 2012, ONCOL LETT, V3, P507, DOI 10.3892/ol.2011.522; Chow SN, 2010, EUR J GYNAECOL ONCOL, V31, P55; [Anonymous], 2014, COLD SPRING HARB PER; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Liu H, 2008, BIOCHEM BIOPH RES CO, V375, P477, DOI 10.1016/j.bbrc.2008.08.046; Xu J, 2005, HUM MOL GENET, V14, P1231, DOI 10.1093/hmg/ddi134; Zhong N, 2006, J BIOL CHEM, V281, P20940, DOI 10.1074/jbc.M601935200; Hod Y, 2004, J CELL BIOCHEM, V92, P1221, DOI 10.1002/jcb.20159; Dias V, 2013, J PARKINSON DIS, V3, P461, DOI 10.3233/JPD-130230; Liu SF, 2010, HEPATO-GASTROENTEROL, V57, P1247; Bonifati V, 2004, J MOL MED-JMM, V82, P163, DOI 10.1007/s00109-003-0512-1; Ariga H, 2013, OXID MED CELL LONGEV, DOI 10.1155/2013/683920; ARIGA H, 1989, EMBO J, V8, P4273; Bande MF, 2012, INVEST OPHTH VIS SCI, V53, P62, DOI 10.1167/iovs.11-7948; Barua A, 2009, INT J GYNECOL CANCER, V19, P500, DOI 10.1111/IGC.0b013e3181a39db1; Bindukumar B, 2008, PROSTATE, V68, P1531, DOI 10.1002/pros.20811; Bonifati Vincenzo, 2014, Parkinsonism Relat Disord, V20 Suppl 1, pS23, DOI 10.1016/S1353-8020(13)70009-9; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; Gao JW, 2011, J PHARMACOL SCI, V115, P36, DOI 10.1254/jphs.10271FP; Giaime E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040501; GUTIERREZ C, 1988, SCIENCE, V240, P1202, DOI 10.1126/science.3287614; Hagio Y, 2006, J CELL BIOCHEM, V97, P145, DOI 10.1002/jcb.20619; Han Ji-Young, 2014, Exp Neurobiol, V23, P345, DOI 10.5607/en.2014.23.4.345; Hattori K, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-9; He XY, 2012, CARCINOGENESIS, V33, P555, DOI 10.1093/carcin/bgs002; Heo JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032629; Hinkle DA, 2011, NEUROPATHOLOGY, V31, P29, DOI 10.1111/j.1440-1789.2010.01124.x; Hirotani M, 2008, MULT SCLER J, V14, P1056, DOI 10.1177/1352458508093616; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365; IGUCHIARIGA SMM, 1989, CELL STRUCT FUNCT, V14, P649; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135; Inden M, 2011, J PHARMACOL SCI, V117, P189, DOI 10.1254/jphs.11151FP; Ishikawa S, 2009, J BIOL CHEM, V284, P28832, DOI 10.1074/jbc.M109.019950; Ishikawa S, 2012, BIOCHEM BIOPH RES CO, V421, P813, DOI 10.1016/j.bbrc.2012.04.095; Kang Wen-Yan, 2014, Front Aging Neurosci, V6, P102, DOI 10.3389/fnagi.2014.00102; Kawase H, 2009, J PROTEOME RES, V8, P4092, DOI 10.1021/pr900468k; Kimura Y, 2007, INT J ONCOL, V31, P829; Kitamura Y, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-48; Krebiehl G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009367; Kuroda TS, 2004, GENE, V340, P83, DOI 10.1016/j.gene.2004.05.025; Liu M., 2013, OXID MED CELL LONGEV, V2013; MacKeigan JP, 2003, CANCER RES, V63, P6928; Maita C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054087; Maita H, 2000, EUR J BIOCHEM, V267, P5168, DOI 10.1046/j.1432-1327.2000.01585.x; Maita H, 2004, EXP CELL RES, V300, P283, DOI 10.1016/j.yexcr.2004.07.029; Martinat C, 2004, PLOS BIOL, V2, P1754, DOI 10.1371/journal.pbio.0020327; Mitsugi H, 2013, FEBS LETT, V587, P2493, DOI 10.1016/j.febslet.2013.06.032; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; Mullett SJ, 2009, NEUROPATHOLOGY, V29, P125, DOI 10.1111/j.1440-1789.2008.00955.x; Narita R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041891; NEGISHI Y, 1994, ONCOGENE, V9, P1133; NEGISHI Y, 1992, ONCOGENE, V7, P543; Nishinaga H, 2005, NEUROSCI LETT, V390, P54, DOI 10.1016/j.neulet.2005.07.053; Oda M, 2012, CANCER SCI, V103, P1172, DOI 10.1111/j.1349-7006.2012.02267.x; Okada M, 2002, BIOL PHARM BULL, V25, P853, DOI 10.1248/bpb.25.853; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; Osman Wesam M, 2013, J Egypt Natl Canc Inst, V25, P223, DOI 10.1016/j.jnci.2013.08.001; Pardo M, 2006, INT J CANCER, V119, P1014, DOI 10.1002/ijc.21942; Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007; Qu W, 2009, J PHARMACOL SCI, V110, P191, DOI 10.1254/jphs.09045FP; Rahl PB, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a020990; Richarme G, 2015, J BIOL CHEM, V290, P1885, DOI 10.1074/jbc.M114.597815; Rizzu P, 2004, ANN NEUROL, V55, P113, DOI 10.1002/ana.10782; Said J, 2014, ADV ANAT PATHOL, V21, P160, DOI 10.1097/PAP.0b013e3182a92cde; Sajjad MU, 2014, HUM MOL GENET, V23, P755, DOI 10.1093/hmg/ddt466; Satou A, 2004, FEBS LETT, V572, P211, DOI 10.1016/j.febslet.2004.07.034; Shen Z, 2011, Eur J Histochem, V55, pe9, DOI 10.4081/ejh.2011.e9; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Shimwell NJ, 2012, BRIT J CANCER, V107, P1595, DOI 10.1038/bjc.2012.405; Shinbo Y, 2006, CELL DEATH DIFFER, V13, P96, DOI 10.1038/sj.cdd.4401704; Shu KY, 2013, INT J GYNECOL CANCER, V23, P1029, DOI 10.1097/IGC.0b013e3182959182; Sörgjerd Karin Margareta, 2013, Biochemistry, V52, P3532, DOI 10.1021/bi301705c; Taira T, 1999, J BIOL CHEM, V274, P24270, DOI 10.1074/jbc.274.34.24270; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Takahashi-Niki K, 2015, J PHARMACOL SCI, V127, P305, DOI 10.1016/j.jphs.2015.01.010; Takayama M, 2000, GENES CELLS, V5, P481, DOI 10.1046/j.1365-2443.2000.00338.x; Tian M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-241; Tsiaousidou A, 2013, PANCREATOLOGY, V13, P564, DOI 10.1016/j.pan.2013.10.005; Tsuboi Y, 2008, FEBS LETT, V582, P2643, DOI 10.1016/j.febslet.2008.06.043; Tu WB, 2015, BBA-GENE REGUL MECH, V1849, P469, DOI 10.1016/j.bbagrm.2014.06.002; Wagenfeld A, 1998, BIOCHEM BIOPH RES CO, V251, P545, DOI 10.1006/bbrc.1998.9512; Wang C, 2013, NEUROPATHOLOGY, V33, P628, DOI 10.1111/neup.12041; Waragai M, 2006, BIOCHEM BIOPH RES CO, V345, P967, DOI 10.1016/j.bbrc.2006.005.011; Yamaguchi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038144; Yamane T, 2013, MOL BIOL, V3, P15; Yamane T, 2014, NUTR RES, V34, P851, DOI 10.1016/j.nutres.2014.09.004; Yamane T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078374; Yamashita S, 2010, J NEUROCHEM, V113, P860, DOI 10.1111/j.1471-4159.2010.06658.x; Yanagida T, 2006, J PHARMACOL SCI, V102, P243, DOI 10.1254/jphs.SC0060098; Yoshida T, 2008, EXP CELL RES, V314, P1217, DOI 10.1016/j.yexcr.2008.01.002; Zhou X, 2015, LEUKEMIA LYMPHOMA, V14, P1; Zhu XL, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-94; Zhu XL, 2010, CANCER SCI, V101, P1320, DOI 10.1111/j.1349-7006.2010.01531.x	197	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					795	808				14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900001		
J	Takahashi, T; Suzuki, T				Takahashi, Tadanobu; Suzuki, Takashi			Role of Sulfatide in Influenza A Virus Replication	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Review						influenza virus; sulfatide; hemagglutinin; virus replication; apoptosis	CEREBROSIDE SULFOTRANSFERASE; MOLECULAR-CLONING; TYROSINE KINASE; NUCLEAR EXPORT; HIV-1 GP120; V3 LOOP; INFECTION; CELLS; EXPRESSION; BINDING	Sulfatide is a 3-O-sulfated galactosylceramide that is abundantly expressed in the gastrointestinal tract, kidney, trachea, and particularly the central nervous system. Cellular sulfatide is mainly localized in the Golgi apparatus, cellular membrane, and lysosomes in cytosol. Since our earlier report showed that the influenza A virus specifically binds to sulfatide, we have investigated the roles of sulfatide in the influenza A virus lifecycle. The viral binding is independent of sialic acids, which function as virus receptors in virus attachment to the host cell surface. Sulfatide is recognized by the ectodomain of the viral envelope glycoprotein hemagglutinin (HA). Nascent HA is transported on the surface membrane of infected cells. The binding of HA with sulfatide on the cell surface induces apoptosis through potential loss of the mitochondrial membrane and nuclear translocation of apoptosis-inducing factor in mitochondria, where PB1-F2 peptide from the viral gene is accumulated. In the nucleus of infected cells, viral ribonucleoprotein (vRNP) complexes are formed from viral RNA genomes, viral nucleoprotein, and viral RNA polymerase subunits, and these complexes are selectively exported into cytosol through the nuclear membrane. The apoptosis significantly enhances the nuclear export of vRNP complexes, resulting in efficient formation of progeny viruses and facilitation of virus replication. At that time, activation of the Raf/mitogen-activated protein extracellular kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway through sulfatide is associated with virus replication. Our studies have demonstrated that sulfatide is not a viral receptor for virus infection, and that the binding of HA with sulfatide functions as an initiation switch for the formation of progeny viruses.	[Takahashi, Tadanobu; Suzuki, Takashi] Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem, Shizuoka 4228526, Japan	Suzuki, T (reprint author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem, Shizuoka 4228526, Japan.	suzukit@u-shizuoka-ken.ac.jp			MEXT/JSPS KAKENHI [18390142, 23590549, 20790357, 26670064]; Sasakawa Scientific Research Grant from The Japan Science Society [20-403, 23-439]; Tokyo Biochemical Research Foundation; Hamamatsu Scientific Research Foundation; Takeda Science Foundation; Research Foundation for Pharmaceutical Sciences; Mizutani Foundation for Glycoscience; Public Foundation of Chubu Science and Technology Center; Waksman Foundation of Japan Inc.; Showa University Medical Foundation; Uehara Memorial Foundation; Foundation for Promotion of Material Science and Technology of Japan; Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) from Japan Science and Technology Agency; CREST from Japan Science and Technology Agency; Gobal COE Program from the Japan Society for the Promotion of Science	We would like to acknowledge people in our laboratory who contributed to this work. We would also like to acknowledge and appreciate Dr. Yasuo Suzuki of Chubu University, Dr. Koichi Honke of Kochi University Medical School, Dr. Kiyoshi Ogura and Dr. Tadashi Tai of Tokyo Metropolitan Institute of Medical Science, and Dr. Hideshi. Yokoyama and Dr. Satoshi Fujii of the University of Shizuoka. This work was supported in part by a Grant-in-Aid from the MEXT/JSPS KAKENHI (Scientific Research B, 18390142; Scientific Research C, 23590549; Young Scientist B, 20790357; Challenging Exploratory Research 26670064), Sasakawa Scientific Research Grant from The Japan Science Society (20-403 and 23-439), Grant-in-Aid from Tokyo Biochemical Research Foundation, Hamamatsu Scientific Research Foundation, Takeda Science Foundation, The Research Foundation for Pharmaceutical Sciences, Mizutani Foundation for Glycoscience, The Public Foundation of Chubu Science and Technology Center, The Waksman Foundation of Japan Inc., Showa University Medical Foundation, The Uehara Memorial Foundation, Foundation for Promotion of Material Science and Technology of Japan, Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) from Japan Science and Technology Agency, CREST from Japan Science and Technology Agency, and the Gobal COE Program from the Japan Society for the Promotion of Science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279; Alpa M, 2008, AUTOIMMUN REV, V8, P56, DOI 10.1016/j.autrev.2008.07.027; Bright RA, 2006, JAMA-J AM MED ASSOC, V295, P891, DOI 10.1001/jama.295.8.joc60020; Delezay O, 1996, BIOCHEMISTRY-US, V35, P15663, DOI 10.1021/bi961205g; de Wit E, 2008, J CLIN VIROL, V41, P1, DOI 10.1016/j.jcv.2007.10.017; Marjuki H, 2006, J BIOL CHEM, V281, P16707, DOI 10.1074/jbc.M510233200; Suzuki T, 1996, BIOCHEM J, V318, P389; Neumann G, 2009, NATURE, V459, P931, DOI 10.1038/nature08157; Kolter T, 2005, ANNU REV CELL DEV BI, V21, P81, DOI 10.1146/annurev.cellbio.21.122303.120013; Suzuki T, 2005, J VIROL, V79, P11705, DOI 10.1128/JVI.79.18.11705-11715.2005; Zeng YC, 2008, BIOCHEM J, V410, P81, DOI 10.1042/BJ20070976; Elton D, 2001, J VIROL, V75, P408, DOI 10.1128/JVI.75.1.408-419.2001; Matrosovich MN, 2004, J VIROL, V78, P12665, DOI 10.1128/JVI.78.22.12665-12667.2004; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Samson M, 2013, ANTIVIR RES, V98, P174, DOI 10.1016/j.antiviral.2013.03.014; Takahashi T, 2008, J VIROL, V82, P5940, DOI 10.1128/JVI.02496-07; Edinger TO, 2014, J GEN VIROL, V95, P263, DOI 10.1099/vir.0.059477-0; Suzuki Y, 2005, BIOL PHARM BULL, V28, P399, DOI 10.1248/bpb.28.399; Bosio A, 1996, GENOMICS, V34, P69, DOI 10.1006/geno.1996.0242; Ohuchi M, 2006, MICROBES INFECT, V8, P1287, DOI 10.1016/j.micinf.2005.12.008; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; Takahashi T, 2012, J LIPID RES, V53, P1437, DOI 10.1194/jlr.R026682; Daugas E, 2000, FASEB J, V14, P729; Kensinger RD, 2004, ANTIMICROB AGENTS CH, V48, P1614, DOI 10.1128/AAC.48.5.1614-1623.2004; Eckhardt M, 2008, MOL NEUROBIOL, V37, P93, DOI 10.1007/s12035-008-8022-3; BURKART T, 1982, J BIOL CHEM, V257, P3151; Chang LK, 2002, J CELL BIOL, V157, P771, DOI 10.1083/jcb.200112130; COOK DG, 1994, VIROLOGY, V201, P206, DOI 10.1006/viro.1994.1287; Fantini J, 1998, VIROLOGY, V246, P211, DOI 10.1006/viro.1998.9216; Hirahara Y, 2000, EUR J BIOCHEM, V267, P1909, DOI 10.1046/j.1432-1327.2000.01139.x; Honke K, 1997, J BIOL CHEM, V272, P4864; Kuwano K, 2005, Med Chem, V1, P49, DOI 10.2174/1573406053402497; LANDE MB, 1994, AM J PHYSIOL, V267, pC367; Lee CM, 2012, P NATL ACAD SCI USA, V109, P20385, DOI 10.1073/pnas.1219155109; Liu Y, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-186; Makhlouf AM, 2004, INT J GYNECOL CANCER, V14, P89; Morichika H, 1996, CANCER, V78, P43, DOI 10.1002/(SICI)1097-0142(19960701)78:1<43::AID-CNCR8>3.3.CO;2-2; Ogura K, 1998, J NEUROCHEM, V71, P1827; Perino J, 2011, BIOL CELL, V103, P319, DOI 10.1042/BC20110012; RAFI MA, 1992, AM J HUM GENET, V50, P1252; SAKAKIBARA N, 1989, CANCER RES, V49, P335; SCHNEIDERSCHAULIES J, 1992, VIROLOGY, V191, P765, DOI 10.1016/0042-6822(92)90252-K; Souayah N, 2007, J NEUROIMMUNOL, V188, P143, DOI 10.1016/j.jneuroim.2007.05.020; Sundell I Birgitta, 2010, J Stem Cells, V5, P33, DOI jsc.2010.5.1.33; Takahashi T, 2010, J BIOCHEM, V147, P459, DOI 10.1093/jb/mvq013; Takahashi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061092; Takahashi T, 2013, GLYCOCONJUGATE J, V30, P709, DOI 10.1007/s10719-013-9477-7; Takahashi T, 2012, J BIOCHEM, V152, P373, DOI 10.1093/jb/mvs080; Trick D, 1999, HISTOCHEM CELL BIOL, V111, P143, DOI 10.1007/s004180050344; VANDENBERG LH, 1992, J NEUROSCI RES, V33, P513; Yaghootfam A, 2007, BIOCHEMISTRY-US, V46, P9260, DOI 10.1021/bi700014q; YODA Y, 1979, J NATL CANCER I, V63, P1153; Zheng WJ, 2013, FEBS LETT, V587, P1206, DOI 10.1016/j.febslet.2013.02.048	53	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					809	816				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900002		
J	Takahashi, T; Suzuki, T				Takahashi, Tadanobu; Suzuki, Takashi			Low-pH Stability of Influenza A Virus Sialidase Contributing to Virus Replication and Pandemic	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Review						influenza virus; sialidase; low-pH stability; virus replication; pandemic	DIVALENT-CATION REQUIREMENTS; H5N1 AVIAN INFLUENZA; HEMADSORPTION ACTIVITY; SUBSTRATE-SPECIFICITY; MOLECULAR-MECHANISM; H1N1 NEURAMINIDASE; VIRAL REPLICATION; N2 NEURAMINIDASES; ACTIVE-SITE; VIRULENCE	The spike glycoprotein neuraminidase (NA) of influenza A virus (IAV) has sialidase activity that cleaves the terminal sialic acids (viral receptors) from oligosaccharide chains of glycoconjugates. A new antigenicity of viral surface glycoproteins for humans has pandemic potential. We found "low-pH stability of sialidase activity" in NA. The low-pH stability can maintain sialidase activity under acidic conditions of pH 4-5. For human IAVs, NAs of all pandemic viruses were low-pH-stable, whereas those of almost all human seasonal viruses were not. The low-pH stability was dependent on amino acid residues near the active site, the calcium ion-binding site, and the subunit interfaces of the NA homotetramer, suggesting effects of the active site and the homotetramer on structural stability. IAVs with the low-pH-stable NA showed much higher virus replication rates than those of IAVs with low-pH-unstable NA, which was correlated with maintenance of sialidase activity under an endocytic pathway of the viral cell entry mechanism, indicating contribution of low-pH stability to high replication rates of pandemic viruses. The low-pH-stable NA of the 1968 H3N2 pandemic virus was derived from the low-pH-stable NA of H2N2 human seasonal virus, one of two types classified by both low-pH stability in N2 NA and a phylogenetic tree of N2 NA genes. The 2009 H1N1 pandemic virus acquired low-pH-stable NA by two amino acid substitutions at the early stage of the 2009 pandemic. It is thought that low-pH stability contributes to infection spread in a pandemic through enhancement of virus replication.	[Takahashi, Tadanobu; Suzuki, Takashi] Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem, Shizuoka 4228526, Japan	Suzuki, T (reprint author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem, Shizuoka 4228526, Japan.	suzukit@u-shizuoka-ken.ac.jp			MEXT/JSPS KAKENHI [18390142, 23590549, 20790357, 26670064]; CREST (Japan Science and Technology Agency); Mochida Memorial Foundation for Medical and Pharmaceutical Research; SRI (Shizuoka Research Institute); Research Foundation for the Electro-technology of Chubu; Global COE Program from the Japan Society for the Promotion of Science	We would like to acknowledge people in our laboratory who contributed to this work. We would also like acknowledge Dr. Yasuo Suzuki of Chubu University, Dr. Kennedy F. Shortridge of the University of Hong Kong, Dr. Takehiko Saito of the National Institute of Infectious Diseases, Dr. Hideo Goto of the University of Tokyo, Dr. Yoshihiro Kawaoka of the University of Tokyo and the University of Wisconsin-Madison, Dr. Jiasheng Song of the University of Wisconsin-Madison. This work was supported in part by a Grant-in-Aid from the MEXT/JSPS KAKENHI (Scientific Research B, 18390142; Scientific Research C, 23590549; Young Scientist B, 20790357; Challenging Exploratory Research 26670064), CREST (Japan Science and Technology Agency), The Mochida Memorial Foundation for Medical and Pharmaceutical Research, The SRI (Shizuoka Research Institute) academic research grant, Research Foundation for the Electro-technology of Chubu, and the Global COE Program from the Japan Society for the Promotion of Science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Van Hoeven N, 2009, P NATL ACAD SCI USA, V106, P3366, DOI 10.1073/pnas.0813172106; Takahashi T, 2001, J BIOCHEM-TOKYO, V130, P279; Takahashi T, 2003, FEBS LETT, V543, P71, DOI 10.1016/S0014-5793(03)00403-4; Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951; Li Q, 2010, NAT STRUCT MOL BIOL, V17, P1266, DOI 10.1038/nsmb.1909; Russell RJ, 2006, NATURE, V443, P45, DOI 10.1038/nature05114; Oxford JS, 2000, REV MED VIROL, V10, P119, DOI 10.1002/(SICI)1099-1654(200003/04)10:2<119::AID-RMV272>3.3.CO;2-F; Johansson BE, 2003, J BIOCHEM, V134, P345, DOI 10.1093/jb/mvg151; KAWAOKA Y, 1989, J VIROL, V63, P4603; Saha RK, 2009, BIOL PHARM BULL, V32, P1188, DOI 10.1248/bpb.32.1188; VARGHESE JN, 1991, J MOL BIOL, V221, P473, DOI 10.1016/0022-2836(91)80068-6; Li FCK, 2008, J EPIDEMIOL COMMUN H, V62, P555, DOI 10.1136/jech.2007.064030; Kobasa D, 1997, J VIROL, V71, P6706; VARGHESE JN, 1992, PROTEINS, V14, P327, DOI 10.1002/prot.340140302; Basler CF, 2008, ANTIVIR RES, V79, P166, DOI 10.1016/j.antiviral.2008.04.006; Van Reeth K, 2007, VET RES, V38, P243, DOI 10.1051/vetres:2006062; Uchida Y, 2008, VIRUS RES, V138, P70, DOI 10.1016/j.virusres.2008.08.007; Munier S, 2010, J VIROL, V84, P940, DOI 10.1128/JVI.01581-09; Robinson JL, 2007, EMERG INFECT DIS, V13, P1865, DOI 10.3201/eid1312.070615; Suzuki T, 2005, J VIROL, V79, P11705, DOI 10.1128/JVI.79.18.11705-11715.2005; Pappas C, 2008, P NATL ACAD SCI USA, V105, P3064, DOI 10.1073/pnas.0711815105; Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062; Matrosovich MN, 2004, J VIROL, V78, P12665, DOI 10.1128/JVI.78.22.12665-12667.2004; Kobasa D, 2001, J VIROL, V75, P11773, DOI 10.1128/JVI.75.23.11773-11780.2001; Kilbourne ED, 2006, EMERG INFECT DIS, V12, P9; Xu XJ, 2008, J VIROL, V82, P10493, DOI 10.1128/JVI.00959-08; KIDA H, 1980, INFECT IMMUN, V30, P547; Kobasa D, 1999, J VIROL, V73, P6743; Gottfredsson M, 2008, P NATL ACAD SCI USA, V105, P1303, DOI 10.1073/pnas.0707659105; WEBSTER RG, 1978, VIROLOGY, V84, P268, DOI 10.1016/0042-6822(78)90247-7; Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810; Suzuki Y, 2005, BIOL PHARM BULL, V28, P399, DOI 10.1248/bpb.28.399; PALESE P, 1974, VIROLOGY, V61, P397, DOI 10.1016/0042-6822(74)90276-1; COLMAN PM, 1983, NATURE, V303, P41, DOI 10.1038/303041a0; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Matsuoka Y, 2009, J VIROL, V83, P4704, DOI 10.1128/JVI.01987-08; Sandhoff K, 2013, J NEUROSCI, V33, P10195, DOI 10.1523/JNEUROSCI.0822-13.2013; Ohuchi M, 2006, MICROBES INFECT, V8, P1287, DOI 10.1016/j.micinf.2005.12.008; Patel S, 2011, CELL CALCIUM, V50, P157, DOI 10.1016/j.ceca.2011.03.011; Li Q, 2012, P NATL ACAD SCI USA, V109, P18897, DOI 10.1073/pnas.1211037109; Zhu XY, 2012, P NATL ACAD SCI USA, V109, P18903, DOI 10.1073/pnas.1212579109; Garten RJ, 2009, SCIENCE, V325, P197, DOI 10.1126/science.1176225; BAKER NJ, 1976, ARCH VIROL, V52, P7, DOI 10.1007/BF01317860; Brett IC, 2006, J BIOCHEM, V139, P439, DOI 10.1093/jb.mvj051; CHONG AKJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P65, DOI 10.1016/0167-4838(91)90526-6; HAUSMANN J, 1995, J GEN VIROL, V76, P1719, DOI 10.1099/0022-1317-76-7-1719; Ito T, 2000, J VIROL, V74, P9300, DOI 10.1128/JVI.74.19.9300-9305.2000; KIDA H, 1988, VIROLOGY, V162, P160, DOI 10.1016/0042-6822(88)90405-9; Li YH, 2011, VIROLOGY, V415, P12, DOI 10.1016/j.virol.2011.03.024; Lindstrom SE, 2004, VIROLOGY, V328, P101, DOI 10.1016/j.virol.2004.06.009; Mochalova L, 2007, ARCH VIROL, V152, P2047, DOI 10.1007/s00705-007-1024-z; Mochalova L, 2010, GLYCOCONJUGATE J, V27, P321, DOI 10.1007/s10719-010-9280-7; NAKAO H, 1993, J GEN VIROL, V74, P1667, DOI 10.1099/0022-1317-74-8-1667; OVERLY CC, 1995, P NATL ACAD SCI USA, V92, P3156, DOI 10.1073/pnas.92.8.3156; Palese P, 2004, NAT MED, V10, pS82, DOI 10.1038/nm1141; Pourceau G, 2011, CHEMBIOCHEM, V12, P2071, DOI 10.1002/cbic.201100128; Reid AH, 2000, P NATL ACAD SCI USA, V97, P6785, DOI 10.1073/pnas.100140097; Shinde V, 2009, NEW ENGL J MED, V360, P2616, DOI 10.1056/NEJMoa0903812; Suzuki T, 2004, FEBS LETT, V557, P228, DOI 10.1016/S0014-5793(03)01503-5; Takahashi T, 2012, FEBS OPEN BIO, V2, P261, DOI 10.1016/j.fob.2012.08.007; Takahashi T, 2010, PLOS ONE, V5; Takahashi T, 2013, PLOS ONE, V8; Tong SX, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003657; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; Uhlendorff J, 2009, ARCH VIROL, V154, P945, DOI 10.1007/s00705-009-0393-x; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VARGHESE JN, 1988, J MOL BIOL, V200, P201, DOI 10.1016/0022-2836(88)90344-0; YASUDA J, 1991, J GEN VIROL, V72, P2007, DOI 10.1099/0022-1317-72-8-2007; Zhou HB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006277	69	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					817	826				10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900003		
J	Tanaka, Y; Yamada, Y; Ishitsuka, Y; Matsuo, M; Shiraishi, K; Wada, K; Uchio, Y; Kondo, Y; Takeo, T; Nakagata, N; Higashi, T; Motoyama, K; Arima, H; Mochinaga, S; Higaki, K; Ohno, K; Irie, T				Tanaka, Yuta; Yamada, Yusei; Ishitsuka, Yoichi; Matsuo, Muneaki; Shiraishi, Koki; Wada, Koki; Uchio, Yushiro; Kondo, Yuki; Takeo, Toru; Nakagata, Naomi; Higashi, Taishi; Motoyama, Keiichi; Arima, Hidetoshi; Mochinaga, Sakiko; Higaki, Katsumi; Ohno, Kousaku; Irie, Tetsumi			Efficacy of 2-Hydroxypropyl-beta-cyclodextrin in Niemann-Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						Niemann-Pick type C; 2-hydroxypropyl-beta-cyclodextrin; Npc1-deficient mouse	HYDROXYPROPYL-BETA-CYCLODEXTRIN; CHOLESTEROL HOMEOSTASIS; MOUSE; CELLS; GENE; NEURODEGENERATION; CHROMATOGRAPHY; COMPLEXATION; REDUCTION; TRANSPORT	Niemann-Pick type C disease (NPC), an autosomal recessive lysosomal storage disorder, is an inherited disease characterized by the accumulation of intracellular unesterified cholesterol. A solubilizing agent of lipophilic compounds, 2-hydroxypropyl-beta-cyclodextrin (HPBCD), is an attractive drug candidate against NPC disease. However, establishment of the optimum dosage of HPBCD remains to be determined. In this study, we evaluated the effective dosage of HPBCD in NPC model (Npc1(-/-)) mice, and determined serum HPBCD concentrations. Subcutaneous injection of 1000-4000 mg/kg HPBCD improved the lifespan of Npc1(-/-) mice. In addition, liver injury and cholesterol sequestration were significantly prevented by 4000 mg/kg HPBCD in Npc1(-/-) mice. Serum HPBCD concentrations, when treated at the effective dosages (1000-4000 mg/kg), were approximately 1200-2500 mu g/mL at 0.5h after subcutaneous injection, and blood HPBCD concentrations were immediately eliminated in Npc1(-/-) mice. Furthermore, we examined serum HPBCD concentrations when treated at 40000 mg (approximately 2500 mg/kg) in a patient with NPC. We observed that the effective concentration in the in vivo study using Npc1(-/-) mice was similar to that in the patient. In the patient, systemic clearance and the volume of distribution of HPBCD were in accordance with the glomerular filtration rate and extracellular fluid volume, respectively. These results could provide useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.	[Tanaka, Yuta; Yamada, Yusei; Ishitsuka, Yoichi; Shiraishi, Koki; Uchio, Yushiro; Kondo, Yuki; Irie, Tetsumi] Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Clin Chem & Informat, Chuo Ku, Kumamoto 8620973, Japan; [Matsuo, Muneaki] Saga Univ, Fac Med, Dept Pediat, Saga 8498501, Japan; [Wada, Koki] Nihon Shokuhin Kako Co Ltd, Res Inst, Fuji, Shizuoka 4178530, Japan; [Takeo, Toru; Nakagata, Naomi] Kumamoto Univ, CARD, Div Reprod Engn, Chuo Ku, Kumamoto 8600811, Japan; [Higashi, Taishi; Motoyama, Keiichi; Arima, Hidetoshi] Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Phys Pharmaceut, Chuo Ku, Kumamoto 8620973, Japan; [Mochinaga, Sakiko] Saga Univ, Fac Med, Dept Pharm, Saga 8498501, Japan; [Higaki, Katsumi] Tottori Univ, Fac Med, Res Ctr Biosci & Technol, Div Funct Genom, Yonago, Tottori 6838503, Japan; [Ohno, Kousaku] Sanin Rosai Hosp, Yonago, Tottori 6838605, Japan	Irie, T (reprint author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Clin Chem & Informat, Chuo Ku, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.	tirie@gpo.kumamoto-u.ac.jp			Japan Society for the Promotion of Science (JSPS) [23590642, 26460221]	We are grateful to Yuka Horikoshi, Shiori Takeuji, Yumiko Hirose, Makiko Taguchi, and all of the staff of the Division of Reproductive Engineering, Center for Animal Resources and Development, Kumamoto University, for breeding the mice. We also gratefully acknowledge financial support from the Japan Society for the Promotion of Science (JSPS KAKENHI Grant Numbers 23590642 and 26460221 to Irie T.).	Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Taylor AM, 2012, J LIPID RES, V53, P2331, DOI 10.1194/jlr.M028241; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Rosenbaum AI, 2011, J NEUROCHEM, V116, P789, DOI 10.1111/j.1471-4159.2010.06976.x; Camargo F, 2001, LIFE SCI, V70, P131, DOI 10.1016/S0024-3205(01)01384-4; Liu B, 2009, P NATL ACAD SCI USA, V106, P2377, DOI 10.1073/pnas.0810895106; Ramirez CM, 2010, PEDIATR RES, V68, P309, DOI 10.1203/00006450-201011001-00604; Matsuo M, 2013, MOL GENET METAB, V108, P76, DOI 10.1016/j.ymgme.2012.11.005; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Rosenbaum AI, 2010, P NATL ACAD SCI USA, V107, P5477, DOI 10.1073/pnas.0914309107; Peake KB, 2012, J BIOL CHEM, V287, P9290, DOI 10.1074/jbc.M111.326405; Vance JE, 2011, CURR OPIN LIPIDOL, V22, P204, DOI 10.1097/MOL.0b013e3283453e69; Aqul A, 2011, J NEUROSCI, V31, P9404, DOI 10.1523/JNEUROSCI.1317-11.2011; Irie T, 1997, J PHARM SCI, V86, P147, DOI 10.1021/js960213f; Davidson CD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006951; FRIJLINK HW, 1990, PHARMACEUT RES, V7, P1248, DOI 10.1023/A:1015929720063; FRIJLINK HW, 1987, J CHROMATOGR-BIOMED, V415, P325, DOI 10.1016/S0378-4347(00)83224-7; Lopez AM, 2014, CLIN EXP PHARMACOL P, V41, P780, DOI 10.1111/1440-1681.12285; SZATHMARY SC, 1989, J CHROMATOGR-BIOMED, V487, P99, DOI 10.1016/S0378-4347(00)83011-X; Tamura A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04356; Tanaka Y, 2014, MOL GENET METAB REP, V1, P19; Vanier MT, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-16; Wojtanik KM, 2003, J BIOL CHEM, V278, P14850, DOI 10.1074/jbc.M300488200; Yu DZ, 2014, J BIOMOL SCREEN, V19, P1164, DOI 10.1177/1087057114537378	24	1	1	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					844	851				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900006		
J	Kimura, K; Kawaguchi, K; Ueda, Y; Arai, S; Morita, M; Imanaka, T; Wada, I				Kimura, Koji; Kawaguchi, Kosuke; Ueda, Yumiko; Arai, Seisuke; Morita, Masashi; Imanaka, Tsuneo; Wada, Ikuo			Characterization of Russell Bodies Accumulating Mutant Antithrombin Derived from the Endoplasmic Reticulum	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						Russell body; endoplasmic reticulum; mutant antithrombin; subcellular localization; photobleaching; living cell image	INTRACELLULAR ACCUMULATION; MEMBRANE-PROTEINS; HUMAN HRD1; ER; CELLS; MUTATION; NETWORK; TUBULES; IMMUNOGLOBULIN; DEGRADATION	The endoplasmic reticulum (ER) adjusts its size and architecture to adapt to change in the surrounding environment. Russell bodies (RBs) were originally described as dilated structures of the ER cisternae containing large amounts of mutant immunoglobulin. Similar structures are observed in a wide variety of mutant proteins accumulated in the ER. We previously prepared Chinese hamster ovary (CHO) cells in which the expression of mutant antithrombin (AT) (C95R) was controlled with a Tet-On system and showed that RBs can be conditionally formed. However the precise architecture and intracellular behavior of RBs have been as yet only poorly characterized. To characterize the properties of RB, we prepared the same system using a green fluorescent protein (GFP)-fused mutant and measured the dynamics and architecture of RBs. We observed the mobile nature of the molecule in the RB lumen and RBs were separated from the rest of the ER network by narrow tubes. Furthermore, we found that the RBs were not simply expanded ER membranes. The RB lumen is filled with misfolded proteins that are surrounded by ER membranes. In addition, RBs mostly maintain their structure during cell division, possess ribosomes on their membranes and synthesize AT(C95R)-GFP. Based on the characterization of the hydrodynamic radius of AT(C95R)-GFP and the effect of Dp1, an ER-shaping protein, we propose that RBs are spontaneously formed as a result of the partitioning of the misfolded AT with the shaping protein.	[Kimura, Koji; Kawaguchi, Kosuke; Ueda, Yumiko; Morita, Masashi; Imanaka, Tsuneo] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Biol Chem, Toyama 9300194, Japan; [Arai, Seisuke; Wada, Ikuo] Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Cell Sci, Fukushima 9601295, Japan	Imanaka, T (reprint author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Biol Chem, 2630 Sugitani, Toyama 9300194, Japan.	imanaka@pha.u-toyama.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [15659017, 20590054, 40182969]	This research was supported in part by the Ministry of Education, Culture, Sports, Science and Technology of Japan (15659017 (TI), 20590054 (TI), and 40182969 (IW). Pacific Edit reviewed the manuscript prior to submission.	ALANEN A, 1987, EUR J IMMUNOL, V17, P1573, DOI 10.1002/eji.1830171108; Puhka M, 2012, MOL BIOL CELL, V23, P2424, DOI 10.1091/mbc.E10-12-0950; Tanaka Y, 2005, J BIOCHEM, V137, P273, DOI 10.1093/jb/mvi/040; Hegde RS, 2010, CURR OPIN CELL BIOL, V22, P437, DOI 10.1016/j.ceb.2010.05.005; Tanaka Y, 2002, J BIOL CHEM, V277, P51058, DOI 10.1074/jbc.M210231200; SOUMPASIS DM, 1983, BIOPHYS J, V41, P95; Nagaya H, 2008, J CELL BIOL, V180, P129, DOI 10.1083/jcb.200704078; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; Shibata Y, 2008, J BIOL CHEM, V283, P18892, DOI 10.1074/jbc.M800986200; Kaneko M, 2002, FEBS LETT, V532, P147, DOI 10.1016/S0014-5793(02)03660-8; Kikkert M, 2004, J BIOL CHEM, V279, P3525, DOI 10.1074/jbc.M307453200; Claessen JHL, 2012, TRENDS CELL BIOL, V22, P22, DOI 10.1016/j.tcb.2011.09.010; Pendin D, 2011, CURR OPIN CELL BIOL, V23, P435, DOI 10.1016/j.ceb.2011.04.007; Shibata Y, 2006, CELL, V126, P435, DOI 10.1016/j.cell.2006.07.019; Friedman JR, 2011, TRENDS CELL BIOL, V21, P709, DOI 10.1016/j.tcb.2011.07.004; Gendron PO, 2008, J FLUORESC, V18, P1093, DOI 10.1007/s10895-008-0357-7; Braakman I, 2011, ANNU REV BIOCHEM, V80, P71, DOI 10.1146/annurev-biochem-062209-093836; Sakurai C, 2012, MOL BIOL CELL, V23, P4849, DOI 10.1091/mbc.E12-01-0069; Shibata Y, 2010, CELL, V143, P774, DOI 10.1016/j.cell.2010.11.007; Hu JJ, 2008, SCIENCE, V319, P1247, DOI 10.1126/science.1153634; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Hu JJ, 2011, CELL, V147, P1226, DOI 10.1016/j.cell.2011.11.022; Brandizzi F, 2013, NAT REV MOL CELL BIO, V14, P382, DOI 10.1038/nrm3588; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; Chen SL, 2012, NAT CELL BIOL, V14, P707, DOI 10.1038/ncb2523; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; Kamada A, 2004, J BIOL CHEM, V279, P21533, DOI 10.1074/jbc.M401403200; Kano F, 2005, GENES CELLS, V10, P333, DOI 10.1111/j.1365-2443.2005.00837.x; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; Ozawa T, 1997, THROMB HAEMOSTASIS, V77, P403; Scheper W, 2009, CURR MED CHEM, V16, P615; SCHWEITZER PA, 1991, J CELL BIOL, V114, P35, DOI 10.1083/jcb.114.1.35; Suzuki T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037551; Umebayashi K, 1997, YEAST, V13, P1009	36	1	1	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					852	861				10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900007		
J	Han, RC; Takahashi, H; Nakamura, M; Bunsupa, S; Yoshimoto, N; Yamamoto, H; Suzuki, H; Shibata, D; Yamazaki, M; Saito, K				Han, Rongchun; Takahashi, Hiroki; Nakamura, Michimi; Bunsupa, Somnuk; Yoshimoto, Naoko; Yamamoto, Hirobumi; Suzuki, Hideyuki; Shibata, Daisuke; Yamazaki, Mami; Saito, Kazuki			Transcriptome Analysis of Nine Tissues to Discover Genes Involved in the Biosynthesis of Active Ingredients in Sophora flavescens	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						Sophora flavescens; RNA-Seq analysis; biosynthesis; quinolizidine alkaloid; isoflavonoid	QUINOLIZIDINE ALKALOID BIOSYNTHESIS; SHORT READ ALIGNMENT; RNA-SEQ; PHYTOCHEMICAL GENOMICS; VAR ANGUSTIFOLIA; MATRINE; TOOL; IDENTIFICATION; CHROMATOGRAPHY; ARABIDOPSIS	Sophora flavescens AITON (kurara) has long been used to treat various diseases. Although several research findings revealed the biosynthetic pathways of its characteristic chemical components as represented by matrine, insufficient analysis of transeriptome data hampered in-depth analysis of the underlying putative genes responsible for the biosynthesis of pharmaceutical chemical components. In this study, more than 200 million fastq format reads were generated by Illumina's next-generation sequencing approach using nine types of tissue from S. flavescens, followed by CLC de novo assembly, ultimately yielding 83325 contigs in total. By mapping the reads back to the contigs, reads per kilobase of the transcript per million mapped reads values were calculated to demonstrate gene expression levels, and overrepresented gene ontology terms were evaluated using Fisher's exact test. In search of the putative genes relevant to essential metabolic pathways, all 1350 unique enzyme commission numbers were used to map pathways against the Kyoto Encyclopedia of Genes and Genomes. By analyzing expression patterns, we proposed some candidate genes involved in the biosynthesis of isoflavonoids and quinolizidine alkaloids. Adopting RNA-Seq analysis, we obtained substantially credible contigs for downstream work. The preferential expression of the gene for putative lysine/ornithine decarboxylase committed in the initial step of matrine biosynthesis in leaves and stems was confirmed in semi-quantitative polymerase chain reaction (PCR) analysis. The findings in this report may serve as a stepping-stone for further research into this promising medicinal plant.	[Han, Rongchun; Nakamura, Michimi; Bunsupa, Somnuk; Yoshimoto, Naoko; Yamazaki, Mami; Saito, Kazuki] Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan; [Han, Rongchun] Liaoning Univ Tradit Chinese Med, Coll Pharm, Dalian 116600, Peoples R China; [Takahashi, Hiroki] Chiba Univ, Med Mycol Res Ctr, Chuo Ku, Chiba 2608673, Japan; [Yamamoto, Hirobumi] Toyo Univ, Fac Life Sci, Itakura 3740193, Gunma, Japan; [Suzuki, Hideyuki; Shibata, Daisuke] Kazusa DNA Res Inst, Kisarazu, Chiba 2920818, Japan	Saito, K (reprint author), Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan.	ksaito@faculty.chiba-u.jp	Yoshimoto, Naoko/A-9038-2010; Saito, Kazuki/D-2670-2009; Takahashi, Hiroki/M-9169-2015		Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Health Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare of Japan	This study was supported, in part, by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan and by Health Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare of Japan.	Anders S, 2010, HTSEQ ANAL HIGH THRO; Fu LM, 2012, BIOINFORMATICS, V28, P3150, DOI 10.1093/bioinformatics/bts565; Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883; Tarazona S, 2011, GENOME RES, V21, P2213, DOI 10.1101/gr.124321.111; Kawaguchi R, 2005, NUCLEIC ACIDS RES, V33, P955, DOI 10.1093/nar/gki240; Gao T, 2011, PLANTA MED, V77, P92, DOI 10.1055/s-0030-1250050; Saito K, 2013, CURR OPIN PLANT BIOL, V16, P373, DOI 10.1016/j.pbi.2013.04.001; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Chen X, 2004, J CHROMATOGR B, V812, P149, DOI 10.1016/j.jchromb.2004.08.032; Funaya N, 2012, J CHROMATOGR A, V1248, P18, DOI 10.1016/j.chroma.2012.05.081; Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Ramilowski JA, 2013, PLANT CELL PHYSIOL, V54, P697, DOI 10.1093/pcp/pct057; Ma XQ, 2004, NAT PROD REP, V21, P752, DOI 10.1039/b409720n; Tian AG, 2004, THEOR APPL GENET, V108, P903, DOI 10.1007/s00122-003-1499-2; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Li LQ, 2012, CELL PHYSIOL BIOCHEM, V30, P631, DOI 10.1159/000341444; Ashburner M, 2000, NAT GENET, V25, P25; Simpson JT, 2009, GENOME RES, V19, P1117, DOI 10.1101/gr.089532.108; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289; Hong SM, 2010, PLANT CELL PHYSIOL, V51, P1694, DOI 10.1093/pcp/pcq128; Sasaki K, 2011, J BIOL CHEM, V286, P24125, DOI 10.1074/jbc.M111.244426; Fullwood MJ, 2009, GENOME RES, V19, P521, DOI 10.1101/gr.074906.107; Serres-Giardi L, 2012, PLANT CELL, V24, P1379, DOI 10.1105/tpc.111.093674; Boiteau L, 1998, ANGEW CHEM INT EDIT, V37, P1128, DOI 10.1002/(SICI)1521-3773(19980504)37:8<1128::AID-ANIE1128>3.0.CO;2-P; Bunsupa S, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00239; Bunsupa S, 2012, PLANT CELL, V24, P1202, DOI 10.1105/tpc.112.095885; Chen G, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-590; Ferreyra MLF, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00222; Hong MH, 2009, TOXICOL IN VITRO, V23, P251, DOI 10.1016/j.tiv.2008.12.002; Ling JY, 2007, J CHROMATOGR A, V1145, P123, DOI 10.1016/j.chroma.2007.01.080; Magrane M, 2011, DATABASE-OXFORD, V2011, DOI [DOI 10.1093/DATABASE/BAR009, 10.1093/database/bar009]; Meyer LR, 2013, NUCLEIC ACIDS RES, V41, pD64, DOI 10.1093/nar/gks1048; Miadoková Eva, 2009, Interdiscip Toxicol, V2, P211, DOI 10.2478/v10102-009-0021-3; Michael TP, 2013, PLANT GENOME, V6, P1; Muranaka T, 2013, PLANT CELL PHYSIOL, V54, P645, DOI 10.1093/pcp/pct058; Nagai N, 1889, YAKUGAKU ZASSHI, V84, P54; OKUDA S, 1966, CHEM PHARM BULL, V14, P314; SAITO K, 1995, STUD NAT PROD CHEM, V15, P519, DOI 10.1016/S1572-5995(06)80142-0; SAITO K, 1989, CHEM PHARM BULL, V37, P3001; Shen Y, 2013, J NAT PROD, V76, P2337, DOI 10.1021/np400784v; Shibata S, 1963, CHEM IND, P1161; Sun MY, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/373219; Takahashi H, 2011, OMICS, V15, P15, DOI 10.1089/omi.2010.0074; [王玲丽 Wang Lingli], 2008, [安徽农业科学, Journal of Anhui Agricultural Sciences], V36, P5691; YAMAMOTO H, 1991, Z NATURFORSCH C, V46, P172; Ye J, 2006, NUCLEIC ACIDS RES, V34, pW293, DOI 10.1093/nar/gkl1031; [张守润 ZHANG Shourun], 2008, [草业科学, Pratacultural Science], V25, P41	50	2	2	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					876	883				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900010		
J	Tsutsui, R; Shinomiya, K; Sendo, T; Kitamura, Y; Kamei, C				Tsutsui, Ryuki; Shinomiya, Kazuaki; Sendo, Toshiaki; Kitamura, Yoshihisa; Kamei, Chiaki			Effects of the 5-HT1A Receptor Agonist Tandospirone on ACTH-Induced Sleep Disturbance in Rats	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						sleep disturbance; adrenocorticotropic hormone; serotonin (5-HT)(1A) receptor; gamma-aminobutyric acid	FORCED SWIM TEST; MAJOR DEPRESSIVE DISORDER; WET-DOG SHAKES; TREATED RATS; CHRONIC INSOMNIA; FULL AGONIST; WATER; IMIPRAMINE; INVOLVEMENT; ANTAGONISTS	The aim of this study was to compare the effect of the serotonin (5-HT)(1A) receptor agonist tandospirone versus that of the benzodiazepine hypnotic flunitrazepam in a rat model of long-term adrenocorticotropic hormone (ACTH)-induced sleep disturbance. Rats implanted with electrodes for recording electroencephalogram and electromyogram were injected with ACTH once daily at a dose of 100 mu g/rat. Administration of ACTH for 10d caused a significant increase in sleep latency, decrease in non-rapid eye movement (non-REM) sleep time, and increase in wake time. Tandospirone caused a significant decrease in sleep latency and increase in non-REM sleep time in rats treated with ACTH. The effect of tandospirone on sleep patterns was antagonized by the 5-HT1A receptor antagonist WAY-100635. In contrast, flunitrazepam had no significant effect on sleep parameters in ACTH-treated rats. These results clearly indicate that long-term administration of ACTH causes sleep disturbance, and stimulating the 5-HT1A receptor by tandospirone may be efficacious for improving sleep in cases in which benzodiazepine hypnotics are ineffective.	[Tsutsui, Ryuki; Sendo, Toshiaki; Kitamura, Yoshihisa] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Pharm, Kita Ku, Okayama 7008558, Japan; [Shinomiya, Kazuaki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Psychopharmaceut Sci, Kita Ku, Okayama 7008530, Japan; [Kamei, Chiaki] Yasuda Womens Univ, Fac Pharmaceut Sci, Dept Pharmacol, Asaminami Ku, Hiroshima 7310513, Japan	Kitamura, Y (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Pharm, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	kitamu-y@cc.okayama-u.ac.jp					Kaneita Y, 2006, J CLIN PSYCHIAT, V67, P196; Monti JM, 2011, SLEEP MED REV, V15, P269, DOI 10.1016/j.smrv.2010.11.003; Fava M, 2003, J CLIN PSYCHIAT, V64, P26; Simon GE, 2006, GEN HOSP PSYCHIAT, V28, P374, DOI 10.1016/j.genhosppsych.2006.05.008; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; van Rijnsoever C, 2004, J NEUROSCI, V24, P6785, DOI 10.1523/JNEUROSCI.1067-04.2004; Kitamura Y, 2002, PHARMACOL BIOCHEM BE, V71, P63, DOI 10.1016/S0091-3057(01)00625-6; Lopes MC, 2007, SLEEP MED, V9, P33, DOI 10.1016/j.sleep.2007.01.011; Shinomiya K, 2005, PSYCHOPHARMACOLOGY, V180, P564, DOI 10.1007/s00213-005-2196-4; Ohayon MM, 2003, J PSYCHIAT RES, V37, P9, DOI 10.1016/S0022-3956(02)00052-3; GODBOUT R, 1991, NEUROPHARMACOLOGY, V30, P679, DOI 10.1016/0028-3908(91)90175-B; Landolt HP, 2009, EUR J NEUROSCI, V29, P1795, DOI 10.1111/j.1460-9568.2009.06718.x; Morairty SR, 2008, SLEEP, V31, P34; Holshoe JM, 2009, PERSPECT PSYCHIATR C, V45, P191, DOI 10.1111/j.1744-6163.2009.00221.x; Savic MM, 2009, INT J NEUROPSYCHOPH, V12, P1179, DOI 10.1017/S1461145709000108; Savic MM, 2008, NEUROPSYCHOPHARMACOL, V33, P332, DOI 10.1038/sj.npp.1301403; Buysse DJ, 2008, AM J PSYCHIAT, V165, P678, DOI 10.1176/appi.ajp.2008.08010129; Chen CY, 2009, PSYCHIAT CLIN NEUROS, V63, P427, DOI 10.1111/j.1440-1819.2009.01953.x; Colenda CC, 2003, AM J GERIAT PSYCHIAT, V11, P448, DOI 10.1176/appi.ajgp.11.4.448; Hirase M, 2008, EUR J PHARMACOL, V597, P46, DOI 10.1016/j.ejphar.2008.08.024; Kitamura Y, 2008, BIOL PHARM BULL, V31, P246, DOI 10.1248/bpb.31.246; Kitamura Y, 2002, PHARMACOL BIOCHEM BE, V72, P397, DOI 10.1016/S0091-3057(01)00769-9; Kitamura Y, 2007, BIOL PHARM BULL, V30, P117, DOI 10.1248/bpb.30.117; Kitamura Y, 2003, EUR J PHARMACOL, V481, P75, DOI 10.1016/j.ejphar.2003.09.008; Marek GJ, 2003, NEUROPSYCHOPHARMACOL, V28, P402, DOI 10.1038/sj.npp.1300057; Rosenberg R, 2008, SLEEP, V31, P1663; Shinomiya K, 2005, BIOL PHARM BULL, V28, P808, DOI 10.1248/bpb.28.808; Shinomiya K, 2003, EUR J PHARMACOL, V460, P139, DOI 10.1016/S0014-2999(02)02915-1; Takeda Y, 2008, J PHARMACOL SCI, V107, P246, DOI 10.1254/jphs.08059FP; Tokunaga S, 2009, BIOL PHARM BULL, V32, P51; Utsu Y, 2007, J PHARMACOL SCI, V105, P112, DOI 10.1254/jphs.FP0070981; Verkuyl JM, 2004, EUR J NEUROSCI, V20, P1665, DOI 10.1111/j.1460-9568.2004.03568.x; Watson C, 2007, RAT BRAIN STEREOTAXI; Yamada K, 2003, PSYCHIAT CLIN NEUROS, V57, P183, DOI 10.1046/j.1440-1819.2003.01099.x	34	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					884	888				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900011		
J	Suzuki, N; Ohtaguro, N; Yoshida, Y; Hirai, M; Matsuo, H; Yamada, Y; Imamura, N; Tsuchiya, T				Suzuki, Naomoto; Ohtaguro, Norihiro; Yoshida, Yasuaki; Hirai, Motoshi; Matsuo, Hirotaka; Yamada, Yoichi; Imamura, Nobutaka; Tsuchiya, Tomofusa			A Compound Inhibits Biofilm Formation of Staphylococcus aureus from Streptomyces	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						biofilm; inhibitor; Staphylococcus aureus; Streptomyces; prodigiosin	BACTERIAL PRODIGININES; PRODIGIOSIN; ANTICANCER; MECHANISMS; RESISTANT	Biofilm is one virulence factor of bacteria. It contributes not only to bacterial adherence to many kinds of infection-establishing surfaces, but also to bacterial resistance against antimicrobial agents and antiseptic agents. Thus, inhibitors of bacterial biofilm formation should be useful in the prevention of infections. We found that a culture of Streptontyces sp. strain MC11024 showed inhibitory activity on biofilm formation by Staphylococcus aureus and isolated streptorubin B as an inhibitor of this formation in S. aureus. The biofilm formation of methicillin resistant S. aureus (MRSA) N315 was reduced to less than 30% at 1 mu g/mL of streptorubin B, and at this concentration cell growth was not affected. Our study suggests that streptorubin B has the potential to be a leading compound of anti-infectious agents of S. aureus.	[Suzuki, Naomoto; Ohtaguro, Norihiro; Yoshida, Yasuaki; Hirai, Motoshi; Matsuo, Hirotaka; Yamada, Yoichi; Imamura, Nobutaka; Tsuchiya, Tomofusa] Ritsumeikan Univ, Coll Pharmaceut Sci, Kusatsu, Shiga 5258577, Japan	Yamada, Y (reprint author), Ritsumeikan Univ, Coll Pharmaceut Sci, 1-1-1 Nojihigashi, Kusatsu, Shiga 5258577, Japan.	y-yamada@fc.ritsumei.ac.jp					Alihosseini F, 2008, BIOTECHNOL PROGR, V24, P742, DOI 10.1021/bp070481r; Otto M, 2008, CURR TOP MICROBIOL, V322, P207; Bjarnsholt T, 2013, APMIS, V121, P1, DOI 10.1111/apm.12099; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; Williamson NR, 2007, FUTURE MICROBIOL, V2, P605, DOI 10.2217/17460913.2.6.605; LAATSCH H, 1991, J ANTIBIOT, V44, P187; O'Neill E, 2008, J BACTERIOL, V190, P3835, DOI 10.1128/JB.00167-08; Periasamy S, 2012, P NATL ACAD SCI USA, V109, P1281, DOI 10.1073/pnas.1115006109; Williamson NR, 2006, NAT REV MICROBIOL, V4, P887, DOI 10.1038/nrmicro1531; Furlani RE, 2013, EUR J MED CHEM, V62, P59, DOI 10.1016/j.ejmech.2012.12.005; Han SB, 1998, INT J IMMUNOPHARMACO, V20, P1, DOI 10.1016/S0192-0561(97)00062-3; Schlievert PM, 2010, J ALLERGY CLIN IMMUN, V125, P39, DOI 10.1016/j.jaci.2009.10.039; Melvin MS, 2000, J AM CHEM SOC, V122, P6333, DOI 10.1021/ja0000798; O'Gara JP, 2007, FEMS MICROBIOL LETT, V270, P179, DOI 10.1111/j.1574-6968.2007.00688.x; Procopio RED, 2012, BRAZ J INFECT DIS, V16, P466, DOI 10.1016/j.bjid.2012.08.014; Croes S, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-229; Fiirstner A, 2005, ANGEW CHEM INT EDIT, V44, P2777; Hanke ML, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00062; Montaner B, 2003, CURR CANCER DRUG TAR, V3, P57, DOI 10.2174/1568009033333772; Rogers SA, 2010, ORG BIOMOL CHEM, V8, P3857, DOI 10.1039/c0ob00063a	20	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					889	892				4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900012		
J	Akanuma, S; Zakoji, N; Kubo, Y; Hosoya, K				Akanuma, Shin-ichi; Zakoji, Nobuyuki; Kubo, Yoshiyuki; Hosoya, Ken-ichi			In Vitro Study of L-Glutamate and L-Glutamine Transport in Retinal Pericytes: Involvement of Excitatory Amino Acid Transporter 1 and Alanine-Serine-Cysteine Transporter 2	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						excitatory amino acid transporter; L-glutamate; retinal pericyte; alanine-serine-cysteine transporter; L-glutamine	HIGH-AFFINITY GLUTAMATE; ENDOTHELIAL-CELL LINE; FUNCTIONAL-CHARACTERIZATION; MEMBRANE-VESICLES; SKELETAL-MUSCLE; SYSTEM X(C)(-); EXPRESSION; SUBSTRATE; CLONING; NA+	L-Glutamate (L-Glu) is known to be a relaxant of pericytes and to induce changes in microcirculatory hemodynamics. Since the concentration of L-Glu which induces the dilation of retinal capillaries is reported to be high compared with the estimated concentration in the retinal interstitial fluid, it is hypothesized that some systems involving concentrative L-Glu release are present in retinal pericytes. The purpose of this study was to investigate the existence of L-Glu-storing systems, which contribute to autocrine L-Glu release, in retinal pericytes using conditionally immortalized rat retinal pericytes (TR-rPCT1 cells), which express mRNAs of L-Glu-synthesizing enzymes from L-glutamine TR-rPCT1 cells express the mRNAs of vesicular L-Glu transporter 1 (VGLUT1), indicating that L-Glu in the cytoplasm is taken up into VGLUT1-expressing vesicles of retinal pericytes. L-Glu and L-Gln are taken up into TR-rPCT1 cells via Na+-dependent saturable process(es) with a K-m value of 22.4 mu m and 163 mu m, respectively. The [H-3]L-Glu uptake was inhibited by ca. 50% in the presence of n-aspartate, a substrate of excitatory amino acid transporter (EAAT) subtypes, whereas substrates of alanine serine cysteine transporter (ASCT) subtypes exhibited only a weak inhibitory effect on [H-3]-Glu uptake compared with n-aspartate. Regarding the L-Gln uptake by TR-rPCT1 cells, the inhibitory effect of ASCT substrates on the [H-3]L-Gln uptake was stronger than that of substrates of other neutral amino acid transport systems. Consequently, it was determined that EAAT1 and ASCT2 play a role in the transport of L-Glu and L-Gln, respectively, from retinal interstitial fluid to the cytoplasm of retinal pericytes.	[Akanuma, Shin-ichi; Zakoji, Nobuyuki; Kubo, Yoshiyuki; Hosoya, Ken-ichi] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Pharmaceut, Toyama 9300194, Japan	Hosoya, K (reprint author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Pharmaceut, 2630 Sugitani, Toyama 9300194, Japan.	hosoyak@pha.u-toyama.ac.jp			Japan Society for the Promotion of Science	This study was supported, in part, by the Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science.	Adachi T, 2010, REDOX REP, V15, P250, DOI 10.1179/135100010X12826446921662; Bringmann A, 2009, NEUROCHEM INT, V54, P143, DOI 10.1016/j.neuint.2008.10.014; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Patel SA, 2004, NEUROPHARMACOLOGY, V46, P273, DOI 10.1016/j.neuropharm.2003.08.006; Bridges R, 2012, PHARMACOL REV, V64, P780, DOI 10.1124/pr.110.003889; Dzubay JA, 1999, J NEUROSCI, V19, P5265; Matsugi T, 1997, INVEST OPHTH VIS SCI, V38, P652; Kanai Y, 2013, MOL ASPECTS MED, V34, P108, DOI 10.1016/j.mam.2013.01.001; Levy LM, 1998, J NEUROSCI, V18, P9620; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; [Anonymous], 2000, ADV IND CON, DOI 10.1046/j.1365-313x.2000.00899.x; Sloan JL, 1999, J BIOL CHEM, V274, P23740, DOI 10.1074/jbc.274.34.23740; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Yamamoto T, 2004, NEUROSCI RES, V49, P101, DOI 10.1016/j.neures.2004.02.004; LOW SY, 1991, BIOCHEM J, V278, P105; Mastroberardino L, 1998, NATURE, V395, P288; Scott GS, 2007, BIOCHEM PHARMACOL, V73, P228, DOI 10.1016/j.bcp.2006.09.021; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; Sarthy VP, 2004, NEUROREPORT, V15, P1895, DOI 10.1097/00001756-200408260-00012; Broer A, 2000, BIOCHEM J, V349, P787; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Hosoya K, 2005, BIOL PHARM BULL, V28, P1, DOI 10.1248/bpb.28.1; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193; Biter A, 1999, J NEUROCHEM, V73, P2184; Bode BP, 2001, J NUTR, V131, p2486S; Bode BP, 2001, J NUTR, V131, p2475S; Bonvento G, 2002, TRENDS NEUROSCI, V25, P359, DOI 10.1016/S0166-2236(02)02168-9; Bridges CC, 2001, INVEST OPHTH VIS SCI, V42, P47; CHAKRAVARTHY U, 1992, MICROVASC RES, V43, P241, DOI 10.1016/0026-2862(92)90022-H; Gameiro A, 2011, BIOPHYS J, V100, P2623, DOI 10.1016/j.bpj.2011.04.034; Hatanaka T, 2000, BBA-BIOMEMBRANES, V1467, P1, DOI 10.1016/S0005-2736(00)00252-2; HEINAMAKI AA, 1986, NEUROCHEM RES, V11, P535, DOI 10.1007/BF00965323; Hosoya Ken-ichi, 2012, Adv Exp Med Biol, V763, P85; HUNDAL HS, 1987, J PHYSIOL-LONDON, V393, P283; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; Kondo T, 2003, CELL STRUCT FUNCT, V28, P145; Laming PR, 2000, NEUROSCI BIOBEHAV R, V24, P295, DOI 10.1016/S0149-7634(99)00080-9; Lin CLG, 1998, MOL BRAIN RES, V63, P174, DOI 10.1016/S0169-328X(98)00256-3; Martin AR, 2000, MICROVASC RES, V59, P131, DOI 10.1006/mvre.1999.2208; Mathur BN, 2008, NEUROSCI LETT, V435, P90, DOI 10.1016/j.neulet.2008.01.082; Matsugi T, 1997, INVEST OPHTH VIS SCI, V38, P2695; Moriyama Y, 2008, BIOL PHARM BULL, V31, P1844, DOI 10.1248/bpb.31.1844; Nakagawa Takayuki, 2013, Curr Mol Pharmacol, V6, P66; Ni YC, 2007, J NEUROCHEM, V103, P1273, DOI 10.1111/j.1471-4159.2007.04864.x; Rajan DP, 2000, J BIOL CHEM, V275, P14331, DOI 10.1074/jbc.275.19.14331; Szeliga M, 2009, NEUROCHEM INT, V55, P71, DOI 10.1016/j.neuint.2009.01.008; Tetsuka K, 2003, J NEUROCHEM, V87, P891, DOI 10.1046/j.1471-4159.2003.02063.x; Umapathy NS, 2008, INVEST OPHTH VIS SCI, V49, P5151, DOI 10.1167/iovs.08-2245; WILDE SW, 1991, BIOCHEM J, V277, P687; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200; Zakoji N, 2015, BIOL PHARM BULL, V38, P257, DOI 10.1248/bpb.b14-00637	55	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					901	908				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900014		
J	Onishi, H; Sakata, O; Yumoto, K				Onishi, Hiraku; Sakata, Osamu; Yumoto, Kei			In Vitro and in Vivo Evaluations of Buccal Tablet Formulations of Ritodrine Hydrochloride	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						ritodrine; buccal tablet formulation; hardness; in vitro dissolution: in vivo absorption	PERFORMANCE LIQUID-CHROMATOGRAPHY; PREGNANT-WOMEN; PHARMACODYNAMICS; PLASMA; PHARMACOKINETICS; ABSORPTION; CLONAZEPAM	Buccal tablets of ritodrine (RD) hydrochloride (HCI), called RD-HCI, were prepared using the direct compression method with alginate (AL), lactose (LC), magnesium stearate (ST), and microcrystalline cellulose (MC) as excipients. The tablets were evaluated based on hardness, and tablets weighing 80mg and with hardness of greater than 30N were chosen as appropriate ones. As a result, tablets composed of RD-HCl (4 mg)/LC (38.5mg)/ST (0.5 mg)/MC (37 mg) and RD-HC1 (4 mg)/AL(7 mg)/LC (28.5mg)/ST (0.5 mg)/MC (37 mg), called D9 and D10, respectively, were selected. These tablets were further evaluated based on in vitro dissolution and in vivo absorption studies in rats. D9 rapidly released RD, achieved an effective plasma concentration from 15 mm to 7h after its buccal administration, and did not exceed the toxic plasma level of 80 ng/mL. D10 gradually released RD, and maintained an effective concentration from 1 h to 7h after its buccal administration, without exceeding the toxic plasma level. The absorption was more prolonged in D10 than D9. Their in vivo release was considered to be caused gradually from the amount of RD remaining in the oral cavity at 7h, in particular D10. The superior retention of D10 in plasma and oral cavity appeared to be related to its higher mucoadhesive properties. Although these results were obtained using rats, they suggest that the chosen tablets should have adequate characteristics from the viewpoints of plasma levels.	[Onishi, Hiraku; Sakata, Osamu; Yumoto, Kei] Hoshi Univ, Dept Drug Delivery Res, Shinagawa Ku, Tokyo 1428501, Japan	Onishi, H (reprint author), Hoshi Univ, Dept Drug Delivery Res, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	onishi@hoshi.ac.jp					Agarwal V, 1999, DRUG DEV IND PHARM, V25, P701, DOI 10.1081/DDC-100102229; Semalty A, 2010, INDIAN J PHARM SCI, V72, P571, DOI 10.4103/0250-474X.78522; BRAY CL, 1991, EUR HEART J, V12, P16; CARITIS SN, 1985, AM J OBSTET GYNECOL, V152, P1026; CARITIS SN, 1988, AM J OBSTET GYNECOL, V158, P380; CARITIS SN, 1983, AM J OBSTET GYNECOL, V147, P752; Chye J.K., 1999, Annals Academy of Medicine Singapore, V28, P193; Dhiman MK, 2008, DRUG DEV IND PHARM, V34, P761, DOI 10.1080/03639040801926337 ; ESSED GGM, 1988, ARCH INT PHARMACOD T, V293, P295; Fujimoto S, 1989, Nihon Sanka Fujinka Gakkai Zasshi, V41, P321; GANDAR R, 1980, EUR J CLIN PHARMACOL, V17, P117, DOI 10.1007/BF00562619; GROSS AS, 1987, J CHROMATOGR-BIOMED, V416, P400, DOI 10.1016/0378-4347(87)80527-3; Konda A, 2009, EUR J CLIN PHARMACOL, V65, P913, DOI 10.1007/s00228-009-0665-0; Kwinta Przemko, 2010, Expert Rev Respir Med, V4, P593, DOI 10.1586/ers.10.59; Liu AX, 2008, J CHROMATOGR B, V867, P144, DOI 10.1016/j.jchromb.2008.03.007; Marzo A, 2010, ARZNEIMITTEL-FORSCH, V60, P510, DOI 10.1055/s-0031-1296320; Mohamed Saifulla P., 2011, Yaoxue Xuebao, V46, P460; Onishi H, 2014, INT J PHARMACEUT, V468, P207, DOI 10.1016/j.ijpharm.2014.04.009; Sakata O, 2013, DRUG DEV IND PHARM, V39, P1414, DOI 10.3109/03639045.2012.704044; Sakata O, 2008, DRUG DEV IND PHARM, V34, P1376, DOI 10.1080/03639040802122977 ; SCHIFF E, 1993, AM J OBSTET GYNECOL, V169, P1059; SCHOLSHENDRIKS MWG, 1995, BRIT J CLIN PHARMACO, V39, P449; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879	23	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					919	925				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900017		
J	Uchino, Y; Matsumoto, J; Watanabe, T; Hamabashiri, M; Tsuchiya, T; Kimura, I; Yamauchi, A; Kataoka, Y				Uchino, Yoshihiro; Matsumoto, Junichi; Watanabe, Takuya; Hamabashiri, Masato; Tsuchiya, Takashi; Kimura, Ikuya; Yamauchi, Atsushi; Kataoka, Yasufumi			Nifedipine Prevents Sodium Caprate-Induced Barrier Dysfunction in Human Epidermal Keratinocyte Cultures	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						epidermal barrier function; nifedipine; sodium caprate; transepithelial electrical resistance; normal human epidermal keratinocyte	TOPICAL NIFEDIPINE; WRINKLES; SKIN	Tight junctions (TJs) of the epidermis play an important role in maintaining the epidermal barrier. TJ breakdown is associated with skin problems, such as wrinkles and transepidermal water loss (TEWL). Clinical studies have reported that topical nifedipine is effective in reducing the depth of wrinkles and improving TEWL. However, it remains unknown whether nifedipine influences the TJ function in the epidermis. In the present study, we investigated the effect of nifedipine on epidermal barrier dysfunction in normal human epidermal keratinocytes (NHEKs) treated with sodium caprate (C10), a TJ inhibitor. Nifedipine reversed the C10-decreased transepithelial electrical resistance values as a measure of disruption of the epidermal barrier. Immunocytochemical observations revealed that nifedipine improved the C10-induced irregular arrangement of claudin-1, a key protein in TJs. Taken together, these findings suggest that nifedipine prevents epidermal barrier dysfunction, at least in part, by reconstituting the irregular claudin-1 localization at TJs in C10-treated NHEKs.	[Uchino, Yoshihiro; Matsumoto, Junichi; Watanabe, Takuya; Hamabashiri, Masato; Tsuchiya, Takashi; Kimura, Ikuya; Yamauchi, Atsushi; Kataoka, Yasufumi] Fukuoka Univ, Dept Pharmaceut Care & Hlth Sci, Fac Pharmaceut Sci, Jonan Ku, Fukuoka 8140180, Japan	Kataoka, Y (reprint author), Fukuoka Univ, Dept Pharmaceut Care & Hlth Sci, Fac Pharmaceut Sci, Jonan Ku, 8-19-1 Nanakuma, Fukuoka 8140180, Japan.	ykataoka@fukuoka-u.ac.jp					Madison KC, 2003, J INVEST DERMATOL, V121, P231, DOI 10.1046/j.1523-1747.2003.12359.x; Suzuki T, 2006, LIFE SCI, V79, P401, DOI 10.1016/j.lfs.2006.01.044; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Segre JA, 2006, J CLIN INVEST, V116, P1150, DOI 10.1172/JCI28521; Calabro G, 2014, J DERMATOL TREAT, V25, P319, DOI 10.3109/09546634.2013.802759; Eberting CL, 2014, J ALLERGY THER, V5, P187; Innocenti M, 2010, J DERMATOL TREAT, V21, P282, DOI 10.3109/09546630903341952; Kurasawa M, 2009, BIOCHEM BIOPH RES CO, V381, P171, DOI 10.1016/j.bbrc.2009.02.005; Kuroda S, 2010, J DERMATOL SCI, V59, P107, DOI 10.1016/j.jdermsci.2010.06.001; LEE SH, 1992, J CLIN INVEST, V89, P530, DOI 10.1172/JCI115617; Sugibayashi K, 2009, EUR J PHARM SCI, V36, P246, DOI 10.1016/j.ejps.2008.09.011	11	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					926	929				4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900018		
J	Takaku, T; Nagahori, H; Sogame, Y; Takagi, T				Takaku, Tomoyuki; Nagahori, Hirohisa; Sogame, Yoshihisa; Takagi, Tatsuya			Quantitative Structure-Activity Relationship Model for the Fetal-Maternal Blood Concentration Ratio of Chemicals in Humans	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						placental transfer; human; quantitative structure-activity relationship; fetal-maternal blood concentration ratio	PLACENTAL-TRANSFER; CORD BLOOD; PREGNANCY; PREDICTION; DESCRIPTORS; NELFINAVIR; TRANSPORT; EXPOSURE; NEWBORNS; DELIVERY	A quantitative structure-activity relationship (QSAR) model of the fetal-maternal blood concentration ratio (F/M ratio) of chemicals was developed to predict the placental transfer in humans. Data on F/M ratio of 55 compounds found in the literature were separated into training (75%, 41 compounds) and testing sets (25%, 14 compounds). The training sets were then subjected to multiple linear regression analysis using the descriptors of molecular weight (MW), topological polar surface area (TopoPSA), and maximum E-state of hydrogen atom (Hmax). Multiple linear regression analysis and a cross-validation showed a relatively high adjusted coefficient of determination (R-a(2)) (0.73) and cross-validated coefficient of determination (Q(2)) (0.71), after removing three outliers. In the external validation, R-2 for external validation (R-pred(2)) was calculated to be 0.51. These results suggested that the QSAR model developed in this study can be considered reliable in terms of its robustness and predictive performance. Since it is difficult to examine the F/M ratio in humans experimentally, this QSAR model for prediction of the placental transfer of chemicals in humans could be useful in risk assessment of chemicals in humans.	[Takaku, Tomoyuki; Nagahori, Hirohisa; Sogame, Yoshihisa] Sumitomo Chem Co Ltd, Environm Hlth Sci Lab, Konohana Ku, Osaka 5548558, Japan; [Takagi, Tatsuya] Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan; [Takagi, Tatsuya] Osaka Univ, Inst Microbial Dis, Suita, Osaka 5650871, Japan	Takaku, T (reprint author), Sumitomo Chem Co Ltd, Environm Hlth Sci Lab, Konohana Ku, 3-1-98 Kasugade Naka, Osaka 5548558, Japan.	takakut@sc.sumitomo-chem.co.jp					Andrews CW, 2000, PHARM RES-DORDR, V17, P639, DOI 10.1023/A:1007556711109; Whyatt RM, 2003, ENVIRON HEALTH PERSP, V111, P749, DOI 10.1289/ehp.5768; Votano JR, 2004, MUTAGENESIS, V19, P365, DOI 10.1093/mutage/geh043; GALVEZ J, 1994, J CHEM INF COMP SCI, V34, P520, DOI 10.1021/ci00019a008; Giaginis C, 2009, J APPL TOXICOL, V29, P724, DOI 10.1002/jat.1466; Boyce PM, 2011, ARCH WOMEN MENT HLTH, V14, P169, DOI 10.1007/s00737-011-0215-5; Yap CW, 2011, J COMPUT CHEM, V32, P1466, DOI 10.1002/jcc.21707; Smith PA, 2003, J MED CHEM, V46, P1617, DOI 10.1021/jm020397c; Platts JA, 1999, J CHEM INF COMP SCI, V39, P835, DOI 10.1021/ci980339t; Vahakangas K, 2006, MUTAT RES-GEN TOX EN, V608, P129, DOI 10.1016/j.mrgentox.2006.02.014; Fukata H, 2005, ENVIRON HEALTH PERSP, V113, P297, DOI 10.1289/ehp.7330; MOREAU G, 1980, NOUV J CHIM, V4, P359; Myren M, 2007, TOXICOL IN VITRO, V21, P1332, DOI 10.1016/j.tiv.2007.05.011; Hewitt M, 2007, SAR QSAR ENVIRON RES, V18, P57, DOI 10.1080/10629360601053893; Gordon AL, 2010, BRIT J CLIN PHARMACO, V70, P895, DOI 10.1111/j.1365-2125.2010.03759.x; Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e; Briggs GG, 2001, DRUGS PREGNACY LACTA, V6th; Caritis SN, 2012, AM J OBSTET GYNECOL, V207; Chappuy H, 2004, ANTIMICROB AGENTS CH, V48, P4332, DOI 10.1128/AAC.48.11.4332-4336.2004; Grafmuller S, 2013, JOVE-J VIS EXP, V76; Gupta RC, 2009, GEN APPL SYSTEMS TOX; Hirt D, 2007, BRIT J CLIN PHARMACO, V64, P634, DOI 10.1111/j.1365-2125.2007.02885.x; Hughes AW, 2003, J STAT PLAN INFER, V115, P397, DOI 10.1016/S0378-3758(02)00159-3; Hutson Janine R, 2011, J Popul Ther Clin Pharmacol, V18, pe533; Kee WDN, 2006, ANESTHESIOLOGY, V104, P14, DOI 10.1097/00000542-200601000-00004; KIER LB, 1990, PHARMACEUT RES, V7, P801, DOI 10.1023/A:1015952613760; Mishra NK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100278; MORGAN DJ, 1977, EUR J CLIN PHARMACOL, V12, P359, DOI 10.1007/BF00562452; Peticca P, 2013, ISRN ENDOCRINOL, V2013; Pratim RP, 2009, MOLECULES, V14, P1660; Ripamonti D, 2007, AIDS, V21, P2409; Rubinchik-Stern M, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00126; Silberschmidt AL, 2008, BJOG-INT J OBSTET GY, V115, P480, DOI 10.1111/j.1471-0528.2007.01630.x; SIOUFI A, 1984, BRIT J CLIN PHARMACO, V18, P453; Utoguchi N, 2000, INT J PHARM, V195, P115, DOI 10.1016/S0378-5173(99)00398-1; van Hoog S, 2012, NETH J MED, V70, P102; Winter SC, 1995, CLIN CHIM ACTA, V243, P87, DOI 10.1016/0009-8981(95)06148-7; Yamashita F, 2002, J PHARM SCI, V91, P2230, DOI 10.1002/jps.10214	38	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					930	934				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900019		
J	Nakamura, K; Yang, JH; Sato, E; Miura, N; Wu, YX				Nakamura, Kasumi; Yang, Jia-Hua; Sato, Eiji; Miura, Naoyuki; Wu, Yi-Xin			Effects of Hydroxy Groups in the A-Ring on the Anti-proteasome Activity of Flavone	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						ubiquitin; flavonoid; proteasome; inhibitor	ANTIINFLAMMATORY ACTIVITY; DIETARY FLAVONOIDS; CANCER-CELLS; PATHWAY; APOPTOSIS; BAICALEIN; INHIBITORS; MITOCHONDRIA; THERAPY; EXTRACT	The ubiquitin-proteasome pathway plays an important role in regulating apoptosis and the cell cycle. Recently, proteasome inhibitors have been shown to have antitumor effects and have been used in anticancer therapy for several cancers such as multiple myeloma. Although some flavones, such as apigenin, chrysin and luteolin, have a specific role in the inhibition of proteasome activity and induced apoptosis in some reports, these findings did not address all flavone types. To further investigate the proteasome-inhibitory mechanism of flavonoids, we examined the inhibitory activity of 5,6,7-trihydroxyflavone, baicalein and 5,6,7,4'-tetrahydroxyflavone, scutellarein on extracted proteasomes from mice and cancer cells. Unlike the other flavones, baicalein and scutellarein did not inhibit proteasome activity or accumulate levels of ubiquitinated proteins. These results indicate that flavones with hydroxy groups at positions 5, 6 and 7 of the A-ring lack the anti-proteasome function.	[Nakamura, Kasumi; Sato, Eiji; Miura, Naoyuki; Wu, Yi-Xin] Hamamatsu Univ Sch Med, Dept Biochem, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Yang, Jia-Hua] Shanghai Univ Tradit Chinese Med, Putuo Hosp, Dept Gen Surg, Shanghai 200062, Peoples R China	Wu, YX (reprint author), Hamamatsu Univ Sch Med, Dept Biochem, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	yixinwu@hama-med.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [23659645]	This work was supported by KAKENHI (23659645) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Morrissey C, 2005, PROSTATE, V63, P131, DOI 10.1002/pros.20167; Pandith H, 2013, J ETHNOPHARMACOL, V147, P434, DOI 10.1016/j.jep.2013.03.033; Goh D, 2005, J AGR FOOD CHEM, V53, P8197, DOI 10.1021/jf051506+; Wu YX, 2010, PLANTA MED, V76, P128, DOI 10.1055/s-0029-1186004; Choi EJ, 2009, J CLIN BIOCHEM NUTR, V44, P260, DOI 10.3164/jcbn.08-230; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Romano B, 2013, PHYTOTHER RES, V27, P1588, DOI 10.1002/ptr.5023; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Kuo HM, 2009, INT J ONCOL, V35, P717, DOI 10.3892/ijo_00000384; Lucas CD, 2013, FASEB J, V27, P1084, DOI 10.1096/fj.12-218990; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Chang WH, 2002, PLANTA MED, V68, P302, DOI 10.1055/s-2002-26760; Fan GW, 2013, INFLAMMATION, V36, P1584, DOI 10.1007/s10753-013-9703-2; Macready AL, 2014, AM J CLIN NUTR, V99, P479, DOI 10.3945/ajcn.113.074237; Chen D, 2007, FRONT BIOSCI, V12, P1935, DOI 10.2741/2199; Gu RH, 2014, BIOL PHARM BULL, V37, P903; Cheng AC, 2005, EUR J PHARMACOL, V509, P1, DOI 10.1016/j.epjhar.2004.12.026; Crawford LJA, 2006, CANCER RES, V66, P6379, DOI 10.1158/0008-5472.CAN-06-0605; Frezza M, 2011, CURR TOP MED CHEM, V11, P2888; Groll M, 1999, P NATL ACAD SCI USA, V96, P10976, DOI 10.1073/pnas.96.20.10976; Jing GP, 2014, CENT EUR J MED, V9, P193, DOI 10.2478/s11536-013-0269-z; Kim YJ, 2013, BIOL PHARM BULL, V36, P1341; Momose Isao, 2001, Journal of Antibiotics (Tokyo), V54, P997; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009; Oh KS, 2012, BIOL PHARM BULL, V35, P1281; Wu YX, 2013, PHYTOTHER RES, V27, P1362, DOI 10.1002/ptr.4878	28	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					935	940				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900020		
J	Quach, HT; Hirano, S; Fukuhara, S; Watanabe, T; Kanoh, N; Iwabuchi, Y; Usui, T; Kataoka, T				Quach, Hue Tu; Hirano, Seiya; Fukuhara, Sayuri; Watanabe, Tsubasa; Kanoh, Naoki; Iwabuchi, Yoshiharu; Usui, Takeo; Kataoka, Takao			Irciniastatin A Induces Potent and Sustained Activation of Extracellular Signal-Regulated Kinase and Thereby Promotes Ectodomain Shedding of Tumor Necrosis Factor Receptor 1 in Human Lung Carcinoma A549 Cells	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						irciniastatin A; extracellular signal-regulated kinase; translation inhibitor; tumor necrosis factor receptor 1; ribotoxic stress response; p38 mitogen-activated protein kinase	P38 MAP KINASE; MARINE NATURAL-PRODUCTS; ALPHA-CONVERTING ENZYME; N-TERMINAL KINASE; PROTEIN-SYNTHESIS; BIOLOGICAL-PROPERTIES; PEDERIN FAMILY; MYCALAMIDE-B; KAPPA-B; DEOXYNIVALENOL	Irciniastatin A is a pederin-type marine product that potently inhibits translation. We have recently shown that irciniastatin A induces ectodomain shedding of tumor necrosis factor (TNF) receptor 1 with slower kinetics than other translation inhibitors. In human lung carcinoma A549 cells, irciniastatin A induced a marked and sustained activation of extracellular signal-regulated kinase (ERK) and induced little activation of p38 mitogen-activated protein (MAP) kinase and c-Jun N-terminal kinase (JNK). Moreover, the TNF receptor 1 shedding induced by irciniastatin A was blocked by the MAP kinase/ERK kinase inhibitor U0126, but not by the p38 MAP kinase inhibitor SB203580 or the JNK inhibitor SP600125. Thus unlike other translation inhibitors that trigger ribotoxic stress response, our results show that irciniastatin A is a unique translation inhibitor that induces a potent and sustained activation of the ERK pathway, and thereby promotes the ectodomain shedding of TNF receptor 1 in A549 cells.	[Quach, Hue Tu; Hirano, Seiya; Fukuhara, Sayuri; Kataoka, Takao] Kyoto Inst Technol, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan; [Watanabe, Tsubasa; Kanoh, Naoki; Iwabuchi, Yoshiharu] Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Organ Chem, Sendai, Miyagi 9808578, Japan; [Usui, Takeo] Univ Tsukuba, Fac Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan	Kataoka, T (reprint author), Kyoto Inst Technol, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan.	takao.kataoka@kit.ac.jp			Japan Society for the Promotion of Science (JSPS) [22380060, 25292061]; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan	This work was supported by a Grant-in-Aid for Scientific Research (KAKENHI, Grant Numbers 22380060 and 25292061 to T.K.) from the Japan Society for the Promotion of Science (JSPS) and a Grant-in-Aid for Scientific Research on Innovated Areas "Chemical Biology of Natural Products" (to N.K. and T.U.) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.	Dang YJ, 2011, RNA, V17, P1578, DOI 10.1261/rna.2624511; Cichewicz RH, 2004, ORG LETT, V6, P1951, DOI 10.1021/ol049503q; Scheller J, 2011, TRENDS IMMUNOL, V32, P380, DOI 10.1016/j.it.2011.05.005; Liu C, 2009, MOL CELL, V35, P26, DOI 10.1016/j.molcel.2009.06.018; Pestka JJ, 2010, ARCH TOXICOL, V84, P663, DOI 10.1007/s00204-010-0579-8; Chung YJ, 2003, TOXICOL APPL PHARM, V193, P188, DOI 10.1016/S0041-008X(03)00299-0; Shifrin VI, 1999, J BIOL CHEM, V274, P13985, DOI 10.1074/jbc.274.20.13985; Islam Z, 2006, TOXICOL APPL PHARM, V213, P235, DOI 10.1016/j.taap.2005.11.001; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; Chinen T, 2010, TOXICOL LETT, V199, P341, DOI 10.1016/j.toxlet.2010.09.017; Xu PL, 2010, MOL CELL, V37, P551, DOI 10.1016/j.molcel.2010.01.034; Soond SM, 2005, J CELL SCI, V118, P2371, DOI 10.1242/jcs.02357; Pettit GR, 2004, J MED CHEM, V47, P1149, DOI 10.1021/jm030207d; Wu CY, 2012, J AM CHEM SOC, V134, P18998, DOI 10.1021/ja3057002; Watanabe T, 2010, ORG LETT, V12, P1040, DOI 10.1021/ol1000389; Sidhu JS, 1998, J BIOL CHEM, V273, P4769, DOI 10.1074/jbc.273.8.4769; Bielitza M, 2013, ANGEW CHEM INT EDIT, V52, P10960, DOI 10.1002/anie.201301259; BURRES NS, 1989, CANCER RES, V49, P2935; Gurel G, 2009, ANTIMICROB AGENTS CH, V53, P5010, DOI 10.1128/AAC.00817-09; Hirano S, 2015, J ANTIBIOT IN PRESS; Hirano S, 2013, EUR J PHARMACOL, V701, P144, DOI 10.1016/j.ejphar.2013.01.019; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373; Kadohara K, 2005, BIOCHEM PHARMACOL, V69, P551, DOI 10.1016/j.bcp.2004.11.009; Kataoka T, 2012, EUR J PHARMACOL, V676, P1, DOI 10.1016/j.ejphar.2011.11.044; Lee KH, 2005, CANCER SCI, V96, P357, DOI 10.1111/j.1349-7006.2005.00055.x; Ogura H, 2008, INT IMMUNOPHARMACOL, V8, P922, DOI 10.1016/j.intimp.2008.02.010; Ogura H, 2008, EXP CELL RES, V314, P1406, DOI 10.1016/j.yexcr.2008.01.019; Yamada Y, 2011, EUR J PHARMACOL, V667, P113, DOI 10.1016/j.ejphar.2011.05.072	28	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					941	946				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900021		
J	Yokoyama, S; Hiramoto, K; Koyama, M; Ooi, K				Yokoyama, Satoshi; Hiramoto, Keiichi; Koyama, Mayu; Ooi, Kazuya			Impaired Skin Barrier Function in Mice with Colon Carcinoma Induced by Azoxymethane and Dextran Sodium Sulfate	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						skin barrier function; azoxymethane; dextran sodium sulfate; type I collagen; colon cancer	FACTOR RECEPTOR INHIBITORS; TOXICITY; CANCER	We have previously reported that impaired skin barrier function was induced by small intestinal injury in mice. Therefore, we postulated that other intestinal diseases might also influence skin barrier function. In this study, we evaluated the skin barrier function of hairless mice with colon carcinoma that was induced by azoxymethane (AOM) and dextran sodium sulfate (DSS). In mice treated with these drugs, we observed elevated transepidermal water loss and reduced skin hydration levels, compared to those in the control mice. In addition, plasma nitrogen di/trioxide (NO2-/NO3-) levels were significantly elevated, and expression of type I collagen was significantly reduced in the treated mice, compared to those in control. These results suggest that impaired skin barrier function occurs in mice when colon carcinoma is present.	[Yokoyama, Satoshi; Hiramoto, Keiichi; Koyama, Mayu; Ooi, Kazuya] Suzuka Univ Med Sci, Fac Pharmaceut Sci, Suzuka, Mie 5138670, Japan	Ooi, K (reprint author), Suzuka Univ Med Sci, Fac Pharmaceut Sci, Suzuka, Mie 5138670, Japan.	zooi@suzuka-u.ac.jp					Paul T, 2014, EUR J CANCER, V50, P1855, DOI 10.1016/j.ejca.2014.04.026; Elias PM, 2007, SEMIN IMMUNOPATHOL, V29, P3, DOI 10.1007/s00281-007-0060-9; Segaert S, 2005, ANN ONCOL, V16, P1425, DOI 10.1093/annonc/mdi279; Schafer M, 2008, PHARMACOL RES, V58, P165, DOI 10.1016/j.phrs.2008.06.004; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Yokoyama S, 2014, EXP DERMATOL, V23, P659, DOI 10.1111/exd.12499; Mascia F, 2010, J INVEST DERMATOL, V130, P682, DOI 10.1038/jid.2009.336; Olsson MG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027505; Suzuki R, 2004, CANCER SCI, V95, P721, DOI 10.1111/j.1349-7006.2004.tb03252.x; Weizman A, 2014, INFLAMM BOWEL DIS, V20, P525, DOI 10.1097/01.MIB.0000442011.60285.68	10	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JUN	2015	38	6					947	950				4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3LQ	WOS:000355385900022		
J	Tan, PL; Lim, PE; Lin, SM; Phang, SM; Draisma, SGA; Liao, LM				Tan, Pui-Ling; Lim, Phaik-Eem; Lin, Showe-Mei; Phang, Siew-Moi; Draisma, Stefano G. A.; Liao, Lawrence M.			Foliose Halymenia species (Halymeniaceae, Rhodophyta) from Southeast Asia, including a new species, Halymenia malaysiana sp nov.	BOTANICA MARINA			English	Article						Halymenia malaysiana sp nov.; red algae; Southeast Asia; taxonomy	SEQUENCE-ANALYSIS; RED ALGAE; MORPHOLOGY; GENUS; GRATELOUPIA	Despite the large number of species discovered in Halymenia, many remain poorly known due to the scarce information available. In order to facilitate species discrimination of foliose Halymenia species in Southeast Asia, molecular analysis and morphological studies were made on Halymenia collections from Malaysia, the Philippines, and Indonesia. The rbcL phylogenetic analyses showed that there are at least six taxa of foliose Halymenia occurring in Southeast Asia. Among the six taxa, a new species, Halymenia malaysiana P.-L. Tan, P.-E. Lim, S.-M. Lin et S.-M. Phang, is proposed based on both rbcL sequence analyses and morphological observations. Halymenia malaysiana is characterized by thalli possessing oblong or suborbiculate blades with a supple cartilaginous structure and gelatinous (slimy) texture, arising from a small discoid holdfast without a stipe, abruptly expanding into a broad blade and having a smooth surface with sinusoidally undulated margins. The phylogenetic analyses also revealed that Halymenia is a polyphyletic genus, which requires further taxonomic studies.	[Tan, Pui-Ling; Lim, Phaik-Eem; Phang, Siew-Moi; Draisma, Stefano G. A.] Univ Malaya, Inst Ocean & Earth Sci, Kuala Lumpur 50603, Malaysia; [Tan, Pui-Ling; Lim, Phaik-Eem; Phang, Siew-Moi] Univ Malaya, Inst Biol Sci, Kuala Lumpur 50603, Malaysia; [Lin, Showe-Mei] Natl Taiwan Ocean Univ, Inst Marine Biol, Keelung 20224, Taiwan; [Draisma, Stefano G. A.] Prince Songkla Univ, Dept Biol, Fac Sci, Hat Yai 90112, Songkhla, Thailand; [Liao, Lawrence M.] Hiroshima Univ, Grad Sch Biosphere Sci, Higashihiroshima 7398528, Japan	Lim, PE (reprint author), Univ Malaya, Inst Ocean & Earth Sci, Kuala Lumpur 50603, Malaysia.	phaikeem@um.edu.my; linsm@ntou.edu.tw	LIM, PHAIK EEM/B-5331-2010; Phang, Siew Moi/A-7653-2008	LIM, PHAIK EEM/0000-0001-9186-1487; 	Ministry of Science, Technology and Innovation, Malaysia [04-01-03-SF0672]; University of Malaya [PG081-2013A]; MOST-Taiwan research grant [102-2628-B-019-002-MY3]; Schure-Beijerinck-Popping Fund (Royal Dutch Academy of Sciences); TREUB maatschappij (Royal Dutch Academy of Sciences); Research Centre for Oceanography of the Indonesian Institute of Sciences (PPO-LIPI), RISTEK, Yosephine Tuti (RCO-LIPI); Borneo Marine Research Institute (Universiti Malaysia Sabah); National Oceanography Directorate (NOD-MOSTI); World Wildlife Fund - Malaysia; Economic Planning Unit Sabah, Sabah Parks; Department of Fisheries Sabah	We thank the Ministry of Science, Technology and Innovation, Malaysia in funding the E-science Fund (04-01-03-SF0672) and the University of Malaya in funding the Postgraduate Research Fund (PG081-2013A) to make the implementation of the project possible, and a MOST-Taiwan research grant (102-2628-B-019-002-MY3) to SML. Support was provided by the Schure-Beijerinck-Popping Fund and the TREUB maatschappij (both of the Royal Dutch Academy of Sciences), and Bert W. Hoeksema (Naturalis Biodiversity Centre); the Research Centre for Oceanography of the Indonesian Institute of Sciences (PPO-LIPI), RISTEK, Yosephine Tuti (RCO-LIPI); the Borneo Marine Research Institute (Universiti Malaysia Sabah), the National Oceanography Directorate (NOD-MOSTI), the World Wildlife Fund - Malaysia, the Economic Planning Unit Sabah, Sabah Parks, and the Department of Fisheries Sabah.	ABBOTT IA, 1967, J PHYCOL, V3, P139, DOI 10.1111/j.1529-8817.1967.tb04648.x; Agardh C. A., 1817, SYNOPSIS ALGARUM SCA, p[i, 1]; Yow YY, 2011, J APPL PHYCOL, V23, P219, DOI 10.1007/s10811-010-9535-5; Wang HW, 2000, PHYCOLOGIA, V39, P228, DOI 10.2216/i0031-8884-39-3-228.1; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Figueroa FL, 2007, EUR J PHYCOL, V42, P231, DOI 10.1080/09670260701327702; Lin SM, 2004, J PHYCOL, V40, P962, DOI 10.1111/j.1529-8817.2004.04055.x; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI 10.1093/molbev/mst197; D'Archino R, 2014, BOT MAR, V57, P185, DOI 10.1515/bot-2014-0008; Tanabe AS, 2007, MOL ECOL NOTES, V7, P962, DOI 10.1111/j.1471-8286.2007.01807.x; WITTMANN W, 1965, STAIN TECHNOL, V40, P161; Gavio B, 2002, EUR J PHYCOL, V37, P349, DOI 10.1017/S0967026202003839; BALAKRISHNAN M. S., 1961, JOUR MADRAS UNIV, V31, P183; Chiang Y. M., 1970, MORPHOLOGICAL STUDIE, V58, P1; De Clerck O, 2005, EUR J PHYCOL, V40, P169, DOI 10.1080/09670260500128343; De Smedt G, 2001, NOVA HEDWIGIA, V73, P293; FRESHWATER DW, 1994, PHYCOLOGIA, V33, P187, DOI 10.2216/i0031-8884-33-3-187.1; GARGIULO GM, 1986, PHYCOLOGIA, V25, P144, DOI 10.2216/i0031-8884-25-2-144.1; GUIRY M. D., 2014, ALGAEBASE; Hernandez-Kantun JJ, 2012, EUR J PHYCOL, V47, P421, DOI 10.1080/09670262.2012.733734; Hernandez-Kantun JJ, 2009, BOT MAR, V52, P248, DOI 10.1515/BOT.2009.042; Huisman JM, 2011, EUR J PHYCOL, V46, P1, DOI 10.1080/09670262.2010.507313; Kawaguchi S., 2002, TAXONOMY EC SEAWEEDS, V8, P259; Kawaguchi S., 1999, TAXONOMY EC SEAWEEDS, V7, P147; Lewmanomont K., 2002, TAXONOMY EC SEAWEEDS, V8, P267; Swofford DP, 2003, PHYLOGENETIC ANAL US; Wang Hong Wei, 2001, Phycological Research, V49, P251, DOI 10.1111/j.1440-1835.2001.tb00255.x; Zanardini G., 1851, FLORA, V34, P33; Zanardini G., 1858, MEMORIE REALE I VENE, V7, P209	29	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0006-8055	1437-4323		BOT MAR	Bot. Marina	JUN	2015	58	3			SI		203	217		10.1515/bot-2015-0004		15	Plant Sciences; Marine & Freshwater Biology	Plant Sciences; Marine & Freshwater Biology	CJ3XA	WOS:000355416600007		
J	Nagasato, C; Terauchi, M; Tanaka, A; Motomura, T				Nagasato, Chikako; Terauchi, Makoto; Tanaka, Atsuko; Motomura, Taizo			Development and function of plasmodesmata in zygotes of Fucus distichus	BOTANICA MARINA			English	Article						brown algae; cell differentiation; microinjection; pit field; plasmodesmata	SECONDARY PLASMODESMATA; BROWN-ALGAE; INTERCELLULAR COMMUNICATION; FLUORESCENT-PROBES; MESSENGER-RNA; CELL-WALL; PHAEOPHYCEAE; TRAFFICKING; MOVEMENT; TRANSLOCATION	Brown algae have plasmodesmata, tiny tubular cytoplasmic channels connecting adjacent cells. The lumen of plasmodesmata is 10-20 nm wide, and it takes a simple form, without a desmotubule (the inner membrane structure consisting of endoplasmic reticulum in the plasmodesmata of green plants). In this study, we analyzed the ultrastructure and distribution of plasmodesmata during development of Fucus distichus zygotes. The first cytokinesis of zygotes in brown algae is not accompanied by plasmodesmata formation. As the germlings develop, plasmodesmata are found in all septal cell walls, including the first cell division plane. Plasmodesmata are formed de novo on the existing cell wall. Pit fields, which are clusters of plasmodesmata, were observed in germlings with differentiated cell layers. Apart from the normal plasmodesmata, these pit fields had branched plasmodesmata that appeared to arise from the lateral preexisting ones. Fluorescent tracers with different molecular sizes were microinjected to examine the size exclusion limit of molecules for transit through the plasmodesmata. Fluorescein isothiocyanate (FITC)-dextran of 3 kDa size was spread over the germlings, and 10 kDa FITC-dextran was tracked only in the rhizoid. The size exclusion limit was <10 kDa for the thallus but <40 kDa for the rhizoid.	[Nagasato, Chikako; Tanaka, Atsuko; Motomura, Taizo] Hokkaido Univ, Field Sci Ctr Northern Biosphere, Muroran Marine Stn, Muroran, Hokkaido 0510013, Japan; [Terauchi, Makoto] Kobe Univ, Res Ctr Inland Seas, Kobe, Hyogo 6578501, Japan	Nagasato, C (reprint author), Hokkaido Univ, Field Sci Ctr Northern Biosphere, Muroran Marine Stn, Muroran, Hokkaido 0510013, Japan.	nagasato@fsc.hokudai.ac.jp			KAKENHI [25291087, 26440160]	I thank Drs. Mark Cock, Susana Coelho, and Martina Strittmatter (UMR 8227 CNRS-UPMC Integrative Biology of Marine Models, Station Biologique Roscoff) for their technical advice on micro-injection. I would also like to express my gratitude to Drs. Toshiaki Ito and Manabu Nagao (Hokkaido University) for their support with electron microscopy. This study was supported by KAKENHI (25291087 and 26440160).	ABE M, 1970, BOT MAG TOKYO, V83, P254; AMAT MA, 1985, J PHYCOL, V21, P330; Kim I, 2002, DEVELOPMENT, V129, P1261; Nagasato C, 2002, PROTOPLASMA, V219, P140, DOI 10.1007/s007090200015; Zavaliev R, 2013, MOL PLANT MICROBE IN, V26, P1016, DOI 10.1094/MPMI-03-13-0062-R; SCHMITZ K, 1976, MAR BIOL, V36, P207, DOI 10.1007/BF00389281; Burch-Smith TM, 2010, CURR BIOL, V20, P989, DOI 10.1016/j.cub.2010.03.064; McLean BG, 1997, PLANT CELL, V9, P1043, DOI 10.1105/tpc.9.7.1043; Bouget FY, 1998, DEVELOPMENT, V125, P1999; Burch-Smith TM, 2012, ANNU REV PLANT BIOL, V63, P239, DOI 10.1146/annurev-arplant-042811-105453; ERWEE MG, 1983, PLANTA, V158, P320, DOI 10.1007/BF00397334; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; Zavaliev R, 2011, PROTOPLASMA, V248, P117, DOI 10.1007/s00709-010-0247-0; Cosgrove DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/nrm1746; Cock JM, 2010, NATURE, V465, P617, DOI 10.1038/nature09016; Oparka KJ, 1999, CELL, V97, P743, DOI 10.1016/S0092-8674(00)80786-2; GOODWIN PB, 1983, PLANTA, V157, P124, DOI 10.1007/BF00393645; Burch-Smith TM, 2011, PROTOPLASMA, V248, P61, DOI 10.1007/s00709-010-0252-3; Michel G, 2010, NEW PHYTOL, V188, P82, DOI 10.1111/j.1469-8137.2010.03374.x; BISALPUT.T, 1966, CAN J BOTANY, V44, P89; Ehlers K, 2001, PROTOPLASMA, V216, P1, DOI 10.1007/BF02680127; Farnham G, 2013, J PHYCOL, V49, P819, DOI 10.1111/jpy.12096; Faulkner C, 2008, PLANT CELL, V20, P1504, DOI 10.1105/tpc.107.056903; HEPLER PK, 1982, PROTOPLASMA, V111, P121, DOI 10.1007/BF01282070; KEMPERS R, 1993, PLANT J, V4, P567, DOI 10.1046/j.1365-313X.1993.04030567.x; Kim JY, 2005, GENE DEV, V19, P788, DOI 10.1101/gad.332805; MOTOMURA T, 1994, PROTOPLASMA, V178, P97, DOI 10.1007/BF01545960; Nagasato C, 2010, PLANTA, V232, P287, DOI 10.1007/s00425-010-1188-8; Nagasato C, 2014, PROTOPLASMA, V251, P1347, DOI 10.1007/s00709-014-0635-y; Provasoli L, 1968, CULTURES COLLECTIONS, P63; Radford JE, 2011, PROTOPLASMA, V248, P205, DOI 10.1007/s00709-010-0244-3; Radford JE, 2001, PROTOPLASMA, V216, P47, DOI 10.1007/BF02680130; Raven JA, 1997, EUR J PHYCOL, V32, P95; ROBARDS AW, 1990, ANNU REV PLANT PHYS, V41, P369, DOI 10.1146/annurev.pp.41.060190.002101; Terauchi M, 2015, J PLANT RES, V128, P7, DOI 10.1007/s10265-014-0677-4; Terauchi M, 2012, PLANTA, V236, P1013, DOI 10.1007/s00425-012-1656-4; TERRY BR, 1987, PLANTA, V171, P145, DOI 10.1007/BF00391090; WAKANA I, 1992, PLANT CELL PHYSIOL, V33, P569	38	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0006-8055	1437-4323		BOT MAR	Bot. Marina	JUN	2015	58	3			SI		229	238		10.1515/bot-2014-0082		10	Plant Sciences; Marine & Freshwater Biology	Plant Sciences; Marine & Freshwater Biology	CJ3XA	WOS:000355416600009		
J	Sugano, A; Ishizu, T; Nakamura, A; Kawamatsu, N; Kato, Y; Takahashi, M; Kanemoto, S; Seo, Y; Horigome, H; Hiramatsu, Y; Aonuma, K				Sugano, Akinori; Ishizu, Tomoko; Nakamura, Akihiro; Kawamatsu, Naoto; Kato, Yoshiaki; Takahashi, Miho; Kanemoto, Shinya; Seo, Yoshihiro; Horigome, Hitoshi; Hiramatsu, Yuji; Aonuma, Kazutaka			Cardiac Resynchronization Therapy in a Patient With a Failing Systemic Right Ventricle	CANADIAN JOURNAL OF CARDIOLOGY			English	Article							CONGENITAL HEART-DISEASE; PEDIATRIC-PATIENTS	Systemic right ventricular dysfunction is 1 of the late complications of the atrial switch operation for transposition of the great arteries. It has been reported that cardiac resynchronization therapy (CRT) for the failing systemic right ventricle (RV) improves symptoms and systolic function. However, patient selection for CRT in congenital heart disease is still challenging because the clinical standard for CRT in these patients is not established. We describe a case of successful implantation of a CRT device for a failing systemic RV aided by multimodality imaging and cardiac hemodynamic studies.	[Sugano, Akinori] Tsukuba Med Ctr Hosp, Dept Cardiol, Ibaraki, Japan; [Sugano, Akinori; Ishizu, Tomoko; Kawamatsu, Naoto; Seo, Yoshihiro; Aonuma, Kazutaka] Univ Tsukuba, Fac Med, Div Cardiovasc, Ibaraki, Japan; [Kanemoto, Shinya; Hiramatsu, Yuji] Univ Tsukuba, Dept Cardiovasc Surg, Ibaraki, Japan; [Nakamura, Akihiro; Kato, Yoshiaki; Takahashi, Miho; Horigome, Hitoshi] Univ Tsukuba, Dept Pediat, Ibaraki, Japan	Ishizu, T (reprint author), Univ Tsukuba, Div Cardiol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	tomoco@md.tsukuba.ac.jp					Dubin AM, 2005, J AM COLL CARDIOL, V46, P2277, DOI 10.1016/j.jacc.2005.05.096; Motonaga KS, 2014, CIRCULATION, V129, P1879, DOI 10.1161/CIRCULATIONAHA.113.001383; Seo Y, 2013, CIRC J, V77, P2481, DOI 10.1253/circj.CJ-13-0380; Suzuki T, 2014, CIRC J, V78, P1710, DOI 10.1253/circj.CJ-13-1379	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0828-282X	1916-7075		CAN J CARDIOL	Can. J. Cardiol.	JUN	2015	31	6							819.e5	10.1016/j.cjca.2015.01.004		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0VW	WOS:000355198200023		
J	Nagata, Y; Konno, T; Fujino, N; Hodatsu, A; Nomura, A; Hayashi, K; Nakamura, H; Kawashiri, MA; Yamagishi, M				Nagata, Yoji; Konno, Tetsuo; Fujino, Noboru; Hodatsu, Akihiko; Nomura, Akihiro; Hayashi, Kenshi; Nakamura, Hiroyuki; Kawashiri, Masa-Aki; Yamagishi, Masakazu			Right Ventricular Hypertrophy Is Associated With Cardiovascular Events in Hypertrophic Cardiomyopathy: Evidence From Study With Magnetic Resonance Imaging	CANADIAN JOURNAL OF CARDIOLOGY			English	Article							HEART-FAILURE; EJECTION FRACTION; EUROPEAN-SOCIETY; TASK-FORCE; CARDIOLOGY; ECHOCARDIOGRAPHY; INVOLVEMENT; DYSFUNCTION; GUIDELINES; MANAGEMENT	Background: Although left ventricular (LV) morphology and function have been well studied in hypertrophic cardiomyopathy (HCM), few data exist regarding the right ventricle. Accordingly, we studied right ventricular (RV) morphology and function and their effect on cardiovascular events in HCM using cardiac magnetic resonance (CMR) imaging. Methods: This retrospective study included 106 HCM patients (age 61.6 +/- 14.5 years) examined using CMR imaging during January 2008 to September 2014. RV hypertrophy (RVH) was defined as RV maximal wall thickness > 5 mm. Results: RVH was observed in 30 of the 106 patients (RVH group), with the remaining 76 patients assigned to the non-RVH group. The RVH group had higher brain natriuretic peptide levels (461.6 +/- 699.8 pg/mL vs 225.3 +/- 254.5 pg/mL; P = 0.01) and also showed a reduced RV end-diastolic volume index (43.4 +/- 16.0 mL/m(2) vs 56.6 +/- 15.2 mL/m(2); P = 0.0001), in keeping with a greater LV mass index (109.1 +/- 24.9 g/m(2) vs 78.6 +/- 23.0 g/m(2); P < 0.0001). The RVH group was prominently associated with RV late gadolinium enhancement compared with the non-RVH group (33.3% vs 0%; P < 0.0001). After CMR imaging, 15 patients developed cardiovascular events that included admission for heart failure, ventricular tachyarrhythmia/fibrillation, stroke, and sudden cardiac death. Cox proportional hazard analysis revealed that RVH was an independent predictor of the occurrence of cardiovascular events after adjustments by sex, age, LV mass index, LV ejection fraction, and LV outflow tract obstruction (hazard ratio, 5.42; 95% confidence interval, 1.16-25.3; P = 0.03). Conclusions: These results suggest that HCM patients with RVH on CMR images have a greater incidence of cardiovascular events than non-RVH patients. Further work is needed to confirm this observation and assess its clinical importance.	[Nagata, Yoji; Konno, Tetsuo; Fujino, Noboru; Hodatsu, Akihiko; Nomura, Akihiro; Hayashi, Kenshi; Kawashiri, Masa-Aki; Yamagishi, Masakazu] Kanazawa Univ, Grad Sch Med, Div Cardiovasc Med, Kanazawa, Ishikawa 9208641, Japan; [Konno, Tetsuo; Nakamura, Hiroyuki; Yamagishi, Masakazu] Kanazawa Univ, Res & Educ Ctr Innovat & Prevent Med, Kanazawa, Ishikawa 9208641, Japan; [Nakamura, Hiroyuki] Kanazawa Univ, Grad Sch Med Sci, Dept Publ Hlth, Kanazawa, Ishikawa 9208641, Japan	Konno, T (reprint author), Kanazawa Univ, Grad Sch Med, Div Cardiovasc Med, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.	konnokontetsu@staff.kanazawa-u.ac.jp			Ministry of Education, Science and Culture of Japan [24790748]	This work was supported by a grant from the Ministry of Education, Science and Culture of Japan (to Dr Konno; Research Project Number: 24790748).	Fujino N, 2013, CLIN CARDIOL, V36, P160, DOI 10.1002/clc.22082; STIERLE U, 1987, JPN HEART J, V28, P115; Mozaffarian D, 2001, CLIN CARDIOL, V24, P2; de Groote P, 1998, J AM COLL CARDIOL, V32, P948, DOI 10.1016/S0735-1097(98)00337-4; Konno T, 2010, P NATL ACAD SCI USA, V107, P18097, DOI 10.1073/pnas.1012826107; Teekakirikul P, 2010, J CLIN INVEST, V120, P3520, DOI 10.1172/JCI42028; Kawut SM, 2012, CIRCULATION, V126, P1681, DOI 10.1161/CIRCULATIONAHA.112.095216; Haddad F, 2008, CIRCULATION, V117, P1717, DOI 10.1161/CIRCULATIONAHA.107.653584; Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010; D'Andrea A, 2010, EUR J ECHOCARDIOGR, V11, P492, DOI 10.1093/ejechocard/jeq007; Maron MS, 2007, AM J CARDIOL, V100, P1293, DOI 10.1016/j.amjcard.2007.05.061; Mertens LL, 2010, NAT REV CARDIOL, V7, P551, DOI 10.1038/nrcardio.2010.118; Meyer P, 2010, CIRCULATION, V121, P252, DOI 10.1161/CIRCULATIONAHA.109.887570; Maron MS, 2012, J CARDIOVASC MAGN R, V14, DOI 10.1186/1532-429X-14-13; Lai WW, 2008, INT J CARDIOVAS IMAG, V24, P691, DOI 10.1007/s10554-008-9314-4; Richardson P, 1996, CIRCULATION, V93, P841; Ellims AH, 2012, J CARDIOVASC MAGN R, V14, DOI 10.1186/1532-429X-14-76; Elliott PM, 2014, EUR HEART J, V35, P2733, DOI 10.1093/eurheartj/ehu284; Fischer Y, 2001, CLIN CHEM, V47, P591; Fluechter S, 2010, J CARDIOVASC MAGN R, V12, DOI 10.1186/1532-429X-12-30; Fujita T, 2013, JACC-HEART FAIL, V1, P459, DOI 10.1016/j.jchf.2013.08.007; Kawashiri M, 2014, HEART VESSELS, V29, P129, DOI 10.1007/s00380-013-0391-5; Keeling AN, 2010, EUR HEART J, V31, P381, DOI 10.1093/eurheartj/ehp528; Konno T, 2010, CURR OPIN CARDIOL, V25, P205, DOI 10.1097/HCO.0b013e3283375698; Larrazet F, 1997, J AM SOC ECHOCARDIOG, V10, P699, DOI 10.1016/S0894-7317(97)70111-1; Maeda M, 1999, JPN CIRC J, V63, P681, DOI 10.1253/jcj.63.681; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Oh JK, 2006, DOPPLER ECHOCARDIOGR, V3rd, P59; Valsangiacomo BE, 2012, EUR HEART J, V33, P949, DOI DOI 10.1093/EURHEARTJ/EHR490; Walker Lori A, 2013, Curr Cardiol Rev, V9, P73; Woodard Pamela K, 2006, J Am Coll Radiol, V3, P665, DOI 10.1016/j.jacr.2006.06.007	31	2	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0828-282X	1916-7075		CAN J CARDIOL	Can. J. Cardiol.	JUN	2015	31	6					702	708		10.1016/j.cjca.2014.12.036		7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0VW	WOS:000355198200004		
J	Takakura, Y				Takakura, Yoshimitsu			Tricholoma matsutake fruit bodies secrete hydrogen peroxide as a potent inhibitor of fungal growth	CANADIAN JOURNAL OF MICROBIOLOGY			English	Article						catalase; fruit body; hydrogen peroxide; pyranose oxidase; Tricholoma matsutake; antimicrobial agent	PHANEROCHAETE-CHRYSOSPORIUM; PYRANOSE OXIDASE; CARBOHYDRATE OXIDASES; GLUCOSE-OXIDASE; S ITO; GLUCOSE-2-OXIDASE; BASIDIOMYCETE; CORTALCERONE; DEHYDRATASE; DEGRADATION	Tricholoma matsutake is an ectomycorrhizal fungus that dominates the microbial communities in the soil of pine and spruce forests. The mycorrhizas of this fungus have antimicrobial activity, although factors responsible for the antimicrobial activity have not been fully elucidated. The present study shows that fruit bodies of T. matsutake secreted hydrogen peroxide (H2O2), which was produced by pyranose oxidase, and that the H2O2 thus secreted strongly inhibited the growth of mycelia of the phytopathological fungus Rhizoctonia solani. These findings suggest that fruit bodies of T. matsutake have antifungal activity and that the pyranose oxidase plays an important role in the antifungal activity.	[Takakura, Yoshimitsu] Japan Tobacco Inc, Plant Innovat Ctr, Iwata, Shizuoka 4380802, Japan	Takakura, Y (reprint author), Japan Tobacco Inc, Leaf Tobacco Res Ctr, 1900 Idei, Oyama, Tochigi 3230808, Japan.	yoshimitsu.takakura@jt.com			Society for Techno-innovation of Agriculture, Forestry and Fisheries of Japan	We thank Hidemasa Imaseki and Toshihiko Komari for their helpful discussion and critical reading of the manuscript. This work was partly supported by a grant from the Society for Techno-innovation of Agriculture, Forestry and Fisheries of Japan. The author declares no conflicts of interest.	Uggla C, 2001, PLANT PHYSIOL, V125, P2029, DOI 10.1104/pp.125.4.2029; OLSON PD, 1993, PLANT J, V4, P887, DOI 10.1046/j.1365-313X.1993.04050887.x; Takakura Y, 2003, BIOSCI BIOTECH BIOCH, V67, P2598, DOI 10.1271/bbb.67.2598; Brudzynski K, 2006, CAN J MICROBIOL, V52, P1228, DOI 10.1139/W06-086; WU GS, 1995, PLANT CELL, V7, P1357; Lian CL, 2006, NEW PHYTOL, V171, P825, DOI 10.1111/j.1469-8137.2006.01801.x; Vaario LM, 2011, APPL ENVIRON MICROB, V77, P8523, DOI 10.1128/AEM.05839-11; Burke RM, 1998, NEW PHYTOL, V139, P637, DOI 10.1046/j.1469-8137.1998.00235.x; Custers JHHV, 2004, PLANT J, V39, P147, DOI 10.1111/j.1365-313X.2004.02117.x; DANIEL G, 1994, APPL ENVIRON MICROB, V60, P2524; ERIKSSON KE, 1986, APPL MICROBIOL BIOT, V23, P257; Flavel D.R., 1991, BIOCONTROL SCI TECHN, V1, P91, DOI [10.1080/09583159109355189, DOI 10.1080/09583159109355189]; KIM KK, 1988, PHYTOPATHOLOGY, V78, P488, DOI 10.1094/Phyto-78-488; KOTHS K, 1992, CARBOHYD RES, V232, P59, DOI 10.1016/S0008-6215(00)90994-7; OHARA H, 1967, NATURE, V213, P528, DOI 10.1038/213528a0; OHARA H, 1966, P JPN ACAD, V42, P503; PENG M, 1992, PHYTOPATHOLOGY, V82, P696, DOI 10.1094/Phyto-82-696; TSURUTA T, 1979, T MYCOL SOC JPN, V20, P211; VOLC J, 1985, FOLIA MICROBIOL, V30, P141, DOI 10.1007/BF02922207; VOLC J, 1991, ARCH MICROBIOL, V156, P297, DOI 10.1007/BF00263001; Xu H., 2003, PLANT PHYSIOL, V133, P170, DOI [10.1104/pp.103.024026, DOI 10.1104/PP.103.024026]	21	0	0	CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS	OTTAWA	65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA	0008-4166	1480-3275		CAN J MICROBIOL	Can. J. Microbiol.	JUN	2015	61	6					447	450		10.1139/cjm-2014-0843		4	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Immunology; Microbiology	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Immunology; Microbiology	CJ0WA	WOS:000355198700008		
J	Murakami, K; Nakagawa, H; Nishimura, K; Matsuo, S				Murakami, Kohei; Nakagawa, Hiroshi; Nishimura, Kazuhiko; Matsuo, Saburo			Changes in peptidergic fiber density in the synovium of mice with collagenase-induced acute arthritis	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article						calcitonin gene-related peptide; ossification; osteoarthritis; osteophyte; peripheral nerve fibers; substance P; synovium	GENE-RELATED PEPTIDE; SYMPATHETIC-NERVE FIBERS; SUBSTANCE-P; OSTEOPHYTE FORMATION; KNEE-JOINT; RHEUMATOID-ARTHRITIS; RAT; OSTEOARTHRITIS; CELLS; TISSUE	The effect of acute osteoarthritis (OA) on peripheral nerve fibers (NFs) in synovial tissue, and their association with histological changes were investigated in collagenase-induced OA mice. Collagenase (10 U in 5 mu L saline) was injected into the right knee, and the same volume of saline was injected into the left knee as the control. Mice were sacrificed 1, 2, 3, and 4 weeks after the collagenase injection. Histopathological changes in the knee joints were evaluated. The numbers of protein gene product (PGP) 9.5-, calcitonin-gene-related peptide (CGRP)-, and substance P (SP)-positive NFs in the synovial tissue were determined, and their densities in the tissue were calculated. The densities of PGP 9.5-and CGRP-positive NFs in the synovium were drastically decreased 1 week after the collagenase injection. However, by week 4, the density of PGP 9.5-and CGRP-positive NFs had recovered to 84% and 79% of their normal levels, respectively. Despite the poor correlation between the synovitis score and the density of CGRP-or SP-positive NFs in the synovium, the ossification rate of chondrophytes in chondro/osteophyte lesions correlated strongly with the density of CGRP-positive NFs (R = 0.855). These results suggest that the ossification of chondrophytes occurred in parallel with the increase in CGRP-positive fiber density in the synovium during the acute phase of collagenase-induced OA.	[Murakami, Kohei; Nakagawa, Hiroshi; Nishimura, Kazuhiko; Matsuo, Saburo] Osaka Prefecture Univ, Toxicol Lab, Grad Sch Life & Environm Sci, Vet Sci, Izumisano, Osaka 5988531, Japan; [Murakami, Kohei] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Clin Pathobiol, Bunkyo Ku, Tokyo 1138657, Japan	Murakami, K (reprint author), Osaka Prefecture Univ, Toxicol Lab, Grad Sch Life & Environm Sci, Vet Sci, 1-58 Rinku Ourai Kita, Izumisano, Osaka 5988531, Japan.	vet.murakami@gmail.com					GRONBLAD M, 1988, J RHEUMATOL, V15, P1807; Straub RH, 2011, ARTHRITIS RHEUM-US, V63, P3234, DOI 10.1002/art.30516; LEVINE JD, 1984, SCIENCE, V226, P547, DOI 10.1126/science.6208609; BUMA P, 1992, HISTOCHEMISTRY, V98, P327, DOI 10.1007/BF00270017; Saxler G, 2007, EUR J PAIN, V11, P67, DOI 10.1016/j.ejpain.2005.12.011; Botter SM, 2008, OSTEOARTHR CARTILAGE, V16, P506, DOI 10.1016/j.joca.2007.08.005; VANDERKRAAN PM, 1989, AM J PATHOL, V135, P1001; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Shih C, 1997, PEPTIDES, V18, P323, DOI 10.1016/S0196-9781(96)00280-X; Wu Z, 2002, HISTOCHEM CELL BIOL, V118, P213, DOI 10.1007/s00418-002-0443-x; MARSHALL KW, 1990, ARTHRITIS RHEUM, V33, P87; Krenn V, 2006, HISTOPATHOLOGY, V49, P358, DOI 10.1111/j.1365-2559.2006.02508.x; Beckmann J, 2013, JOINT BONE SPINE, V80, P188, DOI 10.1016/j.jbspin.2012.03.003; Saito T, 2000, CLIN ORTHOP RELAT R, P172; MCCULLOCH J, 1986, P NATL ACAD SCI USA, V83, P5731, DOI 10.1073/pnas.83.15.5731; Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306-4522(00)00110-X; BJURHOLM A, 1992, J BONE MINER RES, V7, P1011; Blom AB, 2004, OSTEOARTHR CARTILAGE, V12, P627, DOI 10.1016/j.joca.2004.03.003; HUKKANEN M, 1991, J RHEUMATOL, V18, P177; LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770; AHMED M, 1995, ARTHRITIS RHEUM, V38, P699, DOI 10.1002/art.1780380519; Axhausen G, 1925, VIRCHOWS ARCH A, V255, P144, DOI 10.1007/BF01904415; BERNARD GW, 1990, PEPTIDES, V11, P625, DOI 10.1016/0196-9781(90)90171-Z; BILEVICIUTE I, 1993, NEUROSCI LETT, V153, P37, DOI 10.1016/0304-3940(93)90071-R; COLLINS D H, 1955, Postgrad Med J, V31, P602; CRAWFORD A, 1986, BONE, V7, P157, DOI 10.1016/8756-3282(86)90726-X; ILAR (Institute of Laboratory Animal Resources), 1996, NIH PUBLICATION; Imai S, 1997, J BONE MINER RES, V12, P1018, DOI 10.1359/jbmr.1997.12.7.1018; LAM FY, 1993, NEUROSCIENCE, V52, P443, DOI 10.1016/0306-4522(93)90170-K; LIPSON SJ, 1980, ARTHRITIS RHEUM, V23, P319, DOI 10.1002/art.1780230309; Matsuo S, 2002, SOMATOSENS MOT RES, V19, P213, DOI 10.1080/0899022021000009134; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; Nissalo S, 2002, ANN NY ACAD SCI, V966, P384, DOI 10.1111/j.1749-6632.2002.tb04239.x; Ossyssek B, 2011, J ORTHOP RES, V29, P297, DOI 10.1002/jor.21233; Pelletier JP, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1932; Saito T, 1992, Nihon Seikeigeka Gakkai Zasshi, V66, P884; Schaffer M, 1998, ARCH SURG-CHICAGO, V133, P1107, DOI 10.1001/archsurg.133.10.1107; Matayoshi T, 2005, BIOCHEM BIOPH RES CO, V327, P756, DOI 10.1016/j.bbrc.2004.12.055; WEIHE E, 1995, CAN J PHYSIOL PHARM, V73, P1015; Yasuhara O, 2008, J COMP NEUROL, V509, P436, DOI 10.1002/cne.21754; Zhang YB, 2014, BRIT J ORAL MAX SURG, V52, P697, DOI 10.1016/j.bjoms.2014.07.002	41	0	0	CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS	OTTAWA	65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA	0008-4212	1205-7541		CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	JUN	2015	93	6					435	441		10.1139/cjpp-2014-0446		7	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	CJ1IK	WOS:000355237100008		
J	Yamagishi, M				Yamagishi, Masakazu			Resultants of Chebyshev Polynomials: the First, Second, Third, and Fourth Kinds	CANADIAN MATHEMATICAL BULLETIN-BULLETIN CANADIEN DE MATHEMATIQUES			English	Article						resultant; Chebyshev polynomial; cyclotomic polynomial	CYCLOTOMIC POLYNOMIALS	We give an explicit formula for the resultant of Chebyshev polynomials of the first, second, third, and fourth kinds. We also compute the resultant of modified cyclotomic polynomials.	Nagoya Inst Technol, Dept Math, Showa Ku, Nagoya, Aichi 4668555, Japan	Yamagishi, M (reprint author), Nagoya Inst Technol, Dept Math, Showa Ku, Gokiso Cho, Nagoya, Aichi 4668555, Japan.	yamagishi.masakazu@nitech.ac.jp			JSPS KAKENHI [23540014]	This work was supported by JSPS KAKENHI (No. 23540014).	Jacobs DP, 2011, CAN MATH BULL, V54, P288, DOI 10.4153/CMB-2011-013-1; APOSTOL TM, 1970, P AM MATH SOC, V24, P457, DOI 10.2307/2037387; MCKAY JH, 1989, ARCH MATH, V53, P347, DOI 10.1007/BF01195214; Louboutin SR, 2013, CAN MATH BULL, V56, P602, DOI 10.4153/CMB-2012-002-1; Diederichsen F.-E., 1940, ABH MATH SEM HAMBURG, V13, P357; Dresden G, 2012, ROCKY MT J MATH, V42, P1461, DOI 10.1216/RMJ-2012-42-5-1461; Lehmer E.T., 1930, B AM MATH SOC, V36, P291, DOI 10.1090/S0002-9904-1930-04939-3; Lemmermeyer Franz, 2000, SPRINGER MONOGRAPHS; Louboutin S, 1997, PUBL MATH-DEBRECEN, V50, P75; LUNEBURG H, 1984, ARCH MATH, V42, P139, DOI 10.1007/BF01772933; Mason J.C., 2003, CHEBYSHEV POLYNOMIAL; Rivlin T. J., 1990, PURE APPL MATH; Yamagishi M, 2013, J NUMBER THEORY, V133, P2455, DOI 10.1016/j.jnt.2013.01.008	13	0	0	CANADIAN MATHEMATICAL SOC	OTTAWA	209-1725 ST LAURENT BLVD, OTTAWA, ONTARIO K1G 3V4, CANADA	0008-4395	1496-4287		CAN MATH BULL	Can. Math. Bul.-Bul. Can. Math.	JUN	2015	58	2					423	431		10.4153/CMB-2015-002-8		9	Mathematics	Mathematics	CI6XS	WOS:000354908100023		
J	Arai, T; Morice, MC; O'Connor, SA; Yamamoto, M; Eltchaninoff, H; Leguerrier, A; Leprince, P; Laskar, M; Iung, B; Fajadet, J; Prat, A; Lievre, M; Donzeau-Gouge, P; Chevreul, K; Teiger, E; Lefevre, T; Gilard, M				Arai, Takahide; Morice, Marie-Claude; O'Connor, Stephen A.; Yamamoto, Masanori; Eltchaninoff, Helene; Leguerrier, Alain; Leprince, Pascal; Laskar, Marc; Iung, Bernard; Fajadet, Jean; Prat, Alain; Lievre, Michel; Donzeau-Gouge, Patrick; Chevreul, Karine; Teiger, Emmanuel; Lefevre, Thierry; Gilard, Martine		FRANCE 2 Registry Investigators	Impact of pre- and post-procedural anemia on the incidence of acute kidney injury and 1-year mortality in patients undergoing transcatheter aortic valve implantation (from the French Aortic National CoreValve and Edwards 2 [FRANCE 2] Registry)	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS			English	Article						severe symptomatic aortic stenosis; transcatheter aortic valve implantation; anemia; acute kidney injury	HIGH-RISK PATIENTS; PREOPERATIVE ANEMIA; TRANSFUSION; STENOSIS; COMPLICATIONS; REPLACEMENT; OUTCOMES; SURGERY	ObjectivesThe relationship between anemia, renal insufficiency, and the outcomes of TAVI patients has not been thoroughly studied. We aimed to evaluate the influence of pre- and post-procedural anemia on the incidence of renal insufficiency, especially AKI, and on the outcomes of TAVI. MethodsData from the French national TAVI registry were collected in 3,472 patients who underwent TAVI between January 2010 and December 2012. Of these 2,137 were in the no/mild anemia group, 748 were in the moderate anemia group, and 587 were in the severe anemia group before TAVI. Furthermore, we divided the 3,472 patients into three groups according to post-procedural anemia, measured as post-procedural hemoglobin (Hb) drop: <2 g/dl (n=1,633, group 1), 2 to <4 g/dl (n=1,458, group 2), and >4 g/dl (n=381, group 3). Procedure and outcome variables were compared. ResultsIncreased severity of anemia before TAVI was associated with significantly different rates of 1-year mortality (15%, 19%, and 24%, P<0.01), with similar differences in the incidence of AKI (5%, 8%, and 10%, P<0.01). Increased severity of Hb drop was associated with significantly different rates of 1-year mortality (16%, 18%, and 23%, P<0.01), and with similar differences in the incidence of AKI (6%, 7%, and 10%, P=0.04). Both pre- and post-procedural anemia were predictors of the incidence of AKI (OR 1.82, P<0.01; OR 1.82, P<0.01, respectively) and 1-year mortality (HR 1.44, P<0.01; HR 1.50, P<0.01, respectively). ConclusionsBoth pre- and post-procedural anemia were significantly associated AKI and 1-year mortality. (c) 2015 Wiley Periodicals, Inc.	[Arai, Takahide; Morice, Marie-Claude; O'Connor, Stephen A.; Lefevre, Thierry] Inst Cardiovasc Paris Sud, Dept Cardiol, Massy, France; [Yamamoto, Masanori; Chevreul, Karine; Teiger, Emmanuel] CHU Henri Mondor, Dept Cardiol, F-94010 Creteil, France; [Yamamoto, Masanori] Toyohashi Heart Ctr, Dept Cardiol, Toyohashi, Aichi, Japan; [Eltchaninoff, Helene] CHU Rouen, Dept Cardiol, Rouen, France; [Leguerrier, Alain] CHU Rennes, Dept Cardiovasc Surg, Rennes, France; [Leprince, Pascal] CHU Pitie Salpetriere, Dept Cardiovasc Surg, Paris, France; [Laskar, Marc] CHU Dupuytren, Dept Cardiol, Limoges, France; [Iung, Bernard] CHU Bichat, Dept Cardiol, Paris, France; [Fajadet, Jean] Clin Pasteur, Dept Cardiol, Toulouse, France; [Prat, Alain] CHU Lille, Dept Cardiovasc Surg, F-59037 Lille, France; [Lievre, Michel] Univ Lyon 1, Dept Cardiol, F-69365 Lyon, France; [Donzeau-Gouge, Patrick] Inst Cardiovasc Paris Sud, Dept Cardiovasc Surg, Massy, France; [Gilard, Martine] CHU Brest, Dept Cardiol, F-29285 Brest, France	Morice, MC (reprint author), Inst Hosp Jacques Cartier, Dept Intervent Cardiol, 6 Ave Noyer Lambert, FR-91300 Massy, France.	mc.morice@icps.com.fr			Edwards Lifescience; Medtronic	FRANCE 2 registry was supported by Edwards Lifescience and Medtronic.	Eltchaninoff H, 2011, EUR HEART J, V32, P191, DOI 10.1093/eurheartj/ehq261; Tamburino C, 2012, AM J CARDIOL, V109, P1487, DOI 10.1016/j.amjcard.2012.01.364; Genereux P, 2014, J AM COLL CARDIOL, V63, P1100, DOI 10.1016/j.jacc.2013.10.058; Tchetche D, 2012, AM HEART J, V164, P402, DOI 10.1016/j.ahj.2012.07.003; Zahn R, 2011, EUR HEART J, V32, P198, DOI 10.1093/eurheartj/ehq339; Yamamoto M, 2013, J AM COLL CARDIOL, V62, P869, DOI 10.1016/j.jacc.2013.04.057; Gilard M, 2012, NEW ENGL J MED, V366, P1705, DOI 10.1056/NEJMoa1114705; Habib RH, 2005, CRIT CARE MED, V33, P1749, DOI 10.1097/01.CCM.0000171531.06133.B0; Leon MB, 2011, EUR HEART J, V32, P205, DOI 10.1093/eurheartj/ehq406; Nuis RJ, 2013, CIRC-CARDIOVASC INTE, V6, P625, DOI 10.1161/CIRCINTERVENTIONS.113.000409; Ohno Y, 2013, J AM COLL CARDIOL, V62, P1260, DOI 10.1016/j.jacc.2013.03.086; Moat NE, 2011, J AM COLL CARDIOL, V58, P2130, DOI 10.1016/j.jacc.2011.08.050; Nuis RJ, 2012, CIRC-CARDIOVASC INTE, V5, P680, DOI 10.1161/CIRCINTERVENTIONS.112.971291; Webb J, 2011, EUR HEART J, V32, P140, DOI 10.1093/eurheartj/ehq453; Silverberg DS, 2004, BLOOD PURIFICAT, V22, P277, DOI 10.1159/000078698; Leon MB, 2010, NEW ENGL J MED, V363, P1597, DOI 10.1056/NEJMoa1008232; Miceli A, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/1749-8090-9-137; Nutritional anaemias, 1968, WHO TECH REP SER, V405, P5; Previsdomini M, 2007, AM J CARDIOL, V100, P579, DOI 10.1016/j.amjcard.2007.03.065	19	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1522-1946	1522-726X		CATHETER CARDIO INTE	Catheter. Cardiovasc. Interv.	JUN	2015	85	7					1231	1239		10.1002/ccd.25832		9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CI8DU	WOS:000355000100027		
J	Hoshino, S; Kitano, M; Abe, T; Yazaki, S; Kagisaki, K				Hoshino, Shinsuke; Kitano, Masataka; Abe, Tadaaki; Yazaki, Satoshi; Kagisaki, Koji			Efficacy and safety of percutaneous transluminal balloon dilation to prevent progression of banding site stenosis after bilateral pulmonary artery banding	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS			English	Article						hypoplastic left heart syndrome; critical aortic stenosis; Norwood procedure; bidirectional Glenn procedure; Ross procedure	HYPOPLASTIC LEFT-HEART; NORWOOD PROCEDURE; RISK-FACTORS; STAGE-I; HYBRID; PALLIATION; EXPERIENCE; MORTALITY; OUTCOMES; STRATEGY	ObjectivesTo investigate the efficacy and safety of percutaneous transluminal balloon dilation (PTBD) for the treatment of bilateral pulmonary artery banding (bil-PAB) site stenosis. Background: Although bil-PAB is an alternative initial treatment for high-risk neonates with hypoplastic left heart syndrome (HLHS) or critical aortic stenosis (cAS), those patients often suffer from desaturation because of progressive stenosis of the bil-PAB sites during the interstage period. MethodsWe retrospectively evaluated the efficacy and safety of 11 consecutive PTBD procedures performed between 2006 and 2012 to treat bil-PAB site stenosis in four high-risk infants (three females) with HLHS or cAS. ResultsPTBD was repeated twice in two patients and three times in one patient over intervals. The mean balloon diameter (BD) and BD-to-band circumference (BC) ratio were 3.10.5 mm and 0.31 +/- 0.06, respectively. After the procedures, the mean minimum lumen diameter was dilated significantly from 1.1 +/- 0.1 mm to 1.7 +/- 0.3 mm (P<0.01), and the mean peripheral oxygen saturation increased significantly from 75 +/- 8% to 85 +/- 4% (P<0.01). All patients reached the next stage operation involving the Norwood & bidirectional Glenn or Ross procedure, after growth. No complications such as band rupture occurred. ConclusionsFor progressive stenosis of bil-PAB sites, PTBD using a balloon size that did not exceed the BC (BD around 30% of the BC) was an effective and safe procedure. (c) 2015 Wiley Periodicals, Inc.	[Hoshino, Shinsuke; Kitano, Masataka; Abe, Tadaaki; Yazaki, Satoshi] Natl Cerebral & Cardiovasc Ctr, Dept Pediat Cardiol, Suita, Osaka 5658565, Japan; [Kagisaki, Koji] Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Surg, Osaka, Japan	Kitano, M (reprint author), Natl Cerebral & Cardiovasc Ctr, Dept Pediat Cardiol, Fujishirodai 5-7-1, Suita, Osaka 5658565, Japan.	kitanom@ncvc.go.jp					Galantowicz M, 2005, PEDIATR CARDIOL, V26, P190, DOI 10.1007/s00246-004-0962-4; Bacha EA, 2006, J THORAC CARDIOV SUR, V131, P163, DOI 10.1016/j.jtcvs.2005.07.053; Guleserian KJ, 2013, J THORAC CARDIOV SUR, V145, P206, DOI 10.1016/j.jtcvs.2012.09.063; Stasik CN, 2006, J THORAC CARDIOV SUR, V131, P412, DOI 10.1016/j.jtcvs.2005.09.030; Sano S, 2004, ANN THORAC SURG, V78, P1951, DOI 10.1016/j.athoracsur.2004.05.055; Assad RS, 2007, ANN THORAC SURG, V84, P2081, DOI 10.1016/j.athoracsur.2007.05.004; Akintuerk H, 2002, CIRCULATION, V105, P1099, DOI 10.1161/hc0902.104709; Brown S, 2010, EUR J CARDIO-THORAC, V37, P296, DOI 10.1016/j.ejcts.2009.06.056; Knirsch W, 2012, EUR J CARDIO-THORAC, V42, P33, DOI 10.1093/ejcts/ezr286; Hirsch JC, 2012, ANN THORAC SURG, V94, P1365, DOI 10.1016/j.athoracsur.2012.05.135; Gaynor JW, 2002, EUR J CARDIO-THORAC, V22, P82, DOI 10.1016/S1010-7940(02)00198-7; Ashburn DA, 2003, J THORAC CARDIOV SUR, V125, P1070, DOI 10.1067/mtc.2003.183; Kaneko Y, 2014, J THORAC CARDIOV SUR, V147, P1984, DOI 10.1016/j.jtcvs.2014.01.042; Morgan GJ, 2009, CONGENIT HEART DIS, V4, P273, DOI 10.1111/j.1747-0803.2008.00233.x; Yoshimoto Akihiro, 2013, Gen Thorac Cardiovasc Surg, V61, P340, DOI 10.1007/s11748-013-0221-9	15	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1522-1946	1522-726X		CATHETER CARDIO INTE	Catheter. Cardiovasc. Interv.	JUN	2015	85	7					E197	E202		10.1002/ccd.25868		6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CI8DU	WOS:000355000100003		
J	Yoda, T; McNamara, KM; Miki, Y; Onodera, Y; Takagi, K; Nakamura, Y; Ishida, T; Suzuki, T; Ohuchi, N; Sasano, H				Yoda, Tomomi; McNamara, Keely May; Miki, Yasuhiro; Onodera, Yoshiaki; Takagi, Kiyoshi; Nakamura, Yasuhiro; Ishida, Takanori; Suzuki, Takashi; Ohuchi, Noriaki; Sasano, Hironobu			KLF15 in breast cancer: a novel tumor suppressor?	CELLULAR ONCOLOGY			English	Article						Breast cancer; Cell cycle; Immunohistochemistry; KLF15; Proliferation	KRUPPEL-LIKE FACTOR; CYCLIN-DEPENDENT KINASES; CELL-PROLIFERATION; TRANSCRIPTION FACTORS; PROGNOSTIC-FACTOR; STEM-CELLS; EXPRESSION; CARCINOMA; LOCALIZATION; PROGRESSION	Kruppel-like factor 15 (KLF15) is a transcription factor that is involved in various biological processes, including cellular proliferation, differentiation and death. In addition, KLF15 has recently been implicated in the development of several human malignancies, including breast cancer. In vitro breast cancer studies have pointed at a putative role in the regulation of cell proliferation. As yet, however, KLF15 expression analyses in primary human breast cancers have not been reported. Here, we set out to investigate the clinical and biological significance of KLF15 expression in human breast cancers. KLF15 expression was evaluated by immunohistochemistry in 54 primary invasive ductal breast carcinomas, and its status was correlated with various clinicopathological parameters. We also assessed KLF15 expression in vitro in 4 breast cancer-derived cell lines using Western blotting, and examined the effects of exogenous KLF15 expression on cell cycle progression using flow cytometry. Concomitant (changes in) p21, p27 and TOPO2A expression levels were examined using real-time RT-PCR and immunocytochemistry, respectively. In similar to 90 % of the primary breast carcinoma tissues tested, KLF15 was found to be expressed and localized in either the cytoplasm, the nucleus or both. Predominant nuclear immunoreactivity was found to be associated with clinicopathological factors predicting a better clinical outcome (i.e., ER positive, HER2 negative, low grade, low Ki-67 expression). The breast cancer-derived cell lines tested showed a low KLF15 expression with a predominant cytoplasmic localization. Subsequent exogenous KLF15 over-expression resulted in a predominant nuclear localization and a concomitant decreased cellular proliferation and an arrest at the G0/G1 phase of the cell cycle. In addition, we found that nuclear KLF15 expression results in up-regulation of p21, a pivotal suppressor of the G1 to S phase transition of the cell cycle. Our results indicate that nuclear KLF15 expression suppresses breast cancer cell proliferation at least partially through p21 up-regulation and subsequent cell cycle arrest. This is a first study addressing the role of KLF15 in breast cancer development.	[Yoda, Tomomi; McNamara, Keely May; Miki, Yasuhiro; Onodera, Yoshiaki; Nakamura, Yasuhiro; Sasano, Hironobu] Tohoku Univ, Dept Pathol, Sch Med, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Takagi, Kiyoshi; Suzuki, Takashi] Tohoku Univ, Dept Pathol, Sch Med, Sendai, Miyagi 9808575, Japan; [Takagi, Kiyoshi; Suzuki, Takashi] Tohoku Univ, Dept Histotechnol, Sch Med, Sendai, Miyagi 9808575, Japan; [Ishida, Takanori; Ohuchi, Noriaki] Tohoku Univ, Dept Surg, Sch Med, Sendai, Miyagi 9808575, Japan	McNamara, KM (reprint author), Tohoku Univ, Dept Pathol, Sch Med, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	kmcnamara@patholo2.med.tohoku.ac.jp			Japan Society for the Promotion of Science - Australian Academy of Science	Keely McNamara was supported partly by a Japan Society for the Promotion of Science - Australian Academy of Science postdoctoral fellowship. We would also like to acknowledge the support and assistance of the members of the Department of Pathology, Tohoku University School of Medicine and the Department of Disaster Obstetrics and Gynecology, International Research Institute of Disaster Science, Tohoku University.	Fernandez-Zapico ME, 2011, BIOCHEM J, V435, P529, DOI 10.1042/BJ20100773; Ray S, 2012, P NATL ACAD SCI USA, V109, pE1334, DOI 10.1073/pnas.1118515109; Takagi K, 2014, CANCER SCI, V105, P600, DOI 10.1111/cas.12382; Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260; Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591; de Groot JS, 2014, CELL ONCOL, V37, P297, DOI 10.1007/s13402-014-0189-1; Gray S, 2002, J BIOL CHEM, V277, P34322, DOI 10.1074/jbc.M201304200; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Skotheim RI, 2003, J CLIN ONCOL, V21, P4586, DOI 10.1200/JCO.2003.07.067; Tong D, 2006, CLIN CANCER RES, V12, P2442, DOI 10.1158/1078-0432.CCR-05-0964; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Takagi K, 2012, ENDOCR-RELAT CANCER, V19, P741, DOI 10.1530/ERC-12-0017; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Liu R, 2011, MOL ENDOCRINOL, V25, P1137, DOI 10.1210/me.2010-0497; Xia HJ, 2013, J BIOL CHEM, V288, P26731, DOI 10.1074/jbc.M113.483958; HARPER JW, 1993, CELL, V75, P805; Rask L, 2014, CELL ONCOL, V37, P215, DOI 10.1007/s13402-014-0176-6; McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009; Caldon CE, 2006, J CELL BIOCHEM, V97, P261, DOI 10.1002/jcb.20690; Pearson R, 2008, INT J BIOCHEM CELL B, V40, P1996, DOI 10.1016/j.biocel.2007.07.018; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Bureau C, 2009, CURR GENOMICS, V10, P353, DOI 10.2174/138920209788921010; Chen YJ, 2008, CANCER BIOL THER, V7, P777, DOI 10.4161/cbt.7.5.5768; Dai HY, 2005, CANCER RES, V65, P4059, DOI 10.1158/0008-5472.CAN-04-3953; Erdogan ASO, 2014, CELL ONCOL, V37, P289, DOI 10.1007/s13402-014-0185-5; Gehrau RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008929; Hartel M, 2008, EUR J CANCER, V44, P1895, DOI 10.1016/j.ejca.2008.06.030; Hong Q, 2012, CELL PHYSIOL BIOCHEM, V29, P893, DOI 10.1159/000178518; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Liu Y, 2013, BIOCHEM BIOPH RES CO, V436, P162, DOI 10.1016/j.bbrc.2013.05.067; Lu YA, 2010, ARTERIOSCL THROM VAS, V30, P1550, DOI 10.1161/ATVBAHA.110.207050; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806; Takagi K, 2010, ENDOCR-RELAT CANCER, V17, P415, DOI 10.1677/ERC-09-0257; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Wade HE, 2010, MOL CELL BIOL, V30, P1866, DOI 10.1128/MCB.01060-09; Wan SH, 2014, CELL ONCOL, V37, P363, DOI 10.1007/s13402-014-0197-1	37	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	2211-3428	2211-3436		CELL ONCOL	Cell. Oncol.	JUN	2015	38	3					227	235		10.1007/s13402-015-0226-8		9	Oncology; Cell Biology; Pathology	Oncology; Cell Biology; Pathology	CJ0SU	WOS:000355189100006		
J	Imura, N; Hirasawa, I				Imura, Naoko; Hirasawa, Izumi			Solubility Characteristics and Crystallization Behavior of Oxalic Acid in the Presence of Sulfuric Acid	CHEMICAL ENGINEERING & TECHNOLOGY			English	Article						Acidic wastewater; Aluminum sulfate; Cooling crystallization; Oxalic acid; Solubility; Sulfuric acid	DIFFUSION-DIALYSIS; RECOVERY	Acidic wastewater from industrial discharge is generally treated by neutralization. Before neutralization or water treatment, selective recovery of valuable compounds is necessary to reduce the environmental impact of this acid waste. As a contribution to the development of a novel acidic wastewater treatment, oxalic acid is set as target material which is found in acid waste from the metalworking industry. Crystallization of oxalic acid in the presence of sulfuric acid has rarely been reported. Since this acid waste also contains aluminum ions, the effect of sulfuric acid and aluminum ions on oxalic acid solubility and crystallization was clarified. As a result, sulfuric acid concentration affected the oxalic acid solubility, but aluminum ions had no influence. Oxalic acid was precipitated in columnar shape by cooling crystallization from sulfuric acid aqueous solution with aluminum ions.	[Imura, Naoko; Hirasawa, Izumi] Waseda Univ, Tokyo 1698555, Japan	Imura, N (reprint author), Waseda Univ, Shinjuku Ku, 3-4-1 Okubo, Tokyo 1698555, Japan.	naoko.imura@asagi.waseda.jp			Global COE Program for Practical Chemical Wisdom	This work was financially supported by the Global COE Program for Practical Chemical Wisdom.	Xu J, 2009, J HAZARD MATER, V165, P832, DOI 10.1016/j.jhazmat.2008.10.064; Lin SH, 1998, J HAZARD MATER, V60, P247, DOI 10.1016/S0304-3894(98)00099-5; Jeong J, 2005, J HAZARD MATER, V124, P230, DOI 10.1016/j.hazmat.2005.05.005; Kardum JP, 2013, CHEM ENG TECHNOL, V36, P1347, DOI 10.1002/ceat.201300221; Kim KJ, 2006, CHEM ENG TECHNOL, V29, P271, DOI 10.1002/ceat.200500383; Lin SH, 2003, J ENVIRON ENG-ASCE, V129, P472, DOI 10.1061/(ASCE)0733-9372(2003)129:5(472); RODRIGUEZHORNEDO N, 1986, J PHARM SCI, V75, P552, DOI 10.1002/jps.2600750606; Salgado JM, 2010, J SCI FOOD AGR, V90, P2168, DOI 10.1002/jsfa.4065; Shimamura K, 2006, J CHEM ENG JPN, V39, P1119, DOI 10.1252/jcej.39.1119; Shimizu Y, 2012, CHEM ENG TECHNOL, V35, P1051, DOI 10.1002/ceat.201100647; Shimizu Y, 2013, J CHEM ENG JPN, V46, P342, DOI 10.1252/jcej.12we282; Srinivasakannan C, 2002, CHEM BIOCHEM ENG Q, V16, P125	12	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0930-7516	1521-4125		CHEM ENG TECHNOL	Chem. Eng. Technol.	JUN	2015	38	6			SI		1042	1046		10.1002/ceat.201400710		5	Engineering, Chemical	Engineering	CJ1LQ	WOS:000355245500012		
J	Sonobe, Y; Watamura, H; Hirasawa, I				Sonobe, Yuko; Watamura, Hiroto; Hirasawa, Izumi			Polymorphism, Size and Shape Control of Calcium Carbonate Crystals in the Presence of a Polyelectrolyte	CHEMICAL ENGINEERING & TECHNOLOGY			English	Article						Chemical engineering; Crystallization; Polymorphism	CRYSTALLIZATION PHENOMENA; MORPHOLOGY; PARTICLES; PAA	The effects of the presence of a polyelectrolyte on the polymorphism and particle size and shape of calcium carbonate crystals during reactive crystallization were investigated. Crystals were created by the single-jet reaction crystallization method. When polyacrylic acid (PAA) was added, the polymorphism and particle size and shape were different for each molecular weight of PAA and each experimental method. When sodium carboxymethylcellulose was added, the polymorph became different from those made by adding PAA and the particle sizes and shapes were different for each concentration. As a result, it is suggested that the method to achieve supersaturation, such as type of feeding, feed rate, kinds of polyelectrolyte and their concentration, may affect the polymorphism and particle size and shape of calcium carbonate.	[Sonobe, Yuko; Watamura, Hiroto; Hirasawa, Izumi] Waseda Univ, Appl Chem, Tokyo 1698555, Japan	Sonobe, Y (reprint author), Waseda Univ, Appl Chem, Shinjyuku Ku, Tokyo 1698555, Japan.	yuko-sonobe@asagi.waseda.jp					Tang YM, 2008, DESALINATION, V228, P55, DOI 10.1016/j.desal.2007.08.006; Yu JG, 2004, J SOLID STATE CHEM, V177, P681, DOI 10.1016/j.jssc.2003.08.017; El-Sheikh SM, 2013, COLLOID SURFACE A, V422, P44, DOI 10.1016/j.colsurfa.2013.01.020; Euvrard M, 2011, J CRYST GROWTH, V317, P70, DOI 10.1016/j.jcrysgro.2011.01.006; Watamura H, 2013, J CRYST GROWTH, V373, P111, DOI 10.1016/j.jcrysgro.2012.10.060; Watamura H, 2014, CHEM ENG TECHNOL, V37, P1422, DOI 10.1002/ceat.201400017	6	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0930-7516	1521-4125		CHEM ENG TECHNOL	Chem. Eng. Technol.	JUN	2015	38	6			SI		1053	1058		10.1002/ceat.201400731		6	Engineering, Chemical	Engineering	CJ1LQ	WOS:000355245500014		
J	Akiba, H; Ichiji, M; Nagao, H; Hirasawa, I				Akiba, Hiroko; Ichiji, Masumi; Nagao, Hideyuki; Hirasawa, Izumi			Effect of Seeding and pH Conditions on the Size and Shape of Au Nanoparticles in Reduction Crystallization	CHEMICAL ENGINEERING & TECHNOLOGY			English	Article						Gold; Nanoparticle; pH; Particle size distribution; Seeding; Shape	PLASTID TRANSFORMATION; GOLD; PARTICLES; TOBACCO	Efficient and simple methods for gene integration into various plants have been studied by many researchers. The particle gun method using fine metal particles is one of the most potent technologies. However, it is difficult to control the particle size distribution and shape of the metal particles and, thus, to design and create adequate particles of suitable quality for the gene-supporting media. Here, reduction crystallization of nanometer- and submicron-sized Au was investigated in order to clarify the effects of the seeding and reaction conditions on the sizes and shapes of Au particles. The seed size has an influence on the surface roughness of the Au nanoparticles. Experiments to form Au particles were also performed using pH-controlled ascorbic acid. The pH has a great influence on the size and shape of nano/submicron Au particles and the mechanism of reduction crystallization.	[Akiba, Hiroko; Ichiji, Masumi; Nagao, Hideyuki; Hirasawa, Izumi] Waseda Univ, AES Appl Chem, Tokyo 1698555, Japan	Akiba, H (reprint author), Waseda Univ, AES Appl Chem, Shinjuku Ku, 3-4-1 Okubo, Tokyo 1698555, Japan.	hi-roko.a10@suou.waseda.jp			Waseda University	This paper has been supported financially by a research fund under a Waseda University Grant for Special Research Project.	Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+; Kida S, 2013, FRONT CHEM SCI ENG, V7, P60, DOI 10.1007/s11705-013-1313-x; KLEIN TM, 1987, NATURE, V327, P70, DOI 10.1038/327070a0; Sardar R, 2009, LANGMUIR, V25, P13840, DOI 10.1021/la9019475; Goia DV, 1999, COLLOID SURFACE A, V146, P139, DOI 10.1016/S0927-7757(98)00790-0; Goia DV, 1998, NEW J CHEM, V22, P1203, DOI 10.1039/a709236i; Faraday M., 1857, PHILOS T ROY SOC LON, V147, P145, DOI DOI 10.1098/RSTL.1857.0011; Hirasawa I, 2006, CHEM ENG TECHNOL, V29, P212, DOI 10.1002/ceat.200500355; KIKKERT JR, 1993, PLANT CELL TISS ORG, V33, P221, DOI 10.1007/BF02319005; Mikami T, 2010, CHEM ENG RES DES, V88, P1248, DOI 10.1016/j.cherd.2009.08.013; Okuzaki A, 2012, PLANT BIOTECHNOL-NAR, V29, P307, DOI 10.5511/plantbiotechnology.12.0319a; Okuzaki A, 2013, PLANT BIOTECHNOL-NAR, V30, P65, DOI 10.5511/plantbiotechnology.12.1227a; Wang LJ, 2014, CHEM ENG TECHNOL, V37, P1399, DOI 10.1002/ceat.201400207	13	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0930-7516	1521-4125		CHEM ENG TECHNOL	Chem. Eng. Technol.	JUN	2015	38	6			SI		1068	1072		10.1002/ceat.201400671		5	Engineering, Chemical	Engineering	CJ1LQ	WOS:000355245500016		
J	Kato, K; Fukuzawa, K; Mochizuki, Y				Kato, Koichiro; Fukuzawa, Kaori; Mochizuki, Yuji			Modeling of hydroxyapatite-peptide interaction based on fragment molecular orbital method	CHEMICAL PHYSICS LETTERS			English	Article							BINDING PEPTIDE; DYNAMICS SIMULATIONS; GLYCINE ADSORPTION; SURFACES; PROTEIN; SYSTEMS; SPECIFICITY; BIOLOGY; SCHEME; METAL	We have applied the four-body corrected fragment molecular orbital (FMO4) calculations to analyze the interaction between a designed peptide motif (Glu1-Ser2-Gln3-Glu4-Ser5) and the hydroxyapatite (HA) solid mimicked by a cluster model consisting of 1408 atoms. To incorporate statistical fluctuations, a total of 30 configurations were generated through classical molecular dynamics simulation with water molecules and were subjected to FMO4 calculations at the MP2 level. It was found that Ser5 plays a leading role in interacting with the phosphate moieties of HA via charge transfer and also that negatively charged Glu1 and Glu4 provide electrostatic stabilizations with the calcium ions. (C) 2015 Elsevier B.V. All rights reserved.	[Kato, Koichiro] Mizuho Informat & Res Inst Inc, Chiyoda Ku, Tokyo 1018442, Japan; [Fukuzawa, Kaori] Nihon Univ, Sch Dent Matsudo, Matsudo, Chiba 2718587, Japan; [Fukuzawa, Kaori; Mochizuki, Yuji] Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538505, Japan; [Mochizuki, Yuji] Rikkyo Univ, Dept Chem, Toshima Ku, Tokyo 1718501, Japan; [Mochizuki, Yuji] Rikkyo Univ, Res Ctr Smart Mol, Fac Sci, Toshima Ku, Tokyo 1718501, Japan	Mochizuki, Y (reprint author), Rikkyo Univ, Dept Chem, Toshima Ku, 3-34-1 Nishi Ikebukuro, Tokyo 1718501, Japan.	fukuzawa.kaori@nihon-u.ac; fullmoon@rikkyo.ac.jp			'Strategic Programs Innovative Research' (SPIRE) (Field 4 - Industrial Innovation) project at the Institute of Industrial Science (IIS) of the University of Tokyo; SFR-aid of Rikkyo University	This work was supported by the 'Strategic Programs Innovative Research' (SPIRE) (Field 4 - Industrial Innovation) project at the Institute of Industrial Science (IIS) of the University of Tokyo and also partly by the SFR-aid of Rikkyo University. KF and YM acknowledge Prof. Chisachi Kato (IIS) for his continuous encouragement and support. The authors are grateful to Dr. Kiyotaka Shiba (Japanese Foundation for Cancer Research) for fruitful discussions on this work in relation with his works [25,26]. Prof. Shigenori Tanaka (Kobe University) and Dr. Yoshio Okiyama (RIKEN, Yokohama) are acknowledged for helping of the SCIFIE evaluations [49]. Finally, YM thanks Dr. Yuto Komeiji for critical comments on the manuscript.	Almora-Barrios N, 2010, CRYSTENGCOMM, V12, P960, DOI 10.1039/b917179g; Almora-Barrios N, 2010, LANGMUIR, V26, P14535, DOI 10.1021/la101151e; Amari S, 2006, J CHEM INF MODEL, V46, P221, DOI 10.1021/ci050262q; Fedorov DG, 2012, PHYS CHEM CHEM PHYS, V14, P7562, DOI 10.1039/c2cp23784a; Nakano T, 2002, CHEM PHYS LETT, V351, P475, DOI 10.1016/S0009-2614(01)01416-6; Sano KI, 2003, J AM CHEM SOC, V125, P14234, DOI 10.1021/ja038414q; Corno M, 2010, PHYS CHEM CHEM PHYS, V12, P6309, DOI 10.1039/c002146f; Addison WN, 2010, BIOMATERIALS, V31, P9422, DOI 10.1016/j.biomaterials.2010.08.064; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P; Salomon-Ferrer R, 2013, WIRES COMPUT MOL SCI, V3, P198, DOI 10.1002/wcms.1121; Nakano T, 2012, CHEM PHYS LETT, V523, P128, DOI 10.1016/j.cplett.2011.12.004; Tanaka S, 2014, PHYS CHEM CHEM PHYS, V16, P10310, DOI 10.1039/c4cp00316k; Sarikaya M, 2003, NAT MATER, V2, P577, DOI 10.1038/nmat964; Gilbert PUPA, 2005, REV MINERAL GEOCHEM, V59, P157, DOI 10.2138/rmg.2005.59.7; Rimola A, 2008, J AM CHEM SOC, V130, P16181, DOI 10.1021/ja806520d; Watanabe C, 2013, J MOL GRAPH MODEL, V41, P31, DOI 10.1016/j.jmgm.2013.01.006; BROWN S, 1992, P NATL ACAD SCI USA, V89, P8651, DOI 10.1073/pnas.89.18.8651; Calderin L, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.134106; He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945; Segvich SJ, 2009, BIOMATERIALS, V30, P1287, DOI 10.1016/j.biomaterials.2008.11.008; Engel Y, 2012, MATER TODAY, V15, P478, DOI 10.1016/S1369-7021(12)70217-1; Gordon MS, 2012, CHEM REV, V112, P632, DOI 10.1021/cr200093j; Astala R, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.075427; Kitaura K, 1999, CHEM PHYS LETT, V313, P701, DOI 10.1016/S0009-2614(99)00874-X; Roy MD, 2008, ADV MATER, V20, P1830, DOI 10.1002/adma.200702322; Vallee A, 2010, ACCOUNTS CHEM RES, V43, P1297, DOI 10.1021/ar100017n; Rimola A, 2011, J PHYS CHEM LETT, V2, P1390, DOI 10.1021/jz200457x; Whaley SR, 2000, NATURE, V405, P665; REED AE, 1983, J CHEM PHYS, V78, P4066, DOI 10.1063/1.445134; Arakaki A, 2015, ORG BIOMOL CHEM, V13, P974, DOI 10.1039/c4ob01796j; Biswas S, 2013, J BIOMATER NANOBIOTE, V4, P351; Cohavi O, 2010, J MOL RECOGNIT, V23, P259, DOI 10.1002/jmr.993; de Leeuw NH, 2010, J MATER CHEM, V20, P5376, DOI 10.1039/b921400c; Gray JJ, 2004, CURR OPIN STRUC BIOL, V14, P110, DOI 10.1016/j.sbi.2003.12.001; Ishikawa T, 2006, CHEM PHYS LETT, V427, P159, DOI 10.1016/j.cplett.2006.06.103; Kang Y, 2010, J PHYS CHEM C, V114, P14496, DOI 10.1021/jp1037156; Latour R.A., 2008, BIOINTERPHASES, V3, P2; Miyoshi E, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1845392; Mochizuki Y, 2004, CHEM PHYS LETT, V396, P473, DOI 10.1016/j.cplett.2004.08.082; Mochizuki Y, 2008, CHEM PHYS LETT, V457, P396, DOI 10.1016/j.cplett.2008.03.090; Mochizuki Y, 2004, THEOR CHEM ACC, V112, P442, DOI 10.1007/s00214-004-0602-3; Nishiyama K, 2005, JPN J APPL PHYS 1, V44, P8210, DOI 10.1143/JJAP.44.8210; Okiyama Y, 2013, CHEM PHYS LETT, V566, P25, DOI 10.1016/j.cplett.2013.02.020; Szabo A., MODERN QUANTUM CHEM; Tanaka S, 2013, CHEM PHYS LETT, V556, P272, DOI 10.1016/j.cplett.2012.11.085; Tilocca A, 2009, P ROY SOC A-MATH PHY, V465, P1003, DOI 10.1098/rspa.2008.0462; Tsuji T, 2011, J CRYST GROWTH, V314, P190, DOI 10.1016/j.jcrysgro.2010.10.167; Tsuji T, 2010, CHEM COMMUN, V46, P6675, DOI 10.1039/c0cc01512a; Weiger MC, 2010, BIOMATERIALS, V31, P2955, DOI 10.1016/j.biomaterials.2010.01.012	49	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-2614	1873-4448		CHEM PHYS LETT	Chem. Phys. Lett.	JUN 1	2015	629						58	64		10.1016/j.cplett.2015.03.057		7	Chemistry, Physical; Physics, Atomic, Molecular & Chemical	Chemistry; Physics	CJ0DF	WOS:000355142700011		
J	Soya, T; Kim, W; Kim, D; Osuka, A				Soya, Takanori; Kim, Woojae; Kim, Dongho; Osuka, Atsuhiro			Stable [48]-, [50]-, and [52]Dodecaphyrins(1.1.0.1.1.0.1.1.0.1.1.0): The Largest Huckel Aromatic Molecules	CHEMISTRY-A EUROPEAN JOURNAL			English	Article						aromaticity; dodecaphyrins; expanded porphyrins; planar molecules; protonation	SUBSTITUTED EXPANDED PORPHYRINS; INDEPENDENT CHEMICAL-SHIFTS; GEOMETRIC CONTRIBUTIONS; CYCLOPOLYPYRROLES; MACROCYCLES; SEPARATION; CHEMISTRY	[52]Dodecaphyrin(1.1.0.1.1.0.1.1.0.1.1.0) was quantitatively oxidized with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to the corresponding [50]dodecaphyrin. Further oxidation of [50]dodecaphyrin with MnO2 quantitatively afforded [48]dodecaphyrin. Of the three, [50]dodecaphyrin showed Huckel aromatic character as the largest aromatic molecule reported to date. Protonation of [50]dodecaphyrin with methanesulfonic acid (MSA) led to the formation of a planar tetraprotonated species that displayed a sharp and intense Soret-like band at 906nm with epsilon=6.5x10(5)M(-1)cm(-1) and Q-band-like bands at 1346 and 1600nm.	[Soya, Takanori; Osuka, Atsuhiro] Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; [Kim, Woojae; Kim, Dongho] Yonsei Univ, Spect Lab Funct Elect Syst, Seoul 120749, South Korea; [Kim, Woojae; Kim, Dongho] Yonsei Univ, Dept Chem, Seoul 120749, South Korea	Kim, D (reprint author), Yonsei Univ, Spect Lab Funct Elect Syst, Seoul 120749, South Korea.	dongho@yonsei.ac.kr; osuka@kuchem.kyoto-u.ac.jp			JSPS KAKENHI [25220802, 25620031, 20705446]; Global Research Laboratory (GRL) Program of the Ministry of Education, Science, and Technology (MEST) of Korea [2013-8-1472]	The work in Kyoto was supported by JSPS KAKENHI Grant Numbers (25220802, 25620031, and 20705446). The work in Yonsei was supported by Global Research Laboratory (GRL) Program (2013-8-1472) of the Ministry of Education, Science, and Technology (MEST) of Korea.	Anand V. G., 2005, ANGEW CHEM, V117, P7410, DOI 10.1002/ange.200502769; Anand VG, 2005, ANGEW CHEM INT EDIT, V44, P7244, DOI 10.1002/anie.200502769; Osuka A, 2011, CHEM COMMUN, V47, P4330, DOI 10.1039/c1cc10534e; Krygowski TM, 1996, TETRAHEDRON, V52, P1713, DOI 10.1016/0040-4020(95)01007-6; Reddy JS, 2006, ORG LETT, V8, P5541, DOI 10.1021/ol062359j; Shimizu S, 2005, ANGEW CHEM INT EDIT, V44, P2225, DOI 10.1002/anie.200463054; Chandrashekar TK, 2003, ACCOUNTS CHEM RES, V36, P676, DOI 10.1021/ar020284n; Geuenich D, 2005, CHEM REV, V105, P3758, DOI 10.1021/cr0300901; Chen ZF, 2005, CHEM REV, V105, P3842, DOI 10.1021/cr030088+; Saito S, 2011, ANGEW CHEM INT EDIT, V50, P4342, DOI 10.1002/anie.201003909; Ishida S, 2014, ANGEW CHEM INT EDIT, V53, P3427, DOI 10.1002/anie.201400301; Shimizu S, 2006, CHEM-EUR J, V12, P4909, DOI 10.1002/chem.200600158; Krygowski TM, 1996, TETRAHEDRON, V52, P10255, DOI 10.1016/0040-4020(96)00560-1; Shin JY, 2010, CHEM SOC REV, V39, P2751, DOI 10.1039/b925417j; Sessler JL, 2003, ANGEW CHEM INT EDIT, V42, P5134, DOI 10.1002/anie.200200561; Stepien M, 2011, ANGEW CHEM INT EDIT, V50, P4288, DOI 10.1002/anie.201003353; Schleyer PV, 1996, J AM CHEM SOC, V118, P6317, DOI 10.1021/ja960582d; Shin JY, 2001, J AM CHEM SOC, V123, P7190, DOI 10.1021/ja0106624; Zhang Z, 2014, J AM CHEM SOC, V136, P7591, DOI 10.1021/ja503451m; Ishida S.- i., 2014, ANGEW CHEM, V126, P3495; Koide T, 2009, CHEM COMMUN, P6047, DOI 10.1039/b910167e; Lim JM, 2009, CHEM COMMUN, P261, DOI 10.1039/b810718a; Lim JM, 2010, J AM CHEM SOC, V132, P3105, DOI 10.1021/ja909744z; Saito S., 2008, ANGEW CHEM, V120, P9803, DOI 10.1002/ange.200804457; Saito S, 2008, ANGEW CHEM INT EDIT, V47, P9657, DOI 10.1002/anie.200804457; Saito S., 2011, ANGEW CHEM, V50, P4342, DOI DOI 10.1002/ANIE.201003909; Sessler J. L., 2003, ANGEW CHEM, V42, P5134, DOI 10.1002/ange.200200561; Setsune J, 2000, J AM CHEM SOC, V122, P12405, DOI 10.1021/ja005588o; Setsune J, 1999, J AM CHEM SOC, V121, P8957, DOI 10.1021/ja991669c; Shimizu S, 2006, EUR J INORG CHEM, P1319, DOI 10.1002/ejic.200501097; Shimizu S., 2005, ANGEW CHEM, V117, P2265, DOI 10.1002/ange.200463054; Shimizu S, 2008, CHEM-EUR J, V14, P2668, DOI 10.1002/chem.200701909; Stpien M., 2011, ANGEW CHEM, V723, P4376, DOI DOI 10.1002/ANIE.201003353; Tanaka Y, 2008, EUR J ORG CHEM, P1341, DOI 10.1002/ejoc.200701132; Turro N.J., 1991, MODERN MOL PHOTOCHEM; Yoneda T., 2014, ANGEW CHEM, V126, P13385, DOI DOI 10.1002/ANGE.201408506; Yoneda T, 2014, ANGEW CHEM INT EDIT, V53, P13169, DOI 10.1002/anie.201408506	37	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0947-6539	1521-3765		CHEM-EUR J	Chem.-Eur. J.	JUN 1	2015	21	23					8341	8346		10.1002/chem.201500650		6	Chemistry, Multidisciplinary	Chemistry	CJ1QV	WOS:000355260000004		
J	Saito, K; Chikkade, PK; Kanai, M; Kuninobu, Y				Saito, Kenta; Chikkade, Prasanna Kumara; Kanai, Motomu; Kuninobu, Yoichiro			Palladium-Catalyzed Construction of Heteroatom-Containing pi-Conjugated Systems by Intramolecular Oxidative C-H/C-H Coupling Reaction	CHEMISTRY-A EUROPEAN JOURNAL			English	Article						C-H activation; C-H/C-H coupling; heteroatom; palladium; pi-conjugated system	CARBON-HYDROGEN BONDS; ONE-POT SYNTHESIS; DEHYDROGENATIVE CYCLIZATION; ASYMMETRIC-SYNTHESIS; N-ARYLATION; DERIVATIVES; ACTIVATION; RHODIUM; HETEROARENES; ACCESS	Synthesis of heteroatom-containing ladder-type -conjugated molecules was successfully achieved via a palladium-catalyzed intramolecular oxidative CH/CH cross-coupling reaction. This reaction provides a variety of -conjugated molecules bearing heteroatoms, such as nitrogen, oxygen, phosphorus, and sulfur atoms, and a carbonyl group. The -conjugated molecules were synthesized efficiently, even in gram scale, and larger -conjugated molecules were also obtained by a double CH/CH cross-coupling reaction and successive oxidative cycloaromatization.	[Saito, Kenta; Chikkade, Prasanna Kumara; Kanai, Motomu; Kuninobu, Yoichiro] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; [Kanai, Motomu; Kuninobu, Yoichiro] ERATO Japan Sci & Technol Agcy JST, Kanai Life Sci Catalysis Project, Bunkyo Ku, Tokyo 1130033, Japan	Kanai, M (reprint author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kanai@mol.f.u-tokyo.ac.jp; kuninobu@mol.f.u-tokyo.ac.jp	Kuninobu, Yoichiro/N-5109-2015		ERATO from JST; Ministry of Education, Culture, Sports, Science, and Technology of Japan	This work was supported in part by ERATO from JST and the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Dong JX, 2013, ANGEW CHEM INT EDIT, V52, P580, DOI 10.1002/anie.201207196; Wencel-Delord J, 2013, NAT CHEM, V5, P369, DOI 10.1038/nchem.1607; Han W, 2011, SYNLETT, P1951, DOI 10.1055/s-0030-1260941; Malakar CC, 2011, ORG LETT, V13, P1378, DOI 10.1021/ol200065s; Kuninobu Y, 2013, ANGEW CHEM INT EDIT, V52, P1520, DOI 10.1002/anie.201207723; Oechsle P, 2014, ORG LETT, V16, P4086, DOI 10.1021/ol501752f; Yamaguchi S, 2003, J AM CHEM SOC, V125, P13662, DOI 10.1021/ja038487+; Xi PH, 2010, J AM CHEM SOC, V132, P1822, DOI 10.1021/ja909807f; Li Y, 2010, ORG BIOMOL CHEM, V8, P326, DOI 10.1039/b919396k; Wu JS, 2015, CHEM SOC REV, V44, P1113, DOI 10.1039/c4cs00250d; AKERMARK B, 1975, J ORG CHEM, V40, P1365, DOI 10.1021/jo00897a048; Pintori DG, 2011, J AM CHEM SOC, V133, P1209, DOI 10.1021/ja1090854; Li H, 2012, ORG LETT, V14, P4850, DOI 10.1021/ol302181z; Hull KL, 2007, J AM CHEM SOC, V129, P11904, DOI 10.1021/ja074395z; Nishino M, 2013, ANGEW CHEM INT EDIT, V52, P4457, DOI 10.1002/anie.201300587; Shintani R, 2012, J AM CHEM SOC, V134, P7305, DOI 10.1021/ja302278s; Watanabe T, 2009, J ORG CHEM, V74, P4720, DOI 10.1021/jo9003376; Morimoto K, 2012, ANGEW CHEM INT EDIT, V51, P5359, DOI 10.1002/anie.201201526; Wencel-Delord J, 2012, ANGEW CHEM INT EDIT, V51, P13001, DOI 10.1002/anie.201205734; Knolker HJ, 2009, CHEM LETT, V38, P8, DOI 10.1246/cl.2009.8; Scherf U, 1999, J MATER CHEM, V9, P1853, DOI 10.1039/a900447e; Chen RF, 2006, ORG LETT, V8, P203, DOI 10.1021/ol0524499; SHIOTANI A, 1974, ANGEW CHEM INT EDIT, V13, P471, DOI 10.1002/anie.197404711; Ureshino T, 2010, J AM CHEM SOC, V132, P14324, DOI 10.1021/ja107698p; Kitahara M, 2011, J AM CHEM SOC, V133, P2160, DOI 10.1021/ja111401h; Potavathri S, 2008, TETRAHEDRON LETT, V49, P4050, DOI 10.1016/j.tetlet.2008.04.073; Yeung CS, 2011, CHEM REV, V111, P1215, DOI 10.1021/cr100280d; Ma YH, 2013, CHEM-EUR J, V19, P1189, DOI 10.1002/chem.201203354; Stuart DR, 2007, SCIENCE, V316, P1172, DOI 10.1126/science.1141956; Qin XR, 2013, CHEM SCI, V4, P1964, DOI 10.1039/c3sc22241a; Ishida N, 2011, CHEM LETT, V40, P1047, DOI 10.1246/cl.2011.1047; Mochida K, 2009, J AM CHEM SOC, V131, P8350, DOI 10.1021/ja901622b; Li H, 2011, ORG LETT, V13, P276, DOI 10.1021/ol102688e; Do HQ, 2011, J AM CHEM SOC, V133, P13577, DOI 10.1021/ja2047717; Shimizu M, 2008, ANGEW CHEM INT EDIT, V47, P9760, DOI 10.1002/anie.200804146; Ackermann L, 2010, ORG LETT, V12, P2056, DOI 10.1021/ol1005517; Hirano K, 2012, CHEM COMMUN, V48, P10704, DOI 10.1039/c2cc34659a; Nishino M, 2012, ANGEW CHEM INT EDIT, V51, P6993, DOI 10.1002/anie.201201491; Gandeepan P, 2012, CHEM COMMUN, V48, P9379, DOI 10.1039/c2cc34344d; Izawa Y, 2010, ADV SYNTH CATAL, V352, P3223, DOI 10.1002/adsc.201000771; Takimiya K, 2011, ADV MATER, V23, P4347, DOI 10.1002/adma.201102007; Liu B, 2013, CHEM SCI, V4, P2163, DOI 10.1039/c3sc50348h; Xiao Q, 2014, ANGEW CHEM INT EDIT, V53, P3168, DOI 10.1002/anie.201310293; Fukazawa A, 2009, CHEM-ASIAN J, V4, P1386, DOI 10.1002/asia.200900179; Kuhl N, 2012, ANGEW CHEM INT EDIT, V51, P8230, DOI 10.1002/anie.201203792; DUBAC J, 1990, CHEM REV, V90, P215, DOI 10.1021/cr00099a008; Kuninobu Y, 2011, J ORG CHEM, V76, P7370, DOI 10.1021/jo201030j; Stuart DR, 2007, J AM CHEM SOC, V129, P12072, DOI 10.1021/ja0745862; Masui K, 2004, J AM CHEM SOC, V126, P5074, DOI 10.1021/ja031855p; Dwight TA, 2007, ORG LETT, V9, P3137, DOI 10.1021/ol071308z; Dong J., 2013, ANGEW CHEM, V125, P608; Guchhait SK, 2012, TETRAHEDRON LETT, V53, P3919, DOI 10.1016/j.tetlet.2012.05.076; Han W, 2011, ANGEW CHEM INT EDIT, V50, P2178, DOI 10.1002/anie.201006208; Kuhl N., 2012, ANGEW CHEM, V124, P8354, DOI DOI 10.1002/ANGE.201203792; Kuninobu Y., 2013, ANGEW CHEM, V125, P1560; Kuninobu Y, 2012, HETEROCYCLES, V85, P3029, DOI 10.3987/COM-12-12595; Liegault B., 2008, J ORG CHEM, V73, P5022; Meng G, 2012, CHEM COMMUN, V48, P9601, DOI 10.1039/c2cc34158a; Morimoto K., 2012, ANGEW CHEM, V124, P5455; Nishino M., 2012, ANGEW CHEM, V124, P7099; Nishino M., 2013, ANGEW CHEM, V125, P4553; Reddy VP, 2013, ORG BIOMOL CHEM, V11, P2249, DOI 10.1039/c3ob27396b; Shimizu M., 2008, ANGEW CHEM, V120, P9906, DOI 10.1002/ange.200804146; Shiotani A., 1974, ANGEW CHEM, V86, P478, DOI 10.1002/ange.19740861308; Sun MM, 2012, ADV SYNTH CATAL, V354, P835, DOI 10.1002/adsc.201100801; Watanabe T, 2007, CHEM COMMUN, P4516, DOI 10.1039/b707899d; Wencel-Delord J., 2012, ANGEW CHEM, V124, P13175, DOI DOI 10.1002/ANGE.201205734; Xiao Q., 2014, ANGEW CHEM, V126, P3232; You S.-L., 2009, TOP CURR CHEM, V292, P165	69	3	3	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0947-6539	1521-3765		CHEM-EUR J	Chem.-Eur. J.	JUN 1	2015	21	23					8365	8368		10.1002/chem.201501116		4	Chemistry, Multidisciplinary	Chemistry	CJ1QV	WOS:000355260000009		
J	Song, GY; Wang, BL; Nishiura, M; Hou, ZM				Song, Guoyong; Wang, Baoli; Nishiura, Masayoshi; Hou, Zhaomin			Catalytic C-H Bond Addition of Pyridines to Allenes by a Rare-Earth Catalyst	CHEMISTRY-A EUROPEAN JOURNAL			English	Article						alkenylation; allenes; C-H addition; pyridines; scandium	NICKEL/LEWIS ACID CATALYSIS; INSERTION REACTIONS; SELECTIVE ALKENYLATION; METAL-COMPLEXES; ACTIVATION; ALKYL; OLEFINS; FUNCTIONALIZATION; COPOLYMERIZATION; POLYMERIZATION	The catalytic CH addition of pyridines to allenes has been achieved for the first time by using a half-sandwich scandium catalyst, thus constituting a straightforward and atom-economical route for the synthesis of alkenylated pyridine derivatives. The reaction proceeded regio- and stereoselectively, affording a new family of alkenylated pyridine compounds which are otherwise difficult to synthesize. A cationic Sc-(2)-pyridyl species was isolated and confirmed to be a key catalyst species in this transformation.	[Song, Guoyong; Wang, Baoli; Nishiura, Masayoshi; Hou, Zhaomin] RIKEN, Organometall Chem Lab, Wako, Saitama 3510198, Japan; [Song, Guoyong; Wang, Baoli; Nishiura, Masayoshi; Hou, Zhaomin] RIKEN, Ctr Sustainable Resource Sci, Wako, Saitama 3510198, Japan	Hou, ZM (reprint author), RIKEN, Organometall Chem Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	houz@riken.jp	Song, Guoyong/C-9108-2011; Hou, Zhaomin/I-5981-2014	Hou, Zhaomin/0000-0003-2841-5120	Ministry of Education, Culture, Sports, Science and Technology of Japan [26220802]; RIKEN	Financial support by a grant-in-aid for scientific research (S) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 26220802) is gratefully acknowledged. G.S. thanks RIKEN for a FPR fellowship.	Andou T., 2013, ANGEW CHEM, V125, P3295; Ng SS, 2006, TETRAHEDRON, V62, P11350, DOI 10.1016/j.tet.2006.05.006; Le Bras J, 2014, CHEM SOC REV, V43, P3003, DOI 10.1039/c3cs60379b; Zeng R, 2013, J AM CHEM SOC, V135, P18284, DOI 10.1021/ja409861s; Kuang JQ, 2009, J ORG CHEM, V74, P1763, DOI 10.1021/jo802391x; Ye BH, 2013, J AM CHEM SOC, V135, P636, DOI 10.1021/ja311956k; Luo YJ, 2004, J AM CHEM SOC, V126, P13910, DOI 10.1021/ja046063p; Lewis JC, 2007, J AM CHEM SOC, V129, P5332, DOI 10.1021/ja070388z; Michael JP, 2005, NAT PROD REP, V22, P627, DOI 10.1039/b413750g; THOMPSON ME, 1987, J AM CHEM SOC, V109, P203, DOI 10.1021/ja00235a031; Hoffmann-Roder A, 2002, ANGEW CHEM INT EDIT, V41, P2933, DOI 10.1002/1521-3773(20020816)41:16<2933::AID-ANIE2933>3.0.CO;2-6; Nakao Y, 2010, J AM CHEM SOC, V132, P13666, DOI 10.1021/ja106514b; Lyons TW, 2010, CHEM REV, V110, P1147, DOI 10.1021/cr900184e; Ma SM, 2005, CHEM REV, V105, P2829, DOI 10.1021/cr020024j; Zhang LX, 2007, ANGEW CHEM INT EDIT, V46, P1909, DOI 10.1002/anie.200604348; Zhu G, 2002, J AM CHEM SOC, V124, P13658, DOI 10.1021/ja028512w; Ye MC, 2011, J AM CHEM SOC, V133, P6964, DOI 10.1021/ja2021075; Zhang YJ, 2009, ORG LETT, V11, P4248, DOI 10.1021/ol901759t; Tran DN, 2010, ANGEW CHEM INT EDIT, V49, P8181, DOI 10.1002/anie.201004179; JORDAN RF, 1989, J AM CHEM SOC, V111, P778, DOI 10.1021/ja00184a081; Takimoto M, 2009, J AM CHEM SOC, V131, P18266, DOI 10.1021/ja909126k; DEELMAN BJ, 1994, ORGANOMETALLICS, V13, P3881, DOI 10.1021/om00022a025; Kurth DG, 2006, SOFT MATTER, V2, P915, DOI 10.1039/b607485e; Li XF, 2009, J AM CHEM SOC, V131, P13870, DOI 10.1021/ja9056213; Wang HG, 2012, ANGEW CHEM INT EDIT, V51, P7318, DOI 10.1002/anie.201201273; Guan BT, 2013, ANGEW CHEM INT EDIT, V52, P4418, DOI 10.1002/anie.201208867; Tsai CC, 2010, J AM CHEM SOC, V132, P11887, DOI 10.1021/ja1061246; Nakao Y, 2008, J AM CHEM SOC, V130, P2448, DOI 10.1021/ja710766j; Oyamada J, 2012, ANGEW CHEM INT EDIT, V51, P12828, DOI 10.1002/anie.201206233; Colby DA, 2010, CHEM REV, V110, P624, DOI 10.1021/cr900005n; Andou T, 2013, ANGEW CHEM INT EDIT, V52, P3213, DOI 10.1002/anie.201208666; Guan BT, 2011, J AM CHEM SOC, V133, P18086, DOI 10.1021/ja208129t; Chen X, 2009, ANGEW CHEM INT EDIT, V48, P5094, DOI 10.1002/anie.200806273; Nishiura M, 2010, NAT CHEM, V2, P257, DOI 10.1038/nchem.595; Kuninobu Y, 2010, ORG LETT, V12, P4274, DOI 10.1021/ol101627x; Zeng R, 2012, J AM CHEM SOC, V134, P9597, DOI 10.1021/ja303790s; Holliday BJ, 2001, ANGEW CHEM INT EDIT, V40, P2022, DOI 10.1002/1521-3773(20010601)40:11<2022::AID-ANIE2022>3.0.CO;2-D; Bai T, 2009, COORDIN CHEM REV, V253, P423, DOI 10.1016/j.ccr.2008.04.003; Goriya Y, 2012, CHEM-EUR J, V18, P13288, DOI 10.1002/chem.201202379; Song GY, 2012, CHEM SOC REV, V41, P3651, DOI 10.1039/c2cs15281a; Arndt S., 2005, ORGANOMETALLICS, V24, P793; Chen X., 2009, ANGEW CHEM, V121, P5196; Duchateau R, 1997, ORGANOMETALLICS, V16, P5506, DOI 10.1021/om970540d; Guan B.-T., 2013, ANGEW CHEM, V125, P4514; GURAM AS, 1991, ORGANOMETALLICS, V10, P3470, DOI 10.1021/om00056a016; Hoffmann-Roder A., 2002, ANGEW CHEM, V114, P3057, DOI 10.1002/1521-3757(20020816)114:16<3057::AID-ANGE3057>3.0.CO;2-S; Holliday B. J., 2001, ANGEW CHEM, V113, P2076, DOI 10.1002/1521-3757(20010601)113:11<2076::AID-ANGE2076>3.3.CO;2-J; Li ZF, 2008, J ORGANOMET CHEM, V693, P3771, DOI 10.1016/j.jorganchem.2008.08.028; Luo G, 2012, ORGANOMETALLICS, V31, P3930, DOI 10.1021/om300147y; Murakami M, 2003, J AM CHEM SOC, V125, P4720, DOI 10.1021/ja029829z; Nakao Y, 2011, SYNTHESIS-STUTTGART, P3209, DOI 10.1055/s-0030-1260212; Oyamada J., 2012, ANGEW CHEM, V124, P13000; Ozerov OV, 2004, J AM CHEM SOC, V126, P2105, DOI 10.1021/ja036999i; Ramsden C. A., 2010, HDB HETEROCYCLIC CHE; RODEWALD S, 1994, J AM CHEM SOC, V116, P4491, DOI 10.1021/ja00089a054; Song G., 2014, J AM CHEM SOC; Tran D. N., 2013, ANGEW CHEM, V122, P8357; Wang H., 2012, ANGEW CHEM, V124, P7430, DOI DOI 10.1002/ANGE.201201273; Zhang L., 2007, ANGEW CHEM, V119, P1941, DOI 10.1002/ange.200604348	59	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0947-6539	1521-3765		CHEM-EUR J	Chem.-Eur. J.	JUN 1	2015	21	23					8394	8398		10.1002/chem.201501121		5	Chemistry, Multidisciplinary	Chemistry	CJ1QV	WOS:000355260000015		
J	Miyagawa, M; Yamaguchi, M				Miyagawa, Masamichi; Yamaguchi, Masahiko			Helicene-Grafted Silica Nanoparticles Capture Hetero-Double-Helix Intermediates during Self-Assembly Gelation	CHEMISTRY-A EUROPEAN JOURNAL			English	Article						gels; nanoparticles; precipitation; reactive intermediate; reaction mechanisms; self-assembly	PSEUDOENANTIOMERIC ETHYNYLHELICENE OLIGOMERS; MATRIX	A mixture of a pseudoenantiomeric ethynylhelicene (M)-tetramer and a (P)-pentamer forms a hetero-double-helix in a solution, which self-assembles and gelates solvents. When gelation was conducted in the presence of chiral silica (P)-nanoparticles grafted with (P)-helicene, the resulting hetero-double-helix intermediate was adsorbed on the (P)-nanoparticles, and was removed from the solution by aggregation and precipitation. The resulting precipitates contained only the hetero-double-helix, not random coil or clusters of the hetero-double-helix. (P)-Nanoparticles did not extract the hetero-double-helix from the self-assembly gels. The hetero-double-helix was then isolated by liberating it from the precipitates in 2-bromopropionic acid, and was crystallized from the solution. The crystalline hetero-double-helices were isolated for several other combinations of pseudoenantiomeric ethynylhelicene oligomers.	[Miyagawa, Masamichi; Yamaguchi, Masahiko] Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Organ Chem, Sendai, Miyagi 9808578, Japan	Yamaguchi, M (reprint author), Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Organ Chem, 6-3 Aoba, Sendai, Miyagi 9808578, Japan.	yama@m.tohoku.ac.jp			Japan Society for the Promotion of Science [21229001]; Japan Society for Young Japanese Scientists [25-7469]	Financial support from the Japan Society for the Promotion of Science (no. 21229001) is acknowledged. M.M. acknowledges a fellowship from the Japan Society for Young Japanese Scientists (no. 25-7469).	Amemiya R., 2010, ANGEW CHEM, V122, P2039; Amemiya R, 2010, ANGEW CHEM INT EDIT, V49, P1995, DOI 10.1002/anie.200906693; AULT BS, 1988, REV CHEM INTERMED, V9, P233; Wight AP, 2002, CHEM REV, V102, P3589, DOI 10.1021/cr010334m; Saito N, 2011, J ORG CHEM, V76, P4841, DOI 10.1021/jo200658q; Sugiura H, 2004, J AM CHEM SOC, V126, P14858, DOI 10.1021/ja0478882; Saito N, 2012, CHEM-EUR J, V18, P8994, DOI 10.1002/chem.201200280; Ichinose W, 2012, ORG LETT, V14, P3123, DOI 10.1021/ol301206r; FYFE CA, 1978, ACCOUNTS CHEM RES, V11, P277, DOI 10.1021/ar50127a004; Jung C, 2005, BIOCHEM BIOPH RES CO, V338, P355, DOI 10.1016/j.bbrc.2005.08.166; Kleiner CM, 2009, ORG BIOMOL CHEM, V7, P1397, DOI 10.1039/b820232j; Zou H, 2008, CHEM REV, V108, P3893, DOI 10.1021/cr068035q; Miyagawa M, 2014, CHEM-EUR J, V20, P1272, DOI 10.1002/chem.201303486; Graf C, 2012, LANGMUIR, V28, P7598, DOI 10.1021/la204913t; Fersht A., 1999, STRUCTURE MECH PROTE; Grove WS, 2004, HETEROCYCLES, V63, P1; Huang FH, 2011, J NANOPART RES, V13, P3885, DOI 10.1007/s11051-011-0342-y; Kemmitt T, 2009, INT J HYDROGEN ENERG, V34, P5726, DOI 10.1016/j.ijhydene.2009.05.108; Miyagawa M., TETRAHEDRON UNPUB; Orzechowski L, 2007, ORGANOMETALLICS, V26, P2144, DOI 10.1021/om070023n; Peng T, 2012, BIOMACROMOLECULES, V13, P699, DOI 10.1021/bm201587q; Roa AE, 2012, ORGANOMETALLICS, V31, P3185, DOI 10.1021/om3000554; Takamura M, 2012, J APPL POLYM SCI, V124, P3854, DOI 10.1002/app.35523; Tycko R, 2013, ACCOUNTS CHEM RES, V46, P1923, DOI 10.1021/ar300358z; Wentrup C, 1998, J PHYS ORG CHEM, V11, P350; Yamamoto K, 2012, LANGMUIR, V28, P11948, DOI 10.1021/la302759k	26	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0947-6539	1521-3765		CHEM-EUR J	Chem.-Eur. J.	JUN 1	2015	21	23					8408	+		10.1002/chem.201406482		8	Chemistry, Multidisciplinary	Chemistry	CJ1QV	WOS:000355260000002		
J	Schwab, MG; Takase, M; Mavrinsky, A; Pisula, W; Feng, XL; Gamez, JA; Thiel, W; Mali, KS; de Feyter, S; Mullen, K				Schwab, Matthias Georg; Takase, Masayoshi; Mavrinsky, Alexey; Pisula, Wojciech; Feng, Xinliang; Gamez, Jose A.; Thiel, Walter; Mali, Kunal S.; de Feyter, Steven; Muellen, Klaus			Torands Revisited: Metal Sequestration and Self-Assembly of Cyclo-2,9-tris-1,10-phenanthroline Hexaaza Macrocycles	CHEMISTRY-A EUROPEAN JOURNAL			English	Article						liquid crystals; macrocycles; phenanthrolines; scanning probe microscopy; self-assembly	SCANNING-TUNNELING-MICROSCOPY; SHAPE-PERSISTENT MACROCYCLES; COLUMNAR MESOPHASES; M-PHENYLENE; MAKROCYCLISCHEN BINDUNGSSYSTEMEN; SUPRAMOLECULAR CHEMISTRY; CRYSTAL-STRUCTURE; ZUR KONJUGATION; COMPLEXES; PHTHALOCYANINES	A series of novel toroidal cyclo-2,9-tris-1,10-phenanthroline macrocycles with an unusual hexaaza cavity are reported. Nickel-mediated Yamamoto aryl-aryl coupling was found to be a versatile tool for the cyclotrimerization of functionalized 1,10-phenathroline precursors. Due to the now improved processability, both liquid-crystalline behavior in the bulk phase and two-dimensional self-assembly at the molecular level could be studied, for the first time, for a torand system. The macrocycles exhibited a strong affinity for the complexation of different metal cations, as evidenced by MALDI-TOF analysis and spectroscopic methods. Experimental results were correlated to an extensive computational study of the cyclo-2,9-tris-1,10-phenanthroline cavity and its binding mode for metal cations. Due to the combination of several interesting features, toroidal macrocycles may find future applications in the field of ion and charge transport through molecular channels, as well as for chemical sensing and molecular writing in surface-confined monolayers under STM conditions.	[Schwab, Matthias Georg; Mavrinsky, Alexey; Pisula, Wojciech; Feng, Xinliang; Muellen, Klaus] Max Planck Inst Polymer Res, D-55128 Mainz, Germany; [Takase, Masayoshi] Tokyo Metropolitan Univ, Grad Sch Sci & Engn, Dept Chem, Hachioji, Tokyo 1920397, Japan; [Gamez, Jose A.] Rhein Westfal TH Aachen, Inst Tech & Macromol Chem, Div Tech Chem & Petr Chem, D-52074 Aachen, Germany; [Thiel, Walter] Max Planck Inst Kohlenforsch, D-45470 Mulheim, Germany; [Mali, Kunal S.; de Feyter, Steven] Katholieke Univ Leuven, B-3001 Louvain, Belgium	Mullen, K (reprint author), BASF SE, Carl Bosch Str 38, D-67056 Ludwigshafen, Germany.	muellen@mpip-mainz.mpg.de	Mali, Kunal/M-6879-2015		Graduate School Materials Science in Mainz; Alexander von Humboldt Foundation; Fund of Scientific Research-Flanders (FWO), KU Leuven [GOA 11/003]; Belgian Federal Science Policy Office [IAP-7/05]; DFG [SPP 1459, MU 334/36-1]; ERC NANOGRAPH [CNECT-ICT-604391]; European Union UPGRADE; European Union GENIUS; European Union MoQuaS	M.G.S. thanks the "Graduate School Materials Science in Mainz" for a scholarship. K.S.M. thanks the "Fonds Wetenschappelijk Onderzoek Vlaanderen". J.A.G. acknowledges the Alexander von Humboldt Foundation for a postdoctoral fellowship. K.S.M. and S.d.F. thank the Fund of Scientific Research-Flanders (FWO), KU Leuven (GOA 11/003), and Belgian Federal Science Policy Office (IAP-7/05) for financial support. This research was also funded by the DFG Priority Program SPP 1459, DFG Project MU 334/36-1, the ERC grant on NANOGRAPH, Graphene Flagship (No. CNECT-ICT-604391), and the European Union Projects UPGRADE, GENIUS, and MoQuaS.	YAMADA M, 1992, B CHEM SOC JPN, V65, P1006, DOI 10.1246/bcsj.65.1006; BENETOLLO F, 1989, INORG CHEM, V28, P3447, DOI 10.1021/ic00317a011; Tian LL, 2009, J AM CHEM SOC, V131, P17620, DOI 10.1021/ja906474z; Bencini A, 2010, COORDIN CHEM REV, V254, P2096, DOI 10.1016/j.crr.2010.04.008; KOZIAR JC, 1978, ACCOUNTS CHEM RES, V11, P334, DOI 10.1021/ar50129a003; Campagna S, 2007, TOP CURR CHEM, V280, P117, DOI 10.1007/128_2007_133; Herwig P, 1996, ADV MATER, V8, P510, DOI 10.1002/adma.19960080613; Zhang J, 2009, J AM CHEM SOC, V131, P11296, DOI 10.1021/ja9046735; VANNOSTRUM CF, 1994, ANGEW CHEM INT EDIT, V33, P2173, DOI 10.1002/anie.199421731; SAMMES PG, 1994, CHEM SOC REV, V23, P327, DOI 10.1039/cs9942300327; Cui K, 2015, CHEM-EUR J, V21, P1652, DOI 10.1002/chem.201405305; Hipps KW, 1996, J PHYS CHEM-US, V100, P11207, DOI 10.1021/jp960422o; Fu YY, 2007, EUR J ORG CHEM, P2459, DOI 10.1002/ejoc.200601086; Elemans JAAW, 2006, ADV MATER, V18, P1251, DOI 10.1002/adma.200502498; Jasat A, 1997, CHEM REV, V97, P2267, DOI 10.1021/cr950078b; Simpson CD, 2004, J MATER CHEM, V14, P494, DOI 10.1039/b312789c; STABEL A, 1995, ANGEW CHEM INT EDIT, V34, P1609, DOI 10.1002/anie.199516091; Zhang W, 2006, ANGEW CHEM INT EDIT, V45, P4416, DOI 10.1002/anie.200503988; VANDERPOL JF, 1990, MACROMOLECULES, V23, P155, DOI 10.1021/ma00203a027; Pisula W, 2005, CHEM MATER, V17, P4296, DOI 10.1021/cm050251c; Quici S, 2005, INORG CHEM, V44, P529, DOI 10.1021/ic0486466; Accorsi G, 2009, CHEM SOC REV, V38, P1690, DOI 10.1039/b806408n; Mali KS, 2013, PHYS CHEM CHEM PHYS, V15, P12495, DOI 10.1039/c3cp51074c; Beletskaya I, 2009, CHEM REV, V109, P1659, DOI 10.1021/cr800247a; BELL TW, 1993, PURE APPL CHEM, V65, P361, DOI 10.1351/pac199365030361; Lu X, 1996, J AM CHEM SOC, V118, P7197, DOI 10.1021/ja960874e; HENRY MS, 1979, J PHYS CHEM-US, V83, P618, DOI 10.1021/j100468a012; Schmaltz B, 2009, ANGEW CHEM INT EDIT, V48, P720, DOI 10.1002/anie.200803156; Chen YL, 2005, J AM CHEM SOC, V127, P15700, DOI 10.1021/ja054343e; Schwab MG, 2011, CHEM-ASIAN J, V6, P3001, DOI 10.1002/asia.201100258; Fischer M, 2004, J AM CHEM SOC, V126, P214, DOI 10.1021/ja038484x; Kaller M, 2010, CHEM-EUR J, V16, P6326, DOI 10.1002/chem.201000155; Huang JH, 2005, J ORG CHEM, V70, P5827, DOI 10.1021/jo050389e; Pisula W, 2007, CHEM-ASIAN J, V2, P51, DOI 10.1002/asia.200600338; Lu X, 1997, J PHYS CHEM B, V101, P5391, DOI 10.1021/jp9707448; Jousselme B, 2003, J AM CHEM SOC, V125, P1363, DOI 10.1021/ja026819p; ARMAROLI N, 1993, J CHEM SOC DALTON, P3241, DOI 10.1039/dt9930003241; Baxter PNW, 2004, J ORG CHEM, V69, P1813, DOI 10.1021/jo0302410; Beginn U, 2000, ADV MATER, V12, P513, DOI 10.1002/(SICI)1521-4095(200004)12:7<513::AID-ADMA513>3.0.CO;2-S; BEHR JP, 1982, NATURE, V295, P526, DOI 10.1038/295526a0; Bell T. W., 1992, ANGEW CHEM, V104, P321, DOI 10.1002/ange.19921040319; Bell T. W., 1992, ANGEW CHEM, V104, P319, DOI 10.1002/ange.19921040318; BELL TW, 1986, J AM CHEM SOC, V108, P8109, DOI 10.1021/ja00285a049; BELL TW, 1987, J INCLUSION PHENOM, V5, P149, DOI 10.1007/BF00655638; BELL TW, 1984, J AM CHEM SOC, V106, P6111, DOI 10.1021/ja00332a076; BELL TW, 1992, ANGEW CHEM INT EDIT, V31, P348, DOI 10.1002/anie.199203481; BELL TW, 1991, J AM CHEM SOC, V113, P3115, DOI 10.1021/ja00008a046; BELL TW, 1992, ANGEW CHEM INT EDIT, V31, P345, DOI 10.1002/anie.199203451; BOGUSLAVSKY L, 1994, LANGMUIR, V10, P991, DOI 10.1021/la00016a004; BRAUNLIN.H, 1967, CHEM BER-RECL, V100, P880, DOI 10.1002/cber.19671000323; DREW MGB, 1979, J CHEM SOC CHEM COMM, P1033, DOI 10.1039/c39790001033; Grave C, 2002, EUR J ORG CHEM, P3075; HONEYBOU.CL, 1973, TETRAHEDRON, V29, P1549, DOI 10.1016/S0040-4020(01)83396-2; Kaller M, 2009, CHEM-EUR J, V15, P9530, DOI 10.1002/chem.200901173; LEHN JM, 1985, J CHEM SOC CHEM COMM, P1794, DOI 10.1039/c39850001794; Mali KS, 2013, CHEM-ASIAN J, V8, P2497, DOI 10.1002/asia.201300689; Marin L, 2015, J ORG CHEM, V80, P2425, DOI 10.1021/jo502771a; McSkimming A, 2014, CHEM-ASIAN J, V9, P136, DOI 10.1002/asia.201301053; MEYER H, 1969, LIEBIGS ANN CHEM, V724, P30; NEWKOME GR, 1983, J AM CHEM SOC, V105, P5956, DOI 10.1021/ja00356a061; PERCEC V, 1993, J CHEM SOC PERK T 1, P1411, DOI 10.1039/p19930001411; Rahman MJ, 2008, J ORG CHEM, V73, P5542, DOI 10.1021/jo800787u; RANSOHOFF JEB, 1985, TETRAHEDRON LETT, V26, P6179; Schmaltz B., 2009, ANGEW CHEM, V121, P734, DOI DOI 10.1002/ANGE.200803156; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; STAAB HA, 1965, TETRAHEDRON LETT, P45; STAAB HA, 1976, CHEM BER-RECL, V109, P3875, DOI 10.1002/cber.19761091216; Stabel A., 1995, ANGEW CHEM, V107, P1768; Tahara K., 2010, CHEM COMMUN, V46, P9125; TONER JL, 1983, TETRAHEDRON LETT, V24, P2707, DOI 10.1016/S0040-4039(00)88001-6; vanNostrum CF, 1996, CHEM COMMUN, P2385, DOI 10.1039/cc9960002385; van Nostrum C. F., 1994, ANGEW CHEM, V106, P2298, DOI 10.1002/ange.19941062123; Yamamoto T, 1999, B CHEM SOC JPN, V72, P621, DOI 10.1246/bcsj.72.621; YAMAMOTO T, 1992, PROG POLYM SCI, V17, P1153, DOI 10.1016/0079-6700(92)90009-N; Zhang W., 2006, ANGEW CHEM, V778, P4524, DOI 10.1002/ange.200503988; Zhao DH, 2003, CHEM COMMUN, P807, DOI 10.1039/b207442g; Zhao DH, 2002, J ORG CHEM, V67, P3548, DOI 10.1021/jo010918o; Zophel L., 2012, CHEM-EUR J, V18, P3264	78	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0947-6539	1521-3765		CHEM-EUR J	Chem.-Eur. J.	JUN 1	2015	21	23					8426	8434		10.1002/chem.201406602		9	Chemistry, Multidisciplinary	Chemistry	CJ1QV	WOS:000355260000019		
J	Galangau, O; Nakashima, T; Maurel, F; Kawai, T				Galangau, Olivier; Nakashima, Takuyama; Maurel, Francois; Kawai, Tsuyoshi			Substituent Effects on the Photochromic Properties of Benzothiophene-Based Derivatives	CHEMISTRY-A EUROPEAN JOURNAL			English	Article						arylation; helical structures; isomerization; photochromism; substituent effects	N-HETEROCYCLIC CARBENES; DIARYLETHENE DERIVATIVES; EUROPIUM(III) COMPLEX; TRIANGLE TERARYLENES; GATED PHOTOCHROMISM; QUANTUM YIELDS; ETHENE BRIDGE; MOLECULES; SWITCHES; LIGHT	Five diarylethene photochromic derivatives, the structures of which incorporate a central benzothiophene unit, a left-hand thiazole group, and a right-hand benzothiophene group, have been prepared. The compound with a thiazole unit with no substituent on the reaction-center carbon atom reveals an unprecedented transformation upon light irradiation. When the 4-position of thiazole is protected by a methyl group, the compounds show high photosensitivity and photochromic properties. In this case, light irradiation affords new compounds with [5]helicene structures featuring the highest redshifted absorption maxima reported to date.	[Galangau, Olivier; Nakashima, Takuyama; Kawai, Tsuyoshi] Ctr Frontier Sci & Technol NAIST CEMES, Int Collaborat Lab, F-31055 Toulouse, France; [Galangau, Olivier; Kawai, Tsuyoshi] NAIST, Nara Inst Sci & Technol, Grad Sch Mat Sci, Nara 6300192, Japan; [Maurel, Francois] Univ Paris 07, Lab Interfaces Traitements Org & Dynam Syst ITODY, CNRS UMR 7086, Sorbonne Paris Cite, F-75205 Paris 13, France	Galangau, O (reprint author), Ctr Frontier Sci & Technol NAIST CEMES, Int Collaborat Lab, 29 Rue Jeanne Marvig,BP 94347, F-31055 Toulouse, France.	o-galangau@ms.naist.jp; tkawai@ms.naist.jp			Japan Society for Promotion of Science (JSPS); Centre National de la Recherche Scientifique (CNRS)	We thank the Japan Society for Promotion of Science (JSPS) and the Centre National de la Recherche Scientifique (CNRS) for their financial support. A part of the present study has been supported with a Grant-in-Aid for Scientific Research on Priority-Area, Photosynergetics.	Aloise S, 2013, PHYS CHEM CHEM PHYS, V15, P6226, DOI 10.1039/c3cp43806f; Morimitsu K, 2002, J ORG CHEM, V67, P4574, DOI 10.1021/jo020114o; [Anonymous], 2011, ANGEW CHEM; Wigglesworth TJ, 2005, J AM CHEM SOC, V127, P7272, DOI 10.1021/ja050190j; Gostl R, 2012, CHEM-EUR J, V18, P14282, DOI 10.1002/chem.201203111; Morinaka K, 2009, ORG LETT, V11, P3890, DOI 10.1021/ol901497t; Nakagawa H, 2009, ORG LETT, V11, P1475, DOI 10.1021/ol802969b; Szaloki G, 2014, J AM CHEM SOC, V136, P13510, DOI 10.1021/ja506320j; Neilson BM, 2011, ANGEW CHEM INT EDIT, V50, P10322, DOI 10.1002/anie.201105032; Tian H, 2004, CHEM SOC REV, V33, P85, DOI 10.1039/b302356g; Fukaminato T, 2007, J AM CHEM SOC, V129, P5932, DOI 10.1021/ja069131b; de Meijere A, 2007, CHEM-EUR J, V13, P2503, DOI 10.1002/chem.200601316; [Anonymous], 1971, PHOTOCHROMISM; Poon CT, 2011, J AM CHEM SOC, V133, P19622, DOI 10.1021/ja208097a; Nakagawa T, 2008, J PHYS CHEM A, V112, P5096, DOI 10.1021/jp712079n; Fukaminato T, 2004, J AM CHEM SOC, V126, P14843, DOI 10.1021/ja047169n; Nitadori H, 2012, CHEM COMMUN, V48, P10395, DOI 10.1039/c2cc34999j; Taguchi M, 2011, J MATER CHEM, V21, P17425, DOI 10.1039/c1jm12993g; Nakashima T, 2007, EUR J ORG CHEM, P3212, DOI 10.1002/ejoc.200700074; Chen SJ, 2012, J AM CHEM SOC, V134, P13596, DOI 10.1021/ja306748k; Chen SJ, 2012, J MATER CHEM, V22, P5486, DOI 10.1039/c2jm14973g; Beydoun K, 2012, CHEM COMMUN, V48, P11951, DOI 10.1039/c2cc37046h; Delaire JA, 2000, CHEM REV, V100, P1817, DOI 10.1021/cr980078m; Liegault B, 2010, J ORG CHEM, V75, P1047, DOI 10.1021/jo902515z; Ogawa H, 2012, CHEM COMMUN, V48, P11838, DOI 10.1039/c2cc35793c; Fukumoto S, 2011, ANGEW CHEM INT EDIT, V50, P1565, DOI 10.1002/anie.201006844; Lvov AG, 2014, ORG LETT, V16, P4532, DOI 10.1021/ol502073t; Delbaere S, 2012, J ORG CHEM, V77, P1853, DOI 10.1021/jo202466g; Irie M, 2002, NATURE, V420, P759, DOI 10.1038/420759a; Nakashima T, 2008, J AM CHEM SOC, V130, P14570, DOI 10.1021/ja802986y; Li WL, 2014, ANGEW CHEM INT EDIT, V53, P4603, DOI 10.1002/anie.201310438; Sanz R, 2010, J ORG CHEM, V75, P7443, DOI 10.1021/jo101436f; KARIKOMI M, 1995, J AM CHEM SOC, V117, P6791, DOI 10.1021/ja00130a024; Johnson ER, 2010, J AM CHEM SOC, V132, P6498, DOI 10.1021/ja100936w; Yokoyama Y, 2000, CHEM REV, V100, P1717, DOI 10.1021/cr980070c; Nakagawa T, 2007, CHEM LETT, V36, P372, DOI 10.1246/cl.2007.372; Ouhenia-Ouadahi K, 2014, CHEM COMMUN, V50, P7299, DOI 10.1039/c4cc02179g; Zhu WH, 2011, ANGEW CHEM INT EDIT, V50, P10986, DOI 10.1002/anie.201105136; Irie M, 2014, CHEM REV, V114, P12174, DOI 10.1021/cr500249p; Fukumoto S, 2012, DYES PIGMENTS, V92, P868, DOI 10.1016/j.dyepig.2011.05.027; Norel L, 2010, ANGEW CHEM INT EDIT, V49, P99, DOI 10.1002/anie.200905099; Massaad J, 2012, CHEM-EUR J, V18, P6568, DOI 10.1002/chem.201103896; Jeong YC, 2005, CHEM COMMUN, P2503, DOI 10.1039/b501324k; Uno K, 2011, J AM CHEM SOC, V133, P13558, DOI 10.1021/ja204583e; Lee PHM, 2007, J AM CHEM SOC, V129, P6058, DOI 10.1021/ja067425r; Yuan KD, 2014, CHEM-EUR J, V20, P10073, DOI 10.1002/chem.201402768; Wong HL, 2012, ORG LETT, V14, P1862, DOI 10.1021/ol3004595; Yam VWW, 2009, J AM CHEM SOC, V131, P912, DOI 10.1021/ja808791e; Shen Y, 2012, CHEM REV, V112, P1463, DOI 10.1021/cr200087r; Kose M, 2013, J PHOTOCH PHOTOBIO A, V257, P50, DOI 10.1016/j.jphotochem.2013.01.012; Guerchais V, 2010, COORDIN CHEM REV, V254, P2533, DOI 10.1016/j.ccr.2010.01.013; Neilson BM, 2012, J AM CHEM SOC, V134, P12693, DOI 10.1021/ja304067k; Atsumi K., 2009, EUR J ORG CHEM, P3112; Balzani V., 2003, MOL DEVICES MACHINES; Chan J. C.-H., 2013, ANGEW CHEM, V125, P11718; Chan JCH, 2013, ANGEW CHEM INT EDIT, V52, P11504, DOI 10.1002/anie.201304827; Chen JD, 2010, CHEM-EUR J, V16, P11843, DOI 10.1002/chem.201001655; Durr H., 1990, STUDIES ORGANIC CHEM, V40; Erko FG, 2013, TETRAHEDRON LETT, V54, P6366, DOI 10.1016/j.tetlet.2013.09.063; Galangau O, 2014, EUR J ORG CHEM, P7165, DOI 10.1002/ejoc.201402774; Gostl R, 2014, ANGEW CHEM INT EDIT, V53, P8784, DOI 10.1002/anie.201310626; Hasegawa Y, 2010, COORDIN CHEM REV, V254, P2643, DOI 10.1016/j.ccr.2009.12.036; Heynderickx A, 2002, SYNTHESIS-STUTTGART, P213; Irie M., 2000, CHEM REV, V100, P1684; Ito N, 2014, ORG LETT, V16, P2502, DOI 10.1021/ol5008718; Jeong YC, 2009, TETRAHEDRON LETT, V50, P5288, DOI 10.1016/j.tetlet.2009.07.028; Kobatake S., 2005, ANGEW CHEM, V117, P2186, DOI 10.1002/ange.200462426; Kobatake S, 2005, ANGEW CHEM INT EDIT, V44, P2148, DOI 10.1002/anie.200462426; Kutsunugi Y, 2009, NEW J CHEM, V33, P1368, DOI 10.1039/b823413b; Lucas LN, 2003, EUR J ORG CHEM, P155; Meng F., 2013, NAT COMMUN, V5, P3023; Nakamura S, 2007, J PHYS ORG CHEM, V20, P821, DOI 10.1002/poc.1245; Nishi H, 2011, J MATER CHEM, V21, P17249, DOI 10.1039/c1jm12707a; Norel L., 2010, ANGEW CHEM, V122, P103; Norsten TB, 2001, J AM CHEM SOC, V123, P7447, DOI 10.1021/ja015988r; Okuyama T, 2007, J ORG CHEM, V72, P1634, DOI 10.1021/jo0620213; SHOJI H, 2014, CHEM COMMUN, V38, P933; Szaloki G, 2013, CHEM-EUR J, V19, P11124, DOI 10.1002/chem.201301645; Taguchi M, 2013, CHEM COMMUN, V49, P6373, DOI 10.1039/c3cc41825a; Takami S, 2002, EUR J ORG CHEM, P3796; Naraso, 2008, MACROMOLECULES, V41, P3169, DOI 10.1021/ma071857k; Zhu W. H., 2011, ANGEW CHEM, V123, P11178	82	2	2	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0947-6539	1521-3765		CHEM-EUR J	Chem.-Eur. J.	JUN 1	2015	21	23					8471	8482		10.1002/chem.201500647		12	Chemistry, Multidisciplinary	Chemistry	CJ1QV	WOS:000355260000025		
J	Yamasaki, F; Takayasu, T; Nosaka, R; Kenjo, M; Akiyama, Y; Tominaga, A; Sugiyama, K; Kobayashi, M; Kurisu, K				Yamasaki, Fumiyuki; Takayasu, Takeshi; Nosaka, Ryo; Kenjo, Masahiro; Akiyama, Yuji; Tominaga, Atsushi; Sugiyama, Kazuhiko; Kobayashi, Masao; Kurisu, Kaoru			The postirradiation incidence of cavernous angioma is higher in patients with childhood pineoblastoma or primitive neuroectodermal tumors than medulloblastoma	CHILDS NERVOUS SYSTEM			English	Article						Pineoblastoma; Primitive neuroectodermal tumors; Medulloblastoma; Cavernous angioma	LONG-TERM SURVIVORS; ENDOTHELIAL GROWTH-FACTOR; RADIATION-INDUCED TELANGIECTASIA; CRYPTIC VASCULAR MALFORMATIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; NERVOUS-SYSTEM NEOPLASIA; PEDIATRIC BRAIN-TUMORS; CRANIAL IRRADIATION; NATURAL-HISTORY; CHILDREN	The purpose of this study is to investigate the incidence of cavernous angioma (CVA) in long-term survivors of childhood embryonal tumors treated by cranial irradiation. Between 1990 and 2012, we treated 25 patients (13 males, 12 females) with embryonal tumors (17 medulloblastomas, 5 primitive neuroectodermal tumors (PNET), 3 pineoblastomas) with craniospinal irradiation. Follow-up ranged from 15.5 to 289.9 months, the irradiation dose to the whole neural axis from 18 to 36 Gy, and the total local dose from 49.6 to 60 Gy. All patients underwent follow-up magnetic resonance imaging (MRI) studies at least once a year, and the diagnosis of posttreatment CVA was based solely on MRI findings. At the time of this writing, 18 were alive and free of the recurrence of the original disease or the development of secondary neoplasms other than CVA; another 2 were alive with medulloblastoma or diffuse astrocytoma. Posttreatment, 14 patients developed CVAs in the course of a median of 56.7 months; 13 of these presented with multiple CVAs. Patients who underwent radiation therapy (RT) at an age younger than 6 years developed multiple CVAs significantly earlier than those treated at a later age (p = 0.0110). Patients with PNET or pineoblastoma developed Zabramski type 1 and 2 CVA significantly earlier than did medulloblastoma patients (p = 0.0042). We attribute the high rate of post-RT CVA in our long-term follow-up study of pediatric patients to the delivery of cranial irradiation for embryonal tumors, especially PNET and pineoblastoma, and recommend the regular, long-term follow-up of patients whose embryonal tumors were treated by cranial irradiation.	[Yamasaki, Fumiyuki; Takayasu, Takeshi; Nosaka, Ryo; Tominaga, Atsushi; Kurisu, Kaoru] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Neurosurg, Minami Ku, Hiroshima 7348551, Japan; [Sugiyama, Kazuhiko] Hiroshima Univ Hosp, Dept Clin Oncol, Hiroshima 7348551, Japan; [Sugiyama, Kazuhiko] Hiroshima Univ Hosp, Neurooncol Program, Hiroshima 7348551, Japan; [Kobayashi, Masao] Hiroshima Univ, Grad Sch Biomed Sci, Dept Pediat, Hiroshima 7348551, Japan; [Kenjo, Masahiro] Hiroshima Univ, Grad Sch Biomed Sci, Dept Radiat Oncol, Hiroshima 7348551, Japan; [Akiyama, Yuji] Hiroshima Univ Hosp, Dept Clin Radiol, Hiroshima 7348551, Japan	Yamasaki, F (reprint author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Neurosurg, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	fyama@hiroshima-u.ac.jp			Japanese Society of Neuroradiology; Japan Society for the Promotion of Science [25462262]	We thank Ursula Petralia for editorial review. This study was supported by a research grant from the Japanese Society of Neuroradiology and a grant-in-aid from the Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C) number 25462262.	Alexander MJ, 1998, J NEUROSURG, V88, P111, DOI 10.3171/jns.1998.88.1.0111; Humpl T, 1997, EUR J PEDIATR, V156, P367, DOI 10.1007/s004310050616; von Hoff K, 2009, EUR J CANCER, V45, P1209, DOI 10.1016/j.ejca.2009.01.015; Amirjamshidi A, 2000, CHILD NERV SYST, V16, P390, DOI 10.1007/s003819900125; Heckl S, 2002, CANCER, V94, P3285, DOI 10.1002/cncr.10596; Tsao MN, 1999, J NEUROPATH EXP NEUR, V58, P1051, DOI 10.1097/00005072-199910000-00003; Burn S, 2007, J NEUROSURG, V106, P379, DOI 10.3171/ped.2007.106.5.379; Peters S, 2013, NEURORADIOLOGY, V55, P853, DOI 10.1007/s00234-013-1185-2; POUSSAINT TY, 1995, AM J NEURORADIOL, V16, P693; Bergametti F, 2005, AM J HUM GENET, V76, P42, DOI 10.1086/426952; Moriarity JL, 1999, NEUROSURGERY, V44, P1166, DOI 10.1097/00006123-199906000-00003; ALLEN JC, 1991, NEUROLOGY, V41, P148; Baumgartner JE, 2003, PEDIATR NEUROSURG, V39, P201, DOI 10.1159/000072472; GAENSLER EHL, 1994, RADIOLOGY, V193, P629; Frange P, 2009, J NEURO-ONCOL, V95, P271, DOI 10.1007/s11060-009-9927-z; Larson JJ, 1998, J NEUROSURG, V88, P51, DOI 10.3171/jns.1998.88.1.0051; Vinchon M, 2011, CHILD NERV SYST, V27, P445, DOI 10.1007/s00381-011-1390-4; Koike S, 2004, RADIOLOGY, V230, P93, DOI 10.1148/radiol.2301021143; Rivard A, 2000, J BIOL CHEM, V275, P29643, DOI 10.1074/jbc.M001029200; ZABRAMSKI JM, 1994, J NEUROSURG, V80, P422, DOI 10.3171/jns.1994.80.3.0422; BITZER M, 1995, STROKE, V26, P131; BALL WS, 1992, AM J NEURORADIOL, V13, P761; Bejjani GK, 1997, ACTA NEUROCHIR, V139, P583, DOI 10.1007/BF02751004; Brunereau L, 2000, RADIOLOGY, V214, P209; Chang SD, 1998, NEUROL RES, V20, P529; CIRICILLO SF, 1994, PEDIATR NEUROSURG, V20, P137, DOI 10.1159/000120776; Denier C, 2004, AM J HUM GENET, V74, P326, DOI 10.1086/381718; He Y, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000722; Jung KH, 2003, ARCH NEUROL-CHICAGO, V60, P1613, DOI 10.1001/archneur.60.11.1613; LAITT RD, 1995, CANCER, V76, P1846, DOI 10.1002/1097-0142(19951115)76:10<1846::AID-CNCR2820761025>3.0.CO;2-8; Lew SM, 2006, J NEUROSURG, V104, P103, DOI 10.3171/ped.2006.104.2.103; Maeder P, 1998, AM J NEURORADIOL, V19, P1141; Maraire JN, 1999, J NEUROSURG, V90, P234, DOI 10.3171/spi.1999.90.2.0234; Moriarity JL, 1999, NEUROSURGERY, V44, P1172; Novelli PM, 1997, PEDIATR NEUROSURG, V26, P322, DOI 10.1159/000121213; Strenger V, 2008, STRAHLENTHER ONKOL, V184, P276, DOI 10.1007/s00066-008-1817-3; VALK PE, 1991, AM J NEURORADIOL, V12, P45; WILSON CB, 1992, CLIN NEUR, V38, P49	38	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	JUN	2015	31	6					901	907		10.1007/s00381-015-2626-5		7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CJ0ZR	WOS:000355211000012		
J	Wataya, T; Ishizaki, R; Kitagawa, M; Tashiro, Y				Wataya, Takafumi; Ishizaki, Ryuji; Kitagawa, Masashi; Tashiro, Yuzuru			Germinoma in the bilateral basal ganglia presented with cognitive deterioration	CHILDS NERVOUS SYSTEM			English	Article						Germinoma; Cognitive disorder; Basal ganglia; MR spectroscopy; Ventriculoscope	GERM-CELL TUMORS; POSITRON-EMISSION-TOMOGRAPHY; SYNCHRONOUS LESIONS; DIAGNOSIS; SUPRASELLAR; REGIONS; PINEAL	Here, we report a case of pediatric germinoma located in the bilateral basal ganglia, which presented with severe cognitive deteriorations. A 15-year-old boy presented with decreased school performance and mild cognitive disturbances. Magnetic resonance images (MRI) of the brain revealed T2 hyperintensity in the bilateral basal ganglia. The patient was initially observed by a local hospital and had screening for metabolic diseases or inflammatory diseases. Lesions with similar characteristics were also found in the pituitary stalk and infundibulum, and these lesions were enhanced with gadolinium (Gad). MR spectroscopy suggested that these should be neoplastic lesions other than metabolic or inflammatory diseases. Biopsy was performed with ventriculoscope, which proved all lesions of infundibulum, pineal, and basal ganglia were pathologically germinoma. The lesions responded well to the chemotherapy and radiation, and his cognitive function improved significantly. A case of germinoma in the bilateral basal ganglia which significantly affect cognitive functions is reported. Differential diagnoses of cognitive symptoms are various, but germinoma could be considered as a possible pathology for it. Early MRI and tumor marker exams are recommended, unless organic brain diseases are completely denied. MR spectroscopy and biopsy with ventriculoscope are useful for diagnosis.	[Ishizaki, Ryuji; Kitagawa, Masashi; Tashiro, Yuzuru] Shizuoka Childrens Hosp, Dept Neurosurg, Aoi Ku, Shizuoka 4208660, Japan; [Wataya, Takafumi; Ishizaki, Ryuji; Kitagawa, Masashi; Tashiro, Yuzuru] Kyoto Univ, Dept Neurosurg, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan	Wataya, T (reprint author), Shizuoka Childrens Hosp, Dept Neurosurg, Aoi Ku, 860 Urushiyama, Shizuoka 4208660, Japan.	watayatakafumi@yahoo.co.jp					Allen J, 2012, PEDIATR BLOOD CANCER, V59, P1180, DOI 10.1002/pbc.24097; Hegde AN, 2011, RADIOGRAPHICS, V31, P5, DOI 10.1148/rg.311105041; Kawai N, 2008, SURG NEUROL, V70, P408, DOI 10.1016/j.surneu.2007.04.010; Fujii Y, 2008, J NEUROL SCI, V270, P189, DOI 10.1016/j.jns.2008.02.006; Bekiesinska-Figatowska M, 2013, EUR J RADIOL, V82, P837, DOI 10.1016/j.ejrad.2012.12.006; Crawford JR, 2007, NEUROLOGY, V68, P1668, DOI 10.1212/01.wnl.0000261908.36803.ac; Cuccia V, 2010, CHILD NERV SYST, V26, P1043, DOI 10.1007/s00381-010-1120-3; Kawabata Y, 2008, J NEURO-ONCOL, V88, P161, DOI 10.1007/s11060-008-9542-4; Kim CH, 2002, ACTA NEUROCHIR, V144, P145, DOI 10.1007/s007010200017; Phi JH, 2013, CHILD NERV SYST, V29, P1871, DOI 10.1007/s00381-013-2164-y; Phi JH, 2013, J NEUROSURG-PEDIATR, V11, P107, DOI 10.3171/2012.10.PEDS11487; Rossi A, 2008, PEDIATR BLOOD CANCER, V50, P177, DOI 10.1002/pbc.20905; Sonoda Y, 2008, J NEUROS-PEDIATR, V2, P118, DOI 10.3171/PED/2008/2/8/118; SUGIYAMA K, 1992, SURG NEUROL, V38, P114, DOI 10.1016/0090-3019(92)90088-5	14	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	JUN	2015	31	6					953	958		10.1007/s00381-015-2616-7		6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CJ0ZR	WOS:000355211000019		
J	Hayashi, T; Akioka, N; Kashiwazaki, D; Kuwayama, N; Kuroda, S				Hayashi, Tomohide; Akioka, Naoki; Kashiwazaki, Daina; Kuwayama, Naoya; Kuroda, Satoshi			Ischemic stroke in pediatric moyamoya disease associated with immune thrombocytopenia-a case report	CHILDS NERVOUS SYSTEM			English	Article						Moyamoya disease; Immune thrombocytopenia; Chronic subdural hematoma; Cerebral infarction; Surgical revascularization	ACUTE MYOCARDIAL-INFARCTION; INTRAVENOUS IMMUNOGLOBULIN; PURPURA ITP; PATIENT; THROMBOSIS; CHILDREN; BYPASS	A 10-year-old boy developed refractory bleeding and was diagnosed with immune thrombocytopenia (ITP). He was treated with steroids and intravenous immunoglobulin (IVIG). Five months later, however, he developed right homonymous hemianopsia, sensory aphasia, agraphia, and agnosia. MR imaging demonstrated multiple cerebral infarction in the bilateral cerebral hemispheres, and MR angiography revealed severe stenosis of the bilateral internal carotid arteries. He was diagnosed with moyamoya disease and successfully underwent surgical revascularization on both sides under IVIG therapy. However, multiple cerebral infarcts developed in the bilateral cerebral hemispheres 10 days after the second surgical revascularization when platelet counts were within normal limits. Furthermore, chronic subdural hematoma gradually increased in size after each surgery, which required burr hole surgery to resolve increased intracranial pressure, when platelet counts decreased to less than 10 x 10(9)/L. This is the first report presenting a case with moyamoya disease coincident with ITP. Critical managements would be essential to reduce perioperative complications, because ITP is known to provoke both hemorrhagic and ischemic events through multiple mechanisms.	[Hayashi, Tomohide; Akioka, Naoki; Kashiwazaki, Daina; Kuwayama, Naoya; Kuroda, Satoshi] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Neurosurg, Toyama 9300194, Japan	Kuroda, S (reprint author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Neurosurg, Sugitani 2630, Toyama 9300194, Japan.	skuroda@med.u-toyama.ac.jp					REINHART WH, 1992, LANCET, V339, P662, DOI 10.1016/0140-6736(92)90806-E; SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288; Rodeghiero F, 2009, BLOOD, V113, P2386, DOI 10.1182/blood-2008-07-162503; JY W, 1992, J LAB CLIN MED, V119, P334; Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0; Kuroda S, 2010, NEUROSURGERY, V66, P1093, DOI 10.1227/01.NEU.0000369606.00861.91; Voltz R, 1996, NEUROLOGY, V46, P250; Neunert C, 2011, BLOOD, V117, P4190, DOI 10.1182/blood-2010-08-302984; Kurata Y, 2011, INT J HEMATOL, V93, P329, DOI 10.1007/s12185-011-0791-1; Cines DB, 2009, BLOOD, V113, P6511, DOI 10.1182/blood-2009-01-129155; Aledort LM, 2004, AM J HEMATOL, V76, P205, DOI 10.1002/ajh.20104; Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386; McMillan R, 2004, BLOOD, V103, P1364, DOI 10.1182/blood-2003-08-2672; Choi WJ, 2012, J STROKE CEREBROVASC, V21; Fruchter O, 2002, AM J MED SCI, V323, P279, DOI 10.1097/00000441-200205000-00010; Hansen RJ, 2002, BLOOD, V100, P2087; Kazumata K, 2014, J NEUROSURG, V121, P432, DOI 10.3171/2014.1.JNS13946; Kuhne T, 2003, J PEDIATR-US, V143, P605, DOI 10.1067/S0022-3476(03)00535-3; Norgaard M, 2012, THROMB RES, V130, pS74, DOI 10.1016/j.thromres.2012.08.282; Paolini R, 2000, AM J HEMATOL, V65, P177, DOI 10.1002/1096-8652(200010)65:2<177::AID-AJH17>3.0.CO;2-K; Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, 2012, NEUROL MED CHIR TOKY, V52, P245; Rhee HY, 2010, J THROMB THROMBOLYS, V30, P229, DOI 10.1007/s11239-009-0431-2; Stiakaki E, 2012, PEDIATR INT, V54, P524, DOI 10.1111/j.1442-200X.2012.03606.x; Theeler Brett J, 2008, J Stroke Cerebrovasc Dis, V17, P244, DOI 10.1016/j.jstrokecerebrovasdis.2008.01.014; Yagmur J, 2012, TEX HEART I J, V39, P881	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	JUN	2015	31	6					991	996		10.1007/s00381-015-2619-4		6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CJ0ZR	WOS:000355211000025		
J	Tamura, M; Oyamada, M; Shirataki, Y				Tamura, Masafumi; Oyamada, Miki; Shirataki, Yoshiaki			Development of Chiral Building Blocks Having a Bicyclo[3.3.0]Octane Framework Using a Diastereomeric Resolution-Selective Deprotection	CHIRALITY			English	Article						bicyclo[3; 3; 0]octane framework; bicyclo[3; 3; 0]octane-2; 8-dione; chiral building blocks; diastereomeric resolution-selective deprotection	ABSOLUTE-CONFIGURATION; REARRANGEMENT; LIGANDS; DIENE	A protocol is presented for an efficient and practical approach to the synthesis of enantiomerically pure bicyclo[3.3.0]octane derivatives from achiral C-s-symmetric bicyclo[3.3.0]octane-2,8-dione using a diastereomeric resolution-selective deprotection method. This method affords chiral building blocks having bicyclo[3.3.0]octane framework with the same site of diastereotopic carbonyl functional group. Chirality 27:364-369, 2015. (c) 2015 Wiley Periodicals, Inc.	[Tamura, Masafumi; Oyamada, Miki; Shirataki, Yoshiaki] Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 3500295, Japan	Tamura, M (reprint author), Josai Univ, Fac Pharmaceut Sci, 1-1 Keyakidai Sakado, Sakado, Saitama 3500295, Japan.	tamuraty@josai.ac.jp			Office of the President of Josai University	This work was supported in part by a grant from Grant-Aid for Scientific Research, Office of the President of Josai University. The authors thank Dr. Hiroshi Miyamae (Josai University) and Rigaku Corp. for assistance with X-ray analysis.	Anderl T, 2008, SYNTHESIS-STUTTGART, P1619, DOI 10.1055/s-2008-1067012; ANDERSON WK, 1990, J HETEROCYCLIC CHEM, V27, P975; WHITESELL JK, 1988, J AM CHEM SOC, V110, P3585, DOI 10.1021/ja00219a037; Henderson JA, 2008, ANGEW CHEM INT EDIT, V47, P8499, DOI 10.1002/anie.200803593; Wang ZQ, 2007, J AM CHEM SOC, V129, P5336, DOI 10.1021/ja0710914; Zhang SS, 2010, ORG LETT, V12, P5546, DOI 10.1021/ol102521q; Cramer N, 2006, CHEM-EUR J, V12, P2488, DOI 10.1002/chem.200501274; KAGECHIKA K, 1991, J ORG CHEM, V56, P4093, DOI 10.1021/jo00013a004; Bhowmick KC, 2002, TETRAHEDRON-ASYMMETR, V13, P851, DOI 10.1016/S0957-4166(02)00185-4; CHENEY DL, 1989, J ORG CHEM, V54, P3334, DOI 10.1021/jo00275a018; Chos TP, 2010, BIOORG MED CHEM LETT, V20, P3521; Cossys JR, 2014, COMPREHENSIVE CHIRAL, P1; Cuis Z, 2011, J AM CHEM SOC, V133, P12394; Gaichs T, 2014, COMPREHENSIVE CHIRAL, P163; GAIS HJ, 1988, TETRAHEDRON LETT, V29, P1773, DOI 10.1016/S0040-4039(00)82039-0; Gerlachs H, 1993, ORG SYNTH, V71, P48; Guillemonts J, 2014, COMPREHENSIVE CHIRAL, P54; HAGEDORN AA, 1977, J ORG CHEM, V42, P3765, DOI 10.1021/jo00443a035; Hill CL, 2006, SYNLETT, P309, DOI 10.1055/s-2005-923581; Hodgson DM, 1996, CHEM COMMUN, P1015, DOI 10.1039/cc9960001015; Hodgson DM, 2012, HETEROCYCLES, V84, P625, DOI 10.3987/COM-11-S(P)35; Hodgson DM, 2001, ORG LETT, V3, P441, DOI 10.1021/ol006947n; INOUE T, 1995, TETRAHEDRON-ASYMMETR, V6, P31, DOI 10.1016/0957-4166(94)00344-B; Kims M, 2006, J ORG CHEM, V71, P4642; Lemkes K, 1997, TETRAHEDRON-ASYMMETR, V8, P2051; Lesuisses D, 2014, COMPREHENSIVE CHIRAL, P8; Lubells WD, 2014, COMPREHENSIVE CHIRAL, P86; Maryanoffs BE, 2014, COMPREHENSIVE CHIRAL, P105; Mehta G, 2001, TETRAHEDRON LETT, V42, P2855, DOI 10.1016/S0040-4039(01)00288-X; Mignanis S, 2014, COMPREHENSIVE CHIRAL, P217; Nagata H, 1999, TETRAHEDRON LETT, V40, P6617, DOI 10.1016/S0040-4039(99)01321-0; Pariss JM, 2014, COMPREHENSIVE CHIRAL, P30; PERARDVIRET J, 1994, TETRAHEDRON-ASYMMETR, V5, P1, DOI 10.1016/S0957-4166(00)80469-3; Petzoldts K, 1990, LIEBIGS ANN CHEM, V1990, P1087, DOI 10.1002/jlac.1990199001196; PIERS E, 1993, J ORG CHEM, V58, P11, DOI 10.1021/jo00053a005; Shis L, 2010, ANGEW CHEM INT EDIT, V49, P9250; Srikrishna A, 2003, ORG LETT, V5, P2295, DOI 10.1021/ol034635p; Tredwells M, 2014, COMPREHENSIVE CHIRAL, P70; TROST BM, 1980, J AM CHEM SOC, V102, P5699, DOI 10.1021/ja00537a059; Tsantali GG, 2003, J ORG CHEM, V68, P6455, DOI 10.1021/jo034350q; Wendeborns S, 2014, COMPREHENSIVE CHIRAL, P120; WHITESELL JK, 1985, J ORG CHEM, V50, P3025, DOI 10.1021/jo00216a053; Zhong YW, 2002, TETRAHEDRON-ASYMMETR, V13, P2251, DOI 10.1016/S0957-4166(02)00584-0	43	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0899-0042	1520-636X		CHIRALITY	Chirality	JUN	2015	27	6					364	369		10.1002/chir.22450		6	Chemistry, Medicinal; Chemistry, Analytical; Chemistry, Organic; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CI8DJ	WOS:000354998700002		
J	Grasso, C; Capodanno, D; Tamburino, C; Ohno, Y				Grasso, Carmelo; Capodanno, Davide; Tamburino, Corrado; Ohno, Yohei			Current Status and Clinical Development of Transcatheter Approaches for Severe Mitral Regurgitation	CIRCULATION JOURNAL			English	Review						Annuloplasty; MitraClip; Mitral regurgitation; Transcatheter mitral valve implantation; Transcatheter mitral valve repair	PERCUTANEOUS CLIP IMPLANTATION; HIGH-RISK PATIENTS; VALVE REPAIR; HEART-FAILURE; MITRACLIP(R) THERAPY; ANNULOPLASTY DEVICE; EVEREST II; OUTCOMES; REGISTRY; SURGERY	Transcatheter mitral valve intervention has emerged as an effective treatment option for symptomatic severe mitral regurgitation in patients considered to be inoperable or at high operative risk for surgical mitral valve surgery. Most transcatheter approaches are modifications of existing surgical approaches. Transcatheter edge-to-edge mitral valve repair with the MitraClip system has the largest clinical experience to date, as it offers a sustained clinical benefit in selected patients. This review aims to provide an up-to-date overview of transcatheter mitral valve interventions, including leaflet repair, annuloplasty, and mitral valve implantation.	[Grasso, Carmelo; Capodanno, Davide; Tamburino, Corrado; Ohno, Yohei] Univ Catania, Ferrarotto Hosp, Dept Cardiol, I-95124 Catania, Italy; [Capodanno, Davide; Tamburino, Corrado] ETNA Fdn, Catania, Italy; [Ohno, Yohei] Tokai Univ, Sch Med, Dept Cardiol, Isehara, Kanagawa 25911, Japan	Grasso, C (reprint author), Univ Catania, Ferrarotto Hosp, Dept Cardiol, Via Citelli 29, I-95124 Catania, Italy.	melfat75@gmail.com			Japan Heart Foundation; Bayer Yakuhin Research Grant Abroad	Y.O. is supported by a grant from the Japan Heart Foundation and Bayer Yakuhin Research Grant Abroad.	Geidel S, 2014, ANN THORAC SURG, V97, P56, DOI 10.1016/j.athoracsur.2013.07.038; Seeburger J, 2014, J AM COLL CARDIOL, V63, P914, DOI 10.1016/j.jacc.2013.07.090; Nishimura RA, 2014, J AM COLL CARDIOL, V63, P2438, DOI 10.1016/j.jacc.2014.02.537; Agricola E, 2009, EUR J HEART FAIL, V11, P581, DOI 10.1093/eurjhf/hfp051; Grasso C, 2013, AM J CARDIOL, V111, P1482, DOI 10.1016/j.amjcard.2013.01.300; Mihaljevic T, 2007, J AM COLL CARDIOL, V49, P2191, DOI 10.1016/j.jacc.2007.02.043; Surder D, 2013, HEART, V99, P1034, DOI 10.1136/heartjnl-2012-303105; Glower DD, 2014, J AM COLL CARDIOL, V64, P172, DOI 10.1016/j.jacc.2013.12.062; Maisano F, 2012, EUR J CARDIO-THORAC, V42, P524, DOI 10.1093/ejcts/ezs069; Franzen O, 2011, EUR J HEART FAIL, V13, P569, DOI 10.1093/eurjhf/hfr029; Okura H, 2011, CIRC J, V75, P2699, DOI 10.1253/circj.CJ-11-0277; Maselli D, 2006, CIRCULATION, V114, P377, DOI 10.1161/CIRCULATIONAHA.105.609883; Nickenig G, 2014, J AM COLL CARDIOL, V64, P875, DOI 10.1016/j.jacc.2014.06.1166; Rudolph V, 2011, J AM COLL CARDIOL, V58, P2190, DOI 10.1016/j.jacc.2011.07.047; Vahanian A, 2012, EUR HEART J, V33, P2451, DOI 10.1093/eurheartj/ehs109; Nkomo VT, 2006, LANCET, V368, P1005, DOI 10.1016/S0140-6736(06)69208-8; Alfieri O, 2001, J THORAC CARDIOV SUR, V122, P674, DOI 10.1067/mtc.2001.117277; Schofer J, 2009, CIRCULATION, V120, P326, DOI 10.1161/CIRCULATIONAHA.109.849885; De Backer O, 2014, CIRC-CARDIOVASC INTE, V7, P400, DOI 10.1161/CIRCINTERVENTIONS.114.001607; Feldman T, 2011, NEW ENGL J MED, V364, P1395, DOI 10.1056/NEJMoa1009355; Cheung A, 2013, J AM COLL CARDIOL, V61, P1759, DOI 10.1016/j.jacc.2013.01.058; Auricchio A, 2011, J AM COLL CARDIOL, V58, P2183, DOI 10.1016/j.jacc.2011.06.061; Schillinger W, 2013, EUROINTERVENTION, V9, P84, DOI 10.4244/EIJV9I1A13; Gillinov AM, 1998, J THORAC CARDIOV SUR, V116, P734, DOI 10.1016/S0022-5223(98)00450-4; Grasso C, 2014, JACC-CARDIOVASC INTE, V7, pE85, DOI 10.1016/j.jcin.2013.11.027; Otsuji Y, 1997, CIRCULATION, V96, P1999; Munkholm-Larsen S, 2014, HEART, V100, P473, DOI 10.1136/heartjnl-2013-304049; Siminiak T, 2012, EUR J HEART FAIL, V14, P931, DOI 10.1093/eurjhf/hfs076; Treede H, 2012, J THORAC CARDIOV SUR, V143, P78, DOI 10.1016/j.jtcvs.2011.09.033; Mauri L, 2013, J AM COLL CARDIOL, V62, P317, DOI 10.1016/j.jacc.2013.04.030; Neuss M, 2013, EUR J HEART FAIL, V15, P786, DOI 10.1093/eurjhf/hfs214; Attizzani GF, 2015, JACC-CARDIOVASC INTE, V8, P74, DOI 10.1016/j.jcin.2014.07.024; Biancari F, 2013, J CARDIOTHOR VASC AN, V27, P213, DOI 10.1053/j.jvca.2012.11.007; Bouleti C, 2015, JACC-CARDIOVASC INTE, V8, P83, DOI 10.1016/j.jcin.2014.07.026; Bozdag-Turan I, 2014, CARDIOVASC THER, V32, P66, DOI 10.1111/1755-5922.12058; Glower D, 2012, J THORAC CARDIOV SUR, V143, pS60, DOI 10.1016/j.jtcvs.2012.01.047; Goel SS, 2014, J AM COLL CARDIOL, V63, P185, DOI 10.1016/j.jacc.2013.08.723; Grayburn PA, 2011, AM J CARDIOL, V108, P882, DOI 10.1016/j.amjcard.2011.05.013; Maisano F, 2014, JACC-CARDIOVASC INTE, V7, P1326, DOI 10.1016/j.jcin.2014.08.003; Maisano F, 2013, J AM COLL CARDIOL, V62, P1052, DOI 10.1016/j.jacc.2013.02.094; Nardi P, 2011, J CARDIAC SURG, V26, P360, DOI 10.1111/j.1540-8191.2011.01275.x; Ohno Y, 2014, EUR HEART J CARDIOVA, V15, P1246; Siminiak T, 2013, KARDIOL POL, V71, P1287, DOI 10.5603/KP.2013.0325; Taramasso M, 2014, EUROINTERVENTION, V10, P746, DOI [10.4244/EIJV10I6A128, 10.4244/EIJV1016A128]; Yeo KK, 2014, EUROINTERVENTION, V10, P620, DOI 10.4244/EIJV10I5A107	45	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1164	1171		10.1253/circj.CJ-15-0447		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700003		
J	Nakajima, T; Kaneko, Y; Kurabayashi, M				Nakajima, Tadashi; Kaneko, Yoshiaki; Kurabayashi, Masahiko			Unveiling Specific Triggers and Precipitating Factors for Fatal Cardiac Events in Inherited Arrhythmia Syndromes	CIRCULATION JOURNAL			English	Review						Fatal arrhythmias; Genes; Mutations; Precipitating factors; Triggers	LONG-QT-SYNDROME; TORSADES-DE-POINTES; POLYMORPHIC VENTRICULAR-TACHYCARDIA; LIFE-THREATENING ARRHYTHMIAS; ACUTE MYOCARDIAL-INFARCTION; EARLY REPOLARIZATION SYNDROME; ST-SEGMENT ELEVATION; J-WAVE SYNDROMES; BRUGADA-SYNDROME; POTASSIUM CHANNEL	Patients with inherited arrhythmia syndromes, such as long QT syndrome, Brugada syndrome, early repolarization syndrome, catecholaminergic polymorphic ventricular tachycardia, and their latent forms, are at risk for fatal arrhythmias. These diseases are typically associated with genetic mutations that perturb cardiac ionic currents. The analysis of cardiac events by genotype-phenotype correlation studies has revealed that fatal arrhythmias in some genotypes are triggered by physical or emotional stress, and those in the others are more likely to occur during sleep or at rest. Thus, the risk stratification and management of affected patients differ strikingly according to the genetic variant of the inherited arrhythmia syndrome. Risk stratification may be further refined by considering the precipitating factors, such as drugs, bradycardia, electrolyte disturbances, fever, and cardiac memory. Moreover, an increasing number of studies imply that the susceptibility of fatal arrhythmias in patients with acute coronary syndrome or takotsubo cardiomyopathy is at least partly ascribed to the genetic variants causing inherited arrhythmia syndromes. In this article, we review the recent advances in the understanding of the molecular genetics and genotype-phenotype correlations in inherited arrhythmia syndromes and consider the triggers and precipitating factors for fatal arrhythmias in these disorders. Further studies to explore the triggers and precipitating factors specific to the genotypes and diseases are needed for better clinical management.	[Nakajima, Tadashi; Kaneko, Yoshiaki; Kurabayashi, Masahiko] Gunma Univ, Grad Sch Med, Dept Med & Biol Sci, Maebashi, Gumma 3718511, Japan	Nakajima, T (reprint author), Gunma Univ, Grad Sch Med, Dept Med & Biol Sci, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan.	tnakajim@gunma-u.ac.jp			JSPS KAKENHI [26461056]	This work was supported by JSPS KAKENHI Grant Number 26461056.	Abu-Zeitone A, 2014, J AM COLL CARDIOL, V64, P1352, DOI 10.1016/j.jacc.2014.05.068; Amin A S, 2010, Neth Heart J, V18, P165, DOI 10.1007/BF03091755; Amin AS, 2008, J CLIN INVEST, V118, P2552, DOI 10.1172/JCI35337; Guo J, 2009, J CLIN INVEST, V119, P2745, DOI 10.1172/JCI39027; Nyegaard M, 2012, AM J HUM GENET, V91, P703, DOI 10.1016/j.ajhg.2012.08.015; Madias C, 2011, HEART RHYTHM, V8, P555, DOI 10.1016/j.hrthm.2010.12.012; Antzelevitch C, 2012, CIRC J, V76, P1054, DOI 10.1253/circj.CJ-12-0284; LEENHARDT A, 1995, CIRCULATION, V91, P1512; Ackerman MJ, 2003, MAYO CLIN PROC, V78, P1479; Haissaguerre M, 2009, J AM COLL CARDIOL, V53, P612, DOI 10.1016/j.jacc.2008.10.044; Chen QY, 1998, NATURE, V392, P293; Crotti L, 2013, CIRCULATION, V127, P1009, DOI 10.1161/CIRCULATIONAHA.112.001216; Petersen CI, 2004, P NATL ACAD SCI USA, V101, P11773, DOI 10.1073/pnas.0306005101; Kaneko Y, 2014, CIRC-ARRHYTHMIA ELEC, V7, P1122, DOI 10.1161/CIRCEP.114.001806; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Amin AS, 2008, ANN INTERN MED, V149, P216; Lehtonen A, 2007, HEART RHYTHM, V4, P603, DOI 10.1016/j.hrthm.2007.01.019; Shimizu W, 2013, CIRC J, V77, P2867, DOI 10.1253/circj.CJ-13-1217; Shinohara T, 2014, HEART RHYTHM, V11, P1441, DOI 10.1016/j.hrthm.2014.05.001; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Postema PG, 2009, HEART RHYTHM, V6, P1335, DOI 10.1016/j.hrthm.2009.07.002; Bos JM, 2013, CIRC-ARRHYTHMIA ELEC, V6, P705, DOI 10.1161/CIRCEP.113.000102; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Belhassen B, 2004, CIRCULATION, V110, P1731, DOI 10.1161/01.CIR.0000143159.30585.90; Vincent GM, 2009, CIRCULATION, V119, P215, DOI 10.1161/CIRCULATIONAHA.108.772533; Yang P, 2002, CIRCULATION, V105, P1943, DOI 10.1161/01.CIR.0000014448.19052.4C; Schwartz PJ, 2013, J AM COLL CARDIOL, V62, P169, DOI 10.1016/j.jacc.2013.04.044; Jamshidi Y, 2012, J AM COLL CARDIOL, V60, P841, DOI 10.1016/j.jacc.2012.03.031; Yan GX, 1999, CIRCULATION, V100, P1660; Seth R, 2007, J AM COLL CARDIOL, V49, P1092, DOI 10.1016/j.jacc.2006.09.054; Grilo LS, 2010, HEART RHYTHM, V7, P260, DOI 10.1016/j.hrthm.2009.09.026; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391; Yang T, 1997, CIRC RES, V80, P782; Samani K, 2009, HEART RHYTHM, V6, P1318, DOI 10.1016/j.hrthm.2009.05.016; Schwartz PJ, 2001, CIRCULATION, V103, P89; Kaab S, 2012, CIRC-CARDIOVASC GENE, V5, P91, DOI 10.1161/CIRCGENETICS.111.960930; Nakajima T, 2012, CIRC J, V76, P2763, DOI 10.1253/circj.CJ-12-0551; Aizawa Y, 2013, INT J CARDIOL, V168, P5083, DOI 10.1016/j.ijcard.2013.07.187; Watanabe H, 2009, NAT MED, V15, P380, DOI 10.1038/nm.1942; Ruan YF, 2007, CIRCULATION, V116, P1137, DOI 10.1161/CIRCULATIONAHA.107.707877; Kawamura M, 2013, CIRC J, V77, P1705, DOI 10.1253/circj.CJ-12-1460; Nakajima T, 2010, J MOL CELL CARDIOL, V48, P352, DOI 10.1016/j.yjmcc.2009.11.016; Keller DI, 2006, CARDIOVASC RES, V70, P521, DOI 10.1016/j.cardiores.2006.02.030; Leenhardt A, 2012, CIRC-ARRHYTHMIA ELEC, V5, P1044, DOI 10.1161/CIRCEP.111.962027; Viskin S, 1999, LANCET, V354, P1625, DOI 10.1016/S0140-6736(99)02107-8; Itoh H, 2009, CIRC-ARRHYTHMIA ELEC, V2, P511, DOI 10.1161/CIRCEP.109.862649; Haissaguerre M, 2008, NEW ENGL J MED, V358, P2016, DOI 10.1056/NEJMoa071968; Calvillo L, 2014, HEART RHYTHM, V11, P126, DOI 10.1016/j.hrthm.2013.10.029; Cerrone M, 2011, EUR HEART J, V32, P2109, DOI 10.1093/eurheartj/ehr082; Chevalier P, 2007, HEART RHYTHM, V4, P170, DOI 10.1016/j.hrthm.2006.10.004; Crotti L, 2012, HEART RHYTHM, V9, P1104, DOI 10.1016/j.hrthm.2012.02.014; Di Cori A, 2013, J CARDIOVASC ELECTR, V24, P1304, DOI 10.1111/jce.12179; Etheridge SP, 2003, J AM COLL CARDIOL, V42, P1777, DOI 10.1016/j.jacc.2003.07.006; Halkin A, 2001, J AM COLL CARDIOL, V38, P1168, DOI 10.1016/S0735-1097(01)01468-1; Hayashi K, 2011, J MOL CELL CARDIOL, V50, P50, DOI 10.1016/j.yjmcc.2010.10.007; Hu D, 2007, HEART RHYTHM, V4, P1072, DOI 10.1016/j.hrthm.2007.03.040; Jeyaraj D, 2010, PACE, V33, P346, DOI 10.1111/j.1540-8159.2009.02630.x; Jiang M, 2000, CARDIOVASC RES, V48, P34, DOI 10.1016/S0008-6363(00)00159-0; Katsuumi G, 2014, INT J CARDIOL, V172, P519, DOI 10.1016/j.ijcard.2014.01.036; Kubota T, 2001, J CARDIOVASC ELECTR, V12, P1223, DOI 10.1046/j.1540-8167.2001.01223.x; Mahida S, 2015, HEART RHYTHM, V12, P242, DOI 10.1016/j.hrthm.2014.09.048; Mizusawa Y, 2014, CIRC J, V78, P2827, DOI 10.1253/circj.CJ-14-0905; Nakajima T, 1998, CIRC RES, V83, P415; Nakajima T, 1997, EUR HEART J, V18, P530; Nakajima T, 2010, INTERNAL MED, V49, P2587, DOI 10.2169/internalmedicine.49.4245; Nakajima T, 2007, J BIOL CHEM, V282, P5506, DOI 10.1074/jbc.M605976200; Numaguchi H, 2000, CIRC RES, V87, P1012; Oka Y, 2010, CIRC J, V74, P2562, DOI 10.1253/circj.CJ-10-0498; Shibata R, 2009, J JPN SOC INTERN MED, V98, P1996; Subbiah RN, 2010, CAN J CARDIOL, V26, P208; Tange T, 2012, THER RES, V33, P1639; Wilde AAM, 1999, J AM COLL CARDIOL, V33, P327, DOI 10.1016/S0735-1097(98)00578-6; Yoshikawa T., 2014, INT J CARDIOL, V182C, P297; Zhao JT, 2009, J CARDIOVASC ELECTR, V20, P923, DOI 10.1111/j.1540-8167.2009.01468.x	77	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1185	1192		10.1253/circj.CJ-15-0322		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700005		
J	Murohara, T				Murohara, Toyoaki			Report of the American College of Cardiology (ACC) Scientific Sessions 2015, San Diego	CIRCULATION JOURNAL			English	Article						American College of Cardiology; Japanese Circulation Society; Late-breaking clinical trials; Proprotein convertase subtilisin/kexin type 9 (PCSK9); Transcatheter aortic valve replacement (TAVR)	EVEROLIMUS-ELUTING STENTS; CORONARY-DISEASE; BYPASS-SURGERY; VALVE; JAPANESE; IMPLANTATION; TRIAL; PCSK9	The 64th Annual Scientific Sessions and Exposition of the American College of Cardiology (ACC) were held at the San Diego Convention Center from March 14-16, 2015. The ACC Scientific Sessions are 1 of 2 major scientific cardiology meetings in the United States, with nearly 20,000 attendees, including 15,000 cardiovascular professionals. There were over 2,100 oral and poster abstracts, and more than 15 late-breaking clinical trials (LBCTs) abstructs. This report presents the highlights and several key presentations, especially the LBCTs, from the ACC Scientific Sessions 2015. I hope this review will help cardiologists update to the latest information.	[Murohara, Toyoaki] Nagoya Univ, Grad Sch Med, Dept Cardiol, Nagoya, Aichi 4668550, Japan	Murohara, T (reprint author), Nagoya Univ, Grad Sch Med, Dept Cardiol, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	murohara@med.nagoya-u.ac.jp	刘, 李陆/H-8469-2015; Murohara, Toyoaki/M-4958-2014				Sabatine MS, 2015, NEW ENGL J MED, V372, P1500, DOI 10.1056/NEJMoa1500858; Beltrame JF, 1999, J AM COLL CARDIOL, V33, P1442, DOI 10.1016/S0735-1097(99)00073-X; YASUE H, 1988, CIRCULATION, V78, P1; Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Fuku Y, 2014, CIRC J, V78, P1357, DOI 10.1253/circj.CJ-13-1220; Robinson JG, 2015, NEW ENGL J MED, V372, P1489, DOI 10.1056/NEJMoa1501031; Mack MJ, 2015, LANCET, V385, P2477, DOI 10.1016/S0140-6736(15)60308-7; Matsumoto T, 2014, CIRC J, V78, P1782, DOI 10.1253/circj.CJ-14-0681; Sawa Y, 2014, CIRC J, V78, P1083, DOI 10.1253/circj.CJ-14-0162; Kapadia SR, 2015, LANCET, V385, P2485, DOI 10.1016/S0140-6736(15)60290-2; Bangalore S, 2015, NEW ENGL J MED, V372, P1213, DOI 10.1056/NEJMoa1412168; Douglas PS, 2015, NEW ENGL J MED, V372, P1291, DOI 10.1056/NEJMoa1415516; Hirayama A, 2014, CIRC J, V78, P1073, DOI 10.1253/circj.CJ-14-0130; Kohno T, 2015, CIRC J, V79, P34, DOI 10.1253/circj.CJ-14-1329; Kusunose K, 2014, CIRC J, V78, P1311, DOI 10.1253/circj.CJ-14-0411; Maeda K, 2015, CIRC J, V79, P1037, DOI 10.1253/circj.CJ-14-1110; Muramatsu T, 2014, CIRC J, V78, P2610, DOI 10.1253/circj.CJ-14-1088; Park SJ, 2015, NEW ENGL J MED, V372, P1204, DOI 10.1056/NEJMoa1415447; YASUE H, 1983, CIRC RES, V52, P147	19	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1193	1198		10.1253/circj.CJ-15-0396		6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700006		
J	Nakagawa, M				Nakagawa, Mikiko			Stored Intracardiac Electrograms Reveal Patients With Sick Sinus Syndrome Frequently Develop Atrioventricular Block	CIRCULATION JOURNAL			English	Editorial Material							NODE DISEASE; PERMANENT PACEMAKER; NATURAL-HISTORY; FOLLOW-UP; CONDUCTION; MODE		Oita Univ, Med Educ Ctr, Fac Med, Yufu 8795593, Japan	Nakagawa, M (reprint author), Oita Univ, Med Educ Ctr, Fac Med, 1-1 Idaigaoka, Yufu 8795593, Japan.	mikinak@oita-u.ac.jp					Andersen HR, 1998, CIRCULATION, V98, P1315; Savoure A, 2005, PACE, V28, pS43, DOI 10.1111/j.1540-8159.2005.00095.x; SUTTON R, 1986, PACE, V9, P1110, DOI 10.1111/j.1540-8159.1986.tb06678.x; Frohlig G, 2006, EUROPACE, V8, P96, DOI 10.1093/europace/euj024d; Morris GM, 2014, CIRC J, V78, P1272, DOI 10.1253/circj.CJ-14-0419; BERTHOLET M, 1983, ACTA CARDIOL, V38, P227; BRANDT J, 1992, J AM COLL CARDIOL, V20, P633; BREIVIK K, 1979, ACTA MED SCAND, V206, P153; Chida K, 1999, JPN CIRC J, V63, P343, DOI 10.1253/jcj.63.343; DEMOULIN JC, 1978, BRIT HEART J, V40, P1384; Hosoda J, 2015, CIRC J, V79, P1263, DOI 10.1253/circj.CJ-14-1255; JCS Joint Working Group, 2013, CIRC J, V77, P249; ROSENQVIST M, 1989, PACE, V12, P97; VALLIN H, 1981, ACTA MED SCAND, V210, P263	14	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1199	1200		10.1253/circj.CJ-15-0446		2	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700007		
J	Naito, R; Miyauchi, K				Naito, Ryo; Miyauchi, Katsumi			Is an Appropriate Revascularization Selected for Unprotected Left Main Coronary Artery Disease?	CIRCULATION JOURNAL			English	Editorial Material							5-YEAR OUTCOMES; INTERVENTION; GUIDELINES; REGISTRY; SURGERY		[Naito, Ryo; Miyauchi, Katsumi] Juntendo Univ, Dept Cardiol, Sch Med, Tokyo 1138421, Japan	Miyauchi, K (reprint author), Juntendo Univ, Dept Cardiol, Grad Sch Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	ktmmy@med.juntendo.ac.jp					Fihn SD, 2012, CIRCULATION, V126, pE354, DOI 10.1161/CIR.0b013e318277d6a0; Montalescot G, 2013, EUR HEART J, V34, P2949, DOI 10.1093/eurheartj/eht296; Morice MC, 2014, CIRCULATION, V129, P2388, DOI 10.1161/CIRCULATIONAHA.113.006689; Chieffo A, 2010, JACC-CARDIOVASC INTE, V3, P595, DOI 10.1016/j.jcin.2010.03.014; Shiomi H, 2015, CIRC J, V79, P1282, DOI 10.1253/circj.CJ-15-0034; Park DW, 2010, J AM COLL CARDIOL, V56, P117, DOI 10.1016/j.jacc.2010.04.004; Shiomi H, 2012, AM J CARDIOL, V110, P924, DOI 10.1016/j.amjcard.2012.05.022; JCS Joint Working Group, 2012, GUID PRIM PREV ISCH; Fujiwara H, 2013, CIRC J, V77, P1590, DOI 10.1253/circj.CJ-66-0065	9	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1201	1203		10.1253/circj.CJ-15-0439		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700008		
J	Sadahiro, M				Sadahiro, Mitsuaki			Cardiopulmonary Rehabilitation Using Adaptive Servo-Ventilation After Cardiac Surgery	CIRCULATION JOURNAL			English	Editorial Material							CORONARY-ARTERY-BYPASS; POSTOPERATIVE ATRIAL-FIBRILLATION; POSITIVE AIRWAY PRESSURE; CONGESTIVE-HEART-FAILURE; DISEASE; STROKE		Yamagata Univ, Dept Cardiovasc Thorac & Pediat Surg, Dept Surg 2, Fac Med, Yamagata 9909585, Japan	Sadahiro, M (reprint author), Yamagata Univ, Dept Cardiovasc Thorac & Pediat Surg, Dept Surg 2, Fac Med, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.	sadahiro@med.id.yamagata-u.ac.jp					Koyama T, 2012, CIRC J, V76, P2606, DOI 10.1253/circj.CJ-12-0328; Villareal RP, 2004, J AM COLL CARDIOL, V43, P742, DOI 10.1016/j.jacc.2003.11.023; NAUGHTON MT, 1995, CIRCULATION, V91, P1725; Koyama T, 2011, CIRC J, V75, P710, DOI 10.1253/circj.CJ-10-0956; Lahtinen J, 2004, ANN THORAC SURG, V77, P1241, DOI 10.1016/j.athoracsur.2003.09.077; Yoshihisa A, 2012, CIRC J, V76, P2153, DOI 10.1253/circj.CJ-12-0453; Stamou SC, 2001, STROKE, V32, P1508; Kaye DM, 2001, CIRCULATION, V103, P2336; Yamada S, 2013, CIRC J, V77, P1214, DOI 10.1253/circj.CJ-12-1088; Mariscalco G, 2008, CIRCULATION, V118, P1612, DOI 10.1161/CIRCULATIONAHA.108.777789; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; Nohara R, 2014, CIRC J, V78, P2022, DOI 10.1253/circj.CJ-66-0094; Schmidt H, 1997, J CRIT CARE, V12, P22, DOI 10.1016/S0883-9441(97)90022-8; Serruys PW, 2009, NEW ENGL J MED, V360, P961, DOI 10.1056/NEJMoa0804626; Tashiro N, 2015, CIRC J, V79, P1290, DOI 10.1253/circj.CJ-14-1078	15	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1204	1205		10.1253/circj.CJ-15-0407		2	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700009		
J	Sato, Y				Sato, Yukihito			Renin - A Historical Biomarker of Heart Failure -	CIRCULATION JOURNAL			English	Editorial Material							PLASMA NOREPINEPHRINE; BIOCHEMICAL MARKERS; HEFT		Hyogo Kenritsu Amagasaki Hosp, Dept Cardiol, Amagasaki, Hyogo 6600828, Japan	Sato, Y (reprint author), Hyogo Kenritsu Amagasaki Hosp, Dept Cardiol, 1-1-1 Higashidaimotsucho, Amagasaki, Hyogo 6600828, Japan.	cardioys@kuhp.kyoto-u.ac.jp					Ueda T, 2015, CIRC J, V79, P1307, DOI 10.1253/circj.CJ-14-1203; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Latini R, 2004, EUR HEART J, V25, P292, DOI 10.1016/j.ehj.2003.10.030; McMurray JJV, 2010, NEW ENGL J MED, V362, P228, DOI 10.1056/NEJMcp0909392; Tsutamoto T, 2007, CIRC J, V71, P915, DOI 10.1253/circj.71.915; Sakata Y, 2013, CIRC J, V77, P2209, DOI 10.1253/circj.CJ-13-0971; Mentz RJ, 2015, JACC-HEART FAIL, V3, P97, DOI 10.1016/j.jchf.2014.09.003; Sato Y, 2012, J CARDIOL, V59, P1, DOI 10.1016/j.jjcc.2011.11.001; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; FRANCIS GS, 1993, CIRCULATION, V87, P40; Masson S, 2010, J CARD FAIL, V16, P964, DOI 10.1016/j.cardfail.2010.06.417; Nishio Y, 2007, CIRC J, V71, P631, DOI 10.1253/circj.71.631; Schrier RW, 1999, NEW ENGL J MED, V341, P577	13	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1206	1208		10.1253/circj.CJ-15-0256		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700010		
J	Seo, Y; Aonuma, K				Seo, Yoshihiro; Aonuma, Kazutaka			New Index Obtained From Intrathoracic Impedance Measurements - Could MOMOTARO Find the Key to Heart Failure Management in the Modern Treasure Chest? -	CIRCULATION JOURNAL			English	Editorial Material							HOSPITALIZATION		[Seo, Yoshihiro; Aonuma, Kazutaka] Univ Tsukuba, Fac Clin Med, Div Cardiovasc, Tsukuba, Ibaraki 3058575, Japan	Seo, Y (reprint author), Univ Tsukuba, Fac Clin Med, Div Cardiovasc, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	yo-seo@md.tsukuba.ac.jp					Klersy C, 2009, J AM COLL CARDIOL, V54, P1683, DOI 10.1016/j.jacc.2009.08.017; Ushigome R, 2015, CIRC J, V79, P1332, DOI 10.1253/circj.CJ-14-0939; Chaudhry SI, 2010, NEW ENGL J MED, V363, P2301, DOI 10.1056/NEJMoa1010029; Shiba N, 2011, CIRC J, V75, P823, DOI 10.1253/circj.CJ-11-0135; Yu CM, 2005, CIRCULATION, V112, P841, DOI 10.1161/CIRCULATIONAHA.104.492207; Ypenburg C, 2007, AM J CARDIOL, V99, P554, DOI 10.1016/j.amjcard.2006.08.066; Hasan A, 2011, EUR HEART J, V32, P1457, DOI 10.1093/eurheartj/ehr005; Sakata Y, 2013, CIRC J, V77, P2209, DOI 10.1253/circj.CJ-13-0971; Whellan DJ, 2010, J AM COLL CARDIOL, V55, P1803, DOI 10.1016/j.jacc.2009.11.089; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Fang J, 2008, J AM COLL CARDIOL, V52, P428, DOI 10.1016/j.jacc.2008.03.061; Gheorghiade M, 2005, AM J CARDIOL, V96, p11G, DOI 10.1016/j.amjcard.2005.07.016; Nishii N, 2015, CIRC J, V79, P1315, DOI 10.1253/circj.CJ-15-0076; Tsuchihashi-Makaya M, 2009, CIRC J, V73, P1893	14	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1209	1210		10.1253/circj.CJ-15-0421		2	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700011		
J	Tanaka, K; Sata, M				Tanaka, Kimie; Sata, Masataka			Visualization of the Human Coronary Vasa Vasorum In Vivo	CIRCULATION JOURNAL			English	Editorial Material							OPTICAL COHERENCE TOMOGRAPHY; PLAQUE VULNERABILITY; ATHEROSCLEROSIS; NEOVASCULARIZATION; ARTERY; DISEASE		[Tanaka, Kimie] Univ Tokyo, Div Hlth Serv Promot, Tokyo, Japan; [Sata, Masataka] Univ Tokushima, Inst Biomed Sci, Dept Cardiovasc Med, Grad Sch, Tokushima 7708503, Japan	Sata, M (reprint author), Univ Tokushima, Inst Biomed Sci, Dept Cardiovasc Med, Grad Sch, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	masataka.sata@tokushima-u.ac.jp					Sacks HS, 2007, AM HEART J, V153, P907, DOI 10.1016/j.ahj.2007.03.019; Staub D, 2010, STROKE, V41, P41, DOI 10.1161/STROKEAHA.109.560342; Kwon HM, 1998, J CLIN INVEST, V101, P1551, DOI 10.1172/JCI1568; Kitabata H, 2010, AM J CARDIOL, V105, P1673, DOI 10.1016/j.amjcard.2010.01.346; Uemura S, 2012, EUR HEART J, V33, P78, DOI 10.1093/eurheartj/ehr284; Vorpahl M, 2010, EUR HEART J, V31, P1889, DOI 10.1093/eurheartj/ehq087; Moulton KS, 2006, CURR OPIN LIPIDOL, V17, P548, DOI 10.1097/01.mol.0000245261.71129.f0; Vavuranakis M, 2008, INT J CARDIOL, V130, P23, DOI 10.1016/j.ijcard.2007.07.170; Mulligan-Kehoe MJ, 2014, CIRCULATION, V129, P2557, DOI 10.1161/CIRCULATIONAHA.113.007189; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; Galkina E, 2006, J EXP MED, V203, P1273, DOI 10.1084/jem.20052205; Tanaka K, 2011, ATHEROSCLEROSIS, V215, P366, DOI 10.1016/j.atherosclerosis.2011.01.016; Moreno PR, 2004, CIRCULATION, V110, P2032, DOI 10.1161/01.CIR.0000143233.87854.23; Kerwin WS, 2008, MAGN RESON MED, V59, P507, DOI 10.1002/mrm.21532; Nishimiya K, 2015, CIRC J, V79, P1323, DOI 10.1253/circj.CJ-15-0078; Nishimiya K, 2014, CIRC J, V78, P2516, DOI 10.1253/circj.CJ-14-0485; Romero JM, 2013, STROKE, V44, P3344, DOI 10.1161/STROKEAHA.113.002400; Ross R, 1999, NEW ENGL J MED, V340, P115	18	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1211	1212		10.1253/circj.CJ-15-0356		2	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700012		
J	Odagiri, K; Watanabe, H				Odagiri, Keiichi; Watanabe, Hiroshi			Effects of the Rho-Kinase Inhibitor, Fasudil, on Pulmonary Hypertension	CIRCULATION JOURNAL			English	Editorial Material							LONG-TERM TREATMENT; ARTERIAL-HYPERTENSION; SILDENAFIL; RATS; SURVIVAL; THERAPY		[Odagiri, Keiichi; Watanabe, Hiroshi] Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapeut, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan	Odagiri, K (reprint author), Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapeut, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	kodagiri@hama-med.ac.jp					Mouchaers KTB, 2010, EUR RESPIR J, V36, P800, DOI 10.1183/09031936.00130209; Abe K, 2004, CIRC RES, V94, P385, DOI 10.1161/01.RES.0000111804.34509.94; Bei YH, 2013, PULM PHARMACOL THER, V26, P635, DOI 10.1016/j.pupt.2013.07.008; Galie N, 2005, NEW ENGL J MED, V353, P2148, DOI 10.1056/NEJMoa050010; Oka M, 2007, CIRC RES, V100, P923, DOI 10.1161/01.RES.0000261658.12024.18; LEUNG T, 1995, J BIOL CHEM, V270, P29051; Ishikura K, 2006, CIRC J, V70, P174, DOI 10.1253/circj.70.174; Fujita H, 2010, HEART VESSELS, V25, P144, DOI 10.1007/s00380-009-1176-8; BARST RJ, 1994, ANN INTERN MED, V121, P409; Fukumoto Y, 2005, HEART, V91, P391, DOI 10.1136/hrt.2003.029470; Fukumoto Y, 2013, CIRC J, V77, P2619, DOI 10.1253/circj.CJ-13-0443; Elias-Al-Mamun M, 2014, CIRC J, V78, P967, DOI 10.1253/circj.CJ-13-1174; Pulido T, 2013, NEW ENGL J MED, V369, P809, DOI 10.1056/NEJMoa1213917; Shimokawa H, 2002, J CARDIOVASC PHARM, V39, P319, DOI 10.1097/00005344-200203000-00001; Xiao JW, 2015, CIRC J, V79, P1342, DOI 10.1253/circj.CJ-14-1015	15	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1213	1214		10.1253/circj.CJ-15-0443		2	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700013		
J	Tatebe, S				Tatebe, Shunsuke			Cardiologists and the Management of Obstetric Venous Thromboembolism	CIRCULATION JOURNAL			English	Editorial Material							DEEP-VEIN-THROMBOSIS; PULMONARY THROMBOEMBOLISM; EMBOLISM; JAPAN; PREVENTION; GUIDELINES; PREGNANCY; OUTCOMES; REGISTRY		[Tatebe, Shunsuke] Tohoku Univ, Dept Cardiovasc Med, Grad Sch Med, Sendai, Miyagi 9808574, Japan	Tatebe, S (reprint author), Tohoku Univ, Dept Cardiovasc Med, Grad Sch Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	shuntatebe@cardio.med.tohoku.ac.jp					Robinson HE, 2005, OBSTET GYNECOL, V106, P1357, DOI 10.1097/01.AOG.0000188387.88032.41; Minakami H, 2014, J OBSTET GYNAECOL RE, V40, P1469, DOI 10.1111/jog.12419; Nakamura M, 2014, CIRC J, V78, P708, DOI 10.1253/circj.CJ-13-0886; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P259, DOI 10.1016/S0033-0620(75)80017-X; Kobayashi T, 2008, CIRC J, V72, P753, DOI 10.1253/circj.72.753; Sakuma M, 2009, CIRC J, V73, P305; Bates S. M., 2012, CHEST S, V141, pe691S; Guimicheva B, 2015, BRIT J HAEMATOL, V168, P163, DOI 10.1111/bjh.13159; Ando M, 2011, CIRC J, V75, P1258, DOI 10.1253/circj.CJ-88-0010; Kanayama N, 2011, J OBSTET GYNAECOL RE, V37, P58, DOI 10.1111/j.1447-0756.2010.01319.x; Cantwell Roch, 2011, BJOG, V118 Suppl 1, P1, DOI 10.1111/j.1471-0528.2010.02847.x; Ministry of Health Labour and Welfare, 2013, TRENDS MAT DEATHS MA; Royal College of Obstetricians and Gynaecologists, 2009, RED RISK THROMB EMB, V37; Tanaka H, 2015, CIRC J, V79, P1357, DOI 10.1253/circj.CJ-14-1228; Toglia MR, 1996, NEW ENGL J MED, V335, P108, DOI 10.1056/NEJM199607113350207	15	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1215	1217		10.1253/circj.CJ-15-0367		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700014		
J	Fujita, Y; Kawamoto, A				Fujita, Yasuyuki; Kawamoto, Atsuhiko			Ninjurin1-A Novel Regulator of Angiogenesis Mediated by Pericytes -	CIRCULATION JOURNAL			English	Editorial Material							ADHESION MOLECULE; NERVE INJURY; CELLS		[Fujita, Yasuyuki; Kawamoto, Atsuhiko] Inst Biomed Res & Innovat, Div Vasc Regenerat, Unit Regenerat Med, Kobe, Hyogo 6500047, Japan	Kawamoto, A (reprint author), Inst Biomed Res & Innovat, Div Vasc Regenerat, Unit Regenerat Med, Chuo Ku, 2-2 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	kawamoto@fbri.org					Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521; Ifergan I, 2011, ANN NEUROL, V70, P751, DOI 10.1002/ana.22519; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Araki T, 2000, J NEUROSCI, V20, P187; Araki T, 1997, J BIOL CHEM, V272, P21373, DOI 10.1074/jbc.272.34.21373; Lee HJ, 2009, CELL DEATH DIFFER, V16, P1395, DOI 10.1038/cdd.2009.78; Matsuki M, 2015, CIRC J, V79, P1363, DOI 10.1253/circj.CJ-14-1376; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Aburakawa Y, 2013, CIRC J, V77, P1053, DOI 10.1253/circj.CJ-12-0897; Araki T, 1996, NEURON, V17, P353, DOI 10.1016/S0896-6273(00)80166-X; Kabara M, 2014, LAB INVEST, V94, P1340, DOI 10.1038/labinvest.2014.121; Stapor PC, 2014, J VASC RES, V51, P163, DOI 10.1159/000362276; Yin GN, 2013, J SEX MED, V10, P1488, DOI 10.1111/jsm.12129	14	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1218	1219		10.1253/circj.CJ-15-0435		2	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700015		
J	Yoshizumi, M; Yoshizumi, M				Yoshizumi, Masao; Yoshizumi, Masanori			Angiotensin (1-7), Small But Complicated, Needs More Exercise	CIRCULATION JOURNAL			English	Editorial Material							CONVERTING ENZYME 2; INSULIN-RESISTANCE; HYPERTENSIVE-RATS; BLOOD-PRESSURE; NITRIC-OXIDE; ACTIVATION; MUSCLE; RISK		[Yoshizumi, Masao] Hiroshima Univ, Dept Cardiovasc Physiol & Med, Grad Sch Biomed & Hlth Sci, Hiroshima 7348551, Japan; [Yoshizumi, Masanori] Nara Med Univ, Dept Pharmacol, Sch Med, Kashihara, Nara 634, Japan	Yoshizumi, M (reprint author), Hiroshima Univ, Dept Cardiovasc Physiol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	yoshizum-tky@umin.ac.jp					Mora S, 2007, CIRCULATION, V116, P2110, DOI 10.1161/CIRCULATIONAHA.107.729939; Santos RA, 2014, HYPERTENSION, V63, P1138, DOI 10.1161/HYPERTENSIONAHA.113.01274; Green DJ, 2008, J APPL PHYSIOL, V105, P766, DOI 10.1152/japplphysiol.01028.2007; Costa MA, 2010, AM J PHYSIOL-HEART C, V299, pH1205, DOI 10.1152/ajpheart.00850.2009; Kuba K, 2013, CIRC J, V77, P301, DOI 10.1253/circj.CJ-12-1544; Goto C, 2003, CIRCULATION, V108, P530, DOI 10.1161/01.CIR.0000080893.55729.28; Henriksen EJ, 2013, MOL CELL ENDOCRINOL, V378, P15, DOI 10.1016/j.mce.2012.04.011; Ohshima K, 2014, HYPERTENSION, V63, pE53, DOI 10.1161/HYPERTENSIONAHA.113.02426; Dimeo F, 2012, HYPERTENSION, V60, P653, DOI 10.1161/HYPERTENSIONAHA.112.197780; Xu P, 2008, HYPERTENSION, V51, P574, DOI 10.1161/HYPERTENSIONAHA.107.102764; Silva SD, 2015, CIRC J, V79, P1372, DOI 10.1253/circj.CJ-14-1179; Ishizawa K, 2001, EUR J PHARMACOL, V430, P359, DOI 10.1016/S0014-2999(01)01405-4; Izawa Y, 2005, EXP CELL RES, V308, P291, DOI 10.1016/j.yexcr.2005.04.028; Rabelo LA, 2011, HYPERTENS RES, V34, P154, DOI 10.1038/hr.2010.235; Shah A, 2012, AM J PHYSIOL-HEART C, V302, pH2372, DOI 10.1152/ajpheart.00846.2011	15	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1220	1221		10.1253/circj.CJ-15-0448		2	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700016		
J	Kario, K; Ogawa, H; Okumura, K; Okura, T; Saito, S; Ueno, T; Haskin, R; Negoita, M; Shimada, K				Kario, Kazuomi; Ogawa, Hisao; Okumura, Ken; Okura, Takafumi; Saito, Shigeru; Ueno, Takafumi; Haskin, Russel; Negoita, Manuela; Shimada, Kazuyuki		SYMPLICITY HTN-Japan Investigators	SYMPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients -	CIRCULATION JOURNAL			English	Article						Ambulatory blood pressure; Asia; Renal denervation; Resistant hypertension	TREATMENT-RESISTANT HYPERTENSION; BLOOD-PRESSURE; SYMPATHETIC DENERVATION; CARDIOVASCULAR-DISEASE; RISK; MANAGEMENT; SOCIETY; PROFILE; BURDEN; IMPACT	Background: SYMPLICITY HTN-Japan is a prospective, randomized, controlled trial comparing renal artery denervation (RDN) with standard pharmacotherapy for treatment of resistant hypertension (systolic blood pressure [SBP] >= 160 mmHg on >= 3 anti-hypertensive drugs including a diuretic for >= 6 weeks). When SYMPLICITY HTN-3 failed to meet the primary efficacy endpoint, the HTN-Japan enrollment was discontinued before completion. Methods and Results: The 6-month change in office and 24-h ambulatory SBP were compared between RDN (n=22) and control (n=19) subjects. Mean baseline office SBP was 181.0 +/- 18.0 mmHg and 178.7 +/- 17.8 mmHg for the RDN and control groups, respectively. The 6-month office SBP change was -16.6 +/- 18.5 mmHg for RDN subjects (P<0.001) and -7.9 +/- 21.0 mmHg for control subjects (P=0.117); the difference between the 6-month change in RDN and control subjects was -8.64 (95% CI: -21.12 to 3.84, P=0.169). Mean 24-h SBP was 164.7 +/- 18.3 (RDN group) and 163.3 +/- 17.2 mmHg (control group). The 24-h 6-month SBP change for the RDN group was -7.52 +/- 11.98 mmHg (P=0.008) and -1.38 +/- 10.2 mmHg (P=0.563) for control subjects; the between-group difference in SBP change was -6.15 (95% CI: -13.23 to 0.94, P=0.087). No major adverse events were reported. Conclusions: SYMPLICITY HTN-Japan, the first randomized controlled trial of RDN in an Asian population, was underpowered for the primary endpoint analysis and did not demonstrate a significant difference in 6-month BP change between RDN and control subjects.	[Kario, Kazuomi] Jichi Med Univ, Dept Cardiovasc Med, Sch Med, Shimotsuke 3290498, Japan; [Ogawa, Hisao] Kumamoto Univ Hosp, Kumamoto, Japan; [Okumura, Ken] Hirosaki Univ, Sch Med & Hosp, Aomori, Japan; [Okura, Takafumi] Ehime Univ, Matsuyama, Ehime 790, Japan; [Saito, Shigeru] Shonan Kamakura Gen Hosp, Kanagawa, Japan; [Ueno, Takafumi] Kurume Univ Hosp, Fukuoka, Japan; [Haskin, Russel] Medtron Japan, Tokyo, Japan; [Shimada, Kazuyuki] New Oyama Municipal Hosp, Oyama, Tochigi, Japan; [Negoita, Manuela] Medtronic, Santa Rosa, CA USA	Kario, K (reprint author), Jichi Med Univ, Dept Cardiovasc Med, Dept Sleep & Circadian Cardiol, Sch Med, 3311-1 Yakushiji, Shimotsuke 3290498, Japan.	kkario@jichi.ac.jp			Medtronic Japan	The authors gratefully acknowledge all of the HTN-Japan Co-investigators; Daiki Yasuhara, for excellent study management; Martin Fahy, MS, and Minglei Liu, PhD, from Medtronic for statistical support; Colleen Gilbert, PharmD, for assistance with the manuscript; and Sandeep Brar, MD and Myra Fan for study support and expert review. This work was supported by Medtronic Japan (ClinicalTrials.gov NCT01644604). The institutions and primary investigators for the SYMPLICITY HTN-Japan study are listed in Appendix.	Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Kandzari DE, 2015, EUR HEART J, V36, P219, DOI 10.1093/eurheartj/ehu441; Krum H, 2014, LANCET, V383, P622, DOI 10.1016/S0140-6736(13)62192-3; Wray DW, 2010, HYPERTENSION, V55, P1217, DOI 10.1161/HYPERTENSIONAHA.109.147058; Esler MD, 2012, CIRCULATION, V126, P2976, DOI 10.1161/CIRCULATIONAHA.112.130880; Lewington S, 2002, LANCET, V360, P1903; Kario K, 2003, CIRCULATION, V107, P1401, DOI 10.1161/01.CIR.0000056521.67546.AA; de la Sierra A, 2011, HYPERTENSION, V57, P898, DOI 10.1161/HYPERTENSIONAHA.110.168948; Mahfoud F, 2013, CIRCULATION, V128, P132, DOI 10.1161/CIRCULATIONAHA.112.000949; Daugherty SL, 2012, CIRCULATION, V125, P1635, DOI 10.1161/CIRCULATIONAHA.111.068064; Esler MD, 2010, LANCET, V376, P1903, DOI 10.1016/S0140-6736(10)62039-9; Bakris GL, 2014, J AM COLL CARDIOL, V64, P1071, DOI 10.1016/j.jacc.2014.05.012; Bhatt DL, 2014, NEW ENGL J MED, V370, P1393, DOI 10.1056/NEJMoa1402670; Miura K, 2013, CIRC J, V77, P2226, DOI 10.1253/circj.CJ-13-0847; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)17741-1; O'Brien E, 2013, J HYPERTENS, V31, P1731, DOI 10.1097/HJH.0b013e328363e964; Ueshima H, 2008, CIRCULATION, V118, P2702, DOI 10.1161/CIRCULATIONAHA.108.790048; Hering D, 2014, HYPERTENSION, V64, P118, DOI 10.1161/HYPERTENSIONAHA.113.03098; DiBona GF, 2010, AM J PHYSIOL-REG I, V298, pR245, DOI 10.1152/ajpregu.00647.2009; Polimeni A, 2013, CIRC J, V77, P857, DOI 10.1253/circj.CJ-13-0297; Perkovic V, 2007, HYPERTENSION, V50, P991, DOI 10.1161/HYPERTENSIONAHA.107.095497; Kario K, 2013, HYPERTENS RES, V36, P478, DOI 10.1038/hr.2013.19; Woodward M, 2006, INT J EPIDEMIOL, V35, P1412, DOI 10.1093/lje/dyl222; Katsuya T, 2003, HYPERTENS RES, V26, P521, DOI 10.1291/hypres.26.521; Bohm M, 2013, AM HEART J, V166, P306, DOI 10.1016/j.ahj.2013.04.016; Ogihara T, 2009, HYPERTENS RES, V32, P3, DOI 10.1038/hr.2008.15; Ishikawa Y, 2010, J HYPERTENS, V28, P1630, DOI 10.1097/HJH.0b013e32833a8b9f; Stamler Jeremiah, 1997, American Journal of Clinical Nutrition, V65, p626S	28	3	3	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1222	1229		10.1253/circj.CJ-15-0150		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700017		
J	Nakamura, M; Nishikawa, M; Komuro, I; Kitajima, I; Uetsuka, Y; Yamagami, T; Minamiguchi, H; Yoshimatsu, R; Tanabe, K; Matsuoka, N; Kanmuri, K; Ogawa, H				Nakamura, Mashio; Nishikawa, Masakatsu; Komuro, Issei; Kitajima, Isao; Uetsuka, Yoshio; Yamagami, Takuji; Minamiguchi, Hiroki; Yoshimatsu, Rika; Tanabe, Kosuke; Matsuoka, Nobushige; Kanmuri, Kazuhiro; Ogawa, Hisao			Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study)	CIRCULATION JOURNAL			English	Article						Apixaban; Deep vein thrombosis; Japanese; Oral anticoagulant; Pulmonary embolism	ORAL ANTICOAGULANTS; STANDARD THERAPY	Background: Anticoagulation is recommended as standard of care for venous thromboembolism (VTE) (pulmonary embolism [PE]/deep vein thrombosis [DVT]), for which unfractionated heparin (UFH) and warfarin are used in Japan. In the multi-regional AMPLIFY study, a fixed-dose regimen of apixaban alone was non-inferior to conventional therapy for treatment of PE/DVT and was associated with significantly fewer bleeding events. Methods and Results: Japan phase 3 study (AMPLIFY-J), randomized, active-controlled, open-label study in Japanese subjects with acute PE/DVT, was designed based on AMPLIFY. Key objectives were to investigate safety and efficacy of apixaban in symptomatic PE/DVT subjects during 24-week treatment. UFH/warfarin was used as control treatment. Apixaban was initiated at 10 mg twice daily for 7 days, followed by 5 mg twice daily for 23 weeks. All endpoints and imaging for thrombotic burden were assessed by an event adjudication committee. Eighty subjects were randomized, 33 subjects (41.3%) were aged <65 years. Proportion of major/clinically relevant non-major bleeding was lower in apixaban (7.5%) compared with well-controlled UFH/warfarin (28.2%; median TTR, 70.1%). Recurrent VTE occurred in no subjects in apixaban and in 1 subject in UFH/warfarin. Thrombotic burden results were similar in both groups. Proportions of subjects with adverse events was generally similar in both groups. Conclusions: Apixaban was well-tolerated and had a favorable safety profile. No clinically important efficacy difference compared with UFH/warfarin was observed.	[Nakamura, Mashio] Mie Univ, Dept Cardiol & Nephrol, Grad Sch Med, Tsu, Mie 5148507, Japan; [Nishikawa, Masakatsu] Mie Univ Hosp, Clin Res Support Ctr, Tsu, Mie, Japan; [Komuro, Issei] Univ Tokyo, Grad Sch Sci, Dept Cardiovasc Med, Tokyo 113, Japan; [Kitajima, Isao] Toyama Univ, Dept Clin Lab & Mol Pathol, Grad Sch Med & Pharmaceut Sci, Toyama 930, Japan; [Uetsuka, Yoshio] Tokyo Womens Med Univ, Dept Hlth Serv & Hosp Adm, Tokyo, Japan; [Yamagami, Takuji; Yoshimatsu, Rika] Kochi Univ, Dept Radiol, Kochi Med Sch, Nankoku, Kochi, Japan; [Minamiguchi, Hiroki] Wakayama Med Univ, Dept Radiol, Wakayama, Japan; [Tanabe, Kosuke; Kanmuri, Kazuhiro] Pfizer Japan, Clin Res, Dev Japan, Tokyo, Japan; [Matsuoka, Nobushige] Pfizer Japan, Clin Stat, Dev Japan, Tokyo, Japan; [Ogawa, Hisao] Kumamoto Univ, Dept Cardiovasc Med, Grad Sch Med Sci, Kumamoto, Japan; [Ogawa, Hisao] Natl Cerebral & Cardiovasc Ctr, Suita, Osaka, Japan	Nakamura, M (reprint author), Mie Univ, Dept Cardiol & Nephrol, Grad Sch Med, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	mashio@clin.medic.mie-u.ac.jp			Daiichi Sankyo; Bayer Yakuhin; Nippon Boehringer Ingelheim; Astellas Pharma; Takeda Pharmaceutical; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim Japan; Mitsubishi Tanabe Pharma; MSD; Pfizer Japan; Sanofi; Teijin Pharma; Novartis Pharma; Chugai Pharmaceutical; Dainippon Sumitomo Pharma; Kowa; Otsuka Pharmaceutical; Shionogi; Pfizer Inc	M. Nakamura has received remuneration from Daiichi Sankyo, Bayer Yakuhin. M. Nishikawa has received remuneration and research funds from Daiichi Sankyo. I. Komuro has received remuneration from Daiichi Sankyo, Nippon Boehringer Ingelheim, and scholarship funds from Astellas Pharma, Daiichi Sankyo, Takeda Pharmaceutical, Nippon Boehringer Ingelheim, Bristol-Myers Squibb. I. Kitajima has received remuneration from Nippon Boehringer Ingelheim. H.O. has received remuneration from AstraZeneca, Bayer Yakuhin, Boehringer Ingelheim Japan, Bristol-Myers Squibb, Daiichi Sankyo, Mitsubishi Tanabe Pharma, MSD, Pfizer Japan, Sanofi, Takeda Pharmaceutical and Teijin Pharma, and has received research funds from Bayer Yakuhin, Daiichi Sankyo and Novartis Pharma, and has received scholarship funds from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Otsuka Pharmaceutical, Pfizer Japan, Sanofi, Shionogi and Takeda Pharmaceutical. Y.U., T.Y., H.M., R.Y. have no conflict of interest.; This study was funded by Pfizer Inc and Bristol-Myers Squibb.	Amin Alpesh, 2014, J Med Econ, V17, P763, DOI 10.3111/13696998.2014.950670; Agnelli G, 2013, NEW ENGL J MED, V368, P699, DOI 10.1056/NEJMoa1207541; Agnelli G, 2013, NEW ENGL J MED, V369, P799, DOI 10.1056/NEJMoa1302507; Nakamura M, 2014, CIRC J, V78, P708, DOI 10.1253/circj.CJ-13-0886; Buller H, 2008, J THROMB HAEMOST, V6, P1313, DOI 10.1111/j.1538-7836.2008.03054.x; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Buller HR, 2007, NEW ENGL J MED, V357, P1094; Ota M, 2002, HEART VESSELS, V17, P7, DOI 10.1007/s003800200036; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; ICH Steering Committee, 1998, ICHE5R1; JCS Joint Working Group, 2011, CIRC J, V75, P1258; National Institute for Health and Care Excellence, FIN APPR DET AP TREA; Vargas-Castrillon E, 2014, VASC HLTH RISK MANAG, V10, P627; Yeh CH, 2014, BLOOD, V124, P1020, DOI 10.1182/blood-2014-03-563056	14	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1230	+		10.1253/circj.CJ-15-0195		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700018		
J	Sato, N; Takahashi, W; Hirayama, A; Ajioka, M; Takahashi, N; Okishige, K; Wang, XL; Maki, A; Maruyama, H; Ebinger, U; Yamaguchi, M; Pang, YN; Matsumoto, H; Kawana, M				Sato, Naoki; Takahashi, Wataru; Hirayama, Atsushi; Ajioka, Masayoshi; Takahashi, Naoto; Okishige, Kaoru; Wang, XingLi; Maki, Akio; Maruyama, Hideki; Ebinger, Ursula; Yamaguchi, Masayuki; Pang, Yinuo; Matsumoto, Hiroki; Kawana, Masatoshi			Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure	CIRCULATION JOURNAL			English	Article						Efficacy; Pharmacokinetics; Safety; Serelaxin; Tolerability	RECOMBINANT HUMAN RELAXIN-2; CONTROLLED TRIAL; CLINICAL-TRIALS; TASK-FORCE; OUTCOMES; ASSOCIATION; HOSPITALIZATION; EPIDEMIOLOGY; GUIDELINES; REGISTRIES	Background: Serelaxin, a recombinant form of human relaxin-2, is in development for treating acute heart failure (AHF) and a Phase II study in Japanese AHF patients was conducted. Methods and Results: A randomized, double-blind, placebo-controlled study of serelaxin at 10 and 30 mu g.kg(-1).day(-1) continuous intravenous infusion for up to 48 h, added to standard care for Japanese AHF patients. Primary endpoints were adverse events (AEs) through Day 5, serious AEs (SAEs) through Day 14, and serelaxin pharmacokinetics. Secondary endpoints included changes in systolic blood pressure (SBP) and cardiorenal biomarkers. A total of 46 patients received the study drug and were followed for 60 days. The observed AE profile was comparable between the groups, with no AEs of concern. Dose-dependent increase in the serum concentration of serelaxin was observed across the 2 dose rates of serelaxin. A greater reduction in SBP was observed with serelaxin 30 mu g.kg(-1).day(-1) vs. placebo (-7.7 [-16.4, 1.0] mmHg). A greater reduction in NT-proBNP was noted with serelaxin (-50.8% and -54.9% for 10 and 30 mu g.kg(-1).day(-1), respectively at Day 2). Conclusions: Serelaxin was well tolerated in this study with Japanese AHF patients, with no AEs of concern and favorable beneficial trends on efficacy. These findings support further evaluation of serelaxin 30 mu g.kg(-1).day(-1) in this patient population.	[Sato, Naoki; Takahashi, Naoto] Musashi Kosugi Hosp, Cardiol & Intens Care Unit, Nippon Med Sch, Kawasaki, Kanagawa 2118533, Japan; [Takahashi, Wataru] Shinshu Ueda Med Ctr, Natl Hosp Org, Dept Cardiol, Nagano, Japan; [Hirayama, Atsushi] Nihon Univ, Sch Med, Div Cardiol, Tokyo, Japan; [Ajioka, Masayoshi] Tosei Gen Hosp, Dept Cardiol, Aichi, Japan; [Okishige, Kaoru] Yokohama City Minato Red Cross Hosp, Div Cardiol, Kanagawa, Japan; [Wang, XingLi; Ebinger, Ursula] Novartis Pharmaceut, E Hanover, NJ USA; [Pang, Yinuo] Novartis Inst BioMed Res Inc, Cambridge, MA USA; [Maki, Akio; Maruyama, Hideki; Yamaguchi, Masayuki; Matsumoto, Hiroki] Novartis Pharma KK, Tokyo, Japan; [Kawana, Masatoshi] Tokyo Womens Med Univ Hosp, Dept Gen Med, Tokyo, Japan	Sato, N (reprint author), Musashi Kosugi Hosp, Cardiol & Intens Care Unit, Nippon Med Sch, Nakahara Ku, 1-396 Kosugi Cho, Kawasaki, Kanagawa 2118533, Japan.	nms-ns@nms.ac.jp			Novartis; Daiichi Sankyo Co, Ltd; Roche-Japan; Otsuka Pharmaceutical Co, Ltd; Astellas Pharma Inc.; Astellas Pharma Inc; Bayer Yakuhin, Ltd; Chugai-Igakusya; Sumitomo Dainippon Pharma Co, Ltd; Mochida Pharmaceutical Co, Ltd; Goodman Co, Ltd; Shionogi Co, Ltd; Chugai Pharmaceutical Co, Ltd; Novartis Pharma K.K.; Pfizer Japan Inc; Eisai Co, Ltd; MSD K.K.; Kissei Pharmaceutical Co, Ltd; Sanofi K.K.; Mitsubishi Tanabe Pharma Corporation; Nippon Boehringer Ingelheim Co, Ltd; Kowa Company, Ltd; Nihon Medi-Physics Co, Ltd; Kyowa Hakko Kirin Co, Ltd; Takeda Pharmaceutical Company Limited; Astra-Zeneca K.K.; Daiichi Sankyo Co, Ltd.	This study was funded by Novartis.; N.S. received consultancy honoraria from Novartis Pharma K.K., Otsuka Pharmaceutical Co, Ltd, Daiichi Sankyo Co, Ltd, Ono Pharmaceutical Co, Ltd, Bayer Yakuhin, Ltd, and Nippon Boehringer Ingelheim Co, Ltd and received research support to institution from Daiichi Sankyo Co, Ltd, Roche-Japan, Otsuka Pharmaceutical Co, Ltd, and Astellas Pharma Inc. A.H. received consultancy honoraria from Bayer Yakuhin, Ltd, Astellas Pharma Inc, Daiichi-Sankyo Pharmaceutical Co Sanofi K.K., Sanwa Kagaku Kenkyusho Co, Ltd, Nippon Boehringer Ingelheim Co, Ltd, Kyowa Hakko Kirin Co, Ltd, Takeda Pharmaceutical Company Limited, Kowa Company, Ltd, Kissei Pharmaceutical Co, Ltd, MSD K.K., Shionogi & Co, Ltd, Eisai Co, Ltd, Chugai Pharmaceutical Co, Ltd, Pfizer Japan Inc, Otsuka Pharmaceutical Co, Ltd, Mitsubishi Tanabe Pharma Corporation, AstraZeneca K.K., Bristol-Myers K.K., Sumitomo Dainippon Pharma Co, Ltd, Ono Pharmaceutical Co, Ltd, Novartis Pharma K.K., Janssen Pharmaceutical K.K., and Toa Eiyo Ltd, and received research support to institution from Astellas Pharma Inc, Bayer Yakuhin, Ltd, Chugai-Igakusya, Sumitomo Dainippon Pharma Co, Ltd, Mochida Pharmaceutical Co, Ltd, Goodman Co, Ltd, Shionogi & Co, Ltd, Chugai Pharmaceutical Co, Ltd, Novartis Pharma K.K., Pfizer Japan Inc, Eisai Co, Ltd, MSD K.K., Otsuka Pharmaceutical Co, Ltd, Kissei Pharmaceutical Co, Ltd, Sanofi K.K., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co, Ltd, Kowa Company, Ltd, Nihon Medi-Physics Co, Ltd, Kyowa Hakko Kirin Co, Ltd, Takeda Pharmaceutical Company Limited, Astra-Zeneca K.K., and Daiichi Sankyo Co, Ltd. W.T., M.A., N.T., and K.O. have no disclosures to report. A.M., H. Maruyama, U.E., M.Y., Y.P., H. Matsumoto, and X.L.W. are employees of Novartis.	Ambrosy AP, 2014, J AM COLL CARDIOL, V63, P1123, DOI 10.1016/j.jacc.2013.11.053; Alla F, 2007, HEART FAIL REV, V12, P91, DOI 10.1007/s10741-007-9009-2; McMurray JJV, 2007, JAMA-J AM MED ASSOC, V298, P2009, DOI 10.1001/jama.298.17.2009; Metra M, 2013, J AM COLL CARDIOL, V61, P196, DOI 10.1016/j.jacc.2012.11.005; Teerlink JR, 2009, LANCET, V373, P1429, DOI 10.1016/S0140-6736(09)60622-X; Pang PS, 2008, EUR HEART J, V29, P816, DOI 10.1093/eurheartj/ehn048; Cuffe MS, 2002, JAMA-J AM MED ASSOC, V287, P1541, DOI 10.1001/jama.287.12.1541; Greene SJ, 2014, AM HEART J, V168, P142, DOI 10.1016/j.ahj.2014.05.009; Felker GM, 2010, CIRC-HEART FAIL, V3, P314, DOI 10.1161/CIRCHEARTFAILURE.109.893222; Du XJ, 2010, NAT REV CARDIOL, V7, P48, DOI 10.1038/nrcardio.2009.198; Torre-Amione G, 2009, J CARD FAIL, V15, P639, DOI 10.1016/j.cardfail.2009.04.001; Cotter G, 2010, CARDIOLOGY, V115, P29, DOI 10.1159/000249280; Conrad KP, 2011, CURR HYPERTENS REP, V13, P409, DOI 10.1007/s11906-011-0231-x; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Gheorghiade M, 2009, J AM COLL CARDIOL, V53, P557, DOI 10.1016/j.jacc.2008.10.041; Teerlink JR, 2013, LANCET, V381, P29, DOI 10.1016/S0140-6736(12)61855-8; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Okura Y, 2008, CIRC J, V72, P489, DOI 10.1253/circj.72.489; Sakata Y, 2013, CIRC J, V77, P2209, DOI 10.1253/circj.CJ-13-0971; Dahlke M, 2015, J CLIN PHARMACOL, V55, P415, DOI 10.1002/jcph.433; Fang J, 2008, J AM COLL CARDIOL, V52, P428, DOI 10.1016/j.jacc.2008.03.061; Gheorghiade M, 2005, AM J CARDIOL, V96, p11G, DOI 10.1016/j.amjcard.2005.07.016; JCS Joint Working Group, 2013, CIRC J, V77, P2157; Kajimoto K, 2015, AM J CARDIOL, V115, P334, DOI 10.1016/j.amjcard.2014.11.007; Kobalava Z, 2013, CIRCULATION, V128; Metra M, 2010, INT J CARDIOL, V144, P175, DOI 10.1016/j.ijcard.2010.04.003; Teichman Sam L, 2010, Curr Heart Fail Rep, V7, P75, DOI 10.1007/s11897-010-0010-z	27	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1237	+		10.1253/circj.CJ-15-0227		14	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700019		
J	Ishihara, M; Fujino, M; Ogawa, H; Yasuda, S; Noguchi, T; Nakao, K; Ozaki, Y; Kimura, K; Suwa, S; Fujimoto, K; Nakama, Y; Morita, T; Shimizu, W; Saito, Y; Tsujita, K; Nishimura, K; Miyamoto, Y				Ishihara, Masaharu; Fujino, Masashi; Ogawa, Hisao; Yasuda, Satoshi; Noguchi, Teruo; Nakao, Koichi; Ozaki, Yukio; Kimura, Kazuo; Suwa, Satoru; Fujimoto, Kazuteru; Nakama, Yasuharu; Morita, Takashi; Shimizu, Wataru; Saito, Yoshihiko; Tsujita, Kennichi; Nishimura, Kunihiko; Miyamoto, Yoshihiro		J-MINUET Investigators	Clinical Presentation, Management and Outcome of Japanese Patients With Acute Myocardial Infarction in the Troponin Era - Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET) -	CIRCULATION JOURNAL			English	Article						Acute myocardial infarction; Japan; Mortality; Troponin	PERCUTANEOUS CORONARY INTERVENTION; ASSOCIATION TASK-FORCE; ST-ELEVATION; PRACTICE GUIDELINES; RANDOMIZED-TRIAL; TRENDS; MORTALITY; COLLEGE; POPULATION; DISEASE	Background: New criteria for diagnosis of acute myocardial infarction (AMI) were proposed in 2000 as a universal definition, in which cardiac troponin (cTn) was the preferred biomarker. A large number of patients formerly classified by creatine kinase (CK) as unstable angina are now ruled-in by cTn as non-ST-elevation myocardial infarction (NSTEMI). Methods and Results: The Japanese registry of acute Myocardial INfarction diagnosed by Universal dEfiniTion (J-MINUET) is a prospective and multicenter registry conducted in 28 institutions. We enrolled 3,283 consecutive patients with AMI diagnosed by cTn-based criteria who were admitted to participating institutions within 48 h of symptom onset. There were 2,262 patients (68.9%) with STEMI and 1,021 (31.1%) with NSTEMI. CK was not elevated more than twice the upper limit of normal in 458 patients (44.9%) with NSTEMI (NSTEMI-CK). Although there was no significant difference in the in-hospital mortality of STEMI and NSTEMI with CK elevation (NSTEMI+ CK) patients (7.1% vs. 7.8%, P=0.57), it was significantly lower in patients with NSTEMI-CK than in those with STEMI or NSTEMI+ CK (1.7%, P<0.001 for each). Conclusions: J-MINUET revealed the clinical presentation, management and outcomes of Japanese patients with AMI in the current cTn era. We should be aware of the difference between AMI diagnosed by CK-based criteria and AMI diagnosed by cTn-based criteria when using universal definitions for the diagnosis of AMI.	[Ishihara, Masaharu] Hyogo Coll Med, Dept Internal Med, Div Coronary Artery Dis, Nishinomiya, Hyogo 6638501, Japan; [Fujino, Masashi; Ogawa, Hisao; Yasuda, Satoshi; Noguchi, Teruo] Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, Suita, Osaka, Japan; [Kimura, Kazuo; Miyamoto, Yoshihiro] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Med & Epidemiol Informat, Suita, Osaka, Japan; [Nakao, Koichi] Saiseikai Kumamoto Hosp, Cardiovasc Ctr, Div Cardiol, Kumamoto, Japan; [Ozaki, Yukio] Fujita Hlth Univ Hosp, Dept Cardiol, Toyoake, Aichi, Japan; [Kimura, Kazuo] Yokohama City Univ, Div Cardiol, Med Ctr, Yokohama, Kanagawa 232, Japan; [Suwa, Satoru] Juntendo Univ, Shizuoka Hosp, Dept Cardiol, Izunokuni, Japan; [Fujimoto, Kazuteru] Kumamoto Med Ctr, Dept Cardiol, Natl Hosp Org, Kumamoto, Japan; [Nakama, Yasuharu] Hiroshima City Hosp, Dept Cardiol, Hiroshima, Japan; [Morita, Takashi] Osaka Gen Med Ctr, Div Cardiol, Osaka, Japan; [Shimizu, Wataru] Nippon Med Sch, Div Cardiol & Regenerat Med, Tokyo 113, Japan; [Saito, Yoshihiko] Nara Med Univ, Dept Med 1, Kashihara, Nara 634, Japan; [Ogawa, Hisao; Tsujita, Kennichi] Kumamoto Univ, Dept Cardiovasc Med, Grad Sch Med Sci, Kumamoto, Japan	Ishihara, M (reprint author), Hyogo Coll Med, Dept Internal Med, Div Coronary Artery Dis, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	ma-ishihara@hyo-med.ac.jp			Intramural Research Fund [23-4-5]	This study was supported by the Intramural Research Fund, grant number 23-4-5, for Cardiovascular Diseases of the National Cerebral and Cardiovascular Center.	Rogers WJ, 2008, AM HEART J, V156, P1026, DOI 10.1016/j.ahj.2008.07.030; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; Jia HB, 2013, J AM COLL CARDIOL, V62, P1748, DOI 10.1016/j.jacc.2013.05.071; Abbott JD, 2007, AM J CARDIOL, V100, P190, DOI 10.1016/j.amjcard.2007.02.083; Morrow DA, 2001, JAMA-J AM MED ASSOC, V286, P2405, DOI 10.1001/jama.286.19.2405; Thygesen K, 2012, J AM COLL CARDIOL, V60, P1581, DOI 10.1016/j.jacc.2012.08.001; McManus DD, 2011, AM J MED, V124, P40, DOI 10.1016/j.amjmed.2010.07.023; O'Gara PT, 2013, J AM COLL CARDIOL, V61, pE78, DOI 10.1016/j.jacc.2012.11.019; Rosamond WD, 2012, CIRCULATION, V125, P1848, DOI 10.1161/CIRCULATIONAHA.111.047480; Kastrati A, 2006, JAMA-J AM MED ASSOC, V295, P1531, DOI 10.1001/jama.295.13.joc60034; Mueller M, 2013, CIRC J, V77, P1653, DOI 10.1253/circj.CJ-13-0706; Palmerini T, 2012, LANCET, V379, P1393, DOI 10.1016/S0140-6736(12)60324-9; Yeh RW, 2010, NEW ENGL J MED, V362, P2155, DOI 10.1056/NEJMoa0908610; Daida H, 2013, CIRC J, V77, P934, DOI 10.1253/circj.CJ-13-0174; Alpert JS, 2000, J AM COLL CARDIOL, V36, P959; Kushner FG, 2009, J AM COLL CARDIOL, V54, P2205, DOI 10.1016/j.jacc.2009.10.015; Roger VL, 2010, CIRCULATION, V121, P863, DOI 10.1161/CIRCULATIONAHA.109.897249; Hata J, 2013, CIRCULATION, V128, P1198, DOI 10.1161/CIRCULATIONAHA.113.002424; Takii T, 2010, CIRC J, V74, P93, DOI 10.1253/circj.CJ-09-0619; Hassam SE, 2006, J AM COLL CARDIOL, V47, P2413, DOI 10.1016/j.jacc.2005.11.091; Japanese Circulation Society, 2013, GUID DIAGN TREATM CA; Little RJA, 2002, STAT ANAL MISSING DA, V2nd, P65; Ogawa H, 2009, J CARDIOL, V54, P1, DOI 10.1016/j.jjcc.2009.05.005; Song Young Bin, 2010, Am J Cardiol, V106, P1397, DOI 10.1016/j.amjcard.2010.07.010; Yamamoto T, 2005, CIRC J, V69, P774, DOI 10.1253/circj.69.774	25	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1255	1262		10.1253/circj.CJ-15-0217		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700021		
J	Hosoda, J; Ishikawa, T; Sumita, S; Matsushita, K; Matsumoto, K; Kimura, Y; Ogino, Y; Taguchi, Y; Matsushita, H; Nakagawa, T; Sugano, T; Ishigami, T; Kimura, K; Umemura, S				Hosoda, Junya; Ishikawa, Toshiyuki; Sumita, Shinichi; Matsushita, Kohei; Matsumoto, Katsumi; Kimura, Yuichiro; Ogino, Yutaka; Taguchi, Yuka; Matsushita, Hirooki; Nakagawa, Takeshi; Sugano, Teruyasu; Ishigami, Tomoaki; Kimura, Kazuo; Umemura, Satoshi			Development of Atrioventricular Block and Diagnostic Value of Stored Electrograms in Patients With Sick Sinus Syndrome and Implanted Pacemaker	CIRCULATION JOURNAL			English	Article						Beta-blocker; Electrogram; Pacemaker; Sick sinus syndrome	TERM-FOLLOW-UP; DUAL-CHAMBER; ATRIAL-FIBRILLATION; NODE DISEASE; CONSECUTIVE PATIENTS; STIMULATION MODE; RANDOMIZED-TRIAL; PACING MODE; AV BLOCK; CONDUCTION	Background: The incidence of atrioventricular block (AVB) in pacemaker patients with sick sinus syndrome (SSS) is not yet known. The aim of this study was to analyze AVB episodes in SafeR mode based on stored electrograms (EGM), and determine the occurrence rate and risk factors for advanced AVB in a pacemaker population with SSS. Methods and Results: The study included 50 consecutive patients with SSS without a history of advanced AVB who had a dual-chamber pacemaker programmed in SafeR mode. A total of 377 EGM stored in the pacemakers as AVB episodes fulfilling the second-or third-degree criterion were analyzed. Of 377 EGM, 73 EGM (19.4%) were appropriate episodes, whereas the other EGM did not show actual AVB, and showed atrial tachyarrhythmia, ventricular event in the blanking period, or premature atrial contractions with block. On EGM analysis, advanced AVB occurred in 9 patients (18%), and the occurrence rate was 11.7% per year. Moreover, on multivariate analysis beta-blocker use was an independent risk factor for advanced AVB (OR, 9.10; P=0.004). Conclusions: The occurrence rate of advanced AVB in patients with SSS is much higher than previously reported, and beta-blocker use is an independent risk factor for advanced AVB. SafeR is useful to detect latent AVB. Stored EGM, however, sometimes include inaccurately classified events.	[Hosoda, Junya] Yokohama City Univ Med, Dept Cardiol, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Med Ctr, Dept Cardiovasc Ctr, Yokohama, Kanagawa 232, Japan	Hosoda, J (reprint author), Yokohama City Univ Med, Dept Cardiol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	j_hosoda@yokohama-cu.ac.jp					Adachi M, 2008, EUROPACE, V10, P134, DOI 10.1093/europace/eum290; Andersen HR, 1998, CIRCULATION, V98, P1315; Nielsen JC, 2003, J AM COLL CARDIOL, V42, P614, DOI 10.1016/S0735-1097(03)00757-5; Kaufman ES, 2012, HEART RHYTHM, V9, P1241, DOI 10.1016/j.hrthm.2012.03.017; Davy JM, 2012, PACE, V35, P392, DOI 10.1111/j.1540-8159.2011.03314.x; Thibault B, 2009, PACE, V32, pS231, DOI 10.1111/j.1540-8159.2008.02293.x; LECLERCQ C, 1995, AM HEART J, V129, P1133, DOI 10.1016/0002-8703(95)90394-1; Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; Kristensen L, 2004, HEART, V90, P661, DOI 10.1136/hrt.2003.016063; Savoure A, 2005, PACE, V28, pS43, DOI 10.1111/j.1540-8159.2005.00095.x; Pioger G, 2007, PACE, V30, pS66; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; Frohlig G, 2006, EUROPACE, V8, P96, DOI 10.1093/europace/euj024d; Wilkoff BL, 2002, JAMA-J AM MED ASSOC, V288, P3115; Sweeney MO, 2003, CIRCULATION, V107, P2932, DOI 10.1161/01.CIR.0000072769.17295.B1; BRANDT J, 1992, J AM COLL CARDIOL, V20, P633; Hoijer CJ, 2007, PACE, V30, P740, DOI 10.1111/j.1540-8159.2007.00744.x; JCS Joint Working Group, 2013, CIRC J, V77, P249; Ogawa S, 2013, CIRC J, V77, P497, DOI 10.1253/circj.CJ-66-0055; Kristensen L, 2001, PACE, V24, P358, DOI 10.1046/j.1460-9592.2001.00358.x; Matsumoto H, 2004, EUROPACE, V6, P444; Nowak B, 2003, EUROPACE, V5, P103, DOI 10.1053/eupc.2002.0276; Nowak B, 2005, PACE, V28, P620, DOI 10.1111/j.1540-8159.2005.00159.x; PRYSTOWSKY EN, 1988, J CLIN PHARMACOL, V28, P6; ROSENQVIST M, 1991, AM J CARDIOL, V67, P148, DOI 10.1016/0002-9149(91)90437-P; ROSENQVIST M, 1989, PACE, V12, P97; SGARBOSSA EB, 1993, CIRCULATION, V88, P1045; Sweeney MO, 2007, NEW ENGL J MED, V357, P1000, DOI 10.1056/NEJMoa071880	28	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1263	1268		10.1253/circj.CJ-14-1255		6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700022		
J	Hokimoto, S; Sakamoto, K; Akasaka, T; Kaikita, K; Honda, O; Naruse, M; Ogawa, H				Hokimoto, Seiji; Sakamoto, Kenji; Akasaka, Tomonori; Kaikita, Koichi; Honda, Osamu; Naruse, Masahiro; Ogawa, Hisao		Multictr Study Hemodialysis Patien	High Mortality Rate in Hemodialysis Patients Who Undergo Invasive Cardiovascular Procedures Related to Peripheral Artery Disease - Community-Based Observational Study in Kumamoto Prefecture -	CIRCULATION JOURNAL			English	Article						Arteriosclerosis; Cardiovascular disease; Hemodialysis; Mortality; Peripheral artery disease	CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; DIALYSIS PATIENTS; DEATH; EVENTS; RISK; REVASCULARIZATION; INSUFFICIENCY; ASSOCIATION; OUTCOMES	Background: Cardiovascular disease is a major cause of mortality in hemodialysis patients. The aim was to assess the relationship of various invasive cardiovascular procedures (ICP) to clinical outcome in hemodialysis patients. Methods and Results: A total of 5,813 patients at 76 facilities were on maintenance hemodialysis in Kumamoto Prefecture. Of these, 4,807 patients at 58 institutions were enrolled. Of 4,807 patients, 212 ICP (4.4%) were performed for various cardiovascular diseases in 189 patients (3.9%). ICP included PCI (n=80), endovascular treatment (n=59), radiofrequency catheter ablation (n=8), implantation of permanent pacemaker (n=15) and ICD (n=5), thoracotomy for valvular diseases (n=16), CABG (n=14), bypass surgery for peripheral artery disease (PAD; n=8), and artificial vessel replacement for aneurysm or aortic dissection (n=7). The overall mortality rate was 10.1% (19/189 patients). The mortality rate was highest in patients who underwent ICP for PAD, compared with other ICP (PAD, 18.2%; non-PAD, 6.7%, P=0.017). Infection and PAD were significant predictors of mortality (infection: OR, 8.30; 95% CI: 1.29-65.13, P=0.027; PAD: OR, 3.76; 95% CI: 1.35-10.48, P=0.012). The presence of inflammation/malnutrition factors was associated with high mortality (OR, 15.49; 95% CI: 3.22-74.12, P=0.0006). Conclusions: In this community-based registry study of 4,807 hemodialysis patients, the mortality rate of PAD patients was high despite ICP.	[Hokimoto, Seiji; Sakamoto, Kenji; Akasaka, Tomonori; Kaikita, Koichi; Ogawa, Hisao] Kumamoto Univ, Dept Cardiovasc Med, Grad Sch Med Sci, Kumamoto 8608556, Japan; [Honda, Osamu; Naruse, Masahiro] Comm Dialysis Facil Kumamoto, Kumamoto, Japan	Hokimoto, S (reprint author), Kumamoto Univ, Dept Cardiovasc Med, Grad Sch Med Sci, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.	shokimot@kumamoto-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan	This study was supported in part by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Shlipak MG, 2001, J AM COLL CARDIOL, V38, P705, DOI 10.1016/S0735-1097(01)01450-4; O'Hare AM, 2004, J VASC SURG, V39, P709, DOI 10.1016/j.jvs.2003.11.038; Bonello L, 2008, AM J CARDIOL, V102, P535, DOI 10.1016/j.amjcard.2008.04.040; Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80; Charytan D, 2006, AM HEART J, V152, P558, DOI 10.1016/j.ahj.2006.02.021; Bhatt DL, 2006, JAMA-J AM MED ASSOC, V295, P180, DOI 10.1001/jama.295.2.180; Koch M, 2004, NEPHROL DIAL TRANSPL, V19, P2547, DOI 10.1093/ndt/gfh404; Stack AG, 2001, J AM SOC NEPHROL, V12, P1516; Belch JJF, 2003, ARCH INTERN MED, V163, P884, DOI 10.1001/archinte.163.8.884; Malyar N, 2013, EUR HEART J, V34, P2706, DOI 10.1093/eurheartj/eht288; Nakai S, 2013, THER APHER DIAL, V17, P567, DOI 10.1111/1744-9987.12147; Ishii H, 2010, J VASC SURG, V52, P854, DOI 10.1016/j.jvs.2010.05.020; Pifer TB, 2002, KIDNEY INT, V62, P2238, DOI 10.1046/j.1523-1755.2002.00658.x; Levey AS, 1998, AM J KIDNEY DIS, V32, P853, DOI 10.1016/S0272-6386(98)70145-3; Barrett BJ, 1997, AM J KIDNEY DIS, V29, P214, DOI 10.1016/S0272-6386(97)90032-9; DeLoach SS, 2007, CLIN J AM SOC NEPHRO, V2, P839, DOI 10.2215/CJN.04101206; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; Herzog CA, 2011, KIDNEY INT, V80, P572, DOI 10.1038/ki.2011.223; Rajagopalan S, 2006, CIRCULATION, V114, P1914, DOI 10.1161/CIRCULATIONAHA.105.607390; O'Hare AM, 2005, J AM SOC NEPHROL, V16, P514, DOI 10.1681/ASN.2004050409; Cuculich PS, 2007, PACE, V30, P207, DOI 10.1111/j.1540-8159.2007.00651.x; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Bansal N, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-44; Foley R N, 1998, J Am Soc Nephrol, V9, pS16; Hemmelgarn BR, 2004, CIRCULATION, V110, P1890, DOI 10.1161/01.CIR.0000143629.55725.D9; Kiriyama T, 2015, CIRC J, V79, P153, DOI 10.1253/circj.CJ-14-0646; Kuhlmann Martin K, 2004, Hemodial Int, V8, P394, DOI 10.1111/j.1492-7535.2004.80416.x; Kumada Y, 2008, NEPHROL DIAL TRANSPL, V23, P3996, DOI 10.1093/ndt/gfn378; Martin D, 2014, EUR J VASC ENDOVASC, V47, P422, DOI 10.1016/j.ejvs.2013.12.020; Mueller T, 2014, J VASC SURG, V59, P1291, DOI 10.1016/j.jvs.2013.11.063; Sato A, 2015, CIRC J, V79, P47, DOI 10.1253/circj.CJ-14-1238; Steg PG, 2007, JAMA-J AM MED ASSOC, V297, P1197, DOI 10.1001/jama.297.11.1197; Wakasugi M, 2013, THER APHER DIAL, V17, P298, DOI 10.1111/j.1744-9987.2012.01144.x	33	2	2	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1269	1276		10.1253/circj.CJ-14-1308		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700023		
J	Kuma, S; Morisaki, K; Kodama, A; Guntani, A; Fukunaga, R; Soga, Y; Shirai, S; Ishida, M; Okazaki, J; Mii, S				Kuma, Sosei; Morisaki, Koichi; Kodama, Akio; Guntani, Atsushi; Fukunaga, Ryota; Soga, Yoshimitsu; Shirai, Shinichi; Ishida, Masaru; Okazaki, Jin; Mii, Shinsuke			Ultrasound-Guided Percutaneous Thrombin Injection for Post-Catheterization Pseudoaneurysm	CIRCULATION JOURNAL			English	Article						Iatrogenic; Incidence; Ultrasound-guided compression	IATROGENIC PSEUDOANEURYSMS; FEMORAL PSEUDOANEURYSMS; DISEASE; COMPRESSION; ANGIOGRAPHY; EXTREMITY; JAPANESE	Background: The efficacy and safety of ultrasound-guided thrombin injection (UGTI) for the treatment of post-catheterization femoral and brachial artery pseudoaneurysms (PSA) is unclear in Japan. Methods and Results: A retrospective study of 32 consecutive patients undergoing percutaneous UGTI of post-catheterization PSA between February 2011 and February 2014 was performed. There were 23 femoral PSA and 9 brachial PSA treated with UGTI. The prevalence of CAD and smoking history were higher in the brachial PSA patients, but there were no statistically significant differences in other patient demographic factors or in the preprocedural antiplatelet therapy between the femoral and brachial PSA patients. The median dose of thrombin injected was 200 U (range, 100-600 U). The initial success rate, early recurrence rate and surgical conversion rate were 91%, 0% and 4% in the femoral PSA, and 89%, 11% and 11% in the brachial PSA, respectively. There were 2 cases of medial nerve compression in the brachial PSA group, but there were no complications in the femoral PSA group (P=0.0198). On outpatient clinical follow-up in the successfully treated patients, there were no recurrences after an average follow-up of 16 months. Conclusions: UGTI is a feasible, safe and effective less-invasive treatment for post-catheterization PSA. Brachial PSA, however, might require additional attention because of their tendency toward higher recurrence and complications.	[Kuma, Sosei; Ishida, Masaru; Okazaki, Jin] Kokura Mem Hosp, Dept Vasc Surg, Kitakyushu, Fukuoka 8028555, Japan; [Soga, Yoshimitsu; Shirai, Shinichi] Kokura Mem Hosp, Dept Cardiol, Kitakyushu, Fukuoka 8028555, Japan; [Morisaki, Koichi] Kyushu Univ, Dept Surg & Surg Sci, Grad Sch Med, Fukuoka 812, Japan; [Kodama, Akio] Nagoya Univ, Dept Surg, Grad Sch Med, Div Vasc Surg, Nagoya, Aichi 4648601, Japan; [Guntani, Atsushi] Hiroshima Red Cross Hosp, Dept Surg, Hiroshima, Japan; [Guntani, Atsushi] Atom Bomb Survivors Hosp, Hiroshima, Japan; [Fukunaga, Ryota] Hidaka Coloproctol Clin, Dept Surg, Kurume, Fukuoka, Japan; [Mii, Shinsuke] Steel Mem Yawata Hosp, Dept Vasc Surg, Kitakyushu, Fukuoka, Japan	Kuma, S (reprint author), Kokura Mem Hosp, Dept Vasc Surg, Kokurakita Ku, 3-2-1 Asano, Kitakyushu, Fukuoka 8028555, Japan.	kumasosei@yahoo.co.jp		Kuma, Sosei/0000-0001-7291-2912			COLEY BD, 1995, RADIOLOGY, V194, P307; Schneider C, 2009, INT J CARDIOL, V131, P356, DOI 10.1016/j.ijcard.2007.10.052; Kang SS, 2000, J VASC SURG, V31, P289, DOI 10.1016/S0741-5214(00)90160-5; Miura T, 2014, CIRC J, V78, P1097, DOI 10.1253/circj.CJ-14-0129; Soga Y, 2013, CIRC J, V77, P2102, DOI 10.1253/circj.CJ-13-0020; Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526; [Anonymous], 1993, J VASC INTERV RADIOL, V48, P4; Toursarkissian B, 1997, J VASC SURG, V25, P803, DOI 10.1016/S0741-5214(97)70209-X; BABU SC, 1989, J VASC SURG, V10, P113; Calton W C Jr, 2001, Vasc Surg, V35, P379, DOI 10.1177/153857440103500508; Garvin RP, 2014, J VASC SURG, V59, P1664, DOI 10.1016/j.jvs.2014.01.009; Gorog DA, 2011, INT J CARDIOL, V152, P43, DOI 10.1016/j.ijcard.2010.07.002; Grewe PH, 2004, AM J CARDIOL, V93, P1540, DOI 10.1016/j.amjcard.2004.02.068; Hirano Yutaka, 2004, J Cardiol, V43, P259; KATZENSCHLAGER R, 1995, RADIOLOGY, V195, P463; Khoury M, 2002, J VASC SURG, V35, P517, DOI 10.1067/mva.2002.120029; Kitamura A, 2006, STROKE, V37, P1374, DOI 10.1161/01.STR.0000221714.96986.5f; KRESOWIK TF, 1991, J VASC SURG, V13, P328; Kresowik TF, 1991, J VASC SURG, V13, P333; Krueger K, 2005, RADIOLOGY, V236, P1104, DOI 10.1148/radiol.2363040736; Lange P, 2001, EUR J VASC ENDOVASC, V21, P248, DOI 10.1053/ejvs.2001.1325; Liau CS, 1997, J VASC SURG, V26, P18, DOI 10.1016/S0741-5214(97)70141-1; Raskob GE, 2014, SEMIN THROMB HEMOST, V40, P724, DOI 10.1055/s-0034-1390325; Sakatani T, 2003, CIRC J, V67, P895, DOI 10.1253/circj.67.895; Sheiman RG, 2003, AM J ROENTGENOL, V181, P1301; Yoshida M, 2005, CIRC J, V69, P404, DOI 10.1253/circj.69.404	26	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1277	1281		10.1253/circj.CJ-14-1119		5	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700024		
J	Shiomi, H; Morimoto, T; Furukawa, Y; Nakagawa, Y; Sakata, R; Okabayashi, H; Hanyu, M; Shimamoto, M; Nishiwaki, N; Komiya, T; Kimura, T				Shiomi, Hiroki; Morimoto, Takeshi; Furukawa, Yutaka; Nakagawa, Yoshihisa; Sakata, Ryuzo; Okabayashi, Hitoshi; Hanyu, Michiya; Shimamoto, Mitsuomi; Nishiwaki, Noboru; Komiya, Tatsuhiko; Kimura, Takeshi		CREDO-Kyoto PCI CABG Registry Coho	Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Unprotected Left Main Coronary Artery Disease-5-Year Outcome From CREDO-Kyoto PCI/CABG Registry Cohort-2-	CIRCULATION JOURNAL			English	Article						Coronary artery bypass grafting; Drug-eluting stents; Left main disease; Percutaneous coronary intervention	ELUTING STENT IMPLANTATION; MYOCARDIAL REVASCULARIZATION; RANDOMIZED-TRIAL; 5-YEAR OUTCOMES; SYNTAX SCORE; REAL-WORLD; TASK-FORCE; SURGERY; ASSOCIATION; GUIDELINES	Background: Studies evaluating long-term (>= 5 years) outcome of percutaneous coronary intervention (PCI) compared with coronary artery bypass grafting (CABG) in patients with unprotected left main coronary artery disease (ULMCAD) are still limited, despite concerns for late adverse events after drug-eluting stents implantation. Methods and Results: We identified 1,004 patients with ULMCAD (PCI: n=364, CABG: n=640) among 15,939 patients with first coronary revascularization enrolled in the CREDO-Kyoto PCI/CABG registry cohort-2. The primary outcome measure in the current analysis was a composite of death, myocardial infarction, and stroke (death/MI/stroke). The cumulative 5-year incidence of and the adjusted risk for death/MI/stroke were significantly higher in the PCI group than in the CABG group (34.5% vs. 24.1%, log-rank P<0.001, adjusted hazard ratio (HR): 1.48 [95% confidence interval (CI): 1.07-2.05, P=0.02]). The adjusted risks for all-cause death was not significantly different between the 2 groups. Regarding the stratified analysis by the SYNTAX score, the adjusted risk for death/MI/stroke was not significantly different between the 2 groups in patients with low (<23) or intermediate (23-33) SYNTAX score, whereas it was significantly higher in the PCI group than in the CABG group in patients with high (<= 33) SYNTAX score. Conclusions: CABG as compared with PCI was associated with better long-term outcome in patients with ULMCAD, especially those with high anatomical complexity.	[Shiomi, Hiroki; Sakata, Ryuzo; Kimura, Takeshi] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan; [Morimoto, Takeshi] Hyogo Coll Med, Dept Clin Epidemiol, Nishinomiya, Hyogo 6638501, Japan; [Furukawa, Yutaka] Kobe City Med Ctr Gen Hosp, Div Cardiol, Kobe, Hyogo, Japan; [Nakagawa, Yoshihisa] Tenri Hosp, Div Cardiol, Tenri, Nara 632, Japan; [Okabayashi, Hitoshi] Iwate Med Univ, Dept Cardiovasc Surg, Morioka, Iwate 020, Japan; [Hanyu, Michiya] Kokura Mem Hosp, Div Cardiovasc Surg, Kitakyushu, Fukuoka, Japan; [Shimamoto, Mitsuomi] Shizuoka City Shizuoka Hosp, Div Cardiovasc Surg, Shizuoka, Japan; [Nishiwaki, Noboru] Kinki Univ, Fac Med, Nara Hosp, Div Cardiovasc Surg, Ikoma, Japan; [Komiya, Tatsuhiko] Kurashiki Cent Hosp, Div Cardiovasc Surg, Kurashiki, Okayama, Japan	Kimura, T (reprint author), Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	taketaka@kuhp.kyoto-u.ac.jp			Pharmaceuticals and Medical Devices Agency (PMDA) in Japan	Funding Sources: This study was supported by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.	TOPOL E, 1993, NEW ENGL J MED, V329, P673; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; Campos CM, 2014, CIRC J, V78, P1942, DOI 10.1253/circj.CJ-14-0204; Park SJ, 2011, NEW ENGL J MED, V364, P1718, DOI 10.1056/NEJMoa1100452; Fortuna D, 2013, EUR J CARDIO-THORAC, V44, pE16, DOI 10.1093/ejcts/ezt197; Morice MC, 2014, CIRCULATION, V129, P2388, DOI 10.1161/CIRCULATIONAHA.113.006689; Chieffo A, 2010, JACC-CARDIOVASC INTE, V3, P595, DOI 10.1016/j.jcin.2010.03.014; Nakagawa Y, 2010, AM J CARDIOL, V106, P329, DOI 10.1016/j.amjcard.2010.03.031; Park DW, 2010, J AM COLL CARDIOL, V56, P117, DOI 10.1016/j.jacc.2010.04.004; Kimura T, 2012, CIRCULATION, V125, P584, DOI 10.1161/CIRCULATIONAHA.111.046599; Seung KB, 2008, NEW ENGL J MED, V358, P1781, DOI 10.1056/NEJMoa0801441; Natsuaki M, 2014, CIRC-CARDIOVASC INTE, V7, P168, DOI 10.1161/CIRCINTERVENTIONS.113.000987; Morice MC, 2010, CIRCULATION, V121, P2645, DOI 10.1161/CIRCULATIONAHA.109.899211; Wijns W, 2010, EUR HEART J, V31, P2501, DOI 10.1093/eurheartj/ehq277; Shiomi H, 2012, AM J CARDIOL, V110, P924, DOI 10.1016/j.amjcard.2012.05.022; Kimura Takeshi, 2011, Cardiovasc Interv Ther, V26, P234, DOI 10.1007/s12928-011-0065-0; Levine GN, 2011, CIRCULATION, V124, pE574, DOI 10.1161/CIR.0b013e31823ba622; Nishino T, 2013, CIRC J, V77, P1242, DOI 10.1253/circj.CJ-12-0963; Park DW, 2010, J AM COLL CARDIOL, V56, P1366, DOI 10.1016/j.jacc.2010.03.097; Serruys PW, 2009, NEW ENGL J MED, V360, P961, DOI 10.1056/NEJMoa0804626; Shiomi H, 2011, CIRC J, V75, P1130, DOI 10.1253/circj.CJ-10-1112; Tazaki J, 2013, EUROINTERVENTION, V9, P437, DOI 10.4244/EIJV9I4A72; Windecker S, 2014, EUR HEART J, V35, P2541, DOI 10.1093/eurheartj/ehu278	23	2	2	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1282	+		10.1253/circj.CJ-15-0034		9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700025		
J	Tashiro, N; Takahashi, S; Takasaki, T; Katayama, K; Taguchi, T; Watanabe, M; Kurosaki, T; Imai, K; Kimura, H; Sueda, T				Tashiro, Naonori; Takahashi, Shinya; Takasaki, Taiichi; Katayama, Keijiro; Taguchi, Takahiro; Watanabe, Masazumi; Kurosaki, Tatsuya; Imai, Katsuhiko; Kimura, Hiroaki; Sueda, Taijiro			Efficacy of Cardiopulmonary Rehabilitation With Adaptive Servo-Ventilation in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting	CIRCULATION JOURNAL			English	Article						Adaptive servo-ventilation; Cardiopulmonary rehabilitation; Off-pump coronary artery bypass grafting	POSITIVE AIRWAY PRESSURE; RANDOMIZED CONTROLLED-TRIAL; CONGESTIVE-HEART-FAILURE; ATRIAL CONDUCTION TIME; CARDIAC-SURGERY; PULMONARY COMPLICATIONS; MECHANICAL VENTILATION; OUTCOMES; FIBRILLATION; MORTALITY	Background: Postoperative complications after cardiac surgery increase mortality. This study aimed to evaluate the efficacy of cardiopulmonary rehabilitation with adaptive servo-ventilation (ASV) in patients undergoing off-pump coronary artery bypass grafting (OPCAB). Methods and Results: A total of 66 patients undergoing OPCAB were enrolled and divided into 2 groups according to the use of ASV (ASV group, 30 patients; non-ASV group, 36 patients). During the perioperative period, all patients undertook cardiopulmonary rehabilitation. ASV was used from postoperative day (POD) 1 to POD5. Hemodynamics showed a different pattern in the 2 groups. Blood pressure (BP) on POD6 in the ASV group was significantly lower than that in the non-ASV group (systolic BP, 112.9 +/- 12.6 vs. 126.2 +/- 15.8 mmHg, P=0.0006; diastolic BP, 62.3 +/- 9.1 vs. 67.6 +/- 9.3 mmHg, P=0.0277). The incidence of postoperative atrial fibrillation (POAF) was lower in the ASV group than in the non-ASV group (10% vs. 33%, P=0.0377). The duration of oxygen inhalation in the ASV group was significantly shorter than that in the non-ASV group (5.1 +/- 2.2 vs. 7.6 +/- 6.0 days, P=0.0238). The duration of postoperative hospitalization was significantly shorter in the ASV group than in the non-ASV group (23.5 +/- 6.6 vs. 29.0 +/- 13.1 days, P=0.0392). Conclusions: Cardiopulmonary rehabilitation with ASV after OPCAB reduces both POAF occurrence and the duration of hospitalization.	[Tashiro, Naonori; Kimura, Hiroaki] Hiroshima Univ Hosp, Dept Rehabil, Hiroshima 7348551, Japan; [Takahashi, Shinya; Takasaki, Taiichi; Katayama, Keijiro; Taguchi, Takahiro; Watanabe, Masazumi; Kurosaki, Tatsuya; Imai, Katsuhiko; Sueda, Taijiro] Hiroshima Univ Hosp, Dept Cardiovasc Surg, Hiroshima 7348551, Japan	Tashiro, N (reprint author), Hiroshima Univ Hosp, Dept Rehabil, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	tashiro@hiroshima-u.ac.jp					Al Jaaly E, 2013, J THORAC CARDIOV SUR, V146, P912, DOI 10.1016/j.jtcvs.2013.03.014; Chiumello D, 2011, INTENS CARE MED, V37, P918, DOI 10.1007/s00134-011-2210-8; Koyama T, 2012, CIRC J, V76, P2606, DOI 10.1253/circj.CJ-12-0328; Harada D, 2011, AUTON NEUROSCI-BASIC, V161, P95, DOI 10.1016/j.autneu.2010.12.001; Pasquina P, 2004, ANESTH ANALG, V99, P1001, DOI 10.1213/01.ane.0000130621.11024.97; Gust R, 1996, INTENS CARE MED, V22, P1345, DOI 10.1007/s001340050262; SEALS DR, 1990, CIRC RES, V67, P130; Vargas FS, 1997, RESP MED, V91, P629, DOI 10.1016/S0954-6111(97)90010-X; Haruki N, 2011, EUR J HEART FAIL, V13, P1140, DOI 10.1093/eurjhf/hfr103; Pasquina P, 2003, BRIT MED J, V327, P1379, DOI 10.1136/bmj.327.7428.1379; Fujiwara M, 2014, CIRC J, V78, P345, DOI 10.1253/circj.CJ-13-0900; Cleveland JC, 2001, ANN THORAC SURG, V72, P1282, DOI 10.1016/S0003-4975(01)03006-5; NAUGHTON MT, 1995, CIRCULATION, V91, P1725; Koyama T, 2011, CIRC J, V75, P710, DOI 10.1253/circj.CJ-10-0956; Kaye DM, 2001, CIRCULATION, V103, P2336; Lamy A, 2013, NEW ENGL J MED, V368, P1179, DOI 10.1056/NEJMoa1301228; Matte P, 2000, ACTA ANAESTH SCAND, V44, P75, DOI 10.1034/j.1399-6576.2000.440114.x; Hannan EL, 2007, CIRCULATION, V116, P1145, DOI 10.1161/CIRCULATIONAHA.106.675595; Yamada S, 2013, CIRC J, V77, P1214, DOI 10.1253/circj.CJ-12-1088; Lamy A, 2012, NEW ENGL J MED, V366, P1489, DOI 10.1056/NEJMoa1200388; Mathew JP, 1996, JAMA-J AM MED ASSOC, V276, P300, DOI 10.1001/jama.276.4.300; Chertow GM, 1998, AM J MED, V104, P343, DOI 10.1016/S0002-9343(98)00058-8; Herdy AH, 2008, AM J PHYS MED REHAB, V87, P714, DOI 10.1097/PHM.0b013e3181839152; Plomondon ME, 2001, ANN THORAC SURG, V72, P114, DOI 10.1016/S0003-4975(01)02670-4; Borghi-Silva Audrey, 2005, Clinics (Sao Paulo), V60, P465, DOI 10.1590/S1807-59322005000600007; Ferreira LL, 2012, REV BRAS CIR CARDIOV, V27, P446, DOI 10.5935/1678-9741.20120074; Fukui T, 2009, HEART SURG FORUM, V12, pE194, DOI 10.1532/HSF98.20091021; Hieda M, 2013, EUR HEART J SUPPL, V34, P630; Hoffmann B, 2003, THORAC CARDIOV SURG, V51, P142; Hulzebos EHJ, 2006, JAMA-J AM MED ASSOC, V296, P1851, DOI 10.1001/jama.296.15.1851; Jaber Samir, 2010, Best Pract Res Clin Anaesthesiol, V24, P253; Schmidt H, 1997, J CRIT CARE, V12, P22, DOI 10.1016/S0883-9441(97)90022-8; Takahashi S, 2014, CIRC J, V78, P2173, DOI 10.1253/circj.CJ-14-0327; Theerakittikkul T, 2010, CLEV CLIN J MED, V77, P705, DOI 10.3949/ccjm.77a.10060; Tomoyasu Makoto, 2008, Kyobu Geka, V61, P679	35	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1290	1298		10.1253/circj.CJ-14-1078		9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700026		
J	Fukunaga, N; Okada, Y; Konishi, Y; Murashita, T; Koyama, T				Fukunaga, Naoto; Okada, Yukikatsu; Konishi, Yasunobu; Murashita, Takashi; Koyama, Tadaaki			Late Outcome of Tricuspid Annuloplasty Using a Flexible Band/Ring for Functional Tricuspid Regurgitation	CIRCULATION JOURNAL			English	Article						Functional tricuspid regurgitation; Tricuspid annuloplasty	MITRAL-VALVE REPAIR; SUTURE ANNULOPLASTY; SURGERY; SURVIVAL; RING; REPLACEMENT; PERSISTENT; MANAGEMENT; GEOMETRY; FAILURE	Background: We assessed late outcome after tricuspid annuloplasty (TAP) using a flexible band or ring for functional tricuspid regurgitation (FTR). Methods and Results: We reviewed 220 consecutive patients (mean age, 65.4 +/- 11.4 years) who underwent TAP for FTR during mitral valve surgery between January 2000 and December 2010. Indications for TAP included the following: (1) TR grade greater than mild; (2) history of right heart failure; (3) atrial fibrillation; and (4) systolic pulmonary artery pressure (SPAP) >= 50 mmHg. The mean follow-up period was 4.4 +/- 2.6 years. Overall hospital mortality was 5.5% (12/220). The 5- and 10-year survival rates were 90.2 +/- 2.1% and 82.4 +/- 5.6%, respectively. Freedom from recurrent TR at 8 years was 78.0 +/- 6.6%. Twenty patients had a greater than mild TR grade at final follow-up. Elevated SPAP was a predictor of recurrent TR (hazard ratio, 1.091; P=0.0003), which was associated with advanced age, atrial fibrillation, rheumatic etiology and preoperative TR grade. There was a significant difference in freedom from valve-related events between residual TR greater than mild and less than moderate (log-rank test, P=0.0464). Factors affecting residual TR were preoperative TR grade (OR, 7.368; P=0.0267) and mitral valve replacement (OR, 4.369; P=0.0402). Conclusions: Late outcome of TAP in the present series was acceptable. Late outcome can be improved by performing TAP before deterioration of TR.	[Fukunaga, Naoto; Okada, Yukikatsu; Konishi, Yasunobu; Murashita, Takashi; Koyama, Tadaaki] Kobe City Med Ctr Gen Hosp, Dept Cardiovasc Surg, Kobe, Hyogo 6500047, Japan	Fukunaga, N (reprint author), Kobe City Med Ctr Gen Hosp, Dept Cardiovasc Surg, Chuo Ku, 2-1-1 Minatojimaminamimachi, Kobe, Hyogo 6500047, Japan.	naotowakimachi@hotmail.co.jp					Okada Y, 2002, J HEART VALVE DIS, V11, P32; Shiran A, 2009, J AM COLL CARDIOL, V53, P401, DOI 10.1016/j.jacc.2008.09.048; Yiu KH, 2014, CIRCULATION, V129, P87, DOI 10.1161/CIRCULATIONAHA.113.003811; Fukuda S, 2006, CIRCULATION, V114, pI492, DOI 10.1161/CIRCULATIONAHA.105.000257; Rogers JH, 2009, CIRCULATION, V119, P2718, DOI 10.1161/CIRCULATIONAHA.108.842773; Song H, 2009, HEART, V95, P931, DOI 10.1136/hrt.2008.152793; Nath J, 2004, J AM COLL CARDIOL, V43, P405, DOI 10.1016/j.jacc.2003.09.036; McCarthy PM, 2004, J THORAC CARDIOV SUR, V127, P674, DOI 10.1016/j.jtcvs.2003.11.019; Pfannmuller B, 2012, J THORAC CARDIOV SUR, V143, P1050, DOI 10.1016/j.jtcvs.2011.06.019; Fukunaga N, 2014, J THORAC CARDIOV SUR, V148, P1983, DOI 10.1016/j.jtcvs.2013.08.089; Fukunaga N, 2014, CIRC J, V78, P2696, DOI 10.1253/circj.CJ-14-0566; Gatti G, 2001, ANN THORAC SURG, V72, P764, DOI 10.1016/S0003-4975(01)02830-2; Gatti Giuseppe, 2007, Interact Cardiovasc Thorac Surg, V6, P731, DOI 10.1510/icvts.2007.156786; Guenther T, 2013, EUR J CARDIO-THORAC, V43, P58, DOI 10.1093/ejcts/ezs266; Huang XS, 2014, ANN THORAC SURG, V97, P1286, DOI 10.1016/j.athoracsur.2013.10.037; Khorsandi M, 2012, INTERACT CARDIOV TH, V15, P129, DOI 10.1093/icvts/ivs070; Masuda M, 2014, GEN THORAC CARDIOVAS, V62, P734; Morimoto Naoto, 2013, Gen Thorac Cardiovasc Surg, V61, P133, DOI 10.1007/s11748-012-0190-4; Murashita T, 2013, CIRC J, V77, P2288, DOI 10.1253/circj.CJ-13-0221; Murashita T, 2013, SURG TODAY, V43, P341, DOI 10.1007/s00595-012-0259-9; Park CK, 2009, ANN THORAC SURG, V88, P1216, DOI 10.1016/j.athoracsur.2009.04.121; Rajbanshi BG, 2014, J THORAC CARDIOV SUR, V148, P1957, DOI 10.1016/j.jtcvs.2014.04.041; Ruel M, 2004, J THORAC CARDIOV SUR, V128, P278, DOI 10.1016/j.jtcvs.2003.11.048	23	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1299	1306		10.1253/circj.CJ-14-1282		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700027		
J	Ueda, T; Kawakami, R; Nishida, T; Onoue, K; Soeda, T; Okayama, S; Takeda, Y; Watanabe, M; Kawata, H; Uemura, S; Saito, Y				Ueda, Tomoya; Kawakami, Rika; Nishida, Taku; Onoue, Kenji; Soeda, Tsunenari; Okayama, Satoshi; Takeda, Yukiji; Watanabe, Makoto; Kawata, Hiroyuki; Uemura, Shiro; Saito, Yoshihiko			Plasma Renin Activity Is a Strong and Independent Prognostic Indicator in Patients With Acute Decompensated Heart Failure Treated With Renin-Angiotensin System Inhibitors	CIRCULATION JOURNAL			English	Article						Acute decompensated heart failure; Plasma renin activity; Prognosis; Renin-angiotensin system blocker	MYOCARDIAL-INFARCTION; TASK-FORCE; MORBIDITY; MORTALITY; NOREPINEPHRINE; MECHANISMS; GUIDELINES; MANAGEMENT; SURVIVAL; HEFT	Background: The renin-angiotensin system (RAS) is activated in heart failure (HF) as a compensatory mechanism, being related to cardiac remodeling and poor prognosis. Although RAS inhibitors are used as first-line drugs for HF, plasma renin activity (PRA) is upregulated by RAS inhibitors via a negative feedback mechanism. The clinical significance of PRA during RAS inhibitor therapy is poorly understood in acute decompensated HF (ADHF). Therefore we examined the impact of PRA in HF patients already receiving RAS inhibitors. Methods and Results: Of 611 consecutive patients with ADHF and emergency admission to hospital, we studied the impact of PRA on the prognosis of ADHF in 293 patients already receiving RAS inhibitors before admission. The patients were divided into 2 groups according to median PRA (>= vs. <3.4 ng.ml(-1).h(-1)). During a mean follow-up of 29.0 months, there were 124 deaths from all causes. Kaplan-Meier analysis showed that all-cause and cardiovascular mortality were significantly higher in patients with high PRA than low PRA (log-rank P=0.0002 and P<0.0001, respectively). Log PRA was an independent predictor of all-cause and cardiovascular death (HR, 1.194; 95% CI: 1.378-2.678, P<0.0001; and HR, 2.559; 95% CI: 1.610-4.144, P<0.0001, respectively). Conclusions: PRA was associated with an increased risk of all-cause and cardiovascular mortality in ADHF patients already receiving RAS inhibitors, suggesting that PRA would be a useful biomarker during ADHF treatment.	[Ueda, Tomoya; Kawakami, Rika; Nishida, Taku; Onoue, Kenji; Soeda, Tsunenari; Okayama, Satoshi; Takeda, Yukiji; Watanabe, Makoto; Kawata, Hiroyuki; Uemura, Shiro; Saito, Yoshihiko] Nara Med Univ, Dept Internal Med 1, Kashihara, Nara 6348522, Japan; [Saito, Yoshihiko] Nara Med Univ, Dept Regulatory Med Blood Pressure, Kashihara, Nara 6348522, Japan	Kawakami, R (reprint author), Nara Med Univ, Dept Internal Med 1, 840 Shijo, Kashihara, Nara 6348522, Japan.	rkawa@naramed-u.ac.jp			Ministry of Health, Labour and Welfare of Japan; Takeda Science Foundation	The authors thank Yoko Wada for her support with data collection and data entry. This work was supported in part by grants-in-aid from the Ministry of Health, Labour and Welfare of Japan and the Takeda Science Foundation.	Ando T, 2014, CURR PHARM DESIGN, V20, P2371; van de Wal RMA, 2006, INT J CARDIOL, V106, P367, DOI 10.1016/j.ijcard.2005.02.016; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Sato N, 2013, CIRC J, V77, P944, DOI 10.1253/circj.CJ-13-0187; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Pang PS, 2010, EUR HEART J, V31, P784, DOI 10.1093/eurheartj/ehq040; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Kinouchi K, 2010, CIRC RES, V107, P30, DOI 10.1161/CIRCRESAHA.110.224667; Latini R, 2004, EUR HEART J, V25, P292, DOI 10.1016/j.ehj.2003.10.030; Ueda T, 2013, CIRC J, V77, P2766, DOI 10.1253/circj.CJ-13-0718; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; ROULEAU JL, 1994, J AM COLL CARDIOL, V24, P583; Mann DL, 2005, CIRCULATION, V111, P2837, DOI 10.1161/CIRCULATIONAHA.104.500546; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Zannad F, 2011, NEW ENGL J MED, V364, P11, DOI 10.1056/NEJMoa1009492; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Bueno H, 2010, JAMA-J AM MED ASSOC, V303, P2141, DOI 10.1001/jama.2010.748; BRUNNER HR, 1973, AM J MED, V55, P295, DOI 10.1016/0002-9343(73)90131-9; FRANCIS GS, 1993, CIRCULATION, V87, P40; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6; JCS Joint Working Group, 2013, CIRC J, V77, P2157; Lechat P, 1999, LANCET, V353, P9; Opie LH, 2004, HEART DIS, V7th, P457; Schrier RW, 1999, NEW ENGL J MED, V341, P577; Schroten NF, 2012, HEART FAIL REV, V17, P191, DOI 10.1007/s10741-011-9262-2; Vergaro G, 2011, AM J CARDIOL, V108, P246, DOI 10.1016/j.amjcard.2011.03.034	28	2	2	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1307	+		10.1253/circj.CJ-14-1203		10	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700028		
J	Nishii, N; Kubo, M; Okamoto, Y; Fujii, S; Watanabe, A; Toyama, Y; Yamada, T; Doi, M; Morita, H; Ito, H				Nishii, Nobuhiro; Kubo, Motoki; Okamoto, Yoji; Fujii, Satoki; Watanabe, Atsuyuki; Toyama, Yuko; Yamada, Tadakatsu; Doi, Masayuki; Morita, Hiroshi; Ito, Hiroshi		MOMOTARO Investigators	Decreased Intrathoracic Impedance Associated With OptiVol Alert Can Diagnose Increased B-Type Natriuretic Peptide - MOMOTARO (Monitoring and Management of OptiVol Alert to Reduce Heart Failure Hospitalization) Study -	CIRCULATION JOURNAL			English	Article						Brain natriuretic peptide; Heart failure; Intrathoracic impedance; OptiVol alert; Remote monitoring	DEVICE FOLLOW-UP; RISK; FEASIBILITY; PRESSURES; PROGRAM; STROKE; IMPACT; TRIAL; ICD	Background: Ambulatory measurement of intrathoracic impedance (ITI) with an implanted device may detect increases in pulmonary fluid retention early, but the clinical utility of this method is not well established. The goal of this study was to test whether conventional ITI-derived parameters can diagnose fluid retention that may cause early stage heart failure (HF). Methods and Results: HF patients implanted with high-energy devices with OptiVol (Medtronic) monitoring were enrolled in this study. Patients were monitored remotely. At both baseline and OptiVol alert, patients were assessed on standard examinations, including analysis of serum brain natriuretic peptide (BNP). From April 2010 to August 2011, 195 patients from 12 institutes were enrolled. There were 154 primary OptiVol alert events. BNP level at the alerts was not significantly different from that at baseline. Given that ITI was inversely correlated with log BNP, we added a criterion specifying that the OptiVol alert is triggered only when ITI decreases by >= 4% from baseline. This change improved the diagnostic potential of increase in BNP at OptiVol alert (sensitivity, 75%; specificity, 88%). Conclusions: BNP increase could not be identified based on OptiVol alert. Decrease in ITI >= 4% compared with baseline, in addition to the alert, however, may be a useful marker for the likelihood of HF (Clinical trial info: UMIN000003351).	[Nishii, Nobuhiro; Morita, Hiroshi] Okayama Univ, Dept Cardiovasc Therapeut, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008558, Japan; [Kubo, Motoki; Ito, Hiroshi] Okayama Univ, Dept Cardiovasc Med, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008558, Japan; [Okamoto, Yoji; Fujii, Satoki] Kurashiki Cent Hosp, Dept Cardiovasc Med, Kurashiki, Okayama, Japan; [Watanabe, Atsuyuki] Fukuyama City Hosp, Dept Cardiovasc Med, Fukuyama, Hiroshima, Japan; [Toyama, Yuko] Sakakibara Heart Inst Okayama, Dept Cardiovasc Med, Okayama, Japan; [Yamada, Tadakatsu] Ehime Prefectural Cent Hosp, Dept Cardiovasc Med, Matsuyama, Ehime, Japan; [Doi, Masayuki] Kagawa Prefectural Cent Hosp, Dept Cardiovasc Med, Takamatsu, Kagawa, Japan	Nishii, N (reprint author), Okayama Univ, Dept Cardiovasc Therapeut, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	nnishii@md.okayama-u.ac.jp			Medtronic	Conflict of Interest: This study was supported financially by Medtronic. None of the authors had any additional relationships with industry.	Abraham William T, 2011, Congest Heart Fail, V17, P51, DOI 10.1111/j.1751-7133.2011.00220.x; Ritzema J, 2010, CIRCULATION, V121, P1086, DOI 10.1161/CIRCULATIONAHA.108.800490; Cleland JGF, 2003, EUR HEART J, V24, P442, DOI 10.1016/S0195-668X(02)00823-0; Varma N, 2010, CIRCULATION, V122, P325, DOI 10.1161/CIRCULATIONAHA.110.937409; Raatikainen MJP, 2008, EUROPACE, V10, P1145, DOI 10.1093/europace/eun203; Zile MR, 2008, CIRCULATION, V118, P1433, DOI 10.1161/CIRCULATIONAHA.108.783910; Catanzariti D, 2009, PACE, V32, P363, DOI 10.1111/j.1540-8159.2008.02245.x; Taniguchi Y, 2013, CIRC J, V77, P2383, DOI 10.1253/circj.CJ-13-0172; Chaudhry SI, 2010, NEW ENGL J MED, V363, P2301, DOI 10.1056/NEJMoa1010029; Abraham WT, 2011, LANCET, V377, P658, DOI 10.1016/S0140-6736(11)60101-3; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Yu CM, 2005, CIRCULATION, V112, P841, DOI 10.1161/CIRCULATIONAHA.104.492207; Cowie MR, 2013, EUR HEART J, V34, P2472, DOI 10.1093/eurheartj/eht083; Saxon LA, 2010, CIRCULATION, V122, P2359, DOI 10.1161/CIRCULATIONAHA.110.960633; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; van Veldhuisen DJ, 2011, CIRCULATION, V124, P1719, DOI 10.1161/CIRCULATIONAHA.111.043042; Koehler F, 2011, CIRCULATION, V123, P1873, DOI 10.1161/CIRCULATIONAHA.111.018473; Connolly SJ, 2000, NEW ENGL J MED, V342, P1385, DOI 10.1056/NEJM200005113421902; Whellan DJ, 2010, J AM COLL CARDIOL, V55, P1803, DOI 10.1016/j.jacc.2009.11.089; Conraads VM, 2011, EUR HEART J, V32, P2266, DOI 10.1093/eurheartj/ehr050; Brignole M, 2012, J AM COLL CARDIOL, V60, P981, DOI 10.1016/j.jacc.2012.05.014; Luthje L, 2007, EUR J HEART FAIL, V9, P716, DOI 10.1016/j.ejheart.2007.03.005; Knudsen CW, 2005, J AM COLL CARDIOL, V46, P838, DOI 10.1016/j.jacc.2005.05.057; Asada K, 2012, CIRC J, V76, P2592, DOI 10.1253/circj.CJ-12-0187; Small RS, 2009, J CARD FAIL, V15, P475, DOI 10.1016/j.cardfail.2009.01.012; Soga Y, 2011, CIRC J, V75, P129, DOI 10.1253/circj.CJ-10-0730; Vanderheyden M, 2010, CIRC-HEART FAIL, V3, P370, DOI 10.1161/CIRCHEARTFAILURE.109.867549; Vollmann Dirk, 2007, Eur Heart J, V28, P1835, DOI 10.1093/eurheartj/ehl506; Wang L, 2005, PACE, V28, P404, DOI 10.1111/j.1540-8159.2005.40009.x; Watanabe E, 2013, CIRC J, V77, P2704, DOI 10.1253/circj.CJ-13-0387	30	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1315	1322		10.1253/circj.CJ-15-0076		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700029		
J	Nishimiya, K; Matsumoto, Y; Uzuka, H; Oyama, K; Tanaka, A; Taruya, A; Ogata, T; Hirano, M; Shindo, T; Hanawa, K; Hasebe, Y; Hao, K; Tsuburaya, R; Takahashi, J; Miyata, S; Ito, K; Akasaka, T; Shimokawa, H				Nishimiya, Kensuke; Matsumoto, Yasuharu; Uzuka, Hironori; Oyama, Kazuma; Tanaka, Atsushi; Taruya, Akira; Ogata, Tsuyoshi; Hirano, Michinori; Shindo, Tomohiko; Hanawa, Kenichiro; Hasebe, Yuhi; Hao, Kiyotaka; Tsuburaya, Ryuji; Takahashi, Jun; Miyata, Satoshi; Ito, Kenta; Akasaka, Takashi; Shimokawa, Hiroaki			Accuracy of Optical Frequency Domain Imaging for Evaluation of Coronary Adventitial Vasa Vasorum Formation After Stent Implantation in Pigs and Humans - A Validation Study -	CIRCULATION JOURNAL			English	Article						Drug-eluting stents; Imaging; Inflammation; Optical coherence tomography	DRUG-ELUTING STENTS; IN-VIVO; RHO-KINASE; EXPERIMENTAL HYPERCHOLESTEROLEMIA; HYPERCONSTRICTING RESPONSES; ENDOTHELIAL DYSFUNCTION; COHERENCE TOMOGRAPHY; ARTERIES; NEOVASCULARIZATION; ATHEROSCLEROSIS	Background: Coronary adventitia harbors a wide variety of components, such as inflammatory cells and vasa vasorum (VV). Adventitial VV initiates the development of coronary artery diseases as an outside-in supply route of inflammation. We have recently demonstrated that drug-eluting stent implantation causes the enhancement of VV formation, with extending to the stent edges in the porcine coronary arteries, and also that optical frequency domain imaging (OFDI) is capable of visualizing VV in humans in vivo. However, it remains to be fully validated whether OFDI enables the precise measurement of VV formation in pigs and humans. Methods and Results: In the pig protocol, a total of 6 bare-metal stents and 12 drug-eluting stents were implanted into the coronary arteries, and at 1 month, the stented coronary arteries were imaged by OFDI ex vivo. OFDI data including the measurement of VV area at the stent edge portions were compared with histological data. There was a significant positive correlation between VV area on OFDI and that on histology (R=0.91, P<0.01). In the human protocol, OFDI enabled the measurement of the VV area at the stent edges after coronary stent implantation in vivo. Conclusions: These results provide the first direct evidence that OFDI enables the precise measurement of the VV area in coronary arteries after stent implantation in pigs and humans.	[Nishimiya, Kensuke; Matsumoto, Yasuharu; Uzuka, Hironori; Oyama, Kazuma; Ogata, Tsuyoshi; Hirano, Michinori; Shindo, Tomohiko; Hanawa, Kenichiro; Hasebe, Yuhi; Hao, Kiyotaka; Tsuburaya, Ryuji; Takahashi, Jun; Miyata, Satoshi; Ito, Kenta; Shimokawa, Hiroaki] Tohoku Univ, Dept Cardiovasc Med, Grad Sch Med, Sendai, Miyagi 9808574, Japan; [Tanaka, Atsushi; Taruya, Akira; Akasaka, Takashi] Wakayama Med Univ, Dept Cardiovasc Med, Wakayama, Japan	Matsumoto, Y (reprint author), Tohoku Univ, Dept Cardiovasc Med, Grad Sch Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	matsumoto@cardio.med.tohoku.ac.jp			Japanese Ministry of Education, Culture, Sports, Science, and Technology, Tokyo, Japan [18890018, F02, H22-Shinkin-004]; Tohoku University Hospital	This work was supported, in part, by the grants-in-aid for the Scientific Research (18890018) and the Global COE Project (F02), and the grants-in-aid (H22-Shinkin-004) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology, Tokyo, Japan (to H.S.) and the grant for young investigators of translational research from Tohoku University Hospital (to Y.M.).	Wilson SH, 2002, CIRCULATION, V105, P415, DOI 10.1161/hc0402.104119; Laine P, 1999, CIRCULATION, V99, P361; Maiellaro K, 2007, CARDIOVASC RES, V75, P640, DOI 10.1016/j.cardiores.2007.06.023; Kubo T, 2012, CIRC J, V76, P2076, DOI 10.1253/circj.CJ-12-0828; Yun SH, 2004, OPT EXPRESS, V12, P4822, DOI 10.1364/OPEX.12.004822; Shimokawa H, 1996, J CLIN INVEST, V97, P769, DOI 10.1172/JCI118476; Schwartz RS, 2004, J AM COLL CARDIOL, V44, P1373, DOI 10.1016/j.jacc.2004.04.060; Schwartz RS, 2002, CIRCULATION, V106, P1867, DOI 10.1161/01.CIR.0000033485.20594.6F; Shiroto T, 2009, J AM COLL CARDIOL, V54, P2321, DOI 10.1016/j.jacc.2009.07.045; Komatsu R, 1998, CIRCULATION, V98, P224; Mulligan-Kehoe MJ, 2014, CIRCULATION, V129, P2557, DOI 10.1161/CIRCULATIONAHA.113.007189; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; Psaltis PJ, 2014, CIRC RES, V115, P364, DOI 10.1161/CIRCRESAHA.115.303299; Gossl M, 2010, JACC-CARDIOVASC IMAG, V3, P32, DOI 10.1016/j.jcmg.2009.10.009; Tanaka K, 2011, ATHEROSCLEROSIS, V215, P366, DOI 10.1016/j.atherosclerosis.2011.01.016; Yun SH, 2003, OPT EXPRESS, V11, P2953, DOI 10.1364/OE.11.002953; Kandabashi T, 2000, CIRCULATION, V101, P1319; Virmani R, 2005, ARTERIOSCL THROM VAS, V25, P2054, DOI 10.1161/01.ATV.0000178991.71605.18; Ritman EL, 2007, CARDIOVASC RES, V75, P649, DOI 10.1016/j.cardiores.2007.06.020; BLAND JM, 1986, LANCET, V1, P307; Choi BJ, 2014, ARTERIOSCL THROM VAS, V34, P2473, DOI 10.1161/ATVBAHA.114.304445; Herrmann J, 2001, CARDIOVASC RES, V51, P762, DOI 10.1016/S0008-6363(01)00347-9; Kwon HM, 1998, J AM COLL CARDIOL, V32, P2072, DOI 10.1016/S0735-1097(98)00482-3; Muramatsu T, 2013, CIRC J, V77, P2327, DOI 10.1253/circj.CJ-13-0357; Murata A, 2010, JACC-CARDIOVASC IMAG, V3, P76, DOI 10.1016/j.jcmg.2009.09.018; Nishimiya K, 2014, CIRC J, V78, P2516, DOI 10.1253/circj.CJ-14-0485; Nishimiya K, 2014, CIRC J S, V78, pI; Sahler LG, 2008, J MED IMAG RADIAT ON, V52, P570, DOI 10.1111/j.1440-1673.2008.02020.x; Shimokawa H, 2014, EUR HEART J, V35, P3180, DOI 10.1093/eurheartj/ehu427; Tsuburaya R, 2012, EUR HEART J, V33, P791, DOI 10.1093/eurheartj/ehr145; Yun SH, 2006, NAT MED, V12, P1429, DOI 10.1038/nm1450	31	3	3	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1323	+		10.1253/circj.CJ-15-0078		13	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700030		
J	Ushigome, R; Sakata, Y; Nochioka, K; Miyata, S; Miura, M; Tadaki, S; Yamauchi, T; Sato, K; Onose, T; Tsuji, K; Abe, R; Takahashi, J; Shimokawa, H				Ushigome, Ryoichi; Sakata, Yasuhiko; Nochioka, Kotaro; Miyata, Satoshi; Miura, Masanobu; Tadaki, Soichiro; Yamauchi, Takeshi; Sato, Kenjiro; Onose, Takeo; Tsuji, Kanako; Abe, Ruri; Takahashi, Jun; Shimokawa, Hiroaki		CHART-2 Investigators	Improved Long-Term Prognosis of Dilated Cardiomyopathy With Implementation of Evidenced-Based Medication - Report From the CHART Studies	CIRCULATION JOURNAL			English	Article						Beta-blocker; Dilated cardiomyopathy; Lifestyle disease; Prognosis	CHRONIC HEART-FAILURE; VENTRICULAR EJECTION FRACTION; JAPANESE PATIENTS; NATURAL-HISTORY; BETA-BLOCKADE; FOLLOW-UP; OUTCOMES; MORTALITY; SURVIVAL; IMPACT	Background: Recent trends in the clinical characteristics, management and prognosis of dilated cardiomyopathy (DCM) remain to be examined in Japan. Methods and Results: We compared 306 and 710 DCM patients in the Chronic Heart Failure Analysis and Registry in the Tohoku District (CHART)-1 (2000-2005, n=1,278) and the CHART-2 (2006-present, n=10,219) Studies, respectively. Between the 2 groups of DCM patients, there were no significant differences in baseline characteristics. The prevalence of hypertension, dyslipidemia and diabetes mellitus were all significantly increased from the CHART-1 to the CHART-2 Study. The use of beta-blockers and aldosterone antagonists was significantly increased, while that of loop diuretics and digitalis was significantly decreased in the CHART-2 Study. The 3-year mortality rate was significantly improved from 14% in the CHART-1 to 9% in the CHART-2 Study (adjusted HR, 0.60; 95% CI: 0.49-0.81; P=0.001). In particular, 3-year incidence of cardiovascular death was significantly decreased (adjusted HR, 0.26; 95% CI: 0.14-0.50, P<0.001), while that of HF admission was not (adjusted HR, 0.90; 95% CI: 0.59-1.37, P=0.632). The prognostic improvement was noted in patients with BNP <220 pg/ml, LVEF>40%, beta-blocker use and aldosterone antagonist use. Conclusions: Long-term prognosis of DCM patients has been improved, along with the implementation of evidence-based medication in Japan.	[Ushigome, Ryoichi; Sakata, Yasuhiko; Nochioka, Kotaro; Miura, Masanobu; Tadaki, Soichiro; Yamauchi, Takeshi; Sato, Kenjiro; Onose, Takeo; Tsuji, Kanako; Abe, Ruri; Takahashi, Jun; Shimokawa, Hiroaki] Tohoku Univ, Dept Cardiovasc Med, Grad Sch Med, Sendai, Miyagi 9808574, Japan; [Miyata, Satoshi; Shimokawa, Hiroaki] Tohoku Univ, Dept Evidence Based Cardiovasc Med, Grad Sch Med, Sendai, Miyagi 9808574, Japan	Sakata, Y (reprint author), Tohoku Univ, Dept Cardiovasc Med, Grad Sch Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	sakatayk@cardio.med.tohoku.ac.jp			Ministry of Health, Labour, and Welfare	We thank all members of the Tohoku Heart Failure Society and staff of the Department of Evidence-based Cardiovascular Medicine for their kind contributions (Appendix). This study was supported by Grants-in-Aid from a Research Grant from the Ministry of Health, Labour, and Welfare (Y.S., H.S.).	Austin PC, 2010, STAT MED, V29, P2137, DOI 10.1002/sim.3854; Shiba N, 2004, CIRC J, V68, P427, DOI 10.1253/circj.68.427; Hori M, 2004, AM HEART J, V147, P324, DOI 10.1016/j.ahj.2003.07.023; Takada T, 2014, EUR J HEART FAIL, V16, P309, DOI 10.1002/ejhf.22; Miura K, 2008, CIRC J, V72, P343, DOI 10.1253/circj.72.343; Steinberg BA, 2012, CIRCULATION, V126, P65, DOI 10.1161/CIRCULATIONAHA.111.080770; Shiba N, 2011, CIRC J, V75, P823, DOI 10.1253/circj.CJ-11-0135; Nochioka K, 2010, J CARD FAIL, V16, P880, DOI 10.1016/j.cardfail.2010.06.413; de Groote P, 2014, CIRC-HEART FAIL, V7, P434, DOI 10.1161/CIRCHEARTFAILURE.113.000813; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; Yancy CW, 2013, CIRCULATION, V128, pE240, DOI 10.1161/CIR.0b013e31829e8776; Sakata Y, 2013, CIRC J, V77, P2209, DOI 10.1253/circj.CJ-13-0971; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; Basuray A, 2014, CIRCULATION, V129, P2380, DOI 10.1161/CIRCULATIONAHA.113.006855; Merlo M, 2014, EUR J HEART FAIL, V16, P317, DOI 10.1002/ejhf.16; Azuma A, 1999, JPN CIRC J, V63, P333, DOI 10.1253/jcj.63.333; Bouzamondo A, 2003, EUR J HEART FAIL, V5, P281, DOI 10.1016/S1388-9842(03)00042-4; Breiman L., 1984, CLASSIFICATION REGRE; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27; Japan Intractable Diseases Information Center, DIL CARD OP; JCS Joint Working Group, GUID MAN DIL CARD SE; Matsumura Y, 2006, CIRC J, V70, P376, DOI 10.1253/circj.70.376; Miura M, 2013, CIRC J, V77, P2954, DOI 10.1253/circj.CJ-13-0725; LECHAT P, 1994, CIRCULATION, V90, P1765; Yohannes Y, CLASSIFICATION REGRE	25	3	3	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1332	+		10.1253/circj.CJ-14-0939		11	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700031		
J	Ueno, K; Nomura, Y; Morita, Y; Eguchi, T; Masuda, K; Kawano, Y				Ueno, Kentaro; Nomura, Yuichi; Morita, Yasuko; Eguchi, Taisuke; Masuda, Kiminori; Kawano, Yoshifumi			Circulating Platelet-Neutrophil Aggregates Play a Significant Role in Kawasaki Disease	CIRCULATION JOURNAL			English	Article						Coronary artery abnormalities; Kawasaki disease; Platelet-neutrophil aggregates; Prednisolone; Vasculitis	INTRAVENOUS GAMMA-GLOBULIN; LYMPH-NODE SYNDROME; P-SELECTIN; POLYMORPHONUCLEAR LEUKOCYTES; BETA-THROMBOGLOBULIN; PLASMA-LEVELS; INFLAMMATION; ACTIVATION; CHILDREN; PLATELET-FACTOR-4	Background: Circulating platelet-neutrophil aggregates play a crucial role in amplifying acute inflammation and could promote adverse effects involving vascular injury. The aim of this study was to evaluate the role of platelet-neutrophil aggregates in Kawasaki disease (KD). Methods and Results: Forty patients with KD (30 intravenous immunoglobulin [IVIG] responders and 10 IVIG non-responders), 7 febrile patients with bacterial infections, and 9 normal volunteers were analyzed. Thirty-three patients with KD were treated with IVIG, and 7 were treated with IVIG plus prednisolone. We evaluated the rate of platelet-neutrophil aggregates and measured the platelet factor 4 (PF4) and beta-thromboglobulin (beta-TG) levels. The rate of platelet-neutrophil aggregates was significantly higher in patients with KD than those with bacterial infection and normal volunteers. The rate of platelet-neutrophil aggregates was significantly higher in patients with coronary artery abnormalities (CAA) than in those without CAA, and was correlated with PF4 and beta-TG levels in patients with KD. Comparing time-course analysis, the rate of platelet-neutrophil aggregates was significantly decreased in patients treated with IVIG plus prednisolone than in those treated with IVIG alone. Conclusions: The findings demonstrate that platelet-neutrophil aggregates are significantly present in higher rates and are closely related to pathological developments of CAA in KD. Additional prednisolone treatment for patients in the acute phase of KD could suppress platelet-neutrophil aggregates, indicating that platelet-neutrophil aggregates would inhibit amplified reciprocal vascular inflammatory activation.	[Ueno, Kentaro; Nomura, Yuichi; Eguchi, Taisuke; Kawano, Yoshifumi] Kagoshima Univ, Dept Pediat, Grad Sch Med & Dent Sci, Kagoshima 8908544, Japan; [Morita, Yasuko; Masuda, Kiminori] Kagoshima City Hosp, Dept Pediat, Kagoshima, Japan; [Morita, Yasuko; Masuda, Kiminori] Kagoshima Med Assoc Hosp, Dept Pediat, Kagoshima, Japan	Ueno, K (reprint author), Kagoshima Univ, Dept Pediat, Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan.	ukenta@m3.kufm.kagoshima-u.ac.jp			Japan Kawasaki Disease Research Center	We appreciate our patients and their parents for their commitment to this project. This study was supported in part by the Japan Kawasaki Disease Research Center.	Onouchi Y, 2008, NAT GENET, V40, P35, DOI 10.1038/ng.2007.59; Maugeri N, 2006, J THROMB HAEMOST, V4, P1323, DOI 10.1111/j.1538-7836.2006.01968.x; Gawaz M, 1996, THROMB RES, V83, P341, DOI 10.1016/0049-3848(96)00144-2; Ayusawa M, 2005, PEDIATR INT, V47, P232, DOI 10.1111/j.1442-200x.2005.02033.x; KATO H, 1979, PEDIATRICS, V63, P175; KAWASAKI T, 1974, PEDIATRICS, V54, P271; Wagner DD, 2003, ARTERIOSCL THROM VAS, V23, P2131, DOI 10.1161/01.ATV.0000095974.95122.EC; Kobayashi T, 2006, CIRCULATION, V113, P2606, DOI 10.1161/CIRCULATIONAHA.105.592865; KAPLAN KL, 1981, BLOOD, V57, P199; Wang F, 2007, CLIN RHEUMATOL, V26, P768, DOI 10.1007/s10067-007-0550-0; Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499; Suzuki A, 2000, CIRCULATION, V101, P2935; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; Shi GF, 2011, THROMB RES, V127, P387, DOI 10.1016/j.thromres.2010.10.019; Wallace CA, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e78; Nijm J, 2005, AM J CARDIOL, V95, P452, DOI 10.1016/j.amjcard.2004.10.009; Kobayashi T, 2007, CLIN EXP IMMUNOL, V148, P112, DOI 10.1111/j.1365-2249.2007.03326.x; Kobayashi T, 2012, LANCET, V379, P1613, DOI 10.1016/S0140-6736(11)61930-2; Zarbock A, 2007, BLOOD REV, V21, P99, DOI 10.1016/j.blre.2006.06.001; Kirschenbaum LA, 2000, AM J RESP CRIT CARE, V161, P1602; Barnard MR, 2003, CURR PROTOC CYTOM; del Conde I, 2005, ARTERIOSCL THROM VAS, V25, P1065, DOI 10.1161/01.ATV.0000159094.17235.9b; Furie B, 1997, THROMB HAEMOSTASIS, V78, P306; Ishii M, 2001, PEDIATR INT, V43, P211; Huo YQ, 2004, TRENDS CARDIOVAS MED, V14, P18, DOI 10.1016/j.tcm.2003.09.007; Ogawa S, 2014, CIRC J, V78, P2521, DOI 10.1253/circj.CJ-66-0096; KATO H, 1975, J PEDIATR-US, V86, P892, DOI 10.1016/S0022-3476(75)80220-4; Lefer AM, 1998, CIRCULATION, V98, P1322; LEVIN M, 1985, BRIT MED J, V290, P1456; Li A, 2011, THROMB RES, V127, P184; Liverani E, 2012, BIOCHEM PHARMACOL, V83, P1364, DOI 10.1016/j.bcp.2012.02.006; Moraes LA, 2005, BLOOD, V106, P4167, DOI 10.1182/blood-2005-04-1723; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; Ogata S, 2013, INT J CARDIOL, V168, P3825, DOI 10.1016/j.ijcard.2013.06.027; Okada Y, 2003, J PEDIATR-US, V143, P363, DOI 10.1067/S0022-3476(03)00387-1; Polanowska-Grabowska R, 2010, ARTERIOSCL THROM VAS, V30, P2392, DOI 10.1161/ATVBAHA.110.211615; Singbartl K, 2000, FASEB J, V14, P48; Tuttle HA, 2003, CARDIOVASC DIABETOL, V2, P2; Ueno K, 2010, BRIT J HAEMATOL, V148, P85; von Hundelshausen P, 2007, CIRC RES, V100, P27, DOI 10.1161/01.RES.0000252802.25497.b7; Yahata T, 2013, CIRC J, V78, P188; Yamamoto T, 2002, CLIN RHEUMATOL, V21, P501, DOI 10.1007/s100670200123	42	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1349	1356		10.1253/circj.CJ-14-1323		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700033		
J	Tanaka, H; Katsuragi, S; Osato, K; Hasegawa, J; Nakata, M; Murakoshi, T; Yoshimatsu, J; Sekizawa, A; Kanayama, N; Ishiwata, I; Ikeda, T				Tanaka, Hiroaki; Katsuragi, Shinji; Osato, Kazuhiro; Hasegawa, Junichi; Nakata, Masahiko; Murakoshi, Takeshi; Yoshimatsu, Jun; Sekizawa, Akihiko; Kanayama, Naohiro; Ishiwata, Isamu; Ikeda, Tomoaki			Increase in Maternal Death-Related Venous Thromboembolism During Pregnancy in Japan (2010-2013)	CIRCULATION JOURNAL			English	Article						Maternal death; Pregnancy; Pulmonary embolism; Venous thromboembolism	DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; RISK-FACTORS	Background: The aim of the present work was to understand the current circumstances of maternal-death-related venous thromboembolism (MD-VTE) in Japan. We retrospectively investigated the characteristics of cases of MD-VTE, and compared past and present rates of occurrence. Methods and Results: We examined the Japanese data for MD-VTE in 2010-2013, and compared it with that from 1991-1992. MD-VTE occurred in 17 women in 1991-1992, and in 13 women in 2010-2013. The maternal mortality ratio of MD-VTE was 0.7 per 100,000 in 1991-1992 and 0.4 per 100,000 in 2010-2013. Both the maternal mortality ratio and rate of MD-VTE in 2010-2013 deceased significantly compared with 1991-1992 (P<0.05). However, the number of cases of MD-VTE during pregnancy was 6 among 13 women (41%) in 2010-2013, but 1 in 17 women (6%) in 1991-1992, showing an increase (P<0.05). In the present study, cesarean delivery was more frequently associated with MD-VTE. Conclusions: MD-VTE overall has decreased within the past 20 years in Japan. But, MD-VTE during pregnancy in 2010-2013 increased relative to 1991-1992. Future guidelines for prevention of VTE may need to extend beyond the perioperative period to decrease the incidence of MD-VTE.	[Tanaka, Hiroaki; Ikeda, Tomoaki] Mie Univ, Dept Obstet & Gynecol, Sch Med, Tsu, Mie 5148507, Japan; [Katsuragi, Shinji] Sakakibara Heart Inst, Dept Obstet & Gynecol, Tokyo, Japan; [Osato, Kazuhiro] Ise Red Cross Hosp, Dept Obstet & Gynecol, Ise, Japan; [Hasegawa, Junichi; Sekizawa, Akihiko] Showa Univ, Sch Med, Dept Obstet & Gynecol, Tokyo 142, Japan; [Nakata, Masahiko] Kawasaki Univ, Sch Med, Dept Obstet & Gynecol, Kurashiki, Okayama, Japan; [Murakoshi, Takeshi] Seirei Hamamatsu Gen Hosp, Maternal & Perinatal Care Ctr, Div Perinatol, Hamamatsu, Shizuoka, Japan; [Yoshimatsu, Jun] Natl Cerebral & Cardiovasc Ctr, Div Maternal Fetal Med & Gynecol, Suita, Osaka, Japan; [Kanayama, Naohiro] Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Hamamatsu, Shizuoka 4313192, Japan; [Ishiwata, Isamu] Ishiwata Obstet & Gynecol Hosp, Mito, Ibaraki, Japan	Tanaka, H (reprint author), Mie Univ, Dept Obstet & Gynecol, Fac Med, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	h_tanaka@med.miyazaki-u.ac.jp			Japan Association of Obstetricians and Gynecologists	We give special thanks to all the doctors of the facilities reporting maternal deaths. This work was supported by the Japan Association of Obstetricians and Gynecologists.	Nagaya K, 2000, JAMA-J AM MED ASSOC, V283, P2661, DOI 10.1001/jama.283.20.2661; Goldhaber SZ, 2010, J AM COLL CARDIOL, V56, P1, DOI 10.1016/j.jacc.2010.01.057; Greer IA, 1999, LANCET, V353, P1258, DOI 10.1016/S0140-6736(98)10265-9; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; Kobayashi T, 2008, CIRC J, V72, P753, DOI 10.1253/circj.72.753; Heit JA, 2005, ANN INTERN MED, V143, P697; Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809; RUTHERFORD SE, 1991, OBSTET GYN CLIN N AM, V18, P345; Bates S M, 1997, Curr Opin Hematol, V4, P335; Battinelli EM, 2013, THROMBOSIS, V2013, DOI [DOI 10.1155/2013/516420, 10.1155/2013/516420]; BERGQVIST A, 1983, ACTA OBSTET GYN SCAN, V62, P443; Katsuragi S, 2012, CIRC J, V76, P2249, DOI 10.1253/circj.CJ-12-0235; KINSELLA SM, 1994, OBSTET GYNECOL, V83, P774; Kobayashi T, 2005, JPN J OBSTET GYNECOL, V14, P1; Mothers' and Children's Health Organization, 2014, MAT CHILD HLTH STAT; Tanaka H, 2014, CIRC J, V78, P2501, DOI 10.1253/circj.CJ-14-0541; Tanaka H, 2014, CIRC J, V78, P878, DOI 10.1253/circj.CJ-13-1178	17	3	3	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1357	1362		10.1253/circj.CJ-14-1228		6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700034		
J	Matsuki, M; Kabara, M; Saito, Y; Shimamura, K; Minoshima, A; Nishimura, M; Aonuma, T; Takehara, N; Hasebe, N; Kawabe, J				Matsuki, Motoki; Kabara, Maki; Saito, Yukihiro; Shimamura, Kohei; Minoshima, Akiho; Nishimura, Masato; Aonuma, Tatsuya; Takehara, Naofumi; Hasebe, Naoyuki; Kawabe, Jun-ichi			Ninjurin1 Is a Novel Factor to Regulate Angiogenesis Through the Function of Pericytes	CIRCULATION JOURNAL			English	Article						Angiogenesis; Endothelial cells; Ninjurin1; Pericytes	CENTRAL-NERVOUS-SYSTEM; ADHESION MOLECULE; MYELOID CELLS; GROWTH; REGENERATION; INFLAMMATION; MATURATION; RECEPTOR; INJURY; TIE2	Background: Capillary pericytes (cPCs), the mural cells of microvessels, play an important role in the formation and maintenance of microvessels; however, little is known about the mechanisms of how cPCs regulate angiogenesis. To identify factors that modulate cPC function, genes whose levels were altered in cPCs during neovessel formation were identified through a microarray screen. Methods and Results: Ninjurin1 (nerve injury-induced protein, Ninj1) was selected as a candidate factor for angiogenesis regulation. Ninj1 was expressed in capillary cells including endothelial cells (cECs) and was expressed at a higher level in cPCs. Hypoxia induced the gene expression of Ninj1 in addition of vascular endothelial growth factor (VEGF) in cPCs. When cPCs were co-incubated with a thoracic aorta in a three-dimensional Matrigel system, the length of the EC-tubes sprouting from the aorta was increased. Small interfering RNA-mediated downregulation of Ninj1 in cPCs enhanced these cPCs-mediated angiogenic effects, whereas overexpression of Ninj1 attenuated their effects. The production of angiogenic growth factors, such as VEGF and angiopoietin 1, by cPCs was enhanced by the downregulation of Ninj1, and reduced by the overexpression of Ninj1. Conclusions: Ninj1 is a novel regulator for the angiogenic effect of PCs. Specifically, Ninj1 negatively regulates the formation of neovessels, that is, the EC-tube, by reducing the trophic effects of cPCs.	[Matsuki, Motoki; Kabara, Maki; Shimamura, Kohei; Minoshima, Akiho; Nishimura, Masato; Aonuma, Tatsuya; Hasebe, Naoyuki] Asahikawa Med Univ, Dept Med, Div Cardiovasc Resp & Neurol, Asahikawa, Hokkaido 0788510, Japan; [Takehara, Naofumi; Hasebe, Naoyuki; Kawabe, Jun-ichi] Asahikawa Med Univ, Dept Cardiovasc Regenerat & Innovat, Asahikawa, Hokkaido 0788510, Japan; [Saito, Yukihiro] Asahikawa Med Univ, Dept Vasc Surg, Asahikawa, Hokkaido 0788510, Japan	Kawabe, J (reprint author), Asahikawa Med Univ, Dept Cardiovasc Regenerat & Innovat, 2-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	kawabeju@asahikawa-med.ac.jp			Ministry of Education, Science, Sports, and Culture of Japan [22590820, 25461121]; Akiyama Life Science Foundation; Mitsubishi Pharma Research Foundation	We thank K. Kanno, A. Oda, S. Takahashi, Y. Horikawa, and E. Shinokawa for laboratory assistance, and Y. Segawa for secretarial assistance, and T. Kitagawa, A. Yoshimura, S. Baba, A. Masuo, Y. Matsuo and K. Asai for technical support. Funding for this study was provided by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan (22590820 and 25461121); and grants from The Akiyama Life Science Foundation and Mitsubishi Pharma Research Foundation.	Ahn BJ, 2009, BIOCHEM BIOPH RES CO, V387, P321, DOI 10.1016/j.bbrc.2009.07.019; Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521; Dulmovits BM, 2012, INT J BIOCHEM CELL B, V44, P1800, DOI 10.1016/j.biocel.2012.06.031; Ifergan I, 2011, ANN NEUROL, V70, P751, DOI 10.1002/ana.22519; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; Diaz-Flores L, 2009, HISTOL HISTOPATHOL, V24, P909; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Benelli R, 2006, CURR PHARM DESIGN, V12, P3101, DOI 10.2174/138161206777947461; Costa Carla, 2007, Angiogenesis, V10, P149, DOI 10.1007/s10456-007-9074-0; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Yamagishi S, 1999, LAB INVEST, V79, P501; Song B, 2013, CIRC J, V77, P2997, DOI 10.1253/circj.CJ-13-0805; Odoardi F, 2012, NATURE, V488, P675, DOI 10.1038/nature11337; Araki T, 1997, J BIOL CHEM, V272, P21373, DOI 10.1074/jbc.272.34.21373; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Lee HJ, 2009, CELL DEATH DIFFER, V16, P1395, DOI 10.1038/cdd.2009.78; Bach LA, 2015, J MOL ENDOCRINOL, V54, pR1, DOI 10.1530/JME-14-0215; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Fukuhara S, 2010, HISTOL HISTOPATHOL, V25, P387; Aburakawa Y, 2013, CIRC J, V77, P1053, DOI 10.1253/circj.CJ-12-0897; Araki T, 1996, NEURON, V17, P353, DOI 10.1016/S0896-6273(00)80166-X; Asanome A, 2014, BIOCHEM BIOPH RES CO, V443, P150, DOI 10.1016/j.bbrc.2013.11.070; Hoffmann J, 2005, FASEB J, V19, P2035, DOI 10.1096/fj.04-2109fje; Inoki Isao, 2002, FASEB Journal, V16, P219; Jacobo SMP, 2015, J BIOL CHEM, V290, P6349, DOI 10.1074/jbc.M114.634154; Kabara M, 2014, LAB INVEST, V94, P1340, DOI 10.1038/labinvest.2014.121; Kawabe J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/701571.; Lipson Kenneth E, 2012, Fibrogenesis Tissue Repair, V5, pS24, DOI 10.1186/1755-1536-5-S1-S24; Shanahan W R Jr, 1989, J Exp Pathol, V4, P17; Smith SW, 2012, HISTOL HISTOPATHOL, V27, P1503; Yin GN, 2014, P NATL ACAD SCI USA, V111, pE2731, DOI 10.1073/pnas.1403471111	37	2	2	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1363	+		10.1253/circj.CJ-14-1376		10	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700035		
J	Azuma, M; Chihara, Y; Yoshimura, C; Murase, K; Hamada, S; Tachikawa, R; Matsumoto, T; Inouchi, M; Tanizawa, K; Handa, T; Oga, T; Mishima, M; Chin, K				Azuma, Masanori; Chihara, Yuichi; Yoshimura, Chikara; Murase, Kimihiko; Hamada, Satoshi; Tachikawa, Ryo; Matsumoto, Takeshi; Inouchi, Morito; Tanizawa, Kiminobu; Handa, Tomohiro; Oga, Toru; Mishima, Michiaki; Chin, Kazuo			Association Between Endothelial Function (Assessed on Reactive Hyperemia Peripheral Arterial Tonometry) and Obstructive Sleep Apnea, Visceral Fat Accumulation, and Serum Adiponectin	CIRCULATION JOURNAL			English	Article						Adiponectin; Continuous positive airway pressure; Endothelial function; Obstructive sleep apnea; Visceral obesity	DIGITAL VASCULAR FUNCTION; OXIDATIVE STRESS; CARDIOVASCULAR RISK; METABOLIC SYNDROME; DYSFUNCTION; DISEASE; OBESITY; INFLAMMATION; HUMANS; IMPACT	Background: Visceral obesity, low adiponectin, and severe obstructive sleep apnea (OSA) are associated with cardiovascular diseases, but the interactions among these factors on endothelial dysfunction are not well known. Methods and Results: Endothelial function in 133 patients after polysomnography was evaluated as reactive hyperemia index (RHI) on reactive hyperemia peripheral arterial tonometry. Visceral obesity was defined as visceral fat area >= 100 cm(2) on computed tomography. RHI was significantly correlated with apnea hypopnea index (AHI), visceral fat area, and serum adiponectin (r=-0.24, P=0.0055, r=-0.19, P=0.031, and r=0.20, P=0.019, respectively). RHI in patients with visceral obesity was significantly decreased in the presence of severe OSA (AHI >= 30; P=0.042). On multivariate regression analysis, only severe OSA remained as an independent predictive factor of RHI (P=0.024, R-2=5.4%). RHI in patients with severe OSA (n=44) was significantly improved after 3 months of continuous positive airway pressure (CPAP) treatment (1.78 +/- 0.40 before CPAP vs. 2.00 +/- 0.53 after CPAP, P=0.013), similarly to those with AHI <30 (P=0.45). Conclusions: Severe OSA, but not visceral fat area or serum adiponectin, was independently associated with endothelial function according to RHI. In addition, impaired endothelial function was reversible following 3 months of CPAP treatment.	[Azuma, Masanori; Murase, Kimihiko; Hamada, Satoshi; Tachikawa, Ryo; Matsumoto, Takeshi; Handa, Tomohiro; Mishima, Michiaki] Kyoto Univ, Dept Resp Med, Grad Sch Med, Kyoto 6068507, Japan; [Inouchi, Morito; Tanizawa, Kiminobu; Oga, Toru; Chin, Kazuo] Kyoto Univ, Resp Care & Sleep Control Med, Grad Sch Med, Kyoto 6068507, Japan; [Chihara, Yuichi] Otsu Red Cross Hosp, Dept Resp Med, Otsu, Shiga, Japan; [Yoshimura, Chikara] Kyusyu Univ Hosp, Sleep Apnea Ctr, Fukuoka, Japan	Chin, K (reprint author), Kyoto Univ, Dept Resp Care & Sleep Control Med, Grad Sch Med, Sakyo Ku, 54 Shogoin,Kawahara Cho, Kyoto 6068507, Japan.	chink@kuhp.kyoto-u.ac.jp			Philips-Respironics; Teijin Pharma; Fukuda Denshi; Fukuda Lifetec Keiji	This was not an industry-supported study. Morito Inouchi, Kiminobu Tanizawa, Toru Oga, and Kazuo Chin declare that the Department of Respiratory Care and Sleep Control Medicine was funded by endowments from Philips-Respironics, Teijin Pharma, Fukuda Denshi and Fukuda Lifetec Keiji to Kyoto University. The other authors have no conflicts of interest to declare.	Tishler PV, 2003, JAMA-J AM MED ASSOC, V289, P2230, DOI 10.1001/jama.289.17.2230; Ip MSM, 2004, AM J RESP CRIT CARE, V169, P348, DOI 10.1164/rccm.200306.767OC; Ouchi N, 2000, CIRCULATION, V102, P1296; Matsuzawa Y, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000426; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/01.mol.0000103609.38789.96; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; Romero-Corral A, 2010, J AM COLL CARDIOL, V56, P662, DOI 10.1016/j.jacc.2010.03.063; Namtvedt SK, 2013, HEART, V99, P30, DOI 10.1136/heartjnl-2012-303009; Pierce GL, 2009, CIRCULATION, V119, P1284, DOI 10.1161/CIRCULATIONAHA.108.804294; Romero-Corral A, 2006, LANCET, V368, P666, DOI 10.1016/S0140-6736(06)69251-9; Hopkins TA, 2007, CARDIOVASC RES, V74, P11, DOI 10.1016/j.cardiores.2006.10.009; Matsuzawa Y, 2013, CIRC J, V77, P2807, DOI 10.1253/circj.CJ-13-0549; Kritikou I, 2014, EUR RESPIR J, V43, P145, DOI 10.1183/09031936.00126712; Kraiczi H, 2001, CHEST, V119, P1085, DOI 10.1378/chest.119.4.1085; Yoshizumi T, 1999, RADIOLOGY, V211, P283; Britton KA, 2013, J AM COLL CARDIOL, V62, P921, DOI 10.1016/j.jacc.2013.06.027; Yamada S, 2013, CIRC J, V77, P1466, DOI 10.1253/circj.CJ-12-0836; Drager LF, 2013, J AM COLL CARDIOL, V62, P569, DOI 10.1016/j.jacc.2013.05.045; Jordan AS, 2014, LANCET, V383, P736, DOI 10.1016/S0140-6736(13)60734-5; Floras JS, 2014, J CARDIOL, V63, P3, DOI 10.1016/j.jjcc.2013.08.009; Flammer AJ, 2012, CIRCULATION, V126, P753, DOI 10.1161/CIRCULATIONAHA.112.093245; Zhang XL, 2006, RESPIRATION, V73, P73, DOI 10.1159/000088690; Silver AE, 2007, CIRCULATION, V115, P627, DOI 10.1161/CIRCULATIONAHA.106.657486; Bayram NA, 2009, SLEEP, V32, P1257; Jelic S, 2008, CIRCULATION, V117, P2270, DOI 10.1161/CIRCULATIONAHA.107.741512; West SD, 2006, THORAX, V61, P945, DOI 10.1136/thx.2005.057745; Chung S, 2007, SLEEP, V30, P997; Benjamin EJ, 2004, CIRCULATION, V109, P613, DOI 10.1161/01.CIR.0000112565.60887.1E; Jelic S, 2010, CIRCULATION, V121, P1014, DOI 10.1161/CIRCULATIONAHA.109.900357; Bugiardini R, 2004, CIRCULATION, V109, P2518, DOI 10.1161/01.CIR.0000128208.22378.E3; Chung S, 2010, RESPIRATION, V79, P363, DOI 10.1159/000228905; Ryan S, 2009, THORAX, V64, P631, DOI 10.1136/thx.2008.105577; Frystyk J, 2007, J CLIN ENDOCR METAB, V92, P571, DOI 10.1210/jc.2006-1067; Halcox JPJ, 2002, CIRCULATION, V106, P653, DOI 10.1161/01.CIR.0000025404.78001.D8; Hamburg NM, 2008, CIRCULATION, V117, P2467, DOI 10.1161/CIRCULATIONAHA.107.748574; Seif F, 2013, J SLEEP RES, V22, P443, DOI 10.1111/jsr.12026; Clarkson P, 1996, J AM COLL CARDIOL, V28, P573, DOI 10.1016/0735-1097(96)82380-1; Committee on Diagnostic Criteria for Metabolic Syndrome, 2005, J JPN SOC INTERN MED, V94, P794; EEG arousals: Scoring rules and examples, 1992, SLEEP, V15, P173; Faulx Michael D, 2004, Sleep, V27, P1113; Iber C, 2007, AASM MANUAL SCORING; Itzhaki S, 2005, SLEEP, V28, P594; Patt BT, 2010, AM J RESP CRIT CARE, V182, P1540, DOI 10.1164/rccm.201002-0162OC; Randby A, 2013, CHEST, V144, P915, DOI 10.1378/chest.12-2283; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Sanchez-de-la-Torre M, 2012, SLEEP BREATH, V16, P649, DOI 10.1007/s11325-011-0552-7; Silverberg DS, 1997, SLEEP, V20, P794; Suwaidi J A, 2000, Circulation, V101, P948; Matsuzawa Y, 2002, CIRC J, V66, P987; Torigoe M, 2007, CLIN ENDOCRINOL, V67, P276, DOI 10.1111/j.1365-2265.2007.02876.x; Yoshikawa M, 2014, LUNG, V192, P289, DOI 10.1007/s00408-013-9550-9	51	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1381	+		10.1253/circj.CJ-14-1303		11	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700037		
J	Ohe, M; Takii, E; Haraguchi, G; Ito, S; Kumanomido, J; Nitta, Y; Obuchi, A; Honda, A; Okabe, K; Fukumoto, Y				Ohe, Masatsugu; Takii, Eiichi; Haraguchi, Go; Ito, Shogo; Kumanomido, Jun; Nitta, Yoshikazu; Obuchi, Aya; Honda, Akihiro; Okabe, Kouta; Fukumoto, Yoshihiro			Mitral Regurgitation as the Cause of Atrial Tachycardia-3-Dimensional Mapping and 3-Dimensional Transesophageal Echocardiography -	CIRCULATION JOURNAL			English	Editorial Material							CATHETER ABLATION; TACHYCARDIA; FIBRILLATION; DISEASE; SCARS		[Ohe, Masatsugu; Takii, Eiichi; Haraguchi, Go; Ito, Shogo; Kumanomido, Jun; Nitta, Yoshikazu; Obuchi, Aya; Honda, Akihiro; Okabe, Kouta; Fukumoto, Yoshihiro] Kurume Univ, Div Cardiovasc Med, Dept Internal Med, Sch Med, Kurume, Fukuoka 8300011, Japan	Ohe, M (reprint author), Kurume Univ, Div Cardiovasc Med, Dept Internal Med, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	masaax@mint.ocn.ne.jp					Kim KH, 2013, CIRC J, V77, P619, DOI 10.1253/circj.CJ-12-0753; Yoshida K, 2008, CIRC J, V72, P1112, DOI 10.1253/circj.72.1112; Le Tourneau T, 2010, J AM COLL CARDIOL, V56, P570, DOI 10.1016/j.jacc.2010.02.059; Nakagawa H, 2001, CIRCULATION, V103, P699; Anshul M, 2008, CIRC-ARRHYTHMIA ELEC, V1, P14; Goldsmith I, 2000, AM HEART J, V140, P777, DOI 10.1067/mhj.2000.110284; Kumagai K, 2013, CIRC J, V77, P1416, DOI 10.1253/circj.CJ-12-0934; Sonoda K, 2014, CIRC J, V78, P1619, DOI 10.1253/circj.CJ-14-0017; Wakabayashi Y, 2014, CIRC J, V78, P2990, DOI 10.1253/circj.CJ-14-0553	9	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	JUN	2015	79	6					1390	1392		10.1253/circj.CJ-14-1134		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CJ0YK	WOS:000355206700038		
J	Hofmann, M; Wietholter, A; Blaha, I; Jost, H; Heinemann, P; Lehmann, M; Miller, T; Cadar, D; Yanase, T; Kley, N; Eiden, M; Groschup, M; Schmidt-Chanasit, J				Hofmann, Miriam; Wiethoelter, Anke; Blaha, Irena; Joest, Hanna; Heinemann, Patrick; Lehmann, Maria; Miller, Thomas; Cadar, Daniel; Yanase, Tohru; Kley, Nils; Eiden, Martin; Groschup, Martin; Schmidt-Chanasit, Jonas			Surveillance of Batai Virus in Bovines from Germany	CLINICAL AND VACCINE IMMUNOLOGY			English	Article								To estimate the veterinary importance of Batai virus (BATV), we investigated the presence of BATV-specific antibodies and BATV RNA in 548 bovines from southwest Germany, and we demonstrated that 3 cattle serum samples contained BATV-neutralizing antibodies, resulting in a seroprevalence of 0.55%. Thus, our results confirm local transmission and indicate cattle as potential hosts of BATV in southwest Germany.	[Hofmann, Miriam; Joest, Hanna; Heinemann, Patrick; Lehmann, Maria; Cadar, Daniel; Schmidt-Chanasit, Jonas] WHO Collaborating Ctr Arbovirus & Hemorrhag Fever, Bernhard Nocht Inst Trop Med, Hamburg, Germany; [Wiethoelter, Anke; Kley, Nils; Eiden, Martin; Groschup, Martin] Inst Novel & Emerging Infect Dis, Friedrich Loeffler Inst, Greifswald, Germany; [Blaha, Irena; Miller, Thomas] Staatl Tierarztl Untersuchungsamt Diagnost Zentru, Aulendorf, Germany; [Joest, Hanna; Schmidt-Chanasit, Jonas] German Ctr Infect Res DZIF, Hamburg, Germany; [Heinemann, Patrick] Charite, Inst Med Virol, Berlin, Germany; [Yanase, Tohru] NARO, Natl Inst Anim Hlth, Kyushu Res Stn, Kagoshima, Japan	Schmidt-Chanasit, J (reprint author), WHO Collaborating Ctr Arbovirus & Hemorrhag Fever, Bernhard Nocht Inst Trop Med, Hamburg, Germany.	jonassi@gmx.de					American Committee on Arthropod-Borne Viruses, INT CAT ARB; Yanase T, 2006, ARCH VIROL, V151, P2253, DOI 10.1007/s00705-006-0808-x; Becker N, 2014, BUNDESGESUNDHEITSBLA, V57, P531, DOI 10.1007/s00103-013-1918-8; Hubalek Z, 2008, PARASITOL RES, V103, pS29, DOI 10.1007/s00436-008-1064-7; Huhtamo E, 2013, J GEN VIROL, V94, P1242; Jost H, 2011, AM J TROP MED HYG, V85, P551, DOI 10.4269/ajtmh.2011.11-0248; Lambert AJ, 2014, VECTOR-BORNE ZOONOT, V14, P688, DOI 10.1089/vbz.2014.1596; Liu H, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-138; Pavri S., 1969, ARBOVIRUSES CALIFORN, P191; Sluka F., 1969, ARBOVIRUSES CALIFORN, P337	10	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	1556-6811	1556-679X		CLIN VACCINE IMMUNOL	Clin. Vaccine Immunol.	JUN	2015	22	6					672	673		10.1128/CVI.00082-15		2	Immunology; Infectious Diseases; Microbiology	Immunology; Infectious Diseases; Microbiology	CJ0DL	WOS:000355143500008		
J	Chin, AWH; Perera, RAPM; Guan, Y; Halfmann, P; Kawaoka, Y; Peiris, M; Poon, LLM				Chin, Alex W. H.; Perera, Ranawaka A. P. M.; Guan, Yi; Halfmann, Peter; Kawaoka, Yoshihiro; Peiris, Malik; Poon, Leo L. M.			Pseudoparticle Neutralization Assay for Detecting Ebola-Neutralizing Antibodies in Biosafety Level 2 Settings	CLINICAL CHEMISTRY			English	Letter							VIRUSES		[Chin, Alex W. H.; Perera, Ranawaka A. P. M.; Guan, Yi; Peiris, Malik; Poon, Leo L. M.] Univ Hong Kong, Sch Publ Hlth, Influenza Res Ctr, Hong Kong, Hong Kong, Peoples R China; [Peiris, Malik] Univ Hong Kong, HKU Pasteur Pole, Hong Kong, Hong Kong, Peoples R China; [Halfmann, Peter; Kawaoka, Yoshihiro] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA; [Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol, Tokyo, Japan	Poon, LLM (reprint author), Univ Hong Kong, LKS Fac Med, Sch Publ Hlth, 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	llmpoon@hku.hk					Takada A, 2003, J VIROL, V77, P1069, DOI 10.1128/JVI.77.2.1069-1074.2003; Baize S, 2014, NEW ENGL J MED, V371, P1418, DOI 10.1056/NEJMoa1404505; Garcia JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007918; Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574; WHO, LAB GUID EB VIR DIS	5	0	0	AMER ASSOC CLINICAL CHEMISTRY	WASHINGTON	2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA	0009-9147	1530-8561		CLIN CHEM	Clin. Chem.	JUN	2015	61	6					885	886		10.1373/clinchem.2015.238204		2	Medical Laboratory Technology	Medical Laboratory Technology	CJ1SW	WOS:000355265800015		
J	Oshima, H; Yamazaki, T; Benner, L; Miki, T; Michon, I; Wojtkowski, T; Kaibara, A; Mujais, S				Oshima, Hiroyuki; Yamazaki, Takao; Benner, Lauren; Miki, Takashi; Michon, Ingrid; Wojtkowski, Tomasz; Kaibara, Atsunori; Mujais, Salim			Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects	CLINICAL DRUG INVESTIGATION			English	Article							CLOSTRIDIUM-DIFFICILE INFECTION; RISK; EPIDEMIOLOGY; RECURRENCE; UPDATE; QUEBEC	Background and Objectives Fidaxomicin treatment of Clostridium difficile infection is known to produce minimal systemic exposure, as the antibacterial (antibiotic) remains primarily in the gut. In this randomized, double-blind, placebo-controlled study, the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of fidaxomicin were evaluated in healthy Japanese and Caucasian subjects. Methods Thirty-six healthy subjects were randomly assigned in a 3:1 ratio to receive either fidaxomicin or placebo. Cohort 1 (100 mg) and Cohort 2 (200 mg) comprised 12 Japanese subjects each and Cohort 3 (200 mg) comprised 12 Caucasian subjects. Subjects received a single dose of the study drug on Day 1 and received multiple doses for 10 days after a wash-out period. Results After multiple 200 mg dosing of fidaxomicin, both mean maximum plasma concentrations (C-max) in Japanese (8.7 +/- 5.3 ng/mL) and Caucasian (7.0 +/- 3.7 ng/mL) subjects and the area under the concentration-time curve (AUC) were higher in Japanese subjects (58.5 +/- A 36.7 ng center dot h/mL) than in Caucasian subjects (37.6 +/- 15.7 ng center dot h/mL), although variation in both groups was large. The mean fecal concentrations of fidaxomicin in Japanese and Caucasian subjects were 2669 and 2181 mu g/g, respectively. The possibly study drug-related adverse events were diarrhea (n = 1), feeling hot (n = 1), and hypersomnia (n = 2), which were mild in severity. Conclusions In both Japanese and Caucasian subjects, fidaxomicin demonstrated similarly minimal systemic absorption, and was mainly excreted in feces. Fidaxomicin was safe and well-tolerated in all subjects.	[Oshima, Hiroyuki; Miki, Takashi; Kaibara, Atsunori] Astellas Pharma Inc, Chuo Ku, Tokyo 1038411, Japan; [Yamazaki, Takao; Benner, Lauren; Wojtkowski, Tomasz; Mujais, Salim] Astellas Pharma Global Dev Inc, Northbrook, IL USA; [Michon, Ingrid] Astellas Pharma Global Dev Inc, Leiden, Netherlands	Oshima, H (reprint author), Astellas Pharma Inc, Chuo Ku, 2-5-1 Nihonbashi Honcho, Tokyo 1038411, Japan.	hiroyuki.oshima@astellas.com			Astellas Pharma Inc.; Astellas	This study was sponsored by Astellas Pharma Inc. The authors thank Drs. Pam Sears and Yoshi Ichikawa (Cubist Pharmaceuticals, Inc., USA) for supporting and assisting in the development of fidaxomicin and Dr. Tetsuji Asao (SunFlare Co., Ltd.) for scientific writing support, for which he received financial compensation from Astellas. Drs. Oshima, Yamazaki, Benner, Miki, Michon, Wojtkowski, Kaibara, and Mujais played a substantial role in the design and overall management of this study and also in the collection, analysis, and interpretation of data. All authors listed as authors were involved in the critical review and revision of the manuscript, and all provided final approval of the content.	Louie TJ, 2012, CLIN INFECT DIS, V55, pS132, DOI 10.1093/cid/cis338; Forster AJ, 2012, CAN MED ASSOC J, V184, P37, DOI 10.1503/cmaj.110543; Freeman J, 2010, CLIN MICROBIOL REV, V23, P529, DOI 10.1128/CMR.00082-09; Goldstein EJC, 2012, CLIN INFECT DIS, V55, pS143, DOI 10.1093/cid/cis339; Babakhani F, 2011, J MED MICROBIOL, V60, P1213, DOI 10.1099/jmm.0.029470-0; Carroll KC, 2011, ANNU REV MICROBIOL, V65, P501, DOI 10.1146/annurev-micro-090110-102824; Sears P, 2012, CLIN INFECT DIS, V55, pS116, DOI 10.1093/cid/cis337; Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706; Kallen AJ, 2009, INFECT CONT HOSP EP, V30, P264, DOI 10.1086/595694; Louie TJ, 2011, NEW ENGL J MED, V364, P422, DOI 10.1056/NEJMoa0910812; CAVALLERI B, 1988, J ANTIBIOT, V41, P308; McDonald LC, 2005, NEW ENGL J MED, V353, P2433, DOI 10.1056/NEJMoa051590; Pepin J, 2005, CLIN INFECT DIS, V41, P1254, DOI 10.1086/496986; Cornely OA, 2012, LANCET INFECT DIS, V12, P281, DOI 10.1016/S1473-3099(11)70374-7; Slimings C, 2014, J ANTIMICROB CHEMOTH, V69, P881, DOI 10.1093/jac/dkt477; Kurabachew M, 2008, J ANTIMICROB CHEMOTH, V62, P713, DOI 10.1093/jac/dkn269; Pepin J, 2005, CLIN INFECT DIS, V40, P1591, DOI 10.1086/430315; Owens RC, 2008, CLIN INFECT DIS, V46, pS19, DOI 10.1086/521859; Debast SB, 2014, CLIN MICROBIOL INFEC, V20, P1, DOI 10.1111/1469-0691.12418; Eyre DW, 2012, CLIN INFECT DIS, V55, pS77, DOI 10.1093/cid/cis356; Honda H, 2014, ANAEROBE, V25, P5, DOI 10.1016/j.anaerobe.2013.10.004; Kelly Ciarán P, 2008, N Engl J Med, V359, P1932, DOI 10.1056/NEJMra0707500; Shue YK, 2008, ANTIMICROB AGENTS CH, V52, P1391, DOI 10.1128/AAC.01045-07; Takahashi M, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005665; Thomas Claudia, 2003, Commun Dis Intell Q Rep, V27 Suppl, pS28	25	1	1	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.	JUN	2015	35	6					375	384		10.1007/s40261-015-0291-9		10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ2TM	WOS:000355337400004		
J	Ando, M; Tamaki, T; Yoshida, M; Kawakami, M; Kubota, S; Nakagawa, Y; Iwasaki, H; Tsutsui, S; Yamada, H				Ando, Muneharu; Tamaki, Tetsuya; Yoshida, Munehito; Kawakami, Mamoru; Kubota, Seiji; Nakagawa, Yukihiro; Iwasaki, Hiroshi; Tsutsui, Shunji; Yamada, Hiroshi			Intraoperative spinal cord monitoring using combined motor and sensory evoked potentials recorded from the spinal cord during surgery for intramedullary spinal cord tumor	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article							CLINICAL ARTICLE; ELECTRICAL-STIMULATION; ISOFLURANE; RESECTION; SOCIETY		[Ando, Muneharu; Tamaki, Tetsuya] Wakayama Rosai Hosp, Dept Orthoped Surg, Wakayama 6408505, Japan; [Yoshida, Munehito; Nakagawa, Yukihiro; Iwasaki, Hiroshi; Tsutsui, Shunji; Yamada, Hiroshi] Wakayama Med Univ, Dept Orthoped Surg, Wakayama, Japan; [Kawakami, Mamoru] Wakayama Med Univ, Kihoku Hosp, Dept Orthoped Surg, Wakayama, Japan; [Kubota, Seiji] Naga Hosp, Dept Orthoped Surg, Wakayama, Japan	Ando, M (reprint author), Wakayama Rosai Hosp, Dept Orthoped Surg, 93-1 Kinomoto, Wakayama 6408505, Japan.	mando@gaia.eonet.ne.jp					Costa P, 2013, EUR SPINE J, V22, P840, DOI 10.1007/s00586-012-2576-5; Deletis V, 2008, CLIN NEUROPHYSIOL, V119, P248, DOI 10.1016/j.clinph.2007.09.135; MCCORMICK PC, 1990, J NEUROSURG, V72, P523, DOI 10.3171/jns.1990.72.4.0523; HICKS R, 1992, J PHYSIOL-LONDON, V456, P393; Sala F, 2006, NEUROSURGERY, V58, P1129, DOI 10.1227/01.NEU.0000215948.97195.58; Matsuyama Y, 2009, J NEUROSURG-SPINE, V10, P404, DOI 10.3171/2009.2.SPINE08698; MacDonald DB, 2013, CLIN NEUROPHYSIOL, V124, P2291, DOI 10.1016/j.clinph.2013.07.025; Langeloo DD, 2003, SPINE, V28, P1043, DOI 10.1097/00007632-200305150-00017; Cheng JS, 2014, J NEUROSURG-PEDIATR, V13, P591, DOI 10.3171/2014.2.PEDS1392; Hyun SJ, 2009, BRIT J NEUROSURG, V23, P393, DOI 10.1080/02688690902964744; BOYD SG, 1986, J NEUROL NEUROSUR PS, V49, P251, DOI 10.1136/jnnp.49.3.251; DELETIS V, 1993, NEUROSURGERY, V33, P173; DINNER DS, 1986, J NEUROSURG, V65, P807, DOI 10.3171/jns.1986.65.6.0807; EPSTEIN FJ, 1993, J NEUROSURG, V79, P204, DOI 10.3171/jns.1993.79.2.0204; GRUNDY BL, 1982, NEUROSURGERY, V11, P556; Haghighi SS, 1998, NEUROL RES, V20, P555; Iwasaki Hiroshi, 2003, J Orthop Sci, V8, P635, DOI 10.1007/s00776-003-0693-z; KEARSE LA, 1993, J CLIN ANESTH, V5, P392, DOI 10.1016/0952-8180(93)90103-L; KITAGAWA H, 1989, SPINE, V14, P1078, DOI 10.1097/00007632-198910000-00009; Kobayashi S, 2014, J NEUROSURG-SPINE, V20, P102, DOI 10.3171/2013.10.SPINE12944; Kothbauer K, 1997, PEDIATR NEUROSURG, V26, P247, DOI 10.1159/000121199; KOYANAGI I, 1993, NEUROSURGERY, V33, P451; Kubota S, 1997, J ELECTRODIAG SPINAK, V19, P57; Kurokawa T, 1972, JPN J ELECTROENCEPHA, V1, P64; Matsuda H, 1989, NEUROMONITORING SURG, P175; Morota N, 1997, NEUROSURGERY, V41, P1327; Nakagawa Yukihiro, 2002, J Orthop Sci, V7, P102, DOI 10.1007/s776-002-8430-x; Nash CL, 1972, J BONE JOINT SURG AM, V54, P197; Quinones-Hinojosa A, 2005, NEUROSURGERY, V56, P982, DOI 10.1277/01.NEU.0000158203.29369.37; Tamaki T, 1997, SEIKEIGEKA ORTHOPAED, V28, P681; Tamaki T, 1972, JPN J ELECTROENCEPHA, V1, P196; Tanaka S, 1999, CENTRAL J ORTHOP TRA, V42, P1253; Toyoda A, 1984, FUNDAMENTALS CLIN AP, P99; Yamamoto N, 2010, J NEUROSURG-SPINE, V13, P200, DOI 10.3171/2010.3.SPINE08298	34	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	JUN	2015	133						18	23		10.1016/j.clineuro.2015.03.004		6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CJ3BY	WOS:000355359600004		
J	Urano, A; Hotta, M; Ohwada, R; Araki, M				Urano, Ayako; Hotta, Mari; Ohwada, Rina; Araki, Mariko			Vitamin K deficiency evaluated by serum levels of undercarboxylated osteocalcin in patients with anorexia nervosa with bone loss	CLINICAL NUTRITION			English	Article						Anorexia nervosa; Osteoporosis; Undercarboxylated osteocalcin; Vitamin K	HUMAN GUT MICROBIOTA; HOSPITALIZED-PATIENTS; OSTEOPOROSIS; WOMEN; MASS; DISORDERS; TURNOVER; DIET	Background & aims: Osteoporosis is a chief complication in patients with anorexia nervosa. Serum levels of undercarboxylated osteocalcin reflect serum and bone vitamin K deficiency. We investigated vitamin K status in patients with anorexia nervosa to help establish prevention and treatment recommendations for osteoporosis. Methods: Fifty-four female amenorrheic patients with anorexia nervosa (29 restricting-type and 25 binge eating/purging. type) (age, 28.0 (26.7-31.1) (mean (95% CI)) years; body mass index, 14.8 (14.1 15.5) kg/m(2), duration of illness; 107.3 (88.5-126.0) months) and 15 age-matched healthy females were included in this study. We measured serum levels of undercarboxylated osteocalcin, biochemical and nutritional markers, and bone metabolic markers. Dietary vitamin K intake was evaluated by a questionnaire. Results: Lumbar bone mineral density and T-scores in patients with anorexia nervosa were 0.756 (0.721- 0.790) g/cm(2) and -2.4 (-2.1 to -2.7), respectively, indicating bone loss. Serum levels of undercarboxylated osteocalcin in patients with anorexia nervosa were significantly higher than those of controls. The 17% of restricting type and 40% of binge eating/purging type anorexia nervosa patients, serum levels of undercarboxylated osteocalcin were higher than 4.5 ng/ml and were diagnosed with vitamin K deficiency. Serum levels of undercarboxylated osteocalcin correlated significantly and negatively with vitamin K intake in patients with anorexia nervosa. Conclusions: Patients with anorexia nervosa had vitamin K deficiency. Since a supplement of vitamin K might be effective for maintaining bone quality, we provide recommendations regarding vitamin K intake for prevention and treatment of osteoporosis in patients with AN. (C) 2014 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.	[Urano, Ayako; Ohwada, Rina] Saitama Sekishinkai Hosp, Div Endocrinol & Metab, Saitama, Japan; [Hotta, Mari] Natl Grad Inst Policy Studies, Hlth Serv Ctr, Tokyo 1068777, Japan; [Hotta, Mari] Tokyo Womens Med Univ, Inst Womens Hlth, Tokyo, Japan; [Araki, Mariko] Nagai Hitachinomori Hosp, Dept Internal Med, Tsukuba, Ibaraki, Japan	Hotta, M (reprint author), Natl Grad Inst Policy Studies, Hlth Serv Ctr, Minato Ku, 7-22-1 Roppongi, Tokyo 1068777, Japan.	marihs@grips.ac.jp			Japanese Ministry of Health, Labor, and Welfare [H23-Intractable disease-general-010]	We would like to thank SRL (Tachikawa, Tokyo, Japan) for technical assistance with the assays for several hormones, and Eidia Co., Ltd (Tokyo, Japan) for scientific information. This work was supposed in part by a grant for anorexia nervosa research from the Japanese Ministry of Health, Labor, and Welfare (H23-Intractable disease-general-010).	ALPERIN JB, 1987, JAMA-J AM MED ASSOC, V258, P1916, DOI 10.1001/jama.258.14.1916; American Psychiatric Association, 1992, DIAGN STAT MAN MENT, V5<SUP>th</SUP>; Hamidi MS, 2013, J CLIN DENSITOM, V16, P409, DOI 10.1016/j.jocd.2013.08.017; Yamauchi M, 2010, CLIN NUTR, V29, P761, DOI 10.1016/j.clnu.2010.02.010; RIGOTTI NA, 1984, NEW ENGL J MED, V311, P1601, DOI 10.1056/NEJM198412203112503; Furusyo N, 2013, ENDOCRINE, V43, P635, DOI 10.1007/s12020-012-9803-z; Yoshimura N, 2013, OSTEOPOROSIS INT, V24, P2775, DOI 10.1007/s00198-013-2372-z; Kalkwarf HJ, 2004, AM J CLIN NUTR, V80, P1075; Kuwabara A, 2009, OSTEOPOROSIS INT, V20, P935, DOI 10.1007/s00198-008-0764-2; Zhang HS, 2009, P NATL ACAD SCI USA, V106, P2365, DOI 10.1073/pnas.0812600106; Fujita Y, 2012, OSTEOPOROSIS INT, V23, P705, DOI 10.1007/s00198-011-1594-1; CONLY JM, 1994, AM J GASTROENTEROL, V89, P915; SZULC P, 1993, J CLIN INVEST, V91, P1769, DOI 10.1172/JCI116387; Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279; Soyka LA, 1999, J CLIN ENDOCR METAB, V84, P4489, DOI 10.1210/jc.84.12.4489; Miller KK, 2003, J WOMEN HEALTH GEN-B, V12, P145, DOI 10.1089/154099903321576538; Armougom F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007125; Booth SL, 2003, J NUTR, V133, P2565; Hotta M, 2000, J CLIN ENDOCR METAB, V85, P200, DOI 10.1210/jc.85.1.200; Iketani T, 2003, PSYCHIAT RES, V117, P259, DOI 10.1016/S0165-1781(03)00024-6; Iwamoto J, 2006, NUTR REV, V64, P509, DOI 10.1301/nr.2006.dec.509-517; Lobera IJ, 2009, NUTR HOSP, V24, P682, DOI 10.3305/nh.2009.24.6.4552; Paiva SAR, 1998, AM J CLIN NUTR, V68, P699; PINEO GF, 1973, CAN MED ASSOC J, V109, P880; Schoon EJ, 2001, GUT, V48, P473, DOI 10.1136/gut.48.4.473; Shiraki M, 2007, IYAKU YAKUGAKU, V57, P537; Shiraki M, 2009, J BONE MINER METAB, V27, P333, DOI 10.1007/s00774-008-0034-6; SUTTIE JW, 1988, AM J CLIN NUTR, V47, P475; Suzuki MH., 2003, CLIN CALCIUM, V23, P263; Takahashi Y, 1996, J CLIN ENDOCR METAB, V81, P1248, DOI 10.1210/jc.81.3.1248; Toraishi M., 2011, Japanese Journal of Nutrition and Dietetics, V69, P115, DOI 10.5264/eiyogakuzashi.69.115; Uenishi K, 2008, J NUTR SCI VITAMINOL, V54, P25, DOI 10.3177/jnsv.54.25; Uenishi K, 2011, OSTEOPOROS JPN, V19, P195	33	1	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0261-5614	1532-1983		CLIN NUTR	Clin. Nutr.	JUN	2015	34	3					443	448		10.1016/j.clnu.2014.04.016		6	Nutrition & Dietetics	Nutrition & Dietetics	CI8PT	WOS:000355034900016		
J	Umezawa, R; Ota, H; Jingu, K				Umezawa, R.; Ota, H.; Jingu, K.			Re: MRI findings of radiation-induced myocardial damage in patients with oesophageal cancer. A reply	CLINICAL RADIOLOGY			English	Letter									[Umezawa, R.; Ota, H.; Jingu, K.] Tohoku Univ, Sch Med, Sendai, Miyagi 980, Japan	Umezawa, R (reprint author), Tohoku Univ, Sch Med, Sendai, Miyagi 980, Japan.	reirei513@hotmail.com	Ota, Hideki/A-3717-2012	Ota, Hideki/0000-0002-7239-3152			Jingu K, 2006, INT J RADIAT ONCOL, V66, P845, DOI 10.1016/j.ijrobp.2006.06.007; Marks LB, 2005, INT J RADIAT ONCOL, V63, P214, DOI 10.1016/j.ijrobp.2005.01.029; Gayed IW, 2006, J NUCL MED, V47, P1756; Prosnitz RG, 2007, CANCER-AM CANCER SOC, V110, P1840, DOI 10.1002/cncr.22965	4	0	0	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0009-9260	1365-229X		CLIN RADIOL	Clin. Radiol.	JUN	2015	70	6					677	678		10.1016/j.crad.2015.02.008		2	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CI9AG	WOS:000355062200017		
J	Kobayashi, T; Inamasu, K				Kobayashi, Tetsuro; Inamasu, Kazunori			The Knowledge Leveling Effect of Portal Sites	COMMUNICATION RESEARCH			English	Article						portal sites; political knowledge gap; news; entertainment	POLITICAL KNOWLEDGE; SELECTIVE EXPOSURE; NEWS EXPOSURE; SOFT NEWS; TV-NEWS; INTERNET; MEDIA; INFORMATION; CAMPAIGN; ONLINE	The new high-choice media environment has allowed entertainment-oriented people to avoid political news, resulting in a wider gap in political knowledge between entertainment- and news-oriented citizens. On the Internet, however, users tend to be concentrated into a handful of portal sites that offer a mixed information environment in which both news and entertainment are readily available. The simultaneous presentation of news and entertainment headlines on portal sites exposes entertainment-oriented people to the news, which may in turn narrow the knowledge gap between them and news-oriented people. To test this hypothesis, we examined the effects of exposure to major portal sites in Japan, where Yahoo! JAPAN attracts a large majority of Internet users. Two studies using self-reported exposure to portal sites (n = 838) and web browsing histories (n = 1,000) demonstrated that even entertainment-oriented people can acquire political knowledge, and thus portal sites can serve as knowledge levelers.	[Kobayashi, Tetsuro] Natl Inst Informat, Tokyo, Japan; [Inamasu, Kazunori] Musashi Univ, Tokyo, Japan	Kobayashi, T (reprint author), 2-1-2,Hitotsubashi,Chiyoda Ku, Tokyo 1018430, Japan.	k-tetsu@nii.ac.jp			Okawa Foundation for Information and Telecommunications;  [KAKENHI 22240007]	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Study 1 was conducted with financial support from the 2009 Okawa Foundation for Information and Telecommunications. Study 2 was conducted with financial support from a grant-in-aid for scientific research "Integrated analysis of web information structure and user behavior and applications for advancements in information access" (KAKENHI 22240007, PI: Keizo Oyama).	DiMaggio P, 2001, ANNU REV SOCIOL, V27, P307, DOI 10.1146/annurev.soc.27.1.307; BARTELS LM, 1993, AM POLIT SCI REV, V87, P267, DOI 10.2307/2939040; Johnson TJ, 1999, JOURNALISM MASS COMM, V76, P99; Baum MA, 2003, POLIT COMMUN, V20, P173, DOI 10.1080/10584600390211181; Tewksbury D, 2001, JOURNALISM MASS COMM, V78, P533; Baum MA, 2002, AM POLIT SCI REV, V96, P91; Lau RR, 2008, AM J POLIT SCI, V52, P395, DOI 10.1111/j.1540-5907.2008.00319.x; Iyengar S, 2008, J POLIT, V70, P186, DOI 10.1017/S0022381607080139; ZUKIN C, 1984, PUBLIC OPIN QUART, V48, P629, DOI 10.1086/268864; Lau RR, 1997, AM POLIT SCI REV, V91, P585, DOI 10.2307/2952076; Xenos M, 2007, J COMMUN, V57, P704, DOI 10.1111/j.1460-2466.2007.00364.x; ROBINSON MJ, 1976, AM POLIT SCI REV, V70, P409, DOI 10.2307/1959647; Zaller J, 2003, POLIT COMMUN, V20, P109, DOI 10.1080/10584600390211136; PRICE V, 1993, PUBLIC OPIN QUART, V57, P133, DOI 10.1086/269363; Tewksbury D, 2000, JOURNALISM MASS COMM, V77, P457; KRUGMAN HE, 1970, PUBLIC OPIN QUART, V34, P184, DOI 10.1086/267788; Graber D, 2004, ANNU REV PSYCHOL, V55, P545, DOI 10.1146/annurev.psych.55.090902.141550; Valentino NA, 2009, POLIT PSYCHOL, V30, P591; Gilens M, 2001, AM POLIT SCI REV, V95, P379; Jerit J, 2006, AM J POLIT SCI, V50, P266, DOI 10.1111/j.1540-5907.2006.00183.x; Webster JG, 2012, J COMMUN, V62, P39, DOI 10.1111/j.1460-2466.2011.01616.x; Behr F., 2002, TR1202 HARV COMP SCI; Bimber B. A., 2003, INFORM AM DEMOCRACY; Delli-Carpini M. X., 1996, WHAT AM KNOW POLITIC; DOWNS ANTHONY, 1957, EC THEORY DEMOCRACY; Eveland WP, 2002, MEDIA PSYCHOL, V4, P353; Gentzkow M, 2011, Q J ECON, V126, P1799, DOI 10.1093/qje/qjr044; Hilt ML, 2004, EDUC GERONTOL, V30, P57, DOI 10.1080/03601270490249166; Hindman M., 2003, ANN M MIDW POL SCI A, V4, P1; Horrigan J., 2004, PEW INTERNET AM LIFE; IT media Inc, 2011, MIX NEWS NEXT YAH NE; IT Media Inc, 2007, 60 PERC INT US SET Y; Iyengar S., 2010, J ELECTIONS PUBLIC O, V20, P291, DOI DOI 10.1111/J.1460-2466.2009.01470.X; Kenski K, 2006, J BROADCAST ELECTRON, V50, P173, DOI 10.1207/s15506878jobem5002_1; Kobaysahi T., 2011, INTERNET ELECTIONS U, P115; Krauss E. S., 2000, BROADCASTING POLITIC; Kwak N., 2006, MASS COMMUNICATION S, V9, P189, DOI DOI 10.1207/S15327825MCS0902_4; Lau RR, 2001, AM J POLIT SCI, V45, P951, DOI 10.2307/2669334; Mondak JJ, 2001, AM J POLIT SCI, V45, P224, DOI 10.2307/2669369; NetRatings, 2012, LOC NEWS INS NIELS; Neuman R. W., 1986, PARADOX MASS POLITIC; Okumura M., 2010, CREATE YAHOO TOPICS; Popkin Samuel L., 1994, REASONING VOTER COMM; Prior M, 2005, AM J POLIT SCI, V49, P577, DOI 10.1111/j.1540-5907.2005.00143.x; Prior M, 2007, CAMB STUD PUB OPIN, P1; Prior M, 2009, J POLIT, V71, P893, DOI 10.1017/S0022381609090781; Reuters Institute for the Study of Journalism, 2013, REUT I DIG NEWS REP; Tewksbury D., 2012, NEWS ON THE INTERNET; Webster JG, 2002, J BROADCAST ELECTRON, V46, P1, DOI 10.1207/s15506878jobem4601_1; Zaller J, 1992, NATURE ORIGINS MASS	50	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0093-6502	1552-3810		COMMUN RES	Commun. Res.	JUN	2015	42	4					482	502		10.1177/0093650214534965		21	Communication	Communication	CJ2TA	WOS:000355336200002		
J	Tabe, Y; Konopleva, M				Tabe, Yoko; Konopleva, Marina			Role of Microenvironment in Resistance to Therapy in AML	CURRENT HEMATOLOGIC MALIGNANCY REPORTS			English	Article						Bone marrow microenvironment; Acute myeloid leukemia (AML); Leukemia stem cell (LSC); Hematopoietic stem cell (HSC); Endosteal niche; Vascular niche	HEMATOPOIETIC STEM-CELL; ACUTE MYELOID-LEUKEMIA; BONE-MARROW NICHE; IN-VIVO; TUMOR MICROENVIRONMENT; CXCR4 EXPRESSION; PROGENITOR CELLS; STROMAL CELLS; CHEMOTHERAPY; INHIBITION	As part of the dynamic interactions between leukemic cells and cells of the bone marrow microenvironment, specific niches provide a sanctuary where subpopulations of leukemic cells evade chemotherapy-induced death and acquire a drug-resistant phenotype. This review focuses on the cellular and molecular biology of the leukemia stem cell (LSC) niche and of microenvironment/leukemia interactions. Key emerging therapeutic targets include chemokine receptors, adhesion molecules, the sympathetic nervous system, and hypoxia-related proteins, as well as the genetic and epigenetic abnormalities of the leukemia-associated stroma. The complex interplay between LSCs and microenvironment components provides a rationale for appropriately tailored molecular therapies designed to improve outcomes in leukemia. Further understanding of the contribution of the bone marrow niche to the process of leukemogenesis may provide new targets that allow destruction of LSCs without adversely affecting normal stem cell self-renewal.	[Tabe, Yoko; Konopleva, Marina] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Tabe, Yoko] Juntendo Univ Med, Dept Clin Lab Med, Tokyo 1128421, Japan; [Konopleva, Marina] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA	Konopleva, M (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428 Holcombe Blvd 1515, Houston, TX 77030 USA.	mkonople@mdanderson.org; mkonople@mdanderson.org			NIH/NCI [R01 CA155056-04, P30 CA016672]; Leukemia and Lymphoma Society	Supported in part by NIH/NCI R01 CA155056-04 (MK), Leukemia and Lymphoma Society (MK), and NIH/NCI P30 CA016672 (MK)	Winkler IG, 2010, BLOOD, V116, P375, DOI 10.1182/blood-2009-07-233437; Konopleva M, 2009, DRUG RESIST UPDATE, V12, P103, DOI 10.1016/j.drup.2009.06.001; Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017; Mendez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262; Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041; Nervi B, 2009, BLOOD, V113, P6206, DOI 10.1182/blood-2008-06-162123; Raaijmakers MHGP, 2014, CELL STEM CELL, V14, P695, DOI 10.1016/j.stem.2014.05.010; Schepers K, 2013, CELL STEM CELL, V13, P285, DOI 10.1016/j.stem.2013.06.009; Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883; Fiegl M, 2009, BLOOD, V113, P1504, DOI 10.1182/blood-2008-06-161539; Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984; Williams K, 2013, EXP BIOL MED, V238, P324, DOI 10.1177/1535370213480714; Balooch G, 2005, P NATL ACAD SCI USA, V102, P18813, DOI 10.1073/pnas.0507417102; Kfoury Y, 2014, CELL, V158, P228, DOI 10.1016/j.cell.2014.06.019; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Yamazaki S, 2011, CELL, V147, P1146, DOI 10.1016/j.cell.2011.09.053; Koh MY, 2008, MOL CANCER THER, V7, P90, DOI 10.1158/1535-7163.MCT-07-0463; Rombouts EJC, 2004, BLOOD, V104, P550, DOI 10.1182/blood-2004-02-0566; Mussai F, 2013, BLOOD, V122, P749, DOI 10.1182/blood-2013-01-480129; Colmone A, 2008, SCIENCE, V322, P1861, DOI 10.1126/science.1164390; Lucas D, 2013, NAT MED, V19, P695, DOI 10.1038/nm.3155; Simsek T, 2010, CELL STEM CELL, V7, P380, DOI 10.1016/j.stem.2010.07.011; Wellmann S, 2004, LEUKEMIA, V18, P926, DOI 10.1038/sj.leu.2403332; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Christopher MJ, 2009, BLOOD, V114, P1331, DOI [10.1182/blood-2008-10-184754, 10.1182/blood2008-10-184754]; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; Fujisaki J, 2011, NATURE, V474, P216, DOI 10.1038/nature10160; Tabe Y, 2014, BRIT J HAEMATOL, V164, P767, DOI 10.1111/bjh.12725; Walkley CR, 2007, CELL, V129, P1081, DOI 10.1016/j.cell.2007.03.055; Sison EAR, 2013, MOL CANCER RES, V11, P1004, DOI 10.1158/1541-7786.MCR-13-0114; Kunisaki Y, 2013, NATURE, V502, P637, DOI 10.1038/nature12612; Mansour A, 2012, J EXP MED, V209, P537, DOI 10.1084/jem.20110994; Mendelson A, 2014, NAT MED, V20, P833, DOI 10.1038/nm.3647; Zeng Z, 2006, MOL CANCER THER, V5, P3113, DOI 10.1158/1535-7163.MCT-06-0228; Semenza GL, 2007, BIOCHEM J, V405, P1, DOI 10.1042/BJ20070389; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Kiel MJ, 2008, NAT REV IMMUNOL, V8, P290, DOI 10.1038/nri2279; Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783; Hanoun M, 2014, CELL STEM CELL, V15, P365, DOI 10.1016/j.stem.2014.06.020; Zeng ZH, 2009, BLOOD, V113, P6215, DOI 10.1182/blood-2008-05-158311; Rupec RA, 2005, IMMUNITY, V22, P479, DOI 10.1016/j.immuni.2005.02.009; Schroder HC, 2012, J CELL BIOCHEM, V113, P3197, DOI 10.1002/jcb.24196; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Walkley CR, 2007, CELL, V129, P1097, DOI 10.1016/j.cell.2007.05.014; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Redondo-Munoz J, 2008, BLOOD, V112, P169, DOI 10.1182/blood-2007-08-109249; Ferrara F, 2013, LANCET, V381, P484, DOI 10.1016/S0140-6736(12)61727-9; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Hartwell KA, 2013, NAT CHEM BIOL, V9, P840, DOI [10.1038/nchembio.1367, 10.1038/NCHEMBIO.1367]; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851; Medyouf H, 2014, CELL STEM CELL, V14, P824, DOI 10.1016/j.stem.2014.02.014; Nombela-Arrieta C, 2013, NAT CELL BIOL, V15, P533, DOI 10.1038/ncb2730; Perry JM, 2007, CELL, V129, P1045, DOI 10.1016/j.cell.2007.05.053; Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood-2004-11-4422; Jacamo R, 2014, BLOOD, V123, P2691, DOI 10.1182/blood-2013-06-511527; Kuhne MR, 2013, CLIN CANCER RES, V19, P357, DOI 10.1158/1078-0432.CCR-12-2333; Arranz A.M., 2014, J CELL SCI; Doan PL, 2012, LEUKEMIA, V26, P54, DOI 10.1038/leu.2011.236; Duhrsen U, 1996, ANN HEMATOL, V73, P53, DOI 10.1007/s002770050203; Lymperi S, 2011, BLOOD, V117, P1540, DOI 10.1182/blood-2010-05-282855; Nwajei F., 2013, ADV HEMATOL, V2013, DOI DOI 10.1155/2013/953982; Price T, 2014, CELL STEM CELL, V15, P261, DOI 10.1016/j.stem.2014.08.012; Seton-Rogers S, 2013, NAT REV CANCER, V13, DOI 10.1038/nrc3639; Tabe Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062785	69	2	2	CURRENT MEDICINE GROUP	PHILADELPHIA	400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA	1558-8211	1558-822X		CURR HEMATOL MALIG R	Curr. Hematol. Malig. Rep.	JUN	2015	10	2					96	103		10.1007/s11899-015-0253-6		8	Oncology; Hematology	Oncology; Hematology	CJ1AQ	WOS:000355214100004		
J	Nakashima, K; Umeshima, H; Kengaku, M				Nakashima, Kie; Umeshima, Hiroki; Kengaku, Mineko			Cerebellar granule cells are predominantly generated by terminal symmetric divisions of granule cell precursors	DEVELOPMENTAL DYNAMICS			English	Article						neurogenesis; cell cycle; neural stem cells; live-cell imaging; medulloblastoma	MICROTUBULE-ASSOCIATED PROTEIN; DEVELOPING MOUSE CEREBELLUM; PROLIFERATION IN-VITRO; SONIC HEDGEHOG; PROGENITOR PROLIFERATION; MIGRATING NEURONS; CORTICAL-NEURONS; NERVOUS-SYSTEM; NEURAL STEM; NEUROGENESIS	Background: Neurons in the central nervous system (CNS) are generated by symmetric and asymmetric cell division of neural stem cells and their derivative progenitor cells. Cerebellar granule cells are the most abundant neurons in the CNS, and are generated by intensive cell division of granule cell precursors (GCPs) during postnatal development. Dysregulation of GCP cell cycle is causal for some subtypes of medulloblastoma. However, the details and mechanisms underlying neurogenesis from GCPs are not well understood. Results: Using long-term live-cell imaging of proliferating GCPs transfected with a fluorescent newborn-granule cell marker, we found that GCPs underwent predominantly symmetric divisions, generating two GCPs or two neurons, while asymmetric divisions generating a GCP and a neuron were only occasionally observed, in both dissociated culture and within tissues of isolated cerebellar lobules. We found no significant difference in cell cycle length between proliferative and neurogenic divisions, or any consistent changes in cell cycle length during repeated proliferative division. Conclusions: Unlike neural stem cells in the cerebral cortex and spinal cord, which generate many neurons by repeated asymmetric division, cerebellar GCPs produce neurons predominantly by terminal symmetric division. These results indicate diverse mechanisms of neurogenesis in the mammalian brain. Developmental Dynamics 244:748-758, 2015. (c) 2015 Wiley Periodicals, Inc.	[Nakashima, Kie; Kengaku, Mineko] Kyoto Univ, Grad Sch Biostudies, Kyoto 6068501, Japan; [Umeshima, Hiroki; Kengaku, Mineko] Kyoto Univ, Inst Integrated Cell Mat Sci WPI iCeMS, Kyoto 6068501, Japan	Kengaku, M (reprint author), Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan.	kengaku@icems.kyoto-u.ac.jp			Takeda Science Foundation; MEXT Japan [LS064]	Grant sponsor: Takeda Science Foundation; Grant sponsor: MEXT Japan; Grant number: LS064.	Altman J, 1997, GENERATING MOVEMENTS, P334; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Miyata T, 2001, NEURON, V31, P727, DOI 10.1016/S0896-6273(01)00420-2; FUJITA S, 1967, J CELL BIOL, V32, P277, DOI 10.1083/jcb.32.2.277; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Espinosa JS, 2008, J NEUROSCI, V28, P2301, DOI 10.1523/JNEUROSCI.5157-07.2008; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; TAKAHASHI T, 1995, J NEUROSCI, V15, P6046; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Saade M, 2013, CELL REP, V4, P492, DOI 10.1016/j.celrep.2013.06.038; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Umeshima H, 2007, P NATL ACAD SCI USA, V104, P16182, DOI 10.1073/pnas.0708047104; Gotz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739; Haubensak W, 2004, P NATL ACAD SCI USA, V101, P3196, DOI 10.1073/pnas.0308600100; Lui JH, 2011, CELL, V146, P18, DOI 10.1016/j.cell.2011.06.030; Dehay C, 2007, NAT REV NEUROSCI, V8, P438, DOI 10.1038/nrn2097; Lange C, 2009, CELL STEM CELL, V5, P320, DOI 10.1016/j.stem.2009.05.026; Wang X, 2007, J NEUROSCI RES, V85, P3567, DOI 10.1002/jnr.21440; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; RYDER EF, 1994, NEURON, V12, P1011, DOI 10.1016/0896-6273(94)90310-7; Malatesta P, 2000, DEVELOPMENT, V127, P5253; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Taverna E, 2014, ANNU REV CELL DEV BI, V30, P465, DOI 10.1146/annurev-cellbio-101011-155801; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.neuro.18.1.385; FUJITA S, 1966, J COMP NEUROL, V128, P191, DOI 10.1002/cne.901280206; Noctor SC, 2004, NAT NEUROSCI, V7, P136, DOI 10.1038/nn1172; MARES V, 1970, BRAIN RES, V23, P343, DOI 10.1016/0006-8993(70)90061-2; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Paridaen JTML, 2014, EMBO REP, V15, P351, DOI 10.1002/embr.201438447; Pilaz LJ, 2009, P NATL ACAD SCI USA, V106, P21924, DOI 10.1073/pnas.0909894106; Xenaki D, 2011, DEVELOPMENT, V138, P519, DOI 10.1242/dev.051912; Roussel MF, 2011, CURR TOP DEV BIOL, V94, P235, DOI 10.1016/B978-0-12-380916-2.00008-5; Wechsler-Reya RJ, 2001, TRENDS NEUROSCI, V24, P680, DOI 10.1016/S0166-2236(00)02058-0; Miyata T, 2010, CURR OPIN NEUROBIOL, V20, P22, DOI 10.1016/j.conb.2010.01.001; Yamasaki T, 2001, DEVELOPMENT, V128, P3133; Hatten ME, 2011, TRENDS NEUROSCI, V34, P134, DOI 10.1016/j.tins.2011.01.002; Vaillant C, 2009, CEREBELLUM, V8, P291, DOI 10.1007/s12311-009-0094-8; Arai Y, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1155; Frank-Kamenetsky M., 2002, J BIOL, V1, P1; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; Kawaji K, 2004, MOL CELL NEUROSCI, V25, P228, DOI 10.1016/j.mcn.2003.10.006; Miyazawa K, 2000, J NEUROSCI, V20, P5756; Pons S, 2001, DEVELOPMENT, V128, P1481; Ramon y Cajal S., 1911, HISTOLOGY NERVOUS SY, V11, P66; Rios I, 2004, DEVELOPMENT, V131, P3159, DOI 10.1242/dev.01188; Umeshima H, 2013, MOL CELL NEUROSCI, V52, P62, DOI 10.1016/j.mcn.2012.08.005; Vaillant C, 2007, DEVELOPMENT, V134, P1745, DOI 10.1242/dev.02840	51	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1058-8388	1097-0177		DEV DYNAM	Dev. Dyn.	JUN	2015	244	6					748	758		10.1002/dvdy.24276		11	Anatomy & Morphology; Developmental Biology	Anatomy & Morphology; Developmental Biology	CJ1DY	WOS:000355223500004		
J	Harada, M; Omori, A; Nakahara, C; Nakagata, N; Akita, K; Yamada, G				Harada, Masayo; Omori, Akiko; Nakahara, Chiaki; Nakagata, Naomi; Akita, Keiichi; Yamada, Gen			Tissue-specific roles of FGF signaling in external genitalia development	DEVELOPMENTAL DYNAMICS			English	Article						genital tubercle; urethra; hypospadias; outgrowth; cell death; epithelial differentiation	SONIC-HEDGEHOG; WNT/BETA-CATENIN; LIMB DEVELOPMENT; BETA-CATENIN; MOLECULAR-MECHANISMS; MULTIPLE ROLES; MICE; HYPOSPADIAS; EXPRESSION; MOUSE	Background: The developmental processes of the genital tubercle (GT), the anlage of the external genitalia, possess several developmental aspects, including GT outgrowth, urethral tube formation, and epithelial differentiation of the urethra. The GT comprises the mesenchyme derived from the lateral mesoderm, ectodermal epithelium, and endodermal epithelium (embryonic urethral epithelium). The three tissue layers develop the GT coordinately. Results: Around the initial stage of GT outgrowth (E11.5), FGF signaling was detected in the mesenchyme of the GT. FGF signaling was detected in the three tissue layers of the GT around the early stage of urethral formation (E13.5). Subsequently, FGF signaling was predominantly detected in the urethral epithelium (E14.5). Tissue-specific roles of FGF signaling in GT development were revealed by conditional Fgfr gene knockout approaches. Mesenchymal FGF signaling in the early-stage GT is required for its outgrowth. Ectodermal FGF signaling in the GT is required for the differentiation of the ectoderm and urethral epithelium at their junction to form the proper urethral tube. Endodermal FGF signaling in the GT is required for the stratification and cell adhesive characteristics of the urethral epithelium. Conclusions: The current study suggests that spatiotemporally regulated FGF signaling plays tissue-specific roles in multiple processes of external genitalia development. Developmental Dynamics 244:759-773, 2015. (c) 2015 Wiley Periodicals, Inc.	[Harada, Masayo; Omori, Akiko; Nakahara, Chiaki; Yamada, Gen] Kumamoto Univ, Inst Mol Embryol & Genet, Kumamoto, Japan; [Harada, Masayo; Akita, Keiichi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Clin Anat, Tokyo, Japan; [Omori, Akiko; Yamada, Gen] Wakayama Med Univ, Inst Adv Med, Dept Dev Genet, Wakayama 6418509, Japan; [Nakagata, Naomi] Kumamoto Univ, Div Reprod Engn, Ctr Anim Resources & Dev, Kumamoto, Japan	Yamada, G (reprint author), Wakayama Med Univ, Inst Adv Med, Dept Dev Genet, 811-1 Kimiidera, Wakayama 6418509, Japan.	akita.fana@tmd.ac.jp; transg8@wakayama-med.ac.jp			JSPS KAKENHI [25870202]; MEXT KAKENHI [22132006]	Grant sponsor: JSPS KAKENHI Grant-in-Aid for Young Scientists (B); Grant number: 25870202; Grant sponsor: MEXT KAKENHI Grant-in-Aid for Scientific Research on Innovative Areas; Grant number: 22132006.	Rice R, 2004, J CLIN INVEST, V113, P1692, DOI 10.1172/JCI200420384; Bastida MF, 2009, DEVELOPMENT, V136, P3779, DOI 10.1242/dev.036418; Perriton CL, 2002, DEV BIOL, V247, P26, DOI 10.1006/dbio.2002.0668; Mariani FV, 2008, NATURE, V453, P401, DOI 10.1038/nature06876; McKeon F, 2004, GENE DEV, V18, P465, DOI 10.1101/gad.1190504; Yamada G, 2006, DEV DYNAM, V235, P1738, DOI 10.1002/dvdy.20807; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Sun X, 2002, NATURE, V418, P501, DOI 10.1038/nature00902; Miyagawa S, 2009, MOL ENDOCRINOL, V23, P871, DOI 10.1210/me.2008-0478; Lallemand Y, 2005, DEVELOPMENT, V132, P3003, DOI 10.1242/dev.01877; Suzuki K, 2002, EVOL DEV, V4, P133, DOI 10.1046/j.1525-142X.2002.01061.x; Haraguchi R, 2000, DEVELOPMENT, V127, P2471; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Seifert AW, 2009, DEVELOPMENT, V136, P3949, DOI 10.1242/dev.042291; Petiot A, 2005, DEVELOPMENT, V132, P2441, DOI 10.1242/dev.01778; Murakami M, 2011, J CLIN INVEST, V121, P2668, DOI 10.1172/JCI44762; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Hill TP, 2006, DEVELOPMENT, V133, P1219, DOI 10.1242/dev.02298; Blaschko SD, 2012, DIFFERENTIATION, V84, P261, DOI 10.1016/j.diff.2012.06.003; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Baskin LS, 2006, J PEDIATR SURG, V41, P463, DOI 10.1016/j.jpedsurg.2005.11.059; Miyagawa S, 2014, CELL DEATH DIFFER, V21, P990, DOI 10.1038/cdd.2014.21; Yu K, 2008, DEVELOPMENT, V135, P483, DOI 10.1242/dev.013268; Hohenester E, 2013, CELL ADHES MIGR, V7, P56, DOI 10.4161/cam.21831; Winuthayanon W, 2010, P NATL ACAD SCI USA, V107, P19272, DOI 10.1073/pnas.1013226107; Pignon JC, 2013, P NATL ACAD SCI USA, V110, P8105, DOI 10.1073/pnas.1221216110; Boulet AM, 2004, DEV BIOL, V273, P361, DOI 10.1016/j.ydbio.2004.06.012; Harfe BD, 2004, CELL, V118, P517, DOI 10.1016/j.cell.2004.07.024; Haraguchi R, 2001, DEVELOPMENT, V128, P4241; Lin CX, 2008, DEVELOPMENT, V135, P2815, DOI 10.1242/dev.020586; Petiot A, 2003, DEVELOPMENT, V130, P5493, DOI 10.1242/dev.00788; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Miyagawa S, 2009, DEVELOPMENT, V136, P3969, DOI 10.1242/dev.039438; Shih EM, 2014, EUR J MED GENET, V57, P453, DOI 10.1016/j.ejmg.2014.03.003; Seifert AW, 2009, DEVELOPMENT, V136, P2643, DOI 10.1242/dev.036830; Corson LB, 2003, DEVELOPMENT, V130, P4527, DOI 10.1242/dev.00669; Yamada G, 2003, DIFFERENTIATION, V71, P445, DOI 10.1046/j.1432-0436.2003.7108001.x; Seifert AW, 2008, DEV BIOL, V318, P143, DOI 10.1016/j.ydbio.2008.03.017; Lin CX, 2009, DEVELOPMENT, V136, P3959, DOI 10.1242/dev.039768; Ching ST, 2014, DEV BIOL, V386, P1, DOI 10.1016/j.ydbio.2013.12.014; Cox MJ, 2008, J UROLOGY, V180, P2649, DOI 10.1016/j.juro.2008.08.058; Danopoulos S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076248; Garrido-Allepuz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044962; Harada M, 2009, NAT GENET, V41, P289, DOI 10.1038/ng.316; Hardy K, 2011, BMC DEV BIOL, V11, P11; Hatanaka K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037600; Herrera AM, 2014, SCI REP-UK, V4, DOI 10.1038/srep06896; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Huang J, 2009, DEVELOPMENT, V136, P1741, DOI 10.1242/dev.034082; Khalfaoui T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074337; Lin CX, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003231; Mazahery AR, 2013, CONGENIT ANOM, V53, P34, DOI 10.1111/cga.12001; Pearse RV, 2001, DEV BIOL, V239, P15, DOI 10.1006/dbio.2001.0430; Runck LA, 2014, DIS MODEL MECH, V7, P483, DOI 10.1242/dmm.014530; Sasaki C, 2004, ANAT REC PART A, V279A, P761, DOI 10.1002/ar.a.20062; Satoh Y, 2004, ANAT EMBRYOL, V208, P479, DOI 10.1007/s00429-004-0419-9; Soshnikova N, 2003, GENE DEV, V17, P1963, DOI 10.1101/gad.263003; Suzuki K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043453; Suzuki K, 2008, EUR J HUM GENET, V16, P6; Tamura K, 2001, J ANAT, V199, P195, DOI 10.1046/j.1469-7580.2001.19910195.x; Wang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055587; Xu K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029372; Xu XL, 2002, GENESIS, V32, P85, DOI 10.1002/gene.10028; Yang L, 2006, DEVELOPMENT, V133, P575; Yin Y, 2008, DEV BIOL, V319, P26	68	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1058-8388	1097-0177		DEV DYNAM	Dev. Dyn.	JUN	2015	244	6					759	773		10.1002/dvdy.24277		15	Anatomy & Morphology; Developmental Biology	Anatomy & Morphology; Developmental Biology	CJ1DY	WOS:000355223500005		
J	Song, RT; Over, H; Carpenter, M				Song, Ruiting; Over, Harriet; Carpenter, Malinda			Children Draw More Affiliative Pictures Following Priming With Third-Party Ostracism	DEVELOPMENTAL PSYCHOLOGY			English	Article						ostracism; affiliation; drawing; social development; social motivation	WITNESSING PEER REJECTION; SOCIAL EXCLUSION; OVERT AGGRESSION; BEHAVIOR; PRESCHOOL; ADOLESCENTS; ACCEPTANCE; ATTITUDES; BELONG; NEED	Humans have a strong need to belong. Thus, when signs of ostracism are detected, adults often feel motivated to affiliate with others in order to reestablish their social connections. This study investigated the importance of affiliation to young children following priming with ostracism. Four- and 5-year-old children were primed with either ostracism or control videos and their understanding of, and responses to, the videos were measured. Results showed that children were able to report that there was exclusion in the ostracism videos, and that they recognized that the ostracized individual felt sad. Most interestingly, when subsequently asked to draw a picture of themselves and their friend, children primed with ostracism depicted relationships that were significantly more affiliative. Children drew themselves and their friend standing significantly closer together and adults rated their drawings as more affiliative overall. These findings introduce drawing as a useful new method for measuring social motivations and processes following an experimental manipulation, and demonstrate that affiliation is particularly important to children following even a vicarious experience of social exclusion.	[Song, Ruiting; Carpenter, Malinda] Max Planck Inst Evolutionary Anthropol, Dept Dev & Comparat Psychol, Leipzig, Germany; [Over, Harriet] Univ York, Dept Psychol, York YO10 5DD, N Yorkshire, England; [Carpenter, Malinda] Univ St Andrews, Sch Psychol & Neurosci, St Andrews KY16 9AJ, Fife, Scotland	Song, RT (reprint author), Kumamoto Univ, Fac Letters, Div Cognit Psychol, Chuo Ku, 2-40-1 Kurokami, Kumamoto 8609555, Japan.	rsong@kumamoto-u.ac.jp			Economic and Social Research Council [ES/K006702/1]	Harriet Over was supported by the Economic and Social Research Council (Grant number ES/K006702/1).	Abrams D, 2011, BRIT J DEV PSYCHOL, V29, P110, DOI 10.1348/026151010X494089; Aiken L. S., 1991, MULTIPLE REGRESSION; Andersen P., 2013, NONVERBAL COMMUNICAT, P295; Williams KD, 2000, J PERS SOC PSYCHOL, V79, P748, DOI 10.1037/0022-3514.79.5.748; BAUMEISTER RF, 1995, PSYCHOL BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497; Over H, 2009, DEVELOPMENTAL SCI, V12, pF1, DOI 10.1111/j.1467-7687.2008.00820.x; Twenge JM, 2001, J PERS SOC PSYCHOL, V81, P1058, DOI 10.1037/0022-3514.81.6.1058; Casas JF, 2006, J APPL DEV PSYCHOL, V27, P209, DOI 10.1016/j.appdev.2006.02.003; Gardner WL, 2000, PERS SOC PSYCHOL B, V26, P486, DOI 10.1177/0146167200266007; Warburton WA, 2006, J EXP SOC PSYCHOL, V42, P213, DOI 10.1016/j.jesp.2005.03.005; Forstmeier W, 2011, BEHAV ECOL SOCIOBIOL, V65, P47, DOI 10.1007/s00265-010-1038-5; Bargh JA, 2012, TRENDS COGN SCI, V16, P593, DOI 10.1016/j.tics.2012.10.002; DeWall CN, 2009, J PERS SOC PSYCHOL, V96, P729, DOI 10.1037/a0014634; Kinzler KD, 2007, P NATL ACAD SCI USA, V104, P12577, DOI 10.1073/pnas.0705345104; Crick NR, 1996, CHILD DEV, V67, P2317, DOI 10.1111/j.1467-8624.1996.tb01859.x; Watson-Jones RE, 2014, EVOL HUM BEHAV, V35, P204, DOI 10.1016/j.evolhumbehav.2014.01.004; Novelli D, 2010, BRIT J SOC PSYCHOL, V49, P223, DOI 10.1348/014466609X449377; Wesselmann ED, 2009, J EXP SOC PSYCHOL, V45, P1308, DOI 10.1016/j.jesp.2009.08.003; Barkley JE, 2012, PEDIATRICS, V129, pE659, DOI 10.1542/peds.2011-0496; Kawakami K, 2007, J PERS SOC PSYCHOL, V92, P957, DOI 10.1037/0022-3514.92.6.957; Zeileis A, 2008, J STAT SOFTW, V27, P1; Corriveau KH, 2010, DEV PSYCHOL, V46, P437, DOI 10.1037/a0017553; Haun DBM, 2011, CHILD DEV, V82, P1759, DOI 10.1111/j.1467-8624.2011.01666.x; GERGELY G, 1995, COGNITION, V56, P165, DOI 10.1016/0010-0277(95)00661-H; Brewer MB, 2007, AM PSYCHOL, V62, P728, DOI 10.1037/0003-066X.62.8.728; Hamlin JK, 2007, NATURE, V450, P557, DOI 10.1038/nature06288; Lakin JL, 2008, PSYCHOL SCI, V19, P816, DOI 10.1111/j.1467-9280.2008.02162.x; Williams KD, 2007, ANNU REV PSYCHOL, V58, P425, DOI 10.1146/annurev.psych.58.110405.085641; Crick NR, 1996, DEV PSYCHOPATHOL, V8, P367; Dunham Y, 2011, CHILD DEV, V82, P793, DOI 10.1111/j.1467-8624.2011.01577.x; Bierman K. L., 2003, PEER REJECTION DEV P; Bombi A. S., 2007, PICTORIAL ASSESSMENT; Buss D. M., 1998, HDB SOCIAL PSYCHOL, V2, P982; Callaghan T. C., 2008, CHILDRENS UNDERSTAND, P21; Crick NR, 1997, DEV PSYCHOL, V33, P579, DOI 10.1037/0012-1649.33.4.579; DeWall CN, 2010, SOC INFLUENCE, V5, P245, DOI 10.1080/15534511003783536; Dobson AJ, 2002, INTRO GEN LINEAR MOD; Fiske S. T., 2010, SOCIAL BEINGS CORE M; Freeman N. H., 1980, STRATEGIES OF REPRES; Jackman S, 2012, PSCL CLASSES METHODS; Kerr NL, 2008, GROUP DYN-THEOR RES, V12, P39, DOI 10.1037/1089-2699.12.1.39; Killen M., 2011, CHILDREN SOCIAL EXCL; Masten CL, 2010, SOC NEUROSCI-UK, V5, P496, DOI 10.1080/17470919.2010.490673; Masten CL, 2013, DEVELOPMENTAL SCI, V16, P743, DOI 10.1111/desc.12056; Matto H. C., 2007, CLIN ASSESSMENT CHIL, P207; Milbrath C., 2007, CHILDRENS UNDERSTAND; Neal JW, 2014, CHILD DEV, V85, P1366, DOI 10.1111/cdev.12194; Nesdale D, 2007, INT J BEHAV DEV, V31, P115, DOI 10.1177/0165025407073579; Olson K. R., 2013, SOC RES CHILD DEV SE; R Core Team, 2013, R LANG ENV STAT COMP; Spoor JR, 2007, SYD SYM SOC PSYCHOL, P279; THOMAS GV, 1992, J CHILD PSYCHOL PSYC, V33, P1097, DOI 10.1111/j.1469-7610.1992.tb00928.x; Will GJ, 2013, DEV PSYCHOL, V49, P2236, DOI 10.1037/a0032299	53	0	0	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0012-1649	1939-0599		DEV PSYCHOL	Dev. Psychol.	JUN	2015	51	6					831	840		10.1037/a0039176		10	Psychology, Developmental	Psychology	CJ0MA	WOS:000355169100009		
J	Hattori, Y; Hattori, K; Hayashi, T				Hattori, Yuichi; Hattori, Kohshi; Hayashi, Toshio			Pleiotropic Benefits of Metformin: Macrophage Targeting Its Anti-inflammatory Mechanisms	DIABETES			English	Editorial Material							ACTIVATED PROTEIN-KINASE; FACTOR-KAPPA-B; MONOCYTES; CELLS; DIFFERENTIATION; ENTEROCOLITIS; SUPPRESSES; INDUCTION; SUBSETS; STAT3		[Hattori, Yuichi] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Mol & Med Pharmacol, Toyama 930, Japan; [Hattori, Kohshi] Tokyo Univ Hosp, Anesthesiol & Pain Relief Ctr, Tokyo 113, Japan; [Hayashi, Toshio] Nagoya Univ, Grad Sch Med, Dept Geriatr, Nagoya, Aichi 4648601, Japan	Hattori, Y (reprint author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Mol & Med Pharmacol, Toyama 930, Japan.	yhattori@med.u-toyama.ac.jp					Alonzi T, 2004, CYTOKINE, V26, P45, DOI 10.1016/j.cyto.2003.12.002; Foretz M, 2010, J CLIN INVEST, V120, P2355, DOI 10.1172/JCI40671; Hattori Y, 2006, HYPERTENSION, V47, P1183, DOI 10.1161/01.HYP.0000221429.94591.72; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Selvin E, 2008, ARCH INTERN MED, V168, P2070, DOI 10.1001/archinte.168.19.2070; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Fullerton MD, 2013, NAT MED, V19, P1649, DOI 10.1038/nm.3372; Woollard KJ, 2010, NAT REV CARDIOL, V7, P77, DOI 10.1038/nrcardio.2009.228; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Kim J, 2014, J BIOL CHEM, V289, P23246, DOI 10.1074/jbc.M114.577908; Sag D, 2008, J IMMUNOL, V181, P8633; Arai M, 2010, J PHARMACOL EXP THER, V334, P206, DOI 10.1124/jpet.109.164970; Forouzandeh F., 2014, J AM HEART ASSOC, V3, P1202; Isoda K, 2006, ARTERIOSCL THROM VAS, V26, P611, DOI 10.1161/01.ATV.0000201938.78044.75; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Oakhill JS, 2009, ACTA PHYSIOL, V196, P3, DOI 10.1111/j.1748-1716.2009.01977.x; TUCKER GT, 1981, BRIT J CLIN PHARMACO, V12, P235; Turner RC, 1998, LANCET, V352, P854; Vasamsetti SB, 2015, DIABETES, V64, P2028, DOI 10.2337/db14-1225	24	1	1	AMER DIABETES ASSOC	ALEXANDRIA	1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA	0012-1797	1939-327X		DIABETES	Diabetes	JUN	2015	64	6					1907	1909		10.2337/db15-0090		3	Endocrinology & Metabolism	Endocrinology & Metabolism	CJ3GH	WOS:000355370900006		
J	Cook, JR; Matsumoto, M; Banks, AS; Kitamura, T; Tsuchiya, K; Accili, D				Cook, Joshua R.; Matsumoto, Michihiro; Banks, Alexander S.; Kitamura, Tadahiro; Tsuchiya, Kyoichiro; Accili, Domenico			A Mutant Allele Encoding DNA Binding-Deficient FoxO1 Differentially Regulates Hepatic Glucose and Lipid Metabolism	DIABETES			English	Article							TRANSCRIPTION FACTOR FOXO1; FATTY LIVER-DISEASE; DE-NOVO LIPOGENESIS; FORKHEAD TRANSCRIPTION; INSULIN-RESISTANCE; FACTOR FKHR; MICE; GLUCOKINASE; INHIBITION; SENSITIVITY	Insulin signaling in the liver blunts glucose production and stimulates triglyceride biosynthesis. FoxO1 is required for cAMP induction of hepatic glucose production and is permissive for the effect of insulin to suppress this process. Moreover, FoxO1 ablation increases lipogenesis. In this study, we investigated the pleiotropic actions of FoxO1 on glucose and lipid metabolism. To this end, we reconstituted FoxO1 function in mice with a liver-specific deletion of Foxo1 using targeted knock-in of an allele encoding a DNA binding-deficient FoxO1 mutant (L-DBD). Chow-reared L-DBD mice showed defects in hepatic glucose production but normal liver triglyceride content despite increased rates of de novo lipogenesis and impaired fatty acid oxidation in isolated hepatocytes. Gene expression studies indicated that FoxO1 regulates the expression of glucokinase via a cell-nonautonomous coregulatory mechanism, while its regulation of glucose-6-phosphatase proceeds via a cell-autonomous action as a direct transcriptional activator. These conclusions support a differential regulation of hepatic glucose and lipid metabolism by FoxO1 based on the mechanism by which it alters the expression of key target genes involved in each process.	[Cook, Joshua R.; Matsumoto, Michihiro; Banks, Alexander S.; Kitamura, Tadahiro; Tsuchiya, Kyoichiro; Accili, Domenico] Columbia Univ, Dept Med, New York, NY 10027 USA; [Matsumoto, Michihiro] Natl Ctr Global Hlth & Med, Diabet Res Ctr, Dept Mol Metab Regulat, Tokyo, Japan; [Banks, Alexander S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Kitamura, Tadahiro] Gunma Univ, Grad Sch Med, Dept Med & Biol Sci, Maebashi, Gumma, Japan; [Tsuchiya, Kyoichiro] Tokyo Med & Dent Univ, Grad Sch, Dept Clin & Mol Endocrinol, Tokyo, Japan	Accili, D (reprint author), Columbia Univ, Dept Med, New York, NY 10027 USA.	da230@columbia.edu	Banks, Alexander/B-4832-2012	Banks, Alexander/0000-0003-1787-6925	National Institutes of Health [DK-100038, DK-57539, DK-63608]	This work was supported by National Institutes of Health grants DK-100038, DK-57539, and DK-63608 (to Columbia University Diabetes Research Center).	Brent MM, 2008, STRUCTURE, V16, P1407, DOI 10.1016/j.str.2008.06.013; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI12876; Lu MJ, 2012, NAT MED, V18, P388, DOI 10.1038/nm.2686; Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI200523621; Turan S, 2013, GENE, V515, P1, DOI 10.1016/j.gene.2012.11.016; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Gonzalez E, 2011, P NATL ACAD SCI USA, V108, P10162, DOI 10.1073/pnas.1019268108; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Diraison F, 2003, DIABETES METAB, V29, P478, DOI 10.1016/S1262-3636(07)70061-7; Zhao XS, 2004, BIOCHEM J, V378, P839, DOI 10.1042/BJ20031450; Dentin R, 2004, J BIOL CHEM, V279, P20314, DOI 10.1074/jbc.M312475200; Matsumoto M, 2007, CELL METAB, V6, P208, DOI 10.1016/i.cmet.2007.08.006; Han S, 2009, J CLIN INVEST, V119, P1029, DOI 10.1172/JCI36523; Wan M, 2011, CELL METAB, V14, P516, DOI 10.1016/j.cmet.2011.09.001; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Tao RY, 2011, J BIOL CHEM, V286, P14681, DOI 10.1074/jbc.M110.201061; Haeusler RA, 2010, J BIOL CHEM, V285, P35245, DOI 10.1074/jbc.C110.175851; Peter A, 2011, J CLIN ENDOCR METAB, V96, pE1126, DOI 10.1210/jc.2010-2017; Kitamura T, 2007, J CLIN INVEST, V117, P2477, DOI 10.1172/JC132054; Ganjam GK, 2009, J BIOL CHEM, V284, P30783, DOI 10.1074/jbc.M109.045260; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Dong XC, 2008, CELL METAB, V8, P65, DOI 10.1016/j.cmet.2008.06.006; Pajvani UB, 2011, NAT MED, V17, P961, DOI 10.1038/nm.2378; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507; Fan WQ, 2009, J BIOL CHEM, V284, P12188, DOI 10.1074/jbc.M808915200; Haeusler RA, 2012, CELL METAB, V15, P65, DOI 10.1016/j.cmet.2011.11.010; Postic C, 2007, ANNU REV NUTR, V27, P179, DOI 10.1146/annurev.nutr.27.061406.093618; Lin HV, 2011, CELL METAB, V14, P9, DOI 10.1016/j.cmet.2011.06.003; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Banks AS, 2011, CELL METAB, V14, P587, DOI 10.1016/j.cmet.2011.09.012; Buteau J, 2007, J BIOL CHEM, V282, P287, DOI 10.1074/jbc.M606118200; Porcher C, 1999, DEVELOPMENT, V126, P4603; Choi SH, 2011, TRENDS ENDOCRIN MET, V22, P353, DOI 10.1016/j.tem.2011.04.007; Hegarty BD, 2005, P NATL ACAD SCI USA, V102, P791, DOI 10.1073/pnas.0405067102; Matsumoto M, 2006, J CLIN INVEST, V116, P2464, DOI 10.1172/JCI27047; Bandsma RHJ, 2001, DIABETES, V50, P2591, DOI 10.2337/diabetes.50.11.2591; Ferre T, 2003, DIABETOLOGIA, V46, P1662, DOI 10.1007/s00125-003-1244-z; Haeusler RA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6190; Hirota K, 2008, J BIOL CHEM, V283, P32432, DOI 10.1074/jbc.M806179200; Kim-Muller JY, 2011, SCIENCE, V331, P1529, DOI 10.1126/science.1204504; Liu N, 2009, DEVELOPMENT, V136, P933, DOI 10.1242/dev.034025; Naimi M, 2007, ENDOCRINOLOGY, V148, P2424, DOI 10.1210/en.2006-1411; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Pajvani UB, 2013, NAT MED, V19, P1055, DOI 10.1038/nm.3259; Ramnanan CJ, 2013, DIABETES, V62, P74, DOI 10.2337/db12-0148; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; Xiong Y, 2007, J BIOL CHEM, V282, P4975, DOI 10.1074/jbc.M606742200	48	2	2	AMER DIABETES ASSOC	ALEXANDRIA	1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA	0012-1797	1939-327X		DIABETES	Diabetes	JUN	2015	64	6					1951	1965		10.2337/db14-1506		15	Endocrinology & Metabolism	Endocrinology & Metabolism	CJ3GH	WOS:000355370900013		
J	Tamura, Y; Kawao, N; Yano, M; Okada, K; Okumoto, K; Chiba, Y; Matsuo, O; Kaji, H				Tamura, Yukinori; Kawao, Naoyuki; Yano, Masato; Okada, Kiyotaka; Okumoto, Katsumi; Chiba, Yasutaka; Matsuo, Osamu; Kaji, Hiroshi			Role of Plasminogen Activator Inhibitor-1 in Glucocorticoid-Induced Diabetes and Osteopenia in Mice	DIABETES			English	Article							AMELIORATES INSULIN-RESISTANCE; SKELETAL-MUSCLE REGENERATION; CARDIOVASCULAR RISK; BONE-FORMATION; FEMALE MICE; OLD DRUGS; MECHANISMS; RECEPTOR; OBESITY; METABOLISM	Long-term use of glucocorticoids (GCs) causes numerous adverse effects, including glucose/lipid abnormalities, osteoporosis, and muscle wasting. The pathogenic mechanism, however, is not completely understood. In this study, we used plasminogen activator inhibitor-1 (PAI-1)-deficient mice to explore the role of PAI-1 in GC-induced glucose/lipid abnormalities, osteoporosis, and muscle wasting. Corticosterone markedly increased the levels of circulating PAI-1 and the PAI-1 mRNA level in the white adipose tissue of wild-type mice. PAI-1 deficiency significantly reduced insulin resistance and glucose intolerance but not hyperlipidemia induced by GC. An in vitro experiment revealed that active PAI-1 treatment inhibits insulin-induced phosphorylation of Akt and glucose uptake in HepG2 hepatocytes. However, this was not observed in 3T3-L1 adipocytes and C2C12 myotubes, indicating that PAI-1 suppressed insulin signaling in hepatocytes. PAI-1 deficiency attenuated the GC-induced bone loss presumably via inhibition of apoptosis of osteoblasts. Moreover, the PAI-1 deficiency also protected from GC-induced muscle loss. In conclusion, the current study indicated that PAI-1 is involved in GC-induced glucose metabolism abnormality, osteopenia, and muscle wasting in mice. PAI-1 may be a novel therapeutic target to mitigate the adverse effects of GC.	[Tamura, Yukinori; Kawao, Naoyuki; Yano, Masato; Okada, Kiyotaka; Kaji, Hiroshi] Kinki Univ, Fac Med, Dept Physiol & Regenerat Med, Osakasayama, Japan; [Okumoto, Katsumi] Kinki Univ, Life Sci Res Inst, Osakasayama, Japan; [Chiba, Yasutaka] Kinki Univ Hosp, Clin Res Ctr, Osakasayama, Japan; [Matsuo, Osamu] Kinki Univ, Fac Med, Osakasayama, Japan	Kaji, H (reprint author), Kinki Univ, Fac Med, Dept Physiol & Regenerat Med, Osakasayama, Japan.	hkaji@med.kindai.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [26860152, 24590289]; Japan Osteoporosis Foundation; Takeda Science Foundation; Kinki University	This study was supported by grants-in-aid 26860152 and 24590289 from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to Y.T. and H.K., respectively) and grants from the Japan Osteoporosis Foundation, the Takeda Science Foundation, and Kinki University.	Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926; Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084; Ma LJ, 2004, DIABETES, V53, P336, DOI 10.2337/diabetes.53.2.336; Hoekstra T, 2004, THROMB HAEMOSTASIS, V91, P861, DOI 10.1160/TH03-08-0546; Tamura Y, 2008, ARTERIOSCL THROM VAS, V28, P2195, DOI 10.1161/ATVBAHA.108.168633; Tamura Y, 2013, DIABETES, V62, P3170, DOI 10.2337/db12-1552; Kaji H, 2013, CURR OPIN CLIN NUTR, V16, P272, DOI 10.1097/MCO.0b013e32835fe6a5; Darmon P, 2006, AM J PHYSIOL-ENDOC M, V291, pE995, DOI 10.1152/ajpendo.00654.2005; Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006-0459; Pan Y, 2013, MOL CELL ENDOCRINOL, V367, P116, DOI 10.1016/j.mce.2012.12.027; Dovio A, 2004, J CLIN ENDOCR METAB, V89, P4923, DOI 10.1210/jc.2004-0164; Zhang ZF, 2010, PHYTOMEDICINE, V17, P14, DOI 10.1016/j.phymed.2009.09.007; van Raalte DH, 2009, EUR J CLIN INVEST, V39, P81, DOI 10.1111/j.1365-2362.2008.02067.x; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Mathieu P, 2010, CLIN PHARMACOL THER, V87, P407, DOI 10.1038/clpt.2009.311; Erem C, 2009, J ENDOCRINOL INVEST, V32, P169; Conde J, 2011, BIOFACTORS, V37, P413, DOI 10.1002/biof.185; Schakman O, 2009, HORM RES, V72, P36, DOI 10.1159/000229762; Brennan-Speranza TC, 2012, J CLIN INVEST, V122, P4172, DOI 10.1172/JCI63377; Krause MP, 2011, DIABETES, V60, P1964, DOI 10.2337/db11-0007; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Kawao N, 2013, J BONE MINER RES, V28, P1561, DOI 10.1002/jbmr.1921; Naderi J, 2009, AM J PATHOL, V175, P763, DOI 10.2353/ajpath.2009.081009; Strehl C, 2013, MOL CELL ENDOCRINOL, V380, P32, DOI 10.1016/j.mce.2013.01.026; Blackburn D, 2002, J GEN INTERN MED, V17, P717, DOI 10.1046/j.1525-1497.2002.10649.x; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Moutsatsou P, 2012, TRENDS MOL MED, V18, P348, DOI 10.1016/j.molmed.2012.04.005; Tanaka K, 2012, J BIOL CHEM, V287, P11616, DOI 10.1074/jbc.M111.292193; Karasik D, 2008, ANN HUM GENET, V72, P696, DOI 10.1111/j.1469-1809.2008.00447.x; Carmeliet P, 1997, CIRCULATION, V96, P3180; Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006; Kuo T, 2013, MOL CELL ENDOCRINOL, V380, P79, DOI 10.1016/j.mce.2013.03.003; Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105; Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047; Yuen KCJ, 2013, DIABETIC MED, V30, P651, DOI 10.1111/dme.12184; Dimova E, 2008, THROMB HAEMOSTASIS, V100, P992, DOI 10.1160/TH08-07-0490; Hasselgren PO, 2010, CURR OPIN CLIN NUTR, V13, P423, DOI 10.1097/MCO.0b013e32833a5107; Herrmann M, 2009, STEROIDS, V74, P245, DOI 10.1016/j.steroids.2008.11.009; Kaji Hiroshi, 2014, J Bone Metab, V21, P29, DOI 10.11005/jbm.2014.21.1.29; Kim HJ, 2007, ANN NY ACAD SCI, V1116, P335, DOI 10.1196/annals.1402.057; Koh TJ, 2005, AM J PHYSIOL-CELL PH, V289, pC217, DOI 10.1152/ajpcell.00555.2004; KONKLE BA, 1992, BLOOD, V79, P2636; Lopez-Alemany R, 2003, EUR J BIOCHEM, V270, P814, DOI 10.1046/j.1432-1033.2003.03453.x; Miao HM, 2012, INFLAMM RES, V61, P349, DOI 10.1007/s00011-011-0417-3; Morange PE, 2000, ARTERIOSCL THROM VAS, V20, P1150; Oishi K, 2007, THROMB HAEMOSTASIS, V98, P864, DOI 10.1160/TH07-04-0268; Seki T, 2001, J CELL PHYSIOL, V189, P72, DOI 10.1002/jcp.1140; Siegel C, 2010, J NEUROSCI RES, V88, P2765, DOI 10.1002/jnr.22406; Tamura Y, 2014, ENDOCRINOLOGY, V155, P1708, DOI 10.1210/en.2013-1888	50	5	5	AMER DIABETES ASSOC	ALEXANDRIA	1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA	0012-1797	1939-327X		DIABETES	Diabetes	JUN	2015	64	6					2194	2206		10.2337/db14-1192		13	Endocrinology & Metabolism	Endocrinology & Metabolism	CJ3GH	WOS:000355370900033		
J	Nishimura, T; Meguro, S; Sekioka, R; Tanaka, K; Saisho, Y; Irie, J; Tanaka, M; Kawai, T; Itoh, H				Nishimura, Takeshi; Meguro, Shu; Sekioka, Risa; Tanaka, Karin; Saisho, Yoshifumi; Irie, Junichiro; Tanaka, Masami; Kawai, Toshihide; Itoh, Hiroshi			C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes	DIABETES RESEARCH AND CLINICAL PRACTICE			English	Article						Sitagliptin; Long-term effect; C-peptide; Haemoglobin A1c protein; Human	INSULIN-SECRETION CAPACITY; INHIBITOR SITAGLIPTIN; COMBINATION THERAPY; GLUCOSE-TOLERANCE; JAPANESE PATIENTS; GLYCEMIC CONTROL; EFFICACY; SAFETY; MONOTHERAPY; VILDAGLIPTIN	Aims: This retrospective study aimed to determine the hypoglycaemic effect of 2 years of sitagliptin administration in terms of changes in HbA1c and C-peptide immunoreactivity (CPR) index (plasma CPR [ng/mL]/glucose [mg/dL] x 100). Methods: The inclusion criteria for DPP-4 inhibitor-naive outpatients with type 2 diabetes (n = 285) were: continuation of sitagliptin for >= 700 days from initial administration and measurement of HbA1c, serum CPR, and plasma glucose levels at 0, 3, 6, 12, 18, and 24 months after sitagliptin initiation. Logistic regression analyses determined the factors contributing to the response to sitagliptin, based on responder (Delta HbA1c <=-0.4% [<=-4 mmol/mol]) and non-responder (DHbA1c >-0.4% [>- 4 mmol/mol]) groups. Results: The HbA1c level decreased and CPR index increased from baseline to 3, 6, 12, 18, and 24 months after the start of sitagliptin administration (HbA1c: 7.4 perpendicular to 0.8% [57 perpendicular to 9 mmol/mol], 7.3 +/- 0.9% [57 +/- 9 mmol/mol], 7.4 +/- 0.9% [58 +/- 10 mmol/mol], 7.1 +/- 0.8% [55 +/- 9 mmol/mol], and 7.3 +/- 0.9% [57 +/- 10 mmol/mol], respectively, all P < 0.001 vs. baseline [8.0 +/- 1.0%, 64 +/- 11 mmol/mol] and CPR index: 1.69 +/- 0.96, 1.71 +/- 1.10, 1.62 +/- 0.96, 1.64 +/- 0.92, and 1.66 +/- 0.96, respectively, all P < 0.05 vs. baseline [1.47 +/- 0.81]). Higher baseline HbA1c level, shorter diabetes duration, and greater CPR index increase after sitagliptin administration were associated with the response to sitagliptin. Conclusions: Our results suggest that sitagliptin improves glycaemic control via an improved intrinsic insulin response. (c) 2015 Elsevier Ireland Ltd. All rights reserved.	[Nishimura, Takeshi; Meguro, Shu; Sekioka, Risa; Tanaka, Karin; Saisho, Yoshifumi; Irie, Junichiro; Tanaka, Masami; Kawai, Toshihide; Itoh, Hiroshi] Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan	Nishimura, T (reprint author), Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	t-nishimura128@z6.keio.jp			MSD	Hiroshi Itoh and Shu Meguro received a scholarship grant from MSD. All the other authors have no conflict of interest.	Ahrén Bo, 2010, Diabetes Metab Syndr Obes, V3, P31; Takabe M, 2012, DIABETES RES CLIN PR, V98, pE32, DOI 10.1016/j.diabres.2012.09.036; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Williams-Herman D, 2010, DIABETES OBES METAB, V12, P442, DOI 10.1111/j.1463-1326.2010.01204.x; Saisho Y, 2011, ENDOCR J, V58, P315, DOI 10.1507/endocrj.K10E-399; Esposito K, 2014, ENDOCRINE, V46, P43, DOI 10.1007/s12020-013-0090-0; Nonaka K, 2008, DIABETES RES CLIN PR, V79, P291, DOI 10.1016/j.diabres.2007.08.021; Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140-6736(06)69705-5; Kim YG, 2013, DIABETOLOGIA, V56, P696, DOI 10.1007/s00125-012-2827-3; Kubota A, 2014, J DIABETES INVEST, V5, P445, DOI 10.1111/jdi.12182; Foley JE, 2011, DIABETOLOGIA, V54, P1985, DOI 10.1007/s00125-011-2167-8; Nomiyama T, 2012, DIABETES RES CLIN PR, V95, pE27, DOI 10.1016/j.diabres.2011.08.016; Seino Y, 2010, J DIABETES INVEST, V1, P1, DOI 10.1111/j.2040-1124.2010.00005.x; Charbonnel B, 2006, DIABETES CARE, V29, P2638, DOI 10.2337/dc06-0706; Takeda Y, 2012, DIABETOLOGIA, V55, P404, DOI 10.1007/s00125-011-2365-4; Fukushima M, 2004, METABOLISM, V53, P831, DOI 10.1016/j.metabol.2004.02.012; Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004; Saisho Y, 2010, ENDOCR J, V57, P973, DOI 10.1507/endocrj.K10E-231; Weykamp C, 2008, CLIN CHEM, V54, P240, DOI 10.1373/clinchem.2007.097402; Davis D, 1997, INT TXB DIABETES MEL, P1413; Fukushima M, 2004, DIABETES RES CLIN PR, V66, pS37, DOI 10.1016/j.diabres.2003.11.024; TURNER RC, 1995, DIABETES, V44, P1249; Harashima SI, 2012, INT J CLIN PRACT, V66, P465, DOI 10.1111/j.1742-1241.2012.02903.x; Karagiannis T, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1369; Kim Soon Ae, 2011, Diabetes Metab J, V35, P159, DOI 10.4093/dmj.2011.35.2.159; Pratley RE, 2006, HORM METAB RES, V38, P423, DOI 10.1055/s-2006-944546; Williams-Herman D, 2010, BMC ENDOCR DISORD, V10, DOI 10.1186/1472-6823-10-7	27	1	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-8227	1872-8227		DIABETES RES CLIN PR	Diabetes Res. Clin. Pract.	JUN	2015	108	3					441	447		10.1016/j.diabres.2015.02.031		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CI6OM	WOS:000354879700020		
J	Maeda, H; Kubota, A; Kanamori, A; Tanaka, Y; Terauchi, Y; Matsuba, I				Maeda, Hajime; Kubota, Akira; Kanamori, Akira; Tanaka, Yasushi; Terauchi, Yasuo; Matsuba, Ikuro		Study Grp Diabet Comm; Kanagawa Phys Assoc	Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes	DIABETES RESEARCH AND CLINICAL PRACTICE			English	Article						Dipeptidyl peptidase-4 (DPP-4) inhibitor; Sitagliptin; Creatinine; HbA1c	EFFICACY; SAFETY	We found a slight elevation of serum creatinine in the subjects treated with sitagliptin for 2 years and a correlation between creatinine elevation and HbA1c reduction. These results suggest that creatinine elevation is associated with activation of incretin, most possibly with up-regulation of diuretic activity of GLP-1. (c) 2015 Elsevier Ireland Ltd. All rights reserved.	[Maeda, Hajime; Kubota, Akira; Kanamori, Akira; Matsuba, Ikuro] Kanagawa Phys Assoc, Study Grp Diabet Comm, Yokohama, Kanagawa 2310037, Japan; [Tanaka, Yasushi] St Marianna Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Kawasaki, Kanagawa 2168511, Japan; [Terauchi, Yasuo] Yokohama City Univ, Dept Endocrinol & Metab, Yokohama, Kanagawa 2360004, Japan	Maeda, H (reprint author), HEC Sci Clin, Isogo Ku, 4-1-4-102 Yokodai, Yokohama, Kanagawa 2350045, Japan.	hec@asahi-net.email.ne.jp			Japan Diabetes Foundation	This study was supported by a grant from the Japan Diabetes Foundation.	Kubota A, 2012, J DIABETES INVEST, V3, P503, DOI 10.1111/j.2040-1124.2012.00221.x; Ferreira JCA, 2013, DIABETES CARE, V36, P1067, DOI 10.2337/dc12-1365; Katsuya T, 2003, HYPERTENS RES, V26, P521, DOI 10.1291/hypres.26.521; Carraro-Lacroix LR, 2009, AM J PHYSIOL-RENAL, V297, pF1647, DOI 10.1152/ajprenal.00082.2009; Engel Samuel S, 2013, Diabetes Ther, V4, P119, DOI 10.1007/s13300-013-0024-0; Kubota Akira, 2012, J Clin Med Res, V4, P309; Maeda H, 2013, J ENDOCRINOL INVEST, V36, P568, DOI 10.3275/8819; Maeda H, 2012, DIABETES RES CLIN PR, V95, pE20, DOI 10.1016/j.diabres.2011.10.011; Park H, 2012, DIABETES, V46, P1543; Takihata M, 2013, DIABETES OBES METAB, V15, P455, DOI 10.1111/dom.12055; Tanaka T, 2014, KIDNEY INT, V86, P701, DOI 10.1038/ki.2014.236	11	1	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-8227	1872-8227		DIABETES RES CLIN PR	Diabetes Res. Clin. Pract.	JUN	2015	108	3					E42	E45		10.1016/j.diabres.2015.03.008		4	Endocrinology & Metabolism	Endocrinology & Metabolism	CI6OM	WOS:000354879700003		
J	Ninomiya, H; Katakami, N; Osonoi, T; Saitou, M; Yamamoto, Y; Takahara, M; Kawamori, D; Matsuoka, T; Yamasaki, Y; Shimomura, I				Ninomiya, Hiroyo; Katakami, Naoto; Osonoi, Takeshi; Saitou, Miyoko; Yamamoto, Yuichi; Takahara, Mitsuyoshi; Kawamori, Dan; Matsuoka, Taka-aki; Yamasaki, Yoshimitsu; Shimomura, Iichiro			Association between new onset diabetic retinopathy and monocyte chemoattractant protein-1 (MCP-1) polymorphism in Japanese type 2 diabetes	DIABETES RESEARCH AND CLINICAL PRACTICE			English	Article						Retinopathy; SNP; MCP-1	EXPRESSION; CELLS	We longitudinally evaluated the association between monocyte chemoattractant protein-1 (MCP-1) A-2518G polymorphism and new onset of diabetic retinopathy in 758 type 2 diabetic patients. The new onset of retinopathy increased with the increase of the number of G alleles, even after adjustment for age, HbA1c levels, and duration of diabetes. (c) 2015 Elsevier Ireland Ltd. All rights reserved.	[Ninomiya, Hiroyo; Katakami, Naoto; Yamamoto, Yuichi; Takahara, Mitsuyoshi; Kawamori, Dan; Matsuoka, Taka-aki; Yamasaki, Yoshimitsu; Shimomura, Iichiro] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka 5650871, Japan; [Katakami, Naoto] Osaka Univ, Grad Sch Med, Dept Metab & Atherosclerosis, Suita, Osaka 5650871, Japan; [Osonoi, Takeshi; Saitou, Miyoko] Naka Mem Clin, Naka, Ibaraki, Japan	Katakami, N (reprint author), Osaka Univ, Grad Sch Med, Dept Metab Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	katakami@endmet.med.osaka-u.ac.jp					Abu El-Asrar AM, 2006, EUR CYTOKINE NETW, V17, P155, DOI 10.1684/ecn.2006.0033; Rovin BH, 1999, BIOCHEM BIOPH RES CO, V259, P344, DOI 10.1006/bbrc.1999.0796; Fenoglio C, 2004, NEUROBIOL AGING, V25, P1169, DOI 10.1016/j.neurobiolaging.2003.11.008; Jo N, 2003, INVEST OPHTH VIS SCI, V44, P4054, DOI 10.1167/iovs.02-1308; Hong KH, 2005, BLOOD, V105, P1405, DOI 10.1182/blood-2004-08-3178; Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117; Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104; Melgarejo E, 2009, INT J BIOCHEM CELL B, V41, P998, DOI 10.1016/j.biocel.2008.07.018; Bian ZM, 2001, INVEST OPHTH VIS SCI, V42, P1660; Buraczynska M, 2008, CYTOKINE, V44, P361, DOI 10.1016/j.cyto.2008.10.001; Dong L, 2014, GRAEF ARCH CLIN EXP, V252, P1921, DOI 10.1007/s00417-014-2651-1; Harada C, 2006, DIABETES RES CLIN PR, V74, P249, DOI 10.1016/j.diabres.2006.04.017; Katakami Naoto, 2010, Diabetes Res Clin Pract, V89, pe9, DOI 10.1016/j.diabres.2010.04.006; Takaishi H, 2003, BIOCHEM BIOPH RES CO, V305, P122, DOI 10.1016/S0006-291X(03)00712-5	14	1	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-8227	1872-8227		DIABETES RES CLIN PR	Diabetes Res. Clin. Pract.	JUN	2015	108	3					E35	E37		10.1016/j.diabres.2015.04.006		3	Endocrinology & Metabolism	Endocrinology & Metabolism	CI6OM	WOS:000354879700001		
J	Numakura, C; Hashimoto, Y; Daitsu, T; Hayasaka, K; Mitsui, T; Yorifuji, T				Numakura, Chikahiko; Hashimoto, Yukiko; Daitsu, Takashi; Hayasaka, Kiyoshi; Mitsui, Tetsuo; Yorifuji, Tohru			Two patients with HNF4A-related congenital hyperinsulinism and renal tubular dysfunction: A clinical variation which includes transient hepatic dysfunction	DIABETES RESEARCH AND CLINICAL PRACTICE			English	Article						HNF4A; Congenital hyperinsulinism; Fanconi syndrome; Nephrocalcinosis; Hepatomegaly	EXPRESSION; MUTATIONS; HNF4A; LIVER; GENE	The HNF4A p.R76W mutation causes congenital hyperinsulinism with Fanconi syndrome. Here, we report two cases who also presented with increased urinary calcium excretion and one had a transient hepatic dysfunction with hepatomegaly. Clinical variations including transient liver dysfunction is a likely mutation-specific clinical characteristic. (c) 2015 Elsevier Ireland Ltd. All rights reserved.	[Numakura, Chikahiko; Daitsu, Takashi; Hayasaka, Kiyoshi; Mitsui, Tetsuo] Yamagata Univ, Sch Med, Dept Pediat, Yamagata 99023, Japan; [Hashimoto, Yukiko; Yorifuji, Tohru] Osaka City Gen Hosp, Childrens Med Ctr, Dept Pediat Endocrinol & Metab, Osaka, Japan	Numakura, C (reprint author), Yamagata Univ, Sch Med, Dept Pediat, Yamagata 99023, Japan.	cnumakur@med.id.yamagata-u.ac.jp					Stanescu DE, 2012, J CLIN ENDOCR METAB, V97, pE2026, DOI 10.1210/jc.2012-1356; Chandra V, 2013, NATURE, V495, P394, DOI 10.1038/nature11966; Santer R, 1997, NAT GENET, V17, P324, DOI 10.1038/ng1197-324; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; Yorifuji T, 2012, PEDIATR DIABETES, V13, P26, DOI 10.1111/j.1399-5448.2011.00827.x; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hamilton AJ, 2014, J MED GENET, V51, P165, DOI 10.1136/jmedgenet-2013-102066	8	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-8227	1872-8227		DIABETES RES CLIN PR	Diabetes Res. Clin. Pract.	JUN	2015	108	3					E53	E55		10.1016/j.diabres.2015.03.005		3	Endocrinology & Metabolism	Endocrinology & Metabolism	CI6OM	WOS:000354879700006		
J	Hara, M; Takao, S; Shimazu, Y				Hara, Michimaru; Takao, Shinichi; Shimazu, Yukie			Comparison of throat swab and nasopharyngeal aspirate specimens for rapid detection of adenovirus	DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE			English	Article						Adenovirus; Chromatographic immunoassay test; Nasopharyngeal aspirate; Real-time PCR; Throat swab; Viral culture	RESPIRATORY-TRACT INFECTIONS; REAL-TIME PCR; VIRUS ISOLATION; DIAGNOSIS; CHILDREN	Nasopharyngeal aspirate (NPA) and throat swab (TS) specimens from individual patients were compared with regard to usefulness for adenovirus detection. In 153 adenovirus-infected patients, rapid test sensitivities with NPAs (90.8%) were nearly equivalent to those with TSs (91.5%) based on real-time polymerase chain reaction standards, indicating that NPAs are equally useful. (C) 2015 Elsevier Inc. All rights reserved.	[Hara, Michimaru] Hara Pediat Clin, Hiroshima, Japan; [Takao, Shinichi; Shimazu, Yukie] Hiroshima Prefectural Technol Res Inst, Ctr Publ Hlth & Environm, Hiroshima, Japan	Hara, M (reprint author), Hara Pediat Clin, Hiroshima, Japan.	hara-michimaru@mue.biglobe.ne.jp; s-takao84335@pref.hiroshima.jp; y-shimazu89236@pref.hiroshima.lg.jp					Fujimoto T, 2004, J CLIN MICROBIOL, V42, P5489, DOI 10.1128/JCM.42.12.5489-5492.2004; Heim A, 2003, J MED VIROL, V70, P228, DOI 10.1002/jmv.10382; Dominguez O, 2005, PEDIATR INFECT DIS J, V24, P733, DOI 10.1097/01.inf.0000172942.96436.2d; EDWARDS KM, 1985, PEDIATRICS, V76, P420; Hara M, 2010, PEDIATR INFECT DIS J, V29, P267, DOI 10.1097/INF.0b013e3181bd5059; Kawasaki Y, 2002, PEDIATR INFECT DIS J, V21, P370, DOI 10.1097/01.inf.0000012557.03849.89; Ouchi K, 1999, J INFECT CHEMOTHER, V5, P220, DOI 10.1007/s101560050040; RUUSKANEN O, 1985, PEDIATRICS, V76, P79; Tsai HP, 2001, J CLIN MICROBIOL, V39, P111, DOI 10.1128/JCM.39.1.111-118.2001; Tsutsumi H, 1999, J CLIN MICROBIOL, V37, P2007	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0732-8893	1879-0070		DIAGN MICR INFEC DIS	Diagn. Microbiol. Infect. Dis.	JUN	2015	82	2					135	136		10.1016/j.diagmicrobio.2014.11.003		2	Infectious Diseases; Microbiology	Infectious Diseases; Microbiology	CI9CU	WOS:000355068800006		
J	Lee, JH; Kakinuma, K; Okuro, T; Iwasa, Y				Lee, Joung Hun; Kakinuma, Kaoru; Okuro, Toshiya; Iwasa, Yoh			Coupled social and ecological dynamics of herders in Mongolian rangelandse	ECOLOGICAL ECONOMICS			English	Article						Overgrazing; Stochastic best response; Southern Mongolia; Cycle	BIODIVERSITY CONSERVATION; RESOURCE-MANAGEMENT; REGIME SHIFTS; NONEQUILIBRIUM; RESILIENCE; VEGETATION; SYSTEMS; HETEROGENEITY; COMPLEXITY; BEHAVIOR	Motivated by a field study in a southern Mongolian rangeland, we developed a simple model that couples the social and ecological dynamics of herders who choose foraging sites for their animals in the dry season. If grazing pressure is very strong, the grass biomass becomes depleted and more herders choose to move their animals to an alternative rangeland. These herders may return to the focal rangeland when the quantity and quality of the grass improve. Our model assumes that herders tend to choose the foraging site that gives the higher payoff in a manner described by stochastic best response dynamics. In the model, this social dynamics is coupled with the dynamics of the grass biomass. The resulting system generates typical non-linear behaviors. For example, it may exhibit bistability, with two distinct locally stable equilibria suggesting a strong dependence on the initial condition, or perpetual large-amplitude fluctuation: Implications for rangeland management are discussed. (c) 2015 Elsevier B.V. All rights reserved.	[Lee, Joung Hun; Iwasa, Yoh] Kyushu Univ, Dept Biol, Fac Sci, Fukuoka 8128581, Japan; [Lee, Joung Hun] Kyushu Univ, Ctr Decis Sci, Fukuoka 8128581, Japan; [Kakinuma, Kaoru] Tokyo Inst Technol, Dept Civil Engn, Tokyo 1528552, Japan; [Okuro, Toshiya] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Ecosyst Studies, Tokyo, Japan	Lee, JH (reprint author), Kyushu Univ, Dept Biol, Fac Sci, Fukuoka 8128581, Japan.	clinamen2013@gmail.com			Global COE Project of Asian Conservation Biology, Environment Research and Technology Development Fund (S9) of the Ministry of the Environment, Japan	This work was supported by the Global COE Project of Asian Conservation Biology, Environment Research and Technology Development Fund (S9) of the Ministry of the Environment, Japan (to VI), a Grant-in-Aid for Scientific Research (B) (to YI). We thank Marko Jusup and Mayuko Nakamaru for their helpful comments.	Nepstad DC, 2008, PHILOS T R SOC B, V363, P1737, DOI 10.1098/rstb.2007.0036; Liu JG, 2007, SCIENCE, V317, P1513, DOI 10.1126/science.1144004; Vetter S, 2005, J ARID ENVIRON, V62, P321, DOI 10.1016/j.jaridenv.2004.11.015; Coutts SR, 2013, ECOL APPL, V23, P523, DOI 10.1890/12-0599.1; Andersen T, 2009, TRENDS ECOL EVOL, V24, P49, DOI 10.1016/j.tree.2008.07.014; Folke C, 2002, AMBIO, V31, P437, DOI 10.1639/0044-7447(2002)031[0437:RASDBA]2.0.CO;2; Illius AW, 2000, OIKOS, V89, P283, DOI 10.1034/j.1600-0706.2000.890209.x; von Wehrden H, 2012, ECOL APPL, V22, P393, DOI 10.1890/11-0802.1; Peterson G, 2000, ECOL ECON, V35, P323, DOI 10.1016/S0921-8009(00)00217-2; Alos-Ferrer C, 2010, GAME ECON BEHAV, V68, P413, DOI 10.1016/j.geb.2009.08.004; Illius AW, 1999, ECOL APPL, V9, P798, DOI 10.2307/2641330; Tavoni A, 2012, J THEOR BIOL, V299, P152, DOI 10.1016/j.jtbi.2011.07.003; Satake A, 2007, ECOL ECON, V63, P452, DOI 10.1016/j.ecolecon.2006.11.018; Crepin AS, 2009, ENVIRON RESOUR ECON, V44, P29, DOI 10.1007/s10640-008-9258-0; Potts SG, 2010, TRENDS ECOL EVOL, V25, P345, DOI 10.1016/j.tree.2010.01.007; Roy ED, 2011, ECOL ENG, V37, P1661, DOI 10.1016/j.ecoleng.2011.06.044; Okayasu T, 2010, AGR SYST, V103, P180, DOI 10.1016/j.agsy.2009.12.006; Carpenter SR, 2004, ECOL SOC, V9; Clark C.W., 1976, MATH BIOECONOMICS OP; Fernandez-Gimenez ME, 2002, HUM ECOL, V30, P49, DOI 10.1023/A:1014562913014; Fernandez-Gimenez ME, 1999, J APPL ECOL, V36, P871, DOI 10.1046/j.1365-2664.1999.00447.x; Figueiredo J, 2011, LANDSCAPE ECOL, V26, P737, DOI 10.1007/s10980-011-9605-3; Grubov V. I., 1982, KEY VASCULAR PLANTS; Henderson K. A., 2013, PLOS ONE; Holling C. S., 2001, PANARCHY UNDERSTANDI; Humphrey C., 1999, END NOMADISM SOC STA; Iwasa Y, 2013, J THEOR BIOL, V333, P117, DOI 10.1016/j.jtbi.2013.05.007; Iwasa Y, 2007, ECOL ECON, V63, P219, DOI 10.1016/j.ecolecon.2006.11.003; Iwasa Y, 2010, THEOR ECOL-NETH, V3, P113, DOI 10.1007/s12080-009-0061-5; Kakinuma K, 2013, GRASSL SCI, V59, P44, DOI 10.1111/grs.12008; Kakinuma K, 2014, J ARID ENVIRON, V109, P88, DOI 10.1016/j.jaridenv.2014.05.024; Lade S.J., 2013, THEOR ECOL, V6, pSI359; Lee JH, 2012, THEOR POPUL BIOL, V82, P177, DOI 10.1016/j.tpb.2012.06.008; Lee JH, 2014, POPUL ECOL, V56, P27, DOI 10.1007/s10144-013-0423-0; Lee JH, 2011, ECOL ECON, V70, P2350, DOI 10.1016/j.ecolecon.2011.07.013; MCKELVEY RD, 1995, GAME ECON BEHAV, V10, P6, DOI 10.1006/game.1995.1023; Polasky S, 2009, ANNU REV RESOUR ECON, V1, P409, DOI 10.1146/annurev.resource.050708.144110; Reynolds F. J., 2007, SCIENCE, V316, P847; Richter A, 2013, ECOL ECON, V93, P202, DOI 10.1016/j.ecolecon.2013.05.013; Roy ED, 2010, ECOL SOC, V15; Sasaki T, 2009, J ARID ENVIRON, V73, P949, DOI 10.1016/j.jaridenv.2009.04.008; Satake A, 2008, THEOR ECOL-NETH, V1, P189, DOI 10.1007/s12080-008-0019-z; Satake S., 2006, ECOL RES, V21, P370; SCOONES I, 1995, J ARID ENVIRON, V29, P221, DOI 10.1016/S0140-1963(05)80092-8; Smith DMS, 2007, P NATL ACAD SCI USA, V104, P20690, DOI 10.1073/pnas.0704837104; Suzuki Y., 2009, ECOL ECON, V68, P1006; Suzuki Y, 2009, ECOL RES, V24, P479, DOI 10.1007/s11284-008-0548-3; Turner MD, 1999, HUM ECOL, V27, P267, DOI 10.1023/A:1018725327873; Yokomizo H, 2014, POPUL ECOL, V56, P41, DOI 10.1007/s10144-013-0421-2; Zhuang Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105391	50	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-8009	1873-6106		ECOL ECON	Ecol. Econ.	JUN	2015	114						208	217		10.1016/j.ecolecon.2015.03.003		10	Ecology; Economics; Environmental Sciences; Environmental Studies	Environmental Sciences & Ecology; Business & Economics	CI8MM	WOS:000355026400020		
J	Namikawa, T; Fukudome, I; Ogawa, M; Munekage, E; Munekage, M; Shiga, M; Maeda, H; Kitagawa, H; Kobayashi, M; Hanazaki, K				Namikawa, T.; Fukudome, I.; Ogawa, M.; Munekage, E.; Munekage, M.; Shiga, M.; Maeda, H.; Kitagawa, H.; Kobayashi, M.; Hanazaki, K.			Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1)	EJSO			English	Article						Gastric cancer; Immunochemotherapy; Neutrophil to lymphocyte ratio; Oral fluorouracil anticancer drug; Protein-bound polysaccharide-K	IMMUNOSUPPRESSIVE ACIDIC PROTEIN; PREDICTS POOR SURVIVAL; ADJUVANT IMMUNOCHEMOTHERAPY; PREOPERATIVE NEUTROPHIL; RATIO; LYMPHOCYTES; MORTALITY; CARCINOMA; RESECTION; PATTERNS	Background: The aim of the present study was to evaluate the clinical significance of protein-bound polysaccharide K (PSK) in patients with primary gastric cancer who were being treated with an oral fluoropyrimidine (S-1). Methods: Clinical reports of 190 gastric cancer patients treated with S-1 chemotherapy, with or without PSK, at Kochi Medical School between 2007 and 2012 were investigated retrospectively to analyze survival. The neutrophil:lymphocyte ratio (NLR) was also evaluated as indicator of the immunoenhancing effect of PSK. Results: Overall survival was significantly longer in patients treated with S-1 + PSK than in those given S-1 alone (hazard ratio for death, 0.608; 95% confidence interval 0.375-0.985; P = 0.041). Furthermore, there was a tendency for changes in the NLR during chemotherapy to be lower in the S-1 + PSK group than in the S-1 group, but the difference did not reach statistical significance (P = 0.054). When patients were divided into groups based on preoperative NLR (i.e. <2.5 and >= 2.5), the mean (+/- SEM) NLR 1 month after the beginning of chemotherapy in the NLR >= 2.5 subgroup was significantly lower in patients treated with S-1 + PSK rather than S-1 alone (1.7 +/- 0.7 vs. 3.3 +/- 4.1, respectively; P = 0.043). Conclusions: Immunochemotherapy using PSK improves the survival of patients with advanced gastric cancer. The NLR may be a useful biomarker for evaluating prognosis in these patients. (C) 2015 Elsevier Ltd. All rights reserved.	[Namikawa, T.; Fukudome, I.; Ogawa, M.; Munekage, E.; Munekage, M.; Shiga, M.; Maeda, H.; Kitagawa, H.; Kobayashi, M.; Hanazaki, K.] Kochi Med Sch, Dept Surg, Kochi 7838505, Japan	Namikawa, T (reprint author), Kochi Med Sch, Dept Surg, Nanko Ku, Oko Cho, Kochi 7838505, Japan.	tsutomun@kochi-u.ac.jp					Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Yamanaka T, 2007, ONCOLOGY-BASEL, V73, P215, DOI 10.1159/000127412; Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI [10.1016/S1470-2045(08)70035-4, 10.1016/S1470-204S(08)70035-4]; Jung MR, 2011, J SURG ONCOL, V104, P504, DOI 10.1002/jso.21986; Oba K, 2007, CANCER IMMUNOL IMMUN, V56, P905, DOI 10.1007/s00262-006-0248-1; NAKAZATO H, 1994, LANCET, V343, P1122, DOI 10.1016/S0140-6736(94)90233-X; Ito G, 2012, EXP THER MED, V3, P925, DOI 10.3892/etm.2012.537; Hirashima M, 1998, J CANCER RES CLIN, V124, P329, DOI 10.1007/s004320050178; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Shimada H, 2010, GASTRIC CANCER, V13, P170, DOI 10.1007/s10120-010-0554-3; Namikawa T, 2012, ONCOLOGY-BASEL, V82, P147, DOI 10.1159/000336799; Chua W, 2011, BRIT J CANCER, V104, P1288, DOI 10.1038/bjc.2011.100; Aliustaoglu M, 2010, MED ONCOL, V27, P1060, DOI 10.1007/s12032-009-9335-4; Asai H, 2008, CANCER IMMUNOL IMMUN, V57, P1647, DOI 10.1007/s00262-008-0498-1; Jin HL, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-112; Maehara Y, 2012, SURG TODAY, V42, P8, DOI 10.1007/s00595-011-0075-7; Saji S, 1999, SURG TODAY, V29, P504; Sakamoto J, 1996, CANCER, V77, P2206, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2206::AID-CNCR4>3.0.CO;2-N; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; Sobin LH, 2009, TNM CLASSIFICATION M; Tanaka H, 2012, ANTICANCER RES, V32, P3427; Toge T, 2000, ONCOL REP, V7, P1157; Wittekind C, 2003, TNM SUPPLEMENT COMME	23	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0748-7983	1532-2157		EJSO-EUR J SURG ONC	EJSO	JUN	2015	41	6					795	800		10.1016/j.ejso.2015.02.012		6	Oncology; Surgery	Oncology; Surgery	CJ3DP	WOS:000355363900012		
J	Izumi, Y; Musha, I; Suzuki, E; Iso, M; Jinno, T; Horikawa, R; Amemiya, S; Ogata, T; Fukami, M; Ohtake, A				Izumi, Yoko; Musha, Ikuma; Suzuki, Erina; Iso, Manami; Jinno, Tomoko; Horikawa, Reiko; Amemiya, Shin; Ogata, Tsutomu; Fukami, Maki; Ohtake, Akira			Hypogonadotropic hypogonadism in a female patient previously diagnosed as having waardenburg syndrome due to a sox10 mutation	ENDOCRINE			English	Letter							KALLMANN-SYNDROME		[Izumi, Yoko; Suzuki, Erina; Iso, Manami; Jinno, Tomoko; Ogata, Tsutomu; Fukami, Maki] Natl Res Inst Child Hlth & Dev, Dept Mol Endocrinol, Setagaya Ku, Tokyo 1578535, Japan; [Izumi, Yoko] Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, Tokyo 1608582, Japan; [Musha, Ikuma; Amemiya, Shin; Ohtake, Akira] Saitama Med Univ, Dept Pediat, Fac Med, Moroyama, Saitama 3500495, Japan; [Horikawa, Reiko] Natl Ctr Child Hlth & Dev, Dept Endocrinol & Metab, Setagaya Ku, Tokyo 1578535, Japan; [Ogata, Tsutomu] Hamamatsu Univ, Dept Pediat, Sch Med, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan	Fukami, M (reprint author), Natl Res Inst Child Hlth & Dev, Dept Mol Endocrinol, Setagaya Ku, 2-10-1 Ohkura, Tokyo 1578535, Japan.	fukami-m@ncchd.go.jp					Miraoui H, 2013, AM J HUM GENET, V92, P725, DOI 10.1016/j.ajhg.2013.04.008; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Pingault V, 2013, AM J HUM GENET, V92, P707, DOI 10.1016/j.ajhg.2013.03.024; Jelena B, 2014, AM J MED GENET A, V164, P1512, DOI 10.1002/ajmg.a.36446; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; Pingault V, 2010, HUM MUTAT, V31, P391, DOI 10.1002/humu.21211; Vaaralahti K, 2014, PEDIATR RES, V76, P115, DOI 10.1038/pr.2014.60; Zhang H, 2012, HUM GENET, V131, P491, DOI 10.1007/s00439-011-1098-2; FURUKAWA M, 1988, Auris Nasus Larynx, V15, P25; Inada H., 2002, MANUAL ENDOCRINE EXA, V2nd, P5; Iso M, 2008, AM J MED GENET A, V146A, P2162, DOI 10.1002/ajmg.a.32403; Izumi Y, 2014, FERTIL STERIL, V102, P1130, DOI 10.1016/j.fertnstert.2014.06.017; Layman LC, 2013, MOL CELL ENDOCRINOL, V370, P138, DOI 10.1016/j.mce.2013.02.016; Rapaport R., 2007, NELSON TXB PEDIAT, V18th, P2374; Tanaka T., 2009, NEW POCKET GUIDE CLI, V1st, P106	15	1	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1355-008X	1559-0100		ENDOCRINE	Endocrine	JUN	2015	49	2					553	556		10.1007/s12020-014-0434-4		4	Endocrinology & Metabolism	Endocrinology & Metabolism	CJ1GD	WOS:000355230500030		
J	Taguchi, T; Takao, T; Terada, Y				Taguchi, Takafumi; Takao, Toshihiro; Terada, Yoshio			Natural progression of a sporadic pheochromocytoma over 15 years	ENDOCRINE			English	Editorial Material						Pheochromocytoma; Sporadic pheochromocytoma; Natural progression			[Taguchi, Takafumi; Terada, Yoshio] Kochi Univ, Kochi Med Sch, Dept Endocrinol Metab & Nephrol, Nankoku, Kochi 7838505, Japan; [Takao, Toshihiro] Kawasaki Med Univ, Dept Publ Hlth, Kurashiki, Okayama 7010192, Japan	Taguchi, T (reprint author), Kochi Univ, Kochi Med Sch, Dept Endocrinol Metab & Nephrol, Oko Cho, Nankoku, Kochi 7838505, Japan.	ttagu27k@axel.ocn.ne.jp					Mazza A, 2014, ENDOCRINE, V45, P469, DOI 10.1007/s12020-013-0007-y; Lee TH, 2002, RADIOGRAPHICS, V22, P935; Yu Run, 2008, Endocr Pract, V14, P391	3	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1355-008X	1559-0100		ENDOCRINE	Endocrine	JUN	2015	49	2					572	573		10.1007/s12020-014-0431-7		2	Endocrinology & Metabolism	Endocrinology & Metabolism	CJ1GD	WOS:000355230500037		
J	Udagedara, DT; Jayawardana, DT				Udagedara, D. T.; Jayawardana, D. T.			Assessment of chemical variability of major bottled waters in Sri Lanka	ENVIRONMENTAL EARTH SCIENCES			English	Article						Bottled water; Cations; Anions and classification	VOLATILE ORGANIC-COMPOUNDS; DRINKING-WATER; TRACE-ELEMENTS; NITRATE; METROPOLITAN; EXPOSURE; QUALITY; CANADA	Bottled water is one of the major drinking water sources for travellers in tourist hubs in Sri Lanka. In this study, 32 major bottled water brands sold in the country were analyzed with 19 parameters by means of atomic absorption spectrometer, spectrophotometer and titration. The main objective of the present study is to investigate geochemical variations of Sri Lankan bottled waters in order to identify the main geochemical processes. A comparison of the element concentrations and the legal limits (Sri Lanka, US EPA and WHO) shows that only magnesium level in one brand is above the lower level set by Sri Lankan Standard. According to classifications based on European Union mineral water directive, all the brands indicate low mineral content (TDS 0-150 mg/L) and they are suitable for low sodium diets. Hardness of the water fluctuates within soft water (25 brands), moderately hard water (6 brands) and very hard water (1 brand). Accepted water quality classification systems were used to characterize the different bottled water types. Piper and stiff diagrams were used to establish that the dominant chemical types of the bottled waters are magnesium-calcium-bicarbonate (11 brands), magnesium-calcium-sodium-bicarbonate (9 brands), sodium-magnesium-chloride-sulphate (4 brands) and sodium-chloride-sulphate-bicarbonate (3 brands). According to dietary reference intakes, all the bottled water brands are significantly lower than the recommended human mineral requirements. This means that the bottled waters available in the country are useful for low mineral diets rather than sources for the necessary mineral intake.	[Udagedara, D. T.] Uva Wellassa Univ, Badulla 90000, Sri Lanka; [Udagedara, D. T.] Saitama Univ, Geosphere Res Inst, Dept Civil & Environm Engn, Saitama 3388570, Japan; [Jayawardana, D. T.] Univ Sri Jayewardenepura, Fac Sci Appl, Dept Forestry & Environm Sci, Nugegoda, Sri Lanka	Jayawardana, DT (reprint author), Univ Sri Jayewardenepura, Fac Sci Appl, Dept Forestry & Environm Sci, Nugegoda, Sri Lanka.	tharangau@yahoo.com; daham@sci.sjp.ac.lk					ALLEN HE, 1989, ARCH ENVIRON HEALTH, V44, P102; Al-Saleh I, 1998, SCI TOTAL ENVIRON, V216, P181, DOI 10.1016/S0048-9697(98)00137-5; Ensafi AA, 1999, ANAL CHIM ACTA, V382, P15, DOI 10.1016/S0003-2670(98)00755-7; Cidu R, 2011, J FOOD COMPOS ANAL, V24, P184, DOI 10.1016/j.jfca.2010.08.005; Oyebog SA, 2012, J GEOCHEM EXPLOR, V112, P118, DOI 10.1016/j.gexplo.2011.08.003; Ahmed F, 2010, ENVIRON EARTH SCI, V60, P1303, DOI 10.1007/s12665-009-0270-7; Aral MM, 1996, ARCH ENVIRON HEALTH, V51, P300; Azoulay A, 2001, J GEN INTERN MED, V16, P68; Balbus JM, 2001, PEDIATR CLIN N AM, V48, P1129, DOI 10.1016/S0031-3955(05)70365-5; Calabrase DM, 1997, BETTER NUTR, V59, P46; Crittenden J.C., 2005, WATER TREATMENT PRIN; Dharmagunawardhane HA, 1993, ENV MANAGEMENT HLTH, V4, P9, DOI DOI 10.1108/09566169310033422; Dissanayake C. B., 1991, International Journal of Environmental Studies, V38, P137, DOI 10.1080/00207239108710658; DISSANAYAKE CB, 1984, CHEM GEOL, V47, P221, DOI 10.1016/0009-2541(84)90127-X; Dissanayake CB, 1999, EARTH-SCI REV, V47, P219, DOI 10.1016/S0012-8252(99)00033-1; EPA, 2009, 816F09004 EPA; Food control administration unit (FCAU), 2013, LIST BOTTL WAT MAN T; Gulson BL, 1997, SCI TOTAL ENVIRON, V196, P205, DOI 10.1016/S0048-9697(96)05401-0; Herath AT, 2012, J FOOD SCI, V77, P160; Kuo HW, 1997, B ENVIRON CONTAM TOX, V59, P708; Matthess G, 1994, LEHRBUCH HYDROGEOLOG, V2, P499; Misund A, 1999, SCI TOTAL ENVIRON, V243, P21, DOI 10.1016/S0048-9697(99)00307-1; Ozturk N, 2000, WATER RES, V34, P704, DOI 10.1016/S0043-1354(99)00168-2; Panabokke CR, 2005, WATER RESOURCES BOAR, P3; Parslow RC, 1997, DIABETOLOGIA, V40, P550, DOI 10.1007/s001250050714; Peh Z, 2010, J GEOCHEM EXPLOR, V107, P227, DOI 10.1016/j.gexplo.2010.02.002; Pip E, 2000, ENVIRON HEALTH PERSP, V108, P863, DOI 10.2307/3434994; Piper AM, 1953, GRAPHIC PROCEDURE GE, P12; Robles E, 1999, WATER AIR SOIL POLL, V113, P217, DOI 10.1023/A:1005088011681; Ross AC, 2011, DRI DIETARY REFERENC, P1103; Sri Lanka Standard Institute (SLS), 1983, 6142013 SLS; Stiff HAJR, 1951, J PETROL TECH, V3, P15; Vander Aa NGFM, 2003, ENVIRON GEOL, V44, P554; WARBURTON DW, 1993, CAN J MICROBIOL, V39, P158; WHO, 2008, GUID DRINK WAT QUAL, V1, P666; WHO, 2012, CONS DEV STRAT WAT Q; WHO, 2011, GUID DRINK WAT QUAL, V4th, p[177, 227, 412, 423]; Zielinski O, 2011, J SEA RES, V65, P456, DOI 10.1016/j.seares.2011.04.002	38	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1866-6280	1866-6299		ENVIRON EARTH SCI	Environ. Earth Sci.	JUN	2015	73	12					7957	7965		10.1007/s12665-014-3955-5		9	Environmental Sciences; Geosciences, Multidisciplinary; Water Resources	Environmental Sciences & Ecology; Geology; Water Resources	CJ0DG	WOS:000355142800027		
J	Udagedara, DT; Jayawardana, DT; Pelpitiya, SK				Udagedara, D. T.; Jayawardana, D. T.; Pelpitiya, S. K.			Assessment of chemical variability of major bottled waters in Sri Lanka (vol 73, pg 7957, 2015)	ENVIRONMENTAL EARTH SCIENCES			English	Correction									[Udagedara, D. T.; Pelpitiya, S. K.] Uva Wellassa Univ, Badulla 90000, Sri Lanka; [Udagedara, D. T.] Saitama Univ, Geosphere Res Inst, Dept Civil & Environm Engn, Saitama 3388570, Japan; [Jayawardana, D. T.] Univ Sri Jayewardenepura, Fac Sci Appl, Dept Forestry & Environm Sci, Nugegoda, Sri Lanka	Jayawardana, DT (reprint author), Univ Sri Jayewardenepura, Fac Sci Appl, Dept Forestry & Environm Sci, Nugegoda, Sri Lanka.	tharangau@yahoo.com; daham@sci.sjp.ac.lk; sandamrt@gmail.com					Udagedara DT, 2015, ENVIRON EARTH SCI, V73, P7957, DOI 10.1007/s12665-014-3955-5	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1866-6280	1866-6299		ENVIRON EARTH SCI	Environ. Earth Sci.	JUN	2015	73	12					7967	7967		10.1007/s12665-015-4030-6		1	Environmental Sciences; Geosciences, Multidisciplinary; Water Resources	Environmental Sciences & Ecology; Geology; Water Resources	CJ0DG	WOS:000355142800028		
J	Zhang, B; Song, XF; Zhang, YH; Han, DM; Tang, CY; Yang, LH; Wang, ZL				Zhang, Bing; Song, Xianfang; Zhang, Yinghua; Han, Dongmei; Tang, Changyuan; Yang, Lihu; Wang, Zhong-Liang			The relationship between and evolution of surface water and groundwater in Songnen Plain, Northeast China	ENVIRONMENTAL EARTH SCIENCES			English	Article						Surface water and groundwater; Hydrochemical evolution; Stable isotopes; Water management; Songnen Plain	CHEMISTRY; ISOTOPES; AQUIFER; QUALITY; BASIN	To improve water management, the relation and the hydrochemical evolution of surface water and groundwater were studied in the Songnen Plain. The surface water and groundwater samples were evaluated for stable isotopes and hydrochemistry analyses. The stable isotopic compositions (delta O-18, delta D) indicate the groundwater recharges from the precipitation. However, the connectivity between surface water and groundwater is weak, because of the clay layer and the interrupted aquifer. The water evolution is from Ca-Mg-HCO3 to Na-HCO3 by the evaporation, water-rock interaction, and ion exchange processes. The water evaporation and leaching of saline-alkaline soil are the main reasons for water salinity. Further, the leaching of salts in the soil during recharging from backwater and irrigation water intensifies the salinization. The relationship between and evolution of surface water and groundwater provide important guidance for water management not only in the arid and semi-arid area, but also in the soda saline-alkali soil regions of the world.	[Zhang, Bing; Wang, Zhong-Liang] Tianjin Normal Univ, Tianjin Key Lab Water Resources & Environm, Tianjin 300387, Peoples R China; [Zhang, Bing; Song, Xianfang; Zhang, Yinghua; Han, Dongmei; Yang, Lihu] Chinese Acad Sci, Key Lab Water Cycle & Related Land Surface Proc, Inst Geog Sci & Nat Resources Res, Beijing 100101, Peoples R China; [Tang, Changyuan] Chiba Univ, Dept Environm Sci, Fac Hort, Chiba 2718510, Japan; [Tang, Changyuan] Chiba Univ, Dept Landscape Architecture, Fac Hort, Chiba 2718510, Japan	Song, XF (reprint author), Chinese Acad Sci, Key Lab Water Cycle & Related Land Surface Proc, Inst Geog Sci & Nat Resources Res, Beijing 100101, Peoples R China.	bzhangchina@gmail.com; songxf@igsnrr.ac.cn	zhang, bing/C-1476-2010	zhang, bing/0000-0003-3904-3107	Main Direction Program of Knowledge Innovation of the Chinese Academy of Sciences [KZCX2-YW-Q06-1]; National Natural Science Foundation of China [40830636]; Innovation Team Training Plan of the Tianjin Education Committee [TD12-5037]; Doctoral Found of Tianjin Normal University [52XB1401]	This research was supported by the Main Direction Program of Knowledge Innovation of the Chinese Academy of Sciences (No. KZCX2-YW-Q06-1), the Key Program of National Natural Science Foundation of China (No. 40830636), the Innovation Team Training Plan of the Tianjin Education Committee (TD12-5037) and the Doctoral Found of Tianjin Normal University (52XB1401). We sincerely thank the editor and anonymous reviewers for comments that greatly improved this paper.	Edmunds WM, 2003, APPL GEOCHEM, V18, P805, DOI 10.1016/S0883-2927(02)00189-0; Woessner WW, 2000, GROUND WATER, V38, P423, DOI 10.1111/j.1745-6584.2000.tb00228.x; EDMUNDS WM, 1982, GEOCHIM COSMOCHIM AC, V46, P2069, DOI 10.1016/0016-7037(82)90186-7; Sophocleous M, 2002, HYDROGEOL J, V10, P52, DOI 10.1007/s10040-001-0170-8; Liu SH, 2011, AGR WATER MANAGE, V98, P1469, DOI 10.1016/j.agwat.2011.04.016; GIBBS RJ, 1970, SCIENCE, V170, P1088, DOI 10.1126/science.170.3962.1088; Zhu BQ, 2007, CHINESE SCI BULL, V52, P2123, DOI 10.1007/s11434-007-0298-6; Ayenew T, 2008, HYDROL PROCESS, V22, P1548, DOI 10.1002/hyp.6716; Zhang GX, 2007, HYDROL PROCESS, V21, P1055, DOI 10.1002/hyp.6286; Anderson EI, 2005, ADV WATER RESOUR, V28, P315, DOI 10.1016/j.advwatres.2004.11.007; Zhang B, 2012, WATER RES, V46, P2737, DOI 10.1016/j.watres.2012.02.033; Banks EW, 2011, J HYDROL, V404, P30, DOI 10.1016/j.jhydrol.2011.04.017; Baskaran S, 2009, AUST J EARTH SCI, V56, P13, DOI 10.1080/08120090802541887; Bruce JP, 2011, PROTECTING GROUNDWAT, V136; Chen Z, 2010, HYDROGEOL J, V19, P163, DOI 10.1007/s10040-010-0650-9; Heilongjiang land reclamation bureau, 2009, STAT YB HEIL RECL AR; Li B, 2001, ACTA GEOGRAPHICA SIN, V56, P307; Liu JR, 2010, CHINESE SCI BULL, V55, P200, DOI 10.1007/s11434-009-0202-7; Wang HX, 2004, CHINESE GEOGR SCI, V14, P179, DOI 10.1007/s11769-004-0028-9; Wang L, 2009, PADDY WATER ENVIRON, V7, P259, DOI 10.1007/s10333-009-0166-x; Winter T. C., 1998, GROUND WATER SURFACE; Xiao CL, 2009, ADVANCES IN WATER RESOURCES AND HYDRAULIC ENGINEERING, VOLS 1-6, P214, DOI 10.1007/978-3-540-89465-0_40; Yuan L, 2006, GEOL RESOUR, V15, P122; Yuan L, 2006, GEOLOGY RESOURCES, V15, P132; Zhang B, 2014, ENVIRON EARTH SCI, V72, P3901, DOI 10.1007/s12665-014-3279-5; Zhang DF, 2001, ENVIRON GEOL, V40, P1362; Zhang J, 1991, HEILONGJIANG SCI TEC, V4, P1; [赵海卿 ZHAO Haiqing], 2010, [干旱区资源与环境, Journal of Arid Land Resources and Environment], V24, P126	28	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1866-6280	1866-6299		ENVIRON EARTH SCI	Environ. Earth Sci.	JUN	2015	73	12					8333	8343		10.1007/s12665-014-3995-x		11	Environmental Sciences; Geosciences, Multidisciplinary; Water Resources	Environmental Sciences & Ecology; Geology; Water Resources	CJ0DG	WOS:000355142800056		
J	Mouri, G				Mouri, Goro			Assessment of land cover relocation incorporating the effects of human activity in typical urban and rural catchments for the design of management policies	ENVIRONMENTAL SCIENCE & POLICY			English	Article						Compresence; Environmental context; Human activity; Land cover; Rehabilitation	WASTE-WATER TREATMENT; ECOSYSTEM SERVICES; FOREST RESTORATION; STREAM WATER; RICE PADDY; QUALITY; URBANIZATION; MODEL; IMPACT; CHINA	Densification due to the extreme increase in the population of urban and rural regions following rapid economic growth has occurred in many areas of the world. The pollution load in catchments affected by this increased population density far exceeds the self-purifying ability of the catchments. Land use changes in such river basins have affected the hydrological environment, as seen in diminished water quality not only in rivers but also in groundwater and springs, resulting in a decline in the available water resources. In particular, river water, which has different characteristics in urban and rural regions, must be considered, as the increased environmental impacts of changes in land use and human activities can create problems for society. Thus, following the adoption. of a land use regulation system based on land use planning, the balance between the importance of conservation and the impact of human activities such as industrial production, agricultural production, and human waste is an important issue. In this study, using a catchment simulator model, we assessed the effectiveness of environmental management practices that incorporated the effects of alterations in land use, which were determined quantitatively from a catchment management perspective to solve environmental improvement problems based on land use and human activities in Tokyo (urban) and Hokkaido (rural). The results of this study are of use to stakeholders with an interest in the maintenance of social capital with an advanced urban function in the development of rural areas. (C) 2015 Elsevier Ltd. All rights reserved.	Univ Tokyo, Earth Observat Data Integrat & Fus Res Initiat ED, Meguro Ku, Tokyo 1538505, Japan	Mouri, G (reprint author), Univ Tokyo, Earth Observat Data Integrat & Fus Res Initiat ED, Meguro Ku, Be505,4-6-1 Komaba, Tokyo 1538505, Japan.	mouri@rainbow.iis.u-tokyo.ac.jp			New Energy and Industrial Technology Development Organization (NEDO); Data Integration and Analysis System (DIAS) of the Earth Observation Data Integration & Fusion Research Initiative (EDITORIA), Japan; Environmental Research and Technology Development Fund of the Ministry of the Environment, Japan [S-8]; Green Network of Excellence (GRENE); Sumitomo Foundation; Foundation of River and Watershed Environment Management; Ministry of Education, Japan [24560616]; Core Research for Evolutional Science and Technology (CREST), Japan	This study was supported by funding from the New Energy and Industrial Technology Development Organization (NEDO) and the Data Integration and Analysis System (DIAS) of the Earth Observation Data Integration & Fusion Research Initiative (EDITORIA), Japan; the Environmental Research and Technology Development Fund (S-8) of the Ministry of the Environment, Japan; the Green Network of Excellence (GRENE), the Sumitomo Foundation, the Foundation of River and Watershed Environment Management, Grants-in-Aid for Scientific Research (24560616) from the Ministry of Education, Japan; and the Core Research for Evolutional Science and Technology (CREST), Japan. The dataset used in this work was provided by the Ministry of the city of Hachioji and the city of Kuromatsunai, and the authors are grateful for their support. The author benefited from discussions with several colleagues in the course of preparing the draft for this paper. Special thanks go to Kazuo Oki for his helpful input. We are also grateful to two anonymous reviewers and the editors of Environmental Science & Policy, whose comments greatly improved the quality of this manuscript.	Abler D, 2002, CLIMATIC CHANGE, V55, P339, DOI 10.1023/A:1020570526499; Albiac J, 2009, SCIENCE, V326, P665, DOI 10.1126/science.326_665b; Zakkak S, 2014, J NAT CONSERV, V22, P157, DOI 10.1016/j.jnc.2013.11.001; Davis HT, 2014, SCI TOTAL ENVIRON, V490, P1051, DOI 10.1016/j.scitotenv.2014.05.076; Hobbs RJ, 2011, BIOSCIENCE, V61, P442, DOI 10.1525/bio.2011.61.6.6; Grimm NB, 2008, SCIENCE, V319, P756, DOI 10.1126/science.1150195; Schulte RPO, 2014, ENVIRON SCI POLICY, V38, P45, DOI 10.1016/j.envsci.2013.10.002; Butchart SHM, 2010, SCIENCE, V328, P1164, DOI 10.1126/science.1187512; Galloway JN, 2003, BIOSCIENCE, V53, P341, DOI 10.1641/0006-3568(2003)053[0341:TNC]2.0.CO;2; Munteanu C, 2014, LAND USE POLICY, V38, P685, DOI 10.1016/j.landusepol.2014.01.012; Long HL, 2014, HABITAT INT, V44, P536, DOI 10.1016/j.habitatint.2014.10.011; Stanturf JA, 2014, FOREST ECOL MANAG, V331, P292, DOI 10.1016/j.foreco.2014.07.029; Palmer MA, 2014, ECOL ENG, V65, P62, DOI 10.1016/j.ecoleng.2013.07.059; Seabrook L, 2011, LANDSCAPE URBAN PLAN, V100, P407, DOI 10.1016/j.landurbplan.2011.02.015; Mouri G, 2012, ENVIRON MODELL SOFTW, V32, P16, DOI 10.1016/j.envsoft.2011.11.018; Tisa F, 2014, J ENVIRON MANAGE, V146, P260, DOI 10.1016/j.jenvman.2014.07.032; Ciccarese L, 2012, NEW FOREST, V43, P543, DOI 10.1007/s11056-012-9350-8; Blevins ZW, 2013, ECOL INDIC, V24, P224, DOI 10.1016/j.ecolind.2012.06.016; Baral H, 2013, ECOL COMPLEX, V13, P35, DOI 10.1016/j.ecocom.2012.11.001; Sui DZ, 2001, LANDSCAPE URBAN PLAN, V53, P37, DOI 10.1016/S0169-2046(00)00136-5; Rouillard JJ, 2014, LAND USE POLICY, V38, P637, DOI 10.1016/j.landusepol.2014.01.011; LIKENS GE, 1970, ECOL MONOGR, V40, P23, DOI 10.2307/1942440; Soranno PA, 1996, ECOL APPL, V6, P865, DOI 10.2307/2269490; Carpenter SR, 2006, SCIENCE, V314, P257, DOI 10.1126/science.1131946; Mu SJ, 2013, GLOBAL PLANET CHANGE, V108, P29, DOI 10.1016/j.gloplacha.2013.06.007; Sankaran K, 2014, RENEW SUST ENERG REV, V37, P634, DOI 10.1016/j.rser.2014.05.062; Oguchi T, 2001, GEOMORPHOLOGY, V39, P3, DOI 10.1016/S0169-555X(01)00048-4; Shrestha S, 2008, ENVIRON MODELL SOFTW, V23, P182, DOI 10.1016/j.envsoft.2007.05.006; Macleod CJA, 2007, SCI TOTAL ENVIRON, V373, P591, DOI 10.1016/j.scitotenv.2006.12.029; Sadorsky P, 2014, ENERG ECON, V41, P147, DOI 10.1016/j.eneco.2013.11.007; Sarkis J, 2012, J CLEAN PROD, V31, P40, DOI 10.1016/j.jclepro.2012.02.029; Wang H, 2014, ECOL ENG, V70, P206, DOI 10.1016/j.ecoleng.2014.05.027; Thorpe AS, 2011, J APPL ECOL, V48, P275, DOI 10.1111/j.1365-2664.2011.01972.x; Wania F, 1999, ENVIRON POLLUT, V100, P223, DOI 10.1016/S0269-7491(99)00093-7; Bardsley DK, 2010, ENVIRON MANAGE, V45, P1127, DOI 10.1007/s00267-010-9487-1; Beck M.B., 1973, THESIS U CAMBRIDGE; BECK MB, 1975, WATER RES, V9, P769, DOI 10.1016/0043-1354(75)90028-7; BECK MB, 1987, WATER RESOUR RES, V23, P2030, DOI 10.1029/WR023i011p02030; Chereni A, 2007, PHYS CHEM EARTH, V32, P1246, DOI 10.1016/j.pce.2007.07.024; Clarke T, 2002, NATURE, V418, P812, DOI 10.1038/418812a; Clewell AF, 2006, CONSERV BIOL, V20, P420, DOI 10.1111/j.1523-1739.2006.00340.x; El-Fadel M., 2001, WATER POLICY, V3, P425, DOI 10.1016/S1366-7017(01)00079-4; Elgin C, 2013, STRUCT CHANGE ECON D, V27, P36, DOI 10.1016/j.strueco.2013.06.003; Gabriel SA, 2013, REG SCI URBAN ECON, V43, P42, DOI 10.1016/j.regsciurbeco.2012.11.006; Godfray, 2010, SCIENCE, V327, P812, DOI DOI 10.1126/SCIENCE.1185383; Han LJ, 2014, ENVIRON POLLUT, V194, P163, DOI 10.1016/j.envpol.2014.07.022; Haruyama S., 1990, B SCI ENG RES LAB, V130, P50; Kukkonen M., 2014, TANZANIA APPL GEOGR, V55, P193; Lackey RT, 2001, BIOSCIENCE, V51, P437, DOI 10.1641/0006-3568(2001)051[0437:VPAEH]2.0.CO;2; Lewin I, 2014, LIMNOLOGICA, V49, P42, DOI 10.1016/j.limno.2014.09.001; Lo F., 1996, EMERGING WORLD CITIE; Lu HF, 2009, J ENVIRON MANAGE, V90, P2589, DOI 10.1016/j.jenvman.2009.01.019; Lucia C.D., 2015, GASIFICATION SYNTHET, Vfirst, P73; Mancosu E., 2014, ENV SCI POLICY; Matthews TG, 2006, ESTUAR COAST SHELF S, V66, P13, DOI 10.1016/j.ecss.2005.07.019; McGee Terry G., 1995, MEGA URBAN REGIONS S, P3; MCGEE TG, 1991, EXTENDED METROPOLIS, P3; Meybeck M., 1989, GLOBAL FRESHWATER QU; Mouri G., 2014, INT J SUSTAINABLE BU, V3, P47; Mouri G, 2011, J ENVIRON MANAGE, V92, P1837, DOI 10.1016/j.jenvman.2011.03.005; Mouri G, 2010, WATER SCI TECHNOL, V62, P1837, DOI 10.2166/wst.2010.208; Mouri G., 2013, SUSTAIN CITIES SOC C, V9, P23; Mouri G, 2010, WATER SCI TECHNOL, V62, P972, DOI 10.2166/wst.2010.373; Mouri G, 2010, ECOL MODEL, V221, P2808, DOI 10.1016/j.ecolmodel.2010.08.029; Mouri G, 2013, ECOL COMPLEX, V15, P83, DOI 10.1016/j.ecocom.2013.04.001; Mouri G, 2011, ATMOS RES, V101, P164, DOI 10.1016/j.atmosres.2011.02.002; Nastar M, 2014, CITIES, V41, P1, DOI 10.1016/j.cities.2014.04.007; Ojala E, 2002, LANDSCAPE URBAN PLAN, V61, P83, DOI 10.1016/S0169-2046(02)00104-4; Qianyi W., 2014, CITIES, V40, P70; Reda A., 1996, THESIS IMPERIAL COLL; Shen LY, 2014, HABITAT INT, V44, P111, DOI 10.1016/j.habitatint.2014.05.009; Shi Y., 2014, SHENGTAI XUEBAO ACTA, V34, P4943; Sonneveld MPW, 2003, ENVIRON SCI POLICY, V6, P501, DOI 10.1016/j.envsci.2003.08.005; Stanturf JA, 2005, IN ST WA MA, V3, P3; Statistics of Agriculture Forestry and Fisheries (SAFF), 2008, STAT AGR; The State of the World Population (SWP), 2011, INT DAT BAS WORLD PO; Thomann R. V., 1963, J SANIT ENG DIV AM S, V89, P1; United Nations, 2002, WORLD URB PROSP 2001; Wang WJ, 2014, ENVIRON SCI POLICY, V44, P62, DOI 10.1016/j.envsci.2014.07.004; WHITEHEAD PG, 1979, J HYDROL, V40, P1, DOI 10.1016/0022-1694(79)90084-2; Wu RS, 2001, MATH COMPUT MODEL, V33, P649, DOI 10.1016/S0895-7177(00)00269-7; YOUNG PC, 1992, J INST WATER ENV MAN, V6, P598	82	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1462-9011	1873-6416		ENVIRON SCI POLICY	Environ. Sci. Policy	JUN	2015	50						74	87		10.1016/j.envsci.2015.02.004		14	Environmental Sciences	Environmental Sciences & Ecology	CI8QA	WOS:000355035600007		
J	Kessler, RC; Sampson, NA; Berglund, P; Gruber, MJ; Al-Hamzawi, A; Andrade, L; Bunting, B; Demyttenaere, K; Florescu, S; de Girolamo, G; Gureje, O; He, Y; Hu, C; Huang, Y; Karam, E; Kovess-Masfety, V; Lee, S; Levinson, D; Mora, MEM; Moskalewicz, J; Nakamura, Y; Navarro-Mateu, F; Browne, MAO; Piazza, M; Posada-Villa, J; Slade, T; ten Have, M; Torres, Y; Vilagut, G; Xavier, M; Zarkov, Z; Shahly, V; Wilcox, MA				Kessler, R. C.; Sampson, N. A.; Berglund, P.; Gruber, M. J.; Al-Hamzawi, A.; Andrade, L.; Bunting, B.; Demyttenaere, K.; Florescu, S.; de Girolamo, G.; Gureje, O.; He, Y.; Hu, C.; Huang, Y.; Karam, E.; Kovess-Masfety, V.; Lee, S.; Levinson, D.; Medina Mora, M. E.; Moskalewicz, J.; Nakamura, Y.; Navarro-Mateu, F.; Browne, M. A. Oakley; Piazza, M.; Posada-Villa, J.; Slade, T.; ten Have, M.; Torres, Y.; Vilagut, G.; Xavier, M.; Zarkov, Z.; Shahly, V.; Wilcox, M. A.			Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys	EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES			English	Article						Anxious depression; comorbidity; epidemiology	GENERALIZED ANXIETY DISORDER; COGNITIVE-BEHAVIORAL THERAPY; SUBSTANCE USE DISORDERS; CO-MORBIDITY; LONGITUDINAL COMMUNITY; SERVICES UTILIZATION; LIFETIME PREVALENCE; PHYSICAL DISORDERS; PANIC DISORDER; PRIMARY-CARE	Background. To examine cross-national patterns and correlates of lifetime and 12-month comorbid DSM-IV anxiety disorders among people with lifetime and 12-month DSM-IV major depressive disorder (MDD). Method. Nationally or regionally representative epidemiological interviews were administered to 74045 adults in 27 surveys across 24 countries in the WHO World Mental Health (WMH) Surveys. DSM-IV MDD, a wide range of comorbid DSM-IV anxiety disorders, and a number of correlates were assessed with the WHO Composite International Diagnostic Interview (CIDI). Results. 45.7% of respondents with lifetime MDD (32.0-46.5% inter-quartile range (IQR) across surveys) had one of more lifetime anxiety disorders. A slightly higher proportion of respondents with 12-month MDD had lifetime anxiety disorders (51.7%, 37.8-54.0% IQR) and only slightly lower proportions of respondents with 12-month MDD had 12-month anxiety disorders (41.6%, 29.9-47.2% IQR). Two-thirds (68%) of respondents with lifetime comorbid anxiety disorders and MDD reported an earlier age-of-onset (AOO) of their first anxiety disorder than their MDD, while 13.5% reported an earlier AOO of MDD and the remaining 18.5% reported the same AOO of both disorders. Women and previously married people had consistently elevated rates of lifetime and 12-month MDD as well as comorbid anxiety disorders. Consistently higher proportions of respondents with 12-month anxious than non-anxious MDD reported severe role impairment (64.4 v. 46.0%; chi(2)(1)=187.0, p<0.001) and suicide ideation (19.5 v. 8.9%;chi(2)(1)=71.6, p<0.001). Significantly more respondents with 12-month anxious than non-anxious MDD received treatment for their depression in the 12 months before interview, but this difference was more pronounced in high-income countries (68.8 v. 45.4%; chi(2)(1)=108.8, p<0.001) than low/middle-income countries (30.3 v. 20.6%; chi(2)(1)=11.7, p<0.001). Conclusions. Patterns and correlates of comorbid DSM-IV anxiety disorders among people with DSM-IV MDD are similar across WMH countries. The narrow IQR of the proportion of respondents with temporally prior AOO of anxiety disorders than comorbid MDD (69.6-74.7%) is especially noteworthy. However, the fact that these proportions are not higher among respondents with 12-month than lifetime comorbidity means that temporal priority between lifetime anxiety disorders and MDD is not related to MDD persistence among people with anxious MDD. This, in turn, raises complex questions about the relative importance of temporally primary anxiety disorders as risk markers v. causal risk factors for subsequent MDD onset and persistence, including the possibility that anxiety disorders might primarily be risk markers for MDD onset and causal risk factors for MDD persistence.	[Kessler, R. C.; Sampson, N. A.; Gruber, M. J.; Shahly, V.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Berglund, P.] Univ Michigan, Inst Social Res, Ann Arbor, MI USA; [Al-Hamzawi, A.] Al Qadisiya Univ, Coll Med, Diwania Governorate, Iraq; [Andrade, L.] Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil; [Bunting, B.] Univ Ulster, Sch Psychol, Londonberry, Ireland; [Demyttenaere, K.] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Psychiat, Leuven, Belgium; [Florescu, S.] Natl Sch Publ Hlth Management & Profess Dev, Bucharest, Romania; [de Girolamo, G.] IRCCS St John God Clin Res Ctr, Unit Epidemiol & Evaluat Psychiat, Brescia, Italy; [Gureje, O.] Univ Ibadan, Dept Psychiat, Ctr Res & Training Mental Hlth Neurosci Drug & Al, Ibadan, Nigeria; [He, Y.] Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Sch Med, Shanghai 200030, Peoples R China; [Hu, C.] Shenzhen Inst Mental Hlth, Shenzhen, Guangdong, Peoples R China; [Hu, C.] Shenzhen Kanging Hosp, Shenzhen, Guangdong, Peoples R China; [Huang, Y.] Peking Univ, Inst Mental Hlth, Beijing 100871, Peoples R China; [Karam, E.] Balamand Univ, Fac Med, Dept Psychiat & Clin Psychol, Beirut, Lebanon; [Karam, E.] St George Hosp Univ, Med Ctr, Dept Psychiat & Clin Psychol, Beirut, Lebanon; [Karam, E.] IDRAAC, Beirut, Lebanon; [Kovess-Masfety, V.] Paris Descartes Univ, EHESP, EA 4057, Paris, France; [Lee, S.] Chinese Univ Hong Kong, Dept Psychiat, Shatin, Hong Kong, Peoples R China; [Levinson, D.] Minist Hlth Israel, Mental Hlth Serv, Jerusalem, Israel; [Medina Mora, M. E.] Ramond e Fuente Muniz Natl Inst Psychiat, Mexico City, DF, Mexico; [Moskalewicz, J.] Inst Psychiat & Neurol, Warsaw, Poland; [Nakamura, Y.] Jichi Med Univ, Dept Publ Hlth, Shimotsuke, Tochigi, Japan; [Navarro-Mateu, F.] CIBERESP Nodo, IMIB Arrixaca, Serv Murciano Salud, UDIF SM, Murcia, Spain; [Browne, M. A. Oakley] Univ Tasmania, Sch Med, Dept Psychiat, Hobart, Tas 7001, Australia; [Piazza, M.] Natl Inst Hlth, Lima, Peru; [Posada-Villa, J.] Univ Colegio Mayor Cundinamarca, Bogota, Colombia; [Slade, T.] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia; [ten Have, M.] Netherlands Inst Mental Hlth & Addict, Utrecht, Netherlands; [Torres, Y.] CES Univ, Ctr Excellence Res Mental Hlth, Medellin, Colombia; [Vilagut, G.] IMIM Inst Hosp Mar Invest Med, Hlth Serv Res Unit, Edifici PRBB, Barcelona 08003, Spain; [Xavier, M.] Univ Nova Lisboa, Dept Mental Hlth CEDOC, P-1200 Lisbon, Portugal; [Xavier, M.] Univ Nova Lisboa, Fac Ciencias Med, P-1200 Lisbon, Portugal; [Zarkov, Z.] NCPHA, Dept Mental Hlth, Sofia, Bulgaria; [Wilcox, M. A.] Janssen Pharmaceut Res & Dev, Titusville, NJ USA	Kessler, RC (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	kessler@hcp.med.harvard.edu	Lee, Sing/O-2136-2015		United States National Institute of Mental Health [R01MH070884]; John D. and Catherine T. MacArthur Foundation; Pfizer Foundation; US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]; Fogarty International Center [FIRCA R03-TW006481]; Pan American Health Organization; Eli Lilly & Company Foundation; Ortho-McNeil Pharmaceutical, Inc.; GlaxoSmithKline; Bristol-Myers Squibb and Shire; State of Sao Paulo Research Foundation (FAPESP) Thematic Project Grant [03/00204-3]; Ministry of Health; National Center for Public Health Protection; Shenzhen Bureau of Health; Shenzhen Bureau of Science, Technology, and Information; Ministry of Social Protection; European Commission [QLG5-1999-01042, SANCO 2004123]; Piedmont Region (Italy), Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain [FIS 00/0028]; Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]; Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]; WHO (India); Iraqi IMHS team; Japanese and European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF); Israel National Institute for Health Policy and Health Services Research; National Insurance Institute of Israel; Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14TOKUBETSU-026, H16-KOKORO-013]; Lebanese Ministry of Public Health; WHO (Lebanon); Fogarty International; Act for Lebanon; anonymous private donations to IDRAAC; Janssen Cilag; Eli Lilly; Roche; Novartis; National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]; National Council on Science and Technology [CONACyT-G30544-H]; PanAmerican Health Organization (PAHO); New Zealand Ministry of Health; Alcohol Advisory Council; Health Research Council; WHO (Geneva); WHO (Nigeria); Federal Ministry of Health, Abuja, Nigeria; Ministry of Public Health (former Ministry of Health); EAA/Norwegian Financial Mechanisms as well as by the Polish Ministry of Health; US National Institute of Mental Health [R01MH059575]; South African Department of Health; University of Michigan; National Institute of Mental Health (NIMH) [U01-MH60220]; National Institute of Drug Abuse (NIDA); Substance Abuse and Mental Health Services Administration (SAMHSA); Robert Wood Johnson Foundation (RWJF) [044708]; John W. Alden Trust	The WMH surveys were supported by the United States National Institute of Mental Health (R01MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13-MH066849, R01-MH069864 and R01 DA016558), the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health Organization, the Eli Lilly & Company Foundation, Ortho-McNeil Pharmaceutical, Inc., GlaxoSmithKline, Bristol-Myers Squibb and Shire. The Sao Paulo Megacity Mental Health Survey is supported by the State of Sao Paulo Research Foundation (FAPESP) Thematic Project Grant 03/00204-3. The Bulgarian Epidemiological Study of common mental disorders EPIBUL is supported by the Ministry of Health and the National Center for Public Health Protection. The Chinese World Mental Health Survey Initiative is supported by the Pfizer Foundation. The Shenzhen Mental Health Survey is supported by the Shenzhen Bureau of Health and the Shenzhen Bureau of Science, Technology, and Information. The Colombian National Study of Mental Health (NSMH) is supported by the Ministry of Social Protection. The ESEMeD project is funded by the European Commission (Contracts QLG5-1999-01042; SANCO 2004123), the Piedmont Region (Italy), Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain (FIS 00/0028), Ministerio de Ciencia y Tecnologia, Spain (SAF 2000-158-CE), Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted educational grant from GlaxoSmithKline. The WMHI was funded by WHO (India) and helped by Dr R Chandrasekaran, JIPMER. Implementation of the Iraq Mental Health Survey (IMHS) and data entry were carried out by the staff of the Iraqi MOH and MOP with direct support from the Iraqi IMHS team with funding from both the Japanese and European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF). The Israel National Health Survey is funded by the Ministry of Health with support from the Israel National Institute for Health Policy and Health Services Research and the National Insurance Institute of Israel. The World Mental Health Japan (WMHJ) Survey is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14TOKUBETSU- 026, H16-KOKORO-013) from the Japan Ministry of Health, Labour and Welfare. The Lebanese National Mental Health Survey (LEBANON) is supported by the Lebanese Ministry of Public Health, the WHO (Lebanon), Fogarty International, Act for Lebanon, anonymous private donations to IDRAAC, Lebanon, and unrestricted grants from Janssen Cilag, Eli Lilly, GlaxoSmithKline, Roche, and Novartis. The Mexican National Comorbidity Survey (MNCS) is supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544-H), with supplemental support from the PanAmerican Health Organization (PAHO). Te Rau Hinengaro: The New Zealand Mental Health Survey (NZMHS) is supported by the New Zealand Ministry of Health, Alcohol Advisory Council and the Health Research Council. The Nigerian Survey of Mental Health and Wellbeing (NSMHW) is supported by the WHO (Geneva), the WHO (Nigeria), and the Federal Ministry of Health, Abuja, Nigeria.; The Romania WMH study projects 'Policies in Mental Health Area' and 'National Study regarding Mental Health and Services Use' were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health), with technical support of Metro Media Transilvania, the National Institute of Statistics-National Centre for Training in Statistics, SC. Cheyenne Services SRL, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with supplemental support of Eli Lilly Romania SRL. The EZOP - Poland (Epidemiology of Mental Disorders and Access to Care) survey was supported by the grant from the EAA/Norwegian Financial Mechanisms as well as by the Polish Ministry of Health). The South Africa Stress and Health Study (SASH) is supported by the US National Institute of Mental Health (R01MH059575) and National Institute of Drug Abuse with supplemental funding from the South African Department of Health and the University of Michigan. The US National Comorbidity Survey Replication (NCS-R) is supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust.	Andrade L, 2003, INT J METH PSYCH RES, V12, P3, DOI 10.1002/mpr.138; Leon AC, 1997, INT J PSYCHIAT MED, V27, P93; Garber J, 2010, CLIN PSYCHOL-SCI PR, V17, P293, DOI 10.1111/j.1468-2850.2010.01221.x; Leach LS, 2013, SOC PSYCH PSYCH EPID, V48, P417, DOI 10.1007/s00127-012-0559-9; Lamers F, 2011, J CLIN PSYCHIAT, V72, P341, DOI 10.4088/JCP.10m06176blu; Bittner A, 2004, J CLIN PSYCHIAT, V65, P618; Altemus M, 2014, FRONT NEUROENDOCRIN, V35, P320, DOI 10.1016/j.yfrne.2014.05.004; Klein DN, 2013, J ABNORM PSYCHOL, V122, P1, DOI 10.1037/a0029567; Hofmann SG, 2008, J CLIN PSYCHIAT, V69, P621; Moffitt TE, 2007, PSYCHOL MED, V37, P441, DOI 10.1017/S0033291706009640; Haro JM, 2006, INT J METH PSYCH RES, V15, P167, DOI 10.1002/mpr.196; Scott KM, 2010, PSYCHOL MED, V40, P1495, DOI 10.1017/S0033291709991942; Simon GE, 2002, PSYCHOL MED, V32, P585, DOI 10.1017/S0033291702005457; Parker G, 2010, INT REV PSYCHIATR, V22, P429, DOI 10.3109/09540261.2010.492391; Kessler RC, 2011, ARCH GEN PSYCHIAT, V68, P90, DOI 10.1001/archgenpsychiatry.2010.180; Moffitt TE, 2010, PSYCHOL MED, V40, P899, DOI 10.1017/S0033291709991036; McLean PD, 1998, J CONSULT CLIN PSYCH, V66, P240, DOI 10.1037/0022-006X.66.2.240; Merikangas KR, 2011, ARCH GEN PSYCHIAT, V68, P241, DOI 10.1001/archgenpsychiatry.2011.12; Hamdi NR, 2014, PSYCHOL MED, V44, P315, DOI 10.1017/S0033291713000627; Beesdo K, 2010, ARCH GEN PSYCHIAT, V67, P47, DOI 10.1001/archgenpsychiatry.2009.177; Mathew AR, 2011, PSYCHOL MED, V41, P2023, DOI 10.1017/S0033291711000407; Copeland WE, 2009, ARCH GEN PSYCHIAT, V66, P764, DOI 10.1001/archgenpsychiatry.2009.85; Rapee RM, 2013, J AM ACAD CHILD PSY, V52, P47, DOI 10.1016/j.jaac.2012.10.002; de Graaf R, 2013, J AFFECT DISORDERS, V149, P100, DOI 10.1016/j.jad.2013.01.009; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Kessler RC, 2001, PSYCHIAT CLIN N AM, V24, P19, DOI 10.1016/S0193-953X(05)70204-5; FINLAYJONES R, 1981, PSYCHOL MED, V11, P803; Jacobi F, 2004, PSYCHOL MED, V34, P597, DOI 10.1017/S0033291703001399; Takayanagi Y, 2014, JAMA PSYCHIAT, V71, P273, DOI 10.1001/jamapsychiatry.2013.3579; Wang PS, 2007, LANCET, V370, P841, DOI 10.1016/S0140-6736(07)61414-7; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Cummings CM, 2014, PSYCHOL BULL, V140, P816, DOI 10.1037/a0034733; Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P789, DOI 10.1001/archpsyc.60.8.789; Birnbaum HG, 2010, DEPRESS ANXIETY, V27, P78, DOI 10.1002/da.20580; Asselmann E, 2015, PSYCHOL MED, V45, P153, DOI 10.1017/S0033291714001160; Bernert S, 2009, PSYCHIAT RES, V168, P137, DOI 10.1016/j.psychres.2008.04.008; Cuijpers P, 2014, CLIN PSYCHOL REV, V34, P130, DOI 10.1016/j.cpr.2014.01.002; Fichter MM, 2010, ACTA PSYCHIAT SCAND, V122, P75, DOI 10.1111/j.1600-0447.2009.01512.x; First M. B., 2002, STRUCTURED CLIN INTE; Flannery-Schroeder EC, 2006, AM J PREV MED, V31, pS136, DOI 10.1016/j.amepre.2006.07.006; Goodwin R, 2001, AM J PSYCHIAT, V158, P1146, DOI 10.1176/appi.ajp.158.7.1146; Goodwin RD, 2002, AM J PSYCHIAT, V159, P1935, DOI 10.1176/appi.ajp.159.11.1935; Harkness J., 2008, The WHO world mental health surveys: global perspectives on the epidemiology of mental disorders, P91; Hayward C, 2000, J AM ACAD CHILD PSY, V39, P721, DOI 10.1097/00004583-200006000-00010; Heeringa S. G., 2008, The WHO world mental health surveys: global perspectives on the epidemiology of mental disorders, P14; Jakubovski E, 2014, J CLIN PSYCHIAT, V75, P738, DOI 10.4088/JCP.13m08727; Kelly JM, 2014, J CLIN PSYCHIAT; Kessler RC, 2011, CURR OPIN PSYCHIATR, V24, P307, DOI 10.1097/YCO.0b013e3283477b22; Kessler RC, 1995, TXB PSYCHIAT EPIDEMI, P18; Knauper B., 1999, INT J METH PSYCH RES, V8, P39, DOI DOI 10.1002/MPR.55; Li Y, 2014, PSYCHOL MED, V44, P3275, DOI 10.1017/S0033291714000749; Lin CH, 2014, PSYCHIAT RES, V220, P855, DOI 10.1016/j.psychres.2014.08.048; McDowell RD, 2014, PSYCHOL MED, V44, P707, DOI 10.1017/S0033291713001116; McLaughlin TP, 2006, J CLIN PSYCHIAT, V67, P1187; Mineka S, 2008, HDB DEPRESSION, P84; MURPHY JM, 1986, PSYCHOL MED, V16, P117; Ormel J, 2008, BRIT J PSYCHIAT, V192, P368, DOI 10.1192/bjp.bp.107.039107; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; Pennell B. E., 2008, The WHO world mental health surveys: global perspectives on the epidemiology of mental disorders, P33; Research Triangle Institute, 2002, SUDAAN PROF SOFTW SU; Roy-Byrne PP, 2000, BRIT J PSYCHIAT, V176, P229, DOI 10.1192/bjp.176.3.229; Saveanu R., 2014, J PSYCHIAT RES; Schrier AC, 2010, SOC PSYCH PSYCH EPID, V45, P941, DOI 10.1007/s00127-009-0135-0; Shippee ND, 2014, GEN HOSP PSYCHIAT, V36, P563, DOI 10.1016/j.genhosppsych.2014.06.014; Stiles-Shields C, 2014, DEPRESS ANXIETY, V31, P934, DOI 10.1002/da.22323; van Loo HM, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-156; Wolter KM, 1985, INTRO VARIANCE ESTIM; Woody S, 1999, J AFFECT DISORDERS, V53, P163, DOI 10.1016/S0165-0327(98)00117-7; World Bank, 2009, DAT STAT COUNTR GROU; Wu Zhiguo, 2014, Shanghai Arch Psychiatry, V26, P227, DOI 10.3969/j.issn.1002-0829.2014.04.006	70	1	1	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	2045-7960	2045-7979		EPIDEMIOL PSYCH SCI	Epidemiol. Psychiatr. Sci.	JUN	2015	24	3					210	226		10.1017/S2045796015000189		17	Psychiatry	Psychiatry	CJ1VU	WOS:000355273600006		
J	Fuse, S; Takahashi, R; Takahashi, T				Fuse, Shinichiro; Takahashi, Ryota; Takahashi, Takashi			Facile, One-Step Synthesis of 5-Substituted Thieno[3,4-c]pyrrole-4,6-dione by Palladium-Catalyzed Carbonylative Amidation	EUROPEAN JOURNAL OF ORGANIC CHEMISTRY			English	Article						Carbonylation; Multicomponent reactions; Heterocycles; Imides; Palladium	SENSITIZED SOLAR-CELLS; CARBONIC-ANHYDRASE INHIBITORS; MOLECULAR DESIGN PRINCIPLE; N-SUBSTITUTED PHTHALIMIDES; ORGANIC-DYES; PHOTOVOLTAIC PROPERTIES; COUPLING REACTIONS; VINYLIC HALIDES; CYCLIC IMIDES; N',N-BIS(2-HYDROXYETHYL)-PYROMELLITIMIDE UNIT	Described herein is a facile, one-step synthesis of 5-substituted thieno[3,4-c]pyrrole-4,6-diones (TPDs) by a palladium-catalyzed carbonylative amidation of commercially available dibromoaryl compounds under mild conditions. TPDs are important structural components for organic electronics. Our optimal conditions afforded the desired 5-n-octyl-TPD in a 63% yield in one step. This is a considerably improved process compared with the most conventional approach (5 steps in 12-22%) In addition, this method was applied to the syntheses of pyridinopyrroledione (PPD) and pyrroloisoindoletetraone (PIT), which also are important structural components for various functional materials and bioactive compounds. The developed synthetic approach would be a valuable aid to the materials and drug discovery process.	[Fuse, Shinichiro; Takahashi, Ryota] Tokyo Inst Technol, Dept Appl Chem, Meguro Ku, Tokyo 1528552, Japan; [Takahashi, Takashi] Yokohama Coll Pharm, Totsuka Ku, Yokohama, Kanagawa 2450066, Japan	Fuse, S (reprint author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268503, Japan.	sfuse@res.titech.ac.jp	Fuse, Shinichiro/B-9396-2015	Fuse, Shinichiro/0000-0002-6836-4180			Wen SP, 2012, J POLYM SCI POL CHEM, V50, P3758, DOI 10.1002/pola.26164; Abdel-Aziz AAM, 2007, EUR J MED CHEM, V42, P614, DOI 10.1016/j.ejmech.2006.12.003; Fuse S, 2010, CHEM-ASIAN J, V5, P2459, DOI 10.1002/asia.201000534; Kim BG, 2013, CHEM-EUR J, V19, P5220, DOI 10.1002/chem.201204343; Leong CF, 2013, DALTON T, V42, P9831, DOI 10.1039/c3dt00083d; Ouattara MP, 2013, MACROMOLECULES, V46, P6408, DOI 10.1021/ma401030m; Takahashi T, 2003, ANGEW CHEM INT EDIT, V42, P5230, DOI 10.1002/anie.20035229; Yuan MC, 2010, MACROMOLECULES, V43, P6936, DOI 10.1021/ma101523a; Zou YP, 2010, J AM CHEM SOC, V132, P5330, DOI 10.1021/ja101888b; Cao H, 2010, ORG LETT, V12, P4126, DOI 10.1021/ol101714p; Khedkar MV, 2011, ADV SYNTH CATAL, V353, P3415, DOI 10.1002/adsc.201100460; Chen JB, 2014, ORG BIOMOL CHEM, V12, P5578, DOI 10.1039/c4ob00796d; Chen GY, 2011, CHEM COMMUN, V47, P5064, DOI 10.1039/c1cc10585j; Mishra A, 2009, ANGEW CHEM INT EDIT, V48, P2474, DOI 10.1002/anie.200804709; WILHELM E, 1973, CHEM REV, V73, P1, DOI 10.1021/cr60281a001; Kim BG, 2013, NAT MATER, V12, P659, DOI [10.1038/nmat3595, 10.1038/NMAT3595]; Piliego C, 2010, J AM CHEM SOC, V132, P7595, DOI 10.1021/ja103275u; Scozzafava A, 1999, J MED CHEM, V42, P2641, DOI 10.1021/jm9900523; Deb PK, 2012, MOL DIVERS, V16, P803, DOI 10.1007/s11030-012-9394-x; Guo XG, 2011, MACROMOLECULES, V44, P269, DOI 10.1021/ma101878w; Warnan J, 2014, CHEM MATER, V26, P2299, DOI 10.1021/cm500172w; Nielsen CB, 2004, ORG LETT, V6, P3381, DOI 10.1021/ol048659n; Li GB, 2012, DALTON T, V41, P4626, DOI 10.1039/c2dt11815g; Paige M, 2014, BIOORGAN MED CHEM, V22, P478, DOI 10.1016/j.bmc.2013.11.003; Fuse S, 2014, EUR J MED CHEM, V85, P228, DOI 10.1016/j.ejmech.2014.07.095; Wu XF, 2013, ADV SYNTH CATAL, V355, P3581, DOI 10.1002/adsc.201300585; Chen DG, 2012, J MATER CHEM, V22, P14639, DOI 10.1039/c2jm31755a; Najari A, 2012, MACROMOLECULES, V45, P1833, DOI 10.1021/ma202540j; PERRY RJ, 1991, J ORG CHEM, V56, P6573, DOI 10.1021/jo00023a023; Jo J, 2012, ADV ENERGY MATER, V2, P1397, DOI 10.1002/aenm.201200350; Zhang GB, 2010, CHEM COMMUN, V46, P4997, DOI 10.1039/c0cc00098a; Cabanetos C, 2013, J AM CHEM SOC, V135, P4656, DOI 10.1021/ja400365b; Zhang Y, 2010, CHEM MATER, V22, P2696, DOI 10.1021/cm100417z; Berrouard P, 2011, ORG LETT, V13, P38, DOI 10.1021/ol1027514; Van Goethem S, 2008, BIOORG MED CHEM LETT, V18, P4159, DOI 10.1016/j.bmcl.2008.05.079; Fuse S, 2014, ACS COMB SCI, V16, P494, DOI 10.1021/co500071x; Fuse S, 2014, TETRAHEDRON, V70, P8690, DOI 10.1016/j.tet.2014.09.039; Nakagaki T, 2010, ANGEW CHEM INT EDIT, V49, P9676, DOI 10.1002/anie.201004992; Ooyama Y, 2009, EUR J ORG CHEM, P2903, DOI 10.1002/ejoc.200900236; Khedkar MV, 2014, J MOL CATAL A-CHEM, V385, P91, DOI 10.1016/j.molcata.2014.01.018; Saeki A, 2012, J AM CHEM SOC, V134, P19035, DOI 10.1021/ja309524f; Csok Z, 2012, TETRAHEDRON, V68, P2657, DOI 10.1016/j.tet.2012.01.065; Berrouard P, 2012, ANGEW CHEM INT EDIT, V51, P2068, DOI 10.1002/anie.201106411; Fuse S, 2014, CHEM-EUR J, V20, P10685, DOI 10.1002/chem.201402093; Fuse S, 2012, ACS COMB SCI, V14, P545, DOI 10.1021/co3000665; Barn DR, 2001, BIOORGAN MED CHEM, V9, P2609, DOI 10.1016/S0968-0896(01)00017-7; Berrouard P., 2012, ANGEW CHEM, V124, P2110; Blanco MM, 2002, HETEROCYCLES, V57, P1881; Braunecker WA, 2012, CHEM MATER, V24, P1346, DOI 10.1021/cm2038427; Clare BW, 2000, EUR J MED CHEM, V35, P859, DOI 10.1016/S0223-5234(00)00182-3; Doi T, 2008, J COMB CHEM, V10, P135, DOI 10.1021/cc7000925; Fuse S, 2013, EUR J MED CHEM, V66, P180, DOI 10.1016/j.ejmech.2013.05.030; Fuse S, 2012, TETRAHEDRON LETT, V53, P3288, DOI 10.1016/j.tetlet.2012.04.059; Golbraikh A, 2000, EUR J MED CHEM, V35, P123, DOI 10.1016/S0223-5234(00)00108-2; He W., 2014, J APPL POLYM SCI, V131; ISHIZUMI K, 1991, CHEM PHARM BULL, V39, P2288; Kang T. E., 2013, ACS APPL MATER INTER, V5, P1; Lin SJ, 2013, J MACROMOL SCI A, V50, P416, DOI 10.1080/10601325.2013.768159; Lin SJ, 2013, J MACROMOL SCI A, V50, P426, DOI 10.1080/10601325.2013.768427; MACDOWEL.DW, 1972, J ORG CHEM, V37, P1712, DOI 10.1021/jo00976a008; Marosvolgyi-Hasko D, 2011, TETRAHEDRON, V67, P9122, DOI 10.1016/j.tet.2011.09.095; Matsumura K., 2015, CHEM-EUR J, DOI [10.1002/chem.201500979, DOI 10.1002/CHEM.201500979]; Mishra A, 2009, ANGEW CHEM, V121, P2510, DOI DOI 10.1002/ANGE.200804709; Nakagaki T., 2010, ANGEW CHEM, V122, P9870, DOI 10.1002/ange.201004992; SCHOENBE.A, 1974, J AM CHEM SOC, V96, P7761, DOI 10.1021/ja00832a024; SCHOENBE.A, 1974, J ORG CHEM, V39, P3318, DOI 10.1021/jo00937a003; SCHOENBE.A, 1974, J ORG CHEM, V39, P3327, DOI 10.1021/jo00937a004; Shih KC, 2011, BIOORG MED CHEM LETT, V21, P4490, DOI 10.1016/j.bmcl.2011.06.003; SUGIMOTO H, 1992, J MED CHEM, V35, P4542, DOI 10.1021/jm00102a005; Sugiyama S, 2011, TETRAHEDRON, V67, P6654, DOI 10.1016/j.tet.2011.05.023; TAKAHASHI T, 1980, TETRAHEDRON LETT, V21, P3885, DOI 10.1016/0040-4039(80)80207-3; TAKAHASHI T, 1980, CHEM LETT, P369, DOI 10.1246/cl.1980.369; Takahashi T., 2003, ANGEW CHEM, V115, P5388, DOI 10.1002/ange.200352229; TAKAHASHI T, 1981, TETRAHEDRON LETT, V22, P1363, DOI 10.1016/S0040-4039(01)90320-X; TAKAHASHI T, 1982, TETRAHEDRON LETT, V23, P4361, DOI 10.1016/S0040-4039(00)85600-2; Tayi AS, 2012, NATURE, V488, P485, DOI 10.1038/nature11395; Umeyama T, 2011, J MATER CHEM, V21, P12454, DOI 10.1039/c1jm11531f; Vaisburg A, 2004, BIOORG MED CHEM LETT, V14, P283, DOI 10.1016/j.bmcl.08.083; Wang XC, 2013, J POLYM SCI POL CHEM, V51, P4975, DOI 10.1002/pola.26923; Yan B, 2010, J INORG ORGANOMET P, V20, P809, DOI 10.1007/s10904-010-9401-6; Yan XY, 2013, CHEM COMMUN, V49, P10650, DOI 10.1039/c3cc45869e; Yoshida M, 2009, CHEM COMMUN, P2756, DOI 10.1039/b901788g; Zhang GB, 2013, SYNTHETIC MET, V180, P73, DOI 10.1016/j.synthmet.2013.07.019; Zhang GB, 2011, POLYMER, V52, P415, DOI 10.1016/j.polymer.2010.11.022; Zhang QT, 1997, J AM CHEM SOC, V119, P5065, DOI 10.1021/ja9640399; Zhang W, 2012, J MATER SCI, V47, P323, DOI 10.1007/s10853-011-5801-4	86	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1434-193X	1099-0690		EUR J ORG CHEM	Eur. J. Org. Chem.	JUN	2015		16					3430	3434		10.1002/ejoc.201500273		5	Chemistry, Organic	Chemistry	CJ1SP	WOS:000355265000004		
J	Sanada, Y; Urahashi, T; Ihara, Y; Okada, N; Yamada, N; Hirata, Y; Mizuta, K				Sanada, Yukihiro; Urahashi, Taizen; Ihara, Yoshiyuki; Okada, Noriki; Yamada, Naoya; Hirata, Yuta; Mizuta, Koichi			Pretransplant Levels of Endotoxin Can Predict the Risk of Bacterial Infections and Graft Liver Function after Liver Transplantation	EUROPEAN JOURNAL OF PEDIATRIC SURGERY			English	Article						endotoxin activity assay; endotoxin; bacterial infection; hyperbilirubinemia; liver transplantation	NEUTROPHIL-DEPENDENT CHEMILUMINESCENCE; ACTIVITY ASSAY; CIRRHOSIS	BackgroundAlthough endotoxin (Et) has been used as a biological index of bacterial infections, Et can also be used to evaluate liver functions because Et present in the portal vein blood is processed by the hepatic reticuloendothelial system. In the field of posttransplant management, it is important for liver transplant recipients to monitor the presence of posttransplant bacterial infections and graft liver functions because these results are directly correlated with a graft prognosis. Therefore, the measurement of Et during liver transplantation (LT) may be the detection of posttransplant infections and graft liver functions. This retrospective study investigated whether Et measured by the Et activity assay (EAA) in the peripheral venous blood during living donor LT (LDLT) can predict the incidence of posttransplant bacterial infections and graft liver functions. Materials and MethodsThe study subjects consisted of 21 patients who underwent LDLT between April 2010 and February 2011. Et activity (EA) was measured using the EAA in peripheral venous blood samples collected 1 or 2 days before LDLT, and on postoperative days (PODs) 1, 5, 7, and 14. We included LDLT recipients with intra-abdominal infections, respiratory infections, and bacteremia in the group with posttransplant bacterial infections. ResultsThe incidence rates of posttransplant bacterial infections or hyperbilirubinemia after LDLT were 57.1%. The LDLT recipients with posttransplant bacterial infections or hyperbilirubinemia had significantly higher levels of EA in comparison with patients without complications before LDLT (0.220.10 vs. 0.07 +/- 0.05, p<0.001), but they had no statistically significant increase of EA between PODs 1 and 14. Based on a receiver operating characteristic curve analysis of pretransplant levels of EA in patients with posttransplant bacterial infections or hyperbilirubinemia, the recommended cutoff value to diagnose posttransplant bacterial infections or hyperbilirubinemia was set at 0.16 (sensitivity 83.3%, specificity 88.9%, and area under the curve 0.940). ConclusionAt a pretransplant level of EA greater than 0.16, patients had an augmented risk for developing posttransplant bacterial infections or hyperbilirubinemia.	[Sanada, Yukihiro; Urahashi, Taizen; Ihara, Yoshiyuki; Okada, Noriki; Yamada, Naoya; Hirata, Yuta; Mizuta, Koichi] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan	Sanada, Y (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	yuki371@jichi.ac.jp					Chan CC, 1997, SCAND J GASTROENTERO, V32, P942, DOI 10.3109/00365529709011206; Romaschin AD, 1998, J IMMUNOL METHODS, V212, P169, DOI 10.1016/S0022-1759(98)00003-9; Marshall JC, 2004, J INFECT DIS, V190, P527, DOI 10.1086/422254; Marshall JC, 2002, CRIT CARE, V6, P342, DOI 10.1186/cc1522; Hilmi I, 2009, J ORGAN DYSFUNCTION, V54, P254; KIMURA Y, 1995, SURG TODAY, V25, P790; Maring JK, 2000, LIVER TRANSPLANT, V6, P480, DOI 10.1053/jlts.2000.8311; Nakatani Y, 2001, LIVER, V21, P64, DOI 10.1034/j.1600-0676.2001.210110.x; Romaschin A D, 1998, SEPSIS, V2, P119, DOI 10.1023/A:1009769923763; Romaschin AD, 2012, CRIT CARE, V16, DOI 10.1186/cc11495; Sanada Y, 2011, HEPATOL INT, V6, P489; Sanada Y, 2013, J SURG RES, V180, P349, DOI 10.1016/j.jss.2012.05.004	12	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-7248	1439-359X		EUR J PEDIATR SURG	Eur. J. Pediatr. Surg.	JUN	2015	25	3					236	241		10.1055/s-0034-1370781		6	Pediatrics; Surgery	Pediatrics; Surgery	CJ3WX	WOS:000355416300003		
J	Kobayashi, M; Mizuno, M; Matsumoto, A; Wakabayashi, G				Kobayashi, Megumi; Mizuno, Masaru; Matsumoto, Atsushi; Wakabayashi, Go			Neonatal Portal Venous Blood Flowmetry by Doppler Ultrasound for Early Diagnosis of Ischemia in Intestinal Tract	EUROPEAN JOURNAL OF PEDIATRIC SURGERY			English	Article						necrotizing enterocolitis; Doppler ultrasound; portal venous blood flow	NECROTIZING ENTEROCOLITIS; BILIARY ATRESIA; FLOW; DISEASE; INFANTS; RISK; GAS	PurposeThe aim of this article is to evaluate the utility of portal blood flow and other hemodynamic measurements for early diagnosis of ischemia that may cause necrotizing enterocolitis (NEC). Patients and MethodsWe measured neonatal portal blood flow by Doppler ultrasound and performed hemodynamic examinations in 75 newborns without congenital anomalies. All newborns were followed for 1month after birth. The average gestational period was 30.5 weeks, and the average birth weight was 1,172 g. ResultsA positive correlation was observed between both body weight and the following parameters: portal vein cross-sectional area, blood flow velocity, and portal blood flow volume. A greater coefficient of correlation was observed between the portal vein cross-sectional area and weight in newborns weighing1,500g than in those weighing>1,500 g. The portal vein cross-sectional area and blood flow velocity changed over time to maintain a fixed portal blood flow volume. The portal vein blood flow demonstrated a poor increase in patients with poor weight gain after birth. Seven infants demonstrated a reduction in portal vein blood flow before the development of abdominal symptoms. Both the cross-sectional area and blood flow velocity decreased over time before the onset of any symptoms of NEC. ConclusionsA significant decline in portal blood flow volume may be useful for the early diagnosis of NEC.	[Kobayashi, Megumi; Mizuno, Masaru; Wakabayashi, Go] Iwate Med Univ, Dept Surg, Sch Med, Morioka, Iwate 191, Japan; [Matsumoto, Atsushi] Iwate Med Univ, Dept Pediat, Sch Med, Morioka, Iwate 191, Japan	Kobayashi, M (reprint author), Iwate Med Univ, Dept Surg, Sch Med, 19-1 Uchimaru, Morioka, Iwate 191, Japan.	nagoune@nifty.com					BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; Kafetzis DA, 2003, CURR OPIN INFECT DIS, V16, P349, DOI 10.1097/01.qco.0000083567.48197.c2; Thompson AM, 2008, DRUGS, V68, P1227, DOI 10.2165/00003495-200868090-00004; Silva CT, 2007, PEDIATR RADIOL, V37, P274, DOI 10.1007/s00247-006-0393-x; Bohnhorst B, 2011, EUR J PEDIATR SURG, V21, P12, DOI 10.1055/s-0030-1265204; BROWN HS, 1989, GUT, V30, P503, DOI 10.1136/gut.30.4.503; CHARNOCK EL, 1973, PEDIATR CLIN N AM, V20, P275; Faingold R, 2005, RADIOLOGY, V235, P587, DOI 10.1148/radiol.2352031718; Frederico C M, 2009, EINSTEIN, V7, P91; Gephart SM, 2012, ADV NEONATAL CARE, V12, p:88; Kagimoto Seiichi, 1991, Acta Paediatrica Japonica, V33, P693; Koktener A, 2008, J CLIN ULTRASOUND, V36, P341, DOI 10.1002/jcu.20472; LINDLEY S, 1986, J PEDIATR SURG, V21, P530, DOI 10.1016/S0022-3468(86)80226-3; Ludwig D, 1999, GUT, V45, P546; Maconi G, 1996, SCAND J GASTROENTERO, V31, P590, DOI 10.3109/00365529609009132; MERRITT CRB, 1984, AM J ROENTGENOL, V143, P1059; MORIYASU F, 1986, J CLIN ULTRASOUND, V14, P579, DOI 10.1002/jcu.1870140802; Siirci A, 2001, J CLIN ULTRASOUND, V29, P130; Gephart SM, 2012, ADV NEONAT CARE, V12, P77, DOI 10.1097/ANC.0b013e31824cee94; TANAKA K, 1992, PEDIATR SURG INT, V7, P260; WANEK EA, 1990, J PEDIATR SURG, V25, P146, DOI 10.1016/S0022-3468(05)80181-2; Yasuyuki H., 1994, J JPN PEDIAT SOC, V30, P906; Zhang YY, 2011, J PEDIATR SURG, V46, P1475, DOI 10.1016/j.jpedsurg.2011.03.005	23	1	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-7248	1439-359X		EUR J PEDIATR SURG	Eur. J. Pediatr. Surg.	JUN	2015	25	3					292	298		10.1055/s-0034-1374820		7	Pediatrics; Surgery	Pediatrics; Surgery	CJ3WX	WOS:000355416300011		
J	Oyama, Y; Fujisawa, T; Hashimoto, D; Enomoto, N; Nakamura, Y; Inui, N; Kuroishi, S; Yokomura, K; Toyoshima, M; Yamada, T; Shirai, T; Masuda, M; Yasuda, K; Hayakawa, H; Chida, K; Suda, T				Oyama, Yoshiyuki; Fujisawa, Tomoyuki; Hashimoto, Dai; Enomoto, Noriyuki; Nakamura, Yutaro; Inui, Naoki; Kuroishi, Shigeki; Yokomura, Koshi; Toyoshima, Mikio; Yamada, Takashi; Shirai, Toshihiro; Masuda, Masafumi; Yasuda, Kazumasa; Hayakawa, Hiroshi; Chida, Kingo; Suda, Takafumi			Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia	EUROPEAN RESPIRATORY JOURNAL			English	Article							FOLLOW-UP; LUNG-DISEASES; CT FINDINGS; FEATURES	In patients with chronic eosinophilic pneumonia (CEP), dramatic improvements are seen in response to corticosteroid therapy; however, relapse is common after treatment has ceased. The optimal duration of corticosteroid therapy remains unclear. In a randomised, open-label, parallel group study, eligible patients with CEP received oral prednisolone for either 3 months (3-month group) or 6 months (6-month group), followed by 2 years observation. All patients were treated with an initial dose of prednisolone of 0.5 mg.kg(-1).day(-1), which was then tapered and discontinued at either 3 or 6 months. The primary end-point was relapse during the follow-up period. In the final analysis, there were 23 patients in the 3-month group and 21 patients in the 6-month group. All patients showed a good response to prednisolone treatment. There were 12 (52.1%) relapses in the 3-month group and 13 (61.9%) relapses in the 6-month group. No significant difference was found in the cumulative rate of relapse (p=0.56). All relapse cases showed improvement upon resumption of prednisolone treatment. No difference was observed in the rate of relapse between the 3- and 6-month prednisolone treatment groups for patients with CEP.	[Oyama, Yoshiyuki; Fujisawa, Tomoyuki; Hashimoto, Dai; Enomoto, Noriyuki; Nakamura, Yutaro; Suda, Takafumi] Hamamatsu Univ, Div 2, Dept Internal Med, Sch Med, Hamamatsu, Shizuoka, Japan; [Inui, Naoki] Hamamatsu Univ, Dept Clin Pharmacol & Therapeut, Sch Med, Hamamatsu, Shizuoka, Japan; [Kuroishi, Shigeki] Enshu Hosp, Dept Internal Med, Hamamatsu, Shizuoka, Japan; [Yokomura, Koshi] Seirei Mikatahara Gen Hosp, Dept Resp Med, Hamamatsu, Shizuoka, Japan; [Toyoshima, Mikio] Hamamatsu Rosai Hosp, Dept Resp Med, Hamamatsu, Shizuoka, Japan; [Yamada, Takashi] Shizuoka City Shizuoka Hosp, Dept Resp Med, Shizuoka, Japan; [Shirai, Toshihiro] Shizuoka Prefectural Gen Hosp, Dept Resp Med, Shizuoka, Japan; [Masuda, Masafumi] Shizuoka City Shimizu Hosp, Dept Resp Med, Shizuoka, Japan; [Yasuda, Kazumasa] Iwata City Hosp, Dept Resp Med, Iwata, Japan; [Hayakawa, Hiroshi] Tenryu Hosp, Natl Hosp Org, Dept Resp Med, Hamamatsu, Shizuoka, Japan; [Chida, Kingo] Hamamatsu Toyooka Hosp, Dept Internal Med, Hamamatsu, Shizuoka, Japan	Fujisawa, T (reprint author), Hamamatsu Univ, Div 2, Dept Internal Med, Sch Med,Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan.	fujisawa@hama-med.ac.jp					SUDA T, 1995, CHEST, V107, P711, DOI 10.1378/chest.107.3.711; Cottin V, 2005, ALLERGY, V60, P841, DOI 10.1111/j.1398-9995.2005.00812.x; Marchand E, 1998, MEDICINE, V77, P299, DOI 10.1097/00005792-199809000-00001; ALLEN JN, 1994, AM J RESP CRIT CARE, V150, P1423; Arakawa H, 2001, AM J ROENTGENOL, V176, P1053; CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; Durieu J, 1997, EUR RESPIR J, V10, P286, DOI 10.1183/09031936.97.10020286; EBARA H, 1994, J COMPUT ASSIST TOMO, V18, P737, DOI 10.1097/00004728-199409000-00011; FOX B, 1980, THORAX, V35, P570, DOI 10.1136/thx.35.8.570; Fujisawa T, 2005, J RHEUMATOL, V32, P58; Furuiye M, 2010, J COMPUT ASSIST TOMO, V34, P19, DOI 10.1097/RCT.0b013e3181ae2949; GAENSLER EA, 1977, AM J ROENTGENOL, V128, P1; Hansell DM, 2008, RADIOLOGY, V3, P697, DOI DOI 10.1148/RADI0L.2462070712; JEDERLINIC PJ, 1988, MEDICINE, V67, P154; Johkoh T, 2000, RADIOLOGY, V216, P773; LIEBOW AA, 1969, MEDICINE, V48, P251, DOI 10.1097/00005792-196907000-00001; Marchand E, 2006, SEM RESP CRIT CARE M, V27, P134, DOI 10.1055/s-2006-939516; Marchand E, 2003, EUR RESPIR J, V22, P8, DOI 10.1183/09031936.03.00085603; MAYO JR, 1989, AM J ROENTGENOL, V153, P727; NAUGHTON M, 1993, CHEST, V103, P162, DOI 10.1378/chest.103.1.162; PEARSON DJ, 1978, MAYO CLIN PROC, V53, P73; ROBERTSO.CL, 1971, RADIOLOGY, V101, P57	22	0	0	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND	0903-1936	1399-3003		EUR RESPIR J	Eur. Resp. J.	JUN	2015	45	6					1624	1631		10.1183/09031936.00199614		8	Respiratory System	Respiratory System	CJ2QN	WOS:000355329700016		
J	Izumo, T; Sasada, S; Chavez, C; Matsumoto, Y; Tsuchida, T				Izumo, Takehiro; Sasada, Shinji; Chavez, Christine; Matsumoto, Yuji; Tsuchida, Takaaki			Radial endobronchial ultrasound images for ground-glass opacity pulmonary lesions	EUROPEAN RESPIRATORY JOURNAL			English	Article							GUIDED RADIOFREQUENCY ABLATION; LUNG-CANCER; INTERNATIONAL ASSOCIATION; ULTRASONOGRAPHY; DIAGNOSIS; SOCIETY; NODULES; SHEATH; CLASSIFICATION; BRONCHOSCOPY	Radial endobronchial ultrasound (R-EBUS) is a useful tool for precise localisation of peripheral pulmonary lesions, but there have been no detailed reports about the use of R-EBUS images for ground-glass opacity (GGO). The R-EBUS images of 116 patients with GGO, who were diagnosed as having adenocarcinoma by R-EBUS with a guide sheath (EBUS-GS), were compared with the respective chest computed tomography findings. In 103 patients, R-EBUS images were correlated with the histological surgical specimens. R-EBUS images of GGO were identified based on the internal structure of the lesion and classified into two groups. Blizzard showed an enlarged, diffuse hyperintense acoustic shadow. Mixed blizzard showed a combination of blizzard and some diffuse heterogeneity with several hyperechoic dots and vessels. All pure GGO lesions (nine out of nine) were blizzard on R-EBUS. For part-solid GGOs, the percentage of mixed blizzard was inversely related to the amount of the GGO component. Histological findings from surgery revealed that all blizzard lesions were on the spectrum of adenocarcinoma in situ to well differentiated adenocarcinoma while majority (33 out of 64) of mixed blizzard lesions were moderately to poorly differentiated adenocarcinoma. R-EBUS types are important to locate GGOs prior to transbronchial sampling with EBUS-GS.	[Izumo, Takehiro; Sasada, Shinji; Chavez, Christine; Matsumoto, Yuji; Tsuchida, Takaaki] Natl Canc Ctr, Dept Endoscopy, Resp Endoscopy Div, Tokyo 1040045, Japan	Izumo, T (reprint author), Natl Canc Ctr, Dept Endoscopy, Resp Endoscopy Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	drtake1118@gmail.com			National Cancer Center Research and Development Fund [25-A-12]	This work was supported by The National Cancer Center Research and Development Fund (25-A-12).	Izumo T, 2013, J THORAC DIS, V5, P745, DOI 10.3978/j.issn.2072-1439.2013.11.30; Lee HY, 2011, J THORAC IMAG, V26, P106, DOI 10.1097/RTI.0b013e3181fbaa64; Steinfort DP, 2011, EUR RESPIR J, V37, P902, DOI 10.1183/09031936.00075310; Henschke CI, 2002, AM J ROENTGENOL, V178, P1053; Suzuki K, 2006, ANN THORAC SURG, V81, P413, DOI 10.1016/j.athoracsur.2005.07.058; MacMahon H, 2005, RADIOLOGY, V237, P395, DOI 10.1148/radiol.2372041887; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Herth FJF, 2006, CHEST, V129, P147, DOI 10.1378/chest.129.1.147; [Anonymous], 2012, CHEST; Rivera MP, 2013, CHEST, V143, pE142, DOI 10.1378/chest.12-2353; Church TR, 2013, NEW ENGL J MED, V368, P1980, DOI 10.1056/NEJMoa1209120; Travis WD, 2013, ARCH PATHOL LAB MED, V137, P668, DOI 10.5858/arpa.2012-0263-RA; Asano F, 2013, RESPIROLOGY, V18, P284, DOI 10.1111/j.1440-1843.2012.02273.x; Chavez C, 2014, J THORAC DIS, V6, pE81, DOI 10.3978/j.issn.2072-1439.2014.06.06; Ikezawa Y, 2014, RESPIRATION, V88, P137, DOI 10.1159/000362885; Inoue D, 2012, EUR J RADIOL, V81, P354, DOI 10.1016/j.ejrad.2010.11.025; Katsurada M, 2014, JPN J CLIN ONCOL, V44, P257, DOI 10.1093/jjco/hyt224; Kurimoto N, 2002, CHEST, V122, P1887, DOI 10.1378/chest.122.6.1887; Lu CH, 2012, J THORAC ONCOL, V7, P143, DOI 10.1097/JTO.0b013e318233d7dd; Sasada Shinji, 2014, Respir Med Case Rep, V12, P19, DOI 10.1016/j.rmcr.2013.11.003; Sasada S, 2014, JPN J CLIN ONCOL, V44, P826, DOI 10.1093/jjco/hyu079; Takai M, 2014, ANN THORAC CARDIOVAS, V20, P19, DOI 10.5761/atcs.oa.13-00261; Tanabe T, 2010, CHEST, V137, P890, DOI 10.1378/chest.09-1065; Tsushima K, 2007, EUR RESPIR J, V29, P1193, DOI 10.1183/09031936.00111306	24	1	1	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND	0903-1936	1399-3003		EUR RESPIR J	Eur. Resp. J.	JUN	2015	45	6					1661	1668		10.1183/09031936.00167914		8	Respiratory System	Respiratory System	CJ2QN	WOS:000355329700020		
J	Mori, T; Burhan, E				Mori, Toru; Burhan, Erlina		Asian TB Experts Community	Supporting progress towards the post-2015 targets and regional tuberculosis elimination: a statement of intent from the third meeting of the Asian TB Experts Community	EUROPEAN RESPIRATORY JOURNAL			English	Letter							REALITY		[Mori, Toru] Stop TB Partnership Japan, Tokyo, Japan; [Mori, Toru] RIT, Tokyo, Japan; [Mori, Toru] Japan AntiTB Assoc, Tokyo 2048533, Japan; [Burhan, Erlina] Univ Indonesia, Persahabatan Hosp Jakarta, Fac Med, Dept Pulmonol & Resp Med, Jakarta, Indonesia	Mori, T (reprint author), Japan AntiTB Assoc, Res Inst TB, 3-1-24 Matsuyama, Tokyo 2048533, Japan.	tmori-rit@jata.or.jp					[Anonymous], 2013, GLOB STRAT TARG TUB; Diel R, 2013, EUR RESPIR J, V42, P785, DOI 10.1183/09031936.00205512; D'Ambrosio L, 2014, EUR RESPIR J, V43, P1410, DOI 10.1183/09031936.00198813; Diel R, 2013, INT J TUBERC LUNG D, V17, P1515, DOI 10.5588/ijtld.13.0706; Fleck F, 2014, B WORLD HEALTH ORGAN, V92, P316, DOI 10.2471/BLT.14.030514; Sotgiu G, 2014, LANCET INFECT DIS, V14, P364, DOI [10.1016/S1473-3099(14)70030-1, 10.1016/S51473-3099(14)70030-1]; Voniatis C, 2014, EUR RESPIR J, V44, P543, DOI 10.1183/09031936.00044314; World Health Organization, 2013, SYST SCREEN ACT TUB; World Health Organization, 2014, GUID MAN LAT TUB INF	9	0	0	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND	0903-1936	1399-3003		EUR RESPIR J	Eur. Resp. J.	JUN	2015	45	6					1760	1762		10.1183/09031936.00207614		3	Respiratory System	Respiratory System	CJ2QN	WOS:000355329700037		
J	Kamae, T; Luo, J; Tan, B				Kamae, Teturo; Luo, Jun; Tan, Bo			A GLUING LEMMA FOR ITERATED FUNCTION SYSTEMS	FRACTALS-COMPLEX GEOMETRY PATTERNS AND SCALING IN NATURE AND SOCIETY			English	Article						Gluing Lemma; Self-Affine Tile; Schonflies Theorem	SELF-AFFINE TILES; CANONICAL NUMBER SYSTEM; INTERIOR COMPONENTS; SIMILAR SETS; CONNECTEDNESS; BOUNDARY; R-2	We obtain a special version of gluing lemma related to the theory of iterated function systems (IFS). As an application, we verify that a family of concrete n-dimensional self-affine tiles {T-n,T-r : 0 <= r < 3, n >= 3} are homeomorphic with the unit cube [0, 1](n). The tiles T-n,T-r are "nontrivial" in the sense that each of them is neither a self-affine polytope nor the product of an interval with an (n-1)-dimensional self-affine tile.	[Kamae, Teturo] Osaka City Univ, Adv Math Inst, Osaka 5588585, Japan; [Luo, Jun] Sun Yat Sen Univ, Sch Math & Computat Sci, Guangzhou 510275, Guangdong, Peoples R China; [Tan, Bo] Huazhong Univ Sci & Technol, Dept Math, Wuhan 430074, Peoples R China	Luo, J (reprint author), Sun Yat Sen Univ, Sch Math & Computat Sci, Guangzhou 510275, Guangdong, Peoples R China.	kamae@apost.plala.or.jp; luojun3@mail.sysu.edu.cn; tanbo@mail.hust.edu.cn			National Natural Science Foundation of China [10971233, 11171123]	The study of this paper is partially supported by the National Natural Science Foundation of China (Projects 10971233, 11171123).	Akiyama S, 2004, GEOMETRIAE DEDICATA, V109, P89, DOI 10.1007/s10711-004-1774-7; Deng QR, 2011, J MATH ANAL APPL, V380, P493, DOI 10.1016/j.jmaa.2011.03.043; Armstrong M. A., 1983, BASIC TOPOLOGY; Bandt C, 2001, DISCRETE COMPUT GEOM, V26, P591, DOI 10.1007/s00454-001-0034-y; Barnsley M. F., 1993, FRACTALS EVERYWHERE; Bernat J, 2010, FRACTALS, V18, P385, DOI 10.1142/S0218348X10004920; Brown M., 1960, B AM MATH SOC, V66, P74, DOI 10.1090/S0002-9904-1960-10400-4; Conner G. R., SELF AFFINE MANIFOLD; HUTCHINSON JE, 1981, INDIANA U MATH J, V30, P713, DOI 10.1512/iumj.1981.30.30055; Jolivet T., 2014, J FRACTAL GEOM, V1, P427; Lagarias JC, 1996, ADV MATH, V121, P21, DOI 10.1006/aima.1996.0045; Loridant B, 2008, TOPOL APPL, V155, P667, DOI 10.1016/j.topol.2007.10.007; Luo J, 2004, MATH PROC CAMBRIDGE, V137, P397, DOI 10.1017/S0305004104007625; Luo J, 2002, FRACTALS, V10, P223, DOI 10.1142/S0218348X0200104X; Luo J, 2007, TOPOL APPL, V154, P614, DOI 10.1016/j.topol.2006.07.013; Luo J, 2006, ANN I FOURIER, V56, P2493; Munkres James R., 1999, TOPOLOGY; Ngai SM, 2004, FRACTALS, V12, P389, DOI 10.1142/S0218348X04002653; SAGAN H, 1993, MATH INTELL, V15, P37; Tang TM, 2005, ACTA MATH HUNG, V109, P295, DOI 10.1007/s10474-005-0249-0; Whyburn G. T., 1979, UNDERGRADUATE TEXTS	21	0	0	WORLD SCIENTIFIC PUBL CO PTE LTD	SINGAPORE	5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE	0218-348X	1793-6543		FRACTALS	Fractals-Complex Geom. Patterns Scaling Nat. Soc.	JUN	2015	23	2							1550019	10.1142/S0218348X1550019X		10	Mathematics, Interdisciplinary Applications; Multidisciplinary Sciences	Mathematics; Science & Technology - Other Topics	CJ3JO	WOS:000355379400019		
J	Gorenflo, R; Luchko, Y; Yamamoto, M				Gorenflo, Rudolf; Luchko, Yuri; Yamamoto, Masahiro			TIME-FRACTIONAL DIFFUSION EQUATION IN THE FRACTIONAL SOBOLEV SPACES	FRACTIONAL CALCULUS AND APPLIED ANALYSIS			English	Article						Riemann-Liouville integral; Caputo fractional derivative; fractional Sobolev spaces; norm equivalences; fractional diffusion equation in Sobolev spaces; norm estimates of the solutions; initialboundary-value problems; weak solution; existence and uniqueness results	BOUNDARY-VALUE PROBLEMS; MAXIMUM PRINCIPLE; ORDER	The Caputo time-derivative is usually defined pointwise for well-behaved functions, say, for the continuously differentiable functions. Accordingly, in the publications devoted to the theory of the partial fractional differential equations with the Caputo derivatives, the functional spaces where the solutions are looked for are often the spaces of smooth functions that appear to be too narrow for several important applications. In this paper, we propose a definition of the Caputo derivative on a finite interval in the fractional Sobolev spaces and investigate it from the operator theoretic viewpoint. In particular, some important equivalences of the norms related to the fractional integration and differentiation operators in the fractional Sobolev spaces are given. These results are then applied for proving the maximal regularity of the solutions to some initial-boundary-value problems for the time-fractional diffusion equation with the Caputo derivative in the fractional Sobolev spaces.	[Gorenflo, Rudolf] Free Univ Berlin, Dept Math & Informat, D-14195 Berlin, Germany; [Luchko, Yuri] Beuth Tech Univ Appl Sci, Dept Math Phys & Chem, D-13353 Berlin, Germany; [Yamamoto, Masahiro] Univ Tokyo, Dept Math Sci, Meguro Ku, Tokyo 153, Japan	Gorenflo, R (reprint author), Free Univ Berlin, Dept Math & Informat, Arnimallee 3, D-14195 Berlin, Germany.	gorenflo@mi.fu-berlin.de; luchko@beuth-hochschule.de; myama@ms.u-tokyo.ac.jp			A3 Foresight Program "Modeling and Computation of Applied Inverse Problems" by Japan Society of the Promotion of Science	The third named author was partly supported by A3 Foresight Program "Modeling and Computation of Applied Inverse Problems" by Japan Society of the Promotion of Science.	Adams R.A., 1999, SOBOLEV SPACES; Luchko Y, 2012, FRACT CALC APPL ANAL, V15, P141, DOI 10.2478/s13540-012-0010-7; Golding I, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.098102; FUJIWARA D, 1967, P JPN ACAD, V43, P82; Zacher R, 2005, J EVOL EQU, V5, P79, DOI 10.1007/s00028-004-0161-z; Luchko Y, 2009, J MATH ANAL APPL, V351, P218, DOI 10.1016/j.jmaa.2008.10.018; Luchko Y, 2011, FRACT CALC APPL ANAL, V14, P110, DOI 10.2478/s13540-011-0008-6; Luchko Y, 2010, COMPUT MATH APPL, V59, P1766, DOI 10.1016/j.camwa.2009.08.015; Metzler R, 2014, PHYS CHEM CHEM PHYS, V16, P24128, DOI 10.1039/c4cp03465a; Sakamoto K, 2011, J MATH ANAL APPL, V382, P426, DOI 10.1016/j.jmaa.2011.04.058; Bajlekova E., 2001, THESIS EINDHOVEN U T; Beckers S., 2013, CONTROL AND OPTIMIZA, P45; Diethelm K., 2010, ANAL FRACTIONAL DIFF; Ervin VJ, 2006, NUMER METH PART D E, V22, P558, DOI 10.1002/num.20112; Gorenflo R., 2014, MITTAG LEFFLER FUNCT; Gorenflo R., 1991, ABEL INTEGRAL EQUATI; Gorenflo R, 1999, JPN J IND APPL MATH, V16, P137; HENRY D., 1981, GEOMETRIC THEORY SEM; Jin B., MATH COMPUT PUBL, DOI [10.1090/mcom/2960, DOI 10.1090/MCOM/2960]; Kilbas A. A., 2006, THEORY APPL FRACTION; Li ZY, 2014, FRACT CALC APPL ANAL, V17, P1114, DOI 10.2478/s13540-014-0217-x; Lions J.-L., 1972, NONHOMOGENEOUS BOUND; Luchko Y., 1999, ACTA MATH VIETNAMICA, V24, P207; Pazy A., 1983, SEMIGROUPS LINEAR OP; Podlubny I., 1999, FRACTIONAL DIFFERENT; Priiss J., 1993, EVOLUTIONARY INTEGRA; Samko S., 1993, FRACTIONAL INTEGRALS; Tanabe H., 1979, EQUATIONS ECOLUTION; Zacher R, 2009, FUNKC EKVACIOJ-SER I, V52, P1	29	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1311-0454	1314-2224		FRACT CALC APPL ANAL	Fract. Calc. Appl. Anal.	JUN	2015	18	3					799	820		10.1515/fca-2015-0048		22	Mathematics, Applied; Mathematics, Interdisciplinary Applications; Mathematics	Mathematics	CJ0WP	WOS:000355200400017		
J	Emoto, K; Campillo, M; Brenguier, F; Briand, X; Takeda, T				Emoto, K.; Campillo, M.; Brenguier, F.; Briand, X.; Takeda, T.			Asymmetry of coda cross-correlation function: dependence of the epicentre location	GEOPHYSICAL JOURNAL INTERNATIONAL			English	Article						Interferometry; Wave scattering and diffraction; Wave propagation	AMBIENT SEISMIC NOISE; WAVES; RESOLUTION	We analyze the cross-correlation function (CCF) of coda of earthquakes, which is used to retrieve the Green's function between two stations as well as the CCF of ambient noise. We select 74 Hi-net stations located in eastern Japan and 66 earthquakes to calculate the CCF. For each earthquake, we calculate the CCFs between possible pairs for the frequency bands of 0.1-0.2 Hz, 0.2-0.4 Hz and 0.4-0.8 Hz. Then we stack the CCFs for different earthquakes at each pair to obtain the average CCF. Although the correlation coefficients between the average and each CCFs are lower than 0.5 for most of the earthquakes, we obtain the propagating Rayleigh wave trace from average CCFs. We focus on the ratio of the amplitude in the positive lag time of the CCF to that in the negative lag time. CCFs for different earthquakes show different ratios which depend on the angle between the path of two stations and the epicentre. The amplitude in the lag time corresponding to the signal travelling from the near source station to the far source station is larger than that in the opposite lag time. Therefore the energy flux is not isotropic even in the coda and the energy from the source side is dominant. We average the ratios of pairs whose absolute values of angles are less than 45A degrees. The average ratios are 0.5 at 0.1-0.2 Hz. For higher frequencies, the ratio is not clear because of the bad signal-to-noise ratio. According to the diffusion model, the ratio is predicted as 0.6. Therefore, the coda is represented as the diffusion state in 0.1-0.2 Hz with our observation setting.	[Emoto, K.; Campillo, M.; Brenguier, F.; Briand, X.] Univ Grenoble, CNRS, ISTerre, Grenoble, France; [Emoto, K.; Takeda, T.] Natl Res Inst Earth Sci & Disaster Prevent, Tsukuba, Ibaraki, Japan	Emoto, K (reprint author), Univ Grenoble, CNRS, ISTerre, Grenoble, France.	emoto@zisin.gp.tohoku.ac.jp			French National Research Agency; Japan Science and Technology Agency [2011-JAPN-006NAMAZU]	This study was supported by the French National Research Agency and the Japan Science and Technology Agency (project 2011-JAPN-006NAMAZU).	Margerin L, 2000, J GEOPHYS RES-SOL EA, V105, P7873, DOI 10.1029/1999JB900359; Brenguier F, 2008, SCIENCE, V321, P1478, DOI 10.1126/science.1160943; Paul A, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003521; Weaver R, 2009, J ACOUST SOC AM, V126, P1817, DOI 10.1121/1.3203359; Brenguier F, 2014, SCIENCE, V345, P80, DOI 10.1126/science.1254073; Nakata N, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL048800; Lobkis OI, 2001, J ACOUST SOC AM, V110, P3011, DOI 10.1121/1.1417528; Poli P, 2012, SCIENCE, V338, P1063, DOI 10.1126/science.1228194; Clarke D, 2011, GEOPHYS J INT, V186, P867, DOI 10.1111/j.1365-246X.2011.05074.x; Boue P, 2013, GEOPHYS J INT, V194, P844, DOI 10.1093/gji/ggt160; Campillo M, 2003, SCIENCE, V299, P547, DOI 10.1126/science.1078551; Shapiro NM, 2005, SCIENCE, V307, P1615, DOI 10.1126/science.1108339; Yamamoto M, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2009JB007109; Nishida K, 2013, GEOPHYS RES LETT, V40, P1691, DOI 10.1002/grl.50269; Ishimaru A, 1997, WAVE PROPAGATION SCA; Larose E, 2008, J APPL PHYS, V103, DOI 10.1063/1.2939267; Lin F. C., 2013, GEOPHYS RES LETT, V40, P1, DOI DOI 10.1002/GRL.50907; Nakahara H, 2011, B SEISMOL SOC AM, V101, P2243, DOI 10.1785/0120100353; Okada Y, 2004, EARTH PLANETS SPACE, V56, pXV; Sato H, 2012, SEISMIC WAVE PROPAGA; Takagi R, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL051342	21	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0956-540X	1365-246X		GEOPHYS J INT	Geophys. J. Int.	JUN	2015	201	3					1313	1323		10.1093/gji/ggv081		11	Geochemistry & Geophysics	Geochemistry & Geophysics	CJ2NN	WOS:000355321800007		
J	Yoshioka, S; Matsuoka, Y; Ide, S				Yoshioka, Shoichi; Matsuoka, Yoshiko; Ide, Satoshi			Spatiotemporal slip distributions of three long-term slow slip events beneath the Bungo Channel, southwest Japan, inferred from inversion analyses of GPS data	GEOPHYSICAL JOURNAL INTERNATIONAL			English	Article						Inverse theory; Transient deformation; Dynamics and mechanics of faulting	BAYESIAN INFORMATION CRITERION; TIME-DEPENDENT INVERSION; SUBDUCTION ZONE; GEODETIC DATA; NANKAI TROUGH; ASEISMIC SLIP; HYUGA-NADA; EARTHQUAKES; TREMOR; MODEL	We estimated spatiotemporal slip distributions from three long-term slow slip events (L-SSEs) that occurred beneath the Bungo Channel at the convergent plate boundary between the subducting oceanic Philippine Sea plate and the continental Amurian plate in southwest Japan between 1997 and 1998, 2002 and 2004 and 2009 and 2011. For this purpose, we employed an inversion method using a Bayesian Information Criterion (ABIC), which included the following three prior constraints: the spatial slip distribution was smooth to some extent, slip directions were mostly oriented in the direction of plate convergence and the temporal change in slip was smooth to some extent. Our results revealed that the three L-SSEs had a common feature: slipped regions expanded southwestward at accelerating slip velocities. We also found that major slipped regions migrated southwestward by approximately 50-100 km yr(-1). In contrast, southwestward and northeastward migration of the slipped regions, whose direction differed from event to event, was also identified before or after the periods when the slip velocities were at their greatest. Comparing the obtained spatiotemporal slip distributions of the three L-SSEs with slip-deficit rate distributions obtained in our previous study, we investigated the accumulation process of the slip deficit caused by slip-deficit rate distributions and the release processes of the slip deficit caused by the obtained spatiotemporal slip distributions of the three L-SSEs. At the western plate interface of the Bungo Channel, as the slip-deficit rate was small and the amounts of slips associated with the three L-SSEs were large, most of the accumulated slip deficit was estimated to have been released. In contrast, at the eastern plate interface, as the slip-deficit rate was large and the amounts of slips associated with the three L-SSEs were small, the slip deficit was estimated to have accumulated effectively. These results suggest that the slipped regions of the three L-SSEs and the strongly coupled region are not spatially complementary; the accumulated slip deficit showed spatial variation even at approximately the same depth range along the arc.	[Yoshioka, Shoichi] Kobe Univ, Res Ctr Urban Safety & Secur, Kobe, Hyogo 6578501, Japan; [Matsuoka, Yoshiko] NTT DATA Sekisui Syst Corp, Tokyo 1500002, Japan; [Ide, Satoshi] Univ Tokyo, Dept Earth & Planetary Sci, Tokyo 1130033, Japan	Yoshioka, S (reprint author), Kobe Univ, Res Ctr Urban Safety & Secur, Rokkodai Cho 1-1, Kobe, Hyogo 6578501, Japan.	yoshioka@port.kobe-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [21107007]	We thank T. Yabuki for sharing his source code on inversion analysis of geodetic data and J. Nakajima for providing geometry data of the upper surface of the PHS plate. We also thank two anonymous reviewers and the editor D. Agnew for their constructive comments. We used daily coordinate of GEONET, namely, F3 solutions, operated by the Geospatial Information Authority of Japan. All the figures were created using the Generic Mapping Tools (GMT) developed by Wessel & Smith (1998). This study was supported by a Grand-in-Aid for Scientific Research (No. 21107007) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Akaike H., 1980, BAYESIAN STAT, P143; Yagi Y, 2001, EARTH PLANETS SPACE, V53, P793; Ito Y, 2007, SCIENCE, V315, P503, DOI 10.1126/science.1134454; Miyazaki S, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2004JB003426; YABUKI T, 1992, GEOPHYS J INT, V109, P363, DOI 10.1111/j.1365-246X.1992.tb00102.x; Ide S, 2010, NATURE, V466, P356, DOI 10.1038/nature09251; Ozawa S, 2013, EARTH PLANETS SPACE, V65, P67, DOI 10.5047/eps.2012.06.009; Baba T, 2002, PHYS EARTH PLANET IN, V132, P59, DOI 10.1016/S0031-9201(02)00044-4; Yoshioka S, 2013, TECTONOPHYSICS, V600, P165, DOI 10.1016/j.tecto.2013.01.023; Ide S, 2007, NATURE, V447, P76, DOI 10.1038/nature05780; Nakajima J, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004770; Yagi YJ, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL015664; Shelly DR, 2007, NATURE, V446, P305, DOI 10.1038/nature05666; Hirose F, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2007JB005274; Hirose H, 2010, SCIENCE, V330, P1502, DOI 10.1126/science.1197102; Ozawa S, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004643; Miyazaki S, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000456; Dong D, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB003806; Fukahata Y, 2004, GEOPHYS J INT, V156, P140, DOI 10.1111/j.1365-246X.2004.02122.x; Hirose H, 1999, GEOPHYS RES LETT, V26, P3237, DOI 10.1029/1999GL010999; Hirose H., 2010, P AM GEOPH UN FALL M, P3; Kobayashi A, 2011, J GEOPHYS RES-SOL EA, V116, DOI 10.1029/2010JB007822; Liu Z, 2010, GEOPHYS J INT, V181, P1292, DOI 10.1111/j.1365-246X.2010.04599.x; Matsu'ura M, 2007, GEOPHYS J INT, V171, P1342, DOI 10.1111/j.1365-246X.2007.03578.x; Mista P., 2010, GLOBAL POSITIONING S; Nakagawa H., 2009, J GEOGR SURV I, V118, P1; Ozawa S, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019381; Ozawa S, 2001, J GEOPHYS RES-SOL EA, V106, P787, DOI 10.1029/2000JB900317; Segall P, 1997, J GEOPHYS RES-SOL EA, V102, P22391, DOI 10.1029/97JB01795; Sella GF, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000033; Tabei T., 2002, J GEOD SOC JPN, V48, P229; Wdowinski S., 1997, J GEOPHYS RES, V102, P57, DOI DOI 10.1029/96JA01273; WESSEL P, 1998, EOS T AGU, V0079; Yarai H., 2011, P AM GEOPH UN FALL M, P3; Yoshioka S, 2004, PHYS EARTH PLANET IN, V146, P513, DOI 10.1016/j.pepi.2004.05.006	35	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0956-540X	1365-246X		GEOPHYS J INT	Geophys. J. Int.	JUN	2015	201	3					1437	1455		10.1093/gji/ggv022		19	Geochemistry & Geophysics	Geochemistry & Geophysics	CJ2NN	WOS:000355321800018		
J	Maher, SM; Wessel, P; Muller, RD; Williams, SE; Harada, Y				Maher, S. M.; Wessel, P.; Mueller, R. D.; Williams, S. E.; Harada, Y.			Absolute plate motion of Africa around Hawaii-Emperor bend time	GEOPHYSICAL JOURNAL INTERNATIONAL			English	Article						Plate motions; Dynamics of lithosphere and mantle; Dynamics: gravity and tectonics; Africa	WESTERN INDIAN-OCEAN; AGE PROGRESSIVE VOLCANISM; K-AR AGES; SOUTH-ATLANTIC; CANARY-ISLANDS; TECTONIC EVOLUTION; MASCARENE PLATEAU; AR-40/AR-39 AGE; SEAMOUNT CHAIN; HOTSPOT TRACK	Numerous regional plate reorganizations and the coeval ages of the Hawaiian Emperor bend (HEB) and Louisville bend of 50-47 Ma have been interpreted as a possible global tectonic plate reorganization at similar to chron 21 (47.9 Ma). Yet for a truly global event we would expect a contemporaneous change in Africa absolute plate motion (APM) reflected by physical evidence distributed on the Africa Plate. This evidence has been postulated to take the form of the R,union-Mascarene bend which exhibits many HEB-like features, such as a large angular change close to similar to chron 21. However, the R,union hotspot trail has recently been interpreted as a sequence of continental fragments with incidental hotspot volcanism. Here we show that the alternative R,union-Mascarene Plateau trail can also satisfy the age progressions and geometry of other hotspot trails on the Africa Plate. The implied motion, suggesting a pivoting of Africa from 67 to 50 Ma, could explain the apparent bifurcation of the Tristan hotspot chain, the age reversals seen along the Walvis Ridge, the sharp curve of the Canary trail, and the diffuse nature of the St. Helena chain. To test this hypothesis further we made a new Africa APM model that extends back to similar to 80 Ma using a modified version of the Hybrid Polygonal Finite Rotation Method. This method uses seamount chains and their associated hotspots as geometric constraints for the model, and seamount age dates to determine APM through time. While this model successfully explains many of the volcanic features, it implies an unrealistically fast global lithospheric net rotation, as well as improbable APM trajectories for many other plates, including the Americas, Eurasia and Australia. We contrast this speculative model with a more conventional model in which the Mascarene Plateau is excluded in favour of the Chagos-Laccadive Ridge rotated into the Africa reference frame. This second model implies more realistic net lithospheric rotation and far-field APMs, but fails to explain key details of the Atlantic Ocean volcanic chains. Both models predict a Canary plume influence beneath the Madeiras. Neither model, when projected via the global plate circuit into the Pacific, predicts any significant change in plate motion around chron 21. Consequently, Africa APM models do not appear to provide independent support for a chron 21 global reorganization.	[Maher, S. M.; Wessel, P.] Univ Hawaii Manoa, Dept Geol & Geophys, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA; [Mueller, R. D.; Williams, S. E.] Univ Sydney, EarthByte Grp, Sch Geosci, Sydney, NSW 2006, Australia; [Harada, Y.] Tokai Univ, Sch Marine Sci & Technol, Shizuoka 4248610, Japan	Maher, SM (reprint author), Univ Hawaii Manoa, Dept Geol & Geophys, Sch Ocean & Earth Sci & Technol, 1680 East West Rd, Honolulu, HI 96822 USA.	sarahxmaher@gmail.com			NSF [OCE-106054]; Australian Research Council [DP0987713]; Science Industry Endowment Fund [RP04-174]	Support for this work was provided for PW and SM by NSF grant OCE-106054. RDM and SEW were supported by Australian Research Council grant DP0987713 and Science Industry Endowment Fund grant RP04-174. We would also like to thank Graeme Eagles and an anonymous reviewer, whose comments greatly improved the paper. This is SOEST contribution 9300.	Anderson DL, 2001, SCIENCE, V293, P2016, DOI 10.1126/science.1065448; Conrad CP, 2010, GEOCHEM GEOPHY GEOSY, V11, DOI 10.1029/2009GC002970; Collier JS, 2008, EARTH PLANET SC LETT, V272, P264, DOI 10.1016/j.epsl.2008.04.045; DUNCAN RA, 1984, J GEOPHYS RES, V89, P9980, DOI 10.1029/JB089iB12p09980; Rohde JK, 2013, TECTONOPHYSICS, V604, P60, DOI 10.1016/j.tecto.2012.08.026; Chenet AL, 2007, EARTH PLANET SC LETT, V263, P1, DOI 10.1016/j.epsl.2007.07.011; Steinberger B, 2004, NATURE, V430, P167, DOI 10.1038/nature02660; SMALL C, 1995, J GEOPHYS RES-SOL EA, V100, P17931, DOI 10.1029/95JB01377; Copley A, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2009JB006634; O'Connor JM, 2013, GEOCHEM GEOPHY GEOSY, V14, P4564, DOI 10.1002/ggge.20267; van Hinsbergen DJJ, 2011, J GEOPHYS RES-SOL EA, V116, DOI 10.1029/2010JB008051; Tarduno JA, 2003, SCIENCE, V301, P1064, DOI 10.1126/science.1086442; [Anonymous], 1992, GEOL SOC SPEC PUBL, DOI 10.1144/GSL.SP.1992.068.01.09; Muller RD, 2008, GEOCHEM GEOPHY GEOSY, V9, DOI 10.1029/2007GC001743; Guillou H, 1996, J VOLCANOL GEOTH RES, V73, P141, DOI 10.1016/0377-0273(96)00021-2; Livermore R, 2005, EARTH PLANET SC LETT, V236, P459, DOI 10.1016/j.epsl.2005.03.027; Breton T, 2013, EARTH PLANET SC LETT, V376, P126, DOI 10.1016/j.epsl.2013.06.020; Burke K, 2008, EARTH PLANET SC LETT, V265, P49, DOI 10.1016/j.epsl.2007.09.042; Tarduno J, 2009, SCIENCE, V324, P50, DOI 10.1126/science.1161256; Geldmacher J, 2001, J VOLCANOL GEOTH RES, V111, P55, DOI 10.1016/S0377-0273(01)00220-7; Torsvik TH, 2013, NAT GEOSCI, V6, P223, DOI 10.1038/ngeo1736; Milelli L, 2012, EARTH PLANET SC LETT, V335, P80, DOI 10.1016/j.epsl.2012.04.028; Whittaker JM, 2007, SCIENCE, V318, P83, DOI 10.1126/science.1143769; Sharp WD, 2006, SCIENCE, V313, P1281, DOI 10.1126/science.1128489; BONNEVILLE A, 1988, J GEOPHYS RES-SOLID, V93, P4199, DOI 10.1029/JB093iB05p04199; NURNBERG D, 1991, TECTONOPHYSICS, V191, P27, DOI 10.1016/0040-1951(91)90231-G; DUNCAN RA, 1991, REV GEOPHYS, V29, P31, DOI 10.1029/90RG02372; Kumar P, 2007, NATURE, V449, P894, DOI 10.1038/nature06214; Wessel P, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2007JB005499; Cande SC, 2010, GEOPHYS J INT, V183, P127, DOI 10.1111/j.1365-246X.2010.04737.x; Gurnis M, 2012, COMPUT GEOSCI-UK, V38, P35, DOI 10.1016/j.cageo.2011.04.014; Torsvik TH, 2014, P NATL ACAD SCI USA, V111, P8735, DOI 10.1073/pnas.1318135111; MCNUTT M, 1988, J GEOPHYS RES-SOLID, V93, P2784, DOI 10.1029/JB093iB04p02784; Geldmacher J, 2005, EARTH PLANET SC LETT, V237, P85, DOI 10.1016/j.epsl.2005.04.037; ANCOCHEA E, 1994, J VOLCANOL GEOTH RES, V60, P243, DOI 10.1016/0377-0273(94)90054-X; Iaffaldano G, 2014, GEOCHEM GEOPHY GEOSY, V15, P1663, DOI 10.1002/2014GC005309; Courtillot V, 2003, EARTH PLANET SC LETT, V205, P295, DOI 10.1016/S0012-821X(02)01048-8; Koppers AAP, 2001, EARTH PLANET SC LETT, V185, P237, DOI 10.1016/S0012-821X(00)00387-3; Torsvik TH, 2010, EARTH PLANET SC LETT, V291, P106, DOI 10.1016/j.epsl.2009.12.055; Thirlwall MF, 2000, J VOLCANOL GEOTH RES, V103, P247, DOI 10.1016/S0377-0273(00)00227-4; Cande SC, 2015, GEOPHYS J INT, V200, P227, DOI 10.1093/gji/ggu392; Guillou H, 2004, J VOLCANOL GEOTH RES, V135, P221, DOI 10.1016/j.volgerores.2004.03.003; Whittaker JM, 2013, GEOCHEM GEOPHY GEOSY, V14, P1891, DOI 10.1002/ggge.20120; Seton M, 2012, EARTH-SCI REV, V113, P212, DOI 10.1016/j.earscirev.2012.03.002; MOLNAR P, 1987, NATURE, V327, P587, DOI 10.1038/327587a0; OCONNOR JM, 1992, EARTH PLANET SC LETT, V113, P343, DOI 10.1016/0012-821X(92)90138-L; FISHER RL, 1967, GEOL SOC AM BULL, V78, P1247, DOI 10.1130/0016-7606(1967)78[1247:MPWIO]2.0.CO;2; Backman J., 1988, P ODP SCI RES, V115, P233; Bernard A, 2000, CR ACAD SCI II A, V330, P777, DOI 10.1016/S1251-8050(00)00221-4; BUNCE ET, 1966, PHILOS TR R SOC S-A, V259, P218, DOI 10.1098/rsta.1966.0008; Burke KC, 1976, J GEOPHYS RES, V93, P7690; Cande SC, 2011, NATURE, V475, P47, DOI 10.1038/nature10174; CANDE SC, 1982, EARTH PLANET SC LETT, V57, P63, DOI 10.1016/0012-821X(82)90173-X; Cande S.C., 1988, J GEOPHYS RES, V93, P479; Cantagrel J.M., 1984, B VOLCANOL, V47, P597, DOI 10.1007/BF01961229; Coello J.J., 1992, J VOLCANOL GEOTHERM, V532, P251, DOI DOI 10.1016/0377-0273(92)90085-R; Daly M., 1989, GEOLOGICAL SOC SPECI, V44, P309, DOI [10.1144/GSL.SP.1989.044.01.17, DOI 10.1144/GSL.SP.1989.044.01.17]; Deppe J., 2010, GEOPH RES ABSTR, V12; Doubrovine V., 2012, J GEOPHYS RES, V117, DOI [10.1029/2011JB009072., DOI 10.1029/2011JB009072]; DUNCAN RA, 1985, OCEAN BASIN MARGIN, V7, P89; DUNCAN RA, 1990, P OC DRILL PROGR SCI, V0115; Eagles G., 2013, GEOPHYS J INT, V196, P1, DOI DOI 10.1093/GJI/GGT1372; Eagles G, 2013, GEOPHYS J INT, V194, P670, DOI 10.1093/gji/ggt162; EMERICK CM, 1982, EARTH PLANET SC LETT, V60, P415, DOI 10.1016/0012-821X(82)90077-2; Ganerod M, 2011, GEOL SOC SPEC PUBL, V357, P229, DOI 10.1144/SP357.12; Geldmacher J, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB003931; Hall S., 2007, EOS T AM GEOPHYS UN, V88; Harada Y., 2003, EOS T AM GEOPHYS UN, V84; Heine C, 2014, GEOLOGY, V42, P211, DOI 10.1130/G35082.1; Holm PM, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2007JB005339; Koppers AAP, 2012, NAT GEOSCI, V5, P911, DOI [10.1038/ngeo1638, 10.1038/NGEO1638]; MCDOUGAL.I, 1971, GEOCHIM COSMOCHIM AC, V35, P261, DOI 10.1016/0016-7037(71)90037-8; MEYERHOFF AA, 1981, AAPG BULL, V65, P1344; Morgan J.W., 1981, SEA, V7; Morra G, 2013, EARTH PLANET SC LETT, V373, P93, DOI 10.1016/j.epsl.2013.04.020; MULLER RD, 1993, GEOLOGY, V21, P275, DOI 10.1130/0091-7613(1993)021<0275:RPMRTT>2.3.CO;2; Muller R.D., 1999, CARIBBEAN BASINS, P39; OCONNOR JM, 1990, J GEOPHYS RES-SOLID, V95, P17475, DOI 10.1029/JB095iB11p17475; O'Connor JM, 1999, EARTH PLANET SC LETT, V171, P575, DOI 10.1016/S0012-821X(99)00183-1; O'Connor JM, 2012, NAT GEOSCI, V5, P735, DOI [10.1038/ngeo1583, 10.1038/NGEO1583]; O'Neill C, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2004GC000784; Purdy EG, 1993, AM ASS PETROL GEOL S, V34, P1; Raymond C.A., 2000, HIST DYNAMICS GLOBAL, V121, P359; Reusch AM, 2011, GEOPHYS J INT, V187, P1146, DOI 10.1111/j.1365-246X.2011.05239.x; Royer JY, 2006, GEOLOGY, V34, P501, DOI 10.1130/G22463.1; Sager W. W., 2008, EOS T AM GEOPHYS UN, V89; Schlich R., 1982, INDIAN OCEAN, V6, P51; Skolotnev SG, 2010, GEOTECTONICS+, V44, P462, DOI 10.1134/S0016852110060038; Tiwari VM, 2007, EARTH PLANET SC LETT, V264, P9, DOI 10.1016/j.epsl.2007.08.023; Torsvik TH, 2008, REV GEOPHYS, V46, DOI 10.1029/2007RG000227; Torsvik TH, 1998, EARTH PLANET SC LETT, V164, P221, DOI 10.1016/S0012-821X(98)00206-4; TUCHOLKE BE, 1990, J GEOPHYS RES-SOLID, V95, P17555, DOI 10.1029/JB095iB11p17555; VANDAMME D, 1990, GEOPHYS RES LETT, V17, P1105, DOI 10.1029/GL017i008p01105; Wessel P, 2006, GEOCHEM GEOPHY GEOSY, V7, DOI 10.1029/2005GC001000; Wessel P, 2009, EARTH PLANET SC LETT, V284, P467, DOI 10.1016/j.epsl.2009.05.012	95	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0956-540X	1365-246X		GEOPHYS J INT	Geophys. J. Int.	JUN	2015	201	3					1743	1764		10.1093/gji/ggv104		22	Geochemistry & Geophysics	Geochemistry & Geophysics	CJ2NN	WOS:000355321800039		
J	Nakao, S; Kaizu, Y; Yoshida, S; Iida, T; Ishibashi, T				Nakao, Shintaro; Kaizu, Yoshihiro; Yoshida, Shigeo; Iida, Tomohiro; Ishibashi, Tatsuro			Spontaneous remission of acute zonal occult outer retinopathy: follow-up using adaptive optics scanning laser ophthalmoscopy	GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						OCT; mfERG; IS/OS; Ellipsoid	SEGMENT; RETINA	The purpose of this study was to report a case of acute zonal occult outer retinopathy (AZOOR) with spontaneous remission that was followed up using adaptive optics scanning laser ophthalmoscopy (AO-SLO). The right eye of a 31-year old myopic man diagnosed with AZOOR was followed up. The patient underwent a full ophthalmologic examination, spectral-domain optical coherence tomography (SD-OCT), multifocal electroretinography (mfERG) and imaging with prototype AO-SLO systems (Canon Inc) at the first visit, 1 month after, and 2 months after. Images focused on the photoreceptor layer were recorded in the area, and a montage of AO-SLO images was created. The patient presented with acute onset of a blind spot and photopsia in his right eye. On AO-SLO, focal dark areas could be observed on the right eye but not on the left eye at the first examination (cone density 8,589/mm(2), mosaic regularity of cone photoreceptors 38.5 %, cone spacing 0.567). The dark areas on AO-SLO corresponded to areas of disrupted inner segments and outer segments (IS/OS) line or ellipsoid of the IS and abnormal area in mfERG. After 1 and 2 months, his symptoms tended to disappear gradually without any treatment. IS/OS line and mfERG could be nearly normalized. Furthermore, normal cone mosaic could be observed in areas where some focal dark spots could be observed at the first examination (cone density 10,112/mm(2), mosaic regularity of cone photoreceptors 39.9 %, cone spacing 0.606). AO-SLO is a useful tool of diagnosis and follow-up of AZOOR. This study might suggest reversible cone damage could occur in some cases of AZOOR with spontaneous remission.	[Nakao, Shintaro; Kaizu, Yoshihiro; Yoshida, Shigeo; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, Fukuoka 8128582, Japan; [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan	Nakao, S (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	snakao@med.kyushu-u.ac.jp			JSPS KAKENHI [25713057]	We thank Mr. Kazushi Nomura (Canon Inc.) for the technical support. Supported by grants from JSPS KAKENHI, Grant-in-Aid for Young Scientists (A) No. 25713057 (SN).	Spaide RF, 2008, AM J OPHTHALMOL, V146, P111, DOI 10.1016/j.ajo.2008.02.027; Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535; Baraas RC, 2007, J OPT SOC AM A, V24, P1438, DOI 10.1364/JOSAA.24.001438; Mkrtchyan M, 2012, AM J OPHTHALMOL, V153, P757, DOI 10.1016/j.ajo.2011.09.007; Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028; Gass JD, 2002, AM J OPHTHALMOL, V134, P329, DOI 10.1016/S0002-9394(02)01640-9; GASS JDM, 1993, J CLIN NEURO-OPHTHAL, V13, P79; Hirose F, 2011, PROC SPIE, V7885, DOI 10.1117/12.873671; Li D, 2007, ARCH OPHTHALMOL-CHIC, V125, P1194, DOI 10.1001/archopht.125.9.1194; Makiyama Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079447; Rajendram R, 2007, BRIT J OPHTHALMOL, V91, P531, DOI 10.1136/bjo.2006.101576	11	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0721-832X	1435-702X		GRAEF ARCH CLIN EXP	Graefes Arch. Clin. Exp. Ophthalmol.	JUN	2015	253	6					839	843		10.1007/s00417-014-2760-x		5	Ophthalmology	Ophthalmology	CJ1AM	WOS:000355213500002		
J	Tsuboi, K; Nakai, K; Iwahashi, C; Gomi, F; Ikuno, Y; Nishida, K				Tsuboi, Kotaro; Nakai, Kei; Iwahashi, Chiharu; Gomi, Fumi; Ikuno, Yasushi; Nishida, Kohji			Analysis of choroidal folds in acute Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography	GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						Choroidal folds; High-penetration optical coherence tomography; Vogt-Koyanagi-Harada disease	INDOCYANINE GREEN ANGIOGRAPHY; THICKNESS	To characterize patients with Vogt-Koyanagi-Harada (VKH) disease with choroidal folds (CFs) and determine how the foveal choroidal thickness changes after initial treatment using high-penetration optical coherence tomography (HP-OCT). In this retrospective observational study, we analyzed 42 eyes of 21 patients with new-onset VKH disease to determine the demographic and clinical differences between patients with and without CFs. Twenty-four eyes (57.1 %) of 13 patients with VKH disease had CFs. The mean age (p = 0.0009) of patients with CFs was significantly higher than that of those without CFs (49.1 vs 39.4 years respectively). The frequency of disc swelling (p = 0.0001) was significantly higher in eyes with CFs than in those without CFs (95.8 % vs 38.9 %). The choroidal thickness at the first visit (p = 0.0011) was significantly greater in eyes with CFs than in those without CFs (794 +/- 144 mu m vs 649 +/- 113 mu m). The choroid 6 months after the initial treatment (p = 0.0118) was significantly thinner in eyes with CFs than in those without CFs (270 +/- 92 mu m vs 340 +/- 80 mu m). The frequency of sunset glow fundus at 6 months (p = 0.0334) in eyes with CFs was significantly higher than in those without CFs (62.5 % vs 27.8 %). The development of CFs in patients with VKH disease was significantly correlated with age, disc swelling, and choroidal thickness. The eyes with CFs frequently developed a sunset glow fundus. The findings suggested that patients with CFs might have severe and longstanding inflammation of the choroidal tissues.	[Tsuboi, Kotaro; Nakai, Kei; Iwahashi, Chiharu; Gomi, Fumi; Ikuno, Yasushi; Nishida, Kohji] Osaka Univ, Dept Ophthalmol E7, Sch Med, Suita, Osaka 5650871, Japan	Nakai, K (reprint author), Osaka Univ, Dept Ophthalmol E7, Sch Med, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	kei.nakai@ophthal.med.osaka-u.ac.jp					Ruiz-Moreno JM, 2013, INVEST OPHTH VIS SCI, V54, P353, DOI 10.1167/iovs.12-10863; Yang PZ, 2007, OPHTHALMOLOGY, V114, P606, DOI 10.1016/j.ophtha.2006.07.040; MOORTHY RS, 1995, SURV OPHTHALMOL, V39, P265, DOI 10.1016/S0039-6257(05)80105-5; Kiernan DF, 2010, AM J OPHTHALMOL, V149, P18, DOI 10.1016/j.ajo.2009.08.037; Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005; Read RW, 2001, AM J OPHTHALMOL, V131, P647, DOI 10.1016/S0002-9394(01)00925-4; Nakai K, 2012, GRAEF ARCH CLIN EXP, V250, P1089, DOI 10.1007/s00417-011-1910-7; Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053; Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023; Bouchenaki Nadia, 2011, J Ophthalmic Vis Res, V6, P241; Chee SP, 2009, AM J OPHTHALMOL, V147, P154, DOI 10.1016/j.ajo.2008.07.044; Fardeau Christine, 2007, International Ophthalmology, V27, P163, DOI 10.1007/s10792-006-9024-7; Frank W, 1973, AM J OPHTHALMOL, V75, P930; Gupta V, 2009, AM J OPHTHALMOL, V147, P148, DOI 10.1016/j.ajo.2008.07.028; Herbort Carl P., 2007, International Ophthalmology, V27, P173, DOI 10.1007/s10792-007-9060-y; John D Bullock MD, 1974, DOC OPTHALMOL, P261; Kato Y, 2013, JPN J OPHTHALMOL, V57, P90, DOI 10.1007/s10384-012-0212-x; Keane Pearse A, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS67, DOI 10.3928/15428877-20110627-06; Kiyomoto Chihiro, 2007, International Ophthalmology, V27, P149, DOI 10.1007/s10792-007-9067-4; Knecht Pascal B., 2013, International Ophthalmology, V33, P571, DOI 10.1007/s10792-012-9692-4; Nakao K, 2012, INVEST OPHTH VIS SCI, V53, P1917, DOI 10.1167/iovs.11-8984; Onal Sumru, 2014, International Ophthalmology, V34, P401, DOI 10.1007/s10792-013-9822-7; Rao NA, 2010, OPHTHALMOLOGY, V117, P591, DOI 10.1016/j.ophtha.2009.08.030; Shinoda K, 2012, GRAEF ARCH CLIN EXP, V250, P1399, DOI 10.1007/s00417-012-1977-9; Wu WJ, 2007, AM J OPHTHALMOL, V143, P900, DOI 10.1016/j.ajo.2006.11.050; Zhao C, 2009, OCUL IMMUNOL INFLAMM, V17, P282, DOI 10.1080/09273940902807930	26	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0721-832X	1435-702X		GRAEF ARCH CLIN EXP	Graefes Arch. Clin. Exp. Ophthalmol.	JUN	2015	253	6					959	964		10.1007/s00417-015-2945-y		6	Ophthalmology	Ophthalmology	CJ1AM	WOS:000355213500017		
J	Kikuchi, D; Iizuka, T; Yamada, A; Furuhata, T; Yamashita, S; Nomura, K; Kuribayashi, Y; Kimura, R; Matsui, A; Mitani, T; Ogawa, O; Takeda, H; Hoteya, S; Kaise, M				Kikuchi, Daisuke; Iizuka, Toshiro; Yamada, Akihiro; Furuhata, Tsukasa; Yamashita, Satoshi; Nomura, Kosuke; Kuribayashi, Yasutaka; Kimura, Ryuusuke; Matsui, Akira; Mitani, Toshifumi; Ogawa, Osamu; Takeda, Hidehiko; Hoteya, Shu; Kaise, Mitsuru			Utility of magnifying endoscopy with narrow band imaging in determining the invasion depth of superficial pharyngeal cancer	HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK			English	Article						superficial pharyngeal cancer; squamous cell carcinoma; narrow band imaging; magnified endoscopy; invasion depth	SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASIS; SUBMUCOSAL DISSECTION; MUCOSAL RESECTION; MESOPHARYNGEAL	BackgroundMagnifying endoscopy with narrow band imaging (ME-NBI) is useful to diagnose invasion depth of superficial esophageal cancer. The purpose of this study was to evaluate the utility of ME-NBI of superficial pharyngeal cancer. MethodsBetween April 2008 and June 2012, 146 lesions in 104 patients who underwent ME-NBI and en bloc resection were retrospectively analyzed. Based on magnifying endoscopic classification, proposed by the Japan Esophageal Society, microvasculature type was classified into B1, B2, and B3. ResultsB1 alone, B2, and B3 were observed in 128, 14, and 4 lesions, respectively. The frequency of subepithelial cancer were 20.3% (26 of 128), 78.6% (11 of 14), and 100% (4 of 4), respectively (p < .05). Mean invasion distance were 650 m, 720.0 m, and 2256.5 m. Positive and negative predictive value for diagnosing subepithelial cancer based on the presence of B2 or B3 was 83.3% (15 of 18) and 79.7% (102 of 128). ConclusionME-NBI is useful to determining invasion depth of superficial pharyngeal cancer. (c) 2014 Wiley Periodicals, Inc. Head Neck 37: 846-850, 2015	[Kikuchi, Daisuke; Iizuka, Toshiro; Yamada, Akihiro; Furuhata, Tsukasa; Yamashita, Satoshi; Nomura, Kosuke; Kuribayashi, Yasutaka; Kimura, Ryuusuke; Matsui, Akira; Mitani, Toshifumi; Ogawa, Osamu; Hoteya, Shu; Kaise, Mitsuru] Toranomon Gen Hosp, Dept Gastroenterol, Tokyo 1058470, Japan; [Takeda, Hidehiko] Toranomon Gen Hosp, Dept Otorhinolaryngol, Tokyo 1058470, Japan	Kikuchi, D (reprint author), Toranomon Gen Hosp, Dept Gastroenterol, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan.	dkiku1230@gmail.com					Iizuka T, 2009, ENDOSCOPY, V41, P113, DOI 10.1055/s-0028-1119453; Muto M, 2010, J CLIN ONCOL, V28, P1566, DOI 10.1200/JCO.2009.25.4680; Kitajima K, 2004, J GASTROENTEROL, V39, P534, DOI 10.1007/s00535-004-1339-4; Kim DU, 2008, J GASTROEN HEPATOL, V23, P619, DOI 10.1111/j.1440-1746.2007.05259.x; Chemaly M, 2008, ENDOSCOPY, V40, P2, DOI 10.1055/s-2007-966958; Goda K, 2009, DIS ESOPHAGUS, V22, P453, DOI 10.1111/j.1442-2050.2009.00942.x; Arima M, 2005, ESOPHAGUS, V2, P191, DOI DOI 10.1007/S10388-005-0060-6; Attila T, 2009, DIS ESOPHAGUS, V22, P104, DOI 10.1111/j.1442-2050.2008.00878.x; Fujii S, 2010, HISTOPATHOLOGY, V56, P510, DOI 10.1111/j.1365-2559.2010.03512.x; Gotoda T, 2000, GASTRIC CANCER, V3, P219, DOI 10.1007/PL00011720; Iizuka T, 2012, GASTROINTEST ENDOSC, V76, P1034, DOI 10.1016/j.gie.2012.07.013; Iizuka T, 2011, ENDOSCOPY, V43, P839, DOI 10.1055/s-0031-1271112; Inoue H, 1997, DIGEST ENDOSC, V9/1, P16, DOI 10.1111/j.1443-1661.1997.tb00453.x; Kumagai Y, 2002, ENDOSCOPY, V34, P369, DOI 10.1055/s-2002-25285; Nonaka S, 2008, ENDOSCOPY, V40, P347, DOI 10.1055/s-2007-995433; Oyama T, 2012, STOMACH INTESTINE, V47, P1360; Oyama T, 2011, ESOPHAGUS, V8, P247; Shimizu Y, 2006, GASTROINTEST ENDOSC, V64, P260; Shimizu Y, 2006, GASTROINTEST ENDOSC, V64, P255, DOI 10.1016/j.gie.2006.01.049; Taniguchi M, 2011, AURIS NASUS LARYNX, V38, P710, DOI 10.1016/j.anl.2011.01.001; Tomifuji M, 2011, ANN SURG ONCOL, V18, P490, DOI 10.1245/s10434-010-1219-5	21	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1043-3074	1097-0347		HEAD NECK-J SCI SPEC	Head Neck-J. Sci. Spec. Head Neck	JUN	2015	37	6					846	850		10.1002/hed.23683		5	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	CI8HL	WOS:000355012000015		
J	Koh, CP; Ng, CEL; Nah, GSS; Wang, CQ; Tergaonkar, V; Matsumura, T; Yokomizo, T; Suda, T; Osato, M				Koh, Cai Ping; Ng, Cherry Ee Lin; Nah, Giselle Sek Suan; Wang, Chelsia Qiuxia; Tergaonkar, Vinay; Matsumura, Takayoshi; Yokomizo, Tomomasa; Suda, Toshio; Osato, Motomi			Hematopoietic stem cell enhancer: a powerful tool in stem cell biology	HISTOLOGY AND HISTOPATHOLOGY			English	Review						RUNX1; AML1; Hematopoietic stem cell; Cis-regulatory element	FETAL LIVER HEMATOPOIESIS; ENDOTHELIAL-CELLS; TRANSGENIC MICE; SELF-RENEWAL; ADULT-MOUSE; TRANSCRIPTIONAL REGULATION; DEFINITIVE HEMATOPOIESIS; ERYTHROID-CELLS; GENE-EXPRESSION; CRE-RECOMBINASE	There has been considerable interest in identifying a cis-regulatory element that targets gene expression to stem cells. Such an element, termed stem cell enhancer, holds the promise of providing important insights into the transcriptional programs responsible for inherent stem cell-specific properties such as self-renewal capacity. The element also serves as a molecular handle for stem cell-specific marking, transgenesis and gene targeting, thereby becoming invaluable to stem cell research. A series of candidate enhancers have been identified for hematopoietic stem cells (HSCs). This review summarizes currently known HSC enhancers with emphasis on an intronic enhancer in the Runx1 gene which is critical for the generation and maintenance of HSCs. The element, named eR1 (+24m), is active specifically in HSCs, but not in progenitors, and is hence the most definitive HSC enhancer.	[Koh, Cai Ping; Ng, Cherry Ee Lin; Nah, Giselle Sek Suan; Wang, Chelsia Qiuxia; Matsumura, Takayoshi; Yokomizo, Tomomasa; Suda, Toshio; Osato, Motomi] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore; [Nah, Giselle Sek Suan; Wang, Chelsia Qiuxia; Tergaonkar, Vinay] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Yokomizo, Tomomasa] Juntendo Univ, Sch Med, Dept Hematol, Bunkyo Ku, Tokyo 113, Japan; [Suda, Toshio] Keio Univ, Sch Med, Sakaguchi Lab Dev Biol, Dept Cell Differentiat,Shinjuku Ku, Tokyo, Japan; [Osato, Motomi] ASTAR, Inst Bioengn & Nanotechnol, Singapore, Singapore; [Osato, Motomi] Natl Univ Singapore, Dept Paediat, Singapore 117548, Singapore; [Yokomizo, Tomomasa; Suda, Toshio; Osato, Motomi] Kumamoto Univ, Int Res Ctr Med Sci, Chuo Ku, Kumamoto, Japan	Osato, M (reprint author), Natl Univ Singapore, Canc Sci Inst Singapore, 14 Med Dr, Singapore 117599, Singapore.	csimo@nus.edu.sg	Osato, Motomi/N-5056-2014; ASTAR, IMCB/E-2320-2012	Osato, Motomi/0000-0003-3982-9054; 	National Medical Research Council (NMRC); Biomedical Research Council (BMRC); National Research Foundation Singapore; Singapore Ministry of Education under its Research Center of Excellence initiative	We thank Osato laboratory members for their helpful discussion. We apologize to colleagues whose work could not be cited due to space limitations. This work was supported by National Medical Research Council (NMRC), Biomedical Research Council (BMRC), and the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Center of Excellence initiative.	Yamamoto R, 2013, CELL, V154, P1112, DOI 10.1016/j.cell.2013.08.007; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Ma XQ, 2002, STEM CELLS, V20, P514, DOI 10.1634/stemcells.20-6-514; Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Dykstra B, 2007, CELL STEM CELL, V1, P218, DOI 10.1016/j.stem.2007.05.015; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Hirai H, 2003, BLOOD, V101, P886, DOI 10.1182/blood-2002-02-0655; Alva JA, 2006, DEV DYNAM, V235, P759, DOI 10.1002/dvdy.20643; Gottgens B, 2002, EMBO J, V21, P3039, DOI 10.1093/emboj/cdf286; Mao XH, 2001, BLOOD, V97, P324, DOI 10.1182/blood.V97.1.324; Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2; Ng CEL, 2010, STEM CELLS, V28, P1869, DOI 10.1002/stem.507; Emambokus NR, 2003, IMMUNITY, V19, P33, DOI 10.1016/S1074-7613(03)00173-0; North TE, 2004, STEM CELLS, V22, P158, DOI 10.1634/stemcells.22-2-158; Wang YD, 2010, NATURE, V465, P483, DOI 10.1038/nature09002; Kleinjan Dirk-Jan, 2009, Briefings in Functional Genomics & Proteomics, V8, P317, DOI 10.1093/bfgp/elp022; Sanjuan-Pla A, 2013, NATURE, V502, P232, DOI 10.1038/nature12495; Chen MJ, 2009, NATURE, V457, P887, DOI 10.1038/nature07619; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Stadtfeld M, 2005, DEVELOPMENT, V132, P203, DOI 10.1242/dev.01558; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6; Hosoya-Ohmura S, 2011, MOL CELL BIOL, V31, P1894, DOI 10.1128/MCB.05065-11; Hosen N, 2007, STEM CELLS, V25, P1635, DOI 10.1634/stemcells.2006-0229; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Muller-Sieburg CE, 2002, BLOOD, V100, P1302; Tallini YN, 2009, P NATL ACAD SCI USA, V106, P1808, DOI 10.1073/pnas.0808920106; MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302; Gan T, 2010, LEUKEMIA, V24, P1732, DOI 10.1038/leu.2010.171; Koni PA, 2001, J EXP MED, V193, P741, DOI 10.1084/jem.193.6.741; Wolfler A, 2010, BLOOD, V116, P4116, DOI 10.1182/blood-2010-03-275404; Gothert JR, 2005, BLOOD, V105, P2724, DOI 10.1182/blood-2004-08-3037; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Jacob B, 2010, BLOOD, V115, P1610, DOI 10.1182/blood-2009-07-232249; Copley MR, 2012, CELL STEM CELL, V10, P690, DOI 10.1016/j.stem.2012.05.006; Frelin C, 2013, NAT IMMUNOL, V14, P1037, DOI 10.1038/ni.2692; Kobayashi-Osaki M, 2005, MOL CELL BIOL, V25, P7005, DOI 10.1128/MCB.25.16.7005-7020.2005; Wilson NK, 2010, MOL CELL BIOL, V30, P3853, DOI 10.1128/MCB.00032-10; Pimanda JE, 2007, P NATL ACAD SCI USA, V104, P17692, DOI 10.1073/pnas.0707045104; Gustafsson E, 2001, J CELL SCI, V114, P671; de Bruijn MFTR, 2002, IMMUNITY, V16, P673, DOI 10.1016/S1074-7613(02)00313-8; Ogilvy S, 1998, BLOOD, V91, P419; de Boer J, 2003, EUR J IMMUNOL, V33, P314, DOI 10.1002/immu.200310005; Kent DG, 2009, BLOOD, V113, P6342, DOI 10.1182/blood-2008-12-192054; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Hirai H, 2005, BLOOD, V106, P1948, DOI 10.1182/blood-2004-12-4872; Kemp R, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh090; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Motoda L, 2007, STEM CELLS, V25, P2976, DOI 10.1634/stemcells.2007; Monvoisin A, 2006, DEV DYNAM, V235, P3413, DOI 10.1002/dvdy.20982; Grote D, 2006, DEVELOPMENT, V133, P53, DOI 10.1242/dev.02184; Takai J, 2013, BLOOD, V122, P3450, DOI 10.1182/blood-2013-01-476911; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; Pimanda JE, 2007, P NATL ACAD SCI USA, V104, P840, DOI 10.1073/pnas.0607196104; Maillard I, 2003, IMMUNITY, V19, P781, DOI 10.1016/S1074-7613(03)00325-X; Nottingham WT, 2007, BLOOD, V110, P4188, DOI 10.1182/blood-2007-07-100883; Buijs A, 2012, LEUKEMIA, V26, P2151, DOI 10.1038/leu.2012.79; Calaminus SDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051361; Calero-Nieto FJ, 2013, ONCOGENE, V32, P5471, DOI 10.1038/onc.2013.175; Donaldson IJ, 2005, HUM MOL GENET, V14, P595, DOI 10.1093/hmg/ddi056; Georgiades P, 2002, GENESIS, V34, P251, DOI 10.1002/gene.10161; Hallaq H, 2004, DEVELOPMENT, V131, P5197, DOI 10.1242/dev.01393; Hills D, 2011, BLOOD, V117, P3521, DOI 10.1182/blood-2009-12-253989; Joseph C, 2013, CELL STEM CELL, V13, P520, DOI 10.1016/j.stem.2013.10.010; Kataoka K, 2011, J EXP MED, V208, P2402, DOI 10.1084/jem.20110447; Khandekar M, 2007, DEVELOPMENT, V134, P1703, DOI 10.1242/dev.001297; Kimura Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026918; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Landry JR, 2009, BLOOD, V113, P5783, DOI 10.1182/blood-2008-11-187757; MURAKAMI K, 1993, ONCOGENE, V8, P1559; Okuno Y, 2002, P NATL ACAD SCI USA, V99, P6246, DOI 10.1073/pnas.092027799; Pimanda JE, 2008, BLOOD, V112, P4512, DOI 10.1182/blood-2008-05-157560; Robb L, 1996, EMBO J, V15, P4123; Rodriguez TA, 2001, DEV BIOL, V234, P304, DOI 10.1006/dbio.2001.0265; Sanchez MJ, 1999, DEVELOPMENT, V126, P3891; Swiers G, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3924; Takayanagi SI, 2006, BLOOD, V107, P4317, DOI 10.1182/blood-2005-09-3747; Thoms JAI, 2011, BLOOD, V117, P7079, DOI 10.1182/blood-2010-12-317990; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Xie HF, 2014, CELL STEM CELL, V14, P68, DOI 10.1016/j.stem.2013.10.001; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320; Zhong JF, 2005, P NATL ACAD SCI USA, V102, P2448, DOI 10.1073/pnas.0409459102	85	0	0	F HERNANDEZ	MURCIA	PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN	0213-3911	1699-5848		HISTOL HISTOPATHOL	Histol. Histopath.	JUN	2015	30	6					661	672				12	Cell Biology; Pathology	Cell Biology; Pathology	CJ2PA	WOS:000355325700003		
J	Feng, H; Yang, WT; Onozawa, Y; Yoshimura, T; Tamenori, A; Sin, JKO				Feng, Hao; Yang, Wentao; Onozawa, Yuichi; Yoshimura, Takashi; Tamenori, Akira; Sin, Johnny K. O.			A New Fin p-Body Insulated Gate Bipolar Transistor With Low Miller Capacitance	IEEE ELECTRON DEVICE LETTERS			English	Article						Fin p-body; insulated gate bipolar transistor (IGBT); Miller capacitance; gate charge; wide trench	IGBT	A new fin p-body insulated gate bipolar transistor (Fin-p IGBT) is designed and experimentally demonstrated. The device features wide trenches and spacer gates, which is implemented using a simple and low-cost process. Compared with the conventional floating p-body IGBT, the fabricated Fin-p IGBT is able to achieve remarkable reduction in both Miller capacitance (-60% at VCE of 15 V) and gate charge (-46%).	[Feng, Hao; Yang, Wentao; Sin, Johnny K. O.] Hong Kong Univ Sci & Technol, Dept Elect & Comp Engn, Hong Kong, Hong Kong, Peoples R China; [Onozawa, Yuichi; Yoshimura, Takashi; Tamenori, Akira] Fuji Elect Co Ltd, Matsumoto, Nagano 3900821, Japan	Feng, H (reprint author), Hong Kong Univ Sci & Technol, Dept Elect & Comp Engn, Hong Kong, Hong Kong, Peoples R China.	hfeng@ust.hk			Fuji Electric Company, Ltd., Matsumoto, Japan [FEDT04]	This work was supported by Fuji Electric Company, Ltd., Matsumoto, Japan, under Grant FEDT04. The review of this letter was arranged by Editor S.-H. Ryu.	Otsuki M, 2003, IEEE T ELECTRON DEV, V50, P1525, DOI [10.1109/TED.2003.813505, 10.1109/TED.2003813505]; [Anonymous], 2001, MEDICI VERS 2001 4; Toyota Y, 2013, PROC INT SYMP POWER, P29, DOI 10.1109/ISPSD.2013.6694391; Bhalla A., 1999, P ISPSD 99, P41; CHOKHAWALA RS, 1995, IEEE T IND APPL, V31, P603, DOI 10.1109/28.382122; Hu J, 2013, PROC INT SYMP POWER, P25; Kitagawa M., 1993, International Electron Devices Meeting 1993. Technical Digest (Cat. No.93CH3361-3), DOI 10.1109/IEDM.1993.347221; Laska T., 2000, P 12 ISPSD, P355; Machida S, 2009, PROC INT SYMP POWER, P136, DOI 10.1109/ISPSD.2009.5158020; Murari B., 2002, SMART POWER ICS TECH, P188; Onozawa Y, 2007, INT SYM POW SEMICOND, P13, DOI 10.1109/ISPSD.2007.4294920; Oyama K., 2001, Proceedings of the 13th International Symposium on Power Semiconductor Devices & ICs. IPSD '01 (IEEE Cat. No.01CH37216), DOI 10.1109/ISPSD.2001.934642; Takahashi H, 1996, ISPSD '96 - 8TH INTERNATIONAL SYMPOSIUM ON POWER SEMICONDUCTOR DEVICES AND ICS, PROCEEDINGS, P349; Takahashi T, 2008, INT SYM POW SEMICOND, P72	14	1	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0741-3106	1558-0563		IEEE ELECTR DEVICE L	IEEE Electron Device Lett.	JUN	2015	36	6					591	593		10.1109/LED.2015.2426197		3	Engineering, Electrical & Electronic	Engineering	CJ1OE	WOS:000355252300021		
J	Miki, T; Morie, T; Matsukawa, K; Bando, Y; Okumoto, T; Obata, K; Sakiyama, S; Dosho, S				Miki, Takuji; Morie, Takashi; Matsukawa, Kazuo; Bando, Yoji; Okumoto, Takeshi; Obata, Koji; Sakiyama, Shiro; Dosho, Shiro			A 4.2 mW 50 MS/s 13 bit CMOS SAR ADC With SNR and SFDR Enhancement Techniques	IEEE JOURNAL OF SOLID-STATE CIRCUITS			English	Article						ADC; CMOS; dithering; SAR	65 NM CMOS; DB SNDR; QUANTIZATION; 10-BIT	This paper presents a SAR ADC with 71 dB SNDR and 85 dB SFDR at 50 MS/s while keeping low power consumption of 4.2 mW. To achieve high resolution without large increase of power, several SNR and SFDR enhancement techniques are proposed. Firstly, the ADC repeats comparison of LSB by using redundant DAC to average comparator noise and improve SNR. The technique also corrects settling error adaptively, which extends operation speed to 50 MHz even though extra comparison period is added for averaging. Secondly, simple filtering method for reducing DAC noise is introduced to achieve further improvement of SNR. Finally, new dithering method is proposed to enhance SFDR. Injecting noise-shaped, multi-valued and uniform-distributed dither to input of the ADC, spurs caused by capacitance mismatches of DAC can be suppressed more effectively compared with conventional dithering. These techniques can be realized by simple circuits in addition to a basic SAR ADC configuration and do not need high power consumption. The chip is fabricated in a 90 nm CMOS process and occupies 0.1 mm(2) including all correction logic. The ADC achieved a peak figure of merit (FoM) of 168.7 dB.	[Miki, Takuji; Matsukawa, Kazuo; Obata, Koji; Sakiyama, Shiro; Dosho, Shiro] Panasonic Corp, Osaka 5708501, Japan; [Morie, Takashi; Bando, Yoji; Okumoto, Takeshi] Panasonic Corp, Kyoto 6178520, Japan	Miki, T (reprint author), Panasonic Corp, Osaka 5708501, Japan.						van Elzakker M, 2010, IEEE J SOLID-ST CIRC, V45, P1007, DOI 10.1109/JSSC.2010.2043893; Abo AM, 1999, IEEE J SOLID-ST CIRC, V34, P599, DOI 10.1109/4.760369; Miyahara M, 2008, IEEE ASIAN SOLID STA, P269, DOI 10.1109/ASSCC.2008.4708780; Stepanovic D, 2013, IEEE J SOLID-ST CIRC, V48, P971, DOI 10.1109/JSSC.2013.2239005; Liu WB, 2011, IEEE J SOLID-ST CIRC, V46, P2661, DOI 10.1109/JSSC.2011.2163556; MCCREARY JL, 1975, IEEE J SOLID-ST CIRC, V10, P371, DOI 10.1109/JSSC.1975.1050629; Kapusta R, 2013, IEEE J SOLID-ST CIRC, V48, P3059, DOI 10.1109/JSSC.2013.2274113; Hurrell CP, 2010, IEEE J SOLID-ST CIRC, V45, P2647, DOI 10.1109/JSSC.2010.2075310; Chan C., 2012, VLSI CIRC, P86; Harpe P., 2012, IEEE ISSCC, P472; Harpe P, 2014, ISSCC DIG TECH PAP I, V57, P194, DOI 10.1109/ISSCC.2014.6757396; Hesener M., 2007, ISSCC FEB, P248; Janssen E., 2013, ISSCC, P464; LIU CC, 2010, VLSI CIRC, P241; Morie T., 2013, IEEE ISSCC, P272; Murmann B., ADC PERFORMANCE SURV; Pan H, 2004, IEEE T CIRCUITS-I, V51, P1422, DOI 10.1109/TCSI.2004.832755; van der Goes F, 2014, ISSCC DIG TECH PAP I, V57, P200, DOI 10.1109/ISSCC.2014.6757399; WAGDY MF, 1989, IEEE T INSTRUM MEAS, V38, P850, DOI 10.1109/19.31003; Yoshioka K., 2013, VLSI CIRC S, P266	20	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9200	1558-173X		IEEE J SOLID-ST CIRC	IEEE J. Solid-State Circuit	JUN	2015	50	6					1372	1381		10.1109/JSSC.2015.2417803		10	Engineering, Electrical & Electronic	Engineering	CJ0YY	WOS:000355208700004		
J	Lin, J; Paik, D; Lee, S; Miyahara, M; Matsuzawa, A				Lin, James; Paik, Daehwa; Lee, Seungjong; Miyahara, Masaya; Matsuzawa, Akira			An Ultra-Low-Voltage 160 MS/s 7 Bit Interpolated Pipeline ADC Using Dynamic Amplifiers	IEEE JOURNAL OF SOLID-STATE CIRCUITS			English	Article						Analog-to-digital converter; capacitive interpolation; charge-steering; clock-scalable; dynamic amplifier; dual-residue; interpolated pipeline; ultra-low-voltage	NM DIGITAL CMOS; SAR ADC; FLASH ADC; COMPARATOR; SNDR; DB	This paper presents a 0.55 V, 7 bit, 160 MS/s pipeline ADC using dynamic amplifiers. In this ADC, high-speed open-loop dynamic amplifiers with a common-mode detection technique are used as residue amplifiers to increase the ADC's speed, to enhance the robustness against supply voltage scaling, and to realize clock-scalable power consumption. To mitigate the absolute gain constraint of the residue amplifiers in a pipeline ADC, the interpolated pipeline architecture is employed to shift the gain requirement from absolute to relative accuracy. To show the new requirements of the residue amplifiers, the effects of gain mismatch and nonlinearity of the dynamic amplifiers are analyzed. The 7 bit prototype ADC fabricated in 90 nm CMOS demonstrates an ENOB of 6.0 bits at a conversion rate of 160 MS/s with an input close to the Nyquist frequency. At this conversion rate, it consumes 2.43 mW from a 0.55 V supply. The resulting FoM of the ADC is 240 fJ/conversion-step.	[Lin, James; Miyahara, Masaya; Matsuzawa, Akira] Tokyo Inst Technol, Dept Phys Elect, Tokyo 1528552, Japan; [Paik, Daehwa] Samsung Elect, Daegu, South Korea; [Lee, Seungjong] Silicon Works, Taejon, South Korea	Lin, J (reprint author), Analog Devices Inc, Wilmington, MA 01887 USA.	James.Lin@analog.com; masaya@ssc.pe.titech.ac.jp			VDEC; Cadence Design Systems, Inc.	This work was supported in part by NEDO, MIC, CREST in JST, STARC, Huawei, Berkeley Design Automation for the use of the Analog FastSPICE (AFS) Platform, and VDEC in collaboration with Cadence Design Systems, Inc.	Chatterjee S, 2005, IEEE J SOLID-ST CIRC, V40, P2373, DOI 10.1109/JSSC.2005.856280; Miyahara M, 2008, IEEE ASIAN SOLID STA, P269, DOI 10.1109/ASSCC.2008.4708780; Verbruggen B, 2010, IEEE J SOLID-ST CIRC, V45, P2080, DOI 10.1109/JSSC.2010.2061611; Lee S, 2012, IEEE J SOLID-ST CIRC, V47, P1603, DOI 10.1109/JSSC.2012.2191184; Shikata A, 2012, IEEE J SOLID-ST CIRC, V47, P1022, DOI 10.1109/JSSC.2012.2185352; Murmann B, 2003, IEEE J SOLID-ST CIRC, V38, P2040, DOI 10.1109/JSSC.2003.819167; Nuzzo P, 2008, IEEE T CIRCUITS-I, V55, P1441, DOI 10.1109/TCSI.2008.917991; Chiang SHW, 2014, IEEE J SOLID-ST CIRC, V49, P935, DOI 10.1109/JSSC.2014.2300199; Verbruggen B, 2012, IEEE J SOLID-ST CIRC, V47, P2880, DOI 10.1109/JSSC.2012.2217873; Kapusta R, 2013, IEEE J SOLID-ST CIRC, V48, P3059, DOI 10.1109/JSSC.2013.2274113; Pun KP, 2007, IEEE J SOLID-ST CIRC, V42, P496, DOI 10.1109/JSSC.2006.891716; Asada Yusuke, 2009, Proceedings of Technical Papers. 2009 IEEE Asian Solid-State Circuits Conference (A-SSCC 2009), DOI 10.1109/ASSCC.2009.5357198; Daly DC, 2009, IEEE J SOLID-ST CIRC, V44, P3030, DOI 10.1109/JSSC.2009.2032699; Fiorenza JK, 2006, IEEE J SOLID-ST CIRC, V41, P2658, DOI 10.1109/JSSC.2006.884330; Harpe P., 2013, IEEE ISSCC, P270; Shen JH, 2008, IEEE J SOLID-ST CIRC, V43, P787, DOI 10.1109/JSSC.2008.917470; Kim YJ, 2007, IEEE CUST INTEGR CIR, P185; Lin J., 2013, P IEEE CUST INT CIRC; Lin J, 2011, IEEE INT SYMP CIRC S, P21; Liou C., 2013, IEEE ISSCC, P280; Mangelsdorf C., 1993, ISSCC, P64; Matsuzawa A., 1990, IEEE INT SOL STAT CI, P162; Matsuzawa A, 2009, 2009 IEEE 8TH INTERNATIONAL CONFERENCE ON ASIC, VOLS 1 AND 2, PROCEEDINGS, P218, DOI 10.1109/ASICON.2009.5351489; Miyahara M., 2010, P IEEE AS SOL STAT C, P177; Miyahara M., 2011, IEEE S VLSI CIRC JUN, P126; Paik D, 2012, IEICE T FUND ELECTR, VE95A, P456, DOI 10.1587/transfun.E95.A.456; Proesel JE, 2008, IEEE CUST INTEGR CIR, P153; Sinangil ME, 2012, IEEE T CIRCUITS-II, V59, P533, DOI 10.1109/TCSII.2012.2208675; Sushihara K., 2002, IEEE INT SOL STAT CI, P170; Tai HY, 2014, ISSCC DIG TECH PAP I, V57, P196; van der Goes F, 2014, ISSCC DIG TECH PAP I, V57, P200, DOI 10.1109/ISSCC.2014.6757399; Vecchi D, 2011, IEEE J SOLID-ST CIRC, V46, P2834, DOI 10.1109/JSSC.2011.2164301	32	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9200	1558-173X		IEEE J SOLID-ST CIRC	IEEE J. Solid-State Circuit	JUN	2015	50	6					1399	1411		10.1109/JSSC.2015.2415472		13	Engineering, Electrical & Electronic	Engineering	CJ0YY	WOS:000355208700006		
J	Neji, B; Hamrouni, C; Alimi, AM; Nakajima, H; Alim, AR				Neji, Bilel; Hamrouni, Chafaa; Alimi, Adel M.; Nakajima, Hiroshi; Alim, Aslan R.			Hierarchical Fuzzy-Logic-Based Electrical Power Subsystem for Pico Satellite ERPSat-1	IEEE SYSTEMS JOURNAL			English	Article						Fuzzy maximum power point (MPP) tracker; hierarchical fuzzy power management; pico satellite; power conditioning	SYSTEM; DESIGN	Despite the recent advances in space technologies, electrical power systems are still challenging researchers developing small satellites for low earth orbit use. In order to supply their subsystems, these satellites can only use the power stored onboard from solar energy. Therefore, the electrical power system should ensure a maximum exploitation of energy sources and should optimize the distribution of the available electrical power. This paper introduces a new intelligent electrical power subsystem for pico satellites. It is based on fuzzy logic and hierarchical fuzzy logic algorithms allowing a faster energy storage and a better and efficient energy distribution. The developed subsystem is composed of three main blocks, which are the fuzzy maximum power point tracker, the power conditioner, and the hierarchical fuzzy subsystem controller. The intelligent electrical power subsystem was successfully integrated in ERPSat-1 pico satellite. Furthermore, the simulations and experimental data of the proposed system have shown better results compared to other architectures used for previous small satellite electrical power subsystems.	[Neji, Bilel] SUNY Buffalo, Buffalo, NY 14214 USA; [Neji, Bilel; Hamrouni, Chafaa; Alimi, Adel M.] Natl Engn Sch Sfax, Sfax 3038, Tunisia; [Nakajima, Hiroshi] OMRON Corp, Control Technol Lab, Kyoto 6190283, Japan; [Alim, Aslan R.] Istanbul Tech Univ, Astronaut Engn Dept, TR-34381 Istanbul, Turkey	Neji, B (reprint author), SUNY Buffalo, Buffalo, NY 14214 USA.	bilelnej@buffalo.edu; chafaa.hamrouni@ieee.org; adel.alimi@ieee.org; nak@ari.ncl.omron.co.jp; aslanr@itu.edu.tr			Ministry of Defense of Tunisia; National Center for Remote Sensing; Minister of Higher Education and Technologies of Tunisia; Research Group on Intelligent Machines Laboratory, National Engineering School of Sfax; General Direction of Scientific Research (DGRST), Tunisia, under the ARUB program	This work was supported in part by the Ministry of Defense of Tunisia; The National Center for Remote Sensing; the Minister of Higher Education and Technologies of Tunisia; The Research Group on Intelligent Machines Laboratory, National Engineering School of Sfax; and the General Direction of Scientific Research (DGRST), Tunisia, under the ARUB program.	AitCheikh M. S., 2007, J RENEW ENERGY, V10, P387; Al-Atrash H, 2010, IEEE T AERO ELEC SYS, V46, P745, DOI 10.1109/TAES.2010.5461654; Miyatake M, 2011, IEEE T AERO ELEC SYS, V47, P367, DOI 10.1109/TAES.2011.5705681; Ashish P., 2008, IEEE T ENERGY CONVER, V23, P681; Balathandayuthapani S, 2012, IEEE SYST J, V6, P213, DOI 10.1109/JSYST.2011.2162889; Bekhti M, 2008, ELECTR POW SYST RES, V78, P1175, DOI 10.1016/j.epsr.2007.10.008; Blanes JM, 2011, IEEE T AERO ELEC SYS, V47, P1617, DOI 10.1109/TAES.2011.5937254; Canales J. M., 2010, P IEEE AER C BIG SKY, P1; Cole IR, 2012, IEEE J PHOTOVOLT, V2, P62, DOI 10.1109/JPHOTOV.2011.2177445; Czifra D., 2012, P 13 BIENN BEC, P123; Dehbonei H, 2009, IEEE T AERO ELEC SYS, V45, P31, DOI 10.1109/TAES.2009.4805261; Del Corso D, 2011, IEEE T AERO ELEC SYS, V47, P1985, DOI 10.1109/TAES.2011.5937278; Demirel S., 2012, P IEEE AESS ESTEL, P1; Farahani G., 2011, Proceedings of the 2011 5th International Conference on Recent Advances in Space Technologies (RAST), DOI 10.1109/RAST.2011.5966894; Fermia N., 2007, IEEE T AERO ELEC SYS, V43, P934, DOI DOI 10.1109/TAES.2007.4383584; Hamrouni C, 2009, RAST 2009: PROCEEDINGS OF THE 4TH INTERNATIONAL CONFERENCE ON RECENT ADVANCES IN SPACE TECHNOLOGIES, P750; Jing H., 2009, P 6 IEEE INT POW EL, P2103; Mahmood R., 2011, P IEEE AER C, P1; Miyazaki Y, 2013, PROCEEDINGS OF 6TH INTERNATIONAL CONFERENCE ON RECENT ADVANCES IN SPACE TECHNOLOGIES (RAST 2013), P1081; Neji B., 2010, P 4 IEEE SYST C CAL, P255; Neji B., 2011, Proceedings of the 2011 5th International Conference on Recent Advances in Space Technologies (RAST), DOI 10.1109/RAST.2011.5966947; Neji B, 2009, RAST 2009: PROCEEDINGS OF THE 4TH INTERNATIONAL CONFERENCE ON RECENT ADVANCES IN SPACE TECHNOLOGIES, P744; Neji B., 2011, P 1 IAA C U SAT MISS; Shekoofa O, 2013, PROCEEDINGS OF 6TH INTERNATIONAL CONFERENCE ON RECENT ADVANCES IN SPACE TECHNOLOGIES (RAST 2013), P671; Zimmermann U, 2012, IEEE J PHOTOVOLT, V2, P47, DOI 10.1109/JPHOTOV.2011.2174031	25	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1932-8184	1937-9234		IEEE SYST J	IEEE Syst. J.	JUN	2015	9	2					474	486		10.1109/JSYST.2013.2285659		13	Computer Science, Information Systems; Engineering, Electrical & Electronic; Operations Research & Management Science; Telecommunications	Computer Science; Engineering; Operations Research & Management Science; Telecommunications	CJ0ZW	WOS:000355211600015		
J	Sakurama, K; Azuma, S; Sugie, T				Sakurama, Kazunori; Azuma, Shun-ichi; Sugie, Toshiharu			Distributed Controllers for Multi-Agent Coordination Via Gradient-Flow Approach	IEEE TRANSACTIONS ON AUTOMATIC CONTROL			English	Article						Distributed controllers; generalized coordination; gradient-flow method; multi-agent systems	COOPERATIVE CONTROL; MULTIVEHICLE SYSTEMS; CYCLIC PURSUIT; NETWORKS; OPTIMIZATION; INFORMATION; CONSENSUS; FLOCKING; AGENTS	This paper provides a unified solution for a general distributed control problem of multi-agent systems based on the gradient-flow approach. First, a generalized coordination is presented as a control objective which represents a wide range of coordination tasks (e.g., consensus, formation and pattern decision) in a unified manner. Second, a necessary and sufficient condition for the gradient-based controllers to be distributed is derived. It turns out that the notion of clique (i.e., complete subgraph) plays a crucial role to obtain any distributed controllers. Furthermore, all such controllers are explicitly characterized with free design parameters. Third, it is shown how to choose an optimal controller in a systematic way among all distributed ones, where an optimality measure is introduced for the generalized coordination. Finally, the effectiveness of the proposed method is demonstrated through simulations, where a distributed pattern decision is discussed as an example of the generalized coordination.	[Sakurama, Kazunori] Tottori Univ, Grad Sch Engn, Tottori 6808552, Japan; [Azuma, Shun-ichi; Sugie, Toshiharu] Kyoto Univ, Grad Sch Informat, Kyoto 6068501, Japan	Sakurama, K (reprint author), Tottori Univ, Grad Sch Engn, Tottori 6808552, Japan.	sakurama@mech.tottori-u.ac.jp; sazuma@i.kyoto-u.ac.jp; sugie@i.kyoto-u.ac.jp			MEXT/JSPS KAKENHI [24760336]	This work was supported by MEXT/JSPS KAKENHI (24760336). Recommended by Associate Editor S. Zampieri.	ALUFFIPENTINI F, 1985, J OPTIMIZ THEORY APP, V47, P1, DOI 10.1007/BF00941312; Kim TH, 2007, AUTOMATICA, V43, P1426, DOI 10.1016/j.automatica.2007.01.018; Martinez S, 2007, IEEE CONTR SYST MAG, V27, P75, DOI 10.1109/MCS.2007.384124; Cortes J, 2005, ESAIM CONTR OPTIM CA, V11, P691, DOI 10.1051/cocv:2005024; CLARKE FH, 1975, T AM MATH SOC, V205, P247, DOI 10.2307/1997202; Olfati-Saber R, 2002, IEEE DECIS CONTR P, P2965; Cortes J, 2006, IEEE T AUTOMAT CONTR, V51, P1289, DOI 10.1109/TAC.2006.878713; Tanner HG, 2007, IEEE T AUTOMAT CONTR, V52, P863, DOI 10.1109/TAC.2007.895948; Olfati-Saber R, 2007, P IEEE, V95, P215, DOI 10.1109/JPROC.2006.887293; Igarashi Y, 2009, IEEE T CONTR SYST T, V17, P1119, DOI 10.1109/TCST.2009.2014357; Fax JA, 2004, IEEE T AUTOMAT CONTR, V49, P1465, DOI 10.1109/TAC.2004.834433; Marden JR, 2009, IEEE T SYST MAN CY B, V39, P1393, DOI 10.1109/TSMCB.2009.2017273; Murray RM, 2007, J DYN SYST-T ASME, V129, P571, DOI 10.1115/1.2766721; Chen B, 2010, IEEE T INTELL TRANSP, V11, P485, DOI 10.1109/TITS.2010.2048313; Marshall JA, 2004, IEEE T AUTOMAT CONTR, V49, P1963, DOI 10.1109/TAC.2004.837589; Cortes J, 2004, IEEE T ROBOTIC AUTOM, V20, P243, DOI 10.1109/TRA.2004.824698; Ren W, 2010, IEEE T CONTR SYST T, V18, P383, DOI 10.1109/TCST.2009.2016428; Olfati-Saber R, 2004, IEEE T AUTOMAT CONTR, V49, P1520, DOI 10.1109/TAC.2004.834113; Olfati-Saber R, 2006, IEEE T AUTOMAT CONTR, V51, P401, DOI 10.1109/TAC.2005.864190; Bacciotti A., 1999, ESAIM. Control, Optimisation and Calculus of Variations, V4, DOI 10.1051/cocv:1999113; Bolognani S., 2011, P 14 EUR C POW EL AP, P1; Filippov A. F., 1988, DIFFERENTIAL EQUATIO; Giaquinta M., 2012, MATH ANAL FDN ADV TE; Haddad WM, 2008, NONLINEAR DYNAMICAL; Lynch N. A., 1996, DISTRIBUTED ALGORITH; Olfati-Saber R., 2002, P 15 IFAC WORLD C BA, P1; Sakurama K, 2012, IEEE DECIS CONTR P, P5465, DOI 10.1109/CDC.2012.6426835; Shamma J, 2008, COOPERATIVE CONTROL	28	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9286	1558-2523		IEEE T AUTOMAT CONTR	IEEE Trans. Autom. Control	JUN	2015	60	6					1471	1485		10.1109/TAC.2014.2374951		15	Automation & Control Systems; Engineering, Electrical & Electronic	Automation & Control Systems; Engineering	CJ2LM	WOS:000355316200002		
J	Shibata, N; Ohtomo, Y; Nishisaka, M; Sato, Y				Shibata, Nobutaro; Ohtomo, Yusuke; Nishisaka, Mika; Sato, Yasuhiro			An STM-16 Frame Termination VLSI With 2.5-Gb/s/Pin Input/Output Buffers: High-Speed and Low-Power Multi-V-DD CMOS/SIMOX Techniques	IEEE TRANSACTIONS ON VERY LARGE SCALE INTEGRATION (VLSI) SYSTEMS			English	Article						CMOS; FD-SOI; high speed; low power; multi-V-DD; SDH system; SIMOX; STM-16	CMOS; IMPLANTATION; PROCESSOR; DEVICES	Many of the current wireline networks are digitalized. In Japan, a synchronous digital hierarchy (SDH) system is installed in the public switched telephone network, and application data are transferred with a synchronous transfer module (STM). This paper presents an STM-16 frame termination VLSI fabricated with a 0.3-mu m quintuple-metal CMOS/SIMOX process. To reduce power consumption, we employ a multi-V-DD architecture using 2-and 1-V power supplies. Also, fully depleted silicon on insulator (FD-SOI) devices are used to obtain a higher operating speed and to reduce dynamic power dissipation. To install another powerline in every standard cell without increasing the cell size, a stacked multiple powerlines scheme is proposed. In addition, some dedicated standard cells are developed to convert the logical high level without degrading the signal integrity. With regards to hard macros, 2-V MUX/DEMUX macros achieve a high operating speed of 2.5 Gb/s, while a dual-port SRAM macro can operate at a low supply voltage of 1 V. Moreover, 2-V 50-Omega-terminated input/output buffers using a new direct-drive amplifier operate without dedicated power supplies. With our STM-16 frame termination VLSI, the power consumption during the standby is 34 mW, and that for 2.5-Gb/s operation is 1.2 W at 25 degrees C.	[Shibata, Nobutaro; Ohtomo, Yusuke; Nishisaka, Mika; Sato, Yasuhiro] NTT Microsyst Integrat Labs, Atsugi, Kanagawa 2430198, Japan	Shibata, N (reprint author), NTT Microsyst Integrat Labs, Atsugi, Kanagawa 2430198, Japan.						IZUMI K, 1978, ELECTRON LETT, V14, P593, DOI 10.1049/el:19780397; Usami K, 1998, IEEE J SOLID-ST CIRC, V33, P463, DOI 10.1109/4.661212; ASSADERAGHI F, 1994, INTERNATIONAL ELECTRON DEVICES MEETING 1994 - IEDM TECHNICAL DIGEST, P809, DOI 10.1109/IEDM.1994.383301; Assaderaghi F, 1997, IEEE ELECTR DEVICE L, V18, P241, DOI 10.1109/55.585341; Benini L., 1995, INT S LOW POWER  APR, P21; Burd T., 1996, P IC DES SEM BERK CA; CHAPPELL BA, 1988, IEEE J SOLID-ST CIRC, V23, P59, DOI 10.1109/4.257; Gunning B., 1992, ISSCC, P58; Hirano Y., 2003, IEDM, P35; Kasai H., 1993, SDH TRANSMISSION SYS, P30; Mutoh S, 1996, IEEE J SOLID-ST CIRC, V31, P1795, DOI 10.1109/JSSC.1996.542325; Narasimha S., 2012, IEDM, P52; Ohno T, 1998, IEEE T ELECTRON DEV, V45, P1071, DOI 10.1109/16.669534; Ohtomo Y., 1999, IEEE INT S VLSI CIRC, P25; Pelella M. M., 1999, INT S VLSI TECHN SYS, P278; Shibata N., 2004, IEICE EL SOC C SEP, P79; Shibata N, 1999, IEICE T ELECTRON, VE82C, P94; SUH D, 1994, INTERNATIONAL ELECTRON DEVICES MEETING 1994 - IEDM TECHNICAL DIGEST, P661; Tsuchiya R, 2004, IEEE INTERNATIONAL ELECTRON DEVICES MEETING 2004, TECHNICAL DIGEST, P631, DOI 10.1109/IEDM.2004.1419245; Wei A, 1996, IEEE ELECTR DEVICE L, V17, P391, DOI 10.1109/55.511585; Yamashita M., 1998, EASY DIGITAL TRANSMI, P93; Yano K, 1996, IEEE J SOLID-ST CIRC, V31, P792, DOI 10.1109/4.509865; Zhao L., 2011, IEEE 16 AS S PAC DES, P87	23	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1063-8210	1557-9999		IEEE T VLSI SYST	IEEE Trans. Very Large Scale Integr. (VLSI) Syst.	JUN	2015	23	6					1089	1102		10.1109/TVLSI.2014.2333589		14	Computer Science, Hardware & Architecture; Engineering, Electrical & Electronic	Computer Science; Engineering	CJ1BY	WOS:000355218000009		
J	Niitsu, K; Osawa, Y; Harigai, N; Hirabayashi, D; Kobayashi, O; Yamaguchi, TJ; Kobayashi, H				Niitsu, Kiichi; Osawa, Yusuke; Harigai, Naohiro; Hirabayashi, Daiki; Kobayashi, Osamu; Yamaguchi, Takahiro J.; Kobayashi, Haruo			A CMOS PWM Transceiver Using Self-Referenced Edge Detection	IEEE TRANSACTIONS ON VERY LARGE SCALE INTEGRATION (VLSI) SYSTEMS			English	Article						CMOS; jitter; pulsewidth modulation (PWM); self-referenced; transceiver	SERIAL-LINK; CLOCK; SCHEME; JITTER	A CMOS pulsewidth modulation (PWM) transceiver circuit that exploits the self-referenced edge detection technique is presented. By comparing the rising edge that is self-delayed by about 0.5 T and the modulated falling edge in one carrier clock cycle, area-efficient and high-robustness (against timing fluctuations) edge detection enabling PWM communication is achieved without requiring elaborate phase-locked loops. Since the proposed self-referenced edge detection circuit has the capability of timing error measurement while changing the length of self-delay element, adaptive data-rate optimization and delay-line calibration are realized. The measured results with a 65-nm CMOS prototype demonstrate a 2-bit PWM communication, high data rate (3.2 Gb/s), and high reliability (BER >10-12) with small area occupation (540 mu m2). For reliability improvement, error check and correction associated with intercycle edge detection is introduced and its effectiveness is verified by 1-bit PWM measurement.	[Niitsu, Kiichi] Nagoya Univ, Graduated Sch Engn, Dept Elect Engn & Comp Sci, Nagoya, Aichi 4648603, Japan; [Osawa, Yusuke; Harigai, Naohiro; Hirabayashi, Daiki; Kobayashi, Haruo] Gunma Univ, Fac Sci & Technol, Div Elect & Informat, Kiryu, Gumma 3768515, Japan; [Kobayashi, Osamu] STARC, Yokohama, Kanagawa 2220033, Japan; [Yamaguchi, Takahiro J.] Adv Labs Ltd, Sendai, Miyagi 9893124, Japan	Niitsu, K (reprint author), Nagoya Univ, Graduated Sch Engn, Dept Elect Engn & Comp Sci, Nagoya, Aichi 4648603, Japan.	niitsu@nuee.nagoya-u.ac.jp; t09306014@gunma-u.ac.jp; t12801645@gunma-u.ac.jp; takahiro.yamaguchi@jp.advantest.com; k_haruo@el.gunma-u.ac.jp			Japan Science and Technology; Ministry of Economy, Trade and Industry; Starc; VLSI Design and Education Center; University of Tokyo; Cadence Design Systems, Inc.;  [24760266];  [20226009];  [25220906]	This work was supported in part by Japan Science and Technology, in part by the Ministry of Economy, Trade and Industry, in part by Starc and VLSI Design and Education Center, in part by the Grant-in-Aid for Young Scientist (B) under Grant 24760266, in part by the Grant-in-Aid for Scientific Research (S) under Grant 20226009 and Grant 25220906, and in part by the University of Tokyo in collaboration with Cadence Design Systems, Inc.	McNeill JA, 1997, IEEE J SOLID-ST CIRC, V32, P870, DOI 10.1109/4.585289; Chen WH, 2001, IEEE J SOLID-ST CIRC, V36, P1498; Choe WJ, 2007, IEEE J SOLID-ST CIRC, V42, P2012, DOI 10.1109/JSSC.2007.903038; Chung M.-T., 2012, P IEEE C ISSCC FEB, P114; De Caro D, 2010, IEEE J SOLID-ST CIRC, V45, P1048, DOI 10.1109/JSSC.2010.2043461; Ishida M., 2005, P INT SOL STAT CIRC, P512; Niitsu K., 2012, P IEEE S VLSI CIRC J, P142; Niitsu K, 2012, IEEE J SOLID-ST CIRC, V47, P2701, DOI 10.1109/JSSC.2012.2211655; Sai A., 2011, P IEEE INT SOL STAT, P98; Sham KJ, 2006, IEEE CUST INTEGR CIR, P405, DOI 10.1109/CICC.2006.320971; Shen B., 2013, P IEEE S VLSI CIRC J, P192; Takihi M., 2014, P IEEE INT S CIRC SY; Yang CY, 2008, IEEE T INSTRUM MEAS, V57, P1058, DOI 10.1109/TIM.2007.915134	13	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1063-8210	1557-9999		IEEE T VLSI SYST	IEEE Trans. Very Large Scale Integr. (VLSI) Syst.	JUN	2015	23	6					1145	1149		10.1109/TVLSI.2014.2321393		5	Computer Science, Hardware & Architecture; Engineering, Electrical & Electronic	Computer Science; Engineering	CJ1BY	WOS:000355218000014		
J	Muramatsu, D; Makihara, Y; Yagi, Y				Muramatsu, Daigo; Makihara, Yasushi; Yagi, Yasushi			Cross-view gait recognition by fusion of multiple transformation consistency measures	IET BIOMETRICS			English	Article							PERFORMANCE; IDENTIFICATION; IMAGE	Gait is a promising modality for forensic science because it has discrimination ability even if the gait features are extracted from low-quality image sequences captured at a distance. However, in forensic cases the observation view is often different, leading to accuracy degradation. Therefore the authors propose a gait recognition algorithm that achieves high accuracy in cases where observation views are different. They used a view transformation technique, and generated multiple joint gait features by changing the source gait features. They formed a hypothesis that the multiple transformed features and original features should be similar to each other if the target subjects are the same. They calculated multiple scores that measured the consistency of the features, and a likelihood ratio from the scores. To evaluate the accuracy of the proposed method, they drew Tippett plots and empirical cross-entropy plots, together with cumulative match characteristic curves and receiver operator characteristic curves, and evaluated discrimination ability and calibration quality. The results showed that their proposed method achieves good results in terms of discrimination and calibration.	[Muramatsu, Daigo; Makihara, Yasushi; Yagi, Yasushi] Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan	Muramatsu, D (reprint author), Osaka Univ, Inst Sci & Ind Res, 8-1 Mihogaoka, Osaka 5670047, Japan.	muramatsu@am.sanken.osaka-u.ac.jp			JSPS [21220003]; R&D Program for Implementation of Anti-Crime and Anti-Terrorism Technologies for a Safe and Secure Society; Ministry of Education, Culture, Sports, Science and Technology; Japanese Government; JST CREST 'Behaviour Understanding based on Intention-Gait Model' project	This work was partly supported by JSPS Grant-in-Aid for Scientific Research (S) 21220003, 'R&D Program for Implementation of Anti-Crime and Anti-Terrorism Technologies for a Safe and Secure Society', Funds for integrated promotion of social system reform and research and development of the Ministry of Education, Culture, Sports, Science and Technology, the Japanese Government, and the JST CREST "Behaviour Understanding based on Intention-Gait Model' project.	Han J, 2006, IEEE T PATTERN ANAL, V28, P316, DOI 10.1109/TPAMI.2006.38; Larsen PK, 2008, J FORENSIC SCI, V53, P1149, DOI 10.1111/j.1556-4029.2008.00807.x; Liu NN, 2011, IEEE SIGNAL PROC LET, V18, P431, DOI 10.1109/LSP.2011.2157143; Ramos D, 2013, J FORENSIC SCI, V58, P1503, DOI 10.1111/1556-4029.12233; Jean F, 2009, IMAGE VISION COMPUT, V27, P1272, DOI 10.1016/j.imavis.2008.11.009; Chapelle O, 2010, INFORM RETRIEVAL, V13, P201, DOI 10.1007/s10791-009-9109-9; Lam THW, 2011, PATTERN RECOGN, V44, P973, DOI 10.1016/j.patcog.2010.10.011; Iwama H, 2012, IEEE T INF FOREN SEC, V7, P1511, DOI 10.1109/TIFS.2012.2204253; Lu JW, 2010, PATTERN RECOGN LETT, V31, P382, DOI 10.1016/j.patrec.2009.11.006; Sarkar S, 2005, IEEE T PATTERN ANAL, V27, P162, DOI 10.1109/TPAMI.2005.39; Kusakunniran W, 2012, IEEE T CIRC SYST VID, V22, P966, DOI 10.1109/TCSVT.2012.2186744; Bouchrika I, 2011, J FORENSIC SCI, V56, P882, DOI 10.1111/j.1556-4029.2011.01793.x; Fawcett T, 2007, MACH LEARN, V68, P97, DOI 10.1007/s10994-007-5011-0; Iwama H., 2013, IPSJ T COMPUTER VISI, V5, P163; Lynnerup N, 2014, IET BIOMETRICS, V3, P47, DOI 10.1049/iet-bmt.2013.0090; Lynnerup N, 2005, J FORENSIC SCI, V50, P112; Nandakumar K, 2008, IEEE T PATTERN ANAL, V30, P342, DOI 10.1109/TPAMI.2007.70796	17	0	0	INST ENGINEERING TECHNOLOGY-IET	HERTFORD	MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND	2047-4938	2047-4946		IET BIOMETRICS	IET Biom.	JUN	2015	4	2					62	73		10.1049/iet-bmt.2014.0042		12	Computer Science, Artificial Intelligence	Computer Science	CJ1PL	WOS:000355256000004		
J	Ogawa, H; Koizumi, N; Ohnuma, A; Mutemwa, A; Hang'ombe, BM; Mweene, AS; Takada, A; Sugimoto, C; Suzuki, Y; Kida, H; Sawa, H				Ogawa, Hirohito; Koizumi, Nobuo; Ohnuma, Aiko; Mutemwa, Alisheke; Hang'ombe, Bernard M.; Mweene, Aaron S.; Takada, Ayato; Sugimoto, Chihiro; Suzuki, Yasuhiko; Kida, Hiroshi; Sawa, Hirofumi			Molecular epidemiology of pathogenic Leptospira spp. in the straw-colored fruit bat (Eidolon helvum) migrating to Zambia from the Democratic Republic of Congo	INFECTION GENETICS AND EVOLUTION			English	Article						Leptospira; Fruit bat; Eidolon helvum; Zambia; Pathogenic	GENUS LEPTOSPIRA; TRANSMISSION; MADAGASCAR; SEQUENCES; MAMMALS; PCR	The role played by bats as a potential source of transmission of Leptospira spp. to humans is poorly understood, despite various pathogenic Leptospira spp. being identified in these mammals. Here, we investigated the prevalence and diversity of pathogenic Leptospira spp. that infect the straw-colored fruit bat (Eidolon helvum). We captured this bat species, which is widely distributed in Africa, in Zambia during 2008-2013. We detected the flagellin B gene (flaB) from pathogenic Leptospira spp. in kidney samples from 79 of 529 E. helvum (14.9%) bats. Phylogenetic analysis of 70 flaB fragments amplified from E. helvum samples and previously reported sequences, revealed that 12 of the fragments grouped with Leptospira borgpetersenii and Leptospira kirschneri; however, the remaining 58 flaB fragments appeared not to be associated with any reported species. Additionally, the 16S ribosomal RNA gene (rrs) amplified from 27 randomly chosen flaB-positive samples was compared with previously reported sequences, including bat-derived Leptospira spp. All 27 rrs fragments clustered into a pathogenic group. Eight fragments were located in unique branches, the other 19 fragments were closely related to Leptospira spp. detected in bats. These results show that rrs sequences in bats are genetically related to each other without regional variation, suggesting that Leptospira are evolutionarily well-adapted to bats and have uniquely evolved in the bat population. Our study indicates that pathogenic Leptospira spp. in E. helvum in Zambia have unique genotypes. (C) 2015 The Authors. Published by Elsevier B.V.	[Ogawa, Hirohito] Univ Zambia, Sch Vet Med, Hokudai Ctr Zoonosis Control Zambia, Lusaka, Zambia; [Ogawa, Hirohito; Mweene, Aaron S.; Takada, Ayato; Sugimoto, Chihiro; Sawa, Hirofumi] Univ Zambia, Sch Vet Med, Dept Dis Control, Lusaka, Zambia; [Koizumi, Nobuo] Natl Inst Infect Dis, Dept Bacteriol 1, Shinjuku Ku, Tokyo 1628640, Japan; [Ohnuma, Aiko; Kida, Hiroshi] Hokkaido Univ, Res Ctr Zoonosis Control, Kita Ku, Sapporo, Hokkaido 0010020, Japan; [Mutemwa, Alisheke] Copperbelt Prov Vet Off, Ndola, Zambia; [Hang'ombe, Bernard M.] Univ Zambia, Sch Vet Med, Dept Paraclin Studies, Lusaka, Zambia; [Takada, Ayato] Hokkaido Univ, Res Ctr Zoonosis Control, Div Global Epidemiol, Kita Ku, Sapporo, Hokkaido 0010020, Japan; [Takada, Ayato; Sugimoto, Chihiro; Suzuki, Yasuhiko; Kida, Hiroshi; Sawa, Hirofumi] Hokkaido Univ, Global Inst Collaborat Res & Educ, Global Stn Zoonosis Control, Kita Ku, Sapporo, Hokkaido 0010020, Japan; [Sugimoto, Chihiro] Hokkaido Univ, Res Ctr Zoonosis Control, Div Collaborat & Educ, Kita Ku, Sapporo, Hokkaido 0010020, Japan; [Suzuki, Yasuhiko] Hokkaido Univ, Res Ctr Zoonosis Control, Div Bioresources, Kita Ku, Sapporo, Hokkaido 0010020, Japan; [Sawa, Hirofumi] Hokkaido Univ, Res Ctr Zoonosis Control, Div Mol Pathobiol, Kita Ku, Sapporo, Hokkaido 0010020, Japan; [Sawa, Hirofumi] Global Virus Network, Baltimore, MD 21201 USA	Sawa, H (reprint author), Hokkaido Univ, Res Ctr Zoonosis Control, Div Mol Pathobiol, Kita Ku, Kita 20,Nishi 10, Sapporo, Hokkaido 0010020, Japan.	h-sawa@czc.hokudai.acjp	Sawa, Hirofumi/F-6954-2012; Sugimoto, Chihiro/F-6583-2012; Ogawa, Hirohito/F-6918-2012	Sugimoto, Chihiro/0000-0002-8708-0140; 	Japan Initiative for Global Research Network on Infectious Diseases (J-GRID); Science and Technology Research Partnership for Sustainable Development (SATREPS) by the Japan Science and Technology Agency (JST); Japan International Cooperation Agency (JICA)	We thank Ms. Yuka Thomas, Drs. Emiko Nakagawa, Akihiro Ishii, Reiko Yoshida, Yasuko Orba, Ichiro Nakamura, Kimihito Ito, and many PhD students and postdoctoral fellows at the Research Center for Zoonosis Control, Hokkaido University for technical assistance. We also thank Drs. Katendi Chabgula, Edgar Simulundu and Musso Munyeme of the University of Zambia, Dr. Frank Willems of the Kasanka Trust, the Ministry Agriculture and Livestock, the Zambia Wildlife Authority, and Mr. Bwalya Chisha. This work was supported by the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) and the Science and Technology Research Partnership for Sustainable Development (SATREPS) by the Japan Science and Technology Agency (JST) and Japan International Cooperation Agency (JICA).	Ahmed Niyaz, 2006, Ann Clin Microbiol Antimicrob, V5, P28, DOI 10.1186/1476-0711-5-28; Adler B, 2010, VET MICROBIOL, V140, P287, DOI 10.1016/j.vetmic.2009.03.012; Koizumi N, 2008, JPN J INFECT DIS, V61, P465; Richter HV, 2008, J ZOOL, V275, P172, DOI 10.1111/j.1469-7998.2008.00425.x; Lagadec E, 2012, EMERG INFECT DIS, V18, P1696, DOI 10.3201/eid1810.111898; Dietrich M, 2014, MOL ECOL, V23, P2783, DOI 10.1111/mec.12777; Bourhy P, 2014, INT J SYST EVOL MICR, V64, P4061, DOI 10.1099/ijs.0.066597-0; Matthias MA, 2005, AM J TROP MED HYG, V73, P964; Muhldorfer K, 2013, ZOONOSES PUBLIC HLTH, V60, P93, DOI 10.1111/j.1863-2378.2012.01536.x; Bourhy P, 2012, J CLIN MICROBIOL, V50, P307, DOI 10.1128/JCM.05931-11; Victoria B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002752; de Jong Carol, 2011, FAO Animal Production and Health Manual, V12, P1; Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06; Tulsiani SM, 2011, ANN TROP MED PARASIT, V105, P71, DOI 10.1179/136485911X12899838413501; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Bessa TAF, 2010, AM J TROP MED HYG, V82, P315, DOI 10.4269/ajtmh.2010.09-0227; Bunnell JE, 2000, AM J TROP MED HYG, V63, P255; Cox TE, 2005, J WILDLIFE DIS, V41, P753; de Vries SG, 2014, INT J INFECT DIS, V28, P47, DOI 10.1016/j.ijid.2014.06.013; FENNESTAD K L, 1972, Journal of Wildlife Diseases, V8, P343; GRAVEKAMP C, 1993, J GEN MICROBIOL, V139, P1691; Harkin KR, 2014, J WILDLIFE DIS, V50, P651, DOI 10.7589/2013-08-201; Lei BNR, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002738; Muleya W, 2014, J VET MED SCI, V76, P611, DOI 10.1292/jvms.13-0518; Nalam K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012637; Ogawa H., 2015, J INFECT DI IN PRESS; Postic D, 2000, RES MICROBIOL, V151, P333, DOI 10.1016/S0923-2508(00)00156-X; Rahelinirina S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014111; World Health Organization, 2003, HUM LEPT GUID DIAGN	29	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1567-1348	1567-7257		INFECT GENET EVOL	Infect. Genet. Evol.	JUN	2015	32						143	147		10.1016/j.meegid.2015.03.013		5	Infectious Diseases	Infectious Diseases	CI8MV	WOS:000355027300019		
J	Disratthakit, A; Meada, S; Prammananan, T; Thaipisuttikul, I; Doi, N; Chaiprasert, A				Disratthakit, Areeya; Meada, Shinji; Prammananan, Therdsak; Thaipisuttikul, Iyarit; Doi, Norio; Chaiprasert, Angkana			Genotypic diversity of multidrug-, quinolone- and extensively drug-resistant Mycobacterium tuberculosis isolates in Thailand	INFECTION GENETICS AND EVOLUTION			English	Article						Multidrug resistance; Extensively drug-resistant; Tuberculosis; MLVA; Genotypic diversity; Thailand	NEW-YORK-CITY; MOLECULAR EPIDEMIOLOGY; GENETIC DIVERSITY; DISCRIMINATORY ABILITY; BEIJING FAMILY; SOUTH-AFRICA; STRAINS; SPREAD; LOCI; TRANSMISSION	Drug-resistant tuberculosis (TB), which includes multidrug-resistant (MDR-TB), quinolone-resistant (QR-TB) and extensively drug-resistant tuberculosis (XDR-TB), is a serious threat to TB control. We aimed to characterize the genotypic diversity of drug-resistant TB clinical isolates collected in Thailand to establish whether the emergence of drug-resistant TB is attributable to transmitted resistance or acquired resistance. We constructed the first molecular phylogeny of MDR-TB (n = 95), QR-TB (n = 69) and XDR-TB (n = 28) in Thailand based on spoligotyping and proposed 24-locus multilocus variable-number of tandem repeat analysis (MLVA). Clustering analysis was performed using the unweighted pair group method with arithmetic mean. Spoligotyping identified the Beijing strain (SIT1) as the most predominant genotype (n = 139; 72.4%). The discriminatory power of 0.9235 Hunter-Gaston Discriminatory Index (HGDI) with the 15-locus variable-number tandem repeats of mycobacterial interspersed repetitive units typing was improved to a 0.9574 HGDI with proposed 24-locus MLVA, thereby resulting in the subdivision of a large cluster of Beijing strains (SIT1) into 17 subclusters. We identified the spread of drug-resistant TB clones caused by three different MLVA types in the Beijing strain (SIT1) and a specific clone of XDR-TB caused by a rare genotype, the Manu-ancestor strain (SIT523). Overall, 49.5% of all isolates were clustered. These findings suggest that a remarkable transmission of drug-resistant TB occurred in Thailand. The remaining 50% of drug-resistant TB isolates were unique genotypes, which may have arisen from the individual acquisition of drug resistance. Our results suggest that transmitted and acquired resistance have played an equal role in the emergence of drug-resistant TB. Further characterization of whole genome sequences of clonal strains could help to elucidate the mycobacterial genetic factors relevant for drug resistance, transmissibility and virulence. (C) 2015 Elsevier B.V. All rights reserved.	[Disratthakit, Areeya; Thaipisuttikul, Iyarit; Chaiprasert, Angkana] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Microbiol, Bangkok 10700, Thailand; [Meada, Shinji] Japan AntiTB Assoc, Dept Mycobacterium Reference & Res, Res Inst TB, Tokyo 2048533, Japan; [Prammananan, Therdsak] Minist Sci & Technol, Natl Sci & Technol Dev Agcy, Natl Ctr Genet Engn & Biotechnol, Pathum Thani 12120, Thailand; [Doi, Norio] Japan AntiTB Assoc, Res Inst TB, Dept Pathophysiol & Host Def, Tokyo 2048533, Japan	Chaiprasert, A (reprint author), Mahidol Univ, Siriraj Hosp, Fac Med, Dept Microbiol, Bangkok 10700, Thailand.	angkana.cha@mahidol.ac.th			Thailand Research Fund through the Royal Golden Jubilee Ph.D. Program, Thailand [PHD/0328/2552]; Drug-Resistant Tuberculosis Research Fund, Siriraj Foundation, Thailand; Medicine Siriraj Hospital, Mahidol University, Thailand; Japan Science and Technology, Japan/National Science and Technology Development Agency, Thailand (JST/NSTDA) [P-12-01777]; Chalermprakiat Grant from the Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; Research Institute of Tuberculosis, Japan Anti-tuberculosis Association	Financial support for this study was obtained from the Thailand Research Fund through the Royal Golden Jubilee Ph.D. Program (Grant No. PHD/0328/2552), Thailand to Areeya Disratthakit (student) and Angkana Chaipreaert (advisor). Financial support for the laboratories was also obtained from the Drug-Resistant Tuberculosis Research Fund, Siriraj Foundation, Thailand, Research Development Fund from the Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand, and Japan Science and Technology, Japan/National Science and Technology Development Agency, Thailand (JST/NSTDA, Grant No. P-12-01777). AC is supported by the Chalermprakiat Grant from the Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.; We would like to thank the Research Institute of Tuberculosis, Japan Anti-tuberculosis Association for research support to perform the experiments for 2 months.	Lapphra K, 2013, INT J TUBERC LUNG D, V17, P1279, DOI 10.5588/ijtld.13.0858; Blower SM, 2004, NAT MED, V10, P1111, DOI 10.1038/nm1102; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Marais BJ, 2013, J CLIN MICROBIOL, V51, P1818, DOI 10.1128/JCM.00200-13; Hanekom M, 2007, J CLIN MICROBIOL, V45, P1483, DOI 10.1128/JCM.02191-06; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578; Gagneux S, 2009, CLIN MICROBIOL INFEC, V15, P66, DOI 10.1111/j.1469-0691.2008.02685.x; Faksri K, 2011, TUBERCULOSIS, V91, P594, DOI 10.1016/j.tube.2011.08.005; Yang CG, 2012, CLIN INFECT DIS, V55, P1179, DOI 10.1093/cid/cis670; Klopper M, 2013, EMERG INFECT DIS, V19, P449, DOI [10.3201/EID1903.120246, 10.3201/eid1903.120246, 10.3201//EID1903.120246]; Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907; Iwamoto T, 2007, FEMS MICROBIOL LETT, V270, P67, DOI 10.1111/j.1574-6968.2007.00658.x; Iwamoto T, 2009, J CLIN MICROBIOL, V47, P3340, DOI 10.1128/JCM.01061-09; Allix-Beguec C, 2014, J CLIN MICROBIOL, V52, P164, DOI 10.1128/JCM.02519-13; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873; Murase Y, 2008, J MED MICROBIOL, V57, P873, DOI 10.1099/jmm.0.47564-0; Demay C, 2012, INFECT GENET EVOL, V12, P755, DOI 10.1016/j.meegid.2012.02.004; Supply P, 2006, J CLIN MICROBIOL, V44, P4498, DOI 10.1128/JCM.01392-06; van der Spuy GD, 2009, TUBERCULOSIS, V89, P120, DOI 10.1016/j.tube.2008.09.003; Blouin Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052841; Casali N, 2014, NAT GENET, V46, P279, DOI 10.1038/ng.2878; Chaiprasert A, 2014, INT J TUBERC LUNG D, V18, P961, DOI 10.5588/ijtld.13.0197; De Beer J.L, 2014, EURO SURVEILL, V19; Gurjav U, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-455; HUNTER PR, 1988, J CLIN MICROBIOL, V26, P2465; Jiraphongsa C., 2011, J PREVENTIVE MED ASS, V1, P261; Luo T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089726; Mazars E, 2001, P NATL ACAD SCI USA, V98, P1901, DOI 10.1073/pnas.98.4.1901; Munsiff SS, 2002, EMERG INFECT DIS, V8, P1230; Park YK, 2000, J CLIN MICROBIOL, V38, P191; Prodinger WM, 2001, EMERG INFECT DIS, V7, P483; Punnotok J, 2000, INT J TUBERC LUNG D, V4, P537; Shabbeer A, 2012, INFECT GENET EVOL, V12, P789, DOI 10.1016/j.meegid.2012.02.010; Shamputa IC, 2010, J CLIN MICROBIOL, V48, P387, DOI 10.1128/JCM.02167-09; Srilohasin P, 2014, J CLIN MICROBIOL, V52, P4267, DOI 10.1128/JCM.01467-14; Sun J.Y., 2007, INT J TUBERC LUNG D, V11, P436; World Health Organization, 2014, GLOB TUB REP 2014	37	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1567-1348	1567-7257		INFECT GENET EVOL	Infect. Genet. Evol.	JUN	2015	32						432	439		10.1016/j.meegid.2015.03.038		8	Infectious Diseases	Infectious Diseases	CI8MV	WOS:000355027300056		
J	Fujinami, T; Ikeda, M; Koike, M; Matsumoto, N; Oishi, T; Sunatsuki, Y				Fujinami, Takeshi; Ikeda, Mizuki; Koike, Masataka; Matsumoto, Naohide; Oishi, Tomohiro; Sunatsuki, Yukinari			Syntheses, hydrogen-bonded assembly structures, and spin crossover properties of [Fe-III(Him)(2)(n-MeOhapen)]PF6 (Him = imidazole and n-MeOhapen = N,N '-bis(n-methoxy-2-oxyacetophenylidene)ethylenediamine); n=4, 5, 6)	INORGANICA CHIMICA ACTA			English	Article						Iron(III) complex; Spin equilibrium; Imidazole; N2O2 Schiff-base ligand; Hydrogen bonds; Assembly structures	QUADRIDENTATE SCHIFF-BASES; FE-III-COMPLEX; MAGNETIC-PROPERTIES; IRON(III) COMPLEXES; (PORPHINATO)IRON(III) COMPLEXES; THERMAL HYSTERESIS; CRYSTAL-STRUCTURES; LIGAND; STATE; IRON	Three iron(III) complexes, [Fe-III(Him)(2)(n-MeOhapen)]PF6 (1: n = 4, 2: n = 5, 3: n = 6), where Him = imidazole and n-MeOhapen = N,N'-bis(n-methoxy-2-oxyacetophenylidene)ethylenediamine, were synthesized. Each Fe-III ion was coordinated by N4O2 donor atoms of equatorial n-MeOhapen and two axial Him. The saturated FeC2N2 chelate ring involving the ethylenediamine moiety adopted a gauche conformation and the two phenylidene planes of [Fe-III(Him)(2)(n-MeOhapen)](+) were oriented opposite to the FeO2N2 coordination plane. Two adjacent [Fe-III(Him)(2)(4-MeOhapen)](+) cations in 1 were connected via PF6 ions by hydrogen bonds between the imidazole group and PF6 to give a one-dimensional chain. Two adjacent cations in 2 were connected via hydrogen bonds between the phenylidene oxygen and imidazole atoms to form a cyclic dimer structure. Two EtOH molecules were involved in a hydrogen-bonded cyclic dimer structure in 3. Compounds 1 and 2 showed spin crossover behavior, but 3 showed incomplete spin crossover. (C) 2015 Elsevier B.V. All rights reserved.	[Fujinami, Takeshi; Ikeda, Mizuki; Koike, Masataka; Matsumoto, Naohide] Kumamoto Univ, Dept Chem, Fac Sci, Kumamoto 8608555, Japan; [Oishi, Tomohiro] Kumamoto Univ, Tech Div, Fac Engn, Kumamoto 8608555, Japan; [Sunatsuki, Yukinari] Okayama Univ, Dept Chem, Fac Sci, Okayama 7008530, Japan	Fujinami, T (reprint author), Kumamoto Univ, Dept Chem, Fac Sci, Kurokami 2-39-1, Kumamoto 8608555, Japan.	tfujinami@sci.kumamoto-u.ac.jp			Research Fellowship for Young Scientists of the Japan Society for the Promotion of Science, KAKENHI [00248556]	T. Fujinami was supported by the Research Fellowship for Young Scientists of the Japan Society for the Promotion of Science, KAKENHI 00248556.	MATSUMOTO N, 1984, B CHEM SOC JPN, V57, P3307, DOI 10.1246/bcsj.57.3307; SCHEIDT WR, 1983, J AM CHEM SOC, V105, P2625, DOI 10.1021/ja00347a018; ZERNER M, 1966, THEOR CHIM ACTA, V6, P363, DOI 10.1007/BF00528464; Ross TM, 2010, DALTON T, V39, P149, DOI 10.1039/b913234a; Sato T, 2009, INORG CHEM, V48, P7211, DOI 10.1021/ic9006197; BUSCH DH, 1994, CHEM REV, V94, P585, DOI 10.1021/cr00027a003; Fujinami T, 2014, INORG CHEM, V53, P2254, DOI 10.1021/ic402947u; Sunatsuki Y, 2003, ANGEW CHEM INT EDIT, V42, P1614, DOI 10.1002/anie.200250399; COLLMAN JP, 1977, J AM CHEM SOC, V99, P5180, DOI 10.1021/ja00457a049; EWALD AH, 1964, PROC R SOC LON SER-A, V280, P235, DOI 10.1098/rspa.1964.0143; COLLMAN JP, 1994, J AM CHEM SOC, V116, P6245, DOI 10.1021/ja00093a026; NISHIDA Y, 1977, B CHEM SOC JPN, V50, P119, DOI 10.1246/bcsj.50.119; Koike M, 2013, INORG CHIM ACTA, V399, P185, DOI 10.1016/j.ica.2013.01.021; Weber B, 2008, ANGEW CHEM INT EDIT, V47, P10098, DOI 10.1002/anie.200802806; Ikuta Y, 2003, INORG CHEM, V42, P7001, DOI 10.1021/ic034495f; GEIGER DK, 1984, J AM CHEM SOC, V106, P6339, DOI 10.1021/ja00333a038; [Anonymous], 2000, CRYSTALSTRUCTURE 4 0, P2000; KENNEDY BJ, 1987, INORG CHEM, V26, P483, DOI 10.1021/ic00251a003; Real JA, 2005, DALTON T, P2062, DOI 10.1039/b501491c; Yamada M, 2006, CHEM-EUR J, V12, P4536, DOI 10.1002/chem.200500972; Buchen T, 1996, CHEM-EUR J, V2, P1134, DOI 10.1002/chem.19960020915; Fujinami T, 2011, DALTON T, V40, P12301, DOI 10.1039/c1dt11063b; Fukukai T, 2005, B CHEM SOC JPN, V78, P1484, DOI 10.1246/bcsj.78.1484; Furushou D, 2012, POLYHEDRON, V44, P194, DOI 10.1016/j.poly.2012.06.085; Gutlich P., 2004, SPIN CROSSOVER TRANS, V233-235; HARRIS G, 1966, THEOR CHIM ACTA, V5, P379, DOI 10.1007/BF00527040; Hernandez-Molina R, 1998, INORG CHEM, V37, P5102, DOI 10.1021/ic980297q; Kahn O., 1993, MOL MAGNETISM; MAEDA Y, 1986, J CHEM SOC DALTON, P1115, DOI 10.1039/dt9860001115; Masarova P, 2015, NEW J CHEM, V39, P508, DOI 10.1039/c4nj01363h; Nishi K, 2011, INORG CHEM, V50, P11303, DOI 10.1021/ic201993z; NISHIDA Y, 1987, J CHEM SOC DALTON, P1157, DOI 10.1039/dt9870001157; Roberts TD, 2014, DALTON T, V43, P7577, DOI 10.1039/c4dt00355a; Sebastien Floquet, 2014, POLYHEDRON, V80, P60; Sugiyarto KH, 2000, AUST J CHEM, V53, P755, DOI 10.1071/CH00087; Tanimura K, 2005, B CHEM SOC JPN, V78, P1279, DOI 10.1246/bcsj.78.1279; Weber B, 2009, COORDIN CHEM REV, V253, P2432, DOI 10.1016/j.ccr.2008.10.002	37	1	1	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0020-1693	1873-3255		INORG CHIM ACTA	Inorg. Chim. Acta	JUN 1	2015	432						89	95		10.1016/j.ica.2015.03.034		7	Chemistry, Inorganic & Nuclear	Chemistry	CI9YO	WOS:000355127300012		
J	Dien, LX; Yamashita, K; Asano, MS; Sugiura, K				Dien, Luong Xuan; Yamashita, Ken-ichi; Asano, Motoko S.; Sugiura, Ken-ichi			Syntheses of a pyrene-based pi-expanded ligand and the corresponding platinum(II) complex, bis[2-[(octylimino)methyl]-1-pyrenolato-N,O] platinum(II)	INORGANICA CHIMICA ACTA			English	Article						Coordination chemistry; Platinum complex; Pyrene; pi-Expanded ligand; Salicylaldimine	TRANS-BIS(SALICYLALDIMINATO)PLATINUM(II) COMPLEXES; NICKEL(II) COMPLEXES; INFRARED-SPECTRA; SCHIFF-BASES; SALICYLALDEHYDE; LIGHT; ALKYLAMINES; PALLADIUM	A pyrene-based new ligand (1) attaching hydroxyl and imine group, i.e., a salicylaldimine-style ligand based on pyrene, was designed and synthesized. The ligand was prepared from the commercially available pyrene in five steps. A treatment of this ligand 1 (L) with Pt(II) Cl-2(PhCN)(2) in the presence of AcONa in PhCl afforded the corresponding metal complex, Pt(II) L-2 (2) (80%). Single crystal diffraction study revealed that the complex is a square planar four-coordinated platinum(II) complex. The ligands bind to the metal in trans-manner. The coordination geometry, i.e., bond distances and angles for the coordination site, is the typical of the reported platinum(II) salicylaldiminatos, e.g., the mean Pt-N distance (d(Pt-N)): 2.011 and d(Pt-O): 1.994 angstrom, respectively. The expansion of the pi-system of the ligand induces the bathochromic shift in absorption spectra. The lowest excitation energy of 2 was found at 520 nm. Theoretical studies suggest that this phenomenon is attributable to the narrowing intramolecular HOMO-LUMO gap of 2. (C) 2015 Elsevier B.V. All rights reserved.	[Dien, Luong Xuan; Yamashita, Ken-ichi; Asano, Motoko S.; Sugiura, Ken-ichi] Tokyo Metropolitan Univ, Dept Chem, Grad Scholl Sci & Engn, Tokyo 1920397, Japan	Sugiura, K (reprint author), Tokyo Metropolitan Univ, Dept Chem, Grad Scholl Sci & Engn, 1-1 Minami Ohsawa, Tokyo 1920397, Japan.	sugiura@porphyrin.jp			Priority Research Program - Asian Human Resources Fund from Tokyo Metropolitan Government (TMG); Tokyo Metropolitan University (TMU)	This work was supported in part by the Priority Research Program sponsored by the Asian Human Resources Fund from Tokyo Metropolitan Government (TMG). L.X.D. appreciates to Tokyo Metropolitan University (TMU) for a pre-doctoral fellowship. Some preliminary experiments were performed by M.S. Keisuke Kimura (TMU). We appreciate the technical assistance, elemental analyses, provided by Mr. Toshihiko Sakurai (TMU).	Komiya N, 2011, J AM CHEM SOC, V133, P6493, DOI 10.1021/ja110398p; HAY PJ, 1985, J CHEM PHYS, V82, P299, DOI 10.1063/1.448975; Sun X, 2012, ORG LETT, V14, P3420, DOI 10.1021/ol301390g; Komiya N, 2013, CHEM-EUR J, V19, P9497, DOI 10.1002/chem.201301087; Zhou Y, 2011, ORG LETT, V13, P2742, DOI 10.1021/ol200846a; Zhou Y, 2009, ORG LETT, V11, P4442, DOI 10.1021/ol901804n; Zhao JZ, 2012, RSC ADV, V2, P1712, DOI 10.1039/c1ra00665g; WINNIK FM, 1993, CHEM REV, V93, P587, DOI 10.1021/cr00018a001; CALVIN M, 1945, J AM CHEM SOC, V67, P2003, DOI 10.1021/ja01227a043; CALVIN M, 1948, J AM CHEM SOC, V70, P3273, DOI 10.1021/ja01190a021; CESAROTTI E, 1981, J CHEM SOC DALTON, P2147, DOI 10.1039/dt9810002147; Che CM, 2004, CHEM COMMUN, P1484, DOI 10.1039/b402318h; Cox EG, 1935, J CHEM SOC, P459, DOI 10.1039/jr9350000459; DEMERSEMAN P, 1985, J HETEROCYCLIC CHEM, V22, P39; FERNANDEZ JM, 1987, INORG CHEM, V26, P349, DOI 10.1021/ic00250a003; Frasson E., 1962, GAZZ CHIM ITAL, V92, P1470; GOULDEN JDS, 1953, J CHEM SOC, P997; HANSEN PE, 1981, ACTA CHEM SCAND B, V35, P131, DOI 10.3891/acta.chem.scand.35b-0131; Kaplan SF, 2001, EUR J INORG CHEM, P1031; Kogan VA, 1999, MENDELEEV COMMUN, P82; KOVACIC JE, 1967, SPECTROCHIM ACTA A-M, VA 23, P183, DOI 10.1016/0584-8539(67)80219-8; Metelitsa AV, 2006, RUSS J COORD CHEM+, V32, P858, DOI 10.1134/S1070328406120025; Pfeiffer P., 1927, ORGANISCHE MOLEKULVE; SACCONI L, 1957, J AM CHEM SOC, V79, P3933, DOI 10.1021/ja01571a094; Sawodny W, 1999, ACTA CRYSTALLOGR C, V55, P2060, DOI 10.1107/S0108270199010690; TEYSSIE P, 1963, SPECTROCHIM ACTA, V19, P1407, DOI 10.1016/0371-1951(63)80003-X; Tverdova NV, 2009, RUSS J PHYS CHEM A+, V83, P2255, DOI 10.1134/S0036024409130135; Wu W., 2011, DALTON T, V40, P1155; YAMADA S, 1963, B CHEM SOC JPN, V36, P483, DOI 10.1246/bcsj.36.483; Yamada S., 1999, COORDIN CHEM REV, V190-192, P537, DOI DOI 10.1016/S0010-8545(99)00099-5; Zhou Y, 2010, ORG LETT, V12, P1272, DOI 10.1021/ol100160d; Zhou Y, 2011, B KOREAN CHEM SOC, V32, P3097, DOI 10.5012/bkcs.2011.32.8.3097	32	1	1	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0020-1693	1873-3255		INORG CHIM ACTA	Inorg. Chim. Acta	JUN 1	2015	432						103	108		10.1016/j.ica.2015.03.038		6	Chemistry, Inorganic & Nuclear	Chemistry	CI9YO	WOS:000355127300014		
J	Nishikido, T; Oyama, J; Ohira, H; Node, K				Nishikido, Toshiyuki; Oyama, Jun-ichi; Ohira, Hiroshi; Node, Koichi			The effects and safety of vildagliptin on cardiac function after acute myocardial infarction	INTERNATIONAL JOURNAL OF CARDIOLOGY			English	Letter						Vildagliptin; Acute coronary syndrome; Cardiac function	GLUCAGON-LIKE PEPTIDE-1; BLOOD-GLUCOSE CONTROL		[Nishikido, Toshiyuki; Oyama, Jun-ichi; Node, Koichi] Saga Univ Hosp, Dept Cardiovasc Med, Saga, Japan; [Ohira, Hiroshi] Edogawa Hosp, Dept Cardiovasc Med, Tokyo, Japan	Oyama, J (reprint author), Saga Univ, Dept Adv Cardiol, 5-1-1 Nabeshima, Saga 8498501, Japan.	junoyama@cc.saga-u.ac.jp					Patel A, 2008, NEW ENGL J MED, V358, P2560; Nikolaidis LA, 2004, CIRCULATION, V109, P962, DOI 10.1161/01.CIR.0000120505.91348.58; [Anonymous], 2013, N ENGL J MED, V369, P1317; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545; Connelly KA, 2013, CARDIOVASC THER, V31, P259, DOI 10.1111/1755-5922.12005; Liu Q, 2010, CARDIOVASC DIABETOL, V9, DOI [10.1186/1475-2840-9-32, 10.1186/1475-2840-9-76]; SUN DQ, 1994, CIRCULATION, V89, P793; Turner RC, 1998, LANCET, V352, P837	8	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-5273	1874-1754		INT J CARDIOL	Int. J. Cardiol.	JUN 1	2015	188						13	15		10.1016/j.ijcard.2015.03.433		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CI8HW	WOS:000355013600003		
J	Kimura, M; Kataoka, M; Kawakami, T; Inohara, T; Takei, M; Fukuda, K				Kimura, Mai; Kataoka, Masaharu; Kawakami, Takashi; Inohara, Taku; Takei, Makoto; Fukuda, Keiichi			Balloon pulmonary angioplasty using contrast agents improves impaired renal function in patients with chronic thromboembolic pulmonary hypertension	INTERNATIONAL JOURNAL OF CARDIOLOGY			English	Letter						Balloon pulmonary angioplasty; Chronic thromboembolic pulmonary hypertension; Renal function	PERCUTANEOUS CORONARY INTERVENTION; HEART-FAILURE		[Kimura, Mai; Kataoka, Masaharu; Kawakami, Takashi; Inohara, Taku; Takei, Makoto; Fukuda, Keiichi] Keio Univ, Sch Med, Dept Cardiol, Tokyo 1608582, Japan	Kataoka, M (reprint author), Keio Univ, Sch Med, Dept Cardiol, Shinjuku Ku, Shinanomachi 35, Tokyo 1608582, Japan.	m.kataoka09@z5.keio.jp					Mullens W, 2009, J AM COLL CARDIOL, V53, P589, DOI 10.1016/j.jacc.2008.05.068; Mehran R, 2004, J AM COLL CARDIOL, V44, P1393, DOI 10.1016/j.jacc.2004.06.068; Andreassen AK, 2013, HEART, V99, P1415, DOI 10.1136/heartjnl-2012-303549; Kataoka M, 2012, CIRC-CARDIOVASC INTE, V5, P756, DOI 10.1161/CIRCINTERVENTIONS.112.971390; Feinstein JA, 2001, CIRCULATION, V103, P10; Rihal CS, 2002, CIRCULATION, V105, P2259, DOI 10.1161/01.CIR.0000016043.87291.33; Inami T, 2014, AM J RESP CRIT CARE, V189, P1437, DOI 10.1164/rccm.201312-2254LE; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; Tsugu T, 2015, AM J CARDIOL, V115, P256, DOI 10.1016/j.amjcard.2014.10.034	9	1	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-5273	1874-1754		INT J CARDIOL	Int. J. Cardiol.	JUN 1	2015	188						41	42		10.1016/j.ijcard.2015.04.030		2	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CI8HW	WOS:000355013600013		
J	Suzuki, M; Fukamizu, S; Oyama, J; Mizukami, A; Matsumura, A; Hashimoto, Y; Node, K				Suzuki, Makoto; Fukamizu, Seiji; Oyama, Jun-ichi; Mizukami, Akira; Matsumura, Akihiko; Hashimoto, Yuji; Node, Koichi			Rationale and design of the efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: The X-NOAC study	INTERNATIONAL JOURNAL OF CARDIOLOGY			English	Letter						Atrial fibrillation; Chronic kidney disease; Non-Vitamin K antagonist oral anticoagulant; Oral factor Xa inhibitor; Warfarin			[Suzuki, Makoto; Matsumura, Akihiko; Hashimoto, Yuji] Kameda Med Ctr, Dept Cardiol, Chiba, Japan; [Fukamizu, Seiji] Tokyo Metropolitan Hiroo Gen Hosp, Dept Cardiol, Tokyo, Japan; [Oyama, Jun-ichi] Saga Univ, Dept Adv Cardiol, Saga 840, Japan; [Mizukami, Akira] Awa Reg Med Ctr, Dept Cardiol, Chiba, Japan; [Node, Koichi] Saga Univ, Dept Cardiovasc Med, Saga 840, Japan	Suzuki, M (reprint author), Kameda Med Ctr, Dept Cardiol, 929 Higashi Chou, Kamogawa City, Chiba 2968602, Japan.	macmed33@gmail.com					Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Eto M, 2001, CIRC RES, V89, P583, DOI 10.1161/hh1901.097084; Inoue T, 2011, INTERNAL MED, V50, P1273, DOI 10.2169/internalmedicine.50.4059; Mak KH, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001592; Mega JL, 2011, NEW ENGL J MED, V366, P9; Zhou Q., 2011, MEDIAT INFLAMM, P9	6	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-5273	1874-1754		INT J CARDIOL	Int. J. Cardiol.	JUN 1	2015	188						52	53		10.1016/j.ijcard.2015.04.037		2	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CI8HW	WOS:000355013600018		
J	Kato, T; Nakane, E; Funasako, M; Miyamoto, S; Izumi, T; Haruna, T; Nohara, R; Inoko, M				Kato, Takao; Nakane, Eisaku; Funasako, Moritoshi; Miyamoto, Shoichi; Izumi, Toshiaki; Haruna, Tetsuya; Nohara, Ryuji; Inoko, Moriaki			A potential linkage between mitochondrial function of the heart and leg muscles in patients with heart failure	INTERNATIONAL JOURNAL OF CARDIOLOGY			English	Letter						Mitochondrial function; Heart failure; Peripheral muscle; Tc-MIBI	METABOLISM; SESTAMIBI; MODEL		[Kato, Takao; Nakane, Eisaku; Funasako, Moritoshi; Miyamoto, Shoichi; Izumi, Toshiaki; Haruna, Tetsuya; Nohara, Ryuji; Inoko, Moriaki] Kitano Hosp, Cardiovasc Ctr, Tazuke Kofukai Med Res Inst, Osaka 5308480, Japan	Kato, T (reprint author), Kitano Hosp, Cardiovasc Ctr, Tazuke Kofukai Med Res Inst, Kita Ku, 2-4-20 Ohgimachi, Osaka 5308480, Japan.	tkato75@kuhp.kyoto-u.ac.jp					Anker SD, 2004, ANN MED, V36, P518, DOI 10.1080/07853890410017467; Fulster S, 2013, EUR HEART J, V34, P512, DOI 10.1093/eurheartj/ehs381; BOSTROM PA, 1993, ANGIOLOGY, V44, P971, DOI 10.1177/000331979304401208; CRANE P, 1993, EUR J NUCL MED, V20, P20, DOI 10.1007/BF02261241; Fukushima A, 2013, INT J CARDIOL, V168, pE142, DOI 10.1016/j.ijcard.2013.08.073; GLOVER DK, 1993, AM HEART J, V125, P657, DOI 10.1016/0002-8703(93)90154-2; Kato T, 2012, INT J CARDIOL, V161, P130, DOI 10.1016/j.ijcard.2011.07.056; Kawamoto A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117091; Matsuo S, 2007, J NUCL CARDIOL, V14, P215, DOI 10.1016/j.nuclcard.2006.10.022; von Haehling S., 2014, INT J CARDIOL, V184, P736	10	1	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-5273	1874-1754		INT J CARDIOL	Int. J. Cardiol.	JUN 1	2015	188						67	69		10.1016/j.ijcard.2015.04.049		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CI8HW	WOS:000355013600025		
J	Hosokawa, K; Abe, K; Oi, K; Mukai, Y; Hirooka, Y; Sunagawa, K				Hosokawa, Kazuya; Abe, Kohtaro; Oi, Keiji; Mukai, Yasushi; Hirooka, Yoshitaka; Sunagawa, Kenji			Negative acute hemodynamic response to balloon pulmonary angioplasty does not predicate the long-term outcome in patients with chronic thromboembolic pulmonary hypertension	INTERNATIONAL JOURNAL OF CARDIOLOGY			English	Letter						Balloon pulmonary angioplasty; Chronic thromboembolic pulmonary hypertension; Pulmonary hypertension; Endovascular treatment			[Hosokawa, Kazuya; Oi, Keiji; Mukai, Yasushi; Sunagawa, Kenji] Kyushu Univ Hosp, Dept Cardiovasc Med, Fukuoka 812, Japan; [Abe, Kohtaro; Hirooka, Yoshitaka] Kyushu Univ, Grad Sch Med Sci, Dept Adv Cardiovasc Regulat & Therapeut, Fukuoka, Japan	Hosokawa, K (reprint author), Kyushu Univ Hosp, Dept Cardiovasc Med, Fukuoka 812, Japan.						Lang IM, 2014, CIRCULATION, V130, P508, DOI 10.1161/CIRCULATIONAHA.114.009309; RIEDEL M, 1982, CHEST, V81, P151, DOI 10.1378/chest.81.2.151; Pepke-Zaba J, 2011, CIRCULATION, V124, P1973, DOI 10.1161/CIRCULATIONAHA.110.015008; Mizoguchi H, 2012, CIRC-CARDIOVASC INTE, V5, P748, DOI 10.1161/CIRCINTERVENTIONS.112.971077; Inami T, 2014, JACC-CARDIOVASC INTE, V7, P1297, DOI 10.1016/j.jcin.2014.06.010; Inami T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094587; Kim NH, 2013, J AM COLL CARDIOL, V62, pD92, DOI 10.1016/j.jacc.2013.10.024; Kim Nick H S, 2006, Proc Am Thorac Soc, V3, P584, DOI 10.1513/pats.200605-106LR	8	1	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-5273	1874-1754		INT J CARDIOL	Int. J. Cardiol.	JUN 1	2015	188						81	83		10.1016/j.ijcard.2015.04.025		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CI8HW	WOS:000355013600029		
J	Kamishima, K; Yamaguchi, J; Honda, A; Ogawa, H; Hagiwara, N				Kamishima, Kazuho; Yamaguchi, Junichi; Honda, Atsushi; Ogawa, Hiroshi; Hagiwara, Nobuhisa			Effect of concurrent elevation of serum creatinine and C-reactive protein values on the long-term outcome in patients with ST-elevation acute myocardial infarction	INTERNATIONAL JOURNAL OF CARDIOLOGY			English	Letter						Acute myocardial infarction; Creatinine; C-reactive protein; Long-term outcome	HIJAMI REGISTRY; PROGNOSTIC-SIGNIFICANCE; CORONARY INTERVENTION; HEART-INSTITUTE; MORTALITY; JAPAN		[Kamishima, Kazuho; Yamaguchi, Junichi; Honda, Atsushi; Ogawa, Hiroshi; Hagiwara, Nobuhisa] Tokyo Womens Med Univ, Dept Cardiol, Heart Inst Japan, Tokyo, Japan	Yamaguchi, J (reprint author), Tokyo Womens Med Univ, Dept Cardiol, Heart Inst Japan, Tokyo, Japan.	j.yamaguchi0110@gmail.com		Ogawa, Hiroshi/0000-0002-2576-2525			Mielniczuk LM, 2008, AM HEART J, V155, P725, DOI 10.1016/j.ahj.2007.11.031; Kasanuki H, 2005, AM HEART J, V150, P411, DOI 10.1016/j.ahj.2004.10.001; Berger AK, 2003, J AM COLL CARDIOL, V42, P201, DOI 10.1016/S0735-1097(03)00572-2; Maekawa Y, 2002, J AM COLL CARDIOL, V39, P241, DOI 10.1016/S0735-1097(01)01721-1; Wison S, 2003, AM J CARDIOL, V91, P1051, DOI 10.1016/S0002-9149(03)00147-4; Kinjo K, 2003, AM J CARDIOL, V91, P931, DOI 10.1016/S0002-9149(03)00106-1; Yamaguchi J, 2007, CIRC J, V71, P1354, DOI 10.1253/circj.71.1354; Yamaguchi J, 2004, AM J CARDIOL, V93, P1526, DOI 10.1016/j.amjcard.2004.02.065; Yip HK, 2004, CHEST, V126, P1417, DOI 10.1378/chest.126.5.1417; Yip HK, 2005, CHEST, V127, P803, DOI 10.1378/chest.127.3.803	10	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-5273	1874-1754		INT J CARDIOL	Int. J. Cardiol.	JUN 1	2015	188						102	104		10.1016/j.ijcard.2015.04.048		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CI8HW	WOS:000355013600035		
J	Sakaguchi, T; Ichihara, T; Natsume, T; Yao, JW; Yousuf, O; Trost, JC; Lima, JAC; George, RT				Sakaguchi, Takuya; Ichihara, Takashi; Natsume, Takahiro; Yao, Jingwu; Yousuf, Omair; Trost, Jeffrey C.; Lima, Joao A. C.; George, Richard T.			Development of a method for automated and stable myocardial perfusion measurement using coronary X-ray angiography images	INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING			English	Article						Perfusion; Coronary angiography; Model analysis; Patlak plot	IMPULSE-RESPONSE ANALYSIS; TRANSIT-TIME MEASUREMENT; FLOW RESERVE; BLUSH GRADE; ANGIOPLASTY; INFARCTION; QUANTIFICATION; REPERFUSION; MRI	The purpose of this study was to develop a method for automatic and stable determination of the optimal time range for fitting with a Patlak plot model in order to measure myocardial perfusion using coronary X-ray angiography images. A conventional two-compartment model is used to measure perfusion, and the slope of the Patlak plot is calculated to obtain a perfusion image. The model holds for only a few seconds while the contrast agent flows from artery to myocardium. Therefore, a specific time range should be determined for fitting with the model. To determine this time range, automation is needed for routine examinations. The optimal time range was determined to minimize the standard error between data points and their least-squares regression straight line in the Patlak plot. A total of 28 datasets were tested in seven porcine models. The new method successfully detected the time range when contrast agent flowed from artery to myocardium. The mean cross correlation in the linear regression analysis (R-2) was 0.996 +/- A 0.004. The mean length of the optimal time range was 3.61 +/- A 1.29 frames (2.18 +/- A 1.40 s). This newly developed method can automatically determine the optimal time range for fitting with the model.	[Sakaguchi, Takuya] Toshiba Med Syst Corp, Otawara, Tochigi 3248550, Japan; [Sakaguchi, Takuya] Tokyo Inst Technol, Tokyo 152, Japan; [Ichihara, Takashi; Natsume, Takahiro] Fujita Hlth Univ, Fac Radiol Technol, Sch Hlth Sci, Toyoake, Aichi 4701192, Japan; [Yao, Jingwu] Toshiba Med Res Inst USA, Vernon Hills, IL 60061 USA; [Yousuf, Omair; Trost, Jeffrey C.; Lima, Joao A. C.; George, Richard T.] Johns Hopkins Univ, Div Cardiol, Dept Med, Sch Med, Baltimore, MD 21205 USA	Sakaguchi, T (reprint author), Toshiba Med Syst Corp, 1385 Shimoishigami, Otawara, Tochigi 3248550, Japan.	takuya2.sakaguchi@toshiba.co.jp; ichihara@fujita-hu.ac.jp; tnatsume@fujita-hu.ac.jp; jyao@tmriusa.com; oyousuf1@jhmi.edu; jtrost2@jhmi.edu; jlima@jhmi.edu; rgeorge3@jhmi.edu			Toshiba Medical Systems Corporation; Astellas Pharma; GE Healthcare	T. Sakaguchi is an employee of Toshiba Medical Systems Corporation. T. Ichihara has received research grant support from Toshiba Medical Systems Corporation. T. Natsume declares that he has no conflict of interest. J. Yao is an employee of Toshiba Medical Research Institute USA. O. Yousuf declares that he has no conflict of interest. J.C. Trost declares that he has no conflict of interest. J.A.C. Lima, has received research grant support from Toshiba Medical Systems Corporation. R.T. George has received research grant support from Toshiba Medical Systems Corporation, Astellas Pharma, and GE Healthcare, and has consulted for ICON Medical Imaging.	van't Hof AWJ, 1998, CIRCULATION, V97, P2302; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1; Gibson CM, 2000, CIRCULATION, V101, P125; Ichihara T, 2011, IEEE T NUCL SCI, V58, P133, DOI 10.1109/TNS.2010.2084104; Ichihara T, 2009, MAGN RESON MED, V62, P373, DOI 10.1002/mrm.22018; KETY SS, 1951, PHARMACOL REV, V3, P1; Gibson CM, 2004, CIRCULATION, V109, P3096, DOI 10.1161/01.CIR.0000134278.50359.CB; Vogelzang M, 2009, EUR HEART J, V30, P594, DOI 10.1093/eurheartj/ehn542; Henriques JPS, 2003, CIRCULATION, V107, P2115, DOI 10.1161/01.CIR.0000065221.06430.ED; AXEL L, 1983, INVEST RADIOL, V18, P94, DOI 10.1097/00004424-198301000-00018; CUSMA JT, 1987, CIRCULATION, V75, P461; EIGLER NL, 1989, CIRC RES, V64, P853; EIGLER NL, 1991, CIRC RES, V68, P870; Gil D, 2008, IEEE T MED IMAGING, V27, P641, DOI 10.1109/TMI.2007.912814; Hackstein N, 2004, RADIOLOGY, V230, P221, DOI 10.1148/radiol.2301021266; Ichihara T, 2010, IEEE NUCL SCI S MED, DOI [10.1109/NSSMIC.2010.5874200, DOI 10.1109/NSSMIC.2010.5874200]; Jerosch-Herold M, 2003, J MAGN RESON IMAGING, V18, P544, DOI 10.1002/jmri.10384; Sakaguchi T, 2014, INT J CARDIOVAS IMAG, V30, P9, DOI 10.1007/s10554-013-0304-9; SCHUHLEN H, 1994, CIRCULATION, V89, P1004; SCHUHLEN H, 1994, CIRCULATION, V90, P163; SOLZBACH U, 1995, COMPUT BIOMED RES, V28, P371, DOI 10.1006/cbmr.1995.1025; Vallee JPM, 1998, MAGNET RESON MED, V40, P287, DOI 10.1002/mrm.1910400215; Yao J, 2012, IEEE NUCL SCI S MED, DOI [10.1109/NSSMIC.2012.6551680, DOI 10.1109/NSSMIC.2012.6551680]	23	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1569-5794	1573-0743		INT J CARDIOVAS IMAG	Int. J. Cardiovasc. Imaging	JUN	2015	31	5					905	914		10.1007/s10554-015-0658-2		10	Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging	Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging	CJ0FN	WOS:000355151300003		
J	Kashiyama, K; Sonoda, S; Muraoka, Y; Suzuki, Y; Kamezaki, F; Tsuda, Y; Araki, M; Tamura, M; Takeuchi, M; Abe, H; Okazaki, M; Fujino, Y; Otsuji, Y				Kashiyama, Kuninobu; Sonoda, Shinjo; Muraoka, Yoshitaka; Suzuki, Yoshiyuki; Kamezaki, Fumihiko; Tsuda, Yuki; Araki, Masaru; Tamura, Masahito; Takeuchi, Masaaki; Abe, Haruhiko; Okazaki, Masahiro; Fujino, Yoshihisa; Otsuji, Yutaka			Coronary plaque progression of non-culprit lesions after culprit percutaneous coronary intervention in patients with moderate to advanced chronic kidney disease: intravascular ultrasound and integrated backscatter intravascular ultrasound study	INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING			English	Article						Chronic kidney disease; Coronary atherosclerosis; Intravascular ultrasound; Plaque characteristics	GLOMERULAR-FILTRATION-RATE; ATHEROSCLEROTIC PLAQUES; TISSUE CHARACTERIZATION; CARDIOVASCULAR-DISEASE; RISK; CALCIFICATION; TOMOGRAPHY; THROMBOSIS; EVENTS; HEART	Previous studies have suggested that the deterioration of renal function increases the risk of major adverse clinical events not only in culprit lesions but also in non-culprit lesions (NCLs) after percutaneous coronary intervention (PCI). This study evaluated serial coronary plaque change of NCL in patients with different stages of chronic kidney disease (CKD) using intravascular ultrasound (IVUS) and integrated backscatter IVUS (IB-IVUS). In 113 patients (113 NCLs) underwent both IVUS-guided PCI and follow-up IVUS, volumetric IVUS analyses were performed at proximal reference NCLs in de novo target vessels post PCI and at 8-month follow-up. NCLs were divided into 4 groups based on baseline CKD stage: CKD-1, n = 18; CKD-2, n = 42; CKD-3, n = 29; and CKD4-5, n = 24. We compared serial changes of plaque burden and composition among groups under statin treatment. Plaque progression occurred in CKD-3 (+4.6 mm(3), p < 0.001) and CKD4-5 (+9.8 mm(3), p < 0.001) despite anti-atherosclerotic treatment, whereas plaque regression occurred in CKD-1 (-5.4 mm(3), p = 0.002) and CKD-2 (-3.2 mm(3), p = 0.001) mainly due to initiate statin treatment after PCI. Plaque volume change was correlated with eGFR (p < 0.0001). Multivariate analysis showed CKD stage 3-5 was an independent predictor of plaque progression. Regarding IB-IVUS analyses, lipid plaque increased in CKD-3 (+4.6 mm(3), p < 0.001) and CKD4-5 (+5.4 mm(3), p < 0.001), but decreased in CKD-2 (-2.7 mm(3), p < 0.05). Fibrotic plaque also increased in CKD4-5 (+3.4 mm(3), p < 0.001). Moderate to advanced CKD was associated with coronary plaque progression characterized by greater lipid and fibrotic plaque volumes in NCL under statin treatment after culprit PCI.	[Kashiyama, Kuninobu; Sonoda, Shinjo; Muraoka, Yoshitaka; Suzuki, Yoshiyuki; Kamezaki, Fumihiko; Tsuda, Yuki; Araki, Masaru; Tamura, Masahito; Takeuchi, Masaaki; Abe, Haruhiko; Okazaki, Masahiro; Otsuji, Yutaka] Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 2, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; [Fujino, Yoshihisa] Univ Occupat & Environm Hlth, Sch Med, Dept Prevent Med & Community Hlth, Kitakyushu, Fukuoka 807, Japan	Sonoda, S (reprint author), Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 2, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	s-sonoda@med.uoeh-u.ac.jp	Fujino, Yoshihisa/F-3054-2010	Fujino, Yoshihisa/0000-0002-9126-206X			McCullough PA, 2008, CLIN J AM SOC NEPHRO, V3, P1585, DOI 10.2215/CJN.01930408; Nakano T, 2010, AM J KIDNEY DIS, V55, P21, DOI 10.1053/j.ajkd.2009.06.034; Culleton BF, 1999, KIDNEY INT, V56, P2214, DOI 10.1046/j.1523-1755.1999.00773.x; Hayano S, 2012, AM J CARDIOL, V109, P1131, DOI 10.1016/j.amjcard.2011.11.052; Kono K, 2012, KIDNEY INT, V82, P344, DOI 10.1038/ki.2012.118; Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562; Miyagi M, 2010, NEPHROL DIAL TRANSPL, V25, P175, DOI 10.1093/ndt/gfp423; Sano K, 2006, J AM COLL CARDIOL, V47, P734, DOI 10.1016/j.jacc.2005.09.061; Stone GW, 2011, NEW ENGL J MED, V364, P226, DOI 10.1056/NEJMoa1002358; Kawasaki M, 2010, CIRC J, V74, P2641, DOI 10.1253/circj.CJ-10-0547; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; Kawasaki M, 2002, CIRCULATION, V105, P2487, DOI 10.1061/01.CIR.0000017200.47342.10; Gross ML, 2007, CLIN J AM SOC NEPHRO, V2, P121, DOI 10.2215/CJN.01760506; Ogita M, 2009, J CARDIOL, V54, P59, DOI 10.1016/j.jjcc.2009.03.008; Mintz GS, 2011, EUROINTERVENTION, V6, P1123, DOI 10.4244/EIJV6I9A195; Baigent C, 2011, LANCET, V377, P2181, DOI 10.1016/S0140-6736(11)60739-3; DAVIES MJ, 1993, BRIT HEART J, V69, P377; Schwarz U, 2000, NEPHROL DIAL TRANSPL, V15, P218, DOI 10.1093/ndt/15.2.218; FALK E, 1995, CIRCULATION, V92, P657; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Aziz K, 2008, CIRCULATION, V117, P2061, DOI 10.1161/CIRCULATIONAHA.106.652313; Baber U, 2012, J AM COLL CARDIOL, V5, P53; Kataoka Y, 2014, EUR HEART J-CARD IMG, V15, P1035, DOI 10.1093/ehjci/jeu065; Nozue T, 2012, NEPHROLOGY, V17, P628, DOI 10.1111/j.1440-1797.2012.01628.x	25	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1569-5794	1573-0743		INT J CARDIOVAS IMAG	Int. J. Cardiovasc. Imaging	JUN	2015	31	5					935	945		10.1007/s10554-015-0633-y		11	Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging	Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging	CJ0FN	WOS:000355151300006		
J	Kato, K; Sakai, Y; Ishibashi, I; Kobayashi, Y				Kato, Ken; Sakai, Yoshiaki; Ishibashi, Iwao; Kobayashi, Yoshio			Reply: Takotsubo syndrome-induced acute myocardial infarction	INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING			English	Editorial Material									[Kato, Ken; Kobayashi, Yoshio] Chiba Univ, Dept Cardiovasc Med, Grad Sch Med, Chuo Ku, Chiba, Chiba, Japan; [Sakai, Yoshiaki; Ishibashi, Iwao] Chiba Emergency Med Ctr, Dept Cardiol, Chiba, Japan	Kato, K (reprint author), Chiba Univ, Dept Cardiovasc Med, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba, Chiba, Japan.	kkatou0424@yahoo.co.jp					Madias JE, 2015, INT J CARDIOVAS IMAG, V31, P867, DOI 10.1007/s10554-015-0626-x	1	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1569-5794	1573-0743		INT J CARDIOVAS IMAG	Int. J. Cardiovasc. Imaging	JUN	2015	31	5					1019	1019		10.1007/s10554-015-0642-x		1	Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging	Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging	CJ0FN	WOS:000355151300016		
J	Tatsugami, F; Higaki, T; Fukumoto, W; Kaichi, Y; Fujioka, C; Kiguchi, M; Yamamoto, H; Kihara, Y; Awai, K				Tatsugami, Fuminari; Higaki, Toru; Fukumoto, Wataru; Kaichi, Yoko; Fujioka, Chikako; Kiguchi, Masao; Yamamoto, Hideya; Kihara, Yasuki; Awai, Kazuo			Radiation dose reduction for coronary artery calcium scoring at 320-detector CT with adaptive iterative dose reduction 3D	INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING			English	Article						Coronary artery calcium; Iterative reconstruction; Dose reduction; 320-detector CT scanner	MULTIDETECTOR ROW CT; ULTRAFAST COMPUTED-TOMOGRAPHY; TRIGGERED 64-SLICE CT; INTERSCAN VARIABILITY; HEART-ASSOCIATION; CARDIAC CT; QUANTIFICATION; ANGIOGRAPHY; RECONSTRUCTION; REPRODUCIBILITY	To assess the possibility of reducing the radiation dose for coronary artery calcium (CAC) scoring by using adaptive iterative dose reduction 3D (AIDR 3D) on a 320-detector CT scanner. Fifty-four patients underwent routine- and low-dose CT for CAC scoring. Low-dose CT was performed at one-third of the tube current used for routine-dose CT. Routine-dose CT was reconstructed with filtered back projection (FBP) and low-dose CT was reconstructed with AIDR 3D. We compared the calculated Agatston-, volume-, and mass scores of these images. The overall percentage difference in the Agatston-, volume-, and mass scores between routine- and low-dose CT studies was 15.9, 11.6, and 12.6 %, respectively. There were no significant differences in the routine- and low-dose CT studies irrespective of the scoring algorithms applied. The CAC measurements of both imaging modalities were highly correlated with respect to the Agatston- (r = 0.996), volume- (r = 0.996), and mass score (r = 0.997; p < 0.001, all); the Bland-Altman limits of agreement scores were -37.4 to 51.4, -31.2 to 36.4 and -30.3 to 40.9 %, respectively, suggesting that AIDR 3D was a good alternative for FBP. The mean effective radiation dose for routine- and low-dose CT was 2.2 and 0.7 mSv, respectively. The use of AIDR 3D made it possible to reduce the radiation dose by 67 % for CAC scoring without impairing the quantification of coronary calcification.	[Tatsugami, Fuminari; Higaki, Toru; Fukumoto, Wataru; Kaichi, Yoko; Awai, Kazuo] Hiroshima Univ, Dept Diagnost Radiol, Minami Ku, Hiroshima 7348551, Japan; [Fujioka, Chikako; Kiguchi, Masao] Hiroshima Univ, Dept Radiol, Minami Ku, Hiroshima 7348551, Japan; [Yamamoto, Hideya; Kihara, Yasuki] Hiroshima Univ, Dept Cardiovasc Med, Minami Ku, Hiroshima 7348551, Japan	Tatsugami, F (reprint author), Hiroshima Univ, Dept Diagnost Radiol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	sa104@rg8.so-net.ne.jp			Toshiba Medical Systems, Ltd.	Dr. Kazuo Awai is currently receiving a research grant from Toshiba Medical Systems, Ltd. The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.	AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827; McNitt-Gray MF, 2002, RADIOGRAPHICS, V22, P1541, DOI 10.1148/rg.226025128; Glodny B, 2009, EUR RADIOL, V19, P1661, DOI 10.1007/s00330-009-1345-2; Hoffmann U, 2006, EUR J RADIOL, V57, P396, DOI 10.1016/j.ejrad.2005.12.027; Tomizawa N, 2012, J CARDIOVASC COMPUT, V6, P318, DOI 10.1016/j.jcct.2012.02.009; O'Rourke RA, 2000, CIRCULATION, V102, P126; Hong C, 2002, RADIOLOGY, V223, P474, DOI 10.1148/radio.223010909; Gervaise A, 2012, EUR RADIOL, V22, P295, DOI 10.1007/s00330-011-2271-7; Genders TSS, 2010, EUR RADIOL, V20, P2331, DOI 10.1007/s00330-010-1802-y; Hara AK, 2009, AM J ROENTGENOL, V193, P764, DOI 10.2214/AJR.09.2397; Hausleiter J, 2009, JAMA-J AM MED ASSOC, V301, P500, DOI 10.1001/jama.2009.54; McCollough CH, 2007, RADIOLOGY, V243, P527, DOI 10.1148/radiol.2432050808; Mahnken AH, 2003, AM J ROENTGENOL, V181, P533; Wexler L, 1996, CIRCULATION, V94, P1175; Achenbach S, 2001, AM J CARDIOL, V87, P210, DOI 10.1016/S0002-9149(00)01319-9; Chen MY, 2013, INT J CARDIOVAS IMAG, V29, P1167, DOI 10.1007/s10554-013-0190-1; BIELAK LF, 1994, RADIOLOGY, V192, P631; Budoff Matthew J, 2008, Acad Radiol, V15, P58, DOI 10.1016/j.acra.2007.08.011; DEVRIES S, 1995, AM J CARDIOL, V75, P973, DOI 10.1016/S0002-9149(99)80706-1; Hong C, 2003, RADIOLOGY, V227, P795, DOI 10.1148/radiol.2273020369; Horiguchi J, 2009, ACAD RADIOL, V16, P187, DOI 10.1016/j.acra.2008.05.017; Horiguchi J, 2009, KOREAN J RADIOL, V10, P340, DOI 10.3348/kjr.2009.10.4.340; Juri H, 2013, J COMPUT ASSIST TOMO, V37, P52, DOI 10.1097/RCT.0b013e3182742c0e; Kurata A, 2013, EUR RADIOL, V23, P3246, DOI 10.1007/s00330-013-3022-8; Liu YJ, 2007, PHYS MED BIOL, V52, pL5, DOI 10.1088/0031-9155/52/12/L01; Matsuura N, 2008, AM J ROENTGENOL, V190, P1561, DOI 10.2214/AJR.07.3120; Newton TD, 2011, EUR RADIOL, V21, P2121, DOI 10.1007/s00330-011-2159-6; Shemesh J, 2005, RADIOLOGY, V236, P810, DOI 10.1148/radiol.2363040039; Takahashi N, 2003, RADIOLOGY, V228, P101, DOI 10.1148/radiol.2281012035; van der Bijl N, 2010, INT J CARDIOVAS IMAG, V26, P473, DOI 10.1007/s10554-010-9581-8; van Osch JAC, 2014, INT J CARDIOVAS IMAG, V30, P961, DOI 10.1007/s10554-014-0409-9	31	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1569-5794	1573-0743		INT J CARDIOVAS IMAG	Int. J. Cardiovasc. Imaging	JUN	2015	31	5					1045	1052		10.1007/s10554-015-0637-7		8	Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging	Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging	CJ0FN	WOS:000355151300020		
J	Tomiyama, T; Kumita, S; Ishihara, K; Suda, M; Sakurai, M; Hakozaki, K; Hashimoto, H; Takahashi, N; Takano, H; Kobayashi, Y; Kiriyama, T; Fukushima, Y; Shimizu, W				Tomiyama, Takeshi; Kumita, Shin-ichiro; Ishihara, Keiichi; Suda, Masaya; Sakurai, Minoru; Hakozaki, Kenta; Hashimoto, Hidenobu; Takahashi, Naoto; Takano, Hitoshi; Kobayashi, Yasuhiro; Kiriyama, Tomonari; Fukushima, Yoshimitsu; Shimizu, Wataru			Patients with reduced heart rate response to adenosine infusion have low myocardial flow reserve in N-13-ammonia PET studies	INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING			English	Article						Heart rate response; Adenosine; Myocardial blood flow (MBF); Myocardial flow reserve (MFR); N-13-ammonia; Positron emission tomography (PET)	POSITRON-EMISSION-TOMOGRAPHY; BLOOD-FLOW; DIABETES-MELLITUS; PERFUSION SPECT; DIPYRIDAMOLE; ASSOCIATION; PERFORMANCE; STENOSIS; AMMONIA	To assess the effect of adenosine infusion by evaluating the relationship between heart rate (HR) response to adenosine and myocardial flow reserve (MFR) of remote regions supplied by normal coronary arteries in N-13-ammonia PET. Thirty-one consecutive subjects (20 known coronary artery disease patients, 4 chronic heart failure patients, and 7 normal volunteers) except cases having 3-vessel disease underwent rest and adenosine stress N-13-ammonia myocardial perfusion PET. Semi-quantitative, quantitative, and gated analyses were performed. Subjects were divided into two groups with regard to HR response to adenosine. Twenty-two subjects had normal HR response (peak/rest HR > 1.20), while reduced HR response (a parts per thousand currency sign1.20) was observed in nine subjects. There were no differences in rest myocardial blood flow (MBF) of remote regions between the groups. Subjects with reduced HR response had significantly lower stress MBF and MFR of remote regions than those with normal HR response (stress MBF: 1.559 +/- A 0.517 vs. 2.279 +/- A 0.530, p = 0.004, MFR: 1.59 +/- A 0.36 vs. 2.35 +/- A 0.53, p = 0.001). There were no significant differences between the groups by means of semi-quantitative scoring. Rest and stress ejection fraction (EF) in the reduced HR response group was lower than that in the normal HR response group. In a multiple stepwise regression analysis, HR ratio, dyslipidemia, and Brinkman index were identified as predictors of the change in MFR of remote regions. Subjects with reduced HR response to adenosine had lower stress MBF and MFR of remote regions and lower EF. Moreover, HR response was one of the predictors of the change in MFR of remote regions.	[Tomiyama, Takeshi; Kumita, Shin-ichiro; Hashimoto, Hidenobu; Kobayashi, Yasuhiro; Kiriyama, Tomonari; Fukushima, Yoshimitsu] Nippon Med Sch, Dept Radiol, Bunkyo Ku, Tokyo 1138603, Japan; [Ishihara, Keiichi; Suda, Masaya; Sakurai, Minoru; Hakozaki, Kenta] Nippon Med Sch, Clin Imaging Ctr Healthcare, Tokyo 1138603, Japan; [Takahashi, Naoto; Takano, Hitoshi; Shimizu, Wataru] Nippon Med Sch, Dept Cardiovasc Med, Tokyo 1138603, Japan	Tomiyama, T (reprint author), Nippon Med Sch, Dept Radiol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.	tk2@nms.ac.jp					AKSUT SV, 1995, AM HEART J, V130, P67, DOI 10.1016/0002-8703(95)90237-6; Alexanderson E, 2012, J NUCL CARDIOL, V19, P979; Amanullah AM, 1997, AM J CARDIOL, V79, P1319, DOI 10.1016/S0002-9149(97)00132-X; Surti S, 2007, J NUCL MED, V48, P471; Muzik O, 1998, J AM COLL CARDIOL, V31, P534, DOI 10.1016/S0735-1097(97)00526-3; Campisi R, 1998, CIRCULATION, V98, P119; DeGrado TR, 1996, J NUCL CARDIOL, V3, P494, DOI 10.1016/S1071-3581(96)90059-8; Yokoyama I, 1996, CIRCULATION, V94, P3232; CERQUEIRA MD, 1994, J AM COLL CARDIOL, V23, P384; CHAN SY, 1992, J AM COLL CARDIOL, V20, P979; Cerqueira MD, 2002, INT J CARDIOVAS IMAG, V18, P539; Abidov A, 2003, CIRCULATION, V107, P2894, DOI 10.1161/01.CIR.0000072770.27332.75; Dhalla AK, 2006, J PHARMACOL EXP THER, V316, P695, DOI 10.1124/jpet.105.095323; Prior JO, 2005, CIRCULATION, V111, P2291, DOI 10.1161/01.CIR.0000164232.62768.51; Bravo PE, 2008, AM J CARDIOL, V102, P1103, DOI 10.1016/j.amjcard.2008.06.021; Gorur GD, 2012, ANN NUCL MED, V26, P609, DOI 10.1007/s12149-012-0618-z; Lima RDL, 2011, ANN NUCL MED, V25, P7, DOI 10.1007/s12149-010-0420-8; Mathur S, 2010, J NUCL CARDIOL, V17, P617, DOI 10.1007/s12350-010-9242-2; Nakajima K, 2013, EUR J NUCL MED MOL I, V40, P1163, DOI 10.1007/s00259-013-2431-x; UREN NG, 1994, NEW ENGL J MED, V330, P1782, DOI 10.1056/NEJM199406233302503; Vashist A, 2002, AM J CARDIOL, V89, P174, DOI 10.1016/S0002-9149(01)02196-8	21	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1569-5794	1573-0743		INT J CARDIOVAS IMAG	Int. J. Cardiovasc. Imaging	JUN	2015	31	5					1089	1095		10.1007/s10554-015-0654-6		7	Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging	Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging	CJ0FN	WOS:000355151300026		
J	Miura, S; Kobayashi, Y; Kawamura, K; Nakashima, Y; Fujie, MG				Miura, Satoshi; Kobayashi, Yo; Kawamura, Kazuya; Nakashima, Yasutaka; Fujie, Masakatsu G.			Brain activation in parietal area during manipulation with a surgical robot simulator	INTERNATIONAL JOURNAL OF COMPUTER ASSISTED RADIOLOGY AND SURGERY			English	Article						Surgical robot; Surgical simulator; Tele-surgery; Brain activity measurement	NEAR-INFRARED SPECTROSCOPY; TOOL-USE; BODY SCHEMA; SYSTEM; SURGERY; VISION; SPACE; TOUCH; NIRS	we present an evaluation method to qualify the embodiment caused by the physical difference between master-slave surgical robots by measuring the activation of the intraparietal sulcus in the user's brain activity during surgical robot manipulation. We show the change of embodiment based on the change of the optical axis-to-target view angle in the surgical simulator to change the manipulator's appearance in the monitor in terms of hand-eye coordination. The objective is to explore the change of brain activation according to the change of the optical axis-to-target view angle. In the experiments, we used a functional near-infrared spectroscopic topography (f-NIRS) brain imaging device to measure the brain activity of the seven subjects while they moved the hand controller to insert a curved needle into a target using the manipulator in a surgical simulator. The experiment was carried out several times with a variety of optical axis-to-target view angles. Some participants showed a significant peak (P value = 0.037, F-number = 2.841) when the optical axis-to-target view angle was . The positional relationship between the manipulators and endoscope at would be the closest to the human physical relationship between the hands and eyes.	[Miura, Satoshi; Kobayashi, Yo; Fujie, Masakatsu G.] Waseda Univ, Dept Modern Mech Engn, Shinjuku Ku, Tokyo 1698555, Japan; [Kawamura, Kazuya] Natl Univ Corp Chiba Univ Sci & Technol, Grad Sch, Ctr Frontier Med Engn, Fac Engn,Inage Ku, Chiba 2638522, Japan; [Nakashima, Yasutaka] Kyushu Univ, Yamamoto Lab, Nishi Ku, Fukuoka 8190395, Japan	Miura, S (reprint author), Waseda Univ, Dept Modern Mech Engn, Shinjuku Ku, Room 309,Bld 59,3-4-1 Okubo, Tokyo 1698555, Japan.	miura-s@akane.waseda.jp		Kobayashi, Yo/0000-0003-4358-6294	Ministry of Education, Culture, Sports, Science, and Technology, Japan; Waseda University, Tokyo, Japan; High-Tech Research Center Project from Ministry of Education, Culture, Sports, Science and Technology; Council for Science, Technology and Innovation(CSTI), Cross-ministerial Strategic Innovation Promotion Program (SIP), "Development of Intuitive Teleoperation Robot using the Human Measurement" (JST);  [26242061];  [25560243];  [14J07261]	This work was supported in part by The Ministry of Education, Culture, Sports, Science, and Technology, Japan, by Waseda University, Tokyo, Japan, in part by the High-Tech Research Center Project from Ministry of Education, Culture, Sports, Science and Technology, and in part by a Grant-in-Aid for Scientific Research (A) (no. 26242061), a Grant-in-Aid for Challenging Exploratory Research (no. 25560243) and a Grant-in-Aid for JSPS Fellows (14J07261), in part by Council for Science, Technology and Innovation(CSTI), Cross-ministerial Strategic Innovation Promotion Program (SIP), "Development of Intuitive Teleoperation Robot using the Human Measurement" (Funding agency: JST).	Colby CL, 1999, ANNU REV NEUROSCI, V22, P319, DOI 10.1146/annurev.neuro.22.1.319; Germon TJ, 1999, BRIT J ANAESTH, V82, P831; Attenberger A, 2012, 2012 IEEE 19TH INTERNATIONAL CONFERENCE AND WORKSHOPS ON ENGINEERING OF COMPUTER BASED SYSTEMS (ECBS), P188, DOI 10.1109/ECBS.2012.32; Maravita A, 2002, COGNITION, V83, pB25, DOI 10.1016/S0010-0277(02)00003-3; Makin TR, 2007, J NEUROSCI, V27, P731, DOI 10.1523/JNEUROSCI.3653-06.2007; Leven J, 2005, LECT NOTES COMPUT SC, V3749, P811; HOMAN RW, 1987, ELECTROEN CLIN NEURO, V66, P376, DOI 10.1016/0013-4694(87)90206-9; Turchetti G, 2012, SURG ENDOSC, V26, P598, DOI 10.1007/s00464-011-1936-2; Cardinali L, 2009, CURR BIOL, V19, pR478, DOI 10.1016/j.cub.2009.05.009; Fuster J, 2005, NEUROIMAGE, V26, P215, DOI 10.1016/j.neuroimage.2005.01.055; VILLRINGER A, 1993, NEUROSCI LETT, V154, P101, DOI 10.1016/0304-3940(93)90181-J; Ballantyne GH, 2002, SURG ENDOSC, V16, P1389, DOI 10.1007/s00464-001-8283-7; BLADEN JS, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1891; Hawkins J., 2007, INTELLIGENCE; Iriki A, 2001, NEUROSCI RES, V40, P163, DOI 10.1016/S0168-0102(01)00225-5; Lee J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001760; Maravita A, 2004, TRENDS COGN SCI, V8, P79, DOI 10.1016/j.tics.2003.12.008; Obayashi S, 2002, NEUROREPORT, V13, P2349, DOI 10.1097/01.wnr.0000044228.79663.ca; Osa T, 2010, IEEE INT C INT ROBOT, P1837; Rosch E, 1991, EMBODIED MIND COGNIT; Santos VJ, 2006, IEEE T BIO-MED ENG, V53, P155, DOI 10.1109/TBME.2005.862537; Shimizu S., 2011, 2011 IEEE International Conference on Robotics and Biomimetics (ROBIO), DOI 10.1109/ROBIO.2011.6181743; Suh I, 2011, INT J MED ROBOT COMP, V7, P327, DOI 10.1002/rcs.402; Tanaka H, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00545; Wang F, 2008, IEEE ENG MED BIO, P1935; Wilson R, 2011, EMBODIED COGNITION S	26	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1861-6410	1861-6429		INT J COMPUT ASS RAD	Int. J. Comput. Assist. Radiol. Surg.	JUN	2015	10	6			SI		783	790		10.1007/s11548-015-1178-1		8	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging; Surgery	Engineering; Radiology, Nuclear Medicine & Medical Imaging; Surgery	CJ3ZF	WOS:000355422800011		
J	Terashima, O; Sakai, Y; Nagata, K; Ito, Y; Onishi, K; Shouji, Y				Terashima, Osamu; Sakai, Yasuhiko; Nagata, Kouji; Ito, Yasumasa; Onishi, Kazuhiro; Shouji, Yuichi			On the velocity and pressure statistics during the flapping motion in a planar turbulent jet	INTERNATIONAL JOURNAL OF HEAT AND FLUID FLOW			English	Article						Pressure measurement; Turbulent shear flows; Flapping motion; Turbulent energy transport	COHERENT STRUCTURE; SIMILARITY REGION; KL EXPANSION; LARGE EDDIES; PART 1; FLOW; EIGENMODES; DYNAMICS; EQUATION	The role of a large-scale coherent vortex structure in a planar jet, which is intermittently observed and called "flapping motion", on the turbulent energy transport process is investigated experimentally. The experiment is performed by simultaneously measuring the two components of velocity and pressure in the self-preserving region of the jet. The probe for the simultaneous measurement of the velocity and pressure consists of an X-type hot-wire sensor and a static pressure probe. The measurement data are analyzed using a conditional sampling technique and the phase-averaging technique, on the basis of an intermittency function which shows whether the jet is now flapping or not. This intermittency function is obtained by the measurement results of the streamwise velocity fluctuation by means of the two I-type hot-wire sensors set in the self-preserving region of the jet with applying a continuous wavelet transform analysis to the data. The experimental results show that the phase-averaged velocity field during the flapping motion shows a good agreement with those obtained through the 23 points simultaneous measurement of the streamwise velocity in the previous studies. Further, the phase-averaged pressure field during the flapping motion indicates the existence of a large-scale coherent vortex structure, interpreted as a combination of the flapping and puffing motions in the self-preserving region of the jet, In addition, it is found that the production of the turbulent energy and its diffusion from the inner region to the outer region of the jet are enhanced by the flapping motion. In particular, this enhancement of the turbulent energy diffusion is caused by the combination of an increase of the turbulent diffusion to the outer region of the jet and a decrease of the pressure diffusion to the inner region of the jet. (C) 2015 Elsevier Inc. All rights reserved.	[Terashima, Osamu; Sakai, Yasuhiko; Nagata, Kouji; Ito, Yasumasa; Onishi, Kazuhiro; Shouji, Yuichi] Grad Sch Engn, Mech Engn & Sci, Chikusa Ku, Nagoya, Aichi 4648603, Japan	Terashima, O (reprint author), Grad Sch Engn, Mech Engn & Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.	o-terashima@mech.nagoya-u.ac.jp			Ono Acoustic Research Fund, Takahashi Industrial and Economic Research Foundation;  [23760155]	The authors express their gratitude for partial financial support of this study by the Ono Acoustic Research Fund, Takahashi Industrial and Economic Research Foundation, and the Grant-in-Aids for scientific research (No. 23760155).	Gordeyev SV, 2000, J FLUID MECH, V414, P145, DOI 10.1017/S002211200000848X; Tsuji Y, 2007, J FLUID MECH, V585, P1, DOI 10.1017/S0022112007006076; Landel JR, 2012, J FLUID MECH, V692, P347, DOI 10.1017/jfm.2011.518; TOWNSEND AA, 1949, AUST J SCI RES SER A, V2, P451; MUMFORD JC, 1982, J FLUID MECH, V118, P241, DOI 10.1017/S0022112082001062; ANTONIA RA, 1983, J FLUID MECH, V134, P49, DOI 10.1017/S0022112083003213; Sakai Y, 2006, JSME INT J B-FLUID T, V49, P722, DOI 10.1299/jsmeb.49.722; OLER JW, 1982, J FLUID MECH, V123, P523, DOI 10.1017/S0022112082003188; Terashima O, 2012, EXP FLUIDS, V53, P1149, DOI 10.1007/s00348-012-1351-z; EVERITT KW, 1978, J FLUID MECH, V88, P563, DOI 10.1017/S0022112078002281; THOMAS FO, 1986, PHYS FLUIDS, V29, P1788, DOI 10.1063/1.865606; DIMOTAKIS PE, 1983, PHYS FLUIDS, V26, P3185, DOI 10.1063/1.864090; Gordeyev SV, 2002, J FLUID MECH, V460, P349, DOI 10.1017/S0022112002008364; BRADSHAW P, 1981, PHYS FLUIDS, V24, P777, DOI 10.1063/1.863442; Daubechies I., 1992, 10 LECT WAVELETS; GOLDSCHM.VW, 1973, PHYS FLUIDS, V16, P354, DOI 10.1063/1.1694348; Gortari J.C., 1981, ASME J FLUID ENG, V103, P119; Naka Y, 2006, INT J HEAT FLUID FL, V27, P737, DOI 10.1016/j.ijheatfluidflow.2006.02.023; Rajaratnam N., 1976, TURBULENT JETS; Sakai Y, 2007, J FLUID SCI TECHNOL, V2, P611, DOI 10.1299/jfst.2.611; Sakai Y, 2006, JSME INT J B-FLUID T, V49, P115, DOI 10.1299/jsmeb.49.115; Straatman AG, 1998, AIAA J, V36, P929; Suga K, 2004, J FLUID ENG-T ASME, V126, P634, DOI 10.1115/1.1779660; Tsuji Y, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.026309; WYGNANSK.I, 1971, PHYS FLUIDS, V14, P1309, DOI 10.1063/1.1693606; Yoshizawa A, 2002, PHYS FLUIDS, V14, P1736, DOI 10.1063/1.1466823	26	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0142-727X	1879-2278		INT J HEAT FLUID FL	Int. J. Heat Fluid Flow	JUN	2015	53						56	67		10.1016/j.ijheatfluidflow.2015.01.007		12	Thermodynamics; Engineering, Mechanical; Mechanics	Thermodynamics; Engineering; Mechanics	CJ3EZ	WOS:000355367500005		
J	Fu, ZG; Iwaki, Y; Motozawa, M; Tsukahara, T; Kawaguchi, Y				Fu, Zaiguo; Iwaki, Yuichiro; Motozawa, Masaaki; Tsukahara, Takahiro; Kawaguchi, Yasuo			Characteristic turbulent structure of a modified drag-reduced surfactant solution flow via dosing water from channel wall	INTERNATIONAL JOURNAL OF HEAT AND FLUID FLOW			English	Article						Drag-reduced flow; Surfactant solution; Turbulent structure; Turbulence control	DOSED POLYMER-SOLUTION; BOUNDARY-LAYER; STREAMWISE DEVELOPMENT; REYNOLDS-NUMBER; REDUCTION; ADDITIVES; MECHANISM; INJECTION; DIFFUSION; STRESS	The modification of the near-wall structure is very important for the control of wall turbulence. To ascertain the effect of near-wall modulation on the viscoelastic drag-reduced flow, the modified characteristics of a surfactant solution channel flow were investigated experimentally. The modulation was conducted on the boundary of the channel flow by injecting water from the whole surface of one side of the channel wall. The diffusion process of the injected water was observed by using the planar laser-induced fluorescence technique. The velocity statistics and characteristic structure including the spatial distributions of instantaneous streamwise velocity, swirling strength, and Reynolds shear stress were analyzed based on the velocity vectors acquired in the streamwise wall-normal plane by using the particle imaging velocimetry technique. The results indicated that the disturbance of the injected water was constricted within a finite range very near the dosing wall, and the Reynolds shear stress was increased in this region. However, the eventual drag reduction rate was found to be increased due to a relatively large decrement of viscoelastic shear stress in this near-wall region. Moreover, the flow structure under this modulation presented obvious regional characteristics. In the unstable disturbed region, the mixing of high-speed and low-speed fluids and the motions of ejection and sweep occurred actively. Many clockwise vortex cores were also found to be generated. This characteristic structure was similar to that in the ordinary turbulence of Newtonian fluid. Nevertheless, outside this disturbed region, the structure still maintained the characteristics of the drag-reduced flow with non-Newtonian viscoelastic additives. These results proved that the injected Newtonian fluid associated with the modified stress distribution creates a diverse characteristic structure and subsequent enhanced drag reduction. This investigation can provide the experimental basis for further study of turbulence control. (C) 2015 Elsevier Inc. All rights reserved.	[Fu, Zaiguo; Iwaki, Yuichiro; Tsukahara, Takahiro; Kawaguchi, Yasuo] Tokyo Univ Sci, Noda, Chiba 2788510, Japan; [Motozawa, Masaaki] Shizuoka Univ, Naka Ku, Hamamatsu, Shizuoka 4328561, Japan	Kawaguchi, Y (reprint author), Tokyo Univ Sci, Dept Mech Engn, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	fuzaiguo2009@hotmail.com; tmmotoz@ipc.shizuoka.ac.jp; tsuka@rs.noda.tus.ac.jp; yasuo@rs.noda.tus.ac.jp	Tsukahara, Takahiro/A-7118-2014	Tsukahara, Takahiro/0000-0001-8126-9578	Japanese Ministry of Education, Culture, Sports, Science and Technology	The first author would like to thank the Japanese Ministry of Education, Culture, Sports, Science and Technology for its support in the form of the scholarship.	Yu B, 2004, INT J HEAT FLUID FL, V25, P961, DOI 10.1016/j.ijheatfluidflow.2004.02.029; TIEDERMAN WG, 1985, J FLUID MECH, V156, P419, DOI 10.1017/S0022112085002178; Zhou J, 1999, J FLUID MECH, V387, P353, DOI 10.1017/S002211209900467X; Frohnapfel B, 2007, J FLUID MECH, V577, P457, DOI 10.1017/S0022112007005083; Li FC, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1941366; Fukagata K, 2002, PHYS FLUIDS, V14, pL73, DOI 10.1063/1.1516779; Tamano S, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3103884; Warholic MD, 1999, EXP FLUIDS, V27, P461, DOI 10.1007/s003480050371; Zhang Y, 2005, J COLLOID INTERF SCI, V286, P696, DOI 10.1016/j.jcis.2005.01.055; Motozawa M, 2014, INT J HEAT FLUID FL, V50, P51, DOI 10.1016/j.ijheatfluidflow.2014.05.009; Benzi R, 2010, PHYSICA D, V239, P1338, DOI 10.1016/j.physd.2009.07.013; Min T, 2003, J FLUID MECH, V486, P213, DOI 10.1017/S0022112003004610; DEGENNES PG, 1986, PHYSICA A, V140, P9, DOI 10.1016/0378-4371(86)90200-1; DenToonder JMJ, 1997, J FLUID MECH, V337, P193, DOI 10.1017/S0022112097004850; Li FC, 2008, INT J HEAT MASS TRAN, V51, P835, DOI 10.1016/j.ijheatmasstransfer.2007.04.048; Adrian RJ, 2000, J FLUID MECH, V422, P1, DOI 10.1017/S0022112000001580; LUMLEY JL, 1977, J FLUID MECH, V82, P161, DOI 10.1017/S0022112077000585; PERRY AE, 1982, J FLUID MECH, V119, P173, DOI 10.1017/S0022112082001311; Dubief Y, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4820142; Fu ZG, 2014, INT J HEAT MASS TRAN, V77, P860, DOI 10.1016/j.ijheatmasstransfer.2014.06.016; Hou YX, 2008, J FLUID MECH, V597, P31, DOI 10.1017/S0022112007009718; HU YT, 1995, RHEOL ACTA, V34, P450, DOI 10.1007/BF00396558; Ishitsuka S, 2011, J PHYS CONF SER, V318, DOI 10.1088/1742-6596/318/9/092017; Iwamoto K., 2005, PHYS FLUIDS, V17, pL73; Jovanovic J, 2006, J FLUID ENG-T ASME, V128, P118, DOI 10.1115/1.2073227; Jovanovic J., 2005, THERM SCI, V9, P3, DOI 10.2298/TSCI0501003J; Kawada S., 2013, P 8 WORLD C EXP HEAT, P1025; Kawaguchi Y, 2002, INT J HEAT FLUID FL, V23, P700, DOI 10.1016/S0142-727X(02)00166-2; Lu B, 1998, LANGMUIR, V14, P8, DOI 10.1021/la970630n; Lumley J. L., 1973, Journal of Polymer Science, Macromolecular Reviews, V7, DOI 10.1002/pol.1973.230070104; Motozawa M, 2012, FLOW TURBUL COMBUST, V88, P121, DOI 10.1007/s10494-011-9358-8; Motozawa M., 2009, P 7 WORLD C EXP HEAT, P1025; Motozawa M, 2011, NIHON REOROJI GAKK, V39, P99; Motozawa M, 2012, J THERM SCI TECH-JPN, V7, P272, DOI 10.1299/jtst.7.272; ROBINSON SK, 1991, ANNU REV FLUID MECH, V23, P601, DOI 10.1146/annurev.fluid.23.1.601; Takeuchi H., 2009, P 8 INT C SUST EN TE; Toms B., 1948, P 1 INT C RHEOL, V2, P135; Tsukahara T., 2010, J TURBUL, V12, P1; WALKER DT, 1989, EXP FLUIDS, V8, P86, DOI 10.1007/BF00203069; Winkel E.S., 2006, P 26 S NAV HYDR ROM, P17; Yu B, 2005, J FLUID ENG-T ASME, V127, P929, DOI 10.1115/1.2012500; Zakin JL, 1996, AICHE J, V42, P3544, DOI 10.1002/aic.690421223	42	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0142-727X	1879-2278		INT J HEAT FLUID FL	Int. J. Heat Fluid Flow	JUN	2015	53						135	145		10.1016/j.ijheatfluidflow.2015.03.006		11	Thermodynamics; Engineering, Mechanical; Mechanics	Thermodynamics; Engineering; Mechanics	CJ3EZ	WOS:000355367500011		
J	Zare-Behtash, H; Lo, KH; Kontis, K; Ukai, T; Obayashi, S				Zare-Behtash, H.; Lo, K. H.; Kontis, K.; Ukai, T.; Obayashi, S.			Transverse jet-cavity interactions with the influence of an impinging shock	INTERNATIONAL JOURNAL OF HEAT AND FLUID FLOW			English	Article						High-speed flow; Flow visualisation; Shock waves	PRESSURE-SENSITIVE PAINT; SUPERSONIC CROSS-FLOW; SCRAMJET COMBUSTOR; HYPERSONIC FLOW; SHEAR-LAYER; DOUBLE RAMP; INJECTION; PSP	For high-speed air breathing engines, fuel injection and subsequent mixing with air is paramount for combustion. The high freestream velocity poses a great challenge to efficient mixing both in macroscale and microscale. Utilising cavities downstream of fuel injection locations, as a means to hold the flow and stabilise the combustion, is one mechanism which has attracted much attention, requiring further research to study the unsteady flow features and interactions occurring within the cavity. In this study we combine the transverse jet injection upstream of a cavity with an impinging shock to see how this interaction influences the cavity flow, since impinging shocks have been shown to enhance mixing of transverse jets. Utilising qualitative and quantitative methods: schlieren, oilflow, Ply, and PSP the induced flowfield is analysed. The impinging shock lifts the shear layer over the cavity and combined with the instabilities generated by the transverse jet creates a highly complicated flowfield with numerous vertical structures. The interaction between the oblique shock and the jet leads to a relatively uniform velocity distribution within the cavity. (C) 2015 Elsevier Inc. All rights reserved.	[Zare-Behtash, H.; Lo, K. H.; Kontis, K.] Univ Glasgow, Sch Engn, Glasgow G12 8QQ, Lanark, Scotland; [Ukai, T.; Obayashi, S.] Tohoku Univ, Inst Fluid Sci, Sendai, Miyagi 9808577, Japan	Zare-Behtash, H (reprint author), Univ Glasgow, Sch Engn, Glasgow G12 8QQ, Lanark, Scotland.	Hossein.Zare-Behtash@glasgow.ac.uk					Schetz JA, 2010, J PROPUL POWER, V26, P1102, DOI 10.2514/1.49355; Zhuang N, 2006, AIAA J, V44, P2118, DOI 10.2514/1.14879; Yang L, 2012, INT J HEAT FLUID FL, V37, P9, DOI 10.1016/j.ijheatfluidflow.2012.05.004; Zare-Behtash H, 2011, INT J HEAT FLUID FL, V32, P596, DOI 10.1016/j.ijheatfluidflow.2011.02.013; Mai T, 2011, P COMBUST INST, V33, P2335, DOI 10.1016/j.proci.2010.07.056; SAMIMY M, 1991, PHYS FLUIDS A-FLUID, V3, P1915, DOI 10.1063/1.857921; Huang W., 2001, ACTA ASTRONAUT, V73, P1; Huh H., 1996, S INT COMBUSTION, V26, P2933, DOI 10.1016/S0082-0784(96)80135-4; Kontis K, 2004, T JPN SOC AERONAUT S, V47, P131, DOI 10.2322/tjsass.47.131; Kontis K, 2008, SHOCK WAVES, V17, P323, DOI 10.1007/s00193-007-0114-x; Kontis K, 2007, AERONAUT J, V111, P495; Lada C, 2010, J AIRCRAFT, V47, P723, DOI 10.2514/1.46027; Lazar E, 2008, AIAA J, V46, P2987, DOI 10.2514/1.32835; Lee SH, 2006, J PROPUL POWER, V22, P1012, DOI 10.2514/1.14180; Lee SH, 2006, J PROPUL POWER, V22, P1020, DOI 10.2514/1.14185; Lusl W.T., 2011, CONTROL SUPERSONIC C; Moshasrov V., 1998, LUMINESCENT PRESSURE; Quinn MK, 2011, SENSORS-BASEL, V11, P11649, DOI 10.3390/s111211649; Quinn MK, 2013, SENSORS-BASEL, V13, P4404, DOI 10.3390/s130404404; Quinn MK, 2013, EXP THERM FLUID SCI, V48, P58, DOI 10.1016/j.expthermflusci.2013.02.008; Sakamoto K., 1995, 26 AIAA FLUID DYN C; SULLINS GA, 1993, J PROPUL POWER, V9, P515, DOI 10.2514/3.23653; Tomioka S, 2003, J PROPUL POWER, V19, P104, DOI 10.2514/2.6086; Ukai T., 2013, EXP THERM FLUID SCI, V52, P59; Ukai T, 2014, INT J HEAT FLUID FL, V50, P254, DOI 10.1016/j.ijheatfluidflow.2014.08.009; Yang L, 2012, SENSOR ACTUAT B-CHEM, V161, P100, DOI 10.1016/j.snb.2011.09.053; Yang L, 2012, EXP THERM FLUID SCI, V40, P50, DOI 10.1016/j.expthermflusci.2012.01.032; Zare-Behtash H, 2009, J VISUAL-JAPAN, V12, P157; Zare-Behtash H, 2009, INT J HEAT FLUID FL, V30, P561, DOI 10.1016/j.ijheatfluidflow.2009.02.022; Zare-Behtash H, 2010, EXP FLUIDS, V49, P1005, DOI 10.1007/s00348-010-0839-7; Zare-Behtash H, 2009, EXP THERM FLUID SCI, V33, P852, DOI 10.1016/j.expthermflusci.2009.03.002	31	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0142-727X	1879-2278		INT J HEAT FLUID FL	Int. J. Heat Fluid Flow	JUN	2015	53						146	155		10.1016/j.ijheatfluidflow.2015.03.004		10	Thermodynamics; Engineering, Mechanical; Mechanics	Thermodynamics; Engineering; Mechanics	CJ3EZ	WOS:000355367500012		
J	Omori, M; Yamawaki, N; McKyer, EL				Omori, Mika; Yamawaki, Niwako; McKyer, E. Lisako			A Comparative Study of Smoking in American and Japanese Adolescents: Self, Social Influences, and Health Beliefs	INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION			English	Article						Adolescence; Smoking; Perceived social norms; Self; Comparative study	ADVERSE CHILDHOOD EXPERIENCES; MIDWESTERN COMMUNITY SAMPLE; RISK-TAKING BEHAVIORS; CIGARETTE-SMOKING; UNITED-STATES; SUBSTANCE USE; CONSEQUENCES; ADULTHOOD; ESTEEM; PEER	Adolescent health-endangering behaviors are often explained in relation to psychosocial factors. The present study examined how differing psychosocial factors affect smoking by comparing American and Japanese adolescents. Participants in this study were 844 American (374 boys, 401 girls, and 69 undefined) and 734 Japanese (426 boys, 297 girls, and 11 undefined) students from the 7th to 12th grade. The average age of the American sample was 15.24 years old (SD = 2.05); the average age of the Japanese sample was 15.78 (SD = 1.16). Multiple regression analysis with a moderation analysis was conducted to examine the effects of culture on smoking status. A significant moderation effect of culture was found for the perceived prevalence of smoking among peers-perceived prevalence predicted smoking in the past month for Japanese adolescents but not for Americans. The results suggest that Japanese adolescents' smoking behavior is influenced by the collectivistic nature of their culture.	[Omori, Mika] Ochanomizu Univ, Grad Sch Humanities & Sci, Dept Psychol, Bunkyo Ku, Tokyo 1128610, Japan; [Yamawaki, Niwako] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [McKyer, E. Lisako] Texas A&M Univ, Dept Hlth & Kinesiol, College Stn, TX USA	Omori, M (reprint author), Ochanomizu Univ, Grad Sch Humanities & Sci, Dept Psychol, Bunkyo Ku, 2-1-1 Otsuka, Tokyo 1128610, Japan.	omori.mika@ocha.ac.jp			Social Science Research Council; Japanese Society of Promotion of Science [15530450]	This work was supported by the Abe Fellowship from the Social Science Research Council and Grant-in-Aid [grant number 15530450] from the Japanese Society of Promotion of Science.	Chassin L, 2000, HEALTH PSYCHOL, V19, P223, DOI 10.1037//0278-6133.19.3.223; TURNER RA, 1993, HEALTH PSYCHOL, V12, P200, DOI 10.1037//0278-6133.12.3.200; Anda RF, 1999, JAMA-J AM MED ASSOC, V282, P1652, DOI 10.1001/jama.282.17.1652; Kokkevi A, 2007, DRUG ALCOHOL DEPEN, V86, P67, DOI 10.1016/j.drugalcep.2006.05.018; Griesler PC, 1998, J ADOLESCENT HEALTH, V23, P167, DOI 10.1016/S1054-139X(98)00029-9; Beyers JM, 2004, J ADOLESCENT HEALTH, V35, P3, DOI 10.1016/j.jadohealth.2003.08.015; JACCARD J, 1990, MULTIVAR BEHAV RES, V25, P467, DOI 10.1207/s15327906mbr2504_4; Kloep M, 2009, J ADOLESCENCE, V32, P135, DOI 10.1016/j.adolescence.2007.10.010; Pidgeon N, 1998, RELIAB ENG SYST SAFE, V59, P5, DOI 10.1016/S0951-8320(97)00114-2; Kitayama S, 1997, J PERS SOC PSYCHOL, V72, P1245, DOI 10.1037/0022-3514.72.6.1245; Farruggia SP, 2004, J CROSS CULT PSYCHOL, V35, P719, DOI 10.1177/0022022104270114; Turbin MS, 2006, HEALTH PSYCHOL, V25, P445, DOI 10.1037/0278-6133.25.4.445; Simons-Morton B, 2004, HEALTH PSYCHOL, V23, P612, DOI 10.1037/0278-6133.23.6.612; Unger JB, 2000, HEALTH PSYCHOL, V19, P403, DOI 10.1037/0278-6133.19.5.403; Baumeister RF, 1996, PSYCHOL REV, V103, P5, DOI 10.1037/0033-295X.103.1.5; Cooper ML, 1998, J PERS SOC PSYCHOL, V74, P1380, DOI 10.1037//0022-3514.74.5.1380; Frazier PA, 2004, J COUNS PSYCHOL, V51, P115, DOI 10.1037/0022-0167.51.1.115; Hoffman BR, 2007, ADDICT BEHAV, V32, P1546, DOI 10.1016/j.addbeh.2006.11.016; ARNETT J, 1993, CHILD DEV, V64, P1842, DOI 10.1111/j.1467-8624.1993.tb04217.x; BAUMEISTER RF, 1993, J PERS SOC PSYCHOL, V64, P141, DOI 10.1037/0022-3514.64.1.141; Beck KH, 1996, ADDICT BEHAV, V21, P633, DOI 10.1016/0306-4603(95)00087-9; BENTHIN A, 1993, J ADOLESCENCE, V16, P153, DOI 10.1006/jado.1993.1014; Brown DW, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-20; Cabinet Office Government of Japan Headquarters for Youth Development, 2008, NAT YOUTH DEV POL; Center for Disease Control and Prevention [CDC], 2006, CIG SMOK AD US; Chassin L, 2001, HEALTH PSYCHOL, V20, P377, DOI 10.1037/0278-6133.20.5.377; Chen CS, 1998, DEV PSYCHOL, V34, P770, DOI 10.1037//0012-1649.34.4.770; Chopak J. S., 1993, THESIS PENNSYLVANIA; Gakko Hoken, 2010, MIS KITS INSH JOKY N; Gerrard M, 1996, HEALTH PSYCHOL, V15, P344, DOI 10.1037/0278-6133.15.5.344; GIBBONS FX, 1995, J APPL PSYCHOL, V80, P107, DOI 10.1037/0021-9010.80.1.107; IRWIN CE, 1986, J ADOLESCENT HEALTH, V7, pS82; Jessor S. L., 1977, PROBLEM BEHAV PSYCHO; Johnston L. D., 2010, NIH PUBLICATION, VII; Kariya T, 1999, AM J EDUC, V107, P210, DOI 10.1086/444216; Khallad Y, 2010, J HEALTH PSYCHOL, V15, P925, DOI 10.1177/1359105309359543; Kim YH, 2001, J ADOLESCENT HEALTH, V29, P298, DOI 10.1016/S1054-139X(01)00218-X; Krosnick JA, 2006, J COMMUN, V56, pS18, DOI 10.1111/j.1460-2466.2006.00281.x; Lazuras L, 2009, HEALTH PSYCHOL, V28, P770, DOI 10.1037/a0016126; MARKUS HR, 1994, PERS SOC PSYCHOL B, V20, P568, DOI 10.1177/0146167294205013; Ministry of Health Labour and Welfare of Japan, 2007, OUTL RES NAT HLTH NU; Morrell HER, 2010, HEALTH PSYCHOL, V29, P610, DOI 10.1037/a0021237; Offer D., 1988, TEENAGE WORLD ADOLES; Omori M, 2005, J ADOLESCENCE, V28, P17, DOI 10.1016/j.adolescence.2004.04.004; Osaki Y., 2005, Journal of the National Institute of Public Health, V54, P284; PATTON W, 1994, J YOUTH ADOLESCENCE, V23, P19, DOI 10.1007/BF01537140; Snyder T. D., 2011, DIGEST ED STAT MEDIA; Statistics Bureau Ministry of Internal Affairs and Communications Japan, 2007, STAT OBS PREF 2007; Unger J B, 2001, Nicotine Tob Res, V3, P167; Vander Weg MW, 2011, NICOTINE TOB RES, V13, P616, DOI 10.1093/ntr/ntr023	50	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1557-1874	1557-1882		INT J MENT HEALTH AD	Int. J. Mental Health Addict.	JUN	2015	13	3					345	360		10.1007/s11469-014-9539-5		16	Psychology, Clinical; Substance Abuse; Psychiatry	Psychology; Substance Abuse; Psychiatry	CJ1GC	WOS:000355230400004		
J	Liu, Y; Zhao, QN; Zhang, LQ				Liu, Ye; Zhao, Qibin; Zhang, Liqing			Uncorrelated Multiway Discriminant Analysis for Motor Imagery EEG Classification	INTERNATIONAL JOURNAL OF NEURAL SYSTEMS			English	Article						Brain computer interface (BCI); electroencephalography; classification; tensor Factorization	SINGLE-TRIAL EEG; STROKE PATIENTS; SPATIAL-PATTERNS; BCI; REHABILITATION; REORGANIZATION; RECOGNITION; RECOVERY; FILTERS; SET	Motor imagery-based brain-computer interfaces (BCIs) training has been proved to be an effective communication system between human brain and external devices. A practical problem in BCI-based systems is how to correctly and efficiently identify and extract subject-specific features from the blurred scalp electroencephalography (EEG) and translate those features into device commands in order to control external devices. In real BCI-based applications, we usually define frequency bands and channels configuration that related to brain activities beforehand. However, a steady configuration usually loses effects due to individual variability among different subjects in practical applications. In this study, a robust tensor-based method is proposed for a multiway discriminative subspace extraction from tensor-represented EEG data, which performs well in motor imagery EEG classification without the prior neurophysiologic knowledge like channels configuration and active frequency bands. Motor imagery EEG patterns in spatial-spectral-temporal domain are detected directly from the multidimensional EEG, which may provide insights to the underlying cortical activity patterns. Extensive experiment comparisons have been performed on a benchmark dataset from the famous BCI competition III as well as self-acquired data from healthy subjects and stroke patients. The experimental results demonstrate the superior performance of the proposed method over the contemporary methods.	[Liu, Ye; Zhang, Liqing] Shanghai Jiao Tong Univ, Dept Comp Sci & Engn, Key Lab Shanghai Educ Commiss Intelligent Interac, Shanghai 200240, Peoples R China; [Zhao, Qibin] RIKEN, Brain Sci Inst, Lab Adv Brain Signal Proc, Saitama, Japan	Zhang, LQ (reprint author), Shanghai Jiao Tong Univ, Dept Comp Sci & Engn, Key Lab Shanghai Educ Commiss Intelligent Interac, Shanghai 200240, Peoples R China.	lyyx000@sjtu.edu.cn; qbzhao@brain.riken.jp; zhang-lq@cs.sjtu.edu.cn			National Key Basic Research Program of China [2015CB856004]; JSPS KAKENHI [15K15955]; National Natural Science Foundation of China [91120305, 61272251, 61202155]; China Scholarship Council (CSC)	The work was supported by the National Key Basic Research Program of China (Grant No. 2015CB856004), JSPS KAKENHI (Grant No. 15K15955) and the National Natural Science Foundation of China (Grant Nos. 91120305, 61272251, 61202155). This work is also sponsored by China Scholarship Council (CSC).	Lemm S, 2005, IEEE T BIO-MED ENG, V52, P1541, DOI 10.1109/TBME.2005.851521; Pang YW, 2009, IEEE T IMAGE PROCESS, V18, P903, DOI 10.1109/TIP.2008.2011167; Lotte F, 2011, IEEE T BIO-MED ENG, V58, P355, DOI 10.1109/TBME.2010.2082539; Ang KK, 2012, PATTERN RECOGN, V45, P2137, DOI 10.1016/j.patcog.2011.04.018; Li JH, 2013, INT J NEURAL SYST, V23, DOI 10.1142/S0129065713500135; Kranczioch C, 2014, INT J PSYCHOPHYSIOL, V91, P10, DOI 10.1016/j.ijpsycho.2013.10.004; Cabrerizo M, 2012, INT J NEURAL SYST, V22, DOI 10.1142/S0129065712500013; Temko A, 2013, INT J NEURAL SYST, V23, DOI 10.1142/S0129065713500184; Loubinoux I, 2003, NEUROIMAGE, V20, P2166, DOI 10.1016/j.neuroimage.2003.08.017; Olson LD, 2013, INT J NEURAL SYST, V23, DOI 10.1142/S012906571230001X; Blankertz B, 2006, IEEE T NEUR SYS REH, V14, P153, DOI 10.1109/TNSRE.2006.875642; Hsu WY, 2011, INT J NEURAL SYST, V21, P335, DOI 10.1142/S0129065711002870; Lu HP, 2008, IEEE T NEURAL NETWOR, V19, P18, DOI 10.1109/TNN.2007.901277; Blanchard G, 2004, IEEE T BIO-MED ENG, V51, P1062, DOI 10.1109/TBME.2004.826691; Herrera LJ, 2013, INT J NEURAL SYST, V23, DOI 10.1142/S0129065713500123; Ramoser H, 2000, IEEE T REHABIL ENG, V8, P441, DOI 10.1109/86.895946; Tao DC, 2007, IEEE T PATTERN ANAL, V29, P1700, DOI 10.1109/TPAMI.2007.1096; Jang SH, 2003, NEUROREPORT, V14, P1305, DOI 10.1097/01.wnr.0000078700.79393.09; Dornhege G, 2006, IEEE T BIO-MED ENG, V53, P2274, DOI 10.1109/TBME.2006.883649; Liu YF, 2013, STAT INTERFACE, V6, P1; Hsu WY, 2013, INT J NEURAL SYST, V23, DOI 10.1142/S012906571350007X; Wu W, 2008, IEEE T BIO-MED ENG, V55, P1733, DOI 10.1109/TBME.2008.919125; Calautti C, 2001, STROKE, V32, P2534, DOI 10.1161/hs1101.097401; Lu HP, 2009, IEEE T NEURAL NETWOR, V20, P103, DOI 10.1109/TNN.2008.2004625; Tam WK, 2011, IEEE T NEUR SYS REH, V19, P617, DOI 10.1109/TNSRE.2011.2168542; Badawy RAB, 2014, INT J NEURAL SYST, V24, DOI 10.1142/S0129065714300022; Bishop C. M., 2006, PATTERN RECOGNITION; Chang C-C, 2011, ACM T INTEL SYST TEC, V2, P3, DOI DOI 10.1145/1961189.1961199; Chen MSS, 2014, LECT NOTES COMPUT SC, V8836, P202, DOI 10.1007/978-3-319-12643-2_25; Cichocki A., 2009, NONNEGATIVE MATRIX T; He X, 2005, ADV NEURAL INFORM PR, V18, P499; Hill NJ, 2006, LECT NOTES COMPUT SC, V4174, P404; Lee H, 2007, INT J NEURAL SYST, V17, P305, DOI 10.1142/S0129065707001159; Li JH, 2013, IEEE ENG MED BIO, P2200; Li MF, 2014, INT J NEUROSCI, V124, P403, DOI 10.3109/00207454.2013.850082; Liang J., 2013, LNCS, V7952, P284; Liu Y, 2015, INT J PATTERN RECOGN, V29, DOI 10.1142/S0218001415500019; Liu Y, 2014, J NEUROSCI METH, V222, P238, DOI 10.1016/j.jneumeth.2013.11.009; Liu Y., 2013, EMBC 2013, P2204; Liu Y., 2014, P 21 EUR C ART INT, P537; Morup M., 2006, DECOMPOSING TIME FRE; Muller-Putz GR, 2013, INT J NEURAL SYST, V23, DOI 10.1142/S0129065712500372; Rodriguez-Bermudez G, 2013, INT J NEURAL SYST, V23, DOI 10.1142/S0129065713500159; Shahid S., 2010, BMC NEUROSCI, V11, P1; Wang H., 2013, LNCS, V8226, P419; WELCH PD, 1967, IEEE T ACOUST SPEECH, VAU15, P70, DOI 10.1109/TAU.1967.1161901; Zhang Hao, 2013, Conf Proc IEEE Eng Med Biol Soc, V2013, P2208, DOI 10.1109/EMBC.2013.6609974; Zhang YM, 2014, J MANUF PROCESS, V16, P1, DOI 10.1016/j.jmapro.2013.12.004	48	0	0	WORLD SCIENTIFIC PUBL CO PTE LTD	SINGAPORE	5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE	0129-0657	1793-6462		INT J NEURAL SYST	Int. J. Neural Syst.	JUN	2015	25	4							1550013	10.1142/S0129065715500136		14	Computer Science, Artificial Intelligence	Computer Science	CJ2QC	WOS:000355328600003		
J	Shigemura, K; Osawa, K; Yamamichi, F; Tanaka, K; Tokimatsu, I; Arakawa, S; Fujisawa, M				Shigemura, Katsumi; Osawa, Kayo; Yamamichi, Fukashi; Tanaka, Kazushi; Tokimatsu, Issei; Arakawa, Soichi; Fujisawa, Masato			Optimal vancomycin doses for methicillin-resistant Staphylococcus aureus infection in urological renal dysfunction patients	INTERNATIONAL UROLOGY AND NEPHROLOGY			English	Article						Vancomycin (VCM); Therapeutic drug monitoring (TDM); Trough concentration; Methicillin-resistant Staphylococcus aureus (MRSA); Impaired renal function	CRITICALLY-ILL PATIENTS; GLOMERULAR-FILTRATION-RATE; DISEASES SOCIETY; DOSAGE REGIMENS; PHARMACOKINETICS; EPIDEMIOLOGY; ADJUSTMENT; GUIDELINES; AMERICA	To investigate the optimal dose of vancomycin (VCM) for methicillin-resistant Staphylococcus aureus infections in the urological patients including renal dysfunction. We had 143 sets of available data from the consecutive patients treated in the urological department for analysis in VCM dose, VCM trough and estimated glomerular filtration rate: eGFR at VCM trough examination. Patients were classified according to eGFR level, and we calculated the regression line between VCM dose and VCM trough accordingly. Median VCM dose were 1000 (range 500-3500) mg per day, the VCM trough was 15.6 +/- A 7.89 mu g/ml, and eGFR was 61.1 +/- A 27.2 ml/min/1.73 m(2). Our regression analysis (x axis: VCM dose (mg) and y axis: VCM trough (mu g/ml) was statistically significant in the group with eGFR of 30-60 ml/min/1.73 m(2) (y = 26.103x + 481.7; r (2) = 0.1291) and the group with eGFR of 60-90 ml/min/1.73 m(2) (y = 48.891x + 350.75; r (2) = 0.2561) in both with (p = 0.021 and 0.035, respectively) or without (p = 0.012 and 0.004, respectively) adjustments by body weight for VCM doses. These data showed that the optimal dose of VCM varied according to the eGFR value in consecutive urological patients with various renal functions.	[Shigemura, Katsumi; Yamamichi, Fukashi; Tanaka, Kazushi; Arakawa, Soichi; Fujisawa, Masato] Kobe Univ, Grad Sch Med, Fac Med, Div Urol,Dept Organ Therapeut,Chuo Ku, Kobe, Hyogo 6500017, Japan; [Shigemura, Katsumi; Osawa, Kayo; Tokimatsu, Issei; Arakawa, Soichi] Kobe Univ Hosp, Infect Control & Prevent, Chuo Ku, Kobe, Hyogo 6500017, Japan	Shigemura, K (reprint author), Kobe Univ, Grad Sch Med, Fac Med, Div Urol,Dept Organ Therapeut,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	yutoshunta@hotmail.co.jp					Elyasi S, 2012, EUR J CLIN PHARMACOL, V68, P1243, DOI 10.1007/s00228-012-1259-9; Schaumburg F, 2012, J CLIN MICROBIOL, V50, P3186, DOI 10.1128/JCM.01174-12; De Waele JJ, 2013, INT J ANTIMICROB AG, V41, P434, DOI 10.1016/j.ijantimicag.2012.12.015; Liu C, 2011, CLIN INFECT DIS, V52, P285, DOI 10.1093/cid/cir034; El Nekidy Wasim S, 2012, Can J Hosp Pharm, V65, P436; Rybak MJ, 2009, CLIN INFECT DIS, V49, P325, DOI 10.1086/600877; Deng CH, 2013, INT J CLIN PHARM TH, V51, P407, DOI 10.5414/CP201842; Pea F, 2000, J ANTIMICROB CHEMOTH, V45, P329, DOI 10.1093/jac/45.3.329; RODVOLD KA, 1988, ANTIMICROB AGENTS CH, V32, P848; Noel GJ, 2008, ANTIMICROB AGENTS CH, V52, P37, DOI 10.1128/AAC.00551-07; Pottinger PS, 2013, MED CLIN N AM, V97, P601, DOI 10.1016/j.mcna.2013.02.005; Nichol KA, 2013, J ANTIMICROB CHEMOTH, V68, pi47, DOI 10.1093/jac/dkt026; Wong-Beringer A, 2011, INT J ANTIMICROB AG, V37, P95, DOI 10.1016/j.ijantimicag.2010.10.013; Chung J, 2011, ANAESTH INTENS CARE, V39, P1030; Conil JM, 2014, ANAESTH INTENS CARE, V42, P178; Contreiras Claire, 2014, Can J Hosp Pharm, V67, P126; Fahimi F, 2012, IRAN J PHARM RES, V11, P157; Gould IM, 2007, INT J ANTIMICROB AG, V30, pS66, DOI 10.1016/j.ijantimicag.2007.06.023; Hermida J, 2006, THER DRUG MONIT, V28, P326, DOI 10.1097/01.ftd.0000211805.89440.3d; Jelassi ML, 2011, THERAPIE, V66, P29, DOI 10.2515/therapie/2011005; Levin A, 2014, KIDNEY INT, V85, P49; MOELLERING RC, 1981, REV INFECT DIS, V3, pS230; Robles-Piedras Ana Luisa, 2009, Proc West Pharmacol Soc, V52, P21; Shigemura K, 2013, J ANTIBIOT TOKYO, V66, P273	24	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0301-1623	1573-2584		INT UROL NEPHROL	Int. Urol. Nephrol.	JUN	2015	47	6					887	891		10.1007/s11255-015-0973-5		5	Urology & Nephrology	Urology & Nephrology	CJ1AY	WOS:000355215000003		
J	Ichikawa, N; Taniguchi, A; Kaneko, H; Kawamoto, M; Sekita, C; Nakajima, A; Yamanaka, H				Ichikawa, Naomi; Taniguchi, Atsuo; Kaneko, Hirotaka; Kawamoto, Manabu; Sekita, Chieko; Nakajima, Ayako; Yamanaka, Hisashi			Arterial Calcification Due to Deficiency of CD73 (ACDC) As One of Rheumatic Diseases Associated With Periarticular Calcification	JCR-JOURNAL OF CLINICAL RHEUMATOLOGY			English	Article						arterial calcification; CD73; joint calcification	SINGLE-NUCLEOTIDE POLYMORPHISM; ECTO-5'-NUCLEOTIDASE CD73	In 2011, St Hilaire et al (N Engl J Med. 2011; 364: 432-442) identified mutations in the ecto-5'-nucleotidase (NT5E) gene, which encodes CD73, in members of 3 families with symptomatic arterial and joint calcifications. The deficiency of CD73 involves the extracellular adenosine metabolism that influences inorganic pyrophosphate and phosphate metabolism and leads to tissue calcification. Herein, we report an additional case with arterial calcification due to deficiency of CD73. Genetic analyses revealed that the patient was a compound heterozygote of mutations in the NT5E gene. The present case had intermittent monoarthritis of the finger joints and early-onset osteoarthritis in the hands. Occlusion of calcified peripheral arteries is the most important outcome of the disease. However, the rheumatic manifestations may be important clues to the diagnosis. Rheumatologists should recognize deficiency of CD73 as a rheumatic disease.	[Ichikawa, Naomi; Taniguchi, Atsuo; Kaneko, Hirotaka; Kawamoto, Manabu; Sekita, Chieko; Nakajima, Ayako; Yamanaka, Hisashi] Tokyo Womens Med Univ, Inst Rheumatol, Tokyo 1620054, Japan	Ichikawa, N (reprint author), Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, 10-22 Kawada Cho, Tokyo 1620054, Japan.	naomi@twmu.ac.jp					Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399; St Hilaire C, 2011, NEW ENGL J MED, V364, P432, DOI 10.1056/NEJMoa0912923; SHARP J, 1954, ANN RHEUM DIS, V13, P15, DOI 10.1136/ard.13.1.15; Hasko G, 2011, J IMMUNOL, V187, P4256, DOI 10.4049/jimmunol.1003379; Hu YJ, 2007, ANAL BIOCHEM, V369, P54, DOI 10.1016/j.ab.2007.04.042; Jaovisidha K, 2006, CRYSTAL INDUCED ARTH, P117; Kamatani N, 2004, AM J HUM GENET, V75, P190, DOI 10.1086/422853; LEVITIN J, 1945, RADIOLOGY, V44, P489; Magnus-Levy A, 1914, DEUT MED WOCHENSCHR, V40, P1305; MCCARTHY GM, 1993, J RHEUMATOL, V20, P1077; Mori Hideki, 1992, Heart and Vessels, V7, P211, DOI 10.1007/BF01744607; NOSAKA H, 1974, YONAGO ACTA MED, V18, P191; Resnick D, 2002, DIAGNOSIS BONE JOINT, V4th, P1619; THOMSON LF, 1990, TISSUE ANTIGENS, V35, P9, DOI 10.1111/j.1399-0039.1990.tb01750.x	14	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1076-1608	1536-7355		JCR-J CLIN RHEUMATOL	JCR-J. Clin. Rheumatol.	JUN	2015	21	4					216	220		10.1097/RHU.0000000000000245		5	Rheumatology	Rheumatology	CJ1OR	WOS:000355253800010		
J	Fukutani, A; Kurihara, T				Fukutani, Atsuki; Kurihara, Toshiyuki			Tendon Cross-Sectional Area is Not Associated With Muscle Volume	JOURNAL OF APPLIED BIOMECHANICS			English	Article						tendon plasticity; hypertrophy; triceps brachii; quadriceps femoris; triceps surae	MECHANICAL-PROPERTIES; PATELLAR TENDON; ACHILLES-TENDON; IN-VIVO; COLLAGEN-SYNTHESIS; GROWTH-HORMONE; BLOOD-FLOW; EXERCISE; HUMANS; TISSUE	Recent studies have reported that resistance training increases the cross-sectional areas (CSAs) of tendons; however, this finding has not been consistently observed across different studies. If tendon CSA increases through resistance training, resistance-trained individuals should have larger tendon CSAs as compared with untrained individuals. Therefore, in the current study, we aimed to investigate whether resistance training increases tendon CSAs by comparing resistance-trained and untrained individuals. Sixteen males, who were either body builders or rugby players, were recruited as the training group, and 11 males, who did not participate in regular resistance training, were recruited into the control group. Tendon CSAs and muscle volumes of the triceps brachii, quadriceps femoris, and triceps surae were calculated from images obtained by using magnetic resonance imaging. The volumes of the 3 muscles were significantly higher in the training group than in the control group (P < .001 for all muscles). However, a significant difference in tendon CSAs was found only for the distal portion of the triceps surae tendon (P = .041). These findings indicate that tendon CSA is not associated with muscle volume, suggesting that resistance training does not increase tendon CSA.	[Fukutani, Atsuki] Ritsumeikan Univ, Res Org Sci & Technol, Kusatsu, Shiga, Japan; [Fukutani, Atsuki] Japan Soc Promot Sci, Tokyo 1028471, Japan; [Kurihara, Toshiyuki] Ritsumeikan Univ, Fac Sport & Hlth Sci, Kusatsu, Shiga, Japan	Fukutani, A (reprint author), Ritsumeikan Univ, Res Org Sci & Technol, Kusatsu, Shiga, Japan.	atsukifukutani@gmail.com			29th Meiji Yasuda Life Foundation of Health and Welfare;  [13J03159];  [26750313]	We gratefully thank the study participants for their time and dedication to our study. The authors also thank Dr. Kazushige Goto, Faculty of Sport and Health Science, Ritsumeikan University, for planning the experiment. This study was supported by a Grant-in-Aid for JSPS Fellows (13J03159), Grant-in-Aid for Young Scientists B (26750313), and 29th Meiji Yasuda Life Foundation of Health and Welfare.	GORDON AM, 1966, J PHYSIOL-LONDON, V184, P170; Arya S, 2010, J APPL PHYSIOL, V108, P670, DOI 10.1152/japplphysiol.00259.2009; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; Magnusson SP, 2003, EUR J APPL PHYSIOL, V90, P549, DOI 10.1007/s00421-003-0865-8; Seynnes OR, 2009, J APPL PHYSIOL, V107, P523, DOI 10.1152/japplphysiol.00213.2009; Doessing S, 2005, SCAND J MED SCI SPOR, V15, P202, DOI 10.1111/j.1600-0838.2005.00455.x; Reeves ND, 2003, J PHYSIOL-LONDON, V548, P971, DOI 10.1113/jphysiol.2002.035576; Helland C, 2013, BRIT J SPORT MED, V47, P862, DOI 10.1136/bjsports-2013-092275; Kubo K, 2001, J APPL PHYSIOL, V91, P26; Doessing S, 2010, J PHYSIOL-LONDON, V588, P341, DOI 10.1113/jphysiol.2009.179325; Kongsgaard M, 2007, ACTA PHYSIOL, V191, P111, DOI 10.1111/j.1748-1716.2007.01714.x; FUKASHIRO S, 1995, EUR J APPL PHYSIOL O, V71, P555, DOI 10.1007/BF00238560; Fukunaga T, 2001, P ROY SOC B-BIOL SCI, V268, P229; Andersen MB, 2011, J APPL PHYSIOL, V110, P1549, DOI 10.1152/japplphysiol.00037.2010; Boushel R, 2000, J APPL PHYSIOL, V89, P1868; Boushel R, 2000, J PHYSIOL-LONDON, V524, P305, DOI 10.1111/j.1469-7793.2000.t01-2-00305.x; Buchanan CI, 2001, J APPL PHYSIOL, V90, P164; Heinemeier KM, 2012, SCAND J MED SCI SPOR, V22, pE1, DOI 10.1111/j.1600-0838.2012.01459.x; Kubo K, 2012, EUR J APPL PHYSIOL, V112, P2679, DOI 10.1007/s00421-011-2248-x; Malliaras P, 2013, J BIOMECH, V46, P1893, DOI 10.1016/j.jbiomech.2013.04.022; Waugh CM, 2014, J APPL PHYSIOL, V117, P257, DOI 10.1152/japplphysiol.00325.2014	21	0	0	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483	1543-2688		J APPL BIOMECH	J. Appl. Biomech.	JUN	2015	31	3					176	180		10.1123/jab.2014-0183		5	Engineering, Biomedical; Sport Sciences	Engineering; Sport Sciences	CJ1NS	WOS:000355251000007		
J	Ohnuma, K; Homma, A; Sumikura, H; Tsukiya, T; Takewa, Y; Mizuno, T; Mukaibayashi, H; Kojima, K; Katano, K; Taenaka, Y; Tatsumi, E				Ohnuma, Kentaro; Homma, Akihiko; Sumikura, Hirohito; Tsukiya, Tomonori; Takewa, Yoshiaki; Mizuno, Toshihide; Mukaibayashi, Hiroshi; Kojima, Koichi; Katano, Kazuo; Taenaka, Yoshiyuki; Tatsumi, Eisuke			Development of a flow rate monitoring method for the wearable ventricular assist device driver	JOURNAL OF ARTIFICIAL ORGANS			English	Article						Flow rate monitoring; Wearable pneumatic drive unit; Ventricular assist devices (VADs); Air mass flow	MECHANICAL CIRCULATORY SUPPORT; ADVANCED HEART-FAILURE; EXPERIENCE	Our research institute has been working on the development of a compact wearable drive unit for an extracorporeal ventricular assist device (VAD) with a pneumatically driven pump. A method for checking the pump blood flow on the side of the drive unit without modifying the existing blood pump and impairing the portability of it will be useful. In this study, to calculate the pump flow rate indirectly from measuring the flow rate of the driving air of the VAD air chamber, we conducted experiments using a mock circuit to investigate the correlation between the air flow rate and the pump flow rate as well as its accuracy and error factors. The pump flow rate was measured using an ultrasonic flow meter at the inflow and outflow tube, and the air flow was measured using a thermal mass flow meter at the driveline. Similarity in the instantaneous waveform was confirmed between the air flow rate in the driveline and the pump flow rate. Some limitations of this technique were indicated by consideration of the error factors. A significant correlation was found between the average pump flow rate in the ejecting direction and the average air flow rate in the ejecting direction (R (2) = 0.704-0.856), and the air flow rate in the filling direction (R (2) = 0.947-0.971). It was demonstrated that the average pump flow rate was estimated exactly in a wide range of drive conditions using the air flow of the filling phase.	[Ohnuma, Kentaro; Sumikura, Hirohito; Tsukiya, Tomonori; Takewa, Yoshiaki; Mizuno, Toshihide; Taenaka, Yoshiyuki; Tatsumi, Eisuke] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Artificial Organs, Suita, Osaka 5658565, Japan; [Homma, Akihiko; Katano, Kazuo] Tokyo Denki Univ, Sch Sci & Engn, Saitama, Japan; [Mukaibayashi, Hiroshi; Kojima, Koichi] IWAKI Co Ltd, Saitama, Japan	Ohnuma, K (reprint author), Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Artificial Organs, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	ohnuma.kentaro@ri.ncvc.go.jp			Japan Society for the Promotion of Science [24390308, 25670563]; Ministry of Education, Culture, Sports, Science and Technology of Japan	This study was supported in part by Grant-in-Aid for Scientific Research (B) (No. 24390308) and Grant-in-Aid for Challenging Exploratory Research (No. 25670563) from the Japan Society for the Promotion of Science and the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Stewart GC, 2012, CIRCULATION, V125, P1304, DOI 10.1161/CIRCULATIONAHA.111.060830; Nishinaka T, 2007, J ARTIF ORGANS, V10, P236, DOI 10.1007/s10047-007-0389-9; Kirklin JK, 2013, J HEART LUNG TRANSPL, V32, P141, DOI 10.1016/j.healun.2012.12.004; Kyo S, 2012, J CARDIOL, V59, P101, DOI 10.1016/j.jjcc.2012.01.001; Kirklin JK, 2012, J HEART LUNG TRANSPL, V31, P117, DOI 10.1016/j.healun.2011.12.001; Gawlikowski M, 2006, MOL QUANT ACOUST, V27, P89; Gawlikowski M., 2006, MOL QUANT ACOUST, V27, P97; Homma A, 2008, J ARTIF ORGANS, V11, P182, DOI 10.1007/s10047-008-0433-4; Ishii M, 2009, JMAJ, V52, P289; Japanese Association for Clinical Ventricular Assist Systems, 2013, JAP REG VENTR ASS DE; Kamimura T, 2004, JSME INT J C-MECH SY, V47, P1124, DOI 10.1299/jsmec.47.1124; Saito S, 2009, J ARTIF ORGANS, V12, P27, DOI 10.1007/s10047-009-0448-5; SASAKI E, 1994, ARTIF ORGANS, V18, P603, DOI 10.1111/j.1525-1594.1994.tb03385.x; Shiga T, 2011, CIRC J, V75, P121, DOI 10.1253/circj.CJ-10-0770; Slaughter MS, 2010, J HEART LUNG TRANSPL, V29, pS1, DOI 10.1016/j.healun.2010.01.011; TAKANO H, 1993, ANN THORAC SURG, V55, P250; Takano H, 1989, ASAIO Trans, V35, P541, DOI 10.1097/00002480-198907000-00119; Takatani Setsuo, 2005, J Artif Organs, V8, P13, DOI 10.1007/s10047-004-0284-6	18	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1434-7229	1619-0904		J ARTIF ORGANS	J. Artif. Organs	JUN	2015	18	2					106	113		10.1007/s10047-014-0811-z		8	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CJ1OJ	WOS:000355253000002		
J	Matsuda, K; Nishibayashi, A; Toda, K; Fujiwara, T; Fukai, M; Yoshioka, D; Sawa, Y; Hosokawa, K				Matsuda, Ken; Nishibayashi, Akimitsu; Toda, Koichi; Fujiwara, Takashi; Fukai, Megumi; Yoshioka, Daisuke; Sawa, Yoshiki; Hosokawa, Ko			Covering implantable left ventricular assist device (DuraHeart(A (R))) with free flap	JOURNAL OF ARTIFICIAL ORGANS			English	Article						LVAD; Infection; Exposure; Free flap; Continuous flow	HEART-FAILURE; TRANSPLANTATION; INFECTION; PUMP	Severe donor shortage in Japan makes the waiting period for heart transplantation extremely long and the left ventricular assist devices (LVADs) are often used for bridge-to-transplant. We present three cases of infected and exposed DuraHeart(A (R)) LVAD system treated with free flaps. Four free flaps (two latissimus flaps and two anterolateral thigh flaps) were transferred using the right internal thoracic vessels or left deep inferior epigastric vessels as recipients. The potential significance of the continuous low pressure blood flow generated by the LVAD system on microvascular patency has not been previously reported. All flaps survived and worked efficiently to control the infection and cover the devices. Heart transplantation was conducted in the two of three patients. Free flap transfer is an efficient treatment for the patients with infected and exposed implantable LVAD.	[Matsuda, Ken] Niigata Univ, Grad Sch Med, Div Plast & Reconstruct Surg, Chuo Ku, Niigata 9518510, Japan; [Nishibayashi, Akimitsu; Fujiwara, Takashi; Fukai, Megumi; Hosokawa, Ko] Osaka Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Suita, Osaka, Japan; [Toda, Koichi; Yoshioka, Daisuke; Sawa, Yoshiki] Osaka Univ, Grad Sch Med, Dept Cardiovasc Surg, Suita, Osaka, Japan	Matsuda, K (reprint author), Niigata Univ, Grad Sch Med, Div Plast & Reconstruct Surg, Chuo Ku, 1-757 Asahimachi Dori, Niigata 9518510, Japan.	matsuken@med.niigata-u.ac.jp					Slaughter MS, 2010, J CARDIOVASC TRANSL, V3, P618, DOI 10.1007/s12265-010-9222-6; Mehra MR, 2010, J HEART LUNG TRANSPL, V29, P717, DOI 10.1016/j.healun.2010.05.017; Schulman AR, 2009, J HEART LUNG TRANSPL, V28, P237, DOI 10.1016/j.healun.2008.12.007; Rossi M, 2012, INTERACT CARDIOV TH, V15, P733, DOI 10.1093/icvts/ivs297; SUMA H, 1987, ANN THORAC SURG, V44, P394; Kawata M, 2011, J ARTIF ORGANS, V14, P159, DOI 10.1007/s10047-011-0555-y; Hutchinson OZ, 2001, PLAST RECONSTR SURG, V107, P364, DOI 10.1097/00006534-200102000-00011; Kimura M, 2014, ANN THORAC CARDIOVAS, V20, P842, DOI 10.5761/atcs.cr.12.02192; Kitamura Soichiro, 2012, Gen Thorac Cardiovasc Surg, V60, P639, DOI 10.1007/s11748-012-0110-7; Korewicki J, 2012, CARDIOL J, V19, P36, DOI 10.5603/CJ.2012.0007; Nishinaka T, 2006, CIRC J, V70, P1421, DOI 10.1253/circj.70.1421; Shafii AE, 2011, J HEART LUNG TRANSPL, V30, P1421, DOI 10.1016/j.healun.2011.08.007; Slaughter MS, 2009, NEW ENGL J MED, V361, P2241, DOI 10.1056/NEJMoa0909938	13	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1434-7229	1619-0904		J ARTIF ORGANS	J. Artif. Organs	JUN	2015	18	2					114	119		10.1007/s10047-014-0812-y		6	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CJ1OJ	WOS:000355253000003		
J	Imamura, T; Kinugawa, K; Nitta, D; Inaba, T; Maki, H; Hatano, M; Kinoshita, O; Nawata, K; Kyo, S; Ono, M				Imamura, Teruhiko; Kinugawa, Koichiro; Nitta, Daisuke; Inaba, Toshiro; Maki, Hisataka; Hatano, Masaru; Kinoshita, Osamu; Nawata, Kan; Kyo, Shunei; Ono, Minoru			Readmission due to driveline infection can be predicted by new score by using serum albumin and body mass index during long-term left ventricular assist device support	JOURNAL OF ARTIFICIAL ORGANS			English	Article						Nutrition; Cardiac cachexia; Quality of life; VAD	AWAITING HEART-TRANSPLANTATION; NUTRITION ASSESSMENT; DESTINATION THERAPY; CIRCULATORY SUPPORT; FAILURE; OUTCOMES; SYSTEM; IMPLANTATION; MANAGEMENT; PROGNOSIS	Survival in patients with continuous flow left ventricular assist device (CF LVAD) had been increased owing to improved perioperative management procedures. The second target for successful long-term LVAD treatment was to reduce readmission especially due to device-specific infection, which was one of the major unsolved complications. Among 57 enrolled patients who had received CF LVAD and been followed for 530 days on median at our institute between 2008 and 2014, 21 patients experienced readmission due to driveline infection (DLI) at 190 days after the surgery on median. Considering the result of Uni/Multivariate Cox regression analyses demonstrating lower serum albumin concentration (S-ALB) (hazard ratio 0.144) and body mass index (BMI) (hazard ratio 0.843) both obtained at discharge were independent predictors of readmission due to DLI, we constructed a New Score "7 x [S-ALB (g/dL)] + [BMI]", which significantly stratified readmission-free rate into 3 groups [low (> 50 Pt), intermediate (44-50 Pt), and high risk group (< 44 Pt)] during 2-year study period (p = 0.008). Survival remained unchanged irrespective of DLI, whereas those with DLI needed longer in-hospital treatment (p < 0.05). In conclusion, readmission due to DLI could be predicted by using two simple nutrition parameters at discharge. Early nutrition assessment and intervention may reduce readmission and improve patients' quality of life during long-term LVAD support.	[Imamura, Teruhiko; Kinugawa, Koichiro; Kyo, Shunei] Univ Tokyo, Grad Sch Med, Dept Therapeut Strategy Heart Failure, Bunkyo Ku, Tokyo 1138655, Japan; [Nitta, Daisuke; Inaba, Toshiro; Maki, Hisataka; Hatano, Masaru] Univ Tokyo, Dept Cardiovasc Med, Tokyo 1138655, Japan; [Kinoshita, Osamu; Nawata, Kan; Ono, Minoru] Univ Tokyo, Grad Sch Med, Dept Cardiac Surg, Bunkyo Ku, Tokyo 1138655, Japan	Kinugawa, K (reprint author), Univ Tokyo, Grad Sch Med, Dept Therapeut Strategy Heart Failure, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kinugawa-tky@umin.ac.jp					Rose EA, 2001, NEW ENGL J MED, V345, P1435, DOI 10.1056/NEJMoa012175; Mano A, 2009, J HEART LUNG TRANSPL, V28, P428, DOI 10.1016/j.healun.2008.12.020; Toda K, 2012, ANN THORAC SURG, V94, P1387, DOI 10.1016/j.athoracsur.2012.03.021; Holman WL, 2013, J THORAC CARDIOV SUR, V146, P437, DOI 10.1016/j.jtcvs.2013.02.018; Coyle LA, 2010, ARTIF ORGANS, V34, P93, DOI 10.1111/j.1525-1594.2009.00771.x; Zierer A, 2007, ANN THORAC SURG, V84, P515, DOI 10.1016/j.athoracsur.2007.03.085; Holdy K, 2005, J HEART LUNG TRANSPL, V24, P1690, DOI 10.1016/j.healun.2004.11.047; Butler J, 2005, ANN THORAC SURG, V79, P66, DOI 10.1016/j.athoracsur.2004.06.047; Abicht T, 2013, ASAIO J, V59, P188, DOI 10.1097/MAT.0b013e318283820d; Pagani FD, 2009, J AM COLL CARDIOL, V54, P312, DOI 10.1016/j.jacc.2009.03.055; Sharma V, 2012, ANN THORAC SURG, V94, P1381, DOI 10.1016/j.athoracsur.2012.05.074; Goldstein DJ, 2012, J HEART LUNG TRANSPL, V31, P1151, DOI 10.1016/j.healun.2012.05.004; Oz MC, 2003, ANN SURG, V238, P577, DOI 10.1097/01.sla.0000090447.73384.ad; Raymond AL, 2010, ASAIO J, V56, P57, DOI 10.1097/MAT.0b013e3181c879b1; Aggarwal A, 2013, NUTR CLIN PRACT, V28, P112, DOI 10.1177/0884533612457948; Nienaber JJC, 2013, CLIN INFECT DIS, V57, P1438, DOI 10.1093/cid/cit536; Topkara VK, 2010, ANN THORAC SURG, V90, P1270, DOI 10.1016/j.athoracsur.2010.04.093; Kato TS, 2013, AM J CARDIOL, V112, P1484, DOI 10.1016/j.amjcard.2013.06.023; Imamura T, 2012, CIRC J, V76, P1895, DOI 10.1253/circj.CJ-12-0182; Frazier OH, 2001, J THORAC CARDIOV SUR, V122, P1186, DOI 10.1067/mtc.2001.118274; Hannan MM, 2011, J HEART LUNG TRANSPL, V30, P375, DOI 10.1016/j.healun.2011.01.717; Anker SD, 1999, CHEST, V115, P836, DOI 10.1378/chest.115.3.836; BUZBY GP, 1980, AM J SURG, V139, P160, DOI 10.1016/0002-9610(80)90246-9; Arques S, 2011, J CARD FAIL, V17, P451, DOI 10.1016/j.cardfail.2011.02.010; Berry C, 2000, EUR HEART J, V21, P521, DOI 10.1053/euhj.1999.1882; Bomholt T, 2011, SCAND CARDIOVASC J, V45, P273, DOI 10.3109/14017431.2011.577236; de Luis DA, 2014, NUTR HOSP, V30, P509, DOI 10.3305/nh.2014.30.3.7702; Hieda M, 2014, TRANSPL P, V46, P907, DOI 10.1016/j.transproceed.2013.11.106; Leeper Barbara, 2009, Crit Care Nurs Clin North Am, V21, P369, DOI 10.1016/j.ccell.2009.07.003; Leeper B., 2009, CRIT CARE NURS CLIN, V21, pvi; Martin SI, 2010, INTERACT CARDIOV TH, V11, P20, DOI 10.1510/icvts.2009.227801; Miller LW, 2007, NEW ENGL J MED, V357, P885, DOI 10.1056/NEJMoa067758; Monkowski DH, 2007, TRANSPL INFECT DIS, V9, P114, DOI 10.1111/j.1399-3062.2006.00185.x; Oz MC, 2003, ANN SURG, V238, P83; Siegenthaler MP, 2003, EUR J CARDIO-THORAC, V23, P748, DOI 10.1016/S1010-7940(03)00073-3; Siegenthaler MP, 2003, EUR J CARDIO-THORAC, V23, P54; Vega J D, 1990, ASAIO Trans, V36, pM555	37	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1434-7229	1619-0904		J ARTIF ORGANS	J. Artif. Organs	JUN	2015	18	2					120	127		10.1007/s10047-015-0816-2		8	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CJ1OJ	WOS:000355253000004		
J	Togo, K; Takewa, Y; Katagiri, N; Fujii, Y; Kishimoto, S; Date, K; Miyamoto, Y; Tatsumi, E				Togo, Konomi; Takewa, Yoshiaki; Katagiri, Nobumasa; Fujii, Yutaka; Kishimoto, Satoru; Date, Kazuma; Miyamoto, Yuji; Tatsumi, Eisuke			Impact of bypass flow rate and catheter position in veno-venous extracorporeal membrane oxygenation on gas exchange in vivo	JOURNAL OF ARTIFICIAL ORGANS			English	Article						Veno-venous extracorporeal membrane oxygenation; Respiratory support; Cannulation; Bypass flow; Recirculation	LIFE-SUPPORT; RESPIRATORY-FAILURE; LUMEN CATHETER; RECIRCULATION; EXPERIENCE	The clinical use of veno-venous extracorporeal membrane oxygenation (VVECMO) in adult patients with respiratory failure is rapidly increasing. However, recirculation of blood oxygenated by ECMO back into the circuit may occur in VVECMO, resulting in insufficient oxygenation. The cannula position and bypass flow rate are two major factors influencing recirculation, but the relationship and ideal configuration of these factors are not fully understood. In the present study, we attempted to clarify these parameters for effective gas exchange. VVECMO was performed in eight adult goats under general anesthesia. The position of the drainage cannula was fixed in the inferior vena cava (IVC), but the return cannula position was varied between the IVC, right atrium (RA), and superior vena cava (SVC). At each position, the recirculation rates calculated, and the adequacy of oxygen delivery by ECMO in supplying systemic oxygen demand was assessed by measuring the arterial oxygen saturation (SaO(2)) and pressure (PaO2). Although the recirculation rates increased as the bypass flow rates increased, SaO(2) and PaO2 also increased in any position of return cannula. The recirculation rates and PaO2 were 27 +/- A 2 % and 162 +/- A 16 mmHg, 36 +/- A 6 % and 139 +/- A 11 mmHg, and 63 +/- A 6 % and 77 +/- A 9 mmHg in the SVC, RA and IVC position at 4 L/min respectively. In conclusion, the best return cannula position was the SVC, and a high bypass flow rate was advantageous for effective oxygenation. Both the bypass flow rates and cannula position must be considered to achieve effective oxygenation.	[Togo, Konomi; Takewa, Yoshiaki; Katagiri, Nobumasa; Fujii, Yutaka; Kishimoto, Satoru; Date, Kazuma; Tatsumi, Eisuke] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Artificial Organs, Suita, Osaka 5658565, Japan; [Togo, Konomi; Miyamoto, Yuji] Hyogo Coll Med, Dept Cardiovasc Surg, Nishinomiya, Hyogo 6638501, Japan	Togo, K (reprint author), Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Artificial Organs, 5-7-1 Fujishiro Dai, Suita, Osaka 5658565, Japan.	togo.konomi.ri@ncvc.go.jp; takewa@ncvc.go.jp					Nishinaka T, 2007, J ARTIF ORGANS, V10, P240, DOI 10.1007/s10047-007-0390-3; Bartlett RH, 2000, JAMA-J AM MED ASSOC, V283, P904, DOI 10.1001/jama.283.7.904; Javidfar J, 2011, ANN THORAC SURG, V91, P1763, DOI 10.1016/j.athoracsur.2011.03.002; Paden ML, 2013, ASAIO J, V59, P202, DOI 10.1097/MAT.0b013e3182904a52; Wang DF, 2008, ASAIO J, V54, P606, DOI 10.1097/MAT.0b013e31818c69ab; LANGEWOUTERS GJ, 1984, J BIOMECH, V17, P425, DOI 10.1016/0021-9290(84)90034-4; Bridges EJ, 2008, J CARDIOVASC NURS, V23, P105, DOI 10.1097/01.JCN.0000305078.36152.94; Schuerer DJE, 2008, CHEST, V134, P179, DOI 10.1378/chest.07-2512; Schmidt M, 2013, INTENS CARE MED, V39, P838, DOI 10.1007/s00134-012-2785-8; MacLaren G, 2012, INTENS CARE MED, V38, P210, DOI 10.1007/s00134-011-2439-2; Rich PB, 1998, J THORAC CARDIOV SUR, V116, P628, DOI 10.1016/S0022-5223(98)70170-9; Heard ML, 2010, ECMO SPECIALIST TRAI, P59; Herlihy JP, 2009, TEX HEART I J, V36, P337; Korver EPJ, 2012, INTENS CARE MED, V38, P906, DOI 10.1007/s00134-012-2534-z; Kusajima K, 2014, J ARTIF ORGANS, V17, P99, DOI 10.1007/s10047-013-0747-8; Ota K, 2010, J ARTIF ORGANS, V13, P13, DOI 10.1007/s10047-010-0492-1; Pratt Benjamin, 2007, Biomed Instrum Technol, V41, P403, DOI 10.2345/0899-8205(2007)41[403:CAPCOU]2.0.CO;2; Rees NJ, 2010, ECMO SPECIALIST TRAI, V3rd, P37; van Heijst AF, 2001, ASAIO J, V47, P372, DOI 10.1097/00002480-200107000-00015	19	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1434-7229	1619-0904		J ARTIF ORGANS	J. Artif. Organs	JUN	2015	18	2					128	135		10.1007/s10047-014-0810-0		8	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CJ1OJ	WOS:000355253000005		
J	Ishino, N; Fujisato, T				Ishino, Naoaki; Fujisato, Toshia			Decellularization of porcine carotid by the recipient's serum and evaluation of its biocompatibility using a rat autograft model	JOURNAL OF ARTIFICIAL ORGANS			English	Article						Decellularized tissue; Recipient's serum; Complement activity; Graft rejection	GRAFTS	Recently, decellularized tissues for organ transplantation and regeneration have been actively studied in the field of tissue engineering. In the decellularization process, surfactants such as sodium dodecyl sulfate (SDS) have been most commonly used to remove cellular components from the tissue. However, the residual surfactant may be cytotoxic in vivo and has been reported to hinder remodeling after implantation. In addition, treatment with surfactants may destroy the important extracellular matrix (ECM) structure that allows the decellularized tissue to function as a scaffold for cells. In this study, decellularized tissues with high biocompatibility were created using the recipient's serum. By immersing a heterogeneous tissue in serum conditioned to activate the complement system and DNase I, its cellular components could be removed. Compared to an SDS-treated graft, the serum-treated graft preserved the native structure of its ECM. When subcutaneously implanted into an isogenic inbred rat, the graft treated with the recipient's serum resulted in less immunorejection than did the SDS-treated graft.	[Ishino, Naoaki] Aino Univ, Dept Med Engn, Ibaraki, Osaka 5670012, Japan; [Ishino, Naoaki; Fujisato, Toshia] Osaka Inst Technol, Grad Sch Engn, Asahi Ku, Osaka 5358585, Japan	Ishino, N (reprint author), Aino Univ, Dept Med Engn, 4-5-4 Higashioda, Ibaraki, Osaka 5670012, Japan.	n-ishino@me-u.aino.ac.jp; toshiya.fujisato@oit.ac.jp			JSPS KAKENHI [24390307]	The authors are deeply grateful to Chizuka Ide, whose comments on the TEM observations were immensely valuable throughout the course of this study. This work was partly supported by JSPS KAKENHI Grant Number 24390307.	Williams C, 2009, ACTA BIOMATER, V5, P993, DOI 10.1016/j.actbio.2008.11.028; Schmidt CE, 2000, BIOMATERIALS, V21, P2215, DOI 10.1016/S0142-9612(00)00148-4; Funamoto S, 2010, BIOMATERIALS, V31, P3590, DOI 10.1016/j.biomaterials.2010.01.073; CAMPBELL VW, 1980, J BIOL CHEM, V255, P3726; Gillies AR, 2011, TISSUE ENG PART C-ME, V17, P383, DOI 10.1089/ten.TEC.2010.0438; Liem PH, 2013, J ARTIF ORGANS, V16, P332, DOI 10.1007/s10047-013-0708-2; Sasaki S, 2009, MOL VIS, V15, P2022; Petersen TH, 2010, SCIENCE, V329, P538, DOI 10.1126/science.1189345; Ott HC, 2008, NAT MED, V14, P213, DOI 10.1038/nm1684; Hoshiba T, 2010, EXPERT OPIN BIOL TH, V10, P1717, DOI 10.1517/14712598.2010.534079; Crapo PM, 2011, BIOMATERIALS, V32, P3233, DOI 10.1016/j.biomaterials.2011.01.057; Quint C, 2011, P NATL ACAD SCI USA, V108, P9214, DOI 10.1073/pnas.1019506108; Emeis M, 1998, MEDIAT INFLAMM, V7, P417; Hrebikova H, 2015, BIOMED PAP, V159, P12, DOI 10.5507/bp.2013.076; Nagano J, 1996, ARCH ORTHOP TRAUM SU, V115, P10, DOI 10.1007/BF00453210; Neubauer D, 2007, EXP NEUROL, V207, P163, DOI 10.1016/j.expneurol.2007.06.006	16	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1434-7229	1619-0904		J ARTIF ORGANS	J. Artif. Organs	JUN	2015	18	2					136	142		10.1007/s10047-015-0819-z		7	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CJ1OJ	WOS:000355253000006		
J	Mahara, A; Sago, M; Yamaguchi, H; Ehashi, T; Minatoya, K; Tanaka, H; Nakatani, T; Moritan, T; Fujisato, T; Yamaoka, T				Mahara, Atsushi; Sago, Mitsuru; Yamaguchi, Haruka; Ehashi, Tomo; Minatoya, Kenji; Tanaka, Hiroshi; Nakatani, Takeshi; Moritan, Toshiyuki; Fujisato, Toshiya; Yamaoka, Tetsuji			Micro-CT evaluation of high pressure-decellularized cardiovascular tissues transplanted in rat subcutaneous accelerated-calcification model	JOURNAL OF ARTIFICIAL ORGANS			English	Article						Acellular tissue; Calcification; Micro-CT	HEART-VALVES; MATRIX METALLOPROTEINASES; ELASTIN DEGRADATION; ALUMINUM-CHLORIDE; CROSS-LINKING; SCAFFOLDS; RESPONSES	We have succeeded in reducing the calcification of acellular aortas or valves in porcine allogeneic system by removing the DNA and phospholipids, but its further reduction is desirable. Here, the calcification of the acellular tissue was evaluated in rat subcutaneous transplantation model which is known as calcification model. Acellular samples prepared by high-hydrostatic pressure (HHP) protocols with different washing media were implanted and the calcification was monitored under micro-computed tomography for 1 and 3 months. The amount of the calcium deposition was quantitatively evaluated by atomic absorption spectroscopy. A cell culture medium showed very good cell removal ability but led to severe calcification at 1 month, and surprisingly the calcium deposition increased as the washing period increased. This calcification was suppressed by removing the DNA fraction with high DNase concentration. On the other hand, the calcification was greatly reduced when washed with saline even at low DNase concentration after 2 weeks washing. These results suggest that the ion species in the washing medium and the residual DNase cooperatively affect the tendency of in vivo calcification, which led us to the possibility of reduced calcification of acellular cardiac tissues.	[Mahara, Atsushi; Sago, Mitsuru; Yamaguchi, Haruka; Ehashi, Tomo; Fujisato, Toshiya; Yamaoka, Tetsuji] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biomed Engn, Suita, Osaka, Japan; [Sago, Mitsuru; Yamaguchi, Haruka; Moritan, Toshiyuki] Suzuka Univ Med Sci, Dept Clin Engn, Suzuka, Japan; [Minatoya, Kenji; Tanaka, Hiroshi] Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Surg, Suita, Osaka, Japan; [Nakatani, Takeshi] Natl Cerebral & Cardiovasc Ctr, Dept Transplantat, Suita, Osaka, Japan; [Fujisato, Toshiya] Osaka Inst Technol, Dept Biomed Engn, Osaka 535, Japan	Yamaoka, T (reprint author), Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biomed Engn, Suita, Osaka, Japan.	yamtet@ncvc.go.jp			S-innovation Research Program for the "Development of the bio-functional materials for realization of innovative medicine", Japan Science and Technology Agent (JST)	A part of this research was supported by the S-innovation Research Program for the "Development of the bio-functional materials for realization of innovative medicine", Japan Science and Technology Agent (JST).	Zeltinger J, 2001, TISSUE ENG, V7, P9, DOI 10.1089/107632701300003250; Ingram JH, 2007, TISSUE ENG, V13, P1561, DOI 10.1089/ten.2006.0362; Schenke-Layland K, 2003, CARDIOVASC RES, V60, P497, DOI 10.1016/j.cardiores.2003.09.002; Erdbrugger W, 2006, TISSUE ENG, V12, P2059, DOI 10.1089/ten.2006.12.2059; Stegemann JP, 2007, TISSUE ENG, V13, P2601, DOI 10.1089/ten.2007.0196; Iop L, 2009, BIOMATERIALS, V30, P4104, DOI 10.1016/j.biomaterials.2009.04.031; Clark JN, 2005, ANN THORAC SURG, V79, P897, DOI 10.1016/j.athorascur.2004.08.084; Zhou JY, 2010, BIOMATERIALS, V31, P2549, DOI 10.1016/j.biomaterials.2009.11.088; Funamoto S, 2010, BIOMATERIALS, V31, P3590, DOI 10.1016/j.biomaterials.2010.01.073; Nam K, 2009, J ARTIF ORGANS, V12, P47, DOI 10.1007/s10047-008-0443-2; Elkins RC, 2001, ANN THORAC SURG, V71, pS428, DOI 10.1016/S0003-4975(01)02503-6; Simionescu A, 2007, AM J PATHOL, V171, P116, DOI 10.2353/ajpath.2007060930; Mirsadraee S, 2006, TISSUE ENG, V12, P763, DOI 10.1089/ten.2006.12.763; Pyo R, 2000, J CLIN INVEST, V105, P1641, DOI 10.1172/JCI8931; Hu XJ, 2014, J BIOMED MATER RES B, V102, P322, DOI 10.1002/jbm.b.33010; Gilbert TW, 2006, BIOMATERIALS, V27, P3675, DOI 10.1016/j.biomaterials.2006.02.014; Bailey M, 2001, AM J PATHOL, V159, P1981, DOI 10.1016/S0002-9440(10)63048-9; Lovekamp JJ, 2006, BIOMATERIALS, V27, P1507, DOI 10.1016/j.biomaterials.2005.08.003; Lu XQ, 2010, J MATER SCI-MATER M, V21, P473, DOI 10.1007/s10856-009-3924-9; Singelyn JM, 2009, BIOMATERIALS, V30, P5409, DOI 10.1016/j.biomaterials.2009.06.045; Basalyga DM, 2004, CIRCULATION, V110, P3480, DOI 10.1161/01.CIR.0000148367.08413.E9; Fujisato T, 2005, CARDIOVASCULAR REGENERATION THERAPIES USING TISSUE ENGINEERING APPROACHES, P83, DOI 10.1007/4-431-27378-6_7; GERTZ SD, 1988, J CLIN INVEST, V81, P649, DOI 10.1172/JCI113368; Lee JS, 2006, AM J PATHOL, V168, P490, DOI 10.2353/ajpath.2006.050338; Liu Y, 2009, BIOMATERIALS, V30, P3865, DOI 10.1016/j.biomaterials.2009.04.008; Schnüriger Beat, 2011, J Trauma, V70, P766, DOI 10.1097/TA.0b013e31820b8b81; Schnüriger Beat, 2011, J Emerg Trauma Shock, V4, P53, DOI 10.4103/0974-2700.76838; SCHOEN FJ, 1992, BONE MINER, V17, P129, DOI 10.1016/0169-6009(92)90723-Q; Simionescua DT, 2006, BIOMATERIALS, V27, P702, DOI 10.1016/j.biomaterials.2005.06.013; Wang X.D., 2014, J APPL MATH, V2014, P9, DOI DOI 10.1186/1556-276X-9-117	30	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1434-7229	1619-0904		J ARTIF ORGANS	J. Artif. Organs	JUN	2015	18	2					143	150		10.1007/s10047-014-0808-7		8	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CJ1OJ	WOS:000355253000007		
J	Mibu, K; Yatabe, T; Yamasaki, F; Kitagawa, H; Munekage, M; Namikawa, T; Hanazaki, K				Mibu, Kiyo; Yatabe, Tomoaki; Yamasaki, Fumiyasu; Kitagawa, Hiroyuki; Munekage, Masaya; Namikawa, Tsutomu; Hanazaki, Kazuhiro			Questionnaire survey on the use of a novel artificial pancreas by intensive care unit nurses	JOURNAL OF ARTIFICIAL ORGANS			English	Article						Artificial pancreas; Questionnaire survey; Nurse	CRITICALLY-ILL PATIENTS; GLUCOSE CONTROL; POSTOPERATIVE INFECTIONS; GLYCEMIC CONTROL; INSULIN THERAPY; HYPERGLYCEMIA	The introduction of a color liquid-crystal display (LCD) on a novel artificial pancreas (STG-55, Nikkiso Co. Ltd. Tokyo, Japan) allowed nurses to more easily monitor changes in patients' blood glucose levels, compared to the previous model (STG-22). This study was conducted to examine the hypothesis that the STG-55 provided nurses with a feeling of security due to the introduction of the LCD screen. A questionnaire survey was conducted 6 months after the STG-55 was introduced (Survey 2012), among intensive care unit (ICU) nurses who had used both the STG-22 and the STG-55 for patient glycemic control. The results were then compared with the results from a questionnaire survey that was conducted after the STG-22 was introduced (Survey 2006). All ICU nurses (n = 19) responded to Survey 2012, and 95 % of these nurses had responded to Survey 2006 (n = 19). After the introduction of the STG-22, 11 nurses (58 %) reported becoming conscious of anxiety regarding hypoglycemia when they performed conventional glucose control with the sliding scale method. This anxiety awareness increased significantly (19 nurses, 100 %; p < 0.01) after the STG-55 was introduced. However, there were no significant differences in the proportion of respondents who requested improvements in the blood withdrawal process. In conclusion, the results of our survey indicate that all ICU nurses became conscious of anxiety regarding the risk of hypoglycemia when using the conventional sliding scale method after the introduction of the STG-55. However, the respondents were not satisfied with the STG-55, due to difficulties encountered during blood withdrawal.	[Mibu, Kiyo] Kochi Med Sch Hosp, Dept Nursing, Kochi, Japan; [Yatabe, Tomoaki] Kochi Med Sch, Dept Anesthesiol & Intens Care Med, Nankoku, Kochi 7838505, Japan; [Yamasaki, Fumiyasu] Kochi Med Sch Hosp, Clin Lab, Kochi, Japan; [Kitagawa, Hiroyuki; Munekage, Masaya; Namikawa, Tsutomu; Hanazaki, Kazuhiro] Kochi Med Sch, Dept Surg, Nankoku, Kochi 7838505, Japan	Yatabe, T (reprint author), Kochi Med Sch, Dept Anesthesiol & Intens Care Med, Nankoku, Kochi 7838505, Japan.	yatabe@kochi-u.ac.jp; hanazaki@kochi-u.ac.jp					Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Ramos M, 2008, ANN SURG, V248, P585, DOI 10.1097/SLA.0b013e31818990d1; Hanazaki K, 2014, AM J SURG, V207, P935, DOI 10.1016/j.amjsurg.2013.07.048; Kawahito S, 2009, WORLD J GASTROENTERO, V15, P4137, DOI 10.3748/wjg.15.4137; Jacobi J, 2012, CRIT CARE MED, V40, P3251, DOI 10.1097/CCM.0b013e3182653269; Yatabe T, 2011, CRIT CARE MED, V39, P575, DOI 10.1097/CCM.0b013e318206b9ad; Hanazaki K, 2009, WORLD J GASTROENTERO, V15, P4122, DOI 10.3748/wjg.15.4122; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Mibu K, 2012, J ARTIF ORGANS, V15, P71, DOI 10.1007/s10047-011-0611-7	10	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1434-7229	1619-0904		J ARTIF ORGANS	J. Artif. Organs	JUN	2015	18	2					162	165		10.1007/s10047-015-0818-0		4	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CJ1OJ	WOS:000355253000009		
J	Katsuhara, K; Nakada, TA; Yamada, M; Fuse, T; Idoguchi, K; Matsuoka, T				Katsuhara, Kazuhiro; Nakada, Taka-aki; Yamada, Mami; Fuse, Takashi; Idoguchi, Koji; Matsuoka, Tetsuya			Veno-venous extracorporeal membrane oxygenation (ECMO) for acute respiratory failure caused by liver abscess	JOURNAL OF ARTIFICIAL ORGANS			English	Article						VV-ECMO; ARDS; AKI; Septic shock; Multiple organ failure	ABDOMINAL COMPARTMENT SYNDROME; DISTRESS-SYNDROME; INTENSIVE-CARE; ADULT PATIENTS; SEPTIC SHOCK; ARDS; MORTALITY; SUPPORT	Liver abscess remains a life-threatening disease, particularly when it results in systemic organ failure necessitating intensive care. Only few cases of respiratory failure caused by liver abscess and treated with veno-venous extracorporeal membrane oxygenation (ECMO) have been reported. Here we present a case of liver abscess with rapid progression of multiple organ dysfunction, including severe acute respiratory failure on admission to the intensive care unit (ICU). Upon admission, we immediately initiated artificial organ support systems, including ventilator, continuous renal replacement therapy, and cardiovascular drug infusion for septic multiple organ failure and source control. Despite this initial management, respiratory failure deteriorated and V-V ECMO was introduced. The case developed abdominal compartment syndrome, for which we performed a bedside decompressive laparotomy in the ICU. The case gradually recovered from multiple organ failure and was discharged from the ICU on day 22 and from the hospital on day 53. Since liver abscess is potentially lethal and respiratory failure on admission is an additional risk factor of mortality, V-V ECMO may serve as an adjunctive choice of artificial organ support for cases of severe acute respiratory failure caused by liver abscess.	[Katsuhara, Kazuhiro; Nakada, Taka-aki; Yamada, Mami; Fuse, Takashi; Idoguchi, Koji; Matsuoka, Tetsuya] Senshu Trauma & Crit Care Ctr, Osaka 5988577, Japan	Nakada, TA (reprint author), Senshu Trauma & Crit Care Ctr, 2-23 Rinku Orai Kita, Osaka 5988577, Japan.	taka.nakada@nifty.com					Kirkpatrick AW, 2013, INTENS CARE MED, V39, P1190, DOI 10.1007/s00134-013-2906-z; Ko WJ, 2006, J FORMOS MED ASSOC, V105, P422; Lee SSJ, 2008, CLIN INFECT DIS, V47, P642, DOI 10.1086/590932; Agarwal R, 2008, CHEST, V133, P1463, DOI 10.1378/chest.07-2182; Terragni P, 2014, CURR OPIN CRIT CARE, V20, P86, DOI 10.1097/MCC.0000000000000053; Brodie D, 2011, NEW ENGL J MED, V365, P1905, DOI 10.1056/NEJMct1103720; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; Siu LK, 2012, LANCET INFECT DIS, V12, P881, DOI 10.1016/S1473-3099(12)70205-0; Huang CT, 2013, J THORAC CARDIOV SUR, V146, P1041, DOI 10.1016/j.jtcvs.2012.08.022; Augustin P, 2010, ANN THORAC SURG, V90, pE40, DOI 10.1016/j.athoracsur.2010.06.039; Chen CH, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-133; Chen W, 2008, CRIT CARE MED, V36, P1184, DOI [10.1097/CCM.0b013e31816a0a06, 10.1097/CCM0b013e31816a0a06]; Nakada T, 2008, MOL MED, V14, P257, DOI 10.2119/2007-00108.Nakada; Okhuysen-Cawley R, 2007, PEDIATR CRIT CARE ME, V8, P177, DOI 10.1097/01.PCC.0000257102.53488.5E; Prodhan P, 2012, ASAIO J, V58, P143, DOI 10.1097/MAT.0b013e318241ac4c; Schreiber J, 2014, CRIT CARE, V18, DOI 10.1186/cc13925; Sonoo T, 2014, J ARTIF ORGANS, V17, P281, DOI 10.1007/s10047-014-0776-y	17	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1434-7229	1619-0904		J ARTIF ORGANS	J. Artif. Organs	JUN	2015	18	2					173	176		10.1007/s10047-014-0807-8		4	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CJ1OJ	WOS:000355253000012		
J	Okamoto, E; Ishida, Y; Yano, T; Mitamura, Y				Okamoto, Eiji; Ishida, Yuya; Yano, Tetsuya; Mitamura, Yoshinori			Passive magnetic bearing in the 3rd generation miniature axial flow pump-the valvo pump 2	JOURNAL OF ARTIFICIAL ORGANS			English	Article						Axial flow pump; Passive magnetic bearing; Third-generation pump; Valvo pump2	LEFT-VENTRICULAR ASSIST; BLOOD PUMP	The new miniature axial flow pump (valvo pump 2) that is installed at the base of the ascending aorta consists of a six-phase stator, an impeller in which four neodymium magnets are incorporated, and passive magnetic bearings that suspend the impeller for axial levitation. The impeller is sustained by hydrodynamic force between the blade tip of the impeller and the inner housing of the stator. The passive magnetic bearing consists of a ring neodymium magnet and a columnar neodymium magnet. The ring neodymium magnet is set in the stationary side and the columnar neodymium magnet is incorporated in the impeller shaft. Both neodymium magnets are coaxially mounted, and the anterior and posterior passive magnetic bearings suspend the impeller by repulsion force against the hydrodynamic force that acts to move the impeller in the inflow port direction. The passive magnetic bearing was evaluated by a tensile test, and the levitation force of 8.5 N and stiffness of 2.45 N/mm was obtained. Performance of the axial flow pump was evaluated by an in vitro experiment. The passive magnetic bearing showed sufficient levitation capacity to suspend the impeller in an axial direction. In conclusion, the passive magnetic bearing is promising to be one of levitation technology for the third-generation axial flow blood pump.	[Okamoto, Eiji; Ishida, Yuya] Tokai Univ, Grad Sch Sci & Engn, Minami Ku, Sapporo, Hokkaido 0058601, Japan; [Yano, Tetsuya] Akita Prefectural Univ, Fac Syst Sci & Technol, Yurihonjo, Japan; [Mitamura, Yoshinori] Hokkaido Univ, Grad Sch Informat Sci, Sapporo, Hokkaido, Japan	Okamoto, E (reprint author), Tokai Univ, Grad Sch Sci & Engn, Minami Ku, Minami Sawa 5-1-1-1, Sapporo, Hokkaido 0058601, Japan.	okamoto@tspirit.tokai-u.jp			KAKENHI [25350539]	This study was supported by KAKENHI (Grant-in-Aid for Scientific Research-C (No. 25350539)).	Hoshi H, 2006, ARTIF ORGANS, V30, P324, DOI 10.1111/j.1525-1594.2006.00222.x; Okada Y, 2003, ARTIF ORGANS, V27, P887, DOI 10.1046/j.1525-1594.2003.00030.x; Kirklin JK, 2013, J HEART LUNG TRANSPL, V32, P141, DOI 10.1016/j.healun.2012.12.004; Chen HM, 1998, ASAIO J, V44, P728; Mitamura Y, 2011, J ARTIF ORGANS, V14, P23, DOI 10.1007/s10047-010-0526-8; Mitamura Y, 1991, ASAIO Trans, V37, pM510; Qian KX, 2003, IEEE T MAGN, V39, P559, DOI 10.1109/TMAG.2002.806524; Qian KX, 2005, ASAIO J, V51, P736, DOI 10.1097/01.mat.0000185914.88497.9e; Qian K. X., 2005, Journal of Medical Engineering & Technology, V29, P235, DOI 10.1080/0309190512331309335; Schmid C, 2005, J HEART LUNG TRANSPL, V24, P1188, DOI 10.1016/j.healun.2004.08.024; Tanaka H, 2011, J ARTIF ORGANS, V14, P31, DOI 10.1007/s10047-010-0542-8; Wampler R, 1999, ARTIF ORGANS, V23, P780, DOI 10.1046/j.1525-1594.1999.06422.x; Yozu R, 1991, U.S. Patent, Patent No. 4994917	13	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1434-7229	1619-0904		J ARTIF ORGANS	J. Artif. Organs	JUN	2015	18	2					181	184		10.1007/s10047-014-0806-9		4	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CJ1OJ	WOS:000355253000014		
J	Kishimoto, S; Takewa, Y; Nakayama, Y; Date, K; Sumikura, H; Moriwaki, T; Nishimura, M; Tatsumi, E				Kishimoto, Satoru; Takewa, Yoshiaki; Nakayama, Yasuhide; Date, Kazuma; Sumikura, Hirohito; Moriwaki, Takeshi; Nishimura, Motonobu; Tatsumi, Eisuke			Sutureless aortic valve replacement using a novel autologous tissue heart valve with stent (stent biovalve): proof of concept	JOURNAL OF ARTIFICIAL ORGANS			English	Article						Tissue engineered heart valve; Autologous tissue; Aortic valve; Aortic valve replacement; Sutureless valve	YOUNG-ADULTS; IN-BODY; MODEL; ALLOGRAFTS; CHILDREN; CONDUIT	We developed an autologous, trileaflet tissue valve ("biovalve") using in-body tissue architecture technology to overcome the disadvantages of current bioprosthetic valves. We designed a novel biovalve with a balloon-expandable stent: the stent biovalve (SBV). This study evaluated the technical feasibility of sutureless aortic valve replacement using the SBV in an orthotopic position, as well as the functionality of the SBV under systemic circulation, in an acute experimental goat model. Three adult goats (54.5-56.1 kg) underwent sutureless AVR under cardiopulmonary bypass (CPB). The technical feasibility and functionality of the SBVs were assessed using angiography, pressure catheterization, and two-dimensional echocardiography. The sutureless AVR was successful in all goats, and all animals could be weaned off CPB. The mean aortic cross-clamp time was 45 min. Angiogram, after weaning the animals off CPB, showed less than mild paravalvular leakage and central leakage was not detected in any of the goats. The mean peak-to-peak pressure gradient was 6.3 +/- A 5.0 mmHg. Epicardial two-dimensional echocardiograms showed smooth leaflet movement, including adequate closed positions with good coaptation; the open position demonstrated a large orifice area (average aortic valve area 2.4 +/- A 0.1 cm(2)). Sutureless AVR, using SBVs, was feasible in a goat model. The early valvular functionalities of the SBV were sufficient; future long-term experiments are needed to evaluate its durability and histological regeneration potential.	[Kishimoto, Satoru; Takewa, Yoshiaki; Date, Kazuma; Sumikura, Hirohito; Tatsumi, Eisuke] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Artificial Organs, Suita, Osaka 5658565, Japan; [Kishimoto, Satoru; Nishimura, Motonobu] Tottori Univ, Dept Organ Regenerat Surg, Tottori 680, Japan; [Nakayama, Yasuhide; Moriwaki, Takeshi] Natl Cerebral & Cardiovasc Ctr Res Inst, Div Med Engn & Mat, Suita, Osaka 5658565, Japan	Kishimoto, S (reprint author), Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Artificial Organs, 5-7-1 Fujishiro Dai, Suita, Osaka 5658565, Japan.	kishimoto.satoru.ri@mail.ncvc.go.jp; ny@ncvc.go.jp					Emmert MY, 2012, JACC-CARDIOVASC INTE, V5, P874, DOI 10.1016/j.jcin.2012.04.010; Sumikura H, 2014, ARTIF ORGANS, V38, P282, DOI 10.1111/aor.12173; Saleeb SF, 2014, CIRCULATION, V130, P51, DOI 10.1161/CIRCULATIONAHA.114.009835; Konertz W, 2005, J HEART VALVE DIS, V14, P78; Konuma T, 2009, ANN THORAC SURG, V88, P849, DOI 10.1016/j.athoracsur.2009.06.003; Schoen FJ, 2005, ANN THORAC SURG, V79, P1072, DOI 10.1016/j.athoracsur.2004.06.033; Yamanami M, 2010, CIRCULATION, V122, pS100, DOI 10.1161/CIRCULATIONAHA.109.922211; Takewa Y, 2013, J ARTIF ORGANS, V16, P176, DOI 10.1007/s10047-012-0679-8; Hayashida K, 2007, J THORAC CARDIOV SUR, V134, P152, DOI 10.1016/j.jtcvs.2007.01.087; Cebotari S, 2011, CIRCULATION, V124, pS115, DOI 10.1161/CIRCULATIONAHA.110.012161; Furukawa Hiroshi, 2014, Gen Thorac Cardiovasc Surg, V62, P19, DOI 10.1007/s11748-013-0262-0; Gilmanov D, 2014, ANN THORAC SURG, V98, P1585, DOI 10.1016/j.athoracsur.2014.05.092; Nakayama Y, 2015, J BIOMED MATER RES B, V103, P1, DOI 10.1002/jbm.b.33186; Shrestha M, 2014, ANN THORAC SURG, V98, P1294, DOI 10.1016/j.athoracsur.2014.05.033	14	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1434-7229	1619-0904		J ARTIF ORGANS	J. Artif. Organs	JUN	2015	18	2					185	190		10.1007/s10047-015-0817-1		6	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CJ1OJ	WOS:000355253000015		
J	Osozawa, S; Vuong, NV; Tich, VV; Wakabayashi, J				Osozawa, Soichi; Nguyen Van Vuong; Vu Van Tich; Wakabayashi, John			Reactivation of a collisional suture by Miocene transpressional domes associated with the Red River and Song Chay detachment faults, northern Vietnam	JOURNAL OF ASIAN EARTH SCIENCES			English	Article						Gneissose and granitic domes tectonically covered by accretionary complex; Dextral-transpressional ductile shear; Extrusion and brittle detachment fault; Red River fault; Reactivation of collisional suture	SHEAR ZONE; INDO-CHINA; RIDGE SUBDUCTION; SOUTHEAST-ASIA; EVOLUTION; TECTONICS; OPHIOLITE; AGES; GEOCHRONOLOGY; EXHUMATION	Elongate Miocene gneissose and granitic domes in northern Vietnam formed in a dextral-transpressional ductile shear regime, possibly associated with large-scale restraining step-overs along dextral faults. Initial anticlinal D1 doming involved folding of both basement and hanging wall rocks with D1 secondary folds that verge toward the anticlinal axes. Such folds reflect dome-scale flexural slip folding. With continued shortening, D2 detachment faults developed on the flanks of the anticlines along the hanging wall-basement interface, so that the basement was extruded vertically into the overlying hanging wall rocks. The detachment faults were associated with D2 drag folds that verge away from the anticlinal axes. The hanging wall assemblage lacks a well-ordered stratigraphy, displaying primarily block-in-matrix fabric. We identified bedded cherts, associated with umbers and alkalic basaltic intrusions within these hanging wall rocks, a first report of such rocks from Vietnam. The association of cherts, umbers, and basaltic intrusions and extrusions with block-in-matrix units with clastic rocks strongly suggest that the hanging wall rocks comprise part of a subduction complex. Because the base of a subduction complex is a former subduction megathrust horizon, the hanging wall-basement interface represents a reactivated collisional suture. Such a suture was probably associated with the Indosinian orogeny, and the basement should be the Indochina continental block. This structure may have influenced the position of Miocene dextral faulting in addition to controlling the position of the dome detachments. The well-known Red River fault marks the boundary of one of the domes, but in this region it appears to be a detachment (normal) fault rather than a dextral strike-slip fault. However, the association with the dome evolution with large-scale restraining step-overs suggests that dextral faulting associated with dome development may lie further away from the dome axes than the detachment. (C) 2015 Elsevier Ltd. All rights reserved.	[Osozawa, Soichi] Tohoku Univ, Grad Sch Sci, Dept Earth Sci, Sendai, Miyagi 9808578, Japan; [Nguyen Van Vuong; Vu Van Tich] Hanoi Univ Sci, Fac Geol, Hanoi, Vietnam; [Wakabayashi, John] Calif State Univ Fresno, Dept Earth & Environm Sci, Fresno, CA 93740 USA	Osozawa, S (reprint author), Tohoku Univ, Grad Sch Sci, Dept Earth Sci, Sendai, Miyagi 9808578, Japan.	osozawa@m.tohoku.ac.jp; vuongnv@gmail.com; tichvv@vnu.edu.vn; jwakabayashi@csufresno.edu					Anczkiewicz R, 2007, TECTONICS, V26, DOI 10.1029/2006TC001972; Wang PL, 2000, J ASIAN EARTH SCI, V18, P281, DOI 10.1016/S1367-9120(99)00064-4; Usuki T, 2009, GEOSCI J, V13, P245, DOI 10.1007/s12303-009-0024-2; Jolivet L, 2001, TECTONICS, V20, P46, DOI 10.1029/2000TC900021; Lepvrier C, 1997, TECTONOPHYSICS, V283, P105, DOI 10.1016/S0040-1951(97)00151-0; HUTCHISON CS, 1975, GEOL SOC AM BULL, V86, P797, DOI 10.1130/0016-7606(1975)86<797:OISA>2.0.CO;2; Faure M, 2014, J ASIAN EARTH SCI, V79, P260, DOI 10.1016/j.jseaes.2013.09.022; Wang PL, 1998, GEOLOGY, V26, P887, DOI 10.1130/0091-7613(1998)026<0887:TEFTMO>2.3.CO;2; Lan CY, 2001, GEOLOGY, V29, P219, DOI 10.1130/0091-7613(2001)029<0219:FEFACC>2.0.CO;2; Lepvrier C, 2008, CR GEOSCI, V340, P94, DOI 10.1016/j.crte.2007.10.005; Leloup PH, 2001, J GEOPHYS RES-SOL EA, V106, P6683, DOI 10.1029/2000JB900322; Lepvrier C, 2004, TECTONOPHYSICS, V393, P87, DOI 10.1016/j.tecto.2004.07.030; Maluski H, 2001, J ASIAN EARTH SCI, V19, P233, DOI 10.1016/S1367-9120(00)00038-9; Wakabayashi J, 2015, INT GEOL REV, V57, P669, DOI 10.1080/00206814.2014.998728; Cao SY, 2011, GONDWANA RES, V19, P975, DOI 10.1016/j.gr.2010.10.006; Hutchinson C.S., 1989, OXFORD MONOGRAPH GEO, V13; Jolivet L, 1999, GEOLOGY, V27, P67, DOI 10.1130/0091-7613(1999)027<0067:OMBKEG>2.3.CO;2; Koike Toshio, 1991, Science Reports of the Yokohama National University Section II Biology and Geology, V38, P53; Lepvrier C, 2011, J ASIAN EARTH SCI, V41, P56, DOI 10.1016/j.jseaes.2011.01.002; MOORES E, 1970, NATURE, V228, P837, DOI 10.1038/228837a0; Onoue T., 2009, J ASIAN EARTH SCI, V37, P312; Osozawa S, 2012, J ASIAN EARTH SCI, V59, P85, DOI 10.1016/j.jseaes.2012.05.023; Osozawa S, 2012, LITHOSPHERE-US, V4, P497, DOI 10.1130/L205.1; Osozawa S, 2004, TECTONOPHYSICS, V393, P197, DOI 10.1016/j.tecto.2004.07.033; Osozawa S., 2009, GEOLOGICAL SOC AM B, V120, P1190; Osozawa S, 2012, J ASIAN EARTH SCI, V59, P70, DOI 10.1016/j.jseaes.2012.04.001; Osozawa S, 2007, J STRUCT GEOL, V29, P1131, DOI 10.1016/j.jsg.2007.03.014; Roger F, 2000, TECTONOPHYSICS, V321, P449, DOI 10.1016/S0040-1951(00)00085-8; Searle, 2006, J GEOL SOC LONDON, V163, P1025; TAPPONNIER P, 1982, GEOLOGY, V10, P611, DOI 10.1130/0091-7613(1982)10<611:PETIAN>2.0.CO;2; Viola G., 2007, J ASIAN EARTH SCI, V33, P78; Wakabayashi J, 2007, GEOL SOC SPEC PUBL, V290, P169, DOI 10.1144/SP290.4; Wakabayashi J, 2004, TECTONOPHYSICS, V392, P279, DOI 10.1016/j.tecto.2004.04.013; Wakita K., 2005, J ASIAN EARTH SCI, V24, P697; Yeh MW, 2008, J STRUCT GEOL, V30, P1540, DOI 10.1016/j.jsg.2008.08.007; Zhang J., 2014, AGU 2014 FALL M	36	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1367-9120	1878-5786		J ASIAN EARTH SCI	J. Asian Earth Sci.	JUN 1	2015	105						252	269		10.1016/j.jseaes.2015.01.006		18	Geosciences, Multidisciplinary	Geology	CI8WF	WOS:000355051700016		
J	Kuwaki, K; Inaba, H; Yamamoto, T; Dohi, S; Matsumura, T; Morita, T; Amano, A				Kuwaki, K.; Inaba, H.; Yamamoto, T.; Dohi, S.; Matsumura, T.; Morita, T.; Amano, A.			Performance of the EuroSCORE II and the Society of Thoracic Surgeons Score in patients undergoing aortic valve replacement for aortic stenosis	JOURNAL OF CARDIOVASCULAR SURGERY			English	Article						Aortic valve stenosis; Risk assessment; Heart diseases	HIGH-RISK PATIENTS; OUTCOMES; TRANSCATHETER; VALIDATION; MORTALITY; COHORT; SYSTEM	Aim. The aim of this study was to evaluate the performance of the new European System for Cardiac Operative Risk Evaluation (EuroSCORE) II and the Society of Thoracic Surgeons (STS) score in patients undergoing aortic valve replacement (AVR) for aortic stenosis (AS). This study also evaluated the performance of the EuroSCORE II in high-risk patients. Methods. Three hundred and six consecutive adult patients underwent AVR with or without coronary artery bypass grafting at our institution from August 2002 to June 2012. The cut-off value of 6% for the EuroSCORE II and 10% for the STS score was used to identify high-risk in this study. Results. Operative mortality was 3.5% (N.=11). The mean expected mortality for all patients was 3.1% (O/E ratio=1.12) for the EuroSCORE II and 5.1% (O/E ratio=0.68) for the STS score. Observed versus expected mortality for the high-risk patients was 17.2% versus 11.9% (O/E ratio=1.44) for the EuroSCORE II (N.=29) and 19.3% versus 18.5% (O/E ratio=1.04) for the STS score (N.=31), and that for the low-risk was 2.1% versus 2.2% (O/E ratio=0.95) for the EuroSCORE II and 1.8% versus 3.5% (O/E ratio=0.51) for the STS score. Discrimination power of the STS score was good (area under the receiver operating characteristics curve [AUC] 0.74), but that of the EuroSCORE II was suboptimal (AUC 0.66). Conclusion. Good calibration ability of the EuroSCORE II for low-risk patients and that of the STS score for high-risk are observed. However, the EuroSCORE II underestimates the operative mortality in high-risk patients and the STS score overestimates the risk in low-risk patients.	[Kuwaki, K.; Inaba, H.; Yamamoto, T.; Dohi, S.; Matsumura, T.; Morita, T.; Amano, A.] Juntendo Univ, Dept Cardiovasc Surg, Tokyo 1138421, Japan	Kuwaki, K (reprint author), Juntendo Univ, Dept Cardiovasc Surg, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	kuwakikj@yahoo.co.jp					Thourani VH, 2011, ANN THORAC SURG, V91, P49, DOI 10.1016/j.athoracsur.2010.09.040; Kodali SK, 2012, NEW ENGL J MED, V366, P1686, DOI 10.1056/NEJMoa1200384; Bates ER, 2011, CIRCULATION, V124, P355, DOI 10.1161/CIRCULATIONAHA.110.974204; Dewey TM, 2008, J THORAC CARDIOV SUR, V135, P180, DOI 10.1016/j.jtcvs.2007.09.011; Chalmers J, 2013, EUR J CARDIO-THORAC, V43, P688, DOI 10.1093/ejcts/ezs406; Carnero-Alcazar M, 2013, INTERACT CARDIOV TH, V16, P293, DOI 10.1093/icvts/ivs480; Di Dedda U, 2013, EUR J CARDIO-THORAC, V43, P27, DOI 10.1093/ejcts/ezs196; LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220; Brown ML, 2008, J THORAC CARDIOV SUR, V136, P566, DOI 10.1016/j.jtcvs.2007.10.091; Grossi EA, 2008, ANN THORAC SURG, V85, P102, DOI 10.1016/j.athoracsur.2007.05.010; Varadarajan P, 2006, ANN THORAC SURG, V82, P2111, DOI 10.1016/j.athoracsur.2006.07.048; Basraon J, 2011, ANN THORAC SURG, V92, P535, DOI 10.1016/j.athoracsur.2011.04.006; Bonow Robert O, 2008, Circulation, V118, pe523, DOI 10.1161/CIRCULATIONAHA.108.190748; HANLEY JA, 1983, RADIOLOGY, V148, P839; Hosmer DW, 2012, ASSESSING FIT MODEL, P160; Iung B, 2003, EUR HEART J, V13, P1231; Kirmani BH, 2013, EUR J CARDIOTHORAC S; Kuwaki K, 2012, WORLD J CARDIOVASC D, V2, P220; Kuwaki K, 2012, J CARDIAC SURG, V27, P139, DOI 10.1111/j.1540-8191.2011.01398.x; Makker RR, 2012, NEW ENGL J MED, V366, P1969; Nashef SAM, 2012, EUR J CARDIO-THORAC, V41, P734, DOI 10.1093/ejcts/ezs043; Rogues F, 1999, EUR J CARDIO-THORAC, V15, P816; Smith CR, 2011, NEW ENGL J MED, V364, P2187, DOI 10.1056/NEJMoa1103510; Tran Henry A, 2010, Innovations (Phila), V5, P407, DOI 10.1097/IMI.0b013e318202c349; Wendt D, 2009, ANN THORAC SURG, V88, P468, DOI 10.1016/j.athoracsur.2009.04.059	25	0	0	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0021-9509	1827-191X		J CARDIOVASC SURG	J. Cardiovasc. Surg.	JUN	2015	56	3					455	462				8	Cardiac & Cardiovascular Systems; Surgery; Peripheral Vascular Disease	Cardiovascular System & Cardiology; Surgery	CJ3DA	WOS:000355362400017		
J	Nikawa, T; Naya, S; Kimura, T; Tada, H				Nikawa, Tomoyuki; Naya, Shin-ichi; Kimura, Takayoshi; Tada, Hiroaki			Rapid removal and subsequent low-temperature mineralization of gaseous acetaldehyde by the dual thermocatalysis of gold nanoparticle-loaded titanium(IV) oxide	JOURNAL OF CATALYSIS			English	Article						Gold nanoparticle; Titanium dioxide; Acetaldehyde; Adsorption; Mineralization; Environmental catalyst	VISIBLE-LIGHT PHOTOCATALYST; VOLATILE ORGANIC-COMPOUNDS; ACETIC-ACID; PERIMETER SITES; PARTIAL OXIDATION; AU/TIO2 CATALYST; MECHANISTIC INSIGHTS; CARBOXYLIC-ACIDS; TIO2; ADSORPTION	Under ambient humid conditions, the adsorption of acetaldehyde on unmodified TiO2 is small and weak. In contrast, loading Au particles smaller than 3 nm on TiO2 with surface area larger than 17.5 m(2) g(-1) (Au/TiO2) causes the rapid and strong adsorption of gaseous acetaldehyde from a closed space. This striking adsorption phenomenon initiates from the aerobic oxidation of acetaldehyde to acetic acid by the thermocatalysis of Au/TiO2 at room temperature. Acetic acid is moved to the TiO2 surface to be dissociated to acetate ion and proton, which are adsorbed on the Lewis acid and base sites on the surface, respectively. The resulting reproduction of the catalytic sites for the acetaldehyde oxidation enables the continuous removal of acetaldehyde without the release of the harmful product. Further, the adsorbed species on Au/TiO2 are completely oxidized to CO2 by the post-heating at 548 K, whereas the oxidation degree of acetate adsorbed on unmodified TiO2 remains several % even at 570 K with harmful products (Quah et al., 2010). (C) 2015 Published by Elsevier Inc.	[Nikawa, Tomoyuki; Tada, Hiroaki] Kinki Univ, Sch Sci & Engn, Dept Appl Chem, Higashiosaka, Osaka 5778502, Japan; [Naya, Shin-ichi; Tada, Hiroaki] Kinki Univ, Environm Res Lab, Higashiosaka, Osaka 5778502, Japan; [Kimura, Takayoshi] Kinki Univ, Sch Sci & Engn, Dept Chem, Higashiosaka, Osaka 5778502, Japan	Tada, H (reprint author), Kinki Univ, Sch Sci & Engn, Dept Appl Chem, 3-4-1 Kowakae, Higashiosaka, Osaka 5778502, Japan.	h-tada@apch.kindai.ac.jp			MEXT;  [24550239]	We acknowledged Ishihara Sangyo Co. and TAYCA Co. for the gift of TiO<INF>2</INF> samples. This work was partially supported by a Grant-in-Aid for Scientific Research (C) No. 24550239 and MEXT-Supported Program for the Strategic Research Foundation at Private Universities.	AIST, SPECTR DAT ORG COMP; Quah EL, 2010, LANGMUIR, V26, P6411, DOI 10.1021/la9040985; Green IX, 2011, SCIENCE, V333, P736, DOI 10.1126/science.1207272; Wang JG, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.136107; Haruta M, 2005, NATURE, V437, P1098, DOI 10.1038/4371098a; Haruta M, 2001, APPL CATAL A-GEN, V222, P427, DOI 10.1016/S0926-860X(01)00847-X; HARUTA M, 1987, CHEM LETT, P405, DOI 10.1246/cl.1987.405; Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607; Batault F, 2015, CHEM ENG J, V264, P197, DOI 10.1016/j.cej.2014.10.089; Zhang QH, 2011, CHEM COMMUN, V47, P9275, DOI 10.1039/c1cc11723h; Kiyonaga T, 2009, CHEMPHYSCHEM, V10, P2935, DOI 10.1002/cphc.200900596; Kawahara T, 2002, ANGEW CHEM INT EDIT, V41, P2811, DOI 10.1002/1521-3773(20020802)41:15<2811::AID-ANIE2811>3.0.CO;2-#; Stratakis M, 2012, CHEM REV, V112, P4469, DOI 10.1021/cr3000785; Ooyama Y, 2011, ANGEW CHEM INT EDIT, V50, P7429, DOI 10.1002/anie.201102552; Jia JF, 2000, J PHYS CHEM B, V104, P11153, DOI 10.1021/jp001213d; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; Ohko Y, 1998, J PHYS CHEM B, V102, P2699, DOI 10.1021/jp9732524; Rodrigues S, 2005, ADV MATER, V17, P2467, DOI 10.1002/adma.200402064; Mattsson A, 2010, J PHYS CHEM C, V114, P14121, DOI 10.1021/jp103263n; Liao LF, 2001, PHYS CHEM CHEM PHYS, V3, P3831, DOI 10.1039/b103419g; Green IX, 2011, ANGEW CHEM INT EDIT, V50, P10186, DOI 10.1002/anie.201101612; Tada H, 2014, J PHYS CHEM C, V118, P12077, DOI 10.1021/jp412312m; Shekhar M, 2012, J AM CHEM SOC, V134, P4700, DOI 10.1021/ja210083d; Scire S, 2012, APPL CATAL B-ENVIRON, V125, P222, DOI 10.1016/j.apcatb.2012.05.047; Freakley S.J., CATAL LETT; Green IX, 2014, ACCOUNTS CHEM RES, V47, P805, DOI 10.1021/ar400196f; Green IX, 2012, J AM CHEM SOC, V134, P13569, DOI 10.1021/ja305911e; Green IX, 2013, FARADAY DISCUSS, V162, P247, DOI 10.1039/c3fd00002h; Green IX, 2013, TOP CATAL, V56, P1512, DOI 10.1007/s11244-013-0154-7; Haruta M., 2003, CATALYSIS ELECTROCAT; Jin M, 2006, CHEM COMMUN, P4483, DOI 10.1039/b611580b; KIM KS, 1990, J CATAL, V125, P353, DOI 10.1016/0021-9517(90)90309-8; Laursen S, 2009, PHYS CHEM CHEM PHYS, V11, P11006, DOI 10.1039/b912641d; Martyanov IN, 2004, J CATAL, V225, P408, DOI 10.1016/j.jcat.2004.04.019; McEntee M, 2015, ACS CATAL, V5, P744, DOI 10.1021/cs5014255; Minico S, 2000, APPL CATAL B-ENVIRON, V28, P245, DOI 10.1016/S0926-3373(00)00181-8; Nakamoto K., 2009, INFRARED RAMAN SPE B; Potzinger F.P., 2004, J PHYS CHEM B, V108, P5004; Rekoske JE, 1999, LANGMUIR, V15, P2061, DOI 10.1021/la9805140; Ropez N., 2004, J CATAL, V223, P232; Shinha A.K., 2007, ANGEW CHEM INT EDIT, V46, P2891; Somorjai G.A., 1994, INTRO SURFACE CHEM C; SOPYAN I, 1994, CHEM LETT, P723, DOI 10.1246/cl.1994.723; Tada H., 2012, METAL OXIDE SUPPORTE; Tada H, 2011, ANGEW CHEM INT EDIT, V50, P3501, DOI 10.1002/anie.201007869; Tsubota S., 1991, PREPARATION CATALYSI; World Health Organization, 1995, ENV HLTH CRIT, P167; Zehar R.T., 2008, SURF SCI, V602, P2238	48	2	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0021-9517	1090-2694		J CATAL	J. Catal.	JUN	2015	326						9	14		10.1016/j.jcat.2015.03.005		6	Chemistry, Physical; Engineering, Chemical	Chemistry; Engineering	CJ3AX	WOS:000355356900002		
J	Chen, WT; Chan, A; Sun-Waterhouse, D; Moriga, T; Idriss, H; Waterhouse, GIN				Chen, Wan-Ting; Chan, Andrew; Sun-Waterhouse, Dongxiao; Moriga, Toshihiro; Idriss, Hicham; Waterhouse, Geoffrey I. N.			Ni/TiO2: A promising low-cost photocatalytic system for solar H-2 production from ethanol-water mixtures	JOURNAL OF CATALYSIS			English	Article						Hydrogen production; Ethanol; Photocatalysis; Nickel; TiO2	HYDROGEN-PRODUCTION; AU/TIO2 PHOTOCATALYSTS; MESOPOROUS TIO2; ENERGY; METAL; NIO; NANOPARTICLES; NITIO3; BOMBARDMENT; OXIDATION	Low-cost semiconductor photocatalysts that can efficiently harvest solar energy and generate H-2 from water or biofuels will be critical to future hydrogen economies. Here, we evaluate the performance of low-cost Ni/TiO2 photocatalysts (Ni loadings 0-4 wt.%) for H-2 production from ethanol-water mixtures (0-100 vol.% EtOH) under UV excitation. Ni(II) was deposited on P25 TiO2 by the complex precipitation method, followed by H-2 reduction at 500 degrees C for 2 h to obtain Ni/TiO2 photocatalysts. TGA, TEM, XRD, Ni 2p XPS, Ni L-edge NEXAFS, Ni K-edge EXAFS, UV-Vis and photoluminescence measurements confirmed that Ni-0 was the dominant nickel species on the surface of the Ni/TiO2 photocatalysts, with the Ni particle size similar to 1-2 nm. The photocatalytic activity of Ni/TiO2 photocatalysts was highly dependent on the Ni loading, with the optimal Ni loading being 0.5 wt.%, which afforded a H-2 production rate of 11.6 mmol g(-1) h(-1) (or 0.258 mmol m(-2) h(-1)) at an EtOH:H2O volume ratio of 10:90 and a UV flux comparable to that in sunlight. High H-2 production rates were achieved over a wide range of EtOH:H2O concentrations, with a 95:5 volume ratio affording the highest rate (24.3 mmol g(-1) h(-1)). The 0.5 wt.% NifTiO(2) photocatalyst displayed superior photocatalytic activity to a 2 wt.% Au/TiO2 reference photocatalyst at low ethanol concentrations (1-15 vol.%), which is attributed to the high co-catalyst dispersion achieved in the Ni/TiO2 system. Results suggest that Ni/TiO2 photocatalysts are promising alternatives to M/TiO2 (M = Pd, Pt or Au) photocatalysts for solar H-2 production from biofuels. (C) 2015 Elsevier Inc. All rights reserved.	[Chen, Wan-Ting; Chan, Andrew; Sun-Waterhouse, Dongxiao; Waterhouse, Geoffrey I. N.] Univ Auckland, Sch Chem Sci, Auckland 1, New Zealand; [Moriga, Toshihiro] Univ Tokushima, Grad Sch Adv Technol & Sci, Tokushima 770, Japan; [Idriss, Hicham] KAUST, CRI, SABIC, Thuwal, Saudi Arabia; [Waterhouse, Geoffrey I. N.] MacDiarmid Inst Adv Mat & Nanotechnol, Wellington, New Zealand	Waterhouse, GIN (reprint author), Univ Auckland, Sch Chem Sci, Auckland 1, New Zealand.	g.waterhouse@auckland.ac.nz			Energy Education Trust of New Zealand; University of Auckland FRDF fund; New Zealand Synchrotron Group Ltd; MacDiarmid Institute for Advanced Materials and Nanotechnology; Japan Society for the Promotion of Science (JSPS) [S13179]	Wan-Ting Chen thanks the Energy Education Trust of New Zealand for the award of a Doctoral Scholarship. Additional funding support from the University of Auckland FRDF fund, New Zealand Synchrotron Group Ltd and the MacDiarmid Institute for Advanced Materials and Nanotechnology is gratefully acknowledged. Geoff Waterhouse thanks the Japan Society for the Promotion of Science (JSPS) for award of a JSPS Fellowship to work in Japan (S13179). The authors thank Dr. Toshiaki Ina (SPring-8) for his assistance with the collection and processing of the Ni K-edge EXAFS data. The synchrotron radiation experiments were performed at the BL01B1 (XAFS) of SPring-8 with the approval of the Japan Synchrotron Radiation Research Institute (JASRI) (Proposal No. 2014B1065).	Dincer I, 2012, INT J HYDROGEN ENERG, V37, P1954, DOI 10.1016/j.ijhydene.2011.03.173; Bowker M, 2014, J CATAL, V310, P10, DOI 10.1016/j.jcat.2013.04.005; Chen WT, 2013, INT J HYDROGEN ENERG, V38, P15036, DOI 10.1016/j.ijhydene.2013.09.101; SKRIVER HL, 1992, PHYS REV B, V46, P7157, DOI 10.1103/PhysRevB.46.7157; Zanella R, 2002, J PHYS CHEM B, V106, P7634, DOI 10.1021/jp0144810; Tachibana Y, 2012, NAT PHOTONICS, V6, P511, DOI 10.1038/nphoton.2012.175; Martinez I, 2013, INT J HYDROGEN ENERG, V38, P15180, DOI 10.1016/j.ijhydene.2013.09.062; Maeda K, 2010, J PHYS CHEM LETT, V1, P2655, DOI 10.1021/jz1007966; Qu Y, 2012, J MATER CHEM, V22, P16471, DOI 10.1039/c2jm32044d; Shimura K, 2011, ENERG ENVIRON SCI, V4, P2467, DOI 10.1039/c1ee01120k; Chen XB, 2012, CHEM SOC REV, V41, P7909, DOI 10.1039/c2cs35230c; Ikeno H, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.075123; Armor JN, 1999, APPL CATAL A-GEN, V176, P159, DOI 10.1016/S0926-860X(98)00244-0; Simpson AP, 2007, INT J HYDROGEN ENERG, V32, P4811, DOI 10.1016/j.ijhydene.2007.08.025; KUDO A, 1987, CHEM PHYS LETT, V133, P517, DOI 10.1016/0009-2614(87)80070-2; Ding XZ, 1996, J MATER SCI LETT, V15, P1789, DOI 10.1007/BF00275343; Hu CC, 2010, J CATAL, V272, P1, DOI 10.1016/j.jcat.2010.03.020; Townsend TK, 2012, ENERG ENVIRON SCI, V5, P9543, DOI 10.1039/c2ee22665k; Christopher K, 2012, ENERG ENVIRON SCI, V5, P6640, DOI 10.1039/c2ee01098d; Jovic V, 2013, J CATAL, V305, P307, DOI 10.1016/j.jcat.2013.05.031; Wang WG, 2013, PHYS CHEM CHEM PHYS, V15, P12033, DOI 10.1039/c2cp43628k; Chen JG, 1997, SURF SCI REP, V30, P1, DOI 10.1016/S0167-5729(97)00011-3; Murdoch M, 2011, NAT CHEM, V3, P489, DOI [10.1038/nchem.1048, 10.1038/NCHEM.1048]; Waterhouse GIN, 2012, INT J NANOTECHNOL, V9, P113, DOI 10.1504/IJNT.2012.044832; Kudo A, 2009, CHEM SOC REV, V38, P253, DOI 10.1039/b800489g; Khan Z, 2012, J MATER CHEM, V22, P12090, DOI 10.1039/c2jm31148h; ESPINOS JP, 1993, SURF SCI, V295, P402, DOI 10.1016/0039-6028(93)90287-T; Jovic V, 2013, TOP CATAL, V56, P1139, DOI 10.1007/s11244-013-0080-8; Yu JG, 2011, J PHYS CHEM C, V115, P4953, DOI 10.1021/jp111562d; Greaves J, 2006, GOLD BULL, V39, P216; Rulisek L, 1998, J INORG BIOCHEM, V71, P115, DOI 10.1016/S0162-0134(98)10042-9; Barelli L, 2008, ENERGY, V33, P554, DOI 10.1016/j.energy.2007.10.018; DAUDE N, 1977, PHYS REV B, V15, P3229, DOI 10.1103/PhysRevB.15.3229; Yoong LS, 2009, ENERGY, V34, P1652, DOI 10.1016/j.energy.2009.07.024; Hagelin-Weaver HAE, 2004, J ELECTRON SPECTROSC, V134, P139, DOI 10.1016/j.elspec.2003.10.002; Biesinger MC, 2012, PHYS CHEM CHEM PHYS, V14, P2434, DOI 10.1039/c2cp22419d; Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023; Jing DW, 2005, CHEM PHYS LETT, V415, P74, DOI 10.1016/j.cplett.2005.08.080; BAMWENDA GR, 1995, J PHOTOCH PHOTOBIO A, V89, P177, DOI 10.1016/1010-6030(95)04039-I; BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126; Corrias A, 1999, J PHYS CHEM B, V103, P10081, DOI 10.1021/jp9927911; Courtade L, 2008, THIN SOLID FILMS, V516, P4083, DOI 10.1016/j.tsf.2007.09.050; Gonzalez-DelaCruz VM, 2008, J CATAL, V257, P307, DOI 10.1016/j.jcat.2008.05.009; Guillou N, 2006, EUR J INORG CHEM, P4963, DOI 10.1002/ejic.200600663; Lang JW, 2009, J SOLID STATE ELECTR, V13, P333, DOI 10.1007/s10008-008-0560-0; Kwak BS, 2009, B KOREAN CHEM SOC, V30, P1047; LEINEN D, 1993, SURF INTERFACE ANAL, V20, P941, DOI 10.1002/sia.740201203; Reyes-Coronado D, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/14/145605; Richardson JT, 2003, APPL CATAL A-GEN, V246, P137, DOI 10.1016/S0926-860X(02)00669-5; SALVADOR P, 1982, APPL PHYS LETT, V40, P188, DOI 10.1063/1.93003; Simamora A.-J., 2013, INT J PHOTOENERGY, V2013; Sreethawong T, 2005, INT J HYDROGEN ENERG, V30, P1053, DOI 10.1016/j.ijhydene.2004.09.007; Wagner C. D., 1979, HDB XRAY PHOTOELECTR; Zhang DS, 2006, J PHYS CHEM B, V110, P21890, DOI 10.1021/jp0640880	54	3	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0021-9517	1090-2694		J CATAL	J. Catal.	JUN	2015	326						43	53		10.1016/j.jcat.2015.03.008		11	Chemistry, Physical; Engineering, Chemical	Chemistry; Engineering	CJ3AX	WOS:000355356900006		
J	Suzuki, T; Ishii, M				Suzuki, Tatsuo; Ishii, Masayoshi			Interdecadal Baroclinic Sea Level Changes in the North Pacific Based on Historical Ocean Hydrographic Observations	JOURNAL OF CLIMATE			English	Article							SUBTROPICAL MODE WATER; EDDY-RESOLVING OGCM; DECADAL VARIABILITY; TEMPERATURE; OSCILLATIONS; OYASHIO; SHIFTS; GYRE	Using historical ocean hydrographic observations, decadal to multidecadal sea level changes from 1951 to 2007 in the North Pacific were investigated focusing on vertical density structures. Hydrographically, the sea level changes could reflect the following: changes in the depth of the main pycnocline, density gradient changes across the pycnocline, and modification of the water mass density structure within the pycnocline. The first two processes are characterized as the first baroclinic mode. The changes in density stratification across the pycnocline are sufficiently small to maintain the vertical profile of the first baroclinic mode in this analysis period. Therefore, the first mode should represent mainly the dynamical response to the wind stress forcing. Meanwhile, changes in the composite of all modes of order greater than 1 (remaining baroclinic mode) can be attributed to water mass modifications above the pycnocline. The first baroclinic mode is associated with 40-60-yr fluctuations in the subtropical gyre and bidecadal fluctuations of the Kuroshio Extension (KE) in response to basin-scale wind stress changes. In addition to this, the remaining baroclinic mode exhibits strong variability around the recirculation region south of the KE and regions downstream of the KE, accompanied by 40-60-yr and bidecadal fluctuations, respectively. These fluctuations follow spinup/spindown of the subtropical gyre and meridional shifts of the KE shown in the first mode, respectively. A lag correlation analysis suggests that interdecadal sea level changes due to water mass density changes are a secondary consequence of changes in basin-scale wind stress forcing related to the ocean circulation changes associated with the first mode.	[Suzuki, Tatsuo] Japan Agcy Marine Earth Sci & Technol, Dept Integrated Climate Change Project Res, Yokohama, Kanagawa 2360001, Japan; [Ishii, Masayoshi] Japan Meteorol Agcy, Meteorol Res Inst, Tsukuba, Ibaraki, Japan	Suzuki, T (reprint author), Japan Agcy Marine Earth Sci & Technol, Dept Integrated Climate Change Project Res, Kanazawa Ku, 3173-25 Showa Machi, Yokohama, Kanagawa 2360001, Japan.	tsuzuki@jamstec.go.jp			Japanese Ministry of Education, Culture, Sports, Science, and Technology, through the Program for Risk Information on Climate Change	The authors thank Masami Nonaka and Tamaki Yasuda for their discussions and helpful comments. Constructive and valuable comments provided by Anand Gnanadesikan and anonymous reviewers help us to improve the earlier manuscript. This work was supported by the Japanese Ministry of Education, Culture, Sports, Science, and Technology, through the Program for Risk Information on Climate Change.	Mantua NJ, 1997, B AM METEOROL SOC, V78, P1069, DOI 10.1175/1520-0477(1997)078<1069:APICOW>2.0.CO;2; Griffies SM, 2012, OCEAN MODEL, V51, P37, DOI 10.1016/j.ocemod.2012.04.003; Nonaka M, 2006, J CLIMATE, V19, P1970, DOI 10.1175/JCLI3793.1; Ishii M, 2005, INT J CLIMATOL, V25, P865, DOI 10.1002/joc.1169; Sasaki YN, 2011, J PHYS OCEANOGR, V41, P979, DOI 10.1175/2010JPO4550.1; Schneider N, 2002, J CLIMATE, V15, P586, DOI 10.1175/1520-0442(2002)015<0586:AONPDV>2.0.CO;2; Lombard A, 2005, GLOBAL PLANET CHANGE, V47, P1, DOI 10.1016/j.gloplacha.2004.11.016; Lowe JA, 2006, J GEOPHYS RES-OCEANS, V111, DOI 10.1029/2005JC003421; Yu LS, 2007, B AM METEOROL SOC, V88, P527, DOI 10.1175/BAMS-88-4-527; Nonaka M, 2008, J CLIMATE, V21, P6283, DOI 10.1175/2008JCLI2294.1; Qiu B, 2002, J PHYS OCEANOGR, V32, P353, DOI 10.1175/1520-0485(2002)032<0353:LSVITM>2.0.CO;2; Ishii M, 2009, J OCEANOGR, V65, P287, DOI 10.1007/s10872-009-0027-7; Minobe S, 1999, GEOPHYS RES LETT, V26, P855, DOI 10.1029/1999GL900119; Antonov JI, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2001JC000964; Cummins PF, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023642; Cummins PF, 2002, J PHYS OCEANOGR, V32, P3207, DOI 10.1175/1520-0485(2002)032<3207:LFPDVA>2.0.CO;2; GREGORY JM, 1993, J CLIMATE, V6, P2247, DOI 10.1175/1520-0442(1993)006<2247:SLCUIA>2.0.CO;2; Hanawa K, 2001, GEOPHYS RES LETT, V28, P2229, DOI 10.1029/2000GL011716; Hanawa K., 2001, OCEAN CIRCULATION CL, V77, P373, DOI DOI 10.1016/S0074-6142(01)80129-7; Huang RX, 1999, J PHYS OCEANOGR, V29, P779, DOI 10.1175/1520-0485(1999)029<0779:CVIFAL>2.0.CO;2; LAGERLOEF GSE, 1995, J PHYS OCEANOGR, V25, P2242, DOI 10.1175/1520-0485(1995)025<2242:IVITAG>2.0.CO;2; Qiu B, 2003, J PHYS OCEANOGR, V33, P2465, DOI 10.1175/2459.1; Qiu B, 2006, J PHYS OCEANOGR, V36, P1365, DOI 10.1175/JPO2918.1; Suzuki T, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL049326; Suzuki T, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2010GL045693; Teng HY, 2011, CLIM DYNAM, V36, P1813, DOI 10.1007/s00382-010-0749-7; Yasuda T, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL024920; Yasuda T, 2003, J OCEANOGR, V59, P279, DOI 10.1023/A:1025507725222	28	1	1	AMER METEOROLOGICAL SOC	BOSTON	45 BEACON ST, BOSTON, MA 02108-3693 USA	0894-8755	1520-0442		J CLIMATE	J. Clim.	JUN	2015	28	11					4585	4594		10.1175/JCLI-D-13-00103.1		10	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	CI9YE	WOS:000355125900016		
J	Okiyama, N; Fujimoto, M				Okiyama, Naoko; Fujimoto, Manabu			Clinical perspectives and murine models of lichenoid tissue reaction/interface dermatitis	JOURNAL OF DERMATOLOGICAL SCIENCE			English	Review						Lichen planus; Graft-versus-host disease; Drug eruption; Lupus erythematosus; Cytotoxic T cells; Keratinocyte death	TOXIC EPIDERMAL NECROLYSIS; CUTANEOUS LUPUS-ERYTHEMATOSUS; STEVENS-JOHNSON-SYNDROME; REGULATORY T-CELLS; NECROSIS-FACTOR-ALPHA; VERSUS-HOST-DISEASE; PERIPHERAL-BLOOD; DENDRITIC CELLS; TRANSGENIC MICE; DRUG ERUPTIONS	A set of histopathological elements, that is death of epidermal basal cell layer keratinocytes and inflammatory cell infiltration, distinguishes lichenoid tissue reaction (LTR)/interface dermatitis (IFD) from other inflammatory mucocutaneous diseases with histological findings of superficial perivascular dermatitis. The LTR/IFD is observed in inflammatory mucocutaneous diseases such as lichen planus, Stevens-Johnson syndrome/toxic epidermal necrolysis, acute graft-versus-host disease, lupus erythematosus and dermatomyositis. Clinical and basic researches have suggested that keratinocytes are antigen-presenting cells and mediate LTR/IFD reaction via production of cytokines/chemokines and inhibitory molecules such as programmed cell death (PD)-L1, and that cytotoxic CD8(+) T cells producing cytotoxic granules, perforin, granzyme B and granulysin are final effector cells to cause keratinocyte death. Because, interferon-gamma and FasL, which are produced by not only CD8(+) but also CD4(+) T cells, are candidates of the pathogenic molecules in LTR/IFD, CD4(+) T cells may also play a role to develop LTR/IFD. On the other hand, CD4(+) Treg cells accelerate the remission of LTR/IFD. Some murine models of LTR/IFD have been established. For example, LTR/IFD reactions were induced in keratinocyte-specific membrane-binding ovalbumin-transgenic (mOVA Tg) mice by adoptive transfer of CD8(+) T cells with OVA-specific T-cell-receptor. It has also been shown that human CD8(+) T cells are pathogenic immune cells in human skin-xenografted mice. Various immunosuppressants are used to treat patients with mucocutaneous diseases with LTR/IFD. By analysis of the mOVA Tg mice, a JAK inhibitor was suggested to be a new candidate drug to inhibit not only pathogenic T cells but also keratinocyte death in LTR/IFD. More specific treatments for patients with LTR/IFD will be developed in future. (C) 2015 Japanese Society for Investigative Dermatology.	[Okiyama, Naoko; Fujimoto, Manabu] Univ Tsukuba, Fac Med, Dept Dermatol, Tsukuba, Ibaraki 3058575, Japan	Okiyama, N (reprint author), Univ Tsukuba, Fac Med, Dept Dermatol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	naoko.okiyama@md.tsukuba.ac.jp					Janardhanam SB, 2012, ARCH ORAL BIOL, V57, P495, DOI 10.1016/j.archoralbio.2011.10.013; Niihara H, 2014, J DERMATOL SCI, V74, P88, DOI 10.1016/j.jdermsci.2013.11.013; Santoro A, 2005, J PATHOL, V205, P426, DOI 10.1002/path.1699; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Jarvis M, 2002, J CLIN PATHOL, V55, P127; Franz B, 2007, ARTHRITIS RHEUM, V56, P1910, DOI 10.1002/art.22699; Niihara H, 2013, J DERMATOL SCI, V71, P150, DOI 10.1016/j.jdermsci.2013.04.013; Knoechel B, 2005, J EXP MED, V202, P1375, DOI 10.1084/jem.20050855; Saito N, 2013, J ALLERGY CLIN IMMUN, V131, P434, DOI 10.1016/j.jaci.2012.09.014; Abe R, 2009, ANN INTERN MED, V151, P514; Correia O, 2001, DERMATOLOGY, V203, P212, DOI 10.1159/000051751; Kim BS, 2009, J INVEST DERMATOL, V129, P2805, DOI 10.1038/jid.2009.176; Broady R, 2010, BLOOD, V116, P5748, DOI [10.1182/blood-2010-07-295436, 10.1182/blood-2010-07295436]; Takahashi R, 2009, J IMMUNOL, V182, P8071, DOI 10.4049/jimmunol.0804002; Abe R, 2003, AM J PATHOL, V162, P1515, DOI 10.1016/S0002-9440(10)64284-8; Hofmann SC, 2013, J DERMATOL SCI, V71, P22, DOI 10.1016/j.jdermsci.2013.04.012; Shibaki A, 2004, J INVEST DERMATOL, V123, P109, DOI 10.1111/j.0022-202X.2004.22701.x; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Azukizawa H, 2003, EUR J IMMUNOL, V33, P1879, DOI 10.1002/eji.200323630; Hsiao YH, 2014, J DERMATOL SCI, V73, P101, DOI 10.1016/j.jdermsci.2013.10.003; BLASZCZYK M, 1987, BRIT J DERMATOL, V117, P709, DOI 10.1111/j.1365-2133.1987.tb07350.x; Chakraverty R, 2006, J EXP MED, V203, P2021, DOI 10.1084/jem.20060376; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; ChristofidouSolomidou M, 1997, AM J PATHOL, V150, P631; Fogagnolo L, 2014, CLIN EXP DERMATOL, V39, P835, DOI 10.1111/ced.12428; Fujiyama T, 2014, J DERMATOL SCI, V73, P85, DOI 10.1016/j.jdermsci.2013.08.008; Furudate Sadanori, 2013, Case Rep Dermatol, V5, P93, DOI 10.1159/000350561; Gerl V, 2005, ARTHRITIS RHEUM, V52, P531, DOI 10.1002/art.20851; Grassi M, 2009, CLIN EXP DERMATOL, V34, P910, DOI 10.1111/j.1365-2230.2009.03297.x; Jarvinen TM, 2007, BRIT J DERMATOL, V157, P970, DOI 10.1111/j.1365-2133.2007.08166.x; Kubo K, 1996, BLOOD, V87, P3019; McNiff JM, 2008, J CUTAN PATHOL, V35, P452, DOI 10.1111/j.1600-0560.2007.00848.x; Mehling A, 2001, J EXP MED, V194, P615, DOI 10.1084/jem.194.5.615; MIYAUCHI H, 1991, ARCH DERMATOL, V127, P851, DOI 10.1001/archderm.127.6.851; Morel E, 2010, J ALLERGY CLIN IMMUN, V125, P703, DOI 10.1016/j.jaci.2009.10.030; Nakajima M, 1997, CLIN IMMUNOL IMMUNOP, V83, P223, DOI 10.1006/clin.1997.4352; Okiyama N, 2014, J INVEST DERMATOL, V134, P992, DOI 10.1038/jid.2013.476; Okiyama N, 2014, J AUTOIMMUN, V53, P1, DOI 10.1016/j.jaut.2014.06.005; Piccinni MP, 2014, ORAL DIS, V20, P212, DOI 10.1111/odi.12094; Massari LP, 2004, BRIT J DERMATOL, V151, P433, DOI 10.1111/j.1365-2133.2004.06086.x; Saito N., 2014, SCI TRANSL MED, V6; Shimizu M, 1997, ARCH DERMATOL RES, V289, P527, DOI 10.1007/s004030050234; SHIOHARA T, 1987, J INVEST DERMATOL, V89, P8; Shiohara T, 2005, AUTOIMMUN REV, V4, P236, DOI 10.1016/j.autrev.2004.11.005; Sugerman PB, 2000, BRIT J DERMATOL, V142, P449, DOI 10.1046/j.1365-2133.2000.03355.x; Takahashi H, 2011, J CLIN INVEST, V121, P3677, DOI 10.1172/JCI57379; Toungouz M, 1996, TRANSPLANTATION, V62, P1292, DOI 10.1097/00007890-199611150-00020; Tsuchiyama J, 2009, BONE MARROW TRANSPL, V43, P863, DOI 10.1038/bmt.2008.392; Wenzel J, 2006, J CUTAN PATHOL, V33, P672, DOI 10.1111/j.1600-0560.2006.00527.x; Yu HS, 1996, BRIT J DERMATOL, V135, P297	50	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0923-1811	1873-569X		J DERMATOL SCI	J. Dermatol. Sci.	JUN	2015	78	3					167	172		10.1016/j.jdermsci.2015.03.001		6	Dermatology	Dermatology	CI8KT	WOS:000355021900001		
J	Hiromatsu, R; Hatta, M; Okamura, K; Sakagami, R; Yamazaki, J				Hiromatsu, Ryo; Hatta, Mitsutoki; Okamura, Kazuhiko; Sakagami, Ryuji; Yamazaki, Jun			NF-kappa B-regulated transcriptional control of CLCA in a differentiated mouse keratinocyte line	JOURNAL OF DERMATOLOGICAL SCIENCE			English	Article						CLCA; Keratinocyte; NF-kappa B; Differentiation	EPITHELIAL-CELLS; CHLORIDE CHANNEL; EXPRESSION; EPIDERMIS; LOCALIZATION; CULTURE; PROTEIN; GROWTH; SKIN; STRATIFICATION	Background: CLCA was postulated to be a calcium-activated chloride channel accessory protein. Recent reports indicate that CLCA isoforms are likely to be expressed in different layers of the stratified epithelium of the skin. Objective: The present study investigated the transcriptional mechanism by which murine CLCA2 (mCLCA2) is expressed in the transformed keratinocyte line Pam212 that can differentiate. Methods: A luciferase reporter assay, chromatin immunoprecipitation (ChIP) assay, reverse transcription-PCR, and immunocytochemistry were performed using Pam212 cells. Results: Promoter activity of mCLCA2 was inhibited profoundly by site-directed mutagenesis of a putative nuclear factor-kappa B (NF-kappa B) binding site and by treatment with siRNA against p65. ChIP and transcription factor assays showed the specific association of endogenously activated p65 protein with the NF-kappa B binding domain. As confirmed by the nuclear translocation of p65, tumor necrosis factor alpha and caffeic acid phenethyl ester (CAPE) increased and decreased mCLCA2 promoter activity, respectively, but exhibited modest effects on endogenous mCLCA2 expression in cells in culture medium containing 0.05 mM Ca2+ . When the Ca2+ concentration was raised to 1.0 mM, the mRNA and protein levels of mCLCA2 increased as well as those of the differentiation markers keratin 1 (K1) and K10. CAPE profoundly suppressed only the Ca2+-triggered expression of mCLCA2, not K1 or K10. Immunohistochemistry of native skin and organotypic 3D cultures confirmed the distribution of the CLCA2 homolog in differentiated cells. Conclusion: The present study revealed for the first time that basal NF-kappa B activity is involved in the Ca2+-dependent regulation of mCLCA2 expression in a mouse keratinocyte line. (C) 2015 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.	[Hiromatsu, Ryo; Sakagami, Ryuji] Fukuoka Dent Coll, Dept Odontol, Sawara Ku, Fukuoka 8140193, Japan; [Hatta, Mitsutoki; Yamazaki, Jun] Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Sawara Ku, Fukuoka 8140193, Japan; [Okamura, Kazuhiko] Fukuoka Dent Coll, Dept Morphol Biol, Sawara Ku, Fukuoka 8140193, Japan	Yamazaki, J (reprint author), Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Sawara Ku, 2-15-1 Tamura, Fukuoka 8140193, Japan.	junyama@college.fdcnet.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology-Supported Program for the Strategic Research Foundation at Private Universities [S1001059];  [26670104]	A Grant-in-Aid for Challenging Exploratory Research (Grant Number 26670104) (J.Y.) and a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology-Supported Program for the Strategic Research Foundation at Private Universities (S1001059) (J.Y.).	Nakano T, 2006, AM J RESP CRIT CARE, V173, P1216, DOI 10.1164/rccm.200410-1420OC; Takao J, 2003, BRIT J DERMATOL, V148, P680, DOI 10.1046/j.1365-2133.2003.05285.x; Deyrieux AF, 2007, CYTOTECHNOLOGY, V54, P77, DOI 10.1007/s10616-007-9076-1; Plog S, 2012, CELL TISSUE RES, V350, P445, DOI 10.1007/s00441-012-1482-9; Patel AC, 2009, ANNU REV PHYSIOL, V71, P425, DOI 10.1146/annurev.physiol.010908.163253; YUSPA SH, 1980, CANCER RES, V40, P4694; Goldminz AM, 2013, J DERMATOL SCI, V69, P89, DOI 10.1016/j.jdermsci.2012.11.002; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Koster MI, 2007, ANNU REV CELL DEV BI, V23, P93, DOI 10.1146/annurev.cellbio.23.090506.123357; Loewen ME, 2005, PHYSIOL REV, V85, P1061, DOI 10.1152/physrev.00016.2004; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Bart G, 2014, BRIT J DERMATOL, V171, P376, DOI 10.1111/bjd.13038; Bell S, 2002, CELL SIGNAL, V15, P1; Bikle DD, 2012, EXPERT REV ENDOCRINO, V7, P461, DOI DOI 10.1586/EEM.12.34; Braun J, 2010, HISTOCHEM CELL BIOL, V133, P285, DOI 10.1007/s00418-009-0667-0; Connon CJ, 2006, CELL TISSUE RES, V323, P177, DOI 10.1007/s00441-005-0059-2; Connon CJ, 2004, J HISTOCHEM CYTOCHEM, V52, P415; Hata S, 2014, J PHARMACOL SCI, V124, P230, DOI 10.1254/jphs.13209FP; Lee D, 1999, BIOCHEM BIOPH RES CO, V264, P933, DOI 10.1006/bbrc.1999.1583; Leverkoehne I, 2002, HISTOCHEM CELL BIOL, V118, P11, DOI 10.1007/s00418-002-0420-4; Roussa E, 2010, J HISTOCHEM CYTOCHEM, V58, P653, DOI 10.1369/jhc.2010.955211; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; Strong CD, 2006, J CELL BIOL, V175, P661, DOI 10.1083/jcb.200605057; Tanikawa C, 2012, NEOPLASIA, V14, P141, DOI 10.1593/neo.111700; Yamazaki J, 2013, J BIOL CHEM, V288, P4831, DOI 10.1074/jbc.M112.396481; Yamazaki J, 2005, BBA-BIOMEMBRANES, V1715, P132, DOI 10.1016/j.bbamem.2005.08.001	30	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0923-1811	1873-569X		J DERMATOL SCI	J. Dermatol. Sci.	JUN	2015	78	3					189	196		10.1016/j.jdermsci.2015.03.007		8	Dermatology	Dermatology	CI8KT	WOS:000355021900004		
J	Hayashi, R; Inoue, A; Suga, Y; Aoki, J; Shimomura, Y				Hayashi, Ryota; Inoue, Asuka; Suga, Yasushi; Aoki, Junken; Shimomura, Yutaka			Analysis of unique mutations in the LPAR6 gene identified in a Japanese family with autosomal recessive woolly hair/hypotrichosis: Establishment of a useful assay system for LPA(6)	JOURNAL OF DERMATOLOGICAL SCIENCE			English	Article						Woolly hair; Hypotrichosis; LPAR6; LPA(6); LIPH	PROTEIN-COUPLED RECEPTOR; LIPASE-H GENE; LYSOPHOSPHATIDIC ACID RECEPTOR; HUMAN HAIR-GROWTH; P2RY5 GENE; HYPOTRICHOSIS SIMPLEX; PAKISTANI FAMILIES; ACTIVATION ABILITY; DELETION MUTATION; FOUNDER MUTATIONS	Background: Woolly hair (WH) is a hair shaft anomaly characterized by tightly-curled hair and is frequently associated with hypotrichosis. Non-syndromic forms of WH can show either autosomal dominant or recessive inheritance. The autosomal recessive form of WH (ARWH) is caused by mutations in either lipase H (LIPH) or lysophosphatidic acid receptor 6 (LPAR6) gene, encoding an LPA-producing enzyme PA-PLA(1)alpha and an LPA receptor LPA(6), respectively. Objective: To define the molecular basis of ARWH/hypotrichosis in a Japanese family. Methods: We performed mutational analysis of candidate genes and a series of expression and in vitro functional analyses, which we improved in this study, to determine the consequences resulting from the mutations identified in the family. Results: Novel compound heterozygous LPAR6 mutations were identified in the patient. One was a nonsense mutation c.756T > A (p.Tyr252*); the other was a large insertion mutation within the promoter region of LPAR6. Expression studies detected LPAR6 mRNA only from the c.756T > A allele in the patient's hair follicles, suggesting that the insertion in the other allele disrupted the LPAR6 promoter and thus led to a failure of transcription. Furthermore, an improved LPA(6) functional assay developed in this study demonstrated aberrant expression and a subsequent loss of function of the p.Tyr252*-mutant protein. Conclusion: Through establishing a useful assay system for LPA(6), our results further underscore the crucial roles of LPAR6 in hair follicle development and hair growth in humans at molecular levels. (C) 2015 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.	[Hayashi, Ryota; Shimomura, Yutaka] Niigata Univ, Grad Sch Med & Dent Sci, Lab Genet Skin Dis, Niigata 9518510, Japan; [Hayashi, Ryota; Shimomura, Yutaka] Niigata Univ, Grad Sch Med & Dent Sci, Div Dermatol, Niigata 9518510, Japan; [Inoue, Asuka; Aoki, Junken] Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Mol & Cellular Biochem, Sendai, Miyagi 980, Japan; [Inoue, Asuka] Japan Sci & Technol Agcy JST, PRESTO, Kawaguchi, Saitama, Japan; [Suga, Yasushi] Juntendo Univ, Urayasu Hosp, Dept Dermatol, Urayasu, Japan; [Aoki, Junken] JST, CREST, Kawaguchi, Saitama, Japan	Shimomura, Y (reprint author), Niigata Univ, Grad Sch Med & Dent Sci, Lab Genet Skin Dis, Chuo Ku, 1-757 Asahimachidori, Niigata 9518510, Japan.	yshimo@med.niigata-u.ac.jp			Takeda Science Foundation, Japan; Ministry of Health, Labour, and Welfare, Japan [H26-077]; PRESTO (Precursory Research for Embryonic Science and Technology) from Japan Science and Technology Agency (JST); KAKENHI [26440043]; CREST from JST; Ministry of Education, Science, Sports and Culture of Japan (MEXT)	We are grateful to Miho Morikawa for technical assistance with the TGF alpha shedding assay. This study was supported in part by a grant from Takeda Science Foundation, Japan (to Y.S.) and by "Research on Measures for Intractable Diseases" Project: matching fund subsidy (H26-077) from Ministry of Health, Labour, and Welfare, Japan. A.I. was funded by PRESTO (Precursory Research for Embryonic Science and Technology) from Japan Science and Technology Agency (JST) and a Grant-in-Aid for Scientific Research (C) (KAKENHI 26440043). J.A. was funded by CREST from JST and a Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Science, Sports and Culture of Japan (MEXT).	Inoue A, 2011, EMBO J, V30, P4248, DOI 10.1038/emboj.2011.296; Azeem Z, 2008, HUM GENET, V123, P515, DOI 10.1007/s00439-008-0507-7; Kazantseva A, 2006, SCIENCE, V314, P982, DOI 10.1126/science.1133276; Tariq M, 2009, BRIT J DERMATOL, V160, P1006, DOI 10.1111/j.1365-2133.2009.09046.x; Ali G, 2007, HUM GENET, V121, P319, DOI 10.1007/s00439-007-0344-0; Inoue A, 2012, NAT METHODS, V9, P1021, DOI [10.1038/nmeth.2172, 10.1038/NMETH.2172]; Shimomura Y, 2010, ANNU REV GENOM HUM G, V11, P109, DOI 10.1146/annurev-genom-021610-131501; Pasternack SM, 2008, NAT GENET, V40, P329, DOI 10.1038/ng.84; Fujimoto A, 2012, J INVEST DERMATOL, V132, P2342, DOI 10.1038/jid.2012.154; Shimomura Y, 2008, NAT GENET, V40, P335, DOI 10.1038/ng.100; Jiang GW, 2013, BIOORG MED CHEM LETT, V23, P1865, DOI 10.1016/j.bmcl.2013.01.002; Shimomura Y, 2009, J DERMATOL SCI, V56, P205, DOI 10.1016/j.jdermsci.2009.08.005; Azhar A, 2012, EUR J DERMATOL, V22, P464, DOI 10.1684/ejd.2012.1731; Hayashi R, 2014, J DERMATOL, V41, P937, DOI 10.1111/1346-8138.12612; Hayashi R, 2014, J DERMATOL, V41, P890, DOI 10.1111/1346-8138.12623; Herzog H, 1996, GENOME RES, V6, P858, DOI 10.1101/gr.6.9.858; Horev L, 2010, J EUR ACAD DERMATOL, V24, P858, DOI 10.1111/j.1468-3083.2009.03514.x; Kalsoom UE, 2010, ACTA DERM-VENEREOL, V90, P93, DOI 10.2340/00015555-0766; Kurban M, 2013, J EUR ACAD DERMATOL, V27, P545, DOI 10.1111/j.1468-3083.2012.04472.x; Kurban M, 2010, J DERMATOL SCI, V57, P132, DOI 10.1016/j.jdermsci.2009.10.015; Liu LH, 2013, CLIN EXP DERMATOL, V38, P796, DOI 10.1111/ced.12129; Mahmoudi H, 2012, EXP DERMATOL, V21, P469, DOI 10.1111/j.1600-0625.2012.01504.x; Mehmood S, 2014, AUSTRALAS J IN PRESS; Nahum S, 2009, ARCH DERMATOL RES, V301, P391, DOI 10.1007/s00403-008-0903-9; Nahum S, 2011, CLIN EXP DERMATOL, V36, P188, DOI 10.1111/j.1365-2230.2010.03944.x; Naz G, 2009, J DERMATOL SCI, V54, P12, DOI 10.1016/j.jdermsci.2008.12.001; Pasternack SM, 2009, J INVEST DERMATOL, V129, P2772, DOI 10.1038/jid.2009.154; Pasternack SM, 2009, ARCH DERMATOL RES, V301, P621, DOI 10.1007/s00403-009-0971-5; Petukhova L, 2008, GENOMICS, V92, P273, DOI 10.1016/j.ygeno.2008.06.009; Shimomura Y, 2009, J INVEST DERMATOL, V129, P1927, DOI 10.1038/jid.2009.19; Shimomura Y, 2012, J DERMATOL, V39, P3, DOI 10.1111/j.1346-8138.2011.01395.x; Shimomura Y, 2009, J INVEST DERMATOL, V129, P622, DOI 10.1038/jid.2008.290; Shimomura Y, 2010, AM J HUM GENET, V86, P632, DOI 10.1016/j.ajhg.2010.02.025; Shinkuma S, 2010, HUM MUTAT, V31, P602, DOI 10.1002/humu.21235; Shinkuma S, 2012, J INVEST DERMATOL, V132, P2093, DOI 10.1038/jid.2012.96; Sonoda H, 2002, J BIOL CHEM, V277, P34254, DOI 10.1074/jbc.M201659200; Tariq M, 2012, SCI REP-UK, V2, DOI 10.1038/srep00730; Yanagida K, 2009, J BIOL CHEM, V284, P17731, DOI 10.1074/jbc.M808506200; Yoshizawa M, 2013, J DERMATOL SCI, V72, P61, DOI 10.1016/j.jdermsci.2013.05.001	39	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0923-1811	1873-569X		J DERMATOL SCI	J. Dermatol. Sci.	JUN	2015	78	3					197	205		10.1016/j.jdermsci.2015.03.006		9	Dermatology	Dermatology	CI8KT	WOS:000355021900005		
J	Matsumura, S; Terao, M; Murota, H; Katayama, I				Matsumura, Sayaka; Terao, Mika; Murota, Hiroyuki; Katayama, Ichiro			Th2 cytokines enhance TrkA expression, upregulate proliferation, and downregulate differentiation of keratinocytes	JOURNAL OF DERMATOLOGICAL SCIENCE			English	Article						Tyrosine kinase receptor A; Nerve growth factor; Keratinocytes; IL-4; Proliferation; Differentiation	NERVE GROWTH-FACTOR; HIGH-AFFINITY RECEPTOR; ATOPIC-DERMATITIS; SUBSTANCE-P; NEUROTROPHINS; SKIN; EOSINOPHILS; DISEASE	Background: Nerve growth factor (NGF), a neurotrophin that plays a critical role in developmental neurobiology, is released by proliferating keratinocytes and induces proliferation. Objective: The aim of this study was to investigate the role of tyrosine kinase receptor A (TrkA), a high-affinity receptor of NGF, in human keratinocytes. Methods: Expression of TrkA and NGF in skin diseases was investigated by immunohistochemistry. Expression of TrkA in cells was examined by Western blotting and RT-PCR. Cell proliferation was assessed by BrdU assay. Results: We first determined the expression of TrkA and NGF in skin samples from patients with atopic dermatitis, prurigo nodularis, psoriasis vulgaris, and seborrheic keratosis. TrkA was only expressed in proliferating basal cells, and its expression was enhanced in atopic dermatitis samples. NGF expression was enhanced in atopic dermatitis and prurigo nodularis samples and in some samples from seborrheic keratosis patients. Investigation of the role of TrkA in vitro using normal human epidermal keratinocytes (NHEK) revealed that TrkA was significantly enhanced by the T helper type 2 (Th2) cytokines interleukin (IL)-4 and IL-13 but not by other inflammatory cytokines, such as IL-1 beta, tumor necrosis factor alpha, interferon gamma, or epidermal growth factor. On the other hand, expression of NGF was not altered by Th2 cytokines. Notably, inhibition of TrkA significantly reversed the effects of IL-4 on proliferation and differentiation. Furthermore, overexpression of TrkA enhanced proliferation of NHEK. These results indicate that IL-4-induced TrkA expression in keratinocytes modulates proliferation and differentiation of these cells. Conclusion: Increased TrkA expression in keratinocytes in atopic dermatitis may contribute to the observed epidermal hyperproliferation in these patients. (C) 2015 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.	[Matsumura, Sayaka; Terao, Mika; Murota, Hiroyuki; Katayama, Ichiro] Osaka Univ, Grad Sch Med, Dept Dermatol, Suita, Osaka 5650871, Japan	Terao, M (reprint author), Osaka Univ, Grad Sch Med, Dept Dermatol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mterao@derma.med.osaka-u.ac.jp			 [24689045]	This work was supported in part by a Grant-in-Aid for Young Scientists (A) (no. 24689045).	Adly MA, 2006, J CUTAN PATHOL, V33, P559, DOI 10.1111/j.1600-0560.2006.00443.x; Toyoda M, 2002, BRIT J DERMATOL, V147, P71, DOI 10.1046/j.1365-2133.2002.04803.x; Pincelli C, 1997, J INVEST DERMATOL, V109, P757, DOI 10.1111/1523-1747.ep12340768; Omori-Miyake M, 2014, J INVEST DERMATOL, V134, P1342, DOI 10.1038/jid.2013.503; Chang SE, 2007, BRIT J DERMATOL, V156, P1272, DOI 10.1111/j.1365-2133.2007.07935.x; Dou YC, 2006, ARCH DERMATOL RES, V298, P31, DOI 10.1007/s00403-006-0657-1; Meulener MC, 2009, J CUTAN PATHOL, V36, P291, DOI 10.1111/j.1600-0560.2008.01035.x; PINCELLI C, 1994, J INVEST DERMATOL, V103, P13, DOI 10.1111/1523-1747.ep12388914; Nockher WA, 2006, J ALLERGY CLIN IMMUN, V117, P583, DOI 10.1016/j.jaci.2005.11.049; LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166-2236(96)10058-8; Terao M, 2013, EXP DERMATOL, V22, P98, DOI 10.1111/exd.12075; Raap U, 2008, CLIN EXP ALLERGY, V38, P1493, DOI 10.1111/j.1365-2222.2008.03035.x; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Kanda N, 2003, J INVEST DERMATOL, V121, P570, DOI 10.1046/j.1523-1747.2003.12428.x; Hamada A, 1996, BRIT J HAEMATOL, V93, P299, DOI 10.1046/j.1365-2141.1996.5151055.x; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Barouch R, 2000, J NEUROIMMUNOL, V103, P112, DOI 10.1016/S0165-5728(99)00233-7; Burbach GJ, 2001, J INVEST DERMATOL, V117, P1075, DOI 10.1046/j.0022-202x.2001.01498.x; Carr M J, 2001, Curr Opin Pulm Med, V7, P1, DOI 10.1097/00063198-200101000-00001; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; Hayashi K, 2008, J ORAL PATHOL MED, V37, P241, DOI 10.1111/j.1600-0714.2007.00627.x; Johansson O, 2002, ARCH DERMATOL RES, V293, P614, DOI 10.1007/s00403-001-0285-708; Junghans V, 1996, Exp Dermatol, V5, P316, DOI 10.1111/j.1600-0625.1996.tb00135.x; Marconi A, 2003, J INVEST DERMATOL, V121, P1515, DOI 10.1111/j.1523-1747.2003.12624.x; Pincelli C, 2000, J DERMATOL SCI, V22, P71, DOI 10.1016/S0923-1811(99)00065-1; Qian Y, 2010, J CUTAN PATHOL, V37, P1150, DOI 10.1111/j.1600-0560.2010.01563.x; Sehra S, 2010, J IMMUNOL, V184, P3186, DOI 10.4049/jimmunol.0901860; Takano N, 2007, BRIT J DERMATOL, V156, P241, DOI 10.1111/j.1365-2133.2006.07636.x; Truzzi Francesca, 2011, Dermatoendocrinol, V3, P32, DOI 10.4161/derm.3.1.14661; Wilkinson D I, 1994, Exp Dermatol, V3, P239, DOI 10.1111/j.1600-0625.1994.tb00283.x	31	1	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0923-1811	1873-569X		J DERMATOL SCI	J. Dermatol. Sci.	JUN	2015	78	3					215	223		10.1016/j.jdermsci.2015.02.021		9	Dermatology	Dermatology	CI8KT	WOS:000355021900007		
J	Morifuji, M; Oba, C; Ichikawa, S; Ito, K; Kawahata, K; Asami, Y; Ikegami, S; Itoh, H; Sugawara, T				Morifuji, Masashi; Oba, Chisato; Ichikawa, Satomi; Ito, Kyoko; Kawahata, Keiko; Asami, Yukio; Ikegami, Shuji; Itoh, Hiroyuki; Sugawara, Tatsuya			A novel mechanism for improvement of dry skin by dietary milk phospholipids: Effect on epidermal covalently bound ceramides and skin inflammation in hairless mice	JOURNAL OF DERMATOLOGICAL SCIENCE			English	Article						Milk phospholipids; Skin barrier function; Covalently bound ceramides; Skin inflammation; Hairless mice	THYMIC STROMAL LYMPHOPOIETIN; PROTEIN KINASE-C; ATOPIC-DERMATITIS; BARRIER FUNCTION; STRATUM-CORNEUM; BOVINE-MILK; BETA-GLUCOCEREBROSIDASE; ACIDIC SPHINGOMYELINASE; MAIZE GLUCOSYLCERAMIDE; OMEGA-HYDROXYCERAMIDES	Background: Dietary milk phospholipids (MPLs) increase hydration of the stratum corneum and reduced transepidermal water loss (TEWL) in hairless mice fed a standard diet. However, the mechanism by which MPLs improve skin barrier functions has yet to be established. Objective: This study was designed to examine the mechanism by which MPLs may affect covalently bound ceramides and markers of skin inflammation and improve the skin barrier defect in hairless mice fed a magnesium-deficient (HR-AD) diet. Methods: Four-week-old female hairless mice were randomized into four groups (n = 10/group), and fed a standard (control) diet, the HR-AD diet, the HR-AD diet supplemented with either 7.0 g/kg MPLs (low [L]-MPL) or 41.0 g/kg MPLs (high [H]-MPL). Results: Dietary MPLs improved the dry skin condition of hairless mice fed the HR-AD diet. MPLs significantly increased the percentage of covalently bound omega-hydroxy ceramides in the epidermis, and significantly decreased both thymus and activation-regulated chemokine (TARC) mRNA and thymic stromal lymphopoietin (TSLP) mRNA levels in skin, compared with the HR-AD diet. Furthermore, the MPL diets significantly decreased serum concentrations of immunoglobulin-E, TARC, TSLP, and soluble P-selectin versus the HR-AD diet. Conclusion: Our study showed for the first time that dietary MPLs may modulate epidermal covalently bound ceramides associated with formation of lamellar structures and suppress skin inflammation, resulting in improved skin barrier function. (C) 2015 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.	[Morifuji, Masashi; Oba, Chisato; Ichikawa, Satomi; Ito, Kyoko; Kawahata, Keiko; Asami, Yukio; Ikegami, Shuji; Itoh, Hiroyuki] Meiji Co Ltd, Food Sci Res Labs, Odawara, Kanagawa 2500862, Japan; [Sugawara, Tatsuya] Kyoto Univ, Grad Sch Agr, Div Appl Biosci, Sakyo Ku, Kyoto, Kyoto 6068502, Japan	Morifuji, M (reprint author), Meiji Co Ltd, Food Sci Res Labs, 540 Naruda, Odawara, Kanagawa 2500862, Japan.	masashi.morifuji@meiji.com					Sugawara T, 2010, J LIPID RES, V51, P1761, DOI 10.1194/jlr.M002204; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Tanaka A, 2012, EXP ANIM TOKYO, V61, P77; Macheleidt O, 2002, J INVEST DERMATOL, V119, P166, DOI 10.1046/j.1523-1747.2002.01833.x; Byrdwell WC, 2007, J CHROMATOGR A, V1146, P164, DOI 10.1016/j.chroma.2007.01.108; Haruta-Ono Y, 2012, J DERMATOL SCI, V68, P56, DOI 10.1016/j.jdermsci.2012.07.006; Masukawa Y, 2009, J LIPID RES, V50, P1708, DOI 10.1194/jlr.D800055-JLR200; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; NILSSON A, 1969, BIOCHIM BIOPHYS ACTA, V187, P113, DOI 10.1016/0005-2760(69)90138-6; Tamagawa-Mineoka R, 2009, CLIN IMMUNOL, V131, P495, DOI 10.1016/j.clim.2009.01.006; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Alysandratos KD, 2010, ANN ALLERG ASTHMA IM, V105, P403, DOI 10.1016/j.anai.2010.09.017; BROD J, 1991, INT J DERMATOL, V30, P84, DOI 10.1111/j.1365-4362.1991.tb04216.x; Duan JJ, 2012, EXP DERMATOL, V21, P448, DOI 10.1111/j.1600-0625.2012.01501.x; Jin HL, 2009, J INVEST DERMATOL, V129, P31, DOI 10.1038/jid.2008.106; SCHMELZ EM, 1994, J NUTR, V124, P702; SCHURER NY, 1991, ADV LIPID RES, V24, P27; HANNUN YA, 1989, CLIN CHIM ACTA, V185, P333, DOI 10.1016/0009-8981(89)90224-6; Fujii M, 2013, EXP DERMATOL, V22, P272, DOI 10.1111/exd.12120; ELIAS PM, 1991, ADV LIPID RES, V24, P1; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; NILSSON A, 1968, BIOCHIM BIOPHYS ACTA, V164, P575, DOI 10.1016/0005-2760(68)90187-2; Oba C, 2013, PHOTODERMATOL PHOTO, V29, P204, DOI 10.1111/phpp.12051; Kim H, 2012, NUTR RES, V32, P956, DOI 10.1016/j.nutres.2012.09.006; Behne M, 2000, J INVEST DERMATOL, V114, P185, DOI 10.1046/j.1523-1747.2000.00846.x; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Haruta Y, 2008, BIOSCI BIOTECH BIOCH, V72, P2151, DOI 10.1271/bbb.80212; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Fujii M, 2005, EXP DERMATOL, V14, P460, DOI 10.1111/j.0906-6705.2005.00313.x; Ishikawa J, 2010, J INVEST DERMATOL, V130, P2511, DOI 10.1038/jid.2010.161; Bouwstra JA, 2002, J INVEST DERMATOL, V118, P606, DOI 10.1046/j.1523-1747.2002.01706.x; Duan JJ, 2011, LIPIDS, V46, P505, DOI 10.1007/s11745-010-3518-9; Fujii M, 2007, J PHARMACOL SCI, V104, P243, DOI 10.1254/jphs.FP0070436; GUPTA AK, 1988, J INVEST DERMATOL, V91, P486, DOI 10.1111/1523-1747.ep12476635; Hasegawa T, 2011, LIPIDS, V46, P529, DOI 10.1007/s11745-011-3546-0; Kim J, 2013, J MED FOOD, V16, P927, DOI 10.1089/jmf.2012.2734; Meguro S, 2000, ARCH DERMATOL RES, V292, P463, DOI 10.1007/s004030000160; Shimada E, 2011, J OLEO SCI, V60, P321, DOI 10.5650/jos.60.321; Takagi Y, 2004, J INVEST DERMATOL, V123, P1102, DOI 10.1111/j.0022-202X.2004.23491.x; Tsuji K, 2006, J DERMATOL SCI, V44, P101, DOI 10.1016/j.jdermsci.2006.08.005	40	2	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0923-1811	1873-569X		J DERMATOL SCI	J. Dermatol. Sci.	JUN	2015	78	3					224	231		10.1016/j.jdermsci.2015.02.017		8	Dermatology	Dermatology	CI8KT	WOS:000355021900008		
J	Ishii, T; Kobayashi, N; Maeda, A; Kondo, H; Sako, K; Yamada, S; Kagawa, Y				Ishii, Takuya; Kobayashi, Naoki; Maeda, Atsushi; Kondo, Hiromu; Sako, Kazuhiro; Yamada, Shizuo; Kagawa, Yoshiyuki			Absorption improvement of sepantronium bromide (YM155) by aminoalkyl methacrylate copolymers in in situ intestinal tracts of mice	JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY			English	Article						Sepantronium bromide (YM155); Aminoalkyl methacrylate copolymer (Eudragit (R) E); Absorption improvement; Poorly absorbed compounds; Oral formulation; Mucin	MOLECULE SURVIVIN SUPPRESSANT; ABSORBED HYDROPHILIC COMPOUNDS; CACO-2 CELL MONOLAYERS; ANTITUMOR-ACTIVITY; DRUG ABSORPTION; ENHANCERS; BIOAVAILABILITY; COMBINATION; FORMULATION; PERMEATION	Sepantronium bromide (YM155) is a small molecule suppressant of survivin with time-dependent antitumor activity. In Phase II trials, the dosage form is a parenteral solution for continuous intravenous administration for 7 days. Although an oral YM155 formulation is required to improve patient convenience, oral bioavailability is low due to poor membrane permeability. Plasma concentrations of YM155 were significantly increased in intestinal loops pre-washed with phosphate buffered saline (p < 0.05). In addition, plasma concentrations of YM155 significantly decreased in the presence of mucin, which is a typical anionic substance in the intestinal tract (p < 0.05). Freeze-dried powder of aminoalkyl methacrylate copolymer (Eudragit (R) E) with HCI (E-FD) improved YM155 absorption in mice. In addition, E-FD suppressed the interaction between YM155 and mucin. These results suggest that E-FD improves YM155 absorption by reducing the interaction between YM155 and mucin. E-FD is therefore a promising candidate as an absorption-improving agent for the development of oral formulations of YM155. (C) 2015 Elsevier B.V. All rights reserved.	[Ishii, Takuya; Kobayashi, Naoki; Maeda, Atsushi; Kondo, Hiromu; Sako, Kazuhiro] Astellas Pharma Inc, Pharmaceut Res & Technol Labs, Yaizu, Shizuoka 4250072, Japan; [Yamada, Shizuo] Univ Shizuoka, Grad Sch Pharmaceut Sci, Ctr Pharma Food Res, Suruga Ku, Shizuoka 4228526, Japan; [Ishii, Takuya; Kagawa, Yoshiyuki] Univ Shizuoka, Sch Pharmaceut Sci, Dept Clin Pharmaceut, Suruga Ku, Shizuoka 4228526, Japan	Ishii, T (reprint author), Astellas Pharma Inc, Pharmaceut Res & Technol Labs, 180 Ozumi, Yaizu, Shizuoka 4250072, Japan.	takuya.ishii@astellas.com					Iwai M, 2011, DRUG METAB DISPOS, V39, P2314, DOI 10.1124/dmd.111.040733; Dai WG, 2013, INT J PHARMACEUT, V457, P63, DOI 10.1016/j.ijpharm.2013.07.066; Aungst BJ, 2000, J PHARM SCI, V89, P429, DOI 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J; Kita A, 2011, LEUKEMIA RES, V35, P787, DOI 10.1016/j.leukres.2010.11.016; Giaccone G, 2009, J CLIN ONCOL, V27, P4481, DOI 10.1200/JCO.2008.21.1862; Lewis KD, 2011, INVEST NEW DRUG, V29, P161, DOI 10.1007/s10637-009-9333-6; Satoh T, 2009, CLIN CANCER RES, V15, P3872, DOI 10.1158/1078-0432.CCR-08-1946; Nakahara T, 2007, CANCER RES, V67, P8014, DOI 10.1158/0008-5472.CAN-07-1343; Dressman JB, 1998, PHARMACEUT RES, V15, P11, DOI 10.1023/A:1011984216775; Morishita M, 2007, J CONTROL RELEASE, V118, P177, DOI 10.1016/j.jconrel.2006.12.022; Takatsuka S, 2006, EUR J PHARM BIOPHARM, V62, P52, DOI 10.1016/j.ejpb.2005.07.008; Tolcher AW, 2008, J CLIN ONCOL, V26, P5198, DOI 10.1200/JCO.2008.17.2064; LINDMARK T, 1995, J PHARMACOL EXP THER, V275, P958; Yamanaka K, 2011, CLIN CANCER RES, V17, P5423, DOI 10.1158/1078-0432.CCR-10-3410; Kamei N, 2009, J CONTROL RELEASE, V136, P179, DOI 10.1016/j.jconrel.2009.02.015; Leone-Bay A, 1998, J CONTROL RELEASE, V50, P41, DOI 10.1016/S0168-3659(97)00101-6; Iwasa T, 2010, BRIT J CANCER, V103, P36, DOI 10.1038/sj.bjc.6605713; Kita A, 2012, J PHARMACOL EXP THER, V343, P178, DOI 10.1124/jpet.112.195925; Yamamoto A, 1996, J PHARM PHARMACOL, V48, P1285; Jantratid E, 2008, PHARM RES-DORDR, V25, P1663, DOI 10.1007/s11095-008-9569-4; Eisele J, 2011, REGUL TOXICOL PHARM, V61, P32, DOI 10.1016/j.yrtph.2011.05.012; Lee V. H. L., 1990, ADV DRUG DELIV REV, V4, P171; MACADAM A, 1993, ADV DRUG DELIVER REV, V11, P201, DOI 10.1016/0169-409X(93)90010-2; Minematsu T, 2008, BIOMED CHROMATOGR, V22, P763, DOI 10.1002/bmc.996; Nakahara T, 2011, ANTI-CANCER DRUG, V22, P454, DOI 10.1097/CAD.0b013e328344ac68; Perez de la Cruz Moreno M, 2006, J PHARM PHARMACOL, V58, P1079, DOI DOI 10.1211/JPP.58.8.0009; Shah P, 2008, DRUG DEV IND PHARM, V34, P279, DOI 10.1080/03639040701655952 ; Takemura S, 2012, J PHARM SCI-US, V101, P2134, DOI 10.1002/jps.23116; Takemura S, 2013, J PHARM SCI-US, V102, P3128, DOI 10.1002/jps.23484; Ward P. D., 2000, PHARM SCI TECHNOL TO, V3, P346, DOI 10.1016/S1461-5347(00)00302-3; Yoshida T, 2012, INT J PHARMACEUT, V428, P18, DOI 10.1016/j.ijpharm.2012.02.041; Zornoza T, 2004, EUR J PHARM SCI, V22, P347, DOI 10.1016/j.ejps.2004.04.004	32	0	0	EDITIONS SANTE	PARIS	47 RUE GALILEE, 75116 PARIS, FRANCE	1773-2247			J DRUG DELIV SCI TEC	J. Drug Deliv. Sci. Technol.	JUN	2015	27						1	8		10.1016/j.jddst.2015.03.002		8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3BS	WOS:000355359000001		
J	Nagai, K; Ushio, T; Miura, H; Moribe, K; Yamamoto, K				Nagai, Keiko; Ushio, Takanori; Miura, Hidenori; Moribe, Kunikazu; Yamamoto, Keiji			Effect of enantiotropic uniformity of polymorphic crystals on the chemical stability of suplatast tosilate	JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY			English	Article						Suplatast tosilate; Polymorph; Preferential enrichment; Chemical stability; Enantiomer excess; Solid solution	MIXED-CRYSTALS; PREFERENTIAL ENRICHMENT; RACEMIC COMPOUND; DOSAGE FORMS; PREFORMULATION; ENANTIOMERS; TRANSITION; CRYSTALLIZATION; PHARMACEUTICS	The chemical stability of suplatast tosilate (ST) was evaluated under dry conditions at 60 degrees C, with a focus on the polymorphic forms and crystal uniformity. The intact alpha-form, namely alpha-C type crystals, was crystallized rapidly by adding isopropyl ether into an ethanolic solution of ST. The alpha-C type crystals exhibited low stability at 60 degrees C. In addition to the alpha-C type crystals, two types of alpha-form crystals with different uniformities, namely alpha-A and alpha-B type crystals, were prepared. The alpha-A type crystals were prepared by conversion from the eta-form in aqueous acetone, while the alpha-B type crystals were prepared by recrystallization from 2-propanol at a low supersaturation level. The stability of the alpha-form crystals was as follows: alpha-A > alpha-B > alpha-C. The uniformity of ST crystals was determined according to the newly developed high performance liquid chromatography (HPLC) method. The alpha-C type crystals exhibited inferior chemical stability due to unstable crystalline phases. They showed preferential enrichment and exhibited a unique optical resolution phenomenon. The observed unstable crystalline phases were produced during the crystallization process. alpha-A type crystals, which had high regularity, exhibited excellent stability. Overall, we prepared and evaluated the structures of alpha-form crystals with different uniformities. (C) 2015 Elsevier B.V. All rights reserved.	[Nagai, Keiko] Taiho Pharmaceut Co Ltd, Analyt Sci Lab, Kawaguchi, Tokushima 7710194, Japan; [Ushio, Takanori] Ace Japan Co Ltd, Yamagata 9993701, Japan; [Miura, Hidenori] Taiho Pharmaceut Co Ltd, Chem Technol Lab, Kamikawa, Saitama 3670241, Japan; [Nagai, Keiko; Moribe, Kunikazu; Yamamoto, Keiji] Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan	Nagai, K (reprint author), Taiho Pharmaceut Co Ltd, Analyt Sci Lab, Kawaguchi, Tokushima 7710194, Japan.	kei-nagai@taiho.co.jp					Thirunahari S, 2010, J PHARM SCI-US, V99, P2975, DOI 10.1002/jps.22061; Tamura R, 2002, J AM CHEM SOC, V124, P13139, DOI 10.1021/ja020454r; Brittain HG, 2012, J PHARM SCI-US, V101, P464, DOI 10.1002/jps.22788; Chrzanowski F, 2008, AAPS PHARMSCITECH, V9, P639, DOI 10.1208/s12249-008-9067-3; Elliel E.L., 1994, STEREOCHEMISTRY ORGA, P159; Grunenberg A, 1996, INT J PHARMACEUT, V129, P147, DOI 10.1016/0378-5173(95)04283-0; Haget Y, 1999, J APPL CRYSTALLOGR, V32, P481, DOI 10.1107/S0021889899002423; Jacque J., 1981, ENANTIOMERS RACEMATE, P104; Jones W., 1997, ORGANIC MOL SOLIDS P; Kawakami K, 2007, J PHARM SCI-US, V96, P982, DOI 10.1002/jps.20748; KURODA R, 1981, J CHEM SOC DALTON, P1268, DOI 10.1039/dt9810001268; Mastuoka M., 1985, J CRYST GROWTH, V73, P563; Miura H, 2003, CRYST GROWTH DES, V3, P959, DOI 10.1021/cg034051u; Nagai K, 2014, INT J PHARMACEUT, V460, P83, DOI 10.1016/j.ijpharm.2013.10.049; Raijada DK, 2010, J PHARMACEUT BIOMED, V52, P332, DOI 10.1016/j.jpba.2009.05.001; Takahashi H, 2001, ENANTIOMER, V6, P57; Tamura R, 2010, SYMMETRY-BASEL, V2, P112, DOI 10.3390/sym2010112; USHIO T, 1994, J CHROMATOGR A, V684, P235, DOI 10.1016/0021-9673(94)00584-2; Ushio T, 1996, MOL CRYST LIQ CRYS A, V276, P245, DOI 10.1080/10587259608039383; Ushio T, 1996, ANGEW CHEM INT EDIT, V35, P2372, DOI 10.1002/anie.199623721; Yamamoto K, 2011, CHEM PHARM BULL, V59, P147, DOI 10.1248/cpb.59.147	21	0	0	EDITIONS SANTE	PARIS	47 RUE GALILEE, 75116 PARIS, FRANCE	1773-2247			J DRUG DELIV SCI TEC	J. Drug Deliv. Sci. Technol.	JUN	2015	27						37	45		10.1016/j.jddst.2015.04.004		9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CJ3BS	WOS:000355359000005		
J	Jiang, T; Xie, XN; Chen, H; Wang, ZF; Li, XS				Jiang, Tao; Xie, Xinong; Chen, Hui; Wang, Zhenfeng; Li, Xushen			Geochemistry of Pore Water and Associated Diagenetic Reactions in the Diapiric Area of Yinggehai Basin, Northwestern South China Sea	JOURNAL OF EARTH SCIENCE			English	Article						pore water; diagenetic reaction; clay mineral transformation; overpressured system; Yinggehai Basin	FRIO FORMATION OLIGOCENE; SALINE FORMATION WATERS; SEDIMENTARY BASINS; GULF-COAST; GAS-FIELD; MIGRATION; LOUISIANA; CHEMISTRY; FLUIDS; TRANSPORT	This study examined the geochemical features of pore water in the diapiric area of the Yinggehai Basin, northwestern South China Sea, and illuminated the origin and evolution of basin fluids. Pore water with low salinity occurs in marine sediments in the diapiric area even without meteoric water infiltration. The presence of low-salinity water within deep, overpressured compartments is assumed to be due to smectite-illite transformation. Howerver, in shallow portions (less than 2 000 m) of diapiric areas with normal pressure, pore water has a much wider variation and much lower salinity than that in the overpressured intervals. Its total dissolved solid (TDS) content is similar to 5 336 to 35 939 mg/L. Moreover, smectite and chlorite content sharply decreases as kaolinite and illite content increase in shallower intervals. The geochemical variation of pore water in diapiric structures indicates the expulsion of low-salinity, overpressured fluids along vertical faults. Strong injection of hot fluids from deep overpressured sediments results in rapid clay mineral transformation in shallow reservoirs. Consequently, fluid mixing due to fluid expulsion from deeper overpressured deposits leads to variation in salinity and ionic composition as well as some diagenetic reactions. This includes transformation of clay minerals caused by the higher temperatur of deeper hot fluids, e.g., the transfromation of smectite to ante and chlorite to kaolinite. Therefore, variations in salinity and ionic compositions in various pressured systems provide a clue to flow pathways and associated diagenetic reactions.	[Jiang, Tao; Xie, Xinong; Chen, Hui] China Univ Geosci, Minist Educ, Key Lab Tecton & Petr Resources, Wuhan 430074, Peoples R China; [Jiang, Tao] Japan Agcy Marine Earth Sci & Technol, Kochi Inst Core Sample Res, Kochi 7838502, Japan; [Wang, Zhenfeng; Li, Xushen] China Natl Offshore Oil Zhanjiang Ltd Corp, Zhanjiang 524057, Peoples R China	Jiang, T (reprint author), China Univ Geosci, Minist Educ, Key Lab Tecton & Petr Resources, Wuhan 430074, Peoples R China.	taojiang@cug.edu.cn			National Natural Science Foundation of China [91028009, 41476032, 40806019]; Special Foundation for State Major Basic Research Program of China [2011ZX05025-0020-020-03]	This study was a contribution to the projects the National Natural Science Foundation of China (Nos. 91028009, 41476032 and 40806019) and the Special Foundation for State Major Basic Research Program of China (No. 2011ZX05025-0020-020-03). We kindly appreciate the Zhanjiang Branch of China National Offshore Oil Corporation for providing precious geological data.	Huang BJ, 2002, MAR PETROL GEOL, V19, P861, DOI 10.1016/S0264-8172(02)00109-5; Cai CF, 2001, APPL GEOCHEM, V16, P1269, DOI 10.1016/S0883-2927(01)00006-3; Xie XN, 2001, MAR PETROL GEOL, V18, P715, DOI 10.1016/S0264-8172(01)00024-1; Wilkinson M, 1997, AAPG BULL, V81, P803; Li ST, 1999, CHINESE SCI BULL, V44, P10; Seewald JS, 2003, NATURE, V426, P327, DOI 10.1038/nature02132; Petschick R, 1996, MAR GEOL, V130, P203, DOI 10.1016/0025-3227(95)00148-4; Losh S, 2002, AAPG BULL, V86, P1463; Hao F, 2000, AAPG BULL, V84, P607; LAND LS, 1992, AAPG BULL, V76, P1344; Xie X, 2003, GEOFLUIDS, V3, P245, DOI 10.1046/j.1468-8123.2003.00070.x; BJORLYKKE K, 1993, SEDIMENT GEOL, V86, P137, DOI 10.1016/0037-0738(93)90137-T; Lei C, 2011, MAR PETROL GEOL, V28, P980, DOI 10.1016/j.marpetgeo.2011.01.001; Burley S. D., 1992, SOC SEDIMENTARY GEOL, V47, P81; CHEN PPH, 1993, AAPG BULL, V77, P842; DICKEY PA, 1972, AM ASSOC PETR GEOL B, V56, P1530; Gong Z., 1997, CONTINENTAL MARGIN B, P193; Gonzalez F., 2011, 1 BREAK, V29, P51, DOI 10.3997/1365-2397.2011029; HANOR JS, 1987, NATURE, V327, P501, DOI 10.1038/327501a0; Hanor JS, 2001, GEOCHIM COSMOCHIM AC, V65, P3721, DOI 10.1016/S0016-7037(01)00703-7; Huang BJ, 2003, ORG GEOCHEM, V34, P1009, DOI 10.1016/S0146-6380(03)00036-6; Karsten M., 2002, MAR PETROL GEOL, V19, P289, DOI [10.1016/S0264-8172(02)00018-1, DOI 10.1016/S0264-8172(02)00018-1]; LAND LS, 1995, GEOCHIM COSMOCHIM AC, V59, P2163, DOI 10.1016/0016-7037(95)00098-K; Lin G. C., 1997, GULF COAST ASS GEOLO, V47, P419; 吕明, 1999, [天然气工业, Natural Gas Industry], V19, P20; Meng F. J., 2012, ACTA SEDIMENTOLOGICA, V30, P29; MOLDOVANYI EP, 1992, AAPG BULL, V76, P864; MORTON RA, 1987, AAPG BULL, V71, P191; Muggeridge A, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002922; Parnell J, 2002, GEOFLUIDS, V2, P57, DOI 10.1046/j.1468-8123.2002.00035.x; RU K, 1986, AAPG BULL, V70, P1136; Wan ZF, 2012, J EARTH SCI-CHINA, V23, P359, DOI 10.1007/s12583-012-0256-3; Xu H, 2012, J EARTH SCI-CHINA, V23, P828, DOI 10.1007/s12583-012-0293-y	33	0	0	CHINA UNIV GEOSCIENCES	BEIJING	29 XUEYUAN RD, BEIJING, 100083, PEOPLES R CHINA	1674-487X	1867-111X		J EARTH SCI-CHINA	J. Earth Sci.	JUN	2015	26	3					306	316		10.1007/s12583-015-0526-y		11	Geosciences, Multidisciplinary	Geology	CJ4ZZ	WOS:000355498500002		
J	Kadoi, Y; Saito, S				Kadoi, Yuji; Saito, Shigeru			Effects of Adding Remifentanil to Propofol Anesthesia on Systemic Hemodynamics, Cardiac Output, and Middle Cerebral Artery Flow Velocity During Electroconvulsive Therapy A Pilot Study	JOURNAL OF ECT			English	Article						remifentanil; cardiac output; electroconvulsive therapy; cerebral blood flow	SEIZURE DURATION; RESPONSES	Purpose: The purpose of this study was to examine the effects of adding remifentanil to propofol anesthesia on systemic hemodynamics, cardiac output, and middle cerebral artery (MCA) blood flow velocity during electroconvulsive therapy (ECT). Methods: Twelve patients undergoing ECT were enrolled in this study. The patients received anesthesia by one of the following 2 methods: either propofol alone at a dose of 1.0 mg/kg, or propofol 0.75 mg/kg with remifentanil 1.0 mu g/kg in turn during successive ECT sessions, immediately before the administration of succinylcholine. All patients were monitored for blood pressure, heart rate, cardiac output, and MCA flow velocity by transcranial Doppler sonography. Results: Middle cerebral artery flow velocity increased after ECT in both anesthesia method groups and lasted for 2 minutes after ECT. No difference in MCA flow velocity was observed between the 2 methods at any time point. Seizure duration was longer under propofol with remifentanil than under propofol alone [propofol with remifentanil, 32 (3) seconds; propofol alone, 24 (4) seconds; P < 0.01]. In contrast, no difference in time to awakening (time from the ECT stimulus to the patient's ability to open eyes) was observed between the 2 groups [propofol with remifentanil, 183 (19) seconds; propofol alone, 185 (21) seconds]. Conclusions: The addition of remifentanil (1 mu g/kg) is suitable for reduction of the propofol dose during ECT, without any adverse hemodynamic effects, including on cerebral blood flow.	[Kadoi, Yuji; Saito, Shigeru] Gunma Univ Hosp, Dept Anesthesiol, Maebashi, Gunma 3718511, Japan	Kadoi, Y (reprint author), Gunma Univ Hosp, Dept Anesthesiol, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan.	kadoi@gunma-u.ac.jp			Japanese Ministry of Education, Culture, Sports, Science and Technology	This study was supported in part by grants to Dr Kadoi from the Japanese Ministry of Education, Culture, Sports, Science and Technology.	FREDMAN B, 1994, ANESTH ANALG, V79, P75; AVRAMOV MN, 1995, ANESTH ANALG, V81, P596, DOI 10.1097/00000539-199509000-00031; Chen ST, 2011, J ECT, V27, P323, DOI 10.1097/YCT.0b013e31821072d2; FEAR CF, 1994, BRIT J PSYCHIAT, V165, P506, DOI 10.1192/bjp.165.4.506; Kadoi Y, 2014, J ECT, V30, P224, DOI 10.1097/YCT.0000000000000089; Kadoi Y, 2009, CURR PSYCHIAT REV, V5, P276; Nasseri K, 2009, J ECT, V25, P170, DOI 10.1097/YCT.0b013e318199f767; Nishikawa K, 2011, J ANESTH, V25, P29, DOI 10.1007/s00540-010-1049-4; Porter R, 2008, J ECT, V24, P203, DOI 10.1097/YCT.0b013e3181662ca0; Recart A, 2003, ANESTH ANALG, V96, P1047, DOI 10.1213/01.ANE.0000054002.65040.B3; Sienaert P, 2004, J ECT, V20, P130, DOI 10.1097/00124509-200406000-00012; Vishne T, 2005, J ECT, V21, P235, DOI 10.1097/01.yct.0000180040.06338.ac	12	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1095-0680	1533-4112		J ECT	J. ECT	JUN	2015	31	2					98	100		10.1097/YCT.0000000000000202		3	Behavioral Sciences; Psychiatry	Behavioral Sciences; Psychiatry	CI8AA	WOS:000354988100016		
J	Kameda, T; Oba, J; Yoshioka, T				Kameda, Tomohito; Oba, Jumpei; Yoshioka, Toshiaki			Kinetics and equilibrium studies on Mg-Al oxide for removal of fluoride in aqueous solution and its use in recycling	JOURNAL OF ENVIRONMENTAL MANAGEMENT			English	Article						Mg-Al oxide; Recycling; Fluoride; Removal; Kinetics; Equilibrium	LAYERED DOUBLE HYDROXIDES; MAGNESIUM-ALUMINUM OXIDE; COATED DIALDEHYDE CELLULOSE; HYDROCHLORIC-ACID; UREA NITROGEN; ADSORPTION; PYROAURITE; SORPTION; ZEOLITE; MODEL	Mg-Al oxide obtained by the thermal decomposition of Mg-Al layered double hydroxide (LDH) intercalated with CO32- (CO3 center dot Mg-Al LDH) was found to take up fluoride from aqueous solution. Fluoride was removed by rehydration of Mg-Al oxide accompanied by combination with F-. Using five times the stoichiometric quantity of Mg-Al oxide, the residual concentration of F was decreased from 100 to 6.3 mg/L in 480 min, which was below the effluent standard in Japan (8 mg/L). Removal of F- can be represented by pseudo-second-order reaction kinetics. The apparent rate constants at 10 degrees C, 30 degrees C, and 60 degrees C were 23 x 10(-3), 2.2 x 10(-2), and 2.5 x 10(-1) g mmol(-1) min(-1), respectively. The apparent activation energy was 73.3 kJ mol(-1). The rate-determining step for F removal by Mg-Al oxide was consistent with chemical adsorption involving intercalation of F- into the reconstructed Mg-Al LDH due to electrostatic attraction. The adsorption of F by Mg-Al oxide follows a Langmuir-type adsorption. The values of the maximum adsorption and the equilibrium adsorption constant were 3.0 mmol g(-1) and 1.1 x 10(3), respectively, for Mg-Al oxide. The F- in the F center dot Mg-Al LDH thus produced was found to be anion-exchanged with CO32- in solution. The Mg-Al oxide after regeneration treatment had excellent properties for removal of F in aqueous solution. In conclusion, the results of this study indicated that Mg-Al oxide has potential for use in recycling to remove F in aqueous solution. (C) 2015 Elsevier Ltd. All rights reserved.	[Kameda, Tomohito; Oba, Jumpei; Yoshioka, Toshiaki] Tohoku Univ, Grad Sch Environm Studies, Aoba Ku, Sendai, Miyagi 9808579, Japan	Kameda, T (reprint author), Tohoku Univ, Grad Sch Environm Studies, Aoba Ku, 6-6-07 Aoba, Sendai, Miyagi 9808579, Japan.	kameda@env.che.tohoku.ac.jp			Environment Research and Technology Development Fund of the Ministry of Environment, Japan [5RFb-1201]	This research was supported by the Environment Research and Technology Development Fund (5RFb-1201) of the Ministry of Environment, Japan.	ALLMANN R, 1968, ACTA CRYSTALL B-STRU, VB 24, P972, DOI 10.1107/S0567740868003511; Lv L, 2006, J HAZARD MATER, V133, P119, DOI 10.1016/j.jhazmat.2005.10.012; Zou WH, 2006, COLLOID SURFACE A, V279, P238, DOI 10.1016/j.colsurfa.2006.01.008; [Anonymous], 2000, CHEM LETT 1005; INGRAM L, 1967, MINERAL MAG J M SOC, V36, P465, DOI 10.1180/minmag.1967.036.280.01; Wu FC, 2009, CHEM ENG J, V151, P1, DOI 10.1016/j.cej.2009.02.024; Kragovic M, 2013, APPL SURF SCI, V283, P764, DOI 10.1016/j.apsusc.2013.07.016; Liang ZP, 2005, PROCESS BIOCHEM, V40, P3218, DOI 10.1016/j.procbio.2005.03.041; Kameda T, 2003, WATER RES, V37, P1545, DOI 10.1016/S0043-1354(02)00374-3; Carriazo D, 2007, APPL CLAY SCI, V37, P231, DOI 10.1016/j.clay.2007.01.006; Ho YS, 2006, J HAZARD MATER, V136, P681, DOI 10.1016/j.jhazmat.2005.12.043; Yoshioka T, 2007, FRESEN ENVIRON BULL, V16, P928; Mills SJ, 2012, MINERAL MAG, V76, P1289, DOI 10.1180/minmag.2012.076.5.10; Geraud E, 2007, J PHYS CHEM SOLIDS, V68, P818, DOI 10.1016/j.jpcs.2007.02.053; Aksu Z, 2002, PROCESS BIOCHEM, V38, P89, DOI 10.1016/S0032-9592(02)00051-1; Kameda T, 2006, SEP PURIF TECHNOL, V51, P272, DOI 10.1016/j.seppur.2006.02.008; Cavani F, 1991, CATAL TODAY, V11, P173, DOI 10.1016/0920-5861(91)80068-K; Bhatnagar A, 2011, CHEM ENG J, V171, P811, DOI 10.1016/j.cej.2011.05.028; Kameda T, 2002, B CHEM SOC JPN, V75, P595, DOI 10.1246/bcsj.75.595; Liang ZP, 2005, BIOCHEM ENG J, V24, P65, DOI 10.1016/j.bej.2005.02.005; Hosni K, 2008, INORG MATER+, V44, P742, DOI 10.1134/S0020168508070121; Kameda T, 2011, J COLLOID INTERF SCI, V362, P497, DOI 10.1016/j.jcis.2011.06.065; Kameda T, 2012, J ENVIRON SCI HEAL A, V47, P711, DOI 10.1080/10934529.2012.660080; Lv L, 2006, IND ENG CHEM RES, V45, P8623, DOI 10.1021/ie050363d; Ho YS, 1999, PROCESS BIOCHEM, V34, P451, DOI 10.1016/S0032-9592(98)00112-5	25	0	0	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0301-4797	1095-8630		J ENVIRON MANAGE	J. Environ. Manage.	JUN 1	2015	156						252	256		10.1016/j.jenvman.2015.03.043		5	Environmental Sciences	Environmental Sciences & Ecology	CI8QL	WOS:000355036700028		
J	Yarnpakdee, S; Benjakul, S; Kristinsson, HG; Kishimura, H				Yarnpakdee, Suthasinee; Benjakul, Soottawat; Kristinsson, Hordur G.; Kishimura, Hideki			Antioxidant and sensory properties of protein hydrolysate derived from Nile tilapia (Oreochromis niloticus) by one- and two-step hydrolysis	JOURNAL OF FOOD SCIENCE AND TECHNOLOGY-MYSORE			English	Article						Antioxidant activity; Protein hydrolysate; Nile tilapia; Two-step hydrolysis; Commercial proteases	FUNCTIONAL-PROPERTIES; CHEMICAL-COMPOSITIONS; COMMERCIAL PROTEASES; ENZYMATIC-HYDROLYSIS; REDUCING ABILITY; PEPTIDES; MUSCLE; PURIFICATION; FLAVOURZYME; ALCALASE	Antioxidant and sensory properties of Nile tilapia protein hydrolysates prepared by one-and two-step hydrolysis using commercial proteases were investigated. Hydrolysates prepared using single protease including Alcalase (HA), Flavourzyme (HF), Protamex (HPr) and papain (HPa) had increases in antioxidant activities as the degree of hydrolysis (DH) increased up to 40 % (P<0.05). Amongst all hydrolysates, HA having 40 % DH showed the highest antioxidant activities. When HA was further hydrolysed by papain, the resulting hydrolysate (HAPa) exhibited the highest antioxidant activities for all assays tested (P<0.05). ABTS radical scavenging activity and metal chelating of HAPa generally remained constant in a wide pH range (1-11) and during heating at 30-100 degrees C. Both activities increased in the simulated gastrointestinal tract model system, especially in intestine condition. HAPa (100-1,000 ppm) could retard lipid oxidation in beta-carotene-linoleate and lecithin-liposome model systems in a dose dependent manner. Peptides in both HA and HAPa with molecular weight of 513 Da and 1,484 Da possessed the strongest ABTS radical scavenging activity and metal chelating activity, respectively. The amino acid profile of both HA and HAPa contained a high amount of hydrophobic amino acids (38.26-38.85 %) and had glutamic acid/glutamine, lysine and aspartic acid/asparagine as the dominant amino acids. However, HAPa showed a higher acceptability than did HA, owing to the lower bitterness. Therefore, the use of Alcalase in combination with papain for hydrolysis of protein isolate rendered the hydrolysate with antioxidant properties and reduced bitterness, which could serve as the functional supplement.	[Yarnpakdee, Suthasinee; Benjakul, Soottawat] Prince Songkla Univ, Fac Agroind, Dept Food Technol, Hat Yai 90112, Songkhla, Thailand; [Kristinsson, Hordur G.] Matis Iceland Food & Biotechnol R&D, IS-113 Reykjavik, Iceland; [Kristinsson, Hordur G.] Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA; [Kishimura, Hideki] Hokkaido Univ, Res Fac Fisheries Sci, Lab Marine Prod & Food Sci, Hakodate, Hokkaido 0418611, Japan	Benjakul, S (reprint author), Prince Songkla Univ, Fac Agroind, Dept Food Technol, Hat Yai 90112, Songkhla, Thailand.	soottawat.b@psu.ac.th			Thailand Research Fund under Royal Golden Jubilee Ph.D. Program [PHD/0226/2552]; Graduate School, Prince of Songkla University, Thailand; TRF senior research scholar program	This research was supported by the Thailand Research Fund under the Royal Golden Jubilee Ph.D. Program to SuthasineeYarnpakdee (PHD/0226/2552) and the Grant-in-Aid for dissertation from Graduate School, Prince of Songkla University, Thailand. TRF senior research scholar program was also acknowledged for financial support.	Liaset B, 2000, J SCI FOOD AGR, V80, P581, DOI 10.1002/(SICI)1097-0010(200004)80:5<581::AID-JSFA578>3.3.CO;2-9; Wu HC, 2003, FOOD RES INT, V36, P949, DOI 10.1016/S0963-9969(03)00104-2; Tavano OL, 2013, J MOL CATAL B-ENZYM, V90, P1, DOI 10.1016/j.molcatb.2013.01.011; You LJ, 2010, FOOD CHEM, V120, P810, DOI 10.1016/j.foodchem.2009.11.018; Je JY, 2009, FOOD RES INT, V42, P1266, DOI 10.1016/j.foodres.2009.06.013; Raghavan S, 2008, J AGR FOOD CHEM, V56, P10359, DOI 10.1021/jf8017194; Suetsuna K, 2000, J NUTR BIOCHEM, V11, P128, DOI 10.1016/S0955-2863(99)00083-2; Thiansilakul Y, 2007, J FOOD BIOCHEM, V31, P266, DOI 10.1111/j.1745-4514.2007.00111.x; Klompong V, 2008, INT J FOOD SCI TECH, V43, P1019, DOI 10.1111/j.1365-2621.2007.01555.x; Foh MBK, 2010, INT J MOL SCI, V11, P1851, DOI 10.3390/ijms11041851; Decker EA, 2005, J AGR FOOD CHEM, V53, P4303, DOI 10.1021/jf058012x; Bougatef A, 2010, FOOD CHEM, V118, P559, DOI 10.1016/j.foodchem.2009.05.021; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Rajapakse N, 2005, J NUTR BIOCHEM, V16, P562, DOI 10.1016/j.jnutbio.2005.02.005; Jun SY, 2004, EUR FOOD RES TECHNOL, V219, P20, DOI 10.1007/s00217-004-0882-9; Klompong V, 2009, J FOOD SCI, V74, pC126, DOI 10.1111/j.1750-3841.2009.01047.x; Benjakul S, 1997, J AGR FOOD CHEM, V45, P3423, DOI 10.1021/jf970294g; Binsan W, 2008, FOOD CHEM, V106, P185, DOI 10.1016/j.foodchem.2007.05.065; Theodore AE, 2008, J AGR FOOD CHEM, V56, P7459, DOI 10.1021/jf800185f; Khantaphant S, 2011, PROCESS BIOCHEM, V46, P318, DOI 10.1016/j.procbio.2010.09.005; Khantaphant S, 2011, LWT-FOOD SCI TECHNOL, V44, P1139, DOI 10.1016/j.lwt.2010.10.009; Kim SK, 2001, J AGR FOOD CHEM, V49, P1984, DOI 10.1021/jf000494j; Thiansilakul Y, 2007, FOOD CHEM, V103, P1385, DOI 10.1016/j.foodchem.2006.10.055; Yarnpakdee S, 2014, FOOD CHEM, V142, P210, DOI 10.1016/j.foodchem.2013.07.043; Nalinanon S, 2011, FOOD CHEM, V124, P1354, DOI 10.1016/j.foodchem.2010.07.089; Buege J A, 1978, Methods Enzymol, V52, P302; Chandrasekara A, 2010, J AGR FOOD CHEM, V59, P428; FitzGerald RJ, 2006, BIOTECHNOL ADV, V24, P234, DOI 10.1016/j.biotechadv.2005.11.002; Frankel EN, 1997, J AM OIL CHEM SOC, V74, P1309, DOI 10.1007/s11746-997-0062-8; Leksrisompong P, 2012, J FOOD SCI, V77, pS282, DOI 10.1111/j.1750-3841.2012.02800.x; Li X, 2012, J SCI FOOD AGR, V92, P292, DOI 10.1002/jsfa.4574; Meilgaard M., 2007, SENSORY EVALUATION T; Ney KH, 1979, FOOD TASTE CHEM, P149; Ovissipour M, 2013, J SCI FOOD AGR, V93, P1718, DOI 10.1002/jsfa.5957; Robinson HW, 1940, J BIOL CHEM, V135, P727; Saha BC, 2001, BIOTECHNOL ADV, V19, P355, DOI 10.1016/S0734-9750(01)00070-2; SHAHIDI F, 1995, FOOD CHEM, V53, P285, DOI 10.1016/0308-8146(95)93934-J; Steel R.G., 1980, PRINCIPLES PROCEDURE; Wang YG, 2008, J FOOD BIOCHEM, V32, P654, DOI 10.1111/j.1745-4514.2008.00190.x; Wroblewska Barbara, 2005, Polish Journal of Food and Nutrition Sciences, V14, P349; Yarnpakdee S, 2012, INT AQUAT RES, V4, P7, DOI DOI 10.1186/2008-6970-4-7	41	1	1	SPRINGER INDIA	NEW DELHI	7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA	0022-1155	0975-8402		J FOOD SCI TECH MYS	J. Food Sci. Technol.-Mysore	JUN	2015	52	6					3336	3349		10.1007/s13197-014-1394-7		14	Food Science & Technology	Food Science & Technology	CJ0VE	WOS:000355196000017		
J	Shinohara, T; Maeda, Y; Hamada, T; Futakawa, N				Shinohara, Toshiki; Maeda, Yoshiaki; Hamada, Tomonori; Futakawa, Noriaki			Survival Benefit of Surgical Treatment for Liver Metastases from Gastric Cancer	JOURNAL OF GASTROINTESTINAL SURGERY			English	Article						Gastric cancer liver metastases; Hepatectomy; Prognostic factors	COMBINED CURATIVE RESECTION; HEPATIC RESECTION; PROGNOSTIC-FACTORS; RADIOFREQUENCY ABLATION; TUMORS; GASTRECTOMY; STOMACH	Indications for the resection of liver metastases from gastric cancers (GLM) remain controversial, and few previous studies have reported subsequent surgical outcomes. Thus, the present retrospective study was designed to clarify the benefits of surgical treatment and identify prognostic factors. Outcomes of 47 patients with or without hepatectomy for GLM were retrospectively compared. A total of 22 patients received surgical treatment for GLM, and overall 1-, 3-, and 5-year survival rates were 86, 26, and 26 %, respectively, and the median survival time (MST) was 22 months. Among 25 patients who did not receive hepatic surgical treatment, the overall survival rates were 24, 8.0, and 4.0 % at 1-, 3-, and 5-years, respectively, with an MST of 7 months. A significant difference was observed between patients with and without the liver surgical treatment (P < 0.001). Univariate and multivariate analyses of recipients of surgery, only the number of liver metastases (solitary or multiple) was significantly predictive of survival (HR = 0.26, P = 0.029) following hepatic resection for GLM. Surgical treatment of GLM should be considered when complete excision including the primary tumor appears to be possible, particularly in cases of solitary hepatic metastases.	[Shinohara, Toshiki; Maeda, Yoshiaki; Hamada, Tomonori; Futakawa, Noriaki] Natl Hosp Org Hokkaido Canc Ctr, Dept Digest Surg, Shiroishi Ku, Sapporo, Hokkaido 0030804, Japan	Shinohara, T (reprint author), Natl Hosp Org Hokkaido Canc Ctr, Dept Digest Surg, Shiroishi Ku, Kikusui 4-2, Sapporo, Hokkaido 0030804, Japan.	toshishinohara-gi@umin.ac.jp					Nashimoto A, 2013, GASTRIC CANCER, V16, P1, DOI 10.1007/s10120-012-0163-4; Kakeji Y, 2010, SURG TODAY, V40, P287, DOI 10.1007/s00595-009-4152-0; Decadt B, 2004, LANCET ONCOL, V5, P550, DOI 10.1016/S1470-2045(04)01567-0; [Anonymous], 2015, J GASTROINTEST SURG, V19, P1043; Okano K, 2002, ANN SURG, V235, P86, DOI 10.1097/00000658-200201000-00011; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Cheon SH, 2008, ANN ONCOL, V19, P1146, DOI 10.1093/annonc/mdn026; Thelen A, 2008, EJSO-EUR J SURG ONC, V34, P1328, DOI 10.1016/j.ejso.2008.01.022; Chen L, 2013, WORLD J GASTROENTERO, V19, P2097, DOI 10.3748/wjg.v19.i13.2097; Li C, 2010, J GASTROINTEST SURG, V14, P282, DOI 10.1007/s11605-009-1095-0; Saiura A, 2002, HEPATO-GASTROENTEROL, V49, P1062; Koga R, 2007, JPN J CLIN ONCOL, V37, P836, DOI 10.1093/jjco/hym113; Sakamoto Y, 2007, J SURG ONCOL, V95, P534, DOI 10.1002/jso.20739; Dittmar Y, 2012, GASTRIC CANCER, V15, P131, DOI 10.1007/s10120-011-0080-y; Kim HR, 2010, INT J HYPERTHER, V26, P305, DOI 10.3109/02656730903555696; Roh HR, 2005, AM SURGEON, V71, P95; Kerkar SP, 2010, HPB, V12, P589, DOI 10.1111/j.1477-2574.2010.00224.x; OCHIAI T, 1994, BRIT J SURG, V81, P1175, DOI 10.1002/bjs.1800810832; Ueda K, 2009, LANGENBECK ARCH SURG, V394, P647, DOI 10.1007/s00423-008-0311-9; BABA H, 1992, J SURG ONCOL, V51, P104, DOI 10.1002/jso.2930510208; KOGA S, 1980, AM J SURG, V140, P356, DOI 10.1016/0002-9610(80)90167-1; Qiu JL, 2013, EJSO-EUR J SURG ONC, V39, P694, DOI 10.1016/j.ejso.2013.03.006; Wang YN, 2012, BMC SURG, V12, DOI 10.1186/1471-2482-12-20; Yagi Y, 2000, GASTRIC CANCER, V3, P71, DOI 10.1007/PL00011699	24	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1091-255X	1873-4626		J GASTROINTEST SURG	J. Gastrointest. Surg.	JUN	2015	19	6					1043	1051		10.1007/s11605-015-2775-6		9	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ2WB	WOS:000355344300009		
J	Kimura, N; Toyoki, Y; Ishido, K; Kudo, D; Yakoshi, Y; Tsutsumi, S; Miura, T; Wakiya, T; Hakamada, K				Kimura, Norihisa; Toyoki, Yoshikazu; Ishido, Keinosuke; Kudo, Daisuke; Yakoshi, Yuta; Tsutsumi, Shinji; Miura, Takuya; Wakiya, Taiichi; Hakamada, Kenichi			Perioperative blood transfusion as a poor prognostic factor after aggressive surgical resection for hilar cholangiocarcinoma Reply	JOURNAL OF GASTROINTESTINAL SURGERY			English	Letter							LUNG-CANCER		[Kimura, Norihisa; Toyoki, Yoshikazu; Ishido, Keinosuke; Kudo, Daisuke; Yakoshi, Yuta; Tsutsumi, Shinji; Miura, Takuya; Wakiya, Taiichi; Hakamada, Kenichi] Hirosaki Univ, Grad Sch Med, Dept Surg Gastroenterol, Hirosaki, Aomori 0368562, Japan	Kimura, N (reprint author), Hirosaki Univ, Grad Sch Med, Dept Surg Gastroenterol, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	norihisa@hirosaki-u.ac.jp					Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; Muller SA, 2014, ANN SURG ONCOL, V21, P155, DOI 10.1245/s10434-013-3226-9; Warschkow R, 2014, ANN SURG, V259, P131, DOI 10.1097/SLA.0b013e318287ab4d; Boehm K, 2015, WORLD J UROL, V33, P801, DOI 10.1007/s00345-014-1351-0; Cata JP, 2013, BMC ANESTHESIOL, V13, DOI 10.1186/1471-2253-13-42; Hallet J, 2014, TRANSFUS MED REV, V28, P205, DOI 10.1016/j.tmrv.2014.05.004; Kimura N, 2015, J GASTROINTEST SURG, V19, P866, DOI 10.1007/s11605-014-2741-8; Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064261; Luan HX, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-34	9	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1091-255X	1873-4626		J GASTROINTEST SURG	J. Gastrointest. Surg.	JUN	2015	19	6					1194	1195		10.1007/s11605-015-2823-2		2	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ2WB	WOS:000355344300029		
J	Tatebe, M; Imaeda, T; Hirata, H				Tatebe, M.; Imaeda, T.; Hirata, H.			The impact of lunate morphology on Kienbock's disease	JOURNAL OF HAND SURGERY-EUROPEAN VOLUME			English	Letter									[Tatebe, M.] Nagoya Univ, Sch Med, Dept Hand Surg, Nagoya, Aichi 466, Japan; Kinjo Gakuin Univ, Sch Human Life & Environm, Dept Food & Nutr Environm, Nagoya, Aichi, Japan	Tatebe, M (reprint author), Nagoya Univ, Sch Med, Dept Hand Surg, Nagoya, Aichi 466, Japan.	tatebe@med.nagoya-u.ac.jp	Tatebe, Masahiro/Q-1569-2015				Tatebe M, 2012, SURG RADIOL ANAT, V35, P79; TSUGE S, 1993, J HAND SURG-BRIT EUR, V18B, P70, DOI 10.1016/0266-7681(93)90201-P; VIEGAS SF, 1990, J HAND SURG-AM, V15A, P564	3	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1753-1934	2043-6289		J HAND SURG-EUR VOL	J. Hand Surg.-Eur. Vol.	JUN	2015	40	5					534	536		10.1177/1753193413491235		3	Orthopedics; Surgery	Orthopedics; Surgery	CI8BW	WOS:000354993500014		
J	Yokoe, M; Takada, T; Mayumi, T; Yoshida, M; Isaji, S; Wada, K; Itoi, T; Sata, N; Gabata, T; Igarashi, H; Kataoka, K; Hirota, M; Kadoya, M; Kitamura, N; Kimura, Y; Kiriyama, S; Shirai, K; Hattori, T; Takeda, K; Takeyama, Y; Hirota, M; Sekimoto, M; Shikata, S; Arata, S; Hirata, K				Yokoe, Masamichi; Takada, Tadahiro; Mayumi, Toshihiko; Yoshida, Masahiro; Isaji, Shuji; Wada, Keita; Itoi, Takao; Sata, Naohiro; Gabata, Toshifumi; Igarashi, Hisato; Kataoka, Keisho; Hirota, Masahiko; Kadoya, Masumi; Kitamura, Nobuya; Kimura, Yasutoshi; Kiriyama, Seiki; Shirai, Kunihiro; Hattori, Takayuki; Takeda, Kazunori; Takeyama, Yoshifumi; Hirota, Morihisa; Sekimoto, Miho; Shikata, Satoru; Arata, Shinju; Hirata, Koichi			Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Review						Acute pancreatitis; Antibiotics; Bundles; Diagnosis; Guidelines; Intensive care; Nutrition; Pancreas; Post-ERCP pancreatitis; Severity assessment; Surgery	ACUTE NECROTIZING PANCREATITIS; ABDOMINAL COMPARTMENT SYNDROME; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ACUTE BILIARY PANCREATITIS; POST-ERCP PANCREATITIS; REGIONAL ARTERIAL INFUSION; RANDOMIZED CONTROLLED-TRIAL; MILD ACUTE-PANCREATITIS; DOUBLE-BLIND TRIAL; ENHANCED COMPUTED-TOMOGRAPHY	BackgroundJapanese (JPN) guidelines for the management of acute pancreatitis were published in 2006. The severity assessment criteria for acute pancreatitis were later revised by the Japanese Ministry of Health, Labour and Welfare (MHLW) in 2008, leading to their publication as the JPN Guidelines 2010. Following the 2012 revision of the Atlanta Classifications of Acute Pancreatitis, in which the classifications of regional complications of pancreatitis were revised, the development of a minimally invasive method for local complications of pancreatitis spread, and emerging evidence was gathered and revised into the JPN Guidelines. MethodsA comprehensive evaluation was carried out on the evidence for epidemiology, diagnosis, severity, treatment, post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis and clinical indicators, based on the concepts of the GRADE system (Grading of Recommendations Assessment, Development and Evaluation). With the graded recommendations, where the evidence was unclear, Meta-Analysis team for JPN Guidelines 2015 conducted an additional new meta-analysis, the results of which were included in the guidelines. ResultsThirty-nine questions were prepared in 17 subject areas, for which 43 recommendations were made. The 17 subject areas were: Diagnosis, Diagnostic imaging, Etiology, Severity assessment, Transfer indication, Fluid therapy, Nasogastric tube, Pain control, Antibiotics prophylaxis, Protease inhibitor, Nutritional support, Intensive care, management of Biliary Pancreatitis, management of Abdominal Compartment Syndrome, Interventions for the local complications, Post-ERCP pancreatitis and Clinical Indicator (Pancreatitis Bundles 2015). Meta-analysis was conducted in the following four subject areas based on randomized controlled trials: (1) prophylactic antibiotics use; (2) prophylactic pancreatic stent placement for the prevention of post-ERCP pancreatitis; (3) prophylactic non-steroidal anti-inflammatory drugs (NSAIDs) for the prevention of post-ERCP pancreatitis; and (4) peritoneal lavage. Using the results of the meta-analysis, recommendations were graded to create useful information. In addition, a mobile application was developed, which made it possible to diagnose, assess severity and check pancreatitis bundles. ConclusionsThe JPN Guidelines 2015 were prepared using the most up-to-date methods, and including the latest recommended medical treatments, and we are confident that this will make them easy for many clinicians to use, and will provide a useful tool in the decision-making process for the treatment of patients, and optimal medical support. The free mobile application and calculator for the JPN Guidelines 2015 is available via http://www.jshbps.jp/en/guideline/jpn-guideline2015.html	[Yokoe, Masamichi] Japanese Red Cross Nagoya Daini Hosp, Gen Internal Med, Nagoya, Aichi, Japan; [Takada, Tadahiro; Wada, Keita] Teikyo Univ Sch Med, Dept Surg, Tokyo, Japan; [Mayumi, Toshihiko] Univ Occupat & Environm Hlth, Sch Med, Dept Emergency Med, Kitakyushu, Fukuoka, Japan; [Yoshida, Masahiro] Int Univ Hlth & Welf, Chemotherapy Res Inst, Dept Hemodialysis & Surg, Ichikawa, Japan; [Isaji, Shuji] Tokyo Med Univ, Dept Gastroenterol & Hepatol, Tokyo, Japan; [Itoi, Takao] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi, Japan; [Sata, Naohiro] Kanazawa Univ, Sch Med Sci, Dept Radiol, Kanazawa, Ishikawa, Japan; [Gabata, Toshifumi] Kyushu Univ Hosp, Clin Educ Ctr, Fukuoka, Japan; [Igarashi, Hisato] Otsu Municipal Hosp, Shiga, Japan; [Kataoka, Keisho] Kyoto Prefectural Univ Med, Kyoto, Japan; [Kataoka, Keisho] Kumamoto Reg Med Ctr, Dept Surg, Kumamoto, Japan; [Hirota, Masahiko] Shinshu Univ Sch Med, Dept Radiol, Matsumoto, Nagano, Japan; [Kadoya, Masumi] Kimitsu Chuo Hosp, Dept Emergency & Crit Care Med, Kisarazu, Chiba, Japan; [Kitamura, Nobuya] Sapporo Med Univ, Dept Surg, Surg Oncol & Sci, Sapporo, Hokkaido, Japan; [Kimura, Yasutoshi; Hirata, Koichi] Ogaki Municipal Hosp, Dept Gastroenterol, Ogaki, Japan; [Kiriyama, Seiki] Ichinomiya Municipal Hosp, Dept Emergency & Crit Care Med, Ichinomiya, Japan; [Shirai, Kunihiro] Tokyo Metropolitan Hlth & Med Treatment Corp, Ohkubo Hosp, Dept Radiol, Tokyo, Japan; [Hattori, Takayuki] Natl Hosp Org Sendai Med Ctr, Dept Surg, Sendai, Miyagi, Japan; [Takeda, Kazunori] Kinki Univ Fac Med, Dept Surg, Osaka, Japan; [Takeyama, Yoshifumi] Tohoku Univ Grad Sch Med, Div Gastroenterol, Sendai, Miyagi, Japan; [Hirota, Morihisa] Univ Tokyo Grad Sch Publ Policy, Hlth Policy Unit, Tokyo, Japan; [Sekimoto, Miho] Dept Family Med, Mie Prefectural Ichishi, Mie, Japan; [Shikata, Satoru] Yokohama City Univ Med Ctr, Gastroenterol Ctr, Yokohama, Kanagawa, Japan	Mayumi, T (reprint author), Univ Occupat & Environm Hlth, Sch Med, Dept Emergency Med, Yahata-nishi Ku, I-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	mtoshi@med.uoeh-u.ac.jp					Aizawa T, 2001, GASTROINTEST ENDOSC, V54, P209, DOI 10.1067/mge.2001.115730; Al-Omrans M, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858; Alsfasser G, 2012, WORLD J SURG, V36, P1142, DOI 10.1007/s00268-012-1504-5; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kirkpatrick AW, 2013, INTENS CARE MED, V39, P1190, DOI 10.1007/s00134-013-2906-z; Connor S, 2005, SURGERY, V137, P499, DOI 10.1016/j.surg.2005.01.003; van Santvoort HC, 2010, NEW ENGL J MED, V362, P1491, DOI 10.1056/NEJMoa0908821; Mayumi T, 2006, J HEPATO-BILIARY-PAN, V13, P61, DOI 10.1007/s00534-005-1053-5; Atkins D, 2004, BRIT MED J, V328, P1490; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017; Kiriyama S, 2010, J HEPATO-BIL-PAN SCI, V17, P24, DOI 10.1007/s00534-009-0214-3; Brunetti M, 2013, J CLIN EPIDEMIOL, V66, P140, DOI 10.1016/j.jclinepi.2012.04.012; Tenner S, 2004, AM J GASTROENTEROL, V99, P2489, DOI 10.1111/j.1572-0241.2004.40329.x; De Waele JJ, 2005, CRIT CARE, V9, pR452, DOI 10.1186/cc3754; Boerma D, 2002, LANCET, V360, P761, DOI 10.1016/S0140-6736(02)09896-3; PARVEY HR, 1994, AM J ROENTGENOL, V162, P77; Eatock FC, 2005, AM J GASTROENTEROL, V100, P432, DOI 10.1111/j.1572-0241.2005.40587.x; Malbrain MLNG, 2006, INTENS CARE MED, V32, P1722, DOI 10.1007/s00134-006-0349-5; Gislason H, 2001, EUR J SURG, V167, P204; Besselink MGH, 2007, ARCH SURG-CHICAGO, V142, P1194, DOI 10.1001/archsurg.142.12.1194; Harewood GC, 2005, GASTROINTEST ENDOSC, V62, P367, DOI 10.1016/j.gie.2005.04.020; Takahashi N, 2008, EUR RADIOL, V18, P2522, DOI 10.1007/s00330-008-1039-1; Windsor ACJ, 1998, GUT, V42, P431; Bakker OJ, 2011, BRIT J SURG, V98, P1446, DOI 10.1002/bjs.7587; Zhou MT, 2013, PANCREATOLOGY, V13, P212, DOI 10.1016/j.pan.2013.02.004; Dambrauskas Z, 2009, WORLD J GASTROENTERO, V15, P717, DOI 10.3748/wjg.15.717; Pezzilli R, 2010, PANCREATOLOGY, V10, P523, DOI 10.1159/000314602; Amano H, 2010, J HEPATO-BIL-PAN SCI, V17, P53, DOI 10.1007/s00534-009-0211-6; KIVILAAKSO E, 1984, ANN SURG, V199, P426, DOI 10.1097/00000658-198404000-00009; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004; Zaheer A, 2013, ABDOM IMAGING, V38, P125, DOI 10.1007/s00261-012-9908-0; Koizumi M, 2006, J HEPATO-BILIARY-PAN, V13, P25, DOI 10.1007/s00534-005-1048-2; Gardner TB, 2009, PANCREATOLOGY, V9, P770, DOI 10.1159/000210022; Miller FH, 2004, AM J ROENTGENOL, V183, P1637; RANSON JHC, 1977, J SURG RES, V22, P79, DOI 10.1016/0022-4804(77)90045-2; van Brunschot S, 2014, PANCREAS, V43, P665, DOI 10.1097/MPA.0000000000000108; Barthet M, 2008, GASTROINTEST ENDOSC, V67, P245, DOI 10.1016/j.gie.2007.06.014; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Ukai T, 2015, J HEPATO-BIL-PAN SCI, V22, P316, DOI 10.1002/jhbp.221; VALDERRAMA R, 1992, DIGESTION, V51, P65; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Otsuki M, 2013, WORLD J GASTROENTERO, V19, P5798, DOI 10.3748/wjg.v19.i35.5798; Tenner S, 2013, AM J GASTROENTEROL, V108, P1400, DOI 10.1038/ajg.2013.218; Folsch UR, 1997, NEW ENGL J MED, V336, P237, DOI 10.1056/NEJM199701233360401; Louie BE, 2005, CAN J SURG, V48, P298; Vissers RJ, 1999, J EMERG MED, V17, P1027, DOI 10.1016/S0736-4679(99)00136-5; Hwang SS, 2013, JAMA SURG, V148, P867, DOI 10.1001/jamasurg.2013.3033; Kawaguchi Y, 2012, WORLD J GASTROENTERO, V18, P1635, DOI 10.3748/wjg.v18.i14.1635; Kuwabara K, 2011, PANCREATOLOGY, V11, P351, DOI 10.1159/000328965; Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P173, DOI 10.1016/j.jclinepi.2012.08.001; Howard TJ, 2004, SURGERY, V136, P909, DOI 10.1016/j.surg.2004.06.028; Kalfarentzos F, 1997, BRIT J SURG, V84, P1665; Banks PA, 1995, INT J PANCREATOL, V18, P265; [Anonymous], 1980, GUT, V21, P334; MAYER AD, 1985, NEW ENGL J MED, V312, P399, DOI 10.1056/NEJM198502143120703; DEIORIO AV, 1995, SURG ENDOSC-ULTRAS, V9, P392; Singh P, 2004, GASTROINTEST ENDOSC, V60, P544, DOI 10.1016/S0016-5107(04)02013-9; [Anonymous], 1977, LANCET, V2, P632; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1303, DOI 10.1016/j.jclinepi.2011.04.014; Targarona EM, 1996, LANCET, V347, P926, DOI 10.1016/S0140-6736(96)91413-0; Mustafa A, 2014, SURG ENDOSC, V28, P127, DOI 10.1007/s00464-013-3138-6; Fazel A, 2003, GASTROINTEST ENDOSC, V57, P291, DOI 10.1067/mge.2003.124; Marik PE, 2004, BRIT MED J, V328, P1407, DOI 10.1136/bmj.38118.593900.55; Olah A, 2002, BRIT J SURG, V89, P1103, DOI 10.1046/j.1365-2168.2002.02189.x; Isenmann R, 2004, GASTROENTEROLOGY, V126, P997, DOI 10.1053/j.gastro.2003.12.050; Sofuni A, 2011, CLIN GASTROENTEROL H, V9, P851, DOI 10.1016/j.cgh.2011.06.033; Mounzer R, 2012, GASTROENTEROLOGY, V142, P1476, DOI 10.1053/j.gastro.2012.03.005; Dellinger EP, 2007, ANN SURG, V245, P674, DOI 10.1097/01.sla.0000250414.09255.84; YANG CY, 1987, PANCREAS, V2, P698, DOI 10.1097/00006676-198711000-00013; Mouli VP, 2013, GASTROENTEROLOGY, V144, P333, DOI 10.1053/j.gastro.2012.10.004; Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026; Yasuda T, 2007, J GASTROENTEROL, V42, P681, DOI 10.1007/s00535-007-2081-5; Banks PA, 2006, AM J GASTROENTEROL, V101, P2379, DOI 10.1111/j.1572-0241.2006.00856.x; Elmunzer BJ, 2008, GUT, V57, P1262, DOI 10.1136/gut.2007.140756; Ward J, 1997, CLIN RADIOL, V52, P109, DOI 10.1016/S0009-9260(97)80102-X; Mujica VR, 2000, PANCREAS, V21, P329, DOI 10.1097/00006676-200011000-00001; Sarr MG, 2013, ANN SURG, V257, P189, DOI 10.1097/SLA.0b013e318280e19e; Mortele KJ, 2004, EUR J RADIOL, V52, P67, DOI 10.1016/j.ejrad.2003.10.006; Takeda K, 2010, J HEPATO-BIL-PAN SCI, V17, P37, DOI 10.1007/s00534-009-0213-4; Shyu JY, 2014, RADIOGRAPHICS, V34, P1218, DOI 10.1148/rg.345130012; Nguyen GC, 2012, GASTROINTEST ENDOSC, V75, P47, DOI 10.1016/j.gie.2011.08.028; RANSON JHC, 1976, SURG GYNECOL OBSTET, V143, P209; Thoeni RF, 2012, RADIOLOGY, V262, P751, DOI 10.1148/radiol.11110947; Pappas PG, 2009, CLIN INFECT DIS, V48, P503, DOI 10.1086/596757; IMRIE CW, 1978, BRIT J SURG, V65, P337, DOI 10.1002/bjs.1800650514; Trust MD, 2011, SURGERY, V150, P515, DOI 10.1016/j.surg.2011.07.072; Moraes JMM, 2010, J CLIN GASTROENTEROL, V44, P517, DOI 10.1097/MCG.0b013e3181c986b3; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P407, DOI 10.1016/j.jclinepi.2010.07.017; Hirota M, 2002, PANCREAS, V25, P63, DOI 10.1097/00006676-200207000-00015; Petrov MS, 2006, DIGEST SURG, V23, P336, DOI 10.1159/000097949; SKYRING A, 1965, BRIT MED J, V2, P627; Takeda K, 1996, AM J SURG, V171, P394, DOI 10.1016/S0002-9610(97)89617-1; Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P158, DOI 10.1016/j.jclinepi.2012.01.012; Chen HM, 2000, HEPATO-GASTROENTEROL, V47, P1147; Hirota M, 2010, J HEPATO-BIL-PAN SCI, V17, P45, DOI 10.1007/s00534-009-0210-7; NEOPTOLEMOS JP, 1988, LANCET, V2, P979; Warndorf MG, 2011, CLIN GASTROENTEROL H, V9, P705, DOI 10.1016/j.cgh.2011.03.032; Shanmugam N, 2003, PANCREAS, V27, P133, DOI 10.1097/00006676-200308000-00005; van Santvoort HC, 2011, GASTROENTEROLOGY, V141, P1254, DOI 10.1053/j.gastro.2011.06.073; de-Madaria E, 2011, AM J GASTROENTEROL, V106, P1843, DOI 10.1038/ajg.2011.236; Guyatt G, 2013, J CLIN EPIDEMIOL, V66, P151, DOI 10.1016/j.jclinepi.2012.01.006; Cheatham ML, 2007, INTENS CARE MED, V33, P951, DOI 10.1007/s00134-007-0592-4; Sekimoto M, 2006, J HEPATO-BILIARY-PAN, V13, P10, DOI 10.1007/s00534-005-1047-3; Trikudanathan G, 2011, AM J GASTROENTEROL, V106, P1188, DOI 10.1038/ajg.2010.497; Eckerwall GE, 2007, CLIN NUTR, V26, P758, DOI 10.1016/j.clnu.2007.04.007; Tarnasky PR, 1998, GASTROENTEROLOGY, V115, P1518, DOI 10.1016/S0016-5085(98)70031-9; van Baal MC, 2011, BRIT J SURG, V98, P18, DOI 10.1002/bjs.7304; Besselink MGH, 2008, LANCET, V371, P651, DOI 10.1016/S0140-6736(08)60207-X; Horvath K, 2010, ARCH SURG-CHICAGO, V145, P817, DOI 10.1001/archsurg.2010.178; FREI GJ, 1986, AM J SURG, V151, P170, DOI 10.1016/0002-9610(86)90028-0; Wang XY, 2008, JPEN-PARENTER ENTER, V32, P236, DOI 10.1177/0148607108316189; WALTMAN AC, 1986, ARCH SURG-CHICAGO, V121, P439; SMITHLINE A, 1993, GASTROINTEST ENDOSC, V39, P652; Bezmarevic M, 2012, PANCREATOLOGY, V12, P337, DOI 10.1016/j.pan.2012.05.007; Mofidi R, 2009, SURGERY, V146, P72, DOI 10.1016/j.surg.2009.02.013; Mentula P, 2010, ARCH SURG-CHICAGO, V145, P764, DOI 10.1001/archsurg.2010.132; Kimura Y, 2010, J HEPATO-BIL-PAN SCI, V17, P60, DOI 10.1007/s00534-009-0217-0; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012; Wall I, 2011, PANCREAS, V40, P547, DOI 10.1097/MPA.0b013e318215368d; Isaji S, 2006, J HEPATO-BILIARY-PAN, V13, P48, DOI 10.1007/s00534-005-1051-7; TRAPNELL JE, 1967, AM J DIG DIS, V12, P409, DOI 10.1007/BF02241945; Davis PJB, 2013, WORLD J SURG, V37, P318, DOI 10.1007/s00268-012-1821-8; Imaizumi H, 2004, PANCREAS, V28, P369, DOI 10.1097/00006676-200405000-00003; Eckerwall G, 2006, CLIN NUTR, V25, P497, DOI 10.1016/j.clnu.2005.10.012; Fuentes-Orozco C, 2008, JPEN-PARENTER ENTER, V32, P403, DOI 10.1177/0148607108319797; RANSON JHC, 1974, SURG GYNECOL OBSTET, V139, P69; Andrews J, 2013, J CLIN EPIDEMIOL, V66, P719, DOI 10.1016/j.jclinepi.2012.03.013; Piciucchi M, 2010, WORLD J GASTROENTERO, V16, P3692, DOI 10.3748/wjg.v16.i29.3692; Jiang K, 2012, WORLD J GASTROENTERO, V18, P279, DOI 10.3748/wjg.v18.i3.279; TRAPNELL JE, 1974, BRIT J SURG, V61, P177, DOI 10.1002/bjs.1800610303; Levy P, 1997, GUT, V40, P262; Takeda K, 2006, J HEPATO-BILIARY-PAN, V13, P42, DOI 10.1007/s00534-005-1050-8; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P395, DOI 10.1016/j.jclinepi.2010.09.012; Haydock MD, 2013, ANN SURG, V257, P182, DOI 10.1097/SLA.0b013e31827773ff; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Buchler MW, 2000, ANN SURG, V232, P619; Murata A, 2011, PANCREAS, V40, P1018, DOI 10.1097/MPA.0b013e31821bd233; Sharma VK, 2001, PANCREAS, V22, P28, DOI 10.1097/00006676-200101000-00005; Arata S, 2010, J HEPATO-BIL-PAN SCI, V17, P70, DOI 10.1007/s00534-009-0220-5; Zheng MH, 2008, GUT, V57, P1632, DOI 10.1136/gut.2008.153866; Harrison DA, 2007, CRIT CARE MED, V35, P1703, DOI 10.1097/01.CCM.0000269031.13283.C8; Choudhary A, 2011, GASTROINTEST ENDOSC, V73, P275, DOI 10.1016/j.gie.2010.10.039; BUCHLER M, 1993, GASTROENTEROLOGY, V104, P1165; BALLDIN G, 1983, RES EXP MED, V183, P203, DOI 10.1007/BF01855643; Gupta R, 2003, PANCREATOLOGY, V3, P406, DOI 10.1159/000073657; Yang CJ, 2014, DIGEST LIVER DIS, V46, P446, DOI 10.1016/j.dld.2014.01.158; Hirota M, 2006, J HEPATO-BILIARY-PAN, V13, P33, DOI 10.1007/s00534-005-1049-1; Abou-Assi S, 2002, AM J GASTROENTEROL, V97, P2255, DOI 10.1016/S0002-9270(02)04336-8; Chebli JMF, 2005, J GASTROEN HEPATOL, V20, P1385, DOI 10.1111/j.1440-1746.2005.03986.x; Sofuni A, 2007, CLIN GASTROENTEROL H, V5, P1339, DOI 10.1016/j.cgh.2007.07.008; McColl KEL, 2005, GUT, V54, P1, DOI 10.1136/gut.2004.047126; BACHRACH.WH, 1968, ANN NY ACAD SCI, V146, P580, DOI 10.1111/j.1749-6632.1968.tb20316.x; BADEN H., 1967, ACTA CHIR SCAND SUPPL, V378, P97; Bais Y, 2010, AM J GASTROENTEROL, V105, P705; Bais Y, 2008, AM J GASTROENTEROL, V103, P104; Bakkers OJ, 2012, JAMA-J AM MED ASSOC, V14, P1053; BALTHAZAR EJ, 1994, RADIOLOGY, V193, P297; Banks PA, 2012, GUT, V62, P102, DOI DOI 10.1136/GUTJNL-2012-302779; Bassis C, 2003, COCHRANE DB SYST REV; Bello B, 2012, WORLD J GASTROENTERO, V18, P6829, DOI 10.3748/wjg.v18.i46.6829; BERLING R, 1994, J GASTROENTEROL, V29, P479, DOI 10.1007/BF02361247; Bertazzonis ME, 1996, J ANTIMICROB CHEMOTH, V38, P237; Bhandari V, 2013, GUT LIVER, V7, P731, DOI 10.5009/gnl.2013.7.6.731; Bignell M, 2011, J GASTROINTEST SURG, V15, P2205, DOI 10.1007/s11605-011-1729-x; Boone B, 2013, AM SURGEON, V79, P601; BRADLEY EL, 1991, AM J SURG, V161, P19, DOI 10.1016/0002-9610(91)90355-H; BRADLEY EL, 1989, ANN SURG, V210, P495, DOI 10.1097/00000658-198910000-00010; Brown A, 2007, J CLIN GASTROENTEROL, V41, P855; BUCHLER M, 1992, GASTROENTEROLOGY, V103, P1902; Castoldi L, 2013, DIGEST LIVER DIS, V45, P827, DOI 10.1016/j.dld.2013.03.012; Chak A, 1999, GASTROINTEST ENDOSC, V49, P599, DOI 10.1016/S0016-5107(99)70388-3; Chang K, 2012, CLIN BIOCHEM, V45, P1051, DOI 10.1016/j.clinbiochem.2012.04.028; Chas SW, 2013, GASTROINTEST ENDOSC, V77, P209; Chen H, 2008, WORLD J GASTROENTERO, V14, P3541, DOI 10.3748/wjg.14.3541; Cirocchi R, 2013, SURG LAPARO ENDO PER, V23, P8, DOI 10.1097/SLE.0b013e3182754bca; COOPER MJ, 1982, ANN ROY COLL SURG, V64, P422; CRAIG RM, 1975, ANN INTERN MED, V83, P831; Dais HF, 2009, HEPATOB PANCREAT DIS, V8, P11; das Costas DW, 2014, BRIT J SURG, V101, pe65; Delcenserie R, 1996, PANCREAS, V13, P198; De Rai P, 2010, HPB, V12, P597, DOI 10.1111/j.1477-2574.2010.00201.x; Derveniss C, 2011, AM J GASTROENTEROL, V106, P1188; des Vriess AC, 2007, PANCREATOLOGY, V7, P531; De Waele JJ, 2003, CLIN INFECT DIS, V37, P208, DOI 10.1086/375603; Dong ZY, 2010, WORLD J SURG, V34, P2103, DOI 10.1007/s00268-010-0665-3; Dorffel Y, 2000, PANCREAS, V21, P126; Dus XJ, 2011, PANCREAS, V40, P1220; Eckerwall GE, 2006, ANN SURG, V244, P959, DOI 10.1097/01.sla.0000246866.01930.58; Eggimann P, 2006, CRIT CARE, V10, DOI 10.1186/cc5025; Fans ST, 1993, NEW ENGL J MED, V328, P228; FIELD BE, 1979, DIGEST DIS SCI, V24, P339, DOI 10.1007/BF01297118; FINCH WT, 1976, ANN SURG, V183, P667, DOI 10.1097/00000658-197606000-00008; Foitzik T, 2007, PANCREATOLOGY, V7, P80, DOI 10.1159/000101882; FREISE J, 1986, Z GASTROENTEROL, V24, P200; Frossard JL, 2000, AM J MED, V109, P196, DOI 10.1016/S0002-9343(00)00478-2; FULLER RK, 1981, AM J GASTROENTEROL, V75, P349; Garcia-Barrasa A, 2009, J GASTROINTEST SURG, V13, P768, DOI 10.1007/s11605-008-0773-7; Gardner A, 2003, J CLIN GASTROENTEROL, V37, P258, DOI 10.1097/00004836-200309000-00012; GAUTHIER A, 1978, GASTROEN CLIN BIOL, V2, P777; Gloor B, 2003, J GASTROINTEST SURG, V7, P372, DOI 10.1016/S1091-255X(02)00418-3; Goebells H., 1988, DIGESTION, V40, P73; GOFF JS, 1982, DIGEST DIS SCI, V27, P1085, DOI 10.1007/BF01391445; Golub R, 1998, J Gastrointest Surg, V2, P496, DOI 10.1016/S1091-255X(98)80048-6; Grewe M, 1999, J AM COLL SURGEONS, V188, P408, DOI 10.1016/S1072-7515(98)00334-2; Guyatt GH, 2008, BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Guyatt GH, 2008, BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Guyatt GH, 2008, BRIT MED J, V336, P1170, DOI 10.1136/bmj.39504.506319.80; Haghshenasskashani A, 2011, SURG ENDOSC, V25, P3724, DOI 10.1007/s00464-011-1795-x; Hamada T, 2013, CRIT CARE, V17, DOI 10.1186/cc13029; Hes YM, 2003, WORLD J GASTROENTERO, V9, P2619; Hirohashi S, 1997, RADIOLOGY, V203, P411; Hirota M, 2014, J HEPATO-BIL-PAN SCI, V21, P829, DOI 10.1002/jhbp.163; Holodinsky JK, 2013, CRIT CARE, V17, DOI 10.1186/cc13075; HOWES R, 1975, J SURG RES, V18, P197, DOI 10.1016/0022-4804(75)90016-5; IHSE I, 1986, ANN SURG, V204, P122, DOI 10.1097/00000658-198608000-00004; Inos Y, 2008, WORLD J GASTROENTERO, V14, P6382; Itos K, 2010, J GASTROENTEROL, V45, P1183; Jacobs AO, 2014, ANZ J SURG, DOI [10.1111/ans.12707, DOI 10.1111/ANS.12707]; Jaeschke R, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a744; Jakobs R, 2000, SCAND J GASTROENTERO, V35, P1319; JEFFREY RB, 1986, RADIOLOGY, V159, P707; Jins T, 2013, HEPATOB PANCREAT DIS, V12, P355; Kahl S, 2004, DIGESTION, V69, P5, DOI 10.1159/000076541; Kaws M, 2002, GASTROINTEST ENDOSC, V56, P61; Kemppainen E, 1996, BRIT J SURG, V83, P924, DOI 10.1002/bjs.1800830713; Kes L, 2012, WORLD J SURG, V36, P171; Kimura Y, 2006, J HEPATO-BILIARY-PAN, V13, P56, DOI 10.1007/s00534-005-1052-6; Lankisch PG, 2009, CLIN GASTROENTEROL H, V7, P702, DOI 10.1016/j.cgh.2009.02.020; LARVIN M, 1990, BRIT MED J, V300, P1425; Laus JY, 2006, GASTROENTEROLOGY, V130, P96; Lees TH, 2012, GASTROINTEST ENDOSC, V76, P578; Leppaniemi A, 2011, AM SURGEON, V77, P99; LEVANT JA, 1974, JAMA-J AM MED ASSOC, V229, P51, DOI 10.1001/jama.229.1.51; Lins A, 1990, ANN INTERN MED, V112, P166; Lis JY, 2013, PLOS ONE, V8; Lius CL, 2000, GASTROINTEST ENDOSC, V51, P28; Lius CL, 2001, GASTROINTEST ENDOSC, V54, P325; Lius CL, 2005, ALIMENT PHARM THER, V22, P423; LOIUDICE TA, 1984, AM J GASTROENTEROL, V79, P553; Lomas DJ, 1999, EUR RADIOL, V9, P1411, DOI 10.1007/s003300050859; LONDON NJM, 1991, BRIT J SURG, V78, P1452, DOI 10.1002/bjs.1800781216; Magyar A, 1994, Acta Chir Hung, V34, P59; Manes G, 2006, AM J GASTROENTEROL, V101, P1348, DOI 10.1111/j.1572-0241.2006.00567.x; Maos EQ, 2009, CHIN MED J, V122, P169; Maos EQ, 2010, CHIN MED J, V123, P1639; Maravi-Poma E, 2003, INTENS CARE MED, V29, P1974, DOI 10.1007/s00134-003-1956-z; Mayumi T, 2010, J HEPATO-BIL-PAN SCI, V17, P87, DOI 10.1007/s00534-009-0219-y; Mazaki T, 2006, BRIT J SURG, V93, P674, DOI 10.1002/bjs.5389; Mazaki T, 2010, ENDOSCOPY, V42, P842, DOI 10.1055/s-0030-1255781; Mazaki T, 2014, J GASTROENTEROL, V49, P343, DOI 10.1007/s00535-013-0806-1; McCallum IJD, 2011, POSTGRAD MED J, V87, P379, DOI 10.1136/pgmj.2010.002113rep; McClave SA, 1997, JPEN-PARENTER ENTER, V21, P14, DOI 10.1177/014860719702100114; Meng WB, 2013, PANCREATOLOGY, V13, P201, DOI 10.1016/j.pan.2013.02.003; Mier J, 1997, AM J SURG, V173, P71, DOI 10.1016/S0002-9610(96)00425-4; Mole DJ, 2011, HPB, V13, P51, DOI 10.1111/j.1477-2574.2010.00241.x; MOLLER C, 1969, Annales Chirurgiae et Gynaecologiae Fenniae, V58, P296; Morgan DE, 1997, RADIOLOGY, V203, P773; NAEIJE R, 1978, BRIT MED J, V2, P659; NAVARRO S, 1984, DIGESTION, V30, P224; Nordback I, 2001, J GASTROINTEST SURG, V5, P113, DOI 10.1016/S1091-255X(01)80021-4; Norton SA, 2000, BRIT J SURG, V87, P1650, DOI 10.1046/j.1365-2168.2000.01587.x; NOWAK A, 1995, GASTROENTEROLOGY, V108, pA380; Olah A, 2002, NUTRITION, V18, P259, DOI 10.1016/S0899-9007(01)00755-9; Olah A, 2007, HEPATO-GASTROENTEROL, V54, P590; Pans XP, 2011, CELL BIOCH BIOPHYS, V61, P473; Patels R, 1999, GASTROINTEST ENDOSC, V49, p80A; Pearce Callum B, 2006, JOP, V7, P361; PEDERZOLI P, 1993, SURG GYNECOL OBSTET, V176, P480; Peiro AM, 2008, PANCREATOLOGY, V8, P25, DOI 10.1159/000114852; Petrov Maxim S, 2008, Int J Surg, V6, P119, DOI 10.1016/j.ijsu.2008.01.003; Petrov Maxim S, 2008, JOP, V9, P440; Pezzilli R, 2008, DIGEST LIVER DIS, V40, P803, DOI 10.1016/j.dld.2008.02.019; Piacik M, 2010, PANCREAS, V39, P863; Piironen A, 2000, EUR RADIOL, V10, P354, DOI 10.1007/s003300050055; Platell C, 2001, J GASTROEN HEPATOL, V16, P689, DOI 10.1046/j.1440-1746.2001.02497.x; Poma EM, 2013, MED INTENSIVA, V37, P163, DOI 10.1016/j.medin.2013.01.007; Puig I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092922; Pupelis Guntars, 2012, Ann Intensive Care, V2 Suppl 1, pS21, DOI 10.1186/2110-5820-2-S1-S21; Perez LJR, 2014, CIR ESPAN, V92, P107, DOI 10.1016/j.ciresp.2013.01.024; RANSON JHC, 1990, ANN SURG, V211, P708, DOI 10.1097/00000658-199006000-00009; RANSON JHC, 1979, ANN SURG, V189, P654, DOI 10.1097/00000658-197905000-00016; Raratys HG, 2010, ANN SURG, V251, P787; Raus B, 1998, BRIT J SURG, V85, P179; Raus BM, 2007, ANN SURG, V245, P745; Rebours V, 2012, EUR J GASTROEN HEPAT, V24, P143, DOI 10.1097/MEG.0b013e32834d864f; Rodriguez JR, 2008, ANN SURG, V247, P294, DOI 10.1097/SLA.0b013e31815b6976; Rokke O, 2007, SCAND J GASTROENTERO, V42, P771, DOI 10.1080/00365520601173855; Ryall R J, 1966, Anglo Ger Med Rev, V3, P274; SAINIO V, 1995, LANCET, V346, P663, DOI 10.1016/S0140-6736(95)92280-6; Sandzen B, 2012, WORLD J SURG, V36, P2146, DOI 10.1007/s00268-012-1648-3; SANFEY H, 1994, AM SURGEON, V60, P661; Sargent Suzanne, 2006, Br J Nurs, V15, P999; SARR MG, 1986, SURGERY, V100, P500; Saxs HC, 1987, AM J SURG, V153, P117; SCHRODER T, 1991, ANN SURG, V214, P663, DOI 10.1097/00000658-199112000-00004; Schunemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE; Schwarz M, 1997, DEUT MED WOCHENSCHR, V122, P356, DOI 10.1055/s-2008-1047621; Sekimotos M, 2010, J HEPATOBILIARY PANC, V17, P17; Kumar PS, 2012, INT J SURG, V10, P587, DOI 10.1016/j.ijsu.2012.09.027; Seta T, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-102; Sethi S, 2014, PANCREAS, V43, P190, DOI 10.1097/MPA.0000000000000090; Shanbhag ST, 2011, PANCREAS, V40, P1141, DOI 10.1097/MPA.0b013e3182311ecb; Sharma VK, 1999, AM J GASTROENTEROL, V94, P3211; Shen HN, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-112; Shermans S, 1994, GASTROINTEST ENDOSC, V40, P124; Shojania KG, 2001, EVID REP TECHNOL ASS, V43, P1; SILVERSTEIN W, 1981, AM J ROENTGENOL, V137, P497; Singla A, 2009, GASTROENTEROLOGY, V137, P1995, DOI 10.1053/j.gastro.2009.08.056; Skipworth JRA, 2008, CURR OPIN CRIT CARE, V14, P172, DOI 10.1097/MCC.0b013e3282f6a3f9; STONE HH, 1980, SURG GYNECOL OBSTET, V150, P878; Suns E, 2013, J PANCREAS, V14, P221; Suns HL, 2014, SURG-J R COLL SURG E, V12, P141; Takada T, 2010, J HEPATO-BIL-PAN SCI, V17, P3, DOI 10.1007/s00534-009-0216-1; Takada T, 2006, J HEPATO-BILIARY-PAN, V13, P2, DOI 10.1007/s00534-005-1045-5; Taos J, 2003, J HUAZHONG U SCI TEC, V23, P399; TEERENHOVI O, 1989, BRIT J SURG, V76, P370, DOI 10.1002/bjs.1800760418; Tses F, 2013, ENDOSCOPY, V45, P605; Tsuchiya T, 2007, J HEPATO-BILIARY-PAN, V14, P302, DOI 10.1007/s00534-006-1147-8; vans Baals MC, 2014, SURGERY, V155, P442; vans Baals MC, 2012, ANN SURG, V255, P860; Vazquez-Iglesias JL, 2004, SURG ENDOSC, V18, P1442, DOI 10.1007/s00464-003-9185-7; VESENTINI S, 1993, BRIT J SURG, V80, P755, DOI 10.1002/bjs.1800800633; Villatoro E, 2010, COCHRANE DB SYST REV, V12; Villatoros E, 2006, COCHRANE DB SYST REV, V18; VUJIC I, 1984, RADIOLOGY, V150, P51; Wada K, 2010, J HEPATO-BIL-PAN SCI, V17, P79, DOI 10.1007/s00534-009-0218-z; Wittau M, 2011, SCAND J GASTROENTERO, V46, P261, DOI 10.3109/00365521.2010.531486; Working Group IAP/APA Acute Pancreatitis Guidelines, 2013, PANCREATOLOGY S2, V13, pe1, DOI DOI 10.1016/J.PAN.2013.07.063; Wus BU, 2011, CLIN GASTROENTEROL H, V9; Wus BU, 2008, GUT, V57, P1698; Xues P, 2009, J GASTROEN HEPATOL, V24, P736; Xus J, 2013, HEPATO-GASTROENTEROL, V60, P1749; Xus T, 2008, SCAND J GASTROENTERO, V43, P1249; Yaos L, 2010, DIGEST SURG, V27, P442; Yoshida M, 2006, J HEPATO-BILIARY-PAN, V13, P7, DOI 10.1007/s00534-005-1046-4; Yoshida M, 2010, J HEPATO-BIL-PAN SCI, V17, P13, DOI 10.1007/s00534-009-0215-2; Zahngs HB, 2007, CHIN J PANCREATOL, V7, P353	339	2	3	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	JUN	2015	22	6					405	432		10.1002/jhbp.259		28	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ0EY	WOS:000355149200005		
J	Isaji, S; Takada, T; Mayumi, T; Yoshida, M; Wada, K; Yokoe, M; Itoi, T; Gabata, T				Isaji, Shuji; Takada, Tadahiro; Mayumi, Toshihiro; Yoshida, Masahiro; Wada, Keita; Yokoe, Masamichi; Itoi, Takao; Gabata, Toshifumi			Revised Japanese guidelines for the management of acute pancreatitis 2015: revised concepts and updated points	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Enteral nutrition; Pancreatitis bundles; Post-endoscopic retrograde cholangiopancreatography pancreatitis; Prophylactic antibiotics; Therapeutic intervention	ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; POST-ERCP PANCREATITIS; ACUTE NECROTIZING PANCREATITIS; RANDOMIZED CONTROLLED-TRIAL; REGIONAL ARTERIAL INFUSION; HIGH-RISK PATIENTS; JPN GUIDELINES; PERITONEAL-LAVAGE; RECTAL INDOMETHACIN; STENT	BackgroundTaking together the recent dramatic changes of the revised Atlanta classification and evidence newly obtained such as the role of step-up approach for necrotizing pancreatitis, the revision committee of the Japanese (JPN) Guidelines 2015 was prompted to perform an extensive revision of the guidelines. MethodsThe JPN Guidelines 2015 was compared to the former edition 2010, and revision concepts and major revision points were reviewed. We compared the JPN 2015 with the other two guidelines, International Association of Pancreatology (IAP)/American Pancreas Association (APA) 2013 and American College of Gastroenterology (ACG) 2013, in order to clarify the distinct points. ResultsThe meta-analysis team conducted a new meta-analysis of four subjects that have been associated with conflicting results. It is apparent that the revised guidelines have been created more systematically and more objectively. As of antibiotics prophylaxis, its use in early phase (within 72h of onset) for severe acute pancreatitis is recommended in JPN 2015 according to the results of original meta-analysis, whereas the other two guidelines do not recommend its routine use. An approach and management of local complications in necrotizing pancreatitis including infected necrosis are almost similar in the three guidelines. JPN 2015 alone emphasizes the implementation of the pancreatitis bundles that specify the management and treatment within the first 48h after the onset of severe acute pancreatitis. ConclusionThe JPN Guidelines 2015 prove to be the highest quality in terms of systematic literature review conducting original analyses by the meta-analysis team, determining the grading of recommendations and providing pancreatitis bundles.	[Isaji, Shuji] Mie Univ, Grad Sch Med, Hepatobiliary Pancreat & Transplant Surg, Tsu, Mie 5148507, Japan; [Takada, Tadahiro; Wada, Keita] Teikyo Univ, Sch Med, Dept Surg, Tokyo 173, Japan; [Mayumi, Toshihiro] Univ Occupat & Environm Hlth, Sch Med, Dept Emergency Med, Kitakyushu, Fukuoka 807, Japan; [Yoshida, Masahiro] Int Univ Hlth & Welf, Chemotherapy Res Inst, Dept Hemodialysis & Surg, Ichikawa, Japan; [Yokoe, Masamichi] Japanese Red Cross Nagoya Daini Hosp, Gen Internal Med, Nagoya, Aichi, Japan; [Itoi, Takao] Tokyo Med Univ, Dept Gastroenterol & Hepatol, Tokyo 1608402, Japan; [Gabata, Toshifumi] Kanazawa Univ, Sch Med Sci, Dept Radiol, Kanazawa, Ishikawa, Japan	Isaji, S (reprint author), Mie Univ, Grad Sch Med, Hepatobiliary Pancreat & Transplant Surg, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	shujiisaji1@mac.com					Al-Bahrani AZ, 2008, PANCREAS, V36, P39, DOI 10.1097/mpa.0b013e318149f5bf; van Santvoort HC, 2010, NEW ENGL J MED, V362, P1491, DOI 10.1056/NEJMoa0908821; Mayumi T, 2006, J HEPATO-BILIARY-PAN, V13, P61, DOI 10.1007/s00534-005-1053-5; Yadav D, 2006, PANCREAS, V33, P323, DOI 10.1097/01.mpa.0000236733.31617.52; Otsuka T, 2012, J GASTROENTEROL, V47, P912, DOI 10.1007/s00535-012-0554-7; Kiriyama S, 2010, J HEPATO-BIL-PAN SCI, V17, P24, DOI 10.1007/s00534-009-0214-3; Harewood GC, 2005, GASTROINTEST ENDOSC, V62, P367, DOI 10.1016/j.gie.2005.04.020; Amano H, 2010, J HEPATO-BIL-PAN SCI, V17, P53, DOI 10.1007/s00534-009-0211-6; Koizumi M, 2006, J HEPATO-BILIARY-PAN, V13, P25, DOI 10.1007/s00534-005-1048-2; Ukai T, 2015, J HEPATO-BIL-PAN SCI, V22, P316, DOI 10.1002/jhbp.221; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Tenner S, 2013, AM J GASTROENTEROL, V108, P1400, DOI 10.1038/ajg.2013.218; Loveday BPT, 2010, AM J GASTROENTEROL, V105, P1466, DOI 10.1038/ajg.2010.137; Kawaguchi Y, 2012, WORLD J GASTROENTERO, V18, P1635, DOI 10.3748/wjg.v18.i14.1635; MAYER AD, 1985, NEW ENGL J MED, V312, P399, DOI 10.1056/NEJM198502143120703; Fazel A, 2003, GASTROINTEST ENDOSC, V57, P291, DOI 10.1067/mge.2003.124; Murray B, 2003, GASTROENTEROLOGY, V124, P1786, DOI 10.1016/S0016-5085(03)00384-6; Sofuni A, 2011, CLIN GASTROENTEROL H, V9, P851, DOI 10.1016/j.cgh.2011.06.033; Banks PA, 2006, AM J GASTROENTEROL, V101, P2379, DOI 10.1111/j.1572-0241.2006.00856.x; Elmunzer BJ, 2008, GUT, V57, P1262, DOI 10.1136/gut.2007.140756; Takeda K, 1996, AM J SURG, V171, P394, DOI 10.1016/S0002-9610(97)89617-1; Elmunzer BJ, 2012, NEW ENGL J MED, V366, P1414, DOI 10.1056/NEJMoa1111103; Hirota M, 2010, J HEPATO-BIL-PAN SCI, V17, P45, DOI 10.1007/s00534-009-0210-7; Sekimoto M, 2006, J HEPATO-BILIARY-PAN, V13, P10, DOI 10.1007/s00534-005-1047-3; Tarnasky PR, 1998, GASTROENTEROLOGY, V115, P1518, DOI 10.1016/S0016-5085(98)70031-9; SMITHLINE A, 1993, GASTROINTEST ENDOSC, V39, P652; Kimura Y, 2010, J HEPATO-BIL-PAN SCI, V17, P60, DOI 10.1007/s00534-009-0217-0; Isaji S, 2006, J HEPATO-BILIARY-PAN, V13, P48, DOI 10.1007/s00534-005-1051-7; Takeda K, 2006, J HEPATO-BILIARY-PAN, V13, P42, DOI 10.1007/s00534-005-1050-8; Arata S, 2010, J HEPATO-BIL-PAN SCI, V17, P70, DOI 10.1007/s00534-009-0220-5; Hirota M, 2006, J HEPATO-BILIARY-PAN, V13, P33, DOI 10.1007/s00534-005-1049-1; [Anonymous], 2009, OXFORD CTR EVIDENCE; Sofuni A, 2007, CLIN GASTROENTEROL H, V5, P1339, DOI 10.1016/j.cgh.2007.07.008; McColl KEL, 2005, GUT, V54, P1, DOI 10.1136/gut.2004.047126; Badalov Nison, 2009, JOP, V10, P88; Banks PA, 2012, GUT, V62, P102, DOI DOI 10.1136/GUTJNL-2012-302779; BRADLEY EL, 1993, ARCH SURG-CHICAGO, V128, P586; COOPER MJ, 1982, ANN ROY COLL SURG, V64, P422; Doebroente Zoltan, 2012, Orvosi Hetilap, V153, P990, DOI 10.1556/OH.2012.29403; Hamada T, 2013, CRIT CARE, V17, DOI 10.1186/cc13029; Hirota M, 2014, J HEPATO-BIL-PAN SCI, V21, P829, DOI 10.1002/jhbp.163; IHSE I, 1986, ANN SURG, V204, P122, DOI 10.1097/00000658-198608000-00004; Itos K, 2010, J GASTROENTEROL, V45, P1183; Khoshbaten M, 2008, J GASTROEN HEPATOL, V23, pE11, DOI 10.1111/j.1440-1746.2007.05096.x; Kimura Y, 2006, J HEPATO-BILIARY-PAN, V13, P56, DOI 10.1007/s00534-005-1052-6; Lees TH, 2012, GASTROINTEST ENDOSC, V76, P578; Mayumi T, 2010, J HEPATO-BIL-PAN SCI, V17, P87, DOI 10.1007/s00534-009-0219-y; Montanos LA, 2007, REV ESP ENFERM DIG, V99, P330; Pans XP, 2011, CELL BIOCH BIOPHYS, V61, P473; Patels R, 1999, GASTROINTEST ENDOSC, V49, p80A; Piacik M, 2010, PANCREAS, V39, P863; Sekimoto M, 2010, J HEPATO-BIL-PAN SCI, V17, P17, DOI 10.1007/s00534-009-0212-5; Shimosegawas T., 2014, SUMMARY REPORTS 2011, P61; Sotoudehmanesh R, 2007, AM J GASTROENTEROL, V102, P978, DOI 10.1111/j.1572-0241.2007.01165.x; STONE HH, 1980, SURG GYNECOL OBSTET, V150, P878; Takada T, 2007, J HEPATO-BILIARY-PAN, V14, P1, DOI 10.1007/s00534-006-1150-0; Takada T, 2006, J HEPATO-BILIARY-PAN, V13, P2, DOI 10.1007/s00534-005-1045-5; Takedas K, 2010, J HEPATOBILIARY PANC, V17, P37; The Guideline Revision Committee for the management of acute pancreatitis, 2015, CLIN PRACTICE GUIDEL, V4th; Tsuchiya T, 2007, J HEPATO-BILIARY-PAN, V14, P302, DOI 10.1007/s00534-006-1147-8; Uhls W, 2002, PANCREATOLOGY, V2, P565; Villatoros E, 2010, COCHRANE DB SYST REV, V5; Wada K, 2010, J HEPATO-BIL-PAN SCI, V17, P79, DOI 10.1007/s00534-009-0218-z; Wittau M, 2011, SCAND J GASTROENTERO, V46, P261, DOI 10.3109/00365521.2010.531486; Working Group IAP/APA Acute Pancreatitis Guidelines, 2013, PANCREATOLOGY S2, V13, pe1, DOI DOI 10.1016/J.PAN.2013.07.063; Yokoe M, 2015, J HEPATO-BIL-PAN SCI, V22, P405, DOI 10.1002/jhbp.259; Yoshida M, 2006, J HEPATO-BILIARY-PAN, V13, P7, DOI 10.1007/s00534-005-1046-4; Yoshida M, 2010, J HEPATO-BIL-PAN SCI, V17, P13, DOI 10.1007/s00534-009-0215-2; Zahngs HB, 2007, CHIN J PANCREATOL, V7, P353	69	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	JUN	2015	22	6					433	445		10.1002/jhbp.260		13	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ0EY	WOS:000355149200006		
J	Tanaka, K; Matsuo, K; Kawaguchi, D; Murakami, T; Hiroshima, Y; Hirano, A; Sato, S; Endo, I; Taguri, M; Koda, K				Tanaka, Kuniya; Matsuo, Kenichi; Kawaguchi, Daisuke; Murakami, Takashi; Hiroshima, Yukihiko; Hirano, Atsushi; Sato, Sho; Endo, Itaru; Taguri, Masataka; Koda, Keiji			Randomized clinical trial of peritoneal lavage for preventing surgical site infection in elective liver surgery	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Liver surgery; Peritoneal lavage; Surgical site infection	RETROSPECTIVE ANALYSIS; HEPATIC RESECTION; FECAL PERITONITIS; HEPATECTOMY; COMPLICATIONS; MESOTHELIUM; ADHERENCE; SURVIVAL; OUTCOMES	BackgroundAlthough intraoperative peritoneal lavage is often performed routinely with the aim of reducing peritoneal contamination, little evidence of lavage benefits in elective liver resection without bile duct resection is available. We addressed the issue with a randomized clinical trial. MethodsWe prospectively and randomly assigned consecutive patients undergoing liver resection to a lavage group or a non-lavage group. Peritoneal lavage was performed at the end of operation for patients in the lavage group. The primary endpoint was the rate of surgical site infection. ResultsNinety-six patients were assigned to the lavage group and 97 to the non-lavage group. When superficial/deep incisional infection and organ/space infection were considered together, no significant difference in surgical site infection rate was evident between lavage (21.9%) and non-lavage groups (13.4%, P=0.135). However, organ/space infection was significantly more frequent in the lavage group (16.7%) than the non-lavage group (7.2%, P=0.048). Peritoneal lavage was identified as a risk factor for organ/space infection by multivariate analysis (relative risk, 2.977; confidence interval, 1.094 to 8.100; P=0.033). ConclusionIntraoperative peritoneal lavage does not reduce overall incidence of surgical site infection and may increase risk of organ/space infection.	[Tanaka, Kuniya; Matsuo, Kenichi; Kawaguchi, Daisuke; Murakami, Takashi; Hiroshima, Yukihiko; Hirano, Atsushi; Koda, Keiji] Teikyo Univ, Chiba Med Ctr, Dept Surg, Ichihara, Chiba 2990111, Japan; [Sato, Sho; Endo, Itaru] Yokohama City Univ, Grad Sch Med, Dept Surg Gastroenterol, Yokohama, Kanagawa 232, Japan; [Taguri, Masataka] Yokohama City Univ, Grad Sch Med, Dept Biostat & Epidemiol, Yokohama, Kanagawa 232, Japan	Tanaka, K (reprint author), Teikyo Univ, Chiba Med Ctr, Dept Surg, 3426-3 Anesaki, Ichihara, Chiba 2990111, Japan.	U17-92TS@med.teikyo-u.ac.jp					Adam U, 1997, LANGENBECK ARCH CHIR, V382, pS18, DOI 10.1007/PL00014638; BONE RC, 1992, CRIT CARE MED, V20, P864; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Cescon M, 2009, ANN SURG, V249, P995, DOI 10.1097/SLA.0b013e3181a63c74; Koch M, 2011, SURGERY, V149, P680, DOI 10.1016/j.surg.2010.12.002; Feng ZQ, 2008, WORLD J GASTROENTERO, V14, P7247, DOI 10.3748/wjg.14.7247; Rahbari NN, 2011, HPB, V13, P528, DOI 10.1111/j.1477-2574.2011.00319.x; [Anonymous], 2000, HPB, V88, P333; Mullen JT, 2007, J AM COLL SURGEONS, V204, P854, DOI 10.1016/j.jamcollsurg.2006.12.032; Platell C, 2000, J AM COLL SURGEONS, V191, P672, DOI 10.1016/S1072-7515(00)00726-2; MADDAUS MA, 1988, SURG CLIN N AM, V68, P431; MINERVINI S, 1980, DIS COLON RECTUM, V23, P392, DOI 10.1007/BF02586785; Rahbari NN, 2011, SURGERY, V149, P713, DOI 10.1016/j.surg.2010.10.001; Mathur AK, 2010, J GASTROINTEST SURG, V14, P1285, DOI 10.1007/s11605-010-1232-9; Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620; Elola-Olaso AM, 2012, HPB, V14, P136, DOI 10.1111/j.1477-2574.2011.00417.x; Sadamori H, 2013, J HEPATO-BIL-PAN SCI, V20, P186, DOI 10.1007/s00534-011-0503-5; Tanaka K, 2013, SURG TODAY, V43, P372, DOI 10.1007/s00595-012-0254-1; Benzoni E, 2007, HEPATO-GASTROENTEROL, V54, P186; Benzoni Enrico, 2006, Hepatobiliary Pancreat Dis Int, V5, P526; BREBOROWICZ A, 1992, KIDNEY INT, V41, P1280, DOI 10.1038/ki.1992.190; DUMONT AE, 1986, SURG GYNECOL OBSTET, V162, P248; DUNN DL, 1984, ANN SURG, V199, P37, DOI 10.1097/00000658-198401000-00007; EDMISTON CE, 1990, WORLD J SURG, V14, P176; HAAGEN IA, 1990, J INFECT DIS, V161, P266; Hall JC, 1998, GASTROENTEROLOGY, V114, P185, DOI 10.1016/S0016-5085(98)70646-8; LAMPERI S, 1988, CLIN NEPHROL, V30, pS41; Mckay A, 2008, ANN SURG ONCOL, V15, P1348, DOI 10.1245/s10434-008-9838-9; Onodera T, 1984, Nihon Geka Gakkai Zasshi, V85, P1001; ROSENSHEIN N, 1978, GYNECOL ONCOL, V6, P106, DOI 10.1016/0090-8258(78)90010-0; Sato M, 2012, J GASTROENTEROL, V47, P1125, DOI 10.1007/s00535-012-0569-0; Togo S, 2007, J ANTIMICROB CHEMOTH, V59, P964, DOI 10.1093/jac/dkm028; TOLHURST.CL, 1974, BRIT J SURG, V61, P601; WHITAKER D, 1982, CRC CR REV TOXICOL, V10, P81, DOI 10.3109/10408448209041321; Whiteside OJH, 2005, ANN ROY COLL SURG, V87, P255, DOI 10.1308/1478708051847; Yaacobi Y, 1991, J Invest Surg, V4, P31, DOI 10.3109/08941939109140759	36	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	JUN	2015	22	6					446	453		10.1002/jhbp.222		8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ0EY	WOS:000355149200007		
J	Yamashita, K; Sasaki, T; Itoh, R; Kato, D; Hatano, N; Soejima, T; Ishii, K; Takenawa, T; Hiromatsu, K; Yamashita, Y				Yamashita, Kanefumi; Sasaki, Takamitsu; Itoh, Ryota; Kato, Daisuke; Hatano, Naoya; Soejima, Toshinori; Ishii, Kazunari; Takenawa, Tadaomi; Hiromatsu, Kenji; Yamashita, Yuichi			Pancreatic fistulae secondary to trypsinogen activation by Pseudomonas aeruginosa infection after pancreatoduodenectomy	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Bacteria; Pancreatic fistula; Pancreatoduodenectomy; Pseudomonas aeruginosa; Trypsinogen	PROSPECTIVE-RANDOMIZED-TRIAL; DUAL-INSTITUTION TRIAL; GLUE SEALANT DECREASE; HEAD RESECTION; CLINICAL-TRIAL; RISK-FACTORS; PANCREATICOJEJUNOSTOMY; PROTEASE; PANCREATICOGASTROSTOMY; COMPLICATIONS	BackgroundPancreatic fistula after pancreatoduodenectomy (PD) is associated with high mortality and morbidity. Trypsinogen activation and bacteria, although hypothesized to be interrelated etiopathogenetically, have not had their relationship and pathogenic mechanisms elucidated. This study investigated bacterial involvement in pancreatic juice activation perioperatively after PD at sites of pancreatic fistula formation. MethodsFifty patients underwent PD; postoperative pancreatic fistulae were graded based on the International Study Group for Pancreatic Fistula grading criteria. Bacteria were isolated from cultures of drainage fluid. Digested peptides from trypsinogen and bacterial culture supernatants underwent sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) separation and mass spectrometric analysis. Zymography was used to detect the trypsinogen activator. ResultsPseudomonas aeruginosa and Enterobacter cloacae isolated from drainage fluid in patients with grades B and C pancreatic fistulae could cause trypsinogen activation. Trypsinogen activation by P. aeruginosa and E. cloacae were preventable by the use of a serine protease inhibitor in vitro. A protease in the supernatant from P. aeruginosa-positive cultures acted as the trypsinogen activator. ConclusionsInfection with P. aeruginosa perioperatively to PD entails secretion of a protease activator of trypsinogen to trypsin. Bacterial infection control in the perioperative PD period could be crucial to prevent development of pancreatic fistula.	[Yamashita, Kanefumi; Sasaki, Takamitsu; Kato, Daisuke; Yamashita, Yuichi] Fukuoka Univ, Sch Med, Dept Surg Gastroenterol, Jonan Ku, Fukuoka 8140180, Japan; [Itoh, Ryota; Soejima, Toshinori; Ishii, Kazunari; Hiromatsu, Kenji] Fukuoka Univ, Sch Med, Dept Microbiol & Immunol, Jonan Ku, Fukuoka 8140180, Japan; [Hatano, Naoya; Takenawa, Tadaomi] Kobe Univ, Integrated Ctr Mass Spectrometry, Kobe, Hyogo 657, Japan	Sasaki, T (reprint author), Fukuoka Univ, Sch Med, Dept Surg Gastroenterol, Jonan Ku, Nanakuma 7-45-1, Fukuoka 8140180, Japan.	takamitu@fc4.so-net.ne.jp					Regner S, 2008, PANCREATOLOGY, V8, P600, DOI 10.1159/000161011; Hatano N, 2008, J PROTEOME RES, V7, P809, DOI 10.1021/pr700566d; Lillemoe KD, 2004, J GASTROINTEST SURG, V8, P766, DOI 10.1016/j.gassur.2004.06.011; [Anonymous], 2001, ANN SURG, DOI DOI 10.1097/00000658-200110000-00008]; Nagakawa Y, 2013, PANCREAS, V42, P701, DOI 10.1097/MPA.0b013e31826d3a41; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Satoi S, 2008, PANCREAS, V37, P128, DOI 10.1097/MPA.0b013e318162cb53; Bhatia M, 2005, PANCREATOLOGY, V5, P132, DOI 10.1159/000085265; Bassi C, 2005, SURGERY, V138, P8, DOI 10.1016/j.surg.2005.05.001; Bassi C, 2005, ANN SURG, V242, P767, DOI 10.1097/01.sla.0000189124.47589.6d; Motoi F, 2012, BRIT J SURG, V99, P524, DOI 10.1002/bjs.8654; Lowy AM, 1997, ANN SURG, V226, P632, DOI 10.1097/00000658-199711000-00008; Berger AC, 2009, J AM COLL SURGEONS, V208, P738, DOI 10.1016/j.jamcollsurg.2008.12.031; Bassi C, 2010, ANN SURG, V252, P207, DOI 10.1097/SLA.0b013e3181e61e88; Adam U, 2004, AM J SURG, V187, P201, DOI 10.1016/j.amhsurg.2003.11.004; Kessler E, 1998, J BIOL CHEM, V273, P30225, DOI 10.1074/jbc.273.46.30225; Duffas JP, 2005, AM J SURG, V189, P720, DOI 10.1016/j.amjsurg.2005.03.015; Yeo CJ, 2002, ANN SURG, V236, P355, DOI 10.1097/01.SLA.0000027272.08464.0B; Kawai M, 2006, ANN SURG, V244, P1, DOI 10.1097/01.sla.0000218077.14035.a6; Molinari E, 2007, ANN SURG, V246, P281, DOI 10.1097/SLA.0b013e3180caa42f; Sanders WE, 1997, CLIN MICROBIOL REV, V10, P220; YEO CJ, 1995, ANN SURG, V222, P580; Whitcomb DC, 2007, DIGEST DIS SCI, V52, P1, DOI 10.1007/s10620-006-9589-z; Cameron JL, 2006, ANN SURG, V244, P10, DOI 10.1097/01.sla.0000217673.04165.ea; Bassi C, 2005, ANN SURG, V242, P771; Cameron JL, 2009, J AM COLL SURGEONS, V208, P747; Buchler M, 1992, AM J SURG, V163, P130; BUCHLER M, 1992, AM J SURG, V163, P125, DOI 10.1016/0002-9610(92)90264-R; Choe YM, 2008, WORLD J GASTROENTERO, V14, P6970, DOI 10.3748/wjg.14.6970; ELLIOTT BW, 1986, J BIOL CHEM, V261, P1259; Gaiser S, 2011, GUT, V60, P1379, DOI 10.1136/gut.2010.226175; Golovkine G, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003939; Guys O, 1978, BIOCHEMISTRY-US, V17, P1669; Traverso LW, 2004, J GASTROINTEST SURG, V8, P772; MAEDA H, 1995, METHOD ENZYMOL, V248, P395; MATSUMOTO K, 1993, INVEST OPHTH VIS SCI, V34, P1945; NAKAE Y, 1995, PANCREAS, V10, P306, DOI 10.1097/00006676-199504000-00014; Pederzolis P, 1994, ITALIAN STUDY GROUP, V81, P265; Sucs B, 2003, ANN SURG, V237, P57; Tokumitsu H, 2011, BIOCHEMISTRY-US, V50, P8193, DOI 10.1021/bi201005g; TRAVERSO LW, 1987, J SURG RES, V43, P220, DOI 10.1016/0022-4804(87)90074-6; TWINING SS, 1993, INVEST OPHTH VIS SCI, V34, P2699; Yeo CJ, 2002, ANN SURG, V236, P366; Yeo CJ, 1995, ANN SURG, V222, P588; Yeos CJ, 2000, ANN SURG, V232, P419; Zheng X Long, 2009, Front Biosci (Elite Ed), V1, P242	46	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	JUN	2015	22	6					454	462		10.1002/jhbp.223		9	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ0EY	WOS:000355149200008		
J	Yoneda, G; Katagiri, S; Yamamoto, M				Yoneda, Godai; Katagiri, Satoshi; Yamamoto, Masakazu			Reverse Trendelenburg position is a safer technique for lowering central venous pressure without decreasing blood pressure than clamping of the inferior vena cava below the liver	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Bleeding during hepatectomy; Central venous pressure control technique; Infrahepatic inferior vena cava clamping	RANDOMIZED-CONTROLLED-TRIAL; HEPATIC RESECTION; PATIENT POSITION; HEPATECTOMY; ANESTHESIA; MORTALITY; MORBIDITY; OCCLUSION; SURGERY; RISK	BackgroundBleeding remains an important intraoperative complication in patients who undergo hepatectomy. It is generally believed that a reduction in central venous pressure will decrease bleeding from the hepatic venous system. To our knowledge, however, no study has compared the effectiveness of these techniques for controlling bleeding. So we compared the effectiveness of central venous pressure control techniques, such as infrahepatic inferior vena cava clamping, changes in surgical position of the patient, and hypoventilation anesthesia, for lowering central venous pressure. MethodsThe study group comprised 50 patients who underwent hepatectomy in our department from 2012 through 2013. A central venous catheter was inserted into the right internal jugular vein, and the tip was placed in the superior vena cava. A transducer was placed along the mid-axillary line of the left side of the chest. After opening the abdomen, changes in central venous pressure were measured during inferior vena cava clamping, the reverse Trendelenburg position, the Trendelenburg position, and hypoventilation anesthesia. The inclination relative to the transducer, as measured with an inclinometer, was -10 degrees for the Trendelenburg position and +10 degrees for the reverse Trendelenburg position. The tidal volume was set at 10mL/kg during conventional anesthesia and 5mL/kg during hypoventilation anesthesia. ResultsThe mean central venous pressure was 8.0cmH(2)O in the supine position during conventional anesthesia, 5.0cmH(2)O during inferior vena cava clamping, 5.6cmH(2)O during reverse Trendelenburg position, 10.6cmH(2)O during Trendelenburg position, and 7.6cmH(2)O during hypoventilation anesthesia. The mean central venous pressure during inferior vena cava clamping and reverse Trendelenburg position was significantly lower than that during supine position (P=0.0017 and P=0.0231, respectively). The mean central venous pressure during hypoventilation anesthesia was not significantly lower than that during supine position (P=0.9934). Mean systolic blood pressure was significantly decreased during inferior vena cava clamping (P=0.0024), but not during reverse Trendelenburg position (P=0.6344). ConclusionsReverse Trendelenburg position decreased central venous pressure without significantly decreasing the systolic blood pressure, suggesting that it is possible to perform hepatectomy with reverse Trendelenburg position more safely than with inferior vena cava clamping.	[Yoneda, Godai; Katagiri, Satoshi; Yamamoto, Masakazu] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Surg, Shinjuku Ku, Tokyo 1620054, Japan	Katagiri, S (reprint author), Tokyo Womens Med Univ, Inst Gastroenterol, Dept Surg, Shinjuku Ku, 8-1 Kawadacho, Tokyo 1620054, Japan.	katagiri.ige@twmu.ac.jp					Chen H, 2000, J GASTROINTEST SURG, V4, P162, DOI 10.1016/S1091-255X(00)80052-9; Sand L, 2011, ACTA ANAESTH SCAND, V55, P1106, DOI 10.1111/j.1399-6576.2011.02502.x; Jones RM, 1998, BRIT J SURG, V85, P1058; Rees M, 1996, BRIT J SURG, V83, P1526, DOI 10.1002/bjs.1800831110; Buell JF, 2008, ANN SURG, V248, P475, DOI 10.1097/SLA.0b013e318185e647; Otsubo T, 2004, SURGERY, V135, P67, DOI 10.1016/S0039-6060(03)00343-X; Wang WD, 2006, WORLD J GASTROENTERO, V12, P935; Imamura H, 2003, ARCH SURG-CHICAGO, V138, P1198, DOI 10.1001/archsurg.138.11.1198; Melendez JA, 1998, J AM COLL SURGEONS, V187, P620, DOI 10.1016/S1072-7515(98)00240-3; Belghiti J, 1996, ANN SURG, V224, P155, DOI 10.1097/00000658-199608000-00007; Pringle JH, 1908, ANN SURG, V48, P541, DOI 10.1097/00000658-190810000-00005; Rahbari NN, 2011, ANN SURG, V253, P1102, DOI 10.1097/SLA.0b013e318214bee5; Poon RT, 2004, ANN SURG, V240, P698, DOI 10.1097/01.sla.0000141195.66155.0c; MAKUUCHI M, 1987, SURG GYNECOL OBSTET, V164, P155; Artuso D, 2005, ARCH SURG-CHICAGO, V140, P289, DOI 10.1001/archsurg.140.3.289; Chui AKK, 2000, J AM COLL SURGEONS, V190, P760, DOI 10.1016/S1072-7515(00)00324-0; Hasegawa K, 2002, ARCH SURG-CHICAGO, V137, P311, DOI 10.1001/archsurg.137.3.311; Hashimoto T, 2007, ANN SURG, V245, P686, DOI 10.1097/01.sla.0000255562.602154.3b; HEANEY JP, 1966, ANN SURG, V163, P237; Johnson M, 1998, BRIT J SURG, V85, P188; McCall J, 2001, NEW ZEAL MED J, V114, P516; Melendezs JA, 2000, SURG LIVER BILIARY T, V3rd, P545; Moulton CA, 2001, AM J SURG, V181, P366, DOI 10.1016/S0002-9610(01)00570-0; Soonawalla ZF, 2008, LANGENBECK ARCH SURG, V393, P195, DOI 10.1007/s00423-007-0222-1; Takasaki K, 1998, J Hepatobiliary Pancreat Surg, V5, P286, DOI 10.1007/s005340050047; Wus W, 2002, WORLD J GASTROENTERO, V8, P763; Yans CY, 2012, HEPATO-GASTROENTEROL, V59, P501	27	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	JUN	2015	22	6					463	466		10.1002/jhbp.229		4	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ0EY	WOS:000355149200009		
J	Mori, A; Iida, T; Iwasaki, J; Ogawa, K; Fujimoto, Y; Uemura, T; Hatano, E; Okajima, H; Kaido, T; Uemoto, S				Mori, Akira; Iida, Taku; Iwasaki, Junji; Ogawa, Kohei; Fujimoto, Yasuhiro; Uemura, Tadahiro; Hatano, Etsuro; Okajima, Hideaki; Kaido, Toshimi; Uemoto, Shinji			Portal vein reconstruction in adult living donor liver transplantation for patients with portal vein thrombosis in single center experience	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Living donor liver transplantation; Portal vein thrombosis; Reconstruction; Vein graft	SPONTANEOUS SPLENORENAL SHUNTS; RENOPORTAL ANASTOMOSIS; VENOUS GRAFT; FOLLOW-UP; MANAGEMENT; HEMITRANSPOSITION; CIRRHOSIS	BackgroundLiver transplantation (LT) used to be contraindicated in patients with portal vein thrombosis (PVT). In comparison to deceased donor LT, living donor LT (LDLT) still presents additional difficulties in determining appropriate vein grafts and overcoming small-for-size syndrome. Here, we introduce our LDLT strategies and assess their outcomes in adult patients with pre-existing PVT. MethodsWe performed 282 consecutive adult LDLTs between April 2006 and December 2011. Forty-eight patients (17%) had pre-existing PVT (grade I; 15, II; 20, III; 12, IV; 1). ResultsOur preferred treatments for PVT were thrombectomies/thromboendovenectomies in 30 patients, replaced grafts in seven, jump grafts in seven, renoportal anastomosis in one and no surgical intervention owing to minimal thrombosis in three. Post-transplant portal vein complications occurred in eight of 48 (17%) cases, which were treated by surgery, anticoagulation therapy, and/or interventional radiology. Post-transplant survival rates of patients with preexisting PVT at 1 year and 5 years were comparable to a PVT-free cohort (1 year; 81% vs. 77%, 5 years; 81% vs. 73%). ConclusionsThe excellent survival rates in patients with PVT who underwent LDLT could be attributed to our strategies, which included surgical techniques and timely treatment of postoperative complications.	[Mori, Akira; Iida, Taku; Iwasaki, Junji; Ogawa, Kohei; Fujimoto, Yasuhiro; Uemura, Tadahiro; Hatano, Etsuro; Okajima, Hideaki; Kaido, Toshimi; Uemoto, Shinji] Kyoto Univ, Grad Sch Med, Dept Hepatobiliary Pancreat Surg & Transplantat, Sakyo Ku, Kyoto 6068507, Japan	Mori, A (reprint author), Kyoto Univ, Grad Sch Med, Dept Hepatobiliary Pancreat Surg & Transplantat, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	akr@kuhp.kyoto-u.ac.jp					Paskonis M, 2006, CLIN TRANSPLANT, V20, P551, DOI 10.1111/j.1399-0012.2006.00560.x; Kyoden Y, 2008, TRANSPL INT, V21, P1136, DOI 10.1111/j.1432-2277.2008.00752.x; Egawa H, 2006, LIVER TRANSPLANT, V12, P1512, DOI 10.1002/lt.20777; Hibi T, 2014, ANN SURG, V259, P760, DOI 10.1097/SLA.0000000000000252; Abu-Elmagd KM, 2009, ANN SURG, V250, P567, DOI 10.1097/SLA.0b013e3181b67725; Werner KT, 2013, DIGEST DIS SCI, V58, P1776, DOI 10.1007/s10620-012-2548-y; D'Amico G, 2013, TRANSPL P, V45, P2692, DOI 10.1016/j.transproceed.2013.07.046; Moon DB, 2014, TRANSPLANTATION, V97, pS23, DOI 10.1097/01.tp.0000446270.20934.05; Luca A, 2012, RADIOLOGY, V265, P124, DOI 10.1148/radiol.12112236; Francoz C, 2012, J HEPATOL, V57, P203, DOI 10.1016/j.jhep.2011.12.034; Ogura Y, 2010, LIVER TRANSPLANT, V16, P718, DOI 10.1002/lt.22059; Nikitin D, 2009, LIVER TRANSPLANT, V15, P400, DOI 10.1002/lt.21698; Rodriguez-Castro KI, 2012, TRANSPLANTATION, V94, P1145, DOI 10.1097/TP.0b013e31826e8e53; Yerdel MA, 2000, TRANSPLANTATION, V69, P1873, DOI 10.1097/00007890-200005150-00023; Bonnet S, 2010, GASTROEN CLIN BIOL, V34, P23, DOI 10.1016/j.gcb.2009.05.013; Awad N, 2012, EXP CLIN TRANSPLANT, V10, P475, DOI 10.6002/ect.2011.0201; Fouzas I, 2012, TRANSPL P, V44, P2734, DOI 10.1016/j.transproceed.2012.09.024; Ikegami T, 2013, TRANSPLANTATION, V95, P1270, DOI 10.1097/TP.0b013e318288cadc; Kims JD, 2011, J KOREAN SURG SOC, V81, P35; Kims SJ, 2011, CLIN TRANSPLANT, V25, P111; Marubashi S, 2005, TRANSPLANTATION, V80, P1671, DOI 10.1097/01.tp.0000185087.93572.ld; Matsumoto Y, 2013, SURG TODAY, V43, P1316, DOI 10.1007/s00595-012-0351-1; Mizuno S, 2012, TRANSPL P, V44, P356, DOI 10.1016/j.transproceed.2012.01.039; Molmenti EP, 2002, ANN SURG, V235, P292, DOI 10.1097/00000658-200202000-00019; Paloyo S, 2013, LIVER TRANSPLANT, V19, P773, DOI 10.1002/lt.23653; Ponziani FR, 2014, TRANSPLANT REV-ORLAN, V28, P92, DOI 10.1016/j.trre.2014.01.003; Sato K, 2009, TRANSPL P, V41, P195, DOI 10.1016/j.transproceed.2008.08.157; Selvaggi G, 2007, AM J TRANSPLANT, V7, P454, DOI 10.1111/j.1600-6143.2006.01649.x; Wus TH, 2009, CLIN TRANSPLANT, V23, P751	29	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	JUN	2015	22	6					467	474		10.1002/jhbp.235		8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ0EY	WOS:000355149200010		
J	Hamaguchi, Y; Kaido, T; Okumura, S; Ito, T; Fujimoto, Y; Ogawa, K; Mori, A; Hammad, A; Hatano, E; Uemoto, S				Hamaguchi, Yuhei; Kaido, Toshimi; Okumura, Shinya; Ito, Takashi; Fujimoto, Yasuhiro; Ogawa, Kohei; Mori, Akira; Hammad, Ahmed; Hatano, Etsuro; Uemoto, Shinji			Preoperative intramuscular adipose tissue content is a novel prognostic predictor after hepatectomy for hepatocellular carcinoma	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Hepatocellular carcinoma; Intramuscular adipose tissue content; Prognostic factor; Sarcopenia	SKELETAL-MUSCLE; LIVER-TRANSPLANTATION; SARCOPENIA; OBESITY; IMPACT; PREVALENCE; RECURRENCE; RESECTION; SURVIVAL; QUALITY	BackgroundSarcopenia has been shown to be an independent predictor of lower disease-free and overall survival in various kinds of diseases. The quality of skeletal muscle has recently attracted much attention as a new parameter of sarcopenia. MethodsWe performed a retrospective analysis of 477 patients undergoing hepatectomy for hepatocellular carcinoma (HCC) between April 2005 and August 2014. The quality of skeletal muscle was evaluated by intramuscular adipose tissue content (IMAC) using preoperative computed tomography (CT) imaging. The impact of IMAC on outcomes after hepatectomy for HCC was analyzed. ResultsPatients with high IMAC showed older age, higher body mass index, higher indocyanine green retention test at 15min, and more operative blood loss. The overall and recurrence-free survival rates were significantly lower in patients with high IMAC than in patients with normal IMAC (P < 0.0001, P = 0.0012, respectively). Multivariate analysis showed that high IMAC was the significant risk factor for death (hazard ratio [HR] = 2.942; P < 0.0001) and for HCC recurrence (HR = 1.529; P = 0.0007) after hepatectomy. ConclusionsPreoperative quality of skeletal muscle was closely correlated with postoperative mortality and HCC recurrence. IMAC could be incorporated into new selection criteria for hepatectomy for HCC.	[Hamaguchi, Yuhei; Kaido, Toshimi; Okumura, Shinya; Ito, Takashi; Fujimoto, Yasuhiro; Ogawa, Kohei; Mori, Akira; Hammad, Ahmed; Hatano, Etsuro; Uemoto, Shinji] Kyoto Univ, Grad Sch Med, Div Hepatobiliary Pancreat & Transplant Surg, Dept Surg,Sakyo Ku, Kyoto 6068507, Japan	Kaido, T (reprint author), Kyoto Univ, Grad Sch Med, Div Hepatobiliary Pancreat & Transplant Surg, Dept Surg,Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	kaido@kuhp.kyoto-u.ac.jp					Montano-Loza AJ, 2012, CLIN GASTROENTEROL H, V10, P166, DOI 10.1016/j.cgh.2011.08.028; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Goodpaster BH, 2006, J GERONTOL A-BIOL, V61, P1059; Katz SC, 2009, ANN SURG, V249, P617, DOI 10.1097/SLA.0b013e31819ed22f; Sharma D, 2010, HEPATOLOGY, V52, P1713, DOI 10.1002/hep.23892; Kaido T, 2013, AM J TRANSPLANT, V13, P1549, DOI 10.1111/ajt.12221; Harimoto N, 2013, BRIT J SURG, V100, P1523, DOI 10.1002/bjs.9258; Llovet JM, 2005, SEMIN LIVER DIS, V25, P181, DOI 10.1055/s-2005-871198; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937; Marcus RL, 2010, J NUTR HEALTH AGING, V14, P362, DOI 10.1007/s12603-010-0081-2; Chien MY, 2008, J AM GERIATR SOC, V56, P1710, DOI 10.1111/j.1532-5415.2008.01854.x; Kitajima Y, 2013, J GASTROEN HEPATOL, V28, P1507, DOI 10.1111/jgh.12227; Park J, 2014, NAT REV ENDOCRINOL, V10, P455, DOI 10.1038/nrendo.2014.94; Prado CMM, 2008, LANCET ONCOL, V9, P629, DOI [10.1016/S1470-2045(08)70153-0, 10.1016/51470-2045(08)70153-0]; Delmonico MJ, 2009, AM J CLIN NUTR, V90, P1579, DOI 10.3945/ajcn.2009.28047; Lutz CT, 2012, AGING-US, V4, P535; Dalamaga Maria, 2013, World J Exp Med, V3, P26, DOI 10.5493/wjem.v3.i3.26; Drummonds MJ, 1985, J APPL PHYSIOL, V106, P1374; Formers A, 2012, LANCET, V379, P1245; Goodpasters BH, 2000, J APPL PHYSIOL, V89, P104; Hamaguchi Y, 2014, LIVER TRANSPLANT, V20, P1413, DOI 10.1002/lt.23970; Jenssens I, 2002, J AM GERIATR SOC, V50, P889; Tans BH, 2009, CLIN CANCER RES, V15, P6973; vans Vledders MG, 2012, BRIT J SURG, V99, P550; Vissers M, 2002, J AM GERIATR SOC, V50, P897; Voron T, 2014, ANN SURG, DOI [10.1097/SLA.0000000000000743, DOI 10.1097/SLA.0000000000000743]	27	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	JUN	2015	22	6					475	485		10.1002/jhbp.236		11	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ0EY	WOS:000355149200011		
J	Watanabe, T; Hirano, K; Tada, M; Isayama, H; Mizuno, S; Arizumi, T; Toda, N; Sugawara, Y; Kokudo, N; Koike, K				Watanabe, Takeo; Hirano, Kenji; Tada, Minoru; Isayama, Hiroyuki; Mizuno, Suguru; Arizumi, Toshihiko; Toda, Nobuo; Sugawara, Yasuhiko; Kokudo, Norihiro; Koike, Kazuhiko			Short-term prognostic factors for primary sclerosing cholangitis	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Alkaline phosphatase; MELD score; Primary sclerosing cholangitis; Prognosis; Ursodeoxycholic acid	DOSE URSODEOXYCHOLIC ACID; CLINICAL-FEATURES	BackgroundIt was recently reported that alkaline phosphatase (ALP) levels below 1.5 upper limit of normal (ULN) predicted better prognosis in primary sclerosing cholangitis (PSC). We evaluated whether ALP as well as other laboratory values were useful for the short-term prognosis of PSC in a Japanese cohort. MethodsIn 78 patients with PSC (41 males and 37 females, mean onset age 41.9 years), the relationship between nine parameters (albumin, bilirubin, international normalized ratio of prothrombin time [PT-INR], ALP, aspartate aminotransferase [AST], alanine aminotransferase [ALT], -glutamyl transpeptidase [-GTP], platelet, and calculated Model for End-Stage Liver Disease [MELD] score), and liver related clinical endpoints (death due to liver failure, variceal bleeding, liver transplantation, and biliary carcinoma) were retrospectively examined. Using receiver operating characteristic (ROC) analysis, we investigated which parameter was useful for predicting the short-term prognosis. ResultsAverage follow-up period was 8.6 years. The endpoints were evaluated in 40 patients. Seven patients died of liver failure, three patients developed variceal bleeding, nine patients received liver transplantation from a living donor, 13 patients received certified brain-dead liver transplantation, and eight patients developed biliary carcinoma. The parameters with an area under the curve (AUC) of more than 0.8 were albumin, bilirubin, PT-INR, ALP, and MELD score. AUC for ALP was 0.85. The optimal cutoff value was 2.3 ULN. Despite the use or non-use of ursodeoxycholic acid, short-term prognosis of patients with an ALP level below 2.3 ULN was good. ConclusionsWe confirmed that keeping ALP low is associated with better short-term prognosis in a Japanese cohort. In addition, Alb, Bil, PT-INR, and MELD score were good predictors.	[Watanabe, Takeo] Mutual Aid Assoc Publ Sch Teachers, Kanto Cent Hosp, Dept Gastroenterol, Setagaya Ku, Tokyo 1588531, Japan; [Watanabe, Takeo; Hirano, Kenji; Tada, Minoru; Isayama, Hiroyuki; Mizuno, Suguru; Koike, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan; [Hirano, Kenji] Tokyo Takanawa Hosp, Dept Gastroenterol, Tokyo, Japan; [Mizuno, Suguru] Toshiba Gen Hosp, Dept Gastroenterol, Tokyo, Japan; [Arizumi, Toshihiko; Toda, Nobuo] Mitsui Mem Hosp, Dept Gastroenterol, Tokyo 101, Japan; [Sugawara, Yasuhiko; Kokudo, Norihiro] Univ Tokyo, Dept Surg, Artificial Organ & Transplantat Div, Tokyo, Japan	Watanabe, T (reprint author), Mutual Aid Assoc Publ Sch Teachers, Kanto Cent Hosp, Dept Gastroenterol, Setagaya Ku, 6-25-1 Kamiyouga, Tokyo 1588531, Japan.	takeowata@gmail.ac.jp					Al Mamaris S, 2013, HEPATOLOGY, V58, P329; Lindor KD, 2009, HEPATOLOGY, V50, P808, DOI 10.1002/hep.23082; Maggs JRL, 2008, CURR OPIN GASTROEN, V24, P377, DOI 10.1097/MOG.0b013e3282f9e239; Stanich PP, 2011, DIGEST LIVER DIS, V43, P309, DOI 10.1016/j.dld.2010.12.008; Eaton JE, 2011, AM J GASTROENTEROL, V106, P1638, DOI 10.1038/ajg.2011.156; Takikawa H, 2004, HEPATOL RES, V29, P153, DOI 10.1016/j.hepres.2004.03.006; Imam MH, 2011, ALIMENT PHARM THER, V34, P1185, DOI 10.1111/j.1365-2036.2011.04863.x; BEUERS U, 1992, HEPATOLOGY, V16, P707, DOI 10.1002/hep.1840160315; Olsson R, 2005, GASTROENTEROLOGY, V129, P1464, DOI 10.1053/j.gastro.2005.08.017; CHAPMAN RWG, 1980, GUT, V21, P870, DOI 10.1136/gut.21.10.870; CHAZOUILLERES O, 1990, J HEPATOL, V11, P120, DOI 10.1016/0168-8278(90)90281-U; Cullen SN, 2008, J HEPATOL, V48, P792, DOI 10.1016/j.jhep.2007.12.023; Harnois DM, 2001, AM J GASTROENTEROL, V96, P1558; Hirano K, 2008, J GASTROENTEROL, V43, P729, DOI 10.1007/s00535-008-2216-3; Kims WR, 1999, HEPATOLOGY, V29, P1643; Kims WR, 2000, MAYO CLIN P, V75, P688; Lindor KD, 2003, SCHIFFS DIS LIVER, P673; Lindor KD, 1997, NEW ENGL J MED, V336, P691, DOI 10.1056/NEJM199703063361003; OBRIEN CB, 1991, HEPATOLOGY, V14, P838, DOI 10.1002/hep.1840140516; Othman Mohamed O, 2012, Arab J Gastroenterol, V13, P103, DOI 10.1016/j.ajg.2012.06.011; Shis J, 2009, HEPATOL RES, V39, P865; Solano E, 2003, TRANSPLANT P, V35, P2431, DOI 10.1016/j.transproceed.2003.09.017	22	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	JUN	2015	22	6					486	490		10.1002/jhbp.238		5	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ0EY	WOS:000355149200012		
J	Yamaguchi, N; Yokoyama, Y; Ebata, T; Igami, T; Sugawara, G; Asahara, T; Nomoto, K; Nagino, M				Yamaguchi, Naoya; Yokoyama, Yukihiro; Ebata, Tomoki; Igami, Tsuyoshi; Sugawara, Gen; Asahara, Takashi; Nomoto, Koji; Nagino, Masato			Intermittent Pringle maneuver is unlikely to induce bacterial translocation to the portal vein: a study using bacterium-specific ribosomal RNA-targeted reverse transcription-polymerase chain reaction	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Bacterial translocation; Portal vein; Pringle maneuver	POSTOPERATIVE INFECTIOUS COMPLICATIONS; RANDOMIZED CONTROLLED-TRIAL; IN-SITU HYBRIDIZATION; PERIHILAR CHOLANGIOCARCINOMA; LIVER RESECTION; HEPATECTOMY; PCR; ESOPHAGECTOMY; SYNBIOTICS; DRAINAGE	BackgroundThe occurrence of bacterial translocation (BT) to the mesenteric lymph nodes following the Pringle maneuver is well established; however, the incidence of BT to the portal circulation remains unclear. MethodsPortal blood of patients with suspected hilar malignancy who underwent major hepatobiliary resection with cholangiojejunostomy was sampled three times during surgery: immediately after laparotomy (PV-1); before liver transection and after skeletonization of the hepatoduodenal ligament (PV-2); and after completion of the liver transection (PV-3). The samples were analyzed for microbes with a bacterium-specific ribosomal RNA-targeted reverse transcription-polymerase chain reaction method. ResultsFifty patients were enrolled in the study, with a mean total Pringle time of 86min. Microbes in the portal blood were detected in 11 (22%) of the 50 patients. The occurrence of microbes was not different among the PV-1 samples (8%=4/50), PV-2 samples (14%=7/50), and PV-3 samples (14%=7/50) (P=0.567). Obligate anaerobes were predominantly detected. The positivity of the PV-3 samples showed no correlation with the total Pringle time or with the occurrence of postoperative infectious complications. The total Pringle time did not affect the surgical outcomes, including infectious complications, liver failure, or mortality. The concentrations of aspartate aminotransferase and alanine aminotransferase on postoperative day 1 significantly correlated with the total Pringle time. ConclusionsThe intermittent Pringle maneuver is unlikely to induce BT to the portal circulation and is safe, even in difficult, complicated hepatobiliary resections requiring long clamping times.	[Yamaguchi, Naoya; Yokoyama, Yukihiro; Ebata, Tomoki; Igami, Tsuyoshi; Sugawara, Gen; Nagino, Masato] Nagoya Univ, Grad Sch Med, Dept Surg, Showa Ku, Nagoya, Aichi 4668550, Japan; [Asahara, Takashi; Nomoto, Koji] Yakult Cent Inst Microbiol Res, Tokyo, Japan	Nagino, M (reprint author), Nagoya Univ, Grad Sch Med, Dept Surg, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	nagino@med.nagoya-u.ac.jp					Wada M, 2010, J APPL MICROBIOL, V108, P779, DOI 10.1111/j.1365-2672.2009.04476.x; Petrowsky H, 2006, ANN SURG, V244, P921, DOI 10.1097/01.sla.0000246834.07130.5d; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Shigeta H, 2002, LANGENBECK ARCH SURG, V387, P117, DOI 10.1007/s00423-002-0301-2; Nagino M, 2012, J GASTROENTEROL, V47, P1165, DOI 10.1007/s00535-012-0628-6; Harmsen HJM, 2000, FEMS MICROBIOL LETT, V183, P125, DOI 10.1016/S0378-1097(99)00649-7; Matsuda K, 2007, APPL ENVIRON MICROB, V73, P32, DOI 10.1128/AEM.01224-06; Nagino M, 2010, ANN SURG, V252, P115, DOI 10.1097/SLA.0b013e3181e463a7; Nishigaki E, 2014, ANN SURG, V259, P477, DOI 10.1097/SLA.0b013e31828e39e8; Matsuda K, 2009, APPL ENVIRON MICROB, V75, P1961, DOI 10.1128/AEM.01843-08; Sugawara G, 2006, ANN SURG, V244, P706, DOI 10.1097/01.sla.0000219039.20924.88; Kamiya S, 2004, ANN SURG, V239, P510, DOI 10.1097/01.sla.0000118594.23874.89; Franks AH, 1998, APPL ENVIRON MICROB, V64, P3336; Pringle JH, 1908, ANN SURG, V48, P541, DOI 10.1097/00000658-190810000-00005; Kawashima H, 2013, ANN SURG, V257, P121, DOI 10.1097/SLA.0b013e318262b2e9; Sakaguchi S, 2010, J CLIN MICROBIOL, V48, P1624, DOI 10.1128/JCM.01724-09; Dello SAWG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030539; Erenoglu B, 2011, SURG TODAY, V41, P824, DOI 10.1007/s00595-010-4363-4; Ferri M, 1997, ARCH SURG-CHICAGO, V132, P162; GARCIATSAO G, 1993, HEPATOLOGY, V17, P1081, DOI 10.1016/0270-9139(93)90126-8; Ishizaki Y, 2006, ARCH SURG-CHICAGO, V141, P649, DOI 10.1001/archsurg.141.7.649; Kanazawa H, 2005, LANGENBECK ARCH SURG, V390, P104, DOI 10.1007/s00423-004-0536-1; Mizuno T, 2010, ANN SURG, V252, P1013, DOI 10.1097/SLA.0b013e3181f3f355; Nagino M, 2007, BRIT J SURG, V94, P70, DOI 10.1002/bjs.5531; Satos J, 2014, DIABETES CARE, V37, P2342; Sugiyama Y, 2010, BRIT J SURG, V97, P1062, DOI 10.1002/bjs.7039; Torzilli G, 2012, ANN SURG, V255, P270, DOI 10.1097/SLA.0b013e318232b375; Wilson KH, 1996, APPL ENVIRON MICROB, V62, P2273; Yehs DC, 2003, J SURG RES, V111, P209; Yokoyama Y, 2014, BRIT J SURG, V101, P189, DOI 10.1002/bjs.9385; Ypsilantis P, 2011, DIGEST DIS SCI, V56, P1548, DOI 10.1007/s10620-010-1462-4	31	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	JUN	2015	22	6					491	497		10.1002/jhbp.239		7	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ0EY	WOS:000355149200013		
J	Hatanaka, H; Yano, T; Tamada, K				Hatanaka, Hisashi; Yano, Tomonori; Tamada, Kiichi			Tips and tricks of double-balloon endoscopic retrograde cholangiopancreatography (with video)	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Double-balloon endoscopy; Double-balloon ERCP; Endoscopic retrograde cholangiopancreatography; Roux-en-Y reconstruction	EN-Y ANASTOMOSIS; BILLROTH-II GASTRECTOMY; LIVER-TRANSPLANTATION; CASE SERIES; BILE-DUCT; ENTEROSCOPY; ERCP; CHOLANGIOGRAPHY; STONES	Although endoscopic retrograde cholangiopancreatography (ERCP) is technically difficult in patients with altered gastrointestinal tract, double-balloon endoscopy (DBE) allows endoscopic access to pancreato-biliary system in such patients. Balloon dilation of biliary stricture and extraction of bile duct stones, placement of biliary stent in patients with Roux-en-Y or Billroth-II reconstruction, using DBE have been reported. However, two major technical parts are required for double-balloon ERCP (DB-ERCP). One is insertion of DBE and the other is an ERCP-related procedure. The important point of DBE insertion is a sure approach to the afferent limb with Roux-en-Y reconstruction or Braun anastomosis. Short type DBE with working length 152 cm is beneficial for DB-ERCP because it is short enough for most biliary accessory devices. In this paper, we introduce our tips and tricks for successful DB-ERCP.	[Hatanaka, Hisashi; Yano, Tomonori; Tamada, Kiichi] Jichi Med Univ, Dept Gastroenterol, Shimotsuke, Tochigi 3290498, Japan	Hatanaka, H (reprint author), Jichi Med Univ, Dept Gastroenterol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	hatanaka@jichi.ac.jp			Fujifilm Medical	Tomonori Yano serves as a consultant to Fujifilm and receives research funding from Fujifilm Medical.	Shimatani M, 2009, ENDOSCOPY, V41, P849, DOI 10.1055/s-0029-1215108; Itoi T, 2011, SURG ENDOSC, V25, P713, DOI 10.1007/s00464-010-1226-4; Yamamoto H, 2001, GASTROINTEST ENDOSC, V53, P216, DOI 10.1067/mge.2001.112181; OSNES M, 1986, GUT, V27, P1193, DOI 10.1136/gut.27.10.1193; Parlak E, 2010, SURG ENDOSC, V24, P466, DOI 10.1007/s00464-009-0591-3; FORBES A, 1984, GUT, V25, P971, DOI 10.1136/gut.25.9.971; Aabakken L, 2007, ENDOSCOPY, V39, P1068, DOI 10.1055/s-2007-966841; Maaser C, 2008, AM J GASTROENTEROL, V103, P894, DOI 10.1111/j.1572-0241.2007.01745.x; Mehdizadeh S, 2006, GASTROINTEST ENDOSC, V64, P740, DOI 10.1016/j.gie.2006.05.022; Hintze RE, 1997, ENDOSCOPY, V29, P69, DOI 10.1055/s-2007-1004077; Yamamoto H, 2004, CLIN GASTROENTEROL H, V2, P1010, DOI 10.1053/S1542-3565(04)00453-7; Emmett DS, 2007, GASTROINTEST ENDOSC, V66, P1038, DOI 10.1016/j.gie.2007.06.056; Dellon ES, 2009, DIGEST DIS SCI, V54, P1798, DOI 10.1007/s10620-008-0538-x; Haruta H, 2005, LIVER TRANSPLANT, V11, P1608, DOI 10.1002/lt.20623; Hatanaka H, 2012, DIGEST ENDOSC, V24, P479, DOI 10.1111/j.1443-1661.2012.01336.x; Itoi T, 2010, AM J GASTROENTEROL, V105, P93, DOI 10.1038/ajg.2009.559; Itois T, 2011, ENDOSCOPY         S2, V43; Kikuyamas M, 2005, DIGEST ENDOSC, V17, P9, DOI 10.1111/j.1443-1661.2005.00452.x; Koornstra JJ, 2008, NETH J MED, V66, P275; Mays A, 2007, AM J GASTROENTEROL, V102, P527; Monkemuller K, 2008, GASTROINTEST ENDOSC, V67, P992, DOI 10.1016/j.gie.2007.10.023; Nakahara K, 2009, J GASTROENTEROL, V44, P212, DOI 10.1007/s00535-008-2299-x; Nishimura N, 2010, GASTROINTEST ENDOSC, V71, P287, DOI 10.1016/j.gie.2009.08.010; Tsukui D, 2008, GASTROINTEST ENDOSC, V68, P1013, DOI 10.1016/j.gie.2008.02.034; Yamamoto H, 2014, DIGEST ENDOSC, V26, P23, DOI 10.1111/den.12206; Yanos T., 2011, ENDOSCOPIA DIGESTIVA, V23, P418; Yanos T, 2012, ENDOSCOPY         S2, V44	27	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	JUN	2015	22	6					E28	E34		10.1002/jhbp.218		7	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ0EY	WOS:000355149200002		
J	Sugawara, G; Nagino, M				Sugawara, Gen; Nagino, Masato			Response to Re: Management strategy for biliary stricture following laparoscopic cholecystectomy	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Letter									[Sugawara, Gen; Nagino, Masato] Nagoya Univ, Grad Sch Med, Dept Surg, Div Surg Oncol,Showa Ku, Nagoya, Aichi 4668550, Japan	Nagino, M (reprint author), Nagoya Univ, Grad Sch Med, Dept Surg, Div Surg Oncol,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	nagino@med.nagoya-u.ac.jp					Sugawara G, 2014, J HEPATO-BIL-PAN SCI, V21, P889, DOI 10.1002/jhbp.151; Ustundag Y, 2015, J HEPATO-BIL-PAN SCI, V22, pE35, DOI 10.1002/jhbp.242	2	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	JUN	2015	22	6					E36	E36		10.1002/jhbp.243		1	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ0EY	WOS:000355149200004		
J	Tsuji, S; Itoi, T; Sofuni, A; Mukai, S; Tonozuka, R; Moriyasu, F				Tsuji, Shujiro; Itoi, Takao; Sofuni, Atsushi; Mukai, Shuntaro; Tonozuka, Ryosuke; Moriyasu, Fuminori			Tips and tricks in endoscopic papillectomy of ampullary tumors: single-center experience with large case series (with videos)	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Ampullary adenoma; Ampullary tumor; Ampullectomy; Papillectomy	FAMILIAL ADENOMATOUS POLYPOSIS; MAJOR DUODENAL PAPILLA; SNARE EXCISION; VATER; CARCINOMA; CANCER	Endoscopic papillectomy (EP) has been recognized as a safe and reliable treatment for ampullary adenomas. In this article, we describe important tips and tricks in EP of ampullary tumors on the basis of our large case series outcome. Between May 1999 and April 2014, 115 patients underwent EP at Tokyo Medical University hospital. The mean tumor diameter was 16.2 (6-35) mm. The final pathological diagnoses were adenoma, cancer in adenoma, cancer, and hyperplasia in 85, 13, 10, and seven patients, respectively. En bloc or piecemeal EP was performed with a polypectomy snare forceps using Endocut (R) mode. Prophylactic pancreatic duct stents were placed after EP. Consequently, a single treatment session was possible in 93 (80.9%) patients. Additional treatment was required in the remaining 22 (19.1%) patients. For these 22 patients, the postresection pathological diagnoses were adenoma in 15 patients and cancer in seven patients. Two patients with cancer and venous permeation required surgical operation. The final complete resection rate was 98.2%. Several complications observed included pancreatitis (10.4%), bleeding (18.2%), perforation (2.6%), cholangitis (1.7%), and papillary stenosis (4.3%). One patient died of procedure-related complications. In conclusion, endoscopic papillectomy showed a high technical success rate. However, possible complications and occasional fatal complications should be considered when using EP.	[Tsuji, Shujiro; Itoi, Takao; Sofuni, Atsushi; Mukai, Shuntaro; Tonozuka, Ryosuke; Moriyasu, Fuminori] Tokyo Med Univ, Dept Gastroenterol & Hepatol, Shinjuku Ku, Tokyo 1600023, Japan	Tonozuka, R (reprint author), Tokyo Med Univ, Dept Gastroenterol & Hepatol, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	g.shujiro@gmail.com					Dzeletovic I, 2012, GASTROINTEST ENDOSC, V76, P1266, DOI 10.1016/j.gie.2012.08.007; BINMOELLER KF, 1993, GASTROINTEST ENDOSC, V39, P127, DOI 10.1016/S0016-5107(93)70051-6; SEIFERT E, 1992, AM J GASTROENTEROL, V87, P37; Hopper AD, 2010, GASTROINTEST ENDOSC, V71, P967, DOI 10.1016/j.gie.2009.11.021; Norton ID, 2002, GASTROINTEST ENDOSC, V56, P239, DOI 10.1067/mge.2002.126064; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980; YAMAGUCHI K, 1991, GUT, V32, P1558, DOI 10.1136/gut.32.12.1558; Lindor NM, 1998, JNCI-J NATL CANCER I, V90, P1039, DOI 10.1093/jnci/90.14.1039; Itoi T, 2009, GASTROINTEST ENDOSC, V69, P136, DOI 10.1016/j.gie.2008.07.036; Stolte M, 1996, SCAND J GASTROENTERO, V31, P376, DOI 10.3109/00365529609006414; Adler DG, 2006, GASTROINTEST ENDOSC, V64, P849, DOI 10.1016/j.gie.2006.08.044; Heiskanen I, 1999, ENDOSCOPY, V31, P412; Itoi T, 2013, GASTROINTEST ENDOSC, V77, P793, DOI 10.1016/j.gie.2012.12.015; Kims JH, 2009, GASTROINTEST ENDOSC, V69, P1404; Maguchi H, 2003, DIG ENDOSC S, V15, pS33, DOI 10.1046/j.1443-1661.15.s.10.x; Martin John A, 2003, Gastrointest Endosc Clin N Am, V13, P649, DOI 10.1016/S1052-5157(03)00101-6; Mizumotos I, 2001, AM J GASTROENTEROL, V4, P1261; Suzuki K, 1983, PROG DIG ENDOSC, V23, P236	18	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	JUN	2015	22	6					E22	E27		10.1002/jhbp.207		6	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CJ0EY	WOS:000355149200001		
J	Song, GJ; Kusumi, R; Kimura, F; Kimura, T; Deguchi, K; Ohki, S; Fujito, T; Simizu, T				Song, Guangjie; Kusumi, Ryosuke; Kimura, Fumiko; Kimura, Tsunehisa; Deguchi, Kenzo; Ohki, Shinobu; Fujito, Teruaki; Simizu, Tadashi			Single-crystal NMR approach for determining chemical shift tensors from powder samples via magnetically oriented microcrystal arrays	JOURNAL OF MAGNETIC RESONANCE			English	Article						Single crystal NMR; NMR crystallography; Magnetically oriented microcrystalline powder; Cellobiose	PHASE; MAS; CRYSTALLOGRAPHY; DIFFRACTION; ANISOTROPY; RESOLUTION	The single-crystal rotation technique was applied to magnetically oriented microcrystal arrays (MOMAs) of cellobiose (monoclinic) to determine the principal values and principal axes of the chemical shift tensors of Cl and Cl' carbons. Rotations were performed about the magnetic chi 1, chi 2, and chi 3 axes of MOMA, and the measurements were taken at six different orientations with respect to the applied magnetic field. Under these rotations, crowded peaks were reduced and the peaks for the Cl and Cl' carbons were identified by comparing with simulation results. Six components of the chemical shift tensor expressed with respect to the magnetic chi 1 chi 2 chi 3-frame were determined. The tensors thus obtained were transformed into those relative to the molecular frame. (C) 2015 Elsevier Inc. All rights reserved.	[Song, Guangjie; Kusumi, Ryosuke; Kimura, Fumiko; Kimura, Tsunehisa] Kyoto Univ, Div Forest & Biomat Sci, Kyoto 6058502, Japan; [Deguchi, Kenzo; Ohki, Shinobu; Fujito, Teruaki; Simizu, Tadashi] Natl Inst Mat Sci, Tsukuba, Ibaraki 3050003, Japan	Kimura, T (reprint author), Kyoto Univ, Div Forest & Biomat Sci, Kyoto 6058502, Japan.	tkimura@kais.kyoto-u.ac.jp			Japanese Ministry of Education, Culture, Sports, Science and Technology [24350119]	This study was supported by the Japanese Ministry of Education, Culture, Sports, Science and Technology (24350119).	Indris S, 2012, J PHYS CHEM C, V116, P14243, DOI 10.1021/jp3042928; SHERWOOD MH, 1993, J MAGN RESON SER A, V104, P132, DOI 10.1006/jmra.1993.1201; Liu SF, 2002, J MAGN RESON, V155, P15, DOI 10.1006/jmre.2002.2503; Shekar SC, 2002, J MAGN RESON, V155, P257, DOI 10.1006/jmre.2002.2518; Kimura T, 2006, LANGMUIR, V22, P3464, DOI 10.1021/la053479n; Tateishi K, 2014, P NATL ACAD SCI USA, V111, P7527, DOI 10.1073/pnas.1315778111; Kimura T, 2005, LANGMUIR, V21, P4805, DOI 10.1021/la050182g; Kimura T, 2009, J APPL CRYSTALLOGR, V42, P535, DOI 10.1107/S0021889809013430; Bouchevreau B, 2013, CHEM-EUR J, V19, P5009, DOI 10.1002/chem.201203767; Dalal NS, 2003, J PHYS CHEM A, V107, P3471, DOI 10.1021/jp0220478; Dugar S, 2012, J PHYS CHEM B, V116, P9215, DOI 10.1021/jp302189r; Fu M, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.247001; Harris RK, 2004, SOLID STATE SCI, V6, P1025, DOI 10.1016/j.solidstatesciences.2004.03.040; Harris R.K., 2009, NMR CRYSTALLOGRAPHY; Kalenius E, 2008, CHEM-EUR J, V14, P5220, DOI 10.1002/chem.200800075; Kimura F, 2010, J APPL CRYSTALLOGR, V43, P151, DOI 10.1107/S0021889809048006; Kimura F, 2014, CRYSTENGCOMM, V16, P6630, DOI 10.1039/c4ce00839a; Kimura F, 2011, CRYST GROWTH DES, V11, P12, DOI 10.1021/cg100790r; Kimura F, 2010, CRYST GROWTH DES, V10, P48, DOI 10.1021/cg901321h; Klymachyov A, 1997, SOLID STATE NUCL MAG, V9, P85, DOI 10.1016/S0926-2040(97)00048-9; Kusumi R, 2015, CRYST GROWTH DES, V15, P718, DOI 10.1021/cg501483s; Kusumi R, 2012, J MAGN RESON, V223, P68, DOI 10.1016/j.jmr.2012.08.006; Nye J F, 1985, PHYS PROPERTIES CRYS; Potrzebowski MJ, 2002, CHEM COMMUN, P1582, DOI 10.1039/b204627j; SASTRY DL, 1987, CARBOHYD RES, V165, P161, DOI 10.1016/0008-6215(87)80096-4; Song GJ, 2012, JPN J APPL PHYS, V51, DOI 10.1143/JJAP.51.060203; Song GJ, 2013, MACROMOLECULES, V46, P8957, DOI 10.1021/ma401788c; Taulelle F., 2009, EMAGRES, DOI 10.1002/9780470034590.emrstm1003	28	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1090-7807	1096-0856		J MAGN RESON	J. Magn. Reson.	JUN	2015	255						28	33		10.1016/j.jmr.2015.03.009		6	Biochemical Research Methods; Physics, Atomic, Molecular & Chemical; Spectroscopy	Biochemistry & Molecular Biology; Physics; Spectroscopy	CJ3LU	WOS:000355386300003		
J	Horikoshi, S; Nakamura, T; Kawaguchi, M; Serpone, N				Horikoshi, Satoshi; Nakamura, Taichiro; Kawaguchi, Mari; Serpone, Nick			Enzymatic proteolysis of peptide bonds by a metallo-endoproteinase under precise temperature control with 5.8-GHz microwave radiation	JOURNAL OF MOLECULAR CATALYSIS B-ENZYMATIC			English	Article						Microwave non-thermal effects; Magnetic field; Proteolysis; Protein; Enzyme activity	CATALYSIS	The present article examined the advantages of 5.8-GHz microwaves versus the more commonly used 2.45-GHz microwaves using a modular non-commercial apparatus on the proteolysis of the Arg-Arg-Leu-Ile-Glu-Asp-Ala-Glu-Tyr-Ala-Ala-Arg-Gly peptide at the amino side of the aspartic acid (Asp) using the Asp-N metallo-endoproteinase enzyme. The microscale sample was subjected to microwaves' electric field (E-field) and magnetic field (H-field) radiation: good temperature control for samples at the mu L scale was achieved using an apparatus that emitted microwaves at a precise frequency (5.800000 GHz). Temperature-dependent experiments with the Asp-N metallo-enzyme confirmed the activity of this enzyme to be greatest at 37 degrees C reached within 15 s on irradiation with the 5.8-GHz microwaves' H-field component with an input power of 1.7W under air cooling conditions. Enzymatic activity decreased significantly above and below this temperature by a slight temperature change of 1 degrees C. Proteolysis yields of the peptide by the Asp-N enzyme at 30-42 degrees C under microwave E-field and H-field heating and under conventional heating revealed that enhancement of the proteolysis of the peptide at 37 degrees C by E-field irradiation (42.6%) was 1.5 times greater than by conventional heating (27.5%), whereas under microwave H-field irradiation (63.5%) it was 2.3 times greater than conventional heating. The relative dielectric loss factors (epsilon(r)'') of the sample solution (peptide + enzyme) were also determined: 22.19 (5.8 GHz) and 12.78 (2.45 GHz) at 22 degrees C, which decreased with increasing temperature (faster for the 5.8-GHz microwaves) so that the initial heating efficiency of 5.8-GHz microwaves was nearly twofold greater than for 2.45-GHz microwaves. Results indicated that in addition to a thermal factor, microwave non-thermal factors also had a significant influence as the microwaves considerably enhanced the proteolytic process relative to traditional heating. (C) 2015 Elsevier B.V. All rights reserved.	[Horikoshi, Satoshi; Nakamura, Taichiro; Kawaguchi, Mari] Sophia Univ, Fac Sci & Technol, Dept Mat & Life Sci, Chiyoda Ku, Tokyo 1028554, Japan; [Serpone, Nick] Univ Pavia, Dipartimento Chim, PhotoGreen Lab, I-27100 Pavia, Italy	Horikoshi, S (reprint author), Sophia Univ, Fac Sci & Technol, Dept Mat & Life Sci, Chiyoda Ku, 7-1 Kioicho, Tokyo 1028554, Japan.	horikosi@sophia.ac.jp; nick.serpone@unipv.it			Japan Society for the Promotion of Science (JSPS) [C-25420820]; Sophia University-wide Collaborative Research Fund	Financial support from the Japan Society for the Promotion of Science (JSPS; Grant-in-aid for Scientific Research No. C-25420820) is gratefully appreciated. We are also grateful to the Sophia University-wide Collaborative Research Fund for a grant to S.H. One of us (NS) thanks Prof. Albini of the University of Pavia (Italy) for his continued hospitality during the many winter semesters in his laboratory.	Horikoshi S, 2012, J MICROWAVE POWER EE, V46, P215; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741; de Pomerai DI, 2003, FEBS LETT, V543, P93, DOI 10.1016/S0014-5793(03)00413-7; Yadav GD, 2004, J MOL CATAL A-CHEM, V223, P51, DOI 10.1016/j.molcata.2003.09.050; Herrero MA, 2008, J ORG CHEM, V73, P36, DOI 10.1021/jo7022697; Shaw KJ, 2010, LAB CHIP, V10, P1725, DOI 10.1039/c000357n; Porcelli M, 1997, FEBS LETT, V402, P102, DOI 10.1016/S0014-5793(96)01505-0; Horikoshi S, 2012, RADIAT PHYS CHEM, V81, P1885, DOI 10.1016/j.radphyschem.2012.07.011; Horikoshi S, 2013, APPL CATAL A-GEN, V460, P52, DOI 10.1016/j.apcata.2013.04.022; CarrilloMunoz JR, 1996, J ORG CHEM, V61, P7746, DOI 10.1021/jo960309u; Cronin N.J., 1995, MICROWAVE OPTICAL WA, P27; Datta K., 2001, HDB MICROWAVE TECHNO; De La Hoz A., 2012, MICROWAVES ORGANIC S, V1; Fermer C, 2003, EUR J PHARM SCI, V18, P129, DOI 10.1016/S0928-0987(02)00252-X; Horikoshi S., 2012, MICROWAVES ORGANIC S, V3rd; Horikoshi S., 2011, NANOSCALE, V2, P1441; Horikoshi S, 2013, MICROWAVES NANOPARTI; Metaxas A. C., 1988, IEE POWER ENG SERIES, V4; RABINOVI.B, 1967, BIOPHYS J, V7, P187; Rejasse B, 2007, J ENZYM INHIB MED CH, V22, P519, DOI 10.1080/14756360701424959; TETAZ T, 1990, BIOCHEM INT, V22, P561; THOMAS A, 1981, BRIT J RADIOL, V54, P615; VAJDA T, 1980, RADIAT ENVIRON BIOPH, V18, P275, DOI 10.1007/BF01324270; Young DD, 2008, J AM CHEM SOC, V130, P10048, DOI 10.1021/ja802404g; Zhao H., 2010, AQUEOUS MICROWAVE AS	25	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1381-1177	1873-3158		J MOL CATAL B-ENZYM	J. Mol. Catal. B-Enzym.	JUN	2015	116						52	59		10.1016/j.molcatb.2015.03.007		8	Biochemistry & Molecular Biology; Chemistry, Physical	Biochemistry & Molecular Biology; Chemistry	CI8XN	WOS:000355055100008		
J	Hattori, M; Shintani, K; Uchida, H				Hattori, Masazumi; Shintani, Kohei; Uchida, Hirofumi			The Repository of Soft Information within Bank Organizations	JOURNAL OF MONEY CREDIT AND BANKING			English	Article						soft information; authority; organizational structure; banks	SMALL BUSINESS DATA; LENDING RELATIONSHIPS; CREDIT AVAILABILITY; FIRM; COMMUNICATION; AUTHORITY; FINANCE; JAPAN	We examine who is the repository of soft information within bank organizations. Inconsistent with the conventional view of loan officers as the sole repository, we find that branch managers have the most soft information. We also find the repository at a higher hierarchical level at smaller banks. Furthermore, our evidence suggests that branch managers themselves actively collect soft information, especially at smaller banks. These findings suggest the need for a more nuanced view beyond the conventional emphasis on loan officers, and call for studies on the equilibrium design of the collection, processing, and use of soft information within bank organizations.	[Hattori, Masazumi] Bank Int Settlements, Monetary & Econ Dept, Basel, Switzerland; [Uchida, Hirofumi] Kobe Univ, Grad Sch Business Adm, Kobe, Hyogo, Japan	Hattori, M (reprint author), Bank Int Settlements, Monetary & Econ Dept, Basel, Switzerland.	masazumi.hattori@bis.org; kouhei.shintani@boj.or.jp; uchida@b.kobe-u.ac.jp			 [21330076];  [24330103]	This paper developed and spun off a part of the paper "Authority and Soft Information Production within a Bank Organization" that was published as a Bank of Japan IMES Discussion Paper (12-E-07) and was presented at the DNB-EBC-JMCB-KU Post-Banking Crisis conference in 2012. An earlier version of this paper was presented at the Contract Theory Workshop. The authors thank Bob DeYoung (the editor), an anonymous referee, Greg Udell, Loretta Mester, Alberto Zazzaro, Hans Degryse, Fumitoshi Moriya, Makoto Hanazono, Akifumi Ishihara, Hideshi Itoh, Hiroki Yonezawa, and Christian Upper for their comments that significantly helped us in writing this paper. The authors are also grateful to those who commented on, and were research assistants at, the IMES DP. Hirofumi Uchida thanks the Grant-in-Aid for Scientific Research (No. 21330076 and 24330103) for financial support. The views expressed in this paper are those of the authors and do not necessarily reflect the official views of the institutions with which they are affiliated.	Agarwal Sumit, 2009, CHOICE ARMS LE UNPUB; Agarwal Sumit, 2011, AFA 2011 DENV M; Agarwal Sumit, 2011, EFFECTS LOAN O UNPUB; Albareto Giorgio, 2010, BANK ITALY WORKSHOPS, V5, P11; Stein JC, 2002, J FINANC, V57, P1891, DOI 10.1111/0022-1082.00483; Cerqueiro G, 2011, J FINANC INTERMED, V20, P503, DOI 10.1016/j.jfi.2010.12.002; Uchida H, 2012, J FINANC INTERMED, V21, P97, DOI 10.1016/j.jfi.2011.06.002; Berger AN, 2011, J BANK FINANC, V35, P724, DOI 10.1016/j.jbankfin.2010.09.004; Boot AWA, 2000, J FINANC INTERMED, V9, P7, DOI 10.1006/jfin.2000.0282; Aghion P, 1997, J POLIT ECON, V105, P1, DOI 10.1086/262063; Berger AN, 2005, J FINANC ECON, V76, P237, DOI 10.1016/j.jfineco.2004.06.003; Berger AN, 2002, ECON J, V112, pF32, DOI 10.1111/1468-0297.00682; Heider F, 2012, REV FINANC STUD, V25, P2381, DOI 10.1093/rfs/hhs051; Hertzberg A, 2010, J FINANC, V65, P795, DOI 10.1111/j.1540-6261.2010.01553.x; Berger AN, 2006, J BANK FINANC, V30, P2945, DOI 10.1016/j.jbankfin.2006.05.008; Degryse H, 2000, J FINANC INTERMED, V9, P90, DOI 10.1006/jfin.1999.0278; RADNER R, 1993, ECONOMETRICA, V61, P1109, DOI 10.2307/2951495; Uchida H, 2008, J JPN INT ECON, V22, P242, DOI 10.1016/j.jjie.2007.07.003; Liberti JM, 2009, REV FINANC STUD, V22, P4057, DOI 10.1093/rfs/hhn118; BERGER AN, 1995, J BUS, V68, P351, DOI 10.1086/296668; Benvenuti Michele, 2010, 26475 MPRA MUN U; Berg T., 2012, WORKING PAPER; BOLTON P, 1994, Q J ECON, V109, P809, DOI 10.2307/2118349; Brown Martin, 2012, INFORM INSURAN UNPUB; Cole Shawn, 2011, INCENTIVIZING CALCUL; Dessein W, 2002, REV ECON STUD, V69, P811, DOI 10.1111/1467-937X.00227; Ferri Giovanni, 1997, BNL Q REV, P229; Fischer Kari-Herman, 2000, ACQUISITION IN UNPUB; Garcia-Appendini E, 2007, EFA 2007 LJUBLJ M; Gropp Reint, 2012, 2012010 EUR BANK CTR; Hattori Masazumi, 2012, IMES DISCUSSION PAPE, V2012-E-7; Kysucky Vlado, 2012, BENEFITS RELAT UNPUB; Mocetti Saulo, 2010, 752 BANK IT; Nemoto Tadanobu, 2011, 11E053 RIETI; Ono A, 2009, J MONEY CREDIT BANK, V41, P935, DOI 10.1111/j.1538-4616.2009.00239.x; Paravisini Daniel, 2012, TECHNOLOGICAL AGENCY; PETERSEN MA, 1994, J FINANC, V49, P3, DOI 10.2307/2329133; Petersen M.A., 2004, INFORM HARD SO UNPUB; Puri Manju, 2011, RULES VERSUS DISCRET; Scott JA, 2006, J SMALL BUS MANAGE, V44, P544, DOI 10.1111/j.1540-627X.2006.00186.x; Uchida Hirofumi, 2014, OXFORD HDB BANKING, V2nd; UDELL GF, 1989, J BANK FINANC, V13, P367, DOI 10.1016/0378-4266(89)90048-4	42	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-2879	1538-4616		J MONEY CREDIT BANK	J. Money Credit Bank.	JUN	2015	47	4					737	770		10.1111/jmcb.12226		34	Business, Finance; Economics	Business & Economics	CJ1XY	WOS:000355279600007		
J	Osugi, T; Ubuka, T; Tsutsui, K				Osugi, T.; Ubuka, T.; Tsutsui, K.			An Evolutionary Scenario for Gonadotrophin-Inhibitory Hormone in Chordates	JOURNAL OF NEUROENDOCRINOLOGY			English	Review						gonadotrophin-inhibitory hormone; RFamide peptides; reproduction; evolution; chordates; lamprey; amphioxus	RFAMIDE-RELATED PEPTIDE-3; LPXRF-AMIDE PEPTIDES; HYPOTHALAMIC NEUROPEPTIDE; GROWTH-HORMONE; HYPOPHYSIOTROPIC ROLE; LUTEINIZING-HORMONE; FUNCTIONAL-ANALYSIS; CDNA CLONING; LH-SECRETION; IDENTIFICATION	In 2000, we discovered a novel hypothalamic neuropeptide that actively inhibits gonadotrophin release in quail and termed it gonadotrophin-inhibitory hormone (GnIH). GnIH peptides have subsequently been identified in most representative species of gnathostomes. They all share a C-terminal LPXRFamide (X=L or Q) motif. GnIH can inhibit gonadotrophin synthesis and release by decreasing the activity of GnRH neuroes, as well as by directly inhibiting pituitary gonadotrophin secretion in birds and mammals. To investigate the evolutionary origin of GnIH and its ancestral function, we identified a GnIH precursor gene encoding GnIHs from the brain of sea lamprey, the most ancient lineage of vertebrates. Lamprey GnIHs possess a C-terminal PQRFamide motif. In vivo administration of one of lamprey GnIHs stimulated the expression of lamprey GnRH in the hypothalamus and gonadotophin mRNA in the pituitary. Thus, GnIH may have emerged in agnathans as a stimulatory neuropeptide that subsequently diverged to an inhibitory neuropeptide during the course of evolution from basal vertebrates to later-evolved vertebrates, such as birds and mammals. From a structural point of view, pain modulatory neuropeptides, such as neuropeptide FF (NPFF) and neuropeptide AF, share a C-terminal PQRFamide motif. Because agnathans possess both GnIH and NPFF genes, the origin of GnIH and NPFF genes may date back before the emergence of agnathans. More recently, we identified a novel gene encoding RFamide peptides in the amphioxus. Molecular phylogenetic analysis and synteny analysis indicated that this gene is closely related to the genes of GnIH and NPFF of vertebrates. The results suggest that the identified protochordate gene is similar to the common ancestor of GnIH and NPFF genes, indicating that the origin of GnIH and NPFF may date back to the time of the emergence of early chordates. The GnIH and NPFF genes may have diverged by whole-genome duplication during the course of vertebrate evolution.	Waseda Univ, Dept Biol, Shinjuku Ku, Tokyo 1628480, Japan; Waseda Univ, Ctr Med Life Sci, Shinjuku Ku, Tokyo 1628480, Japan	Tsutsui, K (reprint author), Waseda Univ, Dept Biol, Ctr Med Life Sci Waseda Univ, Lab Integrat Brain Sci,Shinjuku Ku, 2-2 Wakamatsu Cho, Tokyo 1628480, Japan.	k-tsutsui@waseda.jp			Ministry of Education, Science and Culture, Japan [18107002, 22132004, 22227002]	This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture, Japan (18107002, 22132004 and 22227002 to K.T.).	Tsutsui K, 2000, BIOCHEM BIOPH RES CO, V275, P661, DOI 10.1006/bbrc.2000.3350; Tsutsui K, 2012, GEN COMP ENDOCR, V177, P305, DOI 10.1016/j.ygcen.2012.02.013; Amano M, 2006, J ENDOCRINOL, V188, P417, DOI 10.1677/joe.1.06494; Ubuka T, 2013, GEN COMP ENDOCR, V181, P179, DOI 10.1016/j.ygcen.2012.09.010; Osugi T, 2012, ENDOCRINOLOGY, V153, P2362, DOI 10.1210/en.2011-2046; Sari IP, 2009, ENDOCRINOLOGY, V150, P5549, DOI 10.1210/en.2009-0775; Bedecarrats GY, 2009, GEN COMP ENDOCR, V163, P7, DOI 10.1016/j.ygcen.2009.03.010; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; Ducret E, 2009, ENDOCRINOLOGY, V150, P2799, DOI 10.1210/en.2008-1623; Ubuka T, 2012, ENDOCRINOLOGY, V153, P373, DOI 10.1210/en.2011-1110; Koda A, 2002, ENDOCRINOLOGY, V143, P411, DOI 10.1210/en.143.2.411; Moussavi M, 2013, J NEUROENDOCRINOL, V25, P506, DOI 10.1111/jne.12024; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; Johnson MA, 2007, HORM BEHAV, V51, P171, DOI 10.1016/j.yhbeh.2006.09.009; Rizwan MZ, 2012, ENDOCRINOLOGY, V153, P3770, DOI 10.1210/en.2012-1133; Shahjahan M, 2011, J NEUROENDOCRINOL, V23, P39, DOI 10.1111/j.1365-2826.2010.02081.x; Tsutsui K, 2010, FRONT NEUROENDOCRIN, V31, P284, DOI 10.1016/j.yfrne.2010.03.001; Ubuka T, 2006, ENDOCRINOLOGY, V147, P1187, DOI 10.1210/en.2005-1178; Smith JT, 2008, ENDOCRINOLOGY, V149, P5770, DOI 10.1210/en.2008-0581; Tsutsui K, 2009, PROG NEUROBIOL, V88, P76, DOI 10.1016/j.pneurobio.2009.02.003; Ukena K, 2005, MASS SPECTROM REV, V24, P469, DOI 10.1002/mas.20031; Clarke IJ, 2008, ENDOCRINOLOGY, V149, P5811, DOI 10.1210/en.2008-0575; Liu QY, 2001, J BIOL CHEM, V276, P36961, DOI 10.1074/jbc.M105308200; Tobari Y, 2010, PEPTIDES, V31, P816, DOI 10.1016/j.peptides.2010.01.015; Chowdhury VS, 2011, J ENDOCRINOL, V209, P211, DOI 10.1530/JOE-10-0494; Tsutsui K, 2006, PEPTIDES, V27, P1121, DOI 10.1016/j.peptides.2005.06.036; Ubuka T, 2008, ENDOCRINOLOGY, V149, P268, DOI 10.1210/en.2007-0983; Osugi T, 2004, J ENDOCRINOL, V182, P33, DOI 10.1677/joe.0.1820033; Kim DK, 2011, GEN COMP ENDOCR, V170, P68, DOI 10.1016/j.ygcen.2010.10.018; Moussavi M, 2012, MOL CELL ENDOCRINOL, V350, P53, DOI 10.1016/j.mce.2011.11.020; Ukena K, 2003, ENDOCRINOLOGY, V144, P3879, DOI 10.1210/en.2003-0359; Kriegsfeld LJ, 2006, P NATL ACAD SCI USA, V103, P2410, DOI 10.1073/pnas.0511003103; MATSUO H, 1971, BIOCHEM BIOPH RES CO, V43, P1334, DOI 10.1016/S0006-291X(71)80019-0; Ubuka T, 2009, J COMP NEUROL, V517, P841, DOI 10.1002/cne.22191; Ubuka T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4061; Lehman MN, 2010, ENDOCRINOLOGY, V151, P3479, DOI 10.1210/en.2010-0022; Fukusumi S, 2001, BBA-MOL CELL RES, V1540, P221, DOI 10.1016/S0167-4889(01)00135-5; Bentley GE, 2006, HORM BEHAV, V49, P550, DOI 10.1016/j.yhbeh.2005.12.005; Ikemoto T, 2005, J REPROD DEVELOP, V51, P359, DOI 10.1262/jrd.16087; Qi X, 2013, MOL CELL ENDOCRINOL, V366, P9, DOI 10.1016/j.mce.2012.11.001; Tsutsui K, 2010, J NEUROENDOCRINOL, V22, P716, DOI 10.1111/j.1365-2826.2010.02018.x; Kadokawa H, 2009, DOMEST ANIM ENDOCRIN, V36, P219, DOI 10.1016/j.domaniend.2009.02.001; Chartrel N, 2002, J COMP NEUROL, V448, P111, DOI 10.1002/cne.10253; BURGUS R, 1972, P NATL ACAD SCI USA, V69, P278, DOI 10.1073/pnas.69.1.278; Sawada K, 2002, EUR J BIOCHEM, V269, P6000, DOI 10.1046/j.1432-1033.2002.03351.x; Satake H, 2001, BIOCHEM J, V354, P379, DOI 10.1042/0264-6021:3540379; Ukena K, 2002, FEBS LETT, V512, P255, DOI 10.1016/S0014-5793(02)02275-5; Zhang Y, 2010, PEPTIDES, V31, P1034, DOI 10.1016/j.peptides.2010.03.003; Murakami M, 2008, J ENDOCRINOL, V199, P105, DOI 10.1677/JOE-08-0197; Roch GJ, 2014, MOL BIOL EVOL, V31, P765, DOI 10.1093/molbev/mst269; Li X, 2013, MOL CELL ENDOCRINOL, V372, P65, DOI 10.1016/j.mce.2013.03.015; Minakata H, 2009, J NEUROENDOCRINOL, V21, P322, DOI 10.1111/j.1365-2826.2009.01852.x; Osugi T, 2006, FEBS J, V273, P1731, DOI 10.1111/j.1742-4658.2006.05187.x; Osugi T, 2011, ENDOCRINOLOGY, V152, P4252, DOI 10.1210/en.2011-1375; Osugi T, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00255; Osugi T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100962; Sawada K, 2002, J ENDOCRINOL, V174, P395, DOI 10.1677/joe.0.1740395; Shimizu M, 2010, GEN COMP ENDOCR, V167, P331, DOI 10.1016/j.ygcen.2010.03.029; Son YL, 2012, ENDOCRINOLOGY, V153, P2332, DOI 10.1210/en.2011-1904; Thorson JF, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.112185; Tobari Y, 2014, J NEUROSCI, V34, P9803, DOI 10.1523/JNEUROSCI.3706-13.2014; Tsutsui K, 2012, HDB BIOL ACTIVE PEPT, P802; Tsutsui K, 2006, J EXP ZOOL PART A, V305A, P801, DOI 10.1002/jez.a.306; Tsutsui K, 2007, GEN COMP ENDOCR, V153, P365, DOI 10.1016/j.gcen.2006.10.005; Tsutsui K, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00060; Ubuka T, 2014, GEN COMP ENDOCR, V209, P148, DOI 10.1016/j.ygcen.2014.09.002; Ubuka T, 2013, GEN COMP ENDOCR, V190, P10, DOI 10.1016/j.ygcen.2013.02.030; Ubuka T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030202; Ubuka T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008400; Venkatesh B, 2007, PLOS BIOL, V5, P932, DOI 10.1371/journal.pbio.0050101; Yin H, 2005, J ENDOCRINOL, V184, P257, DOI 10.1677/joe.1.05926; Yoshida H, 2003, BBA-MOL CELL RES, V1593, P151, DOI 10.1016/S0167-4889(02)00389-0; Yun Seongsik, 2014, Front Endocrinol (Lausanne), V5, P134, DOI 10.3389/fendo.2014.00134	73	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-8194	1365-2826		J NEUROENDOCRINOL	J. Neuroendocrinol.	JUN	2015	27	6			SI		556	566		10.1111/jne.12246		11	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	CJ1HA	WOS:000355233400019		
J	Yamasaki, F; Takayasu, T; Nosaka, R; Amatya, VJ; Doskaliyev, A; Akiyama, Y; Tominaga, A; Takeshima, Y; Sugiyama, K; Kurisu, K				Yamasaki, Fumiyuki; Takayasu, Takeshi; Nosaka, Ryo; Amatya, Vishwa Jeet; Doskaliyev, Aidos; Akiyama, Yuji; Tominaga, Atsushi; Takeshima, Yukio; Sugiyama, Kazuhiko; Kurisu, Kaoru			Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis: a characteristic of malignant lymphoma	JOURNAL OF NEUROSURGERY			English	Article						malignant lymphoma; proton MR spectroscopy; lipids; glioma; oncology	APPARENT DIFFUSION-COEFFICIENTS; HUMAN BRAIN-TUMORS; INTRACRANIAL MASS LESIONS; NERVOUS-SYSTEM LYMPHOMA; PROTON MR SPECTROSCOPY; PRIMARY CNS LYMPHOMA; SINGLE-VOXEL; IN-VIVO; GLIOBLASTOMA-MULTIFORME; CEREBRAL LYMPHOMA	OBJECT The differentiation of malignant lymphomas from gliomas or malignant gliomas by conventional MRI can be difficult. The authors studied Gd-enhanced MR images to obtain a differential diagnosis between malignant lymphomas and gliomas without central necrosis or cystic changes and investigated the diagnostic value of single-voxel proton MR spectroscopy (H-1-MRS) using different parameters, including lipid levels. METHODS This was a retrospective study of patients with primary malignant CNS lymphoma (n = 17) and glioma (n = 122 [Grades I, II, III, and IV in 10, 30, 33, and 49 patients, respectively]) who were treated between 2007 and 2013. The authors focused on 15 patients with homogeneously enhanced primary malignant CNS lymphomas and 7 homogeneously enhanced gliomas. Images of all the included tumors were acquired with H-1-MRS at 3 T, and the diagnoses were histologically confirmed. RESULTS Using a short echo time H-1-MRS, large lipid peaks were observed in all 17 patients with a malignant lymphoma, in 39 patients (79.6%) with a Grade IV glioma, and in 10 patients (30.3%) with a Grade III glioma. A focus on homogeneously enhanced tumors revealed large lipid peaks in 15 malignant lymphomas that were free of central necrosis on Gd-enhanced T1-weighted images. Conversely, in the 7 homogeneously enhanced gliomas (glioblastoma and anaplastic astrocytoma, n = 2 each; anaplastic oligodendroglioma, diffuse astrocytoma, and pilomyxoid astrocytoma, n = 1 each), lipid peaks were small or absent. CONCLUSIONS Large lipid peaks on H-1-MRS images of tumors without central necrosis were characteristic of malignant lymphomas. Conversely, small or absent lipid peaks in intraaxial tumors without central necrosis were strongly suggestive of glioma.	[Yamasaki, Fumiyuki; Takayasu, Takeshi; Nosaka, Ryo; Doskaliyev, Aidos; Tominaga, Atsushi; Kurisu, Kaoru] Hiroshima Univ, Dept Neurosurg, Inst Biomed & Hlth Sci, Minami Ku, Hiroshima 7348551, Japan; [Amatya, Vishwa Jeet; Takeshima, Yukio] Hiroshima Univ, Dept Pathol, Inst Biomed & Hlth Sci, Minami Ku, Hiroshima 7348551, Japan; [Sugiyama, Kazuhiko] Hiroshima Univ, Dept Clin Oncol, Hiroshima 7348551, Japan; [Sugiyama, Kazuhiko] Hiroshima Univ, Neurooncol Program, Hiroshima 7348551, Japan; [Akiyama, Yuji] Hiroshima Univ, Dept Clin Radiol, Hiroshima 7348551, Japan	Kurisu, K (reprint author), Hiroshima Univ, Dept Neurosurg, Grad Sch Biomed & Hlth Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	kuka422@hiroshima-u.ac.jp	AMATYA, VISHWAJEET/B-5164-2009	AMATYA, VISHWAJEET/0000-0002-4986-2109			Martinez-Bisbal MC, 2009, Q J NUCL MED MOL IM, V53, P618; Hollingworth W, 2006, AM J NEURORADIOL, V27, P1404; Toh CH, 2008, AM J NEURORADIOL, V29, P471, DOI 10.3174/ajnr.A0872; Schmitz JE, 2005, MAGNET RESON MED, V54, P43, DOI 10.1002/mrm.20529; Yamashita K, 2013, NEURORADIOLOGY, V55, P135, DOI 10.1007/s00234-012-1089-6; Server A, 2009, ACTA RADIOL, V50, P682, DOI 10.1080/02841850902933123; Chawla S, 2010, J COMPUT ASSIST TOMO, V34, P836, DOI 10.1097/RCT.0b013e3181ec554e; Yamasaki F, 2005, RADIOLOGY, V235, P985, DOI 10.1148/radiol.2353031338; Graham GD, 2001, STROKE, V32, P2797, DOI 10.1161/hs1201.099414; Doskaliyev A, 2012, EUR J RADIOL, V81, P339, DOI 10.1016/j.ejrad.2010.11.005; Kitis O, 2005, EUR J RADIOL, V55, P393, DOI 10.1016/j.ejrad.2005.02.004; Horger M, 2009, AM J ROENTGENOL, V193, P1384, DOI 10.2214/AJR.09.2486; Delikatny EJ, 2011, NMR BIOMED, V24, P592, DOI 10.1002/nbm.1661; Guo AC, 2002, RADIOLOGY, V224, P177, DOI 10.1148/radiol.2241010637; Yamasaki F, 2011, NEURO-ONCOLOGY, V13, P791, DOI 10.1093/neuonc/nor038; Calvar JA, 2005, J NEURO-ONCOL, V72, P273, DOI 10.1007/s11060-004-3342-2; Yamasaki F, 2005, NEUROSURG REV, V28, P267, DOI 10.1007/s10143-005-0398-1; Opstad KS, 2007, NMR BIOMED, V20, P763, DOI 10.1002/nbm.1147; Matsushima N, 2012, ANN NUCL MED, V26, P262, DOI 10.1007/s12149-012-0570-y; Callot V, 2008, EUR J RADIOL, V67, P268, DOI 10.1016/j.ejrad.2008.02.036; POPTANI H, 1995, AM J NEURORADIOL, V16, P1593; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Ducreux D, 2003, NEURORADIOLOGY, V45, P865, DOI 10.1007/s00234-003-1107-9; Fan Guoguang, 2006, Cancer Imaging, V6, P113, DOI 10.1102/1470-7330.2006.0018; Hakumaki JM, 2003, TRENDS PHARMACOL SCI, V24, P146, DOI 10.1016/S0165-6147(03)00032-4; Harting I, 2003, NEUROSCI LETT, V342, P163, DOI 10.1016/S0304-3940(03)00272-6; Hermann M, 1998, INT J CANCER, V75, P675, DOI 10.1002/(SICI)1097-0215(19980302)75:5<675::AID-IJC26>3.0.CO;2-5; JAYASUNDAR R, 1995, MAGN RESON IMAGING, V13, P489, DOI 10.1016/0730-725X(94)00134-O; Kaminogo M, 2001, NEURORADIOLOGY, V43, P353; KING NJC, 1991, FEBS LETT, V287, P97, DOI 10.1016/0014-5793(91)80024-W; King N J, 1994, Immunomethods, V4, P188, DOI 10.1006/immu.1994.1019; Koeller KK, 1997, RADIOGRAPHICS, V17, P1497; Majos C, 2003, EUR RADIOL, V13, P582, DOI 10.1007/s00330-002-1547-3; Mohan S, 2010, Neuroradiol J, V23, P269; Panigrahy A, 2006, AM J NEURORADIOL, V27, P560; Poptani H, 1995, MAGN RESON IMAGING, V13, P1019, DOI 10.1016/0730-725X(95)00045-I; Wright AJ, 2009, MAGN RESON MED, V62, P1646, DOI 10.1002/mrm.22163	37	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2015	122	6					1370	1379		10.3171/2014.9.JNS14106		10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CI8OK	WOS:000355031400016		
J	Fujii, M; Maesawa, S; Motomura, K; Futamura, M; Hayashi, Y; Koba, I; Wakabayashi, T				Fujii, Masazumi; Maesawa, Satoshi; Motomura, Kazuya; Futamura, Miyako; Hayashi, Yuichiro; Koba, Itsuko; Wakabayashi, Toshihiko			Intraoperative subcortical mapping of a language-associated deep frontal tract connecting the superior frontal gyrus to Broca's area in the dominant hemisphere of patients with glioma	JOURNAL OF NEUROSURGERY			English	Article						awake surgery; glioma; subcortical mapping; frontal aslant tract; oncology	SUPPLEMENTARY MOTOR AREA; HUMAN BRAIN; WHITE-MATTER; TRACTOGRAPHY; RECOVERY; APHASIA; ANATOMY	OBJECT The deep frontal pathway connecting the superior frontal gyrus to Broca's area, recently named the frontal aslant tract (FAT), is assumed to be associated with language functions, especially speech initiation and spontaneity. Injury to the deep frontal lobe is known to cause aphasia that mimics the aphasia caused by damage to the supplementary motor area. Although fiber dissection and tractography have revealed the existence of the tract, little is known about its function. The aim of this study was to determine the function of the FAT via electrical stimulation in patients with glioma who underwent awake surgery. METHODS The authors analyzed the data from subcortical mapping with electrical stimulation in 5 consecutive cases (3 males and 2 females, age range 40-54 years) with gliomas in the left frontal lobe. Diffusion tensor imaging (DTI) and tractography of the FAT were performed in all cases. A navigation system and intraoperative MRI were used in all cases. During the awake phase of the surgery, cortical mapping was performed to find the precentral gyrus and Broca's area, followed by tumor resection. After the cortical layer was removed, subcortical mapping was performed to assess. language-associated fibers in the white matter. RESULTS In all 5 cases, positive responses were obtained at the stimulation sites in the subcortical area adjacent to the FAT, which was visualized by the navigation system. Speech arrest was observed in 4 cases, and remarkably slow speech and conversation was observed in 1 case. The location of these sites was also determined on intraoperative MR images and estimated on preoperative MR images with DTI tractography, confirming the spatial relationships among the stimulation sites and white matter tracts. Tumor removal was successfully performed-without damage to this tract, and language function did not deteriorate in any of the cases postoperatively. CONCLUSIONS The authors identified the left FAT and confirmed that it was associated with language functions. This tract should be recognized by clinicians to preserve language function during brain tumor surgery, especially for tumors located in the deep frontal lobe on the language-dominant side.	[Fujii, Masazumi; Motomura, Kazuya; Koba, Itsuko; Wakabayashi, Toshihiko] Nagoya Univ, Dept Neurosurg, Grad Sch Med, Nagoya, Aichi 4648601, Japan; [Maesawa, Satoshi] Nagoya Univ, Brain & Mind Res Ctr, Nagoya, Aichi 4648601, Japan; [Futamura, Miyako] Nagoya Univ, Dept Rehabil, Nagoya, Aichi 4648601, Japan; [Hayashi, Yuichiro] Nagoya Univ, Informat & Commun Headquarters, Nagoya, Aichi 4648601, Japan	Fujii, M (reprint author), 65 Tsurumai Cho,Shown Ku, Nagoya, Aichi 4668550, Japan.	fujiim@med.nagoya-u.ac.jp					Catani M, 2012, CORTEX, V48, P273, DOI 10.1016/j.cortex.2011.12.001; Krainik A, 2004, NEUROLOGY, V62, P1323; Guevara P, 2011, NEUROIMAGE, V54, P1975, DOI 10.1016/j.neuroimage.2010.10.028; Ford A, 2010, NEUROIMAGE, V52, P1230, DOI 10.1016/j.neuroimage.2010.05.018; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; LAPLANE D, 1977, J NEUROL SCI, V34, P301, DOI 10.1016/0022-510X(77)90148-4; Alario FX, 2006, BRAIN RES, V1076, P129, DOI 10.1016/j.brainres.2005.11.104; ROSTOMILY RC, 1991, J NEUROSURG, V75, P62, DOI 10.3171/jns.1991.75.1.0062; FREEDMAN M, 1984, NEUROLOGY, V34, P409; Hickok G, 2004, COGNITION, V92, P67, DOI 10.1016/j.cognition.2003.10.011; Kinoshita M, 2012, J NEUROSURG, V116, P323, DOI 10.3171/2011.10.JNS11434; Catani M, 2013, BRAIN, V136, P2619, DOI 10.1093/brain/awt163; Hickok G, 2012, J COMMUN DISORD, V45, P393, DOI 10.1016/j.jcomdis.2012.06.004; Duffau H, 2008, J NEUROSURG, V109, P461, DOI 10.3171/JNS/2008/109/9/0461; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Coello AF, 2013, J NEUROSURG, V119, P1380, DOI 10.3171/2013.6.JNS122470; Lawes INC, 2008, NEUROIMAGE, V39, P62, DOI 10.1016/j.neuroimage.2007.06.041; Maesawa S, 2010, WORLD NEUROSURG, V74, P153, DOI 10.1016/j.wneu.2010.03.022; Morgan VL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006660	19	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2015	122	6					1390	1396		10.3171/2014.10.JNS14945		7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CI8OK	WOS:000355031400018		
J	Ogiwara, T; Goto, T; Kusano, Y; Kuroiwa, M; Kiuchi, T; Kodama, K; Takemae, T; Hongo, K				Ogiwara, Toshihiro; Goto, Tetsuya; Kusano, Yoshikazu; Kuroiwa, Masafumi; Kiuchi, Takafumi; Kodama, Kunihiko; Takemae, Toshiki; Hongo, Kazuhiro			Subtemporal transtentorial approach for recurrent trigeminal neuralgia after microvascular decompression via the lateral suboccipital approach: case report	JOURNAL OF NEUROSURGERY			English	Article						subtemporal transtentorial approach; microvascular decompression; recurrent trigeminal neuralgia; peripheral nerve	OF-THE-LITERATURE; HEMIFACIAL SPASM; SURGERY	Microvascular decompression (MVD) via lateral suboccipital craniotomy is the standard surgical intervention for trigeminal neuralgia (TN). For recurrent TN, difficulties are sometimes encountered when performing reoperation via the same approach because of adhesions and prosthetic materials used in the previous surgery. In the present case report the authors describe the efficacy of the subtemporal transtentorial approach for use in recurrent TN after MVD via the lateral suboccipital approach. An 86-year-old woman, in whom an MVD via a lateral suboccipital craniotomy had previously been performed for TN, underwent surgery for recurrent TN via the subtemporal transtentorial approach, which provided excellent visualization of the neurovascujar relationships and the trigeminal nerve without adhesions due to the previous surgery. Hr TN disappeared after the MVD. The present approach is ideal for visualizing the trigeminal root entry zone, and the neurovascular complex can be easily dissected using a new surgical trajectory. This approach could be another surgical option for reoperation when the previous MVD had been performed via the suboccipital approach.	[Ogiwara, Toshihiro; Goto, Tetsuya; Kuroiwa, Masafumi; Kiuchi, Takafumi; Hongo, Kazuhiro] Shinshu Univ, Sch Med, Dept Neurosurg, Matsumoto, Nagano 3908621, Japan; [Ogiwara, Toshihiro; Kusano, Yoshikazu; Kodama, Kunihiko; Takemae, Toshiki] Nagano Municipal Hosp, Dept Neurosurg, Nagano, Japan	Goto, T (reprint author), Shinshu Univ, Sch Med, Dept Neurosurg, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	tegotou@shinshu-u.ac.jp					Kondo A, 1997, NEUROSURGERY, V40, P46, DOI 10.1097/00006123-199701000-00009; Tatli M, 2008, ACTA NEUROCHIR, V150, P243, DOI 10.1007/s00701-007-1488-3; Hitotsumatsu T, 2003, NEUROSURGERY, V53, P1436, DOI 10.1227/01.NEU.0000093431.43456.3B; Cohen-Gadol AA, 2011, CLIN NEUROL NEUROSUR, V113, P844, DOI 10.1016/j.clineuro.2011.06.003; GARDNER WJ, 1959, JAMA-J AM MED ASSOC, V170, P1773; Gressot LV, 2012, J NEUROSURG SCI, V56, P151; Huang CF, 2010, J NEUROSURG, V113, P172, DOI 10.3171/2010.8.GKS10915; Inoue H, 2013, NEUROL MED-CHIR, V53, P37; Jannetta P J, 1977, Clin Neurosurg, V24, P538; JANNETTA PJ, 1974, J NEUROSURG, V40, P675; Jannetta P J, 1966, Bull Los Angeles Neurol Soc, V31, P93; Kondo A, 2012, ACTA NEUROCHIR, V154, P773, DOI 10.1007/s00701-012-1277-5; Onoda K, 2009, NO SHINKEI GEKA SOKU, V19, P1065; Payner TD, 1996, NEUROSURGERY, V38, P686; Rhoton Jr AL, 2003, NEUROSURGERY 3, V53, P643; Sanchez-Mejia Rene O, 2005, Neurosurg Focus, V18, pe12; Sugita K, 1985, MICRONEUROSURGICAL A, P110	17	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2015	122	6					1429	1432		10.3171/2014.10.JNS132643		4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CI8OK	WOS:000355031400025		
J	Karasawa, M; Yokouchi, K; Kakegawa, A; Kawagishi, K; Moriizumi, T; Fukushima, N				Karasawa, Mika; Yokouchi, Kumiko; Kakegawa, Akira; Kawagishi, Kyutaro; Moriizumi, Tetsuji; Fukushima, Nanae			Effect of graded nerve pressure injuries on motor function	JOURNAL OF NEUROSURGERY			English	Article						sciatic nerve; common peroneal nerve; crush injury; static sciatic index; slope-walking; peripheral nerve	ESSENTIAL NEURONAL POPULATION; PERIPHERAL-NERVE; MINIMUM NUMBER; SCIATIC-NERVE; RAT; RECOVERY; REGENERATION; SURVIVAL; REPAIR	OBJECT The purpose of this study was to determine the minimum amount of nerve fibers required to maintain normal motor function after nerve injury in rats. METHODS The authors first confirmed that a common peroneal nerve injury caused more aggravating effects on lower limb motor function than tibial nerve injury, as assessed by the static sciatic index (SSI). Thereafter, rats were subjected to varying degrees of crush injury to the common peroneal nerve. At 48 hours after the injury, motor function was assessed using the SSI and slope-walking ability (with slope angles of 30 degrees and 45 degrees). The tibialis anterior muscle, a main muscle innervated by the common peroneal nerve, was removed. Muscle sections were co-labeled with neuronal class III beta-tubulin polyclopal antibody to identify the presence of axons and Alexa Fluor 488-conjugated alpha-bungarotoxin to identify the presence of motor endplates. RESULTS The evaluation of neuromuscular innervation showed a correlation between SSI scores and ratios of residual axons (r(s) = 0.68, p < 0.01), and there was a statistically significant difference between slope-walking ability and ratios of residual axons (p < 0.01). Moreover, the ratios of residual axons in the nerve-crushed rats with normal motor function (SSI above 20) ranged from 36.5% to 88.7%, and those ratios in the success group with slope-walking angles of 30 degrees and 45 degrees ranged from 14.7% to 88.7% and from 39.8% to 88.7%, respectively. CONCLUSIONS In this study of rodents, less than half of the motor axons were sufficient to maintain normal motor function of the lower limb.	[Karasawa, Mika; Yokouchi, Kumiko; Kakegawa, Akira; Kawagishi, Kyutaro; Moriizumi, Tetsuji; Fukushima, Nanae] Shinshu Univ, Dept Anat, Sch Med, Matsumoto, Nagano 3908621, Japan	Fukushima, N (reprint author), Shinshu Univ, Dept Anat, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	nanae@shinshu-u.ac.jp					Guntinas-Lichius O, 2005, EUR J NEUROSCI, V21, P391, DOI 10.1111/j.1460-9568.2005.03877.x; Varejao ASP, 2001, MICROSURG, V21, P383, DOI 10.1002/micr.21803; Bervar M, 2000, J NEUROSCI METH, V102, P109, DOI 10.1016/S0165-0270(00)00281-8; Mensching L, 2012, CELL TISSUE RES, V350, P225, DOI 10.1007/s00441-012-1493-6; Varejao ASP, 2001, J NEUROSCI METH, V108, P1, DOI 10.1016/S0165-0270(01)00378-8; Chen B, 2009, J SURG RES, V152, P303, DOI 10.1016/j.jss.2008.03.032; DEGENS H, 1995, ANN ANAT, V177, P285; Fukushima N, 2014, ARCH ORAL BIOL, V59, P616, DOI 10.1016/j.archoralbio.2014.02.012; Fukushima N, 2002, CHEM SENSES, V27, P1, DOI 10.1093/chemse/27.1.1; Grosheva M, 2008, EXP NEUROL, V209, P131, DOI 10.1016/j.expneurol.2007.09.016; Higashiyama F, 2005, J NEUROSURG, V102, P390; Hirayama S, 2014, CHEM SENSES, V39, P47, DOI 10.1093/chemse/bjt053; Itsubo T, 2012, NEUROL RES, V34, P908, DOI 10.1179/1743132812Y.0000000089; Kakegawa A, 2006, NEUROREPORT, V17, P1149, DOI 10.1097/01.wnr.0000230502.47973.fe; Kakegawa A, 2014, ANAT SCI INT; Kawagishi K, 2009, BRAIN RES, V1276, P50, DOI 10.1016/j.brainres.2009.04.032; Kobayashi S, 2003, NEUROSCI RES, V45, P357, DOI 10.1016/S0168-0102(02)00231-6; Korte N, 2011, MUSCLE NERVE, V44, P63, DOI 10.1002/mus.22023; Koyama J, 2003, NEUROSCI RES, V46, P85, DOI 10.1016/S0168-0102(03)00033-6; Mohammadi R, 2013, INT J SURG, V11, P819, DOI 10.1016/j.ijsu.2013.08.011; Pitman MJ, 2013, LARYNGOSCOPE, V123, P3117, DOI 10.1002/lary.24216; Waters HJ, 1998, EXP NEUROL, V152, P95, DOI 10.1006/exnr.1998.6820	22	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2015	122	6					1438	1443		10.3171/2014.9.JNS141451		6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CI8OK	WOS:000355031400027		
J	Kano, H; Yamamoto, M; Lunsford, LD				Kano, Hideyuki; Yamamoto, Masaaki; Lunsford, L. Dade			Management of hemangioblastomas in patients with von Hippel-Lindau disease: stereotactic radiosurgery compared to surgical excision Response	JOURNAL OF NEUROSURGERY			English	Editorial Material									[Kano, Hideyuki; Lunsford, L. Dade] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Yamamoto, Masaaki] Katsuta Hosp Mito GammaHouse, Hitachinaka, Ibaraki, Japan	Kano, H (reprint author), Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA.						Jagannathan J, 2008, J NEUROSURG, V108, P210, DOI 10.3171/JNS/2008/108/2/0210	1	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2015	122	6					1468	1468				1	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CI8OK	WOS:000355031400032		
J	Kano, H; Shuto, T; Iwai, Y; Sheehan, J; Yamamoto, M; McBride, HL; Sato, M; Seriiawa, T; Yomo, S; Moriki, A; Kohda, Y; Young, B; Suzuki, S; Kenai, H; Duma, C; Kikuchi, Y; Mathieu, D; Akabane, A; Nagano, O; Kondziolka, D; Lunsford, LD				Kano, Hideyuki; Shuto, Takashi; Iwai, Yoshiyasu; Sheehan, Jason; Yamamoto, Masaaki; McBride, Heyoung L.; Sato, Mitsuya; Serizawa, Toru; Yomo, Shoji; Moriki, Akihito; Kohda, Yukihiko; Young, Byron; Suzuki, Satoshi; Kenai, Hiroyuki; Duma, Christopher; Kikuchi, Yasuhiro; Mathieu, David; Akabane, Atsuya; Nagano, Osamu; Kondziolka, Douglas; Lunsford, L. Dade			Stereotactic radiosurgery for intracranial hemangioblastomas: a retrospective international outcome study	JOURNAL OF NEUROSURGERY			English	Article						stereotactic radiosurgery; Gamma Knife; hemangioblastoma; von Hippel-Lindau disease	HIPPEL-LINDAU-DISEASE; CENTRAL-NERVOUS-SYSTEM; GAMMA-KNIFE RADIOSURGERY; CEREBELLAR HEMANGIOBLASTOMAS; SURGICAL-MANAGEMENT; NATURAL-HISTORY; SURGERY; EXPERIENCE	OBJECT. The purpose of this study was to evaluate the role of stereotactic radiosurgery (SRS) in the management of intracranial hemangioblastomas. METHODS. Six participating centers of the North American Gamma Knife Consortium and 13 Japanese Gamma Knife centers identified 186 patients with 517 hemangioblastomas who underwent SRS. Eighty patients had 335 hemangioblastomas associated with von Hippel Lindau disease (VHL) and 106 patients had 182 sporadic hemangioblastomas. The median target volume was 0.2 cm(3) (median diameter 7 mm) in patients with VHL and 0.7 cm(3) (median diameter 11 mm) in those with sporadic hemangioblastoma. The median margin dose was 18 Gy in VHL patients and 15 Gy in those with sporadic hemangioblastomas. RESULTS. At a median of 5 years (range 0.5-18 years) after treatment, 20 patients had died of intracranial disease progression and 9 patients had died of other causes. The overall survival after SRS was 94% at 3 years, 90% at 5 years, and 74% at 10 years. Factors associated with longer survival included younger age, absence of neurological symptoms, fewer tumors, and higher Karnofsky Performance Status. Thirty-three (41%) of the 80 patients with VHL developed new tumors and 17 (16%) of the106 patients with sporadic hemangioblastoma had recurrences of residual tumor from the original tumor. The 5-year rate of developing a new tumor was 43% for VHL patients, and the 5-year rate of developing a recurrence of residual tumor from the original tumor Was 24% for sporadic hemangioblastoma patients. Factors associated with a reduced risk of developing a new tumor or recurrences of residual tumor from the original tumor included younger age, fewer tumors, and sporadic rather than VHL-associated hemangioblastomas. The local tumor control rate for treated tumors was 92% at 3 years, 89% at 5 years, and 79% at 10 years. Factors associated with an improved local tumor control rate included VHL-associated hemangioblastoma, solid tumor, smaller tumor volume, and higher margin dose. Thirteen patients (7%) developed adverse radiation effects (ARE) after SRS, and one of these patients died due to ARE. CONCLUSIONS. When either sporadic or VHL-associated tumors were observed to grow on serial imaging studies, SRS provided tumor control in 79%-92% of tumors.	[Kano, Hideyuki; Lunsford, L. Dade] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Shuto, Takashi] Yokohama Rosai Hosp, Yokohama, Kanagawa, Japan; [Iwai, Yoshiyasu] Osaka City Gen Hosp, Osaka, Japan; [Yamamoto, Masaaki] Katsuta Hosp Mito GammaHouse, Hitachinaka, Ibaraki, Japan; [Sato, Mitsuya] Kitanihon Hosp, Gosen, Japan; [Serizawa, Toru] Tsukiji Neurol Clin, Tokyo, Japan; [Yomo, Shoji] Saitama Gamma Knife Ctr, Saitama, Japan; [Moriki, Akihito] Mominoki Hosp, Kochi, Japan; [Kohda, Yukihiko] Asanogawa Gen Hosp, Kanazawa, Ishikawa, Japan; [Suzuki, Satoshi] Steel Mem Yawata Hosp, Kitakyushyu, Japan; [Kenai, Hiroyuki] Nagatomi Neurosurg Hosp, Oita, Japan; [Kikuchi, Yasuhiro] Southern Tohoku Hosp, Koriyama, Fukushima, Japan; [Akabane, Atsuya] NTT Kanto Hosp, Tokyo, Japan; [Nagano, Osamu] Chiba Cardiovasc Ctr, Ichihara, Chiba, Japan; [Sheehan, Jason] Univ Virginia, Charlottesville, VA USA; [McBride, Heyoung L.] Barrow Neurol Inst, Phoenix, AZ 85013 USA; [Young, Byron] Univ Kentucky, Lexington, KY USA; [Duma, Christopher] Hoag Hosp, Newport Beach, CA USA; [Mathieu, David] Univ Sherbrooke, Ctr Rech Clin Etienne LeBel, Sherbrooke, PQ J1K 2R1, Canada; [Kondziolka, Douglas] NYU, Langone Med Ctr, New York, NY USA	Kano, H (reprint author), Univ Pittsburgh, UPMC Presbyterian, Dept Neurol Surg, Ste B-400,200 Lothrop St, Pittsburgh, PA 15213 USA.	kanoh@upmc.edu					KANNO H, 1994, CANCER RES, V54, P4845; Patrice SJ, 1996, INT J RADIAT ONCOL, V35, P493; Asthagiri AR, 2010, NEURO-ONCOLOGY, V12, P80, DOI 10.1093/neuonc/nop018; Conway JE, 2001, NEUROSURGERY, V48, P55, DOI 10.1097/00006123-200101000-00009; Sora S, 2001, ACTA NEUROCHIR, V143, P893, DOI 10.1007/s007010170019; Wang CC, 2001, SURG NEUROL, V56, P218, DOI 10.1016/S0090-3019(01)00590-0; FILLINGKATZ MR, 1991, NEUROLOGY, V41, P41; Wanebo JE, 2003, J NEUROSURG, V98, P82, DOI 10.3171/jns.2003.98.1.0082; Kano H, 2011, NEUROSURGERY, V68, P379, DOI 10.1227/NEU.0b013e3181ffa12c; Sayer FT, 2011, WORLD NEUROSURG, V75, P99, DOI 10.1016/j.wneu.2010.09.032; Ammerman JM, 2006, J NEUROSURG, V105, P248, DOI 10.3171/jns.2006.105.2.248; Richard S, 1998, J INTERN MED, V243, P547; Sheehan JP, 2012, J NEUROSURG, V117, P246, DOI 10.3171/2012.4.JNS11214; Matsunaga S, 2007, ACTA NEUROCHIR, V149, P1007, DOI 10.1007/s00701-007-1274-2; Kano H, 2011, J NEUROSURG, V114, P1736, DOI 10.3171/2010.3.JNS091843; Chang SD, 1998, NEUROSURGERY, V43, P28, DOI 10.1097/00006123-199807000-00018; Jagannathan J, 2008, J NEUROSURG, V108, P210, DOI 10.3171/JNS/2008/108/2/0210; Kano H, 2008, NEUROSURGERY, V63, P443, DOI 10.1227/01.NEU.0000313120.81565.D7; Chakraborti PR, 1997, BRIT J NEUROSURG, V11, P110; MAHER ER, 1990, J MED GENET, V27, P311, DOI 10.1136/jmg.27.5.311; Miyagami M, 2000, Brain Tumor Pathol, V17, P111, DOI 10.1007/BF02484282; NEUMANN HPH, 1993, NEW ENGL J MED, V329, P1531, DOI 10.1056/NEJM199311183292103; Pan L, 1998, STEREOT FUNCT NEUROS, V70, P179, DOI 10.1159/000056420; Park YS, 2005, J NEUROSURG, V102, P97; SMALLEY SR, 1990, INT J RADIAT ONCOL, V18, P1165; SUNG DI, 1982, CANCER, V49, P553, DOI 10.1002/1097-0142(19820201)49:3<553::AID-CNCR2820490326>3.0.CO;2-A; Tago M, 2005, J NEUROSURG, V102, P171; Wang EM, 2005, J NEUROSURG, V102, P225	28	1	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2015	122	6					1469	1478		10.3171/2014.10.JNS131602		10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CI8OK	WOS:000355031400033		
J	Nakano, T; Kitamura, T; Sugimoto, S; Suga, T; Kamachi, M				Nakano, Toshiya; Kitamura, Tomoyuki; Sugimoto, Shusaku; Suga, Toshio; Kamachi, Masafumi			Long-term variations of North Pacific Tropical Water along the 137A degrees E repeat hydrographic section	JOURNAL OF OCEANOGRAPHY			English	Article						North Pacific Tropical Water; JMA 137 degrees E meridian; Decadal variability; Flesh water flux; Eddy activity	INTERANNUAL VARIABILITY; SUBTROPICAL GYRE; MESOSCALE EDDIES; REGIME SHIFT; TIME SCALES	The spatiotemporal variability of North Pacific Tropical Water (NPTW), characterized as a subsurface salinity maximum, is investigated using a half-century-long repeat hydrographic dataset of the Japan Meteorological Agency (JMA) along the 137A degrees E meridian, historical objective analysis of monthly global temperature and salinity dataset, sea surface dynamic height dataset, and atmospheric dataset. The cross-sectional area of NPTW (S > 34.9) at 137A degrees E shows decreasing trend with freshening after the mid-1970s. Significant decadal-scale variation is also revealed; this resulted from meridional excursion of its northern boundary, fluctuating between 15A degrees N and 25A degrees N. It was found that the northern boundary excursions at 137A degrees E were induced by westward expansion of the NPTW formation region related to excess evaporation and increased Ekman pumping in the formation region. It is also inferred that the larger eddy activity around the northern boundary of the NPTW also possibly influences the northward movement of the NPTW northern boundary at 137A degrees E through enhanced eddy mass transport.	[Nakano, Toshiya; Kitamura, Tomoyuki] Japan Meteorol Agcy, Global Environm & Marine Dept, Chiyoda Ku, Tokyo 1008122, Japan; [Nakano, Toshiya; Kitamura, Tomoyuki; Kamachi, Masafumi] Meteorol Res Inst, Oceanog & Geochem Res Dept, Tsukuba, Ibaraki 305, Japan; [Sugimoto, Shusaku; Suga, Toshio] Tohoku Univ, Grad Sch Sci, Dept Geophys, Sendai, Miyagi 980, Japan	Nakano, T (reprint author), Japan Meteorol Agcy, Global Environm & Marine Dept, Chiyoda Ku, 1-3-4 Otemachi, Tokyo 1008122, Japan.	nakano_t@met.kishou.go.jp					Katsura S, 2013, J PHYS OCEANOGR, V43, P2400, DOI 10.1175/JPO-D-13-031.1; AKIMA H, 1991, ACM T MATH SOFTWARE, V17, P341, DOI 10.1145/114697.116810; Qiu B, 2005, J PHYS OCEANOGR, V35, P2090, DOI 10.1175/JPO2807.1; Qiu B, 2013, J PHYS OCEANOGR, V43, P344, DOI 10.1175/JPO-D-12-0133.1; Kuragano T, 2000, J GEOPHYS RES-OCEANS, V105, P955, DOI 10.1029/1999JC900247; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Oka E, 2009, J OCEANOGR, V65, P151, DOI 10.1007/s10872-009-0015-y; Kobashi F, 2006, J GEOPHYS RES-OCEANS, V111, DOI 10.1029/2006JC003479; Suga T, 2000, PROG OCEANOGR, V47, P223, DOI 10.1016/S0079-6611(00)00037-9; Zhang ZG, 2014, SCIENCE, V345, P322, DOI 10.1126/science.1252418; Yasunaka S, 2005, INT J CLIMATOL, V25, P913, DOI 10.1002/joc.1172; Ishii M, 2009, J OCEANOGR, V65, P287, DOI 10.1007/s10872-009-0027-7; Qiu B, 2010, J PHYS OCEANOGR, V40, P213, DOI 10.1175/2009JPO4285.1; Boyer TP, 2009, NOAA ATLAS NESDIS 66; CANNON GLENN A., 1966, DEEP SEA RES OCEANOGR ABSTR, V13, P1139, DOI 10.1016/0011-7471(66)90705-4; Hasunuma K, 1978, J OCEANOGR, V60, P865; Kaneko I, 1998, J GEOPHYS RES-OCEANS, V103, P12959, DOI 10.1029/97JC03761; Kuragano T., 1997, J OCEANOGR, V53, P585; Lukas R, 2001, GEOPHYS RES LETT, V28, P3485, DOI 10.1029/2001GL013116; Masuzawa J, 1967, OCEANOGR MAG, V19, P95; Nakano T, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031433; Shuto K., 1996, J OCEANOGR, V52, P575, DOI DOI 10.1007/BF02238322; Tsuchiya M, 1968, J HOPKINS OCEANOGRAP, V4, P50; Uda M, 1969, J OCEANOGR SOC JAPAN, V25, P201	24	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0916-8370	1573-868X		J OCEANOGR	J. Oceanogr.	JUN	2015	71	3					229	238		10.1007/s10872-015-0279-3		10	Oceanography	Oceanography	CJ0QF	WOS:000355181400001		
J	Abe, K; Tsujino, M; Kazama, T; Nakagawa, N; Abo, K				Abe, Kazuo; Tsujino, Mutsumi; Kazama, Takehiro; Nakagawa, Norihisa; Abo, Katsuyuki			Underestimation of nutrient fluxes due to possible bacterial activity during a core incubation experiment	JOURNAL OF OCEANOGRAPHY			English	Article						Nutrients; Benthic flux; Core incubation; Sediment-water interface; Western Seto Inland Sea	SETO INLAND SEA; HETEROTROPHIC BACTERIA; BENTHIC FLUXES; NITROGEN; ESTUARY; WATER; SEDIMENTS; JAPAN; VARIABILITY; EXCHANGE	Examinations of sediment core incubation and calculations of diffusive nutrient fluxes based on the difference between the nutrient concentration in pore water and that in the overlying water were carried out to evaluate the benthic fluxes of nutrients such as phosphate (PO4), ammonium (NH4), and silicic acid [Si(OH)(4)] from the sediment-water interface. Test surface-sediment samples were collected in the western area of the Seto Inland Sea in October 2013 and January 2014. They were incubated onboard the ship for intervals of approximately 40-90 h, and changes in the concentrations of nutrients in the overlying water with incubation time were monitored. Furthermore, in order to inhibit bacterial activity, sodium azide (NaN3) was added to the overlying water of another incubation system, whereupon nutrient concentrations in the overlying water were observed to increase linearly with incubation time. On the other hand, when NaN3 was not added, a linear increase was observed in the Si(OH)(4) concentration but not in those of PO4 and NH4. The calculated diffusive fluxes generally agreed with those obtained from core incubation with the addition of NaN3. These findings suggest that the elution of PO4 and NH4 from the sediment-water interface during a core incubation experiment can be affected by bacterial activity, which could potentially lead to the underestimation of benthic fluxes. Therefore, great care should be taken when carrying out incubations of surface sediment, and they should be performed along with calculations of diffusive fluxes.	[Abe, Kazuo; Tsujino, Mutsumi; Kazama, Takehiro; Nakagawa, Norihisa; Abo, Katsuyuki] Natl Res Inst Fisheries & Environm Inland Sea, Hatsukaichi 7390452, Japan	Abe, K (reprint author), Natl Res Inst Fisheries & Environm Inland Sea, 2-17-5 Maruishi, Hatsukaichi 7390452, Japan.	abek@fra.affrc.go.jp					Anneli G, 1997, BIOGEOCHEM, V37, P203; Berelson WM, 2013, CONT SHELF RES, V55, P66, DOI 10.1016/j.csr.2013.01.009; Vopel K, 2012, MAR POLLUT BULL, V64, P2885, DOI 10.1016/j.marpolbul.2012.08.011; WHEELER PA, 1986, LIMNOL OCEANOGR, V31, P998; Middelburg JJ, 2000, MAR ECOL PROG SER, V203, P13, DOI 10.3354/meps203013; Gaertner-Mazouni N, 2012, MAR POLLUT BULL, V65, P500, DOI 10.1016/j.marpolbul.2012.02.013; Yamamoto T, 2003, MAR POLLUT BULL, V47, P37, DOI 10.1016/S0025-326X(02)00416-2; Zhang L, 2013, ESTUAR COAST SHELF S, V133, P182, DOI 10.1016/j.ecss.2013.08.028; Caraco NF, 1998, MAR ECOL PROG SER, V167, P59, DOI 10.3354/meps167059; DEVOL AH, 1993, J MAR RES, V51, P345, DOI 10.1357/0022240933223765; Belias C, 2007, MAR CHEM, V103, P266, DOI 10.1016/j.marchem.2006.06.005; Date E, 2008, B HIROSHIMA PRETECHN, V16, P41; Engelsen A, 2008, ESTUAR COAST SHELF S, V78, P783, DOI 10.1016/j.ecss.2008.02.018; Grandel S, 2000, DEEP-SEA RES PT II, V47, P2707, DOI 10.1016/S0967-0645(00)00046-1; Hirota R, 2010, J BACTERIOL, V192, P111, DOI 10.1128/JB.00954-09; HOCH MP, 1995, LIMNOL OCEANOGR, V40, P886; KIRCHMAN DL, 1994, MICROBIAL ECOL, V28, P255, DOI 10.1007/BF00166816; Middelburg JJ, 2000, MAR ECOL PROG SER, V192, P79, DOI 10.3354/meps192079; Nagao M, 2000, B JPN SOC CIVIL EENG, V53, P109; Orihel DM, 2012, J LIMNOL, V71, P233, DOI 10.4081/jlimnol.2012.e25; Ospina-Alvarez N, 2014, J SEA RES, V85, P349, DOI 10.1016/j.seares.2013.07.002; Reimers CE, 2012, J GEOPHYS RES-OCEANS, V117, DOI 10.1029/2011JC007564; Sarker MJ, 2005, FISHERIES SCI, V71, P593, DOI 10.1111/j.1444-2906.2005.01003.x; Srithongouthai S, 2003, MAR POLLUT BULL, V47, P10, DOI 10.1016/S0025-326X(02)00406-X; Takeoka H, 2002, GEKKAN KAIYO, V34, P406; Vittor CD, 2012, ESTUAR COAST SHELF S, V113, P57; Wilson JG, 2004, ESTUAR COAST SHELF S, V60, P193, DOI 10.1016/j.ecss.2003.12.007; Yanagi T, 2004, J OCEANOGR, V60, P1001, DOI 10.1007/s10872-005-0008-4	28	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0916-8370	1573-868X		J OCEANOGR	J. Oceanogr.	JUN	2015	71	3					263	270		10.1007/s10872-015-0285-5		8	Oceanography	Oceanography	CJ0QF	WOS:000355181400004		
J	Tsuda, A; Saito, H; Kasai, H; Nishioka, J; Nakatsuka, T				Tsuda, Atsushi; Saito, Hiroaki; Kasai, Hiromi; Nishioka, Jun; Nakatsuka, Takeshi			Vertical segregation and population structure of ontogenetically migrating copepods Neocalanus cristatus, N-flemingeri, N-plumchrus, and Eucalanus bungii during the ice-free season in the Sea of Okhotsk	JOURNAL OF OCEANOGRAPHY			English	Article						Neocalanus copepods; Eucalanus bungii; Life cycle; Vertical distribution; Habitat segregation; Sea of Okhotsk	SUB-ARCTIC PACIFIC; DOWNWARD CARBON FLUX; OYASHIO REGION; LIFE-HISTORIES; COMMUNITY STRUCTURE; PLANKTON DYNAMICS; NORTHEAST PACIFIC; GRAZING COPEPODS; OCEAN; MESOZOOPLANKTON	The Sea of Okhotsk is a semi-enclosed marginal sea of the subarctic North Pacific. One of the prominent characteristics of this area is the fast ice coverage during winter and early spring. We investigated the life cycles and vertical distributions of four species of large suspension feeding copepods, Neocalanus plumchrus, N. flemingeri, N. cristatus, and Eucalanus bungii in the southern part of the Sea of Okhotsk during the ice-free season. Neocalanus plumchrus and N. cristatus showed annual life cycles while a major part of the population of N. flemingeri and E. bungii showed biennial life cycles. Their occurrences in the surface layer for grazing and development were 1-2 months later than in the adjacent area of the Pacific Ocean, and they remained longer in the surface layer for development. Consequently, the seasonal overlap among the copepods in the surface productive layer was intensified. In contrast, the vertical distribution of the four species of copepods during the growing period extended to deeper layers and became more finely segregated than those of Oyashio region and open ocean of the North Pacific. Thus, the seasonal segregations in the Oyashio region are replaced by vertical segregation in the Sea of Okhotsk. A major factor modifying the seasonal occurrences in the surface layer was considered to be the presence of fast ice during winter and early spring which greatly reduces the photosynthesis in the water column.	[Tsuda, Atsushi; Saito, Hiroaki] Univ Tokyo, Atmosphere & Ocean Res Inst, Nakano Ku, Tokyo 1648639, Japan; [Kasai, Hiromi] Hokkaido Natl Fisheries Res Inst, Kushiro, Hokkaido 0850802, Japan; [Nishioka, Jun] Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan; [Nakatsuka, Takeshi] Nagoya Univ, Grad Sch Environm Studies, Nagoya, Aichi 4648601, Japan	Tsuda, A (reprint author), Univ Tokyo, Atmosphere & Ocean Res Inst, Nakano Ku, Tokyo 1648639, Japan.	tsuda@aori.u-tokyo.ac.jp			Japan Society for the Promotion of Science [20241003]	We wish to thank the captain and crew of the FRVs Tankai Maru, Hokko Maru, and RV Professor Khromov, and our colleagues onboard during the cruises. A part of the samples were collected by Dr. Y. Kawasaki and Dr. S. Shimode was helpful for production of figures. We are also grateful to Dr. T. Kobari for his helpful comments. This study was supported by the Japan Society for the Promotion of Science (#20241003). The cruise of RV Professor Khromov was carried out as a part of the Amur-Okhotsk Project, promoted by the Research Institute for Humanity and Nature.	ALFULTIS MA, 1987, J GEOPHYS RES-OCEANS, V92, P13013, DOI 10.1029/JC092iC12p13013; Mackas DL, 1999, PROG OCEANOGR, V43, P335, DOI 10.1016/S0079-6611(99)00012-9; Tsuda A, 2004, FISH OCEANOGR, V13, P10, DOI 10.1111/j.1365-2419.2004.00315.x; El-Sabaawi R, 2009, MAR BIOL, V156, P225, DOI 10.1007/s00227-008-1073-1; Liu H, 2006, J PLANKTON RES, V28, P87, DOI 10.1093/plankt/fbi102; Kobari T, 2003, PROG OCEANOGR, V57, P279, DOI 10.1016/S0079-6611(03)00102-2; MILLER CB, 1984, PROG OCEANOGR, V13, P201, DOI 10.1016/0079-6611(84)90009-0; MILLER CB, 1988, PROG OCEANOGR, V20, P293, DOI 10.1016/0079-6611(88)90044-4; Tsuda A, 2014, J OCEANOGR, V70, P123, DOI 10.1007/s10872-013-0214-4; Tsuda A, 1999, MAR BIOL, V135, P533, DOI 10.1007/s002270050654; Bradford-Grieve JM, 2001, J PLANKTON RES, V23, P963, DOI 10.1093/plankt/23.9.963; Batten SD, 2003, FISH OCEANOGR, V12, P201, DOI 10.1046/j.1365-2419.2003.00233.x; Mackas DL, 2007, PROG OCEANOGR, V75, P223, DOI 10.1016/j.pocean.2007.08.010; Itoh H, 2014, PROG OCEANOGR, V126, P224, DOI 10.1016/j.pocean.2014.05.008; Pennak RW, 1943, ECOLOGY, V24, P405, DOI 10.2307/1930542; Kobari T, 2008, DEEP-SEA RES PT II, V55, P1648, DOI 10.1016/j.dsr2.2008.04.016; MILLER CB, 1988, PROG OCEANOGR, V20, P223, DOI 10.1016/0079-6611(88)90042-0; FULTON J, 1973, J FISH RES BOARD CAN, V30, P811; Goldblatt RH, 1999, DEEP-SEA RES PT II, V46, P2619, DOI 10.1016/S0967-0645(99)00078-8; Dagg M, 2009, DEEP-SEA RES PT I, V56, P716, DOI 10.1016/j.dsr.2008.12.012; DAGG M, 1993, DEEP-SEA RES PT I, V40, P1431, DOI 10.1016/0967-0637(93)90121-I; Harrison PJ, 2004, J OCEANOGR, V60, P93, DOI 10.1023/B:JOCE.0000038321.57391.2a; Heinrich AK, 2002, OCEANOLOGY, V42, P77; HOLM-HANSEN OSMUND, 1965, J CONS CONS PERMS INTE EXPLOR MER, V30, P3; Kasai H, 2010, J OCEANOGR, V66, P13; Katsumata K, 2004, J GEOPHYS RES-OCEANS, V109, P1, DOI 10.1029/2003JC001864; Kawasaki Y, 1994, SEA SKY, V70, P71; Kimura N, 1999, J GEOPHYS RES-OCEANS, V104, P11137, DOI 10.1029/1999JC900004; Kobari K, 2001, J PLANKTON RES, V23, P287; Kobari K, 2001, MAR ECOL PROG SER, V209, P243; Kobari K, 1999, MAR BIOL, V134, P683; MACKAS DL, 1993, PROG OCEANOGR, V32, P259, DOI 10.1016/0079-6611(93)90017-8; MILLER CB, 1993, PROG OCEANOGR, V32, P295, DOI 10.1016/0079-6611(93)90018-9; Mustapha MA, 2008, ESTUAR COAST SHELF S, V77, P577, DOI 10.1016/j.ecss.2007.10.021; Nakamura T, 2000, J PHYS OCEANOGR, V30, P1601, DOI 10.1175/1520-0485(2000)030<1601:TGOLAU>2.0.CO;2; OHMAN MD, 1987, LIMNOL OCEANOGR, V32, P1317; PARKINSON CL, 1983, J GEOPHYS RES-OC ATM, V88, P2793, DOI 10.1029/JC088iC05p02793; Saito H, 2002, DEEP-SEA RES PT II, V49, P5463, DOI 10.1016/S0967-0645(02)00204-7; Saitoh S, 1996, J REMOTE SENSING SOC, V16, P86; Shoden S, 2005, MAR BIOL, V146, P497, DOI 10.1007/s00227-004-1450-3; SUZUKI R, 1990, Journal of the Oceanographical Society of Japan, V46, P190, DOI 10.1007/BF02125580; Takahashi K, 2008, PROG OCEANOGR, V78, P222, DOI 10.1016/j.pocean.2008.06.002; Terazaki M, 1997, J ADV MARINE SCI TEC, V3, P127; Tsuda Atsushi, 2001, Journal of Oceanography, V57, P341, DOI 10.1023/A:1012490730792; Tsuda A, 2005, PROG OCEANOGR, V64, P237, DOI 10.1016/j.pocean.2005.02.011; Tsuda A, 2007, J OCEANOGR, V63, P983, DOI 10.1007/s10872-007-0082-x; Tsuda A, 2009, DEEP-SEA RES PT II, V56, P2767, DOI 10.1016/j.dsr2.2009.06.004; Varpe O, 2008, OIKOS, V118, P363	48	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0916-8370	1573-868X		J OCEANOGR	J. Oceanogr.	JUN	2015	71	3					271	285		10.1007/s10872-015-0287-3		15	Oceanography	Oceanography	CJ0QF	WOS:000355181400005		
J	Kitajima, S; Iguchi, N; Honda, N; Watanabe, T; Katoh, O				Kitajima, Satoshi; Iguchi, Naoki; Honda, Naoto; Watanabe, Tatsuro; Katoh, Osamu			Distribution of Nemopilema nomurai in the southwestern Sea of Japan related to meandering of the Tsushima Warm Current	JOURNAL OF OCEANOGRAPHY			English	Article						Jellyfish; Midwater trawl; Nemopilema nomurai; Sea of Japan; Tsushima Warm Current	EAST CHINA SEA; GIANT JELLYFISH; YELLOW SEA; RHIZOSTOMEAE; SCYPHOZOA; BLOOMS; WATERS; VARIABILITY; POPULATION; TRANSPORT	We investigated the horizontal distribution of Nemopilema nomurai medusae using a midwater trawl in the southwestern Sea of Japan from September to October of each year from 2006 to 2012. Numerous medusae of this species found in 2006, 2007, and 2009 were mainly distributed far (> 40 km) from the mainland of Japan in the western part of the survey area, but were distributed in the stations closest (< 25 km) to the mainland in the eastern part, particularly in 2006 and 2009. These distribution patterns were associated with the path of the second branch of the Tsushima Warm Current (TWC) that flows offshore to the west of Oki Islands and usually approaches the mainland of Japan to the east of Oki Islands. Differences in jellyfish distribution across the survey periods were related to the distribution of the second branch being associated with types, position and intensity of eddies in the eastern part of the survey area. Hence, the formations of eddies and consequent variation in the path of the TWC would be responsible for transporting medusae from offshore to near the mainland to the east of Oki Islands. Individuals with large bells accumulated in the northwestern part of the survey area, where a cyclonic eddy was present downstream of the third branch of the TWC. This variation in bell size distribution may be ascribed to differences in the physical and/or biological factors among the three branches of the TWC.	[Kitajima, Satoshi; Iguchi, Naoki; Honda, Naoto; Watanabe, Tatsuro; Katoh, Osamu] Fisheries Res Agcy, Japan Sea Natl Fisheries Res Inst, Chuo Ku, Niigata 9518121, Japan; [Kitajima, Satoshi] Fisheries Res Agcy, Seikai Natl Fisheries Res Inst, Nagasaki 8512213, Japan	Kitajima, S (reprint author), Fisheries Res Agcy, Japan Sea Natl Fisheries Res Inst, Chuo Ku, I-5939-22 Suido Cho, Niigata 9518121, Japan.	kitaji@affrc.go.jp			Fisheries Agency of Japan	We thank Dr. A. Okuno for providing valuable comments on earlier versions of this manuscript; the captains, crew, and scientists on board R/Vs Shunyo-maru and Kaiyo-maru for their cooperation at sea; Ms. K. Saitoh and M. Itoh for their help with summarizing data; the two anonymous reviewers for insightful comments. This research was partially supported by grants from the Fisheries Agency of Japan.	Kawahara M, 2006, TOXICON, V48, P713, DOI 10.1016/j.toxicon.2006.06.015; Yoon WD, 2008, J PLANKTON RES, V30, P251, DOI 10.1093/plankt/fbm102; NAGASAWA T, 1995, JPN J ICHTHYOL, V41, P385; Zhang F, 2012, HYDROBIOLOGIA, V690, P81, DOI 10.1007/s10750-012-1057-5; Fukudome K, 2010, J OCEANOGR, V66, P539; Kawahara M, 2006, MAR ECOL PROG SER, V307, P161, DOI 10.3354/meps307161; Dong ZJ, 2010, MAR POLLUT BULL, V60, P954, DOI 10.1016/j.marpolbul.2010.04.022; Yamada K, 2005, J OCEANOGR, V61, P857, DOI 10.1007/s10872-006-0005-2; Honda N, 2009, FISHERIES SCI, V75, P947, DOI 10.1007/s12562-009-0114-0; Moon JH, 2010, J MARINE SYST, V80, P101, DOI 10.1016/j.jmarsys.2009.10.015; Ishii H, 1998, J PLANKTON RES, V20, P805, DOI 10.1093/plankt/20.5.805; Hase H, 1999, J OCEANOGR, V55, P217, DOI DOI 10.1023/A:1007894030095; Hasegawa D, 2004, GEOPHYS RES LETT, V31, P2; Hyun JH, 2009, AQUAT MICROB ECOL, V54, P45, DOI 10.3354/ame01280; Ichiye T, 1988, LA MER, V26, P69; Iguchi Naoki, 2010, Ocean Science Journal, V45, P129, DOI 10.1007/s12601-010-0011-6; Isoda Y, 1994, J OCEANOGR, V50, P1, DOI 10.1007/BF02233852; Kanaji Y, 2009, FISH RES, V95, P139, DOI 10.1016/j.fishres.2008.08.004; Kang JH, 2004, J PLANKTON RES, V26, P1515, DOI 10.1093/plankt/fbh140; Katoh O, 1996, J OCEANOGR, V52, P747, DOI 10.1007/BF02239463; Katoh O, 1994, J OCEANOGR, V50, P317, DOI 10.1007/BF02239520; Katoh Osamu, 1993, Journal of Oceanography, V49, P1, DOI 10.1007/BF02234004; Lee CI, 2011, OCEAN SCI J, V45, P253; LEE HoJin, 2003, Ocean and Polar Research, V25, P287; Mitchell DA, 2005, DEEP-SEA RES PT II, V52, P1617, DOI 10.1016/j.dsr2.2003.09.005; Morimoto A, 2009, J OCEANOGR, V65, P61, DOI 10.1007/s10872-009-0006-z; Morimoto A, 2009, CONT SHELF RES, V29, P1437, DOI 10.1016/j.csr.2009.03.017; Naganuma K, 1977, KAIYO KAGAKU, V9, P139; Omori Makoto, 2004, Plankton Biology and Ecology, V51, P36; Onitsuka G, 2010, HARMFUL ALGAE, V9, P390, DOI 10.1016/j.hal.2010.01.006; Onitsuka G, 2007, J GEOPHYS RES-OCEANS, V112, DOI 10.1029/2006JC003981; Takikawa T, 2010, UMI SORA, V86, P13; Toyokawa M, 2012, FISHERIES SCI, V78, P1213, DOI 10.1007/s12562-012-0550-0; Uye S, 2010, OCEANOGR JPN, V19, P283; Uye S, 2014, JELLYFISH BLOOMS, P185, DOI 10.1007/978-94-007-7015-7_1; Uye Siain-Icth, 2008, Plankton & Benthos Research, V3, P125, DOI 10.3800/pbr.3.125; Watanabe T, 2006, J OCEANOGR, V62, P527, DOI 10.1007/s10872-006-0073-3; Watanabe T, 2009, J OCEANOGR, V65, P791; Xu YJ, 2013, J OCEANOGR, V69, P511, DOI 10.1007/s10872-013-0189-1	39	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0916-8370	1573-868X		J OCEANOGR	J. Oceanogr.	JUN	2015	71	3					287	296		10.1007/s10872-015-0288-2		10	Oceanography	Oceanography	CJ0QF	WOS:000355181400006		
J	Kawakami, H; Honda, MC; Matsumoto, K; Wakita, M; Kitamura, M; Fujiki, T; Watanabe, S				Kawakami, Hajime; Honda, Makio C.; Matsumoto, Kazuhiko; Wakita, Masahide; Kitamura, Minoru; Fujiki, Tetsuichi; Watanabe, Shuichi			POC fluxes estimated from Th-234 in late spring-early summer in the western subarctic North Pacific	JOURNAL OF OCEANOGRAPHY			English	Article						Biological pump; Th-234; POC flux; High-frequency observations; Western subarctic North Pacific	DISSOLVED INORGANIC CARBON; PARTICULATE ORGANIC-CARBON; STATION KNOT 44-DEGREES-N; TIME-SERIES OBSERVATION; SOUTHERN-OCEAN; MARINE-PHYTOPLANKTON; ZOOPLANKTON CONTROL; EXPORT PRODUCTION; BIOLOGICAL PUMP; PARTICLE-FLUX	Measurements of Th-234, particulate organic carbon (POC), nutrients and net primary production were made at station K2 (47A degrees N, 160A degrees E) in the western subarctic North Pacific Ocean six times from 3 June to 17 July 2006. Net primary productions varied from 263 to 732 mgC m(-2) d(-1). Th-234 was used as a tracer to estimate POC fluxes from the surface layer to 100 m depth. POC fluxes varied from 14 to 284 mgC m(-2) d(-1). The maximum POC flux and net primary production in this study were much higher than those observed previously at station K2 (179 mgC m(-2) d(-1) in July 2003 for POC flux, 552 mgC m(-2) d(-1) in May 2004 for net primary production). Because maximum chlorophyll a in this study (1.3 A mu g L-1) was also much higher than previous values at station K2 (1.0 A mu g L-1 in August 2004), we assumed that high-frequency observations had allowed measurement of a near annual peak of biological production and biological pump activity. The net primary productions and POC fluxes changed greatly during the study period. Biological production and export in this region varied greatly during this season. The export ratio (POC flux/net primary production) in this season (23 +/- A 1 %) was less than the annual export ratio in this region (29 +/- A 1 % in 2002-2005), although this ratio was higher than those in the other oceans (5-10 %). POC export (5.0 +/- A 0.1 gC m(-2)) in late spring-early summer was about half that of net community production (10.2 +/- A 0.6 gC m(-2)) estimated from the drawdown of phosphate during the study period. We suggest that the pathways of carbon export, other than the sinking of particles, were transport by zooplankton and so on.	[Kawakami, Hajime; Wakita, Masahide; Watanabe, Shuichi] Japan Agcy Marine Earth Sci & Technol, Mutsu Inst Oceanog, Mutsu, Aomori 0350022, Japan; [Honda, Makio C.; Matsumoto, Kazuhiko] Japan Agcy Marine Earth Sci & Technol, Dept Environm Geochem Cycle Res, Yokosuka, Kanagawa 2370061, Japan; [Kitamura, Minoru; Fujiki, Tetsuichi] Japan Agcy Marine Earth Sci & Technol, Res & Dev Ctr Global Change, Yokosuka, Kanagawa 2370061, Japan; [Kawakami, Hajime] Japan Agcy Marine Earth Sci & Technol, Publ Relat Dept, Yokosuka, Kanagawa 2370061, Japan	Kawakami, H (reprint author), Japan Agcy Marine Earth Sci & Technol, Mutsu Inst Oceanog, 690 Aza Kitasekine, Mutsu, Aomori 0350022, Japan.	kawakami@jamstec.go.jp					COALE KH, 1985, LIMNOL OCEANOGR, V30, P22; Kemp AES, 2000, DEEP-SEA RES PT II, V47, P2129, DOI 10.1016/S0967-0645(00)00019-9; IKEDA T, 1985, MAR BIOL, V85, P1, DOI 10.1007/BF00396409; BUESSELER KO, 1992, DEEP-SEA RES, V39, P1115, DOI 10.1016/0198-0149(92)90060-7; Steinberg DK, 2008, LIMNOL OCEANOGR, V53, P1327, DOI 10.4319/lo.2008.53.4.1327; Yasuda I, 2003, J OCEANOGR, V59, P389, DOI 10.1023/A:1025580313836; HAMA T, 1983, MAR BIOL, V73, P31, DOI 10.1007/BF00396282; KNAUER GA, 1979, DEEP-SEA RES, V26, P97, DOI 10.1016/0198-0149(79)90089-X; Fujiki T, 2011, J OCEANOGR, V67, P295, DOI 10.1007/s10872-011-0028-1; Matsumoto K, 2014, J GEOPHYS RES-OCEANS, V119, P6523, DOI 10.1002/2014JC009982; BUESSELER KO, 1994, GLOBAL BIOGEOCHEM CY, V8, P179, DOI 10.1029/94GB00207; Benitez-Nelson C, 2001, DEEP-SEA RES PT I, V48, P2595, DOI 10.1016/S0967-0637(01)00032-2; Buesseler KO, 2009, DEEP-SEA RES PT I, V56, P1143, DOI 10.1016/j.dsr.2009.04.001; Louanchi F, 2000, GLOBAL BIOGEOCHEM CY, V14, P957, DOI 10.1029/1999GB001215; Takahashi T, 2002, DEEP-SEA RES PT II, V49, P1601, DOI 10.1016/S0967-0645(02)00003-6; Ebersbach F, 2008, LIMNOL OCEANOGR, V53, P212, DOI 10.4319/lo.2008.53.1.0212; Honda MC, 2003, J OCEANOGR, V59, P671, DOI 10.1023/B:JOCE.0000009596.57705.0c; Imai K, 2002, DEEP-SEA RES PT II, V49, P5395, DOI 10.1016/S0967-0645(02)00198-4; Martiny AC, 2013, NAT GEOSCI, V6, P279, DOI [10.1038/ngeo1757, 10.1038/NGEO1757]; Schmidt S, 2002, DEEP-SEA RES PT I, V49, P1507, DOI 10.1016/S0967-0637(02)00039-0; Savoye N, 2006, MAR CHEM, V100, P234, DOI 10.1016/j.marchem.2005.10.014; Buesseler KO, 1998, GLOBAL BIOGEOCHEM CY, V12, P297, DOI 10.1029/97GB03366; Buesseler KO, 2006, MAR CHEM, V100, P213, DOI 10.1016/j.marchem.2005.10.013; CHEN JH, 1986, EARTH PLANET SC LETT, V80, P241, DOI 10.1016/0012-821X(86)90108-1; Bacon MP, 1996, DEEP-SEA RES PT II, V43, P1133, DOI 10.1016/0967-0645(96)00016-1; Zapata M, 2000, MAR ECOL PROG SER, V195, P29, DOI 10.3354/meps195029; Smetacek V, 2000, NATURE, V406, P574, DOI 10.1038/35020665; Buesseler KO, 2001, MAR CHEM, V74, P15, DOI 10.1016/S0304-4203(00)00092-X; Elskens M, 2008, DEEP-SEA RES PT II, V55, P1594, DOI 10.1016/j.dsr2.2008.04.013; Favorite F., 1976, B INT N PAC COMM, V33, P1; Fujiki T, 2014, LIMNOL OCEANOGR, V59, P887, DOI 10.4319/lo.2014.59.3.0887; Gnaiger E, 1983, POLAROGRAPHIC OXYGEN, P337; Honda MC, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026466; Honda MC, 2002, DEEP-SEA RES PT II, V49, P5595, DOI 10.1016/S0967-0645(02)00201-1; Honda MC, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2009GL041521; Honda MC, 2007, J OCEANOGR, V63, P349, DOI 10.1007/s10872-007-0034-5; Kawakami H, 2007, DEEP-SEA RES PT I, V54, P1070, DOI 10.1016/j.dsr.2007.04.005; Kawakami H, 2007, J OCEANOGR, V63, P967, DOI 10.1007/s10872-007-0081-y; Kawakami H, 2010, 234TH POC DATA N PAC; Kawakami H, 2004, GEOCHEM J, V38, P581; Lee C, 1988, OCEANOGRAPHY, V1, P34; Lourey MJ, 2001, J GEOPHYS RES-OCEANS, V106, P31463, DOI 10.1029/2000JC000287; Monterey G., 1997, NOAA ATLAS NESDIS, V14; ONDRUSEK ME, 1991, DEEP-SEA RES, V38, P243, DOI 10.1016/0198-0149(91)90082-Q; Saino T, 2002, DEEP-SEA RES PT II, V49, P5297, DOI 10.1016/S0967-0645(02)00191-1; Saito H, 2002, DEEP-SEA RES PT II, V49, P5463, DOI 10.1016/S0967-0645(02)00204-7; Savoye N, 2008, DEEP-SEA RES PT II, V55, P841, DOI 10.1016/j.dsr2.2007.12.036; Steinberg DK, 2000, DEEP-SEA RES PT I, V47, P137, DOI 10.1016/S0967-0637(99)00052-7; Tsunogai S, 1976, JOINT OC ASS ED, P156; TSUNOGAI S, 1991, TELLUS B, V43, P256, DOI 10.1034/j.1600-0889.1991.00018.x; Tsurushima N, 2002, DEEP-SEA RES PT II, V49, P5377, DOI 10.1016/S0967-0645(02)00197-2; Ueno H, 2000, J GEOPHYS RES-OCEANS, V105, P16885, DOI 10.1029/2000JC900020; Wakita M, 2013, BIOGEOSCIENCES, V10, P7817, DOI 10.5194/bg-10-7817-2013; Wong CS, 2002, DEEP-SEA RES PT II, V49, P5317, DOI 10.1016/S0967-0645(02)00193-5; Yamaguchi A, 2002, DEEP-SEA RES PT II, V49, P5513, DOI 10.1016/S0967-0645(02)00205-9	55	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0916-8370	1573-868X		J OCEANOGR	J. Oceanogr.	JUN	2015	71	3					311	324		10.1007/s10872-015-0290-8		14	Oceanography	Oceanography	CJ0QF	WOS:000355181400008		
J	Nishiwaki, M; Welsh, M; Gammon, B; Ferreira, LM; Johnson, JA; King, GJW				Nishiwaki, Masao; Welsh, Mark; Gammon, Braden; Ferreira, Louis M.; Johnson, James A.; King, Graham J. W.			Volar Subluxation of the Ulnar Head in Dorsal Translation Deformities of Distal Radius Fractures: An In Vitro Biomechanical Study	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						distal radioulnar joint; distal radius fracture; dorsal translation; dorsal angulation; volar subluxation	RADIOULNAR JOINT MECHANICS; FOREARM ROTATION; EXTRAARTICULAR FRACTURES; WRIST; MALALIGNMENT; KINEMATICS; STABILITY; MALUNION; ADULTS; VIVO	Objectives:To quantify the effects of dorsal translation deformities of the distal radius with and without dorsal angulation on volar displacement of the ulnar head during simulated active forearm rotation, both with the triangular fibrocartilage complex (TFCC) intact and sectioned conditions.Methods:Eight fresh-frozen cadaveric upper extremities were mounted in an active forearm motion simulator, and distal radial deformities of 0, 5, and 10 mm of dorsal translation with 0, 10, 20, and 30 degrees of dorsal angulation were simulated. Volar displacement of the ulnar head at the distal radioulnar joint as a result of each distal radial deformity was quantified during simulated active supination. The data were collected with the TFCC intact and after sectioning the TFCC at its ulnar insertion.Results:Increasing isolated dorsal translation deformities increased volar displacement of the ulnar head when the TFCC was intact (P < 0.001). Increasing dorsal translation combined with dorsal angulation increased volar displacement of the ulnar head compared with isolated dorsal angulation deformities (P < 0.001). Sectioning the TFCC increased the volar displacement of the ulnar head caused by each distal radial deformity (P = 0.001).Conclusions:These results emphasize the clinical importance of evaluating the magnitude of both dorsal translation and dorsal angulation when managing displaced distal radius fractures and malunions.	[Nishiwaki, Masao] Kawasaki Municipal Hosp, Dept Orthopaed Surg, Kawasaki, Kanagawa 2100013, Japan; [Welsh, Mark; Ferreira, Louis M.; Johnson, James A.; King, Graham J. W.] St Josephs Hlth Care London, Hand & Upper Limb Ctr, London, ON, Canada; [Gammon, Braden] Univ Ottawa, Div Orthopaed Surg, Ottawa, ON, Canada	Nishiwaki, M (reprint author), Kawasaki Municipal Hosp, Dept Orthopaed Surg, Kawasaki Ku, 12-1 Shinkawadori, Kawasaki, Kanagawa 2100013, Japan.	nishiwa41@gmail.com	Ferreira, Louis/K-6771-2013	Ferreira, Louis/0000-0001-9881-9177	Canadian Institutes for Health Research [R0598A13]	Supported by Canadian Institutes for Health Research (R0598A13).	Bronstein AJ, 1997, J HAND SURG-AM, V22A, P258, DOI 10.1016/S0363-5023(97)80160-8; Gordon KD, 2003, J HAND SURG-AM, V28A, P943, DOI 10.1016/S0363-5023(03)00487-8; Grewal R, 2007, J HAND SURG-AM, V32A, P962, DOI 10.1016/j.jhsa.2007.05.009; Kihara H, 1996, J HAND SURG-AM, V21A, P40, DOI 10.1016/S0363-5023(96)80152-3; Fraser GS, 2009, J HAND SURG-AM, V34A, P838, DOI 10.1016/j.jhsa.2009.02.011; Azzopardi T, 2005, J BONE JOINT SURG BR, V87B, P837, DOI 10.1302/0301-620X.87B6.15608; POGUE DJ, 1990, J HAND SURG-AM, V15A, P721, DOI 10.1016/0363-5023(90)90143-F; Ishii S, 1998, J HAND SURG-AM, V23A, P909, DOI 10.1016/S0363-5023(98)80172-X; MCQUEEN M, 1988, J BONE JOINT SURG BR, V70, P649; Miyake J, 2012, J HAND SURG-EUR VOL, V37E, P506, DOI 10.1177/1753193412443644; Crisco JJ, 2007, J ORTHOP RES, V25, P547, DOI 10.1002/jor.20322; Nishiwaki M, 2014, J HAND SURG-AM, V39, P656, DOI 10.1016/j.jhsa.2014.01.013; Wong TC, 2010, J HAND SURG-EUR VOL, V35E, P202, DOI 10.1177/1753193409339941; Hirahara H, 2003, J HAND SURG-AM, V28A, P614, DOI 10.1016/S0363-5023(03)00249-1; ADAMS BD, 1993, J HAND SURG-AM, V18A, P492, DOI 10.1016/0363-5023(93)90098-N; GARTLAND JJ, 1951, J BONE JOINT SURG AM, V33-A, P895; Gliatis JD, 2000, J HAND SURG-BRIT EUR, V25B, P535, DOI 10.1054/jhsb.2000.0373; Saito T, 2013, J HAND SURG-EUR VOL, V38, P739, DOI 10.1177/1753193412473036; Moore DC, 2002, J HAND SURG-AM, V27A, P233, DOI 10.1053/jhsu.2002.31156; FERNANDEZ DL, 1982, J BONE JOINT SURG AM, V64, P1164; Prommersberger KJ, 2004, J HAND SURG-AM, V29A, P110, DOI 10.1016/j.jhsa.2003.09.014; SHORT WH, 1987, J HAND SURG-AM, V12A, P529	22	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	JUN	2015	29	6					295	300		10.1097/BOT.0000000000000273		6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CI7WW	WOS:000354977000011		
J	Yoshimura, T; Izumida, H; Nakashima, R; Ishimura, T; Shikazono, N; Kawahata, H; Suzuki, A				Yoshimura, Toshihiro; Izumida, Hisato; Nakashima, Rei; Ishimura, Toyoho; Shikazono, Naotatsu; Kawahata, Hodaka; Suzuki, Atsushi			Stable carbon isotope values in dissolved inorganic carbon of ambient waters and shell carbonate of the freshwater pearl mussel (Hyriopsis sp.)	JOURNAL OF PALEOLIMNOLOGY			English	Article						Mussel; Carbon; Isotope; Dissolved inorganic carbon; Weathering; Soil	METABOLIC CARBON; MARGARITIFERA-FALCATA; BIOLOGICAL CARBONATES; UNITED-STATES; OXYGEN; RIVERS; FRACTIONATION; UNIONIDAE; DIOXIDE; MOLLUSK	We investigated carbon sources and cycling in a canal connected to Lake Kasumigaura (Japan) using stable carbon isotope values (delta C-13) in dissolved inorganic carbon (DIC) of ambient water and in shell carbonate of the commercially cultured freshwater pearl mussel (Hyriopsis sp., Unionidae). The delta C-13(DIC) showed correlations with DIC concentrations, pH, monthly precipitation and pCO(2). Thus, the carbon isotopic composition can be used as a proxy for environmental variables. The pCO(2) ranged from 3,046 to 9,535 mu atm, with a mean value of 6,035 mu atm, and remained well above the atmospheric value throughout the years of study. Changes in CO2 solubility, outgassing and biological processes in the river had only minor influence on the carbon isotope composition. DIC concentration and delta C-13(DIC) were controlled primarily by external inputs of soil and weathering-derived DIC associated with precipitation. The delta C-13 values in different growth zones of the Hyriopsis shells were similar, suggesting that given a constant delta C-13(DIC) source throughout shell formation, the influence of size-related metabolic variations on shell delta C-13 was negligible. Comparison of delta C-13 values in DIC and Hyriopsis shell indicated that mussel ontogeny did not influence carbon isotope fractionation, but inter-specimen differences suggested that physiological factors exert systematic control on delta C-13 values in Hyriopsis. Results also suggest that if the annual mean delta C-13(DIC) value is to be inferred for a fluvial system from shell delta C-13 values, multiple specimens should be sampled, and the annual mean value yields a temporally integrated measure of the stable isotopic composition of the river system. Given the carbon isotope fractionation between ambient DIC and shell is +2.0 +/- A 0.7 aEuro degrees (2 se), we estimated that pCO(2) averaged similar to 6,850 mu atm during shell growth periods from 2002 to 2007. The pCO(2) concentration was an order of magnitude greater than the atmospheric equilibrium value in all years, suggesting that CO2 was lost from surface water to the atmosphere or downstream to the lake. These losses must be accounted for when considering the regional redistribution of CO2. Our results extend the utility of delta C-13 measures in freshwater bivalves for inferring the delta C-13(DIC) history of ambient waters. This tool provides information that is complementary to that gained from direct delta C-13(DIC) measurement and should enable inference of long-term changes in critical variables such as pCO(2).	[Yoshimura, Toshihiro; Kawahata, Hodaka] Univ Tokyo, Atmosphere & Ocean Res Inst, Kashiwa, Chiba 2778564, Japan; [Izumida, Hisato; Shikazono, Naotatsu] Keio Univ, Grad Sch Sci & Technol, Yokohama, Kanagawa 223, Japan; [Nakashima, Rei; Ishimura, Toyoho; Suzuki, Atsushi] Natl Inst Adv Ind Sci & Technol, Geol Survey Japan, Tsukuba, Ibaraki 3058567, Japan	Suzuki, A (reprint author), Natl Inst Adv Ind Sci & Technol, Geol Survey Japan, Tsukuba Cent 7,1-1-1 Higashi, Tsukuba, Ibaraki 3058567, Japan.	a.suzuki@aist.go.jp			Environment Research & Technology Development Fund of the Ministry of the Environment of Japan [34]	We express our appreciation to Mr. Shoichi Kitao of Meiko Pearl Ushiku Kanko Co., Ltd., for providing specimens, Dr. Masayuki Nagao, Dr. Hiroyuki Ushie, and Takuya Manaka for providing valuable comments and advice, Dr. David Strayer of Cary Institute of Ecosystem Studies for reviewing an earlier version of this manuscript. We also acknowledge the constructive comments of anonymous reviewers and the editor. This study was partly supported by grant 34, Research on development of a monitoring system for inland waters suffering from global warming, of the Environment Research & Technology Development Fund of the Ministry of the Environment of Japan.	Barnes RT, 2009, CHEM GEOL, V266, P318, DOI 10.1016/j.chemgeo.2009.06.018; Doctor DH, 2008, HYDROL PROCESS, V22, P2410, DOI 10.1002/hyp.6833; Helie JF, 2002, CHEM GEOL, V186, P117, DOI 10.1016/S0009-2541(01)00417-X; Chauvaud L, 2011, ESTUAR COAST, V34, P211, DOI 10.1007/s12237-010-9267-4; Schone BR, 2008, GEO-MAR LETT, V28, P269, DOI 10.1007/s00367-008-0114-6; Cole JJ, 2007, ECOSYSTEMS, V10, P171, DOI 10.1007/s10021-006-9013-8; Butman D, 2011, NAT GEOSCI, V4, P839, DOI [10.1038/ngeo1294, 10.1038/NGEO1294]; Dubois KD, 2010, J GEOPHYS RES-BIOGEO, V115, DOI 10.1029/2009JG001102; MCCONNAUGHEY T, 1989, GEOCHIM COSMOCHIM AC, V53, P151, DOI 10.1016/0016-7037(89)90282-2; McConnaughey TA, 2008, GEO-MAR LETT, V28, P287, DOI 10.1007/s00367-008-0116-4; Poulain C, 2010, CHEM GEOL, V272, P75, DOI 10.1016/j.chemgeo.2010.02.006; Dettman DL, 1999, GEOCHIM COSMOCHIM AC, V63, P1049, DOI 10.1016/S0016-7037(99)00020-4; Lartaud F, 2010, GEO-MAR LETT, V30, P23, DOI 10.1007/s00367-009-0148-4; Dettman DL, 2001, GEOLOGY, V29, P31, DOI 10.1130/0091-7613(2001)029<0031:SSIEFA>2.0.CO;2; Kaandorp RJG, 2003, PALAEOGEOGR PALAEOCL, V194, P339, DOI 10.1016/S0031-0182(03)00332-8; Vuorio K, 2007, FUND APPL LIMNOL, V169, P237, DOI 10.1127/1863-9135/2007/0169-0237; Lorrain A, 2004, GEOCHIM COSMOCHIM AC, V68, P3509, DOI 10.1016/j.gca.2004.01.025; SCHELSKE CL, 1991, LIMNOL OCEANOGR, V36, P961; McConnaughey TA, 1997, GEOCHIM COSMOCHIM AC, V61, P611, DOI 10.1016/S0016-7037(96)00361-4; GROSSMAN EL, 1986, CHEM GEOL, V59, P59, DOI 10.1016/0009-2541(86)90044-6; ROMANEK CS, 1992, GEOCHIM COSMOCHIM AC, V56, P419, DOI 10.1016/0016-7037(92)90142-6; SUZUKI A, 1995, SEDIMENT GEOL, V99, P259, DOI 10.1016/0037-0738(95)00048-D; Gillikin DP, 2007, GEOCHIM COSMOCHIM AC, V71, P2936, DOI 10.1016/j.gca.2007.04.003; Finlay JC, 2003, BIOGEOCHEMISTRY, V62, P231, DOI 10.1023/A:1021183023963; GRAN G, 1952, ANALYST, V77, P661, DOI 10.1039/an9527700661; TANAKA N, 1986, NATURE, V320, P520, DOI 10.1038/320520a0; Nichols SJ, 2000, CAN J ZOOL, V78, P871, DOI 10.1139/cjz-78-5-871; Karim A, 2000, CHEM GEOL, V170, P153, DOI 10.1016/S0009-2541(99)00246-6; Apolinarska K, 2013, J PALEOLIMNOL, V50, P353, DOI 10.1007/s10933-013-9730-x; Cole JJ, 2001, MAR FRESHWATER RES, V52, P101, DOI 10.1071/MF00084; Stallard RF, 1998, GLOBAL BIOGEOCHEM CY, V12, P231, DOI 10.1029/98GB00741; Howard JK, 2005, HYDROBIOLOGIA, V541, P229, DOI 10.1007/s10750-004-5711-4; Christian AD, 2004, J N AM BENTHOL SOC, V23, P101, DOI 10.1899/0887-3593(2004)023<0101:TPAPFS>2.0.CO;2; Das A, 2005, EARTH PLANET SC LETT, V236, P419, DOI 10.1016/j.epsl.2005.05.009; Dickson AG, 1994, ORNLCDIAC74 US DEP E; Fritz P., 1997, ENV ISOTOPES HYDROGE; Gillikin DP, 2009, J GEOPHYS RES-BIOGEO, V114, DOI 10.1029/2008JG000829; Goewert A, 2007, PALAEOGEOGR PALAEOCL, V252, P637, DOI 10.1016/j.palaco.2007.06.002; Hamada Y, 2003, B TERR ENV RES CENT, V4, P19; Bade DL, 2004, LIMNOL OCEANOGR, V49, P1160; Ibaraki Kasumigaura Environmental Science Center, 2004, 4 CONS PROGR WAT QUA; Ishimura T, 2004, RAPID COMMUN MASS SP, V18, P2883, DOI 10.1002/rcm.1701; Izumida H, 2011, PALAEOGEOGR PALAEOCL, V309, P298, DOI 10.1016/j.palaeo.2011.06.014; Jones JB, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017056; Lynch JK, 2010, J GEOPHYS RES-BIOGEO, V115, DOI [10.1029/2009JG0011.12, 10.1029/2009JG001132]; Manaka T, 2013, AQUAT GEOCHEM, V19, P281, DOI 10.1007/s10498-013-9195-6; Marwick B, 2011, QUATERNARY SCI REV, V30, P3088, DOI 10.1016/j.quascirev.2011.07.007; Miyaji T, 2007, MAR ECOL PROG SER, V336, P141, DOI 10.3354/meps336141; Mook W. G., 1991, BIOGEOCHEMISTRY MAJO, P245; OTSUKI A, 1993, PROC INT ASSOC THEOR, V25, P187; Pawellek Frank, 1994, Israel Journal of Earth Sciences, V43, P187; Richey JE, 2004, SCOPE SER, V62, P329; Schone BR, 2007, INT J EARTH SCI, V96, P525, DOI 10.1007/s00531-006-0109-3; Ushie H, 2010, J GEOPHYS RES-BIOGEO, V115, DOI 10.1029/2009JG001039; Versteegh E. A. A., 2010, GGG, V11, P16; Versteegh EAA, 2009, THESIS VU U AMSTERDA; Wada H, 1999, SCI FOR PEARL; Wallace D., 1998, ORNLCDIAC105; Yoshimura T, 2010, J PALEOLIMNOL, V43, P437, DOI 10.1007/s10933-009-9341-8	59	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0921-2728	1573-0417		J PALEOLIMNOL	J. Paleolimn.	JUN	2015	54	1					37	51		10.1007/s10933-015-9834-6		15	Environmental Sciences; Geosciences, Multidisciplinary; Limnology	Environmental Sciences & Ecology; Geology; Marine & Freshwater Biology	CJ1BZ	WOS:000355218100002		
J	Masuda, K; Ooyama, H; Shikano, K; Kondo, K; Furumitsu, M; Iwakoshi-Ukena, E; Ukena, K				Masuda, Keiko; Ooyama, Haruka; Shikano, Kenshiro; Kondo, Kunihiro; Furumitsu, Megumi; Iwakoshi-Ukena, Eiko; Ukena, Kazuyoshi			Microwave-assisted solid-phase peptide synthesis of neurosecretory protein GL composed of 80 amino acid residues	JOURNAL OF PEPTIDE SCIENCE			English	Article						small protein; NPGL; microwave; solid-phase peptide synthesis; disulfide bond formation	COMPLEX PEPTIDES; REAGENTS; PRODUCT	We recently identified a novel cDNA encoding a small secretory protein of 80 amino acid residues, termed neurosecretory protein GL (NPGL), from the chicken hypothalamus. Homologs of NPGL have been reported to be present in mammals, such as human and rat. NPGL is amidated at its C-terminus, contains an intramolecular disulfide bond, and is hydrophobic in nature. In this study, we have optimized the synthesis of the entire 80-amino acid peptide sequence of rat NPGL by microwave-assisted solid-phase peptide synthesis. NPGL was obtained with a 10% yield when the coupling reactions were performed using 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid hexafluorophosphate (HATU) at 50 degrees C for 5min, and Fmoc deprotections were performed using 40% piperidine containing 0.1M HOBt. Furthermore, the disulfide bond of NPGL was formed with 20% yield with the use of glutathione-containing redox buffer and 50% acetonitrile. Copyright (c) 2015 European Peptide Society and John Wiley & Sons, Ltd.	[Masuda, Keiko; Ooyama, Haruka; Shikano, Kenshiro; Kondo, Kunihiro; Furumitsu, Megumi; Iwakoshi-Ukena, Eiko; Ukena, Kazuyoshi] Hiroshima Univ, Grad Sch Integrated Arts & Sci, Sect Behav Sci, Higashihiroshima 7398521, Japan	Ukena, K (reprint author), Hiroshima Univ, Grad Sch Integrated Arts & Sci, Sect Behav Sci, Higashihiroshima 7398521, Japan.	ukena@hiroshima-u.ac.jp			MEXT/JSPS KAKENHI [22687004, 26291066, 25440171]; Toray Science Foundation; Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry	We are grateful to Dr. Fumio Kumakura (Biotage Japan) for his critical reading of the manuscript. We thank Ms. Tomoko Amimoto, the Natural Science Center for Basic Research and Development (N-BARD), Hiroshima University, for the mass spectrometry. This work was supported by MEXT/JSPS KAKENHI grants (22687004 and 26291066 to K.U. and 25440171 to E.I.-U), Grant-in-Aid for JSPS Fellows (to K.M.), the Toray Science Foundation (K.U.), and the Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry (K.U.).	Malik L, 2010, J PEPT SCI, V16, P506, DOI 10.1002/psc.1269; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Muthusamy K, 2010, BIOPOLYMERS, V94, P323, DOI 10.1002/bip.21370; Bacsa B, 2010, J ORG CHEM, V75, P2103, DOI 10.1021/jo100136r; Sohma Y, 2007, BIOPOLYMERS, V88, P253, DOI 10.1002/bip.20683; El-Faham A, 2009, CHEM-EUR J, V15, P9404, DOI 10.1002/chem.200900615; Ukena K, 2014, BIOCHEM BIOPH RES CO, V446, P298, DOI 10.1016/j.bbrc.2014.02.090; CARPINO LA, 1993, J AM CHEM SOC, V115, P4397, DOI 10.1021/ja00063a082; Wohr T, 1996, J AM CHEM SOC, V118, P9218, DOI 10.1021/ja961509q; Garcia-Martin F, 2006, J COMB CHEM, V8, P213, DOI 10.1021/cc0600019; Pedersen SL, 2012, CHEM SOC REV, V41, P1826, DOI 10.1039/c1cs15214a; Palasek SA, 2007, J PEPT SCI, V13, P143, DOI 10.1002/psc.804; DOLLING R, 1994, J CHEM SOC CHEM COMM, P853, DOI 10.1039/c39940000853; Garcia-Ramos Y, 2010, J PEPT SCI, V16, P675, DOI 10.1002/psc.1282; Sasaki T, 1999, BIOCHEMISTRY-US, V38, P12876, DOI 10.1021/bi990731f; Singer D, 2010, J PEPT SCI, V16, P358, DOI 10.1002/psc.1252; Subiros-Funosas R, 2009, TETRAHEDRON LETT, V50, P6200, DOI 10.1016/j.tetlet.2009.08.117; TAMAMURA H, 1993, TETRAHEDRON LETT, V34, P4931, DOI 10.1016/S0040-4039(00)74049-4; Tofteng AP, 2012, CHEM-EUR J, V18, P9024, DOI 10.1002/chem.201200711; Yus HM, 1992, J ORG CHEM, V57, P4781	20	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1075-2617	1099-1387		J PEPT SCI	J. Pept. Sci.	JUN	2015	21	6					454	460		10.1002/psc.2756		7	Biochemistry & Molecular Biology; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	CI4OY	WOS:000354732200002		
J	Fujii, N; McGinn, R; Halili, L; Singh, MS; Kondo, N; Kenny, GP				Fujii, Naoto; McGinn, Ryan; Halili, Lyra; Singh, Maya Sarah; Kondo, Narihiko; Kenny, Glen P.			Cutaneous vascular and sweating responses to intradermal administration of ATP: a role for nitric oxide synthase and cyclooxygenase?	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							ADENOSINE RECEPTOR INHIBITION; SKIN BLOOD-FLOW; ACTIVE VASODILATION; HEAT-STRESS; THERMAL HYPEREMIA; DYNAMIC EXERCISE; SENSORY NERVES; YOUNG SMOKERS; IN-VIVO; HUMANS	In humans in vivo, the mechanisms behind ATP-mediated cutaneous vasodilatation along with whether and how ATP increases sweating remains uncertain. Recent work has implicated nitric oxide synthase (NOS), cyclooxygenase (COX) and/or adenosine in the modulation of cutaneous vasodilatation and sweat production during both local (i.e. localized heating) and whole-body heat stress (i.e. exercise-induced heat stress). We evaluated whether ATP-mediated cutaneous vasodilatation and sweating is mediated via NOS, COX and/or adenosine. We show that in humans in vivo, intradermal administration of ATP induces pronounced vasodilatation which is partially mediated by NOS, but neither COX nor adenosine influences ATP-mediated vasodilatation, and ATP alone does not induce an increase in sweating. These findings advance our basic physiological knowledge regarding control of skin blood flow and sweating, and provide insight into the mechanisms governing thermoeffector activity, which has major implications for whole-body heat exchange and therefore core temperature regulation in humans during heat stress. AbstractIn humans in vivo, the mechanisms behind ATP-mediated cutaneous vasodilatation and whether and how ATP increases sweating remain uncertain. We evaluated whether ATP-mediated cutaneous vasodilatation and sweating is mediated via nitric oxide synthase (NOS), cyclooxygenase (COX) and/or adenosine-dependent mechanisms. Cutaneous vascular conductance (CVC, laser Doppler perfusion units/mean arterial pressure) and sweat rate (ventilated capsule) were evaluated at intradermal microdialysis forearm skin sites, each receiving pharmacological agents (two separate protocols). In Protocol 1 (n = 12), sites were perfused with: (1) lactated Ringer solution (Control), (2) 10 mmN-nitro-l-arginine (l-NNA, a NOS inhibitor), (3) 10 mm ketorolac (Ketorolac, a COX inhibitor) or (4) a combination of 10 mm l-NNA + 10 mm ketorolac (l-NNA + Ketorolac). In Protocol 2 (n = 8), sites were perfused with: (1) lactated Ringer solution (Control) or (2) 4 mm theophylline (Theophylline, an adenosine receptor inhibitor). At all sites, ATP was simultaneously perfused at 0.12, 1.2, 12, 120 and 1200 nm min(-1) (each for 20 min). Relative to CVC at the Control site with ATP infused at 120 nm min(-1) (71 +/- 9% of max CVC), CVC at the Ketorolac site was comparable (64 +/- 13% of max CVC, P = 0.407), but lower at l-NNA (51 +/- 15% of max CVC, P = 0.040) and l-NNA + Ketorolac (51 +/- 13% of max CVC, P = 0.049) sites. Conversely, across the four skin sites at any other ATP infusion rate (all P > 0.174), no differences in CVC were observed. Theophylline did not influence CVC at any ATP infusion rate (all P > 0.234). Furthermore, no ATP infusion rate elicited an increase in sweating from baseline at any skin site (all P > 0.235). We show that NOS, but neither COX nor adenosine receptors, modulates ATP-mediated cutaneous vasodilatation, whereas ATP does not directly increase sweating.	[Fujii, Naoto; McGinn, Ryan; Halili, Lyra; Singh, Maya Sarah; Kenny, Glen P.] Univ Ottawa, Sch Human Kinet, Human & Environm Physiol Res Unit, Ottawa, ON K1N 6N5, Canada; [Kondo, Narihiko] Kobe Univ, Fac Human Dev, Kobe, Hyogo 657, Japan	Kenny, GP (reprint author), Univ Ottawa, Sch Human Kinet, 125 Univ,Room 367,Montpetit Hall, Ottawa, ON K1N 6N5, Canada.	gkenny@uottawa.ca			Natural Sciences and Engineering Research Council [RGPIN-298159-2009, RGPIN-06313-2014, RGPAS-462252-2014]; Canada Foundation for Innovation [22529]; University of Ottawa Research Chair Award; Human and Environmental Physiology Research Unit; Queen Elizabeth II Graduate Scholarship in Science and Technology	This study was supported by the Natural Sciences and Engineering Research Council Discovery Grant (RGPIN-298159-2009 and RGPIN-06313-2014), Discovery Grants Program - Accelerator Supplements (RGPAS-462252-2014), and by Leaders Opportunity Fund from the Canada Foundation for Innovation (Grant 22529) (Funds held by G.P.K.). G.P.K. was supported by a University of Ottawa Research Chair Award. N.F. was supported by the Human and Environmental Physiology Research Unit. R.M. was supported by a Queen Elizabeth II Graduate Scholarship in Science and Technology.	Fujii N, 2013, AM J PHYSIOL-HEART C, V304, pH667, DOI 10.1152/ajpheart.00731.2012; Machado-Moreira CA, 2012, EXP PHYSIOL, V97, P930, DOI 10.1113/expphysiol.2012.065037; Lee K, 2006, J APPL PHYSIOL, V100, P1355, DOI 10.1152/jappalphysiol.00122.2005; Brunt VE, 2011, MICROCIRCULATION, V18, P347, DOI 10.1111/j.1549-8719.2011.00095.x; Welch G, 2009, J APPL PHYSIOL, V106, P796, DOI 10.1152/japplphysiol.90809.2008; Holowatz LA, 2005, J PHYSIOL-LONDON, V563, P965, DOI 10.1113/jphysiol.2004.080952; Minson CT, 2010, J APPL PHYSIOL, V109, P1239, DOI 10.1152/japplphysiol.00414.2010; Kalsi KK, 2012, EXP PHYSIOL, V97, P419, DOI 10.1113/expphysiol.2011.064238; Metzler-Wilson K, 2014, EXP PHYSIOL, V99, P393, DOI 10.1113/expphysiol.2013.076547; Wingo JE, 2010, J APPL PHYSIOL, V109, P1301, DOI 10.1152/japplphysiol.00646.2010; Brunt VE, 2012, J PHYSIOL-LONDON, V590, P3523, DOI 10.1113/jphysiol.2012.236398; Cracowski JL, 2013, J APPL PHYSIOL, V114, P245, DOI 10.1152/japplphysiol.01085.2012; Yamamoto K, 2000, AM J PHYSIOL-HEART C, V279, pH285; Medow MS, 2008, MICROCIRCULATION, V15, P569, DOI 10.1080/10739680802091526; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3; McCord GR, 2006, AM J PHYSIOL-REG I, V291, pR596, DOI 10.1152/ajpregu.00710.2005; Brunt VE, 2013, J APPL PHYSIOL, V115, P1290, DOI 10.1152/japplphysiol.00358.2013; RABASSEDA X, 1987, FEBS LETT, V213, P337, DOI 10.1016/0014-5793(87)81518-1; Swift B, 2014, EXP PHYSIOL, V99, P196, DOI 10.1113/expphysiol.2013.075200; Wingo JE, 2010, AM J PHYSIOL-REG I, V298, pR1417, DOI 10.1152/ajpregu.00846.2009; Kellogg DL, 2005, J APPL PHYSIOL, V98, P629, DOI 10.1152/japplphysiol.00728.2004; Mortensen SP, 2009, AM J PHYSIOL-REG I, V296, pR1140, DOI 10.1152/ajpregu.90822.2008; Kuwahara T, 2005, AM J PHYSIOL-REG I, V288, pR1347, DOI 10.1152/ajpregu.00547.2004; Lorenzo S, 2007, J PHYSIOL-LONDON, V585, P295, DOI 10.1113/jphysiol.2007.143867; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; KELLOGG DL, 1995, CIRC RES, V77, P1222; Aoki Y, 2003, BRAIN RES, V989, P214, DOI 10.1016/S0006-8993(03)03365-1; Buono MJ, 2011, AM J PHYSIOL-REG I, V300, pR1148, DOI 10.1152/ajpregu.00228.2010; Crain JM, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-24; Fieger SM, 2012, ACTA PHYSIOL, V205, P403, DOI 10.1111/j.1748-1716.2012.02426.x; Fieger SM, 2010, EXP PHYSIOL, V95, P946, DOI 10.1113/expphysiol.2010.053538; Fujii N, 2014, J PHYSIOL-LONDON, V592, P5327, DOI 10.1113/jphysiol.2014.280651; Fujii N, 2014, AM J PHYSIOL-HEART C, V306, pH1507, DOI 10.1152/ajpheart.00886.2013; Fujii N, 1985, J APPL PHYSIOL, V117, P1055; Hodges GJ, 2009, J APPL PHYSIOL, V106, P1112, DOI 10.1152/japplphysiol.91508.2008; Houghton BL, 2006, J PHYSIOL-LONDON, V572, P811, DOI 10.1113/jphysiol.2005.104067; Kellogg DL, 2008, J PHYSIOL-LONDON, V586, P847, DOI 10.1113/jphysiol.2007.144642; Kirby BS, 2010, J PHYSIOL-LONDON, V588, P4017, DOI 10.1113/jphysiol.2010.197814; Lindsay SL, 2002, J PHYSL, V543P, pS210; McGinn R, 2014, PHYSL REP, V2; McGinn R, 2014, J PHYSIOL-LONDON, V592, P2667, DOI 10.1113/jphysiol.2014.274068; McNamara TC, 2014, J PHYSIOL-LONDON, V592, P5317, DOI 10.1113/jphysiol.2014.272898; Pearson J, 2011, AM J PHYSIOL-REG I, V300, pR663, DOI 10.1152/ajpregu.00662.2010; Sato K, 1991, PATHOPHYSIOLOGY DERM, V2nd, P211; Shibasaki M, 2007, J PHYSIOL-LONDON, V585, P627, DOI 10.1113/jphysiol.2007.144030; Wong BJ, 2012, J APPL PHYSIOL, V112, P2037, DOI 10.1152/japplphysiol.00209.2012; Wong BJ, 2013, AM J PHYSIOL-REG I, V304, pR651, DOI 10.1152/ajpregu.00464.2012	47	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	JUN 1	2015	593	11					2515	2525		10.1113/JP270147		11	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	CJ2UQ	WOS:000355340600009		
J	Niki, M; Jyotaki, M; Yoshida, R; Yasumatsu, K; Shigemura, N; DiPatrizio, NV; Piomelli, D; Ninomiya, Y				Niki, Mayu; Jyotaki, Masafumi; Yoshida, Ryusuke; Yasumatsu, Keiko; Shigemura, Noriatsu; DiPatrizio, Nicholas V.; Piomelli, Daniele; Ninomiya, Yuzo			Modulation of sweet taste sensitivities by endogenous leptin and endocannabinoids in mice	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							CHORDA TYMPANI NERVE; DIABETIC DB/DB MOUSE; DIACYLGLYCEROL-LIPASE-ALPHA; CANNABINOID CB1 RECEPTORS; INDUCED OBESE MICE; 2-ARACHIDONOYL GLYCEROL; RESISTANCE; RESPONSES; ANANDAMIDE; SUCROSE	Potential roles of endogenous leptin and endocannabinoids in sweet taste were examined by using pharmacological antagonists and mouse models including leptin receptor deficient (db/db) and diet-induced obese (DIO) mice. Chorda tympani (CT) nerve responses of lean mice to sweet compounds were increased after administration of leptin antagonist (LA) but not affected by administration of cannabinoid receptor antagonist (AM251).db/db mice showed clear suppression of CT responses to sweet compounds after AM251, increased endocannabinoid levels in the taste organ, and enhanced expression of a biosynthesizing enzyme of endocannabinoids in taste cells. The effect of LA was gradually decreased and that of AM251 was increased during the course of obesity in DIO mice. These findings suggest that circulating leptin, but not local endocannabinoids, is a dominant modulator for sweet taste in lean mice and endocannabinoids become more effective modulators of sweet taste under conditions of deficient leptin signalling. AbstractLeptin is an anorexigenic mediator that reduces food intake by acting on hypothalamic receptor Ob-Rb. In contrast, endocannabinoids are orexigenic mediators that act via cannabinoid CB1 receptors in hypothalamus, limbic forebrain, and brainstem. In the peripheral taste system, leptin administration selectively inhibits behavioural, taste nerve and taste cell responses to sweet compounds. Opposing the action of leptin, endocannabinoids enhance sweet taste responses. However, potential roles of endogenous leptin and endocannabinoids in sweet taste remain unclear. Here, we used pharmacological antagonists (Ob-Rb: L39A/D40A/F41A (LA), CB1: AM251) and examined the effects of their blocking activation of endogenous leptin and endocannabinoid signalling on taste responses in lean control, leptin receptor deficient db/db, and diet-induced obese (DIO) mice. Lean mice exhibited significant increases in chorda tympani (CT) nerve responses to sweet compounds after LA administration, while they showed no significant changes in CT responses after AM251. In contrast, db/db mice showed clear suppression of CT responses to sweet compounds after AM251, increased endocannabinoid (2-arachidonoyl-sn-glycerol (2-AG)) levels in the taste organ, and enhanced expression of a biosynthesizing enzyme (diacylglycerol lipase (DAGL)) of 2-AG in taste cells. In DIO mice, the LA effect was gradually decreased and the AM251 effect was increased during the course of obesity. Taken together, our results suggest that circulating leptin, but not local endocannabinoids, may be a dominant modulator for sweet taste in lean mice; however, endocannabinoids may become more effective modulators of sweet taste under conditions of deficient leptin signalling, possibly due to increased production of endocannabinoids in taste tissue.	[Niki, Mayu; Jyotaki, Masafumi; Yoshida, Ryusuke; Yasumatsu, Keiko; Shigemura, Noriatsu; Ninomiya, Yuzo] Kyushu Univ, Grad Sch Dent Sci, Sect Oral Neurosci, Fukuoka 8128582, Japan; [Yasumatsu, Keiko; Ninomiya, Yuzo] Kyushu Univ, Div Sensory Physiol, Res & Dev Ctr Taste & Odor Sensing, Fukuoka 8128582, Japan; [DiPatrizio, Nicholas V.; Piomelli, Daniele] Univ Calif Irvine, Dept Anat & Neurobiol, Sch Med, Irvine, CA 92717 USA; [Piomelli, Daniele] Univ Calif Irvine, Dept Pharmacol, Sch Med, Irvine, CA 92717 USA; [Piomelli, Daniele] Univ Calif Irvine, Dept Biol Chem, Sch Med, Irvine, CA 92717 USA; [Piomelli, Daniele] Italian Inst Technol, Unit Drug Discovery & Dev, Genoa, Italy; [DiPatrizio, Nicholas V.] Univ Calif Riverside, Div Biomed Sci, Sch Med, Riverside, CA 92521 USA	Ninomiya, Y (reprint author), Kyushu Univ, Grad Sch Dent Sci, Sect Oral Neurosci, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yuninom@dent.kyushu-u.ac.jp			KAKENHI from Japan Society for the Promotion of Science [18109013, 18077004, 23249081, 26670810, 23689076, 26462815]; JSPS [24-1445]; Ajinomoto Amino Acid Research Program; US National Institute of Diabetes and Digestive and Kidney Disorders [DK073955]; US National Institute on Drug Abuse grant [K99/R00 DA034009]	This work was supported by KAKENHI grants 18109013, 18077004, 23249081, 26670810 (Y.N.), 23689076, and 26462815 (R.Y.) for Scientific Research from Japan Society for the Promotion of Science, JSPS Grant-in-Aid 24-1445 (M.N.) for JSPS Fellows, the Ajinomoto Amino Acid Research Program (Y.N.), the US National Institute of Diabetes and Digestive and Kidney Disorders grant DK073955 (D.P.) and the US National Institute on Drug Abuse grant K99/R00 DA034009 (N.V.D.).	Damak S, 2003, SCIENCE, V301, P850, DOI 10.1126/science.1087155; Yee CL, 2001, J COMP NEUROL, V440, P97, DOI 10.1002/cne.1372; Yoshida R, 2010, P NATL ACAD SCI USA, V107, P935, DOI 10.1073/pnas.0912048107; Ozcan L, 2009, CELL METAB, V9, P35, DOI 10.1016/j.cmet.2008.12.004; Ninomiya Y, 1998, AM J PHYSIOL-REG I, V274, pR1324; Kirkham TC, 2002, BRIT J PHARMACOL, V136, P550, DOI 10.1038/sj.bjp.0704767; Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/ng0501-58; Shigemura N, 2013, J NEUROSCI, V33, P6267, DOI 10.1523/JNEUROSCI.5599-12.2013; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; DiPatrizio NV, 2012, TRENDS NEUROSCI, V35, P403, DOI 10.1016/j.tins.2012.04.006; Morris DL, 2009, AM J PHYSIOL-ENDOC M, V297, pE1247, DOI 10.1152/ajpendo.00274.2009; NINOMIYA Y, 1995, AM J PHYSIOL-REG I, V269, pR930; Jung KM, 2007, MOL PHARMACOL, V72, P612, DOI 10.1124/mol.107.037796; Kawai K, 2000, P NATL ACAD SCI USA, V97, P11044, DOI 10.1073/pnas.190066697; DiPatrizio NV, 2011, P NATL ACAD SCI USA, V108, P12904, DOI 10.1073/pnas.1104675108; DiPatrizio NV, 2008, J NEUROSCI, V28, P9702, DOI 10.1523/JNEUROSCI.1171-08.2008; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; HAFFNER D, 1994, J CLIN INVEST, V93, P1163, DOI 10.1172/JCI117069; Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Astarita G, 2009, J CHROMATOGR B, V877, P2755, DOI 10.1016/j.jchromb.2009.01.008; Salomon G, 2006, PROTEIN EXPRES PURIF, V47, P128, DOI 10.1016/j.pep.2005.09.016; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Shpilman M, 2011, J BIOL CHEM, V286, P4429, DOI 10.1074/jbc.M110.196402; Talavera K, 2005, NATURE, V438, P1022, DOI 10.1038/nature04248; Jo YH, 2005, NEURON, V48, P1055, DOI 10.1016/j.neuron.2005.10.021; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Zhang J, 2007, AM J PHYSIOL-REG I, V292, pR868, DOI 10.1152/ajpregu.00213.2006; Sako N, 1996, CHEM SENSES, V21, P59, DOI 10.1093/chemse/21.1.59; Martin B, 2010, DIABETES, V59, P1143, DOI 10.2337/db09-0807; Shigemura N, 2004, ENDOCRINOLOGY, V145, P839, DOI 10.1210/en.2003-0602; Rahmouni K, 2008, J CLIN INVEST, V118, P1458, DOI 10.1172/JCI32357; Lu B, 2012, PHYSIOL BEHAV, V107, P533, DOI 10.1016/j.physbeh.2012.04.018; Taschler U, 2011, J BIOL CHEM, V286, P17467, DOI 10.1074/jbc.M110.215434; Hildebrandt AL, 2003, EUR J PHARMACOL, V462, P125, DOI 10.1016/S0014-2999(03)01343-8; Nakamura Y, 2008, DIABETES, V57, P2661, DOI 10.2337/db07-1103; Umabiki M, 2010, TOHOKU J EXP MED, V220, P267, DOI 10.1620/tjem.220.267; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI200317725; Williams CM, 1999, PSYCHOPHARMACOLOGY, V143, P315, DOI 10.1007/s002130050953; Friedman JM, 2004, NAT MED, V10, P563, DOI 10.1038/nm0604-563; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Tanimura A, 2010, NEURON, V65, P320, DOI 10.1016/j.neuron.2010.01.021; Jung KM, 2005, MOL PHARMACOL, V68, P1196, DOI 10.1124/mol.105.013961; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Lawton DM, 2000, EUR J NEUROSCI, V12, P3163, DOI 10.1046/j.1460-9568.2000.00207.x; Arble DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025079; de Lartigue G, 2011, AM J PHYSIOL-ENDOC M, V301, pE187, DOI 10.1152/ajpendo.00056.2011; Higgs S, 2003, PSYCHOPHARMACOLOGY, V165, P370, DOI 10.1007/s00213-002-1263-3; Higuchi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038609; Jamshidi N, 2001, BRIT J PHARMACOL, V134, P1151, DOI 10.1038/sj.bjp.0704379; Jarrett MM, 2005, PHYSIOL BEHAV, V86, P475, DOI 10.1016/j.physbeh.2005.08.033; Murray RG, 1971, HDB SENSORY PHYSIO 2, V4, P31; Wang J, 2009, PROSTAG OTH LIPID M, V89, P112, DOI 10.1016/j.prostaglandins.2008.12.002; White CL, 2008, AM J PHYSIOL-ENDOC M, V296, pE291, DOI 10.1152/ajpendo.90513.2008; Yoshida R, 2013, SEMIN CELL DEV BIOL, V24, P226, DOI 10.1016/j.semcdb.2012.08.004	54	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	JUN 1	2015	593	11					2527	2545		10.1113/JP270295		19	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	CJ2UQ	WOS:000355340600010		
J	Hayakawa, Y; Duan, ZR; Yadake, M; Tsukano, J; Yamaoka, Y; Inatsugi, R; Fujiki, Y; Oikawa, A; Saito, K; Nishida, I				Hayakawa, Yoshinori; Duan, Zhongrui; Yadake, Miki; Tsukano, Jun; Yamaoka, Yasuyo; Inatsugi, Rie; Fujiki, Yuki; Oikawa, Akira; Saito, Kazuki; Nishida, Ikuo			Epigenetic floral homeotic mutation in pD991-AP3-derived T-DNA-tagged lines for CTP:Phosphorylcholine cytidylyltransferase (CCT) Genes: The homeotic mutation of the cct1-1 allele is enhanced by the cct2 allele and alleviated by CCT1 overexpression	JOURNAL OF PLANT BIOLOGY			English	Article						CTP:phosphorylcholine cytidylyltransferase; DNA methylation; Floral homeotic mutation; Homology-dependent gene silencing	CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; AGROBACTERIUM-MEDIATED TRANSFORMATION; ARABIDOPSIS-THALIANA; PLANT TRANSFORMATION; LOW-TEMPERATURE; BINARY VECTORS; ORGAN IDENTITY; MADS-BOX; METHYLATION; APETALA3	The apetala3 (ap3)-like homeotic mutation (ap3-HM) is recognized among pD991-AP3-derived Arabidopsis thaliana T-DNA-tagged lines carrying the -448 to +47 region of AP3 in their T-DNA. In the corresponding mutant lines for CTP:phosphorylcholine cytidylyltransferase genes, cct1-1 and cct2 (Inatsugi et al. 2009), some flowers of cct1-1 (F4) and many flowers of cct1-1 cct2 (F3) showed ap3-HM, and all flowers of cct1-1 (F5) and cct1-1 cct2 (F4) became increasingly homeotic. In contrast, cct2 flowers were normal for all generations tested. These results demonstrated that ap3-HM is linked to the cct1-1 allele and is enhanced by the cct2 allele. The ap3-HM in cct mutants was inversely correlated with AP3 transcript levels in enriched flower buds. Bisulfite sequencing revealed severe methylation within endogenous AP3 promoter regions in cct1-1 (F3; -317 to -2) and cct1-1 cct2 (F3; -473 to -2), but wild-type (Wassilevskaja) and cct2 plants showed no corresponding methylation. The ap3-HM in cct1-1 cct2 mutants was fully rescued by expressing a PISTILLATA promoter-AP3 construct, and was better alleviated in the F-1 offspring of a cross with the CCT1-overexpressing mutant cct1-2 (Columbia) than with the wild type. We discuss possible links between expression of CCT and suppression of ap3-HM.	[Hayakawa, Yoshinori; Duan, Zhongrui; Yadake, Miki; Tsukano, Jun; Yamaoka, Yasuyo; Fujiki, Yuki; Nishida, Ikuo] Saitama Univ, Grad Sch Sci & Engn, Div Life Sci, Lab Plant Mol Physiol,Sakura Ku, Saitama 3388570, Japan; [Inatsugi, Rie] Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; [Oikawa, Akira; Saito, Kazuki] RIKEN, Ctr Sustainable Resource Sci, Yokohama, Kanagawa, Japan	Nishida, I (reprint author), Saitama Univ, Grad Sch Sci & Engn, Div Life Sci, Lab Plant Mol Physiol,Sakura Ku, Shimo Okubo 255, Saitama 3388570, Japan.	nishida@molbiol.saitama-u.ac.jp	Duan, Zhongrui/D-5260-2015; Saito, Kazuki/D-2670-2009		Ministry of Education, Culture, Sports, Science, and Technology (MEXT) [21570034, 24570040, 22114503]; SEKAI KANRYU program at Saitama University, Saitama, Japan	We thank Dr. Tsuyoshi Nakagawa at Shimane University for his generous gift of pGWB504. We are grateful to Michiko Hirabaru and Kyoko Tanaka for helpful assistance in research management, and Akira Sekiguchi for technical assistance. We thank Jun-Young Jin, Prof. Youngsook Lee and Prof. Gynheung An's laboratory at Pohang University of Science and Technology, Korea, for discussions and sequence analysis. This work was supported by the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) [Grants-in-Aid for Scientific Research (C) (grant nos. 21570034 and 24570040 to I.N.) and Scientific Research in Innovative Areas (grant no. 22114503 to I.N.)] and by the SEKAI KANRYU program at Saitama University, Saitama, Japan.	Chan SWL, 2005, NAT REV GENET, V6, P351, DOI 10.1038/nrg1601; Inatsugi R, 2002, PLANT CELL PHYSIOL, V43, P1342, DOI 10.1093/pcp/pcf169; Nakagawa T, 2007, J BIOSCI BIOENG, V104, P34, DOI 10.1263/jbb.104.34; Kosugi S, 2009, P NATL ACAD SCI USA, V106, P10171, DOI 10.1073/pnas.0900604106; Chae E, 2008, DEVELOPMENT, V135, P1235, DOI 10.1242/dev.015842; Sussman MR, 2000, PLANT PHYSIOL, V124, P1465, DOI 10.1104/pp.124.4.1465; Tague Brian W., 2006, V323, P215; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; Sung SB, 2006, NAT GENET, V38, P706, DOI 10.1038/ng1795; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; HILL JP, 1989, CAN J BOT, V67, P2922; Honma T, 2001, NATURE, V409, P525, DOI 10.1038/35054083; Tilly JJ, 1998, DEVELOPMENT, V125, P1647; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Meyer P, 1996, ANNU REV PLANT PHYS, V47, P23, DOI 10.1146/annurev.arplant.47.1.23; Paszkowski J, 2001, CURR OPIN PLANT BIOL, V4, P123, DOI 10.1016/S1369-5266(00)00147-3; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; Niwa Y, 1999, PLANT J, V18, P455, DOI 10.1046/j.1365-313X.1999.00464.x; Miura A, 2001, NATURE, V411, P212, DOI 10.1038/35075612; GOTO K, 1994, GENE DEV, V8, P1548, DOI 10.1101/gad.8.13.1548; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Hill TA, 1998, DEVELOPMENT, V125, P1711; Bouchard E, 2006, THESIS U LAVAL QUEBE; Cavalli G, 2002, CURR OPIN CELL BIOL, V14, P269, DOI 10.1016/S0955-0674(02)00324-1; Davies GJ, 1997, PLANT J, V12, P791, DOI 10.1046/j.1365-313X.1997.12040791.x; Depicker A, 1997, CURR OPIN CELL BIOL, V9, P373, DOI 10.1016/S0955-0674(97)80010-5; Houweling M, 1996, EUR J CELL BIOL, V69, P55; Inatsugi R, 2009, PLANT CELL PHYSIOL, V50, P1727, DOI 10.1093/pcp/pcp115; Nakamura Yuki, 2014, Nat Commun, V5, P3553, DOI 10.1038/ncomms4553; Nerlich A, 2007, THESIS U POTSDAM; Oikawa A, 2011, J SEP SCI, V34, P3561, DOI 10.1002/jssc.201100466; SMYTH DR, 1990, PLANT CELL, V2, P755; Stam M, 1997, ANN BOT, V79, P1; Turck F, 2007, PLOS GENET, V3, P855, DOI 10.1371/journal.pgen.0030086; van Tunen AJ, 1990, DEV REGULATION PLANT, P94; WANG YL, 1995, J BIOL CHEM, V270, P354	38	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1226-9239	1867-0725		J PLANT BIOL	J. Plant Biol.	JUN	2015	58	3					183	192		10.1007/s12374-014-0587-y		10	Plant Sciences	Plant Sciences	CJ2WR	WOS:000355345900005		
J	Kobayashi, S; Hirakawa, T; Fukawa, T; Maegawa, J				Kobayashi, Shinji; Hirakawa, Takashi; Fukawa, Toshihiko; Maegawa, Jiro			Maxillary growth after maxillary protraction: Appliance in conjunction with presurgical orthopedics, gingivoperiosteoplasty, and Furlow palatoplasty for complete bilateral cleft lip and palate patients with protruded premaxilla	JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY			English	Article						Bilateral cleft lip and palate; Presurgical orthopedics; Gingivoper iosteoplasty; Furlow palatoplasty; Maxillary protraction appliance; Maxillary growth	MIDFACIAL GROWTH; LATHAM APPLIANCE; UNILATERAL CLEFTS; FACIAL GROWTH; ALVEOLUS; INFANTS; EXPANSION; NOSE	Background and aims: In bilateral cleft lip and palate (BCLP) with premaxillary protrusion, a good outcome with adequate maxillary development is difficult to achieve. The purpose of this article is to evaluate the maxillary growth after using presurgical orthopedics (PSO), gingivoperiosteoplasty (GPP), Furlow palatoplasty, and maxillary protraction appliance (MPA) for BCLP with premaxillary protrusion. Patients and methods: Seven patients with complete BCLP with premaxillary protrusion were treated by PSO, cheiloplasty, GPP, and Furlow palatoplasty. MPA was used as part of the protocol for 6 months to 1 year for postoperative retardation of maxillary growth cases. Maxillary growth was evaluated by cephalometric analysis at 4 and 10 years of age, and bone formation at the alveolar cleft was evaluated by computed tomography (CT) imaging at 5 years of age. Results: At 4 years of age, three of seven patients had apparent retardation of maxillary growth. The maxillary growth at 10 years of age was equivalent to the average value of normal Japanese after using MPA in three cases. At 5 years of age, only two of seven patients showed sufficient bone formation at the alveolar cleft to avoid alveolar bone grafting (ABG). Subsequently, ABG was performed in five patients. Discussion: Although three of seven patients had apparent crossbite at 4 years of age, the maxillary growth of all patients at 10 years of age was approximately equivalent to the average value of normal Japanese after using MPA. A treatment protocol based on PSO, GPP, Furlow palatoplasty, and MPA may be an option, but long-term growth is unknown. (C) 2015 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.	[Kobayashi, Shinji] Kanagawa Childrens Med Ctr, Dept Plast & Reconstruct Surg, Yokohama, Kanagawa 2328555, Japan; [Hirakawa, Takashi] Hirakawa Orthodont Clin, Hirakawa, Kanagawa, Japan; [Fukawa, Toshihiko] Fukawa Orthodont Clin, Hirakawa, Kanagawa, Japan; [Maegawa, Jiro] Yokohama City Univ Med, Dept Plast & Reconstruct Surg, Yokohama, Kanagawa, Japan	Kobayashi, S (reprint author), Kanagawa Childrens Med Ctr, Dept Plast & Reconstruct Surg, Minami Ku, Mutsukawa 2-138-4, Yokohama, Kanagawa 2328555, Japan.	skobayashi@kcmc.jp					Henkel KO, 1997, J CRANIO MAXILL SURG, V25, P266, DOI 10.1016/S1010-5182(97)80064-9; Berkowitz S, 2009, J CRANIOFAC SURG, V20, P1747, DOI 10.1097/SCS.0b013e3181b5d3ee; Millard DR, 1999, PLAST RECONSTR SURG, V103, P1630, DOI 10.1097/00006534-199905060-00009; Matic DB, 2008, PLAST RECONSTR SURG, V122, P863, DOI 10.1097/PRS.0b013e3181811a6d; Power SM, 2009, PLAST RECONSTR SURG, V124, P573, DOI 10.1097/PRS.0b013e3181addc37; Matic DB, 2008, PLAST RECONSTR SURG, V121, P1343, DOI 10.1097/01.prs.0000304604.89450.ae; Uzel A, 2011, CLEFT PALATE-CRAN J, V48, P587, DOI 10.1597/10-008; Grayson BH, 2001, CLEFT PALATE-CRAN J, V38, P193, DOI 10.1597/1545-1569(2001)038<0193:PNOMIP>2.0.CO;2; Hsieh CHY, 2010, CLEFT PALATE-CRAN J, V47, P439, DOI 10.1597/08-207; MILLARD DR, 1990, PLAST RECONSTR SURG, V86, P856, DOI 10.1097/00006534-199011000-00006; Santiago PE, 1998, CLEFT PALATE-CRAN J, V35, P77, DOI 10.1597/1545-1569(1998)035<0077:RNFABG>2.3.CO;2; Grayson BH, 1999, CLEFT PALATE-CRAN J, V36, P486, DOI 10.1597/1545-1569(1999)036<0486:PNMIIW>2.3.CO;2; Pfeifer TM, 2002, CLEFT PALATE-CRAN J, V39, P26, DOI 10.1597/1545-1569(2002)039<0026:NMAGVA>2.0.CO;2; Wood RJ, 1997, CLEFT PALATE-CRAN J, V34, P17, DOI 10.1597/1545-1569(1997)034<0017:GAMG>2.3.CO;2; Berkowitz S, 2004, PLAST RECONSTR SURG, V113, P1, DOI 10.1097/01.PRS.0000096710.08123.93; Chan TC, 2003, CLEFT PALATE-CRAN J, V40, P511; Fukuyama E, 2006, CLEFT PALATE-CRAN J, V43, P673, DOI 10.1597/05-109; LATHAM RA, 1976, CLEFT PALATE J, V13, P253; Maull DJ, 1999, CLEFT PALATE-CRAN J, V36, P91; Millard DR, 1998, PLAST RECONSTR SURG, V102, P1331, DOI 10.1097/00006534-199810000-00003; MILLARD DR, 1988, CLEFT PALATE J, V25, P403	21	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1748-6815	1878-0539		J PLAST RECONSTR AES	J. Plast. Reconstr. Aesthet. Surg.	JUN	2015	68	6					758	763		10.1016/j.bjps.2015.02.005		6	Surgery	Surgery	CI9ME	WOS:000355093400008		
J	Yoshioka, N; Tominaga, S				Yoshioka, Nobutaka; Tominaga, Shinsuke			Masseteric nerve transfer for short-term facial paralysis following skull base surgery	JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY			English	Article						Facial nerve; Facial paralysis; Facial reanimation; Masseteric nerve; Nerve transfer	MOTOR-NERVE; FREE MUSCLE; HEMIHYPOGLOSSAL NERVE; REANIMATION; PALSY; OUTCOMES; GRAFT; RECONSTRUCTION; ANASTOMOSIS; SMILE	Background: Nerve transfers have been widely used to reanimate paralyzed facial muscles after irreversible proximal injuries to the facial nerve. The author has developed a technique involving masseteric nerve transfer combined with cross-facial nerve grafting for treating skull base surgery-induced facial paralysis. This paper aims to demonstrate that this procedure is effective and causes negligible donor site morbidity. Methods: Seven patients who developed facial paralysis after the removal of skull base tumors were treated with masseteric nerve transfer combined with cross-facial nerve grafting with the aim of reanimating the midface. The mean period of preoperative paralysis was 6 months. The follow-up period ranged from 22 to 65 months (mean: 46 months). The patients were evaluated with physical examinations and video analysis. Results: Successful reanimation of the midface was achieved in all patients except one, whose muscle tone recovered. On average, facial motion developed 4 months after the nerve transfer. Only minimal coordinated eyelid movement was seen during biting. None of the patients experienced impaired masticatory function or visible wasting of the masseter muscle. All of the patients who recovered the ability to contract their paralyzed muscles were able to close their eyes tightly during biting; however, none of the patients have been able to achieve an effortless spontaneous smile. Conclusions: Masseteric nerve transfer is an alternative method for selective reanimation of the midface and does not cause donor site morbidity. (C) 2015 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.	[Yoshioka, Nobutaka; Tominaga, Shinsuke] Tominaga Hosp, Dept Craniofacial Surg & Plast Surg, Osaka 5560017, Japan	Yoshioka, N (reprint author), Tominaga Hosp, Dept Craniofacial Surg & Plast Surg, 1-4-48 Minatomachi, Osaka 5560017, Japan.	Yoshioka0225@aol.com					Klebuc MJA, 2011, PLAST RECONSTR SURG, V127, P1909, DOI 10.1097/PRS.0b013e31820e9138; Hontanilla B, 2014, BRIT J ORAL MAX SURG, V52, P118, DOI 10.1016/j.bjoms.2013.09.017; Lee EI, 2008, J PLAST RECONSTR AES, V61, P250, DOI 10.1016/j.bjps.2007.05.016; SPIRA M, 1978, PLAST RECONSTR SURG, V61, P330, DOI 10.1097/00006534-197803000-00004; Beutner D, 2013, LARYNGOSCOPE, V123, P2392, DOI 10.1002/lary.24115; Coombs CJ, 2009, J PLAST RECONSTR AES, V62, P1580, DOI 10.1016/j.bjps.2008.05.046; Frey M, 2006, PLAST RECONSTR SURG, V117, P597, DOI 10.1097/01.prs.0000197136.56749.c6; Terzis JK, 2009, PLAST RECONSTR SURG, V123, P865, DOI 10.1097/PRS.0b013e31819ba4bb; Manktelow RT, 2006, PLAST RECONSTR SURG, V118, P885, DOI 10.1097/01.prs.0000232195.20293.bd; Hontanilla B, 2014, J RECONSTR MICROSURG, V30, P25, DOI 10.1055/s-0033-1349347; Biglioli F, 2012, J CRANIO MAXILL SURG, V40, P149, DOI 10.1016/j.jcms.2011.03.005; Hayashi A, 2013, J NEUROSURG, V118, P160, DOI 10.3171/2012.9.JNS1270; Lifchez SD, 2005, PLAST RECONSTR SURG, V115, P1472, DOI 10.1097/01.PRS.0000160266.81504.71; Meltzer NE, 2010, CURR OPIN OTOLARYNGO, V18, P232, DOI 10.1097/MOO.0b013e32833bb2d0; Bianchi B, 2014, HEAD NECK-J SCI SPEC, V36, P235, DOI 10.1002/hed.23300; Terzis JK, 2012, PLAST RECONSTR SURG, V129, P925, DOI 10.1097/PRS.0b013e318230e758; Terzis JK, 2008, FACIAL PLAST SURG, V24, P177, DOI 10.1055/s-2008-1075833; Terzis JK, 2009, PLAST RECONSTR SURG, V124, P1499, DOI 10.1097/PRS.0b013e3181babb93; Woollard ACS, 2010, J PLAST RECONSTR AES, V63, P1557, DOI 10.1016/j.bjps.2010.02.018; Collar RM, 2013, PLAST RECONSTR SURG, V132, P183, DOI 10.1097/PRS.0b013e318290f6dc; Krishnan KG, 2010, NEUROSURGERY, V67, P663, DOI 10.1227/01.NEU.0000375531.77489.79; Terzis JK, 2009, PLAST RECONSTR SURG, V124, P1891, DOI 10.1097/PRS.0b013e3181bf81f6; Borschel GH, 2012, J PLAST RECONSTR AES, V65, P363, DOI 10.1016/j.bjps.2011.09.026; Cotrufo S, 2011, J PLAST RECONSTR AES, V64, P1424, DOI 10.1016/j.bjps.2011.05.026; Cheng A, 2013, J PLAST RECONSTR AES, V66, P1438, DOI 10.1016/j.bjps.2013.04.009; Chuang DCC, 2013, PLAST RECONSTR SURG, V132, p117E, DOI 10.1097/PRS.0b013e318290f8cd; Faria JCM, 2010, ANN PLAST SURG, P31; Fattah A, 2012, PLAST RECONSTR SURG, V129, p340E, DOI 10.1097/PRS.0b013e31823aedd9; Fisher MD, 2013, PLAST RECONSTR SURG, V131, P1065, DOI 10.1097/PRS.0b013e318287a095; FRYDMAN WL, 1990, J ORAL MAXIL SURG, V48, P1294, DOI 10.1016/0278-2391(90)90486-L; Galli Suzanne K Doud, 2002, Ear Nose Throat J, V81, P25; Hontanilla B, 2010, EUR J PLAST SURG, V33, P227; Hontanilla B, 2012, PLAST RECONSTR SURG, V130, p662E, DOI 10.1097/PRS.0b013e318267d5e8; Martins RS, 2008, NEUROSURGERY, V63, P310, DOI 10.1227/01.NEU.0000312387.52508.2C; Yoshioka N, 2008, HEAD NECK CANC JAPAN, V34, P552; ZUKER RM, 1989, ANN PLAS SURG, V22, P188, DOI 10.1097/00000637-198903000-00005	36	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1748-6815	1878-0539		J PLAST RECONSTR AES	J. Plast. Reconstr. Aesthet. Surg.	JUN	2015	68	6					764	770		10.1016/j.bjps.2015.02.031		7	Surgery	Surgery	CI9ME	WOS:000355093400009		
J	Yamamoto, T; Ishiura, R; Kato, M				Yamamoto, Takumi; Ishiura, Ryohei; Kato, Motoi			Hands-free vein visualizer for selection of recipient vein with an intact valve in lymphatic supermicrosurgery	JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY			English	Letter							ANASTOMOSIS		[Yamamoto, Takumi; Ishiura, Ryohei; Kato, Motoi] Univ Tokyo, Dept Plast & Reconstruct Surg, Tokyo 1138654, Japan	Yamamoto, T (reprint author), Univ Tokyo, Dept Plast & Reconstruct Surg, Tokyo 1138654, Japan.	tyamamoto-tky@umin.ac.jp					Yamamoto T, 2011, PLAST RECONSTR SURG, V127, P1987, DOI 10.1097/PRS.0b013e31820cf5c6; Yamamoto T, 2014, ANN PLAS SURG, V72, P67, DOI 10.1097/SAP.0b013e3182605580; Yamamoto T, 2011, PLAST RECONSTR SURG, V127, P1979, DOI 10.1097/PRS.0b013e31820cf5df; Yamamoto T, 2014, MICROSURG, V34, P23, DOI 10.1002/micr.22115; Yamamoto T, 2014, J PLAST RECONSTR AES, V67, P1573, DOI 10.1016/j.bjps.2014.06.007	5	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1748-6815	1878-0539		J PLAST RECONSTR AES	J. Plast. Reconstr. Aesthet. Surg.	JUN	2015	68	6					871	873		10.1016/j.bjps.2015.01.021		4	Surgery	Surgery	CI9ME	WOS:000355093400027		
J	Hamamoto, Y; Nagasao, T; Ensako, T; Tanaka, Y				Hamamoto, Yusuke; Nagasao, Tomohisa; Ensako, Toshiya; Tanaka, Yoshio			Segmental marking: A new technique to prevent pedicle twisting	JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY			English	Letter									[Hamamoto, Yusuke; Nagasao, Tomohisa; Ensako, Toshiya; Tanaka, Yoshio] Kagawa Univ, Sch Med, Dept Plast Surg, Takamatsu, Kagawa 760, Japan	Hamamoto, Y (reprint author), Kagawa Univ, Sch Med, Dept Plast Surg, Miki Cho Ikenobe 1750-1, Takamatsu, Kagawa 760, Japan.	nagasao@med.kagawa-u.ac.jp					Lee HJ, 2011, J RECONSTR MICROSURG, V27, P433, DOI 10.1055/s-0031-1281528	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1748-6815	1878-0539		J PLAST RECONSTR AES	J. Plast. Reconstr. Aesthet. Surg.	JUN	2015	68	6					873	874		10.1016/j.bjps.2015.01.020		3	Surgery	Surgery	CI9ME	WOS:000355093400028		
J	Takagi, T; Seki, A; Mochida, J; Takayama, S				Takagi, Takehiko; Seki, Atsuhito; Mochida, Joji; Takayama, Shinichiro			On-top plasty as a treatment for floating finger	JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY			English	Letter							THUMB		[Takagi, Takehiko; Mochida, Joji] Tokai Univ, Sch Med, Dept Orthopaed Surg, Surg Sci, Hiratsuka, Kanagawa 25912, Japan; [Takagi, Takehiko; Seki, Atsuhito; Takayama, Shinichiro] Natl Ctr Child Hlth & Dev, Dept Orthopaed Surg, Tokyo, Japan	Takagi, T (reprint author), Tokai Univ, Sch Med, Dept Orthopaed Surg, Surg Sci, Hiratsuka, Kanagawa 25912, Japan.	ttkg7@me.com					BARSKY AJ, 1964, J BONE JOINT SURG AM, V46, P1707; Hasegawa K, 2013, ACTA MED OKAYAMA, V67, P391; Iba Kousuke, 2013, Hand Surg, V18, P273, DOI 10.1142/S0218810413720192; Iba K, 2013, ANN PLAS SURG, V70, P38, DOI 10.1097/SAP.0b013e31821b6ced; KELLEHER JC, 1968, PLAST RECONSTR SURG, V42, P242, DOI 10.1097/00006534-196809000-00009	5	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1748-6815	1878-0539		J PLAST RECONSTR AES	J. Plast. Reconstr. Aesthet. Surg.	JUN	2015	68	6					876	877		10.1016/j.bjps.2015.02.016		3	Surgery	Surgery	CI9ME	WOS:000355093400030		
J	Mutsumi, O; Kentaro, T; Noriko, U; Satoshi, U; Tsutomu, H; Alisa, O; Mayuko, H; Hiroki, M				Mutsumi, Okazaki; Kentaro, Tanaka; Noriko, Uemura; Satoshi, Usami; Tsutomu, Homma; Alisa, Okubo; Mayuko, Hamanaga; Hiroki, Mori			One-stage dual latissimus dorsi muscle flap transfer with a pair of vascular anastomoses and double nerve suturing for long-standing facial paralysis	JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY			English	Article; Proceedings Paper	19th Annual Meeting of the Japan-Society-for-Innovative-Techniques-in-Plastic-Surgery	FEB 22, 2014	Nagoya, JAPAN	Japan Soc Innovat Tech Plast Surg		Facial paralysis; Double latissimus dorsi muscle transfer; Facial reanimation; Ipsilateral masseteric nerve; Contralateral facial nerve	MASSETER MOTOR-NERVE; CROSS-FACE NERVE; RECONSTRUCTION; REANIMATION; PALSY; TRANSPLANTATION; INNERVATION; ADAPTATION; ANIMATION; SMILE	Objective: Various types of neurovascular free-muscle transfers have been reported as surgical treatments for long-standing facial paralysis. Among one-stage methods, two approaches, that is, latissimus dorsi transfer with nerve suturing to the contralateral facial nerve and gracilis transfer with nerve suturing to the ipsilateral masseteric nerve, have recently become popular. The former method has the advantage of making spontaneous smiling possible, but the contraction strength of the transferred muscle varies, whereas the latter approach has the advantage of guaranteeing voluntary contraction of the transferred muscle, but makes spontaneous smiling difficult. Recently, dual innervation methods have also been reported, but uncertainty remains about the utility of such approaches. To overcome these drawbacks, we devised a hybrid method combining the two previously established techniques. Methods: Two latissimus dorsi muscle flaps containing the thoracodorsal vessels from one side are transferred with a pair of vascular anastomoses. The true trunk of the thoracodorsal nerve, which innervates one of the muscle flaps, is sutured to the contralateral facial nerve, while the short branch of the thoracodorsal nerve, which innervates the other muscle flap, is sutured to the ipsilateral masseteric nerve. From November 2011 to October 2013, we used this method in four patients with long-standing facial paralysis. Results: Smiling was assessed in the three patients who were followed up for more than 1 year, and satisfactory results were obtained (Harii score: 4-5). In one patient, the movement mediated via the contralateral facial nerve was a little weak, but this was compensated for by the muscles controlled by the ipsilateral masseteric nerve. Conclusion: Our novel one-stage method, which involves a combination of two previously established methods, guarantees early voluntary smiling, and spontaneous smiling becomes possible later. In addition, it is free from the uncertainty associated with double innervation and does not require nerve grafts. So, stable results can be expected in most patients with long-standing facial paralysis. (C) 2015 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.	[Mutsumi, Okazaki; Kentaro, Tanaka; Noriko, Uemura; Satoshi, Usami; Tsutomu, Homma; Alisa, Okubo; Mayuko, Hamanaga; Hiroki, Mori] Tokyo Med & Dent Univ, Grad Sch Sci, Dept Plast & Reconstruct Surg, Bunkyo Ku, Tokyo, Japan	Mutsumi, O (reprint author), Tokyo Med & Dent Univ, Grad Sch Sci, Dept Plast & Reconstruct Surg, Bunkyo Ku, 1-5-45 Yushima, Tokyo, Japan.	okazaki-m@umin.ac.jp		mori, hiroki/0000-0003-3190-6852			HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146; HARII K, 1976, PLAST RECONSTR SURG, V57, P133, DOI 10.1097/00006534-197602000-00001; Takushima A, 2013, J PLAST RECONSTR AES, V66, P29, DOI 10.1016/j.bjps.2012.08.004; Bae YC, 2006, PLAST RECONSTR SURG, V117, P2407, DOI 10.1097/01.prs.0000218798.95027.21; VEDUNG S, 1984, SCAND J PLAST RECONS, V18, P201; Takushima A, 2006, J PLAST RECONSTR AES, V59, P465, DOI 10.1016/j.bjps.2005.10.011; Zuker RM, 2000, PLAST RECONSTR SURG, V106, P1, DOI 10.1097/00006534-200007000-00001; Faria JCM, 2007, ANN PLAS SURG, V59, P87, DOI 10.1097/01.sap.0000252042.58200.c3; Manktelow RT, 2006, PLAST RECONSTR SURG, V118, P885, DOI 10.1097/01.prs.0000232195.20293.bd; TERZIS JK, 1989, PLAST RECONSTR SURG, V83, P767, DOI 10.1097/00006534-198905000-00001; Harii K, 1998, PLAST RECONSTR SURG, V102, P941, DOI 10.1097/00006534-199809040-00001; Lifchez SD, 2005, PLAST RECONSTR SURG, V115, P1472, DOI 10.1097/01.PRS.0000160266.81504.71; KOSHIMA I, 1994, PLAST RECONSTR SURG, V94, P421, DOI 10.1097/00006534-199409000-00001; Biglioli F, 2012, J PLAST RECONSTR AES, V65, P1343, DOI 10.1016/j.bjps.2012.04.030; Bianchi B, 2010, J ORAL MAXIL SURG, V68, P1524, DOI 10.1016/j.joms.2009.09.024; Watanabe Y, 2009, J PLAST RECONSTR AES, V62, P1589, DOI 10.1016/j.bjps.2008.07.025; Cuccia G, 2005, ANN PLAS SURG, V54, P66, DOI 10.1097/01.sap.0000141378.23727.1a; Harii K., 1987, J JPN PLAST RECONSTR, V7, P347; OBRIEN BM, 1980, BRIT J PLAST SURG, V33, P202, DOI 10.1016/0007-1226(80)90013-2	19	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1748-6815	1878-0539		J PLAST RECONSTR AES	J. Plast. Reconstr. Aesthet. Surg.	JUN	2015	68	6					E113	E119		10.1016/j.bjps.2015.02.013		7	Surgery	Surgery	CI9ME	WOS:000355093400001		
J	Tashiro, K; Harima, M; Mito, D; Shibata, T; Furuya, M; Kato, M; Yamamoto, T; Yamashita, S; Narushima, M; Iida, T; Koshima, I				Tashiro, Kensuke; Harima, Mitsunobu; Mito, Daisuke; Shibata, Takashi; Furuya, Megumi; Kato, Motoi; Yamamoto, Takumi; Yamashita, Shuji; Narushima, Mitsunaga; Iida, Takuya; Koshima, Isao			Preoperative color Doppler ultrasound assessment of the lateral thoracic artery perforator flap and its branching pattern	JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY			English	Article						Color doppler ultrasound; Lateral thoracic artery perforator flap; Supermicrosurgery; Perforator-to-perforator anastomosis		The anatomy of the lateral thoracic artery perforator flap remains controversial, but this region is extremely useful as a reconstructive donor site. In this report, we describe the usefulness of the preoperative color Doppler ultrasound evaluation for the harvesting of the lateral thoracic artery perforator flap, and we clarify its branching pattern. Twentyseven patients underwent the preoperative color Doppler ultrasound assessment before perforator flaps were harvested. We evaluated the branching pattern and the diameter of the flaps by direct observation. All flaps were successfully transferred, and it was found that the branching pattern of the lateral thoracic perforator is divided into three groups: the superficial branch, the medial branch, and the deep branch. Their appearance ratios were 48.1% (13/27), 14.8% (4/27), and 81.5% (22/27), respectively. The lateral thoracic artery perforator flap has a great deal of anatomical variation, and vessels with relatively small diameters compared to those of other flaps. This is why flaps from this region are not currently popular. This study revealed the superiority of the color Doppler ultrasound for preoperative planning of the lateral thoracic artery perforator flap elevation. Furthermore, the branching pattern and the diameters of the different branches were specified. (C) 2015 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.	[Tashiro, Kensuke; Harima, Mitsunobu; Mito, Daisuke; Shibata, Takashi; Furuya, Megumi; Kato, Motoi; Yamamoto, Takumi; Yamashita, Shuji; Narushima, Mitsunaga; Iida, Takuya; Koshima, Isao] Tokyo Univ Hosp, Dept Plast & Reconstruct Surg, Tokyo 113, Japan	Tashiro, K (reprint author), Univ Tokyo, Dept Plast & Reconstruct Surg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	tashirox@gmail.com					TAYLOR GI, 1975, PLAST RECONSTR SURG, V56, P243, DOI 10.1097/00006534-197509000-00001; Cina A, 2010, RADIOLOGY, V255, P979, DOI 10.1148/radiol.10091166; Kim JT, 2011, J PLAST RECONSTR AES, V64, P1596, DOI 10.1016/j.bjps.2011.06.048; Ensat F, 2012, MICROSURG, V32, P605, DOI 10.1002/micr.20835; Hong JP, 2009, PLAST RECONSTR SURG, V123, P230, DOI 10.1097/PRS.0b013e3181904dc4; Barreiro GC, 2014, J RECONSTR MICROSURG, V30, P389, DOI 10.1055/s-0034-1372482; Blondeel PN, 2003, PLAST RECONSTR SURG, V112, P1378, DOI 10.1097/01.PRS.0000081071.83805.B6; Blondeel PN, 1998, BRIT J PLAST SURG, V51, P202, DOI 10.1016/S0007-1226(98)80010-6; HARII K, 1978, PLAST RECONSTR SURG, V62, P212, DOI 10.1097/00006534-197808000-00009; Isken T, 2009, ANN PLAS SURG, V62, P158, DOI 10.1097/SAP.0b013e31817e9cbd; Kim JT, 2014, J RECONSTR MICROSURG, V30, P443, DOI 10.1055/s-0034-1370358; Kosutic D, 2012, J PLAST RECONSTR AES, V65, P1530, DOI 10.1016/j.bjps.2012.04.045; Loukas M, 2014, SURG RADIOL ANAT, V36, P543, DOI 10.1007/s00276-013-1234-x; Mathes SJ, 1997, RECONSTRUCTIVE SURG; Tashiro K, 2014, J PLAST RECONSTR AES, V67, P1680, DOI 10.1016/j.bjps.2014.08.047	15	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1748-6815	1878-0539		J PLAST RECONSTR AES	J. Plast. Reconstr. Aesthet. Surg.	JUN	2015	68	6					E120	E125		10.1016/j.bjps.2015.02.011		6	Surgery	Surgery	CI9ME	WOS:000355093400002		
J	Endo, R; Setoyama, M; Yamamoto, K; Kadokawa, J				Endo, Ryo; Setoyama, Miwa; Yamamoto, Kazuya; Kadokawa, Jun-ichi			Acetylation of Xanthan Gum in Ionic Liquid	JOURNAL OF POLYMERS AND THE ENVIRONMENT			English	Article						Xanthan gum; Ionic liquid; Acetylation	EXTRACELLULAR POLYSACCHARIDE; XANTHOMONAS-CAMPESTRIS; CHEMICAL-MODIFICATION; CELLULOSE; CHITIN; FUNCTIONALIZATION; DISSOLUTION; CHITOSAN; ACETATE	In this paper, we report acetylation of xanthan gum using acetic anhydride in an ionic liquid solvent, 1-butyl-3-methylimidazolium chloride (BMIMCl). Xanthan gum was dissolved with BMIMCl [2 % (w/w)] and the reaction was carried out in the presence of acetic anhydride (five equiv. for hydroxy groups in a repeating unit) with stirring the solution at elevated temperatures. The structures of xanthan gum acetates were confirmed by the H-1 NMR and IR spectra. The degree of acetylation (DA) values determined by the H-1 NMR analysis increased with the higher reaction temperatures. The thermal gravimetric analysis (TGA) indicated the enhancement of thermal stability by acetylation. Furthermore, the TGA as well as differential scanning calorimetric (DSC) analysis of the products suggested the presence of the highly and less acetylated segments in a xanthan gum chain. The DSC profile of the product with the high DA value also exhibited a small endothermic peak, which might potentially be ascribed to the melting temperature.	[Endo, Ryo; Setoyama, Miwa; Yamamoto, Kazuya; Kadokawa, Jun-ichi] Kagoshima Univ, Grad Sch Sci & Engn, Kagoshima 8900065, Japan; [Kadokawa, Jun-ichi] Muroran Inst Technol, Res Ctr Environm Friendly Mat Engn, Muroran, Hokkaido 0508585, Japan	Kadokawa, J (reprint author), Kagoshima Univ, Grad Sch Sci & Engn, 1-21-40 Korimoto, Kagoshima 8900065, Japan.	kadokawa@eng.kagoshima-u.ac.jp					Heinze T, 2005, MACROMOL BIOSCI, V5, P520, DOI 10.1002/mabi.200500039; Rouilly A, 2002, J MACROMOL SCI-POL R, VC42, P441, DOI 10.1081/MC-120015987; Pinkert A, 2009, CHEM REV, V109, P6712, DOI 10.1021/cr9001947; Barthel S, 2006, GREEN CHEM, V8, P301, DOI 10.1039/b513157j; Zakrzewska ME, 2010, ENERG FUEL, V24, P737, DOI 10.1021/ef901215m; MELTON LD, 1976, CARBOHYD RES, V46, P245, DOI 10.1016/S0008-6215(00)84296-2; Wyatt NB, 2009, J APPL POLYM SCI, V114, P4076, DOI 10.1002/app.31093; JANSSON PE, 1975, CARBOHYD RES, V45, P275, DOI 10.1016/S0008-6215(00)85885-1; Liebert T, 2008, BIORESOURCES, V3, P576; Fundador NGV, 2012, CARBOHYD POLYM, V87, P170, DOI 10.1016/j.carbpol.2011.07.034; Fundador NGV, 2012, POLYMER, V53, P3885, DOI 10.1016/j.polymer.2012.06.038; Kurita K, 2001, PROG POLYM SCI, V26, P1921, DOI 10.1016/S0079-6700(01)00007-7; Swatloski RP, 2002, J AM CHEM SOC, V124, P4974, DOI 10.1021/ja025790m; Izawa H, 2009, J MATER CHEM, V19, P6969, DOI 10.1039/b916864h; Hamcerencu M, 2007, POLYMER, V48, P1921, DOI 10.1016/j.polymer.2007.01.048; Feng L, 2008, J MOL LIQ, V142, P1, DOI 10.1016/j.molliq.2008.06.007; Schlufter K, 2006, MACROMOL RAPID COMM, V27, P1670, DOI 10.1002/marc.200600463; Kaur G, 2013, INT J POLYM MATER PO, V62, P475, DOI 10.1080/00914037.2012.734348; Sashiwa H, 2004, PROG POLYM SCI, V29, P887, DOI 10.1016/j.progpolymsci.2004.04.001; Klemm D, 2011, ANGEW CHEM INT EDIT, V50, P5438, DOI 10.1002/anie.201001273; Izawa H, 2010, J MATER CHEM, V20, P5235, DOI 10.1039/c0jm00595a; Wu J, 2004, BIOMACROMOLECULES, V5, P266, DOI 10.1021/bm034398d; Klemm D, 2005, ANGEW CHEM INT EDIT, V44, P3358, DOI 10.1002/anie.200460587; Mine S, 2009, CARBOHYD RES, V344, P2263, DOI 10.1016/j.carres.2009.08.004; DOELKER E, 1993, ADV POLYM SCI, V107, P199; Enomoto-Rogers Y, 2013, CARBOHYD POLYM, V92, P1827, DOI 10.1016/j.carbpol.2012.11.043; Gibril ME, 2012, INT J ENG SCI TECHNO, V4, P3356; Huang KL, 2011, J AGR FOOD CHEM, V59, P5376, DOI 10.1021/jf104881f; Morimoto M, 2002, TRENDS GLYCOSCI GLYC, V14, P205; Schuerch C., 1986, ENCY POLYM SCI ENG, V13, P87; Stephen A. M., 1995, FOOD POLYSACCHARIDES	31	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1566-2543	1572-8900		J POLYM ENVIRON	J. Polym. Environ.	JUN	2015	23	2					199	205		10.1007/s10924-014-0701-8		7	Engineering, Environmental; Polymer Science	Engineering; Polymer Science	CJ1HF	WOS:000355234000007		
